Lepirudin,Approximately 1.3 hours,Prothrombin,F2,inhibitor,yes
Cetuximab,The mean half-life for Cetuximab is 114 hours (range 75-188 hours).,Epidermal growth factor receptor,EGFR,antagonist,yes
Cetuximab,The mean half-life for Cetuximab is 114 hours (range 75-188 hours).,Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Cetuximab,The mean half-life for Cetuximab is 114 hours (range 75-188 hours).,Complement C1r subcomponent,C1R,,unknown
Cetuximab,The mean half-life for Cetuximab is 114 hours (range 75-188 hours).,Complement C1q subcomponent subunit A,C1QA,,unknown
Cetuximab,The mean half-life for Cetuximab is 114 hours (range 75-188 hours).,Complement C1q subcomponent subunit B,C1QB,,unknown
Cetuximab,The mean half-life for Cetuximab is 114 hours (range 75-188 hours).,Complement C1q subcomponent subunit C,C1QC,,unknown
Cetuximab,The mean half-life for Cetuximab is 114 hours (range 75-188 hours).,Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Cetuximab,The mean half-life for Cetuximab is 114 hours (range 75-188 hours).,Complement C1s subcomponent,C1S,,unknown
Cetuximab,The mean half-life for Cetuximab is 114 hours (range 75-188 hours).,High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Cetuximab,The mean half-life for Cetuximab is 114 hours (range 75-188 hours).,Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Cetuximab,The mean half-life for Cetuximab is 114 hours (range 75-188 hours).,Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Cetuximab,The mean half-life for Cetuximab is 114 hours (range 75-188 hours).,Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Dornase alfa,,DNA,,,yes
Denileukin diftitox,70-80 min,Interleukin-2 receptor subunit alpha,IL2RA,binder,yes
Denileukin diftitox,70-80 min,Interleukin-2 receptor subunit beta,IL2RB,agonist,yes
Denileukin diftitox,70-80 min,Cytokine receptor common subunit gamma,IL2RG,,unknown
Etanercept,102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults.,Tumor necrosis factor,TNF,antibody,yes
Etanercept,102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults.,Tumor necrosis factor receptor superfamily member 1B,TNFRSF1B,,unknown
Etanercept,102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults.,High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Etanercept,102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults.,Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Etanercept,102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults.,Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Etanercept,102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults.,Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Etanercept,102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults.,Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Etanercept,102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults.,Lymphotoxin-alpha,LTA,,unknown
Etanercept,102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults.,Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Etanercept,102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults.,Complement C1s subcomponent,C1S,,unknown
Etanercept,102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults.,Complement C1r subcomponent,C1R,,unknown
Etanercept,102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults.,Complement C1q subcomponent subunit A,C1QA,,unknown
Etanercept,102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults.,Complement C1q subcomponent subunit B,C1QB,,unknown
Etanercept,102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults.,Complement C1q subcomponent subunit C,C1QC,,unknown
Bivalirudin,"* Normal renal function: 25 min (in normal conditions)
* Creatinine clearance 10-29mL/min: 57min
* Dialysis-dependant patients: 3.5h",Prothrombin,F2,inhibitor,yes
Leuprolide,~3 hours,Gonadotropin-releasing hormone receptor,GNRHR,agonist,yes
Peginterferon alfa-2a,The mean terminal half-life of peginterferon alfa-2a is 164 in a range of 84-353 hours [FDA Label].,Interferon alpha/beta receptor 2,IFNAR2,agonist,yes
Peginterferon alfa-2a,The mean terminal half-life of peginterferon alfa-2a is 164 in a range of 84-353 hours [FDA Label].,Interferon alpha/beta receptor 1,IFNAR1,agonist,yes
Alteplase,,Plasminogen,PLG,activator,yes
Alteplase,,Fibrinogen alpha chain,FGA,,yes
Alteplase,,Urokinase plasminogen activator surface receptor,PLAUR,,unknown
Alteplase,,Plasminogen activator inhibitor 1,SERPINE1,,unknown
Sermorelin,11-12 min,Growth hormone-releasing hormone receptor,GHRHR,agonist,yes
Interferon alfa-n1,"1.2 hours (mammalian reticulocytes, in vitro); &gt;20 hours (yeast, in vivo); &gt;10 hours (Escherichia coli, in vivo).",Interferon alpha/beta receptor 2,IFNAR2,agonist,yes
Interferon alfa-n1,"1.2 hours (mammalian reticulocytes, in vitro); &gt;20 hours (yeast, in vivo); &gt;10 hours (Escherichia coli, in vivo).",Interferon alpha/beta receptor 1,IFNAR1,agonist,yes
Darbepoetin alfa,,Erythropoietin receptor,EPOR,agonist,yes
Urokinase,12 minutes. Small fractions of the administered dose are excreted in bile and urine,Plasminogen,PLG,activator,yes
Urokinase,12 minutes. Small fractions of the administered dose are excreted in bile and urine,Urokinase plasminogen activator surface receptor,PLAUR,,yes
Urokinase,12 minutes. Small fractions of the administered dose are excreted in bile and urine,Urokinase-type plasminogen activator,PLAU,,yes
Urokinase,12 minutes. Small fractions of the administered dose are excreted in bile and urine,Tissue-type plasminogen activator,PLAT,,yes
Urokinase,12 minutes. Small fractions of the administered dose are excreted in bile and urine,Plasminogen activator inhibitor 1,SERPINE1,,yes
Urokinase,12 minutes. Small fractions of the administered dose are excreted in bile and urine,Plasminogen activator inhibitor 2,SERPINB2,,yes
Urokinase,12 minutes. Small fractions of the administered dose are excreted in bile and urine,Plasma serine protease inhibitor,SERPINA5,,unknown
Urokinase,12 minutes. Small fractions of the administered dose are excreted in bile and urine,Low-density lipoprotein receptor-related protein 2,LRP2,,unknown
Urokinase,12 minutes. Small fractions of the administered dose are excreted in bile and urine,Suppressor of tumorigenicity 14 protein,ST14,,unknown
Urokinase,12 minutes. Small fractions of the administered dose are excreted in bile and urine,Nidogen-1,NID1,,unknown
Goserelin,4-5 hours,Lutropin-choriogonadotropic hormone receptor,LHCGR,agonist,yes
Goserelin,4-5 hours,Gonadotropin-releasing hormone receptor,GNRHR,agonist,yes
Reteplase,,Plasminogen,PLG,activator,yes
Reteplase,,Fibrinogen alpha chain,FGA,,yes
Reteplase,,Urokinase plasminogen activator surface receptor,PLAUR,,unknown
Reteplase,,Plasminogen activator inhibitor 1,SERPINE1,,unknown
Erythropoietin,"Toxicokinetic results from rats in a 13 week toxicity study after a single subcutaneous dose:

* 7.37 hours (+/- 0.70) with 500 IU/kg [test 1]
* 8.63 hours (+/- 2.78) with 2500 IU/kg [test 2]
* 8.76 hours (+/- 1.46) with 2500 IU/kg [reference dose]",Erythropoietin receptor,EPOR,agonist,yes
Salmon Calcitonin,Half-life elimination (terminal): I.M. 58 minutes; SubQ 59 to 64 minutes; Nasal: ~18 to 23 minutes,Calcitonin receptor,CALCR,agonist,unknown
Interferon alfa-n3,,Interferon alpha/beta receptor 1,IFNAR1,agonist,yes
Interferon alfa-n3,,Interferon alpha/beta receptor 2,IFNAR2,agonist,yes
Pegfilgrastim,15-80 hrs,Granulocyte colony-stimulating factor receptor,CSF3R,agonist,yes
Pegfilgrastim,15-80 hrs,Neutrophil elastase,ELANE,,unknown
Sargramostim,,Granulocyte-macrophage colony-stimulating factor receptor subunit alpha,CSF2RA,agonist,yes
Sargramostim,,Interleukin-3 receptor subunit alpha,IL3RA,agonist,yes
Sargramostim,,Cytokine receptor common subunit beta,CSF2RB,agonist,yes
Sargramostim,,Syndecan-2,SDC2,agonist,unknown
Sargramostim,,Bone marrow proteoglycan,PRG2,,unknown
Secretin,,Secretin receptor,SCTR,agonist,yes
Peginterferon alfa-2b,The mean half-life of elimination of Peginterferon alfa-2b is 40 hours in a range of 22-60 hours [FDA Label].,Interferon alpha/beta receptor 1,IFNAR1,agonist,yes
Peginterferon alfa-2b,The mean half-life of elimination of Peginterferon alfa-2b is 40 hours in a range of 22-60 hours [FDA Label].,Interferon alpha/beta receptor 2,IFNAR2,agonist,yes
Asparaginase Escherichia coli,Plasma half life of L-asparagine derived from _E. coli_ following intravenous injection was 8-30 hrs [FDA Label]. Plasma half-life was 34 to 49 hours after intramuscular injection [FDA Label]. Half-life (mean ± SD) of native _E. coli_ asparaginase is approximately 1.28 ± 0.35 days [A31999].,L-asparagine,,other/unknown,yes
Thyrotropin Alfa,25 ± 10 hours,Thyrotropin receptor,TSHR,agonist,yes
"Antihemophilic factor, human recombinant",8.4-19.3 hrs,Coagulation factor X,F10,activator,yes
"Antihemophilic factor, human recombinant",8.4-19.3 hrs,Coagulation factor IX,F9,cofactor,yes
"Antihemophilic factor, human recombinant",8.4-19.3 hrs,von Willebrand factor,VWF,binder,yes
"Antihemophilic factor, human recombinant",8.4-19.3 hrs,"Phytanoyl-CoA dioxygenase, peroxisomal",PHYH,antagonist,unknown
"Antihemophilic factor, human recombinant",8.4-19.3 hrs,Asialoglycoprotein receptor 2,ASGR2,binder,unknown
"Antihemophilic factor, human recombinant",8.4-19.3 hrs,78 kDa glucose-regulated protein,HSPA5,chaperone,unknown
"Antihemophilic factor, human recombinant",8.4-19.3 hrs,Calreticulin,CALR,chaperone,unknown
"Antihemophilic factor, human recombinant",8.4-19.3 hrs,Calnexin,CANX,chaperone,unknown
"Antihemophilic factor, human recombinant",8.4-19.3 hrs,Protein ERGIC-53,LMAN1,chaperone,unknown
"Antihemophilic factor, human recombinant",8.4-19.3 hrs,Prolow-density lipoprotein receptor-related protein 1,LRP1,modulator,unknown
"Antihemophilic factor, human recombinant",8.4-19.3 hrs,Multiple coagulation factor deficiency protein 2,MCFD2,modulator,unknown
Anakinra,"Healthy subjects = 4 - 6 hours;
NOMID patients = 5.7 hours (range of 3.1 - 28.2 hours).",Interleukin-1 receptor type 1,IL1R1,antagonist,yes
Immune Globulin Human,">20 hours (mammalian reticulocytes, in vitro).",High affinity immunoglobulin gamma Fc receptor I,FCGR1A,antagonist,yes
Immune Globulin Human,">20 hours (mammalian reticulocytes, in vitro).",High affinity immunoglobulin gamma Fc receptor IB,FCGR1B,antagonist,yes
Immune Globulin Human,">20 hours (mammalian reticulocytes, in vitro).",Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,antagonist,yes
Immune Globulin Human,">20 hours (mammalian reticulocytes, in vitro).",Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,antagonist,yes
Immune Globulin Human,">20 hours (mammalian reticulocytes, in vitro).",Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,antagonist,yes
Immune Globulin Human,">20 hours (mammalian reticulocytes, in vitro).",Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,antagonist,yes
Immune Globulin Human,">20 hours (mammalian reticulocytes, in vitro).",Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,antagonist,yes
Immune Globulin Human,">20 hours (mammalian reticulocytes, in vitro).",Complement C3,C3,binder,yes
Immune Globulin Human,">20 hours (mammalian reticulocytes, in vitro).",Complement C4-A,C4A,binder,yes
Immune Globulin Human,">20 hours (mammalian reticulocytes, in vitro).",Complement C4-B,C4B,binder,yes
Immune Globulin Human,">20 hours (mammalian reticulocytes, in vitro).",Complement C5,C5,binder,yes
Anistreplase,,Plasminogen,PLG,activator,yes
Anistreplase,,Fibrinogen alpha chain,FGA,,yes
Anistreplase,,Urokinase plasminogen activator surface receptor,PLAUR,,unknown
Anistreplase,,Plasminogen activator inhibitor 1,SERPINE1,,unknown
Insulin Human,,Insulin receptor,INSR,agonist,yes
Insulin Human,,Insulin-like growth factor 1 receptor,IGF1R,,unknown
Insulin Human,,Retinoblastoma-associated protein,RB1,,unknown
Insulin Human,,Cathepsin D,CTSD,,unknown
Insulin Human,,Insulin-degrading enzyme,IDE,,unknown
Insulin Human,,Neuroendocrine convertase 2,PCSK2,,unknown
Insulin Human,,Carboxypeptidase E,CPE,,unknown
Insulin Human,,Neuroendocrine convertase 1,PCSK1,,unknown
Insulin Human,,Protein NOV homolog,NOV,,unknown
Insulin Human,,Low-density lipoprotein receptor-related protein 2,LRP2,,unknown
Insulin Human,,Insulin-like growth factor-binding protein 7,IGFBP7,,unknown
Insulin Human,,Synaptotagmin-like protein 4,SYTL4,,unknown
Tenecteplase,"1.9 hours (mammalian reticulocytes, in vitro)
>20 hours (yeast, in vivo)
>10 hours (Escherichia coli, in vivo)",Plasminogen,PLG,activator,yes
Tenecteplase,"1.9 hours (mammalian reticulocytes, in vitro)
>20 hours (yeast, in vivo)
>10 hours (Escherichia coli, in vivo)",Fibrinogen alpha chain,FGA,,yes
Tenecteplase,"1.9 hours (mammalian reticulocytes, in vitro)
>20 hours (yeast, in vivo)
>10 hours (Escherichia coli, in vivo)",Urokinase plasminogen activator surface receptor,PLAUR,,unknown
Tenecteplase,"1.9 hours (mammalian reticulocytes, in vitro)
>20 hours (yeast, in vivo)
>10 hours (Escherichia coli, in vivo)",Plasminogen activator inhibitor 1,SERPINE1,,unknown
Tenecteplase,"1.9 hours (mammalian reticulocytes, in vitro)
>20 hours (yeast, in vivo)
>10 hours (Escherichia coli, in vivo)",Plasminogen activator inhibitor 2,SERPINB2,,unknown
Tenecteplase,"1.9 hours (mammalian reticulocytes, in vitro)
>20 hours (yeast, in vivo)
>10 hours (Escherichia coli, in vivo)",Tetranectin,CLEC3B,,unknown
Tenecteplase,"1.9 hours (mammalian reticulocytes, in vitro)
>20 hours (yeast, in vivo)
>10 hours (Escherichia coli, in vivo)","Keratin, type II cytoskeletal 8",KRT8,,unknown
Tenecteplase,"1.9 hours (mammalian reticulocytes, in vitro)
>20 hours (yeast, in vivo)
>10 hours (Escherichia coli, in vivo)",Annexin A2,ANXA2,,unknown
Tenecteplase,"1.9 hours (mammalian reticulocytes, in vitro)
>20 hours (yeast, in vivo)
>10 hours (Escherichia coli, in vivo)",Calreticulin,CALR,,unknown
Tenecteplase,"1.9 hours (mammalian reticulocytes, in vitro)
>20 hours (yeast, in vivo)
>10 hours (Escherichia coli, in vivo)",Calnexin,CANX,,unknown
Tenecteplase,"1.9 hours (mammalian reticulocytes, in vitro)
>20 hours (yeast, in vivo)
>10 hours (Escherichia coli, in vivo)",Prolow-density lipoprotein receptor-related protein 1,LRP1,,unknown
Menotropins,,Follicle-stimulating hormone receptor,FSHR,binder,yes
Menotropins,,Lutropin-choriogonadotropic hormone receptor,LHCGR,,yes
Interferon gamma-1b,,Interferon gamma receptor 1,IFNGR1,binder,yes
Interferon gamma-1b,,Interferon gamma receptor 2,IFNGR2,binder,yes
"Interferon Alfa-2a, Recombinant",The IM half-life of interferon alfa-2a is 6 hours to 8 hours; the half-life for IV infusion is 3.7 hours to 8.5 hours (mean 5.1 hours).,Interferon alpha/beta receptor 1,IFNAR1,,yes
"Interferon Alfa-2a, Recombinant",The IM half-life of interferon alfa-2a is 6 hours to 8 hours; the half-life for IV infusion is 3.7 hours to 8.5 hours (mean 5.1 hours).,Interferon alpha/beta receptor 2,IFNAR2,,yes
Desmopressin,"Following an intranasal dose of 1.66 mcg of desmopressin, the median apparent terminal half-life was 2.8 hours [FDA Label]. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment [FDA Label]. The oral terminal half life of desmopressin ranges from 2 to 3.11 hours [L1184].",Vasopressin V2 receptor,AVPR2,agonist,yes
Desmopressin,"Following an intranasal dose of 1.66 mcg of desmopressin, the median apparent terminal half-life was 2.8 hours [FDA Label]. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment [FDA Label]. The oral terminal half life of desmopressin ranges from 2 to 3.11 hours [L1184].",Vasopressin V1a receptor,AVPR1A,,yes
Desmopressin,"Following an intranasal dose of 1.66 mcg of desmopressin, the median apparent terminal half-life was 2.8 hours [FDA Label]. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment [FDA Label]. The oral terminal half life of desmopressin ranges from 2 to 3.11 hours [L1184].",Vasopressin V1b receptor,AVPR1B,,yes
Coagulation factor VIIa Recombinant Human,,Coagulation factor X,F10,,unknown
Coagulation factor VIIa Recombinant Human,,Serine protease hepsin,HPN,,unknown
Coagulation factor VIIa Recombinant Human,,Tissue factor pathway inhibitor,TFPI,,unknown
Coagulation factor VIIa Recombinant Human,,Vitamin K-dependent gamma-carboxylase,GGCX,,unknown
Coagulation factor VIIa Recombinant Human,,Coagulation factor VII,F7,,unknown
Coagulation factor VIIa Recombinant Human,,Tissue factor,F3,,unknown
Oprelvekin,6.9 +/- 1.7 hrs,Interleukin-11 receptor subunit alpha,IL11RA,agonist,yes
Palifermin,Elimination half-life: 4.5 hours (range: 3.3-5.7 hours),Fibroblast growth factor receptor 2,FGFR2,binder,yes
Palifermin,Elimination half-life: 4.5 hours (range: 3.3-5.7 hours),Neuropilin-1,NRP1,,unknown
Palifermin,Elimination half-life: 4.5 hours (range: 3.3-5.7 hours),Fibroblast growth factor receptor 1,FGFR1,,unknown
Palifermin,Elimination half-life: 4.5 hours (range: 3.3-5.7 hours),Fibroblast growth factor receptor 4,FGFR4,,unknown
Palifermin,Elimination half-life: 4.5 hours (range: 3.3-5.7 hours),Fibroblast growth factor receptor 3,FGFR3,,unknown
Palifermin,Elimination half-life: 4.5 hours (range: 3.3-5.7 hours),Basement membrane-specific heparan sulfate proteoglycan core protein,HSPG2,,unknown
Glucagon recombinant,,Glucagon receptor,GCGR,agonist,yes
Glucagon recombinant,,Glucagon-like peptide 2 receptor,GLP2R,,unknown
Glucagon recombinant,,Glucagon-like peptide 1 receptor,GLP1R,,unknown
Aldesleukin,13 min-85 min,Interleukin-2 receptor subunit beta,IL2RB,agonistmodulator,yes
Aldesleukin,13 min-85 min,Interleukin-2 receptor subunit alpha,IL2RA,agonistmodulator,yes
Aldesleukin,13 min-85 min,Cytokine receptor common subunit gamma,IL2RG,agonist,yes
Botulinum Toxin Type B,,Vesicle-associated membrane protein 2,VAMP2,binder,yes
Botulinum Toxin Type B,,Vesicle-associated membrane protein 1,VAMP1,binder,yes
Botulinum Toxin Type B,,Synaptotagmin-2,SYT2,,yes
Omalizumab,26 days,High affinity immunoglobulin epsilon receptor subunit alpha,FCER1A,,yes
Omalizumab,26 days,High affinity immunoglobulin epsilon receptor subunit beta,MS4A2,antagonist,yes
Lutropin alfa,Biphasic; terminal half-life is approximately 18 hours.,Lutropin-choriogonadotropic hormone receptor,LHCGR,agonist,yes
Lyme disease vaccine (recombinant OspA),"1.2 hours (mammalian reticulocytes, in vitro).",Toll-like receptor 2,TLR2,other/unknown,yes
Insulin Lispro,SubQ administration = 1 hour,Insulin receptor,INSR,agonist,yes
Insulin Lispro,SubQ administration = 1 hour,Insulin-like growth factor 1 receptor,IGF1R,,unknown
Insulin Glargine,Not reported in humans; 30 hours <i>in vitro</i> in mammalian reticulocytes.,Insulin receptor,INSR,agonist,yes
Insulin Glargine,Not reported in humans; 30 hours <i>in vitro</i> in mammalian reticulocytes.,Insulin-like growth factor 1 receptor,IGF1R,agonist,unknown
Collagenase clostridium histolyticum,,Collagen alpha-1(I) chain,COL1A1,,unknown
Collagenase clostridium histolyticum,,Collagen alpha-1(II) chain,COL2A1,,unknown
Collagenase clostridium histolyticum,,Collagen alpha-1(III) chain,COL3A1,,unknown
Collagenase clostridium histolyticum,,Collagen alpha-2(I) chain,COL1A2,,unknown
Rasburicase,18 hours,Uric acid,,metabolizer,yes
Cetrorelix,~62.8 hours,Gonadotropin-releasing hormone receptor,GNRHR,antagonist,yes
Cetrorelix,~62.8 hours,Lutropin-choriogonadotropic hormone receptor,LHCGR,,unknown
Adalimumab,10-20 days.,Tumor necrosis factor,TNF,antibody,yes
Adalimumab,10-20 days.,Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Adalimumab,10-20 days.,Complement C1r subcomponent,C1R,,unknown
Adalimumab,10-20 days.,Complement C1q subcomponent subunit A,C1QA,,unknown
Adalimumab,10-20 days.,Complement C1q subcomponent subunit B,C1QB,,unknown
Adalimumab,10-20 days.,Complement C1q subcomponent subunit C,C1QC,,unknown
Adalimumab,10-20 days.,Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Adalimumab,10-20 days.,Complement C1s subcomponent,C1S,,unknown
Adalimumab,10-20 days.,High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Adalimumab,10-20 days.,Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Adalimumab,10-20 days.,Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Adalimumab,10-20 days.,Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Somatotropin,,Growth hormone receptor,GHR,binder,yes
Somatotropin,,Prolactin receptor,PRLR,,yes
Imiglucerase,3.6-10.4 min,Glucocerebroside,,other/unknown,yes
Abciximab,"Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.",Integrin beta-3,ITGB3,antagonist,yes
Abciximab,"Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.",Integrin alpha-IIb,ITGA2B,antagonist,yes
Abciximab,"Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.",Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Abciximab,"Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.",Complement C1r subcomponent,C1R,,unknown
Abciximab,"Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.",Complement C1q subcomponent subunit A,C1QA,,unknown
Abciximab,"Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.",Complement C1q subcomponent subunit B,C1QB,,unknown
Abciximab,"Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.",Complement C1q subcomponent subunit C,C1QC,,unknown
Abciximab,"Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.",Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Abciximab,"Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.",Complement C1s subcomponent,C1S,,unknown
Abciximab,"Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.",High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Abciximab,"Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.",Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Abciximab,"Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.",Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Abciximab,"Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.",Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Abciximab,"Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.",Vitronectin,VTN,,unknown
Drotrecogin alfa,"5.5 hours (mammalian reticulocytes, in vitro).",Coagulation factor VIII,F8,multitarget,yes
Drotrecogin alfa,"5.5 hours (mammalian reticulocytes, in vitro).",Coagulation factor V,F5,multitarget,yes
Drotrecogin alfa,"5.5 hours (mammalian reticulocytes, in vitro).",Plasminogen activator inhibitor 1,SERPINE1,,unknown
Drotrecogin alfa,"5.5 hours (mammalian reticulocytes, in vitro).",Thrombomodulin,THBD,,unknown
Drotrecogin alfa,"5.5 hours (mammalian reticulocytes, in vitro).",Vitamin K-dependent protein S,PROS1,,unknown
Drotrecogin alfa,"5.5 hours (mammalian reticulocytes, in vitro).",Ceruloplasmin,CP,,unknown
Drotrecogin alfa,"5.5 hours (mammalian reticulocytes, in vitro).",Prothrombin,F2,,unknown
Drotrecogin alfa,"5.5 hours (mammalian reticulocytes, in vitro).",Platelet factor 4,PF4,,unknown
Drotrecogin alfa,"5.5 hours (mammalian reticulocytes, in vitro).",Plasma serine protease inhibitor,SERPINA5,,unknown
Drotrecogin alfa,"5.5 hours (mammalian reticulocytes, in vitro).",Serpin B6,SERPINB6,,unknown
Drotrecogin alfa,"5.5 hours (mammalian reticulocytes, in vitro).",Vitamin K-dependent gamma-carboxylase,GGCX,,unknown
Drotrecogin alfa,"5.5 hours (mammalian reticulocytes, in vitro).",Endothelial protein C receptor,PROCR,,unknown
Gemtuzumab ozogamicin,"In pediatric patients receiving a dose level of 9mg/m^2, the half life was approximately 64±44 h after the first dose [A20377].",Myeloid cell surface antigen CD33,CD33,antibody,yes
Gemtuzumab ozogamicin,"In pediatric patients receiving a dose level of 9mg/m^2, the half life was approximately 64±44 h after the first dose [A20377].",Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Gemtuzumab ozogamicin,"In pediatric patients receiving a dose level of 9mg/m^2, the half life was approximately 64±44 h after the first dose [A20377].",Complement C1r subcomponent,C1R,,unknown
Gemtuzumab ozogamicin,"In pediatric patients receiving a dose level of 9mg/m^2, the half life was approximately 64±44 h after the first dose [A20377].",Complement C1q subcomponent subunit A,C1QA,,unknown
Gemtuzumab ozogamicin,"In pediatric patients receiving a dose level of 9mg/m^2, the half life was approximately 64±44 h after the first dose [A20377].",Complement C1q subcomponent subunit B,C1QB,,unknown
Gemtuzumab ozogamicin,"In pediatric patients receiving a dose level of 9mg/m^2, the half life was approximately 64±44 h after the first dose [A20377].",Complement C1q subcomponent subunit C,C1QC,,unknown
Gemtuzumab ozogamicin,"In pediatric patients receiving a dose level of 9mg/m^2, the half life was approximately 64±44 h after the first dose [A20377].",Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Gemtuzumab ozogamicin,"In pediatric patients receiving a dose level of 9mg/m^2, the half life was approximately 64±44 h after the first dose [A20377].",Complement C1s subcomponent,C1S,,unknown
Gemtuzumab ozogamicin,"In pediatric patients receiving a dose level of 9mg/m^2, the half life was approximately 64±44 h after the first dose [A20377].",High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Gemtuzumab ozogamicin,"In pediatric patients receiving a dose level of 9mg/m^2, the half life was approximately 64±44 h after the first dose [A20377].",Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Gemtuzumab ozogamicin,"In pediatric patients receiving a dose level of 9mg/m^2, the half life was approximately 64±44 h after the first dose [A20377].",Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Gemtuzumab ozogamicin,"In pediatric patients receiving a dose level of 9mg/m^2, the half life was approximately 64±44 h after the first dose [A20377].",Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Indium In-111 satumomab pendetide,"0.8 hours (mammalian reticulocytes, in vitro)",Tumor-associated glycoprotein 72 (TAG-72),,other/unknown,yes
Alpha-1-proteinase inhibitor,,Neutrophil elastase,ELANE,inhibitor,yes
Pegaspargase,IM: ~6 days; half-life decreased to ~3 days (range: 1.4 to 5 days) in patients with previous hypersensitivity to native L-asparaginase; IV: Adults (asparaginase naive): 7 days,L-asparagine,,other/unknown,yes
Interferon beta-1a,10 hrs,Interferon alpha/beta receptor 1,IFNAR1,agonist,yes
Interferon beta-1a,10 hrs,Interferon alpha/beta receptor 2,IFNAR2,,yes
Pegademase bovine,plasma adenosine deaminase elimination half-life is 3 to >6 days,Adenosine,,metabolizer,yes
Pegademase bovine,plasma adenosine deaminase elimination half-life is 3 to >6 days,Growth factor receptor-bound protein 2,GRB2,binder,unknown
Human Serum Albumin,,Apolipoprotein E,APOE,,unknown
Human Serum Albumin,,Serum amyloid A-1 protein,SAA1,,unknown
Human Serum Albumin,,Protein AMBP,AMBP,,unknown
Eptifibatide,Approximately 2.5 hours,Integrin beta-3,ITGB3,,yes
Infliximab,"The median terminal half-life of infliximab is 7.7 to 9.5 days. The data is based on a pharmacokinetic study in patients with Crohn's disease, plaque psoriasis and rheumatoid arthritis receiving a single dose of infliximab [FDA Label].",Tumor necrosis factor,TNF,inhibitor,yes
Follitropin,"Circulation half life of 3-4 hours, elimination half life of 35-40 hours",Follicle-stimulating hormone receptor,FSHR,agonist,yes
Vasopressin,10-20 minutes,Vasopressin V2 receptor,AVPR2,agonist,yes
Vasopressin,10-20 minutes,Vasopressin V1a receptor,AVPR1A,,yes
Vasopressin,10-20 minutes,Vasopressin V1b receptor,AVPR1B,,yes
Interferon beta-1b,,Interferon alpha/beta receptor 1,IFNAR1,agonist,yes
Interferon beta-1b,,Interferon alpha/beta receptor 2,IFNAR2,agonist,yes
Interferon alfacon-1,The terminal half-life following subcutaneous dosing was 1.3 hours in golden Syrian hamsters and 3.4 hours in rhesus monkeys.,Interferon alpha/beta receptor 1,IFNAR1,binder,yes
Interferon alfacon-1,The terminal half-life following subcutaneous dosing was 1.3 hours in golden Syrian hamsters and 3.4 hours in rhesus monkeys.,Interferon alpha/beta receptor 2,IFNAR2,binder,yes
Hyaluronidase,,Hyaluronan,,other,yes
Hyaluronidase,,Transforming growth factor beta-1,TGFB1,inhibitor,unknown
Insulin Pork,,Insulin receptor,INSR,binder,yes
Insulin Pork,,Insulin-like growth factor 1 receptor,IGF1R,,unknown
Insulin Pork,,Insulin-degrading enzyme,IDE,,unknown
Insulin Pork,,"HLA class II histocompatibility antigen, DQ alpha 2 chain",HLA-DQA2,,unknown
Insulin Pork,,"HLA class II histocompatibility antigen, DQ beta 1 chain",HLA-DQB1,,unknown
Insulin Pork,,Retinoblastoma-associated protein,RB1,,unknown
Insulin Pork,,Cathepsin D,CTSD,,unknown
Insulin Pork,,Carboxypeptidase E,CPE,,unknown
Insulin Pork,,Neuroendocrine convertase 2,PCSK2,,unknown
Insulin Pork,,Neuroendocrine convertase 1,PCSK1,,unknown
Insulin Pork,,Protein NOV homolog,NOV,,unknown
Insulin Pork,,Low-density lipoprotein receptor-related protein 2,LRP2,,unknown
Insulin Pork,,Insulin-like growth factor-binding protein 7,IGFBP7,,unknown
Insulin Pork,,Synaptotagmin-like protein 4,SYTL4,,unknown
Trastuzumab,average 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance.,Receptor tyrosine-protein kinase erbB-2,ERBB2,antibody,yes
Trastuzumab,average 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance.,Epidermal growth factor receptor,EGFR,,unknown
Trastuzumab,average 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance.,Complement C1r subcomponent,C1R,,unknown
Trastuzumab,average 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance.,Complement C1q subcomponent subunit A,C1QA,,unknown
Trastuzumab,average 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance.,Complement C1q subcomponent subunit B,C1QB,,unknown
Trastuzumab,average 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance.,Complement C1q subcomponent subunit C,C1QC,,unknown
Trastuzumab,average 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance.,Complement C1s subcomponent,C1S,,unknown
Trastuzumab,average 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance.,High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Trastuzumab,average 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance.,Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Trastuzumab,average 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance.,Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Trastuzumab,average 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance.,Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Trastuzumab,average 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance.,Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Trastuzumab,average 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance.,Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Rituximab,"0.8 hours (mammalian reticulocytes, in vitro)",B-lymphocyte antigen CD20,MS4A1,antibody,yes
Rituximab,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Rituximab,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1r subcomponent,C1R,,unknown
Rituximab,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1q subcomponent subunit A,C1QA,,unknown
Rituximab,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1q subcomponent subunit B,C1QB,,unknown
Rituximab,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1q subcomponent subunit C,C1QC,,unknown
Rituximab,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Rituximab,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1s subcomponent,C1S,,unknown
Rituximab,"0.8 hours (mammalian reticulocytes, in vitro)",High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Rituximab,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Rituximab,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Rituximab,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Basiliximab,7.2 +/- 3.2 days (adults),Interleukin-2 receptor subunit alpha,IL2RA,antibody,yes
Basiliximab,7.2 +/- 3.2 days (adults),Interleukin-2 receptor subunit beta,IL2RB,antibody,unknown
Basiliximab,7.2 +/- 3.2 days (adults),High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Basiliximab,7.2 +/- 3.2 days (adults),Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Basiliximab,7.2 +/- 3.2 days (adults),Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Basiliximab,7.2 +/- 3.2 days (adults),Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Basiliximab,7.2 +/- 3.2 days (adults),Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Basiliximab,7.2 +/- 3.2 days (adults),Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Basiliximab,7.2 +/- 3.2 days (adults),Complement C1s subcomponent,C1S,,unknown
Basiliximab,7.2 +/- 3.2 days (adults),Complement C1r subcomponent,C1R,,unknown
Basiliximab,7.2 +/- 3.2 days (adults),Complement C1q subcomponent subunit A,C1QA,,unknown
Basiliximab,7.2 +/- 3.2 days (adults),Complement C1q subcomponent subunit B,C1QB,,unknown
Basiliximab,7.2 +/- 3.2 days (adults),Complement C1q subcomponent subunit C,C1QC,,unknown
Muromonab,"0.8 hours (mammalian reticulocytes, in vitro)",T-cell surface glycoprotein CD3 delta chain,CD3D,,yes
Muromonab,"0.8 hours (mammalian reticulocytes, in vitro)",T-cell surface glycoprotein CD3 epsilon chain,CD3E,binder,yes
Muromonab,"0.8 hours (mammalian reticulocytes, in vitro)",T-cell surface glycoprotein CD3 gamma chain,CD3G,,yes
Muromonab,"0.8 hours (mammalian reticulocytes, in vitro)",T-cell surface glycoprotein CD3 zeta chain,CD247,,yes
Muromonab,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Muromonab,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1r subcomponent,C1R,,unknown
Muromonab,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1q subcomponent subunit A,C1QA,,unknown
Muromonab,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1q subcomponent subunit B,C1QB,,unknown
Muromonab,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1q subcomponent subunit C,C1QC,,unknown
Muromonab,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Muromonab,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1s subcomponent,C1S,,unknown
Muromonab,"0.8 hours (mammalian reticulocytes, in vitro)",High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Muromonab,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Muromonab,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Muromonab,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Digoxin Immune Fab (Ovine),15-20 hrs,Digoxin,,other/unknown,yes
Ibritumomab tiuxetan,"0.8 hours (mammalian reticulocytes, in vitro)",B-lymphocyte antigen CD20,MS4A1,antibody,yes
Ibritumomab tiuxetan,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Ibritumomab tiuxetan,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1r subcomponent,C1R,,unknown
Ibritumomab tiuxetan,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1q subcomponent subunit A,C1QA,,unknown
Ibritumomab tiuxetan,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1q subcomponent subunit B,C1QB,,unknown
Ibritumomab tiuxetan,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1q subcomponent subunit C,C1QC,,unknown
Ibritumomab tiuxetan,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Ibritumomab tiuxetan,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1s subcomponent,C1S,,unknown
Ibritumomab tiuxetan,"0.8 hours (mammalian reticulocytes, in vitro)",High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Ibritumomab tiuxetan,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Ibritumomab tiuxetan,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Ibritumomab tiuxetan,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Daptomycin,Half-life elimination: 8-9 hours (up to 28 hours in renal impairment),Bacterial outer membrane,,incorporation into and destabilization,yes
Daptomycin,Half-life elimination: 8-9 hours (up to 28 hours in renal impairment),Lipoteichoic acid synthesis,,inhibitor,unknown
Tositumomab,"0.8 hours (mammalian reticulocytes, in vitro)",B-lymphocyte antigen CD20,MS4A1,antibody,yes
Tositumomab,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Tositumomab,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1r subcomponent,C1R,,unknown
Tositumomab,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1q subcomponent subunit A,C1QA,,unknown
Tositumomab,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1q subcomponent subunit B,C1QB,,unknown
Tositumomab,"0.8 hours (mammalian reticulocytes, in vitro)",Complement C1q subcomponent subunit C,C1QC,,unknown
Tositumomab,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Tositumomab,"0.8 hours (mammalian reticulocytes, in vitro)",High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Tositumomab,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Tositumomab,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Tositumomab,"0.8 hours (mammalian reticulocytes, in vitro)",Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Pegvisomant,~6 days,Growth hormone receptor,GHR,antagonist,yes
Botulinum Toxin Type A,,Synaptosomal-associated protein 25,SNAP25,inhibitor,yes
Botulinum Toxin Type A,,Rho-related GTP-binding protein RhoB,RHOB,,unknown
Pancrelipase,"Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so there is no terminal elimination half life.",Dietary fat,,cleavage,yes
Pancrelipase,"Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so there is no terminal elimination half life.",Dietary protein,,cleavage,yes
Pancrelipase,"Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so there is no terminal elimination half life.",Dietary starch,,cleavage,yes
Streptokinase,,Plasminogen,PLG,activator,yes
Streptokinase,,Proteinase-activated receptor 1,F2R,cleavage,unknown
Alemtuzumab,~288 hrs,CAMPATH-1 antigen,CD52,antibody,yes
Alemtuzumab,~288 hrs,Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Alemtuzumab,~288 hrs,Complement C1r subcomponent,C1R,,unknown
Alemtuzumab,~288 hrs,Complement C1q subcomponent subunit A,C1QA,,unknown
Alemtuzumab,~288 hrs,Complement C1q subcomponent subunit B,C1QB,,unknown
Alemtuzumab,~288 hrs,Complement C1q subcomponent subunit C,C1QC,,unknown
Alemtuzumab,~288 hrs,Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Alemtuzumab,~288 hrs,High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Alemtuzumab,~288 hrs,Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Alemtuzumab,~288 hrs,Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Alemtuzumab,~288 hrs,Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Alglucerase,3.6-10.4 min,Glucocerebroside,,other/unknown,yes
Capromab pendetide,,Glutamate carboxypeptidase 2,FOLH1,other/unknown,yes
Laronidase,1.5-3.6 hrs,Iduronic acid,,other/unknown,yes
Cyclosporine,"Biphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.",Calcium signal-modulating cyclophilin ligand,CAMLG,binder,yes
Cyclosporine,"Biphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.",Calcineurin subunit B type 2,PPP3R2,inhibitor,yes
Cyclosporine,"Biphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.",Peptidyl-prolyl cis-trans isomerase A,PPIA,,unknown
Cyclosporine,"Biphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.","Peptidyl-prolyl cis-trans isomerase F, mitochondrial",PPIF,binder,unknown
Alefacept,~270 hours,T-cell surface antigen CD2,CD2,inhibitor,yes
Alefacept,~270 hours,Complement C1r subcomponent,C1R,,unknown
Alefacept,~270 hours,Complement C1q subcomponent subunit A,C1QA,,unknown
Alefacept,~270 hours,Complement C1q subcomponent subunit B,C1QB,,unknown
Alefacept,~270 hours,Complement C1q subcomponent subunit C,C1QC,,unknown
Alefacept,~270 hours,Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Alefacept,~270 hours,High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Alefacept,~270 hours,Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Alefacept,~270 hours,Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Alefacept,~270 hours,Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Alefacept,~270 hours,Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Felypressin,,Vasopressin V1a receptor,AVPR1A,agonist,yes
Urofollitropin,"Circulation half life of 3-4 hours, elimination half life of 35-40 hours",Follicle-stimulating hormone receptor,FSHR,agonist,yes
Efalizumab,5 days,Integrin alpha-L,ITGAL,antibody,yes
Efalizumab,5 days,Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Efalizumab,5 days,Complement C1r subcomponent,C1R,,unknown
Efalizumab,5 days,Complement C1q subcomponent subunit A,C1QA,,unknown
Efalizumab,5 days,Complement C1q subcomponent subunit B,C1QB,,unknown
Efalizumab,5 days,Complement C1q subcomponent subunit C,C1QC,,unknown
Efalizumab,5 days,Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Efalizumab,5 days,High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Efalizumab,5 days,Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Efalizumab,5 days,Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Efalizumab,5 days,Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Choriogonadotropin alfa,The mean terminal half-life is about 29 ± 6 hours (initial half-life is 4.5 ± 0.5 hours).,Lutropin-choriogonadotropic hormone receptor,LHCGR,,yes
Choriogonadotropin alfa,The mean terminal half-life is about 29 ± 6 hours (initial half-life is 4.5 ± 0.5 hours).,Follicle-stimulating hormone receptor,FSHR,binder,yes
Antithymocyte immunoglobulin (rabbit),"2-3 days, may increase after multiple doses administration",T-cell surface glycoprotein CD1a,CD1A,inhibitor,unknown
Antithymocyte immunoglobulin (rabbit),"2-3 days, may increase after multiple doses administration",Major histocompatibility complex class I-related gene protein,MR1,antagonist,yes
Antithymocyte immunoglobulin (rabbit),"2-3 days, may increase after multiple doses administration",Integrin alpha-L,ITGAL,,yes
Antithymocyte immunoglobulin (rabbit),"2-3 days, may increase after multiple doses administration",T-lymphocyte activation antigen CD86,CD86,,yes
Antithymocyte immunoglobulin (rabbit),"2-3 days, may increase after multiple doses administration",Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,yes
Antithymocyte immunoglobulin (rabbit),"2-3 days, may increase after multiple doses administration",T-cell surface glycoprotein CD4,CD4,,yes
Antithymocyte immunoglobulin (rabbit),"2-3 days, may increase after multiple doses administration",Integrin beta-1,ITGB1,,yes
Antithymocyte immunoglobulin (rabbit),"2-3 days, may increase after multiple doses administration",Integrin alpha-V,ITGAV,,yes
Antithymocyte immunoglobulin (rabbit),"2-3 days, may increase after multiple doses administration",Integrin beta-3,ITGB3,,yes
Filgrastim,"Elimination half-life, healthy subjects and cancer patients, Neopogen = 3.5 hours;
Elimination half-life, cancer patients, tbo-filgrastim = 3.2-3.8 hours",Granulocyte colony-stimulating factor receptor,CSF3R,stimulator,yes
Filgrastim,"Elimination half-life, healthy subjects and cancer patients, Neopogen = 3.5 hours;
Elimination half-life, cancer patients, tbo-filgrastim = 3.2-3.8 hours",Neutrophil elastase,ELANE,other/unknown,unknown
Coagulation Factor IX (Recombinant),18.8 ± 5.4 hours,Coagulation factor X,F10,activator,yes
Coagulation Factor IX (Recombinant),18.8 ± 5.4 hours,Coagulation factor XI,F11,ligand,yes
Coagulation Factor IX (Recombinant),18.8 ± 5.4 hours,Coagulation factor VII,F7,ligand,yes
Coagulation Factor IX (Recombinant),18.8 ± 5.4 hours,Coagulation factor VIII,F8,cofactor,yes
Coagulation Factor IX (Recombinant),18.8 ± 5.4 hours,Prothrombin,F2,,unknown
Coagulation Factor IX (Recombinant),18.8 ± 5.4 hours,Prolow-density lipoprotein receptor-related protein 1,LRP1,,unknown
Coagulation Factor IX (Recombinant),18.8 ± 5.4 hours,Vitamin K-dependent gamma-carboxylase,GGCX,,unknown
Becaplermin,,Platelet-derived growth factor receptor beta,PDGFRB,,yes
Becaplermin,,Platelet-derived growth factor receptor alpha,PDGFRA,,unknown
Becaplermin,,Alpha-2-macroglobulin,A2M,,unknown
Agalsidase beta,45-102 min,Globotriaosylceramide,,ligand,yes
Octreotide,,Somatostatin receptor type 1,SSTR1,,yes
Octreotide,,Somatostatin receptor type 5,SSTR5,,yes
Octreotide,,Somatostatin receptor type 2,SSTR2,binder,yes
"Interferon Alfa-2b, Recombinant",The elimination half-life following both intramuscular and subcutaneous injections was approximately 2 to 3 hours. The elimination half-life was approximately 2 hours following intravenous injection.,Interferon alpha/beta receptor 2,IFNAR2,binder,yes
"Interferon Alfa-2b, Recombinant",The elimination half-life following both intramuscular and subcutaneous injections was approximately 2 to 3 hours. The elimination half-life was approximately 2 hours following intravenous injection.,Interferon alpha/beta receptor 1,IFNAR1,binder,yes
Abarelix,13.2 &plusmn; 3.2 days,Gonadotropin-releasing hormone receptor,GNRHR,antagonist,yes
Oxytocin,"1-6 min, this is decreased in late pregnancy and during lactation.",Oxytocin receptor,OXTR,agonist,yes
Oxytocin,"1-6 min, this is decreased in late pregnancy and during lactation.",Oxytocin-neurophysin 1,OXT,binder,unknown
Natalizumab,11 ± 4 days,Integrin alpha-4,ITGA4,antibody,yes
Natalizumab,11 ± 4 days,Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Natalizumab,11 ± 4 days,Complement C1r subcomponent,C1R,,unknown
Natalizumab,11 ± 4 days,Complement C1q subcomponent subunit A,C1QA,,unknown
Natalizumab,11 ± 4 days,Complement C1q subcomponent subunit B,C1QB,,unknown
Natalizumab,11 ± 4 days,Complement C1q subcomponent subunit C,C1QC,,unknown
Natalizumab,11 ± 4 days,Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Natalizumab,11 ± 4 days,High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Natalizumab,11 ± 4 days,Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Natalizumab,11 ± 4 days,Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Natalizumab,11 ± 4 days,Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Natalizumab,11 ± 4 days,Intercellular adhesion molecule 1,ICAM1,,unknown
Enfuvirtide,3.8 +/- 0.6 hrs,Envelope glycoprotein,gp41,,yes
Palivizumab,18-20 days (in adults),Fusion glycoprotein F0,F,,yes
Palivizumab,18-20 days (in adults),Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Palivizumab,18-20 days (in adults),Complement C1r subcomponent,C1R,,unknown
Palivizumab,18-20 days (in adults),Complement C1q subcomponent subunit A,C1QA,,unknown
Palivizumab,18-20 days (in adults),Complement C1q subcomponent subunit B,C1QB,,unknown
Palivizumab,18-20 days (in adults),Complement C1q subcomponent subunit C,C1QC,,unknown
Palivizumab,18-20 days (in adults),Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Palivizumab,18-20 days (in adults),High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Palivizumab,18-20 days (in adults),Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Palivizumab,18-20 days (in adults),Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Palivizumab,18-20 days (in adults),Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Daclizumab,11-38 days,Interleukin-2 receptor subunit alpha,IL2RA,antibody,yes
Daclizumab,11-38 days,Interleukin-2 receptor subunit beta,IL2RB,antibody,yes
Daclizumab,11-38 days,Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Daclizumab,11-38 days,Complement C1r subcomponent,C1R,,unknown
Daclizumab,11-38 days,Complement C1q subcomponent subunit A,C1QA,,unknown
Daclizumab,11-38 days,Complement C1q subcomponent subunit B,C1QB,,unknown
Daclizumab,11-38 days,Complement C1q subcomponent subunit C,C1QC,,unknown
Daclizumab,11-38 days,Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Daclizumab,11-38 days,High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Daclizumab,11-38 days,Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Daclizumab,11-38 days,Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Daclizumab,11-38 days,Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Bevacizumab,approximately 20 days (range: 11–50 days),Vascular endothelial growth factor A,VEGFA,,yes
Bevacizumab,approximately 20 days (range: 11–50 days),Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,,unknown
Bevacizumab,approximately 20 days (range: 11–50 days),Complement C1r subcomponent,C1R,,unknown
Bevacizumab,approximately 20 days (range: 11–50 days),Complement C1q subcomponent subunit A,C1QA,,unknown
Bevacizumab,approximately 20 days (range: 11–50 days),Complement C1q subcomponent subunit B,C1QB,,unknown
Bevacizumab,approximately 20 days (range: 11–50 days),Complement C1q subcomponent subunit C,C1QC,,unknown
Bevacizumab,approximately 20 days (range: 11–50 days),Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,,unknown
Bevacizumab,approximately 20 days (range: 11–50 days),High affinity immunoglobulin gamma Fc receptor I,FCGR1A,,unknown
Bevacizumab,approximately 20 days (range: 11–50 days),Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,,unknown
Bevacizumab,approximately 20 days (range: 11–50 days),Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,,unknown
Bevacizumab,approximately 20 days (range: 11–50 days),Low affinity immunoglobulin gamma Fc region receptor II-c,FCGR2C,,unknown
Technetium Tc-99m arcitumomab,Approximately 1 hour,Carcinoembryonic antigen-related cell adhesion molecule 1,CEACAM1,other/unknown,unknown
Pyridoxal Phosphate,,"Alanine--glyoxylate aminotransferase 2, mitochondrial",AGXT2,cofactor,unknown
Pyridoxal Phosphate,,Glutamate decarboxylase 1,GAD1,cofactor,unknown
Pyridoxal Phosphate,,Cystathionine beta-synthase,CBS,cofactor,unknown
Pyridoxal Phosphate,,Kynureninase,KYNU,cofactor,unknown
Pyridoxal Phosphate,,"Serine hydroxymethyltransferase, cytosolic",SHMT1,cofactor,unknown
Pyridoxal Phosphate,,"Cysteine desulfurase, mitochondrial",NFS1,cofactor,unknown
Pyridoxal Phosphate,,"Aspartate aminotransferase, cytoplasmic",GOT1,activator,unknown
Pyridoxal Phosphate,,"Ornithine aminotransferase, mitochondrial",OAT,cofactor,unknown
Pyridoxal Phosphate,,Ornithine decarboxylase,ODC1,cofactor,unknown
Pyridoxal Phosphate,,"Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial",AADAT,cofactor,unknown
Pyridoxal Phosphate,,"4-aminobutyrate aminotransferase, mitochondrial",ABAT,inhibitor,unknown
Pyridoxal Phosphate,,Pyridoxine-5'-phosphate oxidase,PNPO,cofactor,unknown
Pyridoxal Phosphate,,Sphingosine-1-phosphate lyase 1,SGPL1,cofactor,unknown
Pyridoxal Phosphate,,Tyrosine aminotransferase,TAT,cofactor,unknown
Pyridoxal Phosphate,,Kynurenine--oxoglutarate transaminase 1,CCBL1,cofactor,unknown
Pyridoxal Phosphate,,Threonine synthase-like 1,THNSL1,cofactor,unknown
Pyridoxal Phosphate,,"Glycogen phosphorylase, liver form",PYGL,cofactor,unknown
Pyridoxal Phosphate,,Serine palmitoyltransferase 2,SPTLC2,cofactor,unknown
Pyridoxal Phosphate,,Cysteine sulfinic acid decarboxylase,CSAD,cofactor,unknown
Pyridoxal Phosphate,,Histidine decarboxylase,HDC,cofactor,unknown
Pyridoxal Phosphate,,Arginine decarboxylase,AZIN2,cofactor,unknown
Pyridoxal Phosphate,,L-serine dehydratase/L-threonine deaminase,SDS,cofactor,unknown
Pyridoxal Phosphate,,"2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial",GCAT,cofactor,unknown
Pyridoxal Phosphate,,"Glycine dehydrogenase [decarboxylating], mitochondrial",GLDC,cofactor,unknown
Pyridoxal Phosphate,,Alanine aminotransferase 1,GPT,cofactor,unknown
Pyridoxal Phosphate,,Phosphoserine aminotransferase,PSAT1,cofactor,unknown
Pyridoxal Phosphate,,"5-aminolevulinate synthase, nonspecific, mitochondrial",ALAS1,cofactor,unknown
Pyridoxal Phosphate,,Serine--pyruvate aminotransferase,AGXT,cofactor,unknown
Pyridoxal Phosphate,,Pyridoxal phosphate phosphatase,PDXP,cofactor,unknown
Pyridoxal Phosphate,,Serine palmitoyltransferase 1,SPTLC1,cofactor,unknown
Pyridoxal Phosphate,,Cystathionine gamma-lyase,CTH,cofactor,unknown
Pyridoxal Phosphate,,"Branched-chain-amino-acid aminotransferase, cytosolic",BCAT1,cofactor,unknown
Pyridoxal Phosphate,,"Branched-chain-amino-acid aminotransferase, mitochondrial",BCAT2,cofactor,unknown
Pyridoxal Phosphate,,Proline synthase co-transcribed bacterial homolog protein,PROSC,cofactor,unknown
Pyridoxal Phosphate,,Formimidoyltransferase-cyclodeaminase,FTCD,cofactor,unknown
Pyridoxal Phosphate,,"Aspartate aminotransferase, mitochondrial",GOT2,cofactor,unknown
Pyridoxal Phosphate,,"Glycogen phosphorylase, brain form",PYGB,cofactor,unknown
Pyridoxal Phosphate,,"Glycogen phosphorylase, muscle form",PYGM,cofactor,unknown
Pyridoxal Phosphate,,Aromatic-L-amino-acid decarboxylase,DDC,cofactor,unknown
Pyridoxal Phosphate,,Aspartate aminotransferase,GIG18,cofactor,unknown
Pyridoxal Phosphate,,GAD1 protein,GAD1,cofactor,unknown
Pyridoxal Phosphate,,Serine hydroxymethyltransferase,,cofactor,unknown
Pyridoxal Phosphate,,Selenocysteine lyase variant,,cofactor,unknown
Pyridoxal Phosphate,,Phosphorylase,,cofactor,unknown
Pyridoxal Phosphate,,Ornithine aminotransferase variant,,cofactor,unknown
Pyridoxal Phosphate,,5-aminolevulinate synthase,ALAS1,cofactor,unknown
Pyridoxal Phosphate,,"Glutamate decarboxylase 2 (Pancreatic islets and brain, 65kDa)",GAD2,cofactor,unknown
Pyridoxal Phosphate,,DDC protein,DDC,cofactor,unknown
Pyridoxal Phosphate,,Pyridoxal-dependent decarboxylase domain-containing protein 1,PDXDC1,cofactor,unknown
Pyridoxal Phosphate,,Kynurenine--oxoglutarate transaminase 3,CCBL2,cofactor,unknown
Pyridoxal Phosphate,,Glutamate decarboxylase-like protein 1,GADL1,cofactor,unknown
Pyridoxal Phosphate,,Selenocysteine lyase,SCLY,cofactor,unknown
Pyridoxal Phosphate,,Immunoglobulin superfamily member 10,IGSF10,cofactor,unknown
Pyridoxal Phosphate,,5-phosphohydroxy-L-lysine phospho-lyase,PHYKPL,cofactor,unknown
Pyridoxal Phosphate,,"Glutamate decarboxylase 1 (Brain, 67kDa)",GAD1,cofactor,unknown
Pyridoxal Phosphate,,"Serine hydroxymethyltransferase, mitochondrial",SHMT2,cofactor,unknown
Pyridoxal Phosphate,,"5-aminolevulinate synthase, erythroid-specific, mitochondrial",ALAS2,cofactor,unknown
Pyridoxal Phosphate,,Alanine aminotransferase 2,GPT2,cofactor,unknown
Pyridoxal Phosphate,,Molybdenum cofactor sulfurase,MOCOS,cofactor,unknown
Pyridoxal Phosphate,,Serine dehydratase-like,SDSL,cofactor,unknown
Pyridoxal Phosphate,,P-selectin cytoplasmic tail-associated protein (PCAP),pcap,cofactor,unknown
Pyridoxal Phosphate,,Hepatic peroxysomal alanine:glyoxylate aminotransferase,,cofactor,unknown
Pyridoxal Phosphate,,Serine racemase,SRR,cofactor,unknown
Pyridoxal Phosphate,,O-phosphoseryl-tRNA(Sec) selenium transferase,SEPSECS,cofactor,unknown
Pyridoxal Phosphate,,Serine palmitoyltransferase 3,SPTLC3,cofactor,unknown
Pyridoxal Phosphate,,Glutamic acid decarboxylase,GAD65,cofactor,unknown
Pyridoxal Phosphate,,Alanine-glyoxylate aminotransferase homolog,TLH6,cofactor,unknown
Cyanocobalamin,Approximately 6 days (400 days in the liver).,Methionine synthase,MTR,cofactor,yes
Cyanocobalamin,Approximately 6 days (400 days in the liver).,"Methylmalonyl-CoA mutase, mitochondrial",MUT,cofactor,yes
Cyanocobalamin,Approximately 6 days (400 days in the liver).,Methionine synthase reductase,MTRR,cofactor,unknown
Cyanocobalamin,Approximately 6 days (400 days in the liver).,"Methylmalonic aciduria type A protein, mitochondrial",MMAA,cofactor,unknown
Cyanocobalamin,Approximately 6 days (400 days in the liver).,Methylmalonic aciduria and homocystinuria type C protein,MMACHC,cofactor,unknown
Cyanocobalamin,Approximately 6 days (400 days in the liver).,Methylenetetrahydrofolate reductase,MTHFR,cofactor,unknown
Tetrahydrofolic acid,,"C-1-tetrahydrofolate synthase, cytoplasmic",MTHFD1,cofactor,unknown
Tetrahydrofolic acid,,"Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial",MTHFD2,cofactor,unknown
Tetrahydrofolic acid,,"Aminomethyltransferase, mitochondrial",AMT,cofactor,unknown
Tetrahydrofolic acid,,Cytosolic 10-formyltetrahydrofolate dehydrogenase,ALDH1L1,cofactor,unknown
Tetrahydrofolic acid,,Methionine synthase,MTR,cofactor,unknown
Tetrahydrofolic acid,,Formimidoyltransferase-cyclodeaminase,FTCD,cofactor,unknown
Tetrahydrofolic acid,,Bifunctional purine biosynthesis protein PURH,ATIC,cofactor,unknown
Tetrahydrofolic acid,,"Serine hydroxymethyltransferase, cytosolic",SHMT1,cofactor,unknown
Tetrahydrofolic acid,,"Serine hydroxymethyltransferase, mitochondrial",SHMT2,cofactor,unknown
Tetrahydrofolic acid,,Methylenetetrahydrofolate reductase,MTHFR,cofactor,unknown
Tetrahydrofolic acid,,Serine hydroxymethyltransferase,,cofactor,unknown
Tetrahydrofolic acid,,"Methionyl-tRNA formyltransferase, mitochondrial",MTFMT,cofactor,unknown
Histidine,,Histidine decarboxylase,HDC,,unknown
Histidine,,"Histidine--tRNA ligase, cytoplasmic",HARS,,unknown
Histidine,,Sodium-coupled neutral amino acid transporter 3,SLC38A3,,unknown
Histidine,,Histidine ammonia-lyase,HAL,,unknown
Ademetionine,,Glycine N-methyltransferase,GNMT,cofactor,unknown
Ademetionine,,S-adenosylmethionine decarboxylase proenzyme,AMD1,cofactor,unknown
Ademetionine,,S-adenosylmethionine synthase isoform type-2,MAT2A,cofactor,unknown
Ademetionine,,Cystathionine beta-synthase,CBS,activator,unknown
Ademetionine,,S-adenosylmethionine synthase isoform type-1,MAT1A,cofactor,unknown
Ademetionine,,Catechol O-methyltransferase,COMT,cofactor,unknown
Ademetionine,,Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1,CMTR1,,unknown
Ademetionine,,Arsenite methyltransferase,AS3MT,,unknown
Pyruvic acid,,Monocarboxylate transporter 4,SLC16A3,,unknown
Pyruvic acid,,Monocarboxylate transporter 8,SLC16A2,,unknown
Pyruvic acid,,"Alanine--glyoxylate aminotransferase 2, mitochondrial",AGXT2,,unknown
Pyruvic acid,,Monocarboxylate transporter 6,SLC16A5,,unknown
Pyruvic acid,,Pyruvate kinase PKLR,PKLR,,unknown
Pyruvic acid,,Monocarboxylate transporter 7,SLC16A6,,unknown
Pyruvic acid,,Monocarboxylate transporter 2,SLC16A7,,unknown
Pyruvic acid,,"Pyruvate dehydrogenase E1 component subunit beta, mitochondrial",PDHB,,unknown
Pyruvic acid,,Pyruvate kinase PKM,PKM,,unknown
Pyruvic acid,,"4-aminobutyrate aminotransferase, mitochondrial",ABAT,inhibitor,unknown
Pyruvic acid,,Monocarboxylate transporter 5,SLC16A4,,unknown
Pyruvic acid,,Monocarboxylate transporter 3,SLC16A8,,unknown
Pyruvic acid,,Monocarboxylate transporter 1,SLC16A1,,unknown
Pyruvic acid,,"Pyruvate carboxylase, mitochondrial",PC,,unknown
L-Phenylalanine,,Tyrosine aminotransferase,TAT,,unknown
L-Phenylalanine,,Large neutral amino acids transporter small subunit 2,SLC7A8,,unknown
L-Phenylalanine,,Phenylalanine--tRNA ligase alpha subunit,FARSA,,unknown
L-Phenylalanine,,Phenylalanine-4-hydroxylase,PAH,,unknown
L-Phenylalanine,,"Phenylalanine--tRNA ligase, mitochondrial",FARS2,,unknown
L-Phenylalanine,,Phenylalanine--tRNA ligase beta subunit,FARSB,,unknown
L-Phenylalanine,,Tyrosine 3-monooxygenase,TH,binder,unknown
Biotin,,"Propionyl-CoA carboxylase beta chain, mitochondrial",PCCB,,unknown
Biotin,,Biotin--protein ligase,HLCS,,unknown
Biotin,,Sodium-dependent multivitamin transporter,SLC5A6,,unknown
Biotin,,"Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial",MCCC2,,unknown
Biotin,,Acetyl-CoA carboxylase 2,ACACB,,unknown
Biotin,,"Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial",MCCC1,,unknown
Biotin,,"Pyruvate carboxylase, mitochondrial",PC,,unknown
Biotin,,"Propionyl-CoA carboxylase alpha chain, mitochondrial",PCCA,,unknown
Biotin,,Acetyl-CoA carboxylase 1,ACACA,,unknown
Choline,,Choline-phosphate cytidylyltransferase B,PCYT1B,product of,unknown
Choline,,Acetylcholinesterase,ACHE,product of,unknown
Choline,,Choline-phosphate cytidylyltransferase A,PCYT1A,product of,unknown
Choline,,Phospholipase D2,PLD2,product of,unknown
Choline,,Cholinesterase,BCHE,product of,unknown
Choline,,Phospholipase D1,PLD1,product of,unknown
Choline,,Phosphoethanolamine/phosphocholine phosphatase,PHOSPHO1,product of,unknown
Choline,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,,unknown
L-Lysine,,High affinity cationic amino acid transporter 1,SLC7A1,,unknown
L-Lysine,,Cationic amino acid transporter 4,SLC7A4,,unknown
L-Lysine,,Cationic amino acid transporter 3,SLC7A3,,unknown
L-Lysine,,Low affinity cationic amino acid transporter 2,SLC7A2,,unknown
L-Lysine,,Lysine--tRNA ligase,KARS,,unknown
L-Arginine,,"Nitric oxide synthase, endothelial",NOS3,,unknown
L-Arginine,,Cationic amino acid transporter 3,SLC7A3,,unknown
L-Arginine,,Arginine decarboxylase,AZIN2,,unknown
L-Arginine,,Argininosuccinate lyase,ASL,,unknown
L-Arginine,,"Nitric oxide synthase, inducible",NOS2,,unknown
L-Arginine,,High affinity cationic amino acid transporter 1,SLC7A1,,unknown
L-Arginine,,"Arginase-2, mitochondrial",ARG2,,unknown
L-Arginine,,Cationic amino acid transporter 4,SLC7A4,,unknown
L-Arginine,,Argininosuccinate synthase,ASS1,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Lactase-phlorizin hydrolase,LCT,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Hyaluronate lyase,,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),DNA,,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Xylose isomerase,xylA,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2",PLOD2,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),"Phytanoyl-CoA dioxygenase, peroxisomal",PHYH,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3",PLOD3,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Gamma-butyrobetaine dioxygenase,BBOX1,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Dopamine beta-hydroxylase,DBH,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Peptidyl-glycine alpha-amidating monooxygenase,PAM,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Prolyl 4-hydroxylase subunit alpha-1,P4HA1,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Prolyl 3-hydroxylase 1,P3H1,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2,OGFOD2,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Alpha-ketoglutarate-dependent dioxygenase alkB homolog 2,ALKBH2,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Prolyl 3-hydroxylase 2,P3H2,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Prolyl 3-hydroxylase 3,P3H3,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),2-oxoglutarate and iron-dependent oxygenase domain-containing protein 1,OGFOD1,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Egl nine homolog 2,EGLN2,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3,ALKBH3,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Lysine-specific demethylase 5D,KDM5D,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Egl nine homolog 1,EGLN1,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Solute carrier family 23 member 1,SLC23A1,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1",PLOD1,activator,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Egl nine homolog 3,EGLN3,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),"Trimethyllysine dioxygenase, mitochondrial",TMLHE,,unknown
Vitamin C,16 days (3.4 hours in people who have excess levels of vitamin C),Transmembrane prolyl 4-hydroxylase,P4HTM,,unknown
Spermine,,Spermine synthase,SMS,ligand,yes
Spermine,,Spermine oxidase,SMOX,ligand,yes
Spermine,,DNA,,binder,yes
Spermine,,Ornithine decarboxylase,ODC1,product of,unknown
Spermine,,Extracellular calcium-sensing receptor,CASR,,unknown
Spermine,,Beta-1 adrenergic receptor,ADRB1,,unknown
Spermine,,Beta-2 adrenergic receptor,ADRB2,,unknown
L-Aspartic Acid,,Ribonuclease pancreatic,RNASE1,,unknown
L-Aspartic Acid,,Lysozyme C,LYZ,,unknown
L-Aspartic Acid,,Calcium-binding mitochondrial carrier protein Aralar2,SLC25A13,,unknown
L-Aspartic Acid,,"Aspartate aminotransferase, cytoplasmic",GOT1,,unknown
L-Aspartic Acid,,Aspartoacylase,ASPA,,unknown
L-Aspartic Acid,,Asparagine synthetase [glutamine-hydrolyzing],ASNS,,unknown
L-Aspartic Acid,,Argininosuccinate synthase,ASS1,,unknown
L-Aspartic Acid,,Aminoacylase-1,ACY1,,unknown
L-Aspartic Acid,,"Aspartate aminotransferase, mitochondrial",GOT2,,unknown
L-Aspartic Acid,,"Aspartate--tRNA ligase, cytoplasmic",DARS,,unknown
L-Aspartic Acid,,Calcium-binding mitochondrial carrier protein Aralar1,SLC25A12,,unknown
L-Aspartic Acid,,Aspartyl/asparaginyl beta-hydroxylase,ASPH,,unknown
L-Aspartic Acid,,Multifunctional protein ADE2,PAICS,,unknown
L-Aspartic Acid,,CAD protein,CAD,,unknown
L-Aspartic Acid,,Adenylosuccinate synthetase isozyme 2,ADSS,,unknown
L-Aspartic Acid,,Excitatory amino acid transporter 3,SLC1A1,,unknown
L-Aspartic Acid,,Aspartate aminotransferase,GIG18,,unknown
L-Aspartic Acid,,"Argininosuccinate synthetase, isoform CRA_a",ASS,,unknown
L-Aspartic Acid,,"Aspartate--tRNA ligase, mitochondrial",DARS2,,unknown
L-Aspartic Acid,,Isoaspartyl peptidase/L-asparaginase,ASRGL1,,unknown
L-Aspartic Acid,,Adenylosuccinate synthetase isozyme 1,ADSSL1,,unknown
L-Aspartic Acid,,Aspartoacylase-2,ACY3,,unknown
Ornithine,,"Ornithine aminotransferase, mitochondrial",OAT,,unknown
Ornithine,,"Ornithine carbamoyltransferase, mitochondrial",OTC,,unknown
Ornithine,,Arginase-1,ARG1,,unknown
Ornithine,,Ornithine decarboxylase antizyme 1,OAZ1,,unknown
Ornithine,,Low affinity cationic amino acid transporter 2,SLC7A2,,unknown
Ornithine,,Mitochondrial ornithine transporter 2,SLC25A2,,unknown
Ornithine,,Cationic amino acid transporter 4,SLC7A4,,unknown
Ornithine,,High affinity cationic amino acid transporter 1,SLC7A1,,unknown
Ornithine,,"Arginase-2, mitochondrial",ARG2,,unknown
Ornithine,,Mitochondrial ornithine transporter 1,SLC25A15,,unknown
Ornithine,,Cationic amino acid transporter 3,SLC7A3,,unknown
Ornithine,,Ornithine decarboxylase antizyme 2,OAZ2,,unknown
Ornithine,,"Glycine amidinotransferase, mitochondrial",GATM,,unknown
Ornithine,,Ornithine decarboxylase antizyme 3,OAZ3,,unknown
L-Glutamine,The half life of elimination is 1 h [FDA Label].,CTP synthase 1,CTPS1,antagonist,unknown
L-Glutamine,The half life of elimination is 1 h [FDA Label].,Amidophosphoribosyltransferase,PPAT,product of,unknown
L-Glutamine,The half life of elimination is 1 h [FDA Label].,Glutamine synthetase,GLUL,product of,unknown
Adenosine monophosphate,,Cyclic AMP-responsive element-binding protein 1,CREB1,activator,unknown
Adenosine monophosphate,,DNA,,component of,unknown
Adenosine monophosphate,,Serine/threonine-protein kinase pim-1,PIM1,product of,unknown
Adenosine monophosphate,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,product of,unknown
Adenosine monophosphate,,"Glycogen phosphorylase, liver form",PYGL,activator,unknown
Adenosine monophosphate,,5'-AMP-activated protein kinase subunit beta-1,PRKAB1,activator,unknown
Adenosine monophosphate,,Histidine triad nucleotide-binding protein 1,HINT1,product of,unknown
Adenosine monophosphate,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,product of,unknown
Adenosine monophosphate,,"Acetyl-coenzyme A synthetase 2-like, mitochondrial",ACSS1,product of,unknown
Adenosine monophosphate,,"Acetyl-coenzyme A synthetase, cytoplasmic",ACSS2,product of,unknown
Adenosine monophosphate,,5'-AMP-activated protein kinase catalytic subunit alpha-1,PRKAA1,activator,unknown
Adenosine monophosphate,,5'-AMP-activated protein kinase subunit beta-2,PRKAB2,activator,unknown
Adenosine monophosphate,,Adenylate cyclase type 1,ADCY1,product of,unknown
Adenosine monophosphate,,Long-chain-fatty-acid--CoA ligase 1,ACSL1,product of,unknown
Adenosine monophosphate,,"Fructose-1,6-bisphosphatase 1",FBP1,antagonistinhibitory allosteric modulator,unknown
Adenosine monophosphate,,Adenosine kinase,ADK,product of,unknown
Alpha-Linolenic Acid,,Fatty acid desaturase 1,FADS1,ligand,yes
Alpha-Linolenic Acid,,Fatty acid desaturase 2,FADS2,ligand,yes
Alpha-Linolenic Acid,,Sodium/calcium exchanger 1,SLC8A1,,unknown
Alpha-Linolenic Acid,,Transient receptor potential cation channel subfamily V member 1,TRPV1,,unknown
Alpha-Linolenic Acid,,Elongation of very long chain fatty acids protein 4,ELOVL4,,unknown
Alpha-Linolenic Acid,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Alpha-Linolenic Acid,,Bile acid receptor,NR1H4,agonist,unknown
Alpha-Linolenic Acid,,Peroxisome proliferator-activated receptor delta,PPARD,,unknown
Alpha-Linolenic Acid,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Alpha-Linolenic Acid,,Retinoic acid receptor RXR-alpha,RXRA,,unknown
Serine,,Cystathionine beta-synthase,CBS,,unknown
Serine,,L-serine dehydratase/L-threonine deaminase,SDS,,unknown
Serine,,Serine racemase,SRR,,unknown
Serine,,Serine palmitoyltransferase 2,SPTLC2,,unknown
Serine,,Serine palmitoyltransferase 1,SPTLC1,,unknown
Serine,,"Serine--tRNA ligase, cytoplasmic",SARS,,unknown
Serine,,Serine--pyruvate aminotransferase,AGXT,,unknown
Methionine,,Methionine synthase reductase,MTRR,product of,unknown
Methionine,,Methionine synthase,MTR,product of,unknown
Methionine,,Methionine aminopeptidase 2,METAP2,product of,unknown
Methionine,,Betaine--homocysteine S-methyltransferase 1,BHMT,product of,unknown
Methionine,,S-methylmethionine--homocysteine S-methyltransferase BHMT2,BHMT2,product of,unknown
L-Tyrosine,,Tyrosine 3-monooxygenase,TH,binder,unknown
L-Tyrosine,,"Tyrosine--tRNA ligase, mitochondrial",YARS2,,unknown
L-Tyrosine,,"Tyrosine--tRNA ligase, cytoplasmic",YARS,,unknown
L-Tyrosine,,Tyrosine aminotransferase,TAT,,unknown
Calcitriol,5-8 hours,Vitamin D3 receptor,VDR,antagonist,yes
Calcitriol,5-8 hours,Homeobox protein Hox-A10,HOXA10,,unknown
Calcitriol,5-8 hours,Vitamin D-binding protein,GC,,unknown
Cystine,,Cystine/glutamate transporter,SLC7A11,,unknown
Cystine,,Cystinosin,CTNS,,unknown
Cystine,,"B(0,+)-type amino acid transporter 1",SLC7A9,,unknown
Cystine,,Neutral and basic amino acid transport protein rBAT,SLC3A1,,unknown
Succinic acid,,"Succinate dehydrogenase cytochrome b560 subunit, mitochondrial",SDHC,,unknown
Succinic acid,,Succinate receptor 1,SUCNR1,,unknown
Succinic acid,,"Succinyl-CoA:3-ketoacid coenzyme A transferase 2, mitochondrial",OXCT2,,unknown
Succinic acid,,"Trimethyllysine dioxygenase, mitochondrial",TMLHE,,unknown
Succinic acid,,"Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial",SUCLA2,,unknown
Succinic acid,,Mitochondrial dicarboxylate carrier,SLC25A10,,unknown
Succinic acid,,"Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial",SDHA,,unknown
Succinic acid,,17-beta-hydroxysteroid dehydrogenase type 6,HSD17B6,,unknown
Succinic acid,,Solute carrier family 13 member 3,SLC13A3,,unknown
Succinic acid,,Solute carrier family 13 member 2,SLC13A2,,unknown
Succinic acid,,Solute carrier family 13 member 1,SLC13A1,,unknown
Succinic acid,,"Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial",SUCLG2,,unknown
Succinic acid,,"Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial",SDHD,,unknown
Succinic acid,,Prolyl 4-hydroxylase subunit alpha-2,P4HA2,,unknown
Succinic acid,,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3",PLOD3,,unknown
Succinic acid,,Gamma-butyrobetaine dioxygenase,BBOX1,,unknown
Succinic acid,,Prolyl 4-hydroxylase subunit alpha-1,P4HA1,,unknown
Succinic acid,,"Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial",SDHB,,unknown
Succinic acid,,"Succinate-semialdehyde dehydrogenase, mitochondrial",ALDH5A1,inhibitor,unknown
Succinic acid,,"Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial",SUCLG1,,unknown
Succinic acid,,"Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial",OXCT1,,unknown
Succinic acid,,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1",PLOD1,,unknown
Succinic acid,,Aspartyl/asparaginyl beta-hydroxylase,ASPH,,unknown
Succinic acid,,Prolyl 3-hydroxylase 1,P3H1,,unknown
Succinic acid,,Prolyl 3-hydroxylase 2,P3H2,,unknown
Succinic acid,,Prolyl 3-hydroxylase 3,P3H3,,unknown
Riboflavin,66-84 minutes,Riboflavin kinase,RFK,ligand,yes
Riboflavin,66-84 minutes,Riboflavin synthase,ribC,other,yes
Riboflavin,66-84 minutes,Flavin reductase (NADPH),BLVRB,product of,yes
N-Acetylglucosamine,,"Beta-1,4-galactosyltransferase 3",B4GALT3,,unknown
N-Acetylglucosamine,,"Beta-1,4-galactosyltransferase 4",B4GALT4,,unknown
N-Acetylglucosamine,,"Beta-1,4-galactosyltransferase 2",B4GALT2,,unknown
N-Acetylglucosamine,,N-acetyl-D-glucosamine kinase,NAGK,,unknown
N-Acetylglucosamine,,N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase,NAGPA,,unknown
N-Acetylglucosamine,,Alpha-N-acetylglucosaminidase,NAGLU,activator,unknown
N-Acetylglucosamine,,N-acylglucosamine 2-epimerase,RENBP,,unknown
N-Acetylglucosamine,,"Beta-1,4-galactosyltransferase 1",B4GALT1,,unknown
Glutamic Acid,,Metabotropic glutamate receptor 1,GRM1,,unknown
Glutamic Acid,,Metabotropic glutamate receptor 4,GRM4,,unknown
Glutamic Acid,,"Glutamate receptor ionotropic, kainate 4",GRIK4,,unknown
Glutamic Acid,,"Glutamate receptor ionotropic, kainate 5",GRIK5,,unknown
Glutamic Acid,,Metabotropic glutamate receptor 7,GRM7,,unknown
Glutamic Acid,,Metabotropic glutamate receptor 8,GRM8,,unknown
Glutamic Acid,,Excitatory amino acid transporter 5,SLC1A7,,unknown
Glutamic Acid,,5-oxoprolinase,OPLAH,,unknown
Glutamic Acid,,Phosphoribosylformylglycinamidine synthase,PFAS,,unknown
Glutamic Acid,,"Branched-chain-amino-acid aminotransferase, mitochondrial",BCAT2,,unknown
Glutamic Acid,,"Glutamate receptor ionotropic, NMDA 2D",GRIN2D,,unknown
Glutamic Acid,,"Glutamate receptor ionotropic, delta-2",GRID2,,unknown
Glutamic Acid,,"Glutamate receptor ionotropic, NMDA 3B",GRIN3B,,unknown
Glutamic Acid,,"Glutamyl-tRNA(Gln) amidotransferase subunit B, mitochondrial",GATB,,unknown
Glutamic Acid,,"Glutaminase kidney isoform, mitochondrial",GLS,,unknown
Glutamic Acid,,"Aspartate aminotransferase, mitochondrial",GOT2,,unknown
Glutamic Acid,,Bifunctional glutamate/proline--tRNA ligase,EPRS,,unknown
Glutamic Acid,,Asparagine synthetase [glutamine-hydrolyzing],ASNS,,unknown
Glutamic Acid,,Glutamine synthetase,GLUL,,unknown
Glutamic Acid,,"Aspartate aminotransferase, cytoplasmic",GOT1,,unknown
Glutamic Acid,,Tyrosine aminotransferase,TAT,,unknown
Glutamic Acid,,Alanine aminotransferase 1,GPT,,unknown
Glutamic Acid,,Vitamin K-dependent gamma-carboxylase,GGCX,,unknown
Glutamic Acid,,Excitatory amino acid transporter 1,SLC1A3,,unknown
Glutamic Acid,,Excitatory amino acid transporter 2,SLC1A2,,unknown
Glutamic Acid,,Excitatory amino acid transporter 3,SLC1A1,,unknown
Glutamic Acid,,Glutamate--cysteine ligase catalytic subunit,GCLC,,unknown
Glutamic Acid,,Excitatory amino acid transporter 4,SLC1A6,,unknown
Glutamic Acid,,"Glutamate dehydrogenase 2, mitochondrial",GLUD2,,unknown
Glutamic Acid,,GMP synthase [glutamine-hydrolyzing],GMPS,,unknown
Glutamic Acid,,"Branched-chain-amino-acid aminotransferase, cytosolic",BCAT1,,unknown
Glutamic Acid,,"4-aminobutyrate aminotransferase, mitochondrial",ABAT,,unknown
Glutamic Acid,,"Glutamate receptor ionotropic, NMDA 1",GRIN1,,unknown
Glutamic Acid,,"Folylpolyglutamate synthase, mitochondrial",FPGS,,unknown
Glutamic Acid,,Glutamyl aminopeptidase,ENPEP,,unknown
Glutamic Acid,,"Glutamate receptor ionotropic, NMDA 2A",GRIN2A,,unknown
Glutamic Acid,,"Glutamate receptor ionotropic, NMDA 2B",GRIN2B,,unknown
Glutamic Acid,,"Glutamate receptor ionotropic, NMDA 2C",GRIN2C,,unknown
Glutamic Acid,,Aspartate aminotransferase,GIG18,,unknown
Glutamic Acid,,"Probable glutamate--tRNA ligase, mitochondrial",EARS2,,unknown
Glutamic Acid,,Lengsin,LGSN,,unknown
Glutamic Acid,,Glutamine-dependent NAD(+) synthetase,NADSYN1,,unknown
Glutamic Acid,,Kynurenine--oxoglutarate transaminase 3,CCBL2,,unknown
Glutamic Acid,,"N-acetylglutamate synthase, mitochondrial",NAGS,,unknown
Glutamic Acid,,"Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial",AADAT,,unknown
Glutamic Acid,,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,,unknown
Glutamic Acid,,Alanine aminotransferase 2,GPT2,,unknown
Glutamic Acid,,Mitochondrial glutamate carrier 2,SLC25A18,,unknown
Glutamic Acid,,Mitochondrial glutamate carrier 1,SLC25A22,,unknown
Glutamic Acid,,"Alpha-aminoadipic semialdehyde synthase, mitochondrial",AASS,,unknown
Glutamic Acid,,"Glutaminase liver isoform, mitochondrial",GLS2,,unknown
Glutamic Acid,,Aspartyl aminopeptidase,DNPEP,,unknown
Glutamic Acid,,"Glutamate receptor ionotropic, delta-1",GRID1,,unknown
Glutamic Acid,,Cystine/glutamate transporter,SLC7A11,,unknown
Glutamic Acid,,Carboxypeptidase Q,CPQ,,unknown
Glutamic Acid,,Phosphoserine aminotransferase,PSAT1,,unknown
Glutamic Acid,,"Glutamate dehydrogenase 1, mitochondrial",GLUD1,,unknown
Glutamic Acid,,"Glutamate receptor ionotropic, kainate 1",GRIK1,,unknown
Glutamic Acid,,Glutamate receptor 1,GRIA1,,unknown
Glutamic Acid,,Glutamate--cysteine ligase regulatory subunit,GCLM,,unknown
Glutamic Acid,,Glutamate carboxypeptidase 2,FOLH1,,unknown
Glutamic Acid,,Glutamate decarboxylase 2,GAD2,,unknown
Glutamic Acid,,Glutamate decarboxylase 1,GAD1,,unknown
Glutamic Acid,,Formimidoyltransferase-cyclodeaminase,FTCD,,unknown
Glutamic Acid,,Glutamate receptor 2,GRIA2,,unknown
Glutamic Acid,,Glutamate receptor 3,GRIA3,,unknown
Glutamic Acid,,Glutamate receptor 4,GRIA4,,unknown
Glutamic Acid,,Delta-1-pyrroline-5-carboxylate synthase,ALDH18A1,,unknown
Glutamic Acid,,"Glutamate receptor ionotropic, kainate 2",GRIK2,,unknown
Glutamic Acid,,"Glutamate receptor ionotropic, kainate 3",GRIK3,,unknown
Glutathione,,Microsomal glutathione S-transferase 3,MGST3,,unknown
Glutathione,,Hematopoietic prostaglandin D synthase,HPGDS,,unknown
Glutathione,,Thioredoxin domain-containing protein 12,TXNDC12,,unknown
Glutathione,,Glutathione S-transferase A1,GSTA1,,unknown
Glutathione,,Glutathione S-transferase A2,GSTA2,,unknown
Glutathione,,Microsomal glutathione S-transferase 1,MGST1,,unknown
Glutathione,,S-formylglutathione hydrolase,ESD,,unknown
Glutathione,,Gamma-glutamyltranspeptidase 1,GGT1,,unknown
Glutathione,,Glutathione S-transferase Mu 2,GSTM2,,unknown
Glutathione,,Glutaredoxin-1,GLRX,,unknown
Glutathione,,"Phospholipid hydroperoxide glutathione peroxidase, mitochondrial",GPX4,cofactor,unknown
Glutathione,,Glutathione S-transferase Mu 5,GSTM5,,unknown
Glutathione,,Glutathione peroxidase 6,GPX6,cofactor,unknown
Glutathione,,"Hydroxyacylglutathione hydrolase, mitochondrial",HAGH,,unknown
Glutathione,,Glutathione peroxidase,GPX1,,unknown
Glutathione,,Probable glutathione peroxidase 8,GPX8,,unknown
Glutathione,,Glutathione peroxidase 7,GPX7,cofactor,unknown
Glutathione,,Microsomal glutathione S-transferase 2,MGST2,,unknown
Glutathione,,Glutathione S-transferase omega-2,GSTO2,,unknown
Glutathione,,"Glutaredoxin-2, mitochondrial",GLRX2,,unknown
Glutathione,,Lactoylglutathione lyase,GLO1,,unknown
Glutathione,,Leukotriene C4 synthase,LTC4S,,unknown
Glutathione,,"Glutathione reductase, mitochondrial",GSR,,unknown
Glutathione,,Glutathione synthetase,GSS,,unknown
Glutathione,,Glutathione S-transferase Mu 1,GSTM1,,unknown
Glutathione,,Glutathione S-transferase kappa 1,GSTK1,,unknown
Glutathione,,Glutathione S-transferase A3,GSTA3,,unknown
Glutathione,,Glutathione S-transferase Mu 3,GSTM3,,unknown
Glutathione,,Glutathione S-transferase A4,GSTA4,,unknown
Glutathione,,Glutathione S-transferase Mu 4,GSTM4,,unknown
Glutathione,,Glutathione S-transferase A5,GSTA5,,unknown
Glutathione,,Glutathione S-transferase P,GSTP1,,unknown
Glutathione,,Glutathione S-transferase omega-1,GSTO1,,unknown
Glutathione,,Glutathione peroxidase 1,GPX1,cofactor,unknown
Glutathione,,Glutathione peroxidase 2,GPX2,cofactor,unknown
Glutathione,,Glutathione S-transferase theta-1,GSTT1,,unknown
Glutathione,,Maleylacetoacetate isomerase,GSTZ1,,unknown
Glutathione,,Epididymal secretory glutathione peroxidase,GPX5,cofactor,unknown
Glutathione,,Glutathione peroxidase 3,GPX3,cofactor,unknown
Glutathione,,Aldose reductase,AKR1B1,,unknown
Glutathione,,Matrix metalloproteinase-9,MMP9,,unknown
Glutathione,,Cytochrome P450 3A4,CYP3A4,,unknown
Phosphatidyl serine,,Diacylglycerol kinase gamma,DGKG,,unknown
Phosphatidyl serine,,Diacylglycerol kinase delta,DGKD,,unknown
Phosphatidyl serine,,Phosphatidylserine synthase 2,PTDSS2,,unknown
Phosphatidyl serine,,Sphingomyelin phosphodiesterase 4,SMPD4,,unknown
Phosphatidyl serine,,Sphingomyelin phosphodiesterase 3,SMPD3,,unknown
Phosphatidyl serine,,Probable phospholipid-transporting ATPase IA,ATP8A1,,unknown
Phosphatidyl serine,,Protein kinase C alpha type,PRKCA,,unknown
Phosphatidyl serine,,Phosphatidylserine synthase 1,PTDSS1,,unknown
Phosphatidyl serine,,Phosphatidylserine decarboxylase proenzyme,PISD,,unknown
Phosphatidyl serine,,Scavenger receptor class B member 1,SCARB1,,unknown
Glycine,,"2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial",GCAT,,unknown
Glycine,,"5-aminolevulinate synthase, nonspecific, mitochondrial",ALAS1,,unknown
Glycine,,"5-aminolevulinate synthase, erythroid-specific, mitochondrial",ALAS2,,unknown
Glycine,,"Glycine cleavage system H protein, mitochondrial",GCSH,,unknown
Glycine,,Glycine--tRNA ligase,GARS,,unknown
Glycine,,"Glutamate receptor ionotropic, NMDA 2A",GRIN2A,antagonist,unknown
Glycine,,Bile acid-CoA:amino acid N-acyltransferase,BAAT,,unknown
Glycine,,N-arachidonyl glycine receptor,GPR18,,unknown
Glycine,,Glutathione synthetase,GSS,,unknown
Glycine,,"Glutamate receptor ionotropic, NMDA 2C",GRIN2C,,unknown
Glycine,,Serine hydroxymethyltransferase,,,unknown
Glycine,,Glycine N-acyltransferase,GLYAT,,unknown
Glycine,,Proton-coupled amino acid transporter 1,SLC36A1,,unknown
Glycine,,"Serine hydroxymethyltransferase, mitochondrial",SHMT2,,unknown
Glycine,,Glycine N-acyltransferase-like protein 2,GLYATL2,,unknown
Glycine,,Glycine N-acyltransferase-like protein 1,GLYATL1,,unknown
Glycine,,"Alanine--glyoxylate aminotransferase 2, mitochondrial",AGXT2,,unknown
Glycine,,Vesicular inhibitory amino acid transporter,SLC32A1,,unknown
Glycine,,Peroxisomal sarcosine oxidase,PIPOX,,unknown
Glycine,,Sodium- and chloride-dependent glycine transporter 2,SLC6A5,,unknown
Glycine,,"Glutamate receptor ionotropic, NMDA 3B",GRIN3B,,unknown
Glycine,,"Glycine dehydrogenase [decarboxylating], mitochondrial",GLDC,,unknown
Glycine,,Sodium- and chloride-dependent glycine transporter 1,SLC6A9,,unknown
Glycine,,Glycine receptor subunit alpha-1,GLRA1,,unknown
Glycine,,Serine--pyruvate aminotransferase,AGXT,,unknown
Glycine,,Glycine receptor subunit beta,GLRB,,unknown
Glycine,,"Serine hydroxymethyltransferase, cytosolic",SHMT1,,unknown
Glycine,,Glycine receptor subunit alpha-3,GLRA3,,unknown
Glycine,,Glycine receptor subunit alpha-2,GLRA2,,unknown
Glycine,,Glycine N-methyltransferase,GNMT,,unknown
Glycine,,"Glycine amidinotransferase, mitochondrial",GATM,,unknown
Calcidiol,288 hours,Vitamin D3 receptor,VDR,agonist,yes
Pyridoxal,,Pyridoxal kinase,PDXK,,yes
Creatine,3 hours,Creatine kinase M-type,CKM,ligand,yes
Creatine,3 hours,"Creatine kinase U-type, mitochondrial",CKMT1A,ligand,yes
Creatine,3 hours,Creatine kinase B-type,CKB,ligand,yes
Creatine,3 hours,"Creatine kinase S-type, mitochondrial",CKMT2,ligand,yes
Creatine,3 hours,Sodium- and chloride-dependent creatine transporter 1,SLC6A8,,yes
Creatine,3 hours,Guanidinoacetate N-methyltransferase,GAMT,product of,yes
L-Leucine,,"Probable leucine--tRNA ligase, mitochondrial",LARS2,,unknown
L-Leucine,,"Branched-chain-amino-acid aminotransferase, mitochondrial",BCAT2,,unknown
L-Leucine,,"Branched-chain-amino-acid aminotransferase, cytosolic",BCAT1,,unknown
L-Leucine,,Leucine carboxyl methyltransferase 2,LCMT2,,unknown
L-Leucine,,Leucine carboxyl methyltransferase 1,LCMT1,,unknown
L-Leucine,,"Leucine--tRNA ligase, cytoplasmic",LARS,,unknown
L-Tryptophan,,"Tryptophan--tRNA ligase, mitochondrial",WARS2,inhibitor,unknown
L-Tryptophan,,Tryptophan--tRNA ligase,trpS,inhibitor,unknown
L-Tryptophan,,"Tryptophan--tRNA ligase, cytoplasmic",WARS,inhibitor,unknown
L-Cysteine,,Glutamate--cysteine ligase regulatory subunit,GCLM,,unknown
L-Cysteine,,Glutamate--cysteine ligase catalytic subunit,GCLC,,unknown
L-Cysteine,,"Aspartate aminotransferase, cytoplasmic",GOT1,,unknown
L-Cysteine,,Cystathionine gamma-lyase,CTH,,unknown
L-Cysteine,,Cystathionine beta-synthase,CBS,,unknown
L-Cysteine,,"Cysteine--tRNA ligase, cytoplasmic",CARS,,unknown
L-Cysteine,,Methylated-DNA--protein-cysteine methyltransferase,MGMT,,unknown
L-Cysteine,,Glutathione synthetase,GSS,,unknown
L-Cysteine,,Thiamine transporter 2,SLC19A3,,unknown
L-Cysteine,,"Probable cysteine--tRNA ligase, mitochondrial",CARS2,,unknown
L-Cysteine,,Cysteine sulfinic acid decarboxylase,CSAD,,unknown
L-Cysteine,,"Cysteine desulfurase, mitochondrial",NFS1,,unknown
L-Cysteine,,Cysteine dioxygenase type 1,CDO1,,unknown
Thiamine,,Thiamin pyrophosphokinase 1,TPK1,ligand,yes
Thiamine,,Thiamine transporter 1,SLC19A2,binder,unknown
Ergocalciferol,"19 to 48 hours (however, stored in fat deposits in body for prolonged periods).",Vitamin D3 receptor,VDR,agonist,yes
Dihomo-gamma-linolenic acid,,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Dihomo-gamma-linolenic acid,,Prostaglandin G/H synthase 2,PTGS2,,yes
L-Citrulline,,Argininosuccinate synthase,ASS1,,unknown
L-Citrulline,,"N(G),N(G)-dimethylarginine dimethylaminohydrolase 2",DDAH2,,unknown
L-Citrulline,,"Argininosuccinate synthetase, isoform CRA_a",ASS,,unknown
L-Citrulline,,"N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",DDAH1,,unknown
L-Citrulline,,"Ornithine carbamoyltransferase, mitochondrial",OTC,,unknown
L-Citrulline,,"Nitric oxide synthase, brain",NOS1,,unknown
L-Citrulline,,"Nitric oxide synthase, inducible",NOS2,,unknown
L-Citrulline,,"Nitric oxide synthase, endothelial",NOS3,,unknown
L-Citrulline,,Protein-arginine deiminase type-6,PADI6,,unknown
L-Citrulline,,Protein-arginine deiminase type-1,PADI1,,unknown
L-Citrulline,,Protein-arginine deiminase type-3,PADI3,,unknown
L-Citrulline,,Protein-arginine deiminase type-2,PADI2,,unknown
L-Citrulline,,Protein-arginine deiminase type-4,PADI4,,unknown
L-Threonine,,Threonine synthase-like 1,THNSL1,,unknown
L-Threonine,,"Threonine--tRNA ligase, cytoplasmic",TARS,,unknown
L-Threonine,,"Threonine--tRNA ligase, mitochondrial",TARS2,,unknown
NADH,,UDP-glucose 6-dehydrogenase,UGDH,,unknown
NADH,,Alcohol dehydrogenase 1A,ADH1A,,unknown
NADH,,Sorbitol dehydrogenase,SORD,,unknown
NADH,,Alcohol dehydrogenase 4,ADH4,,unknown
NADH,,Alcohol dehydrogenase 1C,ADH1C,,unknown
NADH,,Alcohol dehydrogenase 1B,ADH1B,,unknown
NADH,,Alcohol dehydrogenase class 4 mu/sigma chain,ADH7,,unknown
NADH,,"Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic",GPD1,,unknown
NADH,,L-lactate dehydrogenase A-like 6A,LDHAL6A,,unknown
NADH,,Alcohol dehydrogenase class-3,ADH5,,unknown
NADH,,Aldose reductase,AKR1B1,,unknown
NADH,,3-hydroxyacyl-CoA dehydrogenase type-2,HSD17B10,,unknown
NADH,,"Malate dehydrogenase, mitochondrial",MDH2,,unknown
NADH,,L-lactate dehydrogenase A chain,LDHA,,unknown
NADH,,"NAD-dependent malic enzyme, mitochondrial",ME2,,unknown
NADH,,Peroxisomal multifunctional enzyme type 2,HSD17B4,,unknown
NADH,,L-lactate dehydrogenase A-like 6B,LDHAL6B,,unknown
NADH,,L-lactate dehydrogenase C chain,LDHC,,unknown
NADH,,L-lactate dehydrogenase B chain,LDHB,,unknown
NADH,,Peroxisomal bifunctional enzyme,EHHADH,,unknown
NADH,,"Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial",HADH,,unknown
NADH,,"NADP-dependent malic enzyme, mitochondrial",ME3,,unknown
NADH,,"D-beta-hydroxybutyrate dehydrogenase, mitochondrial",BDH1,,unknown
NADH,,"Malate dehydrogenase, cytoplasmic",MDH1,,unknown
NADH,,"3-hydroxyisobutyrate dehydrogenase, mitochondrial",HIBADH,,unknown
NADH,,Testosterone 17-beta-dehydrogenase 3,HSD17B3,,unknown
NADH,,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,,unknown
NADH,,NADP-dependent malic enzyme,ME1,,unknown
NADH,,D-3-phosphoglycerate dehydrogenase,PHGDH,,unknown
NADH,,3-keto-steroid reductase,HSD17B7,,unknown
NADH,,"Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial",IDH3G,,unknown
NADH,,"Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial",IDH3B,,unknown
NADH,,"Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial",IDH3A,,unknown
NADH,,Estradiol 17-beta-dehydrogenase 1,HSD17B1,,unknown
NADH,,Estradiol 17-beta-dehydrogenase 2,HSD17B2,,unknown
NADH,,11-cis retinol dehydrogenase,RDH5,,unknown
NADH,,GDH/6PGL endoplasmic bifunctional protein,H6PD,,unknown
NADH,,Estradiol 17-beta-dehydrogenase 8,HSD17B8,,unknown
NADH,,Aldo-keto reductase family 1 member C4,AKR1C4,,unknown
NADH,,Inosine-5'-monophosphate dehydrogenase 2,IMPDH2,,unknown
NADH,,Aldo-keto reductase family 1 member C3,AKR1C3,,unknown
NADH,,15-hydroxyprostaglandin dehydrogenase [NAD(+)],HPGD,,unknown
NADH,,GDP-L-fucose synthase,TSTA3,,unknown
NADH,,Aldo-keto reductase family 1 member C1,AKR1C1,,unknown
NADH,,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
NADH,,3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2,HSD3B2,,unknown
NADH,,3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1,HSD3B1,,unknown
NADH,,Inosine-5'-monophosphate dehydrogenase 1,IMPDH1,,unknown
NADH,,"Trifunctional enzyme subunit alpha, mitochondrial",HADHA,,unknown
NADH,,"Aldehyde dehydrogenase, mitochondrial",ALDH2,,unknown
NADH,,Corticosteroid 11-beta-dehydrogenase isozyme 2,HSD11B2,,unknown
NADH,,Aldo-keto reductase family 1 member C2,AKR1C2,,unknown
NADH,,"Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating",NSDHL,,unknown
NADH,,Aldehyde dehydrogenase family 3 member B2,ALDH3B2,,unknown
NADH,,"Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial",ALDH6A1,,unknown
NADH,,"Aldehyde dehydrogenase, dimeric NADP-preferring",ALDH3A1,,unknown
NADH,,Retinal dehydrogenase 1,ALDH1A1,,unknown
NADH,,"Glyceraldehyde-3-phosphate dehydrogenase, testis-specific",GAPDHS,,unknown
NADH,,4-trimethylaminobutyraldehyde dehydrogenase,ALDH9A1,,unknown
NADH,,Aldehyde dehydrogenase family 1 member A3,ALDH1A3,,unknown
NADH,,"Aldehyde dehydrogenase X, mitochondrial",ALDH1B1,,unknown
NADH,,Aldehyde dehydrogenase family 3 member B1,ALDH3B1,,unknown
NADH,,Glyceraldehyde-3-phosphate dehydrogenase,GAPDH,,unknown
NADH,,Retinal dehydrogenase 2,ALDH1A2,,unknown
NADH,,Fatty aldehyde dehydrogenase,ALDH3A2,,unknown
NADH,,"Succinate-semialdehyde dehydrogenase, mitochondrial",ALDH5A1,,unknown
NADH,,Alpha-aminoadipic semialdehyde dehydrogenase,ALDH7A1,,unknown
NADH,,Flavin reductase (NADPH),BLVRB,,unknown
NADH,,Pyrroline-5-carboxylate reductase 2,PYCR2,,unknown
NADH,,"Pyrroline-5-carboxylate reductase 1, mitochondrial",PYCR1,,unknown
NADH,,"Glutamate dehydrogenase 1, mitochondrial",GLUD1,,unknown
NADH,,"Pyruvate dehydrogenase E1 component subunit beta, mitochondrial",PDHB,,unknown
NADH,,"Pyruvate dehydrogenase E1 component subunit alpha, testis-specific form, mitochondrial",PDHA2,,unknown
NADH,,"Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial",PDHA1,,unknown
NADH,,Biliverdin reductase A,BLVRA,,unknown
NADH,,"Short-chain specific acyl-CoA dehydrogenase, mitochondrial",ACADS,,unknown
NADH,,Dihydrofolate reductase,DHFR,,unknown
NADH,,"2-oxoglutarate dehydrogenase, mitochondrial",OGDH,,unknown
NADH,,"Glutamate dehydrogenase 2, mitochondrial",GLUD2,,unknown
NADH,,7-dehydrocholesterol reductase,DHCR7,,unknown
NADH,,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,,unknown
NADH,,NADH-ubiquinone oxidoreductase chain 2,MT-ND2,binder,unknown
NADH,,"Alpha-aminoadipic semialdehyde synthase, mitochondrial",AASS,,unknown
NADH,,NADH-ubiquinone oxidoreductase chain 3,MT-ND3,binder,unknown
NADH,,"NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial",NDUFS7,,unknown
NADH,,"C-1-tetrahydrofolate synthase, cytoplasmic",MTHFD1,,unknown
NADH,,"Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial",MTHFD2,,unknown
NADH,,"Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial",ALDH4A1,,unknown
NADH,,NADH-cytochrome b5 reductase 3,CYB5R3,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11,NDUFA11,,unknown
NADH,,NADH-ubiquinone oxidoreductase chain 4,MT-ND4,,unknown
NADH,,Dihydropteridine reductase,QDPR,,unknown
NADH,,NADH-ubiquinone oxidoreductase chain 1,MT-ND1,binder,unknown
NADH,,"NAD(P) transhydrogenase, mitochondrial",NNT,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5,NDUFA5,,unknown
NADH,,"NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial",NDUFA9,,unknown
NADH,,NADH-ubiquinone oxidoreductase chain 4L,MT-ND4L,,unknown
NADH,,"NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial",NDUFA10,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7,NDUFA7,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1,NDUFA1,,unknown
NADH,,NADH-ubiquinone oxidoreductase chain 6,MT-ND6,,unknown
NADH,,NADH-ubiquinone oxidoreductase chain 5,MT-ND5,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4,NDUFA4,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6,NDUFA6,,unknown
NADH,,"Acyl carrier protein, mitochondrial",NDUFAB1,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2,NDUFA2,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8,NDUFA8,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3,NDUFA3,,unknown
NADH,,"NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial",NDUFB8,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 subunit C2,NDUFC2,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 1,NDUFB1,,unknown
NADH,,"NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial",NDUFS1,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10,NDUFB10,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4,NDUFB4,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3,NDUFB3,,unknown
NADH,,"NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial",NDUFB2,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7,NDUFB7,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9,NDUFB9,,unknown
NADH,,"NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial",NDUFS2,,unknown
NADH,,"NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial",NDUFB5,,unknown
NADH,,"NADH dehydrogenase [ubiquinone] 1 subunit C1, mitochondrial",NDUFC1,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6,NDUFB6,,unknown
NADH,,"NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial",NDUFV3,,unknown
NADH,,"Dihydrolipoyl dehydrogenase, mitochondrial",DLD,,unknown
NADH,,"NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial",NDUFS3,,unknown
NADH,,"Glutathione reductase, mitochondrial",GSR,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12,NDUFA12,,unknown
NADH,,NADH dehydrogenase [ubiquinone] iron-sulfur protein 5,NDUFS5,,unknown
NADH,,"NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial",NDUFS4,,unknown
NADH,,"NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial",NDUFV1,,unknown
NADH,,"NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial",NDUFV2,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13,NDUFA13,,unknown
NADH,,Cysteine dioxygenase type 1,CDO1,,unknown
NADH,,"NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial",NDUFS6,,unknown
NADH,,NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4-like 2,NDUFA4L2,,unknown
NADH,,"NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial",NDUFS8,,unknown
NADH,,Cytochrome P450 4A11,CYP4A11,,unknown
NADH,,"Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial",DLAT,,unknown
NADH,,"Aminomethyltransferase, mitochondrial",AMT,,unknown
NADH,,Methylsterol monooxygenase 1,MSMO1,,unknown
NADH,,Heme oxygenase 1,HMOX1,,unknown
NADH,,Heme oxygenase 2,HMOX2,,unknown
NADH,,"Steroid 17-alpha-hydroxylase/17,20 lyase",CYP17A1,,unknown
NADH,,Tyrosinase,TYR,,unknown
Folic Acid,,Folate receptor beta,FOLR2,binder,unknown
Folic Acid,,Folate receptor gamma,FOLR3,binder,unknown
Folic Acid,,Folate receptor alpha,FOLR1,,unknown
Icosapent,,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Icosapent,,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Icosapent,,Peroxisome proliferator-activated receptor gamma,PPARG,agonist,yes
Icosapent,,Peroxisome proliferator-activated receptor delta,PPARD,agonist,yes
Icosapent,,Fatty acid desaturase 1,FADS1,agonist,unknown
Icosapent,,Long-chain-fatty-acid--CoA ligase 4,ACSL4,inducer,unknown
Icosapent,,Long-chain-fatty-acid--CoA ligase 3,ACSL3,inducer,unknown
Icosapent,,Free fatty acid receptor 1,FFAR1,agonist,yes
Icosapent,,Sodium/calcium exchanger 1,SLC8A1,inhibitor,yes
Icosapent,,Transient receptor potential cation channel subfamily V member 1,TRPV1,inducer,unknown
Icosapent,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
L-Alanine,,Serine--pyruvate aminotransferase,AGXT,,unknown
L-Alanine,,"4-aminobutyrate aminotransferase, mitochondrial",ABAT,inhibitor,unknown
L-Alanine,,Kynureninase,KYNU,,unknown
L-Alanine,,"Alanine--tRNA ligase, mitochondrial",AARS2,,unknown
L-Alanine,,5-phosphohydroxy-L-lysine phospho-lyase,PHYKPL,,unknown
L-Alanine,,Alanine aminotransferase 2,GPT2,,unknown
L-Alanine,,Alanine aminotransferase 1,GPT,,unknown
L-Alanine,,"Cysteine desulfurase, mitochondrial",NFS1,,unknown
L-Alanine,,Proton-coupled amino acid transporter 1,SLC36A1,,unknown
L-Alanine,,Large neutral amino acids transporter small subunit 2,SLC7A8,,unknown
L-Alanine,,"Alanine--glyoxylate aminotransferase 2, mitochondrial",AGXT2,,unknown
L-Alanine,,"Alanine--tRNA ligase, cytoplasmic",AARS,,unknown
L-Alanine,,Neutral amino acid transporter A,SLC1A4,,unknown
L-Valine,,"Propionyl-CoA carboxylase beta chain, mitochondrial",PCCB,,unknown
L-Valine,,"Branched-chain-amino-acid aminotransferase, cytosolic",BCAT1,,unknown
L-Valine,,Valine--tRNA ligase,VARS,,unknown
Vitamin A,1.9 hours,Retinol dehydrogenase 12,RDH12,,unknown
Vitamin A,1.9 hours,Short-chain dehydrogenase/reductase 3,DHRS3,,unknown
Vitamin A,1.9 hours,Aldehyde dehydrogenase family 1 member A3,ALDH1A3,,unknown
Vitamin A,1.9 hours,"All-trans-retinol 13,14-reductase",RETSAT,,unknown
Vitamin A,1.9 hours,Retinol dehydrogenase 11,RDH11,,unknown
Vitamin A,1.9 hours,Dehydrogenase/reductase SDR family member 4,DHRS4,,unknown
Vitamin A,1.9 hours,Retinol dehydrogenase 14,RDH14,,unknown
Vitamin A,1.9 hours,Retinol dehydrogenase 8,RDH8,,unknown
Vitamin A,1.9 hours,Lecithin retinol acyltransferase,LRAT,,unknown
Vitamin A,1.9 hours,Retinol-binding protein 1,RBP1,,unknown
Vitamin A,1.9 hours,11-cis retinol dehydrogenase,RDH5,,unknown
Vitamin A,1.9 hours,Retinol dehydrogenase 13,RDH13,,unknown
Vitamin A,1.9 hours,Retinol-binding protein 3,RBP3,,unknown
Vitamin A,1.9 hours,Retinal dehydrogenase 2,ALDH1A2,,unknown
Vitamin A,1.9 hours,Retinal dehydrogenase 1,ALDH1A1,,unknown
Vitamin A,1.9 hours,Retinaldehyde-binding protein 1,RLBP1,,unknown
Vitamin A,1.9 hours,Apolipoprotein D,APOD,,unknown
Vitamin A,1.9 hours,Hematopoietic prostaglandin D synthase,HPGDS,,unknown
Vitamin E,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Vitamin E,,Protein kinase C beta type,PRKCB,,unknown
Vitamin E,,Arachidonate 5-lipoxygenase,ALOX5,,unknown
Vitamin E,,Protein kinase C alpha type,PRKCA,,unknown
Vitamin E,,Diacylglycerol kinase alpha,DGKA,,unknown
Vitamin E,,Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform,PPP2CB,,unknown
Vitamin E,,Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform,PPP2CA,,unknown
Vitamin E,,SEC14-like protein 4,SEC14L4,,unknown
Vitamin E,,SEC14-like protein 3,SEC14L3,,unknown
Vitamin E,,SEC14-like protein 2,SEC14L2,,unknown
Pyridoxine,15-20 days,Pyridoxal kinase,PDXK,ligand,yes
Lipoic Acid,,"Lipoyltransferase 1, mitochondrial",LIPT1,,unknown
Lipoic Acid,,"Lipoyl synthase, mitochondrial",LIAS,,unknown
Lipoic Acid,,Sodium-dependent multivitamin transporter,SLC5A6,,unknown
L-Isoleucine,,"Isoleucine--tRNA ligase, mitochondrial",IARS2,,unknown
L-Isoleucine,,"Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial",ACADSB,,unknown
L-Isoleucine,,"Branched-chain-amino-acid aminotransferase, cytosolic",BCAT1,,unknown
L-Isoleucine,,"Branched-chain-amino-acid aminotransferase, mitochondrial",BCAT2,,unknown
L-Isoleucine,,"Isoleucine--tRNA ligase, cytoplasmic",IARS,,unknown
Aspartame,"At room temperature, aspartame is most stable at pH 4.3, where its half-life is nearly 300 days. At pH 7 however, its half-life is only a few days.",Transient receptor potential cation channel subfamily V member 1,TRPV1,inducer,unknown
Aspartame,"At room temperature, aspartame is most stable at pH 4.3, where its half-life is nearly 300 days. At pH 7 however, its half-life is only a few days.",Taste receptor type 1 member 2,TAS1R2,agonist,unknown
Aspartame,"At room temperature, aspartame is most stable at pH 4.3, where its half-life is nearly 300 days. At pH 7 however, its half-life is only a few days.",Taste receptor type 1 member 3,TAS1R3,,unknown
Cholecalciferol,Several weeks,Vitamin D3 receptor,VDR,agonist,yes
Menadione,,Vitamin K-dependent gamma-carboxylase,GGCX,cofactor,yes
Menadione,,Vitamin K epoxide reductase complex subunit 1,VKORC1,cofactor,yes
Menadione,,Vitamin K epoxide reductase complex subunit 1-like protein 1,VKORC1L1,cofactor,yes
Menadione,,Prothrombin,F2,activator,unknown
Menadione,,Coagulation factor VII,F7,activator,unknown
Menadione,,Coagulation factor IX,F9,activator,unknown
Menadione,,Coagulation factor X,F10,activator,unknown
Menadione,,Vitamin K-dependent protein C,PROC,activator,unknown
Menadione,,Vitamin K-dependent protein S,PROS1,activator,unknown
Menadione,,Vitamin K-dependent protein Z,PROZ,activator,unknown
Menadione,,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,,unknown
Menadione,,NAD(P)H dehydrogenase [quinone] 1,NQO1,,unknown
Menadione,,Osteocalcin,BGLAP,agonist,unknown
ATP,,Abelson tyrosine-protein kinase 2,ABL2,inhibitor,unknown
ATP,,Multidrug resistance protein 1,ABCB1,,unknown
ATP,,ATP-binding cassette sub-family G member 1,ABCG1,,unknown
ATP,,Canalicular multispecific organic anion transporter 1,ABCC2,,unknown
ATP,,ATP-binding cassette sub-family A member 1,ABCA1,,unknown
ATP,,"Acetyl-coenzyme A synthetase, cytoplasmic",ACSS2,,unknown
ATP,,ALK tyrosine kinase receptor,ALK,,unknown
ATP,,NEDD8-activating enzyme E1 regulatory subunit,NAE1,,unknown
ATP,,5'-AMP-activated protein kinase catalytic subunit alpha-1,PRKAA1,,unknown
ATP,,Serine/threonine-protein kinase A-Raf,ARAF,,unknown
ATP,,Serine/threonine-protein kinase receptor R3,ACVRL1,,unknown
ATP,,Long-chain-fatty-acid--CoA ligase 1,ACSL1,,unknown
ATP,,Cytosolic purine 5'-nucleotidase,NT5C2,,unknown
ATP,,ATPase ASNA1,ASNA1,,unknown
ATP,,ATP-binding cassette sub-family C member 9,ABCC9,,unknown
ATP,,RAC-alpha serine/threonine-protein kinase,AKT1,,unknown
ATP,,Beta-adrenergic receptor kinase 1,ADRBK1,,unknown
ATP,,Apoptotic protease-activating factor 1,APAF1,,unknown
ATP,,"Acetyl-coenzyme A synthetase 2-like, mitochondrial",ACSS1,,unknown
ATP,,Activin receptor type-1B,ACVR1B,,unknown
ATP,,Activin receptor type-1,ACVR1,,unknown
ATP,,Bile salt export pump,ABCB11,,unknown
ATP,,Asparagine synthetase [glutamine-hydrolyzing],ASNS,,unknown
ATP,,Cyclin-dependent kinase 15,CDK15,,unknown
ATP,,ADP/ATP translocase 1,SLC25A4,,unknown
ATP,,ATP-binding cassette sub-family C member 8,ABCC8,,unknown
ATP,,Argininosuccinate synthase,ASS1,,unknown
ATP,,AFG3-like protein 2,AFG3L2,,unknown
ATP,,Beta-adrenergic receptor kinase 2,ADRBK2,,unknown
ATP,,Anti-Muellerian hormone type-2 receptor,AMHR2,,unknown
ATP,,Activated CDC42 kinase 1,TNK2,,unknown
ATP,,Tyrosine-protein kinase ABL1,ABL1,inhibitor,unknown
ATP,,Adenylate cyclase type 1,ADCY1,,unknown
ATP,,Multidrug resistance-associated protein 6,ABCC6,,unknown
ATP,,Multidrug resistance-associated protein 4,ABCC4,,unknown
ATP,,Multidrug resistance-associated protein 1,ABCC1,,unknown
ATP,,Cystic fibrosis transmembrane conductance regulator,CFTR,cofactor,unknown
ATP,,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",PIK3CA,,unknown
ATP,,Casein kinase II subunit alpha,CSNK2A1,,unknown
ATP,,Casein kinase II subunit beta,CSNK2B,,unknown
ATP,,P2Y purinoceptor 11,P2RY11,,unknown
ATP,,Serine/threonine-protein phosphatase 5,PPP5C,,unknown
L-Proline,,Prolyl 4-hydroxylase subunit alpha-2,P4HA2,,unknown
L-Proline,,"Proline dehydrogenase 1, mitochondrial",PRODH,,unknown
L-Proline,,Peptidyl-prolyl cis-trans isomerase H,PPIH,,unknown
L-Proline,,Proline synthase co-transcribed bacterial homolog protein,PROSC,,unknown
L-Proline,,Prolyl 4-hydroxylase subunit alpha-1,P4HA1,,unknown
L-Proline,,Peptidyl-prolyl cis-trans isomerase B,PPIB,binder,unknown
L-Proline,,"Peptidyl-prolyl cis-trans isomerase F, mitochondrial",PPIF,,unknown
L-Proline,,Peptidyl-prolyl cis-trans isomerase C,PPIC,,unknown
L-Proline,,Peptidyl-prolyl cis-trans isomerase A,PPIA,binder,unknown
L-Proline,,Peptidyl-prolyl cis-trans isomerase G,PPIG,,unknown
L-Proline,,Prolyl 3-hydroxylase 1,P3H1,,unknown
L-Proline,,Pyrroline-5-carboxylate reductase,P5CR2,,unknown
L-Proline,,"Probable proline--tRNA ligase, mitochondrial",PARS2,,unknown
L-Proline,,Prolyl 3-hydroxylase 2,P3H2,,unknown
L-Proline,,Prolyl 3-hydroxylase 3,P3H3,,unknown
L-Proline,,Pyrroline-5-carboxylate reductase 3,PYCRL,,unknown
L-Proline,,Trans-L-3-hydroxyproline dehydratase,L3HYPDH,,unknown
L-Proline,,"Pyrroline-5-carboxylate reductase 1, mitochondrial",PYCR1,,unknown
L-Proline,,Bifunctional glutamate/proline--tRNA ligase,EPRS,,unknown
L-Proline,,Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+),SLC6A14,,unknown
L-Proline,,Sodium-dependent proline transporter,SLC6A7,,unknown
L-Proline,,Pyrroline-5-carboxylate reductase 2,PYCR2,,unknown
Adenine,,Adenine phosphoribosyltransferase,APRT,,unknown
Adenine,,5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase,mtnN,,unknown
Adenine,,Acetyl-CoA carboxylase 2,ACACB,,unknown
Adenine,,Low molecular weight phosphotyrosine protein phosphatase,ACP1,,unknown
Adenine,,Peroxisomal trans-2-enoyl-CoA reductase,PECR,,unknown
Adenine,,A/G-specific adenine glycosylase,mutY,,unknown
Adenine,,Nucleoside deoxyribosyltransferase-I,ptd,,unknown
Adenine,,SRSF protein kinase 2,SRPK2,,unknown
Adenine,,Holliday junction ATP-dependent DNA helicase RuvB,ruvB,,unknown
Adenine,,DNA,,,unknown
Adenine,,S-methyl-5'-thioadenosine phosphorylase,MTAP,,unknown
Adenine,,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
L-Asparagine,,Neutral amino acid transporter B(0),SLC1A5,,unknown
L-Asparagine,,Isoaspartyl peptidase/L-asparaginase,ASRGL1,,unknown
L-Asparagine,,"Probable asparagine--tRNA ligase, mitochondrial",NARS2,,unknown
L-Asparagine,,Sodium-coupled neutral amino acid transporter 3,SLC38A3,,unknown
L-Asparagine,,Asparagine synthetase [glutamine-hydrolyzing],ASNS,,unknown
L-Asparagine,,"Asparagine--tRNA ligase, cytoplasmic",NARS,,unknown
Pravastatin,77 hours,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,inhibitor,yes
Fluvoxamine,15.6 hours [FDA Label].,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Fluvoxamine,15.6 hours [FDA Label].,Potassium voltage-gated channel subfamily H member 2,KCNH2,,unknown
Valsartan,The initial phase t<sub>1/2 &alpha;</sub> is < 1 hour while the terminal phase t<sub>1/2 &beta;</sub> is 5-9 hours.,Type-1 angiotensin II receptor,AGTR1,antagonist,yes
Ramipril,"Plasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.",Angiotensin-converting enzyme,ACE,inhibitor,yes
Ramipril,"Plasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.",B1 bradykinin receptor,BDKRB1,,unknown
Masoprocol,,Arachidonate 5-lipoxygenase,ALOX5,inhibitor,yes
Masoprocol,,Sex hormone-binding globulin,SHBG,,unknown
Flunisolide,1.8 hours,Glucocorticoid receptor,NR3C1,agonist,yes
Baclofen,2.5-4 hours,Gamma-aminobutyric acid type B receptor subunit 1,GABBR1,agonist,yes
Baclofen,2.5-4 hours,Gamma-aminobutyric acid type B receptor subunit 2,GABBR2,agonist,yes
Amphetamine,The half life for adults in the fasted state was found to be 11.25 hr.,Synaptic vesicular amine transporter,SLC18A2,inhibitor,yes
Amphetamine,The half life for adults in the fasted state was found to be 11.25 hr.,Sodium-dependent dopamine transporter,SLC6A3,negative modulator,yes
Amphetamine,The half life for adults in the fasted state was found to be 11.25 hr.,Cocaine- and amphetamine-regulated transcript protein,CARTPT,agonist,yes
Amphetamine,The half life for adults in the fasted state was found to be 11.25 hr.,Trace amine-associated receptor 1,TAAR1,agonist,yes
Amphetamine,The half life for adults in the fasted state was found to be 11.25 hr.,Sodium-dependent noradrenaline transporter,SLC6A2,stimulator,unknown
Amphetamine,The half life for adults in the fasted state was found to be 11.25 hr.,Alpha adrenergic receptor,ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C,agonist,unknown
Amphetamine,The half life for adults in the fasted state was found to be 11.25 hr.,Beta adrenergic receptor,ADRB1ADRB2ADRB3,agonist,unknown
Amphetamine,The half life for adults in the fasted state was found to be 11.25 hr.,D(2) dopamine receptor,DRD2,binder,unknown
Amphetamine,The half life for adults in the fasted state was found to be 11.25 hr.,Amine oxidase [flavin-containing] B,MAOB,,unknown
Amphetamine,The half life for adults in the fasted state was found to be 11.25 hr.,Sodium-dependent serotonin transporter,SLC6A4,binder,unknown
Amphetamine,The half life for adults in the fasted state was found to be 11.25 hr.,Monoamine oxidase,MAOAMAOB,inhibitor,yes
Amphetamine,The half life for adults in the fasted state was found to be 11.25 hr.,vesicular monoamine transporter 2 (VMAT2),VMAT2,,yes
Pentagastrin,10 minutes or less,Gastrin/cholecystokinin type B receptor,CCKBR,agonist,yes
Nicotine,"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours",Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,agonist,yes
Nicotine,"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours",Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,agonist,yes
Nicotine,"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours",Neuronal acetylcholine receptor subunit beta-2,CHRNB2,agonist,yes
Nicotine,"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours",Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,agonist,unknown
Nicotine,"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours",Neuronal acetylcholine receptor subunit alpha-3,CHRNA3,agonist,unknown
Nicotine,"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours",Neuronal acetylcholine receptor subunit alpha-5,CHRNA5,agonist,unknown
Nicotine,"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours",Neuronal acetylcholine receptor subunit alpha-6,CHRNA6,agonist,unknown
Nicotine,"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours",Neuronal acetylcholine receptor subunit alpha-9,CHRNA9,agonist,unknown
Nicotine,"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours",Neuronal acetylcholine receptor subunit alpha-10,CHRNA10,agonist,unknown
Nicotine,"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours",Neuronal acetylcholine receptor subunit beta-3,CHRNB3,agonist,unknown
Nicotine,"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours",Neuronal acetylcholine receptor subunit beta-4,CHRNB4,agonist,unknown
Nicotine,"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours",Cytochrome P450 19A1,CYP19A1,,unknown
Nicotine,"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours",Choline O-acetyltransferase,CHAT,,unknown
Cevimeline,5 &plusmn; 1 hours,Muscarinic acetylcholine receptor M3,CHRM3,agonist,yes
Cevimeline,5 &plusmn; 1 hours,Muscarinic acetylcholine receptor M1,CHRM1,agonist,yes
Lorazepam,"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.",GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Lorazepam,"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.",Translocator protein,TSPO,other,unknown
Esmolol,Rapid distribution half-life of about 2 minutes and an elimination half-life of about 9 minutes. The acid metabolite has an elimination half-life of about 3.7 hours.,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Bortezomib,The mean elimination half-life of bortezomib after first dose ranged from 9 to 15 hours at doses ranging from 1.45 to 2.00 mg/m2 in patients with advanced malignancies.,Proteasome subunit beta type-5,PSMB5,inhibitor,yes
Bortezomib,The mean elimination half-life of bortezomib after first dose ranged from 9 to 15 hours at doses ranging from 1.45 to 2.00 mg/m2 in patients with advanced malignancies.,Proteasome subunit beta type-1,PSMB1,inhibitor,yes
Ethchlorvynol,"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.",GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Carbidopa,1-2 hours,Aromatic-L-amino-acid decarboxylase,DDC,inhibitor,yes
Phentermine,16 to 31 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Phentermine,16 to 31 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Phentermine,16 to 31 hours,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,yes
Phentermine,16 to 31 hours,Amine oxidase [flavin-containing] A,MAOA,antagonist,yes
Phentermine,16 to 31 hours,Amine oxidase [flavin-containing] B,MAOB,antagonist,yes
Indecainide,,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Tramadol,"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.",Mu-type opioid receptor,OPRM1,agonist,yes
Tramadol,"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.",Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Tramadol,"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.",Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Tramadol,"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.",5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Tramadol,"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.",Kappa-type opioid receptor,OPRK1,agonist,unknown
Tramadol,"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.",Delta-type opioid receptor,OPRD1,agonist,no
Tramadol,"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.","Glutamate receptor ionotropic, NMDA 3A",GRIN3A,antagonist,unknown
Tramadol,"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.",Alpha-7 nicotinic cholinergic receptor subunit,CHRNA7,antagonist,unknown
Tramadol,"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.",Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Vidarabine,,DNA polymerase catalytic subunit,,inhibitor,yes
Vidarabine,,DNA,,incorporation into and destabilization,yes
Vidarabine,,Thymidine kinase,TK,inducer,yes
Vidarabine,,Thymidine kinase,TK,inducer,yes
Betaxolol,14-22 hours,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Betaxolol,14-22 hours,Beta-2 adrenergic receptor,ADRB2,antagonist,unknown
Fluconazole,30 hours (range 20-50 hours),Lanosterol 14-alpha demethylase,ERG11,inhibitor,yes
Troglitazone,16-34 hours,Peroxisome proliferator-activated receptor gamma,PPARG,agonist,yes
Troglitazone,16-34 hours,Long-chain-fatty-acid--CoA ligase 4,ACSL4,inhibitor,no
Troglitazone,16-34 hours,Plasminogen activator inhibitor 1,SERPINE1,antagonist,unknown
Troglitazone,16-34 hours,Equilibrative nucleoside transporter 1,SLC29A1,inhibitor,no
Troglitazone,16-34 hours,Estrogen-related receptor gamma,ESRRG,inverse agonist,no
Troglitazone,16-34 hours,Steroid hormone receptor ERR1,ESRRA,inverse agonist,no
Troglitazone,16-34 hours,Peroxisome proliferator-activated receptor delta,PPARD,,unknown
Troglitazone,16-34 hours,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Troglitazone,16-34 hours,Glutathione S-transferase P,GSTP1,,unknown
Oseltamivir,1 to 3 hours in most subjects after oral administration.,Neuraminidase,NA,inhibitor,yes
Oseltamivir,1 to 3 hours in most subjects after oral administration.,Liver carboxylesterase 1,CES1,other,yes
Oseltamivir,1 to 3 hours in most subjects after oral administration.,Sialidase-1,NEU1,inhibitor,unknown
Oseltamivir,1 to 3 hours in most subjects after oral administration.,Sialidase-2,NEU2,inhibitor,unknown
Erythromycin,0.8 - 3 hours,23S rRNA,,inhibitor,yes
Erythromycin,0.8 - 3 hours,Motilin receptor,MLNR,agonist,no
Erythromycin,0.8 - 3 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,no
Erythromycin,0.8 - 3 hours,Serum albumin,ALB,binder,no
Hydroxocobalamin,Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration),Methionine synthase,MTR,cofactor,yes
Hydroxocobalamin,Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration),"Methylmalonyl-CoA mutase, mitochondrial",MUT,cofactor,yes
Hydroxocobalamin,Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration),Methionine synthase reductase,MTRR,other,unknown
Hydroxocobalamin,Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration),"Methylmalonic aciduria type A protein, mitochondrial",MMAA,other/unknown,unknown
Hydroxocobalamin,Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration),Transcobalamin-1,TCN1,other,unknown
Hydroxocobalamin,Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration),Protein amnionless,AMN,other,unknown
Hydroxocobalamin,Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration),Cubilin,CUBN,other,unknown
Hydroxocobalamin,Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration),"Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial",MMAB,other,unknown
Hydroxocobalamin,Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration),Methylmalonic aciduria and homocystinuria type C protein,MMACHC,other/unknown,unknown
Caffeine,"3 to 7 hours in adults, 65 to 130 hours in neonates",Adenosine receptor A1,ADORA1,antagonistmultitarget,yes
Caffeine,"3 to 7 hours in adults, 65 to 130 hours in neonates",Adenosine receptor A2a,ADORA2A,antagonistmultitarget,yes
Caffeine,"3 to 7 hours in adults, 65 to 130 hours in neonates","cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,inhibitor,unknown
Caffeine,"3 to 7 hours in adults, 65 to 130 hours in neonates",Ryanodine receptor 1,RYR1,,unknown
Caffeine,"3 to 7 hours in adults, 65 to 130 hours in neonates",Cyclic nucleotide phosphodiesterase,PDE1APDE1BPDE1CPDE10APDE4APDE4BPDE4CPDE4DPDE7BPDE2APDE3APDE3BPDE5APDE6CPDE11APDE7APDE8APDE8BPDE9APDE6APDE6B,,unknown
Caffeine,"3 to 7 hours in adults, 65 to 130 hours in neonates",DNA-dependent protein kinase catalytic subunit,PRKDC,,unknown
Caffeine,"3 to 7 hours in adults, 65 to 130 hours in neonates","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",PIK3CD,,unknown
Caffeine,"3 to 7 hours in adults, 65 to 130 hours in neonates","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",PIK3CA,,unknown
Caffeine,"3 to 7 hours in adults, 65 to 130 hours in neonates","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",PIK3CB,,unknown
Caffeine,"3 to 7 hours in adults, 65 to 130 hours in neonates","Inositol 1,4,5-trisphosphate receptor",ITPR1ITPR2ITPR3,,unknown
Caffeine,"3 to 7 hours in adults, 65 to 130 hours in neonates",Serine-protein kinase ATM,ATM,,unknown
Succinylcholine,,Neuronal acetylcholine receptor subunit alpha-10,CHRNA10,agonist,yes
Succinylcholine,,Alpha-7 nicotinic cholinergic receptor subunit,CHRNA7,agonist,yes
Succinylcholine,,Muscarinic acetylcholine receptor M1,CHRM1,agonist,yes
Succinylcholine,,Muscarinic acetylcholine receptor M2,CHRM2,agonist,unknown
Succinylcholine,,Muscarinic acetylcholine receptor M3,CHRM3,agonist,unknown
Sildenafil,4 hours,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,inhibitor,yes
Sildenafil,4 hours,"Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma",PDE6G,inhibitor,no
Sildenafil,4 hours,"Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma",PDE6H,inhibitor,no
Dofetilide,10 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,yes
Dofetilide,10 hours,Potassium channel subfamily K member 2,KCNK2,inhibitor,yes
Dofetilide,10 hours,ATP-sensitive inward rectifier potassium channel 12,KCNJ12,inhibitor,yes
Pyrimethamine,96 hours,Dihydrofolate reductase,DHFR,inhibitor,yes
Pyrimethamine,96 hours,Bifunctional dihydrofolate reductase-thymidylate synthase,,inhibitor,yes
Pyrimethamine,96 hours,Beta-hexosaminidase subunit beta,HEXB,,unknown
Reserpine,,Synaptic vesicular amine transporter,SLC18A2,inhibitor,yes
Reserpine,,Chromaffin granule amine transporter,SLC18A1,,unknown
Reserpine,,Baculoviral IAP repeat-containing protein 5,BIRC5,,unknown
Azithromycin,68 hours,23S rRNA,,inhibitor,yes
Azithromycin,68 hours,50S ribosomal protein L4,rplD,inhibitor,yes
Azithromycin,68 hours,50S ribosomal protein L22,rplV,inhibitor,yes
Azithromycin,68 hours,Protein-arginine deiminase type-4,PADI4,,unknown
Ticlopidine,"Half-life following a single 250-mg dose is approximately 7.9 hours in subjects 20 to 43 years of age and 12.6 hours in subjects 65 to 76 years of age. With repeated dosing (250 mg twice a day), half-life is about 4 days in subjects 20 to 43 years of age and about 5 days in subjects 65 to 76 years of age.",P2Y purinoceptor 12,P2RY12,antagonist,yes
Trospium,20 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Adapalene,,Retinoic acid receptor gamma,RARG,agonist,yes
Adapalene,,Retinoic acid receptor beta,RARB,agonist,yes
Adapalene,,Retinoic acid receptor RXR-gamma,RXRG,agonist,yes
Adapalene,,Retinoic acid receptor RXR-beta,RXRB,agonist,yes
Adapalene,,Retinoic acid receptor alpha,RARA,agonist,unknown
Adapalene,,Retinoic acid receptor RXR-alpha,RXRA,other/unknown,no
Midodrine,"The plasma levels of the prodrug peak after about half an hour, and decline with a half-life of approximately 25 minutes, while the metabolite reaches peak blood concentrations about 1 to 2 hours after a dose of midodrine and has a half-life of about 3 to 4 hours.",Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Midodrine,"The plasma levels of the prodrug peak after about half an hour, and decline with a half-life of approximately 25 minutes, while the metabolite reaches peak blood concentrations about 1 to 2 hours after a dose of midodrine and has a half-life of about 3 to 4 hours.",Alpha-1B adrenergic receptor,ADRA1B,agonist,yes
Midodrine,"The plasma levels of the prodrug peak after about half an hour, and decline with a half-life of approximately 25 minutes, while the metabolite reaches peak blood concentrations about 1 to 2 hours after a dose of midodrine and has a half-life of about 3 to 4 hours.",Alpha-1D adrenergic receptor,ADRA1D,agonist,unknown
Remikiren,,Renin,REN,inhibitor,yes
Pantoprazole,1 hour,Potassium-transporting ATPase alpha chain 1,ATP4A,inhibitor,yes
Torasemide,3.5 hours,Solute carrier family 12 member 1,SLC12A1,inhibitor,yes
Citalopram,35 hours [FDA label].,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Citalopram,35 hours [FDA label].,Histamine H1 receptor,HRH1,binder,unknown
Citalopram,35 hours [FDA label].,Alpha-1A adrenergic receptor,ADRA1A,binder,unknown
Citalopram,35 hours [FDA label].,Muscarinic acetylcholine receptor M1,CHRM1,binder,unknown
Citalopram,35 hours [FDA label].,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Eletriptan,The terminal elimination half-life of eletriptan is approximately 4 hours.,5-hydroxytryptamine receptor 1D,HTR1D,agonist,yes
Eletriptan,The terminal elimination half-life of eletriptan is approximately 4 hours.,5-hydroxytryptamine receptor 1B,HTR1B,agonist,yes
Eletriptan,The terminal elimination half-life of eletriptan is approximately 4 hours.,5-hydroxytryptamine receptor 1F,HTR1F,agonist,yes
Eletriptan,The terminal elimination half-life of eletriptan is approximately 4 hours.,5-hydroxytryptamine receptor 1A,HTR1A,agonist,unknown
Eletriptan,The terminal elimination half-life of eletriptan is approximately 4 hours.,5-hydroxytryptamine receptor 1E,HTR1E,agonist,unknown
Eletriptan,The terminal elimination half-life of eletriptan is approximately 4 hours.,5-hydroxytryptamine receptor 2B,HTR2B,agonist,unknown
Eletriptan,The terminal elimination half-life of eletriptan is approximately 4 hours.,5-hydroxytryptamine receptor 7,HTR7,agonist,unknown
Bethanidine,9 hours (range 7 to 11 hours),Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,agonist,yes
Bethanidine,9 hours (range 7 to 11 hours),ATP-sensitive inward rectifier potassium channel 1,KCNJ1,inhibitor,yes
Bethanidine,9 hours (range 7 to 11 hours),Beta adrenergic receptor,ADRB1ADRB2ADRB3,antagonist,unknown
Moxifloxacin,"11.5-15.6 hours (single dose, oral)",DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Moxifloxacin,"11.5-15.6 hours (single dose, oral)",DNA gyrase subunit A,gyrA,inhibitor,yes
Moxifloxacin,"11.5-15.6 hours (single dose, oral)",DNA topoisomerase 2-alpha,TOP2A,inhibitor,unknown
Oxyphenonium,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Nelfinavir,3.5 - 5 hours,HIV-1 protease,HIV-1 protease,inhibitor,yes
Isoetarine,,Beta-1 adrenergic receptor,ADRB1,agonist,yes
Isoetarine,,Beta-2 adrenergic receptor,ADRB2,agonist,unknown
Glimepiride,Approximately 5 hours following single dose.,ATP-sensitive inward rectifier potassium channel 11,KCNJ11,inhibitor,yes
Glimepiride,Approximately 5 hours following single dose.,ATP-sensitive inward rectifier potassium channel 1,KCNJ1,inhibitor,yes
Glimepiride,Approximately 5 hours following single dose.,ATP-binding cassette sub-family C member 8,ABCC8,inducer,yes
Diflorasone,,Glucocorticoid receptor,NR3C1,agonist,yes
Indinavir,1.8 (&plusmn; 0.4) hours,Human immunodeficiency virus type 1 protease,pol,inhibitor,yes
Guanadrel,10 hours,Sodium-dependent noradrenaline transporter,SLC6A2,partial agonist,yes
Lovastatin,5.3 hours,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,inhibitor,yes
Lovastatin,5.3 hours,Integrin alpha-L,ITGAL,other/unknown,no
Lovastatin,5.3 hours,Histone deacetylase 2,HDAC2,other,no
Enflurane,,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Enflurane,,Glycine receptor (alpha-1/beta),GLRA1GLRB,agonist,yes
Enflurane,,Intermediate conductance calcium-activated potassium channel protein 4,KCNN4,inhibitor,unknown
Enflurane,,Potassium voltage-gated channel subfamily A member 1,KCNA1,inducer,yes
Enflurane,,Calcium-transporting ATPase type 2C member 1,ATP2C1,inhibitor,yes
Enflurane,,Glutamate receptor 1,GRIA1,antagonist,yes
Enflurane,,"ATP synthase subunit delta, mitochondrial",ATP5D,other/unknown,unknown
Cefotiam,Approximately 1 hour.,Penicillin-binding protein 1A,pbpA,inducer,yes
Pregabalin,Mean elimination half-life is 6.3 hours in subjects with normal renal function.[A31169],Voltage-dependent P/Q-type calcium channel subunit alpha-1A,CACNA1A,inhibitor,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit pi,GABRP,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit rho-3,GABRR3,potentiator,yes
Temazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit theta,GABRQ,potentiator,yes
Temazepam,10-20 hours,Translocator protein,TSPO,other,unknown
Temazepam,10-20 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Methyclothiazide,,Solute carrier family 12 member 1,SLC12A1,inhibitor,yes
Methyclothiazide,,Carbonic anhydrase 1,CA1,inhibitor,unknown
Methyclothiazide,,Carbonic anhydrase 2,CA2,inhibitor,unknown
Methyclothiazide,,Carbonic anhydrase 4,CA4,inhibitor,unknown
Aminosalicylic Acid,,Prostaglandin G/H synthase 2,PTGS2,inhibitor,unknown
Aminosalicylic Acid,,Inhibitor of nuclear factor kappa-B kinase subunit alpha,CHUK,inhibitor,unknown
Aminosalicylic Acid,,Arachidonate 5-lipoxygenase,ALOX5,inhibitor,unknown
Aminosalicylic Acid,,Group IIE secretory phospholipase A2,PLA2G2E,unknown,unknown
Aminosalicylic Acid,,2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase,folK,unknown,unknown
Reboxetine,12.5 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Milrinone,2.3 hours,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,inhibitor,yes
Pipobroman,,DNA,,cross-linking/alkylation,yes
Butabarbital,,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Butabarbital,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Butabarbital,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Butabarbital,,Glutamate receptor 2,GRIA2,antagonist,unknown
Butabarbital,,"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Nevirapine,45 hours,Reverse transcriptase/RNaseH,pol,inhibitor,yes
Oxiconazole,,Lanosterol 14-alpha demethylase,ERG11,inhibitor,yes
Oxiconazole,,Lanosterol synthase,ERG7,inhibitor,yes
Oxiconazole,,Nuclear receptor subfamily 1 group I member 2,NR1I2,partial agonist,unknown
Alclometasone,,Glucocorticoid receptor,NR3C1,agonist,yes
Butalbital,35 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Butalbital,35 hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Butalbital,35 hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Butalbital,35 hours,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Butalbital,35 hours,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Butalbital,35 hours,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Butalbital,35 hours,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Butalbital,35 hours,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Butalbital,35 hours,Glutamate receptor 2,GRIA2,antagonist,unknown
Butalbital,35 hours,"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Butalbital,35 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Cladribine,5.4 hours,Ribonucleoside-diphosphate reductase large subunit,RRM1,inhibitor,yes
Cladribine,5.4 hours,Ribonucleoside-diphosphate reductase subunit M2,RRM2,inhibitor,yes
Cladribine,5.4 hours,Ribonucleoside-diphosphate reductase subunit M2 B,RRM2B,inhibitor,yes
Cladribine,5.4 hours,DNA,,other/unknown,yes
Cladribine,5.4 hours,DNA polymerase alpha catalytic subunit,POLA1,inhibitor,yes
Cladribine,5.4 hours,DNA polymerase epsilon catalytic subunit A,POLE,inhibitor,yes
Cladribine,5.4 hours,DNA polymerase epsilon subunit 2,POLE2,inhibitor,yes
Cladribine,5.4 hours,DNA polymerase epsilon subunit 3,POLE3,inhibitor,yes
Cladribine,5.4 hours,DNA polymerase epsilon subunit 4,POLE4,inhibitor,yes
Cladribine,5.4 hours,Purine nucleoside phosphorylase,PNP,inducer,yes
Ranolazine,7 hours,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Ranolazine,7 hours,Sodium channel protein type 9 subunit alpha,SCN9A,inhibitor,unknown
Mesalazine,"The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.",Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Mesalazine,"The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.",Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Mesalazine,"The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.",Arachidonate 5-lipoxygenase,ALOX5,inhibitor,yes
Mesalazine,"The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.",Peroxisome proliferator-activated receptor gamma,PPARG,agonist,yes
Mesalazine,"The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.",Inhibitor of nuclear factor kappa-B kinase subunit alpha,CHUK,inhibitor,unknown
Mesalazine,"The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.",Inhibitor of nuclear factor kappa-B kinase subunit beta,IKBKB,inhibitor,unknown
Mesalazine,"The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.",Myeloperoxidase,MPO,,unknown
Mesalazine,"The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.",Arylamine N-acetyltransferase,nat,,unknown
Benzatropine,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Benzatropine,,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,yes
Benzatropine,,Histamine H1 receptor,HRH1,antagonist,unknown
Ziprasidone,7 hours,D(2) dopamine receptor,DRD2,antagonist,yes
Ziprasidone,7 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Ziprasidone,7 hours,D(1A) dopamine receptor,DRD1,antagonist,unknown
Ziprasidone,7 hours,D(1B) dopamine receptor,DRD5,antagonist,unknown
Ziprasidone,7 hours,D(3) dopamine receptor,DRD3,antagonist,unknown
Ziprasidone,7 hours,D(4) dopamine receptor,DRD4,antagonist,unknown
Ziprasidone,7 hours,5-hydroxytryptamine receptor 1A,HTR1A,agonist,unknown
Ziprasidone,7 hours,5-hydroxytryptamine receptor 1B,HTR1B,antagonist,unknown
Ziprasidone,7 hours,5-hydroxytryptamine receptor 1D,HTR1D,antagonist,unknown
Ziprasidone,7 hours,5-hydroxytryptamine receptor 1E,HTR1E,antagonist,unknown
Ziprasidone,7 hours,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Ziprasidone,7 hours,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,unknown
Ziprasidone,7 hours,5-hydroxytryptamine receptor 6,HTR6,antagonist,unknown
Ziprasidone,7 hours,5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Ziprasidone,7 hours,Histamine H1 receptor,HRH1,antagonist,no
Ziprasidone,7 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,no
Ziprasidone,7 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,no
Ziprasidone,7 hours,Alpha-2A adrenergic receptor,ADRA2A,antagonist,no
Ziprasidone,7 hours,Alpha-2B adrenergic receptor,ADRA2B,antagonist,no
Ziprasidone,7 hours,Alpha-2C adrenergic receptor,ADRA2C,antagonist,no
Ziprasidone,7 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,no
Ziprasidone,7 hours,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,no
Ziprasidone,7 hours,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,no
Ziprasidone,7 hours,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,no
Ziprasidone,7 hours,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,no
Methysergide,,5-hydroxytryptamine receptor 2B,HTR2B,antagonist,yes
Methysergide,,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,yes
Methysergide,,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Methysergide,,5-hydroxytryptamine receptor 1A,HTR1A,agonist,yes
Methysergide,,5-hydroxytryptamine receptor 7,HTR7,antagonist,yes
Methysergide,,5-hydroxytryptamine receptor 1B,HTR1B,binder,unknown
Methysergide,,5-hydroxytryptamine receptor 1F,HTR1F,binder,unknown
Methysergide,,5-hydroxytryptamine receptor 1E,HTR1E,binder,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,D(2) dopamine receptor,DRD2,agonist,yes
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,5-hydroxytryptamine receptor 2B,HTR2B,agonist,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,D(3) dopamine receptor,DRD3,agonist,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,5-hydroxytryptamine receptor 2A,HTR2A,agonist,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,Alpha-2B adrenergic receptor,ADRA2B,antagonist,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,5-hydroxytryptamine receptor 1D,HTR1D,agonist,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,D(4) dopamine receptor,DRD4,agonist,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,5-hydroxytryptamine receptor 1A,HTR1A,agonist,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,Alpha-2C adrenergic receptor,ADRA2C,antagonist,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,D(1B) dopamine receptor,DRD5,agonist,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,D(1A) dopamine receptor,DRD1,agonist,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,5-hydroxytryptamine receptor 1B,HTR1B,agonist,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,5-hydroxytryptamine receptor 2C,HTR2C,agonist,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,Alpha-1A adrenergic receptor,ADRA1A,binder,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,Alpha-1B adrenergic receptor,ADRA1B,binder,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,Alpha-1D adrenergic receptor,ADRA1D,binder,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,Beta-1 adrenergic receptor,ADRB1,binder,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,Beta-2 adrenergic receptor,ADRB2,binder,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,D(1) dopamine receptor,DRD1DRD5,agonist,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,D(2S) dopamine receptor,,agonist,unknown
Cabergoline,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,D(2L) dopamine receptor,,agonist,unknown
Idoxuridine,,DNA,,other,yes
Idoxuridine,,Thymidine kinase,TK,unknown,unknown
Dapsone,28 hours (range 10-50 hours),Inactive dihydropteroate synthase 2,folP2,inhibitor,yes
Dapsone,28 hours (range 10-50 hours),Dihydropteroate synthase 1,folP1,inhibitor,yes
Terconazole,6.9 hours (range 4.0-11.3),Lanosterol 14-alpha demethylase,ERG11,antagonist,yes
Phenytoin,22 hours (range of 7 to 42 hours),Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Phenytoin,22 hours (range of 7 to 42 hours),Sodium channel protein type 1 subunit alpha,SCN1A,inhibitor,yes
Phenytoin,22 hours (range of 7 to 42 hours),Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Phenytoin,22 hours (range of 7 to 42 hours),Sodium channel subunit beta-1,SCN1B,,unknown
Phenytoin,22 hours (range of 7 to 42 hours),Sodium channel protein type 3 subunit alpha,SCN3A,,unknown
Medrysone,,Glucocorticoid receptor,NR3C1,agonist,yes
Doxycycline,18-22 hours,30S ribosomal protein S9,rpsI,inhibitor,yes
Doxycycline,18-22 hours,30S ribosomal protein S4,rpsD,inhibitor,yes
Doxycycline,18-22 hours,16S rRNA,,inhibitor,yes
Doxycycline,18-22 hours,Protein-arginine deiminase type-4,PADI4,,unknown
Doxycycline,18-22 hours,Beta-2-microglobulin,B2M,,unknown
Diethylstilbestrol,,Estrogen receptor alpha,ESR1,agonist,yes
Diethylstilbestrol,,Estrogen-related receptor gamma,ESRRG,agonist,yes
Diethylstilbestrol,,Estrogen receptor beta,ESR2,agonist,yes
Diethylstilbestrol,,Steroid hormone receptor ERR1,ESRRA,,unknown
Diethylstilbestrol,,Steroid hormone receptor ERR2,ESRRB,,unknown
Diethylstilbestrol,,Nuclear receptor coactivator 2,NCOA2,,unknown
Diethylstilbestrol,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Diethylstilbestrol,,Androgen receptor,AR,antagonist,unknown
Diethylstilbestrol,,Sex hormone-binding globulin,SHBG,,unknown
Lymecycline,,30S ribosomal protein S9,rpsI,inhibitor,unknown
Lymecycline,,30S ribosomal protein S4,rpsD,inhibitor,unknown
Clotrimazole,2 hours,Lanosterol 14-alpha demethylase,ERG11,antagonistinhibitor,yes
Clotrimazole,2 hours,Intermediate conductance calcium-activated potassium channel protein 4,KCNN4,inhibitor,yes
Clotrimazole,2 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,activator,unknown
Clotrimazole,2 hours,Nuclear receptor subfamily 1 group I member 3,NR1I3,partial agonist,unknown
Calcium Acetate,,Phosphate,,binder,yes
Sulfanilamide,,Dihydropteroate synthase,folP,inhibitor,yes
Cycloserine,"Half-life in patients with normal renal function is 10 hours, and is prolonged in patients with impaired renal function.",D-alanine--D-alanine ligase A,ddlA,inhibitor,yes
Cycloserine,"Half-life in patients with normal renal function is 10 hours, and is prolonged in patients with impaired renal function.",Alanine racemase,alr,inhibitor,yes
Anagrelide,"At fasting and at a dose of 0.5 mg of anagrelide, the plasma half-life is 1.3 hours.","cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,inhibitor,yes
Carmustine,15-30 minutes,DNA,,other/unknown,yes
Carmustine,15-30 minutes,"Glutathione reductase, mitochondrial",GSR,inhibitor,yes
Carmustine,15-30 minutes,RNA,,other/unknown,yes
Sulfisoxazole,,Dihydropteroate synthase,folP,inhibitor,yes
Metoprolol,3-7 hours,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Metoprolol,3-7 hours,Beta-2 adrenergic receptor,ADRB2,antagonist,unknown
Dicoumarol,,Vitamin K epoxide reductase complex subunit 1,VKORC1,inhibitor,yes
Dicoumarol,,NAD(P)H dehydrogenase [quinone] 1,NQO1,inhibitor,unknown
Dicoumarol,,Quinone oxidoreductase,CRYZ,inhibitor,unknown
Cefmenoxime,1 hour,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Cefmenoxime,1 hour,Peptidoglycan synthase FtsI,ftsI,inhibitor,yes
Ropinirole,6 hours,D(3) dopamine receptor,DRD3,agonist,yes
Ropinirole,6 hours,D(2) dopamine receptor,DRD2,agonist,yes
Ropinirole,6 hours,D(4) dopamine receptor,DRD4,agonist,unknown
Ropinirole,6 hours,5-hydroxytryptamine receptor 1A,HTR1A,agonist,unknown
Ropinirole,6 hours,5-hydroxytryptamine receptor 1D,HTR1D,agonist,unknown
Ropinirole,6 hours,5-hydroxytryptamine receptor 2B,HTR2B,agonist,unknown
Ropinirole,6 hours,D(1A) dopamine receptor,DRD1,agonist,unknown
Ropinirole,6 hours,D(1B) dopamine receptor,DRD5,agonist,unknown
Ropinirole,6 hours,5-hydroxytryptamine receptor 1B,HTR1B,agonist,unknown
Ropinirole,6 hours,5-hydroxytryptamine receptor 2A,HTR2A,agonist,unknown
Ropinirole,6 hours,5-hydroxytryptamine receptor 2C,HTR2C,agonist,unknown
Ropinirole,6 hours,Alpha-2A adrenergic receptor,ADRA2A,agonist,unknown
Ropinirole,6 hours,Alpha-2B adrenergic receptor,ADRA2B,agonist,unknown
Ropinirole,6 hours,Alpha-2C adrenergic receptor,ADRA2C,agonist,unknown
Chlorotrianisene,,Estrogen receptor alpha,ESR1,agonist,yes
Isradipine,8 hours,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,inhibitor,yes
Isradipine,8 hours,Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,inhibitor,yes
Isradipine,8 hours,Voltage-dependent L-type calcium channel subunit beta-2,CACNB2,inhibitor,yes
Isradipine,8 hours,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,inhibitor,yes
Isradipine,8 hours,Voltage-dependent calcium channel subunit alpha-2/delta-2,CACNA2D2,inhibitor,yes
Isradipine,8 hours,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,inhibitor,yes
Isradipine,8 hours,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,inhibitor,yes
Betazole,,Histamine H2 receptor,HRH2,agonist,yes
Topiramate,19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,agonist,yes
Topiramate,19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.,Sodium channel protein type 1 subunit alpha,SCN1A,inhibitor,yes
Topiramate,19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.,"Glutamate receptor ionotropic, kainate 1",GRIK1,antagonist,yes
Topiramate,19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.,Carbonic anhydrase 2,CA2,inhibitor,yes
Topiramate,19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.,Carbonic anhydrase 4,CA4,inhibitor,yes
Topiramate,19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Topiramate,19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.,Carbonic anhydrase 1,CA1,inhibitor,unknown
Topiramate,19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.,Carbonic anhydrase 3,CA3,inhibitor,unknown
Cefmetazole,1.50 &plusmn;0.14 hours,Penicillin binding protein 2a,mecA,inhibitor,yes
Cefmetazole,1.50 &plusmn;0.14 hours,Penicillin-binding protein 1A,mrcA,inhibitor,yes
Cefmetazole,1.50 &plusmn;0.14 hours,Penicillin-binding protein 1B,mrcB,inhibitor,yes
Cefmetazole,1.50 &plusmn;0.14 hours,Peptidoglycan synthase FtsI,ftsI,inhibitor,yes
Cefmetazole,1.50 &plusmn;0.14 hours,D-alanyl-D-alanine carboxypeptidase DacA,dacA,inhibitor,yes
Cefmetazole,1.50 &plusmn;0.14 hours,D-alanyl-D-alanine carboxypeptidase DacC,dacC,inhibitor,yes
Olmesartan,The half life is approximately 13 hours.,Type-1 angiotensin II receptor,AGTR1,antagonist,yes
Amsacrine,8-9 hours,DNA,,intercalation,yes
Amsacrine,8-9 hours,DNA topoisomerase 2-alpha,TOP2A,inhibitor,yes
Amsacrine,8-9 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Amsacrine,8-9 hours,Alpha-1-acid glycoprotein 1,ORM1,,unknown
Amsacrine,8-9 hours,Serum albumin,ALB,,unknown
Theophylline,8 hours,Adenosine receptor A1,ADORA1,antagonist,yes
Theophylline,8 hours,Adenosine receptor A2a,ADORA2A,antagonist,yes
Theophylline,8 hours,Adenosine receptor A2b,ADORA2B,antagonist,yes
Theophylline,8 hours,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,inhibitor,yes
Theophylline,8 hours,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,inhibitor,yes
Theophylline,8 hours,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,inhibitor,yes
Theophylline,8 hours,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,inhibitor,yes
Theophylline,8 hours,Histone deacetylase 2,HDAC2,activator,yes
Theophylline,8 hours,Copine-1,CPNE1,,unknown
Theophylline,8 hours,Minor histocompatibility antigen H13,HM13,,unknown
Theophylline,8 hours,Nodal modulator 1,NOMO1,,unknown
Theophylline,8 hours,Poly [ADP-ribose] polymerase 1,PARP1,,unknown
Theophylline,8 hours,Protein RIC-3,RIC3,,unknown
Theophylline,8 hours,Tubulin monoglycylase TTLL3,TTLL3,,unknown
Argatroban,39 and 51 minutes,Prothrombin,F2,inhibitor,yes
Liothyronine,2.5 days,Thyroid hormone receptor alpha,THRA,agonist,yes
Liothyronine,2.5 days,Thyroid hormone receptor beta,THRB,agonist,yes
Liothyronine,2.5 days,Proliferating cell nuclear antigen,PCNA,,unknown
Disopyramide,6.7 hours (range 4-10 hours),Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Disopyramide,6.7 hours (range 4-10 hours),Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Disopyramide,6.7 hours (range 4-10 hours),Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Disopyramide,6.7 hours (range 4-10 hours),Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Disopyramide,6.7 hours (range 4-10 hours),Potassium voltage-gated channel subfamily D member 2,KCND2,inhibitor,unknown
Disopyramide,6.7 hours (range 4-10 hours),Potassium voltage-gated channel subfamily D member 3,KCND3,inhibitor,unknown
Disopyramide,6.7 hours (range 4-10 hours),Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Disopyramide,6.7 hours (range 4-10 hours),Alpha-1-acid glycoprotein 2,ORM2,,unknown
Lidocaine,109 minutes,Sodium channel protein type 10 subunit alpha,SCN10A,inhibitor,yes
Lidocaine,109 minutes,Sodium channel protein type 9 subunit alpha,SCN9A,inhibitor,yes
Lidocaine,109 minutes,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Lidocaine,109 minutes,Epidermal growth factor receptor,EGFR,antagonist,unknown
Lidocaine,109 minutes,Sodium channel protein type 4 subunit alpha,SCN4A,,unknown
Lidocaine,109 minutes,Alpha-1-acid glycoprotein 1,ORM1,,unknown
Lidocaine,109 minutes,Alpha-1-acid glycoprotein 2,ORM2,,unknown
Pamidronate,The mean &plusmn; SD elimination half-life is 28 &plusmn; 7 hours,Farnesyl pyrophosphate synthase,FDPS,inhibitor,yes
Pamidronate,The mean &plusmn; SD elimination half-life is 28 &plusmn; 7 hours,Hydroxylapatite,,antagonist,yes
Clemastine,,Histamine H1 receptor,HRH1,antagonist,yes
Acarbose,Healthy volunteers = 2 hours,"Maltase-glucoamylase, intestinal",MGAM,inhibitor,yes
Acarbose,Healthy volunteers = 2 hours,Pancreatic alpha-amylase,AMY2A,inhibitor,yes
Acarbose,Healthy volunteers = 2 hours,Lysosomal alpha-glucosidase,GAA,inhibitor,yes
Acarbose,Healthy volunteers = 2 hours,"Sucrase-isomaltase, intestinal",SI,inhibitor,yes
Venlafaxine,5 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Venlafaxine,5 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Venlafaxine,5 hours,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,unknown
Conjugated estrogens,"Following a dose of 0.625 mg of conjugated estrogens, the half life of estrone, baseline-adjusted estrone, and equilin was found to be 26.7 hr, 14.8 hr, and 11.4 hr, respectively.",Estrogen receptor alpha,ESR1,agonist,yes
Travoprost,Terminal elimination half-life of travoprost free acid is 45 minutes.,Prostaglandin F2-alpha receptor,PTGFR,agonist,yes
Amcinonide,,Glucocorticoid receptor,NR3C1,agonist,yes
Amcinonide,,Annexin A1,ANXA1,agonist,unknown
Atomoxetine,5 hours,Sodium-dependent noradrenaline transporter,SLC6A2,,yes
Atomoxetine,5 hours,Sodium-dependent serotonin transporter,SLC6A4,,unknown
Atomoxetine,5 hours,Sodium-dependent dopamine transporter,SLC6A3,binder,unknown
Atomoxetine,5 hours,NMDA receptor,GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B,blocker,unknown
Bleomycin,115 minutes,DNA ligase 1,LIG1,inhibitor,unknown
Bleomycin,115 minutes,DNA,,cleavage,yes
Bleomycin,115 minutes,DNA ligase 3,LIG3,inhibitor,unknown
Chlorambucil,1.5 hours,DNA,,cross-linking/alkylation,unknown
Etomidate,75 minutes.,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,agonist,yes
Etomidate,75 minutes.,Alpha-2B adrenergic receptor,ADRA2B,agonist,yes
Etomidate,75 minutes.,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Raltitrexed,198 hours,Thymidylate synthase,TYMS,inhibitor,yes
Raltitrexed,198 hours,"Folylpolyglutamate synthase, mitochondrial",FPGS,antagonist,unknown
Etonogestrel,25 hours,Progesterone receptor,PGR,agonist,yes
Etonogestrel,25 hours,Estrogen receptor alpha,ESR1,agonist,yes
Morphine,2-4 hours,Mu-type opioid receptor,OPRM1,agonist,yes
Morphine,2-4 hours,Kappa-type opioid receptor,OPRK1,agonist,yes
Morphine,2-4 hours,Delta-type opioid receptor,OPRD1,agonist,yes
Morphine,2-4 hours,Lymphocyte antigen 96,LY96,,unknown
Ropivacaine,Approximately 4.2 hours.,Sodium channel protein type 10 subunit alpha,SCN10A,inhibitor,yes
Bupivacaine,2.7 hours in adults and 8.1 hours in neonates,Sodium channel protein type 10 subunit alpha,SCN10A,inhibitor,yes
Bupivacaine,2.7 hours in adults and 8.1 hours in neonates,Prostaglandin E2 receptor EP1 subtype,PTGER1,other/unknown,unknown
Dapiprazole,,Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Dapiprazole,,Alpha-1D adrenergic receptor,ADRA1D,antagonist,yes
Dapiprazole,,Alpha-1B adrenergic receptor,ADRA1B,antagonist,yes
Penciclovir,2 hours,DNA polymerase catalytic subunit,,inhibitor,yes
Penciclovir,2 hours,Thymidine kinase,TK,inducer,yes
Tenofovir disoproxil,"When a single oral dose is given, the terminal elimination half-life is approximately 17 hours.",Reverse transcriptase/RNaseH,pol,inhibitor,yes
Flucloxacillin,0.75–1 hour,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Tranexamic Acid,Biological half-life in the joint fluid is about 3 hours.,Plasminogen,PLG,inhibitor,yes
Ertapenem,The mean plasma half-life is approximately 4 hours.,Penicillin-binding protein 2,mrdA,inhibitor,yes
Ertapenem,The mean plasma half-life is approximately 4 hours.,Penicillin-binding protein 2,mrdA,inhibitor,yes
Ertapenem,The mean plasma half-life is approximately 4 hours.,Peptidoglycan synthase FtsI,ftsI,inhibitor,yes
Ertapenem,The mean plasma half-life is approximately 4 hours.,Peptidoglycan synthase FtsI,ftsI,inhibitor,yes
Ertapenem,The mean plasma half-life is approximately 4 hours.,D-alanyl-D-alanine carboxypeptidase DacB,dacB,inhibitor,yes
Ertapenem,The mean plasma half-life is approximately 4 hours.,Penicillin-binding protein 1A,mrcA,inhibitor,yes
Ertapenem,The mean plasma half-life is approximately 4 hours.,Penicillin-binding protein 1B,mrcB,inhibitor,yes
Ertapenem,The mean plasma half-life is approximately 4 hours.,D-alanyl-D-alanine carboxypeptidase DacC,dacC,inhibitor,yes
Desogestrel,27.8&plusmn;7.2 hours,Progesterone receptor,PGR,agonist,yes
Desogestrel,27.8&plusmn;7.2 hours,Estrogen receptor alpha,ESR1,agonist,yes
Mitomycin,8-48 min,DNA,,antagonistcross-linking/alkylation,yes
Talbutal,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Talbutal,,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Talbutal,,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Talbutal,,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Talbutal,,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Talbutal,,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Talbutal,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Talbutal,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Talbutal,,Glutamate receptor 2,GRIA2,antagonist,unknown
Talbutal,,"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Talbutal,,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Bexarotene,7 hours,Retinoic acid receptor RXR-alpha,RXRA,agonist,yes
Bexarotene,7 hours,Retinoic acid receptor RXR-beta,RXRB,agonist,yes
Bexarotene,7 hours,Retinoic acid receptor RXR-gamma,RXRG,agonist,yes
Ibutilide,6 hours (ranges from 2-12 hours),Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,activator,yes
Ibutilide,6 hours (ranges from 2-12 hours),Voltage-dependent L-type calcium channel subunit beta-1,CACNB1,activator,yes
Ibutilide,6 hours (ranges from 2-12 hours),Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,yes
Ibutilide,6 hours (ranges from 2-12 hours),Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,activator,unknown
Ibutilide,6 hours (ranges from 2-12 hours),Voltage-dependent calcium channel gamma-1 subunit,CACNG1,activator,unknown
Ibutilide,6 hours (ranges from 2-12 hours),Potassium channel subfamily K member 1,KCNK1,inhibitor,unknown
Ibutilide,6 hours (ranges from 2-12 hours),Potassium channel subfamily K member 6,KCNK6,inhibitor,unknown
Ibutilide,6 hours (ranges from 2-12 hours),Potassium voltage-gated channel subfamily H member 6,KCNH6,inhibitor,unknown
Ibutilide,6 hours (ranges from 2-12 hours),Potassium voltage-gated channel subfamily H member 7,KCNH7,inhibitor,unknown
Ibutilide,6 hours (ranges from 2-12 hours),ATP-sensitive inward rectifier potassium channel 11,KCNJ11,inhibitor,unknown
Vindesine,24 hours.,Tubulin beta-1 chain,TUBB1,inhibitor,yes
Chlorthalidone,40 hours,Solute carrier family 12 member 1,SLC12A1,inhibitor,yes
Ethoxzolamide,2.5-5.5 hours,Carbonic anhydrase 1,CA1,inhibitor,yes
Ethoxzolamide,2.5-5.5 hours,Carbonic anhydrase 2,CA2,inhibitor,yes
Ethoxzolamide,2.5-5.5 hours,Carbonic anhydrase 4,CA4,inhibitor,yes
Ethoxzolamide,2.5-5.5 hours,Carbonic anhydrase 7,CA7,inhibitor,yes
Ethoxzolamide,2.5-5.5 hours,Carbonic anhydrase 3,CA3,inhibitor,unknown
Pentobarbital,5 to 50 hours (dose dependent),Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Pentobarbital,5 to 50 hours (dose dependent),Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Pentobarbital,5 to 50 hours (dose dependent),Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Pentobarbital,5 to 50 hours (dose dependent),Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Pentobarbital,5 to 50 hours (dose dependent),Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Pentobarbital,5 to 50 hours (dose dependent),Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Pentobarbital,5 to 50 hours (dose dependent),Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Pentobarbital,5 to 50 hours (dose dependent),Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Pentobarbital,5 to 50 hours (dose dependent),Glutamate receptor 2,GRIA2,antagonist,unknown
Pentobarbital,5 to 50 hours (dose dependent),"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Pentobarbital,5 to 50 hours (dose dependent),GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Pentobarbital,5 to 50 hours (dose dependent),NMDA receptor,GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B,antagonist,unknown
Pentobarbital,5 to 50 hours (dose dependent),Nuclear receptor subfamily 1 group I member 2,NR1I2,activator,unknown
Valproic Acid,9-16 hours (following oral administration of 250 mg to 1000 mg),Histone deacetylase 9,HDAC9,inhibitor,yes
Valproic Acid,9-16 hours (following oral administration of 250 mg to 1000 mg),"4-aminobutyrate aminotransferase, mitochondrial",ABAT,inhibitor,yes
Valproic Acid,9-16 hours (following oral administration of 250 mg to 1000 mg),"Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial",ACADSB,inhibitor,unknown
Valproic Acid,9-16 hours (following oral administration of 250 mg to 1000 mg),"2-oxoglutarate dehydrogenase, mitochondrial",OGDH,inhibitor,unknown
Valproic Acid,9-16 hours (following oral administration of 250 mg to 1000 mg),"Succinate-semialdehyde dehydrogenase, mitochondrial",ALDH5A1,inhibitor,unknown
Valproic Acid,9-16 hours (following oral administration of 250 mg to 1000 mg),Sodium channel protein,SCN1ASCN10ASCN11ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCN1BSCN2BSCN3BSCN4B,,unknown
Valproic Acid,9-16 hours (following oral administration of 250 mg to 1000 mg),Histone deacetylase 2,HDAC2,,unknown
Valproic Acid,9-16 hours (following oral administration of 250 mg to 1000 mg),Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Valproic Acid,9-16 hours (following oral administration of 250 mg to 1000 mg),Peroxisome proliferator-activated receptor delta,PPARD,,unknown
Valproic Acid,9-16 hours (following oral administration of 250 mg to 1000 mg),Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Capreomycin,,70S ribosome,,inhibitor,yes
Zolmitriptan,The mean elimination half-life of zolmitriptan and of the active N-desmethyl metabolite is 3 hours.,5-hydroxytryptamine receptor 1B,HTR1B,agonist,yes
Zolmitriptan,The mean elimination half-life of zolmitriptan and of the active N-desmethyl metabolite is 3 hours.,5-hydroxytryptamine receptor 1D,HTR1D,agonist,yes
Zolmitriptan,The mean elimination half-life of zolmitriptan and of the active N-desmethyl metabolite is 3 hours.,5-hydroxytryptamine receptor 1F,HTR1F,agonist,yes
Zolmitriptan,The mean elimination half-life of zolmitriptan and of the active N-desmethyl metabolite is 3 hours.,5-hydroxytryptamine receptor 1A,HTR1A,agonist,yes
Acetaminophen,1 to 4 hours,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Acetaminophen,1 to 4 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Acetaminophen,1 to 4 hours,Prostaglandin G/H synthase 3,,inhibitor,unknown
Acetaminophen,1 to 4 hours,Fatty-acid amide hydrolase 1,FAAH,inhibitor,unknown
Acetaminophen,1 to 4 hours,Transient receptor potential cation channel subfamily V member 1,TRPV1,,unknown
Acetaminophen,1 to 4 hours,Glutathione S-transferase P,GSTP1,,unknown
Gefitinib,48 hours [IV administration],Epidermal growth factor receptor,EGFR,antagonist,yes
Codeine,Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours.,Mu-type opioid receptor,OPRM1,partial agonist,yes
Codeine,Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours.,Kappa-type opioid receptor,OPRK1,partial agonist,yes
Codeine,Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours.,Delta-type opioid receptor,OPRD1,agonist,yes
Piperacillin,36-72 minutes,Penicillin-binding protein 3,pbp3,inhibitor,yes
Piperacillin,36-72 minutes,Penicillin-binding protein 2B,penA,inhibitor,yes
Piperacillin,36-72 minutes,Penicillin-binding protein 2a,pbp2a,inhibitor,yes
Piperacillin,36-72 minutes,Penicillin-binding protein 1b,pbp1b,inhibitor,yes
Dihydroergotamine,9 hours,5-hydroxytryptamine receptor 1D,HTR1D,agonist,yes
Dihydroergotamine,9 hours,5-hydroxytryptamine receptor 1B,HTR1B,agonist,yes
Dihydroergotamine,9 hours,Alpha-2A adrenergic receptor,ADRA2A,agonist,unknown
Dihydroergotamine,9 hours,5-hydroxytryptamine receptor 2B,HTR2B,agonist,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,5-hydroxytryptamine receptor 1A,HTR1A,inhibitor,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Delta-type opioid receptor,OPRD1,agonist,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Kappa-type opioid receptor,OPRK1,agonist,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,High affinity nerve growth factor receptor,NTRK1,agonist,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,BDNF/NT-3 growth factors receptor,NTRK2,agonist,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Alpha-1A adrenergic receptor,ADRA1A,antagonist,no
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Alpha-1D adrenergic receptor,ADRA1D,antagonist,no
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Alpha-2A adrenergic receptor,ADRA2A,antagonist,no
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Histamine H1 receptor,HRH1,antagonist,no
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,no
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,no
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,no
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,no
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,no
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Potassium voltage-gated channel subfamily KQT member 2,KCNQ2,inhibitor,no
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Potassium voltage-gated channel subfamily A member 1,KCNA1,inhibitor,no
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Potassium voltage-gated channel subfamily D member 2,KCND2,inhibitor,no
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Potassium voltage-gated channel subfamily D member 3,KCND3,inhibitor,no
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Histamine H2 receptor,HRH2,blocker,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Histamine H4 receptor,HRH4,binder,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Sigma non-opioid intracellular receptor 1,SIGMAR1,agonist,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,5-hydroxytryptamine receptor 2C,HTR2C,binder,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,5-hydroxytryptamine receptor 1D,HTR1D,binder,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Mu-type opioid receptor,OPRM1,binder,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,5-hydroxytryptamine receptor 1B,HTR1B,binder,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,5-hydroxytryptamine receptor 6,HTR6,antagonist,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Potassium voltage-gated channel subfamily KQT member 3,KCNQ3,,unknown
Amitriptyline,The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,Beta adrenergic receptor,ADRB1ADRB2ADRB3,binder,unknown
Floxuridine,,Thymidylate synthase,TYMS,,yes
Tolcapone,2-3.5 hours,Catechol O-methyltransferase,COMT,inhibitor,yes
Fluorometholone,,Glucocorticoid receptor,NR3C1,agonist,yes
Nitroprusside,Approximately 2 minutes,Atrial natriuretic peptide receptor 1,NPR1,agonist,yes
Hydromorphone,2.6 hours (oral); 18.6 hours for sustained release Palladone,Mu-type opioid receptor,OPRM1,agonist,yes
Hydromorphone,2.6 hours (oral); 18.6 hours for sustained release Palladone,Delta-type opioid receptor,OPRD1,partial agonist,yes
Hydromorphone,2.6 hours (oral); 18.6 hours for sustained release Palladone,Kappa-type opioid receptor,OPRK1,agonist,yes
Indomethacin,4.5 hours,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Indomethacin,4.5 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Indomethacin,4.5 hours,"Phospholipase A2, membrane associated",PLA2G2A,inhibitor,yes
Indomethacin,4.5 hours,Prostaglandin reductase 2,PTGR2,inhibitor,unknown
Indomethacin,4.5 hours,Peroxisome proliferator-activated receptor gamma,PPARG,activator,unknown
Indomethacin,4.5 hours,Lactoylglutathione lyase,GLO1,inhibitor,unknown
Indomethacin,4.5 hours,Prostaglandin D2 receptor 2,PTGDR2,other/unknown,unknown
Indomethacin,4.5 hours,Peroxisome proliferator-activated receptor alpha,PPARA,agonist,unknown
Indomethacin,4.5 hours,Aldo-keto reductase family 1 member C3,AKR1C3,inhibitor,unknown
Ethambutol,"In patients with normal renal function, 3 to 4 hours. In patients with impaired renal function, up to 8 hours.",Probable arabinosyltransferase C,embC,inhibitor,yes
Ethambutol,"In patients with normal renal function, 3 to 4 hours. In patients with impaired renal function, up to 8 hours.",Probable arabinosyltransferase B,embB,inhibitor,yes
Ethambutol,"In patients with normal renal function, 3 to 4 hours. In patients with impaired renal function, up to 8 hours.",Probable arabinosyltransferase A,embA,inhibitor,yes
Metformin,6.2 hours. Duration of action is 8-12 hours.,5'-AMP-activated protein kinase subunit beta-1,PRKAB1,inducer,yes
Ipratropium bromide,"2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t<sub>1/2 &alpha;</sub>) and terminal elimination-phase half-life (t<sub>1/2 &beta;</sub>) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.",Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Ipratropium bromide,"2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t<sub>1/2 &alpha;</sub>) and terminal elimination-phase half-life (t<sub>1/2 &beta;</sub>) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.",Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Ipratropium bromide,"2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t<sub>1/2 &alpha;</sub>) and terminal elimination-phase half-life (t<sub>1/2 &beta;</sub>) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.",Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Methadone,24-36 hours,Mu-type opioid receptor,OPRM1,agonist,yes
Methadone,24-36 hours,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,antagonist,yes
Methadone,24-36 hours,Neuronal acetylcholine receptor subunit alpha-10,CHRNA10,antagonist,yes
Methadone,24-36 hours,Delta-type opioid receptor,OPRD1,agonist,yes
Methadone,24-36 hours,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,unknown
Methadone,24-36 hours,Lymphocyte antigen 96,LY96,,unknown
Methadone,24-36 hours,Alpha-1-acid glycoprotein 2,ORM2,,unknown
Olanzapine,21 to 54 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Olanzapine,21 to 54 hours,D(2) dopamine receptor,DRD2,antagonistagonist,yes
Olanzapine,21 to 54 hours,D(1A) dopamine receptor,DRD1,antagonist,unknown
Olanzapine,21 to 54 hours,D(1B) dopamine receptor,DRD5,antagonist,unknown
Olanzapine,21 to 54 hours,D(3) dopamine receptor,DRD3,antagonist,unknown
Olanzapine,21 to 54 hours,D(4) dopamine receptor,DRD4,antagonist,unknown
Olanzapine,21 to 54 hours,5-hydroxytryptamine receptor 1A,HTR1A,antagonist,unknown
Olanzapine,21 to 54 hours,5-hydroxytryptamine receptor 1B,HTR1B,antagonist,unknown
Olanzapine,21 to 54 hours,5-hydroxytryptamine receptor 1D,HTR1D,antagonist,unknown
Olanzapine,21 to 54 hours,5-hydroxytryptamine receptor 1E,HTR1E,antagonist,unknown
Olanzapine,21 to 54 hours,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Olanzapine,21 to 54 hours,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,unknown
Olanzapine,21 to 54 hours,5-hydroxytryptamine receptor 6,HTR6,antagonist,unknown
Olanzapine,21 to 54 hours,5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Olanzapine,21 to 54 hours,Histamine H1 receptor,HRH1,antagonist,unknown
Olanzapine,21 to 54 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Olanzapine,21 to 54 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Olanzapine,21 to 54 hours,Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Olanzapine,21 to 54 hours,Alpha-2B adrenergic receptor,ADRA2B,antagonist,unknown
Olanzapine,21 to 54 hours,Alpha-2C adrenergic receptor,ADRA2C,antagonist,unknown
Olanzapine,21 to 54 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Olanzapine,21 to 54 hours,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Olanzapine,21 to 54 hours,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Olanzapine,21 to 54 hours,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,unknown
Olanzapine,21 to 54 hours,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,unknown
Olanzapine,21 to 54 hours,5-hydroxytryptamine receptor 2B,HTR2B,antagonist,unknown
Olanzapine,21 to 54 hours,5-hydroxytryptamine receptor 5A,HTR5A,antagonist,unknown
Olanzapine,21 to 54 hours,D(1) dopamine receptor,DRD1DRD5,antagonist,unknown
Olanzapine,21 to 54 hours,Histamine H2 receptor,HRH2,antagonist,unknown
Olanzapine,21 to 54 hours,Histamine H4 receptor,HRH4,antagonist,unknown
Olanzapine,21 to 54 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,,unknown
Olanzapine,21 to 54 hours,Beta adrenergic receptor,ADRB1ADRB2ADRB3,,unknown
Olanzapine,21 to 54 hours,D(2L) dopamine receptor,,,unknown
Olanzapine,21 to 54 hours,D(2S) dopamine receptor,,,unknown
Atenolol,6-7 hours,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Atenolol,6-7 hours,Beta-2 adrenergic receptor,ADRB2,,unknown
Nitrofural,5 hours,Pyruvate dehydrogenase [ubiquinone],poxB,inhibitor,yes
Nitrofural,5 hours,Glutathione reductase,gor,inhibitor,yes
Nitrofural,5 hours,Malate dehydrogenase,mdh,inhibitor,yes
Nitrofural,5 hours,[Citrate [pro-3S]-lyase] ligase,citC,inhibitor,yes
Pimecrolimus,,Serine/threonine-protein kinase mTOR,MTOR,potentiator,yes
Pimecrolimus,,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,potentiator,unknown
Omeprazole,"0.5-1 hour (healthy subjects, delayed-release capsule); 
3 hours (hepatic impairment)",Potassium-transporting ATPase alpha chain 1,ATP4A,inhibitor,yes
Omeprazole,"0.5-1 hour (healthy subjects, delayed-release capsule); 
3 hours (hepatic impairment)",Aryl hydrocarbon receptor,AHR,agonist,unknown
Pyrazinamide,9-10 hours (normal conditions),Fatty acid synthetase I (FASI),,inhibitor,yes
Metixene,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Metixene,,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,yes
Metixene,,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,yes
Metixene,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Metixene,,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Cetirizine,8.3 hours,Histamine H1 receptor,HRH1,antagonist,yes
Terfenadine,3.5 hours,Histamine H1 receptor,HRH1,antagonist,yes
Terfenadine,3.5 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Terfenadine,3.5 hours,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Terfenadine,3.5 hours,Muscarinic acetylcholine receptor M1,CHRM1,binder,unknown
Terfenadine,3.5 hours,Muscarinic acetylcholine receptor M5,CHRM5,binder,unknown
Terfenadine,3.5 hours,Muscarinic acetylcholine receptor M4,CHRM4,binder,unknown
Terfenadine,3.5 hours,Muscarinic acetylcholine receptor M2,CHRM2,binder,unknown
Diltiazem,3.0 - 4.5 hours,Voltage-dependent calcium channel gamma-1 subunit,CACNG1,inhibitor,yes
Protriptyline,,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Protriptyline,,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Alfuzosin,10 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Alfuzosin,10 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,yes
Alfuzosin,10 hours,Alpha-1D adrenergic receptor,ADRA1D,antagonist,yes
Alfuzosin,10 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,,unknown
Trimethadione,,Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,inhibitor,yes
Nitisinone,~54 hours,4-hydroxyphenylpyruvate dioxygenase,HPD,inhibitor,yes
Clobazam,"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.",GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Minoxidil,4.2 hours,ATP-sensitive inward rectifier potassium channel 1,KCNJ1,inducer,yes
Minoxidil,4.2 hours,Prostaglandin G/H synthase 1,PTGS1,inducer,unknown
Minoxidil,4.2 hours,Renin,REN,,unknown
Megestrol acetate,34 hours,Progesterone receptor,PGR,agonist,yes
Megestrol acetate,34 hours,Glucocorticoid receptor,NR3C1,agonist,unknown
Tioguanine,"When the compound was given in singles doses of 65 to 300 mg/m^2, the median plasma half-disappearance time was 80 minutes (range 25-240 minutes)",DNA,,intercalation,yes
Methylergometrine,3.39 hours,D(1A) dopamine receptor,DRD1,antagonist,yes
Methylergometrine,3.39 hours,5-hydroxytryptamine receptor 2B,HTR2B,,unknown
Buclizine,,Histamine H1 receptor,HRH1,antagonist,yes
Buclizine,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Aztreonam,"The serum half-life of aztreonam averaged 1.7 hours (1.5 to 2.0) in subjects with normal renal function, independent of the dose. In elderly patients and in patients with impaired renal function, the mean serum half-life of aztreonam increased (4.7 to 6 hours and 2.1 hours, respectively).",Penicillin-binding protein 3,pbpC,inhibitor,yes
Aztreonam,"The serum half-life of aztreonam averaged 1.7 hours (1.5 to 2.0) in subjects with normal renal function, independent of the dose. In elderly patients and in patients with impaired renal function, the mean serum half-life of aztreonam increased (4.7 to 6 hours and 2.1 hours, respectively).",Beta-lactamase,ampC,potentiator,yes
Chlorzoxazone,,Calcium-activated potassium channel subunit alpha-1,KCNMA1,,yes
Aminoglutethimide,12.5 &plusmn; 1.6 hours,Cytochrome P450 19A1,CYP19A1,inhibitor,yes
Aminoglutethimide,12.5 &plusmn; 1.6 hours,"Cholesterol side-chain cleavage enzyme, mitochondrial",CYP11A1,inhibitor,yes
Mefloquine,2 to 4 weeks,Fe(II)-protoporphyrin IX,,antagonist,yes
Mefloquine,2 to 4 weeks,Hemoglobin subunit alpha,HBA1,antagonist,yes
Mefloquine,2 to 4 weeks,Adenosine receptor A2a,ADORA2A,antagonist,unknown
Sulfadiazine,,Dihydropteroate synthetase,,inhibitor,yes
Sapropterin,,Phenylalanine-4-hydroxylase,PAH,cofactor,yes
Sapropterin,,"Nitric oxide synthase, endothelial",NOS3,cofactor,yes
Sapropterin,,Tyrosine 3-monooxygenase,TH,cofactor,yes
Sapropterin,,Tryptophan 5-hydroxylase 1,TPH1,cofactor,yes
Vinorelbine,The terminal phase half-life averaged 27.7 to 43.6 hours; the mean plasma clearances ranged from 0.97 to 1.26 L/hr/kg [A32354].,Tubulin beta chain,TUBB,inhibitor,yes
Anidulafungin,40-50 hours,"1,3-beta-glucan synthase component FKS1",fksA,inhibitor,yes
Clozapine,8 hours (range 4-12 hours),D(2) dopamine receptor,DRD2,antagonist,yes
Clozapine,8 hours (range 4-12 hours),5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Clozapine,8 hours (range 4-12 hours),D(1A) dopamine receptor,DRD1,antagonist,unknown
Clozapine,8 hours (range 4-12 hours),D(3) dopamine receptor,DRD3,antagonist,unknown
Clozapine,8 hours (range 4-12 hours),D(4) dopamine receptor,DRD4,antagonist,unknown
Clozapine,8 hours (range 4-12 hours),5-hydroxytryptamine receptor 1A,HTR1A,antagonist,unknown
Clozapine,8 hours (range 4-12 hours),5-hydroxytryptamine receptor 1B,HTR1B,antagonist,unknown
Clozapine,8 hours (range 4-12 hours),5-hydroxytryptamine receptor 1D,HTR1D,antagonist,unknown
Clozapine,8 hours (range 4-12 hours),5-hydroxytryptamine receptor 1E,HTR1E,antagonist,unknown
Clozapine,8 hours (range 4-12 hours),5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Clozapine,8 hours (range 4-12 hours),5-hydroxytryptamine receptor 3A,HTR3A,antagonist,unknown
Clozapine,8 hours (range 4-12 hours),5-hydroxytryptamine receptor 6,HTR6,antagonist,unknown
Clozapine,8 hours (range 4-12 hours),5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Clozapine,8 hours (range 4-12 hours),Histamine H1 receptor,HRH1,antagonist,no
Clozapine,8 hours (range 4-12 hours),Histamine H4 receptor,HRH4,antagonist,no
Clozapine,8 hours (range 4-12 hours),Alpha-1A adrenergic receptor,ADRA1A,antagonist,no
Clozapine,8 hours (range 4-12 hours),Alpha-1B adrenergic receptor,ADRA1B,antagonist,no
Clozapine,8 hours (range 4-12 hours),Alpha-2A adrenergic receptor,ADRA2A,antagonist,no
Clozapine,8 hours (range 4-12 hours),Alpha-2B adrenergic receptor,ADRA2B,antagonist,no
Clozapine,8 hours (range 4-12 hours),Alpha-2C adrenergic receptor,ADRA2C,antagonist,no
Clozapine,8 hours (range 4-12 hours),Muscarinic acetylcholine receptor M1,CHRM1,antagonist,no
Clozapine,8 hours (range 4-12 hours),Muscarinic acetylcholine receptor M2,CHRM2,antagonist,no
Clozapine,8 hours (range 4-12 hours),Muscarinic acetylcholine receptor M3,CHRM3,antagonist,no
Clozapine,8 hours (range 4-12 hours),Muscarinic acetylcholine receptor M4,CHRM4,antagonist,no
Clozapine,8 hours (range 4-12 hours),Muscarinic acetylcholine receptor M5,CHRM5,antagonist,no
Clozapine,8 hours (range 4-12 hours),Neuron-specific vesicular protein calcyon,CALY,unknown,unknown
Clozapine,8 hours (range 4-12 hours),Glutathione S-transferase P,GSTP1,,unknown
Sucralfate,Not known.,Pepsin,,inhibitor,yes
Sucralfate,Not known.,Fibroblast growth factor 2,FGF2,agonist,yes
Sucralfate,Not known.,Pro-epidermal growth factor,EGF,inducer,yes
Sucralfate,Not known.,Fibrinogen alpha chain,FGA,antagonist,unknown
Sucralfate,Not known.,Fibrinogen beta chain,FGB,antagonist,unknown
Sucralfate,Not known.,Fibrinogen gamma chain,FGG,antagonist,unknown
Grepafloxacin,15 &plusmn; 3 hours,DNA gyrase subunit A,gyrA,inhibitor,yes
Grepafloxacin,15 &plusmn; 3 hours,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Doxylamine,10 hours,Histamine H1 receptor,HRH1,antagonist,yes
Doxylamine,10 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Doxylamine,10 hours,Nuclear receptor subfamily 1 group I member 3,NR1I3,,unknown
Levonorgestrel,,Progesterone receptor,PGR,binder,yes
Levonorgestrel,,3-oxo-5-alpha-steroid 4-dehydrogenase 1,SRD5A1,inhibitor,yes
Levonorgestrel,,Estrogen receptor alpha,ESR1,other,yes
Levonorgestrel,,Androgen receptor,AR,agonist,unknown
Levonorgestrel,,Sex hormone-binding globulin,SHBG,,unknown
Norepinephrine,,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Norepinephrine,,Alpha-1B adrenergic receptor,ADRA1B,agonist,yes
Norepinephrine,,Alpha-1D adrenergic receptor,ADRA1D,agonist,yes
Norepinephrine,,Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Norepinephrine,,Alpha-2B adrenergic receptor,ADRA2B,agonist,yes
Norepinephrine,,Alpha-2C adrenergic receptor,ADRA2C,agonist,yes
Norepinephrine,,Beta-1 adrenergic receptor,ADRB1,agonist,yes
Norepinephrine,,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Norepinephrine,,Beta-3 adrenergic receptor,ADRB3,agonist,yes
Norepinephrine,,Phenylalanine-4-hydroxylase,PAH,inhibitor,no
Norepinephrine,,Synaptic vesicular amine transporter,SLC18A2,binder,unknown
Norepinephrine,,Chromaffin granule amine transporter,SLC18A1,binder,unknown
Cidofovir,2.4 to 3.2 hours,DNA polymerase catalytic subunit,UL54,inhibitor,yes
Mirtazapine,20-40 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Mirtazapine,20-40 hours,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,yes
Mirtazapine,20-40 hours,Alpha-2A adrenergic receptor,ADRA2A,antagonist,yes
Mirtazapine,20-40 hours,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Mirtazapine,20-40 hours,Kappa-type opioid receptor,OPRK1,agonist,unknown
Mirtazapine,20-40 hours,Histamine H1 receptor,HRH1,antagonist,no
Mirtazapine,20-40 hours,Alpha-2C adrenergic receptor,ADRA2C,binder,unknown
Mirtazapine,20-40 hours,5-hydroxytryptamine receptor 7,HTR7,binding,unknown
Mirtazapine,20-40 hours,Alpha-1 adrenergic receptors,ADRA1AADRA1BADRA1D,binder,unknown
Mirtazapine,20-40 hours,D(2) dopamine receptor,DRD2,binder,unknown
Mirtazapine,20-40 hours,D(3) dopamine receptor,DRD3,,unknown
Mirtazapine,20-40 hours,Sodium-dependent noradrenaline transporter,SLC6A2,binder,unknown
Mirtazapine,20-40 hours,Sodium-dependent serotonin transporter,SLC6A4,binder,unknown
Mirtazapine,20-40 hours,Sodium-dependent dopamine transporter,SLC6A3,binder,unknown
Mirtazapine,20-40 hours,5-hydroxytryptamine receptor 2B,HTR2B,binder,unknown
Mirtazapine,20-40 hours,D(1) dopamine receptor,DRD1DRD5,binder,unknown
Mirtazapine,20-40 hours,Histamine H3 receptor,HRH3,antagonist,unknown
Mirtazapine,20-40 hours,Alpha-1A adrenergic receptor,ADRA1A,binder,unknown
Mirtazapine,20-40 hours,Beta-1 adrenergic receptor,ADRB1,binder,unknown
Mirtazapine,20-40 hours,Beta-2 adrenergic receptor,ADRB2,binder,unknown
Meprobamate,Plasma half-life is about 10 hours.,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,agonist,yes
Meprobamate,Plasma half-life is about 10 hours.,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,agonist,yes
Meprobamate,Plasma half-life is about 10 hours.,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,agonist,yes
Meprobamate,Plasma half-life is about 10 hours.,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,agonist,yes
Meprobamate,Plasma half-life is about 10 hours.,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,agonist,yes
Meprobamate,Plasma half-life is about 10 hours.,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,agonist,yes
Meprobamate,Plasma half-life is about 10 hours.,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Thiethylperazine,,D(2) dopamine receptor,DRD2,antagonist,unknown
Thiethylperazine,,D(1A) dopamine receptor,DRD1,antagonist,unknown
Thiethylperazine,,D(4) dopamine receptor,DRD4,antagonist,unknown
Timolol,2.5-5 hours,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Timolol,2.5-5 hours,Beta-2 adrenergic receptor,ADRB2,antagonist,yes
Timolol,2.5-5 hours,Lysozyme,E,,unknown
Treprostinil,"Terminal elimination half-life is approximately 2 to 4 hours. Plasma half-life is 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.",Prostacyclin receptor,PTGIR,agonist,yes
Treprostinil,"Terminal elimination half-life is approximately 2 to 4 hours. Plasma half-life is 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.",Peroxisome proliferator-activated receptor delta,PPARD,agonist,yes
Treprostinil,"Terminal elimination half-life is approximately 2 to 4 hours. Plasma half-life is 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.",P2Y purinoceptor 12,P2RY12,agonist,yes
Colestipol,,Bile acids,,binder,yes
Trihexyphenidyl,3.3-4.1 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Trihexyphenidyl,3.3-4.1 hours,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Trihexyphenidyl,3.3-4.1 hours,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Trihexyphenidyl,3.3-4.1 hours,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,unknown
Trihexyphenidyl,3.3-4.1 hours,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,unknown
Palonosetron,Approximately 40 hours,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,yes
Dydrogesterone,"Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours",Progesterone receptor,PGR,agonist,yes
Mexiletine,10-12 hours,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Mexiletine,10-12 hours,Aryl hydrocarbon receptor,AHR,agonist,unknown
Dexrazoxane,2.5 hours,DNA topoisomerase 2-alpha,TOP2A,inhibitor,yes
Dexrazoxane,2.5 hours,DNA topoisomerase 2-beta,TOP2B,,unknown
Amlodipine,30-50 hours,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,inhibitor,yes
Amlodipine,30-50 hours,Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,inhibitor,yes
Amlodipine,30-50 hours,Voltage-dependent L-type calcium channel subunit beta-2,CACNB2,inhibitor,yes
Amlodipine,30-50 hours,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,inhibitor,yes
Amlodipine,30-50 hours,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,inhibitor,yes
Amlodipine,30-50 hours,Voltage-dependent N-type calcium channel subunit alpha-1B,CACNA1B,inhibitor,unknown
Amlodipine,30-50 hours,Voltage-dependent calcium channel subunit alpha-2/delta-3,CACNA2D3,inhibitor,unknown
Amlodipine,30-50 hours,Voltage-gated calcium channel beta 1 subunit splice variant CavB1d,CACNB1,inhibitor,unknown
Amlodipine,30-50 hours,Carbonic anhydrase 1,CA1,inhibitor,unknown
Amlodipine,30-50 hours,Sphingomyelin phosphodiesterase,SMPD1,,unknown
Tacrine,2 to 4 hours,Acetylcholinesterase,ACHE,inhibitor,yes
Tacrine,2 to 4 hours,Cholinesterase,BCHE,inhibitor,yes
Tacrine,2 to 4 hours,Liver carboxylesterase 1,CES1,,unknown
Oxyphencyclimine,,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Oxyphencyclimine,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Oxyphencyclimine,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Triamterene,255 minutes (188 minutes for OH-TA-ester metabolite) after IV administration.,Amiloride-sensitive sodium channel subunit gamma,SCNN1G,inhibitor,yes
Triamterene,255 minutes (188 minutes for OH-TA-ester metabolite) after IV administration.,Amiloride-sensitive sodium channel subunit alpha,SCNN1A,inhibitor,yes
Triamterene,255 minutes (188 minutes for OH-TA-ester metabolite) after IV administration.,Amiloride-sensitive sodium channel subunit beta,SCNN1B,inhibitor,yes
Triamterene,255 minutes (188 minutes for OH-TA-ester metabolite) after IV administration.,Amiloride-sensitive sodium channel subunit delta,SCNN1D,inhibitor,unknown
Valrubicin,,DNA,,intercalation,yes
Valrubicin,,DNA topoisomerase 2-alpha,TOP2A,inhibitor,yes
Procyclidine,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Procyclidine,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Procyclidine,,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,yes
Procyclidine,,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Phenylephrine,2.1 to 3.4 hours,Alpha-1A adrenergic receptor,ADRA1A,,yes
Phenylephrine,2.1 to 3.4 hours,Alpha-1B adrenergic receptor,ADRA1B,,yes
Phenylephrine,2.1 to 3.4 hours,Alpha-1D adrenergic receptor,ADRA1D,,yes
Carbimazole,,Thyroid peroxidase,TPO,inhibitor,yes
Digoxin,3.5 to 5 days,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,,yes
Sulpiride,6 to 8 hours,D(2) dopamine receptor,DRD2,antagonist,yes
Sulpiride,6 to 8 hours,D(3) dopamine receptor,DRD3,antagonist,unknown
Sulpiride,6 to 8 hours,Carbonic anhydrase 2,CA2,inhibitor,unknown
Sulpiride,6 to 8 hours,Carbonic anhydrase 3,CA3,inhibitor,unknown
Ethopropazine,1 to 2 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Ethopropazine,1 to 2 hours,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,antagonist,yes
Ethopropazine,1 to 2 hours,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Nimodipine,1.7-9 hours,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,inhibitor,yes
Nimodipine,1.7-9 hours,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,inhibitor,yes
Nimodipine,1.7-9 hours,Voltage-dependent L-type calcium channel subunit alpha-1F,CACNA1F,inhibitor,yes
Nimodipine,1.7-9 hours,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,inhibitor,yes
Nimodipine,1.7-9 hours,Voltage-dependent L-type calcium channel subunit beta-1,CACNB1,inhibitor,yes
Nimodipine,1.7-9 hours,Voltage-dependent L-type calcium channel subunit beta-2,CACNB2,inhibitor,yes
Nimodipine,1.7-9 hours,Voltage-dependent L-type calcium channel subunit beta-3,CACNB3,inhibitor,yes
Nimodipine,1.7-9 hours,Voltage-dependent L-type calcium channel subunit beta-4,CACNB4,inhibitor,yes
Nimodipine,1.7-9 hours,Mineralocorticoid receptor,NR3C2,antagonist,unknown
Nimodipine,1.7-9 hours,Aryl hydrocarbon receptor,AHR,agonist,unknown
Beclomethasone dipropionate,2.8 hours,Glucocorticoid receptor,NR3C1,agonist,yes
Carisoprodol,8 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,,unknown
Carisoprodol,8 hours,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,,unknown
Carisoprodol,8 hours,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,,unknown
Progesterone,34.8-55.13 hours,Progesterone receptor,PGR,agonist,yes
Progesterone,34.8-55.13 hours,Estrogen receptor alpha,ESR1,agonist,yes
Progesterone,34.8-55.13 hours,Mineralocorticoid receptor,NR3C2,antagonist,yes
Progesterone,34.8-55.13 hours,"Steroid 17-alpha-hydroxylase/17,20 lyase",CYP17A1,inhibitor,unknown
Progesterone,34.8-55.13 hours,Kappa-type opioid receptor,OPRK1,activator,unknown
Progesterone,34.8-55.13 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Progesterone,34.8-55.13 hours,Alpha-1-acid glycoprotein 1,ORM1,,unknown
Progesterone,34.8-55.13 hours,Glucocorticoid receptor,NR3C1,partial agonist,unknown
Progesterone,34.8-55.13 hours,Androgen receptor,AR,,unknown
Progesterone,34.8-55.13 hours,Sex hormone-binding globulin,SHBG,,unknown
Phenylpropanolamine,2.1 to 3.4 hours.,D(1A) dopamine receptor,DRD1,partial agonist,unknown
Phenylpropanolamine,2.1 to 3.4 hours.,Beta-1 adrenergic receptor,ADRB1,agonist,unknown
Phenylpropanolamine,2.1 to 3.4 hours.,Beta-2 adrenergic receptor,ADRB2,agonist,unknown
Phenylpropanolamine,2.1 to 3.4 hours.,Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,,unknown
Sorafenib,25-48 hours,Serine/threonine-protein kinase B-raf,BRAF,inhibitor,yes
Sorafenib,25-48 hours,RAF proto-oncogene serine/threonine-protein kinase,RAF1,inhibitor,yes
Sorafenib,25-48 hours,Vascular endothelial growth factor receptor 3,FLT4,antagonist,yes
Sorafenib,25-48 hours,Vascular endothelial growth factor receptor 2,KDR,antagonist,yes
Sorafenib,25-48 hours,Receptor-type tyrosine-protein kinase FLT3,FLT3,antagonist,yes
Sorafenib,25-48 hours,Platelet-derived growth factor receptor beta,PDGFRB,antagonist,yes
Sorafenib,25-48 hours,Mast/stem cell growth factor receptor Kit,KIT,antagonist,yes
Sorafenib,25-48 hours,Fibroblast growth factor receptor 1,FGFR1,inhibitor,yes
Sorafenib,25-48 hours,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,inhibitor,yes
Sorafenib,25-48 hours,Vascular endothelial growth factor receptor 1,FLT1,inhibitor,yes
Zoledronic acid,146 hours,Farnesyl pyrophosphate synthase,FDPS,inhibitor,yes
Zoledronic acid,146 hours,Geranylgeranyl pyrophosphate synthase,GGPS1,inhibitor,yes
Zoledronic acid,146 hours,Hydroxylapatite,,antagonist,yes
Griseofulvin,9-21 hours,Tubulin beta chain,TUB2,inhibitor,yes
Griseofulvin,9-21 hours,Tubulin alpha chain,TUB1,inhibitor,yes
Griseofulvin,9-21 hours,"Keratin, type I cytoskeletal 12",KRT12,other/unknown,unknown
Nisoldipine,7-12 hours,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,inhibitor,yes
Nisoldipine,7-12 hours,Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,inhibitor,yes
Nisoldipine,7-12 hours,Voltage-dependent L-type calcium channel subunit beta-2,CACNB2,inhibitor,yes
Nisoldipine,7-12 hours,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,inhibitor,yes
Nisoldipine,7-12 hours,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,inhibitor,yes
Eszopiclone,6 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Eszopiclone,6 hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,agonist,unknown
Eszopiclone,6 hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,agonist,unknown
Eszopiclone,6 hours,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,agonist,unknown
Eszopiclone,6 hours,Translocator protein,TSPO,agonist,yes
Eszopiclone,6 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Ceruletide,,Cholecystokinin receptor type A,CCKAR,inducer,yes
Alprazolam,6.3-26.9 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Dexbrompheniramine,25 hours,Histamine H1 receptor,HRH1,antagonist,yes
Gentian Violet,,DNA,,intercalation,yes
Ardeparin,"Elimination half-life for anti-factor Xa activity averages 3.3 hours following a single intravenous dose, while elimination half-life for anti-factor IIa activity averages 1.2 hours following a single intravenous dose.",Antithrombin-III,SERPINC1,potentiator,yes
Ardeparin,"Elimination half-life for anti-factor Xa activity averages 3.3 hours following a single intravenous dose, while elimination half-life for anti-factor IIa activity averages 1.2 hours following a single intravenous dose.",Heparin cofactor 2,SERPIND1,agonist,yes
Loxapine,Oral-4 hours,D(2) dopamine receptor,DRD2,antagonist,yes
Loxapine,Oral-4 hours,D(1A) dopamine receptor,DRD1,antagonist,unknown
Loxapine,Oral-4 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Loxapine,Oral-4 hours,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Loxapine,Oral-4 hours,5-hydroxytryptamine receptor 1A,HTR1A,binder,unknown
Loxapine,Oral-4 hours,5-hydroxytryptamine receptor 1B,HTR1B,binder,unknown
Loxapine,Oral-4 hours,5-hydroxytryptamine receptor 1D,HTR1D,binder,unknown
Loxapine,Oral-4 hours,5-hydroxytryptamine receptor 1E,HTR1E,binder,unknown
Loxapine,Oral-4 hours,5-hydroxytryptamine receptor 3A,HTR3A,binder,unknown
Loxapine,Oral-4 hours,5-hydroxytryptamine receptor 5A,HTR5A,binder,unknown
Loxapine,Oral-4 hours,5-hydroxytryptamine receptor 6,HTR6,binder,unknown
Loxapine,Oral-4 hours,5-hydroxytryptamine receptor 7,HTR7,binder,unknown
Loxapine,Oral-4 hours,Alpha-1A adrenergic receptor,ADRA1A,binder,unknown
Loxapine,Oral-4 hours,Alpha-1B adrenergic receptor,ADRA1B,binder,unknown
Loxapine,Oral-4 hours,Alpha-2A adrenergic receptor,ADRA2A,binder,unknown
Loxapine,Oral-4 hours,Alpha-2B adrenergic receptor,ADRA2B,binder,unknown
Loxapine,Oral-4 hours,Alpha-2C adrenergic receptor,ADRA2C,binder,unknown
Loxapine,Oral-4 hours,Beta-1 adrenergic receptor,ADRB1,binder,unknown
Loxapine,Oral-4 hours,Muscarinic acetylcholine receptor M1,CHRM1,binder,unknown
Loxapine,Oral-4 hours,Muscarinic acetylcholine receptor M2,CHRM2,binder,unknown
Loxapine,Oral-4 hours,Muscarinic acetylcholine receptor M3,CHRM3,binder,unknown
Loxapine,Oral-4 hours,Muscarinic acetylcholine receptor M4,CHRM4,binder,unknown
Loxapine,Oral-4 hours,Muscarinic acetylcholine receptor M5,CHRM5,binder,unknown
Loxapine,Oral-4 hours,D(1) dopamine receptor,DRD1DRD5,binder,unknown
Loxapine,Oral-4 hours,D(3) dopamine receptor,DRD3,binder,unknown
Loxapine,Oral-4 hours,D(4) dopamine receptor,DRD4,binder,unknown
Loxapine,Oral-4 hours,D(1B) dopamine receptor,DRD5,binder,unknown
Loxapine,Oral-4 hours,Histamine H1 receptor,HRH1,binder,unknown
Loxapine,Oral-4 hours,Histamine H2 receptor,HRH2,binder,unknown
Loxapine,Oral-4 hours,Histamine H4 receptor,HRH4,binder,unknown
Loxapine,Oral-4 hours,Sodium-dependent serotonin transporter,SLC6A4,binder,unknown
Loxapine,Oral-4 hours,Sodium-dependent noradrenaline transporter,SLC6A2,binder,unknown
Loxapine,Oral-4 hours,Sodium-dependent dopamine transporter,SLC6A3,binder,unknown
Remoxipride,4-7 hours,D(2) dopamine receptor,DRD2,antagonist,yes
Remoxipride,4-7 hours,D(4) dopamine receptor,DRD4,antagonist,unknown
Remoxipride,4-7 hours,D(3) dopamine receptor,DRD3,antagonist,unknown
Remoxipride,4-7 hours,5-hydroxytryptamine receptor 2A,HTR2A,other/unknown,unknown
Remoxipride,4-7 hours,Sigma non-opioid intracellular receptor 1,SIGMAR1,antagonist,unknown
Mupirocin,20 to 40 minutes,Isoleucine--tRNA ligase,ileS,inhibitor,yes
Carbachol,,Muscarinic acetylcholine receptor M1,CHRM1,agonist,yes
Carbachol,,Muscarinic acetylcholine receptor M2,CHRM2,agonist,yes
Carbachol,,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,agonist,yes
Carbachol,,Acetylcholinesterase,ACHE,,unknown
Carbachol,,Muscarinic acetylcholine receptor M3,CHRM3,,unknown
Carbachol,,Muscarinic acetylcholine receptor M4,CHRM4,,unknown
Rosiglitazone,"3-4 hours (single oral dose, independent of dose)",Peroxisome proliferator-activated receptor gamma,PPARG,agonist,yes
Rosiglitazone,"3-4 hours (single oral dose, independent of dose)",Long-chain-fatty-acid--CoA ligase 4,ACSL4,inhibitor,unknown
Rosiglitazone,"3-4 hours (single oral dose, independent of dose)",Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Rosiglitazone,"3-4 hours (single oral dose, independent of dose)",Peroxisome proliferator-activated receptor delta,PPARD,,unknown
Rosiglitazone,"3-4 hours (single oral dose, independent of dose)",Retinoic acid receptor RXR-alpha,RXRA,,unknown
Rosiglitazone,"3-4 hours (single oral dose, independent of dose)",Retinoic acid receptor RXR-beta,RXRB,,unknown
Rosiglitazone,"3-4 hours (single oral dose, independent of dose)",Retinoic acid receptor RXR-gamma,RXRG,,unknown
Pramipexole,8 hours,D(3) dopamine receptor,DRD3,agonist,yes
Pramipexole,8 hours,D(2) dopamine receptor,DRD2,agonist,yes
Pramipexole,8 hours,D(4) dopamine receptor,DRD4,agonist,yes
Pramipexole,8 hours,Alpha-2B adrenergic receptor,ADRA2B,unknown,unknown
Pramipexole,8 hours,5-hydroxytryptamine receptor 1A,HTR1A,unknown,unknown
Pramipexole,8 hours,5-hydroxytryptamine receptor 1D,HTR1D,unknown,unknown
Pramipexole,8 hours,Alpha-2A adrenergic receptor,ADRA2A,partial agonist,unknown
Pramipexole,8 hours,5-hydroxytryptamine receptor 1B,HTR1B,unknown,unknown
Pramipexole,8 hours,5-hydroxytryptamine receptor 2A,HTR2A,unknown,unknown
Pramipexole,8 hours,5-hydroxytryptamine receptor 2B,HTR2B,unknown,unknown
Pramipexole,8 hours,5-hydroxytryptamine receptor 2C,HTR2C,unknown,unknown
Pramipexole,8 hours,Alpha-2C adrenergic receptor,ADRA2C,unknown,unknown
Pramipexole,8 hours,D(1A) dopamine receptor,DRD1,unknown,unknown
Pramipexole,8 hours,D(1B) dopamine receptor,DRD5,unknown,unknown
Acetohexamide,Elimination half-life of the parent compound is 1.3 hours and the elimination half-life of the active metabolite is approximately 5-6 hours.,ATP-sensitive inward rectifier potassium channel 1,KCNJ1,inhibitor,yes
Ampicillin,,Penicillin-binding protein 2a,pbp2a,inhibitor,yes
Ampicillin,,Penicillin-binding protein 1b,pbp1b,inhibitor,yes
Ampicillin,,Penicillin-binding protein 3,pbp3,inhibitor,yes
Ampicillin,,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Ampicillin,,Penicillin-binding protein 2B,penA,inhibitor,yes
Ampicillin,,Solute carrier family 15 member 1,SLC15A1,,unknown
Ampicillin,,Solute carrier family 15 member 2,SLC15A2,,unknown
Ampicillin,,Angiopoietin-1 receptor,TEK,,unknown
Metocurine Iodide,3 to 4 hours,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,antagonist,yes
Phenoxymethylpenicillin,30 to 40 minutes,Penicillin-binding protein 1A,pbpA,,yes
Phenoxymethylpenicillin,30 to 40 minutes,MecA PBP2' (penicillin binding protein 2'),mecA,inhibitor,yes
Phenoxymethylpenicillin,30 to 40 minutes,D-alanyl-D-alanine carboxypeptidase DacB,dacB,,unknown
Phenoxymethylpenicillin,30 to 40 minutes,Penicillin acylase,,,unknown
Phenoxymethylpenicillin,30 to 40 minutes,Solute carrier family 15 member 1,SLC15A1,,unknown
Secobarbital,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Secobarbital,,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Secobarbital,,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Secobarbital,,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Secobarbital,,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Secobarbital,,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Secobarbital,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Secobarbital,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Secobarbital,,Glutamate receptor 2,GRIA2,antagonist,unknown
Secobarbital,,"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Secobarbital,,NMDA receptor,GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B,antagonist,unknown
Miglustat,The effective half-life of miglustat is approximately 6 to 7 hours.,Ceramide glucosyltransferase,UGCG,inhibitor,yes
Promazine,,D(2) dopamine receptor,DRD2,antagonist,yes
Promazine,,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,unknown
Promazine,,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Promazine,,D(1A) dopamine receptor,DRD1,antagonist,unknown
Promazine,,D(4) dopamine receptor,DRD4,antagonist,unknown
Promazine,,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,unknown
Promazine,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Promazine,,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Promazine,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Promazine,,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Promazine,,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,unknown
Promazine,,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Promazine,,Histamine H1 receptor,HRH1,antagonist,unknown
Promazine,,Alpha-1D adrenergic receptor,ADRA1D,antagonist,unknown
Spironolactone,10 minutes,Mineralocorticoid receptor,NR3C2,antagonist,yes
Spironolactone,10 minutes,Androgen receptor,AR,antagonist,unknown
Spironolactone,10 minutes,Progesterone receptor,PGR,agonist,unknown
Spironolactone,10 minutes,Glucocorticoid receptor,NR3C1,antagonist,unknown
Spironolactone,10 minutes,"Cytochrome P450 11B2, mitochondrial",CYP11B2,antagonist,unknown
Spironolactone,10 minutes,17alpha-hydroxylase,,antagonist,unknown
Spironolactone,10 minutes,"17,20-desmolase",,antagonist,unknown
Spironolactone,10 minutes,3-oxo-5-alpha-steroid 4-dehydrogenase,SRD5A1SRD5A2SRD5A3,antagonist,unknown
Spironolactone,10 minutes,Sex hormone-binding globulin,SHBG,binder,unknown
Spironolactone,10 minutes,Voltage-dependent calcium channel,CACNG1CACNA2D1CACNA2D2CACNA2D3CACNA1CCACNA1DCACNA1FCACNA1SCACNB1CACNB1CACNB2CACNB3CACNB4CACNA1BCACNA1ACACNA1GCACNA1HCACNA1I,,unknown
Spironolactone,10 minutes,Dihydrotestosterone receptor,,,unknown
Spironolactone,10 minutes,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Methylphenidate,"d-methylphenidate = 3-4 hours;
l-methylphenidate = 1-3 hours; 
Ritalinic acid = 3-4 hours;",Sodium-dependent dopamine transporter,SLC6A3,inhibitor,yes
Methylphenidate,"d-methylphenidate = 3-4 hours;
l-methylphenidate = 1-3 hours; 
Ritalinic acid = 3-4 hours;",Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,unknown
Methylphenidate,"d-methylphenidate = 3-4 hours;
l-methylphenidate = 1-3 hours; 
Ritalinic acid = 3-4 hours;",Sodium-dependent serotonin transporter,SLC6A4,inhibitor,unknown
Methocarbamol,1.14-1.24 hours,Carbonic anhydrase 1,CA1,inhibitor,no
Hyoscyamine,2-3.5 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Hyoscyamine,2-3.5 hours,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Hyoscyamine,2-3.5 hours,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Hyoscyamine,2-3.5 hours,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,unknown
Zolpidem,2.6 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Zolpidem,2.6 hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,agonist,unknown
Zolpidem,2.6 hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,agonist,unknown
Zolpidem,2.6 hours,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,agonist,unknown
Zolpidem,2.6 hours,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,agonist,unknown
Famciclovir,10 hours,DNA polymerase catalytic subunit,,inhibitor,yes
Famciclovir,10 hours,DNA polymerase catalytic subunit,,inhibitor,yes
Triprolidine,4 to 6 hours.,Histamine H1 receptor,HRH1,antagonist,yes
Streptozocin,5-15 minutes,DNA,,cross-linking/alkylation,yes
Streptozocin,5-15 minutes,"Solute carrier family 2, facilitated glucose transporter member 2",SLC2A2,ligand,unknown
Streptozocin,5-15 minutes,O-GlcNAcase BT_4395,,antagonist,yes
Streptozocin,5-15 minutes,Bifunctional protein NCOAT,MGEA5,,unknown
Carboprost Tromethamine,,Prostaglandin E2 receptor EP1 subtype,PTGER1,agonist,yes
Cefpiramide,4.44 hours,Peptidoglycan synthase FtsI,ftsI,inhibitor,yes
Cefpiramide,4.44 hours,Penicillin-binding protein 1B,mrcB,inhibitor,yes
Cefpiramide,4.44 hours,Penicillin-binding protein 1A,mrcA,inhibitor,yes
Cefpiramide,4.44 hours,Penicillin-binding protein 1B,ponB,inhibitor,yes
Cefpiramide,4.44 hours,D-alanyl-D-alanine carboxypeptidase DacC,dacC,inhibitor,yes
Cefpiramide,4.44 hours,Penicillin-binding protein 1A,mrcA,inhibitor,yes
Cefpiramide,4.44 hours,Penicillin binding protein 2a,mecA,inhibitor,no
Lindane,18 hours,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,antagonist,yes
Lindane,18 hours,Glycine receptor subunit alpha-1,GLRA1,antagonist,unknown
Lindane,18 hours,Glycine receptor subunit alpha-2,GLRA2,antagonist,unknown
Lindane,18 hours,Glycine receptor subunit alpha-3,GLRA3,antagonist,unknown
Lindane,18 hours,Glycine receptor subunit beta,GLRB,antagonist,unknown
Lindane,18 hours,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,,unknown
Lindane,18 hours,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,,unknown
Lindane,18 hours,Progesterone receptor,PGR,,unknown
Lindane,18 hours,Estrogen receptor alpha,ESR1,,unknown
Lindane,18 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Trifluridine,Approximately 12 to 18 minutes following ophthalmic administration.,Thymidylate synthase,TYMS,inhibitor,yes
Trifluridine,Approximately 12 to 18 minutes following ophthalmic administration.,DNA,,other/unknown,yes
Prochlorperazine,6 to 8 hours,D(2) dopamine receptor,DRD2,antagonist,yes
Cyproheptadine,,Histamine H1 receptor,HRH1,antagonist,yes
Cyproheptadine,,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Cyproheptadine,,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,yes
Cyproheptadine,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Cyproheptadine,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Cyproheptadine,,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Cyproheptadine,,5-hydroxytryptamine receptor 7,HTR7,,unknown
Nitric Oxide,2&ndash;6 seconds,Guanylate cyclase soluble subunit alpha-2,GUCY1A2,inducer,yes
Nitric Oxide,2&ndash;6 seconds,Metallothionein-1A,MT1A,,unknown
Nitric Oxide,2&ndash;6 seconds,"Indoleamine 2,3-dioxygenase 1",IDO1,,unknown
Bendroflumethiazide,8.5 hours,Solute carrier family 12 member 3,SLC12A3,inhibitor,yes
Bendroflumethiazide,8.5 hours,Calcium-activated potassium channel subunit alpha-1,KCNMA1,inducer,yes
Bendroflumethiazide,8.5 hours,Carbonic anhydrase 1,CA1,inhibitor,unknown
Bendroflumethiazide,8.5 hours,Carbonic anhydrase 2,CA2,inhibitor,unknown
Bendroflumethiazide,8.5 hours,Carbonic anhydrase 4,CA4,inhibitor,unknown
Allopurinol,1-3 hours,Xanthine dehydrogenase/oxidase,XDH,inhibitor,yes
Ceftazidime,"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.",Peptidoglycan synthase FtsI,ftsI,inhibitor,yes
Ceftazidime,"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.",Penicillin-binding protein 3,pbp3,inhibitor,yes
Ceftazidime,"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.",Penicillin-binding protein 1A,mrcA,inhibitor,yes
Ceftazidime,"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.",Penicillin-binding protein 1A,pbpA,inhibitor,yes
Ceftazidime,"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.",Penicillin-binding protein 1B,mrcB,inhibitor,yes
Ceftazidime,"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.",Penicillin-binding protein 1B,ponB,inhibitor,yes
Ceftazidime,"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.",Penicillin-binding protein 2,pbpA,inhibitor,yes
Ceftazidime,"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.",Penicillin-binding protein 2,mrdA,inhibitor,yes
Ceftazidime,"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.",D-alanyl-D-alanine endopeptidase,pbpG,inhibitor,no
Cerivastatin,2-3 hours,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,inhibitor,yes
Trimethoprim,8-11 hours in adults with normal renal function,Thymidylate synthase,TYMS,inhibitor,yes
Trimethoprim,8-11 hours in adults with normal renal function,Dihydrofolate reductase,DHFR,inhibitor,no
Gemcitabine,"Gemcitabine half-life for short infusions ranged from 42 to 94 minutes, and the value for long infusions varied from 245 to 638 minutes, depending on age and gender, reflecting a greatly increased volume of distribution with longer infusions.",DNA,,cross-linking/alkylation,yes
Gemcitabine,"Gemcitabine half-life for short infusions ranged from 42 to 94 minutes, and the value for long infusions varied from 245 to 638 minutes, depending on age and gender, reflecting a greatly increased volume of distribution with longer infusions.",Ribonucleoside-diphosphate reductase large subunit,RRM1,inhibitor,yes
Gemcitabine,"Gemcitabine half-life for short infusions ranged from 42 to 94 minutes, and the value for long infusions varied from 245 to 638 minutes, depending on age and gender, reflecting a greatly increased volume of distribution with longer infusions.",Thymidylate synthase,TYMS,inhibitor,unknown
Gemcitabine,"Gemcitabine half-life for short infusions ranged from 42 to 94 minutes, and the value for long infusions varied from 245 to 638 minutes, depending on age and gender, reflecting a greatly increased volume of distribution with longer infusions.",UMP-CMP kinase,CMPK1,inhibitor,unknown
Entecavir,"After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128-149 hours. The phosphorylated metabolite has a half-life of 15 hours.",DNA,,other,yes
Betamethasone,5.6 hours,Glucocorticoid receptor,NR3C1,agonist,yes
Teniposide,5 hours,DNA topoisomerase 2-alpha,TOP2A,inhibitor,yes
Epirubicin,"Half-lives for the alpha, beta, and gamma phases of about 3 minutes, 2.5 hours and 33 hours, respectively",Chromodomain-helicase-DNA-binding protein 1,CHD1,antagonist,yes
Epirubicin,"Half-lives for the alpha, beta, and gamma phases of about 3 minutes, 2.5 hours and 33 hours, respectively",DNA topoisomerase 2-alpha,TOP2A,inhibitor,unknown
Epirubicin,"Half-lives for the alpha, beta, and gamma phases of about 3 minutes, 2.5 hours and 33 hours, respectively",DNA,,intercalation,unknown
Chloramphenicol,"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.",50S ribosomal protein L16,rplP,inhibitor,unknown
Chloramphenicol,"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.",Dr hemagglutinin structural subunit,draA,antagonist,unknown
Chloramphenicol,"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.",Complement decay-accelerating factor,CD55,other,unknown
Loracarbef,1 hour. In subjects with moderate impairment of renal function the plasma half-life was prolonged to approximately 5.6 hours.,Penicillin-binding protein 3,pbp3,inhibitor,yes
Loracarbef,1 hour. In subjects with moderate impairment of renal function the plasma half-life was prolonged to approximately 5.6 hours.,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Lansoprazole,1.5 (&plusmn; 1.0) hours,Potassium-transporting ATPase alpha chain 1,ATP4A,inhibitor,yes
Lansoprazole,1.5 (&plusmn; 1.0) hours,Microtubule-associated protein tau,MAPT,,unknown
Dipivefrin,,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Dipivefrin,,Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Dipivefrin,,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Dipivefrin,,Cholinesterase,BCHE,potentiator,yes
Dipivefrin,,Acetylcholinesterase,ACHE,,unknown
Droperidol,"Biphasic distribution. The rapid distribution phase is 1.4 &plusmn; 0.5 minutes and the slower distribution phase is 14.3 &plusmn; 6.5 minutes. Elimination half-life in adults is 134 &plusmn; 13 minutes and may be increased in geriatric patients. In children, it is 101.5 &plusmn; 26.4 minutes.",D(2) dopamine receptor,DRD2,antagonist,yes
Droperidol,"Biphasic distribution. The rapid distribution phase is 1.4 &plusmn; 0.5 minutes and the slower distribution phase is 14.3 &plusmn; 6.5 minutes. Elimination half-life in adults is 134 &plusmn; 13 minutes and may be increased in geriatric patients. In children, it is 101.5 &plusmn; 26.4 minutes.",Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Levothyroxine,"T<sub>4</sub>, 6 to 7 days. T<sub>3</sub>, 1 to 2 days.",Thyroid hormone receptor alpha,THRA,agonist,yes
Levothyroxine,"T<sub>4</sub>, 6 to 7 days. T<sub>3</sub>, 1 to 2 days.",Thyroid hormone receptor beta,THRB,agonist,yes
Framycetin,,16S rRNA,,inhibitor,yes
Framycetin,,30S ribosomal protein S12,rpsL,inhibitor,yes
Framycetin,,C-X-C chemokine receptor type 4,CXCR4,antagonist,unknown
Clomocycline,,30S ribosomal protein S4,rpsD,inhibitor,yes
Clomocycline,,30S ribosomal protein S9,rpsI,inhibitor,unknown
Clomocycline,,16S rRNA,,inhibitor,no
Pethidine,Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.,Kappa-type opioid receptor,OPRK1,,yes
Pethidine,Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.,"Glutamate receptor ionotropic, NMDA 1",GRIN1,antagonist,unknown
Pethidine,Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.,"Glutamate receptor ionotropic, NMDA 2B",GRIN2B,antagonist,unknown
Pethidine,Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.,"Glutamate receptor ionotropic, NMDA 2A",GRIN2A,antagonist,unknown
Pethidine,Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.,"Glutamate receptor ionotropic, NMDA 2C",GRIN2C,antagonist,unknown
Pethidine,Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.,"Glutamate receptor ionotropic, NMDA 2D",GRIN2D,antagonist,unknown
Pethidine,Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.,Muscarinic acetylcholine receptor,CHRM1CHRM2CHRM3CHRM4CHRM5,binder,unknown
Pethidine,Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.,Mu-type opioid receptor,OPRM1,agonist,unknown
Pethidine,Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.,Sodium-dependent dopamine transporter,SLC6A3,,unknown
Pethidine,Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.,Sodium-dependent noradrenaline transporter,SLC6A2,,unknown
Pethidine,Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.,Sodium-dependent serotonin transporter,SLC6A4,binding,unknown
Pethidine,Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.,Liver carboxylesterase 1,CES1,,unknown
Loratadine,8.4 hours,Histamine H1 receptor,HRH1,antagonist,yes
Loratadine,8.4 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,,unknown
Cefalotin,30 minutes,D-alanyl-D-alanine carboxypeptidase,,inhibitor,yes
Cefalotin,30 minutes,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Cefalotin,30 minutes,Penicillin-binding protein 1b,pbp1b,inhibitor,yes
Cefalotin,30 minutes,Penicillin-binding protein 3,pbp3,inhibitor,yes
Cefalotin,30 minutes,Penicillin-binding protein 2a,pbp2a,inhibitor,yes
Cefalotin,30 minutes,Penicillin-binding protein 2B,penA,inhibitor,yes
Cefalotin,30 minutes,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Cefalotin,30 minutes,Beta-lactamase,ampC,potentiator,yes
Prazosin,2-3 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Prazosin,2-3 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,yes
Prazosin,2-3 hours,Alpha-1D adrenergic receptor,ADRA1D,antagonist,yes
Prazosin,2-3 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Prazosin,2-3 hours,Potassium voltage-gated channel subfamily H member 6,KCNH6,inhibitor,unknown
Prazosin,2-3 hours,Potassium voltage-gated channel subfamily H member 7,KCNH7,inhibitor,unknown
Prazosin,2-3 hours,Alpha-2A adrenergic receptor,ADRA2A,binder,unknown
Prazosin,2-3 hours,Alpha-2B adrenergic receptor,ADRA2B,binder,unknown
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",5-hydroxytryptamine receptor 2A,HTR2A,antagonist,unknown
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Histamine H1 receptor,HRH1,antagonist,no
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Alpha-1A adrenergic receptor,ADRA1A,antagonist,no
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Alpha-1D adrenergic receptor,ADRA1D,antagonist,no
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Muscarinic acetylcholine receptor M1,CHRM1,antagonist,no
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Muscarinic acetylcholine receptor M2,CHRM2,antagonist,no
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Muscarinic acetylcholine receptor M3,CHRM3,antagonist,no
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Muscarinic acetylcholine receptor M4,CHRM4,antagonist,no
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Muscarinic acetylcholine receptor M5,CHRM5,antagonist,no
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Potassium voltage-gated channel subfamily D member 2,KCND2,inhibitor,no
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Potassium voltage-gated channel subfamily D member 3,KCND3,inhibitor,no
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",5-hydroxytryptamine receptor 2C,HTR2C,antagonistbinder,unknown
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",D(1) dopamine receptor,DRD1DRD5,binder,unknown
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",D(2) dopamine receptor,DRD2,binder,unknown
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Sodium-dependent dopamine transporter,SLC6A3,,unknown
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",5-hydroxytryptamine receptor 1A,HTR1A,activator,unknown
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",5-hydroxytryptamine receptor 6,HTR6,binder,unknown
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Potassium voltage-gated channel subfamily H member 1,KCNH1,,unknown
Imipramine,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",Alpha-1-acid glycoprotein 2,ORM2,,unknown
Acitretin,49 hours (range 33 to 96 hours),Retinoic acid receptor RXR-alpha,RXRA,agonist,yes
Acitretin,49 hours (range 33 to 96 hours),Retinoic acid receptor alpha,RARA,agonist,yes
Acitretin,49 hours (range 33 to 96 hours),Retinoic acid receptor beta,RARB,agonist,yes
Acitretin,49 hours (range 33 to 96 hours),Retinoic acid receptor gamma,RARG,agonist,yes
Acitretin,49 hours (range 33 to 96 hours),Retinoic acid receptor RXR-beta,RXRB,agonist,yes
Acitretin,49 hours (range 33 to 96 hours),Retinoic acid receptor RXR-gamma,RXRG,agonist,yes
Acitretin,49 hours (range 33 to 96 hours),Retinol-binding protein 1,RBP1,agonist,unknown
Nabumetone,"Approximately 23 hours for the active metabolite, 6MNA. Increased in patients with renal insufficiency.",Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Nabumetone,"Approximately 23 hours for the active metabolite, 6MNA. Increased in patients with renal insufficiency.",Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Methylscopolamine bromide,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Methylscopolamine bromide,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Methylscopolamine bromide,,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Metharbital,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Metharbital,,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Metharbital,,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Metharbital,,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Metharbital,,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Metharbital,,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Metharbital,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Metharbital,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Metharbital,,Glutamate receptor 2,GRIA2,antagonist,unknown
Metharbital,,"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Metharbital,,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Sodium Tetradecyl Sulfate,,Vitamin K-dependent protein C,PROC,inhibitor,yes
Sodium Tetradecyl Sulfate,,Vitamin K-dependent protein S,PROS1,inhibitor,yes
Ketorolac,2.5 hours for the S-enantiomer compared with 5 hours for the R-enantiomer,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Ketorolac,2.5 hours for the S-enantiomer compared with 5 hours for the R-enantiomer,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Picrotoxin,,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,antagonist,yes
Picrotoxin,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,antagonist,yes
Picrotoxin,,Glycine receptor subunit alpha-2,GLRA2,antagonist,unknown
Picrotoxin,,Glycine receptor subunit alpha-3,GLRA3,antagonist,unknown
Picrotoxin,,Glycine receptor subunit alpha-1,GLRA1,antagonist,unknown
Enoxacin,Plasma half-life is 3 to 6 hours.,DNA gyrase subunit A,gyrA,inhibitor,yes
Enoxacin,Plasma half-life is 3 to 6 hours.,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Enoxacin,Plasma half-life is 3 to 6 hours.,DNA topoisomerase 2-alpha,TOP2A,inhibitor,no
Quinine,Approximately 18 hours,Fe(II)-protoporphyrin IX,,antagonist,yes
Quinine,Approximately 18 hours,Platelet glycoprotein IX,GP9,other,unknown
Quinine,Approximately 18 hours,Intermediate conductance calcium-activated potassium channel protein 4,KCNN4,inhibitor,unknown
Tenoxicam,72 hours (range 59 to 74 hours),Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Tenoxicam,72 hours (range 59 to 74 hours),Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Dronabinol,Alpha phase: approximately 4 hours; Beta phase: 25-36 hours,Cannabinoid receptor 1,CNR1,agonist,yes
Dronabinol,Alpha phase: approximately 4 hours; Beta phase: 25-36 hours,Cannabinoid receptor 2,CNR2,agonist,unknown
Montelukast,2.7-5.5 hours,Cysteinyl leukotriene receptor 1,CYSLTR1,antagonist,yes
Montelukast,2.7-5.5 hours,Arachidonate 5-lipoxygenase,ALOX5,other/unknown,unknown
Fluoxetine,"1-3 days [acute administration];
4-6 days [chronic administration];
4-16 days [norfluoxetine, acute and chronic administration].",Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Fluoxetine,"1-3 days [acute administration];
4-6 days [chronic administration];
4-16 days [norfluoxetine, acute and chronic administration].",Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Fluoxetine,"1-3 days [acute administration];
4-6 days [chronic administration];
4-16 days [norfluoxetine, acute and chronic administration].",5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Fluoxetine,"1-3 days [acute administration];
4-6 days [chronic administration];
4-16 days [norfluoxetine, acute and chronic administration].",Cyclin-dependent kinases regulatory subunit 1,CKS1B,,unknown
Hexylcaine,<10 minutes,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Hexylcaine,<10 minutes,Sodium channel protein type 10 subunit alpha,SCN10A,inhibitor,unknown
Methohexital,5.6 &plusmn; 2.7 minutes,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,antagonist,yes
Chlordiazepoxide,24-48 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Duloxetine,12 hours (range 8-17 hours),Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Duloxetine,12 hours (range 8-17 hours),Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Duloxetine,12 hours (range 8-17 hours),Sodium-dependent dopamine transporter,SLC6A3,inhibitor,unknown
Chlorpromazine,~ 30 hours,D(2) dopamine receptor,DRD2,antagonist,yes
Chlorpromazine,~ 30 hours,D(1A) dopamine receptor,DRD1,antagonist,yes
Chlorpromazine,~ 30 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Chlorpromazine,~ 30 hours,5-hydroxytryptamine receptor 1A,HTR1A,antagonist,yes
Chlorpromazine,~ 30 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Chlorpromazine,~ 30 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,yes
Chlorpromazine,~ 30 hours,Histamine H1 receptor,HRH1,antagonist,yes
Chlorpromazine,~ 30 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,,unknown
Chlorpromazine,~ 30 hours,D(1) dopamine receptor,DRD1DRD5,,unknown
Chlorpromazine,~ 30 hours,D(3) dopamine receptor,DRD3,,unknown
Chlorpromazine,~ 30 hours,D(4) dopamine receptor,DRD4,binder,unknown
Chlorpromazine,~ 30 hours,D(1B) dopamine receptor,DRD5,,unknown
Chlorpromazine,~ 30 hours,5-hydroxytryptamine receptor 2C,HTR2C,binder,unknown
Chlorpromazine,~ 30 hours,5-hydroxytryptamine 2 receptor,HTR2AHTR2BHTR2C,binder,unknown
Chlorpromazine,~ 30 hours,Alpha-1 adrenergic receptors,ADRA1AADRA1BADRA1D,,unknown
Chlorpromazine,~ 30 hours,Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,,unknown
Chlorpromazine,~ 30 hours,Muscarinic acetylcholine receptor M1,CHRM1,,unknown
Chlorpromazine,~ 30 hours,Muscarinic acetylcholine receptor M3,CHRM3,,unknown
Chlorpromazine,~ 30 hours,Sphingomyelin phosphodiesterase,SMPD1,,unknown
Chlorpromazine,~ 30 hours,Calmodulin,CALM1,,unknown
Chlorpromazine,~ 30 hours,alpha1-acid glycoprotein,ORM1ORM2,binder,unknown
Chlorpromazine,~ 30 hours,5-hydroxytryptamine receptor 6,HTR6,binder,unknown
Chlorpromazine,~ 30 hours,5-hydroxytryptamine receptor 7,HTR7,binder,unknown
Chlorpromazine,~ 30 hours,Histamine H4 receptor,HRH4,binder,unknown
Rimantadine,25 to 30 hours in young adults (22 to 44 years old). Approximately 32 hours in elderly (71 to 79 years old) and in patients with chronic liver disease. Approximately 13 to 38 hours in children (4 to 8 years old).,Matrix protein 2,M,other/unknown,yes
Amikacin,2-3 hours,30S ribosomal protein S12,rpsL,inhibitor,yes
Amikacin,2-3 hours,16S rRNA,,inhibitor,unknown
Lenalidomide,"Healthy subjects = 3 hours;
Multiple myeloma or MDS patients = 3 - 5 hours.",Protein cereblon,CRBN,inhibitor,yes
Lenalidomide,"Healthy subjects = 3 hours;
Multiple myeloma or MDS patients = 3 - 5 hours.",Tumor necrosis factor ligand superfamily member 11,TNFSF11,inhibitor,yes
Lenalidomide,"Healthy subjects = 3 hours;
Multiple myeloma or MDS patients = 3 - 5 hours.",Cadherin-5,CDH5,antagonist,unknown
Lenalidomide,"Healthy subjects = 3 hours;
Multiple myeloma or MDS patients = 3 - 5 hours.",Prostaglandin G/H synthase 2,PTGS2,negative modulator,unknown
Raloxifene,27.7,Estrogen receptor alpha,ESR1,agonist,yes
Raloxifene,27.7,Estrogen receptor beta,ESR2,agonist,yes
Raloxifene,27.7,Serpin B9,SERPINB9,,unknown
Raloxifene,27.7,Trefoil factor 1,TFF1,,unknown
Celecoxib,The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Celecoxib,The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.,3-phosphoinositide-dependent protein kinase 1,PDPK1,inhibitor,unknown
Celecoxib,The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.,Carbonic anhydrase 2,CA2,inhibitor,unknown
Celecoxib,The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.,Carbonic anhydrase 3,CA3,inhibitor,unknown
Gallamine Triethiodide,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Gallamine Triethiodide,,Acetylcholinesterase,ACHE,inhibitor,yes
Gallamine Triethiodide,,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,antagonist,unknown
Gallamine Triethiodide,,Muscarinic acetylcholine receptor M1,CHRM1,,unknown
Gallamine Triethiodide,,Muscarinic acetylcholine receptor M5,CHRM5,,unknown
Brimonidine,2 hours [ophthalmic solution],Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Brimonidine,2 hours [ophthalmic solution],Alpha-2B adrenergic receptor,ADRA2B,agonist,yes
Brimonidine,2 hours [ophthalmic solution],Alpha-2C adrenergic receptor,ADRA2C,agonist,yes
Dicloxacillin,The elimination half-life for dicloxacillin is about 0.7 hour.,Penicillin-binding protein 3,pbpC,inhibitor,yes
Dicloxacillin,The elimination half-life for dicloxacillin is about 0.7 hour.,Penicillin-binding protein 1b,pbp1b,inhibitor,yes
Dicloxacillin,The elimination half-life for dicloxacillin is about 0.7 hour.,Penicillin-binding protein 2a,pbp2a,inhibitor,yes
Dicloxacillin,The elimination half-life for dicloxacillin is about 0.7 hour.,Penicillin-binding protein 3,pbp3,inhibitor,yes
Dicloxacillin,The elimination half-life for dicloxacillin is about 0.7 hour.,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Dicloxacillin,The elimination half-life for dicloxacillin is about 0.7 hour.,Penicillin-binding protein 2B,penA,inhibitor,yes
Nabilone,"2 hours, with metabolites around 35 hours.",Cannabinoid receptor 2,CNR2,partial agonist,yes
Nabilone,"2 hours, with metabolites around 35 hours.",Cannabinoid receptor 1,CNR1,partial agonist,yes
Pefloxacin,8.6 hours,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Pefloxacin,8.6 hours,DNA gyrase subunit A,gyrA,inhibitor,yes
Pefloxacin,8.6 hours,DNA topoisomerase 2-alpha,TOP2A,inhibitor,unknown
Pefloxacin,8.6 hours,DNA topoisomerase 1,topA,,unknown
Altretamine,4.7-10.2 hours,DNA,,other/unknown,yes
Sotalol,Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,yes
Sotalol,Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Sotalol,Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.,Beta-2 adrenergic receptor,ADRB2,antagonist,yes
Buspirone,2-3 hours (although the action of a single dose is much longer than the short halflife indicates).,5-hydroxytryptamine receptor 1A,HTR1A,partial agonist,yes
Buspirone,2-3 hours (although the action of a single dose is much longer than the short halflife indicates).,D(2) dopamine receptor,DRD2,antagonist,yes
Miglitol,The elimination half-life of miglitol from plasma is approximately 2 hours.,"Maltase-glucoamylase, intestinal",MGAM,antagonistinhibitor,yes
Miglitol,The elimination half-life of miglitol from plasma is approximately 2 hours.,Lysosomal alpha-glucosidase,GAA,antagonist,yes
Miglitol,The elimination half-life of miglitol from plasma is approximately 2 hours.,Neutral alpha-glucosidase AB,GANAB,antagonist,yes
Miglitol,The elimination half-life of miglitol from plasma is approximately 2 hours.,Neutral alpha-glucosidase C,GANC,antagonist,yes
Fosinopril,12 hours,Angiotensin-converting enzyme,ACE,inhibitor,yes
Cefotaxime,Approximately 1 hour.,Penicillin-binding protein 1b,pbp1b,inhibitor,yes
Cefotaxime,Approximately 1 hour.,Penicillin-binding protein 2a,pbp2a,inhibitor,yes
Cefotaxime,Approximately 1 hour.,Penicillin-binding protein 3,pbpC,inhibitor,yes
Cefotaxime,Approximately 1 hour.,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Cefotaxime,Approximately 1 hour.,Penicillin-binding protein 2B,penA,inhibitor,yes
Cefotaxime,Approximately 1 hour.,Solute carrier family 22 member 6,SLC22A6,,unknown
Cefotaxime,Approximately 1 hour.,Solute carrier family 22 member 8,SLC22A8,,unknown
Cefotaxime,Approximately 1 hour.,Solute carrier family 22 member 11,SLC22A11,,unknown
Cefotaxime,Approximately 1 hour.,Solute carrier family 22 member 7,SLC22A7,,unknown
Cefotaxime,Approximately 1 hour.,Solute carrier family 15 member 1,SLC15A1,,unknown
Cefotaxime,Approximately 1 hour.,Serum albumin,ALB,,unknown
Cefotaxime,Approximately 1 hour.,Beta-lactamase,,,unknown
Cefotaxime,Approximately 1 hour.,Solute carrier family 15 member 2,SLC15A2,,unknown
Entacapone,0.4-0.7 hour,Catechol O-methyltransferase,COMT,inhibitor,yes
Zidovudine,"Elimination half life, HIV-infected patients, IV administration = 1.1 hours (range of 0.5 - 2.9 hours)",Reverse transcriptase/RNaseH,pol,inhibitor,yes
Zidovudine,"Elimination half life, HIV-infected patients, IV administration = 1.1 hours (range of 0.5 - 2.9 hours)",Telomerase reverse transcriptase,TERT,inhibitor,unknown
Darifenacin,The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Darifenacin,The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Darifenacin,The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Darifenacin,The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,unknown
Darifenacin,The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,unknown
Oxycodone,4.5 hours,Mu-type opioid receptor,OPRM1,agonist,yes
Oxycodone,4.5 hours,Kappa-type opioid receptor,OPRK1,agonist,yes
Oxycodone,4.5 hours,Delta-type opioid receptor,OPRD1,agonist,yes
Oxycodone,4.5 hours,Kappa-type opioid receptor 2b,,agonist,unknown
Oxycodone,4.5 hours,alpha1-acid glycoprotein,ORM1ORM2,binder,unknown
Phenindione,5-10 hours,Vitamin K epoxide reductase complex subunit 1,VKORC1,inhibitor,yes
Flutamide,The plasma half-life for the alpha-hydroxylated metabolite of flutamide (an active metabolite) is approximately 6 hours.,Androgen receptor,AR,antagonist,yes
Flutamide,The plasma half-life for the alpha-hydroxylated metabolite of flutamide (an active metabolite) is approximately 6 hours.,Aryl hydrocarbon receptor,AHR,agonist,unknown
Flutamide,The plasma half-life for the alpha-hydroxylated metabolite of flutamide (an active metabolite) is approximately 6 hours.,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Tolmetin,Biphasic elimination from the plasma consisting of a rapid phase with a half-life of one to 2 hours followed by a slower phase with a half-life of about 5 hours.,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Tolmetin,Biphasic elimination from the plasma consisting of a rapid phase with a half-life of one to 2 hours followed by a slower phase with a half-life of about 5 hours.,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Cimetidine,2 hours,Histamine H2 receptor,HRH2,antagonist,yes
Haloperidol,Half-life: 21-24h [L1997],D(2) dopamine receptor,DRD2,antagonist,yes
Haloperidol,Half-life: 21-24h [L1997],D(1A) dopamine receptor,DRD1,antagonist,unknown
Haloperidol,Half-life: 21-24h [L1997],"Glutamate receptor ionotropic, NMDA 2B",GRIN2B,antagonist,unknown
Haloperidol,Half-life: 21-24h [L1997],5-hydroxytryptamine receptor 2A,HTR2A,other/unknown,unknown
Haloperidol,Half-life: 21-24h [L1997],D(3) dopamine receptor,DRD3,inverse agonist,unknown
Haloperidol,Half-life: 21-24h [L1997],Melanin-concentrating hormone receptor 1,MCHR1,,unknown
Haloperidol,Half-life: 21-24h [L1997],Synaptic vesicular amine transporter,SLC18A2,,unknown
Ritonavir,3-5 hours [A19647].,Human immunodeficiency virus type 1 protease,pol,inhibitor,yes
Ritonavir,3-5 hours [A19647].,Nuclear receptor subfamily 1 group I member 2,NR1I2,activator,unknown
Levallorphan,1 hour,Mu-type opioid receptor,OPRM1,partial agonist,yes
Tridihexethyl,,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Tridihexethyl,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Tridihexethyl,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Nitazoxanide,7.3h [L1422],Pyruvate-flavodoxin oxidoreductase,por,antagonistinhibitor,yes
Triflupromazine,,D(1A) dopamine receptor,DRD1,antagonist,yes
Triflupromazine,,D(2) dopamine receptor,DRD2,antagonist,yes
Triflupromazine,,5-hydroxytryptamine receptor 2B,HTR2B,antagonist,yes
Triflupromazine,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Triflupromazine,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Dextrothyroxine,,Thyroid hormone receptor alpha,THRA,agonist,yes
Dextrothyroxine,,Thyroid hormone receptor beta,THRB,agonist,yes
Dextrothyroxine,,Thyroid peroxidase,TPO,,unknown
Acetyldigitoxin,,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,inhibitor,yes
Vancomycin,"Half-life in normal renal patients is approximately 6 hours (range 4 to 11 hours). In anephric patients, the average half-life of elimination is 7.5 days [FDA Label].",D-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan,,ligand,yes
Aminocaproic Acid,The terminal elimination half-life is approximately 2 hours.,Plasminogen,PLG,inhibitor,yes
Aminocaproic Acid,The terminal elimination half-life is approximately 2 hours.,Tissue-type plasminogen activator,PLAT,antagonist,yes
Aminocaproic Acid,The terminal elimination half-life is approximately 2 hours.,Apolipoprotein(a),LPA,other,unknown
Dextromethorphan,3-6 hours,Sigma non-opioid intracellular receptor 1,SIGMAR1,agonist,yes
Dextromethorphan,3-6 hours,"HCG20471, isoform CRA_c",SIGMAR1,agonist,yes
Dextromethorphan,3-6 hours,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,antagonist,yes
Dextromethorphan,3-6 hours,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,antagonist,unknown
Dextromethorphan,3-6 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,unknown
Dextromethorphan,3-6 hours,Membrane-associated progesterone receptor component 1,PGRMC1,binder,unknown
Dextromethorphan,3-6 hours,Neuronal acetylcholine receptor subunit alpha-3,CHRNA3,antagonist,unknown
Dextromethorphan,3-6 hours,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Dextromethorphan,3-6 hours,Neuronal acetylcholine receptor subunit beta-4,CHRNB4,antagonist,unknown
Dextromethorphan,3-6 hours,Neuronal acetylcholine receptor subunit beta-2,CHRNB2,antagonist,unknown
Dextromethorphan,3-6 hours,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Dextromethorphan,3-6 hours,Mu-type opioid receptor,OPRM1,agonist,unknown
Dextromethorphan,3-6 hours,Delta-type opioid receptor,OPRD1,agonist,unknown
Dextromethorphan,3-6 hours,Kappa-type opioid receptor,OPRK1,agonist,unknown
Dextromethorphan,3-6 hours,NADPH oxidase,CYBBCYBANCF1NCF2NCF4RAC1RAC2,inhibitor,unknown
Dextromethorphan,3-6 hours,Sodium-dependent noradrenaline transporter,SLC6A2,,unknown
Cisplatin,Cisplatin decays monoexponentially with a half life of 20 to 30 minutes following administrations of 50 or 100 mg/m^2.  Cisplatin has a plasma half-life of 30 minutes. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more.,DNA,,cross-linking/alkylation,yes
Cisplatin,Cisplatin decays monoexponentially with a half life of 20 to 30 minutes following administrations of 50 or 100 mg/m^2.  Cisplatin has a plasma half-life of 30 minutes. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more.,DNA-3-methyladenine glycosylase,MPG,,unknown
Cisplatin,Cisplatin decays monoexponentially with a half life of 20 to 30 minutes following administrations of 50 or 100 mg/m^2.  Cisplatin has a plasma half-life of 30 minutes. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more.,Alpha-2-macroglobulin,A2M,,unknown
Cisplatin,Cisplatin decays monoexponentially with a half life of 20 to 30 minutes following administrations of 50 or 100 mg/m^2.  Cisplatin has a plasma half-life of 30 minutes. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more.,Serotransferrin,TF,,unknown
Cisplatin,Cisplatin decays monoexponentially with a half life of 20 to 30 minutes following administrations of 50 or 100 mg/m^2.  Cisplatin has a plasma half-life of 30 minutes. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more.,Copper transport protein ATOX1,ATOX1,,unknown
Anisotropine Methylbromide,Not Known,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Anisotropine Methylbromide,Not Known,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Anisotropine Methylbromide,Not Known,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Albendazole,"Terminal elimination half-life ranges from 8 to 12 hours (single dose, 400mg).",Tubulin beta-2 chain,,inhibitor,yes
Albendazole,"Terminal elimination half-life ranges from 8 to 12 hours (single dose, 400mg).",Tubulin alpha-1A chain,TUBA1A,inhibitor,no
Albendazole,"Terminal elimination half-life ranges from 8 to 12 hours (single dose, 400mg).",Tubulin beta-4B chain,TUBB4B,inhibitor,no
Albendazole,"Terminal elimination half-life ranges from 8 to 12 hours (single dose, 400mg).",Fumarate reductase flavoprotein subunit,,inhibitor,unknown
Trandolapril,"The elimination half lives of trandolapril and trandolaprilat are about 6 and 10 hours, respectively, but, similar to all ACE inhibitors, trandolaprilat also has a prolonged terminal elimination phase that involves a small fraction of administered drug. This likely represents drug binding to plasma and tissue ACE. The effective half life of elimination for trandolaprilat is 16-24 hours.",Angiotensin-converting enzyme,ACE,inhibitor,yes
Caspofungin,9-11 hours,"1,3-beta-glucan synthase component FKS1",fksA,inhibitor,yes
Carteolol,,Beta-2 adrenergic receptor,ADRB2,antagonist,yes
Carteolol,,Beta-1 adrenergic receptor,ADRB1,partial agonist,yes
Bentiromide,,Serine protease hepsin,HPN,ligand,yes
Alitretinoin,,Retinoic acid receptor alpha,RARA,agonist,yes
Alitretinoin,,Retinoic acid receptor RXR-alpha,RXRA,agonist,yes
Alitretinoin,,Retinoic acid receptor beta,RARB,agonist,yes
Alitretinoin,,Retinoic acid receptor RXR-beta,RXRB,agonist,yes
Alitretinoin,,Retinoic acid receptor gamma,RARG,agonist,yes
Alitretinoin,,Retinoic acid receptor RXR-gamma,RXRG,agonist,yes
Alitretinoin,,Insulin-like growth factor-binding protein 3,IGFBP3,,unknown
Alitretinoin,,Pregnancy-specific beta-1-glycoprotein 5,PSG5,,unknown
Alitretinoin,,Cytochrome P450 26C1,CYP26C1,,unknown
Metolazone,Approximately 14 hours.,Solute carrier family 12 member 3,SLC12A3,inhibitor,yes
Tolnaftate,,Squalene monooxygenase,ERG1,inhibitor,yes
Oxaliplatin,"The decline of ultrafilterable platinum levels following oxaliplatin administartion is triphasic, with two distribution phases: t1/2α; 0.43 hours and t1/2β; 16.8 hours. This is followed by a long terminal elimination phase that lasts 391 hours (t1/2γ).",DNA,,cross-linking/alkylation,yes
Cinchocaine,,Sodium channel protein type 10 subunit alpha,SCN10A,inhibitor,yes
Cinchocaine,,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Cinchocaine,,Calmodulin,CALM1,inhibitor,unknown
Lercanidipine,,Voltage-dependent calcium channel gamma-1 subunit,CACNG1,inhibitor,yes
Foscarnet,3.3-6.8 hours,DNA polymerase catalytic subunit,UL54,inhibitor,yes
Foscarnet,3.3-6.8 hours,DNA polymerase catalytic subunit,,inhibitor,yes
Erlotinib,Median half-life of 36.2 hours.,Epidermal growth factor receptor,EGFR,antagonist,yes
Erlotinib,Median half-life of 36.2 hours.,Nuclear receptor subfamily 1 group I member 2,NR1I2,agonist,yes
Cyclophosphamide,3-12 hours,DNA,,cross-linking/alkylation,yes
Cyclophosphamide,3-12 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Mephenytoin,Approximately 7 hours,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Mephenytoin,Approximately 7 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,activator,unknown
Rofecoxib,17 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Rofecoxib,17 hours,Elastin,ELN,other/unknown,unknown
Chlormerodrin,,Solute carrier family 12 member 1,SLC12A1,inducer,yes
Chlormerodrin,,"Succinate-semialdehyde dehydrogenase, mitochondrial",ALDH5A1,inhibitor,unknown
Cefdinir,1.7 &plusmn; 0.6 hours,Penicillin-binding protein 2,penA,inhibitor,yes
Cefdinir,1.7 &plusmn; 0.6 hours,PBP3,pbp3,inhibitor,yes
Cefdinir,1.7 &plusmn; 0.6 hours,Myeloperoxidase,MPO,inhibitor,no
Guanidine,7-8 hours,Argininosuccinate synthase,argG,,unknown
Guanidine,7-8 hours,Guanidinoacetate N-methyltransferase,GAMT,,unknown
Guanidine,7-8 hours,Ribonuclease pancreatic,RNASE1,,unknown
Guanidine,7-8 hours,DNA,,,unknown
Guanidine,7-8 hours,Disks large homolog 4,DLG4,,unknown
Guanidine,7-8 hours,Lysozyme,E,,unknown
Guanidine,7-8 hours,"Aldehyde dehydrogenase, mitochondrial",ALDH2,,unknown
Guanidine,7-8 hours,Arginase,rocF,,unknown
Ciprofloxacin,4 hours,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Ciprofloxacin,4 hours,DNA gyrase subunit A,gyrA,inhibitor,yes
Ciprofloxacin,4 hours,DNA topoisomerase 2-alpha,TOP2A,inhibitor,unknown
Ciprofloxacin,4 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,,unknown
Ciprofloxacin,4 hours,DNA gyrase subunit A,gyrA,,unknown
Ciprofloxacin,4 hours,DNA topoisomerase 4 subunit A,parC,,unknown
Ciprofloxacin,4 hours,DNA topoisomerase 4 subunit B,parE,,unknown
Ciprofloxacin,4 hours,DNA gyrase subunit A,gyrA,,unknown
Ciprofloxacin,4 hours,Multidrug resistance protein MdtK,mdtK,,unknown
Ciprofloxacin,4 hours,Gyrase A,,,unknown
Ciprofloxacin,4 hours,DNA gyrase subunit A,gyrA,,unknown
Toremifene,5 days,Estrogen receptor alpha,ESR1,modulator,yes
Toremifene,5 days,Sex hormone-binding globulin,SHBG,,unknown
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,5-hydroxytryptamine receptor 1A,HTR1A,antagonist,unknown
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,Histamine H1 receptor,HRH1,antagonist,no
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,Alpha-1A adrenergic receptor,ADRA1A,antagonist,no
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,Alpha-1D adrenergic receptor,ADRA1D,antagonist,no
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,no
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,no
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,no
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,no
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,no
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,5-hydroxytryptamine receptor 6,HTR6,binder,unknown
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,antagonist,unknown
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,Beta adrenergic receptor,ADRB1ADRB2ADRB3,antagonist,unknown
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,D(2) dopamine receptor,DRD2,antagonist,unknown
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,Sigma receptor,PGRMC1SIGMAR1,binder,unknown
Nortriptyline,The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].,5-hydroxytryptamine receptor 1C,Htr2c,antagonist,unknown
Vincristine,"When intravenously injected into cancer patients, a triphasic serum decay patten was observed. The initial, middle, and terminal half-lives are 5 minutes, 2.3 hours, 85 hours respectively. The range of the terminal half-life is humans is 19 - 155 hours.",Tubulin beta chain,TUBB,inhibitor,yes
Vincristine,"When intravenously injected into cancer patients, a triphasic serum decay patten was observed. The initial, middle, and terminal half-lives are 5 minutes, 2.3 hours, 85 hours respectively. The range of the terminal half-life is humans is 19 - 155 hours.",Tubulin alpha-4A chain,TUBA4A,inhibitor,unknown
Benazepril,10-11 hours,Angiotensin-converting enzyme,ACE,inhibitor,yes
Amoxapine,8 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,unknown
Amoxapine,8 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Amoxapine,8 hours,D(2) dopamine receptor,DRD2,antagonist,unknown
Amoxapine,8 hours,D(1A) dopamine receptor,DRD1,antagonist,unknown
Amoxapine,8 hours,Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Amoxapine,8 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Amoxapine,8 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Amoxapine,8 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,antagonist,unknown
Amoxapine,8 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,unknown
Amoxapine,8 hours,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Amoxapine,8 hours,5-hydroxytryptamine receptor 6,HTR6,antagonist,unknown
Amoxapine,8 hours,5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Amoxapine,8 hours,D(3) dopamine receptor,DRD3,antagonist,unknown
Amoxapine,8 hours,D(4) dopamine receptor,DRD4,antagonist,unknown
Amoxapine,8 hours,Histamine H1 receptor,HRH1,antagonist,unknown
Amoxapine,8 hours,Alpha-1 adrenergic receptors,ADRA1AADRA1BADRA1D,antagonist,unknown
Amoxapine,8 hours,Muscarinic acetylcholine receptor,CHRM1CHRM2CHRM3CHRM4CHRM5,antagonist,unknown
Amoxapine,8 hours,5-hydroxytryptamine receptor 2B,HTR2B,antagonist,unknown
Amoxapine,8 hours,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,unknown
Amoxapine,8 hours,5-hydroxytryptamine receptor 1A,HTR1A,antagonist,unknown
Amoxapine,8 hours,5-hydroxytryptamine receptor 1B,HTR1B,antagonist,unknown
Amoxapine,8 hours,Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,antagonist,unknown
Amoxapine,8 hours,Histamine H4 receptor,HRH4,binder,unknown
Amoxapine,8 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,binder,unknown
Amoxapine,8 hours,Sodium-dependent dopamine transporter,SLC6A3,binder,unknown
Fluorouracil,10-20 minutes,Thymidylate synthase,TYMS,other/unknown,yes
Fluorouracil,10-20 minutes,DNA,,incorporation into and destabilization,yes
Fluorouracil,10-20 minutes,RNA,,incorporation into and destabilization,yes
Pyridostigmine,3 hours following oral administration.,Acetylcholinesterase,ACHE,antagonistinhibitor,yes
Pyridostigmine,3 hours following oral administration.,Cholinesterase,BCHE,antagonist,yes
Pyridostigmine,3 hours following oral administration.,Serum albumin,ALB,,unknown
Adinazolam,Less than 3 hours.,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Adinazolam,Less than 3 hours.,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Adinazolam,Less than 3 hours.,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Adinazolam,Less than 3 hours.,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Adinazolam,Less than 3 hours.,Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Adinazolam,Less than 3 hours.,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,potentiator,yes
Adinazolam,Less than 3 hours.,Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,potentiator,yes
Adinazolam,Less than 3 hours.,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Adinazolam,Less than 3 hours.,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Adinazolam,Less than 3 hours.,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Adinazolam,Less than 3 hours.,Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Adinazolam,Less than 3 hours.,Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Adinazolam,Less than 3 hours.,Gamma-aminobutyric acid receptor subunit pi,GABRP,potentiator,yes
Adinazolam,Less than 3 hours.,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,potentiator,yes
Adinazolam,Less than 3 hours.,Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,potentiator,yes
Adinazolam,Less than 3 hours.,Gamma-aminobutyric acid receptor subunit rho-3,GABRR3,potentiator,yes
Desoximetasone,The half-life of the material was 15 &plusmn; 2 hours (for urine) and 17 &plusmn; 2 hours (for feces) between the third and fifth trial day.,Glucocorticoid receptor,NR3C1,agonist,yes
Azelaic Acid,"The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics.",Thioredoxin reductase,trxB,inhibitor,yes
Azelaic Acid,"The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics.",3-oxo-5-beta-steroid 4-dehydrogenase,AKR1D1,inhibitor,yes
Azelaic Acid,"The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics.",3-oxo-5-alpha-steroid 4-dehydrogenase 2,SRD5A2,inhibitor,yes
Azelaic Acid,"The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics.",Tyrosinase,TYR,inhibitor,yes
Azelaic Acid,"The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics.",DNA polymerase I,polA,inhibitor,yes
Zafirlukast,10 hours,Cysteinyl leukotriene receptor 1,CYSLTR1,antagonist,yes
Propylthiouracil,2 hours,Thyroid peroxidase,TPO,inhibitor,yes
Acetohydroxamic Acid,5-10 hours in patients with normal renal function,Urease subunit alpha,ureC,inhibitor,yes
Acetohydroxamic Acid,5-10 hours in patients with normal renal function,Macrophage metalloelastase,MMP12,inhibitor,unknown
Pentostatin,5.7 hours (with a range between 2.6 and 16 hrs),Adenosine deaminase,ADA,inhibitor,yes
Methoxsalen,Approximately 2 hours,DNA,,intercalation,yes
Piroxicam,30 to 86 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Piroxicam,30 to 86 hours,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Lamotrigine,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.",Voltage-dependent R-type calcium channel subunit alpha-1E,CACNA1E,inhibitor,yes
Lamotrigine,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.",Sodium channel protein type 2 subunit alpha,SCN2A,inhibitor,unknown
Lamotrigine,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.",Adenosine receptor A1,ADORA1,inhibitor,unknown
Lamotrigine,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.",Adenosine receptor A2a,ADORA2A,inhibitor,unknown
Lamotrigine,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.",Alpha-1A adrenergic receptor,ADRA1A,inhibitor,unknown
Lamotrigine,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.",Alpha-2A adrenergic receptor,ADRA2A,inhibitor,unknown
Lamotrigine,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.",Beta-1 adrenergic receptor,ADRB1,inhibitor,unknown
Lamotrigine,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.",D(1) dopamine receptor,DRD1DRD5,inhibitor,unknown
Lamotrigine,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.",D(2) dopamine receptor,DRD2,inhibitor,unknown
Lamotrigine,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.",GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,inhibitor,unknown
Lamotrigine,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.",GABA-A receptor (benzodiazepine site),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRG1GABRG2GABRG3,inhibitor,unknown
Lamotrigine,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.",Histamine H1 receptor,HRH1,inhibitor,unknown
Lamotrigine,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.",Kappa-type opioid receptor,OPRK1,inhibitor,unknown
Lamotrigine,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.",Muscarinic acetylcholine receptor,CHRM1CHRM2CHRM3CHRM4CHRM5,inhibitor,unknown
Lamotrigine,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.",5-hydroxytryptamine receptor 2A,HTR2A,inhibitor,unknown
Lamotrigine,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.",5-hydroxytryptamine receptor 3A,HTR3A,inhibitor,unknown
Hydroxyzine,20 to 25 hours,Histamine H1 receptor,HRH1,antagonist,yes
Zanamivir,2.5-5.1 hours,Neuraminidase,NA,inhibitor,yes
Zanamivir,2.5-5.1 hours,Neuraminidase,NA,inhibitor,yes
Zanamivir,2.5-5.1 hours,Sialidase-2,NEU2,inhibitor,unknown
Bosentan,Terminal elimination half-life is about 5 hours in healthy adult subjects.,Endothelin-1 receptor,EDNRA,antagonist,yes
Bosentan,Terminal elimination half-life is about 5 hours in healthy adult subjects.,Endothelin B receptor,EDNRB,antagonist,yes
Tigecycline,27-43 hours,16S rRNA,,adduct,yes
Tigecycline,27-43 hours,30S ribosomal protein S9,rpsI,adduct,yes
Tigecycline,27-43 hours,30S ribosomal protein S12,rpsL,adduct,yes
Tigecycline,27-43 hours,30S ribosomal protein S13,rpsM,adduct,yes
Tigecycline,27-43 hours,30S ribosomal protein S14,rpsN,adduct,yes
Tigecycline,27-43 hours,30S ribosomal protein S19,rpsS,adduct,yes
Doxapram,,Potassium channel subfamily K member 3,KCNK3,inhibitor,yes
Doxapram,,Potassium channel subfamily K member 9,KCNK9,inhibitor,yes
Benzthiazide,,Solute carrier family 12 member 3,SLC12A3,inhibitor,yes
Benzthiazide,,Carbonic anhydrase 1,CA1,inhibitor,unknown
Benzthiazide,,Carbonic anhydrase 2,CA2,inhibitor,unknown
Benzthiazide,,Carbonic anhydrase 4,CA4,inhibitor,unknown
Benzthiazide,,Carbonic anhydrase 9,CA9,inhibitor,unknown
Benzthiazide,,Carbonic anhydrase 12,CA12,inhibitor,unknown
Methotrexate,Low doses (less than 30 mg/m^2): 3 to 10 hours; High doses: 8 to 15 hours.,Dihydrofolate reductase,DHFR,inhibitor,yes
Carbamazepine,"Initial half-life values range from 25-65 hours, decreasing to 12-17 hours on repeated doses.",Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Carbamazepine,"Initial half-life values range from 25-65 hours, decreasing to 12-17 hours on repeated doses.",Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,,unknown
Carbamazepine,"Initial half-life values range from 25-65 hours, decreasing to 12-17 hours on repeated doses.",Neuronal acetylcholine receptor subunit beta-2,CHRNB2,,unknown
Carbamazepine,"Initial half-life values range from 25-65 hours, decreasing to 12-17 hours on repeated doses.",Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Cisatracurium besylate,Elimination half-life of 22 minutes.,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,inhibitor,yes
Succimer,48 hours,Lead,,chelator,yes
Succimer,48 hours,Mercury,,chelator,yes
Succimer,48 hours,Cadmium,,chelator,yes
Succimer,48 hours,Arsenic,,chelator,yes
Cephalexin,1 hour,Penicillin-binding protein 3,pbp3,inhibitor,yes
Cephalexin,1 hour,Penicillin-binding protein 2a,pbp2a,inhibitor,yes
Cephalexin,1 hour,Penicillin-binding protein 1b,pbp1b,inhibitor,yes
Cephalexin,1 hour,Penicillin-binding protein 2B,penA,inhibitor,yes
Cephalexin,1 hour,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Cinnarizine,,Histamine H1 receptor,HRH1,antagonist,yes
Cinnarizine,,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,inhibitor,yes
Cinnarizine,,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,inhibitor,yes
Cinnarizine,,Voltage-dependent L-type calcium channel subunit alpha-1F,CACNA1F,inhibitor,yes
Cinnarizine,,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,inhibitor,yes
Cinnarizine,,Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,inhibitor,yes
Cinnarizine,,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,inhibitor,yes
Cinnarizine,,Voltage-dependent T-type calcium channel subunit alpha-1I,CACNA1I,inhibitor,yes
Cinnarizine,,D(2) dopamine receptor,DRD2,other/unknown,no
Cinnarizine,,D(1) dopamine receptor,DRD1DRD5,binder,unknown
Cinnarizine,,Muscarinic acetylcholine receptor,CHRM1CHRM2CHRM3CHRM4CHRM5,binder,unknown
Fondaparinux sodium,17-21 hours,Antithrombin-III,SERPINC1,potentiator,yes
Fondaparinux sodium,17-21 hours,Coagulation factor X,F10,inhibitor,yes
Vinblastine,"Triphasic: 35 min, 53 min, and 19 hours",Tubulin alpha-1A chain,TUBA1A,adduct,yes
Vinblastine,"Triphasic: 35 min, 53 min, and 19 hours",Tubulin beta chain,TUBB,adduct,yes
Vinblastine,"Triphasic: 35 min, 53 min, and 19 hours",Tubulin delta chain,TUBD1,adduct,yes
Vinblastine,"Triphasic: 35 min, 53 min, and 19 hours",Tubulin gamma-1 chain,TUBG1,adduct,yes
Vinblastine,"Triphasic: 35 min, 53 min, and 19 hours",Tubulin epsilon chain,TUBE1,adduct,yes
Vinblastine,"Triphasic: 35 min, 53 min, and 19 hours",Transcription factor AP-1,JUN,other/unknown,no
Propranolol,4 hours,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Propranolol,4 hours,Beta-2 adrenergic receptor,ADRB2,antagonist,unknown
Propranolol,4 hours,Beta-3 adrenergic receptor,ADRB3,antagonist,unknown
Propranolol,4 hours,5-hydroxytryptamine receptor 1A,HTR1A,other/unknown,unknown
Propranolol,4 hours,5-hydroxytryptamine receptor 1B,HTR1B,other/unknown,unknown
Atropine,3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Atropine,3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Atropine,3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Atropine,3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,yes
Atropine,3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,yes
Atropine,3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.,Glycine receptor subunit alpha-1,GLRA1,antagonist,unknown
Atropine,3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,,unknown
Atropine,3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.,Neuronal acetylcholine receptor subunit beta-2,CHRNB2,,unknown
Fenoprofen,Plasma half-life is approximately 3 hours.,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Fenoprofen,Plasma half-life is approximately 3 hours.,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Fenoprofen,Plasma half-life is approximately 3 hours.,Peroxisome proliferator-activated receptor alpha,PPARA,activator,unknown
Fenoprofen,Plasma half-life is approximately 3 hours.,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Fenfluramine,20 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Fenfluramine,20 hours,5-hydroxytryptamine receptor 2B,HTR2B,agonist,yes
Fenfluramine,20 hours,5-hydroxytryptamine receptor 2C,HTR2C,agonist,yes
Fenfluramine,20 hours,5-hydroxytryptamine receptor 2A,HTR2A,,unknown
Clonidine,"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.",Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Clonidine,"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.",Alpha-2B adrenergic receptor,ADRA2B,agonist,yes
Clonidine,"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.",Alpha-2C adrenergic receptor,ADRA2C,agonist,yes
Clonidine,"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.",Alpha-1A adrenergic receptor,ADRA1A,agonist,unknown
Clonidine,"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.",Alpha-1B adrenergic receptor,ADRA1B,agonist,unknown
Clonidine,"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.",Alpha-1D adrenergic receptor,ADRA1D,agonist,unknown
Sulfamethizole,3-8 hours,Dihydropteroate synthase,folP,inhibitor,yes
Valaciclovir,2.5-3.3 hours,DNA polymerase catalytic subunit,,inhibitor,yes
Valaciclovir,2.5-3.3 hours,Thymidine kinase,TK,inducer,yes
Carbenicillin,1 hour,Penicillin-binding protein,,inhibitor,yes
Mazindol,10-13 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Mazindol,10-13 hours,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,yes
Mazindol,10-13 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Mazindol,10-13 hours,Synaptic vesicular amine transporter,SLC18A2,,unknown
Valdecoxib,8-11 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Valdecoxib,8-11 hours,Carbonic anhydrase 2,CA2,inhibitor,unknown
Valdecoxib,8-11 hours,Carbonic anhydrase 3,CA3,inhibitor,unknown
Lactulose,1.7-2 hours,Evolved beta-galactosidase subunit alpha,ebgA,other,yes
Voriconazole,,Lanosterol 14-alpha demethylase,ERG11,antagonistinhibitor,yes
L-Carnitine,17.4 hours (elimination) following a single intravenous dose.,Solute carrier family 22 member 4,SLC22A4,,unknown
L-Carnitine,17.4 hours (elimination) following a single intravenous dose.,Solute carrier family 22 member 5,SLC22A5,,unknown
L-Carnitine,17.4 hours (elimination) following a single intravenous dose.,Carnitine O-acetyltransferase,CRAT,,unknown
L-Carnitine,17.4 hours (elimination) following a single intravenous dose.,Mitochondrial carnitine/acylcarnitine carrier protein CACL,SLC25A29,,unknown
L-Carnitine,17.4 hours (elimination) following a single intravenous dose.,Mitochondrial carnitine/acylcarnitine carrier protein,SLC25A20,,unknown
L-Carnitine,17.4 hours (elimination) following a single intravenous dose.,Peroxisomal carnitine O-octanoyltransferase,CROT,,unknown
L-Carnitine,17.4 hours (elimination) following a single intravenous dose.,"Carnitine O-palmitoyltransferase 2, mitochondrial",CPT2,,unknown
L-Carnitine,17.4 hours (elimination) following a single intravenous dose.,"Carnitine O-palmitoyltransferase 1, liver isoform",CPT1A,activator,unknown
L-Carnitine,17.4 hours (elimination) following a single intravenous dose.,Xanthine dehydrogenase/oxidase,XDH,,unknown
L-Carnitine,17.4 hours (elimination) following a single intravenous dose.,Liver carboxylesterase 1,CES1,,unknown
L-Carnitine,17.4 hours (elimination) following a single intravenous dose.,Myeloperoxidase,MPO,,unknown
Enalapril,"< 2 hours for unchanged enalapril in health individuals, may be increased in those with congestive heart failure (3.4 and 5.8 hours for single 5- and 10-mg doses, respectively). The average terminal half life of enalaprilat is 35-38 hours. The effective half life following multiple doses is 11-14 hours.",Angiotensin-converting enzyme,ACE,inhibitor,yes
Nizatidine,1-2 hours,Histamine H2 receptor,HRH2,antagonist,yes
Diclofenac,2 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Diclofenac,2 hours,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Diclofenac,2 hours,Arachidonate 5-lipoxygenase,ALOX5,potentiator,yes
Diclofenac,2 hours,Sodium channel protein type 4 subunit alpha,SCN4A,inhibitor,yes
Diclofenac,2 hours,Acid-sensing ion channel 1,ASIC1,inhibitor,yes
Diclofenac,2 hours,Potassium voltage-gated channel subfamily KQT member 2,KCNQ2,other,yes
Diclofenac,2 hours,Potassium voltage-gated channel subfamily KQT member 3,KCNQ3,other,yes
Diclofenac,2 hours,"Phospholipase A2, membrane associated",PLA2G2A,inhibitor,unknown
Cinalukast,,Cysteinyl leukotriene receptor 1,CYSLTR1,antagonist,yes
Fluticasone propionate,Terminal elimination half-life = 7.8 hours,Glucocorticoid receptor,NR3C1,agonist,yes
Fluticasone propionate,Terminal elimination half-life = 7.8 hours,Progesterone receptor,PGR,agonist,unknown
Fluticasone propionate,Terminal elimination half-life = 7.8 hours,Cytosolic phospholipase A2,PLA2G4A,inhibitor,unknown
Fluticasone propionate,Terminal elimination half-life = 7.8 hours,Mineralocorticoid receptor,NR3C2,antagonist,unknown
Lisuride,,D(2) dopamine receptor,DRD2,agonist,yes
Lisuride,,D(3) dopamine receptor,DRD3,agonist,yes
Lisuride,,D(4) dopamine receptor,DRD4,agonist,yes
Lisuride,,D(1A) dopamine receptor,DRD1,antagonist,unknown
Lisuride,,D(1B) dopamine receptor,DRD5,antagonist,unknown
Lisuride,,5-hydroxytryptamine receptor 1A,HTR1A,agonist,unknown
Lisuride,,5-hydroxytryptamine receptor 1D,HTR1D,agonist,unknown
Lisuride,,5-hydroxytryptamine receptor 2B,HTR2B,antagonist,unknown
Lisuride,,5-hydroxytryptamine receptor 2A,HTR2A,agonist,yes
Lisuride,,5-hydroxytryptamine receptor 2C,HTR2C,agonist,yes
Lisuride,,5-hydroxytryptamine receptor 1B,HTR1B,agonist,unknown
Lisuride,,Alpha-2A adrenergic receptor,ADRA2A,other/unknown,unknown
Lisuride,,Alpha-2B adrenergic receptor,ADRA2B,other/unknown,unknown
Lisuride,,Alpha-2C adrenergic receptor,ADRA2C,other/unknown,unknown
Lisuride,,5-hydroxytryptamine receptor 7,HTR7,,unknown
Doxazosin,22 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Doxazosin,22 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,yes
Doxazosin,22 hours,Alpha-1D adrenergic receptor,ADRA1D,antagonist,yes
Doxazosin,22 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Doxazosin,22 hours,Potassium voltage-gated channel subfamily H member 6,KCNH6,inhibitor,unknown
Doxazosin,22 hours,Potassium voltage-gated channel subfamily H member 7,KCNH7,inhibitor,unknown
Fluocinolone Acetonide,1.3-1.7 hours,Glucocorticoid receptor,NR3C1,agonist,yes
Piperazine,,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,agonist,yes
Ethosuximide,53 hours,Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,inhibitor,yes
Amiloride,Plasma half-life varies from 6 to 9 hours.,Amiloride-sensitive sodium channel subunit alpha,SCNN1A,inhibitor,yes
Amiloride,Plasma half-life varies from 6 to 9 hours.,Amiloride-sensitive sodium channel subunit beta,SCNN1B,inhibitor,yes
Amiloride,Plasma half-life varies from 6 to 9 hours.,Amiloride-sensitive sodium channel subunit gamma,SCNN1G,inhibitor,yes
Amiloride,Plasma half-life varies from 6 to 9 hours.,Amiloride-sensitive sodium channel subunit delta,SCNN1D,inhibitor,yes
Amiloride,Plasma half-life varies from 6 to 9 hours.,Amiloride-sensitive amine oxidase [copper-containing],AOC1,inhibitor,unknown
Amiloride,Plasma half-life varies from 6 to 9 hours.,Acid-sensing ion channel 2,ASIC2,inhibitor,unknown
Amiloride,Plasma half-life varies from 6 to 9 hours.,Acid-sensing ion channel 1,ASIC1,inhibitor,unknown
Amiloride,Plasma half-life varies from 6 to 9 hours.,Sodium/hydrogen exchanger 1,SLC9A1,inhibitor,unknown
Amiloride,Plasma half-life varies from 6 to 9 hours.,Urokinase-type plasminogen activator,PLAU,inhibitor,unknown
Oxytetracycline,,30S ribosomal protein S9,rpsI,inhibitor,yes
Oxytetracycline,,30S ribosomal protein S4,rpsD,inhibitor,yes
Oxytetracycline,,16S rRNA,,inhibitor,unknown
Ulobetasol,,Glucocorticoid receptor,NR3C1,agonist,yes
Labetalol,6-8 hours,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Labetalol,6-8 hours,Beta-2 adrenergic receptor,ADRB2,antagonist,yes
Labetalol,6-8 hours,Alpha-1 adrenergic receptors,ADRA1AADRA1BADRA1D,antagonist,yes
Thiopental,3-8 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Thiopental,3-8 hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Thiopental,3-8 hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Thiopental,3-8 hours,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Thiopental,3-8 hours,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Thiopental,3-8 hours,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Thiopental,3-8 hours,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Thiopental,3-8 hours,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Thiopental,3-8 hours,Glutamate receptor 2,GRIA2,antagonist,unknown
Thiopental,3-8 hours,"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Thiopental,3-8 hours,Fatty-acid amide hydrolase 1,FAAH,inhibitor,unknown
Thiopental,3-8 hours,Muscarinic acetylcholine receptor M3,CHRM3,,unknown
Monobenzone,,Tyrosinase,TYR,inhibitor,unknown
Linezolid,4.5-5.5 hours,23S rRNA,,inhibitor,yes
Ivermectin,16 hours (also reported at 22-28 hours),Glycine receptor subunit alpha-3,GLRA3,agonist,yes
Ivermectin,16 hours (also reported at 22-28 hours),Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,agonist,unknown
Medroxyprogesterone acetate,50 days,Progesterone receptor,PGR,agonist,yes
Medroxyprogesterone acetate,50 days,Estrogen receptor alpha,ESR1,agonist,yes
Cisapride,6-12 hours,5-hydroxytryptamine receptor 4,HTR4,agonist,yes
Cisapride,6-12 hours,5-hydroxytryptamine receptor 3A,HTR3A,agonist,yes
Cisapride,6-12 hours,5-hydroxytryptamine receptor 2A,HTR2A,agonist,yes
Cisapride,6-12 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Sulindac,The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Sulindac,The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Sulindac,The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.,Aldose reductase,AKR1B1,inhibitor,unknown
Sulindac,The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.,Mitogen-activated protein kinase 3,MAPK3,inhibitor,unknown
Sulindac,The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.,Peroxisome proliferator-activated receptor delta,PPARD,negative modulator,unknown
Sulindac,The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.,Prostaglandin D2 receptor 2,PTGDR2,antagonist,unknown
Sulindac,The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.,Aldo-keto reductase family 1 member B10,AKR1B10,inhibitor,unknown
Cyclothiazide,,Sodium/potassium-transporting ATPase subunit gamma,FXYD2,inhibitor,yes
Cyclothiazide,,Carbonic anhydrase 1,CA1,inhibitor,unknown
Cyclothiazide,,Carbonic anhydrase 2,CA2,inhibitor,unknown
Cyclothiazide,,Carbonic anhydrase 4,CA4,inhibitor,unknown
Cyclothiazide,,Secreted frizzled-related protein 4,SFRP4,inhibitor,unknown
Nafcillin,The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.,Penicillin-binding protein 1b,pbp1b,inhibitor,yes
Nafcillin,The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.,Penicillin-binding protein 2B,penA,inhibitor,yes
Nafcillin,The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.,Penicillin-binding protein 2a,pbp2a,inhibitor,yes
Nafcillin,The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.,Penicillin-binding protein 3,pbp3,inhibitor,yes
Nafcillin,The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Chloroquine,1-2 months,Fe(II)-protoporphyrin IX,,antagonist,yes
Chloroquine,1-2 months,Glutathione S-transferase A2,GSTA2,,unknown
Chloroquine,1-2 months,Tumor necrosis factor,TNF,,unknown
Chloroquine,1-2 months,Toll-like receptor 9,TLR9,,unknown
Chloroquine,1-2 months,Glutathione S-transferase,GST,,unknown
Ethionamide,2 to 3 hours,Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,adduct,yes
Ethionamide,2 to 3 hours,Catalase-peroxidase,katG,other/unknown,unknown
Metaraminol,,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Butorphanol,"The elimination half-life of butorphanol is about 18 hours. In renally impaired patients with creatinine clearances &lt;30 mL/min the elimination half-life is approximately doubled. After intravenous administration to patients with hepatic impairment, the elimination half-life of butorphanol was approximately tripled.",Kappa-type opioid receptor,OPRK1,agonist,yes
Butorphanol,"The elimination half-life of butorphanol is about 18 hours. In renally impaired patients with creatinine clearances &lt;30 mL/min the elimination half-life is approximately doubled. After intravenous administration to patients with hepatic impairment, the elimination half-life of butorphanol was approximately tripled.",Delta-type opioid receptor,OPRD1,agonist,yes
Butorphanol,"The elimination half-life of butorphanol is about 18 hours. In renally impaired patients with creatinine clearances &lt;30 mL/min the elimination half-life is approximately doubled. After intravenous administration to patients with hepatic impairment, the elimination half-life of butorphanol was approximately tripled.",Mu-type opioid receptor,OPRM1,partial antagonist,yes
Bisoprolol,9-12 hours; prolonged in the elderly and those with decreased renal function,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Bisoprolol,9-12 hours; prolonged in the elderly and those with decreased renal function,Beta-2 adrenergic receptor,ADRB2,antagonist,no
Amodiaquine,5.2 &plusmn; 1.7 (range 0.4 to 5.5) minutes,Fe(II)-protoporphyrin IX,,adduct,yes
Amodiaquine,5.2 &plusmn; 1.7 (range 0.4 to 5.5) minutes,Histamine N-methyltransferase,HNMT,inhibitor,unknown
Furazolidone,10 minutes,DNA,,cross-linking/alkylation,yes
Rifabutin,45 (&plusmn; 17) hours,DNA-directed RNA polymerase subunit alpha,rpoA,inhibitor,yes
Rifabutin,45 (&plusmn; 17) hours,DNA-directed RNA polymerase subunit beta,rpoB,inhibitor,yes
Rifabutin,45 (&plusmn; 17) hours,DNA-directed RNA polymerase subunit beta',rpoC,inhibitor,yes
Rifabutin,45 (&plusmn; 17) hours,Heat shock protein HSP 90-alpha,HSP90AA1,other/unknown,no
Rifabutin,45 (&plusmn; 17) hours,Endoplasmin,HSP90B1,other/unknown,no
Candoxatril,,Neprilysin,MME,inhibitor,yes
Candoxatril,,Angiotensin-converting enzyme,ACE,inhibitor,unknown
Paramethadione,12 to 24 hours (however the half-life for the active metabolite is not known),Voltage-dependent T-type calcium channel subunit alpha-1I,CACNA1I,suppressor,yes
Demeclocycline,10-17 hours,30S ribosomal protein S9,rpsI,inhibitor,yes
Demeclocycline,10-17 hours,30S ribosomal protein S4,rpsD,inhibitor,yes
Imatinib,"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.",BCR/ABL fusion protein isoform X9,BCR/ABL fusion,inhibitor,yes
Imatinib,"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.",Mast/stem cell growth factor receptor Kit,KIT,antagonistmultitarget,yes
Imatinib,"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.",RET proto-oncogene,RET,inhibitor,yes
Imatinib,"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.",High affinity nerve growth factor receptor,NTRK1,antagonist,unknown
Imatinib,"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.",Macrophage colony-stimulating factor 1 receptor,CSF1R,antagonist,unknown
Imatinib,"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.",Platelet-derived growth factor receptor alpha,PDGFRA,antagonist,unknown
Imatinib,"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.",Epithelial discoidin domain-containing receptor 1,DDR1,antagonist,unknown
Imatinib,"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.",Tyrosine-protein kinase ABL1,ABL1,inhibitor,unknown
Imatinib,"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.",Platelet-derived growth factor receptor beta,PDGFRB,antagonist,unknown
Triamcinolone,88 minutes,Glucocorticoid receptor,NR3C1,agonist,yes
Oxandrolone,"0.55 hours (1st phage), 9 hours (2nd phase)",Androgen receptor,AR,agonist,yes
Nicardipine,8.6 hours,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,inhibitor,yes
Nicardipine,8.6 hours,Voltage-dependent L-type calcium channel subunit beta-2,CACNB2,inhibitor,yes
Nicardipine,8.6 hours,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,inhibitor,yes
Nicardipine,8.6 hours,Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,inhibitor,yes
Nicardipine,8.6 hours,"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A",PDE1A,inhibitor,unknown
Nicardipine,8.6 hours,"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B",PDE1B,inhibitor,unknown
Nicardipine,8.6 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Nicardipine,8.6 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Nicardipine,8.6 hours,Alpha-1D adrenergic receptor,ADRA1D,antagonist,unknown
Nicardipine,8.6 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Nicardipine,8.6 hours,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Nicardipine,8.6 hours,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Nicardipine,8.6 hours,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,unknown
Nicardipine,8.6 hours,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,unknown
Nicardipine,8.6 hours,Calmodulin,CALM1,other/unknown,unknown
Fluphenazine,,D(2) dopamine receptor,DRD2,antagonist,yes
Fluphenazine,,D(1A) dopamine receptor,DRD1,antagonist,yes
Fluphenazine,,Calmodulin,CALM1,inhibitor,unknown
Fluphenazine,,Androgen receptor,AR,,unknown
Fluphenazine,,5-hydroxytryptamine receptor 2A,HTR2A,,unknown
Fluphenazine,,5-hydroxytryptamine receptor 2C,HTR2C,,unknown
Testosterone,10-100 minutes,Androgen receptor,AR,agonist,yes
Testosterone,10-100 minutes,Estrogen receptor alpha,ESR1,,unknown
Testosterone,10-100 minutes,Mineralocorticoid receptor,NR3C2,,unknown
Efavirenz,40-55 hours,Reverse transcriptase/RNaseH,pol,inhibitor,yes
Bacitracin,,C55-isoprenyl pyrophosphate,,antagonist,yes
Bacitracin,,Insulin-degrading enzyme,IDE,inhibitor,yes
Bacitracin,,Alpha-2-macroglobulin,A2M,inhibitor,unknown
Niacin,20-45 minutes.,Hydroxycarboxylic acid receptor 3,HCAR3,agonist,yes
Niacin,20-45 minutes.,Hydroxycarboxylic acid receptor 2,HCAR2,agonist,yes
Niacin,20-45 minutes.,Nicotinate-nucleotide pyrophosphorylase [carboxylating],QPRT,binder,yes
Niacin,20-45 minutes.,Nicotinamide N-methyltransferase,NNMT,binder,yes
Clorazepate,"The serum half-life is about 2 days. Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.",GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Clorazepate,"The serum half-life is about 2 days. Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.",Translocator protein,TSPO,agonist,unknown
Guanabenz,6 hours.,Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Guanabenz,6 hours.,Alpha-2B adrenergic receptor,ADRA2B,binder,unknown
Alendronic acid,>10 years,Farnesyl pyrophosphate synthase,FDPS,inhibitor,yes
Alendronic acid,>10 years,Hydroxylapatite,,antagonist,yes
Alendronic acid,>10 years,Tyrosine-protein phosphatase non-receptor type 4,PTPN4,inhibitor,unknown
Alendronic acid,>10 years,Receptor-type tyrosine-protein phosphatase S,PTPRS,inhibitor,unknown
Alendronic acid,>10 years,Receptor-type tyrosine-protein phosphatase epsilon,PTPRE,inhibitor,unknown
Alendronic acid,>10 years,V-type proton ATPase catalytic subunit A,ATP6V1A,inhibitor,unknown
Clofarabine,The terminal half-life is estimated to be 5.2 hours.,DNA polymerase alpha catalytic subunit,POLA1,inhibitor,yes
Clofarabine,The terminal half-life is estimated to be 5.2 hours.,Ribonucleoside-diphosphate reductase large subunit,RRM1,inhibitor,yes
Clofarabine,The terminal half-life is estimated to be 5.2 hours.,DNA,,other/unknown,yes
Docosanol,,Envelope glycoprotein GP350,,intercalation,yes
Docosanol,,Envelope glycoprotein GP340,,intercalation,unknown
Dexmedetomidine,2 hours,Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Sulfacetamide,7-12.8 hours,Dihydropteroate synthase,folP,inhibitor,yes
Sulfacetamide,7-12.8 hours,Dihydropteroate synthase type-1,sulI,inhibitor,yes
Sulfacetamide,7-12.8 hours,Folic acid synthesis protein FOL1,FOL1,inhibitor,yes
Prednisone,Half life of both the immediate- and delayed- release formulation is 2 to 3 hours.,Glucocorticoid receptor,NR3C1,agonist,yes
Prednisone,Half life of both the immediate- and delayed- release formulation is 2 to 3 hours.,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,ligand,unknown
Clofibrate,Half-life in normal volunteers averages 18 to 22 hours (range 14 to 35 hours) but can vary by up to 7 hours in the same subject at different times.,Peroxisome proliferator-activated receptor alpha,PPARA,agonist,yes
Astemizole,1 day,Histamine H1 receptor,HRH1,antagonist,yes
Astemizole,1 day,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Astemizole,1 day,Potassium voltage-gated channel subfamily H member 1,KCNH1,,unknown
Astemizole,1 day,Microtubule-associated protein tau,MAPT,,unknown
Inulin,2-4 hours,Cycloinulo-oligosaccharide fructanotransferase,cft,binder,no
Butoconazole,,Ergosterol,,other,yes
Adenosine,Less than 10 secs,Adenosine receptor A2a,ADORA2A,agonist,yes
Adenosine,Less than 10 secs,Adenosine receptor A2b,ADORA2B,agonist,yes
Adenosine,Less than 10 secs,Adenosine receptor A3,ADORA3,agonist,yes
Adenosine,Less than 10 secs,Adenosine receptor A1,ADORA1,agonist,yes
Simvastatin,3 hours,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,inhibitor,yes
Simvastatin,3 hours,Integrin beta-2,ITGB2,other,no
Simvastatin,3 hours,Integrin alpha-L,ITGAL,inhibitor,unknown
Pemetrexed,3.5 hours,Thymidylate synthase,TYMS,inhibitor,yes
Pemetrexed,3.5 hours,Bifunctional purine biosynthesis protein PURH,ATIC,inhibitor,yes
Pemetrexed,3.5 hours,Dihydrofolate reductase,DHFR,inhibitor,yes
Pemetrexed,3.5 hours,Trifunctional purine biosynthetic protein adenosine-3,GART,inhibitor,yes
Mebendazole,2.5 to 5.5 hours (range 2.5 to 9 hours) in patients with normal hepatic function. Approximately 35 hours in patients with impaired hepatic function (cholestasis).,Tubulin alpha-1A chain,TUBA1A,inhibitor,yes
Mebendazole,2.5 to 5.5 hours (range 2.5 to 9 hours) in patients with normal hepatic function. Approximately 35 hours in patients with impaired hepatic function (cholestasis).,Tubulin beta-4B chain,TUBB4B,inhibitor,yes
Gonadorelin,"Very short, initial, 2 to 10 minutes; terminal, 10 to 40 minutes",Gonadotropin-releasing hormone receptor,GNRHR,agonist,yes
Gonadorelin,"Very short, initial, 2 to 10 minutes; terminal, 10 to 40 minutes",Putative gonadotropin-releasing hormone II receptor,GNRHR2,agonist,yes
Dyclonine,Approximately 30 to 60 minutes.,Sodium channel protein type 10 subunit alpha,SCN10A,inhibitor,yes
Nystatin,,Ergosterol,,binder,yes
Dextropropoxyphene,6-12 hours,Mu-type opioid receptor,OPRM1,agonist,yes
Dextropropoxyphene,6-12 hours,Delta-type opioid receptor,OPRD1,agonist,yes
Dextropropoxyphene,6-12 hours,Kappa-type opioid receptor,OPRK1,antagonist,yes
Dextropropoxyphene,6-12 hours,Liver carboxylesterase 1,CES1,,unknown
Mitotane,18-159 days,"Cytochrome P450 11B1, mitochondrial",CYP11B1,inducer,yes
Mitotane,18-159 days,"Adrenodoxin, mitochondrial",FDX1,unknown,unknown
Mitotane,18-159 days,Estrogen receptor alpha,ESR1,,unknown
Mitotane,18-159 days,Progesterone receptor,PGR,,unknown
Mitotane,18-159 days,Androgen receptor,AR,antagonist,unknown
Stavudine,0.8-1.5 hours (in adults),Reverse transcriptase/RNaseH,pol,inhibitor,yes
Dyphylline,2 hours (range 1.8 - 2.1 hours),"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,inhibitor,yes
Dyphylline,2 hours (range 1.8 - 2.1 hours),"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,inhibitor,yes
Dyphylline,2 hours (range 1.8 - 2.1 hours),"cAMP-specific 3',5'-cyclic phosphodiesterase 4C",PDE4C,inhibitor,yes
Dyphylline,2 hours (range 1.8 - 2.1 hours),"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,inhibitor,yes
Dyphylline,2 hours (range 1.8 - 2.1 hours),Adenosine receptor A1,ADORA1,antagonist,yes
Dyphylline,2 hours (range 1.8 - 2.1 hours),Adenosine receptor A2a,ADORA2A,antagonist,yes
Dyphylline,2 hours (range 1.8 - 2.1 hours),"High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A",PDE7A,inhibitor,yes
Dyphylline,2 hours (range 1.8 - 2.1 hours),"cAMP-specific 3',5'-cyclic phosphodiesterase 7B",PDE7B,inhibitor,yes
Pentazocine,2 to 3 hours,Mu-type opioid receptor,OPRM1,antagonist,yes
Pentazocine,2 to 3 hours,Kappa-type opioid receptor,OPRK1,agonist,yes
Pentazocine,2 to 3 hours,Sigma non-opioid intracellular receptor 1,SIGMAR1,agonist,yes
Magnesium sulfate,43.2 hours (for newborns),Voltage-dependent calcium channel gamma-1 subunit,CACNG1,,unknown
Magnesium sulfate,43.2 hours (for newborns),Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,,unknown
Magnesium sulfate,43.2 hours (for newborns),Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,,unknown
Magnesium sulfate,43.2 hours (for newborns),Voltage-dependent L-type calcium channel subunit beta-1,CACNB1,,unknown
Magnesium sulfate,43.2 hours (for newborns),Voltage-dependent L-type calcium channel subunit beta-2,CACNB2,,unknown
Magnesium sulfate,43.2 hours (for newborns),Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,,unknown
Latanoprost,17 minutes,Prostaglandin F2-alpha receptor,PTGFR,agonist,yes
Estrone,19 hours,Estrogen receptor alpha,ESR1,agonist,yes
Estrone,19 hours,Estrogen receptor beta,ESR2,,unknown
Estrone,19 hours,Androgen receptor,AR,,unknown
Estrone,19 hours,Cytochrome P450 19A1,CYP19A1,,unknown
Estrone,19 hours,Sex hormone-binding globulin,SHBG,,unknown
Trazodone,Undergoes biphasic elimination with an initial phase t<sub>1/2 &alpha;</sub> of 3-6 hours and a terminal phase t<sub>1/2 &beta;</sub> of 5-9 hours.,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Trazodone,Undergoes biphasic elimination with an initial phase t<sub>1/2 &alpha;</sub> of 3-6 hours and a terminal phase t<sub>1/2 &beta;</sub> of 5-9 hours.,5-hydroxytryptamine receptor 2C,HTR2C,agonist,yes
Trazodone,Undergoes biphasic elimination with an initial phase t<sub>1/2 &alpha;</sub> of 3-6 hours and a terminal phase t<sub>1/2 &beta;</sub> of 5-9 hours.,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Trazodone,Undergoes biphasic elimination with an initial phase t<sub>1/2 &alpha;</sub> of 3-6 hours and a terminal phase t<sub>1/2 &beta;</sub> of 5-9 hours.,5-hydroxytryptamine receptor 1A,HTR1A,partial agonist,yes
Trazodone,Undergoes biphasic elimination with an initial phase t<sub>1/2 &alpha;</sub> of 3-6 hours and a terminal phase t<sub>1/2 &beta;</sub> of 5-9 hours.,Histamine H1 receptor,HRH1,antagonist,unknown
Trazodone,Undergoes biphasic elimination with an initial phase t<sub>1/2 &alpha;</sub> of 3-6 hours and a terminal phase t<sub>1/2 &beta;</sub> of 5-9 hours.,Alpha-1A adrenergic receptor,ADRA1A,antagonist,no
Trazodone,Undergoes biphasic elimination with an initial phase t<sub>1/2 &alpha;</sub> of 3-6 hours and a terminal phase t<sub>1/2 &beta;</sub> of 5-9 hours.,Alpha-2A adrenergic receptor,ADRA2A,antagonist,no
Mecamylamine,,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,inhibitor,yes
Mecamylamine,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,,unknown
Mecamylamine,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,,unknown
Mecamylamine,,Neuronal acetylcholine receptor subunit beta-2,CHRNB2,,unknown
Sevelamer,,Phosphate,,binder,yes
Acamprosate,20 - 33 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive modulator,yes
Acamprosate,20 - 33 hours,Glutamate (NMDA) receptor,GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B,antagonist,yes
Acamprosate,20 - 33 hours,Metabotropic glutamate receptor 5,GRM5,antagonist,yes
Verapamil,2.8-7.4 hours,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,inhibitor,yes
Verapamil,2.8-7.4 hours,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,inhibitor,yes
Verapamil,2.8-7.4 hours,Voltage-dependent L-type calcium channel subunit alpha-1F,CACNA1F,inhibitor,yes
Verapamil,2.8-7.4 hours,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,inhibitor,yes
Verapamil,2.8-7.4 hours,Voltage-dependent L-type calcium channel subunit beta-1,CACNB1,inhibitor,yes
Verapamil,2.8-7.4 hours,Voltage-dependent L-type calcium channel subunit beta-2,CACNB2,inhibitor,yes
Verapamil,2.8-7.4 hours,Voltage-dependent L-type calcium channel subunit beta-3,CACNB3,inhibitor,yes
Verapamil,2.8-7.4 hours,Voltage-dependent L-type calcium channel subunit beta-4,CACNB4,inhibitor,yes
Verapamil,2.8-7.4 hours,Voltage-dependent T-type calcium channel subunit alpha-1I,CACNA1I,inhibitor,unknown
Verapamil,2.8-7.4 hours,Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,inhibitor,unknown
Verapamil,2.8-7.4 hours,Voltage-dependent N-type calcium channel subunit alpha-1B,CACNA1B,inhibitor,unknown
Verapamil,2.8-7.4 hours,Voltage-dependent P/Q-type calcium channel subunit alpha-1A,CACNA1A,inhibitor,unknown
Verapamil,2.8-7.4 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Verapamil,2.8-7.4 hours,Sodium channel protein type 5 subunit alpha,SCN5A,other,unknown
Verapamil,2.8-7.4 hours,ATP-sensitive inward rectifier potassium channel 11,KCNJ11,inhibitor,unknown
Verapamil,2.8-7.4 hours,Sodium-dependent serotonin transporter,SLC6A4,other/unknown,unknown
Verapamil,2.8-7.4 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Verapamil,2.8-7.4 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Verapamil,2.8-7.4 hours,Alpha-1D adrenergic receptor,ADRA1D,antagonist,unknown
Flumethasone,,Glucocorticoid receptor,NR3C1,agonist,yes
Sulfametopyrazine,,Dihydropteroate synthetase,,inhibitor,yes
Nilutamide,38.0-59.1 hours,Androgen receptor,AR,antagonist,yes
Nafarelin,3 hours,Gonadotropin-releasing hormone receptor,GNRHR,agonist,yes
Nafarelin,3 hours,Putative gonadotropin-releasing hormone II receptor,GNRHR2,agonist,yes
Epinephrine,2 minutes,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Epinephrine,2 minutes,Alpha-1B adrenergic receptor,ADRA1B,agonist,yes
Epinephrine,2 minutes,Beta-1 adrenergic receptor,ADRB1,agonist,yes
Epinephrine,2 minutes,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Epinephrine,2 minutes,Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Epinephrine,2 minutes,Alpha-2B adrenergic receptor,ADRA2B,agonist,yes
Epinephrine,2 minutes,Alpha-1D adrenergic receptor,ADRA1D,antagonist,unknown
Epinephrine,2 minutes,Phenylalanine-4-hydroxylase,PAH,antagonist,no
Epinephrine,2 minutes,Alpha-2C adrenergic receptor,ADRA2C,agonist,unknown
Epinephrine,2 minutes,Beta-3 adrenergic receptor,ADRB3,agonist,unknown
Epinephrine,2 minutes,Tumor necrosis factor,TNF,antagonist,unknown
Epinephrine,2 minutes,Superoxide dismutase [Cu-Zn],SOD1,,unknown
Sumatriptan,2.5 hours,5-hydroxytryptamine receptor 1D,HTR1D,agonist,yes
Sumatriptan,2.5 hours,5-hydroxytryptamine receptor 1B,HTR1B,agonist,yes
Sumatriptan,2.5 hours,5-hydroxytryptamine receptor 1F,HTR1F,agonist,yes
Sumatriptan,2.5 hours,5-hydroxytryptamine receptor 1A,HTR1A,agonist,yes
Pirenzepine,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Cefixime,"3-4 hours (may range up to 9 hours). In severe renal impairment (5 to 20 mL/min creatinine clearance), the half-life increased to an average of 11.5 hours.",Penicillin-binding protein 2,mrdA,inhibitor,yes
Chlorpropamide,Approximately 36 hours with interindividual variation ranging from 25-60 hours. Duration of effect persists for at least 24 hours.,ATP-binding cassette sub-family C member 8,ABCC8,inhibitor,yes
Aprepitant,9-13 hours,Substance-P receptor,TACR1,antagonist,yes
Galantamine,7 hours,Acetylcholinesterase,ACHE,inhibitor,yes
Galantamine,7 hours,Acetylcholine receptor subunit alpha,CHRNA1,allosteric modulator,unknown
Galantamine,7 hours,Acetylcholine receptor subunit beta,CHRNB1,allosteric modulator,unknown
Galantamine,7 hours,Acetylcholine receptor subunit delta,CHRND,allosteric modulator,unknown
Galantamine,7 hours,Acetylcholine receptor subunit gamma,CHRNG,allosteric modulator,unknown
Galantamine,7 hours,Acetylcholine receptor subunit epsilon,CHRNE,allosteric modulator,unknown
Galantamine,7 hours,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,allosteric modulator,unknown
Galantamine,7 hours,Neuronal acetylcholine receptor subunit alpha-3,CHRNA3,allosteric modulator,unknown
Galantamine,7 hours,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,allosteric modulator,unknown
Galantamine,7 hours,Neuronal acetylcholine receptor subunit alpha-5,CHRNA5,allosteric modulator,unknown
Galantamine,7 hours,Neuronal acetylcholine receptor subunit alpha-6,CHRNA6,allosteric modulator,unknown
Galantamine,7 hours,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,allosteric modulator,unknown
Galantamine,7 hours,Neuronal acetylcholine receptor subunit alpha-9,CHRNA9,allosteric modulator,unknown
Galantamine,7 hours,Neuronal acetylcholine receptor subunit alpha-10,CHRNA10,allosteric modulator,unknown
Galantamine,7 hours,Neuronal acetylcholine receptor subunit beta-2,CHRNB2,allosteric modulator,unknown
Galantamine,7 hours,Neuronal acetylcholine receptor subunit beta-3,CHRNB3,allosteric modulator,unknown
Galantamine,7 hours,Neuronal acetylcholine receptor subunit beta-4,CHRNB4,allosteric modulator,unknown
Galantamine,7 hours,Cholinesterase,BCHE,inhibitor,unknown
Tamoxifen,The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.,Estrogen receptor alpha,ESR1,antagonistagonist,yes
Tamoxifen,The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.,Estrogen receptor beta,ESR2,antagonistagonist,yes
Tamoxifen,The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.,"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase",EBP,,unknown
Tamoxifen,The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.,Protein kinase C,PRKCAPRKCBPRKCDPRKCEPRKCGPRKCIPRKCQPRKCZ,,unknown
Tamoxifen,The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.,Androgen receptor,AR,,unknown
Tamoxifen,The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Tamoxifen,The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Tamoxifen,The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.,Estrogen-related receptor gamma,ESRRG,,unknown
Tamoxifen,The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.,Sex hormone-binding globulin,SHBG,,unknown
Isoflurophate,,Acetylcholinesterase,ACHE,inhibitor,yes
Isoflurophate,,Cholinesterase,BCHE,inhibitor,yes
Isoflurophate,,Serotransferrin,TF,,unknown
Losartan,The terminal t<sub>1/2</sub> of losartan is 2 hours. The active metabolite has a half-life of 6-9 hours.,Type-1 angiotensin II receptor,AGTR1,antagonist,yes
Thioridazine,21-25 hours,D(2) dopamine receptor,DRD2,antagonist,yes
Thioridazine,21-25 hours,D(1A) dopamine receptor,DRD1,antagonist,yes
Thioridazine,21-25 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Thioridazine,21-25 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,yes
Thioridazine,21-25 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Thioridazine,21-25 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Moricizine,2 hours (range 1.5-3.5 hours).,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Amphotericin B,An elimination half-life of approximately 15 days follows an initial plasma half-life of about 24 hours.,Ergosterol,,binder,yes
Warfarin,R-warfarin t<sub>1/2</sub>=37-89 hours; S-warfarin t<sub>1/2</sub>=21-43 hours.,Vitamin K epoxide reductase complex subunit 1,VKORC1,inhibitor,yes
Warfarin,R-warfarin t<sub>1/2</sub>=37-89 hours; S-warfarin t<sub>1/2</sub>=21-43 hours.,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit pi,GABRP,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit rho-3,GABRR3,potentiator,yes
Midazolam,"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)",Gamma-aminobutyric acid receptor subunit theta,GABRQ,potentiator,yes
Tobramycin,The elimination half-life of tobramycin from serum is approximately 2 hours after intravenous (IV) administration.,30S ribosomal protein S12,rpsL,inhibitor,yes
Tobramycin,The elimination half-life of tobramycin from serum is approximately 2 hours after intravenous (IV) administration.,16S rRNA,,inhibitor,unknown
Trovafloxacin,"Following oral administration, half-life ranged from 9.1 hours to 12.2 hours over the dosage range of 100 to 200 mg tablets. Following intravenous infusion, half-life ranged from 9.4 to 12.7 hours over a dosage range of 100 to 300 mg.",DNA gyrase subunit A,gyrA,inhibitor,yes
Trovafloxacin,"Following oral administration, half-life ranged from 9.1 hours to 12.2 hours over the dosage range of 100 to 200 mg tablets. Following intravenous infusion, half-life ranged from 9.4 to 12.7 hours over a dosage range of 100 to 300 mg.",DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Trovafloxacin,"Following oral administration, half-life ranged from 9.1 hours to 12.2 hours over the dosage range of 100 to 200 mg tablets. Following intravenous infusion, half-life ranged from 9.4 to 12.7 hours over a dosage range of 100 to 300 mg.",DNA topoisomerase 2-alpha,TOP2A,inhibitor,unknown
Pentosan Polysulfate,4.8 hours,Fibroblast growth factor 2,FGF2,antagonist,yes
Pentosan Polysulfate,4.8 hours,Fibroblast growth factor 1,FGF1,antagonist,yes
Pentosan Polysulfate,4.8 hours,Fibroblast growth factor 4,FGF4,inhibitor,unknown
Fludrocortisone,3.5 hours,Mineralocorticoid receptor,NR3C2,agonist,yes
Fludrocortisone,3.5 hours,Glucocorticoid receptor,NR3C1,agonist,unknown
Fludrocortisone,3.5 hours,Androgen receptor,AR,agonist,unknown
Mycophenolate mofetil,"The mean elimination half-life for mycophenolic acid (the active metabolite) ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.",Inosine-5'-monophosphate dehydrogenase 1,IMPDH1,inhibitor,yes
Mycophenolate mofetil,"The mean elimination half-life for mycophenolic acid (the active metabolite) ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.",Inosine-5'-monophosphate dehydrogenase 2,IMPDH2,inhibitor,yes
Cephaloglycin,,Penicillin-binding protein 1 (PBP1),,antagonist,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit pi,GABRP,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit rho-3,GABRR3,potentiator,yes
Flurazepam,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,Gamma-aminobutyric acid receptor subunit theta,GABRQ,potentiator,yes
Moexipril,Moexipril elimination half-life is approximately 1 hour. Moexiprilat elimination half-life is 2 to 9 hours.,Angiotensin-converting enzyme,ACE,inhibitor,yes
Moexipril,Moexipril elimination half-life is approximately 1 hour. Moexiprilat elimination half-life is 2 to 9 hours.,Angiotensin-converting enzyme 2,ACE2,inhibitor,yes
Phentolamine,19 minutes,Alpha-2A adrenergic receptor,ADRA2A,antagonist,yes
Phentolamine,19 minutes,Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Phentolamine,19 minutes,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Phentolamine,19 minutes,Alpha-1D adrenergic receptor,ADRA1D,antagonist,unknown
Fluorescein,,Ig kappa chain V-II region RPMI 6410,,other,no
Fluorescein,,DNA,,other,no
Daunorubicin,18.5 hours,DNA,,intercalation,yes
Daunorubicin,18.5 hours,DNA topoisomerase 2-alpha,TOP2A,inhibitor,yes
Daunorubicin,18.5 hours,DNA topoisomerase 2-beta,TOP2B,inhibitor,yes
Furosemide,2 hours,Solute carrier family 12 member 1,SLC12A1,inhibitor,yes
Furosemide,2 hours,Carbonic anhydrase 2,CA2,,unknown
Ergotamine,2 hours,5-hydroxytryptamine receptor 1D,HTR1D,agonist,yes
Ergotamine,2 hours,5-hydroxytryptamine receptor 1B,HTR1B,agonist,yes
Ergotamine,2 hours,5-hydroxytryptamine receptor 2A,HTR2A,agonist,yes
Ergotamine,2 hours,D(2) dopamine receptor,DRD2,agonist,unknown
Ergotamine,2 hours,Alpha-1A adrenergic receptor,ADRA1A,partial agonist,yes
Ergotamine,2 hours,Alpha-1B adrenergic receptor,ADRA1B,partial agonist,yes
Ergotamine,2 hours,Alpha-1D adrenergic receptor,ADRA1D,partial agonist,yes
Ergotamine,2 hours,Alpha-2A adrenergic receptor,ADRA2A,partial agonist,unknown
Ergotamine,2 hours,Alpha-2B adrenergic receptor,ADRA2B,agonistpartial agonist,unknown
Ergotamine,2 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,unknown
Ergotamine,2 hours,D(1) dopamine receptor,DRD1DRD5,agonist,unknown
Ergotamine,2 hours,5-hydroxytryptamine receptor 1A,HTR1A,agonist,unknown
Ergotamine,2 hours,5-hydroxytryptamine receptor 1F,HTR1F,agonist,unknown
Ergotamine,2 hours,5-hydroxytryptamine receptor 2C,HTR2C,agonist,unknown
Ergotamine,2 hours,5-hydroxytryptamine receptor 2B,HTR2B,,unknown
Tizanidine,2.5 hours,Alpha-2A adrenergic receptor,ADRA2A,agonist,unknown
Tizanidine,2.5 hours,Alpha-2B adrenergic receptor,ADRA2B,agonist,yes
Tizanidine,2.5 hours,Alpha-2C adrenergic receptor,ADRA2C,agonist,yes
Tizanidine,2.5 hours,Nischarin,NISCH,agonist,no
Nitrofurantoin,0.3-1 hour,Probable pyruvate-flavodoxin oxidoreductase,ydbK,potentiator,yes
Nitrofurantoin,0.3-1 hour,Oxygen-insensitive NADPH nitroreductase,nfsA,potentiator,yes
Nitrofurantoin,0.3-1 hour,30S ribosomal protein S10,rpsJ,,unknown
Nicergoline,,Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Eplerenone,4-6 hours,Mineralocorticoid receptor,NR3C2,antagonist,yes
Amprenavir,7.1-10.6 hours,Human immunodeficiency virus type 1 protease,pol,inhibitor,yes
Methazolamide,14 hours,Carbonic anhydrase 1,CA1,inhibitor,yes
Methazolamide,14 hours,Carbonic anhydrase 2,CA2,inhibitor,yes
Methazolamide,14 hours,Carbonic anhydrase 4,CA4,inhibitor,yes
Methazolamide,14 hours,Carbonic anhydrase 7,CA7,inhibitor,yes
Methazolamide,14 hours,Carbonic anhydrase 3,CA3,inhibitor,unknown
Naltrexone,4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.,Delta-type opioid receptor,OPRD1,antagonist,yes
Naltrexone,4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.,Mu-type opioid receptor,OPRM1,antagonist,yes
Naltrexone,4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.,Kappa-type opioid receptor,OPRK1,antagonist,yes
Naltrexone,4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.,"HCG20471, isoform CRA_c",SIGMAR1,antagonist,yes
Delavirdine,5.8 hours,Reverse transcriptase/RNaseH,pol,inhibitor,yes
Tamsulosin,5-7 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Tamsulosin,5-7 hours,Alpha-1D adrenergic receptor,ADRA1D,antagonist,unknown
Tamsulosin,5-7 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Porfimer sodium,10-452 hours,Low-density lipoprotein receptor,LDLR,other/unknown,unknown
Porfimer sodium,10-452 hours,High affinity immunoglobulin gamma Fc receptor I,FCGR1A,antagonist,unknown
Sufentanil,265 minutes,Mu-type opioid receptor,OPRM1,agonist,yes
Sufentanil,265 minutes,Delta-type opioid receptor,OPRD1,agonist,unknown
Sufentanil,265 minutes,Kappa-type opioid receptor,OPRK1,other,unknown
Lamivudine,5 to 7 hours (healthy or HBV-infected patients),Reverse transcriptase/RNaseH,pol,inhibitor,yes
Lamivudine,5 to 7 hours (healthy or HBV-infected patients),DNA,,adduct,yes
Lamivudine,5 to 7 hours (healthy or HBV-infected patients),Protein P,P,inhibitor,yes
Ibandronate,10-60 hours,Farnesyl pyrophosphate synthase,FDPS,inhibitor,yes
Ibandronate,10-60 hours,Hydroxylapatite,,antagonist,yes
Diethylcarbamazine,Approximately 8 hours.,Arachidonate 5-lipoxygenase,ALOX5,inhibitor,yes
Diethylcarbamazine,Approximately 8 hours.,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Flurbiprofen,"R-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours",Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Flurbiprofen,"R-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours",Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Oxacillin,20 to 30 minutes,Penicillin-binding protein 3,pbp3,inhibitor,yes
Oxacillin,20 to 30 minutes,Penicillin-binding protein 2a,pbp2a,inhibitor,yes
Oxacillin,20 to 30 minutes,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Oxacillin,20 to 30 minutes,Penicillin-binding protein 2B,penA,inhibitor,yes
Oxacillin,20 to 30 minutes,Penicillin-binding protein 1b,pbp1b,inhibitor,yes
Oxacillin,20 to 30 minutes,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Oxacillin,20 to 30 minutes,Solute carrier family 15 member 1,SLC15A1,,unknown
Oxacillin,20 to 30 minutes,Penicillin-binding protein 2,mecA,,unknown
Oxacillin,20 to 30 minutes,Solute carrier family 15 member 2,SLC15A2,,unknown
Apomorphine,40 minutes (range 30 - 60 minutes),D(3) dopamine receptor,DRD3,agonist,yes
Apomorphine,40 minutes (range 30 - 60 minutes),D(4) dopamine receptor,DRD4,agonist,yes
Apomorphine,40 minutes (range 30 - 60 minutes),D(2) dopamine receptor,DRD2,agonist,yes
Apomorphine,40 minutes (range 30 - 60 minutes),Alpha-2C adrenergic receptor,ADRA2C,agonist,unknown
Apomorphine,40 minutes (range 30 - 60 minutes),Alpha-2B adrenergic receptor,ADRA2B,agonist,unknown
Apomorphine,40 minutes (range 30 - 60 minutes),5-hydroxytryptamine receptor 2C,HTR2C,agonist,unknown
Apomorphine,40 minutes (range 30 - 60 minutes),D(1B) dopamine receptor,DRD5,agonist,unknown
Apomorphine,40 minutes (range 30 - 60 minutes),5-hydroxytryptamine receptor 1A,HTR1A,agonist,unknown
Apomorphine,40 minutes (range 30 - 60 minutes),5-hydroxytryptamine receptor 2A,HTR2A,agonist,unknown
Apomorphine,40 minutes (range 30 - 60 minutes),5-hydroxytryptamine receptor 2B,HTR2B,agonist,unknown
Apomorphine,40 minutes (range 30 - 60 minutes),Alpha-2A adrenergic receptor,ADRA2A,agonist,unknown
Apomorphine,40 minutes (range 30 - 60 minutes),D(1A) dopamine receptor,DRD1,agonist,unknown
Apomorphine,40 minutes (range 30 - 60 minutes),5-hydroxytryptamine receptor 1D,HTR1D,agonist,unknown
Apomorphine,40 minutes (range 30 - 60 minutes),5-hydroxytryptamine receptor 1B,HTR1B,agonist,unknown
Apomorphine,40 minutes (range 30 - 60 minutes),Neuron-specific vesicular protein calcyon,CALY,agonist,unknown
Paroxetine,21-24 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Paroxetine,21-24 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,unknown
Paroxetine,21-24 hours,5-hydroxytryptamine receptor 2A,HTR2A,other/unknown,unknown
Paroxetine,21-24 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,no
Paroxetine,21-24 hours,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,no
Paroxetine,21-24 hours,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,no
Paroxetine,21-24 hours,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,no
Paroxetine,21-24 hours,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,no
Nedocromil,~3.3 hours,Cysteinyl leukotriene receptor 1,CYSLTR1,suppressor,yes
Nedocromil,~3.3 hours,Cysteinyl leukotriene receptor 2,CYSLTR2,antagonist,yes
Nedocromil,~3.3 hours,fMet-Leu-Phe receptor,FPR1,antagonist,unknown
Nedocromil,~3.3 hours,Prostaglandin D2 receptor,PTGDR,unknown,unknown
Nedocromil,~3.3 hours,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
Norethisterone,8.51 ± 2.19 (when a single dose is given to healthy women),Progesterone receptor,PGR,agonist,unknown
Adefovir Dipivoxil,Plasma adefovir concentrations declined in a biexponential manner with a terminal elimination half-life of 7.48 ± 1.65 hours.,DNA polymerase/reverse transcriptase,P,other,yes
Azatadine,,Histamine H1 receptor,HRH1,antagonist,yes
Clodronic Acid,Approximately 13 hours.,ADP/ATP translocase 1,SLC25A4,inhibitor,yes
Clodronic Acid,Approximately 13 hours.,ADP/ATP translocase 2,SLC25A5,inhibitor,yes
Clodronic Acid,Approximately 13 hours.,ADP/ATP translocase 3,SLC25A6,inhibitor,yes
Clodronic Acid,Approximately 13 hours.,Hydroxylapatite,,antagonist,yes
Procaine,7.7 minutes,Sodium channel protein type 10 subunit alpha,SCN10A,inhibitor,yes
Procaine,7.7 minutes,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,antagonist,yes
Procaine,7.7 minutes,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,yes
Procaine,7.7 minutes,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,yes
Procaine,7.7 minutes,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,antagonist,unknown
Procaine,7.7 minutes,DNA,,binder,unknown
Procaine,7.7 minutes,Calcium-activated potassium channel,KCNMA1KCNMB1KCNMB2KCNMB3KCNMB4KCNN4KCNN1KCNN2KCNN3,binder,unknown
Procaine,7.7 minutes,Phospholipase A2,,,unknown
Procaine,7.7 minutes,Lysophospholipase,,,unknown
Procaine,7.7 minutes,Monoamine oxidase,MAOAMAOB,,unknown
Lisinopril,Effective half life of accumulation following multiple dosing is 12 hours.,Angiotensin-converting enzyme,ACE,inhibitor,yes
Methoxamine,,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Methoxamine,,Alpha-1B adrenergic receptor,ADRA1B,agonist,unknown
Methoxamine,,Alpha-1D adrenergic receptor,ADRA1D,binder,unknown
Imiquimod,"20 hours (topical dose), 2 hours (subcutaneous dose)",Toll-like receptor 7,TLR7,agonist,yes
Imiquimod,"20 hours (topical dose), 2 hours (subcutaneous dose)",Toll-like receptor 8,TLR8,agonist,unknown
Homatropine Methylbromide,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Homatropine Methylbromide,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Homatropine Methylbromide,,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,yes
Homatropine Methylbromide,,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,yes
Homatropine Methylbromide,,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Trimipramine,11-18 hrs,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Trimipramine,11-18 hrs,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Trimipramine,11-18 hrs,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,unknown
Trimipramine,11-18 hrs,5-hydroxytryptamine receptor 2A,HTR2A,agonist,unknown
Trimipramine,11-18 hrs,5-hydroxytryptamine receptor 1A,HTR1A,antagonist,unknown
Trimipramine,11-18 hrs,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Trimipramine,11-18 hrs,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Trimipramine,11-18 hrs,D(2) dopamine receptor,DRD2,other/unknown,unknown
Trimipramine,11-18 hrs,Alpha-2B adrenergic receptor,ADRA2B,other/unknown,unknown
Trimipramine,11-18 hrs,Histamine H1 receptor,HRH1,antagonist,unknown
Trimipramine,11-18 hrs,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Trimipramine,11-18 hrs,5-hydroxytryptamine receptor 3A,HTR3A,binder,unknown
Trimipramine,11-18 hrs,5-hydroxytryptamine receptor 1D,HTR1D,binder,unknown
Trimipramine,11-18 hrs,Alpha-2A adrenergic receptor,ADRA2A,desensitize the target,unknown
Trimipramine,11-18 hrs,D(1) dopamine receptor,DRD1DRD5,binder,unknown
Trimipramine,11-18 hrs,Beta adrenergic receptor,ADRB1ADRB2ADRB3,binder,unknown
Trimipramine,11-18 hrs,Muscarinic acetylcholine receptor,CHRM1CHRM2CHRM3CHRM4CHRM5,binder,unknown
Trimipramine,11-18 hrs,5-hydroxytryptamine receptor 1C,Htr2c,binder,unknown
Nitroglycerin,3 minutes,Atrial natriuretic peptide receptor 1,NPR1,agonist,yes
Rocuronium,"The rapid distribution half-life is 1-2 minutes and the slower distribution half-life is 14-18 minutes. Renal impairment has no net effect on half-life, however, half-life is almost doubled in patients with impaired liver function.",Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,antagonist,yes
Rocuronium,"The rapid distribution half-life is 1-2 minutes and the slower distribution half-life is 14-18 minutes. Renal impairment has no net effect on half-life, however, half-life is almost doubled in patients with impaired liver function.",Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Rocuronium,"The rapid distribution half-life is 1-2 minutes and the slower distribution half-life is 14-18 minutes. Renal impairment has no net effect on half-life, however, half-life is almost doubled in patients with impaired liver function.",5-hydroxytryptamine receptor 3A,HTR3A,antagonist,unknown
Diphemanil Methylsulfate,,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Thiabendazole,The half-life for thiabendazole in both normal and anephric patients is 1.2 hours (range 0.9 to 2 hours). The half-life for the 5-hydroxythiabendazole metabolite in both normal and anephric patients is 1.7 hours (range 1.4 to 2 hours).,Fumarate reductase flavoprotein subunit,frdA,inhibitor,yes
Nateglinide,1.5 hours,ATP-binding cassette sub-family C member 8,ABCC8,inhibitor,yes
Nateglinide,1.5 hours,Peroxisome proliferator-activated receptor gamma,PPARG,agonist,unknown
Atracurium besylate,The elimination half-life is approximately 20 minutes.,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,inhibitor,yes
Pralidoxime,74-77 minutes,Acetylcholinesterase,ACHE,activator,yes
Pralidoxime,74-77 minutes,Cholinesterase,BCHE,activator,yes
Risperidone,"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]",5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Risperidone,"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]",D(2) dopamine receptor,DRD2,antagonist,yes
Risperidone,"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]",D(3) dopamine receptor,DRD3,antagonist,unknown
Risperidone,"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]",D(4) dopamine receptor,DRD4,antagonist,unknown
Risperidone,"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]",Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Risperidone,"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]",Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Risperidone,"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]",5-hydroxytryptamine receptor 1D,HTR1D,antagonist,unknown
Risperidone,"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]",Histamine H1 receptor,HRH1,antagonist,unknown
Risperidone,"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]",Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Risperidone,"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]",Alpha-2B adrenergic receptor,ADRA2B,antagonistagonist,unknown
Risperidone,"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]",Alpha-2C adrenergic receptor,ADRA2C,agonist,unknown
Risperidone,"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]",5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Risperidone,"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]",5-hydroxytryptamine receptor 1A,HTR1A,antagonist,unknown
Risperidone,"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]",D(1A) dopamine receptor,DRD1,antagonist,unknown
Risperidone,"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]",5-hydroxytryptamine receptor 7,HTR7,,unknown
Naftifine,Approximately 2 to 3 days following topical administration.,Squalene monooxygenase,SQLE,inhibitor,yes
Esomeprazole,1-1.5 hours,Potassium-transporting ATPase alpha chain 1,ATP4A,inhibitor,yes
Meclizine,6 hours,Histamine H1 receptor,HRH1,antagonist,yes
Meclizine,6 hours,Nuclear receptor subfamily 1 group I member 3,NR1I3,inverse agonist,unknown
Pentamidine,9.1-13.2 hours,DNA,,intercalation,unknown
Pentamidine,9.1-13.2 hours,tRNA (cytosine(38)-C(5))-methyltransferase,TRDMT1,other,unknown
Hetacillin,,Penicillin-binding protein 2a,pbp2a,inhibitor,yes
Hetacillin,,Penicillin-binding protein 1b,pbp1b,inhibitor,yes
Hetacillin,,Penicillin-binding protein 3,pbp3,inhibitor,yes
Hetacillin,,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Hetacillin,,Penicillin-binding protein 2B,penA,inhibitor,yes
Riluzole,The mean elimination half-life of riluzole is 12 hours (CV=35%) after repeated doses.,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Riluzole,The mean elimination half-life of riluzole is 12 hours (CV=35%) after repeated doses.,Cystine/glutamate transporter,SLC7A11,inducer,yes
Hydrocortisone,6-8 hours,Glucocorticoid receptor,NR3C1,agonist,yes
Hydrocortisone,6-8 hours,Annexin A1,ANXA1,agonist,yes
Hydrocortisone,6-8 hours,Corticosteroid 11-beta-dehydrogenase isozyme 2,HSD11B2,,unknown
Hydrocortisone,6-8 hours,3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1,HSD3B1,,unknown
Zileuton,2.5 hours,Arachidonate 5-lipoxygenase,ALOX5,inhibitor,yes
Modafinil,23-215 hours,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,yes
Modafinil,23-215 hours,Alpha-1B adrenergic receptor,ADRA1B,partial agonist,unknown
Deferoxamine,Biphasic elimination pattern in healthy volunteers with a first rapid phase half life of 1 hour and a second slow phase half-life of 6 hours.,Iron,,chelator,yes
Deferoxamine,Biphasic elimination pattern in healthy volunteers with a first rapid phase half life of 1 hour and a second slow phase half-life of 6 hours.,Aluminum,,chelator,yes
Deferoxamine,Biphasic elimination pattern in healthy volunteers with a first rapid phase half life of 1 hour and a second slow phase half-life of 6 hours.,Amyloid beta A4 protein,APP,,unknown
Scopolamine,4.5 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Scopolamine,4.5 hours,"Sucrase-isomaltase, intestinal",SI,inhibitor,unknown
Scopolamine,4.5 hours,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Scopolamine,4.5 hours,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Scopolamine,4.5 hours,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,unknown
Scopolamine,4.5 hours,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,unknown
Scopolamine,4.5 hours,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,,unknown
Scopolamine,4.5 hours,Neuronal acetylcholine receptor subunit beta-2,CHRNB2,,unknown
Carbinoxamine,10 to 20 hours,Histamine H1 receptor,HRH1,antagonist,yes
Etodolac,"Terminal t<sub>1/2</sub>, 7.3 &plusmn; 4.0 hours. Distribution t<sub>1/2</sub>, 0.71 &plusmn; 0.50 hours",Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Etodolac,"Terminal t<sub>1/2</sub>, 7.3 &plusmn; 4.0 hours. Distribution t<sub>1/2</sub>, 0.71 &plusmn; 0.50 hours",Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Etodolac,"Terminal t<sub>1/2</sub>, 7.3 &plusmn; 4.0 hours. Distribution t<sub>1/2</sub>, 0.71 &plusmn; 0.50 hours",Retinoic acid receptor RXR-alpha,RXRA,other,unknown
Prilocaine,,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Epinastine,12 hours,Histamine H1 receptor,HRH1,antagonist,yes
Epinastine,12 hours,Histamine H2 receptor,HRH2,antagonist,yes
Epinastine,12 hours,Alpha-1A adrenergic receptor,ADRA1A,unknown,unknown
Epinastine,12 hours,Alpha-2A adrenergic receptor,ADRA2A,unknown,unknown
Epinastine,12 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,unknown
Epinastine,12 hours,5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Tranylcypromine,1.5-3.2 hours in patients with normal renal and hepatic function,Amine oxidase [flavin-containing] A,MAOA,inhibitor,yes
Tranylcypromine,1.5-3.2 hours in patients with normal renal and hepatic function,Amine oxidase [flavin-containing] B,MAOB,inhibitor,yes
Isoflurane,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,agonist,yes
Isoflurane,,Calcium-transporting ATPase type 2C member 1,ATP2C1,inhibitor,yes
Isoflurane,,Glycine receptor subunit alpha-1,GLRA1,agonist,yes
Isoflurane,,Glutamate receptor 1,GRIA1,antagonist,yes
Isoflurane,,Potassium voltage-gated channel subfamily A member 1,KCNA1,inducer,yes
Isoflurane,,"ATP synthase subunit delta, mitochondrial",ATP5D,unknown,unknown
Isoflurane,,Calmodulin,CALM1,other/unknown,unknown
Isoflurane,,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Ethotoin,3 to 9 hours,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Ethotoin,3 to 9 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,activator,unknown
Tretinoin,0.5-2 hours,Retinoic acid receptor RXR-beta,RXRB,agonist,yes
Tretinoin,0.5-2 hours,Retinoic acid receptor RXR-gamma,RXRG,agonist,yes
Tretinoin,0.5-2 hours,Retinoic acid receptor gamma,RARG,agonist,yes
Tretinoin,0.5-2 hours,Retinal dehydrogenase 1,ALDH1A1,,unknown
Tretinoin,0.5-2 hours,Retinoic acid-induced protein 3,GPRC5A,,unknown
Tretinoin,0.5-2 hours,Nuclear receptor subfamily 0 group B member 1,NR0B1,,unknown
Tretinoin,0.5-2 hours,Retinal dehydrogenase 2,ALDH1A2,,unknown
Tretinoin,0.5-2 hours,Retinoic acid receptor responder protein 1,RARRES1,agonist,unknown
Tretinoin,0.5-2 hours,Retinoic acid receptor alpha,RARA,,unknown
Tretinoin,0.5-2 hours,Retinoic acid receptor beta,RARB,,unknown
Tretinoin,0.5-2 hours,Lipocalin-1,LCN1,,unknown
Tretinoin,0.5-2 hours,Odorant-binding protein 2a,OBP2A,,unknown
Tretinoin,0.5-2 hours,Retinol-binding protein 4,RBP4,,unknown
Tretinoin,0.5-2 hours,"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial",PDK4,,unknown
Tretinoin,0.5-2 hours,Retinoic acid receptor RXR-alpha,RXRA,,unknown
Tretinoin,0.5-2 hours,Cytochrome P450 26A1,CYP26A1,,unknown
Tretinoin,0.5-2 hours,Cytochrome P450 26B1,CYP26B1,,unknown
Tretinoin,0.5-2 hours,Cytochrome P450 26C1,CYP26C1,,unknown
Tretinoin,0.5-2 hours,Hematopoietic prostaglandin D synthase,HPGDS,,unknown
Hexachlorophene,,D-lactate dehydrogenase,dld,inhibitor,yes
Hexachlorophene,,"Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial",SDHD,inhibitor,yes
Hexachlorophene,,"Glutamate dehydrogenase 1, mitochondrial",GLUD1,inhibitor,unknown
Hexachlorophene,,Estrogen receptor alpha,ESR1,,unknown
Dolasetron,8.1 hours,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,yes
Clopidogrel,Carboxylic acid derivative: 8 hours (after single and multiple doses). Covalent binding to platelets has accounted for 2% of radiolabeled clopidogrel with a half-life of 11 days.,P2Y purinoceptor 12,P2RY12,antagonist,yes
Tetracycline,6-12 hours,30S ribosomal protein S7,rpsG,inhibitor,yes
Tetracycline,6-12 hours,30S ribosomal protein S14,rpsN,inhibitor,yes
Tetracycline,6-12 hours,30S ribosomal protein S3,rpsC,inhibitor,yes
Tetracycline,6-12 hours,30S ribosomal protein S8,rpsH,inhibitor,yes
Tetracycline,6-12 hours,30S ribosomal protein S19,rpsS,inhibitor,yes
Tetracycline,6-12 hours,16S rRNA,,inhibitor,yes
Tetracycline,6-12 hours,Major prion protein,PRNP,inhibitor,unknown
Tetracycline,6-12 hours,Multidrug translocase MdfA,mdfA,,unknown
Tetracycline,6-12 hours,Protein-arginine deiminase type-4,PADI4,,unknown
Meropenem,Approximately 1 hour in adults and children 2 years of age and older with normal renal function. Approximately 1.5 hours in children 3 months to 2 years of age.,D-alanyl-D-alanine carboxypeptidase DacB,dacB,inhibitor,yes
Potassium Chloride,,Solute carrier family 12 member 2,SLC12A2,,unknown
Potassium Chloride,,Solute carrier family 12 member 1,SLC12A1,binder,unknown
Potassium Chloride,,Solute carrier family 12 member 5,SLC12A5,,unknown
Potassium Chloride,,Solute carrier family 12 member 6,SLC12A6,,unknown
Potassium Chloride,,Solute carrier family 12 member 7,SLC12A7,,unknown
Potassium Chloride,,Solute carrier family 12 member 4,SLC12A4,,unknown
Irinotecan,"The half life of irinotecan is about 6 - 12 hours. The terminal elimination half-life of the active metabolite, SN-38 is 10 - 20 hours.",DNA topoisomerase 1,TOP1,inhibitor,yes
Irinotecan,"The half life of irinotecan is about 6 - 12 hours. The terminal elimination half-life of the active metabolite, SN-38 is 10 - 20 hours.","DNA topoisomerase I, mitochondrial",TOP1MT,inhibitor,yes
Methimazole,5-6 hours,Thyroid peroxidase,TPO,inhibitor,yes
Mometasone,5.8 hours,Glucocorticoid receptor,NR3C1,agonist,yes
Mometasone,5.8 hours,Progesterone receptor,PGR,agonist,unknown
Metyrosine,3.4 to 3.7 hours,Tyrosine 3-monooxygenase,TH,binder,yes
Clavulanate,1.0 hour,Beta-lactamase,blaZ,inhibitor,yes
Benzquinamide,1-1.6 hours (for all formulations),Histamine H1 receptor,HRH1,antagonist,yes
Benzquinamide,1-1.6 hours (for all formulations),Muscarinic acetylcholine receptor M4,CHRM4,antagonist,yes
Benzquinamide,1-1.6 hours (for all formulations),Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Benzquinamide,1-1.6 hours (for all formulations),Muscarinic acetylcholine receptor M5,CHRM5,antagonist,yes
Benzquinamide,1-1.6 hours (for all formulations),Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Benzquinamide,1-1.6 hours (for all formulations),Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Olopatadine,3 hours,Histamine H1 receptor,HRH1,antagonist,yes
Olopatadine,3 hours,Protein S100-A1,S100A1,antagonist,unknown
Olopatadine,3 hours,Protein S100-A12,S100A12,antagonist,unknown
Olopatadine,3 hours,Protein S100-B,S100B,other/unknown,unknown
Olopatadine,3 hours,Protein S100-A13,S100A13,other/unknown,unknown
Olopatadine,3 hours,Protein S100-A2,S100A2,antagonist,unknown
Hydrocortamate,,Glucocorticoid receptor,NR3C1,agonist,yes
Alprostadil,"5 to 10 minutes (after a single dose), in healthy adults and neonates.",Prostaglandin E2 receptor EP2 subtype,PTGER2,agonist,yes
Alprostadil,"5 to 10 minutes (after a single dose), in healthy adults and neonates.",Prostaglandin E2 receptor EP1 subtype,PTGER1,agonist,yes
Alprostadil,"5 to 10 minutes (after a single dose), in healthy adults and neonates.",Prostaglandin D2 receptor 2,PTGDR2,agonist,unknown
Clidinium,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Malathion,8-24 hours,Cholinesterase,BCHE,inhibitor,yes
Etoposide,4-11 hours,DNA topoisomerase 2-alpha,TOP2A,inhibitor,yes
Etoposide,4-11 hours,DNA topoisomerase 2-beta,TOP2B,inhibitor,no
Hydroflumethiazide,It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours,Solute carrier family 12 member 1,SLC12A1,inhibitor,yes
Hydroflumethiazide,It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours,Carbonic anhydrase 1,CA1,inhibitor,unknown
Hydroflumethiazide,It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours,Carbonic anhydrase 2,CA2,inhibitor,unknown
Hydroflumethiazide,It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours,Carbonic anhydrase 4,CA4,inhibitor,unknown
Hydroflumethiazide,It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours,Carbonic anhydrase 9,CA9,inhibitor,unknown
Hydroflumethiazide,It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours,Carbonic anhydrase 12,CA12,inhibitor,unknown
Hydroflumethiazide,It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,other/unknown,unknown
Hydroflumethiazide,It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours,Calcium-activated potassium channel subunit alpha-1,KCNMA1,other/unknown,unknown
Tirofiban,2 hours,Integrin alpha-IIb,ITGA2B,antagonist,yes
Tirofiban,2 hours,Integrin beta-3,ITGB3,antagonist,yes
Oxcarbazepine,"The half-life of the parent is about 2 hours, while the half-life of MHD is about 9 hours, so that MHD is responsible for most anti-epileptic activity.",Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Propiomazine,,Histamine H1 receptor,HRH1,antagonist,yes
Propiomazine,,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,unknown
Propiomazine,,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Propiomazine,,D(2) dopamine receptor,DRD2,antagonist,unknown
Propiomazine,,D(1A) dopamine receptor,DRD1,antagonist,unknown
Propiomazine,,D(4) dopamine receptor,DRD4,antagonist,unknown
Propiomazine,,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Propiomazine,,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Propiomazine,,Alpha-1D adrenergic receptor,ADRA1D,antagonist,unknown
Propiomazine,,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Propiomazine,,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,unknown
Propiomazine,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Propiomazine,,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,unknown
Propiomazine,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Roxithromycin,12 hours,50S ribosomal protein L10,rplJ,inhibitor,yes
Roxithromycin,12 hours,Multidrug resistance protein 1,ABCB1,,unknown
Nalidixic Acid,"1.1 to 2.5 hours in healthy adult patients, and up to 21 hours in patients with impaired renal function.",DNA,,other,yes
Phenelzine,After administration phenelzine presents a very short half-life of 11.6 hours in humans.[L1365],Amine oxidase [flavin-containing] A,MAOA,antagonist,yes
Phenelzine,After administration phenelzine presents a very short half-life of 11.6 hours in humans.[L1365],Amine oxidase [flavin-containing] B,MAOB,antagonist,yes
Phenelzine,After administration phenelzine presents a very short half-life of 11.6 hours in humans.[L1365],Membrane primary amine oxidase,AOC3,inhibitor,unknown
Phenelzine,After administration phenelzine presents a very short half-life of 11.6 hours in humans.[L1365],"4-aminobutyrate aminotransferase, mitochondrial",ABAT,inhibitor,unknown
Phenelzine,After administration phenelzine presents a very short half-life of 11.6 hours in humans.[L1365],Alanine aminotransferase 1,GPT,inhibitor,unknown
Phenelzine,After administration phenelzine presents a very short half-life of 11.6 hours in humans.[L1365],Alanine aminotransferase 2,GPT2,inhibitor,unknown
Phenelzine,After administration phenelzine presents a very short half-life of 11.6 hours in humans.[L1365],Glutamic acid decarboxylase,GAD65,inhibitor,unknown
Polymyxin B Sulfate,,Bacterial outer membrane,,incorporation into and destabilization,yes
Propantheline,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Estradiol,36 hours,Estrogen receptor alpha,ESR1,agonist,yes
Estradiol,36 hours,Estrogen receptor beta,ESR2,agonist,yes
Estradiol,36 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Estradiol,36 hours,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,,unknown
Estradiol,36 hours,Nuclear receptor coactivator 2,NCOA2,,unknown
Estradiol,36 hours,G-protein coupled estrogen receptor 1,GPER1,,unknown
Estradiol,36 hours,ATP synthase subunit a,MT-ATP6,,unknown
Estradiol,36 hours,Beclin-1,BECN1,,unknown
Estradiol,36 hours,Estradiol 17-beta-dehydrogenase 2,HSD17B2,,unknown
Estradiol,36 hours,Estrogen-related receptor gamma,ESRRG,ligand,unknown
Mefenamic acid,2 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Mefenamic acid,2 hours,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Cryptenamine,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Cryptenamine,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Cryptenamine,,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Cryptenamine,,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,yes
Cryptenamine,,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,yes
Marimastat,,Interstitial collagenase,MMP1,inhibitor,yes
Marimastat,,72 kDa type IV collagenase,MMP2,inhibitor,yes
Marimastat,,Stromelysin-1,MMP3,antagonist,yes
Marimastat,,Matrilysin,MMP7,antagonist,yes
Marimastat,,Neutrophil collagenase,MMP8,inhibitor,yes
Marimastat,,Matrix metalloproteinase-9,MMP9,inhibitor,yes
Marimastat,,Stromelysin-2,MMP10,antagonist,yes
Marimastat,,Stromelysin-3,MMP11,antagonist,yes
Marimastat,,Macrophage metalloelastase,MMP12,inhibitor,yes
Marimastat,,Collagenase 3,MMP13,inhibitor,yes
Marimastat,,Matrix metalloproteinase-14,MMP14,inhibitor,yes
Marimastat,,Matrix metalloproteinase-15,MMP15,inhibitor,yes
Marimastat,,Matrix metalloproteinase-16,MMP16,inhibitor,yes
Marimastat,,Matrix metalloproteinase-17,MMP17,inhibitor,yes
Marimastat,,Matrix metalloproteinase-19,MMP19,inhibitor,yes
Marimastat,,Matrix metalloproteinase-20,MMP20,inhibitor,yes
Marimastat,,Matrix metalloproteinase-21,MMP21,inhibitor,yes
Marimastat,,Matrix metalloproteinase-23,MMP23A,inhibitor,yes
Marimastat,,Matrix metalloproteinase-24,MMP24,inhibitor,yes
Marimastat,,Matrix metalloproteinase-25,MMP25,inhibitor,yes
Marimastat,,Matrix metalloproteinase-26,MMP26,inhibitor,yes
Marimastat,,Matrix metalloproteinase-27,MMP27,inhibitor,yes
Marimastat,,Matrix metalloproteinase-28,MMP28,inhibitor,yes
Aciclovir,2.5-3.3 hours,Thymidine kinase,TK,potentiator,yes
Aciclovir,2.5-3.3 hours,DNA polymerase catalytic subunit,,inhibitor,yes
Aciclovir,2.5-3.3 hours,DNA polymerase catalytic subunit,,inhibitor,yes
Naproxen,The observed terminal elimination half-life is approximately 15 hours.,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Naproxen,The observed terminal elimination half-life is approximately 15 hours.,Peptostreptococcal albumin-binding protein,pab,,unknown
Naproxen,The observed terminal elimination half-life is approximately 15 hours.,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Gadopentetate dimeglumine,"Distribution half life 12 minutes, elimination half 100 minutes","6-phosphogluconate dehydrogenase, decarboxylating",PGD,inhibitor,unknown
Perindopril,"Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.",Angiotensin-converting enzyme,ACE,inhibitor,yes
Perindopril,"Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.",Secreted frizzled-related protein 4,SFRP4,inhibitor,unknown
Uracil mustard,,DNA,,intercalation,unknown
Tripelennamine,,Histamine H1 receptor,HRH1,antagonist,yes
Primidone,3-23 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Primidone,3-23 hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Primidone,3-23 hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Primidone,3-23 hours,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Primidone,3-23 hours,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Primidone,3-23 hours,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Primidone,3-23 hours,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Primidone,3-23 hours,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Primidone,3-23 hours,Glutamate receptor 2,GRIA2,antagonist,unknown
Primidone,3-23 hours,"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Primidone,3-23 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Sulfasalazine,5-10 hours,Arachidonate 5-lipoxygenase,ALOX5,inhibitor,yes
Sulfasalazine,5-10 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Sulfasalazine,5-10 hours,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Sulfasalazine,5-10 hours,Peroxisome proliferator-activated receptor gamma,PPARG,agonist,yes
Sulfasalazine,5-10 hours,Inhibitor of nuclear factor kappa-B kinase subunit alpha,CHUK,inhibitor,unknown
Sulfasalazine,5-10 hours,Inhibitor of nuclear factor kappa-B kinase subunit beta,IKBKB,inhibitor,unknown
Sulfasalazine,5-10 hours,Cystine/glutamate transporter,SLC7A11,inhibitor,unknown
Sulfasalazine,5-10 hours,"Acetyl-CoA acetyltransferase, mitochondrial",ACAT1,inhibitor,unknown
Sulfasalazine,5-10 hours,Thromboxane-A synthase,TBXAS1,antagonist,unknown
Sulfasalazine,5-10 hours,Phospholipase A2,PLA2G1B,antagonist,unknown
Candesartan cilexetil,Approximately 9 hours.,Type-1 angiotensin II receptor,AGTR1,antagonist,yes
Tolazoline,,Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Tolazoline,,Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Tolazoline,,Histamine H1 receptor,HRH1,agonist,unknown
Tolazoline,,Histamine H2 receptor,HRH2,agonist,unknown
Tolazoline,,Alpha-2C adrenergic receptor,ADRA2C,binder,unknown
Tolazoline,,Alpha-2B adrenergic receptor,ADRA2B,binder,unknown
Gentamicin,3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.,30S ribosomal protein S12,rpsL,adduct,yes
Gentamicin,3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.,16S rRNA,,adduct,yes
Gentamicin,3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.,Low-density lipoprotein receptor-related protein 2,LRP2,other/unknown,no
Gentamicin,3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.,NH(3)-dependent NAD(+) synthetase,nadE,,unknown
Gentamicin,3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.,Dihydrofolate reductase,DHFR,,unknown
Tazarotene,"The half-life of the active form of the drug, tazarotenic acid, is approximately 18 hours in normal and psoriatic patients.",Retinoic acid receptor alpha,RARA,agonist,yes
Tazarotene,"The half-life of the active form of the drug, tazarotenic acid, is approximately 18 hours in normal and psoriatic patients.",Retinoic acid receptor RXR-beta,RXRB,agonist,yes
Tazarotene,"The half-life of the active form of the drug, tazarotenic acid, is approximately 18 hours in normal and psoriatic patients.",Retinoic acid receptor gamma,RARG,agonist,yes
Tazarotene,"The half-life of the active form of the drug, tazarotenic acid, is approximately 18 hours in normal and psoriatic patients.",Retinoic acid receptor beta,RARB,agonist,yes
Fenoldopam,"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.",D(1B) dopamine receptor,DRD5,agonist,yes
Fenoldopam,"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.",D(1A) dopamine receptor,DRD1,agonist,yes
Fenoldopam,"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.",Alpha-2B adrenergic receptor,ADRA2B,antagonist,unknown
Fenoldopam,"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.",Alpha-2C adrenergic receptor,ADRA2C,antagonist,unknown
Fenoldopam,"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.",Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Fenoldopam,"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.",Alpha-1B adrenergic receptor,ADRA1B,,unknown
Fenoldopam,"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.",Alpha-1D adrenergic receptor,ADRA1D,,unknown
Fenoldopam,"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.",Alpha-1A adrenergic receptor,ADRA1A,,unknown
Halazepam,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Halazepam,,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Halazepam,,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Halazepam,,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Halazepam,,Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Halazepam,,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,potentiator,yes
Halazepam,,Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,potentiator,yes
Halazepam,,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Halazepam,,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Halazepam,,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Halazepam,,Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Halazepam,,Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Halazepam,,Gamma-aminobutyric acid receptor subunit pi,GABRP,potentiator,yes
Halazepam,,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,potentiator,yes
Halazepam,,Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,potentiator,yes
Halazepam,,Gamma-aminobutyric acid receptor subunit rho-3,GABRR3,potentiator,yes
Halazepam,,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Alfentanil,90-111 minutes,Mu-type opioid receptor,OPRM1,agonist,yes
Colistin,5 hours,Bacterial outer membrane,,incorporation into and destabilization,yes
Dicyclomine,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Dicyclomine,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Minaprine,,Amine oxidase [flavin-containing] A,MAOA,inhibitor,yes
Minaprine,,5-hydroxytryptamine receptor 2B,HTR2B,antagonist,yes
Minaprine,,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Minaprine,,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,yes
Minaprine,,Acetylcholinesterase,ACHE,inhibitor,yes
Minaprine,,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,unknown
Minaprine,,D(1A) dopamine receptor,DRD1,agonist,unknown
Minaprine,,D(2) dopamine receptor,DRD2,agonist,unknown
Minaprine,,Muscarinic acetylcholine receptor M1,CHRM1,agonist,unknown
Pentoxifylline,0.4-0.8 hours,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,inhibitor,yes
Pentoxifylline,0.4-0.8 hours,Adenosine receptor A1,ADORA1,antagonist,yes
Pentoxifylline,0.4-0.8 hours,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,inhibitor,yes
Pentoxifylline,0.4-0.8 hours,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,inhibitor,yes
Pentoxifylline,0.4-0.8 hours,Adenosine receptor A2a,ADORA2A,antagonist,yes
Pentoxifylline,0.4-0.8 hours,5'-nucleotidase,NT5E,inhibitor,unknown
Proparacaine,,Sodium channel protein type 10 subunit alpha,SCN10A,inhibitor,yes
Indapamide,14 hours (biphasic),Potassium voltage-gated channel subfamily KQT member 1,KCNQ1,inhibitor,yes
Indapamide,14 hours (biphasic),Potassium voltage-gated channel subfamily E member 1,KCNE1,inhibitor,yes
Tropicamide,,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,yes
Tropicamide,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Tropicamide,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Tropicamide,,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Biperiden,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Biperiden,,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,antagonist,yes
Ribavirin,The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].,Inosine-5'-monophosphate dehydrogenase 1,IMPDH1,inhibitor,yes
Ribavirin,The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].,Adenosine kinase,ADK,activator,yes
Ribavirin,The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].,Inosine-5'-monophosphate dehydrogenase 2,IMPDH2,,unknown
Ribavirin,The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].,RNA-directed RNA polymerase L,L,antagonist,yes
Ribavirin,The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].,RNA-directed RNA polymerase catalytic subunit,PB1,inhibitor,unknown
Ribavirin,The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].,Cytosolic purine 5'-nucleotidase,NT5C2,inducer,unknown
Ribavirin,The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].,Ectonucleotide pyrophosphatase/phosphodiesterase family member 1,ENPP1,inhibitor,unknown
Ribavirin,The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].,Genome polyprotein,,,unknown
Phenylbutazone,,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Phenylbutazone,,Prostacyclin synthase,PTGIS,inhibitor,yes
Phenylbutazone,,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Fentanyl,7  hours (range 3-12),Mu-type opioid receptor,OPRM1,agonist,yes
Fentanyl,7  hours (range 3-12),Delta-type opioid receptor,OPRD1,agonist,yes
Fentanyl,7  hours (range 3-12),Kappa-type opioid receptor,OPRK1,agonist,unknown
Meloxicam,15-20 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Meloxicam,15-20 hours,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Orciprenaline,6 hours,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Rosoxacin,,DNA gyrase subunit B,gyrB,inhibitor,yes
Rosoxacin,,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Propofol,Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Propofol,Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Propofol,Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.,Sodium channel protein type 4 subunit alpha,SCN4A,inhibitor,unknown
Propofol,Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.,Sodium channel protein type 2 subunit alpha,SCN2A,inhibitor,unknown
Propofol,Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Acetazolamide,3 to 9 hours,Carbonic anhydrase 1,CA1,inhibitor,yes
Acetazolamide,3 to 9 hours,Carbonic anhydrase 2,CA2,inhibitor,yes
Acetazolamide,3 to 9 hours,Carbonic anhydrase 4,CA4,inhibitor,yes
Acetazolamide,3 to 9 hours,Carbonic anhydrase 12,CA12,inhibitor,yes
Acetazolamide,3 to 9 hours,Carbonic anhydrase 14,CA14,inhibitor,yes
Acetazolamide,3 to 9 hours,Carbonic anhydrase 3,CA3,inhibitor,yes
Acetazolamide,3 to 9 hours,Carbonic anhydrase 7,CA7,inhibitor,yes
Acetazolamide,3 to 9 hours,Aquaporin-1,AQP1,inhibitor,unknown
Tadalafil,17.5 hours,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,inhibitor,yes
Tadalafil,17.5 hours,"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A",PDE11A,inhibitor,unknown
Carprofen,Approximately 8 hours (range 4.5&ndash;9.8 hours) in dogs.,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Carprofen,Approximately 8 hours (range 4.5&ndash;9.8 hours) in dogs.,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Disulfiram,,"Aldehyde dehydrogenase, mitochondrial",ALDH2,inhibitor,yes
Disulfiram,,Dopamine beta-hydroxylase,DBH,inhibitor,yes
Ethynodiol diacetate,,Progesterone receptor,PGR,agonist,yes
Ethynodiol diacetate,,Estrogen receptor alpha,ESR1,agonist,yes
Enprofylline,1.9 hours,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,inhibitor,yes
Enprofylline,1.9 hours,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,inhibitor,yes
Enprofylline,1.9 hours,Adenosine receptor A2b,ADORA2B,antagonist,yes
Enprofylline,1.9 hours,Adenosine receptor A1,ADORA1,,unknown
Enprofylline,1.9 hours,Adenosine receptor A2a,ADORA2A,,unknown
Enprofylline,1.9 hours,Adenosine receptor A3,ADORA3,,unknown
Menthol,,Transient receptor potential cation channel subfamily M member 8,TRPM8,inducer,yes
Menthol,,Transient receptor potential cation channel subfamily A member 1,TRPA1,inducer,yes
Menthol,,Transient receptor potential cation channel subfamily V member 3,TRPV3,inducer,yes
Menthol,,Kappa-type opioid receptor,OPRK1,agonist,unknown
Natamycin,,Ergosterol,,binder,yes
Cinoxacin,The mean serum half-life is 1.5 hours. Half-life in patients with impaired renal function may exceed 10 hours.,DNA gyrase subunit A,gyrA,inhibitor,yes
Cinoxacin,The mean serum half-life is 1.5 hours. Half-life in patients with impaired renal function may exceed 10 hours.,DNA,,intercalation,unknown
Fosfomycin,5.7 (&plusmn; 2.8) hours. The elimination half-life is 40 hours in anuric patients undergoing hemodialysis.,UDP-N-acetylglucosamine 1-carboxyvinyltransferase,murA,inhibitor,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit pi,GABRP,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit rho-3,GABRR3,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Gamma-aminobutyric acid receptor subunit theta,GABRQ,potentiator,yes
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",Translocator protein,TSPO,potentiator,unknown
Diazepam,"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.",GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Phenmetrazine,16 to 31 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Phenmetrazine,16 to 31 hours,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,yes
Trifluoperazine,10-20 hours,D(2) dopamine receptor,DRD2,antagonist,yes
Trifluoperazine,10-20 hours,Neuron-specific vesicular protein calcyon,CALY,antagonist,yes
Trifluoperazine,10-20 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Trifluoperazine,10-20 hours,Calmodulin,CALM1,inhibitor,unknown
Trifluoperazine,10-20 hours,"Troponin C, slow skeletal and cardiac muscles",TNNC1,,unknown
Trifluoperazine,10-20 hours,Protein S100-A4,S100A4,inhibitor,unknown
Cefaclor,0.6-0.9 hour,Penicillin-binding protein 3,pbp3,inhibitor,yes
Cefaclor,0.6-0.9 hour,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Mifepristone,18 hours,Progesterone receptor,PGR,antagonist,yes
Mifepristone,18 hours,Glucocorticoid receptor,NR3C1,antagonist,yes
Mifepristone,18 hours,Prostate-specific antigen,KLK3,,unknown
Mifepristone,18 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Brompheniramine,,Histamine H1 receptor,HRH1,antagonist,yes
Brompheniramine,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Brompheniramine,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Brompheniramine,,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Brompheniramine,,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,unknown
Brompheniramine,,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,unknown
Loperamide,9.1 to 14.4 hours (average 10.8 hours),Mu-type opioid receptor,OPRM1,agonist,yes
Loperamide,9.1 to 14.4 hours (average 10.8 hours),Delta-type opioid receptor,OPRD1,agonist,yes
Loperamide,9.1 to 14.4 hours (average 10.8 hours),Kappa-type opioid receptor,OPRK1,agonist,yes
Loperamide,9.1 to 14.4 hours (average 10.8 hours),Voltage-dependent P/Q-type calcium channel subunit alpha-1A,CACNA1A,inhibitor,unknown
Loperamide,9.1 to 14.4 hours (average 10.8 hours),Pro-opiomelanocortin,POMC,modulator,unknown
Loperamide,9.1 to 14.4 hours (average 10.8 hours),Calmodulin,CALM1,inhibitor,unknown
Loperamide,9.1 to 14.4 hours (average 10.8 hours),Nuclear receptor subfamily 1 group I member 3,NR1I3,,unknown
Progabide,4 hours,Gamma-aminobutyric acid type B receptor subunit 1,GABBR1,agonist,yes
Progabide,4 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,agonist,yes
Clocortolone,,Glucocorticoid receptor,NR3C1,agonist,yes
Tolazamide,The average biological half-life of the drug is 7 hours.,"Sulfonylurea receptor 1, Kir6.2",ABCC8KCNJ11,blocker,yes
Dobutamine,2 minutes,Beta-1 adrenergic receptor,ADRB1,agonist,yes
Dobutamine,2 minutes,Beta-2 adrenergic receptor,ADRB2,agonist,unknown
Dobutamine,2 minutes,Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,,unknown
Dobutamine,2 minutes,Estrogen receptor alpha,ESR1,,unknown
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit pi,GABRP,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit rho-3,GABRR3,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),Gamma-aminobutyric acid receptor subunit theta,GABRQ,potentiator,yes
Oxazepam,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours),GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Donepezil,70 hours,Acetylcholinesterase,ACHE,inhibitor,yes
Donepezil,70 hours,5-hydroxytryptamine receptor 2A,HTR2A,other/unknown,unknown
Nalbuphine,"The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.",Kappa-type opioid receptor,OPRK1,agonist,yes
Nalbuphine,"The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.",Mu-type opioid receptor,OPRM1,antagonist,yes
Nalbuphine,"The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.",Delta-type opioid receptor,OPRD1,antagonist,yes
Clofazimine,"10 days following a single dose, 70 days after long-term, high-dose therapy.",DNA,,intercalation,yes
Clofazimine,"10 days following a single dose, 70 days after long-term, high-dose therapy.",Uncharacterized oxidoreductase CzcO-like,,inhibitor,yes
Clofazimine,"10 days following a single dose, 70 days after long-term, high-dose therapy.",Bile salt export pump,ABCB11,,unknown
Flurandrenolide,,Glucocorticoid receptor,NR3C1,agonist,yes
Cysteamine,,Cystine,,cleavage,unknown
Cysteamine,,Somatostatin,SST,binder,unknown
Cysteamine,,Neuropeptide Y receptor type 2,NPY2R,other/unknown,unknown
Levamisole,4.4-5.6 hours (biphasic),Neuronal acetylcholine receptor subunit alpha-3,CHRNA3,agonist,yes
Levamisole,4.4-5.6 hours (biphasic),"Alkaline phosphatase, placental-like",ALPPL2,inhibitor,unknown
Levamisole,4.4-5.6 hours (biphasic),Acetylcholine receptor subunit alpha-type unc-38,unc-38,activator,unknown
Levamisole,4.4-5.6 hours (biphasic),Acetylcholine receptor subunit alpha-type unc-63,unc-63,activator,unknown
Levamisole,4.4-5.6 hours (biphasic),Acetylcholine receptor subunit beta-type lev-1,lev-1,activator,unknown
Levamisole,4.4-5.6 hours (biphasic),Acetylcholine receptor subunit beta-type unc-29,unc-29,activator,unknown
Methylphenobarbital,34 (range 11-67) hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Methylphenobarbital,34 (range 11-67) hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Methylphenobarbital,34 (range 11-67) hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Methylphenobarbital,34 (range 11-67) hours,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Methylphenobarbital,34 (range 11-67) hours,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Methylphenobarbital,34 (range 11-67) hours,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Methylphenobarbital,34 (range 11-67) hours,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Methylphenobarbital,34 (range 11-67) hours,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Methylphenobarbital,34 (range 11-67) hours,Glutamate receptor 2,GRIA2,antagonist,unknown
Methylphenobarbital,34 (range 11-67) hours,"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Methylphenobarbital,34 (range 11-67) hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,activator,unknown
Perphenazine,"8-12 hours, but ranges up to 20 hours.",D(2) dopamine receptor,DRD2,antagonist,yes
Perphenazine,"8-12 hours, but ranges up to 20 hours.",D(1A) dopamine receptor,DRD1,antagonist,yes
Perphenazine,"8-12 hours, but ranges up to 20 hours.",Calmodulin,CALM1,inhibitor,unknown
Dacarbazine,5 hours,DNA,,cross-linking/alkylation,yes
Dacarbazine,5 hours,DNA polymerase alpha subunit B,POLA2,other/unknown,unknown
Dacarbazine,5 hours,"6-phosphogluconate dehydrogenase, decarboxylating",PGD,inhibitor,unknown
Pseudoephedrine,9-16 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Pseudoephedrine,9-16 hours,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,yes
Pseudoephedrine,9-16 hours,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Pseudoephedrine,9-16 hours,Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Pseudoephedrine,9-16 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Pseudoephedrine,9-16 hours,Beta-2 adrenergic receptor,ADRB2,partial agonist,unknown
Pseudoephedrine,9-16 hours,Beta-1 adrenergic receptor,ADRB1,agonistpartial agonist,unknown
Pseudoephedrine,9-16 hours,"Nuclear factor of activated T-cells, cytoplasmic 1",NFATC1,,unknown
Pseudoephedrine,9-16 hours,Tumor necrosis factor,TNF,,unknown
Pseudoephedrine,9-16 hours,Nuclear factor kappa-light-chain-enhancer of activated B cells,,,unknown
Pseudoephedrine,9-16 hours,activator protein 1,ATF1ATF2ATF3ATF4ATF5ATF6ATF7JDP2FOSJUN,,unknown
Pseudoephedrine,9-16 hours,Interleukin-2,IL2,,unknown
Temozolomide,Approximately 1.8 hours.,DNA,,cross-linking/alkylation,yes
Levorphanol,11-16 hours,Mu-type opioid receptor,OPRM1,agonist,yes
Levorphanol,11-16 hours,Delta-type opioid receptor,OPRD1,agonist,unknown
Levorphanol,11-16 hours,Kappa-type opioid receptor,OPRK1,agonist,unknown
Aminolevulinic acid,Mean half-life is 0.70 &plusmn; 0.18 h after the oral dose and 0.83 &plusmn; 0.05 h after the intravenous dose.,Delta-aminolevulinic acid dehydratase,ALAD,inducer,yes
Terbinafine,36 hours,Squalene monooxygenase,SQLE,inhibitor,yes
Drostanolone,,Androgen receptor,AR,agonist,yes
Penicillamine,1 hour,Copper,,chelator,yes
Prednisolone,2-3 hours,Glucocorticoid receptor,NR3C1,agonist,yes
Diflunisal,8 to 12 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Diflunisal,8 to 12 hours,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Vardenafil,4-5 hours,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,inhibitor,yes
Vardenafil,4-5 hours,"Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma",PDE6G,allosteric modulator,unknown
Vardenafil,4-5 hours,"Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma",PDE6H,allosteric modulator,unknown
Ranitidine,2.8-3.1 hours,Histamine H2 receptor,HRH2,antagonist,yes
Ranitidine,2.8-3.1 hours,Acetylcholinesterase,ACHE,,unknown
Ranitidine,2.8-3.1 hours,Cholinesterase,BCHE,,unknown
Tacrolimus,"The elimination half life in adult healthy volunteers, kidney transplant patients, liver transplants patients, and heart transplant patients are approximately 35, 19, 12, 24 hours, respectively. The elimination half life in pediatric liver transplant patients was 11.5±3.8 hours, in pediatric kidney transplant patients was 10.2±5.0 (range 3.4-25) hours.",Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,inhibitor,yes
Benzphetamine,16 to 31 hours,Synaptic vesicular amine transporter,SLC18A2,inducer,yes
Benzphetamine,16 to 31 hours,Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Benzphetamine,16 to 31 hours,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Benzphetamine,16 to 31 hours,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,unknown
Alprenolol,2-3 hours,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Alprenolol,2-3 hours,Beta-2 adrenergic receptor,ADRB2,antagonist,yes
Alprenolol,2-3 hours,5-hydroxytryptamine receptor 1A,HTR1A,antagonist,yes
Alprenolol,2-3 hours,Beta-3 adrenergic receptor,ADRB3,antagonist,unknown
Ritodrine,1.7-2.6 hours,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Benzonatate,3-8 hours,Sodium channel protein type 5 subunit alpha,SCN5A,antagonist,unknown
Dorzolamide,4 months,Carbonic anhydrase 2,CA2,inhibitor,yes
Dorzolamide,4 months,Carbonic anhydrase 4,CA4,inhibitor,unknown
Dorzolamide,4 months,Carbonic anhydrase 1,CA1,inhibitor,unknown
Dorzolamide,4 months,Carbonic anhydrase 3,CA3,inhibitor,unknown
Suprofen,,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Suprofen,,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Terbutaline,5.5-5.9 hours,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Terbutaline,5.5-5.9 hours,Beta-3 adrenergic receptor,ADRB3,agonist,unknown
Terbutaline,5.5-5.9 hours,Beta-1 adrenergic receptor,ADRB1,antagonist,unknown
Conivaptan,5 hours,Vasopressin V1a receptor,AVPR1A,antagonist,yes
Conivaptan,5 hours,Vasopressin V2 receptor,AVPR2,antagonist,yes
Loteprednol,,Glucocorticoid receptor,NR3C1,agonist,yes
Flupentixol,19 to 39 hours,D(2) dopamine receptor,DRD2,antagonist,yes
Flupentixol,19 to 39 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Flupentixol,19 to 39 hours,D(1A) dopamine receptor,DRD1,antagonist,yes
Flupentixol,19 to 39 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Flupentixol,19 to 39 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Eprosartan,The terminal elimination half-life of eprosartan following oral administration is typically 5 to 9 hours.,Type-1 angiotensin II receptor,AGTR1,antagonist,yes
Sirolimus,57-63 hours,Serine/threonine-protein kinase mTOR,MTOR,inhibitor,yes
Sirolimus,57-63 hours,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,other,yes
Sirolimus,57-63 hours,Fibroblast growth factor 2,FGF2,other/unknown,yes
Chlorhexidine,,Bacterial outer membrane,,incorporation into and destabilization,yes
Emtricitabine,10 hours,Reverse transcriptase/RNaseH,pol,inhibitor,yes
Chlorothiazide,45-120 minutes,Solute carrier family 12 member 3,SLC12A3,inhibitor,yes
Chlorothiazide,45-120 minutes,Carbonic anhydrase 1,CA1,inhibitor,yes
Chlorothiazide,45-120 minutes,Carbonic anhydrase 2,CA2,inhibitor,yes
Chlorothiazide,45-120 minutes,Carbonic anhydrase 4,CA4,inhibitor,yes
Quinapril,Elimination half life is 2 hours with a prolonged terminal phase of 25 hours.,Angiotensin-converting enzyme,ACE,inhibitor,yes
Clomifene,5-7 days,Estrogen receptor alpha,ESR1,antagonistagonist,yes
Clomifene,5-7 days,Sex hormone-binding globulin,SHBG,,unknown
Isosorbide Dinitrate,1 hour,Atrial natriuretic peptide receptor 1,NPR1,agonist,yes
Risedronate,1.5 hours,Farnesyl pyrophosphate synthase,FDPS,inhibitor,yes
Risedronate,1.5 hours,Hydroxylapatite,,antagonist,yes
Omapatrilat,,Angiotensin-converting enzyme,ACE,,unknown
Omapatrilat,,Neprilysin,MME,,yes
Bumetanide,60-90 minutes,Solute carrier family 12 member 1,SLC12A1,inhibitor,yes
Bumetanide,60-90 minutes,Solute carrier family 12 member 2,SLC12A2,inhibitor,yes
Bumetanide,60-90 minutes,Solute carrier family 12 member 4,SLC12A4,inhibitor,yes
Bumetanide,60-90 minutes,Solute carrier family 12 member 5,SLC12A5,inhibitor,yes
Bumetanide,60-90 minutes,Cystic fibrosis transmembrane conductance regulator,CFTR,antagonist,unknown
Mechlorethamine,15 minutes,DNA,,intercalation,yes
Granisetron,"4-6 hours in healthy patients, 9-12 hours in cancer patients",5-hydroxytryptamine receptor 3A,HTR3A,antagonist,yes
Dienestrol,,Estrogen receptor alpha,ESR1,agonist,yes
Dienestrol,,Sex hormone-binding globulin,SHBG,,unknown
Sulfapyridine,6-14 hours.,Dihydropteroate synthase type-1,sulI,inhibitor,unknown
Oxybuprocaine,,Sodium channel protein type 10 subunit alpha,SCN10A,inhibitor,yes
Iron Dextran,5 hours (some indications that it can be as long as 10 hours),Hemoglobin subunit beta,HBB,activator,yes
Iron Dextran,5 hours (some indications that it can be as long as 10 hours),Hemoglobin subunit alpha,HBA1,activator,yes
Iron Dextran,5 hours (some indications that it can be as long as 10 hours),Ferritin heavy chain,FTH1,other,yes
Iron Dextran,5 hours (some indications that it can be as long as 10 hours),Ferritin light chain,FTL,other,yes
Testolactone,,Cytochrome P450 19A1,CYP19A1,inhibitor,yes
Benzylpenicilloyl Polylysine,,High affinity immunoglobulin epsilon receptor subunit gamma,FCER1G,agonist,yes
Benzylpenicilloyl Polylysine,,High affinity immunoglobulin epsilon receptor subunit alpha,FCER1A,agonist,yes
Rimexolone,"The serum half-life of rimexolone could not be reliably estimated due to the large number of samples below the quantitation limit of the assay (80 pg/mL). However, based on the time required to reach steady-state, the half-life appears to be short (1-2 hours).",Glucocorticoid receptor,NR3C1,agonist,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit pi,GABRP,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit rho-3,GABRR3,potentiator,yes
Triazolam,1.5-5.5 hours,Gamma-aminobutyric acid receptor subunit theta,GABRQ,potentiator,yes
Triazolam,1.5-5.5 hours,Translocator protein,TSPO,other,unknown
Triazolam,1.5-5.5 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Ethanol,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,agonist,yes
Ethanol,,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,antagonist,yes
Ethanol,,Glycine receptor subunit alpha-1,GLRA1,agonist,yes
Ethanol,,Glycine receptor subunit alpha-2,GLRA2,agonist,yes
Ethanol,,Voltage-dependent L-type calcium channel subunit beta-1,CACNB1,,unknown
Ethanol,,5-hydroxytryptamine receptor 3A,HTR3A,,unknown
Ethanol,,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,,unknown
Ethanol,,Neuronal acetylcholine receptor subunit alpha-10,CHRNA10,,unknown
Ethanol,,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,,unknown
Ethanol,,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,,unknown
Ethanol,,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,,unknown
Ethanol,,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,,unknown
Ethanol,,Glutamate receptor 1,GRIA1,,unknown
Ethanol,,Voltage-dependent calcium channel gamma-1 subunit,CACNG1,,unknown
Ethanol,,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,,unknown
Ethanol,,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,,unknown
Ethanol,,Glutamate receptor 2,GRIA2,,unknown
Ethanol,,Glutamate receptor 4,GRIA4,,unknown
Ethanol,,Glutamate receptor 3,GRIA3,,unknown
Ethanol,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,,unknown
Ethanol,,Neuronal acetylcholine receptor subunit beta-2,CHRNB2,,unknown
Ethanol,,G protein-activated inward rectifier potassium channel 1,KCNJ3,,unknown
Ethanol,,G protein-activated inward rectifier potassium channel 2,KCNJ6,,unknown
Ethanol,,Vascular cell adhesion protein 1,VCAM1,,unknown
Ethanol,,Equilibrative nucleoside transporter 1,SLC29A1,,unknown
Ethanol,,G protein-activated inward rectifier potassium channel 4,KCNJ5,,unknown
Ethanol,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,,unknown
Ethanol,,Neuronal acetylcholine receptor subunit alpha-9,CHRNA9,,unknown
Ethanol,,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,,unknown
Ethanol,,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,,unknown
Ethanol,,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,,unknown
Ethanol,,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,,unknown
Ethanol,,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,,unknown
Ethanol,,Neuronal acetylcholine receptor subunit beta-4,CHRNB4,,unknown
Ethanol,,Neuronal acetylcholine receptor subunit alpha-3,CHRNA3,,unknown
Ethanol,,Neuronal acetylcholine receptor subunit alpha-5,CHRNA5,,unknown
Ethanol,,Neuronal acetylcholine receptor subunit alpha-6,CHRNA6,,unknown
Ethanol,,Neuronal acetylcholine receptor subunit beta-3,CHRNB3,,unknown
Ethanol,,Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,,unknown
Ethanol,,Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,,unknown
Ethanol,,Gamma-aminobutyric acid receptor subunit epsilon,GABRE,,unknown
Ethanol,,Gamma-aminobutyric acid receptor subunit pi,GABRP,,unknown
Ethanol,,Gamma-aminobutyric acid receptor subunit theta,GABRQ,,unknown
Ethanol,,Gamma-aminobutyric acid receptor subunit delta,GABRD,,unknown
Ethanol,,Equilibrative nucleoside transporter 2,SLC29A2,,unknown
Ethanol,,5-hydroxytryptamine receptor 3E,HTR3E,,unknown
Ethanol,,5-hydroxytryptamine receptor 3B,HTR3B,,unknown
Ethanol,,5-hydroxytryptamine receptor 3D,HTR3D,,unknown
Ethanol,,5-hydroxytryptamine receptor 3C,HTR3C,,unknown
Ethanol,,Voltage-dependent calcium channel gamma-2 subunit,CACNG2,,unknown
Ethanol,,G protein-activated inward rectifier potassium channel 3,KCNJ9,,unknown
Ethanol,,Neural cell adhesion molecule L1,L1CAM,,unknown
Remifentanil,1-20 minutes,Mu-type opioid receptor,OPRM1,agonist,yes
Remifentanil,1-20 minutes,Delta-type opioid receptor,OPRD1,agonist,unknown
Remifentanil,1-20 minutes,Kappa-type opioid receptor,OPRK1,agonist,unknown
Didanosine,30 minutes in plasma and more than 12 hours in intracellular environment.,Reverse transcriptase/RNaseH,pol,inhibitor,yes
Didanosine,30 minutes in plasma and more than 12 hours in intracellular environment.,Purine nucleoside phosphorylase,PNP,,unknown
Bitolterol,,Beta-2 adrenergic receptor,ADRB2,,yes
Methdilazine,,Histamine H1 receptor,HRH1,antagonist,yes
Etacrynic acid,,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,inhibitor,yes
Etacrynic acid,,Solute carrier family 12 member 1,SLC12A1,inhibitor,yes
Etacrynic acid,,Lymphoid enhancer-binding factor 1,LEF1,,unknown
Etacrynic acid,,Glutathione S-transferase P,GSTP1,inhibitor,unknown
Ondansetron,5.7 hours,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,yes
Ondansetron,5.7 hours,5-hydroxytryptamine receptor 4,HTR4,agonist,unknown
Ondansetron,5.7 hours,Mu-type opioid receptor,OPRM1,other/unknown,unknown
Ondansetron,5.7 hours,5-hydroxytryptamine receptor 1A,HTR1A,other/unknown,unknown
Ondansetron,5.7 hours,5-hydroxytryptamine receptor 1B,HTR1B,other/unknown,unknown
Bimatoprost,Elimination half-life is approximately 45 minutes.,Prostaglandin F2-alpha receptor,PTGFR,agonist,yes
Bimatoprost,Elimination half-life is approximately 45 minutes.,Prostaglandin E2 receptor EP1 subtype,PTGER1,agonist,yes
Bimatoprost,Elimination half-life is approximately 45 minutes.,Prostaglandin E2 receptor EP3 subtype,PTGER3,agonist,yes
Bimatoprost,Elimination half-life is approximately 45 minutes.,Aldo-keto reductase family 1 member C3,AKR1C3,,unknown
Tiagabine,7-9 hours,Sodium- and chloride-dependent GABA transporter 1,SLC6A1,inhibitor,yes
Cocaine,1 hour,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,yes
Cocaine,1 hour,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Cocaine,1 hour,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Cocaine,1 hour,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Cocaine,1 hour,Sodium channel protein type 11 subunit alpha,SCN11A,inhibitor,unknown
Cocaine,1 hour,Sodium channel protein type 10 subunit alpha,SCN10A,inhibitor,unknown
Cocaine,1 hour,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Cocaine,1 hour,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Cocaine,1 hour,Sigma non-opioid intracellular receptor 1,SIGMAR1,,unknown
Cocaine,1 hour,Liver carboxylesterase 1,CES1,,unknown
Quinidine,6-8 hours,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Quinidine,6-8 hours,Potassium channel subfamily K member 1,KCNK1,inhibitor,unknown
Quinidine,6-8 hours,Potassium channel subfamily K member 6,KCNK6,inhibitor,unknown
Quinidine,6-8 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Quinidine,6-8 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Quinidine,6-8 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Quinidine,6-8 hours,Alpha-1D adrenergic receptor,ADRA1D,antagonist,unknown
Zonisamide,63 hours,Sodium channel protein type 1 subunit alpha,SCN1A,inhibitor,yes
Zonisamide,63 hours,Sodium channel protein type 2 subunit alpha,SCN2A,inhibitor,yes
Zonisamide,63 hours,Sodium channel protein type 3 subunit alpha,SCN3A,inhibitor,yes
Zonisamide,63 hours,Sodium channel protein type 4 subunit alpha,SCN4A,inhibitor,yes
Zonisamide,63 hours,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Zonisamide,63 hours,Sodium channel protein type 9 subunit alpha,SCN9A,inhibitor,yes
Zonisamide,63 hours,Sodium channel protein type 11 subunit alpha,SCN11A,inhibitor,yes
Zonisamide,63 hours,Sodium channel subunit beta-1,SCN1B,inhibitor,yes
Zonisamide,63 hours,Sodium channel subunit beta-2,SCN2B,inhibitor,yes
Zonisamide,63 hours,Sodium channel subunit beta-3,SCN3B,inhibitor,yes
Zonisamide,63 hours,Sodium channel subunit beta-4,SCN4B,inhibitor,yes
Zonisamide,63 hours,Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,inhibitor,yes
Zonisamide,63 hours,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,inhibitor,yes
Zonisamide,63 hours,Voltage-dependent T-type calcium channel subunit alpha-1I,CACNA1I,inhibitor,yes
Zonisamide,63 hours,Carbonic anhydrase 1,CA1,inhibitor,unknown
Zonisamide,63 hours,Carbonic anhydrase 2,CA2,inhibitor,unknown
Zonisamide,63 hours,Carbonic anhydrase 3,CA3,inhibitor,unknown
Zonisamide,63 hours,Carbonic anhydrase 4,CA4,inhibitor,unknown
Zonisamide,63 hours,"Carbonic anhydrase 5A, mitochondrial",CA5A,inhibitor,unknown
Zonisamide,63 hours,"Carbonic anhydrase 5B, mitochondrial",CA5B,inhibitor,unknown
Zonisamide,63 hours,Carbonic anhydrase 6,CA6,inhibitor,unknown
Zonisamide,63 hours,Carbonic anhydrase 7,CA7,inhibitor,unknown
Zonisamide,63 hours,Carbonic anhydrase-related protein,CA8,inhibitor,unknown
Zonisamide,63 hours,Carbonic anhydrase 9,CA9,inhibitor,unknown
Zonisamide,63 hours,Carbonic anhydrase-related protein 10,CA10,inhibitor,unknown
Zonisamide,63 hours,Carbonic anhydrase-related protein 11,CA11,inhibitor,unknown
Zonisamide,63 hours,Carbonic anhydrase 12,CA12,inhibitor,unknown
Zonisamide,63 hours,Carbonic anhydrase 13,CA13,inhibitor,unknown
Zonisamide,63 hours,Carbonic anhydrase 14,CA14,inhibitor,unknown
Zonisamide,63 hours,Amine oxidase [flavin-containing] B,MAOB,inhibitor,unknown
Zonisamide,63 hours,Amine oxidase [flavin-containing] A,MAOA,inhibitor,unknown
Paricalcitol,4 to 6 hours,Vitamin D3 receptor,VDR,agonist,yes
Tinidazole,Elimination half-life is 13.2 &plusmn; 1.4 hours. Plasma half-life is 12 to 14 hours.,DNA,,binder,yes
Repaglinide,1 hour,ATP-binding cassette sub-family C member 8,ABCC8,inhibitor,yes
Repaglinide,1 hour,Peroxisome proliferator-activated receptor gamma,PPARG,agonist,unknown
Anileridine,,Mu-type opioid receptor,OPRM1,agonist,yes
Phenformin,,5'-AMP-activated protein kinase catalytic subunit alpha-1,PRKAA1,activator,yes
Phenformin,,ATP-sensitive inward rectifier potassium channel 8,KCNJ8,inhibitor,unknown
Amantadine,"Mean half-lives ranged from 10 to 14 hours, however renal function impairment causes a severe increase in half life to 7 to 10 days.",Matrix protein 2,M,inhibitor,yes
Amantadine,"Mean half-lives ranged from 10 to 14 hours, however renal function impairment causes a severe increase in half life to 7 to 10 days.","Glutamate receptor ionotropic, NMDA 3A",GRIN3A,antagonist,yes
Amantadine,"Mean half-lives ranged from 10 to 14 hours, however renal function impairment causes a severe increase in half life to 7 to 10 days.",D(2) dopamine receptor,DRD2,agonist,yes
Metronidazole,6-8 hours,DNA,,binder,yes
Metronidazole,6-8 hours,Oxygen-insensitive NADPH nitroreductase,rdxA,potentiator,yes
Metronidazole,6-8 hours,Iron hydrogenase 1,,inhibitor,unknown
Metronidazole,6-8 hours,Lanosterol 14-alpha demethylase,CYP51A1,,unknown
Dinoprostone,Less than 5 minutes.,Prostaglandin E2 receptor EP2 subtype,PTGER2,agonist,yes
Dinoprostone,Less than 5 minutes.,Prostaglandin E2 receptor EP1 subtype,PTGER1,agonist,yes
Dinoprostone,Less than 5 minutes.,Prostaglandin E2 receptor EP3 subtype,PTGER3,agonist,yes
Dinoprostone,Less than 5 minutes.,Prostaglandin E2 receptor EP4 subtype,PTGER4,agonist,yes
Dinoprostone,Less than 5 minutes.,Prostaglandin D2 receptor 2,PTGDR2,agonist,unknown
Almotriptan,3-4 hours,5-hydroxytryptamine receptor 1B,HTR1B,agonist,unknown
Almotriptan,3-4 hours,5-hydroxytryptamine receptor 1D,HTR1D,agonist,unknown
Spectinomycin,1 to 3 hours in patients with normal renal function and 10 to 30 hours in patients with impaired renal function with a creatinine clearance &lt; 20 mL per minute.,30S ribosomal protein S12,rpsL,inhibitor,yes
Ketotifen,21 hours (for elimination),Histamine H1 receptor,HRH1,antagonist,yes
Ketotifen,21 hours (for elimination),"6-phosphogluconate dehydrogenase, decarboxylating",PGD,inhibitor,unknown
Buprenorphine,"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours.",Mu-type opioid receptor,OPRM1,partial agonist,yes
Buprenorphine,"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours.",Kappa-type opioid receptor,OPRK1,antagonist,yes
Buprenorphine,"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours.",Delta-type opioid receptor,OPRD1,antagonist,unknown
Buprenorphine,"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours.",Nociceptin receptor,OPRL1,,unknown
Levosimendan,Eliminination half-life is approximately 1 hour.,"Troponin C, slow skeletal and cardiac muscles",TNNC1,potentiator,yes
Levosimendan,Eliminination half-life is approximately 1 hour.,ATP-sensitive inward rectifier potassium channel 11,KCNJ11,inducer,yes
Levosimendan,Eliminination half-life is approximately 1 hour.,ATP-sensitive inward rectifier potassium channel 8,KCNJ8,inducer,yes
Levosimendan,Eliminination half-life is approximately 1 hour.,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,inhibitor,unknown
Ceforanide,2.6 to 2.98 hours,Penicillin-binding protein 2,pbpA,inhibitor,yes
Cyclobenzaprine,18 hours (range 8-37 hours),5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Phenoxybenzamine,24 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Phenoxybenzamine,24 hours,Alpha-2A adrenergic receptor,ADRA2A,antagonist,yes
Phenoxybenzamine,24 hours,Alpha-2C adrenergic receptor,ADRA2C,antagonist,unknown
Phenoxybenzamine,24 hours,Alpha-2B adrenergic receptor,ADRA2B,antagonist,unknown
Phenoxybenzamine,24 hours,Calmodulin,CALM1,inhibitor,unknown
Phenoxybenzamine,24 hours,Beta-2 adrenergic receptor,ADRB2,,unknown
Phenoxybenzamine,24 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Phenoxybenzamine,24 hours,Alpha-1D adrenergic receptor,ADRA1D,antagonist,unknown
Etretinate,"In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.",Retinoic acid receptor alpha,RARA,agonist,yes
Etretinate,"In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.",Retinoic acid receptor RXR-alpha,RXRA,agonist,yes
Etretinate,"In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.",Retinoic acid receptor beta,RARB,agonist,yes
Etretinate,"In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.",Retinoic acid receptor RXR-gamma,RXRG,agonist,yes
Etretinate,"In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.",Retinoic acid receptor RXR-beta,RXRB,agonist,yes
Etretinate,"In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.",Retinoic acid receptor gamma,RARG,agonist,yes
Famotidine,2.5-3.5 hours,Histamine H2 receptor,HRH2,antagonist,yes
Azacitidine,Mean elimination half-life is approximately 4 hours.,DNA (cytosine-5)-methyltransferase 1,DNMT1,inhibitor,yes
Azacitidine,Mean elimination half-life is approximately 4 hours.,RNA,,other,yes
Azacitidine,Mean elimination half-life is approximately 4 hours.,DNA,,other,yes
Misoprostol,20-40 minutes,Prostaglandin E2 receptor EP3 subtype,PTGER3,agonist,yes
Misoprostol,20-40 minutes,Prostaglandin E2 receptor EP2 subtype,PTGER2,agonist,yes
Misoprostol,20-40 minutes,Prostaglandin E2 receptor EP4 subtype,PTGER4,agonist,unknown
Colesevelam,,Bile acids,,binder,yes
Methacycline,14 hours,16S rRNA,,inhibitor,yes
Tipranavir,5-6 hours,Human immunodeficiency virus type 1 protease,pol,inhibitor,yes
Mesoridazine,24 to 48 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Mesoridazine,24 to 48 hours,D(2) dopamine receptor,DRD2,antagonist,yes
Maprotiline,Average ~ 51 hours (range: 27-58 hours),Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Maprotiline,Average ~ 51 hours (range: 27-58 hours),Histamine H1 receptor,HRH1,antagonist,no
Maprotiline,Average ~ 51 hours (range: 27-58 hours),Muscarinic acetylcholine receptor M1,CHRM1,antagonist,no
Maprotiline,Average ~ 51 hours (range: 27-58 hours),Muscarinic acetylcholine receptor M2,CHRM2,antagonist,no
Maprotiline,Average ~ 51 hours (range: 27-58 hours),Muscarinic acetylcholine receptor M3,CHRM3,antagonist,no
Maprotiline,Average ~ 51 hours (range: 27-58 hours),Muscarinic acetylcholine receptor M4,CHRM4,antagonist,no
Maprotiline,Average ~ 51 hours (range: 27-58 hours),Muscarinic acetylcholine receptor M5,CHRM5,antagonist,no
Maprotiline,Average ~ 51 hours (range: 27-58 hours),Alpha-1 adrenergic receptors,ADRA1AADRA1BADRA1D,antagonist,no
Maprotiline,Average ~ 51 hours (range: 27-58 hours),5-hydroxytryptamine receptor 2A,HTR2A,binder,unknown
Maprotiline,Average ~ 51 hours (range: 27-58 hours),5-hydroxytryptamine receptor 2C,HTR2C,binder,unknown
Maprotiline,Average ~ 51 hours (range: 27-58 hours),5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Maprotiline,Average ~ 51 hours (range: 27-58 hours),D(2) dopamine receptor,DRD2,binder,unknown
Maprotiline,Average ~ 51 hours (range: 27-58 hours),Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,antagonist,unknown
Oxymetazoline,,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Oxymetazoline,,Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Oxymetazoline,,Alpha-2C adrenergic receptor,ADRA2C,agonist,unknown
Oxymetazoline,,Alpha-2B adrenergic receptor,ADRA2B,binder,unknown
Oxymetazoline,,Alpha-1B adrenergic receptor,ADRA1B,agonist,unknown
Oxymetazoline,,Alpha-1D adrenergic receptor,ADRA1D,agonist,unknown
Salicylic acid,,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Salicylic acid,,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Salicylic acid,,Aldo-keto reductase family 1 member C1,AKR1C1,inhibitor,unknown
Diethylpropion,"Using a phosphorescence assay that is specific for basic compounds containing benzoyl group, the plasma half-life of the aminoketone metabolites is estimated to be between 4 to 6 hours.",Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Diethylpropion,"Using a phosphorescence assay that is specific for basic compounds containing benzoyl group, the plasma half-life of the aminoketone metabolites is estimated to be between 4 to 6 hours.",Sodium-dependent dopamine transporter,SLC6A3,inhibitor,yes
Salmeterol,5.5 hours,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Salmeterol,5.5 hours,Beta-1 adrenergic receptor,ADRB1,agonist,unknown
Salmeterol,5.5 hours,Beta-3 adrenergic receptor,ADRB3,agonist,unknown
Meclofenamic acid,In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Meclofenamic acid,In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Meclofenamic acid,In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.,Arachidonate 5-lipoxygenase,ALOX5,inhibitor,yes
Meclofenamic acid,In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.,Potassium voltage-gated channel subfamily KQT member 2,KCNQ2,other,unknown
Meclofenamic acid,In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.,Potassium voltage-gated channel subfamily KQT member 3,KCNQ3,other,unknown
Methantheline,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Methantheline,,Histamine H2 receptor,HRH2,antagonist,yes
Hexafluronium,,Cholinesterase,BCHE,inhibitor,yes
Cycrimine,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Zalcitabine,2 hours,Reverse transcriptase/RNaseH,pol,inhibitor,yes
Demecarium,,Acetylcholinesterase,ACHE,inhibitor,yes
Demecarium,,Cholinesterase,BCHE,inhibitor,unknown
Acetylsalicylic acid,"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.",Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Acetylsalicylic acid,"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.",Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Acetylsalicylic acid,"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.",Aldo-keto reductase family 1 member C1,AKR1C1,inhibitor,unknown
Acetylsalicylic acid,"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.",5'-AMP-activated protein kinase,PRKAA1PRKAA2PRKAB1PRKAB2PRKAG1PRKAG2PRKAG3,activator,unknown
Acetylsalicylic acid,"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.",Endothelin-1 receptor,EDNRA,,unknown
Acetylsalicylic acid,"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.",Inhibitor of nuclear factor kappa-B kinase subunit beta,IKBKB,,unknown
Acetylsalicylic acid,"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.",Cellular tumor antigen p53,TP53,acetylation,unknown
Acetylsalicylic acid,"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.",78 kDa glucose-regulated protein,HSPA5,binding,unknown
Acetylsalicylic acid,"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.",Ribosomal protein S6 kinase alpha-3,RPS6KA3,,unknown
Acetylsalicylic acid,"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.",NF-kappa-B inhibitor alpha,NFKBIA,,unknown
Acetylsalicylic acid,"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.",Nuclear factor NF-kappa-B,NFKB2NFKB1,antagonist,unknown
Phenprocoumon,5-6 days,Vitamin K epoxide reductase complex subunit 1,VKORC1,inhibitor,yes
Fulvestrant,40 days,Estrogen receptor alpha,ESR1,antagonist,yes
Mezlocillin,1.3 to 4.4 hours,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Mezlocillin,1.3 to 4.4 hours,Penicillin-binding protein 3,pbp3,inhibitor,yes
Mezlocillin,1.3 to 4.4 hours,Penicillin-binding protein 2,mrdA,inhibitor,unknown
Felbamate,20-23 hours,"Glutamate receptor ionotropic, NMDA 2B",GRIN2B,antagonist,yes
Felbamate,20-23 hours,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,antagonist,yes
Felbamate,20-23 hours,"Glutamate receptor ionotropic, NMDA 2A",GRIN2A,antagonist,yes
Fexofenadine,14.4 hours,Histamine H1 receptor,HRH1,antagonist,yes
Isoniazid,Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.,Catalase-peroxidase,katG,other/unknown,yes
Isoniazid,Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.,Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,adduct,yes
Isoniazid,Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.,Cytochrome P450 2C8,CYP2C8,,unknown
Isoniazid,Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.,Cytochrome P450 1A2,CYP1A2,,unknown
Isoniazid,Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.,Cytochrome P450 3A4,CYP3A4,,unknown
Isoniazid,Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.,Cytochrome P450 2C19,CYP2C19,,unknown
Isoniazid,Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.,Dihydrofolate reductase,folA,,unknown
Naratriptan,5-8 hours,5-hydroxytryptamine receptor 1D,HTR1D,agonist,yes
Naratriptan,5-8 hours,5-hydroxytryptamine receptor 1B,HTR1B,agonist,yes
Naratriptan,5-8 hours,5-hydroxytryptamine receptor 1F,HTR1F,agonist,yes
Naratriptan,5-8 hours,5-hydroxytryptamine receptor 1A,HTR1A,agonist,yes
Rizatriptan,2-3 hours,5-hydroxytryptamine receptor 1D,HTR1D,agonist,yes
Rizatriptan,2-3 hours,5-hydroxytryptamine receptor 1B,HTR1B,agonist,yes
Rizatriptan,2-3 hours,5-hydroxytryptamine receptor 1F,HTR1F,agonist,yes
Dirithromycin,"The mean plasma half-life of erythromycylamine was estimated to be about 8 h (2 to 36 h), with a mean urinary terminal elimination half-life of about 44 h (16 to 65 h) in patients with normal renal function.",23S rRNA,,inhibitor,yes
Netilmicin,2.5 hours,30S ribosomal protein S12,rpsL,inhibitor,yes
Netilmicin,2.5 hours,16S rRNA,,inhibitor,yes
Hydrocodone,1.25-3 hours,Mu-type opioid receptor,OPRM1,agonist,yes
Hydrocodone,1.25-3 hours,Delta-type opioid receptor,OPRD1,agonist,yes
Norgestimate,12-30 hours,Progesterone receptor,PGR,agonist,yes
Norgestimate,12-30 hours,Estrogen receptor alpha,ESR1,agonist,yes
Norgestimate,12-30 hours,Androgen receptor,AR,partial agonist,unknown
Carboplatin,"Initial plasma half-life (alpha) = 1.1 to 2 hours;
Post distribution plasma half-life (beta) = 2.6 - 5.9 hours.",DNA,,cross-linking/alkylation,yes
Methylprednisolone,1-3 hours,Glucocorticoid receptor,NR3C1,agonist,yes
Pindolol,3 to 4 hours,Beta-1 adrenergic receptor,ADRB1,partial agonist,yes
Pindolol,3 to 4 hours,Beta-2 adrenergic receptor,ADRB2,partial agonist,yes
Pindolol,3 to 4 hours,5-hydroxytryptamine receptor 1A,HTR1A,antagonist,unknown
Pindolol,3 to 4 hours,5-hydroxytryptamine receptor 1B,HTR1B,other/unknown,unknown
Pindolol,3 to 4 hours,Beta-3 adrenergic receptor,ADRB3,agonist,unknown
Mepivacaine,The half-life of mepivacaine in adults is 1.9 to 3.2 hours and in neonates 8.7 to 9 hours.,Sodium channel protein type 10 subunit alpha,SCN10A,inhibitor,yes
Zaleplon,Approximately 1 hour,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Zaleplon,Approximately 1 hour,Translocator protein,TSPO,other,yes
Bromfenac,,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Bromfenac,,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Apraclonidine,8 hours,Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Apraclonidine,8 hours,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Apraclonidine,8 hours,Alpha-2B adrenergic receptor,ADRA2B,agonist,unknown
Telmisartan,Bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.,Type-1 angiotensin II receptor,AGTR1,antagonist,yes
Telmisartan,Bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.,Peroxisome proliferator-activated receptor gamma,PPARG,partial agonist,yes
Desloratadine,50 hours,Histamine H1 receptor,HRH1,antagonist,yes
Methyldopa,The plasma half-life of methyldopa is 105 minutes.,Alpha-2A adrenergic receptor,ADRA2A,,yes
Methyldopa,The plasma half-life of methyldopa is 105 minutes.,Aromatic-L-amino-acid decarboxylase,DDC,,unknown
Alosetron,1.5 hours,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,yes
Dactinomycin,36 hours,DNA,,adduct,yes
Dactinomycin,36 hours,DNA topoisomerase 2,TOP2ATOP2B,,unknown
Azelastine,"Elimination half-life (based on intravenous and oral administration) is 22 hours. Elimination half-life of the active metabolite, desmethylazelastine, is 54 hours (after oral administration of azelastine).",Histamine H1 receptor,HRH1,antagonist,yes
Ezetimibe,22 hours (both ezetimibe and ezetimibe-glucuronide).,Sterol O-acyltransferase 1,SOAT1,inhibitor,yes
Ezetimibe,22 hours (both ezetimibe and ezetimibe-glucuronide).,Niemann-Pick C1-like protein 1,NPC1L1,inhibitor,yes
Ezetimibe,22 hours (both ezetimibe and ezetimibe-glucuronide).,Aminopeptidase N,ANPEP,other,unknown
Edetic Acid,The half life of edetate calcium disodium is 20 to 60 minutes.,Lead,,chelator,yes
Edetic Acid,The half life of edetate calcium disodium is 20 to 60 minutes.,Iron,,chelator,unknown
Edetic Acid,The half life of edetate calcium disodium is 20 to 60 minutes.,Manganese cation,,chelator,unknown
Dipyridamole,40 minutes,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",PDE10A,inhibitor,yes
Dipyridamole,40 minutes,Adenosine deaminase,ADA,inhibitor,yes
Dipyridamole,40 minutes,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,inhibitor,yes
Dipyridamole,40 minutes,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,inhibitor,yes
Dipyridamole,40 minutes,Calcipressin-1,RCAN1,,unknown
Dipyridamole,40 minutes,Alpha-1-acid glycoprotein 1,ORM1,,unknown
Telithromycin,Main elimination half-life is 2-3 hours; terminal elimination half-life is 10 hours,23S rRNA,,inhibitor,yes
Ethinyl Estradiol,36 +/- 13 hours,Estrogen receptor alpha,ESR1,agonist,yes
Ethinyl Estradiol,36 +/- 13 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,agonist,unknown
Ethinyl Estradiol,36 +/- 13 hours,Sex hormone-binding globulin,SHBG,,unknown
Lomefloxacin,8 hours,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Lomefloxacin,8 hours,DNA gyrase subunit A,gyrA,inhibitor,yes
Lomefloxacin,8 hours,DNA topoisomerase 2-alpha,TOP2A,inhibitor,unknown
Cyclopentolate,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Ramelteon,~1-2.6 hours,Melatonin receptor type 1A,MTNR1A,multitarget,yes
Ramelteon,~1-2.6 hours,Melatonin receptor type 1B,MTNR1B,multitarget,yes
Physostigmine,,Acetylcholinesterase,ACHE,inhibitor,yes
Physostigmine,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,,unknown
Physostigmine,,Neuronal acetylcholine receptor subunit beta-2,CHRNB2,,unknown
Isotretinoin,17-50 hours,Retinoic acid receptor alpha,RARA,other/unknown,unknown
Formoterol,10 hours,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Formoterol,10 hours,Beta-1 adrenergic receptor,ADRB1,agonist,unknown
Formoterol,10 hours,Beta-3 adrenergic receptor,ADRB3,agonist,unknown
Nandrolone phenpropionate,The elimination half-life from plasma is very short.,Androgen receptor,AR,agonist,yes
Dimenhydrinate,1 to 4 hours,Histamine H1 receptor,HRH1,antagonist,yes
Glycopyrronium,0.6-1.2 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Glycopyrronium,0.6-1.2 hours,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Glycopyrronium,0.6-1.2 hours,Muscarinic acetylcholine receptor M2,CHRM2,binder,unknown
Cytarabine,10 minutes,DNA,,cross-linking/alkylation,yes
Cytarabine,10 minutes,DNA polymerase beta,POLB,inhibitor,yes
Dopamine,2 minutes,D(2) dopamine receptor,DRD2,agonist,yes
Dopamine,2 minutes,D(1A) dopamine receptor,DRD1,agonist,yes
Dopamine,2 minutes,D(1B) dopamine receptor,DRD5,agonist,yes
Dopamine,2 minutes,D(3) dopamine receptor,DRD3,agonist,yes
Dopamine,2 minutes,D(4) dopamine receptor,DRD4,agonist,yes
Dopamine,2 minutes,Sodium-dependent dopamine transporter,SLC6A3,inducer,yes
Dopamine,2 minutes,Dopamine beta-hydroxylase,DBH,ligand,yes
Dopamine,2 minutes,5-hydroxytryptamine receptor 1A,HTR1A,binder,unknown
Dopamine,2 minutes,5-hydroxytryptamine receptor 7,HTR7,binder,unknown
Dopamine,2 minutes,D(1) dopamine receptor,DRD1DRD5,agonist,unknown
Dopamine,2 minutes,Sodium-dependent noradrenaline transporter,SLC6A2,,unknown
Dopamine,2 minutes,Sodium-dependent serotonin transporter,SLC6A4,,unknown
Dopamine,2 minutes,5-hydroxytryptamine receptor 3A,HTR3A,,unknown
Dopamine,2 minutes,5-hydroxytryptamine receptor 3B,HTR3B,,unknown
Dopamine,2 minutes,Superoxide dismutase [Cu-Zn],SOD1,,unknown
Dopamine,2 minutes,Synaptic vesicular amine transporter,SLC18A2,,unknown
Rivastigmine,1.5 hours,Acetylcholinesterase,ACHE,inhibitor,yes
Rivastigmine,1.5 hours,Cholinesterase,BCHE,inhibitor,yes
Exemestane,24 hours,Cytochrome P450 19A1,CYP19A1,inhibitor,yes
Oxaprozin,54.9 hours,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Oxaprozin,54.9 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Methyl aminolevulinate,,High affinity immunoglobulin gamma Fc receptor I,FCGR1A,antibody,unknown
Azathioprine,,Hypoxanthine-guanine phosphoribosyltransferase,HPRT1,inhibitor,yes
Azathioprine,,Ras-related C3 botulinum toxin substrate 1,RAC1,,unknown
Neomycin,2 to 3 hours,30S ribosomal protein S12,rpsL,inhibitor,yes
Neomycin,2 to 3 hours,16S rRNA,,inhibitor,yes
Neomycin,2 to 3 hours,Extracellular calcium-sensing receptor,CASR,,unknown
Auranofin,,"Peroxiredoxin-5, mitochondrial",PRDX5,inhibitor,yes
Auranofin,,Inhibitor of nuclear factor kappa-B kinase subunit beta,IKBKB,inhibitor,yes
Gabapentin,5-7 hours,Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,inhibitor,yes
Gabapentin,5-7 hours,Voltage-dependent calcium channel subunit alpha-2/delta-2,CACNA2D2,inhibitor,yes
Gabapentin,5-7 hours,Voltage-dependent N-type calcium channel subunit alpha-1B,CACNA1B,inhibitor,yes
Gabapentin,5-7 hours,Adenosine receptor A1,ADORA1,agonist,unknown
Gabapentin,5-7 hours,NMDA receptor,GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B,,unknown
Gabapentin,5-7 hours,Gamma-aminobutyric acid type B receptor subunit 1,GABBR1,,unknown
Gabapentin,5-7 hours,Gamma-aminobutyric acid type B receptor subunit 2,GABBR2,,unknown
Doxorubicin,Terminal half life = 20 - 48 hours.,DNA,,intercalation,yes
Doxorubicin,Terminal half life = 20 - 48 hours.,DNA topoisomerase 2-alpha,TOP2A,inhibitor,yes
Doxorubicin,Terminal half life = 20 - 48 hours.,Nucleolar and coiled-body phosphoprotein 1,NOLC1,,unknown
Frovatriptan,26 hours,5-hydroxytryptamine receptor 1D,HTR1D,agonist,yes
Frovatriptan,26 hours,5-hydroxytryptamine receptor 1B,HTR1B,agonist,yes
Hydrochlorothiazide,5.6 and 14.8 hours,Solute carrier family 12 member 3,SLC12A3,inhibitor,yes
Hydrochlorothiazide,5.6 and 14.8 hours,Carbonic anhydrase 1,CA1,inhibitor,unknown
Hydrochlorothiazide,5.6 and 14.8 hours,Carbonic anhydrase 2,CA2,inhibitor,unknown
Hydrochlorothiazide,5.6 and 14.8 hours,Carbonic anhydrase 4,CA4,inhibitor,unknown
Hydrochlorothiazide,5.6 and 14.8 hours,Carbonic anhydrase 9,CA9,inhibitor,unknown
Hydrochlorothiazide,5.6 and 14.8 hours,Carbonic anhydrase 12,CA12,inhibitor,unknown
Hydrochlorothiazide,5.6 and 14.8 hours,Calcium-activated potassium channel subunit alpha-1,KCNMA1,other/unknown,unknown
Cyclacillin,,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Cyclacillin,,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Cyclacillin,,Penicillin-binding protein 3,pbp3,inhibitor,yes
Cyclacillin,,Penicillin binding protein 2a,mecA,inhibitor,yes
Salbutamol,1.6 hours,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Salbutamol,1.6 hours,Beta-1 adrenergic receptor,ADRB1,agonist,unknown
Salbutamol,1.6 hours,Beta-3 adrenergic receptor,ADRB3,,unknown
Levobupivacaine,3.3 hours,Sodium channel protein type 10 subunit alpha,SCN10A,inhibitor,yes
Cromoglicic acid,1.3 hours,Calcium-activated potassium channel subunit alpha-1,KCNMA1,inhibitor,yes
Cromoglicic acid,1.3 hours,Protein S100-P,S100P,antagonist,unknown
Ganciclovir,"2.5 to 3.6 hours (mean 2.9 hours) when administered intravenously in adults. 3.1 to 5.5 hours when administered orally in adults. Renal function impairment causes a marked increase in half life (9 to 30 hours intravenously, 15.7 to 18.2 hours orally).",DNA polymerase catalytic subunit,,inhibitor,yes
Ganciclovir,"2.5 to 3.6 hours (mean 2.9 hours) when administered intravenously in adults. 3.1 to 5.5 hours when administered orally in adults. Renal function impairment causes a marked increase in half life (9 to 30 hours intravenously, 15.7 to 18.2 hours orally).",DNA,,incorporation into and destabilization,yes
Ganciclovir,"2.5 to 3.6 hours (mean 2.9 hours) when administered intravenously in adults. 3.1 to 5.5 hours when administered orally in adults. Renal function impairment causes a marked increase in half life (9 to 30 hours intravenously, 15.7 to 18.2 hours orally).",Thymidine kinase,TK,inducer,yes
Hydroxyurea,3-4 hours,Ribonucleoside-diphosphate reductase large subunit,RRM1,inhibitor,yes
Letrozole,2 days,Cytochrome P450 19A1,CYP19A1,antagonist,yes
Tioconazole,,Lanosterol 14-alpha demethylase,ERG11,antagonist,yes
Tioconazole,,Lanosterol 14-alpha demethylase,CYP51A1,inhibitor,unknown
Busulfan,2.6 hours,DNA,,cross-linking/alkylation,yes
Ketoprofen,"Conventional capsules: 1.1-4 hours
<p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p>",Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Ketoprofen,"Conventional capsules: 1.1-4 hours
<p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p>",Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Ketoprofen,"Conventional capsules: 1.1-4 hours
<p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p>",C-X-C chemokine receptor type 1,CXCR1,other,unknown
Edrophonium,Distribution half-life is 7 to 12 minutes. Elimination half-life is 33 to 110 minutes.,Acetylcholinesterase,ACHE,inhibitor,yes
Edrophonium,Distribution half-life is 7 to 12 minutes. Elimination half-life is 33 to 110 minutes.,Cholinesterase,BCHE,inhibitor,yes
Metyrapone,1.9 &plusmn;0.7 hours.,"Cytochrome P450 11B1, mitochondrial",CYP11B1,inhibitor,yes
Metyrapone,1.9 &plusmn;0.7 hours.,Camphor 5-monooxygenase,camC,other/unknown,unknown
Cinacalcet,"Terminal half-life is 30 to 40 hours. The mean half-life of cinacalcet is prolonged by 33% and 70% in patients with moderate and severe hepatic impairment, respectively.",Extracellular calcium-sensing receptor,CASR,agonist,yes
Clobetasol propionate,,Glucocorticoid receptor,NR3C1,agonist,yes
Balsalazide,Half-life could not be determined.,Peroxisome proliferator-activated receptor gamma,PPARG,agonist,yes
Balsalazide,Half-life could not be determined.,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Balsalazide,Half-life could not be determined.,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Balsalazide,Half-life could not be determined.,Arachidonate 5-lipoxygenase,ALOX5,inhibitor,yes
Sulfamethoxazole,10 hours,Dihydropteroate synthase,folP,inhibitor,yes
Sulfamethoxazole,10 hours,Bifunctional protein FolC,folC,inhibitor,yes
Sulfamethoxazole,10 hours,Glutathione S-transferase P,GSTP1,,unknown
Glyburide,1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.,"Sulfonylurea receptor 1, Kir6.2",ABCC8KCNJ11,blocker,yes
Glyburide,1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.,G protein-activated inward rectifier potassium channel 4,KCNJ5,inhibitor,unknown
Glyburide,1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.,ATP-binding cassette sub-family C member 9,ABCC9,modulator,unknown
Glyburide,1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.,Bile salt export pump,ABCB11,inhibitor,unknown
Glyburide,1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.,ATP-binding cassette sub-family A member 1,ABCA1,inhibitor,unknown
Glyburide,1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.,Cystic fibrosis transmembrane conductance regulator,CFTR,antagonist,unknown
Glyburide,1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.,Mitochondrial ATP-sensitive potassium channel,KCNJ11KCNJ8,,unknown
Glyburide,1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.,"Carnitine O-palmitoyltransferase 1, liver isoform",CPT1A,,unknown
Minocycline,11-22 hours,30S ribosomal protein S9,rpsI,inhibitor,yes
Minocycline,11-22 hours,30S ribosomal protein S4,rpsD,inhibitor,yes
Minocycline,11-22 hours,16S rRNA,,inhibitor,unknown
Minocycline,11-22 hours,Interleukin-1 beta,IL1B,modulator,unknown
Minocycline,11-22 hours,Arachidonate 5-lipoxygenase,ALOX5,inhibitor,unknown
Minocycline,11-22 hours,Matrix metalloproteinase-9,MMP9,inhibitor,unknown
Minocycline,11-22 hours,Vascular endothelial growth factor A,VEGFA,inhibitor,unknown
Minocycline,11-22 hours,Caspase-1,CASP1,negative modulator,unknown
Minocycline,11-22 hours,Caspase-3,CASP3,negative modulator,unknown
Minocycline,11-22 hours,Cytochrome c,CYCS,negative modulator,unknown
Guanfacine,17 hours (range 10-30 hours),Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Guanfacine,17 hours (range 10-30 hours),Alpha-2B adrenergic receptor,ADRA2B,binder,unknown
Bethanechol,,Muscarinic acetylcholine receptor M2,CHRM2,agonist,yes
Bethanechol,,Muscarinic acetylcholine receptor M1,CHRM1,,unknown
Bethanechol,,Muscarinic acetylcholine receptor M3,CHRM3,,unknown
Bethanechol,,Muscarinic acetylcholine receptor M4,CHRM4,,unknown
Isosorbide Mononitrate,5 hours,Guanylate cyclase soluble subunit alpha-2,GUCY1A2,inducer,yes
Trichlormethiazide,,Solute carrier family 12 member 1,SLC12A1,inhibitor,yes
Trichlormethiazide,,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,inhibitor,yes
Trichlormethiazide,,Carbonic anhydrase 1,CA1,inhibitor,unknown
Trichlormethiazide,,Carbonic anhydrase 2,CA2,inhibitor,unknown
Trichlormethiazide,,Carbonic anhydrase 4,CA4,inhibitor,unknown
Phylloquinone,,Vitamin K-dependent gamma-carboxylase,GGCX,inducer,yes
Phylloquinone,,Osteocalcin,BGLAP,agonist,unknown
Felodipine,17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,inhibitor,yes
Felodipine,17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.,Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,inhibitor,yes
Felodipine,17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.,Voltage-dependent L-type calcium channel subunit beta-2,CACNB2,inhibitor,yes
Felodipine,17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,inhibitor,yes
Felodipine,17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,inhibitor,yes
Felodipine,17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,inhibitor,unknown
Felodipine,17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.,Voltage-dependent calcium channel subunit alpha-2/delta-2,CACNA2D2,inhibitor,unknown
Felodipine,17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.,Calmodulin,CALM1,other,unknown
Felodipine,17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.,"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B",PDE1B,inhibitor,unknown
Felodipine,17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.,"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A",PDE1A,inhibitor,unknown
Felodipine,17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.,Mineralocorticoid receptor,NR3C2,antagonist,unknown
Felodipine,17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.,"Troponin C, skeletal muscle",TNNC2,other,unknown
Felodipine,17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.,"Troponin C, slow skeletal and cardiac muscles",TNNC1,other,unknown
Mycophenolic acid,"The mean elimination half-life for mycophenolic acid ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.",Inosine-5'-monophosphate dehydrogenase 1,IMPDH1,inhibitor,yes
Mycophenolic acid,"The mean elimination half-life for mycophenolic acid ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.",Inosine-5'-monophosphate dehydrogenase 2,IMPDH2,inhibitor,yes
Amlexanox,Elimination half-life is 3.5 &plusmn; 1.1 hours.,Protein S100-A12,S100A12,antagonist,unknown
Amlexanox,Elimination half-life is 3.5 &plusmn; 1.1 hours.,Protein S100-A13,S100A13,antagonist,unknown
Amlexanox,Elimination half-life is 3.5 &plusmn; 1.1 hours.,Interleukin-3,IL3,antagonist,unknown
Amlexanox,Elimination half-life is 3.5 &plusmn; 1.1 hours.,Fibroblast growth factor 1,FGF1,inhibitor,unknown
Ketoconazole,2 hours,Lanosterol 14-alpha demethylase,ERG11,inhibitor,yes
Ketoconazole,2 hours,Androgen receptor,AR,binder,unknown
Ketoconazole,2 hours,17-hydroxylase,,,unknown
Ketoconazole,2 hours,Steroid 21-hydroxylase,CYP21A2,,unknown
Ketoconazole,2 hours,11-hydroxylase,,,unknown
Ketoconazole,2 hours,Cytochrome P450 19A1,CYP19A1,,unknown
Ketoconazole,2 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Ketoconazole,2 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,antagonist,unknown
Ketoconazole,2 hours,Nuclear receptor subfamily 1 group I member 3,NR1I3,,unknown
Methoxyflurane,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,agonist,yes
Methoxyflurane,,Glutamate receptor 1,GRIA1,antagonist,yes
Methoxyflurane,,Glycine receptor subunit alpha-1,GLRA1,agonist,yes
Methoxyflurane,,Calcium-transporting ATPase type 2C member 1,ATP2C1,inhibitor,unknown
Methoxyflurane,,Potassium voltage-gated channel subfamily A member 1,KCNA1,inducer,yes
Methoxyflurane,,"ATP synthase subunit delta, mitochondrial",ATP5D,unknown,unknown
Methoxyflurane,,NADH-ubiquinone oxidoreductase chain 1,MT-ND1,unknown,unknown
Methoxyflurane,,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Irbesartan,11-15 hours,Type-1 angiotensin II receptor,AGTR1,antagonist,yes
Irbesartan,11-15 hours,Transcription factor AP-1,JUN,other/unknown,unknown
Topotecan,2-3 hours,DNA topoisomerase 1,TOP1,inhibitor,yes
Topotecan,2-3 hours,"DNA topoisomerase I, mitochondrial",TOP1MT,inhibitor,unknown
Topotecan,2-3 hours,DNA,,intercalation,yes
Ethinamate,2.5 hours,Carbonic anhydrase 1,CA1,inhibitor,yes
Ethinamate,2.5 hours,Carbonic anhydrase 2,CA2,inhibitor,yes
Probenecid,6-12 hours,Solute carrier family 22 member 6,SLC22A6,inhibitor,yes
Probenecid,6-12 hours,Solute carrier family 22 member 11,SLC22A11,inhibitor,yes
Probenecid,6-12 hours,Solute carrier family 22 member 8,SLC22A8,inhibitor,yes
Probenecid,6-12 hours,Pannexin-1,PANX1,antagonist,unknown
Probenecid,6-12 hours,Taste receptor type 2 member 16,TAS2R16,,unknown
Mercaptopurine,"Triphasic: 45 minutes, 2.5 hours, and 10 hours.",Hypoxanthine-guanine phosphoribosyltransferase,HPRT1,inhibitor,yes
Mercaptopurine,"Triphasic: 45 minutes, 2.5 hours, and 10 hours.",Amidophosphoribosyltransferase,PPAT,,unknown
Mercaptopurine,"Triphasic: 45 minutes, 2.5 hours, and 10 hours.",Inosine-5'-monophosphate dehydrogenase,IMPDH1IMPDH2,inhibitor,unknown
Cerulenin,,3-oxoacyl-[acyl-carrier-protein] synthase 1,fabB,inhibitor,yes
Cerulenin,,3-oxoacyl-[acyl-carrier-protein] synthase 2,fabF,inhibitor,yes
Cerulenin,,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,inhibitor,yes
Cerulenin,,Fatty acid synthase,FASN,inhibitor,yes
Procainamide,~2.5-4.5 hours,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,unknown
Procainamide,~2.5-4.5 hours,DNA (cytosine-5)-methyltransferase 1,DNMT1,other,unknown
Procainamide,~2.5-4.5 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Tolterodine,1.9-3.7 hours,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Tolterodine,1.9-3.7 hours,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Tolterodine,1.9-3.7 hours,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,yes
Tolterodine,1.9-3.7 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Tolterodine,1.9-3.7 hours,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,yes
Selegiline,1.2-2 hours,Amine oxidase [flavin-containing] B,MAOB,inhibitor,yes
Selegiline,1.2-2 hours,Amine oxidase [flavin-containing] A,MAOA,inhibitor,no
Carphenazine,,D(2) dopamine receptor,DRD2,antagonist,yes
Carphenazine,,D(1A) dopamine receptor,DRD1,antagonist,yes
Carphenazine,,D(1B) dopamine receptor,DRD5,antagonist,yes
Fenofibrate,20 hours,Peroxisome proliferator-activated receptor alpha,PPARA,agonist,yes
Fenofibrate,20 hours,Metalloproteinase,mmp20,inhibitor,unknown
Fenofibrate,20 hours,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Fenofibrate,20 hours,Peroxisome proliferator-activated receptor delta,PPARD,,unknown
Fenofibrate,20 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,partial agonist,unknown
Hydroxystilbamidine Isethionate,,DNA,,other/unknown,yes
Thalidomide,The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.,Protein cereblon,CRBN,inhibitor,yes
Thalidomide,The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.,Tumor necrosis factor,TNF,inhibitor,yes
Thalidomide,The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.,Nuclear factor NF-kappa-B p105 subunit,NFKB1,antagonist,yes
Thalidomide,The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.,DNA,,intercalation,yes
Thalidomide,The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.,Fibroblast growth factor receptor 2,FGFR2,antagonist,yes
Thalidomide,The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.,Prostaglandin G/H synthase 2,PTGS2,antagonist,unknown
Thalidomide,The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.,Nuclear factor kappa-light-chain-enhancer of activated B cells,,,unknown
Thalidomide,The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.,alpha1-acid glycoprotein,ORM1ORM2,binder,unknown
Melphalan,1.5 (&plusmn;0.83) hours,DNA,,cross-linking/alkylation,yes
Memantine,60-100 hours,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,antagonist,yes
Memantine,60-100 hours,"Glutamate receptor ionotropic, NMDA 2A",GRIN2A,antagonist,yes
Memantine,60-100 hours,"Glutamate receptor ionotropic, NMDA 2B",GRIN2B,antagonist,yes
Memantine,60-100 hours,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,unknown
Memantine,60-100 hours,Alpha-7 nicotinic cholinergic receptor subunit,CHRNA7,antagonist,unknown
Memantine,60-100 hours,D(2) dopamine receptor,DRD2,agonist,unknown
Memantine,60-100 hours,"Glutamate receptor ionotropic, NMDA 1",GRIN1,binder,unknown
Gatifloxacin,7-14 hours,DNA gyrase subunit A,gyrA,inhibitor,yes
Gatifloxacin,7-14 hours,DNA gyrase subunit B,gyrB,inhibitor,yes
Gatifloxacin,7-14 hours,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Gatifloxacin,7-14 hours,DNA topoisomerase 4 subunit B,parE,inhibitor,yes
Rifampicin,3.35 (+/- 0.66) hours,DNA-directed RNA polymerase subunit beta,rpoB,inhibitor,yes
Rifampicin,3.35 (+/- 0.66) hours,DNA-directed RNA polymerase subunit beta',rpoC,inhibitor,yes
Rifampicin,3.35 (+/- 0.66) hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,agonist,unknown
Rifampicin,3.35 (+/- 0.66) hours,Solute carrier organic anion transporter family member 1B1,SLCO1B1,,unknown
Rifampicin,3.35 (+/- 0.66) hours,Solute carrier organic anion transporter family member 1A2,SLCO1A2,,unknown
Rifampicin,3.35 (+/- 0.66) hours,Solute carrier organic anion transporter family member 1B3,SLCO1B3,,unknown
Rifampicin,3.35 (+/- 0.66) hours,Lanosterol 14-alpha demethylase,CYP51A1,,unknown
Rifampicin,3.35 (+/- 0.66) hours,Serum albumin,ALB,,unknown
Rifampicin,3.35 (+/- 0.66) hours,Solute carrier organic anion transporter family member 2B1,SLCO2B1,,unknown
Lubiprostone,0.9 to 1.4 hours,Chloride channel protein 2,CLCN2,inducer,yes
Fluocinonide,,Glucocorticoid receptor,NR3C1,agonist,yes
Fluocinonide,,Smoothened homolog,SMO,agonist,unknown
Abacavir,1.54 ± 0.63 hours,Reverse transcriptase/RNaseH,pol,inhibitor,yes
Abacavir,1.54 ± 0.63 hours,"HLA class I histocompatibility antigen, B-57 alpha chain",HLA-B,,unknown
Ergoloid mesylate,3.5 hours,Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,antagonist,yes
Ergoloid mesylate,3.5 hours,Alpha-1 adrenergic receptors,ADRA1AADRA1BADRA1D,antagonist,yes
Ergoloid mesylate,3.5 hours,Solute carrier organic anion transporter family member 2B1,SLCO2B1,inhibitor,yes
Ergoloid mesylate,3.5 hours,Serotonin Receptors,HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR6HTR7,antagonist,unknown
Ergoloid mesylate,3.5 hours,D(1A) dopamine receptor,DRD1,antagonistagonist,unknown
Ergoloid mesylate,3.5 hours,D(2) dopamine receptor,DRD2,antagonistagonist,unknown
Ergoloid mesylate,3.5 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,agonist,unknown
Ibuprofen,2-4 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Ibuprofen,2-4 hours,Prostaglandin G/H synthase 1,PTGS1,,yes
Ibuprofen,2-4 hours,Apoptosis regulator Bcl-2,BCL2,modulator,unknown
Ibuprofen,2-4 hours,Thrombomodulin,THBD,modulator,unknown
Ibuprofen,2-4 hours,Tissue-type plasminogen activator,PLAT,negative modulator,unknown
Ibuprofen,2-4 hours,"Fatty acid-binding protein, intestinal",FABP2,binder,unknown
Ibuprofen,2-4 hours,Peroxisome proliferator-activated receptor gamma,PPARG,activator,unknown
Ibuprofen,2-4 hours,Cystic fibrosis transmembrane conductance regulator,CFTR,inhibitor,unknown
Ibuprofen,2-4 hours,Solute carrier family 15 member 1,SLC15A1,,unknown
Ibuprofen,2-4 hours,Peroxisome proliferator-activated receptor alpha,PPARA,activator,unknown
Novobiocin,6 hours,DNA gyrase subunit B,gyrB,inhibitor,yes
Novobiocin,6 hours,DNA topoisomerase 1,topA,,unknown
Benzylpenicillin,In adults with normal renal function is reportedly 0.4–0.9 hours,Penicillin-binding protein 3,pbp3,inhibitor,unknown
Benzylpenicillin,In adults with normal renal function is reportedly 0.4–0.9 hours,Beta-lactamase TEM,bla,,unknown
Benzylpenicillin,In adults with normal renal function is reportedly 0.4–0.9 hours,Solute carrier family 22 member 8,SLC22A8,,unknown
Benzylpenicillin,In adults with normal renal function is reportedly 0.4–0.9 hours,Solute carrier family 15 member 1,SLC15A1,,unknown
Benzylpenicillin,In adults with normal renal function is reportedly 0.4–0.9 hours,Solute carrier family 15 member 2,SLC15A2,,unknown
Nitrendipine,,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,inhibitor,yes
Nitrendipine,,Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,inhibitor,yes
Nitrendipine,,Voltage-dependent L-type calcium channel subunit beta-2,CACNB2,inhibitor,yes
Nitrendipine,,Voltage-dependent calcium channel gamma-1 subunit,CACNG1,inhibitor,yes
Nitrendipine,,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,inhibitor,yes
Nitrendipine,,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,inhibitor,yes
Nitrendipine,,Voltage-dependent calcium channel subunit alpha-2/delta-2,CACNA2D2,inhibitor,unknown
Nitrendipine,,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,inhibitor,unknown
Mimosine,,"Serine hydroxymethyltransferase, cytosolic",SHMT1,inhibitor,yes
Mimosine,,C-C motif chemokine 2,CCL2,inhibitor,yes
Mimosine,,Tyrosinase,TYR,inhibitor,unknown
Tocainide,The average plasma half-life in patients is approximately 15 hours. May be prolonged up to 35 hours in patients with severe renal function impairment (creatinine clearance less than 30 mL per min per 1.73 square meters of body surface area.,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Echothiophate,,Cholinesterase,BCHE,inhibitor,yes
Praziquantel,0.8-1.5 hours (in serum),Schistosome calcium ion (Ca2+) channels,,other/unknown,yes
Norfloxacin,3-4 hours,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Norfloxacin,3-4 hours,DNA gyrase subunit A,gyrA,inhibitor,yes
Norfloxacin,3-4 hours,DNA topoisomerase 2-alpha,TOP2A,inhibitor,unknown
Amoxicillin,61.3 minutes,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Azlocillin,"Mean elimination half-life is 1.3 to 1.5 hours. Longer in neonates, and 2 to 6 hours in patients with renal impairment.",Penicillin-binding protein 1A,pbpA,inhibitor,yes
Oxybutynin,12.4-13.2 hours,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Oxybutynin,12.4-13.2 hours,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Oxybutynin,12.4-13.2 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Acetophenazine,,D(2) dopamine receptor,DRD2,antagonist,yes
Acetophenazine,,D(1A) dopamine receptor,DRD1,antagonist,yes
Acetophenazine,,Androgen receptor,AR,,unknown
Isoprenaline,,Beta-1 adrenergic receptor,ADRB1,agonist,yes
Isoprenaline,,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Isoprenaline,,Beta-3 adrenergic receptor,ADRB3,agonist,yes
Isoprenaline,,Mitogen-activated protein kinase 1,MAPK1,inducer,unknown
Isoprenaline,,Phosphatidylinositol 3-kinase regulatory subunit alpha,PIK3R1,agonist,unknown
Isoprenaline,,Phosphatidylinositol 3-kinase regulatory subunit beta,PIK3R2,agonist,unknown
Isoprenaline,,Phosphatidylinositol 3-kinase regulatory subunit gamma,PIK3R3,agonist,unknown
Isoprenaline,,CAMP phosphodiesterase,PDE4,activator,unknown
Isoprenaline,,Superoxide dismutase [Cu-Zn],SOD1,,unknown
Melatonin,35 to 50 minutes,Melatonin receptor type 1A,MTNR1A,agonist,yes
Melatonin,35 to 50 minutes,Melatonin receptor type 1B,MTNR1B,agonist,yes
Melatonin,35 to 50 minutes,Estrogen receptor alpha,ESR1,antagonist,unknown
Melatonin,35 to 50 minutes,Nuclear receptor ROR-beta,RORB,agonist,unknown
Melatonin,35 to 50 minutes,Calmodulin,CALM1,,unknown
Melatonin,35 to 50 minutes,Myeloperoxidase,MPO,inhibitor,unknown
Melatonin,35 to 50 minutes,Eosinophil peroxidase,EPX,inhibitor,unknown
Melatonin,35 to 50 minutes,Calreticulin,CALR,,unknown
Melatonin,35 to 50 minutes,Acetylserotonin O-methyltransferase,ASMT,,unknown
Melatonin,35 to 50 minutes,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,,unknown
Cefditoren,Mean terminal elimination half-life is 1.6 &plusmn; 0.4 hours in young healthy adults.,Penicillin-binding protein 2B,penA,inhibitor,yes
Cefditoren,Mean terminal elimination half-life is 1.6 &plusmn; 0.4 hours in young healthy adults.,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Glipizide,2-5 hours,ATP-binding cassette sub-family C member 8,ABCC8,inhibitor,yes
Glipizide,2-5 hours,Peroxisome proliferator-activated receptor gamma,PPARG,agonist,unknown
Clonazepam,30-40 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Clonazepam,30-40 hours,Translocator protein,TSPO,other/unknown,unknown
Clonazepam,30-40 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,partial agonist,unknown
Promethazine,16-19 hours,Histamine H1 receptor,HRH1,antagonist,yes
Promethazine,16-19 hours,D(2) dopamine receptor,DRD2,antagonist,unknown
Promethazine,16-19 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Promethazine,16-19 hours,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Promethazine,16-19 hours,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Promethazine,16-19 hours,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,unknown
Promethazine,16-19 hours,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,unknown
Promethazine,16-19 hours,Alpha-1A adrenergic receptor,ADRA1A,unknown,unknown
Promethazine,16-19 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,unknown
Promethazine,16-19 hours,Calmodulin,CALM1,inhibitor,unknown
Promethazine,16-19 hours,Histamine H2 receptor,HRH2,antagonist,unknown
Dihydrotachysterol,,Vitamin D3 receptor,VDR,agonist,yes
Mequitazine,,Histamine H1 receptor,HRH1,antagonist,yes
Atazanavir,Elimination half-life in adults (healthy and HIV infected) is approximately 7 hours (following a 400 mg daily dose with a light meal). Elimination half-life in hepatically impaired is 12.1 hours (following a single 400 mg dose).,Human immunodeficiency virus type 1 protease,pol,inhibitor,yes
Fludarabine,20 hours,Ribonucleoside-diphosphate reductase large subunit,RRM1,inhibitor,yes
Fludarabine,20 hours,DNA polymerase alpha catalytic subunit,POLA1,inhibitor,yes
Fludarabine,20 hours,DNA,,incorporation into and destabilization,yes
Fludarabine,20 hours,Deoxycytidine kinase,DCK,agonist,yes
Perhexiline,"Variable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days.","Carnitine O-palmitoyltransferase 1, liver isoform",CPT1A,inhibitor,yes
Perhexiline,"Variable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days.","Carnitine O-palmitoyltransferase 2, mitochondrial",CPT2,inhibitor,yes
Perhexiline,"Variable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days.",Potassium voltage-gated channel subfamily H member 2,KCNH2,,unknown
Diphenhydramine,1-4 hours,Histamine H1 receptor,HRH1,antagonist,yes
Diphenhydramine,1-4 hours,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Atorvastatin,"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites",3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,inhibitor,yes
Atorvastatin,"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites",Dipeptidyl peptidase 4,DPP4,inhibitor,no
Atorvastatin,"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites",Aryl hydrocarbon receptor,AHR,agonist,unknown
Etidronic acid,"In normal subjects, plasma half-life of etidronic acid, based on non-compartmental pharmacokinetics is 1 to 6 hours.",Adenosine triphosphate (ATP),,inhibitor,yes
Etidronic acid,"In normal subjects, plasma half-life of etidronic acid, based on non-compartmental pharmacokinetics is 1 to 6 hours.",Hydroxylapatite,,antagonist,yes
Etidronic acid,"In normal subjects, plasma half-life of etidronic acid, based on non-compartmental pharmacokinetics is 1 to 6 hours.",Receptor-type tyrosine-protein phosphatase S,PTPRS,inhibitor,unknown
Etidronic acid,"In normal subjects, plasma half-life of etidronic acid, based on non-compartmental pharmacokinetics is 1 to 6 hours.",V-type proton ATPase catalytic subunit A,ATP6V1A,inhibitor,unknown
Deslanoside,36 hours,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,inhibitor,yes
Tegaserod,11 &plusmn; 5 hours,5-hydroxytryptamine receptor 4,HTR4,antagonistpartial agonist,yes
Tegaserod,11 &plusmn; 5 hours,5-hydroxytryptamine receptor 2B,HTR2B,antagonist,unknown
Tegaserod,11 &plusmn; 5 hours,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Tegaserod,11 &plusmn; 5 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,unknown
Vigabatrin,"Neonates, 50 mg/kg = 7.5 ± 2.1 hours (due to reduced renal function); 
Infants = 5.7 hours;
Adults = 7.5 hours;
Elderly = 12 - 13 hours",Gamma-aminobutyric acid type B receptor subunit 1,GABBR1,agonist,yes
Vigabatrin,"Neonates, 50 mg/kg = 7.5 ± 2.1 hours (due to reduced renal function); 
Infants = 5.7 hours;
Adults = 7.5 hours;
Elderly = 12 - 13 hours","4-aminobutyrate aminotransferase, mitochondrial",ABAT,inhibitor,yes
Diphenoxylate,12-14 hours,Mu-type opioid receptor,OPRM1,agonist,yes
Diphenoxylate,12-14 hours,Delta-type opioid receptor,OPRD1,agonist,unknown
Streptomycin,5 - 6 hours in adults with normal renal function,30S ribosomal protein S12,rpsL,inhibitor,yes
Streptomycin,5 - 6 hours in adults with normal renal function,16S rRNA,,inhibitor,yes
Streptomycin,5 - 6 hours in adults with normal renal function,Protein-arginine deiminase type-4,PADI4,,unknown
Orlistat,1 to 2 hours.,Pancreatic triacylglycerol lipase,PNLIP,inhibitor,yes
Orlistat,1 to 2 hours.,Gastric triacylglycerol lipase,LIPF,inhibitor,yes
Orlistat,1 to 2 hours.,Fatty acid synthase,FASN,inhibitor,yes
Emedastine,The elimination half-life of oral emedastine in plasma is 3-4 hours.,Histamine H1 receptor,HRH1,antagonist,yes
Pilocarpine,0.76 hours,Muscarinic acetylcholine receptor M3,CHRM3,agonist,yes
Pilocarpine,0.76 hours,Muscarinic acetylcholine receptor M1,CHRM1,agonist,yes
Pilocarpine,0.76 hours,Muscarinic acetylcholine receptor M2,CHRM2,agonist,yes
Pilocarpine,0.76 hours,Muscarinic acetylcholine receptor M4,CHRM4,partial agonist,unknown
Benzocaine,,Sodium channel protein type 10 subunit alpha,SCN10A,inhibitor,yes
Primaquine,3.7-7.4 hours,Fe(II)-protoporphyrin IX,,antagonist,yes
Primaquine,3.7-7.4 hours,"Keratin, type II cytoskeletal 7",KRT7,other/unknown,unknown
Primaquine,3.7-7.4 hours,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,inhibitor,unknown
Iloprost,20-30 minutes,Prostacyclin receptor,PTGIR,agonist,yes
Iloprost,20-30 minutes,Prostaglandin E2 receptor EP1 subtype,PTGER1,agonist,yes
Iloprost,20-30 minutes,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,inducer,unknown
Iloprost,20-30 minutes,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,inducer,unknown
Iloprost,20-30 minutes,"cAMP-specific 3',5'-cyclic phosphodiesterase 4C",PDE4C,inducer,unknown
Iloprost,20-30 minutes,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,inducer,unknown
Iloprost,20-30 minutes,Tissue-type plasminogen activator,PLAT,other/unknown,unknown
Iloprost,20-30 minutes,Prostaglandin D2 receptor 2,PTGDR2,agonist,unknown
Deserpidine,,Synaptic vesicular amine transporter,SLC18A2,inhibitor,yes
Pentolinium,,Neuronal acetylcholine receptor subunit alpha-10,CHRNA10,antagonist,yes
Pentolinium,,Neuronal acetylcholine receptor subunit alpha-3,CHRNA3,antagonist,yes
Pentolinium,,Neuronal acetylcholine receptor subunit beta-4,CHRNB4,antagonist,yes
Butenafine,"Following topical application, a biphasic decline of plasma butenafine concentrations was observed with the half-lives estimated to be 35 hours initial and over 150 hours terminal.",Squalene monooxygenase,SQLE,inhibitor,yes
Ouabain,,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,inhibitor,yes
Ouabain,,Sodium/potassium-transporting ATPase subunit alpha-2,ATP1A2,inhibitor,unknown
Ouabain,,Sodium/potassium-transporting ATPase subunit alpha-3,ATP1A3,inhibitor,unknown
Hesperetin,,Sterol O-acyltransferase 1,SOAT1,inhibitor,yes
Hesperetin,,Sterol O-acyltransferase 2,SOAT2,inhibitor,unknown
Hesperetin,,Microsomal triglyceride transfer protein large subunit,MTTP,antagonist,yes
Hesperetin,,Sex hormone-binding globulin,SHBG,,unknown
Fluvastatin,3 hours,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,inhibitor,yes
Oxamniquine,1-2.5 hours,DNA,,other/unknown,yes
Leflunomide,2 weeks,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,inhibitor,yes
Leflunomide,2 weeks,Aryl hydrocarbon receptor,AHR,agonist,unknown
Leflunomide,2 weeks,Protein-tyrosine kinase 2-beta,PTK2B,antagonist,unknown
Rosuvastatin,19 hours,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,inhibitor,yes
Flucytosine,2.4 to 4.8 hours.,DNA,,cross-linking/alkylation,yes
Flucytosine,2.4 to 4.8 hours.,DNA (cytosine-5)-methyltransferase 1,DNMT1,other,unknown
Flucytosine,2.4 to 4.8 hours.,Thymidylate synthase,TMP1,inhibitor,unknown
Pimozide,29 &plusmn; 10 hours (single-dose study of healthy volunteers).,D(2) dopamine receptor,DRD2,antagonist,yes
Pimozide,29 &plusmn; 10 hours (single-dose study of healthy volunteers).,D(3) dopamine receptor,DRD3,antagonist,yes
Pimozide,29 &plusmn; 10 hours (single-dose study of healthy volunteers).,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,yes
Pimozide,29 &plusmn; 10 hours (single-dose study of healthy volunteers).,Calmodulin,CALM1,inhibitor,unknown
Capecitabine,45-60 minutes for capecitabine and its metabolites.,Thymidylate synthase,TYMS,inhibitor,yes
Capecitabine,45-60 minutes for capecitabine and its metabolites.,DNA,,incorporation into and destabilization,yes
Capecitabine,45-60 minutes for capecitabine and its metabolites.,RNA,,incorporation into and destabilization,yes
Arbutamine,Elimination half-life is approximately 8 minutes.,Beta-1 adrenergic receptor,ADRB1,agonist,yes
Arbutamine,Elimination half-life is approximately 8 minutes.,Beta-2 adrenergic receptor,ADRB2,agonist,unknown
Arbutamine,Elimination half-life is approximately 8 minutes.,Beta-3 adrenergic receptor,ADRB3,agonist,unknown
Quinacrine,5 to 14 days,DNA,,intercalation,yes
Quinacrine,5 to 14 days,85/88 kDa calcium-independent phospholipase A2,PLA2G6,inhibitor,yes
Quinacrine,5 to 14 days,Cytosolic phospholipase A2,PLA2G4A,inhibitor,yes
Quinacrine,5 to 14 days,Inactive phospholipase C-like protein 1,PLCL1,inhibitor,yes
Sertraline,The elimination half-life of sertraline is approximately 25-26 hours. The elimination half-life of desmethylsertraline is approximately 62-104 hours [FDA Label].,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Sertraline,The elimination half-life of sertraline is approximately 25-26 hours. The elimination half-life of desmethylsertraline is approximately 62-104 hours [FDA Label].,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,unknown
Sertraline,The elimination half-life of sertraline is approximately 25-26 hours. The elimination half-life of desmethylsertraline is approximately 62-104 hours [FDA Label].,Sigma receptor,PGRMC1SIGMAR1,antagonist,unknown
Sibutramine,1.1 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Sibutramine,1.1 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Sibutramine,1.1 hours,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,yes
Levocabastine,36 hours (after oral administration),Histamine H1 receptor,HRH1,antagonist,yes
Levocabastine,36 hours (after oral administration),Neurotensin receptor type 2,NTSR2,partial antagonist,yes
Methyprylon,6-16 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,agonist,yes
Methyprylon,6-16 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Trilostane,8 hours.,3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1,HSD3B1,inhibitor,yes
Trilostane,8 hours.,3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2,HSD3B2,inhibitor,yes
Trilostane,8 hours.,Estrogen receptor alpha,ESR1,allosteric modulator,yes
Trilostane,8 hours.,Estrogen receptor beta,ESR2,allosteric modulator,yes
Heparin,"1.5 hours. 

The plasma half-life of heparin increases from about 60 minutes with a 100 unit/kg dose to about 150 minutes with a 400 unit/kg dose.",Antithrombin-III,SERPINC1,potentiator,yes
Heparin,"1.5 hours. 

The plasma half-life of heparin increases from about 60 minutes with a 100 unit/kg dose to about 150 minutes with a 400 unit/kg dose.",Coagulation factor X,F10,inhibitor,yes
Heparin,"1.5 hours. 

The plasma half-life of heparin increases from about 60 minutes with a 100 unit/kg dose to about 150 minutes with a 400 unit/kg dose.",P-selectin,SELP,inhibitor,unknown
Heparin,"1.5 hours. 

The plasma half-life of heparin increases from about 60 minutes with a 100 unit/kg dose to about 150 minutes with a 400 unit/kg dose.",Fibroblast growth factor receptor 4,FGFR4,,unknown
Heparin,"1.5 hours. 

The plasma half-life of heparin increases from about 60 minutes with a 100 unit/kg dose to about 150 minutes with a 400 unit/kg dose.",Fibroblast growth factor 4,FGF4,,unknown
Heparin,"1.5 hours. 

The plasma half-life of heparin increases from about 60 minutes with a 100 unit/kg dose to about 150 minutes with a 400 unit/kg dose.",Fibroblast growth factor 19,FGF19,,unknown
Heparin,"1.5 hours. 

The plasma half-life of heparin increases from about 60 minutes with a 100 unit/kg dose to about 150 minutes with a 400 unit/kg dose.",Fibroblast growth factor receptor 1,FGFR1,,unknown
Heparin,"1.5 hours. 

The plasma half-life of heparin increases from about 60 minutes with a 100 unit/kg dose to about 150 minutes with a 400 unit/kg dose.",Fibroblast growth factor 1,FGF1,,unknown
Heparin,"1.5 hours. 

The plasma half-life of heparin increases from about 60 minutes with a 100 unit/kg dose to about 150 minutes with a 400 unit/kg dose.",Fibroblast growth factor receptor 2,FGFR2,,unknown
Heparin,"1.5 hours. 

The plasma half-life of heparin increases from about 60 minutes with a 100 unit/kg dose to about 150 minutes with a 400 unit/kg dose.",Fibroblast growth factor 2,FGF2,,unknown
Heparin,"1.5 hours. 

The plasma half-life of heparin increases from about 60 minutes with a 100 unit/kg dose to about 150 minutes with a 400 unit/kg dose.",Platelet factor 4,PF4,,unknown
Heparin,"1.5 hours. 

The plasma half-life of heparin increases from about 60 minutes with a 100 unit/kg dose to about 150 minutes with a 400 unit/kg dose.",Hepatocyte growth factor,HGF,,unknown
Miconazole,,Lanosterol 14-alpha demethylase,ERG11,inhibitor,yes
Miconazole,,"Nitric oxide synthase, endothelial",NOS3,inhibitor,unknown
Miconazole,,"Nitric oxide synthase, inducible",NOS2,inhibitor,unknown
Miconazole,,Calcium-activated potassium channel subunit alpha-1,KCNMA1,inhibitor,unknown
Miconazole,,Calcium-activated potassium channel subunit beta-1,KCNMB1,inhibitor,unknown
Miconazole,,Calcium-activated potassium channel subunit beta-2,KCNMB2,inhibitor,unknown
Miconazole,,Calcium-activated potassium channel subunit beta-3,KCNMB3,inhibitor,unknown
Miconazole,,Calcium-activated potassium channel subunit beta-4,KCNMB4,inhibitor,unknown
Miconazole,,Intermediate conductance calcium-activated potassium channel protein 4,KCNN4,inhibitor,unknown
Miconazole,,Small conductance calcium-activated potassium channel protein 1,KCNN1,inhibitor,unknown
Miconazole,,Small conductance calcium-activated potassium channel protein 2,KCNN2,inhibitor,unknown
Miconazole,,Small conductance calcium-activated potassium channel protein 3,KCNN3,inhibitor,unknown
Miconazole,,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Miconazole,,Potassium voltage-gated channel subfamily H member 6,KCNH6,inhibitor,unknown
Miconazole,,Potassium voltage-gated channel subfamily H member 7,KCNH7,inhibitor,unknown
Miconazole,,Nuclear receptor subfamily 1 group I member 2,NR1I2,partial agonist,unknown
Colistimethate,"2-3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants.",Bacterial outer membrane,,incorporation into and destabilization,yes
Cefuroxime,Approximately 80 minutes following intramuscular or intravenous injection.,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Papaverine,0.5-2 hours,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,inhibitor,yes
Papaverine,0.5-2 hours,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",PDE10A,inhibitor,unknown
Chlorphenamine,21-27 hours,Histamine H1 receptor,HRH1,antagonist,yes
Chlorphenamine,21-27 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,unknown
Chlorphenamine,21-27 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,unknown
Chlorphenamine,21-27 hours,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,unknown
Nifedipine,2 hours,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,inhibitor,yes
Nifedipine,2 hours,Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,inhibitor,yes
Nifedipine,2 hours,Voltage-dependent L-type calcium channel subunit beta-2,CACNB2,inhibitor,yes
Nifedipine,2 hours,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,inhibitor,yes
Nifedipine,2 hours,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,inhibitor,yes
Nifedipine,2 hours,Calmodulin,CALM1,inhibitor,unknown
Nifedipine,2 hours,Potassium voltage-gated channel subfamily A member 1,KCNA1,inhibitor,unknown
Nifedipine,2 hours,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,inhibitor,unknown
Nifedipine,2 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Trimethaphan,,Neuronal acetylcholine receptor subunit alpha-10,CHRNA10,antagonist,yes
Atovaquone,2.2 to 3.2 days,Cytochrome b,MT-CYB,inhibitor,yes
Atovaquone,2.2 to 3.2 days,"Dihydroorotate dehydrogenase (quinone), mitochondrial",,inhibitor,yes
Atovaquone,2.2 to 3.2 days,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,inhibitor,unknown
Amiodarone,58 days (range 15-142 days),Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,yes
Amiodarone,58 days (range 15-142 days),Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Amiodarone,58 days (range 15-142 days),Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,inhibitor,unknown
Amiodarone,58 days (range 15-142 days),Voltage-dependent calcium channel subunit alpha-2/delta-2,CACNA2D2,inhibitor,yes
Amiodarone,58 days (range 15-142 days),Thyroid hormone receptor alpha,THRA,,unknown
Amiodarone,58 days (range 15-142 days),Thyroid hormone receptor beta,THRB,,unknown
Amiodarone,58 days (range 15-142 days),Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Diazoxide,28 &plusmn;8.3 hours in normal adults.,ATP-sensitive inward rectifier potassium channel 11,KCNJ11,inducer,yes
Diazoxide,28 &plusmn;8.3 hours in normal adults.,Carbonic anhydrase 1,CA1,inhibitor,yes
Diazoxide,28 &plusmn;8.3 hours in normal adults.,Carbonic anhydrase 2,CA2,inhibitor,yes
Diazoxide,28 &plusmn;8.3 hours in normal adults.,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,other,unknown
Diazoxide,28 &plusmn;8.3 hours in normal adults.,Calcium-activated potassium channel subunit alpha-1,KCNMA1,other,unknown
Diazoxide,28 &plusmn;8.3 hours in normal adults.,Solute carrier family 12 member 3,SLC12A3,unknown,unknown
Gliclazide,10.4 hours. Duration of action is 10-24 hours.,ATP-binding cassette sub-family C member 8,ABCC8,binder,yes
Gliclazide,10.4 hours. Duration of action is 10-24 hours.,Vascular endothelial growth factor A,VEGFA,other/unknown,unknown
Phenacemide,22-25 hours.,Sodium channel protein type 1 subunit alpha,SCN1A,inhibitor,yes
Ambenonium,,Acetylcholinesterase,ACHE,inhibitor,yes
Proflavine,,DNA,,intercalation,yes
Proflavine,,Prothrombin,F2,other/unknown,no
Proflavine,,HTH-type transcriptional regulator QacR,qacR,,unknown
Proflavine,,TetR family transcriptional repressor LfrR,lfrR,,unknown
Tolbutamide,"Approximately 7 hours with interindividual variations ranging from 4-25 hours. Tolbutamide has the shortest duration of action, 6-12 hours, of the antidiabetic sulfonylureas.",ATP-binding cassette sub-family C member 8,ABCC8,inhibitor,yes
Tolbutamide,"Approximately 7 hours with interindividual variations ranging from 4-25 hours. Tolbutamide has the shortest duration of action, 6-12 hours, of the antidiabetic sulfonylureas.",ATP-sensitive inward rectifier potassium channel 1,KCNJ1,inhibitor,unknown
Anisindione,Not Known,Vitamin K-dependent gamma-carboxylase,GGCX,inhibitor,yes
Dutasteride,5 weeks,3-oxo-5-alpha-steroid 4-dehydrogenase 2,SRD5A2,inhibitor,yes
Dutasteride,5 weeks,3-oxo-5-alpha-steroid 4-dehydrogenase 1,SRD5A1,inhibitor,yes
Econazole,,Lanosterol 14-alpha demethylase,ERG11,antagonist,yes
Econazole,,Nuclear receptor subfamily 1 group I member 2,NR1I2,partial agonist,unknown
Bicalutamide,5.9 days,Androgen receptor,AR,antagonist,yes
Rabeprazole,1-2 hours (in plasma),Potassium-transporting ATPase alpha chain 1,ATP4A,inhibitor,yes
Prednicarbate,,Glucocorticoid receptor,NR3C1,agonist,yes
Proguanil,Approximately 20 hours,Dihydrofolate reductase,DHFR,inhibitor,yes
Proguanil,Approximately 20 hours,Bifunctional dihydrofolate reductase-thymidylate synthase,,inhibitor,unknown
Pioglitazone,"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].",Peroxisome proliferator-activated receptor gamma,PPARG,agonist,yes
Pioglitazone,"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].",Peroxisome proliferator-activated receptor delta,PPARD,,unknown
Pioglitazone,"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].",Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Pioglitazone,"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].",Amine oxidase [flavin-containing] B,MAOB,,unknown
Tiludronic acid,"Half-life in healthy subjects is 50 hours following administration of a 400 mg single oral dose. Half-life in pagetic patients is about 150 hours following administration of 400 mg tiludronate a day for 12 days. In patients with renal insufficiency (creatinine clearance between 11 and 18 mL per minute [mL/min]), half-life is 205 hours from plasma after administration of a single, oral dose equivalent to 400 mg tiludronate.",Adenosine triphosphate (ATP),,inhibitor,yes
Tiludronic acid,"Half-life in healthy subjects is 50 hours following administration of a 400 mg single oral dose. Half-life in pagetic patients is about 150 hours following administration of 400 mg tiludronate a day for 12 days. In patients with renal insufficiency (creatinine clearance between 11 and 18 mL per minute [mL/min]), half-life is 205 hours from plasma after administration of a single, oral dose equivalent to 400 mg tiludronate.",Hydroxylapatite,,antagonist,yes
Tiludronic acid,"Half-life in healthy subjects is 50 hours following administration of a 400 mg single oral dose. Half-life in pagetic patients is about 150 hours following administration of 400 mg tiludronate a day for 12 days. In patients with renal insufficiency (creatinine clearance between 11 and 18 mL per minute [mL/min]), half-life is 205 hours from plasma after administration of a single, oral dose equivalent to 400 mg tiludronate.",V-type proton ATPase catalytic subunit A,ATP6V1A,inhibitor,unknown
Tiludronic acid,"Half-life in healthy subjects is 50 hours following administration of a 400 mg single oral dose. Half-life in pagetic patients is about 150 hours following administration of 400 mg tiludronate a day for 12 days. In patients with renal insufficiency (creatinine clearance between 11 and 18 mL per minute [mL/min]), half-life is 205 hours from plasma after administration of a single, oral dose equivalent to 400 mg tiludronate.",Tyrosine-protein phosphatase non-receptor type 1,PTPN1,inhibitor,unknown
Desoxycorticosterone Pivalate,,Mineralocorticoid receptor,NR3C2,agonist,yes
Doxacurium chloride,99 minutes in normal healthy adults.,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,antagonist,yes
Doxacurium chloride,99 minutes in normal healthy adults.,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Carvedilol,7-10 hours,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Carvedilol,7-10 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Carvedilol,7-10 hours,NADH dehydrogenase [ubiquinone] 1 subunit C2,NDUFC2,inhibitor,unknown
Carvedilol,7-10 hours,Beta-2 adrenergic receptor,ADRB2,antagonist,unknown
Carvedilol,7-10 hours,Vascular endothelial growth factor A,VEGFA,other,unknown
Carvedilol,7-10 hours,Natriuretic peptides B,NPPB,other,unknown
Carvedilol,7-10 hours,Gap junction alpha-1 protein,GJA1,other,unknown
Carvedilol,7-10 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Carvedilol,7-10 hours,Vascular cell adhesion protein 1,VCAM1,inhibitor,unknown
Carvedilol,7-10 hours,Alpha-1D adrenergic receptor,ADRA1D,antagonist,unknown
Carvedilol,7-10 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Carvedilol,7-10 hours,Alpha-2C adrenergic receptor,ADRA2C,antagonist,unknown
Carvedilol,7-10 hours,Alpha-2B adrenergic receptor,ADRA2B,antagonist,unknown
Carvedilol,7-10 hours,Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Carvedilol,7-10 hours,E-selectin,SELE,inhibitor,unknown
Carvedilol,7-10 hours,Hypoxia-inducible factor 1-alpha,HIF1A,modulator,unknown
Carvedilol,7-10 hours,Inward rectifier potassium channel 4,KCNJ4,,unknown
Levofloxacin,6-8 hours,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Levofloxacin,6-8 hours,DNA gyrase subunit A,gyrA,inhibitor,yes
Levofloxacin,6-8 hours,DNA topoisomerase 2-alpha,TOP2A,inhibitor,yes
Sulfinpyrazone,Approximately 4-6 hours,Canalicular multispecific organic anion transporter 1,ABCC2,inhibitor,yes
Sulfinpyrazone,Approximately 4-6 hours,Multidrug resistance-associated protein 1,ABCC1,inhibitor,yes
Sulfinpyrazone,Approximately 4-6 hours,Solute carrier family 22 member 12,SLC22A12,inhibitor,yes
Sulfinpyrazone,Approximately 4-6 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,activator,unknown
Cefapirin,,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Cefadroxil,1.5 hours,Penicillin-binding protein 3,pbp3,inhibitor,yes
Cefadroxil,1.5 hours,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Cefadroxil,1.5 hours,Penicillin-binding protein 1b,pbp1b,inhibitor,yes
Cefadroxil,1.5 hours,Penicillin-binding protein 2B,penA,inhibitor,yes
Micafungin,14-17 hours,"1,3-beta-glucan synthase component FKS1",fksA,inhibitor,yes
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Histamine H1 receptor,HRH1,antagonist,yes
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Histamine H2 receptor,HRH2,antagonist,yes
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",5-hydroxytryptamine receptor 2B,HTR2B,antagonist,yes
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",5-hydroxytryptamine receptor 2C,HTR2C,antagonist,yes
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Muscarinic acetylcholine receptor M4,CHRM4,antagonist,yes
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Muscarinic acetylcholine receptor M5,CHRM5,antagonist,yes
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Alpha-1D adrenergic receptor,ADRA1D,antagonist,unknown
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",5-hydroxytryptamine receptor 1A,HTR1A,antagonist,yes
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Alpha-2B adrenergic receptor,ADRA2B,antagonist,unknown
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Alpha-2C adrenergic receptor,ADRA2C,antagonist,unknown
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",D(2) dopamine receptor,DRD2,antagonist,unknown
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",5-hydroxytryptamine receptor 6,HTR6,binder,unknown
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Histamine H4 receptor,HRH4,binder,unknown
Doxepin,"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].",Potassium voltage-gated channel subfamily H member 2,KCNH2,,unknown
Amifostine,8 minutes,"Alkaline phosphatase, placental-like",ALPPL2,inducer,yes
Amifostine,8 minutes,Ectonucleotide pyrophosphatase/phosphodiesterase family member 1,ENPP1,inducer,unknown
Diclofenamide,,Carbonic anhydrase 1,CA1,inhibitor,yes
Diclofenamide,,Carbonic anhydrase 2,CA2,inhibitor,yes
Diclofenamide,,Carbonic anhydrase 4,CA4,inhibitor,yes
Diclofenamide,,Carbonic anhydrase 7,CA7,inhibitor,yes
Diclofenamide,,Carbonic anhydrase 3,CA3,inhibitor,unknown
Sulfoxone,3-8 hours,Dihydropteroate synthetase,,inhibitor,yes
Diphenylpyraline,,Histamine H1 receptor,HRH1,antagonist,yes
Diphenylpyraline,,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,unknown
Cloxacillin,,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Cloxacillin,,Beta-lactamase,ampC,inducer,unknown
Cloxacillin,,Penicillin-binding protein 2a,pbp2a,inhibitor,yes
Cloxacillin,,Penicillin-binding protein 2B,penA,inhibitor,yes
Cloxacillin,,Penicillin-binding protein 3,pbpB,inhibitor,yes
Cloxacillin,,D-alanyl-D-alanine carboxypeptidase DacA,dacA,inhibitor,unknown
Flavoxate,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Flavoxate,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Nefazodone,2-4 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Nefazodone,2-4 hours,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,yes
Nefazodone,2-4 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Nefazodone,2-4 hours,5-hydroxytryptamine receptor 1A,HTR1A,antagonist,yes
Nefazodone,2-4 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Nefazodone,2-4 hours,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,unknown
Nefazodone,2-4 hours,Alpha-1B adrenergic receptor,ADRA1B,other/unknown,unknown
Nefazodone,2-4 hours,Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Nefazodone,2-4 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,no
Nefazodone,2-4 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,antagonist,unknown
Cefprozil,1.3 hours,Penicillin-binding protein 1A,ponA,inhibitor,yes
Cefprozil,1.3 hours,Penicillin-binding protein 2x,pbpX,inhibitor,yes
Cefprozil,1.3 hours,Penicillin-binding protein 2B,penA,inhibitor,yes
Desipramine,7-60+ hours; 70% eliminated renally,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Desipramine,7-60+ hours; 70% eliminated renally,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Desipramine,7-60+ hours; 70% eliminated renally,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Desipramine,7-60+ hours; 70% eliminated renally,Beta-2 adrenergic receptor,ADRB2,antagonist,unknown
Desipramine,7-60+ hours; 70% eliminated renally,Beta-1 adrenergic receptor,ADRB1,other,unknown
Desipramine,7-60+ hours; 70% eliminated renally,Sphingomyelin phosphodiesterase,SMPD1,inhibitor,unknown
Desipramine,7-60+ hours; 70% eliminated renally,Histamine H1 receptor,HRH1,antagonist,no
Desipramine,7-60+ hours; 70% eliminated renally,Alpha-1 adrenergic receptors,ADRA1AADRA1BADRA1D,antagonist,no
Desipramine,7-60+ hours; 70% eliminated renally,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,no
Desipramine,7-60+ hours; 70% eliminated renally,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,no
Desipramine,7-60+ hours; 70% eliminated renally,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,no
Desipramine,7-60+ hours; 70% eliminated renally,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,no
Desipramine,7-60+ hours; 70% eliminated renally,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,no
Desipramine,7-60+ hours; 70% eliminated renally,5-hydroxytryptamine receptor 1A,HTR1A,binder,unknown
Desipramine,7-60+ hours; 70% eliminated renally,5-hydroxytryptamine receptor 2C,HTR2C,binder,unknown
Desipramine,7-60+ hours; 70% eliminated renally,D(2) dopamine receptor,DRD2,binder,unknown
Desipramine,7-60+ hours; 70% eliminated renally,Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,binder,unknown
Candicidin,,Ergosterol,,antagonist,yes
Sertaconazole,,Lanosterol 14-alpha demethylase,ERG11,inhibitor,yes
Thiamylal,"Although no studies have been performed on humans, the half-life in cats is 14.3 hours.",Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,agonist,yes
Thiamylal,"Although no studies have been performed on humans, the half-life in cats is 14.3 hours.",ATP-sensitive inward rectifier potassium channel 8,KCNJ8,inhibitor,yes
Thiamylal,"Although no studies have been performed on humans, the half-life in cats is 14.3 hours.",ATP-sensitive inward rectifier potassium channel 11,KCNJ11,inhibitor,yes
Gemifloxacin,7 (&plusmn; 2) hours,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Gemifloxacin,7 (&plusmn; 2) hours,DNA gyrase subunit A,gyrA,inhibitor,yes
Bupropion,24 hours,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,yes
Bupropion,24 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Bupropion,24 hours,Neuronal acetylcholine receptor subunit alpha-3,CHRNA3,antagonist,unknown
Trimetrexate,11 to 20 hours,Dihydrofolate reductase,DHFR,inhibitor,yes
Bretylium,"The terminal half-life in four normal volunteers averaged 7.8&plusmn;0.6 hours (range 6.9-8.1). During hemodialysis, this patient's arterial and venous bretylium concentrations declined rapidly, resulting in a half-life of 13 hours.",Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,inhibitor,yes
Halothane,,Potassium channel subfamily K member 3,KCNK3,binder,yes
Halothane,,Potassium channel subfamily K member 9,KCNK9,binder,yes
Halothane,,Calcium-activated potassium channel subunit alpha-1,KCNMA1,inhibitor,unknown
Halothane,,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,antagonist,unknown
Halothane,,"Glutamate receptor ionotropic, NMDA 3B",GRIN3B,antagonist,unknown
Halothane,,"Glutamate receptor ionotropic, NMDA 2A",GRIN2A,antagonist,unknown
Halothane,,Glycine receptor subunit alpha-1,GLRA1,allosteric modulator,unknown
Halothane,,Rhodopsin,RHO,other,unknown
Halothane,,G protein-activated inward rectifier potassium channel 2,KCNJ6,inhibitor,unknown
Halothane,,G protein-activated inward rectifier potassium channel 1,KCNJ3,inhibitor,unknown
Halothane,,NADH-ubiquinone oxidoreductase chain 1,MT-ND1,inhibitor,unknown
Halothane,,Intermediate conductance calcium-activated potassium channel protein 4,KCNN4,inhibitor,unknown
Halothane,,"ATP synthase subunit delta, mitochondrial",ATP5D,other/unknown,unknown
Halothane,,Calcium-transporting ATPase type 2C member 1,ATP2C1,other/unknown,unknown
Halothane,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,other/unknown,unknown
Halothane,,Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2,GNG2,other/unknown,unknown
Halothane,,Neuropeptide S receptor,NPSR1,other/unknown,unknown
Halothane,,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Dinoprost Tromethamine,The half-life of dinoprost in amniotic fluid is 3 to 6 hours. The plasma half-life of dinoprost after intravenous administration is reported to be less than 1 minute.,Prostaglandin F2-alpha receptor,PTGFR,agonist,yes
Dinoprost Tromethamine,The half-life of dinoprost in amniotic fluid is 3 to 6 hours. The plasma half-life of dinoprost after intravenous administration is reported to be less than 1 minute.,Prostacyclin receptor,PTGIR,antagonist,unknown
Chloroprocaine,21 +/- 2 seconds,Sodium channel protein type 10 subunit alpha,SCN10A,inhibitor,yes
Chloroprocaine,21 +/- 2 seconds,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,antagonist,unknown
Chloroprocaine,21 +/- 2 seconds,Neuronal acetylcholine receptor subunit alpha-10,CHRNA10,antagonist,unknown
Chloroprocaine,21 +/- 2 seconds,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,unknown
Chloroprocaine,21 +/- 2 seconds,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,unknown
Terazosin,12 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Terazosin,12 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,yes
Terazosin,12 hours,Alpha-1D adrenergic receptor,ADRA1D,antagonist,yes
Terazosin,12 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Terazosin,12 hours,Potassium voltage-gated channel subfamily H member 6,KCNH6,inhibitor,unknown
Terazosin,12 hours,Potassium voltage-gated channel subfamily H member 7,KCNH7,inhibitor,unknown
Amdinocillin,Approximately 1 hour in patients with normal renal function. Increases to 3 to 6 hours in anephric patients.,Penicillin-binding protein 2a,pbp2a,inhibitor,yes
Amdinocillin,Approximately 1 hour in patients with normal renal function. Increases to 3 to 6 hours in anephric patients.,Penicillin-binding protein 2,mrdA,inhibitor,yes
Amdinocillin,Approximately 1 hour in patients with normal renal function. Increases to 3 to 6 hours in anephric patients.,Penicillin-binding protein 3,pbp3,inhibitor,yes
Amdinocillin,Approximately 1 hour in patients with normal renal function. Increases to 3 to 6 hours in anephric patients.,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Amdinocillin,Approximately 1 hour in patients with normal renal function. Increases to 3 to 6 hours in anephric patients.,Penicillin-binding protein 2B,penA,inhibitor,yes
Amdinocillin,Approximately 1 hour in patients with normal renal function. Increases to 3 to 6 hours in anephric patients.,Penicillin-binding protein 1b,pbp1b,inhibitor,yes
Calcium Chloride,,Protein S100-A13,S100A13,,unknown
Ofloxacin,9 hours,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Ofloxacin,9 hours,DNA gyrase subunit A,gyrA,inhibitor,yes
Ofloxacin,9 hours,DNA topoisomerase 2-alpha,TOP2A,inhibitor,unknown
Cilostazol,11-13 hours.,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,inhibitor,yes
Itraconazole,21 hours,Lanosterol 14-alpha demethylase,CYP51A1,inhibitor,yes
Itraconazole,21 hours,Lanosterol 14-alpha demethylase,ERG11,inhibitor,yes
Procarbazine,10 minutes,DNA,,cross-linking/alkylation,yes
Procarbazine,10 minutes,Monoamine oxidase,MAOAMAOB,inhibitor,yes
Arsenic trioxide,,Inhibitor of nuclear factor kappa-B kinase subunit beta,IKBKB,inducer,yes
Arsenic trioxide,,"Thioredoxin reductase 1, cytoplasmic",TXNRD1,inhibitor,yes
Arsenic trioxide,,Transcription factor AP-1,JUN,inducer,yes
Arsenic trioxide,,G1/S-specific cyclin-D1,CCND1,antagonist,yes
Arsenic trioxide,,Mitogen-activated protein kinase 3,MAPK3,inducer,yes
Arsenic trioxide,,Mitogen-activated protein kinase 1,MAPK1,inducer,yes
Arsenic trioxide,,RAC-alpha serine/threonine-protein kinase,AKT1,inducer,unknown
Arsenic trioxide,,Cyclin-dependent kinase inhibitor 1,CDKN1A,,unknown
Arsenic trioxide,,Histone deacetylase 1,HDAC1,,unknown
Arsenic trioxide,,Protein PML,PML,,unknown
Guanethidine,1.5 days,Sodium-dependent noradrenaline transporter,SLC6A2,inducer,yes
Moclobemide,1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted,Amine oxidase [flavin-containing] A,MAOA,antagonistinhibitor,yes
Moclobemide,1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted,Monoamine oxidase,MAOAMAOB,antagonist,unknown
Moclobemide,1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted,Amine oxidase [flavin-containing] B,MAOB,antagonist,unknown
Kanamycin,2.5 hours,30S ribosomal protein S12,rpsL,inhibitor,yes
Kanamycin,2.5 hours,16S rRNA,,inhibitor,yes
Orphenadrine,13-20 hours,"Glutamate receptor ionotropic, NMDA 2D",GRIN2D,antagonist,yes
Orphenadrine,13-20 hours,"Glutamate receptor ionotropic, NMDA 1",GRIN1,antagonist,yes
Orphenadrine,13-20 hours,"Glutamate receptor ionotropic, NMDA 3B",GRIN3B,antagonist,yes
Orphenadrine,13-20 hours,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,antagonist,yes
Orphenadrine,13-20 hours,Histamine H1 receptor,HRH1,antagonist,yes
Orphenadrine,13-20 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Orphenadrine,13-20 hours,Sodium channel protein type 10 subunit alpha,SCN10A,inhibitor,unknown
Phenobarbital,53 to 118 hours (mean 79 hours),Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Phenobarbital,53 to 118 hours (mean 79 hours),Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Phenobarbital,53 to 118 hours (mean 79 hours),Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Phenobarbital,53 to 118 hours (mean 79 hours),Glutamate receptor 2,GRIA2,antagonist,unknown
Phenobarbital,53 to 118 hours (mean 79 hours),"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Phenobarbital,53 to 118 hours (mean 79 hours),NMDA receptor,GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B,antagonist,unknown
Phenobarbital,53 to 118 hours (mean 79 hours),Nuclear receptor subfamily 1 group I member 2,NR1I2,activator,unknown
Escitalopram,27-32 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Escitalopram,27-32 hours,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,unknown
Escitalopram,27-32 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,unknown
Escitalopram,27-32 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Escitalopram,27-32 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Escitalopram,27-32 hours,Histamine H1 receptor,HRH1,antagonist,unknown
Cyclizine,20 hours,Histamine H1 receptor,HRH1,antagonist,yes
Cyclizine,20 hours,Estrogen sulfotransferase,SULT1E1,inhibitor,unknown
Idarubicin,22 hours,DNA,,intercalation,yes
Idarubicin,22 hours,DNA topoisomerase 2-alpha,TOP2A,inhibitor,yes
Chlormezanone,,Translocator protein,TSPO,agonist,yes
Podofilox,1.0 to 4.5 hours.,DNA topoisomerase 2-alpha,TOP2A,inhibitor,yes
Podofilox,1.0 to 4.5 hours.,Tubulin alpha-4A chain,TUBA4A,inhibitor,yes
Podofilox,1.0 to 4.5 hours.,Tubulin beta chain,TUBB,inhibitor,yes
Rescinnamine,,Angiotensin-converting enzyme,ACE,inhibitor,yes
Ifosfamide,7-15 hours. The elimination half-life increase appeared to be related to the increase in ifosfamide volume of distribution with age.,DNA,,other/unknown,yes
Ifosfamide,7-15 hours. The elimination half-life increase appeared to be related to the increase in ifosfamide volume of distribution with age.,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Propafenone,2-10 hours,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Propafenone,2-10 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,yes
Propafenone,2-10 hours,Beta-1 adrenergic receptor,ADRB1,antagonist,unknown
Propafenone,2-10 hours,Beta-2 adrenergic receptor,ADRB2,antagonist,unknown
Naloxone,"0.4mg IM injection = 1.24 hr
Nasal spray (one 2mg spray) = 1.85 hr
Nasal spray (one 4mg spray) = 2.08 hr",Mu-type opioid receptor,OPRM1,antagonist,yes
Naloxone,"0.4mg IM injection = 1.24 hr
Nasal spray (one 2mg spray) = 1.85 hr
Nasal spray (one 4mg spray) = 2.08 hr",Delta-type opioid receptor,OPRD1,antagonist,yes
Naloxone,"0.4mg IM injection = 1.24 hr
Nasal spray (one 2mg spray) = 1.85 hr
Nasal spray (one 4mg spray) = 2.08 hr",Kappa-type opioid receptor,OPRK1,antagonist,yes
Naloxone,"0.4mg IM injection = 1.24 hr
Nasal spray (one 2mg spray) = 1.85 hr
Nasal spray (one 4mg spray) = 2.08 hr",Cyclic AMP-responsive element-binding protein 1,CREB1,other/unknown,no
Naloxone,"0.4mg IM injection = 1.24 hr
Nasal spray (one 2mg spray) = 1.85 hr
Nasal spray (one 4mg spray) = 2.08 hr",Estrogen receptor alpha,ESR1,antagonistother/unknown,no
Naloxone,"0.4mg IM injection = 1.24 hr
Nasal spray (one 2mg spray) = 1.85 hr
Nasal spray (one 4mg spray) = 2.08 hr",Toll-like receptor 4,TLR4,inhibitor,unknown
Naloxone,"0.4mg IM injection = 1.24 hr
Nasal spray (one 2mg spray) = 1.85 hr
Nasal spray (one 4mg spray) = 2.08 hr",Liver carboxylesterase 1,CES1,,unknown
Domperidone,7 hours,D(2) dopamine receptor,DRD2,antagonist,yes
Domperidone,7 hours,D(3) dopamine receptor,DRD3,antagonist,yes
Fluoxymesterone,9.2 hours,Androgen receptor,AR,agonist,yes
Fluoxymesterone,9.2 hours,Estrogen receptor alpha,ESR1,antagonist,yes
Fluoxymesterone,9.2 hours,Prolactin receptor,PRLR,antagonist,yes
Fluoxymesterone,9.2 hours,Glucocorticoid receptor,NR3C1,antagonist,unknown
Fluoxymesterone,9.2 hours,Corticosteroid 11-beta-dehydrogenase isozyme 2,HSD11B2,inhibitor,unknown
Pergolide,27 hours,D(2) dopamine receptor,DRD2,agonist,yes
Pergolide,27 hours,D(3) dopamine receptor,DRD3,agonist,yes
Pergolide,27 hours,D(4) dopamine receptor,DRD4,agonist,unknown
Pergolide,27 hours,5-hydroxytryptamine receptor 1A,HTR1A,agonist,unknown
Pergolide,27 hours,5-hydroxytryptamine receptor 2B,HTR2B,agonist,unknown
Pergolide,27 hours,5-hydroxytryptamine receptor 2A,HTR2A,agonist,unknown
Pergolide,27 hours,5-hydroxytryptamine receptor 1D,HTR1D,agonist,unknown
Pergolide,27 hours,Alpha-2B adrenergic receptor,ADRA2B,agonist,unknown
Pergolide,27 hours,Alpha-2A adrenergic receptor,ADRA2A,agonist,unknown
Pergolide,27 hours,Alpha-2C adrenergic receptor,ADRA2C,agonist,unknown
Pergolide,27 hours,D(1B) dopamine receptor,DRD5,agonist,unknown
Pergolide,27 hours,D(1A) dopamine receptor,DRD1,agonist,unknown
Pergolide,27 hours,5-hydroxytryptamine receptor 1B,HTR1B,agonist,unknown
Pergolide,27 hours,5-hydroxytryptamine receptor 2C,HTR2C,agonist,unknown
Pergolide,27 hours,Alpha-1A adrenergic receptor,ADRA1A,agonist,unknown
Pergolide,27 hours,Alpha-1B adrenergic receptor,ADRA1B,agonist,unknown
Pergolide,27 hours,Alpha-1D adrenergic receptor,ADRA1D,agonist,unknown
Ciclopirox,1.7 hours for 1% topical solution.,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,binder,yes
Desflurane,,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Desflurane,,Glycine receptor subunit alpha-1,GLRA1,agonist,yes
Desflurane,,Glutamate receptor 1,GRIA1,antagonist,yes
Desflurane,,Potassium voltage-gated channel subfamily A member 1,KCNA1,inducer,yes
Desflurane,,Calcium-transporting ATPase type 2C member 1,ATP2C1,inhibitor,yes
Desflurane,,"ATP synthase subunit delta, mitochondrial",ATP5D,other/unknown,unknown
Desflurane,,NADH-ubiquinone oxidoreductase chain 1,MT-ND1,unknown,unknown
Clindamycin,2.4 hours,50S ribosomal protein L10,rplJ,inhibitor,yes
Clindamycin,2.4 hours,23S rRNA,,inhibitor,yes
Dexfenfluramine,17-20 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Dexfenfluramine,17-20 hours,5-hydroxytryptamine receptor 2C,HTR2C,agonist,unknown
Oxymorphone,1.3 (+/-0.7) hours,Mu-type opioid receptor,OPRM1,agonist,yes
Oxymorphone,1.3 (+/-0.7) hours,Delta-type opioid receptor,OPRD1,antagonist,unknown
Acebutolol,"The plasma elimination half-life is approximately 3 to 4 hours. The half-life of its metabolite, diacetolol, is 8 to 13 hours.",Beta-1 adrenergic receptor,ADRB1,partial agonist,yes
Acebutolol,"The plasma elimination half-life is approximately 3 to 4 hours. The half-life of its metabolite, diacetolol, is 8 to 13 hours.",Beta-2 adrenergic receptor,ADRB2,partial agonist,unknown
Brinzolamide,111 days,Carbonic anhydrase 2,CA2,inhibitor,yes
Brinzolamide,111 days,Carbonic anhydrase 1,CA1,inhibitor,unknown
Brinzolamide,111 days,Carbonic anhydrase 4,CA4,inhibitor,unknown
Brinzolamide,111 days,"Carbonic anhydrase 5A, mitochondrial",CA5A,inhibitor,unknown
Brinzolamide,111 days,Carbonic anhydrase 3,CA3,inhibitor,unknown
Flecainide,20 hours (range 12-27 hours),Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Flecainide,20 hours (range 12-27 hours),Sodium channel protein type 4 subunit alpha,SCN4A,inhibitor,yes
Flecainide,20 hours (range 12-27 hours),Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Estramustine,20 hours,Microtubule-associated protein 2,MAP2,antagonist,yes
Estramustine,20 hours,Microtubule-associated protein 1A,MAP1A,antagonist,yes
Estramustine,20 hours,Estrogen receptor alpha,ESR1,agonist,yes
Estramustine,20 hours,Estrogen receptor beta,ESR2,other/unknown,yes
Captopril,2 hours,Angiotensin-converting enzyme,ACE,inhibitor,yes
Captopril,2 hours,72 kDa type IV collagenase,MMP2,inhibitor,unknown
Captopril,2 hours,Matrix metalloproteinase-9,MMP9,inhibitor,unknown
Captopril,2 hours,Leukotriene A-4 hydrolase,LTA4H,,unknown
Captopril,2 hours,B1 bradykinin receptor,BDKRB1,,unknown
Zopiclone,Elimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Zopiclone,Elimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Zopiclone,Elimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Zopiclone,Elimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Zopiclone,Elimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.,Translocator protein,TSPO,agonist,unknown
Tubocurarine,1-2 hours,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,antagonist,yes
Tubocurarine,1-2 hours,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,yes
Tubocurarine,1-2 hours,Acetylcholinesterase,ACHE,inhibitor,unknown
Tubocurarine,1-2 hours,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,,unknown
Bromocriptine,2-8 hours,D(2) dopamine receptor,DRD2,agonist,yes
Bromocriptine,2-8 hours,D(3) dopamine receptor,DRD3,agonist,yes
Bromocriptine,2-8 hours,5-hydroxytryptamine receptor 1D,HTR1D,agonist,unknown
Bromocriptine,2-8 hours,Alpha-2A adrenergic receptor,ADRA2A,agonist,unknown
Bromocriptine,2-8 hours,5-hydroxytryptamine receptor 1A,HTR1A,agonist,unknown
Bromocriptine,2-8 hours,Alpha-2C adrenergic receptor,ADRA2C,agonist,unknown
Bromocriptine,2-8 hours,Alpha-2B adrenergic receptor,ADRA2B,agonist,unknown
Bromocriptine,2-8 hours,5-hydroxytryptamine receptor 2B,HTR2B,agonist,unknown
Bromocriptine,2-8 hours,D(4) dopamine receptor,DRD4,antagonist,unknown
Bromocriptine,2-8 hours,5-hydroxytryptamine receptor 2A,HTR2A,agonist,unknown
Bromocriptine,2-8 hours,5-hydroxytryptamine receptor 1B,HTR1B,agonist,unknown
Bromocriptine,2-8 hours,5-hydroxytryptamine receptor 2C,HTR2C,agonist,unknown
Bromocriptine,2-8 hours,D(1B) dopamine receptor,DRD5,agonist,unknown
Bromocriptine,2-8 hours,D(1A) dopamine receptor,DRD1,agonist,unknown
Bromocriptine,2-8 hours,Alpha-1A adrenergic receptor,ADRA1A,agonist,unknown
Bromocriptine,2-8 hours,Alpha-1B adrenergic receptor,ADRA1B,agonist,unknown
Bromocriptine,2-8 hours,Alpha-1D adrenergic receptor,ADRA1D,agonist,unknown
Bromocriptine,2-8 hours,5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Rifapentine,,DNA-directed RNA polymerase subunit beta',rpoC,inhibitor,yes
Levetiracetam,6-8 hours,Synaptic vesicle glycoprotein 2A,SV2A,agonist,yes
Levetiracetam,6-8 hours,Voltage-dependent N-type calcium channel subunit alpha-1B,CACNA1B,inhibitor,yes
Nadolol,14-24 hours,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Nadolol,14-24 hours,Beta-2 adrenergic receptor,ADRB2,antagonist,unknown
Mitoxantrone,75 hours,DNA,,intercalation,yes
Mitoxantrone,75 hours,DNA topoisomerase 2-alpha,TOP2A,inhibitor,yes
Flumazenil,"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).",Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,antagonist,yes
Flumazenil,"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).",Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,antagonist,yes
Flumazenil,"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).",Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,antagonist,yes
Flumazenil,"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).",GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Lomustine,"Approximately 94 minutes, however the metabolites have a serum half-life of 16 to 48 hours.",DNA,,cross-linking/alkylation,yes
Lomustine,"Approximately 94 minutes, however the metabolites have a serum half-life of 16 to 48 hours.",Stathmin-4,STMN4,antagonist,unknown
Ridogrel,,Thromboxane A2 receptor,TBXA2R,antagonist,yes
Ridogrel,,Thromboxane-A synthase,TBXAS1,inhibitor,yes
Sparfloxacin,Mean terminal elimination half-life of 20 hours (range 16-30 hours). Prolonged in patients with renal impairment (creatinine clearance &lt;50 mL/min).,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Sparfloxacin,Mean terminal elimination half-life of 20 hours (range 16-30 hours). Prolonged in patients with renal impairment (creatinine clearance &lt;50 mL/min).,DNA gyrase subunit A,gyrA,inhibitor,yes
Sparfloxacin,Mean terminal elimination half-life of 20 hours (range 16-30 hours). Prolonged in patients with renal impairment (creatinine clearance &lt;50 mL/min).,DNA topoisomerase 2-alpha,TOP2A,inhibitor,yes
Dezocine,"Elimination half-life following intramuscular administration averages 2.2 hours. Elimination half-life following a 5mg intravenous dose averages 1.7 to 2.6 hours (range 0.6 to 4.4 hours) while a 10mg dose averages 2.4 to 2.6 hours (range 1.2 to 7.4 hours). In patients with hepatic cirrhosis, the half-life is increased by 30 to 50%.",Mu-type opioid receptor,OPRM1,agonist,yes
Dezocine,"Elimination half-life following intramuscular administration averages 2.2 hours. Elimination half-life following a 5mg intravenous dose averages 1.7 to 2.6 hours (range 0.6 to 4.4 hours) while a 10mg dose averages 2.4 to 2.6 hours (range 1.2 to 7.4 hours). In patients with hepatic cirrhosis, the half-life is increased by 30 to 50%.",Kappa-type opioid receptor,OPRK1,antagonist,yes
Levobunolol,20 hours,Beta-2 adrenergic receptor,ADRB2,antagonist,yes
Levobunolol,20 hours,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Clarithromycin,3-4 hours,50S ribosomal protein L10,rplJ,inhibitor,yes
Clarithromycin,3-4 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,,unknown
Clarithromycin,3-4 hours,Solute carrier organic anion transporter family member 1B1,SLCO1B1,,unknown
Clarithromycin,3-4 hours,Solute carrier organic anion transporter family member 1B3,SLCO1B3,,unknown
Ceftriaxone,5.8-8.7 hours,Penicillin-binding protein 2B,penA,inhibitor,yes
Ceftriaxone,5.8-8.7 hours,Solute carrier family 22 member 11,SLC22A11,,unknown
Ceftriaxone,5.8-8.7 hours,Solute carrier family 22 member 6,SLC22A6,,unknown
Ceftriaxone,5.8-8.7 hours,Solute carrier family 22 member 8,SLC22A8,,unknown
Ceftriaxone,5.8-8.7 hours,Solute carrier family 15 member 1,SLC15A1,,unknown
Fomepizole,"The plasma half-life of Antizol varies with dose, even in patients with normal renal function, and has not been calculated.",Alcohol dehydrogenase 1A,ADH1A,inhibitor,yes
Fomepizole,"The plasma half-life of Antizol varies with dose, even in patients with normal renal function, and has not been calculated.",Alcohol dehydrogenase 1B,ADH1B,inhibitor,yes
Fomepizole,"The plasma half-life of Antizol varies with dose, even in patients with normal renal function, and has not been calculated.",Alcohol dehydrogenase 1C,ADH1C,inhibitor,yes
Fomepizole,"The plasma half-life of Antizol varies with dose, even in patients with normal renal function, and has not been calculated.",Catalase,CAT,inhibitor,yes
Metipranolol,,Beta-2 adrenergic receptor,ADRB2,antagonist,yes
Metipranolol,,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,potentiator,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,potentiator,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,Gamma-aminobutyric acid receptor subunit pi,GABRP,potentiator,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,potentiator,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,potentiator,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,Gamma-aminobutyric acid receptor subunit rho-3,GABRR3,potentiator,yes
Estazolam,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Finasteride,4.5 hours (range 3.3-13.4 hours),3-oxo-5-alpha-steroid 4-dehydrogenase 2,SRD5A2,inhibitor,yes
Finasteride,4.5 hours (range 3.3-13.4 hours),3-oxo-5-alpha-steroid 4-dehydrogenase 1,SRD5A1,inhibitor,unknown
Finasteride,4.5 hours (range 3.3-13.4 hours),3-oxo-5-beta-steroid 4-dehydrogenase,AKR1D1,inhibitor,unknown
Anastrozole,50 hours,Cytochrome P450 19A1,CYP19A1,inhibitor,yes
Halofantrine,6-10 days,Fe(II)-protoporphyrin IX,,antagonist,yes
Halofantrine,6-10 days,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,yes
Halofantrine,6-10 days,Plasmepsin-2,,inhibitor,unknown
Dantrolene,"The mean biologic half-life after intravenous administration is variable, between 4 to 8 hours under most experimental conditions, while oral is 8.7 hours for a 100mg dose.",Ryanodine receptor 1,RYR1,antagonist,yes
Rifaximin,Approximately 6 hours.,DNA-directed RNA polymerase subunit beta,rpoB,inhibitor,yes
Rifaximin,Approximately 6 hours.,Nuclear receptor subfamily 1 group I member 2,NR1I2,agonist,no
Ketamine,The reported half-life in preclinical studies for ketamine is 186 min.[A31883],"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,antagonist,yes
Ketamine,The reported half-life in preclinical studies for ketamine is 186 min.[A31883],Substance-P receptor,TACR1,antagonist,unknown
Ketamine,The reported half-life in preclinical studies for ketamine is 186 min.[A31883],D(2) dopamine receptor,DRD2,agonistpartial agonist,unknown
Ketamine,The reported half-life in preclinical studies for ketamine is 186 min.[A31883],Delta-type opioid receptor,OPRD1,binder,unknown
Ketamine,The reported half-life in preclinical studies for ketamine is 186 min.[A31883],Sodium-dependent noradrenaline transporter,SLC6A2,,unknown
Ketamine,The reported half-life in preclinical studies for ketamine is 186 min.[A31883],Kappa-type opioid receptor,OPRK1,agonist,unknown
Ketamine,The reported half-life in preclinical studies for ketamine is 186 min.[A31883],Mu-type opioid receptor,OPRM1,binder,unknown
Ketamine,The reported half-life in preclinical studies for ketamine is 186 min.[A31883],Muscarinic acetylcholine receptor,CHRM1CHRM2CHRM3CHRM4CHRM5,binder,unknown
Ketamine,The reported half-life in preclinical studies for ketamine is 186 min.[A31883],5-hydroxytryptamine receptor 2,HTR2AHTR2BHTR2C,antagonist,unknown
Ketamine,The reported half-life in preclinical studies for ketamine is 186 min.[A31883],5-hydroxytryptamine receptor 1,HTR1AHTR1BHTR1DHTR1EHTR1F,antagonist,unknown
Ketamine,The reported half-life in preclinical studies for ketamine is 186 min.[A31883],5-hydroxytryptamine receptor 3A,HTR3A,potentiator,yes
Ketamine,The reported half-life in preclinical studies for ketamine is 186 min.[A31883],Alpha-7 nicotinic cholinergic receptor subunit,CHRNA7,antagonist,yes
Ketamine,The reported half-life in preclinical studies for ketamine is 186 min.[A31883],Cholinesterase,BCHE,inhibitor,yes
Ketamine,The reported half-life in preclinical studies for ketamine is 186 min.[A31883],"Nitric oxide synthase, brain",NOS1,inhibitor,yes
Budesonide,"Following IV administration of budesonide, the elimination half-life is 2.0 to 3.6 hours. This value does not differ between healthy adults and patients with Crohn’s disease.",Glucocorticoid receptor,NR3C1,antagonist,yes
Aminophylline,7-9 hours,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,inhibitor,yes
Aminophylline,7-9 hours,Adenosine receptor A1,ADORA1,antagonist,yes
Aminophylline,7-9 hours,Adenosine receptor A3,ADORA3,antagonist,yes
Aminophylline,7-9 hours,Histone deacetylase 2,HDAC2,activator,yes
Quetiapine,6 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Quetiapine,6 hours,D(2) dopamine receptor,DRD2,antagonist,yes
Quetiapine,6 hours,5-hydroxytryptamine receptor 1A,HTR1A,antagonist,unknown
Quetiapine,6 hours,5-hydroxytryptamine receptor 1B,HTR1B,other/unknown,unknown
Quetiapine,6 hours,5-hydroxytryptamine receptor 1D,HTR1D,other/unknown,unknown
Quetiapine,6 hours,5-hydroxytryptamine receptor 1E,HTR1E,other/unknown,unknown
Quetiapine,6 hours,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Quetiapine,6 hours,5-hydroxytryptamine receptor 3A,HTR3A,other/unknown,unknown
Quetiapine,6 hours,5-hydroxytryptamine receptor 6,HTR6,other/unknown,unknown
Quetiapine,6 hours,5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Quetiapine,6 hours,D(1A) dopamine receptor,DRD1,antagonist,unknown
Quetiapine,6 hours,D(1B) dopamine receptor,DRD5,antagonist,unknown
Quetiapine,6 hours,D(3) dopamine receptor,DRD3,antagonist,unknown
Quetiapine,6 hours,D(4) dopamine receptor,DRD4,antagonist,unknown
Quetiapine,6 hours,Histamine H1 receptor,HRH1,antagonist,unknown
Quetiapine,6 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Quetiapine,6 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Quetiapine,6 hours,Alpha-1D adrenergic receptor,ADRA1D,antagonist,unknown
Quetiapine,6 hours,Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Quetiapine,6 hours,Alpha-2B adrenergic receptor,ADRA2B,antagonist,unknown
Quetiapine,6 hours,Alpha-2C adrenergic receptor,ADRA2C,antagonist,unknown
Quetiapine,6 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Quetiapine,6 hours,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Quetiapine,6 hours,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Quetiapine,6 hours,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,unknown
Quetiapine,6 hours,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,unknown
Enoxaparin,4.5 hours,Antithrombin-III,SERPINC1,potentiator,yes
Enoxaparin,4.5 hours,Coagulation factor X,F10,inhibitor,yes
Mivacurium,"The mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value.",Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,antagonist,yes
Mivacurium,"The mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value.",Muscarinic acetylcholine receptor M2,CHRM2,antagonistpartial agonist,no
Mivacurium,"The mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value.",Muscarinic acetylcholine receptor M3,CHRM3,antagonist,no
Mivacurium,"The mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value.",Cholinesterase,BCHE,,unknown
Levomethadyl Acetate,2.6 days,Mu-type opioid receptor,OPRM1,agonist,yes
Levomethadyl Acetate,2.6 days,Neuronal acetylcholine receptor subunit beta-4,CHRNB4,other/unknown,unknown
Levomethadyl Acetate,2.6 days,Neuronal acetylcholine receptor subunit alpha-3,CHRNA3,antagonist,unknown
Encainide,1-2 hours,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Paclitaxel,"When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.",Tubulin beta-1 chain,TUBB1,inhibitor,yes
Paclitaxel,"When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.",Apoptosis regulator Bcl-2,BCL2,inhibitor,yes
Paclitaxel,"When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.",Nuclear receptor subfamily 1 group I member 2,NR1I2,inducer,unknown
Paclitaxel,"When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.",Microtubule-associated protein 4,MAP4,,yes
Paclitaxel,"When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.",Microtubule-associated protein 2,MAP2,,yes
Paclitaxel,"When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.",Microtubule-associated protein tau,MAPT,,yes
Diphenidol,4 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Diphenidol,4 hours,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Diphenidol,4 hours,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Saquinavir,,Human immunodeficiency virus type 1 protease,pol,inhibitor,yes
Metoclopramide,5-6 hr,D(2) dopamine receptor,DRD2,antagonist,yes
Metoclopramide,5-6 hr,Muscarinic acetylcholine receptor M1,CHRM1,agonist,yes
Metoclopramide,5-6 hr,5-hydroxytryptamine receptor 4,HTR4,agonist,unknown
Metoclopramide,5-6 hr,5-hydroxytryptamine receptor 3A,HTR3A,agonist,unknown
Metoclopramide,5-6 hr,Acetylcholinesterase,ACHE,inhibitor,unknown
Dexamethasone,36-54 hours,Glucocorticoid receptor,NR3C1,agonist,yes
Dexamethasone,36-54 hours,Nuclear receptor subfamily 0 group B member 1,NR0B1,stimulator,unknown
Dexamethasone,36-54 hours,Annexin A1,ANXA1,agonist,unknown
Dexamethasone,36-54 hours,"Nitric oxide synthase, inducible",NOS2,negative modulator,unknown
Dexamethasone,36-54 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Levodopa,50 to 90 minutes,D(1A) dopamine receptor,DRD1,agonist,yes
Levodopa,50 to 90 minutes,D(1B) dopamine receptor,DRD5,agonist,yes
Levodopa,50 to 90 minutes,D(2) dopamine receptor,DRD2,agonist,yes
Levodopa,50 to 90 minutes,D(3) dopamine receptor,DRD3,agonist,yes
Levodopa,50 to 90 minutes,D(4) dopamine receptor,DRD4,agonist,yes
Sevoflurane,15-23 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,agonist,yes
Sevoflurane,15-23 hours,Glycine receptor subunit alpha-1,GLRA1,agonist,yes
Sevoflurane,15-23 hours,Glutamate receptor 1,GRIA1,antagonist,yes
Sevoflurane,15-23 hours,Potassium voltage-gated channel subfamily A member 1,KCNA1,inducer,yes
Sevoflurane,15-23 hours,Calcium-transporting ATPase type 2C member 1,ATP2C1,inhibitor,yes
Sevoflurane,15-23 hours,"ATP synthase subunit delta, mitochondrial",ATP5D,other/unknown,unknown
Sevoflurane,15-23 hours,NADH-ubiquinone oxidoreductase chain 1,MT-ND1,unknown,unknown
Sevoflurane,15-23 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Bromodiphenhydramine,1 to 4 hours,Histamine H1 receptor,HRH1,antagonist,yes
Aripiprazole,75-146 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Aripiprazole,75-146 hours,D(2) dopamine receptor,DRD2,antagonistpartial agonist,yes
Aripiprazole,75-146 hours,5-hydroxytryptamine receptor 1A,HTR1A,antagonistpartial agonist,unknown
Aripiprazole,75-146 hours,5-hydroxytryptamine receptor 1B,HTR1B,antagonist,unknown
Aripiprazole,75-146 hours,5-hydroxytryptamine receptor 1D,HTR1D,antagonist,unknown
Aripiprazole,75-146 hours,5-hydroxytryptamine receptor 1E,HTR1E,antagonist,unknown
Aripiprazole,75-146 hours,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Aripiprazole,75-146 hours,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,unknown
Aripiprazole,75-146 hours,5-hydroxytryptamine receptor 6,HTR6,antagonist,unknown
Aripiprazole,75-146 hours,5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Aripiprazole,75-146 hours,D(1A) dopamine receptor,DRD1,antagonistpartial agonist,unknown
Aripiprazole,75-146 hours,D(1B) dopamine receptor,DRD5,antagonistpartial agonist,unknown
Aripiprazole,75-146 hours,D(3) dopamine receptor,DRD3,antagonistpartial agonist,unknown
Aripiprazole,75-146 hours,D(4) dopamine receptor,DRD4,antagonistpartial agonist,unknown
Aripiprazole,75-146 hours,Histamine H1 receptor,HRH1,antagonist,no
Aripiprazole,75-146 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,no
Aripiprazole,75-146 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,no
Aripiprazole,75-146 hours,Alpha-2A adrenergic receptor,ADRA2A,antagonist,no
Aripiprazole,75-146 hours,Alpha-2B adrenergic receptor,ADRA2B,antagonist,no
Aripiprazole,75-146 hours,Alpha-2C adrenergic receptor,ADRA2C,antagonistother/unknown,no
Aripiprazole,75-146 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,no
Aripiprazole,75-146 hours,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,no
Aripiprazole,75-146 hours,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,no
Aripiprazole,75-146 hours,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,no
Aripiprazole,75-146 hours,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,no
Chlorprothixene,8 to 12 hours,D(2) dopamine receptor,DRD2,antagonist,yes
Chlorprothixene,8 to 12 hours,D(1A) dopamine receptor,DRD1,antagonist,yes
Chlorprothixene,8 to 12 hours,D(3) dopamine receptor,DRD3,antagonist,yes
Chlorprothixene,8 to 12 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Chlorprothixene,8 to 12 hours,5-hydroxytryptamine receptor 2B,HTR2B,antagonist,yes
Chlorprothixene,8 to 12 hours,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,yes
Chlorprothixene,8 to 12 hours,Histamine H1 receptor,HRH1,antagonist,unknown
Chlorprothixene,8 to 12 hours,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,no
Chlorprothixene,8 to 12 hours,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,no
Chlorprothixene,8 to 12 hours,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,no
Chlorprothixene,8 to 12 hours,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,no
Chlorprothixene,8 to 12 hours,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,no
Epoprostenol,The in vitro half-life of epoprostenol in human blood at 37&deg;C and pH 7.4 is approximately 6 minutes; the in vivo half-life of epoprostenol in humans is therefore expected to be no greater than 6 minutes.,P2Y purinoceptor 12,P2RY12,agonist,yes
Epoprostenol,The in vitro half-life of epoprostenol in human blood at 37&deg;C and pH 7.4 is approximately 6 minutes; the in vivo half-life of epoprostenol in humans is therefore expected to be no greater than 6 minutes.,Prostacyclin receptor,PTGIR,agonist,yes
Epoprostenol,The in vitro half-life of epoprostenol in human blood at 37&deg;C and pH 7.4 is approximately 6 minutes; the in vivo half-life of epoprostenol in humans is therefore expected to be no greater than 6 minutes.,Prostacyclin synthase,PTGIS,inducer,yes
Gemfibrozil,1.5 hours,Peroxisome proliferator-activated receptor alpha,PPARA,agonist,yes
Clomipramine,"Following oral administration of a single 150 mg dose of clomipramine, the average elimination half-life of clomipramine was 32 hours (range: 19-37 hours) and of desmethylclomipramine was 69 hours (range: 54-77 hours). Elimination half-life may vary substantially with different doses due to saturable kinetics (i.e. metabolism).",Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Clomipramine,"Following oral administration of a single 150 mg dose of clomipramine, the average elimination half-life of clomipramine was 32 hours (range: 19-37 hours) and of desmethylclomipramine was 69 hours (range: 54-77 hours). Elimination half-life may vary substantially with different doses due to saturable kinetics (i.e. metabolism).",5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Clomipramine,"Following oral administration of a single 150 mg dose of clomipramine, the average elimination half-life of clomipramine was 32 hours (range: 19-37 hours) and of desmethylclomipramine was 69 hours (range: 54-77 hours). Elimination half-life may vary substantially with different doses due to saturable kinetics (i.e. metabolism).",5-hydroxytryptamine receptor 2B,HTR2B,antagonist,yes
Clomipramine,"Following oral administration of a single 150 mg dose of clomipramine, the average elimination half-life of clomipramine was 32 hours (range: 19-37 hours) and of desmethylclomipramine was 69 hours (range: 54-77 hours). Elimination half-life may vary substantially with different doses due to saturable kinetics (i.e. metabolism).",5-hydroxytryptamine receptor 2C,HTR2C,antagonist,yes
Clomipramine,"Following oral administration of a single 150 mg dose of clomipramine, the average elimination half-life of clomipramine was 32 hours (range: 19-37 hours) and of desmethylclomipramine was 69 hours (range: 54-77 hours). Elimination half-life may vary substantially with different doses due to saturable kinetics (i.e. metabolism).",Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,unknown
Clomipramine,"Following oral administration of a single 150 mg dose of clomipramine, the average elimination half-life of clomipramine was 32 hours (range: 19-37 hours) and of desmethylclomipramine was 69 hours (range: 54-77 hours). Elimination half-life may vary substantially with different doses due to saturable kinetics (i.e. metabolism).",Glutathione S-transferase P,GSTP1,inhibitor,unknown
Bepridil,24-50 hours,Voltage-dependent P/Q-type calcium channel subunit alpha-1A,CACNA1A,inhibitor,yes
Bepridil,24-50 hours,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,inhibitor,yes
Bepridil,24-50 hours,Voltage-dependent calcium channel subunit alpha-2/delta-2,CACNA2D2,inhibitor,yes
Bepridil,24-50 hours,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,inhibitor,unknown
Bepridil,24-50 hours,Potassium voltage-gated channel subfamily KQT member 1,KCNQ1,inhibitor,unknown
Bepridil,24-50 hours,"Troponin C, slow skeletal and cardiac muscles",TNNC1,other,unknown
Bepridil,24-50 hours,Calmodulin,CALM1,binder,unknown
Bepridil,24-50 hours,"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B",PDE1B,inhibitor,unknown
Bepridil,24-50 hours,"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A",PDE1A,inhibitor,unknown
Bepridil,24-50 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Decamethonium,,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,partial agonist,yes
Decamethonium,,Acetylcholinesterase,ACHE,inhibitor,unknown
Decamethonium,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,,unknown
Decamethonium,,Neuronal acetylcholine receptor subunit beta-2,CHRNB2,,unknown
Alimemazine,,Histamine H1 receptor,HRH1,antagonist,yes
Isocarboxazid,The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. The isocarboxazid half-life is of little interest as it is an irreversible monoamine oxidase inhibitor.[T117] These drugs present a very short half-life of 1.5-4 hours due to rapid hepatic metabolism.[T114],Amine oxidase [flavin-containing] A,MAOA,inhibitor,yes
Isocarboxazid,The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. The isocarboxazid half-life is of little interest as it is an irreversible monoamine oxidase inhibitor.[T117] These drugs present a very short half-life of 1.5-4 hours due to rapid hepatic metabolism.[T114],Amine oxidase [flavin-containing] B,MAOB,inhibitor,yes
Docetaxel,"Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.",Tubulin beta-1 chain,TUBB1,,yes
Docetaxel,"Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.",Apoptosis regulator Bcl-2,BCL2,,unknown
Docetaxel,"Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.",Microtubule-associated protein 2,MAP2,,yes
Docetaxel,"Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.",Microtubule-associated protein 4,MAP4,,yes
Docetaxel,"Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.",Microtubule-associated protein tau,MAPT,,yes
Docetaxel,"Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.",Nuclear receptor subfamily 1 group I member 2,NR1I2,binder,unknown
Olsalazine,"Olsalazine has an elimination half-life of 0.9 hours, however, olsalazine-S has a half-life of 7 days.",Thiopurine S-methyltransferase,TPMT,inhibitor,yes
Olsalazine,"Olsalazine has an elimination half-life of 0.9 hours, however, olsalazine-S has a half-life of 7 days.",Interferon gamma,IFNG,,yes
Gliquidone,The mean terminal half-life was approximately 8 hours (range 5.7-9.4 hours),ATP-binding cassette sub-family C member 8,ABCC8,inhibitor,yes
Gliquidone,The mean terminal half-life was approximately 8 hours (range 5.7-9.4 hours),ATP-sensitive inward rectifier potassium channel 8,KCNJ8,inhibitor,yes
Mitiglinide,,ATP-binding cassette sub-family C member 8,ABCC8,inhibitor,yes
Mitiglinide,,Peroxisome proliferator-activated receptor gamma,PPARG,agonist,unknown
Ergonovine,t<sub>1/2 &alpha;</sub>=10 minutes; t<sub>1/2 &beta;</sub>=2 hours,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Tyrosine-protein kinase ABL1,ABL1,multitarget,yes
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Proto-oncogene tyrosine-protein kinase Src,SRC,multitarget,yes
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Ephrin type-A receptor 2,EPHA2,antagonist,yes
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Tyrosine-protein kinase Lck,LCK,multitarget,yes
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Tyrosine-protein kinase Yes,YES1,inhibitor,yes
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Mast/stem cell growth factor receptor Kit,KIT,antagonist,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Platelet-derived growth factor receptor beta,PDGFRB,antagonist,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Signal transducer and activator of transcription 5B,STAT5B,inhibitor,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Abelson tyrosine-protein kinase 2,ABL2,multitarget,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Tyrosine-protein kinase Fyn,FYN,multitarget,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Tyrosine-protein kinase BTK,BTK,,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Nuclear receptor subfamily 4 group A member 3,NR4A3,,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Breakpoint cluster region protein,BCR,,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Tyrosine-protein kinase CSK,CSK,,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Ephrin type-A receptor 5,EPHA5,,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Ephrin type-B receptor 4,EPHB4,,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Tyrosine-protein kinase Fgr,FGR,,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Tyrosine-protein kinase FRK,FRK,,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Heat shock cognate 71 kDa protein,HSPA8,,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Tyrosine-protein kinase Lyn,LYN,,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Mitogen-activated protein kinase kinase kinase MLT,ZAK,,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Mitogen-activated protein kinase 14,MAPK14,,unknown
Dasatinib,The overall mean terminal half-life of dasatinib is 3-5 hours.,Amidophosphoribosyltransferase,PPAT,,unknown
Lisdexamfetamine,"The plasma elimination half-life of lisdexamfetamine typically averaged less 
than one hour.",Sodium-dependent dopamine transporter,SLC6A3,inhibitor,yes
Lisdexamfetamine,"The plasma elimination half-life of lisdexamfetamine typically averaged less 
than one hour.",Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Retapamulin,,50S ribosomal protein L3,rplC,inhibitor,yes
Eculizumab,272 &plusmn; 82 hrs (mean &plusmn; SD),Complement C5,C5,antibody,yes
Lapatinib,"Single-dose terminal half life: 14.2 hours
Effective multiple-dose half life: 24 hours",Epidermal growth factor receptor,EGFR,antagonist,yes
Lapatinib,"Single-dose terminal half life: 14.2 hours
Effective multiple-dose half life: 24 hours",Receptor tyrosine-protein kinase erbB-2,ERBB2,antagonist,yes
Desonide,,Glucocorticoid receptor,NR3C1,agonist,yes
Sitagliptin,12.4 hours,Dipeptidyl peptidase 4,DPP4,inhibitor,yes
Decitabine,The terminal phase elimination half-life is 0.51 &plusmn; 0.31 hours.,DNA,,other/unknown,yes
Decitabine,The terminal phase elimination half-life is 0.51 &plusmn; 0.31 hours.,DNA (cytosine-5)-methyltransferase 1,DNMT1,inhibitor,yes
Posaconazole,Posaconazole is eliminated with a mean half-life (t&frac12;) of 35 hours (range 20 to 66 hours).,Lanosterol 14-alpha demethylase,ERG11,antagonist,yes
Darunavir,The terminal elimination half-life of darunavir was approximately 15 hours when combined with ritonavir.,Human immunodeficiency virus type 1 protease,pol,inhibitor,yes
Telbivudine,Approximately 15 hours.,Protein P,P,,yes
Telbivudine,Approximately 15 hours.,DNA,,,yes
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,D(2) dopamine receptor,DRD2,antagonist,yes
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,Histamine H1 receptor,HRH1,agonist,unknown
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,D(4) dopamine receptor,DRD4,antagonist,yes
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,5-hydroxytryptamine receptor 1D,HTR1D,antagonist,unknown
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,D(3) dopamine receptor,DRD3,antagonist,yes
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,yes
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,Alpha-2B adrenergic receptor,ADRA2B,antagonist,unknown
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,Alpha-2C adrenergic receptor,ADRA2C,agonist,unknown
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,5-hydroxytryptamine receptor 1A,HTR1A,antagonist,unknown
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,D(1A) dopamine receptor,DRD1,antagonist,unknown
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,Cytochrome P450 3A4,CYP3A4,,unknown
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,Cytochrome P450 2D6,CYP2D6,,unknown
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,Cytochrome P450 3A5,CYP3A5,,unknown
Paliperidone,The terminal elimination half-life of paliperidone is approximately 23 hours.,5-hydroxytryptamine receptor 7,HTR7,,unknown
Sunitinib,"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.",Platelet-derived growth factor receptor beta,PDGFRB,inhibitor,yes
Sunitinib,"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.",Vascular endothelial growth factor receptor 1,FLT1,inhibitor,yes
Sunitinib,"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.",Mast/stem cell growth factor receptor Kit,KIT,inhibitor,yes
Sunitinib,"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.",Vascular endothelial growth factor receptor 2,KDR,inhibitor,yes
Sunitinib,"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.",Vascular endothelial growth factor receptor 3,FLT4,inhibitor,yes
Sunitinib,"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.",Receptor-type tyrosine-protein kinase FLT3,FLT3,inhibitor,yes
Sunitinib,"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.",Macrophage colony-stimulating factor 1 receptor,CSF1R,inhibitor,yes
Sunitinib,"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.",Platelet-derived growth factor receptor alpha,PDGFRA,inhibitor,yes
Panitumumab,7.5 days (range: 4-11 days),Epidermal growth factor receptor,EGFR,suppressor,yes
Ranibizumab,Approximately 9 days.,Vascular endothelial growth factor A,VEGFA,,yes
Idursulfase,44 &plusmn; 19 minutes,Dermatan sulfate,,,yes
Idursulfase,44 &plusmn; 19 minutes,Heparan sulfate,,,yes
Idursulfase,44 &plusmn; 19 minutes,Perilipin-3,PLIN3,,no
Alglucosidase alfa,2.3 &plusmn; 0.4 hours.,Cation-dependent mannose-6-phosphate receptor,M6PR,binder,yes
Alglucosidase alfa,2.3 &plusmn; 0.4 hours.,Glycogen,,cleavage,yes
Varenicline,The elimination half-life of varenicline is approximately 24 hours,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,partial agonist,yes
Varenicline,The elimination half-life of varenicline is approximately 24 hours,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,agonist,unknown
Varenicline,The elimination half-life of varenicline is approximately 24 hours,Neuronal acetylcholine receptor subunit alpha-3,CHRNA3,partial agonist,unknown
Varenicline,The elimination half-life of varenicline is approximately 24 hours,Neuronal acetylcholine receptor subunit alpha-6,CHRNA6,partial agonist,unknown
Varenicline,The elimination half-life of varenicline is approximately 24 hours,Neuronal acetylcholine receptor subunit beta-2,CHRNB2,partial agonist,unknown
Arformoterol,"In COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours.",Beta-2 adrenergic receptor,ADRB2,agonist,yes
Hydralazine,3 to 7 hours,Membrane primary amine oxidase,AOC3,inhibitor,yes
Hydralazine,3 to 7 hours,Prolyl 4-hydroxylase subunit alpha-1,P4HA1,inhibitor,unknown
Exenatide,Mean terminal half-life is 2.4 hours.,Glucagon-like peptide 1 receptor,GLP1R,agonist,yes
Mecasermin,2 hours,Insulin-like growth factor 1 receptor,IGF1R,agonist,yes
Mecasermin,2 hours,Insulin-like growth factor-binding protein 3,IGFBP3,,unknown
Mecasermin,2 hours,Insulin receptor,INSR,,unknown
Mecasermin,2 hours,Cation-independent mannose-6-phosphate receptor,IGF2R,,unknown
Pramlintide,Approximately 48 minutes,Calcitonin receptor,CALCR,agonist,yes
Pramlintide,Approximately 48 minutes,Receptor activity-modifying protein 1,RAMP1,agonist,yes
Pramlintide,Approximately 48 minutes,Receptor activity-modifying protein 2,RAMP2,agonist,yes
Pramlintide,Approximately 48 minutes,Receptor activity-modifying protein 3,RAMP3,agonist,yes
Galsulfase,"9 (6 to 21) minutes during the first week of treatment, 26 (8 to 40) minutes by the 24th week.",Dermatan sulfate,,,yes
Galsulfase,"9 (6 to 21) minutes during the first week of treatment, 26 (8 to 40) minutes by the 24th week.",Perilipin-3,PLIN3,,yes
Nelarabine,Nelarabine and ara-G are rapidly eliminated from plasma with a half-life of approximately 30 minutes and 3 hours.,DNA,,incorporation into and destabilization,yes
Nelarabine,Nelarabine and ara-G are rapidly eliminated from plasma with a half-life of approximately 30 minutes and 3 hours.,DNA polymerase alpha catalytic subunit,POLA1,inhibitor,unknown
Abatacept,"16.7 (12-23) days in healthy subjects; 
13.1 (8-25) days in RA subjects;
14.3 days when subcutaneously administered to adult RA patients.",T-lymphocyte activation antigen CD80,CD80,antagonist,yes
Abatacept,"16.7 (12-23) days in healthy subjects; 
13.1 (8-25) days in RA subjects;
14.3 days when subcutaneously administered to adult RA patients.",T-lymphocyte activation antigen CD86,CD86,antagonist,yes
Carbetocin,40 minutes,Oxytocin receptor,OXTR,agonist,yes
Lumiracoxib,Terminal half-life is approximately 4 hours.,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Lumiracoxib,Terminal half-life is approximately 4 hours.,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Tetracosactide,About 15 minutes following intravenous administration.,Adrenocorticotropic hormone receptor,MC2R,antagonist,yes
Corticotropin,About 15 minutes following intravenous administration.,Adrenocorticotropic hormone receptor,MC2R,agonist,yes
Corticotropin,About 15 minutes following intravenous administration.,Corticoliberin,CRH,agonist,unknown
Fenoterol,,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Fenoterol,,Beta-1 adrenergic receptor,ADRB1,agonist,unknown
Fenoterol,,Beta-3 adrenergic receptor,ADRB3,agonist,unknown
Glisoxepide,,ATP-sensitive inward rectifier potassium channel 8,KCNJ8,inhibitor,yes
Pirbuterol,The plasma half-life measured after oral administration is about two hours.,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Pirbuterol,The plasma half-life measured after oral administration is about two hours.,Beta-1 adrenergic receptor,ADRB1,agonist,unknown
Bevantolol,,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Bevantolol,,Beta-2 adrenergic receptor,ADRB2,antagonist,unknown
Bevantolol,,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Glucosamine,,Matrix metalloproteinase-9,MMP9,antagonist,yes
Glucosamine,,Nuclear factor NF-kappa-B p100 subunit,NFKB2,antagonist,unknown
Glucosamine,,Tumor necrosis factor,TNF,,unknown
Glucosamine,,Interferon gamma,IFNG,,unknown
Glucosamine,,Chitosanase,csn,,unknown
Practolol,,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Sulfacytine,,Dihydropteroate synthase,folP,inhibitor,yes
Sulfadoxine,,Dihydropteroate synthetase,,,yes
Sulfadoxine,,Bifunctional dihydrofolate reductase-thymidylate synthase,,inhibitor,unknown
Rolitetracycline,,30S ribosomal protein S9,rpsI,inhibitor,yes
Rolitetracycline,,16S rRNA,,inhibitor,yes
Oxtriphylline,"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.","cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,inhibitor,yes
Oxtriphylline,"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.","cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,inhibitor,yes
Oxtriphylline,"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.",Adenosine receptor A2a,ADORA2A,antagonist,yes
Oxtriphylline,"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.",Adenosine receptor A1,ADORA1,antagonist,yes
Oxtriphylline,"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.",Histone deacetylase 2,HDAC2,activator,yes
Insulin Aspart,81 minutes (following subcutaneous administration in healthy subjects).,Insulin receptor,INSR,agonist,yes
Insulin Detemir,"5 - 7 hours depending on dose. The half life also differs between age groups (type 1 diabetes patients):
Children (6-12 years) = 302 ± 100 minutes;
Adolescents (13-17 years) = 301 ± 107 minutes; 
Adults (18-65 years) = 425 ± 78 minutes",Insulin receptor,INSR,agonist,yes
Insulin Glulisine,Elimination half life= 42 minutes (following subcutaneous injection),Insulin receptor,INSR,agonist,yes
Fosamprenavir,The plasma elimination half-life of amprenavir (the active metabolite) is approximately 7.7 hours.,Human immunodeficiency virus type 1 protease,pol,inhibitor,yes
Fosphenytoin,Fosphenytoin has a half-life of approximately 15 minutes.,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Josamycin,,50S ribosomal protein L4,rplD,inhibitor,yes
Polythiazide,,Solute carrier family 12 member 3,SLC12A3,inhibitor,yes
Quinethazone,,Carbonic anhydrase 1,CA1,inhibitor,yes
Quinethazone,,Carbonic anhydrase 2,CA2,inhibitor,yes
Quinethazone,,Solute carrier family 12 member 1,SLC12A1,inhibitor,yes
Quinethazone,,Solute carrier family 12 member 2,SLC12A2,inhibitor,yes
Quinethazone,,Solute carrier family 12 member 3,SLC12A3,inhibitor,yes
Cefamandole,"The half-life after an intravenous dose is 32 minutes; after intramuscular administration, the half-life is 60 minutes.",Penicillin-binding protein 2,pbpA,inhibitor,yes
Cefazolin,The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.,Penicillin-binding protein 1A,mrcA,inhibitor,yes
Cefazolin,The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.,Penicillin-binding protein 1B,mrcB,inhibitor,yes
Cefazolin,The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.,Penicillin-binding protein 1C,pbpC,inhibitor,yes
Cefazolin,The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.,Penicillin-binding protein 2,mrdA,inhibitor,yes
Cefazolin,The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.,Peptidoglycan synthase FtsI,ftsI,inhibitor,yes
Cefazolin,The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.,Serum paraoxonase/arylesterase 1,PON1,inhibitor,unknown
Cefazolin,The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.,Interleukin-15,IL15,inhibitor,unknown
Cefazolin,The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.,Interleukin-2,IL2,inhibitor,unknown
Cefonicid,4.5 hours,Penicillin-binding protein 1A,mrcA,inhibitor,yes
Cefonicid,4.5 hours,Peptidoglycan synthase FtsI,ftsI,inhibitor,yes
Cefonicid,4.5 hours,Penicillin-binding protein 1B,mrcB,inhibitor,yes
Cefonicid,4.5 hours,D-alanyl-D-alanine carboxypeptidase DacB,dacB,inhibitor,yes
Cefonicid,4.5 hours,Penicillin-binding protein 2,mrdA,inhibitor,yes
Cefoperazone,"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.",Peptidoglycan synthase FtsI,ftsI,inhibitor,yes
Cefoperazone,"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.",Penicillin-binding protein 1B,mrcB,inhibitor,yes
Cefoperazone,"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.",Penicillin-binding protein 2,mrdA,inhibitor,yes
Cefoperazone,"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.",Penicillin-binding protein 1A,mrcA,inhibitor,yes
Cefoperazone,"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.",Penicillin-binding protein 1B,ponB,inhibitor,yes
Cefoperazone,"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.",D-alanyl-D-alanine carboxypeptidase DacC,dacC,inhibitor,yes
Cefoperazone,"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.",Penicillin-binding protein 1A,mrcA,inhibitor,yes
Cefoperazone,"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.",D-alanyl-D-alanine carboxypeptidase DacA,dacA,inhibitor,yes
Cefoperazone,"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.",D-alanyl-D-alanine carboxypeptidase DacB,dacB,inhibitor,yes
Cefotetan,"In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged",Penicillin-binding protein 3,pbp3,inhibitor,yes
Cefoxitin,The half-life after an intravenous dose is 41 to 59 minutes.,D-alanyl-D-alanine carboxypeptidase DacC,dacC,inhibitor,yes
Cefoxitin,The half-life after an intravenous dose is 41 to 59 minutes.,D-alanyl-D-alanine carboxypeptidase DacA,dacA,inhibitor,yes
Cefoxitin,The half-life after an intravenous dose is 41 to 59 minutes.,D-alanyl-D-alanine endopeptidase,pbpG,inhibitor,yes
Cefoxitin,The half-life after an intravenous dose is 41 to 59 minutes.,D-alanyl-D-alanine carboxypeptidase DacB,dacB,inhibitor,yes
Cefoxitin,The half-life after an intravenous dose is 41 to 59 minutes.,Penicillin-binding protein 1A,mrcA,inhibitor,yes
Cefoxitin,The half-life after an intravenous dose is 41 to 59 minutes.,Penicillin-binding protein 1B,mrcB,inhibitor,yes
Cefoxitin,The half-life after an intravenous dose is 41 to 59 minutes.,Peptidoglycan synthase FtsI,ftsI,inhibitor,yes
Cefoxitin,The half-life after an intravenous dose is 41 to 59 minutes.,Penicillin-binding protein 3,pbp3,inhibitor,yes
Cefoxitin,The half-life after an intravenous dose is 41 to 59 minutes.,Penicillin-binding protein 1b,pbp1b,inhibitor,yes
Cefoxitin,The half-life after an intravenous dose is 41 to 59 minutes.,Penicillin-binding protein 2a,pbp2a,inhibitor,yes
Cefoxitin,The half-life after an intravenous dose is 41 to 59 minutes.,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Cefoxitin,The half-life after an intravenous dose is 41 to 59 minutes.,Penicillin-binding protein 2B,penA,inhibitor,yes
Ceftizoxime,,MecA PBP2' (penicillin binding protein 2'),mecA,inhibitor,yes
Ceftizoxime,,Penicillin-binding protein 1A,mrcA,inhibitor,yes
Ceftizoxime,,Penicillin-binding protein 1B,mrcB,inhibitor,yes
Ceftizoxime,,Peptidoglycan synthase FtsI,ftsI,inhibitor,yes
Cefradine,,Penicillin-binding protein 1A,mrcA,inhibitor,yes
Metocurine,,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,antagonist,yes
Metocurine,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Pancuronium,1.5 to 2.7 hours.,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,antagonist,yes
Pancuronium,1.5 to 2.7 hours.,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Pancuronium,1.5 to 2.7 hours.,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Pipecuronium,"Distribution Normal renal function: 6.22 (range, 1.34 to 10.66) minutes. Renal function impairment: 4.33 (range, 1.69 to 6.17) minutes. Elimination Normal renal function: 1.7 (range, 0.9 to 2.7) hours. The elimination half-life is not altered by hypothermia and bypass. Renal function impairment: 4 (range, 2 to 8.2) hours. [PharmGKB]",Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,antagonist,yes
Pipecuronium,"Distribution Normal renal function: 6.22 (range, 1.34 to 10.66) minutes. Renal function impairment: 4.33 (range, 1.69 to 6.17) minutes. Elimination Normal renal function: 1.7 (range, 0.9 to 2.7) hours. The elimination half-life is not altered by hypothermia and bypass. Renal function impairment: 4 (range, 2 to 8.2) hours. [PharmGKB]",Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Pipecuronium,"Distribution Normal renal function: 6.22 (range, 1.34 to 10.66) minutes. Renal function impairment: 4.33 (range, 1.69 to 6.17) minutes. Elimination Normal renal function: 1.7 (range, 0.9 to 2.7) hours. The elimination half-life is not altered by hypothermia and bypass. Renal function impairment: 4 (range, 2 to 8.2) hours. [PharmGKB]",Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Vecuronium,51–80 minutes,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,antagonist,yes
Cilazapril,Half-lives for the periods 1 to 4 hours and 1 to 7 days after the intravenous administration of 2.5 mg cilazaprilat are 0.90 and 46.2 hours respectively.,Angiotensin-converting enzyme,ACE,inhibitor,yes
Dihydroquinidine barbiturate,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Forasartan,,Type-1 angiotensin II receptor,AGTR1,antagonist,yes
Tolevamer,none,Potassium,,binder,yes
Potassium,,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,,unknown
Quinidine barbiturate,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Quinidine barbiturate,,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Quinidine barbiturate,,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Quinidine barbiturate,,Potassium channel subfamily K member 1,KCNK1,inhibitor,unknown
Quinidine barbiturate,,Glutamate receptor 2,GRIA2,antagonist,unknown
Saprisartan,,Type-1 angiotensin II receptor,AGTR1,antagonist,yes
Spirapril,30 to 35 hours,Angiotensin-converting enzyme,ACE,inhibitor,yes
Tasosartan,,Type-1 angiotensin II receptor,AGTR1,antagonist,yes
Tasosartan,,Type-2 angiotensin II receptor,AGTR2,antagonist,unknown
Amobarbital,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Amobarbital,,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Amobarbital,,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Amobarbital,,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Amobarbital,,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Amobarbital,,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Amobarbital,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Amobarbital,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Amobarbital,,Glutamate receptor 2,GRIA2,antagonist,unknown
Amobarbital,,"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Aprobarbital,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Aprobarbital,,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Aprobarbital,,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Aprobarbital,,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Aprobarbital,,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Aprobarbital,,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Aprobarbital,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Aprobarbital,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Aprobarbital,,Glutamate receptor 2,GRIA2,antagonist,unknown
Aprobarbital,,"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Butethal,37 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Butethal,37 hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Butethal,37 hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Butethal,37 hours,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Butethal,37 hours,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Butethal,37 hours,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Butethal,37 hours,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Butethal,37 hours,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Butethal,37 hours,Glutamate receptor 2,GRIA2,antagonist,unknown
Butethal,37 hours,"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Heptabarbital,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Heptabarbital,,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Heptabarbital,,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Heptabarbital,,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Heptabarbital,,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Heptabarbital,,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Heptabarbital,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Heptabarbital,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Heptabarbital,,Glutamate receptor 2,GRIA2,antagonist,unknown
Heptabarbital,,"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Hexobarbital,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Hexobarbital,,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Hexobarbital,,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Hexobarbital,,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Hexobarbital,,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Hexobarbital,,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Hexobarbital,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Hexobarbital,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Hexobarbital,,Glutamate receptor 2,GRIA2,antagonist,unknown
Hexobarbital,,"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Lithium,,Glycogen synthase kinase-3 beta,GSK3B,inhibitor,unknown
Lithium,,Inositol monophosphatase 1,IMPA1,inhibitor,unknown
Lithium,,Inositol monophosphatase 2,IMPA2,inhibitor,unknown
Lithium,,Glutamate receptor 3,GRIA3,potentiator,unknown
Mestranol,,Estrogen receptor alpha,ESR1,agonist,yes
Penbutolol,"Plasma= approximately 5h
Conjugated= approximately 20h in healthy persons, 25h in healthy elderly persons, and 100h in patients on renal dialysis.",Beta-1 adrenergic receptor,ADRB1,antagonistpartial agonist,yes
Penbutolol,"Plasma= approximately 5h
Conjugated= approximately 20h in healthy persons, 25h in healthy elderly persons, and 100h in patients on renal dialysis.",Beta-2 adrenergic receptor,ADRB2,antagonistpartial agonist,yes
Penbutolol,"Plasma= approximately 5h
Conjugated= approximately 20h in healthy persons, 25h in healthy elderly persons, and 100h in patients on renal dialysis.",5-hydroxytryptamine receptor 1A,HTR1A,antagonist,yes
Penbutolol,"Plasma= approximately 5h
Conjugated= approximately 20h in healthy persons, 25h in healthy elderly persons, and 100h in patients on renal dialysis.",5-hydroxytryptamine receptor 1B,HTR1B,antagonist,unknown
Ephedra,,Sodium-dependent dopamine transporter,SLC6A3,negative modulator,yes
Ephedra,,Sodium-dependent noradrenaline transporter,SLC6A2,negative modulator,yes
Ephedra,,Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Ephedra,,Alpha-2B adrenergic receptor,ADRA2B,agonist,yes
Ephedra,,Alpha-2C adrenergic receptor,ADRA2C,agonist,yes
Ephedra,,Amine oxidase [flavin-containing] A,MAOA,inhibitor,yes
Ephedra,,Amine oxidase [flavin-containing] B,MAOB,inhibitor,yes
Ephedra,,Beta-1 adrenergic receptor,ADRB1,agonist,yes
Ephedra,,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Ephedra,,Beta-3 adrenergic receptor,ADRB3,agonist,yes
Ephedra,,Sodium-dependent serotonin transporter,SLC6A4,negative modulator,yes
Ephedra,,Synaptic vesicular amine transporter,SLC18A2,inhibitor,yes
Ephedra,,Chromaffin granule amine transporter,SLC18A1,inhibitor,yes
Ephedrine,3-6 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inverse agonist,unknown
Ephedrine,3-6 hours,Alpha-1A adrenergic receptor,ADRA1A,,unknown
Ephedrine,3-6 hours,Synaptic vesicular amine transporter,SLC18A2,inhibitor,unknown
Ephedrine,3-6 hours,Acetylcholinesterase,ACHE,,unknown
Mephentermine,17 to 18 hours.,Alpha adrenergic receptor,ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C,agonist,yes
Mephentermine,17 to 18 hours.,Beta adrenergic receptor,ADRB1ADRB2ADRB3,agonist,unknown
Procaterol,,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Rasagiline,Rasagiline has a mean steady-state half life of 3 hours but there is no correlation of pharmacokinetics with its pharmacological effect because of its irreversible inhibition of MAO-B.,Amine oxidase [flavin-containing] B,MAOB,inhibitor,yes
Rasagiline,Rasagiline has a mean steady-state half life of 3 hours but there is no correlation of pharmacokinetics with its pharmacological effect because of its irreversible inhibition of MAO-B.,Apoptosis regulator Bcl-2,BCL2,activator,yes
Quinupristin,3.1 hours,23S rRNA,,inhibitor,yes
Quinupristin,3.1 hours,50S ribosomal protein L10,rplJ,inhibitor,yes
Quinupristin,3.1 hours,50S ribosomal protein L22,rplV,inhibitor,yes
Aluminium,,Serotransferrin,TF,,unknown
Aluminium,,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,binder,unknown
Aluminium,,Kallikrein-1,KLK1,inhibitor,unknown
Aluminium,,Amyloid beta A4 protein,APP,,unknown
Calcium,,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,ligand,yes
Calcium,,Calcium-transporting ATPase type 2C member 1,ATP2C1,agonist,yes
Calcium,,"Troponin C, skeletal muscle",TNNC2,agonist,yes
Calcium,,"Troponin C, slow skeletal and cardiac muscles",TNNC1,agonist,yes
Calcium,,"Spectrin beta chain, non-erythrocytic 1",SPTBN1,agonist,unknown
Calcium,,Protein S100-B,S100B,,unknown
Calcium,,Calpastatin,CAST,,unknown
Calcium,,Cartilage oligomeric matrix protein,COMP,,unknown
Calcium,,Calmodulin,CALM1,,unknown
Calcium,,Amiloride-sensitive amine oxidase [copper-containing],AOC1,,unknown
Calcium,,Protein S100-A13,S100A13,,unknown
Calcium,,"Alkaline phosphatase, placental type",ALPP,,unknown
Calcium,,Protein S100-A8,S100A8,,unknown
Calcium,,Protein S100-A9,S100A9,,unknown
Calcium,,Protein S100-A2,S100A2,,unknown
Calcium,,Ceruloplasmin,CP,,unknown
Calcium,,Bone morphogenetic protein 4,BMP4,,unknown
Calcium,,Matrix Gla protein,MGP,,unknown
Calcium,,Protocadherin-19,PCDH19,,unknown
Calcium,,Programmed cell death protein 6,PDCD6,,unknown
Aluminium monostearate,,"Troponin C, slow skeletal and cardiac muscles",TNNC1,stimulator,unknown
Aluminium monostearate,,Voltage-dependent anion-selective channel protein 1,VDAC1,inhibitor,unknown
Aluminium monostearate,,Voltage-dependent anion-selective channel protein 2,VDAC2,inhibitor,unknown
Aluminium monostearate,,Voltage-dependent anion-selective channel protein 3,VDAC3,inhibitor,unknown
Magnesium,,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,,unknown
Cortisone acetate,,Glucocorticoid receptor,NR3C1,agonist,yes
Ginkgo biloba,,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,unknown
Ginkgo biloba,,"Phospholipase A2, membrane associated",PLA2G2A,inhibitor,unknown
Ginkgo biloba,,Glycine receptor subunit alpha-1,GLRA1,antagonist,unknown
Ginkgo biloba,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,negative modulator,unknown
Ginkgo biloba,,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,negative modulator,unknown
Ginkgo biloba,,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,negative modulator,unknown
Glycodiazine,4 hours.,ATP-sensitive inward rectifier potassium channel 1,KCNJ1,other/unknown,yes
Glycodiazine,4 hours.,ATP-binding cassette sub-family C member 8,ABCC8,inducer,unknown
Paramethasone,,Glucocorticoid receptor,NR3C1,agonist,yes
Mibefradil,17 to 25 hours at steady state.,Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,inhibitor,yes
Mibefradil,17 to 25 hours at steady state.,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,inhibitor,yes
Mibefradil,17 to 25 hours at steady state.,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,inhibitor,yes
Mibefradil,17 to 25 hours at steady state.,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,inhibitor,yes
Mibefradil,17 to 25 hours at steady state.,Voltage-dependent L-type calcium channel subunit alpha-1F,CACNA1F,inhibitor,yes
Mibefradil,17 to 25 hours at steady state.,Voltage-dependent T-type calcium channel subunit alpha-1I,CACNA1I,inhibitor,yes
Mibefradil,17 to 25 hours at steady state.,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,inhibitor,yes
Mibefradil,17 to 25 hours at steady state.,Voltage-dependent L-type calcium channel subunit beta-1,CACNB1,inhibitor,yes
Mibefradil,17 to 25 hours at steady state.,Voltage-dependent L-type calcium channel subunit beta-2,CACNB2,inhibitor,yes
Mibefradil,17 to 25 hours at steady state.,Voltage-dependent L-type calcium channel subunit beta-3,CACNB3,inhibitor,yes
Mibefradil,17 to 25 hours at steady state.,Voltage-dependent L-type calcium channel subunit beta-4,CACNB4,inhibitor,yes
Sodium bicarbonate,,Hydrogen ions,,neutralizer,yes
Yohimbine,Elimination half-life is approximately 36 minutes.,Alpha-2A adrenergic receptor,ADRA2A,antagonist,yes
Yohimbine,Elimination half-life is approximately 36 minutes.,Alpha-2B adrenergic receptor,ADRA2B,antagonist,yes
Yohimbine,Elimination half-life is approximately 36 minutes.,Alpha-2C adrenergic receptor,ADRA2C,antagonist,yes
Yohimbine,Elimination half-life is approximately 36 minutes.,5-hydroxytryptamine receptor 1A,HTR1A,partial agonist,unknown
Yohimbine,Elimination half-life is approximately 36 minutes.,5-hydroxytryptamine receptor 1B,HTR1B,antagonist,unknown
Yohimbine,Elimination half-life is approximately 36 minutes.,5-hydroxytryptamine receptor 1D,HTR1D,antagonist,unknown
Yohimbine,Elimination half-life is approximately 36 minutes.,D(2) dopamine receptor,DRD2,antagonist,unknown
Yohimbine,Elimination half-life is approximately 36 minutes.,D(3) dopamine receptor,DRD3,antagonist,unknown
Yohimbine,Elimination half-life is approximately 36 minutes.,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,unknown
Yohimbine,Elimination half-life is approximately 36 minutes.,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Yohimbine,Elimination half-life is approximately 36 minutes.,ATP-sensitive potassium channel,KCNJ1KCNJ10KCNJ11KCNJ12KCNJ14KCNJ15KCNJ8,,unknown
Yohimbine,Elimination half-life is approximately 36 minutes.,5-hydroxytryptamine receptor 2B,HTR2B,antagonist,unknown
Bezafibrate,1-2 hours,Peroxisome proliferator-activated receptor alpha,PPARA,agonist,yes
Bezafibrate,1-2 hours,Peroxisome proliferator-activated receptor delta,PPARD,agonist,yes
Bezafibrate,1-2 hours,Peroxisome proliferator-activated receptor gamma,PPARG,agonist,yes
Bezafibrate,1-2 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,partial agonist,unknown
Bezafibrate,1-2 hours,Retinoic acid receptor RXR-alpha,RXRA,agonist,unknown
Bezafibrate,1-2 hours,Retinoic acid receptor RXR-beta,RXRB,agonist,unknown
Bezafibrate,1-2 hours,Retinoic acid receptor RXR-gamma,RXRG,agonist,unknown
Colchicine,"Elimination half-life is approximately 1 hour in healthy subjects, although a study with an extended sampling time reported mean terminal elimination half-life values of approximately 9 to 10.5 hours. Other studies have reported half-life values of approximately 2 hours in patients with alcoholic cirrhosis and approximately 2.5 hours in patients with familial Mediterranean fever.",Tubulin beta-1 chain,TUBB1,inhibitor,yes
Colchicine,"Elimination half-life is approximately 1 hour in healthy subjects, although a study with an extended sampling time reported mean terminal elimination half-life values of approximately 9 to 10.5 hours. Other studies have reported half-life values of approximately 2 hours in patients with alcoholic cirrhosis and approximately 2.5 hours in patients with familial Mediterranean fever.",Tubulin beta chain,TUBB,inhibitor,yes
Drospirenone,30 hours,Progesterone receptor,PGR,agonist,yes
Drospirenone,30 hours,Mineralocorticoid receptor,NR3C2,antagonist,yes
Drospirenone,30 hours,Androgen receptor,AR,antagonist,yes
Digitoxin,,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,inhibitor,yes
Magnesium salicylate,,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Magnesium salicylate,,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Salsalate,The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Salsalate,The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Neostigmine,The half-life ranged from 42 to 60 minutes with a mean half-life of 52 minutes.,Acetylcholinesterase,ACHE,inhibitor,yes
Choline magnesium trisalicylate,,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Choline magnesium trisalicylate,,Prostaglandin G/H synthase 2,PTGS2,inhibitor,unknown
Methotrimeprazine,Approximately 20 hours.,D(2) dopamine receptor,DRD2,antagonist,yes
Methotrimeprazine,Approximately 20 hours.,D(1A) dopamine receptor,DRD1,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,D(1B) dopamine receptor,DRD5,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,D(3) dopamine receptor,DRD3,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,D(4) dopamine receptor,DRD4,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,Histamine H1 receptor,HRH1,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,Alpha-1D adrenergic receptor,ADRA1D,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,Alpha-2B adrenergic receptor,ADRA2B,antagonist,unknown
Methotrimeprazine,Approximately 20 hours.,Alpha-2C adrenergic receptor,ADRA2C,antagonist,unknown
Ginseng,,Interleukin-6,IL6,antagonist,unknown
Ginseng,,Prostaglandin G/H synthase 2,PTGS2,inhibitor,unknown
Ginseng,,Aryl hydrocarbon receptor,AHR,agonist,unknown
Temafloxacin,Approximately 8 hours in patients with normal renal function.,DNA gyrase subunit A,gyrA,inhibitor,yes
Temafloxacin,Approximately 8 hours in patients with normal renal function.,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Danazol,Approximately 24 hours.,Estrogen receptor alpha,ESR1,agonist,yes
Danazol,Approximately 24 hours.,Androgen receptor,AR,agonist,yes
Danazol,Approximately 24 hours.,Progesterone receptor,PGR,agonist,yes
Danazol,Approximately 24 hours.,Gonadotropin-releasing hormone receptor,GNRHR,negative modulator,yes
Danazol,Approximately 24 hours.,Putative gonadotropin-releasing hormone II receptor,GNRHR2,negative modulator,yes
Danazol,Approximately 24 hours.,C-C motif chemokine 2,CCL2,inhibitor,unknown
Clenbuterol,36-39 hours,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Clenbuterol,36-39 hours,Beta-1 adrenergic receptor,ADRB1,agonist,unknown
Clenbuterol,36-39 hours,Beta-3 adrenergic receptor,ADRB3,agonist,unknown
Clenbuterol,36-39 hours,Beta-nerve growth factor,NGF,stimulator,unknown
Clenbuterol,36-39 hours,Tumor necrosis factor,TNF,other/unknown,unknown
Bambuterol,13 hours for bambuterol and 21 hours for the primary active metabolite terbutaline.,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Tiotropium,5-6 days,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Tiotropium,5-6 days,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Tiotropium,5-6 days,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Tiotropium,5-6 days,Muscarinic acetylcholine receptor M4,CHRM4,,unknown
Tiotropium,5-6 days,Muscarinic acetylcholine receptor M5,CHRM5,,unknown
Ciclesonide,,Glucocorticoid receptor,NR3C1,agonist,yes
Pranlukast,,Cysteinyl leukotriene receptor 1,CYSLTR1,antagonist,yes
Pranlukast,,Tumor necrosis factor,TNF,other/unknown,unknown
Pranlukast,,Interleukin-5,IL5,antagonist,unknown
Pranlukast,,Eosinophil cationic protein,RNASE3,other/unknown,unknown
Pranlukast,,Nuclear factor NF-kappa-B p105 subunit,NFKB1,other/unknown,unknown
Pranlukast,,Mucin-2,MUC2,other/unknown,unknown
Theobromine,,Adenosine receptor A1,ADORA1,antagonist,yes
Theobromine,,Adenosine receptor A2a,ADORA2A,antagonist,yes
Theobromine,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,inhibitor,unknown
Cefepime,2.0 (&plusmn; 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (&plusmn; 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (&plusmn; 2.0) hours.,Penicillin-binding protein 2,mrdA,inhibitor,yes
Cefepime,2.0 (&plusmn; 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (&plusmn; 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (&plusmn; 2.0) hours.,Peptidoglycan synthase FtsI,ftsI,inhibitor,yes
Cefepime,2.0 (&plusmn; 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (&plusmn; 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (&plusmn; 2.0) hours.,Penicillin-binding protein 3,pbpB,inhibitor,yes
Cefepime,2.0 (&plusmn; 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (&plusmn; 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (&plusmn; 2.0) hours.,Penicillin-binding protein 2,pbpA,inhibitor,yes
Cefacetrile,1.2 hours,Penicillin-binding protein 1A,mrcA,inhibitor,yes
Cefacetrile,1.2 hours,Penicillin-binding protein 1B,mrcB,inhibitor,yes
Ceftibuten,,Peptidoglycan synthase FtsI,ftsI,inhibitor,yes
Ceftibuten,,Penicillin-binding protein 1A,mrcA,inhibitor,yes
Ceftibuten,,Penicillin-binding protein 1B,mrcB,inhibitor,yes
Ceftibuten,,Penicillin-binding protein 2,mrdA,inhibitor,yes
Cefpodoxime,2.09 to 2.84 hours,Peptidoglycan synthase FtsI,ftsI,inhibitor,yes
Acenocoumarol,8 to 11 hours.,Vitamin K epoxide reductase complex subunit 1,VKORC1,inhibitor,yes
Antrafenine,,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Antrafenine,,Prostaglandin G/H synthase 2,PTGS2,inhibitor,unknown
Testosterone propionate,"Testosterone propionate presents a the shortest half life of all testosterone esters, being of 4.5 days. This characteristic produces a higher administration requirement.[L1159]",Androgen receptor,AR,agonist,yes
Paromomycin,,30S ribosomal protein S10,rpsJ,inhibitor,yes
Paromomycin,,16S rRNA,,inhibitor,yes
Nitroxoline,,Methionine aminopeptidase 2,METAP2,inhibitor,yes
Nitroxoline,,Magnesium cation,,chelator,unknown
Nitroxoline,,Manganese cation,,chelator,unknown
Alizapride,3 hours,D(2) dopamine receptor,DRD2,antagonist,yes
Ajmaline,,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Amrinone,5 to 8 hours,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,inhibitor,yes
Amrinone,5 to 8 hours,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,inhibitor,unknown
Amrinone,5 to 8 hours,Tumor necrosis factor,TNF,inhibitor,unknown
Amrinone,5 to 8 hours,"cAMP-specific 3',5'-cyclic phosphodiesterase 3",,,unknown
Oxybenzone,,Progesterone receptor,PGR,antagonist,unknown
Oxybenzone,,Androgen receptor,AR,antagonist,unknown
Oxybenzone,,Estrogen receptor alpha,ESR1,,unknown
Oxybenzone,,Estrogen receptor beta,ESR2,,unknown
Aprindine,,Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,yes
Aprindine,,Calmodulin,CALM1,inhibitor,unknown
Almitrine,,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,binder,yes
Allylestrenol,,Progesterone receptor,PGR,agonist,yes
Allylestrenol,,Estrogen receptor alpha,ESR1,agonist,unknown
Cholestyramine,6 minutes,Bile acids,,binder,yes
Methadyl Acetate,,Mu-type opioid receptor,OPRM1,agonist,yes
Antipyrine,,Prostaglandin G/H synthase 2,PTGS2,inhibitor,unknown
Antipyrine,,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Alfacalcidol,,Vitamin D3 receptor,VDR,agonist,yes
Alfacalcidol,,"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial",CYP27B1,,unknown
Alfacalcidol,,Retinoic acid receptor RXR-alpha,RXRA,,unknown
Glutethimide,10-12 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,agonist,yes
Glutethimide,10-12 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Phenazopyridine,7.35 hours,Sodium channel protein type 1 subunit alpha,SCN1A,inhibitor,yes
3-Methylthiofentanyl,,Mu-type opioid receptor,OPRM1,agonist,yes
3-Methylthiofentanyl,,Delta-type opioid receptor,OPRD1,agonist,yes
3-Methylthiofentanyl,,Kappa-type opioid receptor,OPRK1,agonist,yes
Gamma Hydroxybutyric Acid,30 to 60 minutes,Gamma-hydroxybutyrate (GHB) receptor,SLC52A2,agonist,yes
Gamma Hydroxybutyric Acid,30 to 60 minutes,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,agonist,yes
MMDA,,5-hydroxytryptamine receptor 2A,HTR2A,agonist,yes
MMDA,,Sodium-dependent dopamine transporter,SLC6A3,negative modulator,yes
MMDA,,Sodium-dependent serotonin transporter,SLC6A4,negative modulator,yes
MMDA,,Sodium-dependent noradrenaline transporter,SLC6A2,negative modulator,yes
MMDA,,Synaptic vesicular amine transporter,SLC18A2,inhibitor,yes
MMDA,,Chromaffin granule amine transporter,SLC18A1,inhibitor,yes
MMDA,,Amine oxidase [flavin-containing] A,MAOA,inhibitor,yes
MMDA,,Amine oxidase [flavin-containing] B,MAOB,inhibitor,yes
Dimethylthiambutene,,Mu-type opioid receptor,OPRM1,agonist,yes
Dimethylthiambutene,,Delta-type opioid receptor,OPRD1,agonist,unknown
Heroin,<10 minutes,Mu-type opioid receptor,OPRM1,agonist,yes
Heroin,<10 minutes,Kappa-type opioid receptor,OPRK1,agonist,unknown
Heroin,<10 minutes,Delta-type opioid receptor,OPRD1,agonist,unknown
Heroin,<10 minutes,Liver carboxylesterase 1,CES1,,unknown
Midomafetamine,6–10 (though duration of effects is typically actually 3–5 hours),Sodium-dependent serotonin transporter,SLC6A4,negative modulator,yes
Midomafetamine,6–10 (though duration of effects is typically actually 3–5 hours),Synaptic vesicular amine transporter,SLC18A2,inhibitor,yes
Midomafetamine,6–10 (though duration of effects is typically actually 3–5 hours),Sodium-dependent dopamine transporter,SLC6A3,negative modulator,unknown
Midomafetamine,6–10 (though duration of effects is typically actually 3–5 hours),5-hydroxytryptamine receptor 2A,HTR2A,agonist,unknown
Midomafetamine,6–10 (though duration of effects is typically actually 3–5 hours),5-hydroxytryptamine receptor 2B,HTR2B,agonist,unknown
Midomafetamine,6–10 (though duration of effects is typically actually 3–5 hours),5-hydroxytryptamine receptor 2C,HTR2C,agonist,unknown
Midomafetamine,6–10 (though duration of effects is typically actually 3–5 hours),Sodium-dependent noradrenaline transporter,SLC6A2,negative modulator,yes
Fencamfamine,,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,yes
Ethylmorphine,,Mu-type opioid receptor,OPRM1,agonist,yes
4-Methoxyamphetamine,,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,yes
4-Methoxyamphetamine,,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
4-Methoxyamphetamine,,Synaptic vesicular amine transporter,SLC18A2,inhibitor,yes
4-Methoxyamphetamine,,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
4-Methoxyamphetamine,,Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
4-Methoxyamphetamine,,Amine oxidase [flavin-containing] A,MAOA,inhibitor,unknown
4-Methoxyamphetamine,,Amine oxidase [flavin-containing] B,MAOB,inhibitor,unknown
1-Testosterone,,Androgen receptor,AR,agonist,yes
Barbital,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Barbital,,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Barbital,,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Barbital,,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Barbital,,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Barbital,,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Barbital,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Barbital,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Barbital,,Glutamate receptor 2,GRIA2,antagonist,unknown
Barbital,,"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Dimethyltryptamine,,5-hydroxytryptamine receptor 6,HTR6,,yes
Dimethyltryptamine,,5-hydroxytryptamine receptor 2A,HTR2A,,unknown
Dimethyltryptamine,,Sigma non-opioid intracellular receptor 1,SIGMAR1,,unknown
Barbituric acid derivative,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Barbituric acid derivative,,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Barbituric acid derivative,,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Barbituric acid derivative,,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Barbituric acid derivative,,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Barbituric acid derivative,,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Barbituric acid derivative,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,antagonist,unknown
Barbituric acid derivative,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,antagonist,unknown
Barbituric acid derivative,,Glutamate receptor 2,GRIA2,antagonist,unknown
Barbituric acid derivative,,"Glutamate receptor ionotropic, kainate 2",GRIK2,antagonist,unknown
Etorphine,,Mu-type opioid receptor,OPRM1,agonist,yes
Etorphine,,Delta-type opioid receptor,OPRD1,agonist,yes
Etorphine,,Kappa-type opioid receptor,OPRK1,agonist,yes
Etorphine,,Nociceptin receptor,OPRL1,agonist,unknown
Etorphine,,E3 ubiquitin-protein ligase TRIM13,TRIM13,agonist,unknown
Etorphine,,Pro-opiomelanocortin,POMC,,unknown
Tenocyclidine,,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,antagonist,yes
Tenocyclidine,,"Glutamate receptor ionotropic, NMDA 3B",GRIN3B,antagonist,yes
Tenocyclidine,,"Glutamate receptor ionotropic, NMDA 2A",GRIN2A,antagonist,yes
Tenocyclidine,,"Glutamate receptor ionotropic, NMDA 2C",GRIN2C,antagonist,yes
Tenocyclidine,,"Glutamate receptor ionotropic, NMDA 2B",GRIN2B,antagonist,yes
Tenocyclidine,,"Glutamate receptor ionotropic, NMDA 2D",GRIN2D,antagonist,unknown
Tenocyclidine,,Alpha-7 nicotinic cholinergic receptor subunit,CHRNA7,antagonist,unknown
Carfentanil,,Mu-type opioid receptor,OPRM1,agonist,yes
Carfentanil,,Delta-type opioid receptor,OPRD1,agonist,yes
Carfentanil,,Kappa-type opioid receptor,OPRK1,agonist,unknown
Androstenedione,,Estradiol 17-beta-dehydrogenase 1,HSD17B1,inducer,yes
Androstenedione,,3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1,HSD3B1,positive allosteric modulator,yes
Androstenedione,,6-deoxyerythronolide B hydroxylase,eryF,inducer,unknown
Androstenedione,,Aldo-keto reductase family 1 member C3,AKR1C3,inducer,unknown
"4-Bromo-2,5-dimethoxyphenethylamine",,5-hydroxytryptamine receptor 2C,HTR2C,partial agonist,yes
"4-Bromo-2,5-dimethoxyphenethylamine",,5-hydroxytryptamine receptor 2A,HTR2A,partial agonist,unknown
Boldenone,14 days,Androgen receptor,AR,agonist,yes
Flunitrazepam,18-26 hours,Translocator protein,TSPO,agonist,yes
Flunitrazepam,18-26 hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Flunitrazepam,18-26 hours,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,agonist,yes
Flunitrazepam,18-26 hours,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Flunitrazepam,18-26 hours,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Flunitrazepam,18-26 hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Flunitrazepam,18-26 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,agonist,unknown
Flunitrazepam,18-26 hours,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,agonist,unknown
Flunitrazepam,18-26 hours,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,agonist,unknown
Diprenorphine,,Mu-type opioid receptor,OPRM1,antagonist,yes
Diprenorphine,,Delta-type opioid receptor,OPRD1,antagonist,yes
Diprenorphine,,Kappa-type opioid receptor,OPRK1,antagonist,unknown
Diprenorphine,,E3 ubiquitin-protein ligase TRIM13,TRIM13,,unknown
Rolicyclidine,,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,,yes
Rolicyclidine,,D(2) dopamine receptor,DRD2,,unknown
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit pi,GABRP,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit rho-3,GABRR3,potentiator,yes
Bromazepam,10-20 hours,Gamma-aminobutyric acid receptor subunit theta,GABRQ,potentiator,yes
Clotiazepam,4 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Clotiazepam,4 hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Clotiazepam,4 hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Clotiazepam,4 hours,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Clotiazepam,4 hours,Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Clotiazepam,4 hours,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,potentiator,yes
Clotiazepam,4 hours,Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,potentiator,yes
Clotiazepam,4 hours,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Clotiazepam,4 hours,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Clotiazepam,4 hours,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Clotiazepam,4 hours,Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Clotiazepam,4 hours,Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Clotiazepam,4 hours,Gamma-aminobutyric acid receptor subunit pi,GABRP,potentiator,yes
Clotiazepam,4 hours,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,potentiator,yes
Clotiazepam,4 hours,Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,potentiator,yes
Clotiazepam,4 hours,Gamma-aminobutyric acid receptor subunit rho-3,GABRR3,potentiator,yes
Androstanedione,,Estradiol 17-beta-dehydrogenase 1,HSD17B1,,unknown
Androstanedione,,Steroid Delta-isomerase,ksi,,unknown
Calusterone,,Androgen receptor,AR,,yes
Dihydromorphine,,Mu-type opioid receptor,OPRM1,agonist,yes
Dihydromorphine,,Delta-type opioid receptor,OPRD1,agonist,unknown
Dihydromorphine,,Kappa-type opioid receptor,OPRK1,agonist,unknown
Dihydromorphine,,E3 ubiquitin-protein ligase TRIM13,TRIM13,agonist,unknown
Dihydromorphine,,Pro-opiomelanocortin,POMC,agonist,unknown
Fludiazepam,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Fludiazepam,,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Fludiazepam,,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Fludiazepam,,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Fludiazepam,,Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Fludiazepam,,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,potentiator,yes
Fludiazepam,,Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,potentiator,yes
Fludiazepam,,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Fludiazepam,,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Fludiazepam,,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Fludiazepam,,Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Fludiazepam,,Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Fludiazepam,,Gamma-aminobutyric acid receptor subunit pi,GABRP,potentiator,yes
Fludiazepam,,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,potentiator,yes
Fludiazepam,,Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,potentiator,yes
Fludiazepam,,Gamma-aminobutyric acid receptor subunit rho-3,GABRR3,potentiator,yes
Formebolone,,Corticosteroid 11-beta-dehydrogenase isozyme 2,HSD11B2,inhibitor,unknown
3-Methylfentanyl,,Mu-type opioid receptor,OPRM1,agonist,yes
3-Methylfentanyl,,Delta-type opioid receptor,OPRD1,agonist,yes
3-Methylfentanyl,,Kappa-type opioid receptor,OPRK1,agonist,yes
Dextroamphetamine,10-28 hours (average is approximately 12 hours),Synaptic vesicular amine transporter,SLC18A2,inducer,yes
Dextroamphetamine,10-28 hours (average is approximately 12 hours),Sodium-dependent noradrenaline transporter,SLC6A2,negative modulator,yes
Dextroamphetamine,10-28 hours (average is approximately 12 hours),Sodium-dependent dopamine transporter,SLC6A3,negative modulator,yes
Dextroamphetamine,10-28 hours (average is approximately 12 hours),Trace amine-associated receptor 1,TAAR1,agonist,unknown
Dextroamphetamine,10-28 hours (average is approximately 12 hours),Alpha-1A adrenergic receptor,ADRA1A,,unknown
Dextroamphetamine,10-28 hours (average is approximately 12 hours),Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Methamphetamine,The biological half-life has been reported in the range of 4 to 5 hours.,Sodium-dependent dopamine transporter,SLC6A3,negative modulator,yes
Methamphetamine,The biological half-life has been reported in the range of 4 to 5 hours.,Sodium-dependent serotonin transporter,SLC6A4,negative modulator,yes
Methamphetamine,The biological half-life has been reported in the range of 4 to 5 hours.,Sodium-dependent noradrenaline transporter,SLC6A2,negative modulator,yes
Methamphetamine,The biological half-life has been reported in the range of 4 to 5 hours.,Synaptic vesicular amine transporter,SLC18A2,inhibitor,yes
Methamphetamine,The biological half-life has been reported in the range of 4 to 5 hours.,Chromaffin granule amine transporter,SLC18A1,inhibitor,yes
Methamphetamine,The biological half-life has been reported in the range of 4 to 5 hours.,Trace amine-associated receptor 1,TAAR1,agonist,yes
Methamphetamine,The biological half-life has been reported in the range of 4 to 5 hours.,Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Methamphetamine,The biological half-life has been reported in the range of 4 to 5 hours.,Alpha-2B adrenergic receptor,ADRA2B,agonist,yes
Methamphetamine,The biological half-life has been reported in the range of 4 to 5 hours.,Alpha-2C adrenergic receptor,ADRA2C,agonist,yes
Methamphetamine,The biological half-life has been reported in the range of 4 to 5 hours.,Amine oxidase [flavin-containing] A,MAOA,inhibitor,yes
Methamphetamine,The biological half-life has been reported in the range of 4 to 5 hours.,Amine oxidase [flavin-containing] B,MAOB,inhibitor,yes
Phendimetrazine,19-24 hours,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Phendimetrazine,19-24 hours,Sodium-dependent noradrenaline transporter,SLC6A2,negative modulator,yes
Phendimetrazine,19-24 hours,Alpha-1B adrenergic receptor,ADRA1B,agonist,unknown
Oxprenolol,1-2 hours,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Oxprenolol,1-2 hours,Beta-2 adrenergic receptor,ADRB2,antagonist,unknown
Oxprenolol,1-2 hours,Beta-3 adrenergic receptor,ADRB3,,unknown
Sulfamerazine,,Dihydropteroate synthase,folP,inhibitor,yes
Sulfamethazine,,Dihydropteroate synthase,folP,inhibitor,yes
Liotrix,,Thyroid hormone receptor alpha,THRA,agonist,yes
Liotrix,,Thyroid hormone receptor beta,THRB,agonist,yes
Ursodeoxycholic acid,,Aldo-keto reductase family 1 member C2,AKR1C2,inducer,yes
Ursodeoxycholic acid,,Bile acid receptor,NR1H4,,unknown
Ketazolam,26-200 hours,Translocator protein,TSPO,agonist,yes
Ketazolam,26-200 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Ketazolam,26-200 hours,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Ketazolam,26-200 hours,Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Ketazolam,26-200 hours,Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Ketazolam,26-200 hours,Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Prazepam,36-200 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Prazepam,36-200 hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Prazepam,36-200 hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Prazepam,36-200 hours,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Prazepam,36-200 hours,Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Prazepam,36-200 hours,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,potentiator,yes
Prazepam,36-200 hours,Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,potentiator,yes
Prazepam,36-200 hours,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Prazepam,36-200 hours,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Prazepam,36-200 hours,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Prazepam,36-200 hours,Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Prazepam,36-200 hours,Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Prazepam,36-200 hours,Gamma-aminobutyric acid receptor subunit pi,GABRP,potentiator,yes
Prazepam,36-200 hours,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,potentiator,yes
Prazepam,36-200 hours,Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,potentiator,yes
Prazepam,36-200 hours,Gamma-aminobutyric acid receptor subunit rho-3,GABRR3,potentiator,yes
Prazepam,36-200 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Quazepam,39 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Quazepam,39 hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Quazepam,39 hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Quazepam,39 hours,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Quazepam,39 hours,Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Quazepam,39 hours,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,potentiator,yes
Quazepam,39 hours,Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,potentiator,yes
Quazepam,39 hours,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Quazepam,39 hours,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Quazepam,39 hours,Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Quazepam,39 hours,Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Quazepam,39 hours,Gamma-aminobutyric acid receptor subunit pi,GABRP,potentiator,yes
Quazepam,39 hours,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,potentiator,yes
Quazepam,39 hours,Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,potentiator,yes
Quazepam,39 hours,Gamma-aminobutyric acid receptor subunit rho-3,GABRR3,potentiator,yes
Quazepam,39 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,positive allosteric modulator,yes
Everolimus,~30 hours.,Serine/threonine-protein kinase mTOR,MTOR,inhibitor,yes
Solifenacin,The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Solifenacin,The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Solifenacin,The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Solifenacin,The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,unknown
Solifenacin,The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,unknown
Iron,,Transferrin receptor protein 1,TFRC,,unknown
Iron,,Egl nine homolog 1,EGLN1,,unknown
Iron,,Histone deacetylase 8,HDAC8,cofactor,unknown
Iron,,Alpha-hemoglobin-stabilizing protein,AHSP,,unknown
Iron,,Hemoglobin subunit alpha,HBA1,,unknown
Iron,,"Frataxin, mitochondrial",FXN,,unknown
Iron,,Ferritin heavy chain,FTH1,,unknown
Iron,,Flap endonuclease 1,FEN1,,unknown
Iron,,Endonuclease 8-like 1,NEIL1,,unknown
Iron,,Endonuclease 8-like 2,NEIL2,,unknown
Iron,,DNA polymerase beta,POLB,,unknown
Iron,,Ceruloplasmin,CP,,unknown
Iron,,Serotransferrin,TF,,unknown
Zinc,,B1 bradykinin receptor,BDKRB1,,unknown
Zinc,,Methylated-DNA--protein-cysteine methyltransferase,MGMT,,unknown
Zinc,,Fructose-bisphosphate aldolase A,ALDOA,,unknown
Zinc,,Elongation factor 1-alpha 1,EEF1A1,,unknown
Zinc,,Alpha-enolase,ENO1,,unknown
Zinc,,"Glyceraldehyde-3-phosphate dehydrogenase, testis-specific",GAPDHS,,unknown
Zinc,,Nucleoside diphosphate kinase A,NME1,,unknown
Zinc,,Protein disulfide-isomerase,P4HB,,unknown
Zinc,,Protein disulfide-isomerase A3,PDIA3,,unknown
Zinc,,Peroxiredoxin-1,PRDX1,,unknown
Zinc,,Phosphoserine phosphatase,PSPH,,unknown
Zinc,,Triosephosphate isomerase,TPI1,,unknown
Zinc,,"Elongation factor Tu, mitochondrial",TUFM,,unknown
Zinc,,Estrogen receptor alpha,ESR1,cofactor,unknown
Zinc,,Interleukin-3,IL3,,unknown
Zinc,,Metallothionein-2,MT2A,,unknown
Zinc,,Copper chaperone for superoxide dismutase,CCS,,unknown
Zinc,,Histone deacetylase 1,HDAC1,cofactor,unknown
Zinc,,Histone deacetylase 4,HDAC4,cofactor,unknown
Zinc,,DNA-3-methyladenine glycosylase,MPG,,unknown
Zinc,,Semenogelin-1,SEMG1,,unknown
Zinc,,Superoxide dismutase [Cu-Zn],SOD1,,unknown
Zinc,,Histone deacetylase 8,HDAC8,cofactor,unknown
Zinc,,Apoptosis regulatory protein Siva,SIVA1,,unknown
Zinc,,Glycine receptor subunit alpha-1,GLRA1,,unknown
Zinc,,E3 ubiquitin-protein ligase Mdm2,MDM2,,unknown
Zinc,,Insulin,INS,,unknown
Zinc,,Utrophin,UTRN,,unknown
Zinc,,Aspartoacylase,ASPA,cofactor,unknown
Zinc,,Protein S100-A8,S100A8,,unknown
Zinc,,Protein S100-A9,S100A9,,unknown
Zinc,,Matrix metalloproteinase-9,MMP9,,unknown
Zinc,,Tumor protein p73,TP73,cofactor,unknown
Zinc,,Protein S100-A2,S100A2,,unknown
Zinc,,Cellular tumor antigen p53,TP53,,unknown
Zinc,,Metallothionein-3,MT3,,unknown
Zinc,,Programmed cell death protein 6,PDCD6,,unknown
Zinc,,DAN domain family member 5,DAND5,cofactor,unknown
Zinc,,Metallothionein-1A,MT1A,,unknown
Zinc,,Alpha-1B-glycoprotein,A1BG,,unknown
Zinc,,Alpha-2-macroglobulin,A2M,,unknown
Zinc,,Angiotensinogen,AGT,,unknown
Zinc,,Alpha-2-HS-glycoprotein,AHSG,,unknown
Zinc,,Serum amyloid P-component,APCS,,unknown
Zinc,,Apolipoprotein A-I,APOA1,,unknown
Zinc,,Apolipoprotein A-II,APOA2,,unknown
Zinc,,Apolipoprotein A-IV,APOA4,,unknown
Zinc,,Apolipoprotein B receptor,APOBR,,unknown
Zinc,,Apolipoprotein E,APOE,,unknown
Zinc,,Apolipoprotein L1,APOL1,,unknown
Zinc,,Complement C1q subcomponent subunit B,C1QB,,unknown
Zinc,,Complement C1q subcomponent subunit C,C1QC,,unknown
Zinc,,Complement C1r subcomponent,C1R,,unknown
Zinc,,Complement C1s subcomponent,C1S,,unknown
Zinc,,Complement C3,C3,,unknown
Zinc,,Complement C4-B,C4B,,unknown
Zinc,,C4b-binding protein alpha chain,C4BPA,,unknown
Zinc,,C4b-binding protein beta chain,C4BPB,,unknown
Zinc,,Complement C5,C5,,unknown
Zinc,,Lys-63-specific deubiquitinase BRCC36,BRCC3,,unknown
Zinc,,Complement component C8 alpha chain,C8A,,unknown
Zinc,,Complement component C8 beta chain,C8B,,unknown
Zinc,,Complement component C8 gamma chain,C8G,,unknown
Zinc,,Complement factor B,CFB,,unknown
Zinc,,Complement factor H,CFH,,unknown
Zinc,,Complement factor I,CFI,,unknown
Zinc,,Clusterin,CLU,,unknown
Zinc,,Ceruloplasmin,CP,,unknown
Zinc,,Carboxypeptidase N catalytic chain,CPN1,,unknown
Zinc,,Carboxypeptidase N subunit 2,CPN2,,unknown
Zinc,,Dermcidin,DCD,,unknown
Zinc,,Desmoplakin,DSP,,unknown
Zinc,,Coagulation factor XII,F12,,unknown
Zinc,,Coagulation factor XIII B chain,F13B,,unknown
Zinc,,Prothrombin,F2,,unknown
Zinc,,Ficolin-3,FCN3,,unknown
Zinc,,Fibrinogen alpha chain,FGA,,unknown
Zinc,,Fibronectin,FN1,,unknown
Zinc,,Gelsolin,GSN,,unknown
Zinc,,Hemoglobin subunit alpha,HBA1,,unknown
Zinc,,Hemoglobin subunit beta,HBB,,unknown
Zinc,,Haptoglobin-related protein,HPR,,unknown
Zinc,,Hornerin,HRNR,,unknown
Zinc,,Insulin-like growth factor-binding protein complex acid labile subunit,IGFALS,,unknown
Zinc,,Ig alpha-1 chain C region,IGHA1,,unknown
Zinc,,Ig mu chain C region,IGHM,,unknown
Zinc,,Immunoglobulin kappa variable 1-17,IGKV1-17,,unknown
Zinc,,Ig kappa chain V-III region GOL,,,unknown
Zinc,,Immunoglobulin lambda variable 3-21,IGLV3-21,,unknown
Zinc,,Inter-alpha-trypsin inhibitor heavy chain H1,ITIH1,,unknown
Zinc,,Inter-alpha-trypsin inhibitor heavy chain H2,ITIH2,,unknown
Zinc,,Inter-alpha-trypsin inhibitor heavy chain H3,ITIH3,,unknown
Zinc,,Inter-alpha-trypsin inhibitor heavy chain H4,ITIH4,,unknown
Zinc,,Immunoglobulin J chain,JCHAIN,,unknown
Zinc,,Junction plakoglobin,JUP,,unknown
Zinc,,Plasma kallikrein,KLKB1,,unknown
Zinc,,Kininogen-1,KNG1,,unknown
Zinc,,"Keratin, type II cytoskeletal 1",KRT1,,unknown
Zinc,,"Keratin, type I cytoskeletal 10",KRT10,,unknown
Zinc,,"Keratin, type I cytoskeletal 14",KRT14,,unknown
Zinc,,"Keratin, type I cytoskeletal 16",KRT16,,unknown
Zinc,,"Keratin, type II cytoskeletal 2 epidermal",KRT2,,unknown
Zinc,,"Keratin, type II cytoskeletal 5",KRT5,,unknown
Zinc,,"Keratin, type II cytoskeletal 6A",KRT6A,,unknown
Zinc,,"Keratin, type I cytoskeletal 9",KRT9,,unknown
Zinc,,Alpha-1-acid glycoprotein 2,ORM2,,unknown
Zinc,,N-acetylmuramoyl-L-alanine amidase,PGLYRP2,,unknown
Zinc,,Serum paraoxonase/arylesterase 1,PON1,,unknown
Zinc,,Pregnancy zone protein,PZP,,unknown
Zinc,,Protein S100-A7,S100A7,,unknown
Zinc,,Selenoprotein P,SEPP1,,unknown
Zinc,,Alpha-1-antitrypsin,SERPINA1,,unknown
Zinc,,Alpha-1-antichymotrypsin,SERPINA3,,unknown
Zinc,,Kallistatin,SERPINA4,,unknown
Zinc,,Corticosteroid-binding globulin,SERPINA6,,unknown
Zinc,,Heparin cofactor 2,SERPIND1,,unknown
Zinc,,Sex hormone-binding globulin,SHBG,,unknown
Zinc,,Serotransferrin,TF,,unknown
Zinc,,Transthyretin,TTR,,unknown
Zinc,,Vitronectin,VTN,,unknown
Zinc,,Amyloid-like protein 1,APLP1,cofactor,unknown
Zinc,,Amyloid-like protein 2,APLP2,cofactor,unknown
Zinc,,Amyloid beta A4 protein,APP,cofactor,unknown
Zinc,,Poly [ADP-ribose] polymerase 1,PARP1,,unknown
Cinolazepam,9 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Cinolazepam,9 hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Cinolazepam,9 hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Cinolazepam,9 hours,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Cinolazepam,9 hours,Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Cinolazepam,9 hours,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,potentiator,yes
Cinolazepam,9 hours,Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,potentiator,yes
Cinolazepam,9 hours,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Cinolazepam,9 hours,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Cinolazepam,9 hours,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Cinolazepam,9 hours,Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Cinolazepam,9 hours,Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Cinolazepam,9 hours,Gamma-aminobutyric acid receptor subunit pi,GABRP,potentiator,yes
Cinolazepam,9 hours,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,potentiator,yes
Cinolazepam,9 hours,Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,potentiator,yes
Cinolazepam,9 hours,Gamma-aminobutyric acid receptor subunit rho-3,GABRR3,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit gamma-1,GABRG1,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit gamma-3,GABRG3,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit delta,GABRD,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit epsilon,GABRE,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit pi,GABRP,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit rho-3,GABRR3,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Gamma-aminobutyric acid receptor subunit theta,GABRQ,potentiator,yes
Nitrazepam,15-38 hours (mean elimination half life 26 hours).,Sodium channel protein type 1 subunit alpha,SCN1A,other/unknown,unknown
Cilastatin,,Dipeptidase 1,DPEP1,inhibitor,yes
Imipenem,1 hour,Penicillin-binding protein 2,mrdA,inhibitor,yes
Imipenem,1 hour,Penicillin-binding protein 1B,mrcB,inhibitor,yes
Imipenem,1 hour,Penicillin-binding protein 1A,mrcA,inhibitor,yes
Imipenem,1 hour,Penicillin-binding protein 3,pbpC,inhibitor,yes
Imipenem,1 hour,Beta-lactamase,blaZ,other/unknown,yes
Probucol,"Ranges from 12 hours to more than 500 hours, the longest half-life probably being in adipose tissue.",ATP-binding cassette sub-family A member 1,ABCA1,inhibitor,yes
Probucol,"Ranges from 12 hours to more than 500 hours, the longest half-life probably being in adipose tissue.",Liver carboxylesterase 1,CES1,,unknown
Tiaprofenic acid,1.5-2.5 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Tiaprofenic acid,1.5-2.5 hours,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Lopinavir,,Human immunodeficiency virus type 1 protease,pol,inhibitor,yes
Bacampicillin,,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Meticillin,25-60 minutes,MecA PBP2' (penicillin binding protein 2'),mecA,inhibitor,yes
Meticillin,25-60 minutes,Penicillin-binding protein 2a,pbp2a,inhibitor,yes
Meticillin,25-60 minutes,Penicillin-binding protein 1b,pbp1b,inhibitor,yes
Meticillin,25-60 minutes,Penicillin-binding protein 2B,penA,inhibitor,yes
Meticillin,25-60 minutes,Penicillin-binding protein 3,pbp3,inhibitor,yes
Meticillin,25-60 minutes,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Pivampicillin,Approximately 1 hour.,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Pivmecillinam,,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Tazobactam,,Beta-lactamase SHV-1,bla,inhibitor,unknown
Tazobactam,,Beta-lactamase TEM,bla,inhibitor,yes
Ticarcillin,1.1 hours,Penicillin binding protein 2a,mecA,inhibitor,yes
Propericiazine,,D(1A) dopamine receptor,DRD1,antagonist,yes
Propericiazine,,Alpha-2A adrenergic receptor,ADRA2A,antagonist,yes
Propericiazine,,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Propericiazine,,Androgen receptor,AR,,unknown
Deferasirox,The mean elimination half-life ranged from 8 to 16 hours following oral administration.,Iron,,chelator,yes
Valganciclovir,Approximately 4.08 hours. Increased in patients with renal function impairment.,DNA,,adduct,yes
Hydroxychloroquine,Terminal elimination half-life In blood is approximately 50 days. In plasma it is approximately 32 days.,DNA,,cross-linking/alkylation,yes
Hydroxychloroquine,Terminal elimination half-life In blood is approximately 50 days. In plasma it is approximately 32 days.,Toll-like receptor 7,TLR7,antagonist,yes
Hydroxychloroquine,Terminal elimination half-life In blood is approximately 50 days. In plasma it is approximately 32 days.,Toll-like receptor 9,TLR9,antagonist,yes
Amyl Nitrite,,Atrial natriuretic peptide receptor 1,NPR1,agonist,yes
Erythrityl Tetranitrate,,Atrial natriuretic peptide receptor 1,NPR1,agonist,yes
Erythrityl Tetranitrate,,Atrial natriuretic peptide receptor 2,NPR2,agonist,yes
Acepromazine,3 hours in horses.,D(2) dopamine receptor,DRD2,antagonist,yes
Acepromazine,3 hours in horses.,D(1A) dopamine receptor,DRD1,antagonist,yes
Acepromazine,3 hours in horses.,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Acepromazine,3 hours in horses.,5-hydroxytryptamine receptor 1A,HTR1A,antagonist,yes
Acepromazine,3 hours in horses.,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Acepromazine,3 hours in horses.,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Aceprometazine,,Histamine H1 receptor,HRH1,antagonist,yes
Alverine,The plasma half-life averages 0.8 hours for alverine and 5.7 hours for the active primary metabolite.,5-hydroxytryptamine receptor 1A,HTR1A,antagonist,yes
Molindone,,D(2) dopamine receptor,DRD2,antagonist,yes
Molindone,,5-hydroxytryptamine receptor 1A,HTR1A,antagonist,unknown
Molindone,,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,unknown
Molindone,,Muscarinic acetylcholine receptor M1,CHRM1,other/unknown,unknown
Phenindamine,,Histamine H1 receptor,HRH1,antagonist,yes
Pheniramine,,Histamine H1 receptor,HRH1,antagonist,yes
Pheniramine,,Nuclear receptor subfamily 1 group I member 3,NR1I3,,unknown
Pipotiazine,,D(2) dopamine receptor,DRD2,antagonist,yes
Pipotiazine,,D(1A) dopamine receptor,DRD1,antagonist,yes
Pipotiazine,,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Pipotiazine,,5-hydroxytryptamine receptor 1A,HTR1A,antagonist,yes
Thioproperazine,,D(2) dopamine receptor,DRD2,antagonist,yes
Thioproperazine,,D(1A) dopamine receptor,DRD1,antagonist,unknown
Thioproperazine,,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Thioproperazine,,5-hydroxytryptamine receptor 1A,HTR1A,antagonist,yes
Thioproperazine,,Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Thioproperazine,,Alpha-1B adrenergic receptor,ADRA1B,antagonist,yes
Thiothixene,10-20 hours,D(2) dopamine receptor,DRD2,antagonist,yes
Thiothixene,10-20 hours,D(1A) dopamine receptor,DRD1,antagonist,yes
Thiothixene,10-20 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Zuclopenthixol,"20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.",D(1A) dopamine receptor,DRD1,antagonist,yes
Zuclopenthixol,"20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.",D(1B) dopamine receptor,DRD5,antagonist,yes
Zuclopenthixol,"20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.",D(2) dopamine receptor,DRD2,antagonist,yes
Zuclopenthixol,"20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.",Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Zuclopenthixol,"20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.",Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Zuclopenthixol,"20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.",5-hydroxytryptamine receptor 2A,HTR2A,antagonist,unknown
Zuclopenthixol,"20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.",Histamine H1 receptor,HRH1,antagonist,unknown
Isopropamide,,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Isopropamide,,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,unknown
Pargyline,,Amine oxidase [flavin-containing] B,MAOB,inhibitor,yes
Pargyline,,Amine oxidase [flavin-containing] A,MAOA,inhibitor,unknown
Lincomycin,"The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours. The serum half-life of lincomycin may be prolonged in patients with severe impairment of renal function compared to patients with normal renal function. In patients with abnormal hepatic function, serum half-life may be twofold longer than in patients with normal hepatic function.",50S ribosomal protein L10,rplJ,inhibitor,yes
Etoricoxib,22 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
5-Fluorouridine,,Uridine phosphorylase,udp,,unknown
5-Fluorouridine,,Superoxide dismutase [Cu-Zn],SOD1,,unknown
SC-74020,,72 kDa type IV collagenase,MMP2,,unknown
Methyl Nonanoate (Ester),,Neutrophil gelatinase-associated lipocalin,LCN2,,unknown
Methyl Nonanoate (Ester),,Ig gamma-1 chain C region,IGHG1,,unknown
Alpha-Phosphoribosylpyrophosphoric Acid,,Hypoxanthine-guanine phosphoribosyltransferase,HGPRTase,,unknown
Alpha-Phosphoribosylpyrophosphoric Acid,,Adenine phosphoribosyltransferase,APRT,,unknown
Alpha-Phosphoribosylpyrophosphoric Acid,,Anthranilate phosphoribosyltransferase,trpD,,unknown
Alpha-Phosphoribosylpyrophosphoric Acid,,Hypoxanthine-guanine phosphoribosyltransferase,HPRT1,,unknown
Alpha-Phosphoribosylpyrophosphoric Acid,,Orotate phosphoribosyltransferase,pyrE,,unknown
Alpha-Phosphoribosylpyrophosphoric Acid,,Uridine-cytidine kinase-like 1,UCKL1,,unknown
Deoxy-2-Fluoro-B-D-Cellotrioside,,Endoglucanase 5A,cel5A,,unknown
2-Oxy-4-Hydroxy-5-(2-Hydrazinopyridine)Phenylalanine,,Primary amine oxidase,tynA,,unknown
Sorbitol,,Xylose isomerase,xylA,,unknown
Sorbitol,,Xylose isomerase,xylA,,unknown
Sorbitol,,Xylose isomerase,xylA,,unknown
Sorbitol,,Malate synthase G,glcB,,unknown
N-Methyl-Pyridoxal-5'-Phosphate,,Aspartate aminotransferase,aspC,,unknown
"(5r)-6-(4-{[2-(3-Iodobenzyl)-3-Oxocyclohex-1-En-1-Yl]Amino}Phenyl)-5-Methyl-4,5-Dihydropyridazin-3(2h)-One",,"cGMP-inhibited 3',5'-cyclic phosphodiesterase B",PDE3B,,unknown
O1-Methyl-Glucose,,Endoglucanase 5A,cel5A,,unknown
O1-Methyl-Glucose,,Endoglucanase F,celCCF,,unknown
O1-Methyl-Glucose,,"Possible cellulase CelA1 (Endoglucanase) (Endo-1,4-beta-glucanase) (FI-cmcase) (Carboxymethyl cellulase)",celA1,,unknown
Thymidine-5'-Phosphate,,Thymidylate kinase,tmk,,unknown
Thymidine-5'-Phosphate,,Thymidylate kinase,DTYMK,,unknown
Thymidine-5'-Phosphate,,Thymidine kinase,TK,,unknown
Thymidine-5'-Phosphate,,PCZA361.16,,,unknown
Thymidine-5'-Phosphate,,DNA polymerase III subunit epsilon,dnaQ,,unknown
Thymidine-5'-Phosphate,,Glucose-1-phosphate thymidylyltransferase,rmlA,,unknown
Thymidine-5'-Phosphate,,Thymidylate synthase,TYMS,,unknown
Thymidine-5'-Phosphate,,Thymidylate synthase,thyA,,unknown
Thymidine-5'-Phosphate,,DNA topoisomerase 1,topA,,unknown
"3,6-Dihydroxy-Xanthene-9-Propionic Acid",,"Glutathione reductase, mitochondrial",GSR,,unknown
Genistein,,Estrogen receptor beta,ESR2,,unknown
Genistein,,DNA topoisomerase 2-alpha,TOP2A,,unknown
Genistein,,Protein-tyrosine kinase 2-beta,PTK2B,,unknown
Genistein,,Nuclear receptor coactivator 1,NCOA1,,unknown
Genistein,,Estrogen receptor alpha,ESR1,,unknown
Genistein,,Nuclear receptor coactivator 2,NCOA2,,unknown
Genistein,,Steroid hormone receptor ERR2,ESRRB,agonist,unknown
Genistein,,Steroid hormone receptor ERR1,ESRRA,agonist,unknown
Genistein,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Genistein,,RAC-alpha serine/threonine-protein kinase,AKT1,,unknown
Genistein,,G-protein coupled estrogen receptor 1,GPER1,,unknown
Genistein,,Cytochrome P450 1B1,CYP1B1,,unknown
Genistein,,Sex hormone-binding globulin,SHBG,,unknown
N-Acetylmethionine,,N-acylamino acid racemase,Aaar,,unknown
N-Acetylmethionine,,Rhodopsin,RHO,,unknown
Daxalipram,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,,unknown
7-Methyl-Gpppa,,m7GpppX diphosphatase,DCPS,,unknown
7-Methyl-Gpppa,,Eukaryotic translation initiation factor 4E,EIF4E,,unknown
trans-2-hydroxycinnamic acid,,Major NAD(P)H-flavin oxidoreductase,,,unknown
"Methyl 4,6-O-[(1r)-1-Carboxyethylidene]-Beta-D-Galactopyranoside",,Serum amyloid P-component,APCS,,unknown
4-Hydroxybenzoyl Coenzyme A,,4-chlorobenzoyl CoA dehalogenase,fcbB,,unknown
4-Hydroxybenzoyl Coenzyme A,,4-hydroxybenzoyl-CoA thioesterase,,,unknown
L-gulonic acid 6-phosphate,,3-keto-L-gulonate-6-phosphate decarboxylase UlaD,ulaD,,unknown
Roflumilast,Plasma half-life of roflumilast is 17 hours and its metabolite is 30 hours (oral dose).,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,inhibitor,unknown
Roflumilast,Plasma half-life of roflumilast is 17 hours and its metabolite is 30 hours (oral dose).,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,inhibitor,unknown
Roflumilast,Plasma half-life of roflumilast is 17 hours and its metabolite is 30 hours (oral dose).,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,inhibitor,unknown
Roflumilast,Plasma half-life of roflumilast is 17 hours and its metabolite is 30 hours (oral dose).,"cAMP-specific 3',5'-cyclic phosphodiesterase 4C",PDE4C,inhibitor,unknown
"2-Amino-3-[4-Hydroxy-6-Oxo-3-(2-Phenyl-Cyclopropylimino)-Cyclohexa-1,4-Dienyl]-Propionic Acid",,Primary amine oxidase,tynA,,unknown
1-(5-phospho-D-ribosyl)-ATP,,ATP phosphoribosyltransferase,hisG,,unknown
Trans-O-Hydroxy-Alpha-Methyl Cinnamate,,Chymotrypsinogen B,CTRB1,,unknown
"Lambda-Bis(2,2'-Bipyridine)-(5-Methyl-2-2'-Bipyridine)-C9-Adamantane Ruthenium (II)",,Camphor 5-monooxygenase,camC,,unknown
(S)-Des-Me-Ampa,,Glutamate receptor 2,GRIA2,,unknown
ZK-800270,,Trypsin-1,PRSS1,,unknown
D-Myo-Inositol-Hexasulphate,,Myo-inositol hexaphosphate phosphohydrolase,phyA,,unknown
D-Myo-Inositol-Hexasulphate,,Follistatin,FST,,unknown
8-azaguanine,,Purine nucleoside phosphorylase,PNP,,unknown
Nanaomycin D,,ActVA 6 protein,actVA 6,,unknown
Virginiamycin M1,,Streptogramin A acetyltransferase,vatD,,unknown
Propyl Acetate,,Carboxylesterase,est,,unknown
4-(Hydroxymercury)Benzoic Acid,,Carbonic anhydrase 2,CA2,,unknown
"2,3-Dihydroxy-Benzoic Acid",,"2,3-dihydroxybenzoate-AMP ligase",dhbE,,unknown
"2,3-Dihydroxy-Benzoic Acid",,Neutrophil gelatinase-associated lipocalin,LCN2,,unknown
Uridine-5'-Diphosphate-N-Acetylmuramoyl-L-Alanine,,UDP-N-acetylmuramoylalanine--D-glutamate ligase,murD,,unknown
Uridine-5'-Diphosphate-N-Acetylmuramoyl-L-Alanine,,UDP-N-acetylmuramate--L-alanine ligase,murC,,unknown
Methacrylyl-Coenzyme A,,"Isobutyryl-CoA dehydrogenase, mitochondrial",ACAD8,,unknown
Trinitrotoluene,,Pentaerythritol tetranitrate reductase,onr,,unknown
Fumaric Acid,,Malate dehydrogenase,mdh,,unknown
Fumaric Acid,,Fumarate reductase flavoprotein subunit,fccA,,unknown
Fumaric Acid,,Fumarate reductase flavoprotein subunit,,,unknown
Fumaric Acid,,"NAD-dependent malic enzyme, mitochondrial",ME2,,unknown
Fumaric Acid,,Fumarylacetoacetase,FAH,,unknown
RU84687,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
Benzene Hexacarboxylic Acid,,Phosphoglycerate mutase 2,PGAM2,,unknown
Chymostatin,,Peptide amidase,pam,,unknown
1-Hydroxy-1-Thio-Glycerol,,Prolyl endopeptidase,PREP,,unknown
Topiroxostat,The mean half life of topiroxostat after a single oral dose of 20mg topiroxostat is 5 hours under fasting condition. The complex of molybdenum (IV)- topiroxostat has an approximate half life of 20.4 hours [L867].,Xanthine dehydrogenase/oxidase,XDH,,unknown
"N,N-dimethylarginine",,"Nitric oxide synthase, inducible",NOS2,,unknown
"N,N-dimethylarginine",,"Nitric oxide synthase, endothelial",NOS3,,unknown
P-Cresol,,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
Inhibitor Idd 384,,Aldose reductase,AKR1B1,,unknown
Bis(Adenosine)-5'-Triphosphate,,Dephospho-CoA kinase,coaE,,unknown
Indole Naphthyridinone,,Enoyl-[acyl-carrier-protein] reductase [NADH] FabI,fabI,,unknown
Dithioerythritol,,Listeriolysin regulatory protein,prfA,,unknown
Dithioerythritol,,"6,7-dimethyl-8-ribityllumazine synthase",ribH,,unknown
Dithioerythritol,,"Thymidine kinase, cytosolic",TK1,,unknown
D-tartaric acid,,"2,3-diketo-L-gulonate reductase",dlgD,,unknown
D-tartaric acid,,Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1,B3GAT1,,unknown
D-tartaric acid,,Triggering receptor expressed on myeloid cells 1,TREM1,,unknown
D-tartaric acid,,Probable ATP-dependent RNA helicase DDX6,DDX6,,unknown
D-tartaric acid,,Cytochrome P450,,,unknown
D-tartaric acid,,Hypoxia-inducible factor 1-alpha inhibitor,HIF1AN,,unknown
D-tartaric acid,,D-3-phosphoglycerate dehydrogenase,serA,,unknown
D-tartaric acid,,Acyl-[acyl-carrier-protein]--UDP-N-acetylglucosamine O-acyltransferase,lpxA,,unknown
D-tartaric acid,,V-type proton ATPase subunit C 1,ATP6V1C1,,unknown
D-tartaric acid,,"dTDP-4-dehydrorhamnose 3,5-epimerase",rmlC,,unknown
D-tartaric acid,,Putative uncharacterized protein,,,unknown
D-tartaric acid,,Phosphonoacetate hydrolase,phnA,,unknown
D-tartaric acid,,Putative uncharacterized protein,,,unknown
N-Hydroxy-4-Phosphono-Butanamide,,Triosephosphate isomerase,TPI1,,unknown
Rutin,,Aldo-keto reductase family 1 member C3,AKR1C3,,unknown
Rutin,,Carbonyl reductase [NADPH] 1,CBR1,,unknown
(4e)-4-Aminohex-4-Enoic Acid,,"4-aminobutyrate aminotransferase, mitochondrial",ABAT,,unknown
AICA ribonucleotide,,Bifunctional purine biosynthesis protein PURH,ATIC,,unknown
"1,2-Dichloro-Propane",,Haloalkane dehalogenase,linB,,unknown
"2-(3,4-Dihydroxyphenyl)Acetic Acid",,DNA,,,unknown
"2-(3,4-Dihydroxyphenyl)Acetic Acid",,"3,4-dihydroxyphenylacetate 2,3-dioxygenase",mndD,,unknown
"2-(3,4-Dihydroxyphenyl)Acetic Acid",,"Homoprotocatechuate 2,3-dioxygenase",,,unknown
"2-(3,4-Dihydroxyphenyl)Acetic Acid",,Penicillin G acylase,pac,,unknown
"2-(3,4-Dihydroxyphenyl)Acetic Acid",,"Protocatechuate 3,4-dioxygenase alpha chain",pcaG,,unknown
"2-(3,4-Dihydroxyphenyl)Acetic Acid",,"Protocatechuate 3,4-dioxygenase beta chain",pcaH,,unknown
N-(2-Ferrocenylethyl)Maleimide,,Camphor 5-monooxygenase,camC,,unknown
"2,4-Dihydroxy-Trans Cinnamic Acid",,Chymotrypsinogen B,CTRB1,,unknown
Bis(5-Amidino-Benzimidazolyl)Methane,,Trypsin-1,PRSS1,,unknown
Bis(5-Amidino-Benzimidazolyl)Methane,,Botulinum neurotoxin type B,botB,,unknown
Prasterone,12 hours,Estrogen receptor alpha,ESR1,binder,unknown
Prasterone,12 hours,Estrogen receptor beta,ESR2,activator,unknown
Prasterone,12 hours,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,antagonist,unknown
Prasterone,12 hours,NMDA receptor,GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B,agonist,unknown
Prasterone,12 hours,Androgen receptor,AR,agonist,unknown
Prasterone,12 hours,Estradiol 17-beta-dehydrogenase 1,HSD17B1,,unknown
Prasterone,12 hours,Bile salt sulfotransferase,SULT2A1,,unknown
Prasterone,12 hours,Sulfotransferase family cytosolic 2B member 1,SULT2B1,,unknown
Prasterone,12 hours,Peroxisome proliferator-activated receptor alpha,PPARA,activator,unknown
Prasterone,12 hours,Sigma non-opioid intracellular receptor 1,SIGMAR1,agonist,unknown
Prasterone,12 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,activator,unknown
Prasterone,12 hours,Nuclear receptor subfamily 1 group I member 3,NR1I3,activator,unknown
Prasterone,12 hours,Steroid Delta-isomerase,ksi,,unknown
Prasterone,12 hours,Cholesterol oxidase,choB,,unknown
2-phospho-D-glyceric acid,,2-dehydro-3-deoxyphosphooctonate aldolase,kdsA,,unknown
2-phospho-D-glyceric acid,,"2,3-bisphosphoglycerate-independent phosphoglycerate mutase",gpmI,,unknown
2-phospho-D-glyceric acid,,Triosephosphate isomerase,TPI,,unknown
2-phospho-D-glyceric acid,,Beta-enolase,ENO3,,unknown
Porphyrin Fe(III),,Myoglobin,MB,,unknown
"2,3,4,5,6-Pentafluorobenzyl Alcohol",,Alcohol dehydrogenase 1C,ADH1C,,unknown
"(3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Phenylalanine Ethyl Ester",,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,,unknown
Udp-Alpha-D-Xylopyranose,,UDP-glucose 6-dehydrogenase,hasB,,unknown
"7,8-Diamino-Nonanoic Acid",,ATP-dependent dethiobiotin synthetase BioD 1,bioD1,,unknown
Bis(Adenosine)-5'-Pentaphosphate,,Adenylate kinase,adk,,unknown
Bis(Adenosine)-5'-Pentaphosphate,,Adenylate kinase,adk,,unknown
Bis(Adenosine)-5'-Pentaphosphate,,Adenylate kinase,adk,,unknown
Bis(Adenosine)-5'-Pentaphosphate,,"Adenylate kinase 2, mitochondrial",AK2,,unknown
Bis(Adenosine)-5'-Pentaphosphate,,Adenylate kinase 8,AK8,,unknown
Bis(Adenosine)-5'-Pentaphosphate,,Adenylate kinase,adk,,unknown
Bis(Adenosine)-5'-Pentaphosphate,,Adenylate kinase isoenzyme 1,AK1,,unknown
Cetrimonium,,Cyclopropane mycolic acid synthase MmaA2,mmaA2,,unknown
Cetrimonium,,Cyclopropane mycolic acid synthase 1,cmaA1,,unknown
Thio-Maltopentaose,,Cyclomaltodextrin glucanotransferase,,,unknown
(2z)-2-(Benzoylamino)-3-[4-(2-Bromophenoxy)Phenyl]-2-Propenoic Acid,,Genome polyprotein,,,unknown
Analogue of Indinavir Drug,,Gag-Pol polyprotein,gag-pol,,unknown
"{3-[3-(3,4-Dimethoxy-Phenyl)-1-(1-{1-[2-(3,4,5-Trimethoxy-Phenyl)-Butyryl]-Piperidin-2yl}-Vinyloxy)-Propyl]-Phenoxy}-Acetic Acid",,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,,unknown
"2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamide",,Trypsin-1,PRSS1,,unknown
"2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamide",,Prothrombin,F2,,unknown
"2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamide",,Urokinase-type plasminogen activator,PLAU,,unknown
2-Aminophenol,,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
Isocitric Acid,,Isocitrate dehydrogenase [NADP],icd,,unknown
Isocitric Acid,,Isocitrate dehydrogenase [NADP],icd,,unknown
Isocitric Acid,,"Aconitate hydratase, mitochondrial",ACO2,,unknown
Isocitric Acid,,"Isocitrate dehydrogenase [NADP], mitochondrial",IDH2,,unknown
Isocitric Acid,,Isocitrate dehydrogenase [NADP] cytoplasmic,IDH1,,unknown
Isocitric Acid,,Methylisocitrate lyase,prpB,,unknown
"3-[Aminoethylphosphoryl]-[1,2-Di-Palmitoyl]-Sn-Glycerol",,Rhodopsin,RHO,,unknown
(S)-Wiskostatin,,Wiskott-Aldrich syndrome protein,WAS,,unknown
"(4r,5s,6s,7r)-1,3-Dibenzyl-4,7-Bis(Phenoxymethyl)-5,6-Dihydroxy-1,3 Diazepan-2-One",,Gag-Pol polyprotein,gag-pol,,unknown
L-Phospholactate,,Pyruvate kinase PKM,PKM,,unknown
3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
3-Chloroalaninate,,1-aminocyclopropane-1-carboxylate deaminase,acdS,,unknown
[3-(Dodecanoylamino)Propyl](Hydroxy)Dimethylammonium,,ADP/ATP translocase 1,SLC25A4,,unknown
"Nalpha-(2-Naphthylsulfonylglycyl)-3-Amidino-D,L-Phenylalanine-Isopropylester",,Trypsin-1,PRSS1,,unknown
Phosphorylcolamine,,Protein kinase C beta type,PRKCB,,unknown
CRA_17693,,Trypsin-1,PRSS1,,unknown
(3r)-1-Acetyl-3-Methylpiperidine,,Peptidyl-prolyl cis-trans isomerase A,PPIA,,unknown
Camphor,,Camphor 5-monooxygenase,camC,,unknown
N-Alpha-(2-Naphthylsulfonyl)-N(3-Amidino-L-Phenylalaninyl)Isopipecolinic Acid Methyl Ester,,Trypsin-1,PRSS1,,unknown
Coprogen,,Iron(3+)-hydroxamate-binding protein FhuD,fhuD,,unknown
N-Benzyl-4-Sulfamoyl-Benzamide,,Carbonic anhydrase 2,CA2,,unknown
1-naphthaleneacetic acid,,S-phase kinase-associated protein 1,SKP1,,unknown
S-adenosyl-L-homocysteine,,Release factor glutamine methyltransferase,prmC,,unknown
S-adenosyl-L-homocysteine,,Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase,PAPS,,unknown
S-adenosyl-L-homocysteine,,Cobalt-precorrin-4 C(11)-methyltransferase,cbiF,,unknown
S-adenosyl-L-homocysteine,,Protein-L-isoaspartate(D-aspartate) O-methyltransferase,PCMT1,,unknown
S-adenosyl-L-homocysteine,,Genome polyprotein,,,unknown
S-adenosyl-L-homocysteine,,Phenylethanolamine N-methyltransferase,PNMT,,unknown
S-adenosyl-L-homocysteine,,Cyclopropane mycolic acid synthase 2,cmaA2,,unknown
S-adenosyl-L-homocysteine,,Modification methylase RsrI,rsrIM,,unknown
S-adenosyl-L-homocysteine,,Release factor glutamine methyltransferase,prmC,,unknown
S-adenosyl-L-homocysteine,,Protein arginine N-methyltransferase 3,PRMT3,,unknown
S-adenosyl-L-homocysteine,,Histamine N-methyltransferase,HNMT,,unknown
S-adenosyl-L-homocysteine,,Ribosomal RNA small subunit methyltransferase H,rsmH,,unknown
S-adenosyl-L-homocysteine,,rRNA adenine N-6-methyltransferase,ermC',,unknown
S-adenosyl-L-homocysteine,,tRNA (cytosine(38)-C(5))-methyltransferase,TRDMT1,,unknown
S-adenosyl-L-homocysteine,,Glycine N-methyltransferase,GNMT,,unknown
S-adenosyl-L-homocysteine,,tRNA (cytidine(34)-2'-O)-methyltransferase,trmL,,unknown
S-adenosyl-L-homocysteine,,Modification methylase PvuII,pvuIIM,,unknown
S-adenosyl-L-homocysteine,,DNA adenine methylase,DAM,,unknown
S-adenosyl-L-homocysteine,,Cyclopropane mycolic acid synthase 3,pcaA,,unknown
S-adenosyl-L-homocysteine,,Protein arginine N-methyltransferase 1,PRMT1,,unknown
S-adenosyl-L-homocysteine,,Siroheme synthase,cysG,,unknown
S-adenosyl-L-homocysteine,,Modification methylase HhaI,hhaIM,,unknown
S-adenosyl-L-homocysteine,,Histone-lysine N-methyltransferase SETD7,SETD7,,unknown
S-adenosyl-L-homocysteine,,tRNA (guanine-N(1)-)-methyltransferase,trmD,,unknown
S-adenosyl-L-homocysteine,,Cyclopropane mycolic acid synthase MmaA2,mmaA2,,unknown
S-adenosyl-L-homocysteine,,Diphthine synthase,DPH5,,unknown
S-adenosyl-L-homocysteine,,RdmB,rdmB,,unknown
S-adenosyl-L-homocysteine,,tRNA (guanine-N(1)-)-methyltransferase,trmD,,unknown
S-adenosyl-L-homocysteine,,Uroporphyrinogen-III C-methyltransferase,cobA,,unknown
S-adenosyl-L-homocysteine,,Uncharacterized protein,,,unknown
S-adenosyl-L-homocysteine,,Chemotaxis protein methyltransferase,cheR,,unknown
S-adenosyl-L-homocysteine,,Modification methylase TaqI,taqIM,,unknown
S-adenosyl-L-homocysteine,,Protein-L-isoaspartate O-methyltransferase,pcm,,unknown
S-adenosyl-L-homocysteine,,Catechol O-methyltransferase domain-containing protein 1,COMTD1,,unknown
S-adenosyl-L-homocysteine,,Carminomycin 4-O-methyltransferase,dnrK,,unknown
S-adenosyl-L-homocysteine,,Guanidinoacetate N-methyltransferase,GAMT,,unknown
4-Oxo-Nicotinamide-Adenine Dinucleotide Phosphate,,NADPH-ferredoxin reductase FprA,fprA,,unknown
"3,4-Dihydroxy-1-Methylquinolin-2(1h)-One",,Serine/threonine-protein kinase pim-1,PIM1,,unknown
N-[Isoleucinyl]-N'-[Adenosyl]-Diaminosufone,,Isoleucine--tRNA ligase,ileS,,unknown
4-phospho-L-threonic acid,,Ribose-5-phosphate isomerase,RPIA,,unknown
3-Iodo-Tyrosine,,Tyrosine--tRNA ligase,tyrS,,unknown
2-Methoxy-3-Isopropylpyrazine,,Epididymal-specific lipocalin-9,LCN9,,unknown
4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine,,Mitogen-activated protein kinase 14,MAPK14,,unknown
Acetoacetic Acid,,Fumarylacetoacetase,FAH,,unknown
7-thionicotinamide-adenine-dinucleotide phosphate,,"NAD(P) transhydrogenase, mitochondrial",NNT,,unknown
Dalfopristin,The elimination half-life is approximately 0.70 hours.,Streptogramin A acetyltransferase,vatD,inhibitor,yes
"(5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid",,Casein kinase II subunit alpha,CSNK2A1,,unknown
Beta-(2-Naphthyl)-Alanine,,"Tyrosine--tRNA ligase, cytoplasmic",YARS,,unknown
Beta-(2-Naphthyl)-Alanine,,Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1,PIN1,,unknown
Beta-(2-Naphthyl)-Alanine,,Prothrombin,F2,,unknown
Hemi-Babim,,Trypsin-1,PRSS1,,unknown
Hemi-Babim,,Prothrombin,F2,,unknown
Methylumbelliferyl Sialic Acid,,Trans-sialidase,,,unknown
CRA_10991,,Trypsin-1,PRSS1,,unknown
"3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione",,Glycogen synthase kinase-3 beta,GSK3B,,unknown
4-[3-Carboxymethyl-3-(4-Phosphonooxy-Benzyl)-Ureido]-4-[(3-Cyclohexyl-Propyl)-Methyl-Carbamoyl]Butyric Acid,,Tyrosine-protein kinase transforming protein Src,V-SRC,,unknown
Adenosine-5'-Monophosphate Glucopyranosyl-Monophosphate Ester,,ADP-L-glycero-D-manno-heptose-6-epimerase,hldD,,unknown
Dihydroxyacetone,,Dihydroxyacetone kinase,dhaK,,unknown
M-Cresol,,Insulin,INS,,unknown
Coa-S-Trimethylene-Acetyl-Tryptamine,,Serotonin N-acetyltransferase,AANAT,,unknown
"8-Amino-1,3-Dimethyl-3,7-Dihydropurine-2,6-Dione",,Dihydroneopterin aldolase,folB,,unknown
Glycerol-2-Phosphate,,Triosephosphate isomerase,TPI,,unknown
Fusicoccin,,14-3-3 protein epsilon,YWHAE,,unknown
"2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One",,Mitogen-activated protein kinase 10,MAPK10,,unknown
"2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One",,C-Jun-amino-terminal kinase-interacting protein 1,MAPK8IP1,,unknown
"2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One",,Mitogen-activated protein kinase 8,MAPK8,,unknown
"2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One",,Dual specificity protein kinase TTK,TTK,,unknown
Pantothenic acid,,Pantothenate kinase,coaA,,unknown
4-Flourobenzenesulfonamide,,Carbonic anhydrase 2,CA2,,unknown
Dimethylallyl Diphosphate,,Farnesyl pyrophosphate synthase,FDPS,,unknown
Dimethylallyl Diphosphate,,Isopentenyl-diphosphate Delta-isomerase 1,IDI1,,unknown
Dimethylallyl Diphosphate,,4-hydroxy-3-methylbut-2-enyl diphosphate reductase,ispH,,unknown
D-Alanine,,Thermolysin,nprS,,unknown
D-Alanine,,D-alanyl-D-alanine carboxypeptidase,,,unknown
4-Imino-5-Methidyl-2-Methylpyrimidine,,Thiamine-phosphate synthase,thiE,,unknown
"1-Amino-2,3-Dihydroxy-5-Hydroxymethyl Cyclohex-5-Ene",,Cyclomaltodextrin glucanotransferase,,,unknown
"Sp-Adenosine-3',5'-Cyclic-Monophosphorothioate",,cAMP-dependent protein kinase type I-alpha regulatory subunit,PRKAR1A,,unknown
Piclamilast,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,,unknown
Piclamilast,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,,unknown
Piclamilast,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4C",PDE4C,,unknown
Piclamilast,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,,unknown
Adenylyl-3'-5'-Phospho-Uridine-3'-Monophosphate,,Diphtheria toxin,,,unknown
SB-409513,,Glycogen synthase kinase-3 beta,GSK3B,,unknown
Phenyl Boronic Acid,,Cocaine esterase,cocE,,unknown
Quinolinic Acid,,Nicotinate-nucleotide pyrophosphorylase [carboxylating],nadC,,unknown
Quinolinic Acid,,Nicotinate-nucleotide pyrophosphorylase [carboxylating],nadC,,unknown
4-Hydroxy-3-Methyl Butyl Diphosphate,,Isopentenyl-diphosphate Delta-isomerase,idi,,unknown
"N,4-Dihydroxy-N-Oxo-3-(Sulfooxy)Benzenaminium",,Tyrosine-protein phosphatase YopH,yopH,,unknown
"N,4-Dihydroxy-N-Oxo-3-(Sulfooxy)Benzenaminium",,Arylsulfatase A,ARSA,,unknown
2-(Trimethylammonium)Ethyl Thiol,,NPQTN specific sortase B,srtB,,unknown
"2-Ammoniobut-3-Enoate, 2-Amino-3-Butenoate",,1-aminocyclopropane-1-carboxylate deaminase,acdS,,unknown
Monoisopropylphosphorylserine,,Trypsin-2,PRSS2,,unknown
Monoisopropylphosphorylserine,,Subtilisin BPN',apr,,unknown
Monoisopropylphosphorylserine,,Trypsin-1,PRSS1,,unknown
Monoisopropylphosphorylserine,,Acetylcholinesterase,ACHE,,unknown
"10-{4-Dimethylamino-5-[4-Hydroxy-6-Methyl-5-(6-Methyl-5-Oxo-Tetrahydro-Pyran-2-Yloxy)-Tetrahydro-Pyrane-2-Yloxy]-6-Methyl-Tetrahydro-Pyran-2-Yloxy}-8-Ethyl-1,8,11-Trihydroxy-7,8,9,10-Tetrahydro-Naphthacene-5,12-Dione",,RdmC,rdmC,,unknown
"N-[(3z)-5-Tert-Butyl-2-Phenyl-1,2-Dihydro-3h-Pyrazol-3-Ylidene]-N'-(4-Chlorophenyl)Urea",,Mitogen-activated protein kinase 14,MAPK14,,unknown
Thiarsahydroxy-Cysteine,,Arsenate reductase,arsC,,unknown
"1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine",,Tyrosine-protein kinase HCK,HCK,,unknown
"1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine",,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,,unknown
"[1-(1-Methyl-4,5-Dioxo-Pent-2-Enylcarbamoyl)-2-Phenyl-Ethyl]-Carbamic Acid Benzyl Ester",,Cruzipain,,,unknown
"[1-(1-Methyl-4,5-Dioxo-Pent-2-Enylcarbamoyl)-2-Phenyl-Ethyl]-Carbamic Acid Benzyl Ester",,Cathepsin F,CTSF,,unknown
"3h-Indole-5,6-Diol",,Lactotransferrin,LTF,,unknown
Adenosine-3'-5'-Diphosphate,,Heparan sulfate glucosamine 3-O-sulfotransferase 1,HS3ST1,,unknown
Adenosine-3'-5'-Diphosphate,,Sulfotransferase family cytosolic 2B member 1,SULT2B1,,unknown
Adenosine-3'-5'-Diphosphate,,Non-secretory ribonuclease,RNASE2,,unknown
Adenosine-3'-5'-Diphosphate,,Sulfotransferase 1A1,SULT1A1,,unknown
Adenosine-3'-5'-Diphosphate,,Heparan sulfate glucosamine 3-O-sulfotransferase 3A1,HS3ST3A1,,unknown
Adenosine-3'-5'-Diphosphate,,Ribonuclease pancreatic,RNASE1,,unknown
Adenosine-3'-5'-Diphosphate,,Bile salt sulfotransferase,SULT2A1,,unknown
Adenosine-3'-5'-Diphosphate,,Estrogen sulfotransferase,SULT1E1,,unknown
Adenosine-3'-5'-Diphosphate,,Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1,NDST1,,unknown
Adenosine-3'-5'-Diphosphate,,Holo-[acyl-carrier-protein] synthase,acpS,,unknown
Adenosine-3'-5'-Diphosphate,,Sulfotransferase family cytosolic 1B member 1,SULT1B1,,unknown
Adenosine-3'-5'-Diphosphate,,DNA topoisomerase 1,topA,,unknown
Pyridoxyl-Glutamic Acid-5'-Monophosphate,,Branched-chain-amino-acid aminotransferase,ilvE,,unknown
Pyridoxyl-Glutamic Acid-5'-Monophosphate,,Histidinol-phosphate aminotransferase,hisC,,unknown
2-Tridecanoyloxy-Pentadecanoic Acid,,Ferrichrome-iron receptor,fhuA,,unknown
Nz-(Dicarboxymethyl)Lysine,,Transaldolase B,talB,,unknown
Castanospermine,,"Glucan 1,3-beta-glucosidase",XOG1,,unknown
Threonine-Aspartic Ester,,L-asparaginase 2,ansB,,unknown
O3-Sulfonylgalactose,,Mannose-binding protein C,MBL2,,unknown
Phosphoenolpyruvate,,"Phospho-2-dehydro-3-deoxyheptonate aldolase, Phe-sensitive",aroG,,unknown
Phosphoenolpyruvate,,2-dehydro-3-deoxyphosphooctonate aldolase,kdsA,,unknown
Phosphoenolpyruvate,,Beta-enolase,ENO3,,unknown
Phosphoenolpyruvate,,Capsule biosynthesis protein,synC,,unknown
Phosphoenolpyruvate,,"Phosphoenolpyruvate carboxykinase, cytosolic [GTP]",PCK1,,unknown
Phosphoenolpyruvate,,2-dehydro-3-deoxyphosphooctonate aldolase,kdsA,,unknown
Phosphoenolpyruvate,,Phospho-2-dehydro-3-deoxyheptonate aldolase,aroF,,unknown
"Compound 12, N-Acetyl-4-[(Carboxycarbonyl)(2-Carboxyphenyl)Amino]-N-Pentyl-1-Napthylalaniamide",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
"L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide",,"Nitric oxide synthase, endothelial",NOS3,,unknown
"L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide",,"Nitric oxide synthase, brain",NOS1,,unknown
"(4R,5R)-1,2-dithiane-4,5-diol",,Penicillin acylase,,,unknown
Beta-D-Glucopyranose Spirohydantoin,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
"(3s)-Tetrahydrofuran-3-Yl (1r,2s)-3-[4-((1r)-2-{[(S)-Amino(Hydroxy)Methyl]Oxy}-2,3-Dihydro-1h-Inden-1-Yl)-2-Benzyl-3-Oxopyrrolidin-2-Yl]-1-Benzyl-2-Hydroxypropylcarbamate",,Gag-Pol polyprotein,gag-pol,,unknown
2-Amino-8-Methylquinazolin-4(3h)-One,,Queuine tRNA-ribosyltransferase,tgt,,unknown
N-Butyl Isocyanide,,Camphor 5-monooxygenase,camC,,unknown
N-Butyl Isocyanide,,Cytochrome c',,,unknown
N-Butyl Isocyanide,,Group 1 truncated hemoglobin GlbN,glbN,,unknown
N-Butyl Isocyanide,,Myoglobin,MB,,unknown
"2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide",,Galectin-3,LGALS3,,unknown
Methylamine,,Ammonia channel,amtB,,unknown
Desulfo-Coenzyme A,,Chloramphenicol acetyltransferase,cat,,unknown
"{4-[2-Acetylamino-2-(3-Carbamoyl-2-Cyclohexylmethoxy-6,7,8,9-Tetrahydro-5h-Benzocyclohepten-5ylcarbamoyl)-Ethyl]-2-Phosphono-Phenyl}-Phosphonic Acid",,Tyrosine-protein kinase Lck,LCK,,unknown
Tryptophanyl-5'amp,,"Tryptophan--tRNA ligase, cytoplasmic",WARS,,unknown
Tryptophanyl-5'amp,,Tryptophan--tRNA ligase,trpS,,unknown
4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid,,Fumarylacetoacetase,FAH,,unknown
L-2-Amino-4-(Guanidinooxy)Butyric Acid,,"Nitric oxide synthase, endothelial",NOS3,,unknown
"(9R,10R)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene",,Glutathione S-transferase P,GSTP1,,unknown
"(9R,10R)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene",,Glutathione S-transferase Mu 1,GSTM1,,unknown
4r-Fluoro-N6-Ethanimidoyl-L-Lysine,,"Nitric oxide synthase, inducible",NOS2,,unknown
"[4-(6-Chloro-Naphthalene-2-Sulfonyl)-Piperazin-1-Yl]-(3,4,5,6-Tetrahydro-2h-[1,4']Bipyridinyl-4-Yl)-Methanone",,Trypsin-1,PRSS1,,unknown
O-acetyl-L-serine,,Prostaglandin G/H synthase 1,PTGS1,,unknown
Propylene glycol,,Coagulation factor XIII A chain,F13A1,,unknown
Propylene glycol,,Haloalkane dehalogenase,linB,,unknown
Propylene glycol,,Clavaminate synthase 1,cs1,,unknown
Propylene glycol,,Lactaldehyde reductase,fucO,,unknown
Propylene glycol,,B12-independent glycerol dehydratase,dhaB1,,unknown
2-Deoxy-D-Glucitol 6-(E)-Vinylhomophosphonate,,Inositol-3-phosphate synthase 1,ISYNA1,,unknown
"4,6-Dideoxyglucose",,Neopullulanase 1,tvaI,,unknown
"4,6-Dideoxyglucose",,Cyclomaltodextrin glucanotransferase,cgt,,unknown
"4,6-Dideoxyglucose",,"Glucan 1,4-alpha-maltohexaosidase",,,unknown
"4,6-Dideoxyglucose",,Alpha-amylase,amyE,,unknown
"4,6-Dideoxyglucose",,Cyclomaltodextrin glucanotransferase,,,unknown
3'-Phosphate-Adenosine-5'-Diphosphate,,Ribonuclease pancreatic,RNASE1,,unknown
3'-Phosphate-Adenosine-5'-Diphosphate,,Aminoglycoside 2'-N-acetyltransferase,aac,,unknown
"3-Amino-8,9,10-Trihydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
"N,N-dimethylformamide",,Chymotrypsin-like elastase family member 1,CELA1,,unknown
"N,N-dimethylformamide",,Renin,REN,,unknown
Oxidized Coenzyme A,,Formyl-coenzyme A transferase,frc,,unknown
Oxidized Coenzyme A,,Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex,,,unknown
N-Carbamyl-D-Valine,,N-carbamoyl-D-amino acid hydrolase,,,unknown
Tetrabutylammonium Ion,,pH-gated potassium channel KcsA,kcsA,,unknown
Tetrabutylammonium Ion,,Ig kappa chain C region,IGKC,,unknown
Kaempherol,,UDP-glucuronosyltransferase 3A1,UGT3A1,,unknown
Bacteriochlorophyll A,,Bacteriochlorophyll a protein,,,unknown
Bacteriochlorophyll A,,Bacteriochlorophyll a protein,fmoA,,unknown
5-Bromonicotinamide,,GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1,ART1,,unknown
Pimelic Acid,,"2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase",dapD,,unknown
Phosphoaspartate,,Beta-phosphoglucomutase,pgmB,,unknown
Phosphoaspartate,,Nitrogen regulation protein NR(I),glnG,,unknown
[1-(4-Fluorobenzyl)Cyclobutyl]Methyl (1s)-1-[Oxo(1h-Pyrazol-5-Ylamino)Acetyl]Pentylcarbamate,,Cathepsin K,CTSK,,unknown
4-Diphosphocytidyl-2-C-Methyl-D-Erythritol 2-Phosphate,,"2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase",ispF,,unknown
Cordycepin Triphosphate,,Poly(A) polymerase alpha,PAPOLA,,unknown
Uridine diphosphate glucose,,WbpP,,,unknown
Uridine diphosphate glucose,,Glycogenin-1,GYG1,,unknown
Uridine diphosphate glucose,,"Alpha,alpha-trehalose-phosphate synthase [UDP-forming]",otsA,,unknown
Uridine diphosphate glucose,,Galactose-1-phosphate uridylyltransferase,galT,,unknown
Uridine diphosphate glucose,,UDP-glucose 4-epimerase,GALE,,unknown
Uridine diphosphate glucose,,Glucose-1-phosphate thymidylyltransferase,rmlA,,unknown
Uridine diphosphate glucose,,UDP-glucose 4-epimerase,galE,,unknown
Uridine diphosphate glucose,,DNA beta-glucosyltransferase,bgt,,unknown
Uridine diphosphate glucose,,Glycosyltransferase 6 domain-containing protein 1,GLT6D1,,unknown
Isopropyl beta-D-thiogalactopyranoside,,Beta-galactosidase,lacZ,,unknown
Isopropyl beta-D-thiogalactopyranoside,,Galactoside O-acetyltransferase,lacA,,unknown
Isopropyl beta-D-thiogalactopyranoside,,Lactose operon repressor,lacI,,unknown
"Inositol 1,3,4,5-Tetrakisphosphate",,RAC-alpha serine/threonine-protein kinase,AKT1,,unknown
"Inositol 1,3,4,5-Tetrakisphosphate",,Pleckstrin homology domain-containing family A member 4,PLEKHA4,,unknown
"Inositol 1,3,4,5-Tetrakisphosphate",,Tyrosine-protein kinase BTK,BTK,,unknown
"Inositol 1,3,4,5-Tetrakisphosphate",,Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide,DAPP1,,unknown
"Inositol 1,3,4,5-Tetrakisphosphate",,Inositol-trisphosphate 3-kinase A,ITPKA,,unknown
"Inositol 1,3,4,5-Tetrakisphosphate",,Cytohesin-2,CYTH2,,unknown
"Inositol 1,3,4,5-Tetrakisphosphate",,Cytohesin-3,CYTH3,,unknown
"Inositol 1,3,4,5-Tetrakisphosphate",,3-phosphoinositide-dependent protein kinase 1,PDPK1,,unknown
5'-Guanosine-Diphosphate-Monothiophosphate,,ADP-ribosylation factor 6,ARF6,,unknown
5'-Guanosine-Diphosphate-Monothiophosphate,,Protein-glutamine gamma-glutamyltransferase E,TGM3,,unknown
5'-Guanosine-Diphosphate-Monothiophosphate,,Cell division protein FtsZ,ftsZ,,unknown
5'-Guanosine-Diphosphate-Monothiophosphate,,Ras-related protein Rab-11A,RAB11A,,unknown
3-(6-Aminopyridin-3-Yl)-N-Methyl-N-[(1-Methyl-1h-Indol-2-Yl)Methyl]Acrylamide,,Enoyl-[acyl-carrier-protein] reductase [NADH] FabI,fabI,,unknown
RU79256,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
Glycyl-L-a-Aminopimelyl-E-(D-2-Aminoethyl)Phosphonate,,D-alanyl-D-alanine carboxypeptidase,,,unknown
"1,4-dithio-alpha-D-glucopyranose",,Alpha-amylase 2B,AMY2B,,unknown
[1-(1-Benzyl-3-Hydroxy-2-Oxo-Propylcarbamoyl)-2-Phenyl-Ethyl]-Carbamic Acid Benzyl Ester,,Cruzipain,,,unknown
[1-(1-Benzyl-3-Hydroxy-2-Oxo-Propylcarbamoyl)-2-Phenyl-Ethyl]-Carbamic Acid Benzyl Ester,,Cathepsin F,CTSF,,unknown
2-deoxy-2-acetamido-beta-D-galactose-4-sulfate,,Chondroitinase (Chondroitin lyase),,,unknown
2-deoxy-2-acetamido-beta-D-galactose-4-sulfate,,Chondroitinase-B,cslB,,unknown
2-deoxy-2-acetamido-beta-D-galactose-4-sulfate,,Hyaluronate lyase,,,unknown
2-deoxy-2-acetamido-beta-D-galactose-4-sulfate,,Chondroitinase-AC,cslA,,unknown
Epothilone D,,Tubulin alpha-3C/D chain,TUBA3C,,unknown
Epothilone D,,Tubulin beta chain,TUBB,,unknown
Epothilone D,,Tubulin beta-1 chain,TUBB1,,unknown
Epothilone D,,Tubulin beta-4B chain,TUBB4B,,unknown
Epothilone D,,Tubulin beta-4A chain,TUBB4A,,unknown
Epothilone D,,Tubulin alpha-4A chain,TUBA4A,,unknown
Epothilone D,,Tubulin beta-3 chain,TUBB3,,unknown
Epothilone D,,Tubulin alpha-1C chain,TUBA1C,,unknown
Epothilone D,,Tubulin alpha-8 chain,TUBA8,,unknown
Epothilone D,,Tubulin alpha-1B chain,TUBA1B,,unknown
Epothilone D,,Tubulin alpha-1A chain,TUBA1A,,unknown
8-Azaxanthine,,Uric acid degradation bifunctional protein,uao,,unknown
Bis(5-Amidino-2-Benzimidazolyl)Methanone,,Trypsin-1,PRSS1,,unknown
"N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide",,Stromelysin-1,MMP3,,unknown
Benzophenone,,Estrogen receptor alpha,ESR1,,unknown
Benzophenone,,Estrogen receptor beta,ESR2,,unknown
(S)-2-{Methyl-[2-(Naphthalene-2-Sulfonylamino)-5-(Naphthalene-2-Sulfonyloxy)-Benzoyl]-Amino}-Succinicacid,,UDP-N-acetylglucosamine 1-carboxyvinyltransferase,murA,,unknown
"3,4-Dihydroxycinnamic Acid",,Photoactive yellow protein,pyp,,unknown
"3,4-Dihydroxycinnamic Acid",,Histidine ammonia-lyase,hutH,,unknown
"3,4-Dihydroxycinnamic Acid",,Macrophage migration inhibitory factor,MIF,,unknown
"2-Methylpentane-1,2,4-Triol",,Xylose isomerase,xylA,,unknown
"(2s)-2-Amino-4-(Methylsulfanyl)-1-Pyridin-2-Ylbutane-1,1-Diol",,Methionine aminopeptidase,map,,unknown
"(2s)-2-Amino-4-(Methylsulfanyl)-1-Pyridin-2-Ylbutane-1,1-Diol",,Methionine aminopeptidase,map,,unknown
N-(Sulfanylacetyl)Tyrosylprolylmethioninamide,,Lethal factor,lef,,unknown
2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One,,Dipeptidyl peptidase 4,DPP4,,unknown
D-Galctopyranosyl-1-On,,Beta-galactosidase,lacZ,,unknown
Inhibitor BEA369,,Gag-Pol polyprotein,gag-pol,,unknown
Inhibitor BEA369,,Gag-Pol polyprotein,gag-pol,,unknown
"4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide",,Cyclin-dependent kinase 2,CDK2,,unknown
"16,17-Androstene-3-Ol",,Nuclear receptor subfamily 1 group I member 3,NR1I3,,unknown
"N,N-Bis(3-(D-gluconamido)propyl)deoxycholamide",,Insulin-like growth factor I,IGF1,,unknown
"N,N-Bis(3-(D-gluconamido)propyl)deoxycholamide",,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Tl-3-093,,Gag-Pol polyprotein,gag-pol,,unknown
Tl-3-093,,Pol polyprotein,pol,,unknown
Hyperforin,9 hours,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Hyperforin,9 hours,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Hyperforin,9 hours,Arachidonate 5-lipoxygenase,ALOX5,inhibitor,unknown
N6-Benzyl Adenosine-5'-Diphosphate,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
Aspartyl-Adenosine-5'-Monophosphate,,Aspartate--tRNA ligase,aspS,,unknown
M-Aminophenylboronic Acid,,Beta-lactamase,ampC,,unknown
2-(2f-Benzothiazolyl)-5-Styryl-3-(4f-Phthalhydrazidyl)Tetrazolium Chloride,,Hematopoietic prostaglandin D synthase,HPGDS,,unknown
Nd1-Phosphonohistidine,,Phosphocarrier protein HPr,ptsH,,unknown
Sucrosofate,,Fibroblast growth factor 1,FGF1,,unknown
Sucrosofate,,Fibroblast growth factor receptor 2,FGFR2,ligand,unknown
"1-Ethyl-Pyrrolidine-2,5-Dione",,Vesicle-fusing ATPase,NSF,,unknown
"1-Ethyl-Pyrrolidine-2,5-Dione",,ERO1-like protein beta,ERO1B,,unknown
5-Bromo-2'-Deoxyuridine-5'-Monophosphate,,Thymidylate synthase ThyX,thyX,,unknown
D-Xylitol,,Xylose isomerase,xylA,,unknown
D-Xylitol,,Xylose isomerase,xylA,,unknown
D-Xylitol,,Xylose isomerase,xylA,,unknown
D-Xylitol,,Xylose isomerase,xylA,,unknown
D-Xylitol,,Hyaluronate lyase,,,unknown
2-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine,,Trypsin-1,PRSS1,,unknown
2-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine,,Urokinase-type plasminogen activator,PLAU,,unknown
"3-(5-Amino-7-Hydroxy-[1,2,3]Triazolo[4,5-D]Pyrimidin-2-Yl)-Benzoic Acid",,Dihydroneopterin aldolase,folB,,unknown
RU85493,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
Alpha-Cyclodextrin (Cyclohexa-Amylose),,Cyclomaltodextrin glucanotransferase,,,unknown
Sinefungin,,RdmB,rdmB,,unknown
Sinefungin,,rRNA adenine N-6-methyltransferase,ermC',,unknown
Sinefungin,,Modification methylase TaqI,taqIM,,unknown
Sinefungin,,Modification methylase RsrI,rsrIM,,unknown
N-Methylmesoporphyrin,,Ferrochelatase,hemH,,unknown
"2,2':6',2''-Terpyridine Platinum(Ii)",,Autolysin,lytA,,unknown
"2,2':6',2''-Terpyridine Platinum(Ii)",,Truncated transposase,tnp,,unknown
S-Hydroxycysteine,,Complement C3,C3,,unknown
S-Hydroxycysteine,,Azurin,azu,,unknown
S-Hydroxycysteine,,Glutathione S-transferase P,GSTP1,,unknown
S-Hydroxycysteine,,"Acetyl-CoA acetyltransferase, cytosolic",ACAT2,,unknown
S-Hydroxycysteine,,Glutathione S-transferase A1,GSTA1,,unknown
S-Hydroxycysteine,,Myelin P2 protein,PMP2,,unknown
S-Hydroxycysteine,,Acetyl-CoA acetyltransferase,phbA,,unknown
S-Hydroxycysteine,,Subtilisin BPN',apr,,unknown
Putrescine,,Ornithine decarboxylase,ODC1,,unknown
Putrescine,,S-adenosylmethionine decarboxylase proenzyme,AMD1,,unknown
Putrescine,,Putrescine-binding periplasmic protein,potF,,unknown
Putrescine,,Beta-1 adrenergic receptor,ADRB1,,unknown
Putrescine,,Beta-2 adrenergic receptor,ADRB2,,unknown
[Methyltelluro]Acetate,,Monomeric sarcosine oxidase,soxA,,unknown
Pentanal,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
1-O-[O-Nitrophenyl]-Beta-D-Galactopyranose,,Beta-galactosidase,lacZ,,unknown
Xylose-Derived Lactam Oxime,,Exoglucanase/xylanase,cex,,unknown
"Maltosyl-Alpha (1,4)-D-Gluconhydroximo-1,5-Lactam",,Pancreatic alpha-amylase,AMY2A,,unknown
L-Xylulose 5-Phosphate,,3-keto-L-gulonate-6-phosphate decarboxylase UlaD,ulaD,,unknown
"2'-Chloro-Biphenyl-2,3-Diol",,"Biphenyl-2,3-diol 1,2-dioxygenase",bphC,,unknown
Carboxymycobactin S,,Neutrophil gelatinase-associated lipocalin,LCN2,,unknown
Duroquinone,,NAD(P)H dehydrogenase [quinone] 1,NQO1,,unknown
"5-Chloryl-2,4,6-Quinazolinetriamine",,Dihydrofolate reductase,DFR1,,unknown
"5-Chloryl-2,4,6-Quinazolinetriamine",,"Dihydrofolate reductase, mitochondrial",DHFRL1,,unknown
"2,4-Dihydroxy-3,3-Dimethyl-Butyrate",,Pantothenate synthetase,panC,,unknown
"Dcka, 5,7-Dichlorokynurenic Acid",,"Glutamate receptor ionotropic, NMDA 1",GRIN1,,unknown
5-Methylpyrrole,,Lysozyme,E,,unknown
7-Hydroxystaurosporine,,3-phosphoinositide-dependent protein kinase 1,PDPK1,,unknown
"N-Methyl-N-(10-Methylundecanoyl)-D-Seryl-L-Alanyl-N~1~-[(7s,10s,13s)-13-Carboxy-3,18-Dihydroxy-10-Methyl-8,11-Dioxo-9,12-Diazatricyclo[13.3.1.1~2,6~]Icosa-1(19),2(20),3,5,15,17-Hexaen-7-Yl]-N~1~-Methylglycinamide",,Signal peptidase I,lepB,,unknown
3-{[(1r)-1-Benzyl-2-Sulfanylethyl]Amino}-3-Oxopropanoic Acid,,Thermolysin,nprS,,unknown
3-{[(1r)-1-Benzyl-2-Sulfanylethyl]Amino}-3-Oxopropanoic Acid,,Thermolysin,npr,,unknown
alpha-D-arabinofuranose,,Ribokinase,rbsK,,unknown
Guanosine-2'-Monophosphate,,Guanyl-specific ribonuclease Sa,rnaSA,,unknown
L-Histidine Beta Naphthylamide,,Hut operon positive regulatory protein,hutP,,unknown
5-Amidino-Benzimidazole,,Trypsin-1,PRSS1,,unknown
Balanol Analog 2,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
"6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-Tetrahydronaphthalen-2-Yl)Cyclopropyl]Pyridine-3-Carboxylic Acid",,Retinoic acid receptor RXR-beta,RXRB,,unknown
Formic Acid,,Heme oxygenase 1,HMOX1,,unknown
Formic Acid,,Ribonuclease pancreatic,RNASE1,,unknown
Formic Acid,,Dihydroorotate dehydrogenase (quinone),pyrD,,unknown
Formic Acid,,(S)-2-haloacid dehalogenase,dhlB,,unknown
Formic Acid,,Beta-lactamase OXA-2,bla,,unknown
Formic Acid,,Catalase,katA,,unknown
Formic Acid,,Signal recognition particle protein,ffh,,unknown
Formic Acid,,Streptavidin,,,unknown
Formic Acid,,Methylglyoxal synthase,mgsA,,unknown
Formic Acid,,C-terminal-binding protein 1,CTBP1,,unknown
Formic Acid,,6-phosphogluconolactonase,pgl,,unknown
Formic Acid,,Citrate lyase subunit beta-like protein,citE,,unknown
Formic Acid,,Peripheral plasma membrane protein CASK,CASK,,unknown
Formic Acid,,Guanylate kinase,gmk,,unknown
Formic Acid,,Probable butyrate kinase 2,buk2,,unknown
Formic Acid,,Gamma-glutamylaminecyclotransferase,GGACT,,unknown
Formic Acid,,Parvalbumin alpha,PVALB,,unknown
Formic Acid,,Acylphosphatase-2,ACYP2,,unknown
Formic Acid,,Uncharacterized protein,,,unknown
Formic Acid,,Arginine N-succinyltransferase subunit alpha,astA,,unknown
Formic Acid,,Putative mannose-6-phosphate isomerase YvyI,yvyI,,unknown
Formic Acid,,"Nitric oxide synthase, brain",NOS1,,unknown
Formic Acid,,"ABC-type transporter, periplasmic subunit",,,unknown
Formic Acid,,Probable phosphatase YcdX,ycdX,,unknown
Formic Acid,,Phenazine biosynthesis protein PhzD,phzD1,,unknown
Formic Acid,,Oxalate decarboxylase OxdC,oxdC,,unknown
Formic Acid,,Putative ketoacyl reductase,actIII,,unknown
Formic Acid,,Gephyrin,GPHN,,unknown
Formic Acid,,Glyoxalase family protein,,,unknown
Formic Acid,,Cytohesin-2,CYTH2,,unknown
Formic Acid,,Glutaconyl-CoA decarboxylase subunit alpha,gcdA,,unknown
Formic Acid,,"Transcriptional regulator, IclR family",,,unknown
Formic Acid,,Catalase,katA,,unknown
Formic Acid,,Putative L-rhamnose mutarotase,,,unknown
Formic Acid,,Glutathione S-transferase,GST,,unknown
Formic Acid,,Hypoxanthine-guanine phosphoribosyltransferase,HGPRTase,,unknown
Formic Acid,,Glutaminase 1,glsA1,,unknown
Formic Acid,,Glutaminase 1,glsA1,,unknown
Formic Acid,,Molybdopterin synthase catalytic subunit,moaE,,unknown
Formic Acid,,"Aminotransferase, putative",,,unknown
Formic Acid,,Iron binding protein FbpA,fbpA,,unknown
Formic Acid,,DNA gyrase subunit B,gyrB,,unknown
Formic Acid,,Putative hydroxypyruvate isomerase YgbM,ygbM,,unknown
Formic Acid,,Delta-aminolevulinic acid dehydratase,hemB,,unknown
Formic Acid,,3-phosphoshikimate 1-carboxyvinyltransferase,aroA,,unknown
Formic Acid,,Subtilisin Carlsberg,apr,,unknown
Formic Acid,,Fibroblast growth factor 1,FGF1,,unknown
Formic Acid,,Peptide deformylase,def,,unknown
Formic Acid,,Para-aminobenzoate synthase component 1,pabB,,unknown
Formic Acid,,Carbonic anhydrase 2,CA2,,unknown
(S)-blebbistatin,,Myosin-14,MYH14,,unknown
"3-[1-(3-Aminopropyl)-1h-Indol-3-Yl]-4-(1-Methyl-1h-Indol-3-Yl)-1h-Pyrrole-2,5-Dione",,3-phosphoinositide-dependent protein kinase 1,PDPK1,,unknown
"3-[1-(3-Aminopropyl)-1h-Indol-3-Yl]-4-(1-Methyl-1h-Indol-3-Yl)-1h-Pyrrole-2,5-Dione",,Myotonin-protein kinase,DMPK,,unknown
RU78262,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
"1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One",,Mitogen-activated protein kinase 14,MAPK14,,unknown
"2-Amino-N,3,3-Trimethylbutanamide",,Matrix metalloproteinase-9,MMP9,,unknown
"N-(4-Methoxybenzyl)-N'-(5-Nitro-1,3-Thiazol-2-Yl)Urea",,Glycogen synthase kinase-3 beta,GSK3B,,unknown
Gpi-1046,,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,,unknown
"1,N6-Ethenoadenine",,Endonuclease III,,,unknown
Inhibitor of P38 Kinase,,Mitogen-activated protein kinase 14,MAPK14,,unknown
Rolipram,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,,unknown
Rolipram,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,,unknown
"1,4-Butanediol",,"Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase",MAN1B1,,unknown
"1,4-Butanediol",,"Phospholipase A2, membrane associated",PLA2G2A,,unknown
"1,4-Butanediol",,Group IIE secretory phospholipase A2,PLA2G2E,,unknown
"1,4-Butanediol",,Ribosomal small subunit pseudouridine synthase A,rsuA,,unknown
"1,4-Butanediol",,Penicillin-insensitive murein endopeptidase,mepA,,unknown
Taurine,Oral administration of taurine in healthy individuals gave a plasma elimination half-life that ranged from 0.7-1.4 h.[A31400],Alpha-ketoglutarate-dependent taurine dioxygenase,tauD,,unknown
Taurine,Oral administration of taurine in healthy individuals gave a plasma elimination half-life that ranged from 0.7-1.4 h.[A31400],Choloylglycine hydrolase,cbh,,unknown
Taurine,Oral administration of taurine in healthy individuals gave a plasma elimination half-life that ranged from 0.7-1.4 h.[A31400],Glycine receptor subunit alpha-1,GLRA1,agonist,unknown
Taurine,Oral administration of taurine in healthy individuals gave a plasma elimination half-life that ranged from 0.7-1.4 h.[A31400],"Glutamate receptor ionotropic, NMDA 2B",GRIN2B,inhibitor,yes
Taurine,Oral administration of taurine in healthy individuals gave a plasma elimination half-life that ranged from 0.7-1.4 h.[A31400],Glycine receptor subunit alpha-2,GLRA2,agonist,yes
Taurine,Oral administration of taurine in healthy individuals gave a plasma elimination half-life that ranged from 0.7-1.4 h.[A31400],Glycine receptor subunit alpha-3,GLRA3,agonist,yes
Taurine,Oral administration of taurine in healthy individuals gave a plasma elimination half-life that ranged from 0.7-1.4 h.[A31400],GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,agonist,yes
Taurine,Oral administration of taurine in healthy individuals gave a plasma elimination half-life that ranged from 0.7-1.4 h.[A31400],Gamma-aminobutyric acid type B receptor subunit 1,GABBR1,agonist,yes
3-Chlorophenol,,Lysozyme,E,,unknown
"5-[4-Tert-Butylphenylsulfanyl]-2,4-Quinazolinediamine",,Dihydrofolate reductase,DFR1,,unknown
"5-[4-Tert-Butylphenylsulfanyl]-2,4-Quinazolinediamine",,"Dihydrofolate reductase, mitochondrial",DHFRL1,,unknown
"3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester",,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,,unknown
"3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester",,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,,unknown
7n-Methyl-8-Hydroguanosine-5'-Diphosphate,,m7GpppX diphosphatase,DCPS,,unknown
7n-Methyl-8-Hydroguanosine-5'-Diphosphate,,Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase,PAPS,,unknown
7n-Methyl-8-Hydroguanosine-5'-Diphosphate,,Eukaryotic translation initiation factor 4E,EIF4E,,unknown
Cytidine 3'-monophosphate,,Ribonuclease pancreatic,RNASE1,,unknown
Phosphonotyrosine,,Tyrosine-protein kinase HCK,HCK,,unknown
Phosphonotyrosine,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
Phosphonotyrosine,,Mast/stem cell growth factor receptor Kit,KIT,,unknown
Phenylethane Boronic Acid,,Chymotrypsinogen B,CTRB1,,unknown
AL5424,,Carbonic anhydrase 2,CA2,,unknown
"2'-Deoxyuridine 5'-Alpha,Beta-Imido-Triphosphate",,Deoxyuridine 5'-triphosphate nucleotidohydrolase,dut,,unknown
"2'-Deoxyuridine 5'-Alpha,Beta-Imido-Triphosphate",,Deoxyuridine 5'-triphosphate nucleotidohydrolase,dut,,unknown
Di-Stearoyl-3-Sn-Phosphatidylethanolamine,,Proactivator polypeptide,PSAP,,unknown
"N-{3-[(7ar,12as,12bs)-7-Oxo-1,3,4,6,7,7a,12a,12b-Octahydroindolo[2,3-a]Quinolizin-12(2h)-Yl]Propyl}Propane-2-Sulfonamide",,Cell division protein ZipA homolog,zipA,,unknown
"N-{3-[(7ar,12as,12bs)-7-Oxo-1,3,4,6,7,7a,12a,12b-Octahydroindolo[2,3-a]Quinolizin-12(2h)-Yl]Propyl}Propane-2-Sulfonamide",,Cell division protein ZipA,zipA,,unknown
2-Thioethenamine,,Lantibiotic mersacidin,mrsA,,unknown
Trifluoroacetonyl Coenzyme A,,"Citrate synthase, mitochondrial",CS,,unknown
"Hg9a-9, Nonanoyl-N-Hydroxyethylglucamide",,"cGMP-inhibited 3',5'-cyclic phosphodiesterase B",PDE3B,,unknown
trans-urocanic acid,,Urocanate hydratase,hutU,,unknown
Guanosine-5'-Monophosphate,,Guanylate kinase,GUK1,,unknown
Guanosine-5'-Monophosphate,,Response regulator PleD,pleD,,unknown
Guanosine-5'-Monophosphate,,DNA polymerase,43,,unknown
Guanosine-5'-Monophosphate,,Disks large homolog 4,DLG4,,unknown
Guanosine-5'-Monophosphate,,GMP reductase 1,GMPR,,unknown
Guanosine-5'-Monophosphate,,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,,unknown
Guanosine-5'-Monophosphate,,Histidine triad nucleotide-binding protein 1,HINT1,,unknown
Guanosine-5'-Monophosphate,,Bifunctional purine biosynthesis protein PURH,ATIC,,unknown
Guanosine-5'-Monophosphate,,Bifunctional protein PyrR,pyrR,,unknown
Guanosine-5'-Monophosphate,,Amidophosphoribosyltransferase,purF,,unknown
Guanosine-5'-Monophosphate,,Protein-glutamine gamma-glutamyltransferase E,TGM3,,unknown
Guanosine-5'-Monophosphate,,Xanthine phosphoribosyltransferase,gpt,,unknown
Guanosine-5'-Monophosphate,,Bifunctional adenosylcobalamin biosynthesis protein CobU,cobU,,unknown
Guanosine-5'-Monophosphate,,Amidophosphoribosyltransferase,purF,,unknown
O-Benzylsulfonyl-Serine,,Subtilisin Savinase,,,unknown
O-Benzylsulfonyl-Serine,,Trypsin-2,PRSS2,,unknown
O-Benzylsulfonyl-Serine,,Carboxymethylenebutenolidase,clcD,,unknown
O-Benzylsulfonyl-Serine,,Capsid scaffolding protein,UL80,,unknown
O-Benzylsulfonyl-Serine,,Alkaline protease,,,unknown
AMPCPR,,ADP-ribose pyrophosphatase,nudF,,unknown
AMPCPR,,MutT/nudix family protein,,,unknown
6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine,,Urokinase-type plasminogen activator,PLAU,,unknown
"7,9-Dimethylguanine",,Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase,PAPS,,unknown
Methyl alpha-D-mannoside,,Mannose-binding protein C,MBL2,,unknown
Para-Iodo-D-Phenylalanine Hydroxamic Acid,,Bacterial leucyl aminopeptidase,,,unknown
"3,6-Anhydro-D-Galactose-2-Sulfate",,Iota-carrageenase,cgiA,,unknown
D-Mannuronic Acid,,AlgQ1,algQ1,,unknown
D-Mannuronic Acid,,AlgQ2,algQ2,,unknown
2(S)-Amino-6-Boronohexanoic Acid,,Arginase-1,ARG1,,unknown
N-Alpha-L-Acetyl-Arginine,,Clavaminate synthase 1,cs1,,unknown
3-Fluoro-2-Methyl-Aniline,,Lysozyme,E,,unknown
Cocarboxylase,,Benzoylformate decarboxylase,mdlC,,unknown
Cocarboxylase,,Pyruvate oxidase,pox5,,unknown
Cocarboxylase,,DNA,,,unknown
Cocarboxylase,,Pyruvate dehydrogenase E1 component,aceE,,unknown
Cocarboxylase,,Pyruvate-flavodoxin oxidoreductase,por,,unknown
Cocarboxylase,,Indole-3-pyruvate decarboxylase,ipdC,,unknown
Cocarboxylase,,Carboxyethylarginine synthase,ceaS,,unknown
Cocarboxylase,,Transketolase 1,tktA,,unknown
Cocarboxylase,,"Acetolactate synthase, catabolic",budB,,unknown
6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine,,Mitogen-activated protein kinase 14,MAPK14,,unknown
Carbobenzoxy-Pro-Lys-Phe-Y(Po2)-Ala-Pro-Ome,,Tolloid-like protein 2,TLL2,,unknown
Cholesterol-Sulfate,,Nuclear receptor ROR-alpha,RORA,,unknown
Tu-514,,UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase,lpxC,,unknown
Coenzyme A,,Acetyl-coenzyme A synthetase,acs,,unknown
Coenzyme A,,Acyl-CoA-binding protein,DBI,,unknown
Coenzyme A,,Formyl-coenzyme A transferase,frc,,unknown
Coenzyme A,,Carnitine O-acetyltransferase,CRAT,,unknown
Coenzyme A,,Crotonobetainyl-CoA:carnitine CoA-transferase,caiB,,unknown
Coenzyme A,,Formate acetyltransferase 1,pflB,,unknown
Coenzyme A,,Malate synthase G,glcB,,unknown
Coenzyme A,,3-hydroxy-3-methylglutaryl-coenzyme A reductase,mvaA,,unknown
Coenzyme A,,Phosphopantetheine adenylyltransferase,coaD,,unknown
Coenzyme A,,Holo-[acyl-carrier-protein] synthase,acpS,,unknown
Coenzyme A,,Protease synthase and sporulation negative regulatory protein PAI 1,paiA,,unknown
Coenzyme A,,Gentamicin 3'-acetyltransferase,aacC1,,unknown
Coenzyme A,,Galactoside O-acetyltransferase,lacA,,unknown
Coenzyme A,,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,,unknown
Coenzyme A,,Fatty acid metabolism regulator protein,fadR,,unknown
Coenzyme A,,Histone acetyltransferase KAT5,KAT5,,unknown
Coenzyme A,,"2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase",dapD,,unknown
Coenzyme A,,"Acetyl-CoA acetyltransferase, cytosolic",ACAT2,,unknown
Coenzyme A,,Acetyl-CoA acetyltransferase,phbA,,unknown
Coenzyme A,,Streptogramin A acetyltransferase,vatD,,unknown
Coenzyme A,,"Citrate synthase, mitochondrial",CS,,unknown
Coenzyme A,,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,,unknown
Coenzyme A,,Formyl-coenzyme A transferase,frc,,unknown
Coenzyme A,,Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex,,,unknown
Coenzyme A,,Pantothenate kinase,coaA,,unknown
Coenzyme A,,Acetyl transferase,rimL,,unknown
Coenzyme A,,Uncharacterized N-acetyltransferase YvbK,yvbK,,unknown
Coenzyme A,,Aminoglycoside N(6')-acetyltransferase type 1,,,unknown
Coenzyme A,,Acyl-CoA hydrolase,,,unknown
Coenzyme A,,Uncharacterized acyl-CoA thioester hydrolase HI_0827,,,unknown
Coenzyme A,,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,,unknown
Coenzyme A,,Mycothiol acetyltransferase,mshD,,unknown
Coenzyme A,,Histone acetyltransferase KAT2A,KAT2A,,unknown
Coenzyme A,,Acyl-CoA hydrolase,,,unknown
Coenzyme A,,Histone acetyltransferase KAT2B,KAT2B,,unknown
Coenzyme A,,"1,4-Dihydroxy-2-naphthoyl-CoA synthase",menB,,unknown
Coenzyme A,,Citrate synthase,cit,,unknown
Coenzyme A,,Aminoglycoside 2'-N-acetyltransferase,aac,,unknown
Coenzyme A,,Aac(6')-Ii protein,aac(6')-Ii,,unknown
Coenzyme A,,4'-phosphopantetheinyl transferase sfp,sfp,,unknown
Coenzyme A,,Uncharacterized protein,,,unknown
Coenzyme A,,Serine acetyltransferase,cysE,,unknown
Coenzyme A,,Citrate synthase,gltA,,unknown
Coenzyme A,,4-hydroxybenzoyl-CoA thioesterase,fcbC,,unknown
Coenzyme A,,Bifunctional protein GlmU,glmU,,unknown
N-(5'-Phosphopyridoxyl)-D-Alanine,,Alanine racemase,alr,,unknown
3-Methylpyridine,,Collagenase 3,MMP13,,unknown
3-Methylpyridine,,Stromelysin-1,MMP3,,unknown
3-Bromo-7-Nitroindazole,,"Nitric oxide synthase, endothelial",NOS3,,unknown
3-Bromo-7-Nitroindazole,,"Nitric oxide synthase, brain",NOS1,,unknown
3-Bromo-7-Nitroindazole,,"Nitric oxide synthase, inducible",NOS2,,unknown
"2-[3,4-Dihydroxy-2-Hydroxymethyl-5-(2-Hydroxy-Nonyl)-Tetrahydro-Furan-2-Yloxy]-6-Hydroxymethyl-Tetra Hydro-Pyran-3,4,5-Triol",,Alpha-1-antitrypsin,SERPINA1,,unknown
"5-(4-Morpholin-4-Yl-Phenylsulfanyl)-2,4-Quinazolinediamine",,Dihydrofolate reductase,DFR1,,unknown
"5-(4-Morpholin-4-Yl-Phenylsulfanyl)-2,4-Quinazolinediamine",,"Dihydrofolate reductase, mitochondrial",DHFRL1,,unknown
"5-(Aminomethyl)-6-(2,4-Dichlorophenyl)-2-(3,5-Dimethoxyphenyl)Pyrimidin-4-Amine",,Dipeptidyl peptidase 4,DPP4,,unknown
2-Oxo-3-Pentenoic Acid,,2-hydroxymuconate tautomerase,xylH,,unknown
alpha-D-glucose 6-phosphate,,Hexokinase-1,HK1,,unknown
alpha-D-glucose 6-phosphate,,Phosphomannomutase/phosphoglucomutase,algC,,unknown
alpha-D-glucose 6-phosphate,,Maltose-6'-phosphate glucosidase,glvA,,unknown
alpha-D-glucose 6-phosphate,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
alpha-D-glucose 6-phosphate,,"Alpha,alpha-trehalose-phosphate synthase [UDP-forming]",otsA,,unknown
alpha-D-glucose 6-phosphate,,Glutamine--fructose-6-phosphate aminotransferase [isomerizing],glmS,,unknown
alpha-D-glucose 6-phosphate,,6-phospho-beta-glucosidase BglT,bglT,,unknown
alpha-D-glucose 6-phosphate,,Glucose-6-phosphate isomerase,GPI,,unknown
alpha-D-glucose 6-phosphate,,Aldose reductase,AKR1B1,,unknown
1-(2-Fluorobenzyl)-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine,,"Phosphoenolpyruvate carboxykinase, cytosolic [GTP]",PCK1,,unknown
"L-756,423",,Gag-Pol polyprotein,gag-pol,,unknown
Staurosporine,,Tyrosine-protein kinase Lck,LCK,,unknown
Staurosporine,,Serine/threonine-protein kinase pim-1,PIM1,,unknown
Staurosporine,,Tyrosine-protein kinase ITK/TSK,ITK,,unknown
Staurosporine,,Tyrosine-protein kinase SYK,SYK,,unknown
Staurosporine,,MAP kinase-activated protein kinase 2,MAPKAPK2,,unknown
Staurosporine,,Glycogen synthase kinase-3 beta,GSK3B,,unknown
Staurosporine,,Tyrosine-protein kinase CSK,CSK,,unknown
Staurosporine,,Cyclin-dependent kinase 2,CDK2,,unknown
Staurosporine,,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,,unknown
Staurosporine,,3-phosphoinositide-dependent protein kinase 1,PDPK1,,unknown
Staurosporine,,Protein kinase C theta type,PRKCQ,,unknown
Staurosporine,,Tyrosine-protein kinase ZAP-70,ZAP70,,unknown
Staurosporine,,Muscarinic acetylcholine receptor M1,CHRM1,,unknown
N-(Phosphonoacetyl)-L-Ornithine,,"Ornithine carbamoyltransferase, mitochondrial",OTC,,unknown
Compound 9,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
Dihydrofolic Acid,,Dihydrofolate reductase,folA,,unknown
Dihydrofolic Acid,,Putative pteridine reductase 2,ptr2,,unknown
R048-8071,,Lanosterol synthase,LSS,,unknown
Imidazole-Derived Cellobiose,,Endoglucanase 5A,cel5A,,unknown
Amido Phenyl Pyruvic Acid,,Tryptase beta-2,TPSB2,,unknown
Acetyl Dithranol,,ActVA 6 protein,actVA 6,,unknown
Alrestatin,,Aldose reductase,AKR1B1,,unknown
Fidarestat,,Aldose reductase,AKR1B1,inhibitor,unknown
Fidarestat,,Aldo-keto reductase family 1 member B10,AKR1B10,inhibitor,unknown
4-Amino-5-Hydroxymethyl-2-Methylpyrimidine,,Thiaminase-2,tenA,,unknown
4-Amino-5-Hydroxymethyl-2-Methylpyrimidine,,Hydroxymethylpyrimidine/phosphomethylpyrimidine kinase,thiD,,unknown
8-Oxo-2'-Deoxy-Guanosine-5'-Monophosphate,,8-oxo-dGTP diphosphatase,mutT,,unknown
3-phenylpropionic acid,,Aspartate aminotransferase,aspC,,unknown
3-phenylpropionic acid,,Aromatic-amino-acid aminotransferase,tyrB,,unknown
3-phenylpropionic acid,,Aminotransferase,,,unknown
"Furo[2,3d]Pyrimidine Antifolate",,Dihydrofolate reductase,,,unknown
N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N'-Nitroguanidine,,"Nitric oxide synthase, endothelial",NOS3,,unknown
N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N'-Nitroguanidine,,"Nitric oxide synthase, brain",NOS1,,unknown
"(1R,2R,3S,4R,6S)-3,4,6-Trihydroxy-5-{[(S)-hydroxy(3-hydroxy-2-oxopropoxy)phosphoryl]oxy}-1,2-cyclohexanediyl bis[dihydrogen (phosphate)]",,Tubby protein homolog,TUB,,unknown
N-Cyclohexyl-N'-(4-Iodophenyl)Urea,,Bifunctional epoxide hydrolase 2,EPHX2,,unknown
Alpha-Ribazole-5'-Phosphate,,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
"(6S)-5,6,7,8-tetrahydrofolate",,Nitric oxide synthase oxygenase,nos,,unknown
"(6S)-5,6,7,8-tetrahydrofolate",,Thymidylate synthase,thyA,,unknown
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid,,Angiotensin-converting enzyme,ACE,,unknown
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid,,FEZ-1 protein,blaFEZ-1,,unknown
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid,,Carbapenem-hydrolyzing beta-lactamase BlaB-1,blaB1,,unknown
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid,,Metallo-beta-lactamase L1,,,unknown
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid,,Beta-lactamase,cphA,,unknown
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid,,"Organic hydroperoxide resistance protein, putative",,,unknown
"N-(3-Cyclopropyl(5,6,7,8,9,10-Hexahydro-2-Oxo-2h-Cycloocta[B]Pyran-3-Yl)Methyl)Phenylbenzensulfonamide",,Gag-Pol polyprotein,gag-pol,,unknown
Tridolgosir,,Alpha-mannosidase 2,MAN2A1,,unknown
1-Hexadecylsulfonyl Fluoride,,Palmitoyl-protein thioesterase 1,PPT1,,unknown
"2-(3,4-Dihydro-3-Oxo-2h-Benzo[B][1,4]Thiazin-2-Yl)-N-Hydroxyacetamide",,Peptide deformylase,def,,unknown
"D-[3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl]-N,O-cycloserylamide",,Aminodeoxychorismate lyase,pabC,,unknown
"D-[3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl]-N,O-cycloserylamide",,Alanine racemase,alr,,unknown
"D-[3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl]-N,O-cycloserylamide",,UDP-4-amino-4-deoxy-L-arabinose--oxoglutarate aminotransferase,arnB,,unknown
"D-[3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl]-N,O-cycloserylamide",,"2,2-dialkylglycine decarboxylase",dgdA,,unknown
S-Acetyl-Cysteine,,Histone acetyltransferase KAT5,KAT5,,unknown
S-Acetyl-Cysteine,,Acetyl-CoA acetyltransferase,phbA,,unknown
S-Acetyl-Cysteine,,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,,unknown
S-Acetyl-Cysteine,,3-hydroxy-3-methylglutaryl CoA synthase,mvaS,,unknown
Isoluminol,,Queuine tRNA-ribosyltransferase,tgt,,unknown
2-(2-{2-[2-(2-Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol,,ActVA 6 protein,actVA 6,,unknown
2-(2-{2-[2-(2-Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol,,mRNA interferase EndoA,ndoA,,unknown
"1,2-Dipalmitoyl-Phosphatidyl-Glycerole",,V-type sodium ATPase subunit K,ntpK,,unknown
N-(3-(Aminomethyl)Benzyl)Acetamidine,,"Nitric oxide synthase, endothelial",NOS3,,unknown
N-(3-(Aminomethyl)Benzyl)Acetamidine,,"Nitric oxide synthase, inducible",NOS2,,unknown
N-(3-(Aminomethyl)Benzyl)Acetamidine,,"Nitric oxide synthase, brain",NOS1,,unknown
Amylamine,,Trypsin-1,PRSS1,,unknown
N-[(Furan-2-Yl)Carbonyl]-(S)-Leucyl-(R)-[1-Amino-2(1h-Indol-3-Yl)Ethyl]-Phosphonic Acid,,Disintegrin and metalloproteinase domain-containing protein 28,ADAM28,,unknown
"2-(1,1'-Biphenyl-4-Yl)Propanoic Acid",,Prostaglandin G/H synthase 1,PTGS1,,unknown
"1,2,4-Triazole-Carboxamidine",,"Nitric oxide synthase, endothelial",NOS3,,unknown
2-{4-[4-(4-Chloro-Phenoxy)-Benzenesulfonyl]-Tetrahydro-Pyran-4-Yl}-N-Hydroxy-Acetamide,,Collagenase 3,MMP13,,unknown
3-[N-[Benzyloxycarbonyl]-Phenylalaninyl-Amino]-5-Phenyl-Pentane-1-Sulfonic Acid 4-Nitro-Phenyl Ester,,Cruzipain,,,unknown
Indirubin-3'-Monoxime,,Cyclin-dependent kinase 5,CDK5,inhibitor,unknown
Indirubin-3'-Monoxime,,Cyclin-dependent kinase 1,CDK1,binder,unknown
Indirubin-3'-Monoxime,,Glycogen synthase kinase-3 beta,GSK3B,,unknown
Indirubin-3'-Monoxime,,Cyclin-dependent kinase 5 activator 1,CDK5R1,,unknown
Indirubin-3'-Monoxime,,Cyclin-dependent kinase 2,CDK2,inhibitor,unknown
Indirubin-3'-Monoxime,,Aryl hydrocarbon receptor,AHR,agonist,unknown
Ribose-5-phosphate,,Ribose-5-phosphate isomerase A,rpiA,,unknown
Ribose-5-phosphate,,2-dehydro-3-deoxyphosphooctonate aldolase,kdsA,,unknown
Ribose-5-phosphate,,ADP-ribose pyrophosphatase,ndx4,,unknown
Gabaculine,,"Ornithine aminotransferase, mitochondrial",OAT,,unknown
Gabaculine,,"Glutamate-1-semialdehyde 2,1-aminomutase",hemL,,unknown
Prostaglandin D2,,Aldo-keto reductase family 1 member C3,AKR1C3,,unknown
Prostaglandin D2,,Prostaglandin D2 receptor 2,PTGDR2,,unknown
(S)-AMPA,,Glutamate receptor 2,GRIA2,,unknown
SU4984,,Fibroblast growth factor receptor 2,FGFR2,,unknown
SU4984,,Fibroblast growth factor receptor 1,FGFR1,,unknown
Adenosine-5-Diphosphoribose,,"CDP-glucose 4,6-dehydratase",rfbG,,unknown
Adenosine-5-Diphosphoribose,,Elongation factor 2,EEF2,,unknown
Adenosine-5-Diphosphoribose,,Glyceraldehyde-3-phosphate dehydrogenase,GAPDH,,unknown
Adenosine-5-Diphosphoribose,,Lactaldehyde reductase,fucO,,unknown
Adenosine-5-Diphosphoribose,,"NAD-dependent protein deacylase sirtuin-5, mitochondrial",SIRT5,,unknown
Adenosine-5-Diphosphoribose,,p-hydroxybenzoate hydroxylase,pobA,,unknown
Adenosine-5-Diphosphoribose,,ADP-ribose pyrophosphatase,nudF,,unknown
Adenosine-5-Diphosphoribose,,MutT/nudix family protein,,,unknown
Adenosine-5-Diphosphoribose,,ADP compounds hydrolase NudE,nudE,,unknown
Adenosine-5-Diphosphoribose,,ADP-ribose pyrophosphatase,ndx4,,unknown
Adenosine-5-Diphosphoribose,,"NAD-dependent protein deacetylase sirtuin-3, mitochondrial",SIRT3,,unknown
Cyclohexanone,,Pentaerythritol tetranitrate reductase,onr,,unknown
Cellobiose,,Endoglucanase G,celCCG,,unknown
Cellobiose,,Endoglucanase 5A,cel5A,,unknown
Cellobiose,,Endoglucanase,,,unknown
"N-[3-[(1-Aminoethyl)(Hydroxy)Phosphoryl]-2-(1,1'-Biphenyl-4-Ylmethyl)Propanoyl]Alanine",,Neprilysin,MME,,unknown
"N-[3-[(1-Aminoethyl)(Hydroxy)Phosphoryl]-2-(1,1'-Biphenyl-4-Ylmethyl)Propanoyl]Alanine",,Leukotriene A-4 hydrolase,LTA4H,,unknown
CRA_16847,,Trypsin-1,PRSS1,,unknown
4-Deoxylactose,,Glycosyl transferase,lgtC,,unknown
N7-Methyl-Formycin A,,Purine nucleoside phosphorylase DeoD-type,deoD,,unknown
Triglu-5-Formyl-Tetrahydrofolate,,"Serine hydroxymethyltransferase, cytosolic",SHMT1,,unknown
Delta-Amino Valeric Acid,,"Glycine amidinotransferase, mitochondrial",GATM,,unknown
Delta-Amino Valeric Acid,,Delta-aminolevulinic acid dehydratase,ALAD,,unknown
N-(2-Flouro-Benzyl)-4-Sulfamoyl-Benzamide,,Carbonic anhydrase 2,CA2,,unknown
WAY-151693,,Collagenase 3,MMP13,,unknown
"2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
Biliverdine IX Alpha,,Heme oxygenase 1,HMOX1,,unknown
Biliverdine IX Alpha,,Myoglobin,MB,,unknown
Biliverdine IX Alpha,,Flavin reductase (NADPH),BLVRB,,unknown
"(1s)-1(9-Deazahypoxanthin-9yl)1,4-Dideoxy-1,4-Imino-D-Ribitol-5-Phosphate",,Hypoxanthine-guanine-xanthine phosphoribosyltransferase,LACZ,,unknown
6-phospho-D-gluconic acid,,"6-phosphogluconate dehydrogenase, decarboxylating",PGD,,unknown
6-phospho-D-gluconic acid,,Glucose-6-phosphate isomerase,GPI,,unknown
6-phospho-D-gluconic acid,,Thermoresistant gluconokinase,gntK,,unknown
L-N(Omega)-Nitroarginine-(4r)-Amino-L-Proline Amide,,"Nitric oxide synthase, endothelial",NOS3,,unknown
L-N(Omega)-Nitroarginine-(4r)-Amino-L-Proline Amide,,"Nitric oxide synthase, brain",NOS1,,unknown
Triglyme,,Outer-membrane lipoprotein LolB,lolB,,unknown
Triglyme,,Profilin-2,PFN2,,unknown
Triglyme,,Outer-membrane lipoprotein LolB,lolB,,unknown
Triglyme,,Uncharacterized protein,,,unknown
Triglyme,,Serine acetyltransferase,cysE,,unknown
Triglyme,,Tyrosine-protein kinase Fyn,FYN,,unknown
Triglyme,,"Peptidyl-prolyl cis-trans isomerase F, mitochondrial",PPIF,,unknown
Triglyme,,"Transcriptional regulator, GntR family",,,unknown
Triglyme,,"ABC transporter, periplasmic substrate-binding protein",,,unknown
Triglyme,,Transketolase,tkt2,,unknown
Aminooxyacetic acid,,Serine--pyruvate aminotransferase,AGXT,,unknown
"1-{2-[2-(2-Methoxyethoxy)Ethoxy]Ethoxy}-4-(1,1,3,3-Tetramethylbutyl)Benzene",,"Phospholipase A2, membrane associated",PLA2G2A,,unknown
"1-{2-[2-(2-Methoxyethoxy)Ethoxy]Ethoxy}-4-(1,1,3,3-Tetramethylbutyl)Benzene",,Signal peptidase I,lepB,,unknown
Bis-Benzamidine,,Trypsin-1,PRSS1,,unknown
Phosphoaminophosphonic Acid Guanylate Ester,,Ras-related protein Rab-8B,RAB8B,,unknown
"N,N-dimethylglycine",,Monomeric sarcosine oxidase,soxA,,unknown
CRA_17312,,Trypsin-1,PRSS1,,unknown
1-Aminocyclopropanecarboxylic Acid,,1-aminocyclopropane-1-carboxylate deaminase,acdS,,unknown
"(3,4-Dihydroxy-Phenyl)-Triphenyl-Arsonium",,Gag-Pol polyprotein,gag-pol,,unknown
"3,5-Difluorobenzenesulfonamide",,Carbonic anhydrase 2,CA2,,unknown
Norleucine Phosphonate,,Methionine aminopeptidase,map,,unknown
CP-526423,,"Glycogen phosphorylase, liver form",PYGL,,unknown
A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor,,Stromelysin-1,MMP3,,unknown
"4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine",,Cyclin-A2,CCNA2,,unknown
Cholesteryl Linoleate,,Lipase 3,LIP3,,unknown
5-Phospho-D-Arabinohydroxamic Acid,,Glucose-6-phosphate isomerase,GPI,,unknown
N-2-Thiophen-2-Yl-Acetamide Boronic Acid,,Beta-lactamase,ampC,,unknown
Isatin,,Amine oxidase [flavin-containing] B,MAOB,,unknown
FR221647,,Adenosine deaminase,ADA,,unknown
Cytidine,,Uridine-cytidine kinase 2,UCK2,,unknown
Adenosine-2'-5'-Diphosphate,,Eosinophil cationic protein,RNASE3,,unknown
Adenosine-2'-5'-Diphosphate,,Ribonuclease pancreatic,RNASE1,,unknown
Adenosine-2'-5'-Diphosphate,,Non-secretory ribonuclease,RNASE2,,unknown
"(S,R)-fidarestat",,Aldose reductase,AKR1B1,,unknown
DMP450,,Gag-Pol polyprotein,gag-pol,,unknown
2-Chlorodideoxyadenosine,,Endoplasmin,HSP90B1,,unknown
"2,4-Diamino-5-Methyl-6-[(3,4,5-Trimethoxy-N-Methylanilino)Methyl]Pyrido[2,3-D]Pyrimidine",,Dihydrofolate reductase,DHFR,,unknown
"3,5-Dinitrocatechol",,Catechol O-methyltransferase,COMT,,unknown
"[3,5-Dibromo-4-(4-Hydroxy-3-Phenethylcarbamoyl-Phenoxy)-Phenyl]-Acetic Acid",,Thyroid hormone receptor beta,THRB,,unknown
Leucine - Reduced Carbonyl,,Serine protease inhibitor Kazal-type 6,SPINK6,,unknown
2-Aminoethanimidic Acid,,Cathepsin B,CTSB,,unknown
Hadacidin,,Adenylosuccinate synthetase,purA,,unknown
Hadacidin,,Adenylosuccinate synthetase isozyme 1,ADSSL1,,unknown
Hadacidin,,Adenylosuccinate synthetase,Adss,inhibitor,unknown
Protoporphyrin Ix Containing Co,,Prostaglandin G/H synthase 1,PTGS1,,unknown
Protoporphyrin Ix Containing Co,,Cytochrome c,CYCS,,unknown
3-Hydroxyisoxazole-4-Carboxylic Acid,,L-lactate dehydrogenase,,,unknown
Zk-806450,,Trypsin-1,PRSS1,,unknown
6-Methylpurine,,Purine nucleoside phosphorylase DeoD-type,deoD,,unknown
Para-Isopropylaniline,,Chymotrypsin-like elastase family member 1,CELA1,,unknown
Daidzin,,"Aldehyde dehydrogenase, mitochondrial",ALDH2,,unknown
Olomoucine,,Cyclin-dependent kinase 2,CDK2,inhibitor,unknown
Olomoucine,,Cyclin-dependent kinase 5,CDK5,inhibitor,unknown
Olomoucine,,Cyclin-dependent kinase 1,CDK1,binder,unknown
Olomoucine,,Mitogen-activated protein kinase 1,MAPK1,,unknown
CP-271485,,Macrophage metalloelastase,MMP12,,unknown
"6-Hydroxymethyl-7,8-Dihydropterin",,2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase,folK,,unknown
"6-Hydroxymethyl-7,8-Dihydropterin",,Dihydroneopterin aldolase,folB,,unknown
"6-Amino-4-Hydroxymethyl-Cyclohex-4-Ene-1,2,3-Triol",,Cyclomaltodextrin glucanotransferase,cgt,,unknown
"6-Amino-4-Hydroxymethyl-Cyclohex-4-Ene-1,2,3-Triol",,Cyclomaltodextrin glucanotransferase,,,unknown
"6-Amino-4-Hydroxymethyl-Cyclohex-4-Ene-1,2,3-Triol",,"Glucan 1,4-alpha-maltohexaosidase",,,unknown
"6-Amino-4-Hydroxymethyl-Cyclohex-4-Ene-1,2,3-Triol",,Alpha-amylase,amyE,,unknown
"6-Amino-4-Hydroxymethyl-Cyclohex-4-Ene-1,2,3-Triol",,Neopullulanase 1,tvaI,,unknown
Butyramide,,Aliphatic amidase expression-regulating protein,amiC,,unknown
4-iodo-acetamido phenylboronic acid,,Beta-lactamase,ampC,,unknown
4-iodo-acetamido phenylboronic acid,,Beta-lactamase OXA-10,bla,,unknown
4-iodo-acetamido phenylboronic acid,,Beta-lactamase AmpC,ampC,,unknown
Glycochenodeoxycholic Acid,,7-alpha-hydroxysteroid dehydrogenase,hdhA,,unknown
"(2s,3s)-Trans-2,3-Dihydro-3-Hydroxyanthranilic Acid",,"Trans-2,3-dihydro-3-hydroxyanthranilate isomerase",phzF,,unknown
Adamantanone,,Camphor 5-monooxygenase,camC,,unknown
4-Carboxycinnamic Acid,,Hemoglobin subunit alpha,HBA1,,unknown
4-Carboxycinnamic Acid,,Hemoglobin subunit beta,HBB,,unknown
Methylphosphonic Acid Diisopropyl Ester,,Parathion hydrolase,opd,,unknown
Methylphosphonic Acid Diisopropyl Ester,,Parathion hydrolase,opd,,unknown
[1-(3-Hydroxy-2-Oxo-1-Phenethyl-Propylcarbamoyl)2-Phenyl-Ethyl]-Carbamic Acid Pyridin-4-Ylmethyl Ester,,Cruzipain,,,unknown
Dihydroorotic Acid,,Dihydroorotase,pyrC,,unknown
Vanillic acid,,Chorismate--pyruvate lyase,ubiC,,unknown
N-1-Methylheptylformamide,,Alcohol dehydrogenase 1C,ADH1C,,unknown
Zenarestat,,Aldose reductase,AKR1B1,,unknown
Chlorophyll A,,Beta-lactamase 2,blm,,unknown
Xanthine,,Purine nucleoside phosphorylase 2,xapA,,unknown
Xanthine,,Xanthine phosphoribosyltransferase,gpt,,unknown
"4-{2,6,8-Trioxo-9-[(2R,3S,4R)-2,3,4,5-Tetrahydroxypentyl]-1,2,3,6,8,9-Hexahydro-7h-Purin-7-Yl}Butyl Dihydrogen Phosphate",,"6,7-dimethyl-8-ribityllumazine synthase",ribH,,unknown
Cephalosporin Analog,,D-alanyl-D-alanine carboxypeptidase,,,unknown
Molybdenum Cofactor,,Aldehyde oxidoreductase,mop,,unknown
Diethyl 4-Methylbenzylphosphonate,,Parathion hydrolase,opd,,unknown
Diethyl 4-Methylbenzylphosphonate,,Parathion hydrolase,opd,,unknown
(2e)-N-Allyl-4-{[3-(4-Bromophenyl)-5-Fluoro-1-Methyl-1h-Indazol-6-Yl]Oxy}-N-Methyl-2-Buten-1-Amine,,Squalene--hopene cyclase,shc,,unknown
N1-(1-Dimethylcarbamoyl-2-Phenyl-Ethyl)-2-Oxo-N4-(2-Pyridin-2-Yl-Ethyl)-Succinamide,,Pro-cathepsin H,CTSH,,unknown
"S,S'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea",,"Nitric oxide synthase, endothelial",NOS3,,unknown
Pyridoxamine-5'-Phosphate,,Alanine racemase,alr,,unknown
Pyridoxamine-5'-Phosphate,,"Glutamate-1-semialdehyde 2,1-aminomutase",hemL,,unknown
Pyridoxamine-5'-Phosphate,,Histidinol-phosphate aminotransferase,hisC,,unknown
Pyridoxamine-5'-Phosphate,,D-alanine aminotransferase,dat,,unknown
Pyridoxamine-5'-Phosphate,,Aspartate aminotransferase,aspC,,unknown
Pyridoxamine-5'-Phosphate,,4-aminobutyrate aminotransferase GabT,gabT,,unknown
Pyridoxamine-5'-Phosphate,,Kynurenine--oxoglutarate transaminase 1,CCBL1,,unknown
Pyridoxamine-5'-Phosphate,,Histidinol-phosphate aminotransferase,hisC,,unknown
Pyridoxamine-5'-Phosphate,,"Branched-chain-amino-acid aminotransferase, mitochondrial",BCAT2,,unknown
Pyridoxamine-5'-Phosphate,,UDP-4-amino-4-deoxy-L-arabinose--oxoglutarate aminotransferase,arnB,,unknown
N-Isopropyl-N'-Hydroxyguanidine,,"Nitric oxide synthase, brain",NOS1,,unknown
"1,2-diacyl-sn-glycero-3-phosphoinositol",,Phosphatidylinositol transfer protein alpha isoform,PITPNA,,unknown
Butyl alcohol,,Haloalkane dehalogenase,linB,,unknown
Cyclo-Tetrametavanadate,,Mono-ADP-ribosyltransferase C3,C3,,unknown
3-Amino-4-Oxybenzyl-2-Butanone,,Cathepsin B,CTSB,,unknown
Methionine Phosphonate,,Methionine--tRNA ligase,metG,,unknown
Methionine Phosphonate,,Methionine aminopeptidase,map,,unknown
K-252a,,Hepatocyte growth factor receptor,MET,,unknown
K-252a,,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,,unknown
3-Sulfinoalanine,,Pyridoxamine kinase,pdxY,,unknown
3-Sulfinoalanine,,Beta-lactamase 2,blm,,unknown
3-Sulfinoalanine,,Poly(A) polymerase alpha,PAPOLA,,unknown
3-Sulfinoalanine,,Chorismate mutase AroH,aroH,,unknown
3-Sulfinoalanine,,"Glutathione reductase, mitochondrial",GSR,,unknown
3-Sulfinoalanine,,S-ribosylhomocysteine lyase,luxS,,unknown
3-Sulfinoalanine,,Carboxymethylenebutenolidase,clcD,,unknown
3-Sulfinoalanine,,Dimethyl sulfoxide/trimethylamine N-oxide reductase,dmsA,,unknown
3-Sulfinoalanine,,Peroxiredoxin-2,PRDX2,,unknown
3-Sulfinoalanine,,Peptide deformylase,def,,unknown
3-Sulfinoalanine,,Malonamidase E2,,,unknown
3-Sulfinoalanine,,HMG-CoA synthase,mvaS,,unknown
3-Sulfinoalanine,,Osmotically inducible protein C,tthHB8IM,,unknown
"2,3-Bis-Benzo[1,3]Dioxol-5-Ylmethyl-Succinic Acid",,Beta-lactamase IMP-1,,,unknown
"2,3-Bis-Benzo[1,3]Dioxol-5-Ylmethyl-Succinic Acid",,Beta-lactamase,blaIMP-1,,unknown
Balanol Analog 8,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
"(1s)-1-(9-Deazaadenin-9-Yl)-1,4,5-Trideoxy-1,4-Imino-5-Methylthio-D-Ribitol",,S-methyl-5'-thioadenosine phosphorylase,MTAP,,unknown
"(1s)-1-(9-Deazaadenin-9-Yl)-1,4,5-Trideoxy-1,4-Imino-5-Methylthio-D-Ribitol",,5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase,mtnN,,unknown
(R)-Propylene glycol,,Isocitrate dehydrogenase [NADP],icd,,unknown
(R)-Propylene glycol,,Lysozyme C,LYZ,,unknown
S-Butyryl-Cystein,,Acetyl-CoA acetyltransferase,phbA,,unknown
Hydroxy-Phenyl-Acetic Acid 8-Methyl-8-Aza-Bicyclo[3.2.1]Oct-3-Yl Ester,,Liver carboxylesterase 1,CES1,,unknown
5'-O-(N-Ethyl-Sulfamoyl)Adenosine,,Histidine triad nucleotide-binding protein 1,HINT1,,unknown
"2,5-Xylidine",,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
N-Sulfo-Flavin Mononucleotide,,Hydroxyacid oxidase 1,HAO1,,unknown
Zinc Trihydroxide,,Glutathione S-transferase Mu 1,GSTM1,,unknown
Propidium,,Acetylcholinesterase,ACHE,,unknown
Bromopurine,,Nucleoside deoxyribosyltransferase-I,ptd,,unknown
"9,10-Deepithio-9,10-Didehydroacanthifolicin",,Serine/threonine-protein phosphatase PP1-gamma catalytic subunit,PPP1CC,,unknown
"1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One",,Casein kinase II subunit alpha,CSNK2A1,,unknown
"2,5-Dideoxy-2,5-Imino-D-Glucitol",,Xylose isomerase,xylA,,unknown
D-Glutamine,,Glutamate racemase,murI,,unknown
Malonic acid,,Sigma factor SigB regulation protein RsbQ,rsbQ,,unknown
Malonic acid,,Aspartate 1-decarboxylase,panD,,unknown
Malonic acid,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
Malonic acid,,Putative cytochrome P450,cyp158a2,,unknown
Malonic acid,,U1 small nuclear ribonucleoprotein A,SNRPA,,unknown
Malonic acid,,Malonamidase E2,,,unknown
Malonic acid,,Acetyl transferase,rimL,,unknown
1-Acetyl-4-(4-{4-[(2-Ethoxyphenyl)Thio]-3-Nitrophenyl}Pyridin-2-Yl)Piperazine,,Integrin alpha-L,ITGAL,,unknown
Phenylacetaldehyde,,Primary amine oxidase,tynA,,unknown
Myristoyl-Coa,,Glycylpeptide N-tetradecanoyltransferase,NMT1,,unknown
Myristoyl-Coa,,Glycylpeptide N-tetradecanoyltransferase 2,NMT2,,unknown
2'-Deoxyguanosine-5'-Triphosphate,,Nucleoside diphosphate kinase A,NME1,,unknown
2'-Deoxyguanosine-5'-Triphosphate,,Anaerobic ribonucleoside-triphosphate reductase,NRDD,,unknown
Hybrid Between B and C Type Hemes (Protoporphyrin Ixcontaining Fe),,Soluble cytochrome b562,cybC,,unknown
Adenosine-5'-Ditungstate,,Histidine triad nucleotide-binding protein 1,HINT1,,unknown
"D-1,4-dithiothreitol",,"6,7-dimethyl-8-ribityllumazine synthase",ribH,,unknown
"2,4-Dihydroxy-7-(Methyloxy)-2h-1,4-Benzoxazin-3(4h)-One",,Lactase-like protein,LCTL,,unknown
N-Acetyl-D-Galactosamine 6-Sulfate,,Chondroitinase-AC,cslA,,unknown
N-Acetyl-D-Galactosamine 6-Sulfate,,Hyaluronate lyase,,,unknown
Equilin,,Estradiol 17-beta-dehydrogenase 1,HSD17B1,,unknown
Equilin,,Estrogen receptor alpha,ESR1,,unknown
N-Methylmesoporphyrin Containing Copper,,Ferrochelatase,hemH,,unknown
"2',3'-Dideoxyadenosine-5'-Triphosphate",,DNA nucleotidylexotransferase,DNTT,,unknown
(S)-oxalosuccinic acid,,Isocitrate dehydrogenase [NADP],icd,,unknown
"(7as,12ar,12bs)-1,2,3,4,7a,12,12a,12b-Octahydroindolo[2,3-a]Quinolizin-7(6h)-One",,Cell division protein ZipA homolog,zipA,,unknown
"(7as,12ar,12bs)-1,2,3,4,7a,12,12a,12b-Octahydroindolo[2,3-a]Quinolizin-7(6h)-One",,Cell division protein ZipA,zipA,,unknown
Phenylethyl alcohol,,Parathion hydrolase,opd,,unknown
"3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine",,Mitogen-activated protein kinase 14,MAPK14,,unknown
Uridine-Diphosphate-N-Acetylgalactosamine,,Exostosin-like 2,EXTL2,,unknown
Uridine-Diphosphate-N-Acetylgalactosamine,,UDP-N-acetylhexosamine pyrophosphorylase,UAP1,,unknown
Uridine-Diphosphate-N-Acetylgalactosamine,,UDP-glucose 4-epimerase,GALE,,unknown
Uridine-Diphosphate-N-Acetylgalactosamine,,UDP-N-acetylglucosamine 2-epimerase,wecB,,unknown
Uridine-Diphosphate-N-Acetylgalactosamine,,Histo-blood group ABO system transferase,ABO,,unknown
Uridine-Diphosphate-N-Acetylgalactosamine,,UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase,murG,,unknown
Uridine-Diphosphate-N-Acetylgalactosamine,,WbpP,,,unknown
"4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide",,Cyclin-dependent kinase 2,CDK2,,unknown
2-Bromoacetyl Group,,Prostaglandin G/H synthase 1,PTGS1,,unknown
3-[N-[Benzyloxycarbonyl]-Phenylalaninyl-Amino]-5-Phenyl-Pentane-1-Sulfonylmethylbenzene,,Cruzipain,,,unknown
Malonate Ion,,Chorismate mutase AroH,aroH,,unknown
Malonate Ion,,Stromal cell-derived factor 2,SDF2,,unknown
"6-(1,1-Dimethylallyl)-2-(1-Hydroxy-1-Methylethyl)-2,3-Dihydro-7h-Furo[3,2-G]Chromen-7-One",,"Glyceraldehyde-3-phosphate dehydrogenase, glycosomal",,,unknown
"6-(1,1-Dimethylallyl)-2-(1-Hydroxy-1-Methylethyl)-2,3-Dihydro-7h-Furo[3,2-G]Chromen-7-One",,"Glyceraldehyde-3-phosphate dehydrogenase, testis-specific",GAPDHS,,unknown
7-Nitroindazole,,"Nitric oxide synthase, endothelial",NOS3,,unknown
7-Nitroindazole,,"Nitric oxide synthase, inducible",NOS2,,unknown
Pyridoxine phosphate,,Pyridoxine 5'-phosphate synthase,pdxJ,,unknown
Pyridoxine phosphate,,Ornithine decarboxylase,ODC1,,unknown
"Hexane-1,6-Diol",,"Chain A, Red Copper Protein Nitrosocyanin",,,unknown
"Hexane-1,6-Diol",,GTPase HRas,HRAS,,unknown
"Hexane-1,6-Diol",,Glucocorticoid receptor,NR3C1,,unknown
"Hexane-1,6-Diol",,Lysozyme,E,,unknown
"Hexane-1,6-Diol",,Holliday junction ATP-dependent DNA helicase RuvB,ruvB,,unknown
"Hexane-1,6-Diol",,Phospholipase A2,PLA2G1B,,unknown
N-Methyl-N-Propargyl-1(R)-Aminoindan,,Amine oxidase [flavin-containing] B,MAOB,,unknown
Metanitrophenyl-Alpha-D-Galactoside,,Heat-labile enterotoxin B chain,eltB,,unknown
Metanitrophenyl-Alpha-D-Galactoside,,Cholera enterotoxin subunit B,ctxB,,unknown
"6,7-Dioxo-5h-8-Ribitylaminolumazine",,"6,7-dimethyl-8-ribityllumazine synthase",ribH,,unknown
Furoyl-Leucine,,Disintegrin and metalloproteinase domain-containing protein 28,ADAM28,,unknown
S-Methylcysteine,,Cathepsin D,CTSD,,unknown
S-Methylcysteine,,Methylated-DNA--protein-cysteine methyltransferase,MGMT,,unknown
Dpb-T,,"5'(3')-deoxyribonucleotidase, mitochondrial",NT5M,,unknown
"N-[4-hydroxymethyl-cyclohexan-6-yl-1,2,3-triol]-4,6-dideoxy-4-aminoglucopyranoside",,Pancreatic alpha-amylase,AMY2A,,unknown
"N-[4-hydroxymethyl-cyclohexan-6-yl-1,2,3-triol]-4,6-dideoxy-4-aminoglucopyranoside",,Amylase,,,unknown
"N-[4-hydroxymethyl-cyclohexan-6-yl-1,2,3-triol]-4,6-dideoxy-4-aminoglucopyranoside",,Alpha-amylase 2B,AMY2B,,unknown
AL7089A,,Carbonic anhydrase 2,CA2,,unknown
"4-(Aminosulfonyl)-N-[(2,4,6-Trifluorophenyl)Methyl]-Benzamide",,Carbonic anhydrase 2,CA2,,unknown
"2,6-Diamino-(S)-9-[2-(Phosphonomethoxy)Propyl]Purine",,Purine nucleoside phosphorylase,PNP,,unknown
LY231514 Tetra Glu,,Thymidylate synthase,thyA,,unknown
"1,2-Di-N-Pentanoyl-Sn-Glycero-3-Dithiophosphocholine",,Phospholipase C,plc,,unknown
"3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-4-Yl]Hexyl]-Phenanthridinium",,Acetylcholinesterase,ACHE,,unknown
"4,5-Dihydroxy-Tetrahydro-Pyran-2-Carboxylic Acid",,Chondroitinase (Chondroitin lyase),,,unknown
2-deoxy-2-fluoro-β-D-galactose,,Beta-galactosidase,lacZ,,unknown
5'-O-[(L-methionyl)-sulphamoyl]adenosine,,Methionine--tRNA ligase,metG,,unknown
Immucillin-G,,Purine nucleoside phosphorylase,PNP,,unknown
"1,2-Dihydroxybenzene",,"Catechol 1,2-dioxygenase",catA,,unknown
"1,2-Dihydroxybenzene",,"Biphenyl-2,3-diol 1,2-dioxygenase",bphC,,unknown
6-hydroxy-D-norleucine,,L-asparaginase,ansB,,unknown
S-Ethylisothiourea,,Nitric oxide synthase oxygenase,nos,,unknown
S-Ethylisothiourea,,"Nitric oxide synthase, inducible",NOS2,,unknown
S-Ethylisothiourea,,"Nitric oxide synthase, endothelial",NOS3,,unknown
L-methionine (R)-S-oxide,,Protease,PROF,,unknown
L-methionine (R)-S-oxide,,Amyloid beta A4 protein,APP,,unknown
L-methionine (R)-S-oxide,,Catalase,katA,,unknown
Glycinamide Ribonucleotide,,Phosphoribosylglycinamide formyltransferase 2,purT,,unknown
Glycinamide Ribonucleotide,,Phosphoribosylglycinamide formyltransferase,purN,,unknown
Glycinamide Ribonucleotide,,Trifunctional purine biosynthetic protein adenosine-3,GART,,unknown
Maltotetraose,,"Glucan 1,4-alpha-maltotetraohydrolase",amyP,,unknown
Maltotetraose,,Neopullulanase 2,tvaII,,unknown
4-(Methylsulfanyl)-2-Oxobutanoic Acid,,Aminotransferase,,,unknown
Laevulinic Acid,,Delta-aminolevulinic acid dehydratase,ALAD,,unknown
Quinacrine mustard,,Trypanothione reductase,TPR,inhibitor,unknown
Cyclohexane Propionic Acid,,Aromatic-amino-acid aminotransferase,tyrB,,unknown
4-Morpholin-4-Yl-Piperidine-1-Carboxylic Acid [1-(3-Benzenesulfonyl-1-Propyl-Allylcarbamoyl)-2-Phenylethyl]-Amide,,Cathepsin F,CTSF,,unknown
Hydrolyzed Cephalothin,,Beta-lactamase,ampC,,unknown
2-Ethoxyethanol,,Alcohol dehydrogenase 1C,ADH1C,,unknown
O-Succinylbenzoate,,N-acylamino acid racemase,Aaar,,unknown
O-Succinylbenzoate,,o-succinylbenzoate synthase,menC,,unknown
O-Succinylbenzoate,,O-succinylbenzoate-CoA synthase,menC,,unknown
Iodophenyl,,Endoglucanase F,celCCF,,unknown
"(1r)-4-[(1e,3e,5e,7z,9e,11z,13e,15e)-17-Hydroxy-3,7,12,16-Tetramethylheptadeca-1,3,5,7,9,11,13,15-Octaen-1-Yl]-3,5,5-Trimethylcyclohex-3-En-1-Ol",,"Apocarotenoid-15,15'-oxygenase",,,unknown
Trifluoro-thiamin phosphate,,Thiamine-phosphate synthase,thiE,,unknown
GM6001,,Lethal factor,lef,,unknown
GM6001,,Disintegrin and metalloproteinase domain-containing protein 28,ADAM28,,unknown
GM6001,,Aggrecan core protein,ACAN,,unknown
2'-Deoxyuridine,,Uridine phosphorylase,udp,,unknown
2'-Deoxyuridine,,Thymidylate synthase,thyA,,unknown
N-Bromoacetyl-Aminoethyl Phosphate,,Glucose-6-phosphate isomerase B,pgiB,,unknown
SR11254,,Retinoic acid receptor gamma,RARG,,unknown
"3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
4-Oxosebacic Acid,,Delta-aminolevulinic acid dehydratase,hemB,,unknown
4-Oxosebacic Acid,,Delta-aminolevulinic acid dehydratase,ALAD,,unknown
Platelet Activating Factor,,Ganglioside GM2 activator,GM2A,,unknown
Platelet Activating Factor,,Platelet-activating factor receptor,PTAFR,,unknown
Orotic Acid,,Dihydroorotate dehydrogenase A (fumarate),pyrDA,,unknown
Orotic Acid,,Orotate phosphoribosyltransferase,pyrE,,unknown
Orotic Acid,,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
Orotic Acid,,Dihydroorotate dehydrogenase (quinone),pyrD,,unknown
Orotic Acid,,Dihydroorotase,pyrC,inhibitor,unknown
Glyceraldehyde-3-Phosphate,,Glyceraldehyde-3-phosphate dehydrogenase,gap,,unknown
Glyceraldehyde-3-Phosphate,,NADP-dependent glyceraldehyde-3-phosphate dehydrogenase,gapN,,unknown
Glyceraldehyde-3-Phosphate,,Glyceraldehyde-3-phosphate dehydrogenase A,gapA,,unknown
O2-Sulfo-Glucuronic Acid,,Fibroblast growth factor 1,FGF1,,unknown
O2-Sulfo-Glucuronic Acid,,Hepatocyte growth factor,HGF,,unknown
O2-Sulfo-Glucuronic Acid,,Heparan sulfate glucosamine 3-O-sulfotransferase 3A1,HS3ST3A1,,unknown
O2-Sulfo-Glucuronic Acid,,Complement control protein C3,,,unknown
Ethyl-Trimethyl-Silane,,Tetanus toxin,tetX,,unknown
Flufenamic Acid,,Prostaglandin G/H synthase 2,PTGS2,,unknown
Flufenamic Acid,,Prostaglandin G/H synthase 1,PTGS1,,unknown
Flufenamic Acid,,Aldo-keto reductase family 1 member C3,AKR1C3,,unknown
Flufenamic Acid,,Androgen receptor,AR,,unknown
Flufenamic Acid,,Peroxisome proliferator-activated receptor alpha,PPARA,activator,unknown
Flufenamic Acid,,Peroxisome proliferator-activated receptor gamma,PPARG,agonist,unknown
Argininosuccinate,,Argininosuccinate lyase,ASL,,unknown
Argininosuccinate,,Argininosuccinate synthase,argG,,unknown
4-(Acetylamino)-3-Amino Benzoic Acid,,Neuraminidase,NA,,unknown
[4-({[5-Benzyloxy-1-(3-Carbamimidoyl-Benzyl)-1h-Indole-2-Carbonyl]-Amino}-Methyl)-Phenyl]-Trimethyl-Ammonium,,Trypsin-1,PRSS1,,unknown
Dimethylallyl S-Thiolodiphosphate,,Farnesyl diphosphate synthase,ispA,,unknown
Dimethylallyl S-Thiolodiphosphate,,Adenylate dimethylallyltransferase,tzs,,unknown
Dimethylallyl S-Thiolodiphosphate,,tRNA dimethylallyltransferase,miaA,,unknown
S-(2-Oxo)Pentadecylcoa,,Glycylpeptide N-tetradecanoyltransferase 2,NMT2,,unknown
Porphobilinogen,,Delta-aminolevulinic acid dehydratase,ALAD,,unknown
7-Keto-8-Aminopelargonic Acid,,Adenosylmethionine-8-amino-7-oxononanoate aminotransferase,bioA,,unknown
(S)-2-(Phosphonoxy)Caproyl-L-Leucyl-P-Nitroanilide,,Peptide deformylase,def,,unknown
1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea,,Mitogen-activated protein kinase 14,MAPK14,,unknown
"7,8-Dihydro-7,7-Dimethyl-6-Hydroxypterin",,2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase,folK,,unknown
Benzoylformic Acid,,Hydroxyacid oxidase 1,HAO1,,unknown
(R)-Mandelic acid,,Benzoylformate decarboxylase,mdlC,,unknown
(R)-Mandelic acid,,Mandelate racemase,mdlA,,unknown
Formycin,,5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase,mtnN,,unknown
Formycin,,S-methyl-5'-thioadenosine phosphorylase,MTAP,,unknown
5'-Deoxy-5'-Methylthioadenosine,,Modification methylase RsrI,rsrIM,,unknown
5'-Deoxy-5'-Methylthioadenosine,,S-methyl-5'-thioadenosine phosphorylase,MTAP,,unknown
2-Phenylamino-Ethanesulfonic Acid,,Catabolite control protein A,ccpA,,unknown
Protoporphyrin,,Ferritin light chain,FTL,,unknown
2-(2-Hydroxy-Phenyl)-3h-Benzoimidazole-5-Carboxamidine,,Prothrombin,F2,,unknown
2-(2-Hydroxy-Phenyl)-3h-Benzoimidazole-5-Carboxamidine,,Trypsin-1,PRSS1,,unknown
2-(2-Hydroxy-Phenyl)-3h-Benzoimidazole-5-Carboxamidine,,Urokinase-type plasminogen activator,PLAU,,unknown
CRA_9334,,Trypsin-1,PRSS1,,unknown
2-Aminopropanedioic Acid,,Arylsulfatase,atsA,,unknown
"3-{2,6,8-trioxo-9-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,6,8,9-hexahydro-7H-purin-7-Yl}propyl dihydrogen phosphate",,"6,7-dimethyl-8-ribityllumazine synthase",ribH,,unknown
Irosustat,,Carbonic anhydrase 2,CA2,,unknown
Irosustat,,Steryl-sulfatase,STS,inhibitor,unknown
"(5R,6S,7S,8S)-5-hydroxymethyl-6,7,8-trihydroxy-tetrazolo[1,5-A]piperidine",,Beta-galactosidase,lacZ,,unknown
1-Hydroxy-3-Methylbutane,,Renin,REN,,unknown
2-Amino-6-Chloropyrazine,,Cyclin-dependent kinase 2,CDK2,,unknown
Arginineamide,,Potassium voltage-gated channel subfamily A member 4,KCNA4,,unknown
Calcipotriol,,Vitamin D3 receptor,VDR,antagonist,unknown
"5,10-Methylene-6-Hydrofolic Acid",,Thymidylate synthase,thyA,,unknown
"5,10-Methylene-6-Hydrofolic Acid",,Folylpolyglutamate synthase,fgs,,unknown
"5,10-Methylene-6-Hydrofolic Acid",,Thymidylate synthase,thyA,,unknown
"N3, N4-Dimethylarginine",,Haloalkane dehalogenase,linB,,unknown
"(5s)-5-Iododihydro-2,4(1h,3h)-Pyrimidinedione",,Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,,unknown
"4,5-Dehydro-D-Glucuronic Acid",,Chondroitinase-AC,cslA,,unknown
Palmitoyl-Linoleoyl Phosphatidylcholine,,Phosphatidylcholine transfer protein,PCTP,,unknown
N-(1-Carboxy-3-Phenylpropyl)Phenylalanyl-Alpha-Asparagine,,Pseudolysin,lasB,,unknown
"4-(1,3,2-Dioxaborolan-2-Yloxy)Butan-1-Aminium",,Trypsin-3,PRSS3,,unknown
5--Monophosphate-9-Beta-D-Ribofuranosyl Xanthine,,Bifunctional purine biosynthesis protein PURH,ATIC,,unknown
5--Monophosphate-9-Beta-D-Ribofuranosyl Xanthine,,Hypoxanthine-guanine phosphoribosyltransferase,HPRT1,,unknown
"3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium",,Methionine aminopeptidase 2,METAP2,,unknown
Methyl Methylsulfinylmethyl Sulfide,,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,,unknown
beta-D-galactose 6-phosphate,,6-phospho-beta-galactosidase,lacG,,unknown
4-{2-(4-Fluoro-Benzyl)-6-Methyl-5-[(5-Methyl-Isoxazole-3-Carbonyl)-Amino]-4-Oxo-Heptanoylamino}-5-(2-Oxo-Pyrrolidin-3-Yl)-Pentanoic Acid Ethyl Ester,,Genome polyprotein,,,unknown
Uridine-5'-Diphosphate-N-Acetylmuramoyl-L-Alanine-D-Glutamate,,"UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--2,6-diaminopimelate ligase",murE,,unknown
Uridine-5'-Diphosphate-N-Acetylmuramoyl-L-Alanine-D-Glutamate,,UDP-N-acetylmuramoylalanine--D-glutamate ligase,murD,,unknown
Cyclic Guanosine Monophosphate,,"cGMP-dependent 3',5'-cyclic phosphodiesterase",PDE2A,,unknown
Cyclic Guanosine Monophosphate,,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2,HCN2,,unknown
Cyclic Guanosine Monophosphate,,cAMP-dependent protein kinase type I-alpha regulatory subunit,PRKAR1A,,unknown
"1-(5-Carboxypentyl)-5-[(2,6-Dichlorobenzyl)Oxy]-1 H-Indole-2-Carboxylic Acid",,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,,unknown
Alpha-D-Galactose-1-Phosphate,,Beta-phosphoglucomutase,pgmB,,unknown
2-deoxy-2-fluoro-alpha-D-mannosyl fluoride,,Alpha-mannosidase 2,MAN2A1,,unknown
"5,6-Dihydroxy-Nadp",,Alcohol dehydrogenase YqhD,yqhD,,unknown
1-N-Acetyl-Beta-D-Glucosamine,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
1-N-Acetyl-Beta-D-Glucosamine,,"Glycogen phosphorylase, liver form",PYGL,,unknown
"5-(3-Amino-4,4-Dihyroxy-Butylsulfanylmethyl)-Tetrahydro-Furan-2,3,4-Triol",,S-ribosylhomocysteine lyase,luxS,,unknown
Heparin Disaccharide I-S,,C-C motif chemokine 5,CCL5,,unknown
EM-1745,,Estradiol 17-beta-dehydrogenase 1,HSD17B1,,unknown
5-Iodo-2'-Deoxyuridine-5'-Monophosphate,,Thymidine kinase,TK,,unknown
Isopropyl Alcohol,,mRNA-capping enzyme,RNGTT,,unknown
Isopropyl Alcohol,,FMN-dependent NADH-azoreductase,azoR,,unknown
Isopropyl Alcohol,,Transcription termination/antitermination protein NusG,nusG,,unknown
Isopropyl Alcohol,,"1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase",ADI1,,unknown
Isopropyl Alcohol,,GTP cyclohydrolase 1,GCH1,,unknown
Isopropyl Alcohol,,Growth/differentiation factor 5,GDF5,,unknown
Isopropyl Alcohol,,Subtilisin BPN',apr,,unknown
Isopropyl Alcohol,,Ig kappa chain V-IV region Len,,,unknown
Isopropyl Alcohol,,Ribonuclease pancreatic,RNASE1,,unknown
Isopropyl Alcohol,,Pectate lyase,pelA,,unknown
Isopropyl Alcohol,,Trypsin-2,PRSS2,,unknown
Isopropyl Alcohol,,Gag polyprotein,gag,,unknown
Isopropyl Alcohol,,Aldehyde oxidoreductase,mop,,unknown
Isopropyl Alcohol,,"Phospholipase A2, membrane associated",PLA2G2A,,unknown
Isopropyl Alcohol,,Ganglioside GM2 activator,GM2A,,unknown
Isopropyl Alcohol,,Thermolysin,nprS,,unknown
Isopropyl Alcohol,,Scaffolding dockerin binding protein A,sdbA,,unknown
Isopropyl Alcohol,,Chitotriosidase-1,CHIT1,,unknown
Isopropyl Alcohol,,Alr1529 protein,,,unknown
Isopropyl Alcohol,,L-xylulose reductase,DCXR,,unknown
Isopropyl Alcohol,,Peroxiredoxin-6,PRDX6,,unknown
Isopropyl Alcohol,,"Hydrolase, TatD family",,,unknown
Isopropyl Alcohol,,Tumor necrosis factor,TNF,,unknown
Isopropyl Alcohol,,Tartrate-resistant acid phosphatase type 5,ACP5,,unknown
Isopropyl Alcohol,,Adenosylhomocysteinase,AHCY,,unknown
Isopropyl Alcohol,,Spliceosome RNA helicase DDX39B,DDX39B,,unknown
Isopropyl Alcohol,,DNA mismatch repair protein MutL,mutL,,unknown
Isopropyl Alcohol,,Gag-Pro-Pol polyprotein,gag-pro-pol,,unknown
Isopropyl Alcohol,,Lysozyme,R,,unknown
Isopropyl Alcohol,,Glucarate dehydratase,gudD,,unknown
1-Hydroxyamine-2-Isobutylmalonic Acid,,Neutrophil collagenase,MMP8,,unknown
Triethylene glycol,,"Acetolactate synthase, catabolic",budB,,unknown
Triethylene glycol,,"Arabinogalactan endo-1,4-beta-galactosidase",ganB,,unknown
Triethylene glycol,,Phosphoserine aminotransferase,serC,,unknown
2-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Imino]-5-Phosphono-Pent-3-Enoic Acid,,Cystathionine gamma-lyase,CTH,,unknown
Carbenoxolone,,3-alpha-(or 20-beta)-hydroxysteroid dehydrogenase,,,unknown
Carbenoxolone,,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,inhibitor,unknown
"(2s)-2-[(5-Benzofuran-2-Yl-Thiophen-2-Ylmethyl)-(2,4-Dichloro-Benzoyl)-Amino]-3-Phenyl-Propionic Acid",,Genome polyprotein,,,unknown
Flavin-N7 Protonated-Adenine Dinucleotide,,Cholesterol oxidase,choA,,unknown
Deoxyuridine-5'-Triphosphate,,Septum formation protein Maf,maf,,unknown
Deoxyuridine-5'-Triphosphate,,Pol polyprotein,pol,,unknown
Deoxyuridine-5'-Triphosphate,,Deoxycytidine triphosphate deaminase,dcd,,unknown
Deoxyuridine-5'-Triphosphate,,Deoxyuridine 5'-triphosphate nucleotidohydrolase,dut,,unknown
Deoxyuridine-5'-Triphosphate,,Deoxyuridine 5'-triphosphate nucleotidohydrolase,dut,,unknown
(R)-2-Hydroxy-3-Sulfopropanoic Acid,,Probable 2-phosphosulfolactate phosphatase,comB,,unknown
2-Aminothiazoline,,"Nitric oxide synthase, endothelial",NOS3,,unknown
RU83876,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
S-(D-Carboxybutyl)-L-Homocysteine,,Betaine--homocysteine S-methyltransferase 1,BHMT,,unknown
Nadph Dihydro-Nicotinamide-Adenine-Dinucleotidephosphate,,"Thioredoxin reductase 1, cytoplasmic",TXNRD1,,unknown
Nadph Dihydro-Nicotinamide-Adenine-Dinucleotidephosphate,,Glucose-6-phosphate 1-dehydrogenase,zwf,,unknown
Nadph Dihydro-Nicotinamide-Adenine-Dinucleotidephosphate,,Pteridine reductase 1,PTR1,,unknown
Nadph Dihydro-Nicotinamide-Adenine-Dinucleotidephosphate,,Glucose--fructose oxidoreductase,gfo,,unknown
Nadph Dihydro-Nicotinamide-Adenine-Dinucleotidephosphate,,Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,,unknown
Nadph Dihydro-Nicotinamide-Adenine-Dinucleotidephosphate,,"Alpha-aminoadipic semialdehyde synthase, mitochondrial",AASS,,unknown
Allyl-{6-[3-(4-Bromo-Phenyl)-Benzofuran-6-Yloxy]-Hexyl-}-Methyl-Amin,,Squalene--hopene cyclase,shc,,unknown
N-Acetyl-Serine,,Coagulation factor XIII A chain,F13A1,,unknown
"Mdl 101,146",,Chymotrypsin-like elastase family member 1,CELA1,,unknown
"Mdl 101,146",,Neutrophil elastase,ELANE,,unknown
2-Methoxyestradiol,,Hypoxia-inducible factor 1-alpha,HIF1A,,unknown
2-Methoxyestradiol,,Catechol O-methyltransferase,COMT,,unknown
2-Methoxyestradiol,,Cytochrome P450 1A1,CYP1A1,,unknown
2-Methoxyestradiol,,Cytochrome P450 1B1,CYP1B1,,unknown
2-Methoxyestradiol,,Cytochrome P450 19A1,CYP19A1,,unknown
"3,6,9,12,15-Pentaoxaheptadecane",,Kynureninase,kynU,,unknown
"3,6,9,12,15-Pentaoxaheptadecane",,Glutamate racemase,murI,,unknown
"3,6,9,12,15-Pentaoxaheptadecane",,Acetylcholinesterase,ACHE,,unknown
Selenocysteine,,Cathelicidin antimicrobial peptide,CAMP,,unknown
Selenocysteine,,Nucleoside diphosphate kinase A,NME1,,unknown
Selenocysteine,,Formate dehydrogenase H,fdhF,,unknown
Selenocysteine,,Cysteine desulfurase,sufS,,unknown
3'-O-N-Octanoyl-a-D-Glucopyranosyl-B-D-Fructofuranoside,,Probable cysteine desulfurase,csd,,unknown
2-Amino-3-(5-Tert-Butyl-3-(Phosphonomethoxy)-4-Isoxazolyl)Propionic Acid,,Glutamate receptor 2,GRIA2,,unknown
Fluoro-Phosphite Ion,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
"N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide",,Stromelysin-1,MMP3,,unknown
3-(Benzyloxy)Pyridin-2-Amine,,Mitogen-activated protein kinase 14,MAPK14,,unknown
3-(Benzyloxy)Pyridin-2-Amine,,Leukotriene A-4 hydrolase,LTA4H,,unknown
Heparin Disaccharide Iii-S,,C-C motif chemokine 5,CCL5,,unknown
4-{[1-Methyl-5-(2-Methyl-Benzoimidazol-1-Ylmethyl)-1h-Benzoimidazol-2-Ylmethyl]-Amino}-Benzamidine,,Trypsin-1,PRSS1,,unknown
Adenosine-5'-Rp-Alpha-Thio-Triphosphate,,Adenylate cyclase,cyaC,,unknown
LY374571,,"C-1-tetrahydrofolate synthase, cytoplasmic",MTHFD1,,unknown
"9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
Bis-Napthyl Beta-Ketophosphonic Acid,,Cathepsin G,CTSG,,unknown
S-Methyl Thiocysteine Group,,Endoglucanase G,celCCG,,unknown
Aminobenzoic acid,,p-hydroxybenzoate hydroxylase,pobA,,unknown
Aminobenzoic acid,,p-hydroxybenzoate hydroxylase,pobA,,unknown
2'-Monophosphoadenosine-5'-Diphosphate,,Shikimate dehydrogenase,aroE,,unknown
2'-Monophosphoadenosine-5'-Diphosphate,,Ribonuclease pancreatic,RNASE1,,unknown
2'-Monophosphoadenosine-5'-Diphosphate,,Dihydrofolate reductase,folA,,unknown
2-Amino-3-(Diethoxy-Phosphoryloxy)-Propionic Acid,,Acyl-CoA thioesterase I,tesA,,unknown
"1,10-Phenanthroline",,Methyl-accepting chemotaxis protein II,tar,,unknown
"1,10-Phenanthroline",,Metallo-beta-lactamase L1,,,unknown
CRA_10762,,Trypsin-1,PRSS1,,unknown
(1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine,,Stromelysin-1,MMP3,,unknown
N-Acetyl-L-Citrulline,,N-acetylornithine carbamoyltransferase,argF',,unknown
Nz-(1-Carboxyethyl)-Lysine,,4-hydroxy-tetrahydrodipicolinate synthase,dapA,,unknown
"2-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Ethanesulfonic Acid",,Complement C1s subcomponent,C1S,,unknown
Adenosine Monotungstate,,Bis(5'-adenosyl)-triphosphatase,FHIT,,unknown
Xylose-Derived Imidazole,,Exoglucanase/xylanase,cex,,unknown
Myricetin,,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,,unknown
Myricetin,,Tyrosine-protein kinase JAK1,JAK1,,unknown
"D-gluconhydroximo-1,5-lactam",,Lactase-phlorizin hydrolase,LCT,,unknown
Guanine,,Purine nucleoside phosphorylase,,,unknown
Guanine,,Purine nucleoside phosphorylase,PNP,,unknown
Guanine,,Purine nucleoside phosphorylase 2,xapA,,unknown
Guanine,,Xanthine phosphoribosyltransferase,gpt,,unknown
Guanine,,GTP cyclohydrolase 1,GCH1,inhibitor,unknown
MMI-175,,Beta-secretase 1,BACE1,,unknown
Beta-D-Glucose,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
Beta-D-Glucose,,Xylose isomerase,xylA,,unknown
Beta-D-Glucose,,Glucokinase,GCK,,unknown
Beta-D-Glucose,,Ferrichrome-iron receptor,fhuA,,unknown
Beta-D-Glucose,,Aldose 1-epimerase,galM,,unknown
Beta-D-Glucose,,"Possible cellulase CelA1 (Endoglucanase) (Endo-1,4-beta-glucanase) (FI-cmcase) (Carboxymethyl cellulase)",celA1,,unknown
Beta-D-Glucose,,Glucokinase,glk,,unknown
Beta-D-Glucose,,Amylase,,,unknown
Beta-D-Glucose,,Fucose-binding lectin PA-IIL,lecB,,unknown
Beta-D-Glucose,,BH0236 protein,,,unknown
Beta-D-Glucose,,Laminarinase,,,unknown
Beta-D-Glucose,,"Endo-1,4-beta-xylanase A",xynA,,unknown
Beta-D-Glucose,,Cellulase B,celB,,unknown
Beta-D-Glucose,,Endoglucanase C,cenC,,unknown
Beta-D-Glucose,,"Cellulose 1,4-beta-cellobiosidase (reducing end) CelS",celS,,unknown
Beta-D-Glucose,,D-galactose-binding periplasmic protein,mglB,,unknown
Beta-D-Glucose,,Glycosyltransferase 6 domain-containing protein 1,GLT6D1,,unknown
Beta-D-Glucose,,Glucosamine-6-phosphate isomerase 1,GNPDA1,,unknown
Beta-D-Glucose,,Beta-amylase,spoII,,unknown
Beta-D-Glucose,,"ADP-ribose pyrophosphatase, mitochondrial",NUDT9,,unknown
Beta-D-Glucose,,SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5,SMARCA5,,unknown
Beta-D-Glucose,,Cyclomaltodextrin glucanotransferase,amyA,,unknown
Beta-D-Glucose,,Enterotoxin type B,entB,,unknown
Beta-D-Glucose,,Alpha-amylase 1,AMY1A,,unknown
Beta-D-Glucose,,Maltodextrin phosphorylase,malP,,unknown
Beta-D-Glucose,,Shiga-like toxin 1 subunit B,stxB,,unknown
Beta-D-Glucose,,Neurocan core protein,NCAN,,unknown
Beta-D-Glucose,,Beta-glucanase,,,unknown
Beta-D-Glucose,,Quinoprotein glucose dehydrogenase B,gdhB,,unknown
Beta-D-Glucose,,Alpha-amylase,,,unknown
Beta-D-Glucose,,DNA,,,unknown
Beta-D-Glucose,,Alpha-amylase,amy,,unknown
Beta-D-Glucose,,Cellulase B,celB,,unknown
Beta-D-Glucose,,Chondroitinase-B,cslB,,unknown
Beta-D-Glucose,,Aspartate ammonia-lyase,aspA,,unknown
Beta-D-Glucose,,Endoglucanase 5A,cel5A,,unknown
Beta-D-Glucose,,Lactase-like protein,LCTL,,unknown
Beta-D-Glucose,,Amylosucrase,ams,,unknown
Beta-D-Glucose,,Pancreatic alpha-amylase,AMY2A,,unknown
Beta-D-Glucose,,Putative monooxygenase MoxC,moxC,,unknown
Beta-D-Glucose,,Endoglucanase E1,,,unknown
Beta-D-Glucose,,D-galactose-binding periplasmic protein,mglB,,unknown
Beta-D-Glucose,,Ecotin,eco,,unknown
Beta-D-Glucose,,A/G-specific adenine glycosylase,mutY,,unknown
Beta-D-Glucose,,Keratin-associated protein 5-2,KRTAP5-2,,unknown
Beta-D-Glucose,,Sialoadhesin,SIGLEC1,,unknown
Beta-D-Glucose,,Neopullulanase,nplT,,unknown
Beta-D-Glucose,,"Endo-1,4-beta-xylanase A",xynA,,unknown
Beta-D-Glucose,,Maltoporin,lamB,,unknown
Beta-D-Glucose,,Hexokinase,,,unknown
Beta-D-Glucose,,Neopullulanase 1,tvaI,,unknown
Beta-D-Glucose,,"Endo-1,4-beta-xylanase",,,unknown
Beta-D-Glucose,,Cyclomaltodextrin glucanotransferase,,,unknown
Beta-D-Glucose,,Maltoporin,lamB,,unknown
Beta-D-Glucose,,Myoglobin,MB,,unknown
Beta-D-Glucose,,Galectin-2,LGALS2,,unknown
Beta-D-Glucose,,Prostaglandin G/H synthase 1,PTGS1,,unknown
Beta-D-Glucose,,Hexokinase-1,HK1,,unknown
Beta-D-Glucose,,Malto-oligosyltrehalose trehalohydrolase,treZ,,unknown
Beta-D-Glucose,,Alpha-amylase,amyE,,unknown
Beta-D-Glucose,,Inorganic polyphosphate/ATP-glucomannokinase,ppgmk,,unknown
Beta-D-Glucose,,Exoglucanase/xylanase,cex,,unknown
Beta-D-Glucose,,Diacetyl reductase [(S)-acetoin forming],budC,,unknown
Beta-D-Glucose,,Cyclomaltodextrin glucanotransferase,cgt,,unknown
Beta-D-Glucose,,Capsid protein VP1,,,unknown
Beta-D-Glucose,,Endoglucanase G,celCCG,,unknown
Beta-D-Glucose,,Hydrolase,,,unknown
Beta-D-Glucose,,Galectin-7,LGALS7,,unknown
Beta-D-Glucose,,Cholera enterotoxin subunit B,ctxB,,unknown
Beta-D-Glucose,,Keratin-associated protein 5-3,KRTAP5-3,,unknown
Beta-D-Glucose,,Dimethyl sulfoxide/trimethylamine N-oxide reductase,dmsA,,unknown
Beta-D-Glucose,,Endoglucanase C307,celC307,,unknown
Beta-D-Glucose,,Alpha-amylase 2B,AMY2B,,unknown
Beta-D-Glucose,,"Endo-1,4-beta glucanase EngF",engF,,unknown
Beta-D-Glucose,,Neopullulanase 2,tvaII,,unknown
Beta-D-Glucose,,Endoglucanase E-4,celD,,unknown
Beta-D-Glucose,,Botulinum neurotoxin type B,botB,,unknown
Beta-D-Glucose,,Orf protein,stx2eB,,unknown
Beta-D-Glucose,,Tetanus toxin,tetX,,unknown
Beta-D-Glucose,,Xylose isomerase,xylA,,unknown
Beta-D-Glucose,,"Glucan 1,4-alpha-maltohexaosidase",,,unknown
Beta-D-Glucose,,"Glucan 1,4-alpha-maltotetraohydrolase",amyP,,unknown
Beta-D-Glucose,,Endoglucanase F,celCCF,,unknown
Beta-D-Glucose,,Glucose--fructose oxidoreductase,gfo,,unknown
Beta-D-Glucose,,Bifunctional tail protein,9,,unknown
Beta-D-Glucose,,"Glycogen phosphorylase, liver form",PYGL,,unknown
Beta-D-Glucose,,Pulmonary surfactant-associated protein D,SFTPD,,unknown
Beta-D-Glucose,,Interferon beta,IFNB1,,unknown
Beta-D-Glucose,,Maltose-binding periplasmic protein,malE,,unknown
Beta-D-Glucose,,Enoyl-[acyl-carrier-protein] reductase [NADH] FabI,fabI,,unknown
Beta-D-Glucose,,Endoglucanase A,celA,,unknown
nor-NOHA,,Arginase-1,ARG1,,unknown
Namn,,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
Namn,,Nicotinate-nucleotide pyrophosphorylase [carboxylating],nadC,,unknown
Tolrestat,,Aldose reductase,AKR1B1,inhibitor,unknown
Tolrestat,,Alcohol dehydrogenase [NADP(+)],AKR1A1,,unknown
Tolrestat,,Aldo-keto reductase family 1 member B10,AKR1B10,,unknown
(E)-2-Fluoro-P-Hydroxycinnamate,,Tautomerase PptA,pptA,,unknown
Leucine Phosphonic Acid,,Cytosol aminopeptidase,LAP3,,unknown
Leucine Phosphonic Acid,,Bacterial leucyl aminopeptidase,,,unknown
"Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine",,Mitogen-activated protein kinase 10,MAPK10,,unknown
"2-Amino-7-[2-(2-Hydroxy-1-Hydroxymethyl-Ethylamino)-Ethyl]-1,7-Dihydro-Purin-6-One",,Purine nucleoside phosphorylase,PNP,,unknown
"D-Gluco-2,5-Anhydro-1-Deoxy-1-Phosphonohexitol-6-Phosphate",,"6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1",PFKFB1,,unknown
Oxiranpseudoglucose,,Cyclomaltodextrin glucanotransferase,,,unknown
"3-Hydroxymethyl-5-Aziridinyl-1methyl-2-[1h-Indole-4,7-Dione]-Propanol",,NAD(P)H dehydrogenase [quinone] 1,NQO1,,unknown
Methylethylamine,,Myoglobin,MB,,unknown
6-[N-(4-(Aminomethyl)Phenyl)Carbamyl]-2-Naphthalenecarboxamidine,,Urokinase-type plasminogen activator,PLAU,,unknown
L-Rhamnitol,,L-rhamnose isomerase,rhaA,,unknown
"5-Methoxy-1,2-Dimethyl-3-(4-Nitrophenoxymethyl)Indole-4,7-Dione",,NAD(P)H dehydrogenase [quinone] 1,NQO1,,unknown
"4-Hydroxy-1,2,5-Oxadiazole-3-Carboxylic Acid",,L-lactate dehydrogenase,,,unknown
"4-Hydroxy-1,2,5-Oxadiazole-3-Carboxylic Acid",,L-lactate dehydrogenase B chain,LDHB,,unknown
"5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine",,Dihydrofolate reductase,DFR1,,unknown
"5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine",,"Dihydrofolate reductase, mitochondrial",DHFRL1,,unknown
2-Fluoroaniline,,Lysozyme,E,,unknown
1-Deoxy-1-Thio-Heptaethylene Glycol,,Acetylcholinesterase,ACHE,,unknown
12-Bromododecanoic Acid,,Glycodelin,PAEP,,unknown
N-Valeric Acid,,"2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase",cumD,,unknown
6-O-Cyclohexylmethyl Guanine,,Cyclin-dependent kinase 2,CDK2,,unknown
6-O-Cyclohexylmethyl Guanine,,Cyclin-A2,CCNA2,,unknown
"(3s)-3-Amino-1-(Cyclopropylamino)Heptane-2,2-Diol",,Methionine aminopeptidase,map,,unknown
"(3s)-3-Amino-1-(Cyclopropylamino)Heptane-2,2-Diol",,Methionine aminopeptidase,map,,unknown
"2-Acetyl-3-[(4-Amino-2-Methyl-5-Pyrimidinyl)Methyl]-4-Methyl-5-(4,6,6-Trihydroxy-3,5-Dioxa-4,6-Diphosphahex-1-Yl)Thiazolium Inner Salt P,P'-Dioxide",,Pyruvate-flavodoxin oxidoreductase,por,,unknown
"2-(11-{2-[Benzenesulfonyl-(3-Methyl-Butyl)-Amino]-1-Hydroxy-Ethyl}-6,9-Dioxo-2-Oxa-7,10-Diaza-Bicyclo[11.2.2]Heptadeca-1(16),13(17),14-Trien-8-Yl)-Acetamide, Inhibitor 2",,Gag-Pol polyprotein,gag-pol,,unknown
Hydroxyethylcysteine,,Gag-Pro-Pol polyprotein,gag-pro-pol,,unknown
"(3s,8ar)-3-(1h-Imidazol-5-Ylmethyl)Hexahydropyrrolo[1,2-a]Pyrazine-1,4-Dione",,Chitinase B,chiB,,unknown
N-Octyl-2-Hydroxyethyl Sulfoxide,,Ferrichrome-iron receptor,fhuA,,unknown
N-Octyl-2-Hydroxyethyl Sulfoxide,,Colicin I receptor,cirA,,unknown
N-Octyl-2-Hydroxyethyl Sulfoxide,,Outer membrane porin C,ompC,,unknown
"(R,R)-2,3-Butanediol",,Ubiquitin-conjugating enzyme E2 D2,UBE2D2,,unknown
Ethyl Oxo(Piperidin-1-Yl)Acetate,,Peptidyl-prolyl cis-trans isomerase A,PPIA,,unknown
"[[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
Uridine-5'-Diphosphate-Mannose,,UDP-glucose 4-epimerase,galE,,unknown
Methyl-2-S-(Alpha-D-Mannopyranosyl)-2-Thio-Alpha-D-Mannopyranoside,,"Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase",MAN1B1,,unknown
Geldanamycin,,Heat shock protein HSP 90-beta,HSP90AB1,,unknown
Geldanamycin,,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
Geldanamycin,,Endoplasmin,HSP90B1,inhibitor,unknown
Hexadecyl Octanoate,,HTH-type transcriptional regulator EthR,ethR,,unknown
Carboxyatractyloside,,ADP/ATP translocase 1,SLC25A4,,unknown
"2,4-Diamino-6-[N-(2',5'-Dimethoxybenzyl)-N-Methylamino]Quinazoline",,Dihydrofolate reductase,,,unknown
"2,4-Diamino-6-[N-(2',5'-Dimethoxybenzyl)-N-Methylamino]Quinazoline",,Dihydrofolate reductase,DHFR,,unknown
Quinaldic Acid,,Gag-Pol polyprotein,gag-pol,,unknown
4-(Aminosulfonyl)-N-[(4-Fluorophenyl)Methyl]-Benzamide,,Carbonic anhydrase 2,CA2,,unknown
Trehalose-6-Phosphate,,HTH-type transcriptional regulator TreR,treR,,unknown
Cytidine-5'-Triphosphate,,CCA-adding enzyme,cca,,unknown
Cytidine-5'-Triphosphate,,Glucose-1-phosphate cytidylyltransferase,rfbF,,unknown
Cytidine-5'-Triphosphate,,2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase,ispD,,unknown
Cytidine-5'-Triphosphate,,Glycerol-3-phosphate cytidylyltransferase,tagD,,unknown
Cytidine-5'-Triphosphate,,2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase,ispD,,unknown
Cytidine-5'-Triphosphate,,3-deoxy-manno-octulosonate cytidylyltransferase,kpsU,,unknown
Cytidine-5'-Triphosphate,,Uridine-cytidine kinase 2,UCK2,,unknown
Cytidine-5'-Triphosphate,,Coenzyme A biosynthesis bifunctional protein CoaBC,coaBC,,unknown
RU90395,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
"{[(2,2-Dihydroxy-Ethyl)-(2,3,4,5-Tetrahydroxy-6-Phosphonooxy-Hexyl)-Amino]-Methyl}-Phosphonic Acid",,2-dehydro-3-deoxyphosphooctonate aldolase,kdsA,,unknown
"{[(2,2-Dihydroxy-Ethyl)-(2,3,4,5-Tetrahydroxy-6-Phosphonooxy-Hexyl)-Amino]-Methyl}-Phosphonic Acid",,2-dehydro-3-deoxyphosphooctonate aldolase,kdsA,,unknown
4-(2-Thienyl)Butyric Acid,,Aromatic-amino-acid aminotransferase,tyrB,,unknown
Aminomethylcyclohexane,,UDP-N-acetylglucosamine 1-carboxyvinyltransferase,murA,,unknown
Aminomethylcyclohexane,,Trypsin-1,PRSS1,,unknown
2-{4-[(2s)-2-[({[(1s)-1-Carboxy-2-Phenylethyl]Amino}Carbonyl)Amino]-3-Oxo-3-(Pentylamino)Propyl]Phenoxy}Malonic Acid,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
(5r)-5-Amino-6-Hydroxyhexylcarbamic Acid,,Isoaspartyl dipeptidase,iadA,,unknown
(5r)-5-Amino-6-Hydroxyhexylcarbamic Acid,,Parathion hydrolase,opd,,unknown
(5r)-5-Amino-6-Hydroxyhexylcarbamic Acid,,Bifunctional protein FolC,folC,,unknown
3-O-Methylfructose in Linear Form,,Xylose isomerase,xylA,,unknown
"2-Butyl-5,6-Dihydro-1h-Imidazo[4,5-D]Pyridazine-4,7-Dione",,Queuine tRNA-ribosyltransferase,tgt,,unknown
Dioxyselenocysteine,,Subtilisin BPN',apr,,unknown
Methicillin Acyl-Serine,,Beta-lactam-inducible penicillin-binding protein,pbp,,unknown
2-Deoxy-2-Amino Glucitol-6-Phosphate,,Glucosamine-6-phosphate isomerase 1,GNPDA1,,unknown
2-Deoxy-2-Amino Glucitol-6-Phosphate,,Glucosamine-6-phosphate deaminase,nagB,,unknown
2-Deoxy-2-Amino Glucitol-6-Phosphate,,Glutamine--fructose-6-phosphate aminotransferase [isomerizing],glmS,,unknown
Glutamine Hydroxamate,,Glutamine--fructose-6-phosphate aminotransferase [isomerizing],glmS,,unknown
"3,8,9,10-Tetrahydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
N-Tridecanoic Acid,,"Phospholipase A2, membrane associated",PLA2G2A,,unknown
N-Tridecanoic Acid,,Phospholipase A2,PLA2G1B,,unknown
N-Tridecanoic Acid,,Group IIE secretory phospholipase A2,PLA2G2E,,unknown
3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid,,Stromelysin-1,MMP3,,unknown
"2-Benzo[1,3]Dioxol-5-Ylmethyl-3-Benzyl-Succinic Acid",,Beta-lactamase IMP-1,,,unknown
"2-Benzo[1,3]Dioxol-5-Ylmethyl-3-Benzyl-Succinic Acid",,Beta-lactamase,blaIMP-1,,unknown
Thymidine-5'-Triphosphate,,Glucose-1-phosphate thymidylyltransferase,rmlA,,unknown
Thymidine-5'-Triphosphate,,Glucose-1-phosphate thymidylyltransferase 2,rffH,,unknown
Thymidine-5'-Triphosphate,,DNA primase/helicase,,,unknown
Thymidine-5'-Triphosphate,,Glucose-1-phosphate thymidylyltransferase,rmlA,,unknown
Thymidine-5'-Triphosphate,,"Thymidine kinase 2, mitochondrial",TK2,,unknown
Thymidine-5'-Triphosphate,,Thymidine kinase,tdk,,unknown
Thymidine-5'-Triphosphate,,Ribonucleoside-diphosphate reductase 2 subunit alpha,nrdE,,unknown
Thymidine-5'-Triphosphate,,"Thymidine kinase, cytosolic",TK1,,unknown
Thymidine-5'-Triphosphate,,Anaerobic ribonucleoside-triphosphate reductase,NRDD,,unknown
Thymidine-5'-Triphosphate,,Thymidylate kinase,tmk,,unknown
Trihydroxyantimonite(Iii),,Arsenical pump-driving ATPase,arsA,,unknown
Aracytidine 5'-monophosphate,,Cytidylate kinase,cmk,,unknown
Undecyl-Phosphinic Acid Butyl Ester,,Gastric triacylglycerol lipase,LIPF,,unknown
"S-(2,4-dinitrophenyl)glutathione",,Glutathione S-transferase Mu 1,GSTM1,,unknown
"S-(2,4-dinitrophenyl)glutathione",,Glutathione S-transferase Mu 2,GSTM2,,unknown
4-Guanidinobenzoic Acid,,Complement factor B,CFB,,unknown
Hydrogenobyrinic Acid,,Precorrin-8X methylmutase,cobH,,unknown
S-Methyl Phosphocysteine,,Chemotaxis protein CheY,cheY,,unknown
Thiocoumarin,,"Nitric oxide synthase, inducible",NOS2,,unknown
2-(2-Hydroxy-Phenyl)-1h-Indole-5-Carboxamidine,,Trypsin-1,PRSS1,,unknown
Benzylamine,,Trypsin-2,PRSS2,,unknown
Benzylamine,,Trypsin-1,PRSS1,,unknown
Methoxy arachidonyl fluorophosphonate,,Fatty-acid amide hydrolase 1,FAAH,,unknown
"4-[3-Oxo-3-(5,5,8,8-Tetramethyl-5,6,7,8-Tetrahydro-Naphthalen-2-Yl)-Propenyl]-Benzoic Acid",,Retinoic acid receptor gamma,RARG,,unknown
L-methionine (S)-S-oxide,,"Possible cellulase CelA1 (Endoglucanase) (Endo-1,4-beta-glucanase) (FI-cmcase) (Carboxymethyl cellulase)",celA1,,unknown
L-methionine (S)-S-oxide,,Ras-related protein Rab-5A,RAB5A,,unknown
L-methionine (S)-S-oxide,,Cellulase B,celB,,unknown
L-methionine (S)-S-oxide,,Amicyanin,mauC,,unknown
L-methionine (S)-S-oxide,,Aminopeptidase S,,,unknown
L-methionine (S)-S-oxide,,Thymidylate synthase,thyA,,unknown
12-Phenylheme,,Heme oxygenase 1,HMOX1,,unknown
"4,6-dideoxy-4-amino-beta-D-glucopyranoside",,Cyclomaltodextrin glucanotransferase,,,unknown
D-Glycero-D-Mannopyranose-7-Phosphate,,Phosphoheptose isomerase,gmhA,,unknown
Nojirimycine Tetrazole,,Lactase-phlorizin hydrolase,LCT,,unknown
Nojirimycine Tetrazole,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
Nojirimycine Tetrazole,,Lactase-like protein,LCTL,,unknown
"6-Hydroxy-7,8-Dihydro Purine Nucleoside",,Adenosine deaminase,ADA,,unknown
"6-[N-(1-Isopropyl-3,4-Dihydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine",,Urokinase-type plasminogen activator,PLAU,,unknown
Bmsc-0013,,Cholera enterotoxin subunit B,ctxB,,unknown
Deoxyguanidinoproclavaminic acid,,Clavaminate synthase 1,cs1,,unknown
[Cyclohexylethyl]-[[[[4-[2-Methyl-1-Imidazolyl-Butyl]Phenyl]Acetyl]-Seryl]-Lysinyl]-Amine,,Glycylpeptide N-tetradecanoyltransferase,NMT1,,unknown
(R)-N-(3-Indol-1-Yl-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide,,Carbonic anhydrase 2,CA2,,unknown
(S)-4-bromo-3-hydroxy-3-methylbutyl diphosphate,,Isopentenyl-diphosphate Delta-isomerase,idi,,unknown
N-Benzylformamide,,Alcohol dehydrogenase 1B,ADH1B,,unknown
Phosphonothreonine,,Rhodopsin,RHO,,unknown
Phosphonothreonine,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
Phosphonothreonine,,cAMP-dependent protein kinase catalytic subunit beta,PRKACB,,unknown
Phosphonothreonine,,Cyclin-dependent kinase 7,CDK7,,unknown
Phosphonothreonine,,Threonine-phosphate decarboxylase,cobD,,unknown
Phosphonothreonine,,Protein S100-A11,S100A11,,unknown
Phosphonothreonine,,Mitogen-activated protein kinase 12,MAPK12,,unknown
Phosphonothreonine,,Protein kinase C theta type,PRKCQ,,unknown
Phosphonothreonine,,Aurora kinase A,AURKA,,unknown
Phosphonothreonine,,Mitogen-activated protein kinase 1,MAPK1,,unknown
Etheno-Nad,,L-lactate dehydrogenase A chain,LDHA,,unknown
Etheno-Nad,,ADP-ribosyl cyclase 2,BST1,,unknown
Cytidine 5'-Diphosphoglycerol,,Glycerol-3-phosphate cytidylyltransferase,tagD,,unknown
Cytidine-5'-Monophosphate-5-N-Acetylneuraminic Acid,,N-acylneuraminate cytidylyltransferase,CMAS,,unknown
2-Hydroxyethyl Disulfide,,Glutathione S-transferase A1,GSTA1,,unknown
2-Hydroxyethyl Disulfide,,Lysozyme,E,,unknown
9-Methylguanine,,Dihydroneopterin aldolase,folB,,unknown
(Diaminomethyl-Methyl-Amino)-Acetic Acid,,Creatine kinase M-type,CKM,,unknown
4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine,,Fibroblast growth factor receptor 2,FGFR2,,unknown
Ghavamiol,,Alpha-mannosidase 2,MAN2A1,,unknown
Hydantocidin-5'-Phosphate,,Adenylosuccinate synthetase,purA,,unknown
Alpha-Hydroxy-Beta-Phenyl-Propionic Acid,,L-phenylalanine dehydrogenase,pdh,,unknown
Alpha-Hydroxy-Beta-Phenyl-Propionic Acid,,60S ribosomal protein L10-like,RPL10L,,unknown
Alpha-Hydroxy-Beta-Phenyl-Propionic Acid,,60S ribosomal protein L13a,RPL13A,,unknown
Alpha-Hydroxy-Beta-Phenyl-Propionic Acid,,60S ribosomal protein L23,RPL23,,unknown
Alpha-Hydroxy-Beta-Phenyl-Propionic Acid,,60S ribosomal protein L15,RPL15,,unknown
Alpha-Hydroxy-Beta-Phenyl-Propionic Acid,,60S ribosomal protein L19,RPL19,,unknown
Alpha-Hydroxy-Beta-Phenyl-Propionic Acid,,60S ribosomal protein L23a,RPL23A,,unknown
Alpha-Hydroxy-Beta-Phenyl-Propionic Acid,,Probable ribosome biogenesis protein RLP24,RSL24D1,,unknown
Alpha-Hydroxy-Beta-Phenyl-Propionic Acid,,60S ribosomal protein L26-like 1,RPL26L1,,unknown
Alpha-Hydroxy-Beta-Phenyl-Propionic Acid,,60S ribosomal protein L8,RPL8,,unknown
Alpha-Hydroxy-Beta-Phenyl-Propionic Acid,,60S ribosomal protein L37,RPL37,,unknown
Alpha-Hydroxy-Beta-Phenyl-Propionic Acid,,60S ribosomal protein L3,RPL3,,unknown
Alpha-Hydroxy-Beta-Phenyl-Propionic Acid,,60S ribosomal protein L11,RPL11,,unknown
Alpha-Hydroxy-Beta-Phenyl-Propionic Acid,,NHP2-like protein 1,SNU13,,unknown
Alpha-Hydroxy-Beta-Phenyl-Propionic Acid,,Carboxypeptidase A1,CPA1,,unknown
9-(4-hydroxybutyl)-N2-phenylguanine,,Thymidine kinase,TK,,unknown
1-Deoxy-D-xylulose 5-phosphate,,1-deoxy-D-xylulose 5-phosphate reductoisomerase,dxr,,unknown
1-Deoxy-D-xylulose 5-phosphate,,Pyridoxine 5'-phosphate synthase,pdxJ,,unknown
L-Alpha-Glycerophosphorylserine,,Annexin A5,ANXA5,,unknown
Carba-Nicotinamide-Adenine-Dinucleotide,,Poly [ADP-ribose] polymerase 1,PARP1,,unknown
Dinor-N(Omega)-Hydroxy-L-Arginine,,Arginase-1,ARG1,,unknown
6-(Dihydroxy-Isobutyl)-Thymine,,Thymidine kinase,TK,,unknown
N~2~-Succinylarginine,,N-succinylarginine dihydrolase,astB,,unknown
4-(Carboxyvin-2-Yl)Phenylboronic Acid,,Beta-lactamase,ampC,,unknown
[3-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Propyl-]-Phosphonic Acid,,"Phospholipase A2, membrane associated",PLA2G2A,,unknown
N-(R-Carboxy-Ethyl)-Alpha-(S)-(2-Phenylethyl),,Plasmepsin-2,,,unknown
"2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid",,Serine/threonine-protein phosphatase PP1-alpha catalytic subunit,PPP1CA,,unknown
"2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid",,Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform,PPP2R1A,,unknown
"2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid",,Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform,PPP2CA,,unknown
"2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid",,Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform,PPP2R5C,,unknown
"2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid",,Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform,PPP2R2A,,unknown
4-Hydroxy-3-[(1s)-3-Oxo-1-Phenylbutyl]-2h-Chromen-2-One,,Cytochrome P450 2C9,CYP2C9,,unknown
Isopentyl Pyrophosphate,,Farnesyl diphosphate synthase,ispA,,unknown
Isopentyl Pyrophosphate,,Farnesyl pyrophosphate synthase,FDPS,,unknown
Isopentyl Pyrophosphate,,Pentaerythritol tetranitrate reductase,onr,,unknown
Isopentyl Pyrophosphate,,Geranyltranstransferase (Farnesyldiphosphate synthase),ispA,,unknown
Farnesol,,Amine oxidase [flavin-containing] B,MAOB,,unknown
Farnesol,,Bile acid receptor,NR1H4,agonist,unknown
'5'-O-(N-(L-Prolyl)-Sulfamoyl)Adenosine,,Bifunctional glutamate/proline--tRNA ligase,EPRS,,unknown
2-Hydroxy-5-({1-[(2-Naphthyloxy)Methyl]-3-Oxoprop-1-Enyl}Amino)Tyrosine,,Phenylethylamine oxidase,,,unknown
"1,6-Fructose Diphosphate (Linear Form)",,Fructose-bisphosphate aldolase A,ALDOA,,unknown
"1,6-Fructose Diphosphate (Linear Form)",,Fructose-bisphosphate aldolase B,ALDOB,,unknown
(2Z)-3-{[Oxido(oxo)phosphoranyl]oxy}-2-phenylacrylate,,D-alanyl-D-alanine carboxypeptidase,,,unknown
3-Phosphoglycerol,,"6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1",PFKFB1,,unknown
3-Phosphoglycerol,,Fructose-bisphosphate aldolase B,ALDOB,,unknown
3-Phosphoglycerol,,Pyridoxine 5'-phosphate synthase,pdxJ,,unknown
3-Phosphoglycerol,,Triosephosphate isomerase,TPI,,unknown
"O5'-(4-(3-{2-[2-((R)-3-Hydroxy-4-(Trimethylammonio)-1-Oxo-Butyl)Sulfanyl-Ethylcarbamoyl]-Ethylcarbamoyl}-(R)-3-Hydroxy-2,2-Dimethyl-Propyl)-1-Hydroxy-3-Oxido-1,3-Dioxo-2,4-Dioxa-1,3-Diphosphabut-1-Yl) 3'-Phospho-Adenosine",,Crotonobetainyl-CoA:carnitine CoA-transferase,caiB,,unknown
D-Glutamic Acid,,Thermolysin,nprS,,unknown
N-Acetylalanine,,Aldose reductase,AKR1B1,,unknown
Indirubin-5-Sulphonate,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
Indirubin-5-Sulphonate,,Cell division control protein 2 homolog,CRK2,,unknown
"2,5,7-Trihydroxynaphthoquinone",,Putative cytochrome P450,cyp158a2,,unknown
"2,5,7-Trihydroxynaphthoquinone",,Prenyltransferase,,,unknown
Phosphonopyruvate,,"Pyruvate, phosphate dikinase",ppdK,,unknown
"2',3'-O-{4-[Hydroxy(oxido)-λ5-azanylidene]-2,6-dinitro-2,5-cyclohexadiene-1,1-diyl}adenosine 5'-(tetrahydrogen triphosphate)",,Chemotaxis protein CheA,cheA,,unknown
CRA_10655,,Trypsin-1,PRSS1,,unknown
CRA_10655,,Urokinase-type plasminogen activator,PLAU,,unknown
Cyclic Adenosine Monophosphate,,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2,HCN2,,unknown
Cyclic Adenosine Monophosphate,,cAMP-dependent protein kinase type I-alpha regulatory subunit,PRKAR1A,,unknown
Cyclic Adenosine Monophosphate,,cAMP-dependent protein kinase type II-beta regulatory subunit,PRKAR2B,,unknown
Cyclic Adenosine Monophosphate,,Adenylate cyclase,cyaB2,,unknown
Cyclic Adenosine Monophosphate,,Cyclic nucleotide-gated potassium channel mll3241,,,unknown
Cyclic Adenosine Monophosphate,,cAMP-activated global transcriptional regulator CRP,crp,,unknown
Tetrazolyl Histidine,,Myoglobin,MB,,unknown
"5-N-Acetyl-4-Amino-6-Diethylcarboxamide-4,5-Dihydro-2h-Pyran-2-Carboxylic Acid",,Neuraminidase,NA,,unknown
gamma-Aminobutyric acid,,"Glycine amidinotransferase, mitochondrial",GATM,,unknown
gamma-Aminobutyric acid,,Gamma-aminobutyric acid type B receptor subunit 1,GABBR1,,unknown
gamma-Aminobutyric acid,,Gamma-aminobutyric acid type B receptor subunit 2,GABBR2,,unknown
Isobutyric Acid,,"2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase",cumD,,unknown
"2,4,6-Triaminoquinazoline",,Pteridine reductase 1,PTR1,,unknown
"2,4,6-Triaminoquinazoline",,Putative dehydrogenase/reductase SDR family member 4-like 2,DHRS4L1,,unknown
2-Allylphenol,,Lysozyme,E,,unknown
Aminodi(Ethyloxy)Ethylaminocarbonylbenzenesulfonamide,,Carbonic anhydrase 2,CA2,,unknown
2-Hydroxy-5-({1-[(4-Methylphenoxy)Methyl]-3-Oxoprop-1-Enyl}Amino)-L-Tyrosine,,Phenylethylamine oxidase,,,unknown
"N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide",,Cyclin-dependent kinase 2,CDK2,,unknown
"(10S)-10-Formyl-5,8,10-Trideazafolic Acid",,Phosphoribosylglycinamide formyltransferase,purN,,unknown
4-Hydroxybutan-1-Aminium,,Trypsin-3,PRSS3,,unknown
(4s)-5-Fluoro-L-Leucine,,Polyubiquitin-B,UBB,,unknown
Pyrrole-2-Carboxylate,,Monomeric sarcosine oxidase,soxA,,unknown
"N-(6-{[3-(4-Bromophenyl)-1,2-Benzisothiazol-6-Yl]Oxy}Hexyl)-N-Methylprop-2-En-1-Amine",,Squalene--hopene cyclase,shc,,unknown
Fexaramine,,Bile acid receptor,NR1H4,,unknown
Vorinostat,2 hours,Histone deacetylase 1,HDAC1,inhibitor,yes
Vorinostat,2 hours,Histone deacetylase 2,HDAC2,inhibitor,yes
Vorinostat,2 hours,Histone deacetylase 3,HDAC3,inhibitor,yes
Vorinostat,2 hours,Histone deacetylase 6,HDAC6,inhibitor,yes
Vorinostat,2 hours,Histone deacetylase 8,HDAC8,,unknown
Vorinostat,2 hours,Acetoin utilization protein,acuC1,,unknown
Guanosine-5'-Diphosphate-Rhamnose,,"GDP-mannose 4,6 dehydratase",GMDS,,unknown
D-glucitol 6-phosphate,,Glucose-6-phosphate isomerase,GPI,,unknown
3'-O-Acetylthymidine-5'-Diphosphate,,"dTDP-4-dehydrorhamnose 3,5-epimerase",rfbC,,unknown
"8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"6-[N-(4-Ethyl-1,2,3,4-Tetrahydro-6-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine",,Urokinase-type plasminogen activator,PLAU,,unknown
Geranyl Diphosphate,,"2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase",ispF,,unknown
Geranyl Diphosphate,,Bifunctional enzyme IspD/IspF,ispDF,,unknown
Geranyl Diphosphate,,"2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase",ispF,,unknown
Geranyl Diphosphate,,Farnesyl pyrophosphate synthase,FDPS,,unknown
Geranyl Diphosphate,,Prenyltransferase,,,unknown
Geranyl Diphosphate,,Geranylgeranyl pyrophosphate synthase,GGPS1,,unknown
Geranyl Diphosphate,,"(2Z,6E)-farnesyl diphosphate synthase",,,unknown
Geranyl Diphosphate,,Decaprenyl diphosphate synthase,uppS,,unknown
Glutathionylspermidine Disulfide,,"Glutathione reductase, mitochondrial",GSR,,unknown
SP4160,,Interleukin-2,IL2,,unknown
D-Phenylalanine,,Kynurenine--oxoglutarate transaminase 1,CCBL1,,unknown
D-Phenylalanine,,Corticoliberin,CRH,,unknown
Phosphoramidon,,Neprilysin,MME,inhibitor,unknown
Phosphoramidon,,Kell blood group glycoprotein,KEL,,unknown
N-(3-Phenyl-2-Sulfanylpropanoyl)Phenylalanylalanine,,Neprilysin,MME,,unknown
"6-(Octahydro-1h-Indol-1-Ylmethyl)Decahydroquinazoline-2,4-Diamine",,Dihydrofolate reductase,DHFR,,unknown
"6-(Octahydro-1h-Indol-1-Ylmethyl)Decahydroquinazoline-2,4-Diamine",,Dihydrofolate reductase,,,unknown
[(1S)-1-acetamido-2-(4-chlorophenyl)ethyl]-[(2S)-2-amino-3-hydroxy-3-oxo-propoxy]-dihydroxy-boron,,Subtilisin Carlsberg,apr,,unknown
Beta-D-Fructopyranose,,Fucose-binding lectin PA-IIL,lecB,,unknown
"Quinonoid 7,8-Tetrahydrobiopterin",,Phenylalanine-4-hydroxylase,PAH,,unknown
Hexanoyl-CoA,,"Enoyl-CoA hydratase, mitochondrial",ECHS1,,unknown
4-Dimethylamino-N-(6-Hydroxycarbamoyethyl)Benzamide-N-Hydroxy-7-(4-Dimethyla Minobenzoyl)Aminoheptanamide,,Histone deacetylase 8,HDAC8,,unknown
8-Hydroxy-4-(1-Hydroxyethyl)Quinoline-2-Carboxylic Acid,,Thiostrepton,tpdA,,unknown
8-Hydroxy-4-(1-Hydroxyethyl)Quinoline-2-Carboxylic Acid,,50S ribosomal protein L11,rplK,,unknown
PD173955,,Tyrosine-protein kinase transforming protein Abl,ABL,,unknown
Peldesine,,Purine nucleoside phosphorylase,PNP,,unknown
"2',3'-Dehydro-2',3'-Deoxy-Thymidine 5'-Diphosphate",,Nucleoside diphosphate kinase A,NME1,,unknown
PD150606,,Calpain small subunit 1,CAPNS1,,unknown
2-Amino-6-Oxo-Hexanoic Acid,,Glutaminase-asparaginase,ansB,,unknown
BV4,,Cholera enterotoxin subunit B,ctxB,,unknown
"2'-Deoxycytidine-2'-Deoxyadenosine-3',5'-Monophosphate",,Ribonuclease pancreatic,RNASE1,,unknown
BV2,,Cholera enterotoxin subunit B,ctxB,,unknown
F-Loop of Vitamin B12,,Methylaspartate mutase S chain,glmS,,unknown
Glycyl-L-Alpha-Amino-Epsilon-Pimelyl-D-Alanyl-D-Alanine,,D-alanyl-D-alanine carboxypeptidase,,,unknown
Acrylic Acid,,Beta-lactamase SHV-1,bla,,unknown
Pentaglyme,,Profilin-2,PFN2,,unknown
Pentaglyme,,Restriction endonuclease R.BpuJI,bpuJIR,,unknown
Pentaglyme,,Eight-heme nitrite reductase,nir,,unknown
Pentaglyme,,Uncharacterized protein,,,unknown
Pentaglyme,,"Sensor cyclic diguanylate phosphodiesterase, GAF and GAF domain-containing",,,unknown
Pentaglyme,,Putative uncharacterized protein,,,unknown
Pentaglyme,,"2,3-bisphosphoglycerate-dependent phosphoglycerate mutase",gpmA,,unknown
Pentaglyme,,Adenylosuccinate synthetase,purA,,unknown
Pentaglyme,,Hypothetical cytosolic protein,,,unknown
Pentaglyme,,"EDD domain protein, DegV family",,,unknown
Pentaglyme,,Uncharacterized protein,,,unknown
"5-[2,3-Dichloro-4-(5-{1-[2-(2-Guanidino-4-Methyl-Pentanoylamino)-Acetyl]-Piperidin-4-Yl}-1-Methyl-1h-Pyrazol-3-Yl)-Phenoxymethyl]-Furan-2-Carboxylic Acid",,Interleukin-2,IL2,,unknown
"N6-(2,5-Dimethoxy-Benzyl)-N6-Methyl-Pyrido[2,3-D]Pyrimidine-2,4,6-Triamine",,Dihydrofolate reductase,DHFR,,unknown
4-(Hydroxymethyl)Benzamidine,,Trypsin-3,PRSS3,,unknown
"4,7-Dimethyl-[1,10]Phenanthroline",,Azurin,azu,,unknown
Colforsin,,Adenylate cyclase type 2,ADCY2,,unknown
Colforsin,,Guanine nucleotide-binding protein G(s) subunit alpha isoforms short,GNAS,,unknown
Colforsin,,Adenylate cyclase type 5,ADCY5,,unknown
Colforsin,,Cystic fibrosis transmembrane conductance regulator,CFTR,inhibitor,unknown
Moxalactam Derivative,,Beta-lactamase,ampC,,unknown
Se-Ethyl-Isoselenourea,,"Nitric oxide synthase, endothelial",NOS3,,unknown
Abequose,,Bifunctional tail protein,9,,unknown
"5,6-Dimethylbenzimidazole",,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
Carbaphosphonate,,3-dehydroquinate synthase,aroB,,unknown
"7,8-Dihydroxy-1-Methoxy-3-Methyl-10-Oxo-4,10-Dihydro-1h,3h-Pyrano[4,3-B]Chromene-9-Carboxylic Acid",,Beta-lactamase type II,ccrA,,unknown
2'-Deoxycytidine,,Class B acid phosphatase,aphA,,unknown
2'-Deoxycytidine,,"Thymidine kinase 2, mitochondrial",TK2,,unknown
2'-Deoxycytidine,,Deoxycytidine kinase,DCK,,unknown
Bulgecin A,,Soluble lytic murein transglycosylase,slt,,unknown
Bulgecin A,,Membrane-bound lytic murein transglycosylase B,mltB,,unknown
"Alpha,Beta-Methyleneadenosine-5'-Triphosphate",,2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase,folK,,unknown
"Alpha,Beta-Methyleneadenosine-5'-Triphosphate",,Pantothenate synthetase,panC,,unknown
"Alpha,Beta-Methyleneadenosine-5'-Triphosphate",,NH(3)-dependent NAD(+) synthetase,nadE,,unknown
"Alpha,Beta-Methyleneadenosine-5'-Triphosphate",,Nicotinamide mononucleotide adenylyltransferase 3,NMNAT3,,unknown
"Alpha,Beta-Methyleneadenosine-5'-Triphosphate",,Adenylate cyclase,cyaC,,unknown
"Alpha,Beta-Methyleneadenosine-5'-Triphosphate",,NTPase P4,4,,unknown
"Alpha,Beta-Methyleneadenosine-5'-Triphosphate",,Probable lignin peroxidase LipJ,lipJ,,unknown
"Alpha,Beta-Methyleneadenosine-5'-Triphosphate",,Carbapenam-3-carboxylate synthase,carA,,unknown
"[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala",,Thermolysin,nprS,,unknown
"[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala",,Neprilysin,MME,,unknown
"[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala",,Thermolysin,npr,,unknown
"N-Alpha-Acetyl-3,5-Diiodotyrosylglycine",,Peptidyl-glycine alpha-amidating monooxygenase,PAM,,unknown
"2,6-Diamino-8-Propylsulfanylmethyl-3h-Quinazoline-4-One",,Queuine tRNA-ribosyltransferase,tgt,,unknown
5-N-Acetyl-3-(1-Ethylpropyl)-1-Cyclohexene-1-Carboxylic Acid,,Neuraminidase,NA,,unknown
AL7182,,Carbonic anhydrase 2,CA2,,unknown
1-Amino-6-Cyclohex-3-Enylmethyloxypurine,,Cyclin-dependent kinase 2,CDK2,,unknown
2-Deoxy-Glucose-6-Phosphate,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
2-Butanol,,NADP-dependent isopropanol dehydrogenase,adh,,unknown
Adenosine Phosphonoacetic Acid,,Nucleoside diphosphate kinase A,NME1,,unknown
N-Acetyl-P-Nitrophenylserinol,,Chloramphenicol 3-O phosphotransferase,,,unknown
4-Hydroxy-L-Threonine-5-Monophosphate,,4-hydroxythreonine-4-phosphate dehydrogenase,pdxA,,unknown
"N-(2,3,4,5,6-Pentaflouro-Benzyl)-4-Sulfamoyl-Benzamide",,Carbonic anhydrase 2,CA2,,unknown
Balanol Analog 1,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
"Decylamine-N,N-Dimethyl-N-Oxide",,Ferrichrome-iron receptor,fhuA,,unknown
"Decylamine-N,N-Dimethyl-N-Oxide",,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
"Decylamine-N,N-Dimethyl-N-Oxide",,Autolysin,lytA,,unknown
"Decylamine-N,N-Dimethyl-N-Oxide",,Pancreatic lipase-related protein 2,PNLIPRP2,,unknown
1(R)-1-Acetamido-2-(3-Carboxyphenyl)Ethyl Boronic Acid,,Beta-lactamase TEM,bla,,unknown
1(R)-1-Acetamido-2-(3-Carboxyphenyl)Ethyl Boronic Acid,,Beta-lactamase TEM,bla,,unknown
Compound 19,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
Compound 19,,Estrogen receptor alpha,ESR1,,unknown
FR117016,,Adenosine deaminase,ADA,,unknown
"1-(N-Imidazolyl)-2-Hydroxy-2-(2,3-Dichlorophenyl)Octane",,Camphor 5-monooxygenase,camC,,unknown
Sp7343-Sp7964,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
Latrunculin A,,"Actin, alpha skeletal muscle",ACTA1,inhibitor,unknown
Latrunculin A,,Gelsolin,GSN,,unknown
Latrunculin A,,Iota toxin component Ia,,,unknown
2-(Oxalyl-Amino)-Benzoic Acid,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
Aminophosphonic Acid-Guanylate Ester,,Cell division control protein 42 homolog,CDC42,,unknown
Homoserine Lactone,,Sodium/hydrogen exchanger 1,SLC9A1,,unknown
(2r)-2-{[Formyl(Hydroxy)Amino]Methyl}Hexanoic Acid,,"Formylmethionine deformylase, putative",,,unknown
Phenylferricrocin-Iron,,Ferrichrome-iron receptor,fhuA,,unknown
"4,4'-Biphenyldiboronic Acid",,Beta-lactamase,ampC,,unknown
"1-[3,3-Dimethyl-2-(2-Methylamino-Propionylamino)-Butyryl]-Pyrrolidine-2-Carboxylic Acid(1,2,3,4-Tetrahydro-Naphthalen-1-Yl)-Amide",,E3 ubiquitin-protein ligase XIAP,XIAP,,unknown
Inhibitor Bea403,,Gag-Pol polyprotein,gag-pol,,unknown
L-xylitol 5-phosphate,,3-keto-L-gulonate-6-phosphate decarboxylase UlaD,ulaD,,unknown
4-nitrophenyl-beta-D-galactoside,,Galactoside O-acetyltransferase,lacA,,unknown
4-nitrophenyl-beta-D-galactoside,,Beta-galactosidase,lacZ,,unknown
Cibacron Blue,,NAD(P)H dehydrogenase [quinone] 1,NQO1,,unknown
Cibacron Blue,,Glutathione S-transferase P,GSTP1,,unknown
N-[O-Phosphono-Pyridoxyl]-Isoleucine,,"Branched-chain-amino-acid aminotransferase, mitochondrial",BCAT2,,unknown
"9-Hydroxy-8-Methoxy-6-Nitro-Phenanthrol[3,4-D][1,3]Dioxole-5-Carboxylic Acid",,Group IIE secretory phospholipase A2,PLA2G2E,,unknown
Oxaloacetate Ion,,"Citrate synthase, mitochondrial",CS,,unknown
Oxaloacetate Ion,,Malate dehydrogenase,mdh,,unknown
Oxaloacetate Ion,,Sepiapterin reductase,SPR,,unknown
Oxaloacetate Ion,,Methylmalonyl-CoA carboxyltransferase 5S subunit,,,unknown
Oxaloacetate Ion,,Citrate lyase subunit beta-like protein,,,unknown
Terlipressin,,Vasopressin V2 receptor,AVPR2,agonist,yes
Terlipressin,,Vasopressin V1b receptor,AVPR1B,,unknown
Terlipressin,,Vasopressin V1a receptor,AVPR1A,stimulator,unknown
Fumagillin,,Methionine aminopeptidase 2,METAP2,ligand,unknown
Heptanamide,,"Limonene-1,2-epoxide hydrolase",limA,,unknown
[[N-(Benzyloxycarbonyl)Amino]Methyl]Phosphate,,Beta-lactamase TEM,bla,,unknown
[[N-(Benzyloxycarbonyl)Amino]Methyl]Phosphate,,Beta-lactamase TEM,bla,,unknown
[[N-(Benzyloxycarbonyl)Amino]Methyl]Phosphate,,Beta-lactamase,blaZ,,unknown
"N-Dodecyl-N,N-Dimethyl-3-Ammonio-1-Propanesulfonate",,Penton protein,,,unknown
"N-Dodecyl-N,N-Dimethyl-3-Ammonio-1-Propanesulfonate",,Insulin-like growth factor I,IGF1,,unknown
"N-Dodecyl-N,N-Dimethyl-3-Ammonio-1-Propanesulfonate",,Amine oxidase [flavin-containing] B,MAOB,,unknown
N-Omega-Propyl-L-Arginine,,"Nitric oxide synthase, inducible",NOS2,,unknown
N-Omega-Propyl-L-Arginine,,"Nitric oxide synthase, brain",NOS1,,unknown
"3,4-Epoxybutyl-Alpha-D-Glucopyranoside",,Beta-amylase,spoII,,unknown
Nitrosoethane,,Myoglobin,MB,,unknown
N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide,,Cyclin-dependent kinase 2,CDK2,,unknown
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium,,Carnitine O-acetyltransferase,CRAT,,unknown
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium,,Peroxisomal carnitine O-octanoyltransferase,CROT,,unknown
3-Amino-3-Oxopropanoic Acid,,Malonamidase E2,,,unknown
"{[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
L-[(N-Hydroxyamino)Carbonyl]Phenylalanine,,Carboxypeptidase A1,CPA1,,unknown
D-Aspartic Acid,,Thermolysin,nprS,,unknown
D-Aspartic Acid,,L-asparaginase,ansB,,unknown
LY-294002,,Serine/threonine-protein kinase pim-1,PIM1,,unknown
LY-294002,,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,,unknown
Glucosamine 6-Phosphate,,Glutamine--fructose-6-phosphate aminotransferase [isomerizing],glmS,,unknown
Glucosamine 6-Phosphate,,N-acetylglucosamine-6-phosphate deacetylase,nagA,,unknown
"2,4-Dinitrophenyl 2-Deoxy-2-Fluoro-Beta-D-Allopyranoside",,Beta-glucosidase A,bglA,,unknown
Cholic Acid,,"Ferrochelatase, mitochondrial",FECH,,unknown
Cholic Acid,,Alcohol dehydrogenase 1C,ADH1C,,unknown
Cholic Acid,,Estrogen-related receptor gamma,ESRRG,,unknown
Cholic Acid,,Gastrotropin,FABP6,,unknown
Cholic Acid,,"Cytochrome c oxidase subunit 4 isoform 1, mitochondrial",COX4I1,,unknown
Cholic Acid,,Cytochrome c oxidase subunit 1,MT-CO1,,unknown
Cholic Acid,,Cytochrome c oxidase subunit 2,MT-CO2,,unknown
Cholic Acid,,Cytochrome c oxidase subunit 3,MT-CO3,,unknown
Cholic Acid,,"Cytochrome c oxidase subunit 5A, mitochondrial",COX5A,,unknown
Cholic Acid,,"Cytochrome c oxidase subunit 5B, mitochondrial",COX5B,,unknown
Cholic Acid,,Cytochrome c oxidase subunit 6C,COX6C,,unknown
Cholic Acid,,"Cytochrome c oxidase subunit 7B, mitochondrial",COX7B,,unknown
Cholic Acid,,"Cytochrome c oxidase subunit 7C, mitochondrial",COX7C,,unknown
Cholic Acid,,"Cytochrome c oxidase subunit 8A, mitochondrial",COX8A,,unknown
Cholic Acid,,"Cytochrome c oxidase subunit 6A2, mitochondrial",COX6A2,,unknown
Cholic Acid,,Cytochrome c oxidase subunit 6B1,COX6B1,,unknown
Cholic Acid,,"Cytochrome c oxidase subunit 7A1, mitochondrial",COX7A1,,unknown
Cholic Acid,,Phospholipase A2,PLA2G1B,,unknown
Cholic Acid,,Liver carboxylesterase 1,CES1,,unknown
Cholic Acid,,Ferrochelatase,DKFZp686P18130,,unknown
Cholic Acid,,Choloylglycine hydrolase,cbh,,unknown
Cholic Acid,,Bile acid receptor,NR1H4,,unknown
Cholic Acid,,G-protein coupled bile acid receptor 1,GPBAR1,,unknown
Filaminast,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,,unknown
"Adenosine-5'-Diphosphate-2',3'-Vanadate",,Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1,PAPSS1,,unknown
Novo Nordisk a/S Compound,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
2-Amino-4-(Hydroxymethyl-Phosphinyl)Butanoic Acid,,Glutamine synthetase,glnA,,unknown
1-Butane Boronic Acid,,Bacterial leucyl aminopeptidase,,,unknown
"(1R,2S)-2-Phenylcyclopropanaminium",,Trypsin-1,PRSS1,,unknown
(C8-R)-Hydantocidin 5'-Phosphate,,Adenylosuccinate synthetase,purA,,unknown
Factor IIIm,,5-methyltetrahydrofolate--homocysteine S-methyltransferase,,,unknown
"Je-2147, Ag1776, Kni-764",,Gag-Pol polyprotein,gag-pol,,unknown
RB106,,Thermolysin,nprS,,unknown
RB106,,Thermolysin,npr,,unknown
4-Deoxy-Alpha-D-Glucose,,Cyclomaltodextrin glucanotransferase,,,unknown
4-Deoxy-Alpha-D-Glucose,,SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5,SMARCA5,,unknown
1-Methylimidazole,,Myoglobin,MB,,unknown
1-Methylimidazole,,Sensor protein FixL,fixL,,unknown
"(4ar,6s,8ar)-11-[8-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Octyl]-6-Hydroxy-3-Methoxy-5,6,9,10-Tetrahydro-4ah-[1]Benzofuro[3a,3,2-Ef][2]Benzazepin-11-Ium",,Acetylcholinesterase,ACHE,,unknown
"4-(2-Oxo-Hexahydro-Thieno[3,4-D]Imidazol-4-Yl)-Butyricacid",,Streptavidin,,,unknown
"2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol",,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,,unknown
D-naphthyl-1-acetamido boronic acid alanine,,Subtilisin Carlsberg,apr,,unknown
2-Deoxy-2-Aminogalactose,,Galectin-7,LGALS7,,unknown
Cyanamide,,Carbonic anhydrase 2,CA2,,unknown
Cyanamide,,Cathepsin K,CTSK,,unknown
Dinitrophenylene,,"Mannan endo-1,4-beta-mannosidase",manA,,unknown
Meta Vanadate,,Cyclin-dependent kinases regulatory subunit 1,CKS1B,,unknown
Meta Vanadate,,Uridine phosphorylase,udp,,unknown
Inhibitor Bea428,,Gag-Pol polyprotein,gag-pol,,unknown
5'-O-(N-(L-Cysteinyl)-Sulfamoyl)Adenosine,,Bifunctional glutamate/proline--tRNA ligase,EPRS,,unknown
3-Methylphenylalanine,,Cathepsin B,CTSB,,unknown
Undecyl-Beta-D-Maltopyranoside,,V-type sodium ATPase subunit K,ntpK,,unknown
"2,3-Didehydroalanine",,Lantibiotic mersacidin,mrsA,,unknown
S-{2-[Amino(Dihydroxy)-Lambda~4~-Sulfanyl]Ethyl}-D-Cysteine,,Arginase-1,ARG1,,unknown
NU1025,,Poly [ADP-ribose] polymerase 1,PARP1,,unknown
Glycocholic acid,,Gastrotropin,FABP6,,unknown
"(4S,5S)-1,2-dithiane-4,5-diol",,"6,7-dimethyl-8-ribityllumazine synthase",ribH,,unknown
Pantoyl Adenylate,,Pantothenate synthetase,panC,,unknown
O1-Pentyl-Mannose,,Cyanovirin-N,,,unknown
"6-Aminohexyl-Uridine-C1,5'-Diphosphate",,"Beta-1,4-galactosyltransferase 1",B4GALT1,,unknown
Hydroxyaminovaline,,Collagenase 3,MMP13,,unknown
Hydroxyaminovaline,,Stromelysin-1,MMP3,,unknown
3-Deoxy-D-Glucosamine,,Ferrichrome-iron receptor,fhuA,,unknown
Nicotinamide,,Exotoxin A,eta,,unknown
Nicotinamide,,L-lactate dehydrogenase A chain,LDHA,,unknown
Nicotinamide,,Poly [ADP-ribose] polymerase 1,PARP1,binder,unknown
Nicotinamide,,"NAD-dependent protein deacylase sirtuin-5, mitochondrial",SIRT5,,unknown
Nicotinamide,,ADP-ribosyl cyclase 2,BST1,,unknown
XV638,,Gag-Pol polyprotein,gag-pol,,unknown
Fusidic Acid,Approximately 5 to 6 hours in adults.,Elongation factor G,fusA,inhibitor,yes
Fusidic Acid,Approximately 5 to 6 hours in adults.,Chloramphenicol acetyltransferase,cat,inhibitor,unknown
Fusidic Acid,Approximately 5 to 6 hours in adults.,Chloramphenicol acetyltransferase 3,cat3,inhibitor,unknown
"(2r,3r,4r,5r)-3,4-Dihydroxy-N,N'-Bis[(1s,2r)-2-Hydroxy-2,3-Dihydro-1h-Inden-1-Yl]-2,5-Bis(2-Phenylethyl)Hexanediamide",,Gag-Pol polyprotein,gag-pol,,unknown
"6-[N-(1-Isopropyl-1,2,3,4-Tetrahydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine",,Urokinase-type plasminogen activator,PLAU,,unknown
Mercaptocarboxylate Inhibitor,,Beta-lactamase IMP-1,,,unknown
Resveratrol,,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,,unknown
Resveratrol,,Casein kinase II subunit alpha,CSNK2A1,,unknown
Resveratrol,,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Resveratrol,,Prostaglandin G/H synthase 2,PTGS2,inhibitor,unknown
Resveratrol,,Arachidonate 15-lipoxygenase,ALOX15,,unknown
Resveratrol,,Arachidonate 5-lipoxygenase,ALOX5,,unknown
Resveratrol,,Aryl hydrocarbon receptor,AHR,,unknown
Resveratrol,,Phosphatidylinositol 4-kinase type 2-beta,PI4K2B,,unknown
Resveratrol,,Integrin alpha-5,ITGA5,,unknown
Resveratrol,,Integrin beta-3,ITGB3,,unknown
Resveratrol,,Amyloid beta A4 protein,APP,,unknown
Resveratrol,,Alpha-synuclein,SNCA,,unknown
Resveratrol,,Estrogen receptor alpha,ESR1,,unknown
Resveratrol,,Melatonin receptor type 1A,MTNR1A,,unknown
Resveratrol,,Melatonin receptor type 1B,MTNR1B,,unknown
Resveratrol,,C-type lectin domain family 14 member A,CLEC14A,,unknown
Resveratrol,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Resveratrol,,Nuclear receptor subfamily 1 group I member 3,NR1I3,,unknown
Resveratrol,,"Solute carrier family 2, facilitated glucose transporter member 1",SLC2A1,,unknown
Resveratrol,,Carbonyl reductase [NADPH] 1,CBR1,inhibitor,unknown
Resveratrol,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Resveratrol,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Resveratrol,,RAC-alpha serine/threonine-protein kinase,AKT1,inhibitor,unknown
Resveratrol,,Far upstream element-binding protein 2,KHSRP,,unknown
Resveratrol,,"Tyrosine--tRNA ligase, cytoplasmic",YARS,inhibitor,unknown
"2,3,-Dihydroxybenzoylserine",,Neutrophil gelatinase-associated lipocalin,LCN2,,unknown
"4-{2,6,8-Trioxo-9-[(2S,3R,4R)-2,3,4,5-Tetrahydroxypentyl]-1,2,3,6,8,9-Hexahydro-7h-Purin-7-Yl}Butyl Dihydrogen Phosphate",,"6,7-dimethyl-8-ribityllumazine synthase",ribH,,unknown
Sorbinil,,Aldose reductase,AKR1B1,inhibitor,unknown
Acetylamino-Acetic Acid,,Glycine oxidase,thiO,,unknown
3'-Uridinemonophosphate,,Ribonuclease pancreatic,RNASE1,,unknown
Compound 18,,Estrogen receptor alpha,ESR1,,unknown
7-Methyl-Guanosine-5'-Triphosphate,,Eukaryotic translation initiation factor 4E,EIF4E,,unknown
Cellotetraose,,"Cellulose 1,4-beta-cellobiosidase",cbhA,,unknown
C-(1-Hydrogyl-Beta-D-Glucopyranosyl) Formamide,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
Alpha-D-Glucopyranosyl-2-Carboxylic Acid Amide,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
4-Iodopyrazole,,Mycocyclosin synthase,cyp121,,unknown
4-Iodopyrazole,,Alcohol dehydrogenase 1C,ADH1C,,unknown
4-Iodopyrazole,,Alcohol dehydrogenase 1B,ADH1B,,unknown
4-Iodopyrazole,,Alcohol dehydrogenase 1A,ADH1A,,unknown
4-O-methyl-beta-D-glucuronic acid,,Alpha-glucuronidase,aguA,,unknown
"4-Oxo-2-Phenylmethanesulfonyl-Octahydro-Pyrrolo[1,2-a]Pyrazine-6-Carboxylic Acid [1-(N-Hydroxycarbamimidoyl)-Piperidin-4-Ylmethyl]-Amide",,Prothrombin,F2,,unknown
Delta-2-Albomycin A1,,Iron(3+)-hydroxamate-binding protein FhuD,fhuD,,unknown
Delta-2-Albomycin A1,,Ferrichrome-iron receptor,fhuA,,unknown
"2-Amino-4-(4-Amino-Cyclohexa-2,5-Dienyl)-Butyric Acid",,Adenosylmethionine-8-amino-7-oxononanoate aminotransferase,bioA,,unknown
2-Phosphoglycolic Acid,,Glucosamine-6-phosphate deaminase 1,nagB,,unknown
2-Phosphoglycolic Acid,,6-phosphofructokinase,pfkA,,unknown
2-Phosphoglycolic Acid,,Triosephosphate isomerase,TPI1,,unknown
2-Phosphoglycolic Acid,,Pyruvate kinase PKM,PKM,,unknown
2-Phosphoglycolic Acid,,Triosephosphate isomerase,tpiA,,unknown
2-Phosphoglycolic Acid,,Methylglyoxal synthase,mgsA,,unknown
2-Phosphoglycolic Acid,,Gamma-enolase,ENO2,,unknown
2-Phosphoglycolic Acid,,Triosephosphate isomerase,tpiA,,unknown
2-Phosphoglycolic Acid,,"Phospho-2-dehydro-3-deoxyheptonate aldolase, Phe-sensitive",aroG,,unknown
2-Phosphoglycolic Acid,,Pyruvate kinase PKLR,PKLR,,unknown
2-Phosphoglycolic Acid,,Triosephosphate isomerase,TPI,,unknown
2-Phosphoglycolic Acid,,2-deoxyglucose-6-phosphate phosphatase,yniC,,unknown
2-Phosphoglycolic Acid,,Beta-enolase,ENO3,,unknown
N-Butyl-N'-Hydroxyguanidine,,"Nitric oxide synthase, brain",NOS1,,unknown
7-Hydroxy-2-Oxo-Chromene-3-Carboxylic Acid Ethyl Ester,,Macrophage migration inhibitory factor,MIF,,unknown
SD146,,Gag-Pol polyprotein,gag-pol,,unknown
4-Methylthio-Alpha-D-Mannose,,Alpha-amylase 2B,AMY2B,,unknown
Ethylmercurithiosalicylic acid,,"Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial",OXCT1,,unknown
Ethylmercurithiosalicylic acid,,Multi-sensor signal transduction histidine kinase,,,unknown
Purvalanol,,Cell division control protein 2 homolog,CRK2,,unknown
Purvalanol,,Cyclin-dependent kinase 4,CDK4,,unknown
Purvalanol,,Mitogen-activated protein kinase 1,MAPK1,inhibitor,unknown
Purvalanol,,Mitogen-activated protein kinase 3,MAPK3,inhibitor,unknown
Purvalanol,,Cyclin-dependent kinase 2,CDK2,,unknown
Purvalanol,,SRSF protein kinase 2,SRPK2,,unknown
4-Deoxy-D-Mannuronic Acid,,AlgQ1,algQ1,,unknown
4-Deoxy-D-Mannuronic Acid,,AlgQ2,algQ2,,unknown
2-Amino-3-Oxo-4-Sulfo-Butyric Acid,,Steryl-sulfatase,STS,,unknown
Acetamide,,Aliphatic amidase expression-regulating protein,amiC,,unknown
Adenosine-5'-Pentaphosphate,,Diadenosine hexaphosphate hydrolase,ndx1,,unknown
3-Indolebutyric Acid,,Aromatic-amino-acid aminotransferase,tyrB,,unknown
3-Indolebutyric Acid,,Beta-2-microglobulin,B2M,,unknown
3-Indolebutyric Acid,,T-cell receptor alpha chain C region,TRAC,,unknown
3-Indolebutyric Acid,,T-cell receptor beta-1 chain C region,TRBC1,,unknown
3-Indolebutyric Acid,,"HLA class I histocompatibility antigen, A-2 alpha chain",HLA-A,,unknown
CD564,,Retinoic acid receptor gamma,RARG,,unknown
Kifunensine,,"Mannosyl-oligosaccharide alpha-1,2-mannosidase",MSDC,,unknown
Kifunensine,,Alpha-mannosidase 2,MAN2A1,,unknown
Kifunensine,,"Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase",MAN1B1,,unknown
beta-D-galactopyranosyl-(1->4)-beta-D-galactopyranose,,"Arabinogalactan endo-1,4-beta-galactosidase",ganB,,unknown
RPR131247,,Trypsin-1,PRSS1,,unknown
Uridine,,U6 snRNA-associated Sm-like protein LSm6,LSM6,,unknown
Uridine,,Nucleoside-specific channel-forming protein tsx,tsx,,unknown
Phthalic Acid,,Nicotinate-nucleotide pyrophosphorylase [carboxylating],nadC,,unknown
Phthalic Acid,,Estrogen receptor alpha,ESR1,,unknown
Phthalic Acid,,Progesterone receptor,PGR,,unknown
Phthalic Acid,,Estrogen receptor beta,ESR2,,unknown
Phthalic Acid,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Phthalic Acid,,Peroxisome proliferator-activated receptor delta,PPARD,,unknown
Phthalic Acid,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Phthalic Acid,,Retinoic acid receptor RXR-alpha,RXRA,,unknown
Phthalic Acid,,Retinoic acid receptor RXR-beta,RXRB,,unknown
Phthalic Acid,,Retinoic acid receptor RXR-gamma,RXRG,,unknown
Pyromellitic Acid,,Fumarate hydratase class II,fumC,,unknown
S-(Methylmercury)-L-Cysteine,,Elongation factor Tu GTP-binding domain-containing protein 1,EFTUD1,,unknown
Glycocyamine,,Guanidinoacetate N-methyltransferase,GAMT,,unknown
Tosyl-D-Proline,,Thymidylate synthase,thyA,,unknown
Selenoinosine,,Nucleoside deoxyribosyltransferase-I,ptd,,unknown
"9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine",,Heat shock protein HSP 90-beta,HSP90AB1,,unknown
"9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
1-3 Sugar Ring of Pentamannosyl 6-Phosphate,,Cation-dependent mannose-6-phosphate receptor,M6PR,,unknown
Pyrazole,,Alcohol dehydrogenase 1C,ADH1C,,unknown
Pyrazole,,Estrogen receptor alpha,ESR1,,unknown
Pyrazole,,Estrogen receptor beta,ESR2,,unknown
Indolylpropionic Acid,,Aspartate aminotransferase,aspC,,unknown
Indolylpropionic Acid,,Aromatic-amino-acid aminotransferase,tyrB,,unknown
Indolylpropionic Acid,,Group IIE secretory phospholipase A2,PLA2G2E,,unknown
4-Methylumbelliferyl Chitobiose,,Lysozyme C,LYZ,,unknown
S-Mercaptocysteine,,3-mercaptopyruvate sulfurtransferase,MST,,unknown
S-Mercaptocysteine,,L-cysteine/cystine lyase C-DES,c-des,,unknown
S-Mercaptocysteine,,3-mercaptopyruvate sulfurtransferase,sseA,,unknown
S-Mercaptocysteine,,Hydroxylamine reductase,hcp,,unknown
S-Mercaptocysteine,,Thiosulfate sulfurtransferase,TST,,unknown
S-Mercaptocysteine,,Sulfurtransferase,,,unknown
S-Mercaptocysteine,,Thiosulfate sulfurtransferase GlpE,glpE,,unknown
S-Mercaptocysteine,,Hydroxylamine reductase,hcp,,unknown
S-Mercaptocysteine,,Cysteine desulfurase,sufS,,unknown
RU79072,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
5-Mercapto-2-Nitro-Benzoic Acid,,Protein ArsC,arsC,,unknown
5-Mercapto-2-Nitro-Benzoic Acid,,Interleukin-12 subunit beta,IL12B,,unknown
R-9-(2-hydroxypropyl)adenine,,Thymidine kinase,TK,,unknown
(3r)-3-{[(Benzyloxy)Carbonyl]Amino}-2-Oxo-4-Phenylbutane-1-Diazonium,,Streptopain,speB,,unknown
3-Hydroxy-Myristic Acid,,Ferrichrome-iron receptor,fhuA,,unknown
3-Hydroxy-Myristic Acid,,Protein TonB,tonB,,unknown
3-Hydroxy-Myristic Acid,,Lymphocyte antigen 96,LY96,,unknown
3-Hydroxy-Myristic Acid,,Toll-like receptor 4,TLR4,,unknown
Tert-Butyloxycarbonyl Group,,Gag-Pol polyprotein,gag-pol,,unknown
7-Alpha-D-Ribofuranosyl-2-Aminopurine-5'-Phosphate,,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
Sucrose,,Beta-glucosidase,bgl3,,unknown
Sucrose,,Amylosucrase,ams,,unknown
Sucrose,,Beta-lactamase,blaCTX-M-9a,,unknown
Sucrose,,Beta-lactamase CTX-M,blaCTX-M-14,,unknown
Sucrose,,Heme oxygenase,hmuO,,unknown
Sucrose,,Copper transport protein ATOX1,ATOX1,,unknown
Sucrose,,tRNA-splicing ligase RtcB homolog,RTCB,,unknown
Sucrose,,Orange carotenoid-binding protein,,,unknown
Sucrose,,Sucrose porin,scrY,,unknown
Sucrose,,Levansucrase,sacB,,unknown
Sucrose,,Beta-lactamase CTX-M-27,blaCTX-M-27,,unknown
Sucrose,,GDP-mannose 6-dehydrogenase,algD,,unknown
Sucrose,,"Actin, alpha skeletal muscle",ACTA1,,unknown
Sucrose,,Beta-lactamase,ampC,,unknown
Sucrose,,Nitric oxide synthase oxygenase,nos,,unknown
Sucrose,,Lysozyme C,LYZ,,unknown
Sucrose,,Septum formation protein Maf,maf,,unknown
Sucrose,,Taste receptor type 1 member 2,TAS1R2,,unknown
(3-Chloro-4-Propoxy-Phenyl)-Acetic Acid,,Prostaglandin G/H synthase 1,PTGS1,,unknown
"1,3-Propandiol",,ADP-ribosylation factor 1,ARF1,,unknown
"1,3-Propandiol",,Haloalkane dehalogenase,linB,,unknown
1-Hexadecanosulfonic Acid,,Hydrolase,,,unknown
1-Hexadecanosulfonic Acid,,Lipase 1,LIP1,,unknown
"2,5-Anhydroglucitol-1,6-Biphosphate",,"Fructose-1,6-bisphosphatase 1",FBP1,,unknown
Dodecane-Trimethylamine,,Tyrosine-protein phosphatase non-receptor type 11,PTPN11,,unknown
Beta-3-Cysteine,,Envelope glycoprotein gp160,env,,unknown
4'-Deoxy-4'-Acetylyamino-Pyridoxal-5'-Phosphate,,"Aspartate aminotransferase, mitochondrial",GOT2,,unknown
4'-Deoxy-4'-Acetylyamino-Pyridoxal-5'-Phosphate,,4-aminobutyrate aminotransferase GabT,gabT,,unknown
N-[4-(2-{2-[3-(2-Bromo-Acetylamino)-Propionylamino]-3-Hydroxy-Propionylamino}-Ethyl)-Phenyl]-Oxalamic Acid,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
N-[2(S)-Cyclopentyl-1(R)-Hydroxy-3(R)Methyl]-5-[(2(S)-Tertiary-Butylamino-Carbonyl)-4-(N1-(2)-(N-Methylpiperazinyl)-3-Chloro-Pyrazinyl-5-Carbonyl)-Piperazino]-4(S)-Hydroxy-2(R)-Phenylmethyl-Pentanamide,,Gag-Pol polyprotein,gag-pol,,unknown
2-Anhydro-3-Fluoro-Quinic Acid,,3-dehydroquinate dehydratase,aroQ,,unknown
N-Acetylmannosaminitol,,Capsule biosynthesis protein,synC,,unknown
Pregnenolone,,Sulfotransferase family cytosolic 2B member 1,SULT2B1,,unknown
Pregnenolone,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Phenyl-Uridine-5'-Diphosphate,,UDP-glucose 4-epimerase,galE,,unknown
Isochorismic Acid,,Phenazine biosynthesis protein PhzD,phzD1,,unknown
N-[5'-O-Phosphono-Ribofuranosyl]-2-[2-Hydroxy-2-[4-[Glutamic Acid]-N-Carbonylphenyl]-3-[2-Amino-4-Hydroxy-Quinazolin-6-Yl]-Propanylamino]-Acetamide,,Phosphoribosylglycinamide formyltransferase,purN,,unknown
P-Anisic Acid,,Phospholipase A2,PLA2G1B,,unknown
P-Anisic Acid,,Group IIE secretory phospholipase A2,PLA2G2E,,unknown
9-Deazainosine,,Purine nucleoside phosphorylase,PNP,,unknown
3-Nitrophenylboronic Acid,,Beta-lactamase,ampC,,unknown
Alpha-Methylene Adenosine Monophosphate,,Ribose-phosphate pyrophosphokinase,prs,,unknown
N-[2-(1-Maleimidyl)Ethyl]-7-Diethylaminocoumarin-3-Carboxamide,,Phosphate-binding protein PstS,pstS,,unknown
5-Hydroxymethylene-6-Hydrofolic Acid,,"Serine hydroxymethyltransferase, cytosolic",SHMT1,,unknown
5-Hydroxymethylene-6-Hydrofolic Acid,,Probable 5-formyltetrahydrofolate cyclo-ligase,,,unknown
"2,3 -Anhydro-Quinic Acid",,3-dehydroquinate dehydratase,aroQ,,unknown
"2,3 -Anhydro-Quinic Acid",,3-dehydroquinate dehydratase,aroQ,,unknown
5-Aminocarbonyl-3-Nitrophenyl-Alpha-D-Galactopyranose,,Cholera enterotoxin subunit B,ctxB,,unknown
"3-Phenyl-1,2-Propandiol",,Renin,REN,,unknown
A-98881,,Gag-Pol polyprotein,gag-pol,,unknown
Uracil arabinose-3'-phosphate,,Ribonuclease pancreatic,RNASE1,,unknown
"Brodimoprim-4,6-Dicarboxylate",,Dihydrofolate reductase,folA,,unknown
N-(2-Acetamido)Iminodiacetic Acid,,Peptide deformylase,def,,unknown
Diethylphosphono Group,,Cholinesterase,BCHE,,unknown
Diethylphosphono Group,,Diacylglycerol acyltransferase/mycolyltransferase Ag85C,fbpC,,unknown
"(2s,4r)-1-Acetyl-N-[(1s)-4-[(Aminoiminomethyl)Amino]-1-(2-Benzothiazolylcarbonyl)Butyl]-4-Hydroxy-2-Pyrrolidinecarboxamide",,Trypsin-1,PRSS1,,unknown
"2-Acetamido-2-Deoxy-D-Glucono-1,5-Lactone",,Chitinase B,chiB,,unknown
"2-Acetamido-2-Deoxy-D-Glucono-1,5-Lactone",,Beta-hexosaminidase subunit beta,HEXB,,unknown
"7-(1-Methyl-1,2,3-Triazol-4-Yl)-6-Formyl-2,7-Dihydro-[1,4]Thiazepine-3-Carboxylic Acid, Brl42715, C6-(N1-Methyl-1,2,3-Triazolylmethylene)Penem",,Beta-lactamase,ampC,,unknown
5-Exo-Hydroxycamphor,,Camphor 5-monooxygenase,camC,,unknown
Iodo-Willardiine,,Glutamate receptor 2,GRIA2,,unknown
"Mono-[3,4-Dihydroxy-5-(5-Methyl-Benzoimidazol-1-Yl)-Tetrahydor-Furan-2-Ylmethyl] Ester",,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
"1-Azepan-1-Yl-2-Phenyl-2-(4-Thioxo-1,4-Dihydro-Pyrazolo[3,4-D]Pyrimidin-5-Yl)Ethanone Adduct",,3-hydroxyacyl-CoA dehydrogenase type-2,HSD17B10,,unknown
Canaline,,"Ornithine aminotransferase, mitochondrial",OAT,inhibitor,unknown
Para-Bromobenzyl Alcohol,,Alcohol dehydrogenase 1C,ADH1C,,unknown
Phosphonoacetic Acid,,Alkaline phosphatase,phoA,,unknown
N-Pyridoxyl-Glycine-5-Monophosphate,,L-allo-threonine aldolase,,,unknown
N-Pyridoxyl-Glycine-5-Monophosphate,,Serine hydroxymethyltransferase,glyA,,unknown
N-Pyridoxyl-Glycine-5-Monophosphate,,"Serine hydroxymethyltransferase, cytosolic",SHMT1,,unknown
N-Pyridoxyl-Glycine-5-Monophosphate,,Ornithine decarboxylase,ODC1,,unknown
Methylphosphonic Acid Ester Group,,Acetylcholinesterase,ACHE,,unknown
"7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
5-Fluorolevulinic Acid,,Delta-aminolevulinic acid dehydratase,hemB,,unknown
4-(Acetylamino)-3-[(Aminoacetyl)Amino]Benzoic Acid,,Neuraminidase,NA,,unknown
FR236913,,Adenosine deaminase,ADA,,unknown
Dihydrogenphosphate Ion,,Phosphate-binding protein PstS,pstS,,unknown
Dihydrogenphosphate Ion,,L-xylulose reductase,DCXR,,unknown
Siroheme,,Sulfite reductase [NADPH] hemoprotein beta-component,cysI,,unknown
[4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine,,Cyclin-dependent kinase 2,CDK2,,unknown
[4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine,,Cyclin-A2,CCNA2,,unknown
IDD552,,Aldose reductase,AKR1B1,,unknown
"Alpha-D-Glucose 1,6-Bisphosphate",,Beta-phosphoglucomutase,pgmB,,unknown
"Alpha-D-Glucose 1,6-Bisphosphate",,Phosphoglucomutase-1,PGM1,,unknown
Guanosine 5'-Diphosphate 2':3'-Cyclic Monophosphate,,Adenylosuccinate synthetase,purA,,unknown
Guanosine 5'-Diphosphate 2':3'-Cyclic Monophosphate,,Bifunctional (p)ppGpp synthase/hydrolase RelA,relA,,unknown
O4-Sulfonylgalactose,,Mannose-binding protein C,MBL2,,unknown
"3,4-Dihydro-2h-Pyrrolium-5-Carboxylate",,D-amino-acid oxidase,DAO,,unknown
"2,4-Dihydroxybenzoic Acid",,p-hydroxybenzoate hydroxylase,pobA,,unknown
"2,4-Dihydroxybenzoic Acid",,p-hydroxybenzoate hydroxylase,pobA,,unknown
"4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
[(2-Ethoxy-1-Naphthoyl)Amino]Methylboronic Acid,,Beta-lactamase,blaCTX-M-9a,,unknown
[(2-Ethoxy-1-Naphthoyl)Amino]Methylboronic Acid,,Beta-lactamase TEM,bla,,unknown
[(2-Ethoxy-1-Naphthoyl)Amino]Methylboronic Acid,,Beta-lactamase TEM,bla,,unknown
9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide,,DNA,,intercalation,unknown
alpha-D-glucose-1-phosphate,,Phosphomannomutase/phosphoglucomutase,algC,,unknown
alpha-D-glucose-1-phosphate,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
alpha-D-glucose-1-phosphate,,Glucose-1-phosphate thymidylyltransferase,rmlA,,unknown
alpha-D-glucose-1-phosphate,,Maltodextrin phosphorylase,malP,,unknown
alpha-D-glucose-1-phosphate,,Glucose-1-phosphatase,agp,,unknown
"S-Adenosyl-1,8-Diamino-3-Thiooctane",,Spermidine synthase,speE,,unknown
Methylphosphinic Acid,,Esterase,estA,,unknown
Methylphosphinic Acid,,Cholinesterase,BCHE,,unknown
Methylphosphinic Acid,,Acetylcholinesterase,ACHE,,unknown
L-thioproline,,Annexin A5,ANXA5,,unknown
"{4-[3-(6,7-Diethoxy-Quinazolin-4-Ylamino)-Phenyl]-Thiazol-2-Yl}-Methanol",,"Fructose-1,6-bisphosphatase 1",FBP1,,unknown
N-Pyridoxyl-1-Amino-Cyclopropanecarboxylic Acid-5-Monophosphate,,"2,2-dialkylglycine decarboxylase",dgdA,,unknown
(1-Tert-Butyl-5-Hydroxy-1h-Pyrazol-4-Yl)-(6-Methanesulfonyl-4'-Methoxy-2-Methyl-Biphenyl-3-Yl)-Methanone,,4-hydroxyphenylpyruvate dioxygenase,HPD,,unknown
Thiocamphor,,Camphor 5-monooxygenase,camC,,unknown
Domoic Acid,,"Glutamate receptor ionotropic, kainate 2",GRIK2,,unknown
Aetiocholanolone,,Bile salt sulfotransferase,SULT2A1,,unknown
Aetiocholanolone,,Estradiol 17-beta-dehydrogenase 11,HSD17B11,,unknown
Aetiocholanolone,,3-alpha-(or 20-beta)-hydroxysteroid dehydrogenase,fabG3,,unknown
Aetiocholanolone,,Ig gamma-2 chain C region,IGHG2,,unknown
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline,,Cathepsin B,CTSB,,unknown
Methyl-Carbamic Acid Ethyl Ester,,Shiga-like toxin 1 subunit B,stxB,,unknown
Guanosine,,DNA polymerase,43,,unknown
Guanosine,,Purine nucleoside phosphorylase,PNP,,unknown
Guanosine,,Purine nucleoside phosphorylase,,,unknown
3-(4-Benzenesulfonyl-Thiophene-2-Sulfonylamino)-Phenylboronic Acid,,Beta-lactamase,ampC,,unknown
Soraphen A,,Acetyl-CoA carboxylase 2,ACACB,,unknown
Calyculin A,,Serine/threonine-protein phosphatase PP1-gamma catalytic subunit,PPP1CC,,unknown
"4-(Aminosulfonyl)-N-[(3,4,5-Trifluorophenyl)Methyl]-Benzamide",,Carbonic anhydrase 2,CA2,,unknown
Glucosamine 4-Phosphate,,Ferrichrome-iron receptor,fhuA,,unknown
Dansylamide,,Carbonic anhydrase 2,CA2,,unknown
D-Mannose 1-Phosphate,,Phosphomannomutase/phosphoglucomutase,algC,,unknown
"3''-(Beta-Chloroethyl)-2'',4''-Dioxo-3, 5''-Spiro-Oxazolidino-4-Deacetoxy-Vinblastine",,Calmodulin,CALM1,,unknown
3-amino-5-phenylpentane,,Cathepsin L2,CTSV,,unknown
3-amino-5-phenylpentane,,Cathepsin K,CTSK,,unknown
N-Allyl-Aniline,,Lysozyme,E,,unknown
3-Butylthiolane 1-Oxide,,Alcohol dehydrogenase 1C,ADH1C,,unknown
"Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone",,E3 ubiquitin-protein ligase Mdm2,MDM2,,unknown
"1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One",,Mitogen-activated protein kinase 14,MAPK14,,unknown
CRA_1802,,Trypsin-1,PRSS1,,unknown
"3-(4-Carbamoyl-1-Carboxy-2-Methylsulfonyl-Buta-1,3-Dienylamino)-Indolizine-2-Carboxylic Acid",,Beta-lactamase,ampC,,unknown
Arotinoid acid,,Retinoic acid receptor beta,RARB,,unknown
3-(2-Aminoethyl)-4-(Aminomethyl)Heptanedioic Acid,,Delta-aminolevulinic acid dehydratase,ALAD,,unknown
"2,3-Di-O-Sulfo-Alpha-D-Glucopyranose",,47 kDa membrane antigen,,,unknown
"2',3'-Dideoxycytidine-5'-Monophosphate",,Cytidylate kinase,cmk,,unknown
Beta-Cyclohexyl-Alanine,,Zinc finger Y-chromosomal protein,ZFY,,unknown
4-Imino-5-Methidyl-2-Trifluoromethylpyrimidine,,Thiamine-phosphate synthase,thiE,,unknown
"2',3'-Dehydro-2',3'-Deoxy-Thymidine 5'-Triphosphate",,Nucleoside diphosphate kinase A,NME1,,unknown
FKB-001,,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,,unknown
"4-O-(4,6-Dideoxy-4-{[4,5,6-Trihydroxy-3-(Hydroxymethyl)Cyclohex-2-En-1-Yl]Amino}-Beta-D-Lyxo-Hexopyranosyl)-Alpha-D-Erythro-Hexopyranose",,Pancreatic alpha-amylase,AMY2A,,unknown
6-Hydroxyuridine-5'-Phosphate,,Uridine 5'-monophosphate synthase,UMPS,,unknown
6-Hydroxyuridine-5'-Phosphate,,Orotidine 5'-phosphate decarboxylase,pyrF,,unknown
L-2-Amino-6-Methylene-Pimelic Acid,,Meso-diaminopimelate D-dehydrogenase,ddh,,unknown
D-Methionine,,Methionine aminopeptidase 2,METAP2,,unknown
D-Methionine,,"Transcriptional regulator, HTH_3 family",,,unknown
"Sulfamic Acid 2,3-O-(1-Methylethylidene)-4,5-O-Sulfonyl-Beta-Fructopyranose Ester",,Carbonic anhydrase 2,CA2,,unknown
3-(Prop-2-Ene-1-Sulfinyl)-Propene-1-Thiol,,"Glutathione reductase, mitochondrial",GSR,,unknown
Methylthioinosine,,Purine nucleoside phosphorylase DeoD-type,deoD,,unknown
Acetylphosphate,,GDP-L-fucose synthase,fcl,,unknown
Acetylphosphate,,Phosphate acetyltransferase,pta,,unknown
5-{[(2-Amino-9h-Purin-6-Yl)Oxy]Methyl}-2-Pyrrolidinone,,Cyclin-dependent kinase 2,CDK2,,unknown
N-Carboxymethionine,,Thymidylate synthase,thyA,,unknown
N-Carboxymethionine,,Urease subunit alpha,ureC,,unknown
N-Carboxymethionine,,Urease subunit beta,ureB,,unknown
N-Carboxymethionine,,Urease subunit gamma,ureA,,unknown
N-Carboxymethionine,,Light-harvesting protein B-800/850 alpha chain,,,unknown
N-Carboxymethionine,,Light-harvesting protein B-800/850 beta chain,,,unknown
N-Carboxymethionine,,Probable rRNA methylase,rsmF,,unknown
alpha-D-mannose 6-phosphate,,Phosphomannomutase/phosphoglucomutase,algC,,unknown
alpha-D-mannose 6-phosphate,,Cation-independent mannose-6-phosphate receptor,IGF2R,,unknown
alpha-D-mannose 6-phosphate,,Cation-dependent mannose-6-phosphate receptor,M6PR,,unknown
Stanolone,,Estradiol 17-beta-dehydrogenase 1,HSD17B1,,unknown
Stanolone,,Androgen receptor,AR,,unknown
Stanolone,,Estrogen receptor alpha,ESR1,,unknown
Stanolone,,Mineralocorticoid receptor,NR3C2,,unknown
3'-Phosphate-Adenosine-5'-Phosphate Sulfate,,Estrogen sulfotransferase,SULT1E1,,unknown
BV3,,Cholera enterotoxin subunit B,ctxB,,unknown
Beta-3-Serine,,Envelope glycoprotein gp160,env,,unknown
"Phosphoric Acid Mono-[3,4-Dihydroxy-5-(5-Hydroxy-Benzoimidazol-1-Yl)Tetrahydro-Furan-2-Ylmethyl] Ester",,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
"(2s,4s)-Alpha-Campholinic Acid",,6-oxocamphor hydrolase,camK,,unknown
2-Amino-Vinyl-Phosphate,,Ferrichrome-iron receptor,fhuA,,unknown
RU78783,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
5-(2-Chlorophenyl)Furan-2-Carboxylic Acid,,Methionine aminopeptidase,map,,unknown
5-(2-Chlorophenyl)Furan-2-Carboxylic Acid,,Methionine aminopeptidase 2,map,,unknown
Octanoyl-Coenzyme A,,"Enoyl-CoA hydratase, mitochondrial",ECHS1,,unknown
Octanoyl-Coenzyme A,,"Enoyl-CoA delta isomerase 1, mitochondrial",ECI1,,unknown
Octanoyl-Coenzyme A,,"Medium-chain specific acyl-CoA dehydrogenase, mitochondrial",ACADM,,unknown
"2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine",,"Nitric oxide synthase, endothelial",NOS3,,unknown
Propanoyl-CoA,,Propionyl-CoA carboxylase complex B subunit,pccB,,unknown
"4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine",,Cyclin-A2,CCNA2,,unknown
N-Hydroxy-4-(Methyl{[5-(2-Pyridinyl)-2-Thienyl]Sulfonyl}Amino)Benzamide,,Histone deacetylase 8,HDAC8,,unknown
6-(4-Difluoromethoxy-3-Methoxy-Phenyl)-2h-Pyridazin-3-One,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,,unknown
"2,4-Diamino-6-[N-(3',4',5'-Trimethoxybenzyl)-N-Methylamino]Pyrido[2,3-D]Pyrimidine",,Dihydrofolate reductase,DHFR,,unknown
(South)-Methanocarba-Thymidine,,Thymidine kinase,TK,,unknown
"Biphenyl-2,3-Diol",,"Biphenyl-2,3-diol 1,2-dioxygenase",bphC,,unknown
"Biphenyl-2,3-Diol",,"Biphenyl-2,3-diol 1,2-dioxygenase",bphC,,unknown
"Biphenyl-2,3-Diol",,"1,2-dihydroxynaphthalene dioxygenase",doxG,,unknown
"(4R)-limonene 1α,2α-epoxide",,Epididymal-specific lipocalin-9,LCN9,,unknown
Piretanide,,Solute carrier family 12 member 1,SLC12A1,inhibitor,unknown
"Mixed Carbamic Phosphoric Acid Anhydride of 7,8-Diaminononanic Acid",,ATP-dependent dethiobiotin synthetase BioD 1,bioD1,,unknown
3-Amino-6-Hydroxy-Tyrosine,,Primary amine oxidase,tynA,,unknown
K201,,Annexin A5,ANXA5,,unknown
Adenosine 5'-[γ-thio]triphosphate,,ADP-ribosyl cyclase 2,BST1,,unknown
Adenosine 5'-[γ-thio]triphosphate,,Synapsin-1,SYN1,,unknown
Adenosine 5'-[γ-thio]triphosphate,,"[3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial",BCKDK,,unknown
Adenosine 5'-[γ-thio]triphosphate,,"6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1",PFKFB1,,unknown
Adenosine 5'-[γ-thio]triphosphate,,Mismatch repair endonuclease PMS2,PMS2,,unknown
Adenosine 5'-[γ-thio]triphosphate,,Protein RecA,recA,,unknown
Adenosine 5'-[γ-thio]triphosphate,,Protein RecA,recA,,unknown
Adenosine 5'-[γ-thio]triphosphate,,Protein RecA,recA,,unknown
Adenosine 5'-[γ-thio]triphosphate,,Chloramphenicol 3-O phosphotransferase,,,unknown
Adenosine 5'-[γ-thio]triphosphate,,Phosphoribosylglycinamide formyltransferase 2,purT,,unknown
Adenosine 5'-[γ-thio]triphosphate,,ATP-dependent DNA helicase RecQ,recQ,,unknown
Adenosine 5'-[γ-thio]triphosphate,,DNA polymerase III subunit tau,dnaX,,unknown
Adenosine 5'-[γ-thio]triphosphate,,Serine/threonine-protein kinase PknB,pknB,,unknown
Adenosine 5'-[γ-thio]triphosphate,,Cag alpha,cag-alfa,,unknown
Coa-S-Acetyl Tryptamine,,Serotonin N-acetyltransferase,AANAT,,unknown
(R)-Bicalutamide,,Androgen receptor,AR,,unknown
5'-Deoxy-5'-(Methylthio)-Tubercidin,,S-methyl-5'-thioadenosine phosphorylase,MTAP,,unknown
5'-Deoxy-5'-(Methylthio)-Tubercidin,,5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase,mtnN,,unknown
9-(6-deoxy-alpha-L-talofuranosyl)-6-methylpurine,,Purine nucleoside phosphorylase DeoD-type,deoD,,unknown
Diglyme,,Endoplasmin,HSP90B1,,unknown
4-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Butyric Acid,,"Phospholipase A2, membrane associated",PLA2G2A,,unknown
"Gamma-Arsono-Beta, Gamma-Methyleneadenosine-5'-Diphosphate",,NH(3)-dependent NAD(+) synthetase,nadE,,unknown
"Gamma-Arsono-Beta, Gamma-Methyleneadenosine-5'-Diphosphate",,Glycerol kinase,glpK,,unknown
Heptanoic Acid,,Phospholipase A2,PLA2G1B,,unknown
"(4s)-2-[(1e)-1-Aminoprop-1-Enyl]-4,5-Dihydro-1,3-Thiazole-4-Carboxylic Acid",,Thiostrepton,tpdA,,unknown
"(4s)-2-[(1e)-1-Aminoprop-1-Enyl]-4,5-Dihydro-1,3-Thiazole-4-Carboxylic Acid",,50S ribosomal protein L11,rplK,,unknown
3-(1-Aminoethyl)Nonanedioic Acid,,ATP-dependent dethiobiotin synthetase BioD 1,bioD1,,unknown
"Inositol 1,3-Bisphosphate",,Early endosome antigen 1,EEA1,,unknown
N-(4-Aminobutanoyl)-S-(4-Methoxybenzyl)-L-Cysteinylglycine,,Glutathione S-transferase A1,GSTA1,,unknown
alpha-L-iduronic acid,,Chondroitinase-AC,cslA,,unknown
2-Fluoro-2'-Deoxyadenosine,,Purine nucleoside phosphorylase DeoD-type,deoD,,unknown
Fosmidomycin,,1-deoxy-D-xylulose 5-phosphate reductoisomerase,dxr,,unknown
2-Acetyl-Protoporphyrin Ix,,Cytochrome c-552,cycA,,unknown
Hymenialdisine,,Cyclin-dependent kinase 5,CDK5,inhibitor,unknown
Hymenialdisine,,Cyclin-dependent kinase 1,CDK1,,unknown
Hymenialdisine,,Cyclin-dependent kinase 2,CDK2,inhibitor,unknown
3-Hydroxypyruvic Acid,,Triosephosphate isomerase,TPI,,unknown
3-Hydroxypyruvic Acid,,N-acetylneuraminate lyase,nanA,,unknown
Alpha-Aminoisobutyric Acid,,Corticoliberin,CRH,,unknown
Alpha-Aminoisobutyric Acid,,Pro-neuropeptide Y,NPY,,unknown
2-Thiomethyl-3-Phenylpropanoic Acid,,Neutrophil collagenase,MMP8,,unknown
(Carboxyhydroxyamino)Ethanoic Acid,,Adenylosuccinate synthetase,purA,,unknown
(Carboxyhydroxyamino)Ethanoic Acid,,Adenylosuccinate synthetase,purA,,unknown
Ricinoleic Acid,,Cannabinoid receptor 1,CNR1,,unknown
Ricinoleic Acid,,Cannabinoid receptor 2,CNR2,,unknown
Ricinoleic Acid,,Transient receptor potential cation channel subfamily V member 1,TRPV1,,unknown
Pentasulfide-Sulfur,,Sulfide dehydrogenase,sud,,unknown
Oxitriptan,,Tryptophan--tRNA ligase 2,trpS2,,unknown
Rhamnose,,L-rhamnose isomerase,rhaA,,unknown
Benzimidazole,,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
"(5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine",,Cyclin-dependent kinase 2,CDK2,,unknown
"8,9,10-Trihydroxy-7-Hydroxymethyl-2-Thioxo-6-Oxa-1,3-Diaza-Spiro[4.5]Decan-4-One",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
Ndelta-(N'-Sulphodiaminophosphinyl)-L-Ornithine,,Ornithine carbamoyltransferase chain I,argI,,unknown
Fluoro-Willardiine,,Glutamate receptor 2,GRIA2,,unknown
N-Ethylmaleimide,,Galectin-10,CLC,,unknown
Penicillin G Acyl-Serine,,Regulatory protein BlaR1,blaR1,,unknown
Penicillin G Acyl-Serine,,Beta-lactam-inducible penicillin-binding protein,pbp,,unknown
4-Methyl-5-Hydroxyethylthiazole,,Hydroxyethylthiazole kinase,thiM,,unknown
2-Propyl-Aniline,,Lysozyme,E,,unknown
1-Benzyl-(R)-Propylamine,,Gag-Pol polyprotein,gag-pol,,unknown
4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide,,Cyclin-dependent kinase 2,CDK2,,unknown
4-(4-Chlorophenyl)Imidazole,,Cytochrome P450 2B6,CYP2B6,,unknown
GE-2270A,,Elongation factor Tu,tufA,,unknown
Uridine-5'-monophosphate 2-deoxy-2-fluoro-galactopyranosyl-monophosphate ester,,Glycosyl transferase,lgtC,,unknown
Uridine-5'-monophosphate 2-deoxy-2-fluoro-galactopyranosyl-monophosphate ester,,LgtC,lgtC,,unknown
PNU177836,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
"N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane",,"Nitric oxide synthase, endothelial",NOS3,,unknown
Thymidine-5'-(Dithio)Phosphate,,Nuclease P1,,,unknown
Vitamin B6 Complexed with 2-Amino-Hexanoic Acid,,Aspartate aminotransferase,aspC,,unknown
Para-Mercury-Benzenesulfonic Acid,,Galectin-10,CLC,,unknown
Para-Mercury-Benzenesulfonic Acid,,Estrogen receptor beta,ESR2,,unknown
"4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline",,Mitogen-activated protein kinase 14,MAPK14,,unknown
8-Iodo-Guanine,,Purine nucleoside phosphorylase,punA,,unknown
"N-(2-Thienylmethyl)-2,5-Thiophenedisulfonamide",,Carbonic anhydrase 2,CA2,,unknown
Cysteine-S-Acetamide,,2'-5'-oligoadenylate synthase 1,OAS1,,unknown
Cysteine-S-Acetamide,,Ribonuclease pancreatic,RNASE1,,unknown
Imino-Tryptophan,,D-amino-acid oxidase,DAO,,unknown
CRA_10972,,Trypsin-1,PRSS1,,unknown
C16-Fatty-Acyl-Substrate-Mimic,,Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,,unknown
S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea,,"Nitric oxide synthase, brain",NOS1,,unknown
1-Deoxy-6-O-Phosphono-1-[(Phosphonomethyl)Amino]-L-Threo-Hexitol,,2-dehydro-3-deoxyphosphooctonate aldolase,kdsA,,unknown
Cacodylic acid,,Gag-Pol polyprotein,gag-pol,,unknown
Cacodylic acid,,"Nitric oxide synthase, endothelial",NOS3,,unknown
Cacodylic acid,,Aldose reductase,AKR1B1,,unknown
Cacodylic acid,,Guanine nucleotide-binding protein G(t) subunit alpha-1,GNAT1,,unknown
Cyclohexylammonium Ion,,UDP-N-acetylglucosamine 1-carboxyvinyltransferase,murA,,unknown
2-(Thiomethylene)-4-Methylpentanoic Acid,,Disintegrin and metalloproteinase domain-containing protein 28,ADAM28,,unknown
Methyltrienolone,,Progesterone receptor,PGR,,unknown
Methyltrienolone,,Androgen receptor,AR,,unknown
Methyltrienolone,,Nuclear receptor coactivator 2,NCOA2,,unknown
Methyltrienolone,,Mineralocorticoid receptor,NR3C2,,unknown
Quisqualate,,Glutamate receptor 2,GRIA2,,unknown
Quisqualate,,"Glutamate receptor ionotropic, kainate 2",GRIK2,,unknown
S-9-(2-hydroxypropyl)adenine,,Thymidine kinase,TK,,unknown
Glutathione Sulfonic Acid,,Glutathione S-transferase GstA,gstA,,unknown
Glutathione Sulfonic Acid,,Glutathione S-transferase Mu 4,GSTM4,,unknown
Glutathione Sulfonic Acid,,Glutathione S-transferase A1,GSTA1,,unknown
Glutathione Sulfonic Acid,,Glutathione S-transferase P,GSTP1,,unknown
"3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-5-Yl]Hexyl]-Phenanthridinium",,Acetylcholinesterase,ACHE,,unknown
Arsanilic acid,,Lysozyme C,LYZ,,unknown
5-fluoro-beta-L-gulosyl fluoride,,Alpha-mannosidase 2,MAN2A1,,unknown
Patupilone,,Tubulin alpha-3C/D chain,TUBA3C,,unknown
Patupilone,,Tubulin beta chain,TUBB,,unknown
Patupilone,,Tubulin beta-1 chain,TUBB1,,unknown
Patupilone,,Tubulin beta-4B chain,TUBB4B,,unknown
Patupilone,,Tubulin beta-4A chain,TUBB4A,,unknown
Patupilone,,Tubulin alpha-4A chain,TUBA4A,,unknown
Patupilone,,Tubulin beta-3 chain,TUBB3,,unknown
Patupilone,,Tubulin alpha-1C chain,TUBA1C,,unknown
Patupilone,,Tubulin alpha-8 chain,TUBA8,,unknown
Patupilone,,Tubulin alpha-1B chain,TUBA1B,,unknown
Patupilone,,Tubulin alpha-1A chain,TUBA1A,,unknown
Adenosine-5'-(Dithio)Phosphate,,Nuclease P1,,,unknown
Phenylalanine-N-Sulfonamide,,Carboxypeptidase A1,CPA1,,unknown
Di(N-Acetyl-D-Glucosamine),,Chitobiase,chb,,unknown
Di(N-Acetyl-D-Glucosamine),,Lysozyme C,LYZ,,unknown
Di(N-Acetyl-D-Glucosamine),,"Beta-1,4-galactosyltransferase 1",B4GALT1,,unknown
"6-Hydroxy-1,6-Dihydro Purine Nucleoside",,Adenosine deaminase,ADA,,unknown
CRA_1801,,Trypsin-1,PRSS1,,unknown
Lauric Acid,,Alcohol dehydrogenase class-3,ADH5,,unknown
Lauric Acid,,3-oxoacyl-[acyl-carrier-protein] synthase 1,fabB,,unknown
Lauric Acid,,Ferrichrome-iron receptor,fhuA,,unknown
Lauric Acid,,Ganglioside GM2 activator,GM2A,,unknown
Lauric Acid,,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,,unknown
Lauric Acid,,Genome polyprotein,,,unknown
Lauric Acid,,Genome polyprotein,,,unknown
Lauric Acid,,Genome polyprotein,,,unknown
Lauric Acid,,Hepatocyte nuclear factor 4-alpha,HNF4A,,unknown
Lauric Acid,,"Phospholipase A2, membrane associated",PLA2G2A,,unknown
Lauric Acid,,Very low-density lipoprotein receptor,VLDLR,,unknown
Lauric Acid,,Glycolipid transfer protein,GLTP,,unknown
Lauric Acid,,3-oxoacyl-[acyl-carrier-protein] synthase 2,fabF,,unknown
Lauric Acid,,Lactotransferrin,LTF,,unknown
Lauric Acid,,Protein TonB,tonB,,unknown
Lauric Acid,,Complement component C8 gamma chain,C8G,,unknown
Lauric Acid,,Group IID secretory phospholipase A2,PLA2G2D,,unknown
Lauric Acid,,Acyl-homoserine lactone acylase PvdQ,pvdQ,,unknown
Lauric Acid,,Lymphocyte antigen 96,LY96,,unknown
Lauric Acid,,Toll-like receptor 4,TLR4,,unknown
Lauric Acid,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
"3,4-Dimethylaniline",,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
"4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine",,Cyclin-dependent kinase 2,CDK2,,unknown
5-Beta-D-Ribofuranosylnicotinamide Adenine Dinucleotide,,Alcohol dehydrogenase 1C,ADH1C,,unknown
Ulapualide A,,"Actin, alpha skeletal muscle",ACTA1,,unknown
"3-{2,6,8-trioxo-9-[(2R,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,6,8,9-hexahydro-7H-purin-7-Yl}propyl dihydrogen phosphate",,"6,7-dimethyl-8-ribityllumazine synthase",ribH,,unknown
"1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine",,Tyrosine-protein kinase Lck,LCK,,unknown
"1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine",,Tyrosine-protein kinase Lyn,LYN,,unknown
"1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine",,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
2-Methyl-3-(2-Aminothiazolo)Propanal,,Renin,REN,,unknown
Phosphoglycolohydroxamic Acid,,Triosephosphate isomerase,TPI1,,unknown
Phosphoglycolohydroxamic Acid,,Methylglyoxal synthase,mgsA,,unknown
Phosphoglycolohydroxamic Acid,,Rhamnulose-1-phosphate aldolase,rhaD,,unknown
Phosphoglycolohydroxamic Acid,,L-fuculose phosphate aldolase,fucA,,unknown
Phosphoglycolohydroxamic Acid,,"D-tagatose-1,6-bisphosphate aldolase subunit KbaY",kbaY,,unknown
Phosphoglycolohydroxamic Acid,,Fructose-bisphosphate aldolase class 2,fbaA,,unknown
1h-Benoximidazole-2-Carboxylic Acid,,Cathepsin D,CTSD,,unknown
4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole,,Enoyl-[acyl-carrier-protein] reductase [NADH] FabI,fabI,,unknown
Adamantane-1-Carboxylic Acid-5-Dimethylamino-Naphthalene-1-Sulfonylamino-Octyl-Amide,,Camphor 5-monooxygenase,camC,,unknown
S-Octylglutathione,,Glutathione S-transferase Mu 4,GSTM4,,unknown
1-Methyloxy-4-Sulfone-Benzene,,Collagenase 3,MMP13,,unknown
1-Methyloxy-4-Sulfone-Benzene,,Stromelysin-1,MMP3,,unknown
D-Levofloxacin,,Autolysin,lytA,,unknown
"1,8-Di-Hydroxy-4-Nitro-Anthraquinone",,Casein kinase II subunit alpha,CSNK2A1,,unknown
Oxidized Acetyl Dithranol,,ActVA 6 protein,actVA 6,,unknown
LY341770,,Thymidylate synthase,thyA,,unknown
"4-(Aminosulfonyl)-N-[(2,5-Difluorophenyl)Methyl]-Benzamide",,Carbonic anhydrase 2,CA2,,unknown
Nitrilotriacetic Acid,,Lactotransferrin,LTF,,unknown
UDP-alpha-D-glucuronic acid,,UDP-glucose 6-dehydrogenase,hasB,,unknown
UDP-alpha-D-glucuronic acid,,Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3,B3GAT3,,unknown
UDP-alpha-D-glucuronic acid,,UDP-glucose 4-epimerase,GALE,substrate,unknown
5-Phosphoarabinonic Acid,,Glucose-6-phosphate isomerase B,pgiB,,unknown
5-Phosphoarabinonic Acid,,Glucose-6-phosphate isomerase,GPI,,unknown
1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea,,Mitogen-activated protein kinase 14,MAPK14,,unknown
Pantothenyl-Aminoethanol-Acetate Pivalic Acid,,Acetyl-CoA acetyltransferase,phbA,,unknown
7-Methoxy-8-[1-(Methylsulfonyl)-1h-Pyrazol-4-Yl]Naphthalene-2-Carboximidamide,,Urokinase-type plasminogen activator,PLAU,,unknown
6-Carboxymethyluracil,,Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,,unknown
S-Selanyl Cysteine,,Cysteine desulfurase,sufS,,unknown
Tetrahydrofuran-2-Carboxylic Acid,,Quinohemoprotein ethanol dehydrogenase type-1,qheDH,,unknown
Tetrahydrofuran-2-Carboxylic Acid,,Bifunctional protein PutA,putA,,unknown
Dazoxiben,,Thromboxane-A synthase,TBXAS1,inhibitor,unknown
1-Aminocyclopropylphosphonate,,1-aminocyclopropane-1-carboxylate deaminase,acdS,,unknown
4-Piperidino-Piperidine,,Liver carboxylesterase 1,CES1,,unknown
Malonaldehyde,,Beta-lactamase SHV-1,bla,,unknown
2-Aminobenzyl alcohol,,Complement factor D,CFD,,unknown
Acetoacetyl-CoA,,"1,4-Dihydroxy-2-naphthoyl-CoA synthase",menB,,unknown
Acetoacetyl-CoA,,"Acyl-CoA dehydrogenase, short-chain specific",,,unknown
Acetoacetyl-CoA,,HMG-CoA synthase,mvaS,,unknown
Acetoacetyl-CoA,,3-hydroxy-3-methylglutaryl CoA synthase,mvaS,,unknown
Acetoacetyl-CoA,,"Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial",HADH,,unknown
Acetoacetyl-CoA,,Acetyl-CoA acetyltransferase,phbA,,unknown
Acetoacetyl-CoA,,"Short-chain specific acyl-CoA dehydrogenase, mitochondrial",ACADS,,unknown
Acetoacetyl-CoA,,"Enoyl-CoA hydratase, mitochondrial",ECHS1,,unknown
Sri-9662,,Dihydrofolate reductase,DHFR,,unknown
(R)-N-(1-Methyl-Hexyl)-Formamide,,Alcohol dehydrogenase 1C,ADH1C,,unknown
(1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone,,Glycylpeptide N-tetradecanoyltransferase,NMT1,,unknown
(1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone,,Glycylpeptide N-tetradecanoyltransferase 1,NMT1,,unknown
"N-(1-Benzyl-3-{[3-(1,3-Dioxo-1,3-Dihydro-Isoindol-2-Yl)-Propionyl]-[2-(Hexahydro-Benzo[1,3]Dioxol-5-Yl)-Ethyl]-Amino}-2-Hydroxy-Propyl)-4-Benzyloxy-3,5-Dimethoxy-Benzamide",,Plasmepsin-2,,,unknown
"3-Decyl-2,5-Dioxo-4-Hydroxy-3-Pyrroline",,Hydroxyacid oxidase 1,HAO1,,unknown
7-Nitroindazole-2-Carboxamidine,,"Nitric oxide synthase, endothelial",NOS3,,unknown
D-Lactic acid,,(S)-2-haloacid dehalogenase,,,unknown
"4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
Zebularine,,Cytidine deaminase,cdd,,unknown
Cytidine-5'-Diphospho-Beta-D-Xylose,,"CDP-glucose 4,6-dehydratase",rfbG,,unknown
Selenazole-4-Carboxyamide-Adenine Dinucleotide,,Inosine-5'-monophosphate dehydrogenase 2,IMPDH2,,unknown
"2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone",,Poly [ADP-ribose] polymerase 1,PARP1,,unknown
3-Methoxybenzamide,,Poly [ADP-ribose] polymerase 1,PARP1,,unknown
7-Deaza-7-Cyano-Guanine,,Queuine tRNA-ribosyltransferase,tgt,,unknown
(Diphosphono)Aminophosphonic Acid,,S-adenosylmethionine synthase,metK,,unknown
AHA047,,Gag-Pol polyprotein,gag-pol,,unknown
"3-Amino-4-{3-[2-(2-Propoxy-Ethoxy)-Ethoxy]-Propylamino}-Cyclobut-3-Ene-1,2-Dione",,Cholera enterotoxin subunit B,ctxB,,unknown
"3-Amino-4-{3-[2-(2-Propoxy-Ethoxy)-Ethoxy]-Propylamino}-Cyclobut-3-Ene-1,2-Dione",,Cholera enterotoxin B subunit,ctxB,,unknown
PASBN,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
Alpha-Ribazole-5'-Phosphate Derivative,,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
Crc200 (Chiron-Behring),,Trypsin-1,PRSS1,,unknown
6-[(Z)-Amino(Imino)Methyl]-N-[4-(Aminomethyl)Phenyl]-4-(Pyrimidin-2-Ylamino)-2-Naphthamide,,Urokinase-type plasminogen activator,PLAU,,unknown
IC261,,Casein kinase I isoform gamma-2,CSNK1G2,,unknown
"Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine",,Mitogen-activated protein kinase 10,MAPK10,,unknown
Glycolic acid,,Glucose-6-phosphate 1-dehydrogenase,G6PD,,unknown
Glycolic acid,,Glycine oxidase,thiO,,unknown
"N'-(2s,3r)-3-Amino-4-Cyclohexyl-2-Hydroxy-Butano-N-(4-Methylphenyl)Hydrazide",,Methionine aminopeptidase 2,METAP2,,unknown
2-(Sec-Butyl)Thiazole,,Epididymal-specific lipocalin-9,LCN9,,unknown
Pidolic Acid,,Vascular endothelial growth factor A,VEGFA,,unknown
Pidolic Acid,,Pancreatic alpha-amylase,AMY2A,,unknown
Pidolic Acid,,Ig lambda-1 chain C regions,IGLC1,,unknown
Pidolic Acid,,Ig lambda chain V-II region MGC,,,unknown
Pidolic Acid,,Trefoil factor 2,TFF2,,unknown
Pidolic Acid,,Cytochrome c2,cycA,,unknown
Pidolic Acid,,Disintegrin and metalloproteinase domain-containing protein 28,ADAM28,,unknown
Pidolic Acid,,"Endo-1,4-beta-xylanase",,,unknown
Pidolic Acid,,Dissimilatory copper-containing nitrite reductase,nir,,unknown
Pidolic Acid,,Keratin-associated protein 5-2,KRTAP5-2,,unknown
Pidolic Acid,,Orexin,HCRT,,unknown
Pidolic Acid,,C-C motif chemokine 8,CCL8,,unknown
Pidolic Acid,,Cytochrome c',,,unknown
Pidolic Acid,,Alpha-amylase 2B,AMY2B,,unknown
Pidolic Acid,,Angiogenin,ANG,,unknown
Pidolic Acid,,Chondroitinase-B,cslB,,unknown
Pidolic Acid,,Alpha-amylase 1,AMY1A,,unknown
Ethylaminobenzylmethylcarbonyl Group,,Candidapepsin-2,SAP2,,unknown
4-Amido-4-Carbamoyl-Butyric Acid,,ATP synthase subunit b,atpF,,unknown
5-Hydroxymethyl-Chonduritol,,Alpha-amylase 1,AMY1A,,unknown
5-Hydroxymethyl-Chonduritol,,Pancreatic alpha-amylase,AMY2A,,unknown
5-Hydroxymethyl-Chonduritol,,Alpha-amylase 2B,AMY2B,,unknown
"8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
Tetramethylammonium Ion,,UDP-glucose 4-epimerase,GALE,,unknown
N-Aminoethylmorpholine,,Cathepsin D,CTSD,,unknown
"Pmp-Hydroxyisoxazole, Pyridoxamine-5-Phosphate-Hydroxyisoxazole",,Alanine racemase,alr,,unknown
[Methylseleno]Acetate,,Monomeric sarcosine oxidase,soxA,,unknown
6-Nitroindazole,,"Nitric oxide synthase, inducible",NOS2,,unknown
6-Nitroindazole,,"Nitric oxide synthase, endothelial",NOS3,,unknown
Ribose-1-Phosphate,,Uridine phosphorylase,udp,,unknown
Ribose-1-Phosphate,,Purine nucleoside phosphorylase,PNP,,unknown
"2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
Thymidine-5'- Diphosphate,,Nucleoside diphosphate kinase A,NME1,,unknown
RU82129,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
scyllo-inositol,,1-phosphatidylinositol phosphodiesterase,,,unknown
scyllo-inositol,,Glucosylceramidase,GBA,,unknown
scyllo-inositol,,1-phosphatidylinositol phosphodiesterase,plcA,,unknown
scyllo-inositol,,CDP-diacylglycerol--inositol 3-phosphatidyltransferase,CDIPT,inhibitor,unknown
Beta-Alanine,,Pantothenate synthetase,panC,,unknown
4-phospho-D-erythronic acid,,Ribose-5-phosphate isomerase B,rpiB,,unknown
N-Acetyl-D-Allosamine,,Chitinase B,chiB,,unknown
N-Acetyl-D-Allosamine,,Chitinase A,chiA,,unknown
N-Acetyl-D-Allosamine,,Chitotriosidase-1,CHIT1,,unknown
2-Chlorophenol,,Mitogen-activated protein kinase 14,MAPK14,,unknown
Glucosamine 1-Phosphate,,Ferrichrome-iron receptor,fhuA,,unknown
"6-(2-Oxo-Hexahydro-Thieno[3,4-D]Imidazol-4-Yl)-Hexanoic Acid",,Streptavidin,,,unknown
3-Fluoro-2-(Phosphonooxy)Propanoic Acid,,2-dehydro-3-deoxyphosphooctonate aldolase,kdsA,,unknown
PAS219,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
"5-Bromo-N-(2,3-Dihydroxypropoxy)-3,4-Difluoro-2-[(2-Fluoro-4-Iodophenyl)Amino]Benzamide",,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,,unknown
5-(1-Carboxy-1-Phosphonooxy-Ethoxyl)-Shikimate-3-Phosphate,,3-phosphoshikimate 1-carboxyvinyltransferase,aroA,,unknown
2-Carboxypropyl-Coenzyme A,,Methylmalonyl-CoA decarboxylase,scpB,,unknown
1-(5-Chloroindol-3-Yl)-3-Hydroxy-3-(2h-Tetrazol-5-Yl)-Propenone,,Gag-Pol polyprotein,gag-pol,,unknown
Para-Toluene Sulfonate,,Lysozyme C,LYZ,,unknown
Para-Toluene Sulfonate,,Pro-cathepsin H,CTSH,,unknown
(1-Benzyl-5-methoxy-2-methyl-1H-indol-3-yl)acetic acid,,"Phospholipase A2, membrane associated",PLA2G2A,,unknown
5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid,,Caspase-3,CASP3,,unknown
"2,4-Diamino-5-(3,4,5-Trimethoxy-Benzyl)-Pyrimidin-1-Ium",,Dihydrofolate reductase,folA,,unknown
"2,4-Diamino-5-(3,4,5-Trimethoxy-Benzyl)-Pyrimidin-1-Ium",,Dihydrofolate reductase,DHFR,,unknown
Mant-Adp,,Myosin-14,MYH14,,unknown
Benzamidine,,Kallikrein-6,KLK6,,unknown
Benzamidine,,Trypsin-2,PRSS2,,unknown
Benzamidine,,Trypsin-3,PRSS3,,unknown
Benzamidine,,Copper transport protein ATOX1,ATOX1,,unknown
Benzamidine,,"Enoyl-CoA delta isomerase 1, mitochondrial",ECI1,,unknown
Benzamidine,,Trypsin,sprT,,unknown
Benzamidine,,Suppressor of tumorigenicity 14 protein,ST14,,unknown
Benzamidine,,Urokinase-type plasminogen activator,PLAU,,unknown
Benzamidine,,Trypsin-1,PRSS1,,unknown
Benzamidine,,Casein kinase II subunit alpha,CSNK2A1,,unknown
Benzamidine,,Kallikrein-1,KLK1,,unknown
Acetylcholine,,Acetylcholinesterase,ACHE,,unknown
Acetylcholine,,Muscarinic acetylcholine receptor M1,CHRM1,,unknown
Acetylcholine,,Muscarinic acetylcholine receptor M2,CHRM2,,unknown
Acetylcholine,,Muscarinic acetylcholine receptor M3,CHRM3,,unknown
Acetylcholine,,Muscarinic acetylcholine receptor M4,CHRM4,,unknown
Acetylcholine,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,,unknown
"[3-(1,3,2-Dioxaborolan-2-Yloxy)Propyl]Guanidine",,Trypsin-3,PRSS3,,unknown
S-P-Nitrobenzyloxycarbonylglutathione,,Lactoylglutathione lyase,GLO1,,unknown
3-(2-Benzothiazolylthio)-1-Propanesulfonic Acid,,"Triosephosphate isomerase, glycosomal",,,unknown
3-(2-Benzothiazolylthio)-1-Propanesulfonic Acid,,Triosephosphate isomerase,TPI1,,unknown
"2-(Beta-D-Glucopyranosyl)-5-Methyl-1,2,3-Benzimidazole",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
2-Aminopimelic Acid,,"2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase",dapD,,unknown
[2(Formyl-Hydroxy-Amino)-Ethyl]-Phosphonic Acid,,Triosephosphate isomerase,TPI1,,unknown
4-Iodobenzo[B]Thiophene-2-Carboxamidine,,Prothrombin,F2,,unknown
4-Iodobenzo[B]Thiophene-2-Carboxamidine,,Trypsin-1,PRSS1,,unknown
4-Iodobenzo[B]Thiophene-2-Carboxamidine,,Urokinase-type plasminogen activator,PLAU,,unknown
"8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
Perchlorate,,Protein ArsC,arsC,,unknown
"6-[5-(2-Oxo-Hexahydro-Thieno[3,4-D]Imidazol-4-Yl)-Pentanoylamino]-Hexanoic Acid",,Streptavidin,,,unknown
4-Carboxyphenylboronic Acid,,Beta-lactamase,ampC,,unknown
"3-{[(5R,6R)-5-Benzyl-6-hydroxy-2,4-bis(4-hydroxybenzyl)-3-oxo-1,2,4-triazepan-1-yl]sulfonyl}benzonitril",,Gag-Pol polyprotein,gag-pol,,unknown
"3-{[(5R,6R)-5-Benzyl-6-hydroxy-2,4-bis(4-hydroxybenzyl)-3-oxo-1,2,4-triazepan-1-yl]sulfonyl}benzonitril",,V-1 protease,ORF,,unknown
Alpha-L-Arabinose,,Arabinose operon regulatory protein,araC,,unknown
Alpha-L-Arabinose,,L-arabinose-binding periplasmic protein,araF,,unknown
Alpha-L-Arabinose,,Aldose 1-epimerase,galM,,unknown
Nonan-1-Ol,,"ATP synthase subunit c, sodium ion specific",atpE,,unknown
N-Omega-Hydroxy-L-Arginine,,"Nitric oxide synthase, endothelial",NOS3,,unknown
N-Omega-Hydroxy-L-Arginine,,Nitric oxide synthase oxygenase,nos,,unknown
N-Omega-Hydroxy-L-Arginine,,"Nitric oxide synthase, inducible",NOS2,,unknown
N-Omega-Hydroxy-L-Arginine,,Arginase-1,ARG1,,unknown
N-Omega-Hydroxy-L-Arginine,,"Nitric oxide synthase, brain",NOS1,,unknown
4-Methyl-5-Hydroxyethylthiazole Phosphate,,Thiamine-phosphate synthase,thiE,,unknown
2-deazo-6-thiophosphate guanosine-5'-monophosphate,,Adenylosuccinate synthetase,purA,,unknown
Flavin adenine dinucleotide,,UDP-galactopyranose mutase,glf,,unknown
Flavin adenine dinucleotide,,Flavohemoprotein,hmp,,unknown
Flavin adenine dinucleotide,,Glycine oxidase,thiO,,unknown
Flavin adenine dinucleotide,,NADPH--cytochrome P450 reductase,POR,,unknown
Flavin adenine dinucleotide,,"Glutaryl-CoA dehydrogenase, mitochondrial",GCDH,,unknown
Flavin adenine dinucleotide,,"Medium-chain specific acyl-CoA dehydrogenase, mitochondrial",ACADM,,unknown
Flavin adenine dinucleotide,,D-amino-acid oxidase,DAO,,unknown
Flavin adenine dinucleotide,,Bifunctional protein PutA,putA,,unknown
Flavin adenine dinucleotide,,Deoxyribodipyrimidine photo-lyase,phr,,unknown
Flavin adenine dinucleotide,,Amine oxidase [flavin-containing] A,MAOA,,unknown
Flavin adenine dinucleotide,,"Short-chain specific acyl-CoA dehydrogenase, mitochondrial",ACADS,,unknown
Flavin adenine dinucleotide,,L-amino-acid oxidase,IL4I1,,unknown
Flavin adenine dinucleotide,,"2,4-dienoyl-CoA reductase [NADPH]",fadH,,unknown
Flavin adenine dinucleotide,,"2-oxopropyl-CoM reductase, carboxylating",xecC,,unknown
Flavin adenine dinucleotide,,p-hydroxybenzoate hydroxylase,pobA,,unknown
Flavin adenine dinucleotide,,"Nitric oxide synthase, brain",NOS1,,unknown
Flavin adenine dinucleotide,,NAD(P)H dehydrogenase [quinone] 1,NQO1,,unknown
Flavin adenine dinucleotide,,p-hydroxybenzoate hydroxylase,pobA,,unknown
Flavin adenine dinucleotide,,Fumarate reductase flavoprotein subunit,,,unknown
Flavin adenine dinucleotide,,ERO1-like protein beta,ERO1B,,unknown
Flavin adenine dinucleotide,,"Glutathione reductase, mitochondrial",GSR,,unknown
Flavin adenine dinucleotide,,NADPH-ferredoxin reductase FprA,fprA,,unknown
Flavin adenine dinucleotide,,NADH-cytochrome b5 reductase 3,CYB5R3,,unknown
Flavin adenine dinucleotide,,Cholesterol oxidase,choA,,unknown
Flavin adenine dinucleotide,,Thymidylate synthase ThyX,thyX,,unknown
Flavin adenine dinucleotide,,Pyruvate oxidase,pox5,,unknown
Flavin adenine dinucleotide,,Thioredoxin reductase,trxB,,unknown
Flavin adenine dinucleotide,,Glutathione reductase,gor,,unknown
Flavin adenine dinucleotide,,"5,10-methylenetetrahydrofolate reductase",metF,,unknown
Flavin adenine dinucleotide,,Monomeric sarcosine oxidase,soxA,,unknown
Flavin adenine dinucleotide,,Trypanothione reductase,TPR,,unknown
Flavin adenine dinucleotide,,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,,unknown
Flavin adenine dinucleotide,,"Isovaleryl-CoA dehydrogenase, mitochondrial",IVD,,unknown
Flavin adenine dinucleotide,,Xanthine dehydrogenase/oxidase,XDH,,unknown
Flavin adenine dinucleotide,,Cholesterol oxidase,choB,,unknown
Flavin adenine dinucleotide,,"N,N-dimethylglycine oxidase",dmg,,unknown
Flavin adenine dinucleotide,,NADH peroxidase,npr,,unknown
Flavin adenine dinucleotide,,Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,,unknown
Flavin adenine dinucleotide,,Ferredoxin--NADP reductase,petH,,unknown
Flavin adenine dinucleotide,,D-lactate dehydrogenase,dld,,unknown
Flavin adenine dinucleotide,,Sulfite reductase [NADPH] flavoprotein alpha-component,cysJ,,unknown
Flavin adenine dinucleotide,,"Thioredoxin reductase 1, cytoplasmic",TXNRD1,,unknown
Flavin adenine dinucleotide,,Ferredoxin--NADP reductase,fpr,,unknown
Flavin adenine dinucleotide,,"Isobutyryl-CoA dehydrogenase, mitochondrial",ACAD8,,unknown
Flavin adenine dinucleotide,,"Acyl-CoA dehydrogenase, short-chain specific",,,unknown
Flavin adenine dinucleotide,,"Apoptosis-inducing factor 1, mitochondrial",AIFM1,,unknown
Flavin adenine dinucleotide,,Ferredoxin reductase,bphA4,,unknown
Flavin adenine dinucleotide,,Dihydrolipoyl dehydrogenase,,,unknown
Flavin adenine dinucleotide,,"Amine oxidase, flavin-containing protein",,,unknown
Flavin adenine dinucleotide,,Deoxyribodipyrimidine photo-lyase,phrB,,unknown
Flavin adenine dinucleotide,,Deoxyribodipyrimidine photo-lyase,phr,,unknown
Flavin adenine dinucleotide,,L-aspartate oxidase,nadB,,unknown
Flavin adenine dinucleotide,,Cryptochrome DASH,cry,,unknown
Flavin adenine dinucleotide,,"Dihydrolipoyl dehydrogenase, mitochondrial",DLD,,unknown
Flavin adenine dinucleotide,,Fumarate reductase flavoprotein subunit,ifcA,,unknown
Flavin adenine dinucleotide,,NADH-cytochrome b5 reductase 1,CYB5R1,,unknown
Flavin adenine dinucleotide,,Oxidoreductase,,,unknown
Flavin adenine dinucleotide,,Amine oxidase [flavin-containing] B,MAOB,,unknown
Flavin adenine dinucleotide,,"NADPH:adrenodoxin oxidoreductase, mitochondrial",FDXR,,unknown
Flavin adenine dinucleotide,,Peroxisomal acyl-coenzyme A oxidase 1,ACOX1,,unknown
Flavin adenine dinucleotide,,UDP-N-acetylenolpyruvoylglucosamine reductase,murB,,unknown
Flavin adenine dinucleotide,,FAD-linked sulfhydryl oxidase ALR,GFER,,unknown
Flavin adenine dinucleotide,,UDP-N-acetylenolpyruvoylglucosamine reductase,murB,,unknown
Flavin adenine dinucleotide,,Flavohemoprotein,hmp,,unknown
Flavin adenine dinucleotide,,Phenol 2-hydroxylase component B,pheA2,,unknown
Flavin adenine dinucleotide,,Methylenetetrahydrofolate reductase,metF,,unknown
Flavin adenine dinucleotide,,Putidaredoxin reductase,camA,,unknown
Flavin adenine dinucleotide,,NAD(P)H dehydrogenase (quinone),lpdA,,unknown
Flavin adenine dinucleotide,,UDP-galactopyranose mutase,glf,,unknown
Flavin adenine dinucleotide,,4-hydroxybutyryl-CoA dehydratase/vinylacetyl-CoA-Delta-isomerase,abfD,,unknown
Flavin adenine dinucleotide,,4-cresol dehydrogenase [hydroxylating] flavoprotein subunit,pchF,,unknown
Flavin adenine dinucleotide,,Alkyl hydroperoxide reductase subunit F,ahpF,,unknown
Flavin adenine dinucleotide,,Outer membrane protein p64k or PM-6,m-6,,unknown
Flavin adenine dinucleotide,,Glutathione reductase,GR2,,unknown
Flavin adenine dinucleotide,,Phenylacetone monooxygenase,pamO,,unknown
Flavin adenine dinucleotide,,"Benzoate 1,2-dioxygenase electron transfer component",benC,,unknown
Flavin adenine dinucleotide,,Putative acyl-CoA dehydrogenase,,,unknown
Flavin adenine dinucleotide,,FkbI,fkbI,,unknown
Flavin adenine dinucleotide,,Dihydrolipoyl dehydrogenase,lpdV,,unknown
Flavin adenine dinucleotide,,Dihydrolipoyl dehydrogenase,lpd,,unknown
Flavin adenine dinucleotide,,Alkyl hydroperoxide reductase subunit F,ahpF,,unknown
Flavin adenine dinucleotide,,Ferredoxin--NADP reductase,petH,,unknown
Flavin adenine dinucleotide,,Ferredoxin--NADP reductase,fpr,,unknown
Flavin adenine dinucleotide,,Mersacidin decarboxylase,mrsD,,unknown
Flavin adenine dinucleotide,,Fumarate reductase flavoprotein subunit,fccA,,unknown
Flavin adenine dinucleotide,,"NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial",NDUFA9,cofactor,unknown
Phosphomethylphosphonic Acid Adenosyl Ester,,Ribose-phosphate pyrophosphokinase,prs,,unknown
Phosphomethylphosphonic Acid Adenosyl Ester,,DNA,,,unknown
Phosphomethylphosphonic Acid Adenosyl Ester,,MutT/nudix family protein,,,unknown
Phosphomethylphosphonic Acid Adenosyl Ester,,Protein UshA,ushA,,unknown
"2',3'-Dideoxythymidine-5'-Monophosphate",,Thymidylate kinase,DTYMK,,unknown
(Mu-4-Sulfido)-Tetra-Nuclear Copper Ion,,Oxidoreductase,,,unknown
(Mu-4-Sulfido)-Tetra-Nuclear Copper Ion,,Nitrous-oxide reductase,nosZ,,unknown
B-2-Octylglucoside,,"DNA polymerase I, thermostable",polA,,unknown
B-2-Octylglucoside,,Aquaporin Z,aqpZ,,unknown
B-2-Octylglucoside,,Protein-glutamine gamma-glutamyltransferase E,TGM3,,unknown
B-2-Octylglucoside,,H subunit of photosynthetic reaction center complex,puhA,,unknown
B-2-Octylglucoside,,Aquaporin Z,aqpZ,,unknown
B-2-Octylglucoside,,Cytochrome b,petB,,unknown
B-2-Octylglucoside,,Ubiquinol-cytochrome c reductase iron-sulfur subunit,petA,,unknown
B-2-Octylglucoside,,Cytochrome c1,petC,,unknown
B-2-Octylglucoside,,Rhodopsin,RHO,,unknown
"3h-Pyrazolo[4,3-D]Pyrimidin-7-Ol",,Hypoxanthine-guanine phosphoribosyltransferase,HPRT1,,unknown
{[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
"1-(2-Deoxy-2-Fluoro-3-O-Phosphono-Beta-L-Ribofuranosyl)Pyrimidine-2,4(1h,3h)-Dione",,Ribonuclease pancreatic,RNASE1,,unknown
D-Glucuronic Acid,,Hyaluronate lyase,,,unknown
D-Glucuronic Acid,,Chondroitinase-AC,cslA,,unknown
D-Glucuronic Acid,,Alpha-glucuronidase,aguA,,unknown
"N,O-Didansyl-L-Tyrosine",,Thymidylate synthase,thyA,,unknown
"D-Myo-Inositol-1,4-Bisphosphate",,"Type II inositol 1,4,5-trisphosphate 5-phosphatase",INPP5B,,unknown
CRA_8696,,Prothrombin,F2,,unknown
CRA_8696,,Trypsin-1,PRSS1,,unknown
CRA_8696,,Urokinase-type plasminogen activator,PLAU,,unknown
N-Pyridoxyl-7-Keto-8-Aminopelargonic Acid-5'-Monophosphate,,8-amino-7-oxononanoate synthase,bioF,,unknown
Thymidine-5'-Diphospho-Beta-D-Xylose,,"dTDP-glucose 4,6-dehydratase",rmlB,,unknown
Thymidine-5'-Diphospho-Beta-D-Xylose,,"DTDP-4-dehydrorhamnose 3,5-epimerase",rmlC,,unknown
"4-Hydroxy-1,2,5-Thiadiazole-3-Carboxylic Acid",,L-lactate dehydrogenase,,,unknown
2-oxopropyl-CoM,,"2-oxopropyl-CoM reductase, carboxylating",xecC,,unknown
6-Amino-1-Methylpurine,,Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase,PAPS,,unknown
2-Dimethylamino-Ethyl-Diphosphate,,Isopentenyl-diphosphate Delta-isomerase,idi,,unknown
(S)-Hmg-Coa,,3-hydroxy-3-methylglutaryl-coenzyme A reductase,mvaA,,unknown
(S)-Hmg-Coa,,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,,unknown
(S)-Hmg-Coa,,3-hydroxy-3-methylglutaryl CoA synthase,mvaS,,unknown
Dephospho Coenzyme A,,Phosphopantetheine adenylyltransferase,coaD,,unknown
Indole-3-Propanol Phosphate,,Tryptophan synthase alpha chain,trpA,,unknown
Indole-3-Propanol Phosphate,,Tryptophan synthase alpha chain,trpA,,unknown
Indole-3-Propanol Phosphate,,Tryptophan synthase beta chain,trpB,,unknown
Tubercidin,,Purine nucleoside phosphorylase DeoD-type,deoD,,unknown
CRA_10433,,Trypsin-1,PRSS1,,unknown
Phosphonoacetaldehyde,,Phosphonoacetaldehyde hydrolase,phnX,,unknown
Propyl alcohol,,Lysozyme C,LYZ,,unknown
KB-141,,Thyroid hormone receptor beta,THRB,,unknown
KB-141,,Thyroid hormone receptor alpha,THRA,,unknown
5-methylbenzimidazole,,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
"Guanosine-2',3'-Cyclophosphorothioate",,Guanyl-specific ribonuclease Sa,rnaSA,,unknown
Sinapoyl Coenzyme A,,Catechol O-methyltransferase domain-containing protein 1,COMTD1,,unknown
"4,5-Dimethyl-1,2-Phenylenediamine",,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
"2-[4-(4-Hydroxy-3-Isopropyl-Phenoxy)-3,5-Dimethyl-Phenyl]-2h-[1,2,4]Triazine-3,5-Dione",,Thyroid hormone receptor beta,THRB,,unknown
Alpha-Fluoro-Carboxymethyldethia Coenzyme a Complex,,"Citrate synthase, mitochondrial",CS,,unknown
"1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester",,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,,unknown
"1-Beta-Ribofuranosyl-1,3-Diazepinone",,Cytidine deaminase,CDA,,unknown
U-Pi-a-Pi,,Ribonuclease pancreatic,RNASE1,,unknown
6-(Hydroxyethyldithio)-8-(Aminomethylthio)Octanoic Acid,,"Glycine cleavage system H protein, mitochondrial",GCSH,,unknown
Cu-Cyclam,,Lysozyme C,LYZ,,unknown
"N-Octanoyl-B-D-Fructofuranosyl-a-D-Glucopyranoside,Sucrose Monocaproylate",,Penicillin-binding protein 2X,pbpX,,unknown
3-Oxiran-2ylalanine,,S-adenosylmethionine synthase isoform type-1,MAT1A,,unknown
3r-Hydroxydecanoyl-Coa,,Peroxisomal multifunctional enzyme type 2,HSD17B4,,unknown
Stearic acid,,Group IID secretory phospholipase A2,PLA2G2D,,unknown
Stearic acid,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
beta-L-methyl-fucose,,Mannose-binding protein C,MBL2,,unknown
"Phosphoric Acid Mono-[3-Fluoro-5-(5-Methyl-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Tetrahyro-Furan-2-Ylmethyl] Ester",,Thymidylate kinase,DTYMK,,unknown
4-Nitrophenyl-Ara,,Intracellular exo-alpha-(1->5)-L-arabinofuranosidase,abfA,,unknown
6-Hydroxymethylpterin,,2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase,folK,,unknown
Thio-Maltohexaose,,Cyclomaltodextrin glucanotransferase,,,unknown
4-Methoxy-E-Rhodomycin T,,Carminomycin 4-O-methyltransferase,dnrK,,unknown
7-Alpha-D-Ribofuranosyl-Purine-5'-Phosphate,,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
D-Cysteine,,Carboxypeptidase A1,CPA1,,unknown
"2-[5-Methanesulfonylamino-2-(4-Aminophenyl)-6-Oxo-1,6-Dihydro-1-Pyrimidinyl]-N-(3,3,3-Trifluoro-1-Isopropyl-2-Oxopropyl)Acetamide",,Chymotrypsin-like elastase family member 1,CELA1,,unknown
Sphingosine,,Glycolipid transfer protein,GLTP,,unknown
Sphingosine,,Genome polyprotein,,,unknown
Sphingosine,,Genome polyprotein,,,unknown
Sphingosine,,Genome polyprotein,,,unknown
Sphingosine,,Genome polyprotein,,,unknown
Sphingosine,,Poliovirus receptor,PVR,,unknown
Pyrroloquinoline Quinone,,Quinohemoprotein ethanol dehydrogenase type-1,qheDH,,unknown
Pyrroloquinoline Quinone,,Quinoprotein glucose dehydrogenase B,gdhB,,unknown
Pyrroloquinoline Quinone,,Quinohemoprotein alcohol dehydrogenase ADH IIB,qbdA,,unknown
Pyrroloquinoline Quinone,,Pyrroloquinoline-quinone synthase,pqqC,,unknown
Pyrroloquinoline Quinone,,Quinoprotein ethanol dehydrogenase,exaA,,unknown
Duvoglustat,,"Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase",MAN1B1,,unknown
Duvoglustat,,"Mannosyl-oligosaccharide alpha-1,2-mannosidase",MSDC,,unknown
Duvoglustat,,Xylose isomerase,xylA,,unknown
Duvoglustat,,Beta-glucosidase A,bglA,,unknown
Duvoglustat,,Cyclomaltodextrin glucanotransferase,cgt,,unknown
"2-(Biphenyl-4-Sulfonyl)-1,2,3,4-Tetrahydro-Isoquinoline-3-Carboxylic Acid",,Neutrophil collagenase,MMP8,,unknown
4-Aminohydrocinnamic Acid,,Aromatic-amino-acid aminotransferase,tyrB,,unknown
(3-Formyl-but-3-Enyl)-Phosphonic Acid,,"Glyceraldehyde-3-phosphate dehydrogenase, glycosomal",,,unknown
4-Deoxyglucarate,,Glucarate dehydratase,gudD,,unknown
Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone,,Trypsin-1,PRSS1,,unknown
Vinylglycine,,1-aminocyclopropane-1-carboxylate synthase-like protein 1,ACCS,,unknown
Vinylglycine,,L-amino-acid oxidase,IL4I1,,unknown
"(2s,5s)-5-Carboxymethylproline",,Carbapenam-3-carboxylate synthase,carA,,unknown
"(1'r,2's)-9-(2-Hydroxy-3'-Keto-Cyclopenten-1-Yl)Adenine",,Adenosylhomocysteinase,AHCY,,unknown
DPI59,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
N-Acetyl-N'-Beta-D-Glucopyranosyl Urea,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
11-Deoxy-Beta-Rhodomycin,,RdmB,rdmB,,unknown
FR233623,,Adenosine deaminase,ADA,,unknown
AL7099A,,Carbonic anhydrase 2,CA2,,unknown
dATP,,DNA primase/helicase,,,unknown
dATP,,DNA polymerase beta,POLB,,unknown
dATP,,Ribonucleoside-diphosphate reductase 2 subunit alpha,nrdE,,unknown
dATP,,Anaerobic ribonucleoside-triphosphate reductase,NRDD,,unknown
dATP,,Protein RecA,recA,,unknown
dATP,,Protein RecA,recA,,unknown
Diphthamide,,Elongation factor 2,EEF2,,unknown
2-Formyl-Protoporphryn Ix,,Cytochrome c-552,cycA,,unknown
D-Tryptophan,,D-amino-acid oxidase,DAO,,unknown
Trifluoroethanol,,Alcohol dehydrogenase,,,unknown
Trifluoroethanol,,Alcohol dehydrogenase 1C,ADH1C,,unknown
Trifluoroethanol,,GTPase HRas,HRAS,,unknown
Nicotinamide Mononucleotide,,Nicotinamide mononucleotide adenylyltransferase 1,NMNAT1,,unknown
Nicotinamide Mononucleotide,,Nicotinamide mononucleotide adenylyltransferase 3,NMNAT3,,unknown
Nicotinamide Mononucleotide,,ADP-ribosyl cyclase 2,BST1,,unknown
Nicotinamide Mononucleotide,,DNA ligase,ligA,,unknown
"5-[Bis-2(Chloro-Ethyl)-Amino]-2,4-Dintro-Benzamide",,Oxygen-insensitive NAD(P)H nitroreductase,nfsB,,unknown
2-Oxo-4-Methylpentanoic Acid,,Deacetoxycephalosporin C synthase,cefE,,unknown
2-Oxo-4-Methylpentanoic Acid,,D-2-hydroxyisocaproate dehydrogenase,,,unknown
Adenosine-5'-Propylphosphate,,Acetyl-coenzyme A synthetase,acs,,unknown
"3-(5-Amino-7-oxo-3,7-dihydro-2H-[1,2,3]triazolo[4,5-d]pyrimidin-2-yl)-N-(2-{[2-(hydroxymethyl)phenyl]sulfanyl}benzyl)benzamide",,Dihydroneopterin aldolase,folB,,unknown
"2-[(2e,6e,10e,14e,18e,22e,26e)-3,7,11,15,19,23,27,31-Octamethyldotriaconta-2,6,10,14,18,22,26,30-Octaenyl]Phenol",,Protein YceI,yceI,,unknown
"Phosphoric Acid Mono-[3-Amino-5-(5-Methyl-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Tetrahydro-Furan-2-Ylmethyl] Ester",,Thymidylate kinase,DTYMK,,unknown
"(4'-{[Allyl(Methyl)Amino]Methyl}-1,1'-Biphenyl-4-Yl)(4-Bromophenyl)Methanone",,Squalene--hopene cyclase,shc,,unknown
N-{3-[4-(3-aminopropyl)piperazin-1-yl]propyl}-3-(alpha-D-galactopyranosyloxy)-5-nitrobenzamide,,Cholera enterotoxin subunit B,ctxB,,unknown
"2,3-Dihydroxy-5-Oxo-Hexanedioate",,Glucarate dehydratase,gudD,,unknown
"3,5-Difluoroaniline",,Lysozyme,E,,unknown
"(S)-2-Amino-3-(1,3,5,7-Pentahydro-2,4-Dioxo-Cyclopenta[E]Pyrimidin-1-Yl) Proionic Acid",,Glutamate receptor 2,GRIA2,,unknown
1-Amino-1-Carbonyl Pentane,,Candidapepsin-2,SAP2,,unknown
P-Aminophenyl-Alpha-D-Galactopyranoside,,Heat-labile enterotoxin B chain,eltB,,unknown
4-Fluorobenzylamine,,Trypsin-1,PRSS1,,unknown
S-4-Nitrobutyryl-Coa,,"Glutaryl-CoA dehydrogenase, mitochondrial",GCDH,,unknown
Beta-L-Arabinose,,L-arabinose-binding periplasmic protein,araF,,unknown
Flavin mononucleotide,,Trimethylamine dehydrogenase,tmd,,unknown
Flavin mononucleotide,,Rubredoxin-oxygen oxidoreductase,roo,,unknown
Flavin mononucleotide,,Riboflavin biosynthesis protein RibF,,,unknown
Flavin mononucleotide,,Morphinone reductase,morB,,unknown
Flavin mononucleotide,,NADPH-flavin oxidoreductase,frp,,unknown
Flavin mononucleotide,,Ribosomal protein S6 kinase alpha-4,RPS6KA4,,unknown
Flavin mononucleotide,,Phenazine biosynthesis protein PhzG,phzG,,unknown
Flavin mononucleotide,,Hydroxyacid oxidase 2,HAO2,,unknown
Flavin mononucleotide,,NAD(P)H dehydrogenase (quinone),,,unknown
Flavin mononucleotide,,Flavodoxin-1,fldA,,unknown
Flavin mononucleotide,,Isopentenyl-diphosphate delta-isomerase,fni,,unknown
Flavin mononucleotide,,NADH dehydrogenase,nox,,unknown
Flavin mononucleotide,,FMN-binding protein,,,unknown
Flavin mononucleotide,,Nitroreductase family protein,,,unknown
Flavin mononucleotide,,NADPH--cytochrome P450 reductase,POR,,unknown
Flavin mononucleotide,,Phosphopantothenoylcysteine decarboxylase,PPCDC,,unknown
Flavin mononucleotide,,PhzG,phzG,,unknown
Flavin mononucleotide,,Ferredoxin-dependent glutamate synthase 2,gltS,,unknown
Flavin mononucleotide,,Pyridoxine/pyridoxamine 5'-phosphate oxidase,pdxH,,unknown
Flavin mononucleotide,,Flavodoxin,,,unknown
Flavin mononucleotide,,Oxygen-insensitive NAD(P)H nitroreductase,nfsB,,unknown
Flavin mononucleotide,,Chorismate synthase,aroC,,unknown
Flavin mononucleotide,,"2,4-dienoyl-CoA reductase [NADPH]",fadH,,unknown
Flavin mononucleotide,,Dihydroorotate dehydrogenase A (fumarate),pyrDA,,unknown
Flavin mononucleotide,,Flavin reductase (NADPH),BLVRB,,unknown
Flavin mononucleotide,,Hydroxyacid oxidase 1,HAO1,,unknown
Flavin mononucleotide,,Pyridoxine-5'-phosphate oxidase,PNPO,,unknown
Flavin mononucleotide,,Major NAD(P)H-flavin oxidoreductase,,,unknown
Flavin mononucleotide,,Riboflavin kinase,RFK,,unknown
Flavin mononucleotide,,Oxygen-insensitive NADPH nitroreductase,nfsA,,unknown
Flavin mononucleotide,,"Nitric oxide synthase, brain",NOS1,,unknown
Flavin mononucleotide,,Dihydroorotate dehydrogenase (quinone),pyrD,,unknown
Flavin mononucleotide,,Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,,unknown
Flavin mononucleotide,,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
Flavin mononucleotide,,Pentaerythritol tetranitrate reductase,onr,,unknown
Flavin mononucleotide,,FMN-dependent NADH-azoreductase,azoR,,unknown
Flavin mononucleotide,,Epidermin decarboxylase,epiD,,unknown
Flavin mononucleotide,,FMN-dependent NADH-azoreductase,azoR,,unknown
Flavin mononucleotide,,Chorismate synthase,aroC,,unknown
Flavin mononucleotide,,Flavodoxin,isiB,,unknown
Flavin mononucleotide,,Flavodoxin,,,unknown
Flavin mononucleotide,,Flavodoxin,isiB,,unknown
Flavin mononucleotide,,Putative uncharacterized protein,,,unknown
Flavin mononucleotide,,Putative monooxygenase MoxC,moxC,,unknown
Flavin mononucleotide,,tRNA-dihydrouridine synthase,,,unknown
Flavin mononucleotide,,Protein NrdI,nrdI,,unknown
Flavin mononucleotide,,Probable aromatic acid decarboxylase,ecdB,,unknown
Flavin mononucleotide,,(S)-mandelate dehydrogenase,mdlB,,unknown
Flavin mononucleotide,,FMN-dependent NADPH-azoreductase,azr,,unknown
Flavin mononucleotide,,Flavodoxin,fldA,,unknown
Flavin mononucleotide,,Serine/threonine-protein kinase Sgk1,SGK1,,unknown
Flavin mononucleotide,,Oxygen-insensitive NAD(P)H nitroreductase,nfsB,,unknown
Flavin mononucleotide,,Nitric oxide reductase,fprA,,unknown
Flavin mononucleotide,,Isopentenyl-diphosphate delta-isomerase,fni,,unknown
2-(Phosphonooxy)Butanoic Acid,,2-dehydro-3-deoxyphosphooctonate aldolase,kdsA,,unknown
"2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Benzothiazole",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
RWJ-51084,,Trypsin-1,PRSS1,,unknown
D-Lysine,,"Alanine racemase, catabolic",dadX,,unknown
D-Lysine,,Diaminopimelate decarboxylase,lysA,,unknown
(2s)-Pyrrolidin-2-Ylmethylamine,,Dipeptidyl peptidase 4,DPP4,,unknown
4-Phenyl-1h-Imidazole,,Putative cytochrome P450,cyp158a2,,unknown
Phenol,,Thermolysin,nprS,,unknown
Phenol,,Lysozyme,E,,unknown
Phenol,,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
Phenol,,Serum albumin,ALB,,unknown
(6R)-Folinic acid,,"N,N-dimethylglycine oxidase",dmg,,unknown
(6R)-Folinic acid,,Serine hydroxymethyltransferase,glyA,,unknown
(6R)-Folinic acid,,Aminomethyltransferase,gcvT,,unknown
(6R)-Folinic acid,,Bifunctional polymyxin resistance protein ArnA,arnA,,unknown
(6R)-Folinic acid,,Formimidoyltransferase-cyclodeaminase,FTCD,,unknown
"5-[1-(Acetylamino)-3-Methylbutyl]-2,5-Anhydro-3,4-Dideoxy-4-(Methoxycarbonyl)Pentonic Acid",,Neuraminidase,NA,,unknown
2'-Deoxycytidine 5'-triphosphate,,"DNA polymerase I, thermostable",polA,,unknown
2'-Deoxycytidine 5'-triphosphate,,Ribonucleoside-diphosphate reductase 2 subunit alpha,nrdE,,unknown
2'-Deoxycytidine 5'-triphosphate,,Anaerobic ribonucleoside-triphosphate reductase,NRDD,,unknown
2'-Deoxycytidine 5'-triphosphate,,Deoxycytidine triphosphate deaminase,dcd,,unknown
"2',6'-Dichloro-Biphenyl-2,6-Diol",,"Biphenyl-2,3-diol 1,2-dioxygenase",bphC,,unknown
"1,6-Diaminohexane",,"Agmatinase, putative",,,unknown
"Al-6619, [2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide,2-(3-Hydroxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide]",,Carbonic anhydrase 2,CA2,,unknown
Dodecyl-Coa,,Fatty acid metabolism regulator protein,fadR,,unknown
Dodecyl-Coa,,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,,unknown
1-Allyl-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine,,"Phosphoenolpyruvate carboxykinase, cytosolic [GTP]",PCK1,,unknown
RU82197,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
"2,6-Difluorobenzenesulfonamide",,Carbonic anhydrase 2,CA2,,unknown
3'-Oxo-Adenosine,,Adenosylhomocysteinase,AHCY,,unknown
2'-5'dideoxyuridine,,Thymidylate synthase,thyA,,unknown
"4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid",,Growth factor receptor-bound protein 2,GRB2,,unknown
alpha-maltotriose,,Maltose binding protein,malE,,unknown
alpha-maltotriose,,Alpha-amylase 2B,AMY2B,,unknown
D-Treitol,,Formate acetyltransferase 1,pflB,,unknown
Dodecyl-Alpha-D-Maltoside,,Retinoic acid receptor gamma,RARG,,unknown
P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate,,Thymidylate kinase,DTYMK,,unknown
P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate,,Thymidylate kinase,tmk,,unknown
P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate,,Thymidine kinase,TK,,unknown
P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate,,Thymidine kinase,TK,,unknown
P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate,,Thymidylate kinase,tmk,,unknown
beta-L-fucose,,"Alpha-L-fucosidase, putative",,,unknown
beta-L-fucose,,Acetylcholinesterase,ACHE,,unknown
"2,6-Anhydro-3-Deoxy-D-Erythro-Hex-2-Enonic Acid",,Chondroitinase (Chondroitin lyase),,,unknown
C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
5-Chloro-1h-Indole-2-Carboxylic Acid{[Cyclopentyl-(2-Hydroxy-Ethyl)-Carbamoyl]-Methyl}-Amide,,"Glycogen phosphorylase, liver form",PYGL,,unknown
Thiarsa Dihydroxy Cysteine,,Arsenate reductase,arsC,,unknown
L-naphthyl-1-acetamido boronic acid alanine,,Subtilisin Carlsberg,apr,,unknown
3-Phosphono-D-alanine,,Phosphoserine phosphatase,PSPH,,unknown
"1-Methyl-3-Oxo-1,3-Dihydro-Benzo[C]Isothiazole-5-Sulfonic Acid Amide",,Carbonic anhydrase 2,CA2,,unknown
Lactose Sialic Acid,,Trans-sialidase,,,unknown
Benzylsulfinic Acid,,Serine protease hepsin,HPN,,unknown
Benzylsulfinic Acid,,Extracellular subtilisin-like serine proteinase,,,unknown
Benzylsulfinic Acid,,Carboxylesterase 2,estB,,unknown
Benzylsulfinic Acid,,Sigma factor SigB regulation protein RsbQ,rsbQ,,unknown
Benzylsulfinic Acid,,"Superoxide dismutase [Mn], mitochondrial",SOD2,,unknown
Benzylsulfinic Acid,,Chymase,CMA1,,unknown
Benzylsulfinic Acid,,Subtilisin BPN',apr,,unknown
Phenylphosphate,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
N-Succinyl Phenylglycine,,N-acylamino acid racemase,Aaar,,unknown
Pterin Cytosine Dinucleotide,,Aldehyde oxidoreductase,MOD,,unknown
2-Allyl-6-Methyl-Phenol,,Lysozyme,E,,unknown
7-Deaza-7-Aminomethyl-Guanine,,Queuine tRNA-ribosyltransferase,tgt,,unknown
N5-Iminoethyl-L-Ornithine,,"Nitric oxide synthase, endothelial",NOS3,,unknown
RU78300,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide,,Cyclin-dependent kinase 2,CDK2,,unknown
L-Leucyl-Hydroxylamine,,Thermolysin,nprS,,unknown
N-Cyclohexyltaurine,,Phosphoprotein,P/V,,unknown
N-Cyclohexyltaurine,,Nitrite reductase,nirS,,unknown
N-Cyclohexyltaurine,,Homeobox protein engrailed-2,EN2,,unknown
N-Cyclohexyltaurine,,Ribonuclease PH,rph,,unknown
N-Cyclohexyltaurine,,Cyanovirin-N,,,unknown
N-Cyclohexyltaurine,,Sulfotransferase family cytosolic 2B member 1,SULT2B1,,unknown
Glutathione disulfide,,Glutathione S-transferase Mu 2,GSTM2,,unknown
Glutathione disulfide,,"Glutathione reductase, mitochondrial",GSR,,unknown
"3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
Brivudine,,Thymidine kinase,TK,,unknown
Cephalosporin C,,D-alanyl-D-alanine carboxypeptidase,,,unknown
Cephalosporin C,,Penicillin-binding protein 1b,pbp1b,inhibitor,yes
Cephalosporin C,,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Cephalosporin C,,Penicillin-binding protein 2B,penA,inhibitor,yes
Cephalosporin C,,Penicillin-binding protein 2a,pbp2a,inhibitor,yes
Cephalosporin C,,Penicillin-binding protein 3,pbp3,inhibitor,yes
Fluorotryptophane,,Triosephosphate isomerase,TPI1,,unknown
Fluorotryptophane,,Glutathione S-transferase Mu 1,GSTM1,,unknown
Guanosine 3'-monophosphate,,Ribonuclease,,,unknown
Guanosine 3'-monophosphate,,Bifunctional protein PyrR,pyrR,,unknown
"1,4-Diethylene Dioxide",,Subtilisin Carlsberg,apr,,unknown
"1,4-Diethylene Dioxide",,Tumor necrosis factor ligand superfamily member 13B,TNFSF13B,,unknown
"1,4-Diethylene Dioxide",,Epsin-1,EPN1,,unknown
"1,4-Diethylene Dioxide",,Structural polyprotein,,,unknown
"1,4-Diethylene Dioxide",,Transforming growth factor beta-3,TGFB3,,unknown
Heme C,,Cytochrome c-552,nrfA,,unknown
Heme C,,Cytochrome c2,cycA,,unknown
Heme C,,Cytochrome c-550,psbV,,unknown
Heme C,,Cytochrome c-552,cycM,,unknown
Heme C,,Cytochrome c-551,nirM,,unknown
Heme C,,Cytochrome c3,cyd,,unknown
Heme C,,Split-Soret cytochrome c,,,unknown
Heme C,,Group 1 truncated hemoglobin GlbN,glbN,,unknown
Heme C,,Cytochrome c-553,,,unknown
Heme C,,Cytochrome P450 2C9,CYP2C9,,unknown
Heme C,,Nine-heme cytochrome c,,,unknown
Heme C,,"Cytochrome c3, 13 kDa",,,unknown
Heme C,,Cytochrome c551 peroxidase,ccpA,,unknown
Heme C,,Cytochrome c3,,,unknown
Heme C,,Cytochrome c',cycP,,unknown
Heme C,,Cytochrome c3,cytc3,,unknown
Heme C,,Nitrite reductase,nirS,,unknown
Heme C,,High-molecular-weight cytochrome c,hmcA,,unknown
Heme C,,Cytochrome c'',cycA,,unknown
Heme C,,Quinohemoprotein ethanol dehydrogenase type-1,qheDH,,unknown
Heme C,,Nitrite reductase,nirS,,unknown
Heme C,,Cytochrome c4,cc4,,unknown
Heme C,,Cytochrome c,CYCS,,unknown
(S)-ATPA,,Glutamate receptor 2,GRIA2,,unknown
3-Amino-Alanine,,Envelope glycoprotein gp160,env,,unknown
"4-Amino-2-Deoxy-2,3-Dehydro-N-Neuraminic Acid",,Neuraminidase,NA,,unknown
Maltose,,Cyclomaltodextrin glucanotransferase,,,unknown
Maltose,,Alpha-amylase 2B,AMY2B,,unknown
Maltose,,Alpha-glucosidase,aglA,,unknown
Maltose,,Maltose binding protein,malE,,unknown
Maltose,,Malto-oligosyltrehalose trehalohydrolase,treZ,,unknown
Maltose,,Maltose-binding periplasmic protein,malE,,unknown
Maltose,,Beta-amylase,spoII,,unknown
Maltose,,Maltogenic alpha-amylase,amyM,,unknown
Maltose,,Maltodextrin phosphorylase,malP,,unknown
Tyrosyladenylate,,Tyrosine--tRNA ligase,tyrS,,unknown
"deoxycytidylyl-3',5'-guanosine",,Ribonuclease pancreatic,RNASE1,,unknown
{1-[(3-Hydroxy-Methyl-5-Phosphonooxy-Methyl-Pyridin-4-Ylmethyl)-Amino]-Ethyl}-Phosphonic Acid,,Alanine racemase,alr,,unknown
dioxothiomolybdenum(VI) ion,,Xanthine dehydrogenase/oxidase,XDH,,unknown
2-Pyridinethiol,,Cathepsin B,CTSB,,unknown
S-(N-Hydroxy-N-Iodophenylcarbamoyl)Glutathione,,Lactoylglutathione lyase,GLO1,,unknown
"N-Naphthalen-1-Ylmethyl-2'-[3,5-Dimethoxybenzamido]-2'-Deoxy-Adenosine",,"Glyceraldehyde-3-phosphate dehydrogenase, testis-specific",GAPDHS,,unknown
"5,6-Cyclic-Tetrahydropteridine",,"Nitric oxide synthase, endothelial",NOS3,,unknown
(4-sulfamoyl-phenyl)-thiocarbamic acid O-(2-thiophen-3-yl-ethyl) ester,,Carbonic anhydrase 2,CA2,,unknown
1-Bromopropane-2-Ol,,Haloalkane dehalogenase,linB,,unknown
BIA,,Catechol O-methyltransferase,COMT,,unknown
1-(2-Amidinophenyl)-3-(Phenoxyphenyl)Urea,,Trypsin-1,PRSS1,,unknown
Heptyl-Beta-D-Glucopyranoside,,Peroxisome proliferator-activated receptor delta,PPARD,,unknown
Heptyl-Beta-D-Glucopyranoside,,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,,unknown
3-[(1-Amino-2-Carboxy-Ethyl)-Hydroxy-Phosphinoyl]-2-Methyl-Propionic Acid,,Beta-Ala-Xaa dipeptidase,pepV,,unknown
Coa-S-Acetyl 5-Bromotryptamine,,Serotonin N-acetyltransferase,AANAT,,unknown
4-(Acetylamino)-3-Guanidinobenzoic Acid,,Neuraminidase,NA,,unknown
Malate Like Intermediate,,Fumarate reductase flavoprotein subunit,fccA,,unknown
"Inositol-(1,3,4,5,6)-Pentakisphosphate",,Cytohesin-3,CYTH3,,unknown
Beta-Mercaptoethanol,,Lysozyme,E,,unknown
Beta-Mercaptoethanol,,Lactoylglutathione lyase,GLO1,,unknown
Beta-Mercaptoethanol,,Pyridoxine-5'-phosphate oxidase,PNPO,,unknown
Beta-Mercaptoethanol,,Glucose--fructose oxidoreductase,gfo,,unknown
Beta-Mercaptoethanol,,Alpha-1-antitrypsin,SERPINA1,,unknown
Beta-Mercaptoethanol,,Galectin-1,LGALS1,,unknown
Beta-Mercaptoethanol,,Protein ninB,ninB,,unknown
Beta-Mercaptoethanol,,Polycomb protein SCMH1,SCMH1,,unknown
Beta-Mercaptoethanol,,Pyridoxine/pyridoxamine 5'-phosphate oxidase,pdxH,,unknown
Beta-Mercaptoethanol,,Endonuclease III,,,unknown
"3,5,3',5'-Tetrachloro-Biphenyl-4,4'-Diol",,Estrogen sulfotransferase,SULT1E1,,unknown
Triethyl Phosphate,,Parathion hydrolase,opd,,unknown
Triethyl Phosphate,,Parathion hydrolase,opd,,unknown
Triethyl Phosphate,,Cellular tumor antigen p53,TP53,,unknown
Huperzine B,,Acetylcholinesterase,ACHE,,unknown
8-Bromo-Adenosine-5'-Monophosphate,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,,unknown
8-Bromo-Adenosine-5'-Monophosphate,,Histidine triad nucleotide-binding protein 1,HINT1,,unknown
Cobalt Hexammine Ion,,Outer membrane protein TolC,tolC,,unknown
Cobalt Hexammine Ion,,Chorismate synthase,aroC,,unknown
Sri-9439,,Dihydrofolate reductase,DHFR,,unknown
S-Arsonocysteine,,Arsenate reductase,arsC,,unknown
S-Arsonocysteine,,3-mercaptopyruvate sulfurtransferase,MST,,unknown
S-Arsonocysteine,,Protein ArsC,arsC,,unknown
2-Iminobiotin,,Streptavidin,,,unknown
"2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Oxadiazole",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
5'-O-(N-(L-Threonyl)-Sulfamoyl)Adenosine,,Threonine--tRNA ligase,thrS,,unknown
5'-O-(N-(L-Threonyl)-Sulfamoyl)Adenosine,,Threonine--tRNA ligase,thrS,,unknown
(S)-Mandelic acid,,Mandelate racemase,mdlA,,unknown
7n-Methyl-8-Hydroguanosine-5'-Triphosphate,,Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase,PAPS,,unknown
"M-(N,N,N-Trimethylammonio)-2,2,2-Trifluoro-1,1-Dihydroxyethylbenzene",,Acetylcholinesterase,ACHE,,unknown
N-Acetylproline,,(5R)-carbapenem-3-carboxylate synthase,carC,,unknown
"2-{(9as)-9a-[(1s)-1-Hydroxyethyl]-2,7-Dimethyl-9a,10-Dihydro-5h-Pyrimido[4,5-D][1,3]Thiazolo[3,2-a]Pyrimidin-8-Yl}Ethyl Trihydrogen Diphosphate",,"Acetolactate synthase, catabolic",budB,,unknown
3-Acetylpyridine Adenine Dinucleotide,,4-hydroxy-tetrahydrodipicolinate reductase,dapB,,unknown
N-Carbamyl-D-Methionine,,N-carbamoyl-D-amino acid hydrolase,,,unknown
"4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline",,Cyclin-dependent kinase 2,CDK2,,unknown
Imidazole,,Monomeric sarcosine oxidase,soxA,,unknown
Imidazole,,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
Imidazole,,Myoglobin,MB,,unknown
Imidazole,,"Nitric oxide synthase, inducible",NOS2,,unknown
Imidazole,,"Adenylate kinase 2, mitochondrial",AK2,,unknown
Imidazole,,Serine/threonine-protein kinase pim-1,PIM1,,unknown
Imidazole,,Isopentenyl-diphosphate Delta-isomerase,idi,,unknown
Imidazole,,"Alpha,alpha-trehalose-phosphate synthase [UDP-forming]",otsA,,unknown
Imidazole,,A/G-specific adenine glycosylase,mutY,,unknown
Imidazole,,YopE regulator,yerA,,unknown
Imidazole,,Unconventional myosin-Ie,MYO1E,,unknown
Imidazole,,Meiotic recombination protein DMC1/LIM15 homolog,DMC1,,unknown
Imidazole,,Guanine deaminase,guaD,,unknown
Imidazole,,"Endo-1,4-beta-xylanase A",xlnA,,unknown
Imidazole,,Bacterial hemoglobin,vhb,,unknown
Imidazole,,Molybdenum cofactor biosynthesis protein B,moaB,,unknown
Imidazole,,Uracil-DNA glycosylase inhibitor,UGI,,unknown
Imidazole,,Recombination protein RecR,recR,,unknown
Imidazole,,Leukotriene A-4 hydrolase,LTA4H,,unknown
Imidazole,,Acyl-CoA thioesterase I,tesA,,unknown
Imidazole,,Gephyrin,GPHN,,unknown
Imidazole,,Acyl carrier protein,acpP,,unknown
Imidazole,,Sensor protein FixL,fixL,,unknown
Imidazole,,Cytochrome c,CYCS,,unknown
Imidazole,,Circadian clock protein KaiB,kaiB,,unknown
Imidazole,,Histidinol dehydrogenase,hisD,,unknown
PF-00356231,,Macrophage metalloelastase,MMP12,,unknown
"5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione",,Stromelysin-1,MMP3,,unknown
9-Aminophenanthrene,,6-deoxyerythronolide B hydroxylase,eryF,,unknown
FR239087,,Adenosine deaminase,ADA,,unknown
Modified Ribosylated Glutamyl Ester,,Nucleoside deoxyribosyltransferase-I,ptd,,unknown
"3-Mercapto-1-(1,3,4,9-Tetrahydro-B-Carbolin-2-Yl)-Propan-1-One",,Interleukin-2,IL2,,unknown
ZK-806711,,Trypsin-1,PRSS1,,unknown
"3,5-Diiodotyrosine",,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
"3,5-Diiodotyrosine",,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
"3,5-Diiodotyrosine",,Alpha-amylase G-6,,,unknown
"3,5-Diiodotyrosine",,Trypsin-1,PRSS1,,unknown
"3,5-Diiodotyrosine",,Nickel-binding periplasmic protein,nikA,,unknown
"3,5-Diiodotyrosine",,Iodotyrosine dehalogenase 1,IYD,,unknown
'5'-O-(N-(L-Alanyl)-Sulfamoyl)Adenosine,,Bifunctional glutamate/proline--tRNA ligase,EPRS,,unknown
2-Carboxyethylphosphonic Acid,,Triosephosphate isomerase,TPI1,,unknown
L-Tyrosinamide,,Pro-neuropeptide Y,NPY,,unknown
L-Tyrosinamide,,Valacyclovir hydrolase,BPHL,,unknown
Hexadecanal,,Rhodopsin,RHO,,unknown
Hexadecanal,,Acyl-CoA-binding protein,DBI,,unknown
S-oxy-L-cysteine,,Aspartate 1-decarboxylase,panD,,unknown
S-oxy-L-cysteine,,Prolyl endopeptidase,PREP,,unknown
S-oxy-L-cysteine,,Exopolyphosphatase,ppx,,unknown
S-oxy-L-cysteine,,Conserved protein,,,unknown
S-oxy-L-cysteine,,Probable thiol peroxidase,tpx,,unknown
S-oxy-L-cysteine,,Superoxide dismutase [Cu-Zn],SOD1,,unknown
S-oxy-L-cysteine,,NADH peroxidase,npr,,unknown
5-Chloro-1h-Indole-2-Carboxylic Acid [1-(4-Fluorobenzyl)-2-(4-Hydroxypiperidin-1yl)-2-Oxoethyl]Amide,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
Fica,,Caspase-7,CASP7,,unknown
4-Methylimidazole,,Carbonic anhydrase 2,CA2,,unknown
4-Methylimidazole,,Myoglobin,MB,,unknown
4-Methylimidazole,,"Carbonic anhydrase 5A, mitochondrial",CA5A,,unknown
"3-[(2,4-Dichlorobenzoyl)(Isopropyl)Amino]-5-Phenylthiophene-2-Carboxylic Acid",,Genome polyprotein,,,unknown
alpha-D-Xylopyranose,,Chondroitinase-B,cslB,,unknown
alpha-D-Xylopyranose,,Chondroitinase-AC,cslA,,unknown
alpha-D-Xylopyranose,,Exoglucanase/xylanase,cex,,unknown
alpha-D-Xylopyranose,,Aldose 1-epimerase,galM,,unknown
alpha-D-Xylopyranose,,"Endo-beta-1,4-xylanase",xyn10C,,unknown
alpha-D-Xylopyranose,,Reducing end xylose-releasing exo-oligoxylanase,,,unknown
alpha-D-Xylopyranose,,"Endo-1,4-beta-xylanase",,,unknown
alpha-D-Xylopyranose,,"Endo-1,4-beta-xylanase",,,unknown
alpha-D-Xylopyranose,,"Endo-1,4-beta-xylanase A",xynA,,unknown
alpha-D-Xylopyranose,,"Endo-1,4-beta-xylanase A",xlnA,,unknown
alpha-D-Xylopyranose,,"Endo-1,4-beta-xylanase",xlnA,,unknown
alpha-D-Xylopyranose,,Hydrolase,,,unknown
alpha-D-Xylopyranose,,"Endo-1,4-beta-xylanase",xyl,,unknown
alpha-D-Xylopyranose,,Lactase-phlorizin hydrolase,LCT,,unknown
alpha-D-Xylopyranose,,Endoxylanase,xynC,,unknown
alpha-D-Xylopyranose,,Beta-amylase,spoII,,unknown
N-Propyl-Tartramic Acid,,Prostatic acid phosphatase,ACPP,,unknown
"(3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
"(3s,6s,9r,10r,11s,12s,13e,15e,18s,21s)-18-{(1e,3e,7s,8s)-9-[(2s,3r,4s,5s,6r,9s,11s)-9-Ethyl-4-Hydroxy-3,5,11-Trimethyl-8-Oxo-1-Oxa-7-Azaspiro[5.5]Undec-2-Yl]-8-Hydroxy-1,7-Dimethylnona-1,3-Dienyl}-10,12-Dihydroxy-3-(3-Hydroxybenzyl)-6-Isopropyl-11-Methyl-",,Peptidyl-prolyl cis-trans isomerase A,PPIA,,unknown
Enalkiren,,Renin,REN,inhibitor,unknown
"(E)-(2r,3r,4s,5r)-3,4,5-Trihydroxy-2-Methoxy-8,8-Dimethyl-Non-6-Enoic Acid ((3s,6r)-6-Hydroxy-2-Oxo-Azepan-3-Yl)-Amide",,Methionine aminopeptidase 2,METAP2,,unknown
Uridine-Diphosphate-N-Acetylglucosamine,,Bifunctional protein GlmU,glmU,,unknown
Uridine-Diphosphate-N-Acetylglucosamine,,UDP-N-acetylhexosamine pyrophosphorylase,UAP1,,unknown
Uridine-Diphosphate-N-Acetylglucosamine,,UDP-N-acetylglucosamine 1-carboxyvinyltransferase,murA,,unknown
Uridine-Diphosphate-N-Acetylglucosamine,,UDP-glucose 4-epimerase,GALE,,unknown
Uridine-Diphosphate-N-Acetylglucosamine,,Bifunctional protein GlmU,glmU,,unknown
Uridine-Diphosphate-N-Acetylglucosamine,,UDP-glucose 4-epimerase,galE,,unknown
Uridine-Diphosphate-N-Acetylglucosamine,,Exostosin-like 2,EXTL2,,unknown
Uridine-Diphosphate-N-Acetylglucosamine,,"Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase",MGAT1,,unknown
Ethyl Isocyanide,,Myoglobin,MB,,unknown
3-(P-Tolyl)Propionic Acid,,Aromatic-amino-acid aminotransferase,tyrB,,unknown
"1D-myo-inositol 1,4,5-trisphosphate",,Cytohesin-2,CYTH2,,unknown
"1D-myo-inositol 1,4,5-trisphosphate",,Epsin-1,EPN1,,unknown
"1D-myo-inositol 1,4,5-trisphosphate",,"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1",PLCD1,,unknown
"1D-myo-inositol 1,4,5-trisphosphate",,Radixin,RDX,,unknown
"1D-myo-inositol 1,4,5-trisphosphate",,"Spectrin beta chain, non-erythrocytic 1",SPTBN1,,unknown
"1D-myo-inositol 1,4,5-trisphosphate",,"Inositol 1,4,5-trisphosphate receptor type 1",ITPR1,,unknown
"1D-myo-inositol 1,4,5-trisphosphate",,Inositol-trisphosphate 3-kinase A,ITPKA,,unknown
Cytidine-5'-Monophosphate,,Bifunctional enzyme IspD/IspF,ispDF,,unknown
Cytidine-5'-Monophosphate,,UMP-CMP kinase,CMPK1,,unknown
Cytidine-5'-Monophosphate,,"2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase",ispF,,unknown
Cytidine-5'-Monophosphate,,Cytidylate kinase,cmk,,unknown
Cytidine-5'-Monophosphate,,Uridine-cytidine kinase 2,UCK2,,unknown
Cytidine-5'-Monophosphate,,3-deoxy-manno-octulosonate cytidylyltransferase,kpsU,,unknown
Cytidine-5'-Monophosphate,,"2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase",ispF,,unknown
Cytidine-5'-Monophosphate,,"Alpha-2,3-/2,8-sialyltransferase",cst-II,,unknown
Cytidine-5'-Monophosphate,,Coenzyme A biosynthesis bifunctional protein CoaBC,coaBC,,unknown
N2-[(Benzyloxy)carbonyl]-N-[(3R)-1-{N-[(benzyloxy)carbonyl]-L-leucyl}-4-oxo-3-pyrrolidinyl]-L-leucinamide,,Cathepsin K,CTSK,,unknown
gamma-Glutamylcysteine,,Glutathione synthetase,GSS,,unknown
4-hydroxycoumarin,,Major NAD(P)H-flavin oxidoreductase,,,unknown
"2-Hydroxymethyl-Pyrrolidine-3,4-Diol",,Purine nucleoside phosphorylase,punA,,unknown
6-hydroxy-L-norleucine,,L-asparaginase,ansB,,unknown
Deoxyuridine-5'-Diphosphate,,"Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial",DUT,,unknown
Deoxyuridine-5'-Diphosphate,,Deoxyuridine 5'-triphosphate nucleotidohydrolase,dut,,unknown
Deoxyuridine-5'-Diphosphate,,Deoxyuridine 5'-triphosphate nucleotidohydrolase,dut,,unknown
Deoxyuridine-5'-Diphosphate,,Deoxyuridine triphosphatase,Tcdut,,unknown
Deoxyuridine-5'-Diphosphate,,Pol polyprotein,pol,,unknown
5-Thio-a/B-D-Mannopyranosylamine,,Alpha-mannosidase 2,MAN2A1,,unknown
3-Thiaoctanoyl-Coenzyme A,,"Medium-chain specific acyl-CoA dehydrogenase, mitochondrial",ACADM,,unknown
Thiamine(1+) monophosphate,,Thiamine-phosphate synthase,thiE,,unknown
1-(4-Tert-Butylcarbamoyl-Piperazine-1-Carbonyl)-3-(3-Guanidino-Propyl)-4-Oxo-Azetidine-2-Carboxylic Acid,,Trypsin-1,PRSS1,,unknown
Uracil,,Ribosomal small subunit pseudouridine synthase A,rsuA,,unknown
Uracil,,Uracil-DNA glycosylase,,,unknown
Uracil,,Uracil-DNA glycosylase,ung,,unknown
Uracil,,Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,,unknown
Uracil,,Uridine-cytidine kinase-like 1,UCKL1,,unknown
Uracil,,Uracil-DNA glycosylase,udg,,unknown
Uracil,,Pyrimidine-nucleoside phosphorylase,pdp,,unknown
"2,4-Deoxy-4-Guanidino-5-N-Acetyl-Neuraminic Acid",,Neuraminidase,NA,,unknown
"2-Phenethyl-2,3-Dihydro-Phthalazine-1,4-Dione",,Heat-labile enterotoxin B chain,eltB,,unknown
S-Adenosyl-L-Homoselenocysteine,,tRNA (cmo5U34)-methyltransferase,cmoA,,unknown
Ubenimex,,Leukotriene A-4 hydrolase,LTA4H,,unknown
Ubenimex,,Bacterial leucyl aminopeptidase,,,unknown
"2s,4r-4-Methylglutamate",,"Glutamate receptor ionotropic, kainate 2",GRIK2,,unknown
SU9516,,Cyclin-dependent kinase 5,CDK5,inhibitor,unknown
SU9516,,Cyclin-dependent kinase 1,CDK1,binder,unknown
SU9516,,Cyclin-dependent kinase 2,CDK2,inhibitor,unknown
Cardiolipin,,ADP/ATP translocase 1,SLC25A4,,unknown
(2s)-Hydroxy(4-Hydroxyphenyl)Ethanenitrile,,Lactase-like protein,LCTL,,unknown
{3-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Amino]-2-Methyl-Propyl}-Phosphonic Acid,,Threonine-phosphate decarboxylase,cobD,,unknown
3[N-Morpholino]Propane Sulfonic Acid,,Alpha-xylosidase,yicI,,unknown
3[N-Morpholino]Propane Sulfonic Acid,,Granulysin,GNLY,,unknown
3[N-Morpholino]Propane Sulfonic Acid,,Phosphoribosylglycinamide formyltransferase 2,purT,,unknown
Uridine-5'-Diphosphate,,Exostosin-like 2,EXTL2,,unknown
Uridine-5'-Diphosphate,,Glycosyltransferase 6 domain-containing protein 1,GLT6D1,,unknown
Uridine-5'-Diphosphate,,Spore coat polysaccharide biosynthesis protein SpsA,spsA,,unknown
Uridine-5'-Diphosphate,,UMP-CMP kinase,CMPK1,,unknown
Uridine-5'-Diphosphate,,DNA beta-glucosyltransferase,bgt,,unknown
Uridine-5'-Diphosphate,,UDP-glucose 4-epimerase,galE,,unknown
Uridine-5'-Diphosphate,,Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3,B3GAT3,,unknown
Uridine-5'-Diphosphate,,UDP-N-acetylglucosamine 2-epimerase,wecB,,unknown
Uridine-5'-Diphosphate,,Histo-blood group ABO system transferase,ABO,,unknown
Uridine-5'-Diphosphate,,Galactose-1-phosphate uridylyltransferase,galT,,unknown
Uridine-5'-Diphosphate,,Pol polyprotein,pol,,unknown
Uridine-5'-Diphosphate,,Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1,B3GAT1,,unknown
Uridine-5'-Diphosphate,,"Alpha,alpha-trehalose-phosphate synthase [UDP-forming]",otsA,,unknown
Uridine-5'-Diphosphate,,UDP-galactose 4-epimerase,galE,,unknown
Uridine-5'-Diphosphate,,Glycogenin-1,GYG1,,unknown
Gallichrome,,Iron(3+)-hydroxamate-binding protein FhuD,fhuD,antagonist,unknown
"2-{1-[2-(2-Amino-Thiazol-4-Yl)-2-Methoxyimino-Acetylamino]-2-Oxo-Ethyl}-5,5-Dimethyl-Thiazolidine-4-Carboxylic Acid",,Beta-lactamase,ampC,,unknown
"4,6-dideoxy-4-amino-alpha-D-glucose",,Alpha-amylase 1,AMY1A,,unknown
"4,6-dideoxy-4-amino-alpha-D-glucose",,Pancreatic alpha-amylase,AMY2A,,unknown
N-Hexadecanoylglycine,,Bifunctional P-450/NADPH-P450 reductase,cyp102A1,,unknown
2-Benzyl-3-Iodopropanoic Acid,,Carboxypeptidase A1,CPA1,,unknown
2-[5-Hydroxy-3-Methyl-1-(2-Methyl-4-Sulfo-Phenyl)-1h-Pyrazol-4-Ylazo]-4-Sulfo-Benzoic Acid,,Bifunctional purine biosynthesis protein PURH,ATIC,,unknown
Bis(5-Amidino-Benzimidazolyl)Methanone Zinc,,Trypsin-1,PRSS1,,unknown
"(3e)-6'-Bromo-2,3'-Biindole-2',3(1h,1'h)-Dione 3-Oxime",,Glycogen synthase kinase-3 beta,GSK3B,,unknown
"(3S)-3-(dioxidosulfanyl)-N-[(1E)-3-oxoprop-1-en-1-yl]-4-(1H-1,2,3-triazol-1-yl)-D-valine",,Beta-lactamase SHV-1,bla,,unknown
3-Benzylaminocarbonylphenyl-Alpha-D-Galactoside,,Heat-labile enterotoxin B chain,eltB,,unknown
Uridylyl-2'-5'-Phospho-Adenosine,,Ribonuclease pancreatic,RNASE1,,unknown
2'-Deoxyuridine 3'-Monophosphate,,Ribonuclease 4,RNASE4,,unknown
2'-Deoxyuridine 3'-Monophosphate,,Ribonuclease pancreatic,RNASE1,,unknown
N-(4-(2-((3-Chlorophenylmethyl)Amino)Ethyl)Phenyl)-2-Thiophecarboxamidine,,"Nitric oxide synthase, inducible",NOS2,,unknown
N-(4-(2-((3-Chlorophenylmethyl)Amino)Ethyl)Phenyl)-2-Thiophecarboxamidine,,"Nitric oxide synthase, brain",NOS1,,unknown
Cephalothin Group,,Beta-lactamase Toho-1,bla,,unknown
Cephalothin Group,,D-alanyl-D-alanine carboxypeptidase,,,unknown
"1-alpha, 25-dihydroxyl-20-epi-22-oxa-24, 26 ,27-trihomovitamin D3",,Vitamin D3 receptor,VDR,,unknown
3-Trimethylsilylsuccinic Acid,,Fumarate hydratase class II,fumC,,unknown
(R)—N[2-[1-(aminoiminomethyl)-3-piperidinyl]-1-oxoethyl]-4-(phenylethynyl)-l-phenylalanine methylester,,Interleukin-2,IL2,,unknown
"3-methyl-benzene-1,2-diol",,"Biphenyl-2,3-diol 1,2-dioxygenase",bphC,,unknown
(1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid,,Interleukin-2,IL2,,unknown
N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide,,Cathepsin K,CTSK,,unknown
Sparfosic acid,,Aspartate carbamoyltransferase catalytic chain,pyrB,,unknown
Sparfosic acid,,CAD protein,CAD,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Alcohol dehydrogenase 1B,ADH1B,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,NADPH--cytochrome P450 reductase,POR,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Shikimate dehydrogenase,aroE,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,NADP-dependent isopropanol dehydrogenase,adh,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,GDP-L-fucose synthase,fcl,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Aspartate-semialdehyde dehydrogenase,asd,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,"2,4-dienoyl-CoA reductase [NADPH]",fadH,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,NADP-dependent malic enzyme,ME1,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,NAD(P) transhydrogenase subunit beta,pntB,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,3-oxoacyl-[acyl-carrier-protein] reductase FabG,fabG,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Isocitrate dehydrogenase [NADP],icd,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Aldose reductase,AKR1B1,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Glucose-6-phosphate 1-dehydrogenase,zwf,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Aldo-keto reductase family 1 member C2,AKR1C2,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Estradiol 17-beta-dehydrogenase 1,HSD17B1,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,"NAD(P) transhydrogenase, mitochondrial",NNT,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Sepiapterin reductase,SPR,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Pteridine reductase 1,PTR1,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,L-xylulose reductase,DCXR,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Isocitrate dehydrogenase [NADP] cytoplasmic,IDH1,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Dihydrofolate reductase,folA,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Aldo-keto reductase family 1 member C1,AKR1C1,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,"Nitric oxide synthase, brain",NOS1,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Glucose-6-phosphate 1-dehydrogenase,G6PD,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Dihydrofolate reductase,DHFR,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,ADP-L-glycero-D-manno-heptose-6-epimerase,hldD,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,"C-1-tetrahydrofolate synthase, cytoplasmic",MTHFD1,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Aldo-keto reductase family 1 member C3,AKR1C3,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Flavin reductase (NADPH),BLVRB,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Isocitrate dehydrogenase [NADP],icd,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Dihydrofolate reductase,,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Quinone oxidoreductase,CRYZ,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Dehydrogenase/reductase SDR family member 11,DHRS11,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,"Malate dehydrogenase, cytoplasmic",MDH1,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Oxidoreductase YdhF,ydhF,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Putative pteridine reductase 2,ptr2,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Estradiol 17-beta-dehydrogenase 8,HSD17B8,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Alcohol dehydrogenase [NADP(+)],AKR1A1,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Putative ketoacyl reductase,actIII,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,"2,4-dienoyl-CoA reductase, mitochondrial",DECR1,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,"Oxidoreductase, short chain dehydrogenase/reductase family",,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Prostaglandin F synthase,,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,General stress protein 69,yhdN,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Ferredoxin--NADP reductase,petH,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Bifunctional protein MdtA,mtdA,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Alcohol dehydrogenase,,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,"NADPH:adrenodoxin oxidoreductase, mitochondrial",FDXR,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Ferredoxin--NADP reductase,petH,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,"2,5-diketo-D-gluconic acid reductase A",dkgA,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Protein IolS,iolS,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,NADP-dependent glyceraldehyde-3-phosphate dehydrogenase,gapN,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Prostaglandin reductase 1,PTGR1,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Sulfite reductase [NADPH] flavoprotein alpha-component,cysJ,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Aldo-keto reductase family 1 member B10,AKR1B10,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Alcohol dehydrogenase (NADP(+)),,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,NADP-dependent fatty aldehyde dehydrogenase,aldH,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Putative dehydrogenase/reductase SDR family member 4-like 2,DHRS4L1,,unknown
2'-Monophosphoadenosine 5'-Diphosphoribose,,Aldehyde reductase,,,unknown
Thymine,,Deoxyribodipyrimidine photo-lyase,phr,,unknown
Thymine,,Thymidine phosphorylase,deoA,,unknown
Formycin-5'-Monophosphate,,AMP nucleosidase,amn,,unknown
BMS184394,,Retinoic acid receptor gamma,RARG,,unknown
Naringenin,,HTH-type transcriptional regulator TtgR,ttgR,,unknown
Naringenin,,Estrogen receptor alpha,ESR1,,unknown
Naringenin,,Aldo-keto reductase family 1 member C1,AKR1C1,antagonist,unknown
Naringenin,,Cytochrome P450 1B1,CYP1B1,,unknown
Naringenin,,KAT8 regulatory NSL complex subunit 3,KANSL3,,unknown
Naringenin,,Sex hormone-binding globulin,SHBG,,unknown
Naringenin,,Cytochrome P450 19A1,CYP19A1,inhibitor,unknown
Naringenin,,Estrogen receptor beta,ESR2,partial agonist,unknown
"1,2,3,4-Tetrahydro-Isoquinoline-7-Sulfonic Acid Amide",,Phenylethanolamine N-methyltransferase,PNMT,,unknown
Heme D,,Nitrite reductase,nirS,,unknown
Heme D,,Nitrite reductase,nirS,,unknown
Trypanothione,,Trypanothione reductase,TPR,,unknown
6-Phenyl-4(R)-(7-Phenyl-Heptanoylamino)-Hexanoic Acid,,"Phospholipase A2, membrane associated",PLA2G2A,,unknown
Cyclohexyl-Hexyl-Beta-D-Maltoside,,Beta-lactamase SHV-2,bla,,unknown
Cyclohexyl-Hexyl-Beta-D-Maltoside,,Beta-lactamase SHV-1,bla,,unknown
N5-Methylglutamine,,Release factor glutamine methyltransferase,prmC,,unknown
"1-[4-Carboxy-2-(3-Pentylamino)Phenyl]-5,5'-Di(Hydroxymethyl)Pyrrolidin-2-One",,Neuraminidase,NA,,unknown
Trans-6-(2-Phenylcyclopropyl)-Naphthalene-2-Carboxamidine,,Urokinase-type plasminogen activator,PLAU,,unknown
1-Phenylsulfonamide-3-Trifluoromethyl-5-Parabromophenylpyrazole,,Prostaglandin G/H synthase 2,PTGS2,,unknown
2'-O-Acetyl Adenosine-5-Diphosphoribose,,"NAD-dependent protein deacylase sirtuin-5, mitochondrial",SIRT5,,unknown
"8,9,10-Trihydroxy-7-Hydroxymethyl-3-Methyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
Brequinar Analog,,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
"5,10-Dimethylene Tetrahydromethanopterin",,Formaldehyde-activating enzyme,fae,,unknown
8-Demethyl-8-Dimethylamino-Flavin-Adenine-Dinucleotide,,p-hydroxybenzoate hydroxylase,pobA,,unknown
4-Benzoylamino-4-{1-{1-Carbamoyl-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethylcarbamoyl}-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethylcarbamoyl}-Butyric Acid,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
L-Alpha-Glycerophosphorylethanolamine,,Annexin A5,ANXA5,,unknown
Alpha-D-Fucose,,Lactotransferrin,LTF,,unknown
Alpha-D-Fucose,,L-arabinose-binding periplasmic protein,araF,,unknown
Phosphomethylphosphonic Acid Guanosyl Ester,,Soluble calcium-activated nucleotidase 1,CANT1,,unknown
3-Aminosuccinimide,,Lysozyme C,LYZ,,unknown
3-Aminosuccinimide,,Chemotaxis protein CheY,cheY,,unknown
Uridine-5'-diphosphate-2-deoxy-2-fluoro-alpha-D-galactose,,"Alpha,alpha-trehalose-phosphate synthase [UDP-forming]",otsA,,unknown
2-Keto-3-Deoxygluconate,,2-keto-3-deoxy-gluconate kinase,,,unknown
"3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole",,Cyclin-dependent kinase 2,CDK2,,unknown
2'-Deoxyguanosine-5'-Diphosphate,,Nucleoside diphosphate kinase A,NME1,,unknown
"lambda-bis(2,2'-bipyridine)imidazole osmium (II)",,Azurin,azu,,unknown
7-Methylguanosine,,Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase,PAPS,,unknown
"4,6-Dideoxy-4-{[4,5,6-Trihydroxy-3-(Hydroxymethyl)Cyclohex-2-En-1-Yl]Amino}-Alpha-D-Lyxo-Hexopyranosyl-(1->4)-Alpha-D-Threo-Hexopyranosyl-(1->6)-Alpha-L-Threo-Hexopyranose",,Pancreatic alpha-amylase,AMY2A,,unknown
Alvocidib,,Cyclin-dependent kinase 2,CDK2,inhibitor,unknown
Alvocidib,,Cyclin-dependent kinase 5,CDK5,,unknown
Alvocidib,,Cyclin-dependent kinase 9,CDK9,,unknown
Alvocidib,,Cyclin-dependent kinase 1,CDK1,,unknown
Alvocidib,,Cyclin-dependent kinase 6,CDK6,,unknown
Alvocidib,,Epidermal growth factor receptor,EGFR,,unknown
Alvocidib,,Cyclin-dependent kinase 4,CDK4,,unknown
Alvocidib,,Cyclin-dependent kinase 8,CDK8,,unknown
Alvocidib,,Cyclin-dependent kinase 7,CDK7,,unknown
Alvocidib,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
Alvocidib,,"Glycogen phosphorylase, brain form",PYGB,,unknown
Alvocidib,,"Glycogen phosphorylase, liver form",PYGL,,unknown
Mercaptomethyl Phosphonate,,Alkaline phosphatase,phoA,,unknown
Malate Ion,,Circadian clock protein KaiB,kaiB,,unknown
Malate Ion,,Fumarate hydratase class II,fumC,,unknown
Malate Ion,,Malate synthase G,glcB,,unknown
Malate Ion,,"NAD-dependent malic enzyme, mitochondrial",ME2,,unknown
Malate Ion,,"Citrate synthase, mitochondrial",CS,,unknown
Malate Ion,,Capsule biosynthesis protein,synC,,unknown
Tricosanoic Acid,,Lipase 3,LIP3,,unknown
Galactose-uridine-5'-diphosphate,,"Beta-1,4-galactosyltransferase 1",B4GALT1,,unknown
Galactose-uridine-5'-diphosphate,,Histo-blood group ABO system transferase,ABO,,unknown
Galactose-uridine-5'-diphosphate,,UDP-glucose 4-epimerase,GALE,,unknown
(4s)-4-{[(2s)-2-Amino-3-Oxopropyl]Sulfanyl}-L-Homoserinate,,Aspartate-semialdehyde dehydrogenase,asd,,unknown
"4-Acetyl-4-Guanidino-6-Methyl(Propyl)Carboxamide-4,5-Dihydro-2h-Pyran-2-Carboxylic Acid",,Neuraminidase,NA,,unknown
"9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"2,6-Diaminoquinazolin-4(3h)-One",,Queuine tRNA-ribosyltransferase,tgt,,unknown
9-Deazaadenine,,Adenine phosphoribosyltransferase,APRT,,unknown
"6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One",,Tumor necrosis factor receptor superfamily member 1A,TNFRSF1A,,unknown
2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide,,Poly [ADP-ribose] polymerase 1,PARP1,,unknown
6-O-Phosphoryl Inosine Monophosphate,,Adenylosuccinate synthetase isozyme 1,ADSSL1,,unknown
6-O-Phosphoryl Inosine Monophosphate,,Adenylosuccinate synthetase,Adss,,unknown
"Uridine-2',3'-Vanadate",,Ribonuclease pancreatic,RNASE1,,unknown
Equilenin,,Steroid Delta-isomerase,ksi,,unknown
Equilenin,,Steroid Delta-isomerase,ksi,,unknown
Eniluracil,,Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,,unknown
Eniluracil,,Aldehyde oxidase,AOX1,,unknown
Eniluracil,,Xanthine dehydrogenase/oxidase,XDH,inhibitor,unknown
[Methylthio]Acetate,,Monomeric sarcosine oxidase,soxA,,unknown
Mevalonic acid,,3-hydroxy-3-methylglutaryl-coenzyme A reductase,mvaA,,unknown
Aspartic Acid-4-Carboxymethyl Ester,,(S)-2-haloacid dehalogenase,dhlB,,unknown
Brequinar,,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
"N-{3-[4-(3-Amino-Propyl)-Piperazin-1-Yl]-Propyl}-3-(2-Thiophen-2-Yl-Acetylamino)-5-(3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yloxy)-Benzamide",,Cholera enterotoxin subunit B,ctxB,,unknown
RU79073,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
AL5927,,Carbonic anhydrase 2,CA2,,unknown
9-Beta-D-Xylofuranosyl-Adenine,,Purine nucleoside phosphorylase DeoD-type,deoD,,unknown
Acylated Ceftazidime,,Regulatory protein BlaR1,blaR1,,unknown
Acylated Ceftazidime,,Beta-lactamase,ampC,,unknown
Flavin-Adenine Dinucleotide-N5-Isobutyl Ketone,,D-amino-acid oxidase,DAO,,unknown
Phosphomethylphosphonic Acid Guanylate Ester,,Cell division protein FtsZ,ftsZ,,unknown
Glycoluril,,Streptavidin,,,unknown
3-[(Acetyl-Methyl-Amino)-Methyl]-4-Amino-N-Methyl-N-(1-Methyl-1h-Indol-2-Ylmethyl)-Benzamide,,Enoyl-[acyl-carrier-protein] reductase [NADH] FabI,fabI,,unknown
Z-Pro-Prolinal,,Prolyl endopeptidase,PREP,,unknown
Z-Pro-Prolinal,,Prolyl endopeptidase,,,unknown
Benzoyl-Arginine-Alanine-Methyl Ketone,,Cruzipain,,,unknown
Benzoyl-Arginine-Alanine-Methyl Ketone,,Cathepsin F,CTSF,,unknown
2-(Acetylamino)-2-Deoxy-6-O-Methyl-Alpha-D-Allopyranose,,Chitotriosidase-1,CHIT1,,unknown
Norcamphor,,Camphor 5-monooxygenase,camC,,unknown
"10-Propargyl-5,8-Dideazafolic Acid",,Thymidylate synthase,THYA,,unknown
"10-Propargyl-5,8-Dideazafolic Acid",,Thymidylate synthase,thyA,,unknown
"10-Propargyl-5,8-Dideazafolic Acid",,Thymidylate synthase,thyA,,unknown
"10-Propargyl-5,8-Dideazafolic Acid",,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,,unknown
"10-Propargyl-5,8-Dideazafolic Acid",,Thymidylate synthase,TYMS,,unknown
"10-Propargyl-5,8-Dideazafolic Acid",,Putative dehydrogenase/reductase SDR family member 4-like 2,DHRS4L1,,unknown
L-Myo-Inositol-1-Phosphate,,Inositol monophosphatase 1,IMPA1,,unknown
1-(O-Carboxy-Phenylamino)-1-Deoxy-D-Ribulose-5-Phosphate,,N-(5'-phosphoribosyl)anthranilate isomerase,trpF,,unknown
1-(O-Carboxy-Phenylamino)-1-Deoxy-D-Ribulose-5-Phosphate,,Tryptophan biosynthesis protein TrpCF,trpC,,unknown
S-Phosphocysteine,,Enamine/imine deaminase,ridA,,unknown
S-Phosphocysteine,,"N,N'-diacetylchitobiose-specific phosphotransferase enzyme IIB component",chbB,,unknown
"N-({4-[(1R)-4-[(2R,4S,5S)-2,4-diamino-6-oxohexahydropyrimidin-5-yl]-1-(2,2,2-trifluoro-1,1-dihydroxyethyl)butyl]phenyl}carbonyl)-L-glutamic acid",,Trifunctional purine biosynthetic protein adenosine-3,GART,,unknown
3-deoxy-α-D-manno-oct-2-ulopyranosonic acid,,Ferrichrome-iron receptor,fhuA,,unknown
Biotinyl P-Nitroaniline,,Streptavidin,,,unknown
"(3R,4R)-3-Hydroxy-4-(hydroxymethyl)-1-[(4-oxo-4,4a,5,7a-tetrahydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]pyrrolidinium",,Purine nucleoside phosphorylase,PNP,,unknown
"(3R,4R)-3-Hydroxy-4-(hydroxymethyl)-1-[(4-oxo-4,4a,5,7a-tetrahydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]pyrrolidinium",,Purine nucleoside phosphorylase,punA,,unknown
3-Tyrosine,,Tyrosine 3-monooxygenase,TH,,unknown
Glutaric Acid,,Aspartate aminotransferase,aspC,,unknown
Glutaric Acid,,Glutamate decarboxylase alpha,gadA,,unknown
Glutaric Acid,,Branched-chain-amino-acid aminotransferase,ilvE,,unknown
5-Iodouracil,,Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,,unknown
CRA_11092,,Trypsin-1,PRSS1,,unknown
"2-(2-{2-[2-(2-{2-[2-(2-Ethoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol, Polyethyleneglycol Peg400",,Carbonyl reductase [NADPH] 1,CBR1,,unknown
"2-(2-{2-[2-(2-{2-[2-(2-Ethoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol, Polyethyleneglycol Peg400",,DevB protein,,,unknown
N-{1-[5-(1-Carbamoyl-2-Mercapto-Ethylcarbamoyl)-Pentylcarbamoyl]-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethyl}-3-{2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Acetylamino}-Succinamic Acid,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
Sp-876,,Thymidylate synthase,thyA,,unknown
Cyclohexylformamide,,Alcohol dehydrogenase 1C,ADH1C,,unknown
Cyclohexylformamide,,Alcohol dehydrogenase 4,ADH4,,unknown
Tetrahydrodeoxyuridine,,Cytidine deaminase,cdd,,unknown
"(4r)-2-Methylpentane-2,4-Diol",,1-pyrroline-5-carboxylate dehydrogenase,,,unknown
"(4r)-2-Methylpentane-2,4-Diol",,Xylose isomerase,xylA,,unknown
1-O-Octyl-2-Heptylphosphonyl-Sn-Glycero-3-Phosphoethanolamine,,Phospholipase A2,PLA2G1B,,unknown
Spermidine,,Spermidine/putrescine-binding periplasmic protein,potD,,unknown
Spermidine,,"Thioredoxin reductase 1, cytoplasmic",TXNRD1,,unknown
Spermidine,,Gentamicin 3'-acetyltransferase,aacC1,,unknown
Spermidine,,Beta-1 adrenergic receptor,ADRB1,,unknown
Spermidine,,Beta-2 adrenergic receptor,ADRB2,,unknown
Butyric Acid,,Cholinesterase,BCHE,,unknown
Butyric Acid,,"2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase",cumD,,unknown
Butyric Acid,,(S)-2-haloacid dehalogenase,,,unknown
"4,5-Dehydro-L-Iduronic Acid",,Chondroitinase-AC,cslA,,unknown
Tris-Hydroxymethyl-Methyl-Ammonium,,Pantothenate synthetase,panC,,unknown
Tris-Hydroxymethyl-Methyl-Ammonium,,Azurin,azu,,unknown
Tris-Hydroxymethyl-Methyl-Ammonium,,Regulatory protein TenI,tenI,,unknown
"3-(5-Amino-7-Hydroxy-[1,2,3]Triazolo[4,5-D]Pyrimidin-2-Yl)-N-(3,5-Dichlorobenzyl)-Benzamide",,Dihydroneopterin aldolase,folB,,unknown
FR230513,,Adenosine deaminase,ADA,,unknown
WRR-99,,Cruzipain,,,unknown
WRR-99,,Cathepsin F,CTSF,,unknown
Ferricrocin-Iron,,Ferrichrome-iron receptor,fhuA,,unknown
Phencyclidine,,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,antagonist,yes
Phencyclidine,,Sigma non-opioid intracellular receptor 1,SIGMAR1,,unknown
N-Pyridoxyl-Threonine-5-Monophosphate,,L-allo-threonine aldolase,,,unknown
Alpha-Benzyl-Aminobenzyl-Phosphonic Acid,,Prostatic acid phosphatase,ACPP,,unknown
Glucose-6-Phosphate,,Glutamine--fructose-6-phosphate aminotransferase [isomerizing],glmS,,unknown
Glucose-6-Phosphate,,Glucose-6-phosphate isomerase,GPI,,unknown
N~2~-Succinylornithine,,N-succinylarginine dihydrolase,astB,,unknown
"(2e,3s)-3-Hydroxy-5'-[(4-Hydroxypiperidin-1-Yl)Sulfonyl]-3-Methyl-1,3-Dihydro-2,3'-Biindol-2'(1'h)-One",,Cyclin-dependent kinase 2,CDK2,,unknown
4-Thio-beta-D-glucopyranose,,"Possible cellulase CelA1 (Endoglucanase) (Endo-1,4-beta-glucanase) (FI-cmcase) (Carboxymethyl cellulase)",celA1,,unknown
4-Thio-beta-D-glucopyranose,,Endoglucanase 5A,cel5A,,unknown
4-Thio-beta-D-glucopyranose,,Endoglucanase F,celCCF,,unknown
4-Thio-beta-D-glucopyranose,,Endoglucanase G,celCCG,,unknown
Oxyphenbutazone,,Group IIE secretory phospholipase A2,PLA2G2E,,unknown
"(3R,4R,5S,6R)-6-Fluoro-3,4,5-trihydroxytetrahydro-2H-pyran-2-olate",,Alpha-xylosidase,yicI,,unknown
Pyruvaldehyde,,Phospholipase A2,PLA2G1B,,unknown
Diphenylacetic Acid,,Cathepsin B,CTSB,,unknown
Alpha-Ketomalonic Acid,,"NAD-dependent malic enzyme, mitochondrial",ME2,,unknown
"2,6-Diaminopimelic Acid",,"UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--2,6-diaminopimelate ligase",murE,,unknown
"2,6-Diaminopimelic Acid",,Meso-diaminopimelate D-dehydrogenase,ddh,,unknown
RU82209,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
Pterin-6-Yl-Methyl-Monophosphate,,Dihydropteroate synthase,folP,,unknown
Pterin-6-Yl-Methyl-Monophosphate,,Dihydropteroate synthase 1,folP1,,unknown
N7-Methyl-Guanosine-5'-Monophosphate,,m7GpppX diphosphatase,DCPS,,unknown
"1,2,4-Triazole",,Carbonic anhydrase 2,CA2,,unknown
CRA_9785,,Trypsin-1,PRSS1,,unknown
N-[2-(1h-Indol-5-Yl)-Butyl]-4-Sulfamoyl-Benzamide,,Carbonic anhydrase 2,CA2,,unknown
Gamma-Glutamyl[S-(2-Iodobenzyl)Cysteinyl]Glycine,,"High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A",PDE9A,,unknown
Gamma-Glutamyl[S-(2-Iodobenzyl)Cysteinyl]Glycine,,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,,unknown
Gamma-Glutamyl[S-(2-Iodobenzyl)Cysteinyl]Glycine,,Glutathione S-transferase Mu 4,GSTM4,,unknown
"Al-6629, [2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide,2-(3-Methoxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide]",,Carbonic anhydrase 2,CA2,,unknown
Capric acid,,3-oxoacyl-[acyl-carrier-protein] synthase 1,fabB,,unknown
Capric acid,,Furin,FURIN,,unknown
Capric acid,,Peptostreptococcal albumin-binding protein,pab,,unknown
Capric acid,,Glycolipid transfer protein,GLTP,,unknown
Capric acid,,Octanoyltransferase,lipB,,unknown
Capric acid,,Putative uncharacterized protein tcp14,tcp14,,unknown
Capric acid,,Peroxisome proliferator-activated receptor gamma,PPARG,ligand,unknown
S-Benzyl-Glutathione,,Glutathione S-transferase A1,GSTA1,,unknown
S-Benzyl-Glutathione,,Lactoylglutathione lyase,GLO1,,unknown
Glucaric acid,,Glucarate dehydratase,gudD,,unknown
Tiratricol,,Thyroid hormone receptor beta,THRB,,unknown
"(2s)-2-[(2,4-Dichloro-Benzoyl)-(3-Trifluoromethyl-Benzyl)-Amino]-3-Phenyl-Propionic Acid",,Genome polyprotein,,,unknown
(S)-Rolipram,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,,unknown
(S)-Rolipram,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,inhibitor,unknown
[(1R)-1-acetamido-2-(4-chlorophenyl)ethyl]-[(2S)-2-amino-3-hydroxy-3-oxo-propoxy]-dihydroxy-boron,,Subtilisin Carlsberg,apr,,unknown
Diminazene,,"Peroxiredoxin-5, mitochondrial",PRDX5,,unknown
Diminazene,,HTH-type transcriptional regulator QacR,qacR,,unknown
Diminazene,,Trypsin-1,PRSS1,,unknown
Diminazene,,Amiloride-sensitive amine oxidase [copper-containing],AOC1,,unknown
3-Deoxyguanosine,,Purine nucleoside phosphorylase,PNP,,unknown
L-2-amino-4-methoxy-cis-but-3-enoic acid,,S-adenosylmethionine synthase isoform type-1,MAT1A,,unknown
3-Hydroxybutyryl-Coenzyme A,,"Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial",HADH,,unknown
4-Hydroxyphenacyl Coenzyme A,,4-hydroxybenzoyl-CoA thioesterase,fcbC,,unknown
4-Hydroxyphenacyl Coenzyme A,,4-hydroxybenzoyl-CoA thioesterase,,,unknown
Methylcobalamin,,Methionine synthase,metH,,unknown
Ribostamycin,,Aminoglycoside N(6')-acetyltransferase type 1,,,unknown
Ribostamycin,,Aminoglycoside 2'-N-acetyltransferase,aac,,unknown
Ribostamycin,,Protein disulfide-isomerase,P4HB,,unknown
Ribostamycin,,30S ribosomal protein S12,rpsL,,unknown
Kabiramide C,,"Actin, alpha skeletal muscle",ACTA1,,unknown
Deoxycholic Acid,,Steroid Delta-isomerase,ksi,,unknown
Deoxycholic Acid,,PpcA,ppcA,,unknown
Deoxycholic Acid,,Elongation factor Tu GTP-binding domain-containing protein 1,EFTUD1,,unknown
Deoxycholic Acid,,Choloylglycine hydrolase,cbh,,unknown
Deoxycholic Acid,,Lactaldehyde dehydrogenase,aldA,,unknown
Deoxycholic Acid,,Acriflavine resistance protein B,acrB,,unknown
Deoxycholic Acid,,Cytochrome c oxidase subunit 1,ctaD,,unknown
Deoxycholic Acid,,Cytochrome c oxidase subunit 2,ctaC,,unknown
Deoxycholic Acid,,Bile acid receptor,NR1H4,,unknown
Deoxycholic Acid,,Glutathione S-transferase P,GSTP1,,unknown
Deoxycholic Acid,,G-protein coupled bile acid receptor 1,GPBAR1,,unknown
"L-709,587",,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,,unknown
"2-Hydroxy-5-[4-(2-Hydroxy-Ethyl)-Piperidin-1-Yl]-5-Phenyl-1h-Pyrimidine-4,6-Dione",,Neutrophil collagenase,MMP8,,unknown
"9-(4-Hydroxyphenyl)-2,7-Phenanthroline",,Mitogen-activated protein kinase 10,MAPK10,,unknown
7-(Carboxyamino)-8-Amino-Nonanoic Acid,,ATP-dependent dethiobiotin synthetase BioD 1,bioD1,,unknown
"5-Methoxy-1,2-Dimethyl-3-(Phenoxymethyl)Indole-4,7-Dione",,NAD(P)H dehydrogenase [quinone] 1,NQO1,,unknown
Adamantane,,Camphor 5-monooxygenase,camC,,unknown
ISO24,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
Pyridoxal-5'-Phosphate-N-Oxide,,Aspartate aminotransferase,aspC,,unknown
"3-(4-Hydroxy-3-Imino-6-Oxo-Cyclohexa-1,4-Dienyl)-Alanine",,Primary amine oxidase,tynA,,unknown
Argifin,,Chitinase,chiB1,,unknown
Argifin,,Chitotriosidase-1,CHIT1,,unknown
Lpc-Ether,,Ganglioside GM2 activator,GM2A,,unknown
Lpc-Ether,,Phospholipase A2,PLA2G1B,,unknown
Ethanesulfonic Acid,,Phosphonoacetaldehyde hydrolase,phnX,,unknown
Ethanesulfonic Acid,,Platelet basic protein,PPBP,,unknown
Glycinamid,,Neutrophil collagenase,MMP8,,unknown
Guanidine-3-Propanol,,Trypsin-3,PRSS3,,unknown
1-Guanidinium-7-Aminoheptane,,Deoxyhypusine synthase,DHPS,inhibitor,unknown
Beta-Hydroxyaspartic Acid,,Beta-lactamase TEM,bla,,unknown
"2'-deoxyuridine 5'-alpha,beta-imido-diphosphate",,DUTPase,dut,,unknown
Benzofuran-2-Carboxylic Acid {(S)-3-Methyl-1-[3-Oxo-1-(Pyridin-2-Ylsulfonyl)Azepan-4-Ylcarbamoyl]Butyl}Amide,,Cathepsin K,CTSK,,unknown
CRA_1144,,Trypsin-1,PRSS1,,unknown
CRA_1144,,Serine protease hepsin,HPN,,unknown
3-Hydroxyanthranilic Acid,,"Trans-2,3-dihydro-3-hydroxyanthranilate isomerase",phzF,,unknown
Phosphonoacetohydroxamic Acid,,Beta-enolase,ENO3,,unknown
3-[Isopropyl(4-Methylbenzoyl)Amino]-5-Phenylthiophene-2-Carboxylic Acid,,Genome polyprotein,,,unknown
2-{N'-[2-(5-Amino-1-Phenylcarbamoyl-Pentylcarbamoyl)-Hexyl]-Hydrazinomethyl}-Hexanoic Acid(5-Amino-1-Phenylcarbamoyl-Pentyl)-Amide,,"Formylmethionine deformylase, putative",,,unknown
"[{(5-Chloro-2-Pyridinyl)Amino} Methylene]-1,1-Bisphosphonate",,1-deoxy-D-xylulose 5-phosphate reductoisomerase,dxr,,unknown
(3e)-3-[(4-Hydroxyphenyl)Imino]-1h-Indol-2(3h)-One,,Serine/threonine-protein kinase pim-1,PIM1,,unknown
Picric acid,,Pentaerythritol tetranitrate reductase,onr,,unknown
beta-D-Galactopyranuronic acid,,AlgQ1,algQ1,,unknown
beta-D-Galactopyranuronic acid,,AlgQ2,algQ2,,unknown
"S,S-Propylthiocysteine",,Listeriolysin regulatory protein,prfA,,unknown
"S,S-Propylthiocysteine",,Thermonuclease,nuc,,unknown
1-Deoxy-1-Methoxycarbamido-Beta-D-Glucopyranose,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
"2-{1-[2-Amino-2-(4-Hydroxy-Phenyl)-Acetylamino]-2-Oxo-Ethyl}-5,5-Dimethyl-Thiazolidine-4-Carboxylic Acid",,Beta-lactamase,ampC,,unknown
Butylamine,,Candidapepsin-2,SAP2,,unknown
4-Iodo-L-phenylalanine,,Lysozyme,E,,unknown
4-Iodo-L-phenylalanine,,Pseudomonalisin,pcp,,unknown
4-Iodo-L-phenylalanine,,Dipeptidyl peptidase 4,DPP4,,unknown
4-Iodo-L-phenylalanine,,Aminopeptidase S,,,unknown
Cysteinesulfonic Acid,,Beta-lactamase class B VIM-2,blaVIM-2,,unknown
Cysteinesulfonic Acid,,Ribose 5-phosphate isomerase B,,,unknown
Cysteinesulfonic Acid,,Cathepsin L1,CTSL,,unknown
Cysteinesulfonic Acid,,Methylaspartate ammonia-lyase,,,unknown
Cysteinesulfonic Acid,,1-cys peroxiredoxin,prx,,unknown
Cysteinesulfonic Acid,,Peptide deformylase,def,,unknown
Cysteinesulfonic Acid,,Golgi-associated plant pathogenesis-related protein 1,GLIPR2,,unknown
Cysteinesulfonic Acid,,Glutamine amidotransferase class-I,,,unknown
Cysteinesulfonic Acid,,Peptide deformylase,def,,unknown
Cysteinesulfonic Acid,,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,,unknown
Cysteinesulfonic Acid,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
Cysteinesulfonic Acid,,Penicillin acylase,,,unknown
Cysteinesulfonic Acid,,S-ribosylhomocysteine lyase,luxS,,unknown
Cysteinesulfonic Acid,,Deoxynucleotide monophosphate kinase,1,,unknown
Cysteinesulfonic Acid,,M-phase inducer phosphatase 2,CDC25B,,unknown
Vitamin B6 Complexed with 2-Amino-Pentanoic Acid,,Aspartate aminotransferase,aspC,,unknown
"1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol",,Cyclin-dependent kinase 2,CDK2,,unknown
UP5,,UMP-CMP kinase,CMPK1,,unknown
3'-Azido-3'-Deoxythymidine-5'-Monophosphate,,Thymidylate kinase,DTYMK,,unknown
3'-Azido-3'-Deoxythymidine-5'-Monophosphate,,Thymidylate kinase,tmk,,unknown
Acetic Acid Salicyloyl-Amino-Ester,,Prostaglandin G/H synthase 1,PTGS1,,unknown
1-(5'-Phospho-Beta-D-Ribofuranosyl)Barbituric Acid,,Orotidine 5'-phosphate decarboxylase,pyrF,,unknown
4-Fluorophenethyl Alcohol,,Lysozyme,E,,unknown
"2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
9-N-Phenylmethylamino-Tacrine,,Cholinesterase,BCHE,,unknown
Beta(2-Thienyl)Alanine,,Phenylalanine-4-hydroxylase,PAH,,unknown
Cystein-S-Yl Cacodylate,,"Proteinase inhibitor I4, serpin",,,unknown
Cystein-S-Yl Cacodylate,,Gag-Pol polyprotein,gag-pol,,unknown
N-Cyclohexyl-N'-Decylurea,,Bifunctional epoxide hydrolase 2,EPHX2,,unknown
2-Hydroxy-Tryptophan,,Quinohemoprotein ethanol dehydrogenase type-1,qheDH,,unknown
Tartronate,,"NAD-dependent malic enzyme, mitochondrial",ME2,,unknown
Tartronate,,"NADP-dependent malic enzyme, mitochondrial",ME3,,unknown
2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid,,Matrix metalloproteinase-9,MMP9,,unknown
Uridine monophosphate,,Ribosomal small subunit pseudouridine synthase A,rsuA,,unknown
Uridine monophosphate,,Uridine-cytidine kinase-like 1,UCKL1,,unknown
Uridine monophosphate,,Galactose-1-phosphate uridylyltransferase,galT,,unknown
Uridine monophosphate,,Thymidylate synthase,thyA,,unknown
Uridine monophosphate,,Glycosyltransferase 6 domain-containing protein 1,GLT6D1,,unknown
Uridine monophosphate,,U6 snRNA-associated Sm-like protein LSm6,LSM6,,unknown
Uridine monophosphate,,Uracil phosphoribosyltransferase,upp,,unknown
Uridine monophosphate,,"Beta-1,4-galactosyltransferase 1",B4GALT1,,unknown
Uridine monophosphate,,Interferon-stimulated gene 20 kDa protein,ISG20,,unknown
Uridine monophosphate,,Orotidine 5'-phosphate decarboxylase,pyrF,,unknown
Uridine monophosphate,,Bifunctional protein PyrR,pyrR,,unknown
Uridine monophosphate,,Uracil phosphoribosyltransferase,upp,,unknown
Uridine monophosphate,,Bifunctional polymyxin resistance protein ArnA,arnA,,unknown
S-(P-Nitrobenzyl)Glutathione,,Glutathione S-transferase P,GSTP1,,unknown
4-Diphosphocytidyl-2-C-Methyl-D-Erythritol,,"2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase",ispF,,unknown
4-Diphosphocytidyl-2-C-Methyl-D-Erythritol,,4-diphosphocytidyl-2-C-methyl-D-erythritol kinase,ispE,,unknown
4-Diphosphocytidyl-2-C-Methyl-D-Erythritol,,2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase,ispD,,unknown
3-Hydroxy-Propanoic Acid,,Pimelyl-[acyl-carrier protein] methyl ester esterase,bioH,,unknown
"(Z,Z)-4-Hydroxy-N,N,N-Trimethyl-10-Oxo-7-[(1-Oxo-9-Octadecenyl)Oxy]-3,5,9-Trioxa-4-Phosphaheptacos-18-En-1-Aminium-4-Oxide",,Phosphatidylinositol transfer protein alpha isoform,PITPNA,,unknown
WRR-112,,Cruzipain,,,unknown
WRR-112,,Cathepsin F,CTSF,,unknown
1-Hexadecanosulfonyl-O-L-Serine,,Phospholipase A1,pldA,,unknown
N-(2-Aminoethyl)-5-Chloroisoquinoline-8-Sulfonamide,,Casein kinase I isoform gamma-2,CSNK1G2,,unknown
Piritrexim,,Dihydrofolate reductase,DHFR,,unknown
Lanosterol,,Lanosterol synthase,LSS,,unknown
4-Sulfonamide-[1-(4-Aminobutane)]Benzamide,,Carbonic anhydrase 2,CA2,,unknown
5-Mercaptoethanol-2-Decenoyl-Coenzyme A,,"2,4-dienoyl-CoA reductase [NADPH]",fadH,,unknown
Succinyl-Coenzyme A,,"2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase",dapD,,unknown
D-Threonine,,Thermolysin,nprS,,unknown
Vanoxerine,,Sodium-dependent dopamine transporter,SLC6A3,,unknown
"2-[4-[[(S)-1-[[(S)-2-[[(Rs)-3,3,3-Trifluoro-1-Isopropyl-2-Oxopropyl]Aminocarbonyl]Pyrrolidin-1-Yl-]Carbonyl]-2-Methylpropyl]Aminocarbonyl]Benzoylamino]Acetic Acid",,Chymotrypsin-like elastase family member 1,CELA1,,unknown
Cyclohexanol,,Alcohol dehydrogenase 1B,ADH1B,,unknown
12-Hydroxydodecanoic Acid,,Alcohol dehydrogenase class-3,ADH5,,unknown
6-Methylamino-5-Nitroisocytosine,,Dihydropteroate synthase,folP,,unknown
1-Hydroxy-2-S-Glutathionyl-3-Para-Nitrophenoxy-Propane,,Glutathione S-transferase Mu 4,GSTM4,,unknown
S-Ethyl-N-Phenyl-Isothiourea,,"Nitric oxide synthase, endothelial",NOS3,,unknown
S-Ethyl-N-Phenyl-Isothiourea,,"Nitric oxide synthase, brain",NOS1,,unknown
Adenosine 5'-phosphosulfate,,ATP sulfurylase (Sulfate adenylyltransferase),,,unknown
Adenosine 5'-phosphosulfate,,Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1,PAPSS1,,unknown
Bicine,,UDP-galactopyranose mutase,glf,,unknown
Bicine,,Plasminogen,PLG,,unknown
Bicine,,Membrane-bound lytic murein transglycosylase B,mltB,,unknown
N5-(1-Imino-3-Butenyl)-L-Ornithine,,"Nitric oxide synthase, brain",NOS1,,unknown
6-Hydroxy-6-Methyl-Heptan-3-One,,Epididymal-specific lipocalin-9,LCN9,,unknown
RU85053,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
4-Carbamoyl-4-{[6-(Difluoro-Phosphono-Methyl)-Naphthalene-2-Carbonyl]-Amino}-Butyric Acid,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
5'-Fluoro-5'-Deoxyadenosine,,5'-fluoro-5'-deoxy-adenosine synthase,flA,,unknown
"3-Hydroxy-4-(3,4,5-Trihydroxy-Tetrahydro-Pyran-2-Yloxy)-Piperidin-2-One",,Exoglucanase/xylanase,cex,,unknown
N-Ethyl-5'-Carboxamido Adenosine,,Endoplasmin,HSP90B1,,unknown
N-acetyl-alpha-neuraminic acid,,3-deoxy-manno-octulosonate cytidylyltransferase,kpsU,,unknown
N-acetyl-alpha-neuraminic acid,,Fiber,L5,,unknown
N-acetyl-alpha-neuraminic acid,,Sialoadhesin,SIGLEC1,,unknown
N-acetyl-alpha-neuraminic acid,,Zinc-alpha-2-glycoprotein,AZGP1,,unknown
N-acetyl-alpha-neuraminic acid,,Capsid protein VP1,,,unknown
N-acetyl-alpha-neuraminic acid,,Fiber,L5,,unknown
N-acetyl-alpha-neuraminic acid,,Liver carboxylesterase 1,CES1,,unknown
N-acetyl-alpha-neuraminic acid,,Tetanus toxin,tetX,,unknown
N-acetyl-alpha-neuraminic acid,,Cholera enterotoxin subunit B,ctxB,,unknown
N-acetyl-alpha-neuraminic acid,,Botulinum neurotoxin type B,botB,,unknown
N-acetyl-alpha-neuraminic acid,,P-selectin,SELP,,unknown
N-acetyl-alpha-neuraminic acid,,Mannose-binding protein C,MBL2,,unknown
N-acetyl-alpha-neuraminic acid,,E-selectin,SELE,,unknown
N-acetyl-alpha-neuraminic acid,,Lithostathine-1-alpha,REG1A,,unknown
N-acetyl-alpha-neuraminic acid,,Endo-N-acetylneuraminidase,,,unknown
N-acetyl-alpha-neuraminic acid,,Enterotoxin type B,entB,,unknown
N-acetyl-alpha-neuraminic acid,,Neuraminidase,NA,,unknown
N-acetyl-alpha-neuraminic acid,,Hemagglutinin-neuraminidase,HN,,unknown
"3,4-Dihydro-5-Methyl-Isoquinolinone",,Poly [ADP-ribose] polymerase 1,PARP1,,unknown
2'-Deoxy-Thymidine-Beta-L-Rhamnose,,Glucose-1-phosphate thymidylyltransferase,rmlA,,unknown
2'-Deoxy-Thymidine-Beta-L-Rhamnose,,dTDP-4-dehydrorhamnose reductase,rfbD,,unknown
Phosphomethylphosphonic Acid-Guanylate Ester,,"Phosphoenolpyruvate carboxykinase, cytosolic [GTP]",PCK1,,unknown
Purine Riboside-5'-Monophosphate,,Ribonuclease pancreatic,RNASE1,,unknown
Coproporphyrin I,,Uroporphyrinogen decarboxylase,UROD,,unknown
p-Chlorobenzoic acid,,4-chlorobenzoyl CoA ligase,,,unknown
2-Amino-5-Hydroxy-Benzimidazole,,Urokinase-type plasminogen activator,PLAU,,unknown
"3,9-Dimethyladenine",,Endonuclease III,,,unknown
S-2-(Boronoethyl)-L-Cysteine,,Arginase-1,ARG1,,unknown
S-2-(Boronoethyl)-L-Cysteine,,"Arginase-2, mitochondrial",ARG2,,unknown
Etheno-Nadp,,ADP-ribosyl cyclase 2,BST1,,unknown
Ethylene Dichloride,,Haloalkane dehalogenase,linB,,unknown
Xylarohydroxamate,,Glucarate dehydratase,gudD,,unknown
9-(2-Deoxy-Beta-D-Ribofuranosyl)-6-Methylpurine,,Purine nucleoside phosphorylase DeoD-type,deoD,,unknown
2-Cyclopropylmethylenepropanal,,Renin,REN,,unknown
"4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One",,Cyclin-dependent kinase 2,CDK2,,unknown
Pantothenoylaminoethenethiol,,Phosphopantothenoylcysteine decarboxylase,PPCDC,,unknown
3-Hydroxyimino Quinic Acid,,3-dehydroquinate dehydratase,aroQ,,unknown
N-acetyl-alpha-D-glucosamine,,Fucose-binding lectin PA-IIL,lecB,,unknown
N-acetyl-alpha-D-glucosamine,,Envelope glycoprotein gp160,env,,unknown
N-acetyl-alpha-D-glucosamine,,Ig gamma-1 chain C region,IGHG1,,unknown
N-acetyl-alpha-D-glucosamine,,Angiotensin-converting enzyme,ACE,,unknown
N-acetyl-alpha-D-glucosamine,,Acetylcholinesterase,ACHE,,unknown
N-acetyl-alpha-D-glucosamine,,Glucosylceramidase,GBA,,unknown
N-acetyl-alpha-D-glucosamine,,Probable polysaccharide deacetylase PdaA,pdaA,,unknown
N-acetyl-alpha-D-glucosamine,,Sialic acid-binding Ig-like lectin 7,SIGLEC7,,unknown
N-acetyl-alpha-D-glucosamine,,Hemagglutinin-neuraminidase,HN,,unknown
2-Methylbutanoic Acid,,"2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase",cumD,,unknown
Compound 4-D,,Estrogen receptor alpha,ESR1,,unknown
"Cp403700, (S)-1-{2-[(5-Chloro-1h-Indole-2-Carbonyl)-Amino]-3-Phenyl-Propionyl}-Azetidine-3-Carboxylate",,"Glycogen phosphorylase, liver form",PYGL,,unknown
Arabinose-5-phosphate,,2-dehydro-3-deoxyphosphooctonate aldolase,kdsA,,unknown
Arabinose-5-phosphate,,Ribose-5-phosphate isomerase A,rpiA,,unknown
"3-Amino-4,5-Dihydroxy-Cyclohex-1-Enecarboxylate",,3-dehydroquinate dehydratase,aroD,,unknown
"3ar,5r,6s,7r,7ar-5-Hydroxymethyl-2-Methyl-5,6,7,7a-Tetrahydro-3ah-Pyrano[3,2-D]Thiazole-6,7-Diol",,B-N-acetylhexosaminidase,hex,,unknown
"3ar,5r,6s,7r,7ar-5-Hydroxymethyl-2-Methyl-5,6,7,7a-Tetrahydro-3ah-Pyrano[3,2-D]Thiazole-6,7-Diol",,Beta-hexosaminidase subunit beta,HEXB,,unknown
Methyl-[4-(4-Piperidine-1-Ylmethyl-Phenyl)-Cyclohexyl]-Carbaminic Acid-(4-Chlorophenyl)-Ester,,Squalene--hopene cyclase,shc,,unknown
"4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
Isovaleric Acid,,"2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase",cumD,,unknown
Isovaleric Acid,,Aspartate aminotransferase,aspC,,unknown
Isovaleric Acid,,Pseudomonalisin,pcp,,unknown
2'deoxy-Thymidine-5'-Diphospho-Alpha-D-Glucose,,"DTDP-4-dehydrorhamnose 3,5-epimerase",rmlC,,unknown
2'deoxy-Thymidine-5'-Diphospho-Alpha-D-Glucose,,"dTDP-glucose 4,6-dehydratase",rmlB,,unknown
2'deoxy-Thymidine-5'-Diphospho-Alpha-D-Glucose,,Glucose-1-phosphate thymidylyltransferase,rmlA,,unknown
2'deoxy-Thymidine-5'-Diphospho-Alpha-D-Glucose,,"dTDP-glucose 4,6-dehydratase",desIV,,unknown
2'deoxy-Thymidine-5'-Diphospho-Alpha-D-Glucose,,"dTDP-glucose 4,6-dehydratase",rfbB,,unknown
P-(2'-Iodo-5'-Thenoyl)Hydrotropic Acid,,Prostaglandin G/H synthase 1,PTGS1,,unknown
Flurbiprofen Methyl Ester,,Prostaglandin G/H synthase 1,PTGS1,,unknown
Tromethamine,,Autolysin,lytA,,unknown
Tromethamine,,Cytochrome c4,cc4,,unknown
Tromethamine,,Soluble calcium-activated nucleotidase 1,CANT1,,unknown
Tromethamine,,Lipoprotein NlpI,nlpI,,unknown
Tromethamine,,DNA protection during starvation protein,dps,,unknown
Tromethamine,,Putative glucose-6-phosphate 1-epimerase,,,unknown
Tromethamine,,Endonuclease 8-like 1,NEIL1,,unknown
Tromethamine,,Cholera enterotoxin subunit B,ctxB,,unknown
Tromethamine,,S-adenosylmethionine decarboxylase proenzyme,AMD1,,unknown
Tromethamine,,Biotin synthase,bioB,,unknown
Tromethamine,,Vascular endothelial growth factor A,VEGFA,,unknown
Tromethamine,,6-phosphogluconolactonase,pgl,,unknown
Tromethamine,,Decorin,DCN,,unknown
"Adenosine-5'-[Beta, Gamma-Methylene]Tetraphosphate",,Folylpolyglutamate synthase,fgs,,unknown
Doconexent,Approximately 20 hours [A19370].,Peroxisome proliferator-activated receptor alpha,PPARA,ligand,yes
Doconexent,Approximately 20 hours [A19370].,Peroxisome proliferator-activated receptor gamma,PPARG,ligand,yes
Doconexent,Approximately 20 hours [A19370].,Retinoic acid receptor RXR-alpha,RXRA,activator,yes
Doconexent,Approximately 20 hours [A19370].,Retinoic acid receptor RXR-beta,RXRB,activator,yes
Doconexent,Approximately 20 hours [A19370].,Retinoic acid receptor RXR-gamma,RXRG,activator,yes
Doconexent,Approximately 20 hours [A19370].,Sterol regulatory element-binding protein 1,SREBF1,inhibitor,unknown
(Tert-Butyloxycarbonyl)-Alanyl-Alanyl-Amine,,Chymotrypsin-like elastase family member 1,CELA1,,unknown
Radicicol,,Heat shock protein HSP 90-beta,HSP90AB1,,unknown
Radicicol,,Endoplasmin,HSP90B1,,unknown
Radicicol,,"Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial",DLAT,,unknown
Radicicol,,"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 3, mitochondrial",PDK3,,unknown
Radicicol,,Virulence sensor histidine kinase PhoQ,phoQ,,unknown
FG-9041,,Glutamate receptor 2,GRIA2,,unknown
Dihydrolipoic Acid,,Aminomethyltransferase,gcvT,,unknown
Dihydrolipoic Acid,,"Glycine cleavage system H protein, mitochondrial",GCSH,,unknown
Dihydrolipoic Acid,,"Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial",DLAT,,unknown
Dihydrolipoic Acid,,"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 3, mitochondrial",PDK3,,unknown
5-Fluoro-2'-Deoxyuridine-5'-Monophosphate,,Thymidylate synthase 1,thyA1,,unknown
5-Fluoro-2'-Deoxyuridine-5'-Monophosphate,,Thymidylate synthase,thyA,,unknown
5-Fluoro-2'-Deoxyuridine-5'-Monophosphate,,Thymidylate synthase,thyA,,unknown
5-Fluoro-2'-Deoxyuridine-5'-Monophosphate,,Thymidylate synthase ThyX,thyX,,unknown
5-Methyl-2'-Deoxypseudouridine,,Nucleoside deoxyribosyltransferase,ntd,,unknown
2'-cytidylic acid,,Ribonuclease pancreatic,RNASE1,,unknown
Propanoic Acid,,Non-heme chloroperoxidase,cpo,,unknown
Propanoic Acid,,Gephyrin,GPHN,,unknown
Propanoic Acid,,"2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase",cumD,,unknown
Propanoic Acid,,Alanine racemase,alr,,unknown
Morpholine-4-Carboxylic Acid [1s-(2-Benzyloxy-1r-Cyano-Ethylcarbamoyl)-3-Methyl-Butyl]Amide,,Cathepsin S,CTSS,,unknown
"N-[2-Hydroxy-2-(8-Isopropyl-6,9-Dioxo-2-Oxa-7,10-Diaza-Bicyclo[11.2.2]Heptadeca-1(16),13(17),14-Trien-11-Yl)-Ethyl]-N-(3-Methyl-Butyl)-Benzenesulfonamide,Inhibitor 3",,Gag-Pol polyprotein,gag-pol,,unknown
D-Eritadenine,,Adenosylhomocysteinase,AHCY,,unknown
Allyl-{4-[3-(4-Bromo-Phenyl)-Benzofuran-6-Yloxy]-but-2-Enyl}-Methyl-Amine,,Squalene--hopene cyclase,shc,,unknown
"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,5-Diol",,Histo-blood group ABO system transferase,ABO,,unknown
alpha-D-quinovopyranose,,Pancreatic alpha-amylase,AMY2A,,unknown
alpha-D-quinovopyranose,,Cyclomaltodextrin glucanotransferase,,,unknown
alpha-D-quinovopyranose,,Alpha-amylase,,,unknown
alpha-D-quinovopyranose,,Aldose 1-epimerase,galM,,unknown
alpha-D-quinovopyranose,,Cyclomaltodextrin glucanotransferase,amyA,,unknown
D-Dethiobiotin,,Biotin synthase,bioB,,unknown
D-Dethiobiotin,,ATP-dependent dethiobiotin synthetase BioD 1,bioD1,,unknown
D-Dethiobiotin,,ATP-dependent dethiobiotin synthetase BioD,bioD,,unknown
Rbt205 Inhibitor,,Serine/threonine-protein kinase pim-1,PIM1,,unknown
Rbt205 Inhibitor,,3-phosphoinositide-dependent protein kinase 1,PDPK1,,unknown
Rbt205 Inhibitor,,Protein kinase C iota type,PRKCI,,unknown
Glucosaminyl-(Alpha-6)-D-Myo-Inositol,,1-phosphatidylinositol phosphodiesterase,,,unknown
2-Aminoquinazolin-4(3h)-One,,Queuine tRNA-ribosyltransferase,tgt,,unknown
"2-[4-(2,4-Dichlorophenoxy)Phenoxy]Propanoic Acid",,Acetyl-CoA carboxylase 2,ACACB,,unknown
N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea,,Urokinase-type plasminogen activator,PLAU,,unknown
Phenacetin,,Prostaglandin G/H synthase 1,PTGS1,,unknown
Elaidoylamide,,"Phospholipase A2, membrane associated",PLA2G2A,,unknown
"(3r,5r)-7-((1r,2r,6s,8r,8as)-2,6-Dimethyl-8-{[(2r)-2-Methylbutanoyl]Oxy}-1,2,6,7,8,8a-Hexahydronaphthalen-1-Yl)-3,5-Dihydroxyheptanoic Acid",,3-hydroxy-3-methylglutaryl-coenzyme A reductase,mvaA,,unknown
"[5-hydroxy-6-methyl-4-({[(4E)-3-oxo-1,2-oxazolidin-4-ylidene]amino}methyl)pyridin-3-yl]methyl dihydrogen phosphate",,"2,2-dialkylglycine decarboxylase",dgdA,,unknown
GC-24,,Thyroid hormone receptor beta,THRB,,unknown
S-Dioxymethionine,,Catalase,katA,,unknown
"(3-{3-[[2-Chloro-3-(Trifluoromethyl)Benzyl](2,2-Diphenylethyl)Amino]Propoxy}Phenyl)Acetic Acid",,Oxysterols receptor LXR-beta,NR1H2,,unknown
"5-Amino-1h-Pyrimidine-2,4-Dione",,Ribonuclease pancreatic,RNASE1,,unknown
Benzoic Acid,,Hydrogen peroxide-inducible genes activator,oxyR,,unknown
Benzoic Acid,,HTH-type transcriptional regulator MalT,malT,,unknown
Benzoic Acid,,Tautomerase PptA,pptA,,unknown
Benzoic Acid,,D-amino-acid oxidase,DAO,,unknown
Benzoic Acid,,Ribonuclease UK114,HRSP12,,unknown
Benzoic Acid,,"Chlorocatechol 1,2-dioxygenase",clcA,,unknown
Benzoic Acid,,Ras-related protein Rab-9A,RAB9A,,unknown
Benzoic Acid,,"2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase",cumD,,unknown
Benzoic Acid,,Non-heme chloroperoxidase,cpo,,unknown
Benzoic Acid,,Oxygen-insensitive NAD(P)H nitroreductase,nfsB,,unknown
Benzoic Acid,,"Hydroxyquinol 1,2-dioxygenase",chqB,,unknown
Benzoic Acid,,Replication protein,repA,,unknown
Benzoic Acid,,"Peroxiredoxin-5, mitochondrial",PRDX5,,unknown
Benzoic Acid,,Heat-labile enterotoxin B chain,eltB,,unknown
Benzoic Acid,,Cocaine esterase,cocE,,unknown
Benzoic Acid,,Solute carrier family 15 member 1,SLC15A1,,unknown
2-Dehydropantoate,,3-methyl-2-oxobutanoate hydroxymethyltransferase,panB,,unknown
Palmitic Acid,,Glycodelin,PAEP,,unknown
Palmitic Acid,,Hepatocyte nuclear factor 4-gamma,HNF4G,,unknown
Palmitic Acid,,Lipid binding protein,,,unknown
Palmitic Acid,,Cytochrome P450 2C8,CYP2C8,,unknown
Palmitic Acid,,Trafficking protein particle complex subunit 3,TRAPPC3,,unknown
Palmitic Acid,,Fatty acid-binding protein TM_1468,,,unknown
Palmitic Acid,,Rhodopsin,RHO,,unknown
Palmitic Acid,,SEC14-like protein 2,SEC14L2,,unknown
Palmitic Acid,,Palmitoyl-protein thioesterase 1,PPT1,,unknown
Palmitic Acid,,Myelin P2 protein,PMP2,,unknown
Palmitic Acid,,Alpha-lactalbumin,LALBA,,unknown
Palmitic Acid,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
2'-Deoxycytidine-5'-Monophosphate,,Deoxycytidylate 5-hydroxymethyltransferase,42,,unknown
2'-Deoxycytidine-5'-Monophosphate,,Thymidylate synthase,thyA,,unknown
Trifluoromethionine,,Methionine aminopeptidase,map,,unknown
Trifluoromethionine,,Methionine--tRNA ligase,metG,,unknown
2'-deoxyuridylic acid,,Thymidylate synthase,THYA,,unknown
2'-deoxyuridylic acid,,Deoxyuridine 5'-triphosphate nucleotidohydrolase,dut,,unknown
2'-deoxyuridylic acid,,Thymidylate synthase,thyA,,unknown
2'-deoxyuridylic acid,,Thymidylate synthase,thyA,,unknown
2'-deoxyuridylic acid,,Thymidylate synthase,TYMS,,unknown
2'-deoxyuridylic acid,,Thymidylate synthase ThyX,thyX,,unknown
2'-deoxyuridylic acid,,Pol polyprotein,pol,,unknown
2'-deoxyuridylic acid,,Deoxyuridine 5'-triphosphate nucleotidohydrolase,dut,,unknown
Lysine Nz-Carboxylic Acid,,D-hydantoinase,hyuA,,unknown
Lysine Nz-Carboxylic Acid,,Beta-lactamase OXA-1,bla,,unknown
Lysine Nz-Carboxylic Acid,,L-hydantoinase,lhyD,,unknown
Lysine Nz-Carboxylic Acid,,D-hydantoinase,,,unknown
Lysine Nz-Carboxylic Acid,,Methylmalonyl-CoA carboxyltransferase 5S subunit,,,unknown
Lysine Nz-Carboxylic Acid,,Isoaspartyl dipeptidase,iadA,,unknown
Lysine Nz-Carboxylic Acid,,Beta-lactamase OXA-2,bla,,unknown
Lysine Nz-Carboxylic Acid,,"Alanine racemase, catabolic",dadX,,unknown
Lysine Nz-Carboxylic Acid,,Endonuclease III,,,unknown
Lysine Nz-Carboxylic Acid,,Hydrolase,,,unknown
Lysine Nz-Carboxylic Acid,,"Alpha-L-fucosidase, putative",,,unknown
Lysine Nz-Carboxylic Acid,,Beta-lactamase OXA-10,bla,,unknown
Lysine Nz-Carboxylic Acid,,UDP-N-acetylmuramoylalanine--D-glutamate ligase,murD,,unknown
Lysine Nz-Carboxylic Acid,,Alanine racemase,alr,,unknown
Lysine Nz-Carboxylic Acid,,"UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--2,6-diaminopimelate ligase",murE,,unknown
Lysine Nz-Carboxylic Acid,,Parathion hydrolase,opd,,unknown
Lysine Nz-Carboxylic Acid,,Folylpolyglutamate synthase,fgs,,unknown
Lysine Nz-Carboxylic Acid,,Dihydroorotase,pyrC,,unknown
Lysine Nz-Carboxylic Acid,,Cyclin-dependent kinase 2,CDK2,,unknown
"1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol",,Estrogen receptor alpha,ESR1,,unknown
Inhibitor Msa367,,Gag-Pol polyprotein,gag-pol,,unknown
5-Bromothienyldeoxyuridine,,Thymidine kinase,TK,,unknown
"1-(2-Chlorophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester",,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,,unknown
Hexamidine,,HTH-type transcriptional regulator QacR,qacR,,unknown
Hexamidine,,HTH-type transcriptional regulator QacR,qacR,,unknown
9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine,,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
Histidinol,,Histidinol dehydrogenase,hisD,,unknown
Histidinol,,Histidine--tRNA ligase,hisS,,unknown
"3-{2,6,8-trioxo-9-[(2S,3R,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,6,8,9-hexahydro-7H-purin-7-Yl}propyl dihydrogen phosphate",,"6,7-dimethyl-8-ribityllumazine synthase",ribH,,unknown
2-Decenoyl N-Acetyl Cysteamine,,3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase,fabA,,unknown
2-Decenoyl N-Acetyl Cysteamine,,3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase,fabA,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Acetylcholinesterase,ACHE,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Glutamine--fructose-6-phosphate aminotransferase [isomerizing],glmS,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Dihydrofolate reductase,DFR1,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Copper-containing nitrite reductase,nirK,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Bifunctional protein GlmU,glmU,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Hydroxylamine reductase,hcp,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Diaminopimelate decarboxylase,lysA,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Alpha-xylosidase,yicI,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,"Limonene-1,2-epoxide hydrolase",limA,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,"Mannan endo-1,4-beta-mannosidase",manA,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,"Beta-1,4-galactosyltransferase 1",B4GALT1,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Tyrosine-protein kinase transforming protein Abl,ABL,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Thiol:disulfide interchange protein DsbC,dsbC,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Glyceraldehyde-3-phosphate dehydrogenase A,gapA,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,(S)-mandelate dehydrogenase,mdlB,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Dissimilatory copper-containing nitrite reductase,nir,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,33 kDa chaperonin,hslO,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Free methionine-R-sulfoxide reductase,msrC,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Ornithine cyclodeaminase,,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Dihydropteridine reductase,QDPR,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Argininosuccinate lyase,ASL,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,O-acetyl-ADP-ribose deacetylase,ymdB,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,ADP-ribosylation factor-like protein 3,ARL3,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Beta-lactamase,blaB,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,3-deoxy-D-manno-octulosonate 8-phosphate phosphatase KdsC,,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Lethal(3)malignant brain tumor-like protein 1,L3MBTL1,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Cholinesterase,BCHE,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Ribonuclease Z,rnz,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Peroxiredoxin-6,PRDX6,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Hypothetical gliding protein,mglB,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Prolyl endopeptidase Pep,pep,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Pulmonary surfactant-associated protein A1,SFTPA1,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Manganese catalase,,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Chorismate mutase AroH,aroH,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Putative cytochrome P450,cyp158a2,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Interferon-inducible GTPase 5,IRGC,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Chymase,CMA1,,unknown
2-(N-Morpholino)-Ethanesulfonic Acid,,Glutathione S-transferase P,GSTP1,,unknown
Fucitol,,L-fucose isomerase,fucI,,unknown
Difluoromethionine,,Methionine--tRNA ligase,metG,,unknown
"2,4-Diaminobutyric Acid",,Envelope glycoprotein gp160,env,,unknown
N-[Tosyl-D-Prolinyl]Amino-Ethanethiol,,Thymidylate synthase,thyA,,unknown
"(2s,5r,6r)-6-{[(6r)-6-(Glycylamino)-7-Oxido-7-Oxoheptanoyl]Amino}-3,3-Dimethyl-7-Oxo-4-Thia-1-Azabicyclo[3.2.0]Heptane-2-Carboxylate",,D-alanyl-D-alanine carboxypeptidase,,,unknown
2-Amino-3-Hydroxy-3-Phosphonooxy-Propionic Acid,,Arylsulfatase A,ARSA,,unknown
Ethyl Dihydrogen Phosphate,,Parathion hydrolase,opd,,unknown
Ethyl Dihydrogen Phosphate,,Cholinesterase,BCHE,,unknown
"7-Iodo-1,2,3,4-Tetrahydro-Isoquinoline",,Phenylethanolamine N-methyltransferase,PNMT,,unknown
Rhodamine 6G,,HTH-type transcriptional regulator QacR,qacR,,unknown
Rhodamine 6G,,Acriflavine resistance protein B,acrB,,unknown
"(3s)-3,4-Di-N-Hexanoyloxybutyl-1-Phosphocholine",,Phospholipase C,plc,,unknown
RU78299,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
Phosphorylated Dihydropteroate,,Bifunctional protein FolC,folC,,unknown
"3-Carboxy-N,N,N-Trimethyl-2-(Octanoyloxy)Propan-1-Aminium",,Peroxisomal carnitine O-octanoyltransferase,CROT,,unknown
"2-Prolyl-5-Tert-Butyl-[1,3,4]Oxadiazole",,Proline iminopeptidase,pip,,unknown
"(3S)-3-(dioxidosulfanyl)-N-[(1Z)-3-oxoprop-1-en-1-yl]-4-(1H-1,2,3-triazol-1-yl)-D-valine",,Beta-lactamase SHV-1,bla,,unknown
"N-[(5S,7R,8S,9S,10R)-8,9,10-Trihydroxy-7-(hydroxymethyl)-2,4-dioxo-6-oxa-1,3-diazaspiro[4.5]dec-3-yl]acetamide",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
"1,3,5-Trichloro-Benzene",,Camphor 5-monooxygenase,camC,,unknown
Morpholine-4-Carboxylic Acid (1-(3-Benzenesulfonyl-1-Phenethylallylcarbamoyl)-3-Methylbutyl)-Amide,,Cathepsin S,CTSS,,unknown
Tetra(Imidazole)Diaquacopper (Ii),,Azurin,azu,,unknown
Y-700,,Xanthine dehydrogenase/oxidase,XDH,,unknown
2-Chloro-6-Methyl-Aniline,,Lysozyme,E,,unknown
Formaldehyde,,D-alanyl-D-alanine carboxypeptidase,,,unknown
"N-(2,6-Diflouro-Benzyl)-4-Sulfamoyl-Benzamide",,Carbonic anhydrase 2,CA2,,unknown
P1-(5'-Adenosyl)P5-(5'-(3'azido-3'-Deoxythymidyl))Pentaphosphate,,Thymidylate kinase,DTYMK,,unknown
5-Hydroxymethyluridine-2'-Deoxy-5'-Monophosphate,,Thymidylate kinase,tmk,,unknown
Gamma-Carboxy-Glutamic Acid,,Prothrombin,F2,,unknown
Gamma-Carboxy-Glutamic Acid,,Osteocalcin,BGLAP,,unknown
Gamma-Carboxy-Glutamic Acid,,Coagulation factor X,F10,,unknown
Benzenesulfinic acid,,Oxysterols receptor LXR-beta,NR1H2,,unknown
Cilomilast,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,inhibitor,yes
Cilomilast,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,inhibitor,yes
Jaspisamide A,,"Actin, alpha skeletal muscle",ACTA1,,unknown
"Pentane-1,5-Diamine",,2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase,ispD,,unknown
L-Threonohydroxamate 4-Phosphate,,3-keto-L-gulonate-6-phosphate decarboxylase UlaD,ulaD,,unknown
L-Eflornithine,,Ornithine decarboxylase,ODC1,,unknown
"1,4-dithio-beta-D-glucopyranose",,Endoglucanase F,celCCF,,unknown
1-Thio-Beta-D-Glucopyranose,,Endoglucanase G,celCCG,,unknown
"N-Butyl-11-[(7r,8r,9s,13s,14s,17s)-3,17-Dihydroxy-13-Methyl-7,8,9,11,12,13,14,15,16,17-Decahydro-6h-Cyclopenta[a]Phenanthren-7-Yl]-N-Methylundecanamide",,Estrogen receptor beta,ESR2,,unknown
"(2r,3r,4s,5r)-2-Acetamido-3,4-Dihydroxy-5-Hydroxymethyl-Piperidinium",,Beta-hexosaminidase subunit beta,HEXB,,unknown
"(2r,3r,4s,5r)-2-Acetamido-3,4-Dihydroxy-5-Hydroxymethyl-Piperidinium",,Calcium-activated potassium channel subunit beta-2,KCNMB2,,unknown
Tetrahydrooxazine,,Endoglucanase 5A,cel5A,,unknown
Tetrahydrooxazine,,Beta-glucosidase A,bglA,,unknown
2-O-methyl fucose,,Chondroitinase-AC,cslA,,unknown
2-O-methyl fucose,,Chondroitinase-B,cslB,,unknown
Monothioglycerol,,Prolyl endopeptidase,PREP,,unknown
6-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-Carboxamidine,,Prothrombin,F2,,unknown
6-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-Carboxamidine,,Trypsin-1,PRSS1,,unknown
6-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-Carboxamidine,,Urokinase-type plasminogen activator,PLAU,,unknown
6-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-Carboxamidine,,Serine protease hepsin,HPN,,unknown
Prostaglandin G2,,Prostaglandin G/H synthase 2,PTGS2,,unknown
Meta-Nitro-Tyrosine,,"Glutathione reductase, mitochondrial",GSR,,unknown
3-Dehydroquinic Acid,,3-dehydroquinate dehydratase,aroQ,,unknown
5'-O-(N-(L-Seryl)-Sulfamoyl)Adenosine,,Threonine--tRNA ligase,thrS,,unknown
"Ara-Alpha(1,3)-Xyl",,Intracellular exo-alpha-(1->5)-L-arabinofuranosidase,abfA,,unknown
"lambda-bis(2,2'-bipyridine)imidazole ruthenium (II)",,Azurin,azu,,unknown
"(4e,8e,12z,16z)-N,N,4,8,13,17,21-Heptamethyldocosa-4,8,12,16,20-Pentaen-1-Amine",,Squalene--hopene cyclase,shc,,unknown
"Thieno[2,3-B]Pyridine-2-Carboxamidine",,Trypsin-1,PRSS1,,unknown
"Thieno[2,3-B]Pyridine-2-Carboxamidine",,Urokinase-type plasminogen activator,PLAU,,unknown
AL4623,,Carbonic anhydrase 2,CA2,,unknown
N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide,,Tyrosine-protein kinase transforming protein Abl,ABL,,unknown
N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide,,Tyrosine-protein kinase ABL1,ABL1,,unknown
alpha-L-methyl-fucose,,Mannose-binding protein C,MBL2,,unknown
alpha-L-methyl-fucose,,Chondroitinase-AC,cslA,,unknown
Batimastat,,Neutrophil collagenase,MMP8,,unknown
Batimastat,,Macrophage metalloelastase,MMP12,,unknown
Batimastat,,Matrix metalloproteinase-16,MMP16,,unknown
Batimastat,,Disintegrin and metalloproteinase domain-containing protein 28,ADAM28,,unknown
Batimastat,,A disintegrin and metalloproteinase with thrombospondin motifs 5,ADAMTS5,,unknown
MT-Immucillin-H,,Purine nucleoside phosphorylase,PNP,,unknown
MT-Immucillin-H,,"Purine nucleotide phosphorylase, putative",,,unknown
"5-Alpha-Androstane-3-Beta,17beta-Diol",,Estrogen receptor beta,ESR2,agonist,unknown
Phenylpyruvic acid,,L-phenylalanine dehydrogenase,pdh,,unknown
Phenylpyruvic acid,,Hydroxyacid oxidase 1,HAO1,,unknown
Phenylpyruvic acid,,Indole-3-pyruvate decarboxylase,ipdC,,unknown
Phenylpyruvic acid,,Putative uncharacterized protein,,,unknown
Phenylpyruvic acid,,Bacilysin biosynthesis protein BacB,bacB,,unknown
Phenylpyruvic acid,,Probable chorismate mutase,pheA,,unknown
Biopterin,,Sepiapterin reductase,SPR,,unknown
Biopterin,,6-pyruvoyl tetrahydrobiopterin synthase,PTS,,unknown
Biopterin,,Dihydrofolate reductase,DHFR,,unknown
Alpha-Adenosine Monophosphate,,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
N-Allyl-6-{[3-(4-bromophenyl)-1-methyl-1H-indazol-6-yl]oxy}-N-methyl-1-hexanamine,,Squalene--hopene cyclase,shc,,unknown
S-(N-Hydroxy-N-Bromophenylcarbamoyl)Glutathione,,"Hydroxyacylglutathione hydrolase, mitochondrial",HAGH,,unknown
N-[2-(1-Formyl-2-Methyl-Propyl)-1-(4-Piperidin-1-Yl-but-2-Enoyl)-Pyrrolidin-3-Yl]-Methanesulfonamide,,Chymotrypsin-like elastase family member 1,CELA1,,unknown
"1,5-Bis(N-Benzyloxycarbonyl-L-Leucinyl)Carbohydrazide",,Cathepsin K,CTSK,,unknown
5-N-Allyl-Arginine,,"Nitric oxide synthase, brain",NOS1,,unknown
Thionicotinamide-Adenine-Dinucleotide,,Glyceraldehyde-3-phosphate dehydrogenase,GAPDH,,unknown
N-Propargyl-1(S)-Aminoindan,,Amine oxidase [flavin-containing] B,MAOB,,unknown
Malachite Green,,HTH-type transcriptional regulator QacR,qacR,,unknown
Triphosphoric acid,,Poly(A) polymerase alpha,PAPOLA,,unknown
Hydroxyphenyl Propionic Acid,,Tyrosine phenol-lyase,tpl,,unknown
Hydroxyphenyl Propionic Acid,,Tyrosine phenol-lyase,tpl,,unknown
Hydroxyphenyl Propionic Acid,,Prephenate dehydrogenase,tyrA,,unknown
9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine,,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
2-Methyl-2-Propanol,,Ribonuclease pancreatic,RNASE1,,unknown
2-Methyl-2-Propanol,,Triosephosphate isomerase,TPI1,,unknown
2-Methyl-2-Propanol,,Methionine aminopeptidase 2,METAP2,,unknown
2-Methyl-2-Propanol,,"Biphenyl-2,3-diol 1,2-dioxygenase",bphC,,unknown
2-Methyl-2-Propanol,,Calmodulin,CALM1,,unknown
5-Oxo-Pyrrolidine-2-Carbaldehyde,,Acidic cytochrome c3,,,unknown
Oxalic Acid,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
Tmr,,"Actin, alpha skeletal muscle",ACTA1,,unknown
Urea,,Arginase-1,ARG1,,unknown
Urea,,Carbonic anhydrase 2,CA2,,unknown
Urea,,Structural polyprotein,,,unknown
Urea,,Catenin beta-1,CTNNB1,,unknown
Urea,,Sulfoxide reductase catalytic subunit YedY,yedY,,unknown
Urea,,Dihydrofolate reductase,folA,,unknown
Succinamide-Coa,,"2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase",dapD,,unknown
2-Phenylheme,,Heme oxygenase 1,HMOX1,,unknown
"N-{3-[5-(6-Amino-Purin-9-Yl)-3,4-Dihydroxy-Tetrahydro-Furan-2-Yl]-Allyl}-2,3-Dihydroxy-5-Nitro-Benzamide",,Catechol O-methyltransferase,COMT,,unknown
Inhibitor Bea322,,Gag-Pol polyprotein,gag-pol,,unknown
"Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate",,Folylpolyglutamate synthase,fgs,,unknown
"Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate",,Chemotaxis protein CheA,cheA,,unknown
"Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate",,UDP-N-acetylmuramate--L-alanine ligase,murC,,unknown
"Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate",,Thermoresistant gluconokinase,gntK,,unknown
"Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate",,Phosphoribosylglycinamide formyltransferase 2,purT,,unknown
"Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate",,Insulin receptor,INSR,,unknown
"Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate",,Sarcoplasmic/endoplasmic reticulum calcium ATPase 1,ATP2A1,,unknown
"Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate",,Pyridoxal kinase,PDXK,,unknown
"Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate",,Phosphoglycerate kinase 1,PGK1,,unknown
"Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate",,Serine/threonine-protein kinase PknB,pknB,,unknown
"Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate",,Ribokinase,rbsK,,unknown
"Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate",,Putative sugar kinase,,,unknown
"Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate",,Probable butyrate kinase 2,buk2,,unknown
"Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate",,Kinesin-like protein KIF1A,KIF1A,,unknown
"S,S'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea",,"Nitric oxide synthase, endothelial",NOS3,,unknown
L-Xylopyranose,,Xylose isomerase,xylA,,unknown
4'-Phosphopantetheine,,Phosphopantetheine adenylyltransferase,coaD,,unknown
4'-Phosphopantetheine,,Phosphopantetheine adenylyltransferase,coaD,,unknown
4'-Phosphopantetheine,,Phosphopantetheine adenylyltransferase,coaD,,unknown
2-Amino-3-Ketobutyric Acid,,2-amino-3-ketobutyrate coenzyme A ligase,kbl,,unknown
4-{2-[4-(2-Aminoethyl)Piperazin-1-Yl]Pyridin-4-Yl}-N-(3-Chloro-4-Methylphenyl)Pyrimidin-2-Amine,,Cell division protein ZipA homolog,zipA,,unknown
4-{2-[4-(2-Aminoethyl)Piperazin-1-Yl]Pyridin-4-Yl}-N-(3-Chloro-4-Methylphenyl)Pyrimidin-2-Amine,,Cell division protein ZipA,zipA,,unknown
"6S-5,6,7,8-Tetrahydrobiopterin",,"Nitric oxide synthase, endothelial",NOS3,,unknown
Ethyl-Carbamic Acid Methyl Ester,,Shiga-like toxin 1 subunit B,stxB,,unknown
4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline,,TGF-beta receptor type-1,TGFBR1,,unknown
Feruloyl Coenzyme A,,Catechol O-methyltransferase domain-containing protein 1,COMTD1,,unknown
"5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone",,Casein kinase II subunit alpha,CSNK2A1,,unknown
Freselestat,,Neutrophil elastase,ELANE,inhibitor,unknown
Freselestat,,Chymotrypsin-like elastase family member 1,CELA1,,unknown
Glycyl-L-Alpha-Amino-Epsilon-Pimelyl-D-Alanine,,D-alanyl-D-alanine carboxypeptidase,,,unknown
"Carboxymethylthio-3-(3-Chlorophenyl)-1,2,4-Oxadiazol",,Cystathionine gamma-lyase,CTH,,unknown
D-Serine,,Glycine receptor subunit alpha-1,GLRA1,,unknown
D-Serine,,"Glutamate receptor ionotropic, NMDA 1",GRIN1,,unknown
D-Serine,,Serpin B3,SERPINB3,,unknown
D-Serine,,Head decoration protein,shp,,unknown
Diguanosine-5'-Triphosphate,,mRNA-capping enzyme,,,unknown
LFA703,,Integrin alpha-L,ITGAL,,unknown
C-1027 Aromatized Chromophore,,Antitumor antibiotic C-1027 apoprotein,cagA,,unknown
Protoporphyrin Ix Containing Zn,,Cytochrome c,CYCS,,unknown
"1,4-Dideoxy-O2-Sulfo-Glucuronic Acid",,Fibroblast growth factor 2,FGF2,,unknown
"1,4-Dideoxy-O2-Sulfo-Glucuronic Acid",,Annexin A5,ANXA5,,unknown
1-Deoxy-Ribofuranose-5'-Phosphate,,2-dehydro-3-deoxyphosphooctonate aldolase,kdsA,,unknown
Erythose-4-Phosphate,,2-dehydro-3-deoxyphosphooctonate aldolase,kdsA,,unknown
Erythose-4-Phosphate,,Glucose-6-phosphate isomerase,GPI,,unknown
Erythose-4-Phosphate,,Phospho-2-dehydro-3-deoxyheptonate aldolase,aroF,,unknown
Deacetoxycephalosporin-C,,Deacetoxycephalosporin C synthase,cefE,,unknown
"4-Hydroxy-3,4-Dihydro-1h-Pyrimidin-2-One",,Cytosine deaminase,codA,,unknown
Oxamic Acid,,L-lactate dehydrogenase,,,unknown
Oxamic Acid,,L-lactate dehydrogenase,ldh,,unknown
Oxamic Acid,,L-lactate dehydrogenase A chain,LDHA,,unknown
Oxamic Acid,,L-lactate dehydrogenase B chain,LDHB,,unknown
Oxamic Acid,,Formate acetyltransferase 1,pflB,,unknown
Oxamic Acid,,D-lactate dehydrogenase,,,unknown
Carboxylic PRPP,,Amidophosphoribosyltransferase,purF,,unknown
Carboxylic PRPP,,Pur operon repressor,purR,,unknown
Carboxylic PRPP,,Xanthine phosphoribosyltransferase,gpt,,unknown
"5-[1-(3,4-Dimethoxy-Benzoyl)-1,2,3,4-Tetrahydro-Quinolin-6-Yl]-6-Methyl-3,6-Dihydro-[1,3,4]Thiadiazin-2-One",,"Troponin C, slow skeletal and cardiac muscles",TNNC1,,unknown
"N,N,N-Trimethyl-2-(phosphonooxy)ethanaminium",,C-reactive protein,CRP,,unknown
"N,N,N-Trimethyl-2-(phosphonooxy)ethanaminium",,Epididymal sperm-binding protein 1,ELSPBP1,,unknown
"N,N,N-Trimethyl-2-(phosphonooxy)ethanaminium",,Gamma-hemolysin component B,hlgB,,unknown
D-Xylulose,,Xylose isomerase,xylA,,unknown
"6-Chloropurine Riboside, 5'-Monophosphate",,Inosine-5'-monophosphate dehydrogenase 1,IMPDH1,,unknown
"6-Chloropurine Riboside, 5'-Monophosphate",,Inosine-5'-monophosphate dehydrogenase 2,IMPDH2,,unknown
(2-Sulfanyl-3-Phenylpropanoyl)-Phe-Tyr,,Thermolysin,nprS,,unknown
(S)-N-(3-Indol-1-Yl-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide,,Carbonic anhydrase 2,CA2,,unknown
N-acetyl-D-glucosamine-6-phosphate,,Glucosamine-6-phosphate isomerase 1,GNPDA1,,unknown
N-acetyl-D-glucosamine-6-phosphate,,Glucosamine-6-phosphate deaminase,nagB,,unknown
9-(6-deoxy-beta-D-allofuranosyl)-6-methylpurine,,Purine nucleoside phosphorylase DeoD-type,deoD,,unknown
L-Thiocitrulline,,"Nitric oxide synthase, inducible",NOS2,,unknown
1-deoxymannojirimycin,,Alpha-mannosidase 2,MAN2A1,,unknown
"Inositol 2,4,5-trisphosphate",,"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1",PLCD1,,unknown
SP2456,,Interleukin-2,IL2,,unknown
7-methyl-guanosine-5'-triphosphate-5'-guanosine,,m7GpppX diphosphatase,DCPS,,unknown
7-methyl-guanosine-5'-triphosphate-5'-guanosine,,RNA-directed RNA polymerase lambda-3,L1,,unknown
"N,O6-Disulfo-Glucosamine",,Fibroblast growth factor 2,FGF2,,unknown
"N,O6-Disulfo-Glucosamine",,Fibroblast growth factor 1,FGF1,,unknown
"N,O6-Disulfo-Glucosamine",,Heparan sulfate glucosamine 3-O-sulfotransferase 3A1,HS3ST3A1,,unknown
"N,O6-Disulfo-Glucosamine",,Hepatocyte growth factor,HGF,,unknown
"N,O6-Disulfo-Glucosamine",,Complement control protein C3,,,unknown
"N,O6-Disulfo-Glucosamine",,Annexin A5,ANXA5,,unknown
"2c-Methyl-D-Erythritol 2,4-Cyclodiphosphate",,"2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase",ispF,,unknown
Nicotinamide 8-Bromo-Adenine Dinucleotide Phosphate,,"6-phosphogluconate dehydrogenase, decarboxylating",PGD,,unknown
S-(Dimethylarsenic)Cysteine,,Toll-like receptor 2,TLR2,,unknown
S-(Dimethylarsenic)Cysteine,,Capsid scaffolding protein,UL80,,unknown
S-(Dimethylarsenic)Cysteine,,Gag-Pol polyprotein,gag-pol,,unknown
S-(Dimethylarsenic)Cysteine,,"Nitric oxide synthase, endothelial",NOS3,,unknown
S-(Dimethylarsenic)Cysteine,,Coatomer subunit gamma-1,COPG1,,unknown
S-(Dimethylarsenic)Cysteine,,Genome polyprotein,,,unknown
S-(Dimethylarsenic)Cysteine,,DNA repair protein XRCC4,XRCC4,,unknown
S-(Dimethylarsenic)Cysteine,,Peptide methionine sulfoxide reductase MsrA,msrA,,unknown
4-Hydroxy-Aconitate Ion,,"Aconitate hydratase, mitochondrial",ACO2,,unknown
Clorobiocin,,DNA gyrase subunit B,gyrB,,unknown
Dodecyl Sulfate,,Lysozyme C,LYZ,,unknown
Dodecyl Sulfate,,Lipid A palmitoyltransferase PagP,pagP,,unknown
"1-Methyl-2-Oxy-5,5-Dimethyl Pyrrolidine",,Renin,REN,,unknown
"(7R)-7-(6,7-Dihydro-5H-cyclopenta[d]imidazo[2,1-b][1,3]thiazol-2-yl)-2,7-dihydro-1,4-thiazepine-3,6-dicarboxylic acid",,Beta-lactamase,ampC,,unknown
"(7R)-7-(6,7-Dihydro-5H-cyclopenta[d]imidazo[2,1-b][1,3]thiazol-2-yl)-2,7-dihydro-1,4-thiazepine-3,6-dicarboxylic acid",,Beta-lactamase SHV-1,bla,,unknown
"(7R)-7-(6,7-Dihydro-5H-cyclopenta[d]imidazo[2,1-b][1,3]thiazol-2-yl)-2,7-dihydro-1,4-thiazepine-3,6-dicarboxylic acid",,Beta-lactamase SHV-1,bla,,unknown
"(7R)-7-(6,7-Dihydro-5H-cyclopenta[d]imidazo[2,1-b][1,3]thiazol-2-yl)-2,7-dihydro-1,4-thiazepine-3,6-dicarboxylic acid",,Class C beta-lactamase,,,unknown
Acarbose Derived Hexasaccharide,,Maltogenic alpha-amylase,amyM,,unknown
Acarbose Derived Hexasaccharide,,Pancreatic alpha-amylase,AMY2A,,unknown
"3-{2,6,8-trioxo-9-[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,6,8,9-hexahydro-7H-purin-7-Yl}propyl dihydrogen phosphate",,"6,7-dimethyl-8-ribityllumazine synthase",ribH,,unknown
L-Homoarginine,,"Nitric oxide synthase, endothelial",NOS3,,unknown
Mercuribenzoic Acid,,Divalent-cation tolerance protein CutA,cutA,,unknown
Mercuribenzoic Acid,,Carbonic anhydrase 2,CA2,,unknown
Phosphorylisopropane,,Capsid scaffolding protein,,,unknown
Phosphorylisopropane,,Trypsin-1,PRSS1,,unknown
Phosphorylisopropane,,Trypsin-2,PRSS2,,unknown
Phosphorylisopropane,,Chymotrypsinogen B,CTRB1,,unknown
N-Trimethyllysine,,Cytochrome c,CYCS,,unknown
N-Trimethyllysine,,Calmodulin,CALM1,,unknown
Tyrosinal,,Tyrosine--tRNA ligase,tyrS,,unknown
Tyrosinal,,Pseudomonalisin,pcp,,unknown
Tyrosinal,,"Tyrosine--tRNA ligase, cytoplasmic",YARS,,unknown
Tyrosinal,,Tyrosine--tRNA ligase,YARS,,unknown
1-[Glycerolylphosphonyl]-2-[8-(2-Hexyl-Cyclopropyl)-Octanal-1-Yl]-3-[Hexadecanal-1-Yl]-Glycerol,,Flavohemoprotein,hmp,,unknown
4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole,,Mitogen-activated protein kinase 14,MAPK14,,unknown
"1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid",,Annexin A5,ANXA5,,unknown
"1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid",,Fibroblast growth factor 2,FGF2,,unknown
"1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid",,Heparan sulfate glucosamine 3-O-sulfotransferase 3A1,HS3ST3A1,,unknown
"Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
"(Molybdopterin-S,S)-Dioxo-Thio-Molybdenum(V)",,"Sulfite oxidase, mitochondrial",SUOX,,unknown
Morpholine-4-Carboxylic Acid [1-(2-Benzylsulfanyl-1-Formyl-Ethylcarbamoyl)-2-Phenyl-Ethyl]-Amide,,Cathepsin S,CTSS,,unknown
6-Methyl-Formycin A,,Purine nucleoside phosphorylase DeoD-type,deoD,,unknown
"2,4-Diamino-6-[N-(3',5'-Dimethoxybenzyl)-N-Methylamino]Pyrido[2,3-D]Pyrimidine",,Dihydrofolate reductase,,,unknown
"2,4-Diamino-6-[N-(3',5'-Dimethoxybenzyl)-N-Methylamino]Pyrido[2,3-D]Pyrimidine",,Dihydrofolate reductase,DHFR,,unknown
"2,6-Diamino-Hexanoic Acid Amide",,Pituitary adenylate cyclase-activating polypeptide,ADCYAP1,,unknown
D-Allopyranose,,D-allose-binding periplasmic protein,alsB,,unknown
"2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid",,Hemagglutinin-neuraminidase,HN,,unknown
"2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid",,Sialidase,nedA,,unknown
"2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid",,Neuraminidase,NA,,unknown
"2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid",,Hemagglutinin-neuraminidase,HN,,unknown
"2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid",,Sialidase-2,NEU2,,unknown
4-Methyl Valeric Acid,,Branched-chain-amino-acid aminotransferase,ilvE,,unknown
Ethanolamine,,Surface protein A,nspA,,unknown
Ethanolamine,,Annexin A3,ANXA3,,unknown
Betadex,,Neopullulanase 2,tvaII,,unknown
Betadex,,Maltose-binding periplasmic protein,malE,,unknown
Betadex,,Maltogenic amylase,,,unknown
"3-[(5s)-1-Acetyl-3-(2-Chlorophenyl)-4,5-Dihydro-1h-Pyrazol-5-Yl]Phenol",,Kinesin-like protein KIF11,KIF11,,unknown
L-histidinol phosphate,,Histidinol-phosphate aminotransferase,hisC,,unknown
L-histidinol phosphate,,Histidinol-phosphate aminotransferase,hisC,,unknown
Butylphosphonate,,Lipase,lip,,unknown
Bromo-Willardiine,,Glutamate receptor 2,GRIA2,,unknown
6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
4-Sulfonamide-[4-(Thiomethylaminobutane)]Benzamide,,Carbonic anhydrase 2,CA2,,unknown
{4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid,,Tyrosine-protein kinase Lck,LCK,,unknown
"2,6-Diamino-8-(2-Dimethylaminoethylsulfanylmethyl)-3h-Quinazolin-4-One",,Queuine tRNA-ribosyltransferase,tgt,,unknown
Uridine 5'-triphosphate,,Uridine-cytidine kinase 2,UCK2,,unknown
Uridine 5'-triphosphate,,Genome polyprotein,,,unknown
Uridine 5'-triphosphate,,Genome polyprotein,,,unknown
"[2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone",,Cyclin-dependent kinase 2,CDK2,,unknown
Bromo-WR99210,,Dihydrofolate reductase,folA,,unknown
Bis(5-Amidino-Benzimidazolyl)Methane Zinc,,Trypsin-1,PRSS1,,unknown
Dimethyl Propionate Ester Heme,,Cytochrome b5,CYB5A,,unknown
2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide,,Poly [ADP-ribose] polymerase 1,PARP1,,unknown
"(3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Leucine",,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,,unknown
1-Deoxy-1-Methoxycarbamido-Beta-D-Gluco-2-Heptulopyranosonamide,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
Alsterpaullone,,Cyclin-dependent kinase 5,CDK5,,unknown
Alsterpaullone,,Cyclin-dependent kinase 1,CDK1,inhibitor,unknown
Alsterpaullone,,Glycogen synthase kinase-3 beta,GSK3B,,unknown
Methionine Phosphinate,,Methionine--tRNA ligase,metG,,unknown
Methionine Phosphinate,,Methionine aminopeptidase,map,,unknown
2-[3-({Methyl[1-(2-Naphthoyl)Piperidin-4-Yl]Amino}Carbonyl)-2-Naphthyl]-1-(1-Naphthyl)-2-Oxoethylphosphonic Acid,,Cathepsin G,CTSG,,unknown
2-[3-({Methyl[1-(2-Naphthoyl)Piperidin-4-Yl]Amino}Carbonyl)-2-Naphthyl]-1-(1-Naphthyl)-2-Oxoethylphosphonic Acid,,Chymase,CMA1,,unknown
"N-Methyl-N-Propargyl-3-(2,4-Dichlorophenoxy)Propylamine",,Amine oxidase [flavin-containing] A,MAOA,,unknown
S-Isopropyl-Isothiourea,,"Nitric oxide synthase, endothelial",NOS3,,unknown
"4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol",,Estrogen receptor beta,ESR2,,unknown
MF268,,Acetylcholinesterase,ACHE,,unknown
"Guanosine-5',3'-Tetraphosphate",,Xanthine phosphoribosyltransferase,xpt,,unknown
"Guanosine-5',3'-Tetraphosphate",,GTPase ObgE,obg,,unknown
"Guanosine 5'-(Trihydrogen Diphosphate), P'-D-Mannopyranosyl Ester",,GDP-mannose 6-dehydrogenase,algD,,unknown
N'-L-Seryl-3'-Amino-(3'-Deoxy)-Adenosine,,Threonine--tRNA ligase,thrS,,unknown
D-Arginine,,Creatine kinase M-type,CKM,,unknown
Tyvelose,,Bifunctional tail protein,9,,unknown
Phenylalanine Amide,,Genome polyprotein,,,unknown
Phenylalanine Amide,,Genome polyprotein,,,unknown
Phenylalanine Amide,,D-Amino acid amidase,daaA,,unknown
"1,3,4,9-Tetrahydro-2-(Hydroxybenzoyl)-9-[(4-Hydroxyphenyl)Methyl]-6-Methoxy-2h-Pyrido[3,4-B]Indole",,Enoyl-[acyl-carrier-protein] reductase [NADH] FabI,fabI,,unknown
Serine Vanadate,,Alkaline phosphatase,phoA,,unknown
Adamantane-1-Carboxylic Acid-5-Dimethylamino-Naphthalene-1-Sulfonylamino-Butyl-Amide,,Camphor 5-monooxygenase,camC,,unknown
Z-Ala Prolinal,,Prolyl endopeptidase Pep,pep,,unknown
Ribulose-5-Phosphate,,3-keto-L-gulonate-6-phosphate decarboxylase UlaD,ulaD,,unknown
Pinacol[[2-Amino-Alpha-(1-Carboxy-1-Methylethoxyimino)-4-Thiazoleacetyl]Amino]Methaneboronate,,Beta-lactamase CTX-M,blaCTX-M-14,,unknown
Pinacol[[2-Amino-Alpha-(1-Carboxy-1-Methylethoxyimino)-4-Thiazoleacetyl]Amino]Methaneboronate,,Beta-lactamase,ampC,,unknown
Pinacol[[2-Amino-Alpha-(1-Carboxy-1-Methylethoxyimino)-4-Thiazoleacetyl]Amino]Methaneboronate,,Beta-lactamase TEM,bla,,unknown
Coenzyme a Persulfide,,"Isovaleryl-CoA dehydrogenase, mitochondrial",IVD,,unknown
"N,N-Bis(4-Chlorobenzyl)-1h-1,2,3,4-Tetraazol-5-Amine",,Beta-lactamase TEM,bla,,unknown
"N,N-Bis(4-Chlorobenzyl)-1h-1,2,3,4-Tetraazol-5-Amine",,Beta-lactamase TEM,bla,,unknown
3-Oxo-Pentadecanoic Acid,,Ferrichrome-iron receptor,fhuA,,unknown
3-Oxo-Pentadecanoic Acid,,Vitamin B12 transporter BtuB,btuB,,unknown
3-Oxo-Pentadecanoic Acid,,Colicin-E3,ceaC,,unknown
"N-(2-Morpholin-4-Yl-1-Morpholin-4-Ylmethyl-Ethyl)-3-Nitro-5-(3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yloxy)-Benzamide",,Heat-labile enterotoxin B chain,eltB,,unknown
Nitrocefin Acyl-Serine,,Beta-lactam-inducible penicillin-binding protein,pbp,,unknown
"2-[4-(Hydroxy-Methoxy-Methyl)-Benzyl]-7-(4-Hydroxymethyl-Benzyl)-1,1-Dioxo-3,6-Bis-Phenoxymethyl-1lambda6-[1,2,7]Thiadiazepane-4,5-Diol",,Gag-Pol polyprotein,gag-pol,,unknown
Carboxymycobactin T,,Neutrophil gelatinase-associated lipocalin,LCN2,,unknown
4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
Methylmalonyl-Coenzyme A,,Methylmalonyl-CoA carboxyltransferase 12S subunit,,,unknown
[Pterin-6-Yl Methanyl]-Phosphonophosphate,,Dihydropteroate synthase,folP,,unknown
[Pterin-6-Yl Methanyl]-Phosphonophosphate,,2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase,folK,,unknown
N-Carbamoyl-Alanine,,Peroxiredoxin-2,PRDX2,,unknown
N-Propyl Isocyanide,,Myoglobin,MB,,unknown
5-Phenylvaleric Acid,,Aromatic-amino-acid aminotransferase,tyrB,,unknown
"3,4-Dimethylphenol",,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
Hypophosphite,,Thiosulfate sulfurtransferase,rhdA,,unknown
"9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
"Beta-Dadf, Msa, Multisubstrate Adduct Inhibitor",,Bifunctional purine biosynthesis protein PURH,ATIC,,unknown
D-[(Amino)Carbonyl]Phenylalanine,,N-carbamoyl-D-amino acid hydrolase,,,unknown
D-[(Amino)Carbonyl]Phenylalanine,,Carboxypeptidase A1,CPA1,,unknown
8-(Pyrimidin-2-Ylamino)Naphthalene-2-Carboximidamide,,Urokinase-type plasminogen activator,PLAU,,unknown
Beta-D-Fucose,,Arabinose operon regulatory protein,araC,,unknown
Beta-D-Fucose,,L-arabinose-binding periplasmic protein,araF,,unknown
2-Methylleucine,,Branched-chain-amino-acid aminotransferase,ilvE,,unknown
Nogalaviketone,,Nogalonic acid methyl ester cyclase,snoaL,,unknown
N-Cyclopentyl-N-Cyclobutylformamide,,Alcohol dehydrogenase 1A,ADH1A,,unknown
para-Coumaric Acid,,PPH,pph,,unknown
para-Coumaric Acid,,Photoactive yellow protein,pyp,,unknown
para-Coumaric Acid,,Prostaglandin reductase 1,PTGR1,,unknown
para-Coumaric Acid,,Histidine ammonia-lyase,hutH,,unknown
4-Hydroxybenzyl Coenzyme A,,4-hydroxybenzoyl-CoA thioesterase,fcbC,,unknown
4-Hydroxybenzyl Coenzyme A,,4-hydroxybenzoyl-CoA thioesterase,,,unknown
Fudp,,Nucleoside diphosphate kinase A,NME1,,unknown
"5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine",,Death-associated protein kinase 1,DAPK1,,unknown
6-Deoxyerythronolide B,,6-deoxyerythronolide B hydroxylase,eryF,,unknown
Cpad,,Alcohol dehydrogenase 1C,ADH1C,,unknown
Alpha-Methylisocitric Acid,,"Aconitate hydratase, mitochondrial",ACO2,,unknown
N-{3-[4-(3-aminopropyl)piperazin-1-yl]propyl}-3-(beta-D-galactopyranosyloxy)-5-nitrobenzamide,,Cholera enterotoxin subunit B,ctxB,,unknown
Alpha-ketoisovalerate,,3-methyl-2-oxobutanoate hydroxymethyltransferase,panB,,unknown
Alpha-ketoisovalerate,,Deacetoxycephalosporin C synthase,cefE,,unknown
Alpha-ketoisovalerate,,2-isopropylmalate synthase,leuA,,unknown
Alpha-ketoisovalerate,,"Branched-chain-amino-acid aminotransferase, mitochondrial",BCAT2,,unknown
N-Acetyl-L-Glutamate,,Acetylglutamate kinase,argB,,unknown
N-Acetyl-L-Glutamate,,Acetylglutamate kinase,argB,,unknown
Hypoxanthine,,Purine nucleoside phosphorylase,PNP,,unknown
"Heptane-1,2,3-Triol",,Fimbrial protein,pilE1,,unknown
"Heptane-1,2,3-Triol",,Fe(3+) dicitrate transport protein FecA,fecA,,unknown
"Heptane-1,2,3-Triol",,Rhodopsin,RHO,,unknown
RU78191,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
"(4s-Trans)-4-(Methylamino)-5,6-Dihydro-6-Methyl-4h-Thieno(2,3-B)Thiopyran-2-Sulfonamide-7,7-Dioxide",,Carbonic anhydrase 2,CA2,,unknown
Decyloxy-Methanol,,Ribosome-recycling factor,frr,,unknown
Decyloxy-Methanol,,Ribosome-recycling factor,frr,,unknown
N'-Pyridoxyl-Lysine-5'-Monophosphate,,Aspartate aminotransferase,,,unknown
N'-Pyridoxyl-Lysine-5'-Monophosphate,,L-allo-threonine aldolase,,,unknown
N'-Pyridoxyl-Lysine-5'-Monophosphate,,Methionine gamma-lyase,mdeA,,unknown
N'-Pyridoxyl-Lysine-5'-Monophosphate,,Cystathionine gamma-synthase,metB,,unknown
N'-Pyridoxyl-Lysine-5'-Monophosphate,,Tyrosine aminotransferase,,,unknown
N'-Pyridoxyl-Lysine-5'-Monophosphate,,Kynurenine--oxoglutarate transaminase 1,CCBL1,,unknown
N'-Pyridoxyl-Lysine-5'-Monophosphate,,Ornithine decarboxylase,ODC1,,unknown
N'-Pyridoxyl-Lysine-5'-Monophosphate,,Adenosylmethionine-8-amino-7-oxononanoate aminotransferase,bioA,,unknown
N'-Pyridoxyl-Lysine-5'-Monophosphate,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
N'-Pyridoxyl-Lysine-5'-Monophosphate,,Serine--pyruvate aminotransferase,AGXT,,unknown
N'-Pyridoxyl-Lysine-5'-Monophosphate,,Aspartate aminotransferase,aspC,,unknown
2-deoxy-2-fluoro-α-D-mannose,,"Mannan endo-1,4-beta-mannosidase",manA,,unknown
"1-[Pyrrol-1-Yl-2,5-Dione-Methoxymethyl]-Pyrrole-2,5-Dione",,Azurin,azu,,unknown
"2',4'-Dinitrophenyl-2deoxy-2-Fluro-B-D-Cellobioside",,Endoglucanase 5A,cel5A,,unknown
Open Form of 2'-Deoxy-Ribofuranose-5'-Phosphate,,Deoxyribose-phosphate aldolase,deoC,,unknown
Open Form of 2'-Deoxy-Ribofuranose-5'-Phosphate,,Deoxyribose-phosphate aldolase,deoC,,unknown
N-(Allyloxycarbonyl)-4-[N-(Carboxy-Formyl)-2-(Benzoic Acid)-Amino]-L-Phenylalaninyl-Amino-Butyloxy-(6-Hydroxy-Benzoic Acid Methyl Ester),,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
AL5300,,Carbonic anhydrase 2,CA2,,unknown
RH-1,,NAD(P)H dehydrogenase [quinone] 1,NQO1,,unknown
Apstatin,,Xaa-Pro aminopeptidase,pepP,,unknown
4-Hydroxy-2-Butanone,,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,,unknown
9-Deazahypoxanthine,,Purine nucleoside phosphorylase,punA,,unknown
Uridine-5'-Diphosphate-4-Deoxy-4-Fluoro-Alpha-D-Galactose,,UDP-glucose 4-epimerase,galE,,unknown
Balanol,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
Deamido-Nad+,,NH(3)-dependent NAD(+) synthetase,nadE,,unknown
Deamido-Nad+,,Nicotinamide mononucleotide adenylyltransferase 1,NMNAT1,,unknown
Deamido-Nad+,,Nicotinate-nucleotide adenylyltransferase,nadD,,unknown
Deamido-Nad+,,Nicotinamide mononucleotide adenylyltransferase 3,NMNAT3,,unknown
Deamido-Nad+,,NH(3)-dependent NAD(+) synthetase,nadE,,unknown
Deamido-Nad+,,NH(3)-dependent NAD(+) synthetase,nadE,,unknown
"(1,10 Phenanthroline)-(Tri-Carbon Monoxide) Rhenium (I)",,Azurin,azu,,unknown
"N-[4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)Pyrimidin-2-Yl]-N'-Hydroxyimidoformamide",,Cyclin-dependent kinase 2,CDK2,,unknown
3-Methylcytosine,,Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase,PAPS,,unknown
3-Methyladenine,,DNA-3-methyladenine glycosylase 1,tag,,unknown
N-Heptylformamide,,Alcohol dehydrogenase 1B,ADH1B,,unknown
Fotemustine,,"Thioredoxin reductase 1, cytoplasmic",TXNRD1,,unknown
[(1-{2[(4-Carbamimidoyl-Phenylamino)-Methyl]-1-Methyl-1h-Benzoimidazol-5-Yl}-Cyclopropyl)-Pyridin-2-Yl-Methyleneaminooxy]-Acetic Acid Ethyl Ester,,Trypsin-1,PRSS1,,unknown
"(2s,3r)-3-Amino-2-Hydroxy-5-(Ethylsulfanyl)Pentanoyl-((S)-(-)-(1-Naphthyl)Ethyl)Amide",,Methionine aminopeptidase 2,METAP2,,unknown
"[4-(1,3,2-Dioxaborolan-2-Yloxy)Methyl]Benzamidine",,Trypsin-3,PRSS3,,unknown
1-Octadecyl-2-Acetamido-2-Deoxy-Sn-Glycerol-3-Phosphoethylmethyl Sulfide,,"Phospholipase A2, membrane associated",PLA2G2A,,unknown
N-Formylpiperidine,,Alcohol dehydrogenase 1C,ADH1C,,unknown
"3-Chloro-9-Ethyl-6,7,8,9,10,11-Hexahydro-7,11-Methanocycloocta[B]Quinolin-12-Amine",,Acetylcholinesterase,ACHE,,unknown
Berberine,,HTH-type transcriptional regulator QacR,qacR,,unknown
Berberine,,Baculoviral IAP repeat-containing protein 5,BIRC5,,unknown
Allolactose,,Beta-galactosidase,lacZ,,unknown
"4-(N,N-Dimethylamino)Cinnamoyl-Coa",,"Enoyl-CoA hydratase, mitochondrial",ECHS1,,unknown
Hexatantalum Dodecabromide,,Calcium/calmodulin-dependent protein kinase type II subunit alpha,CAMK2A,,unknown
Hexatantalum Dodecabromide,,Ubiquitin-like modifier-activating enzyme 1,UBA1,,unknown
"4-Methyl-1,2-Benzenediol",,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
"4-Methyl-1,2-Benzenediol",,"Catechol 1,2-dioxygenase",catA,,unknown
Guanosine-3'-Monophosphate-5'-Diphosphate,,ADP-ribosylation factor 1,ARF1,,unknown
beta-D-glucose 6-phosphate,,Glucose-6-phosphate 1-dehydrogenase,zwf,,unknown
(P-Iodophenylacetylamino)Methylphosphinic Acid,,Beta-lactamase,ampC,,unknown
Aurodox,,Elongation factor Tu-B,tufB,,unknown
N-Alpha-(2-Naphthylsulfonyl)-N(3-Amidino-L-Phenylalaninyl)-4-Acetyl-Piperazine,,Trypsin-1,PRSS1,,unknown
N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-2-Methyl-Butane,,Cathepsin B,CTSB,,unknown
N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-2-Methyl-Butane,,Pro-cathepsin H,CTSH,,unknown
beta-D-arabinofuranose 5-phosphate,,Ribose-5-phosphate isomerase A,rpiA,,unknown
"5-Nitroso-6-Ribityl-Amino-2,4(1h,3h)-Pyrimidinedione",,"6,7-dimethyl-8-ribityllumazine synthase",ribH,,unknown
Willardiine,,Glutamate receptor 2,GRIA2,,unknown
5-Methoxybenzimidazole,,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
"10-(4-Dimethylamino-5-Hydroxy-6-Methyl-Tetrahydro-Pyran-2-Yloxy)-8-Ethyl-1,8,11-Trihydroxy-7,8,9,10-Tetrahydro-Naphthacene-5,12-Dione",,RdmC,rdmC,,unknown
S-Hexylglutathione,,Lactoylglutathione lyase,GLO1,,unknown
S-Hexylglutathione,,Glutathione S-transferase Mu 4,GSTM4,,unknown
S-Hexylglutathione,,Glutathione S-transferase P,GSTP1,,unknown
S-Hexylglutathione,,Glutathione S-transferase,GST,,unknown
S-Hexylglutathione,,Glutathione S-transferase A1,GSTA1,,unknown
S-Hexylglutathione,,Glutathione S-transferase theta-2,GSTT2,,unknown
Degraded Cephaloridine,,Beta-lactamase,blaZ,,unknown
Degraded Cephaloridine,,Penicillin-binding protein 1A,pbpA,inhibitor,yes
"5-Fluoro-4-(S)-Hydroxy-3,4-Dihydropyrimidine",,Cytosine deaminase,codA,,unknown
Lysophosphotidylserine,,Prothrombin,F2,,unknown
Guanosine-5'-Triphosphate,,Ras-related protein Rab-5A,RAB5A,,unknown
Guanosine-5'-Triphosphate,,Probable GTP-binding protein EngB,engB,,unknown
Guanosine-5'-Triphosphate,,RNA-directed RNA polymerase,P2,,unknown
Guanosine-5'-Triphosphate,,Uridine-cytidine kinase-like 1,UCKL1,,unknown
Guanosine-5'-Triphosphate,,GTPase HRas,HRAS,,unknown
Guanosine-5'-Triphosphate,,Genome polyprotein,,,unknown
Guanosine-5'-Triphosphate,,Rho-related GTP-binding protein RhoE,RND3,,unknown
Guanosine-5'-Triphosphate,,Genome polyprotein,,,unknown
Guanosine-5'-Triphosphate,,GTP-binding protein Rheb,RHEB,,unknown
Guanosine-5'-Triphosphate,,GTP cyclohydrolase 1,folE,,unknown
Guanosine-5'-Triphosphate,,"6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1",PFKFB1,,unknown
Guanosine-5'-Triphosphate,,mRNA-capping enzyme,,,unknown
Guanosine-5'-Triphosphate,,Genome polyprotein,,,unknown
Guanosine-5'-Triphosphate,,ADP-ribosylation factor 1,ARF1,,unknown
Guanosine-5'-Triphosphate,,Molybdenum cofactor guanylyltransferase,mobA,,unknown
Guanosine-5'-Triphosphate,,"Ornithine decarboxylase, inducible",odcI,,unknown
Guanosine-5'-Triphosphate,,"Glutamate dehydrogenase 1, mitochondrial",GLUD1,,unknown
Guanosine-5'-Triphosphate,,Adenylosuccinate synthetase isozyme 1,ADSSL1,,unknown
Guanosine-5'-Triphosphate,,Ras-related protein Rap-2a,RAP2A,,unknown
"2,4-Dinitro,5-[Bis(2-Bromoethyl)Amino]-N-(2',3'-Dioxopropyl)Benzamide",,Oxygen-insensitive NAD(P)H nitroreductase,nfsB,,unknown
6-Hydroxypropylthymine,,Thymidine kinase,TK,,unknown
1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide,,Stromelysin-1,MMP3,,unknown
"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,Histo-blood group ABO system transferase,ABO,,unknown
"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,"Cytochrome c1, heme protein, mitochondrial",CYC1,,unknown
"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,Cytochrome b,MT-CYB,,unknown
"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,"Cytochrome b-c1 complex subunit 1, mitochondrial",UQCRC1,,unknown
"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,"Cytochrome b-c1 complex subunit 2, mitochondrial",UQCRC2,,unknown
"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,"Cytochrome b-c1 complex subunit 6, mitochondrial",UQCRH,,unknown
"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,Cytochrome b-c1 complex subunit 8,UQCRQ,,unknown
"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,"Cytochrome b-c1 complex subunit Rieske, mitochondrial",UQCRFS1,,unknown
"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,Cytochrome b-c1 complex subunit 7,UQCRB,,unknown
"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,Cytochrome b-c1 complex subunit 9,UQCR10,,unknown
"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,"Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial",SDHA,,unknown
"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,"Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial",SDHB,,unknown
"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,"Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial",SDHD,,unknown
"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,"Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial",ETFDH,,unknown
"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,"Succinate dehydrogenase cytochrome b560 subunit, mitochondrial",SDHC,,unknown
"3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
Indole-3-Glycerol Phosphate,,Tryptophan synthase alpha chain,trpA,,unknown
Indole-3-Glycerol Phosphate,,Tryptophan synthase beta chain,trpB,,unknown
"Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone",,E3 ubiquitin-protein ligase Mdm2,MDM2,,unknown
Lauryl Dimethylamine-N-Oxide,,Fe(3+) dicitrate transport protein FecA,fecA,,unknown
Lauryl Dimethylamine-N-Oxide,,Long-chain fatty acid transport protein,fadL,,unknown
Lauryl Dimethylamine-N-Oxide,,Lipid A palmitoyltransferase PagP,pagP,,unknown
Lauryl Dimethylamine-N-Oxide,,Amine oxidase [flavin-containing] B,MAOB,,unknown
Lauryl Dimethylamine-N-Oxide,,Acyl-CoA thioesterase 2,tesB,,unknown
Lauryl Dimethylamine-N-Oxide,,Reaction center protein L chain,pufL,,unknown
Lauryl Dimethylamine-N-Oxide,,Reaction center protein M chain,pufM,,unknown
Lauryl Dimethylamine-N-Oxide,,Reaction center protein H chain,puhA,,unknown
Lauryl Dimethylamine-N-Oxide,,Cytochrome c oxidase subunit 1-beta,ctaDII,,unknown
Lauryl Dimethylamine-N-Oxide,,Cytochrome c oxidase subunit 2,ctaC,,unknown
Lauryl Dimethylamine-N-Oxide,,Ig kappa chain V-I region Bi,,,unknown
Lauryl Dimethylamine-N-Oxide,,Ig heavy chain V-III region VH26,IGHV3-23,,unknown
Lauryl Dimethylamine-N-Oxide,,Photosynthetic reaction center cytochrome c subunit,pufC,,unknown
Lauryl Dimethylamine-N-Oxide,,Reaction center protein H chain,puhA,,unknown
Lauryl Dimethylamine-N-Oxide,,Reaction center protein L chain,pufL,,unknown
Lauryl Dimethylamine-N-Oxide,,Reaction center protein M chain,pufM,,unknown
Lauryl Dimethylamine-N-Oxide,,H subunit of photosynthetic reaction center complex,puhA,,unknown
Lauryl Dimethylamine-N-Oxide,,Destrin,DSTN,,unknown
Lauryl Dimethylamine-N-Oxide,,Rhodopsin,RHO,,unknown
Lauryl Dimethylamine-N-Oxide,,Cytochrome c2,cycA,,unknown
Lauryl Dimethylamine-N-Oxide,,Nuclear factor erythroid 2-related factor 1,NFE2L1,,unknown
Lauryl Dimethylamine-N-Oxide,,Squalene--hopene cyclase,shc,,unknown
Lauryl Dimethylamine-N-Oxide,,Vitamin B12 transporter BtuB,btuB,,unknown
Lauryl Dimethylamine-N-Oxide,,Colicin-E3,ceaC,,unknown
Lauryl Dimethylamine-N-Oxide,,Fe(3+)-pyochelin receptor,fptA,,unknown
Lauryl Dimethylamine-N-Oxide,,Myelin P2 protein,PMP2,,unknown
Lauryl Dimethylamine-N-Oxide,,Outer membrane protein W,ompW,,unknown
Lauryl Dimethylamine-N-Oxide,,Light-harvesting protein B-800/850 alpha chain,,,unknown
Lauryl Dimethylamine-N-Oxide,,Light-harvesting protein B-800/850 beta chain,,,unknown
Lauryl Dimethylamine-N-Oxide,,Protein TonB,tonB,,unknown
Lauryl Dimethylamine-N-Oxide,,Colicin I receptor,cirA,,unknown
Lauryl Dimethylamine-N-Oxide,,Colicin-Ia,cia,,unknown
Lauryl Dimethylamine-N-Oxide,,Cofilin-1,CFL1,,unknown
Lauryl Dimethylamine-N-Oxide,,Rhomboid protease GlpG,glpG,,unknown
Lauryl Dimethylamine-N-Oxide,,Outer membrane protein G,ompG,,unknown
Lauryl Dimethylamine-N-Oxide,,Outer membrane usher protein PapC,papC,,unknown
Lauryl Dimethylamine-N-Oxide,,Probable N-acetylneuraminic acid outer membrane channel protein NanC,nanC,,unknown
Lauryl Dimethylamine-N-Oxide,,Reaction center protein H chain,puhA,,unknown
Lauryl Dimethylamine-N-Oxide,,Reaction center protein L chain,pufL,,unknown
Lauryl Dimethylamine-N-Oxide,,Reaction center protein M chain,pufM,,unknown
Lauryl Dimethylamine-N-Oxide,,Outer membrane protein II,porB,,unknown
Lauryl Dimethylamine-N-Oxide,,Cyclic nucleotide-gated potassium channel mll3241,,,unknown
Lauryl Dimethylamine-N-Oxide,,Ammonia channel,amtB,,unknown
Lauryl Dimethylamine-N-Oxide,,Penicillin-binding protein 2,pbp2,,unknown
Lauryl Dimethylamine-N-Oxide,,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
Lauryl Dimethylamine-N-Oxide,,TraO protein,traO,,unknown
Lauryl Dimethylamine-N-Oxide,,TraF protein,traF,,unknown
Lauryl Dimethylamine-N-Oxide,,TraN protein,traN,,unknown
Lauryl Dimethylamine-N-Oxide,,"Outer membrane porin, OprD family",,,unknown
(R)-Rolipram,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,inhibitor,unknown
(R)-Rolipram,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,,unknown
Threonine Derivative,,Peptidyl-glycine alpha-amidating monooxygenase,PAM,,unknown
4-Methyl-Histidine,,"Actin, alpha skeletal muscle",ACTA1,,unknown
"2-Amino-3-(3-Hydroxy-7,8-Dihydro-6h-Cyclohepta[D]-4-Isoxazolyl)Propionic Acid",,Glutamate receptor 2,GRIA2,,unknown
S-Hydroxymethyl Glutathione,,Alcohol dehydrogenase class-3,ADH5,,unknown
"N-Methyl-N-[3-(6-Phenyl[1,2,4]Triazolo[4,3-B]Pyridazin-3-Yl)Phenyl]Acetamide",,Cell division protein ZipA homolog,zipA,,unknown
"N-Methyl-N-[3-(6-Phenyl[1,2,4]Triazolo[4,3-B]Pyridazin-3-Yl)Phenyl]Acetamide",,Cell division protein ZipA,zipA,,unknown
2-Fluoro-2-Deoxy-Beta-D-Galactopyranosyl-Beta-D-Glucopyranose,,Beta-galactosidase,lacZ,,unknown
Aspartate Beryllium Trifluoride,,Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1,CTDSP1,,unknown
Aspartate Beryllium Trifluoride,,Sugar phosphatase YbiV,ybiV,,unknown
Aspartate Beryllium Trifluoride,,Chemotaxis protein CheY,cheY,,unknown
N-[(Aminooxy)Carbonyl]Aniline,,Chitinase B,chiB,,unknown
"6-(Adenosine Tetraphosphate-Methyl)-7,8-Dihydropterin",,2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase,folK,,unknown
Pyrophosphoric acid,,Adenylosuccinate synthetase,purA,,unknown
Pyrophosphoric acid,,NH(3)-dependent NAD(+) synthetase,nadE,,unknown
Pyrophosphoric acid,,Thymidylate kinase,tmk,,unknown
Pyrophosphoric acid,,Ferrichrome-iron receptor,fhuA,,unknown
Pyrophosphoric acid,,Farnesyl diphosphate synthase,ispA,,unknown
Pyrophosphoric acid,,Isopentenyl-diphosphate Delta-isomerase,idi,,unknown
"5-Nitro-6-Ribityl-Amino-2,4(1h,3h)-Pyrimidinedione",,"6,7-dimethyl-8-ribityllumazine synthase 2",ribH2,,unknown
"5-Nitro-6-Ribityl-Amino-2,4(1h,3h)-Pyrimidinedione",,"6,7-dimethyl-8-ribityllumazine synthase",ribH,,unknown
"5-Phenylsulfanyl-2,4-Quinazolinediamine",,Dihydrofolate reductase,DFR1,,unknown
"5-Phenylsulfanyl-2,4-Quinazolinediamine",,"Dihydrofolate reductase, mitochondrial",DHFRL1,,unknown
"1,4-Deoxy-4-((5-Hydroxymethyl-2,3,4-Trihydroxycyclohex-5-Enyl)Amino)Fructose",,Alpha-amylase,amy,,unknown
Valpromide,,"Limonene-1,2-epoxide hydrolase",limA,,unknown
Anthranilic acid,,L-amino-acid oxidase,IL4I1,,unknown
Anthranilic acid,,D-amino-acid oxidase,DAO,,unknown
Aceglutamide,,N-acylamino acid racemase,menC,,unknown
2-Amino-5-Bromo-6-Phenylpyrimidin-4-Ol,,Dihydroneopterin aldolase,folB,,unknown
"3,5-Diaminophthalhydrazide",,Queuine tRNA-ribosyltransferase,tgt,,unknown
4-bromo-3-hydroxy-3-methyl butyl diphosphate,,Isopentenyl-diphosphate Delta-isomerase,idi,,unknown
"[2,4,6-Triisopropyl-Phenylsulfonyl-L-[3-Amidino-Phenylalanine]]-Piperazine-N'-Beta-Alanine",,Urokinase-type plasminogen activator,PLAU,,unknown
Fructose,,Maltoporin,lamB,,unknown
Fructose,,Bis(5'-adenosyl)-triphosphatase,FHIT,,unknown
3'-1-Carboxy-1-Phosphonooxy-Ethoxy-Uridine-Diphosphate-N-Acetylglucosamine,,UDP-N-acetylglucosamine 1-carboxyvinyltransferase,murA,,unknown
Mdl-29951,,"Fructose-1,6-bisphosphatase 1",FBP1,,unknown
"Phosporic Acid Mono-[3,4-Dihydroxy-5-(5-Methoxy-Benzoimidazol-1-Yl)-Tetrahydro-Furan-2-Ylmethyl] Ester",,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
Di-Stearoyl-3-Sn-Phosphatidylcholine,,Bactericidal permeability-increasing protein,BPI,,unknown
Di-Stearoyl-3-Sn-Phosphatidylcholine,,ADP/ATP translocase 1,SLC25A4,,unknown
Benzofuran,,Lysozyme,E,,unknown
"4-(Aminosulfonyl)-N-[(2,4-Difluorophenyl)Methyl]-Benzamide",,Carbonic anhydrase 2,CA2,,unknown
"(S)-2-Amino-4-[(2s,3r)-2,3,5-Trihydroxy-4-Oxo-Pentyl]Mercapto-Butyric Acid",,S-ribosylhomocysteine lyase,luxS,,unknown
Methylmalonic Acid,,Methylmalonyl-CoA carboxyltransferase 12S subunit,,,unknown
Norvaline,,"Ornithine carbamoyltransferase, mitochondrial",OTC,,unknown
Norvaline,,"Glycine amidinotransferase, mitochondrial",GATM,,unknown
"N'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea",,Cyclin-dependent kinase 2,CDK2,,unknown
"(9S,10S)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene",,Glutathione S-transferase Mu 1,GSTM1,,unknown
Inhibitor Bea425,,Gag-Pol polyprotein,gag-pol,,unknown
Skf 107457,,Gag-Pol polyprotein,gag-pol,,unknown
Chitotriose,,Lysozyme C,LYZ,,unknown
Heptulose-2-Phosphate,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
Pteroic Acid,,Dihydropteroate synthase,folP,,unknown
Descarboxy-nor-N(Omega)-Hydroxy-L-Arginine,,Arginase-1,ARG1,,unknown
Formycin B,,Hypoxanthine-guanine phosphoribosyltransferase,HGPRTase,,unknown
Formycin B,,Purine nucleoside phosphorylase DeoD-type,deoD,,unknown
1-Monohexanoyl-2-Hydroxy-Sn-Glycero-3-Phosphate,,Lipoprotein MxiM,mxiM,,unknown
1-Monohexanoyl-2-Hydroxy-Sn-Glycero-3-Phosphate,,Lipoprotein MxiM,mxiM,,unknown
1-Monohexanoyl-2-Hydroxy-Sn-Glycero-3-Phosphate,,GrlR,,,unknown
Matairesinol,,Dehydrogenase/reductase SDR family member 4-like 2,DHRS4L2,,unknown
Histidyl-Adenosine Monophosphate,,Histidine--tRNA ligase,hisS,,unknown
Histidyl-Adenosine Monophosphate,,Histidine--tRNA ligase,hisS,,unknown
3-Mercuri-4-Aminobenzenesulfonamide,,Carbonic anhydrase 2,CA2,,unknown
[(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
"Thymidine-3',5'-Diphosphate",,DNA topoisomerase 1,topA,,unknown
"Thymidine-3',5'-Diphosphate",,Thermonuclease,nuc,,unknown
Nz2-Tryptophan,,Lysozyme,R,,unknown
N-(5-Amino-5-Carboxypentyl)Glutamic Acid,,"Alpha-aminoadipic semialdehyde synthase, mitochondrial",AASS,,unknown
"3-(3,4-Dimethoxyphenyl)Propionic Acid",,Aromatic-amino-acid aminotransferase,tyrB,,unknown
Dequalinium,,Acriflavine resistance protein B,acrB,,unknown
Dequalinium,,HTH-type transcriptional regulator QacR,qacR,,unknown
Dequalinium,,E3 ubiquitin-protein ligase XIAP,XIAP,antagonistinhibitor,yes
Dequalinium,,cGMP-gated cation channel alpha-1,CNGA1,blocker,unknown
Dequalinium,,Calcium-activated potassium channel subunit alpha-1,KCNMA1,inhibitor,unknown
BV1,,Cholera enterotoxin subunit B,ctxB,,unknown
2-Iminiopropanoate,,1-aminocyclopropane-1-carboxylate deaminase,acdS,,unknown
N-Cyclohexyl-N'-(Propyl)Phenyl Urea,,Bifunctional epoxide hydrolase 2,EPHX2,,unknown
4-Nitrophenyl Phosphate,,Low molecular weight phosphotyrosine protein phosphatase,ACP1,,unknown
4-Nitrophenyl Phosphate,,Dual specificity protein phosphatase 23,DUSP23,,unknown
CRA_9076,,Trypsin-1,PRSS1,,unknown
Quercetin,,Tyrosine-protein kinase HCK,HCK,,unknown
Quercetin,,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,,unknown
Quercetin,,UDP-glucuronosyltransferase 3A1,UGT3A1,,unknown
Quercetin,,"ATP synthase subunit alpha, mitochondrial",ATP5A1,,unknown
Quercetin,,"ATP synthase subunit beta, mitochondrial",ATP5B,,unknown
Quercetin,,"ATP synthase subunit gamma, mitochondrial",ATP5C1,,unknown
Quercetin,,Serine/threonine-protein kinase pim-1,PIM1,,unknown
Quercetin,,HTH-type transcriptional regulator TtgR,ttgR,,unknown
Quercetin,,"3-hydroxyisobutyryl-CoA hydrolase, mitochondrial",HIBCH,,unknown
Quercetin,,3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ,fabZ,,unknown
Quercetin,,Serine/threonine-protein kinase 17B,STK17B,,unknown
Quercetin,,Estrogen receptor alpha,ESR1,,unknown
Quercetin,,Estrogen receptor beta,ESR2,,unknown
Quercetin,,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,inhibitor,unknown
Quercetin,,Aryl hydrocarbon receptor,AHR,,unknown
Quercetin,,Cytochrome P450 1B1,CYP1B1,,unknown
Quercetin,,"Actin, cytoplasmic 1",ACTB,,unknown
Quercetin,,Casein kinase II subunit alpha,CSNK2A1,,unknown
Quercetin,,Casein kinase II subunit beta,CSNK2B,,unknown
Quercetin,,Eukaryotic translation initiation factor 3 subunit F,EIF3F,,unknown
Quercetin,,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
Quercetin,,Heat shock-related 70 kDa protein 2,HSPA2,,unknown
Quercetin,,RuvB-like 2,RUVBL2,,unknown
Quercetin,,Splicing factor 3B subunit 3,SF3B3,,unknown
Quercetin,,Ubiquitin-like modifier-activating enzyme 1,UBA1,,unknown
Quercetin,,Sex hormone-binding globulin,SHBG,,unknown
Quercetin,,Carbonyl reductase [NADPH] 1,CBR1,,unknown
Quercetin,,CCAAT/enhancer-binding protein beta,CEBPB,inhibitor,unknown
Quercetin,,Nuclear receptor subfamily 1 group I member 2,NR1I2,activator,unknown
L-2-amino-3-butynoic acid,,Cystathionine gamma-lyase,CTH,,unknown
L-2-amino-3-butynoic acid,,Cysteine desulfurase,sufS,,unknown
1-Deaza-Adenosine,,Adenosine deaminase,ADA,,unknown
CGP 4832,,Ferrichrome-iron receptor,fhuA,,unknown
Didecyldimethylammonium,,Cyclopropane mycolic acid synthase 2,cmaA2,,unknown
Nitroarginine,,"Nitric oxide synthase, endothelial",NOS3,,unknown
Nitroarginine,,"Nitric oxide synthase, brain",NOS1,,unknown
Oleic Acid,,Glycolipid transfer protein,GLTP,,unknown
Oleic Acid,,14 kDa fatty acid-binding protein,,,unknown
Oleic Acid,,Myelin P2 protein,PMP2,,unknown
Oleic Acid,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Oleic Acid,,Peroxisome proliferator-activated receptor delta,PPARD,,unknown
Oleic Acid,,Retinoic acid receptor RXR-alpha,RXRA,,unknown
Oleic Acid,,Peroxisome proliferator-activated receptor gamma,PPARG,ligand,unknown
"9-Amino-2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid",,Neuraminidase,NA,,unknown
"7,10,13-Tri(Carboxymethyl)-5,15-Dioxo-4,7,10,13,16-Pentaaza-1,19-Dithianonadecane",,Pseudoazurin,,,unknown
Nitromethyldethia Coenzyme A,,"Citrate synthase, mitochondrial",CS,,unknown
Tetra(Imidazole)Diaquacopper (I),,Azurin,azu,,unknown
N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide,,Stromelysin-1,MMP3,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Outer membrane protein X,ompX,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Outer membrane protein A,ompA,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Porin,opmA,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Outer membrane protein F,ompF,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Long-chain fatty acid transport protein,fadL,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Squalene--hopene cyclase,shc,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Vitamin B12 transporter BtuB,btuB,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Colipase,CLPS,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Pancreatic triacylglycerol lipase,PNLIP,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Rhodopsin,RHO,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,"Apocarotenoid-15,15'-oxygenase",,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Outer membrane protein G,ompG,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Outer membrane protein W,ompW,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Adhesin,hia,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Porin P,oprP,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Porin D,oprD,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Porin,,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Vanillate porin OpdK,opdK,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Outer membrane usher protein PapC,papC,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Outer membrane porin C,ompC,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,TbuX,tbuX,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Membrane protein involved in aromatic hydrocarbon degradation,,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Probable outer membrane protein,,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Hypothetical conserved protein,,,unknown
(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,Esterase EstA,estA,,unknown
N2-({[(4-Bromophenyl)Methyl]Oxy}Carbonyl)-N1-[(1s)-1-Formylpentyl]-L-Leucinamide,,Cathepsin K,CTSK,,unknown
4-Amino Hexanoic Acid,,"4-aminobutyrate aminotransferase, mitochondrial",ABAT,,unknown
Tris(Hydroxyethyl)Aminomethane,,Alpha-amylase 1,AMY1A,,unknown
Tris(Hydroxyethyl)Aminomethane,,"Chlorocatechol 1,2-dioxygenase",clcA,,unknown
Tris(Hydroxyethyl)Aminomethane,,Alpha-lytic protease,alpha-LP,,unknown
N-Alpha-(2-Naphthylsulfonyl)-N-(3-Amidino-L-Phenylalaninyl)-D-Pipecolinic Acid,,Trypsin-1,PRSS1,,unknown
2-Amino-6-Aminomethyl-8-Phenylsulfanylmethyl-3h-Quinazolin-4-One,,Queuine tRNA-ribosyltransferase,tgt,,unknown
N-Pyridoxyl-2-Methylalanine-5-Phosphate,,"2,2-dialkylglycine decarboxylase",dgdA,,unknown
P-Hydroxybenzoic Acid,,4-hydroxybenzoyl-CoA thioesterase,fcbC,,unknown
P-Hydroxybenzoic Acid,,p-hydroxybenzoate hydroxylase,pobA,,unknown
P-Hydroxybenzoic Acid,,Chorismate--pyruvate lyase,ubiC,,unknown
P-Hydroxybenzoic Acid,,p-hydroxybenzoate hydroxylase,pobA,,unknown
5-Methyluridine 5'-Monophosphate,,Single-stranded DNA-binding protein,ssb,,unknown
(2R)-2-(3-Biphenylyl)-N-{(2R)-2-hydroxy-3-[(2-pyridinylsulfonyl)amino]propyl}-4-methylpentanamide,,Cathepsin K,CTSK,,unknown
CRA_23653,,Trypsin-1,PRSS1,,unknown
beta-(1->4)-galactotriose,,"Arabinogalactan endo-1,4-beta-galactosidase",ganB,,unknown
Zinc Substituted Heme C,,Cytochrome c,CYCS,,unknown
Butyrylthiocholine,,Cholinesterase,BCHE,,unknown
N-Carbamoyl-L-Aspartate,,Dihydroorotase,pyrC,,unknown
Tretazicar,,Oxygen-insensitive NAD(P)H nitroreductase,nfsB,,unknown
Tretazicar,,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,,unknown
"8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
Inhibitor Bea388,,Gag-Pol polyprotein,gag-pol,,unknown
4-(1-Amino-1-Carboxy-Ethyl)-Benzoic Acid,,Metabotropic glutamate receptor 1,GRM1,,unknown
Palmitoleic Acid,,Fatty-acid peroxygenase,cypC,,unknown
Palmitoleic Acid,,Bifunctional P-450/NADPH-P450 reductase,cyp102A1,,unknown
Palmitoleic Acid,,UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase,lpxC,,unknown
Seocalcitol,,Vitamin D3 receptor,VDR,,unknown
"9-(5,5-Difluoro-5-Phosphonopentyl)Guanine",,Purine nucleoside phosphorylase,PNP,,unknown
Carbamic Acid,,Beta-lactamase,penP,,unknown
3-(7-hydroxy-8-ribityllumazine-6-yl) propionic acid,,"6,7-dimethyl-8-ribityllumazine synthase",ribH,,unknown
Geneticin,,Ornithine decarboxylase,ODC1,,unknown
"(10R)-10-Formyl-5,8,10-Trideazafolic Acid",,Phosphoribosylglycinamide formyltransferase,purN,,unknown
N-acetyl-beta-neuraminic acid,,Sialidase,nedA,,unknown
N-acetyl-beta-neuraminic acid,,Endo-N-acetylneuraminidase,,,unknown
N-acetyl-beta-neuraminic acid,,Hemagglutinin-neuraminidase,HN,,unknown
N-acetyl-beta-neuraminic acid,,Tetanus toxin,tetX,,unknown
Dipicolinic Acid,,4-hydroxy-tetrahydrodipicolinate reductase,dapB,,unknown
Dipicolinic Acid,,4-hydroxy-tetrahydrodipicolinate reductase,dapB,,unknown
Methylumbelliferyl Chitotriose,,Lysozyme C,LYZ,,unknown
Cyclotheonamide A,,Trypsin-1,PRSS1,,unknown
(S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
"3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester",,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,,unknown
Citric Acid,,KHG/KDPG aldolase,eda,,unknown
Citric Acid,,Molybdenum cofactor guanylyltransferase,mobA,,unknown
Citric Acid,,Fumarate hydratase class II,fumC,,unknown
Citric Acid,,6-phosphogluconolactonase,pgl,,unknown
Citric Acid,,Oxygen-insensitive NAD(P)H nitroreductase,nfsB,,unknown
Citric Acid,,Gag-Pro-Pol polyprotein,gag-pro-pol,,unknown
Citric Acid,,L-amino-acid oxidase,IL4I1,,unknown
Citric Acid,,Macrophage migration inhibitory factor,MIF,,unknown
Citric Acid,,Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1,CTDSP1,,unknown
Citric Acid,,1-deoxy-D-xylulose 5-phosphate reductoisomerase,dxr,,unknown
Citric Acid,,Tryptophan synthase alpha chain,trpA,,unknown
Citric Acid,,Sialidase,nedA,,unknown
Citric Acid,,Cytochrome c peroxidase,,,unknown
Citric Acid,,Hepatocyte growth factor-regulated tyrosine kinase substrate,HGS,,unknown
Citric Acid,,Invasin,,,unknown
Citric Acid,,Intron-associated endonuclease 1,ITEVIR,,unknown
Citric Acid,,Short tail fiber protein,12,,unknown
Citric Acid,,"Malate dehydrogenase, mitochondrial",MDH2,,unknown
Citric Acid,,N5-carboxyaminoimidazole ribonucleotide mutase,purE,,unknown
Citric Acid,,50S ribosomal protein L4,rplD,,unknown
Citric Acid,,Carboxypeptidase B,CPB1,,unknown
Citric Acid,,Hexon protein,,,unknown
Citric Acid,,Riboflavin biosynthesis protein RibF,,,unknown
Citric Acid,,Beta-fructosidase,bfrA,,unknown
Citric Acid,,Putative stringent starvation protein A,sspA,,unknown
Citric Acid,,Citrate synthase,cit,,unknown
Citric Acid,,RNA 3'-terminal phosphate cyclase,rtcA,,unknown
Citric Acid,,U6 snRNA-associated Sm-like protein LSm6,LSM6,,unknown
Citric Acid,,Pleckstrin homology domain-containing family A member 1,PLEKHA1,,unknown
Citric Acid,,Fe(3+)-binding periplasmic protein,fbpA,,unknown
Citric Acid,,Signal recognition particle receptor FtsY,ftsY,,unknown
Citric Acid,,Nicotinate-nucleotide adenylyltransferase,nadD,,unknown
Citric Acid,,N utilization substance protein B homolog,nusB,,unknown
Citric Acid,,Complement component C8 gamma chain,C8G,,unknown
Citric Acid,,Ribonucleoside-diphosphate reductase subunit beta,nrdF,,unknown
Citric Acid,,Glutamine synthetase 1,glnA1glnA1,,unknown
Citric Acid,,Citrate synthase,gltA,,unknown
Citric Acid,,Prostaglandin F synthase,,,unknown
Citric Acid,,Cell division protein FtsZ,ftsZ,,unknown
Citric Acid,,Adenine phosphoribosyltransferase,APRT,,unknown
Citric Acid,,Angiogenin,ANG,,unknown
Citric Acid,,Glucose-1-phosphate thymidylyltransferase,rmlA,,unknown
Citric Acid,,Beta-lactamase 2,blm,,unknown
Citric Acid,,Glyoxalase family protein,,,unknown
Citric Acid,,Uridine-cytidine kinase 2,UCK2,,unknown
Citric Acid,,Tumor necrosis factor ligand superfamily member 13B,TNFSF13B,,unknown
Citric Acid,,Laccase domain protein YfiH,yfiH,,unknown
Citric Acid,,Betaine--homocysteine S-methyltransferase 1,BHMT,,unknown
Citric Acid,,Ribose-5-phosphate isomerase A,rpiA,,unknown
Citric Acid,,Tryptophan--tRNA ligase,trpS,,unknown
Citric Acid,,GMP synthase [glutamine-hydrolyzing],guaA,,unknown
Citric Acid,,Aldose reductase,AKR1B1,,unknown
Citric Acid,,Inosine triphosphate pyrophosphatase,ITPA,,unknown
Citric Acid,,"Citrate synthase, mitochondrial",CS,,unknown
Citric Acid,,Lysozyme,17,,unknown
Citric Acid,,Heparan sulfate glucosamine 3-O-sulfotransferase 3A1,HS3ST3A1,,unknown
Citric Acid,,Glycerol uptake operon antiterminator regulatory protein,,,unknown
Citric Acid,,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,,unknown
Citric Acid,,"3-carboxy-cis,cis-muconate cycloisomerase",pcaB,,unknown
Citric Acid,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
Citric Acid,,Pyruvate decarboxylase,pdc,,unknown
Citric Acid,,Ribonuclease pancreatic,RNASE1,,unknown
Citric Acid,,Isocitrate dehydrogenase [NADP],icd,,unknown
Citric Acid,,Glycine N-methyltransferase,GNMT,,unknown
Citric Acid,,Eosinophil cationic protein,RNASE3,,unknown
Citric Acid,,Beta-lactamase,penP,,unknown
"8,9-Dichloro-2,3,4,5-Tetrahydro-1h-Benzo[C]Azepine",,Phenylethanolamine N-methyltransferase,PNMT,,unknown
N-Acetyl Serotonin,,Sepiapterin reductase,SPR,,unknown
N-[N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-Butyl]-Guanidine,,NPQTN specific sortase B,srtB,,unknown
N-[N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-Butyl]-Guanidine,,Calpain-1 catalytic subunit,CAPN1,,unknown
Fructose -6-Phosphate,,Glucosamine-6-phosphate deaminase 1,nagB,,unknown
2-[2-(2-Cyclohexyl-2-Guanidino-Acetylamino)-Acetylamino]-N-(3-Mercapto-Propyl)-Propionamide,,Interleukin-2,IL2,,unknown
3-Isopropylmalic Acid,,3-isopropylmalate dehydrogenase,leuB,,unknown
3-Isopropylmalic Acid,,Isocitrate dehydrogenase [NADP],icd,,unknown
"((2r,3s,5r)-3-Hydroxy-5-(4-Hydroxy-2-Oxo-3,4-Dihydropyrimidin-1(2h)-Yl)-Tetrahydrofuran-2-Yl)Methyldihydrogen Phosphate",,Deoxycytidylate deaminase,CD,,unknown
"2-[4-(4-Chlorophenyl)Cyclohexylidene]-3,4-Dihydroxy-1(2h)-Naphthalenone",,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
2-deoxy-2-fluoro-α-D-glucose,,Cellulase B,celB,,unknown
2-deoxy-2-fluoro-α-D-glucose,,Beta-glucosidase A,bglA,,unknown
2-deoxy-2-fluoro-α-D-glucose,,Lactase-phlorizin hydrolase,LCT,,unknown
2-deoxy-2-fluoro-α-D-glucose,,Exoglucanase/xylanase,cex,,unknown
L-proline betaine,,Glycine betaine-binding periplasmic protein,proX,,unknown
"{4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
beta-D-Ribopyranose,,D-ribose-binding periplasmic protein,rbsB,,unknown
beta-D-Ribopyranose,,D-ribose pyranase,rbsD,,unknown
(S)-5-(4-Benzyloxy-Phenyl)-4-(7-Phenyl-Heptanoylamino)-Pentanoic Acid,,"Phospholipase A2, membrane associated",PLA2G2A,,unknown
2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine,,Cyclin-dependent kinase 2,CDK2,,unknown
Genz-10850,,Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,,unknown
[2-Cytidylate-O'-Phosphonyloxyl]-Ethyl-Trimethyl-Ammonium,,LicC protein,licC,,unknown
7-(2-Amino-2-Phenyl-Acetylamino)-3-Chloro-8-Oxo-1-Aza-Bicyclo[4.2.0]Oct-2-Ene-2-Carboxylic Acid,,Beta-lactamase,ampC,,unknown
5-Phosphoribosyl-1-(Beta-Methylene) Pyrophosphate,,Nicotinate-nucleotide pyrophosphorylase [carboxylating],nadC,,unknown
N-Benzoyl-N'-Beta-D-Glucopyranosyl Urea,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
5-Oxo-L-Norleucine,,Amidophosphoribosyltransferase,purF,,unknown
"7-[4-(Dimethylamino)Phenyl]-N-Hydroxy-4,6-Dimethyl-7-Oxo-2,4-Heptadienamide",,Histone deacetylase 8,HDAC8,,unknown
"7-[4-(Dimethylamino)Phenyl]-N-Hydroxy-4,6-Dimethyl-7-Oxo-2,4-Heptadienamide",,Acetoin utilization protein,acuC1,,unknown
"7-[4-(Dimethylamino)Phenyl]-N-Hydroxy-4,6-Dimethyl-7-Oxo-2,4-Heptadienamide",,Histone deacetylase 7,HDAC7,,unknown
"3-(4-Amino-2-Tert-Butyl-5-Methyl-Phenylsulfanyl)-6-Cyclopentyl-4-Hydroxy-6-[2-(4-Hydroxy-Phenyl)-Ethyl]-5,6-Dihydro-Pyran-2-One",,Genome polyprotein,,,unknown
Maleic Acid,,"Aspartate aminotransferase, cytoplasmic",GOT1,,unknown
Maleic Acid,,Aspartate aminotransferase,aspC,,unknown
Maleic Acid,,Trypanothione reductase,TPR,,unknown
Maleic Acid,,Aspartate aminotransferase,aspC,,unknown
Maleic Acid,,Aromatic-amino-acid aminotransferase,tyrB,,unknown
Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone Hydrate,,Trypsin-1,PRSS1,,unknown
"4-Hydroxy-3,5-Dimethyl-5-(2-Methyl-Buta-1,3-Dienyl)-5h-Thiophen-2-One",,3-oxoacyl-[acyl-carrier-protein] synthase 1,fabB,,unknown
"4-Hydroxy-3,5-Dimethyl-5-(2-Methyl-Buta-1,3-Dienyl)-5h-Thiophen-2-One",,3-oxoacyl-[acyl-carrier-protein] synthase 1,kasA,,unknown
4-O-methyl-alpha-D-glucuronic acid,,Endoxylanase,xynC,,unknown
4-O-methyl-alpha-D-glucuronic acid,,Alpha-glucuronidase,aguA,,unknown
L-Gluconic Acid,,Beta-glucosidase A,bglA,,unknown
"5-[(4-Methylphenyl)Sulfanyl]-2,4-Quinazolinediamine",,Dihydrofolate reductase,DFR1,,unknown
"5-[(4-Methylphenyl)Sulfanyl]-2,4-Quinazolinediamine",,"Dihydrofolate reductase, mitochondrial",DHFRL1,,unknown
5-Hydroxy-N-Propargyl-1(R)-Aminoindan,,Amine oxidase [flavin-containing] B,MAOB,,unknown
2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide,,Peptide deformylase 2,,,unknown
2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide,,Peptide deformylase,def,,unknown
2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide,,Peptide deformylase,def,,unknown
2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide,,Peptide deformylase,def,,unknown
2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide,,Peptide deformylase,def,,unknown
2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide,,Peptide deformylase,def,,unknown
2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide,,Peptide deformylase 1,def1,,unknown
2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide,,Peptide deformylase 2,def2,,unknown
2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide,,Peptide deformylase,def,,unknown
2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide,,Peptide deformylase,def,,unknown
2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide,,"Peptide deformylase, mitochondrial",PDF,,unknown
4-Phenylbutylamine,,Trypsin-1,PRSS1,,unknown
"2,3-Difluorobenzyl Alcohol",,Alcohol dehydrogenase 1C,ADH1C,,unknown
1-Methylcytosine,,Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase,PAPS,,unknown
Guanosine-5'-Diphosphate,,Adenylosuccinate synthetase isozyme 1,ADSSL1,,unknown
Guanosine-5'-Diphosphate,,Elongation factor G,fusA,,unknown
Guanosine-5'-Diphosphate,,"Elongation factor Tu, mitochondrial",TUFM,,unknown
Guanosine-5'-Diphosphate,,GTPase Der,der,,unknown
Guanosine-5'-Diphosphate,,GDP-mannose mannosyl hydrolase,gmm,,unknown
Guanosine-5'-Diphosphate,,Probable GTP-binding protein EngB,engB,,unknown
Guanosine-5'-Diphosphate,,Eukaryotic translation initiation factor 2 subunit 3,EIF2S3,,unknown
Guanosine-5'-Diphosphate,,Guanine nucleotide-binding protein G(i) subunit alpha-1,GNAI1,,unknown
Guanosine-5'-Diphosphate,,Signal recognition particle protein,ffh,,unknown
Guanosine-5'-Diphosphate,,Guanine nucleotide-binding protein G(t) subunit alpha-1,GNAT1,,unknown
Guanosine-5'-Diphosphate,,Elongation factor Tu-B,tufB,,unknown
Guanosine-5'-Diphosphate,,Ras-related protein Rab-9A,RAB9A,,unknown
Guanosine-5'-Diphosphate,,Nucleoside diphosphate kinase A,NME1,,unknown
Guanosine-5'-Diphosphate,,GTP-binding protein Rheb,RHEB,,unknown
Guanosine-5'-Diphosphate,,Cell division control protein 42 homolog,CDC42,,unknown
Guanosine-5'-Diphosphate,,Elongation factor Tu,tufA,,unknown
Guanosine-5'-Diphosphate,,ADP-ribosylation factor 1,ARF1,,unknown
Guanosine-5'-Diphosphate,,Elongation factor 2,EEF2,,unknown
Guanosine-5'-Diphosphate,,Bifunctional (p)ppGpp synthase/hydrolase RelA,relA,,unknown
Guanosine-5'-Diphosphate,,Ras-related protein Rap-2a,RAP2A,,unknown
Guanosine-5'-Diphosphate,,Elongation factor Tu GTP-binding domain-containing protein 1,EFTUD1,,unknown
Guanosine-5'-Diphosphate,,ADP-ribosylation factor-like protein 1,ARL1,,unknown
Guanosine-5'-Diphosphate,,GTP-binding nuclear protein Ran,RAN,,unknown
Guanosine-5'-Diphosphate,,Ras-related protein Rab-7a,RAB7A,,unknown
Guanosine-5'-Diphosphate,,Interferon-inducible GTPase 5,IRGC,,unknown
Guanosine-5'-Diphosphate,,Eukaryotic peptide chain release factor GTP-binding subunit ERF3A,GSPT1,,unknown
Guanosine-5'-Diphosphate,,Ras-related protein Rab-5A,RAB5A,,unknown
Guanosine-5'-Diphosphate,,GTPase HRas,HRAS,,unknown
Guanosine-5'-Diphosphate,,Elongation factor 1-alpha 1,EEF1A1,,unknown
Guanosine-5'-Diphosphate,,Transforming protein RhoA,RHOA,,unknown
Guanosine-5'-Diphosphate,,ADP-ribosylation factor 4,ARF4,,unknown
Guanosine-5'-Diphosphate,,Protein-glutamine gamma-glutamyltransferase 2,TGM2,,unknown
Guanosine-5'-Diphosphate,,"GDP-mannose 4,6 dehydratase",GMDS,,unknown
Guanosine-5'-Diphosphate,,Ras-related protein Rab-11A,RAB11A,,unknown
Guanosine-5'-Diphosphate,,Ras-related protein Ral-A,RALA,,unknown
Guanosine-5'-Diphosphate,,Adenylosuccinate synthetase,purA,,unknown
Guanosine-5'-Diphosphate,,Elongation factor Tu,tuf,,unknown
Guanosine-5'-Diphosphate,,ADP-ribosylation factor-like protein 5B,ARL5B,,unknown
Guanosine-5'-Diphosphate,,Cell division protein FtsZ,ftsZ,,unknown
Guanosine-5'-Diphosphate,,Protein-glutamine gamma-glutamyltransferase E,TGM3,,unknown
Guanosine-5'-Diphosphate,,GTPase (Rab6),rab6,,unknown
Guanosine-5'-Diphosphate,,Ras-related protein Rab-8B,RAB8B,,unknown
Guanosine-5'-Diphosphate,,ADP-ribosylation factor 6,ARF6,,unknown
Guanosine-5'-Diphosphate,,ADP-ribosylation factor-like protein 3,ARL3,,unknown
Guanosine-5'-Diphosphate,,Nucleoside diphosphate kinase B,NME2,,unknown
Guanosine-5'-Diphosphate,,"GDP-mannose 4,6-dehydratase",gmd,,unknown
Guanosine-5'-Diphosphate,,Ras-related C3 botulinum toxin substrate 1,RAC1,,unknown
Guanosine-5'-Diphosphate,,Putative ribosome biogenesis GTPase RsgA,rsgA,,unknown
Guanosine-5'-Diphosphate,,GTP-binding protein SAR1b,SAR1B,,unknown
Guanosine-5'-Diphosphate,,Adenylosuccinate synthetase,Adss,,unknown
Guanosine-5'-Diphosphate,,ADP-ribosylation factor-like protein 5A,ARL5A,,unknown
D-[(N-Hydroxyamino)Carbonyl]Phenylalanine,,Carboxypeptidase A1,CPA1,,unknown
"3,3-Dichloro-2-Phosphonomethyl-Acrylic Acid",,Phosphoenolpyruvate carboxylase,ppc,,unknown
Nα-[(2S)-2-{[(S)-[(1S)-1-{[(Benzyloxy)carbonyl]amino}-2-phenylethyl](hydroxy)phosphoryl]methyl}-5-phenylpentanoyl]-L-tryptophanamide,,Stromelysin-3,MMP11,,unknown
2-Bromo-2-Propene-1-Ol,,Haloalkane dehalogenase,linB,,unknown
LY249543,,"C-1-tetrahydrofolate synthase, cytoplasmic",MTHFD1,,unknown
Ovalicin,,Methionine aminopeptidase 2,METAP2,,unknown
Ovalicin,,Methionine aminopeptidase 1,METAP1,,unknown
Phenethylamine,,Primary amine oxidase,tynA,,unknown
Phenethylamine,,Trypsin-2,PRSS2,,unknown
Phenethylamine,,Trypsin-1,PRSS1,,unknown
Dihydroxyacetone phosphate,,Fructose-bisphosphate aldolase A,ALDOA,,unknown
Dihydroxyacetone phosphate,,Triosephosphate isomerase,TPI1,,unknown
Dihydroxyacetone phosphate,,Fructose-bisphosphate aldolase B,ALDOB,,unknown
Dihydroxyacetone phosphate,,L-fuculose phosphate aldolase,fucA,,unknown
Phosphatidylethanolamine,,Bacteriorhodopsin,,,unknown
Phosphatidylethanolamine,,Endothelial protein C receptor,PROCR,,unknown
Phosphatidylethanolamine,,"Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN",PTEN,substrate,unknown
Shikimate-3-Phosphate,,3-phosphoshikimate 1-carboxyvinyltransferase,aroA,,unknown
Shikimate-3-Phosphate,,3-phosphoshikimate 1-carboxyvinyltransferase,aroA,,unknown
Bilh 434,,Regulatory protein E2,E2,,unknown
Monastrol,,Kinesin-like protein KIF11,KIF11,,unknown
6-hydroxydopa quinone,,Membrane primary amine oxidase,AOC3,,unknown
6-hydroxydopa quinone,,Primary amine oxidase,tynA,,unknown
6-hydroxydopa quinone,,Phenylethylamine oxidase,,,unknown
Inosine,,IAG-nucleoside hydrolase,,,unknown
Inosine,,Purine nucleoside phosphorylase,PNP,,unknown
Inosine,,Purine nucleoside phosphorylase DeoD-type,deoD,,unknown
1-(4-Amidinophenyl)-3-(4-Chlorophenyl)Urea,,Trypsin-1,PRSS1,,unknown
Methyl Isocyanide,,Myoglobin,MB,,unknown
SB220025,,Mitogen-activated protein kinase 14,MAPK14,,unknown
SB220025,,Mitogen-activated protein kinase 1,MAPK1,,unknown
Carbocisteine,,Glutathione S-transferase P,GSTP1,,unknown
2-[(Dioxidophosphoranyl)oxy]benzoate,,D-alanyl-D-alanine carboxypeptidase,,,unknown
7-((Carboxy(4-Hydroxyphenyl)Acetyl)Amino)-7-Methoxy-(3-((1-Methyl-1h-Tetrazol-5-Yl)Thio)Methyl)-8-Oxo-5-Oxa-1-Azabicyclo[4.2.0]Oct-2-Ene-2-Carboxylic Acid,,Beta-lactamase OXA-10,bla,,unknown
Glyoxylic acid,,Malate synthase G,glcB,,unknown
Glyoxylic acid,,Isocitrate lyase,icl,,unknown
Glyoxylic acid,,Malate synthase G,glcB,,unknown
Glyoxylic acid,,Putative regulator of ribonuclease activity,rraA,,unknown
"7,8-dimethylalloxazine",,Riboflavin biosynthesis protein RibF,,,unknown
"7,8-dimethylalloxazine",,Flavin reductase (NADPH),BLVRB,,unknown
"(2r,4s)-2-Methyl-2,3,3,4-Tetrahydroxytetrahydrofuran",,Autoinducer 2-binding protein LsrB,lsrB,,unknown
3-Dehydroshikimate,,3-dehydroquinate dehydratase,aroD,,unknown
3-Dehydroshikimate,,3-dehydroquinate dehydratase,aroQ,,unknown
Taurocholic Acid,,Bile salt-activated lipase,CEL,,unknown
Taurocholic Acid,,Gastrotropin,FABP6,,unknown
Taurocholic Acid,,Bile acid receptor,NR1H4,,unknown
"(S)-propane-1,2-diol",,Isocitrate dehydrogenase [NADP],icd,,unknown
"(S)-propane-1,2-diol",,Sigma factor SigB regulation protein RsbQ,rsbQ,,unknown
Argadin,,Chitinase,chiB1,,unknown
Argadin,,Chitotriosidase-1,CHIT1,,unknown
Aconitate Ion,,"Aconitate hydratase, mitochondrial",ACO2,,unknown
Aconitate Ion,,Aconitate hydratase 2,acnB,,unknown
beta-D-Ribose-5-phosphate,,D-ribose pyranase,rbsD,,unknown
beta-D-Ribose-5-phosphate,,"ADP-ribose pyrophosphatase, mitochondrial",NUDT9,,unknown
{(1s)-1-Benzyl-4-[3-Carbamoyl-1-(1-Carbamoyl-2-Phenyl-Ethylcarbamoyl)-(S)-Propylcarbamoyl]-2-Oxo-5-Phenyl-Pentyl}-Carbamic Acid Tert-Butyl Ester,,Gag-Pol polyprotein,gag-pol,,unknown
9-Deazaguanine,,Hypoxanthine-guanine phosphoribosyltransferase,HPRT1,,unknown
Vinylsulphonic Acid,,Phosphonoacetaldehyde hydrolase,phnX,,unknown
Benzo[B]Thiophene-2-Boronic Acid,,Beta-lactamase,ampC,,unknown
Methyldiazene,,Quinoprotein glucose dehydrogenase B,gdhB,,unknown
Mesobiliverdin Iv Alpha,,Flavin reductase (NADPH),BLVRB,,unknown
Arecoline,,Muscarinic acetylcholine receptor M1,CHRM1,,unknown
Arecoline,,Muscarinic acetylcholine receptor M3,CHRM3,,unknown
3'-Deoxy 3'-Amino Adenosine-5'-Diphosphate,,Nucleoside diphosphate kinase A,NME1,,unknown
Debromohymenialdisine,,Activated CDC42 kinase 1,TNK2,,unknown
Debromohymenialdisine,,Dual specificity protein kinase CLK1,CLK1,,unknown
Bb-3497,,Peptide deformylase,def,,unknown
Bb-3497,,"Peptide deformylase, mitochondrial",PDF,inhibitor,unknown
"1,3,2-Dioxaborolan-2-Ol",,Trypsin-3,PRSS3,,unknown
AL6528,,Carbonic anhydrase 2,CA2,,unknown
Di-Linoleoyl-3-Sn-Phosphatidylcholine,,Phosphatidylcholine transfer protein,PCTP,,unknown
"4-Amino-N-{4-[2-(2,6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-Pentyl}-Benzamide",,Plasmepsin-2,,,unknown
"4-Carboxy-5-(1-Pentyl)Hexylsulfanyl-1,2,3-Triazole",,Hydroxyacid oxidase 1,HAO1,,unknown
13-Acetylphorbol,,Protein kinase C delta type,PRKCD,,unknown
3-Hydroxy-3-Methyl-Glutaric Acid,,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,,unknown
"3-Amino-N-{4-[2-(2,6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-Pentyl}-Benzamide",,Plasmepsin-2,,,unknown
N-Methyl-N-(Methylbenzyl)Formamide,,Renin,REN,,unknown
Diureido-Acetate,,Allantoate amidohydrolase,allC,,unknown
Crotonaldehyde,,"Aldehyde dehydrogenase, mitochondrial",ALDH2,,unknown
2-Deoxy-Beta-D-Galactose,,Beta-galactosidase,lacZ,,unknown
3-Deazacytidine,,Cytidine deaminase,cdd,,unknown
"4,6-O-(1-Carboxyethylidene)-Beta-D-Glucose",,Xanthan lyase,xly,,unknown
1-Hydroxy-2-Amino-3-Cyclohexylpropane,,Renin,REN,,unknown
1-Hydroxy-2-Amino-3-Cyclohexylpropane,,Candidapepsin-2,SAP2,,unknown
4-Carboxy-4-Aminobutanal,,Glutaminase-asparaginase,ansB,,unknown
Ado-P-Ch2-P-Ps-Ado,,Bis(5'-adenosyl)-triphosphatase,FHIT,,unknown
Aeruginosin 98-B,,Trypsin-1,PRSS1,,unknown
"Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone]",,Oxygen-insensitive NAD(P)H nitroreductase,nfsB,,unknown
"Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone]",,NAD(P)H dehydrogenase [quinone] 1,NQO1,,unknown
"Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone]",,FMN-dependent NADH-azoreductase,azoR,,unknown
Soneclosan,,Enoyl-[acyl-carrier-protein] reductase [NADH] FabI,fabI,,unknown
3-Nitro-4-(2-Oxo-Pyrrolidin-1-Yl)-Benzenesulfonamide,,Carbonic anhydrase 2,CA2,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,ATP-dependent protease ATPase subunit HslU,hslU,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Ephrin type-B receptor 2,EPHB2,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,TrwB,trwB,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Cystic fibrosis transmembrane conductance regulator,CFTR,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Transitional endoplasmic reticulum ATPase,VCP,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Transient receptor potential cation channel subfamily M member 7,TRPM7,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Kinesin-like protein KIF1A,KIF1A,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,T-complex protein 1 subunit gamma,CCT3,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Rod shape-determining protein MreB,,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,SRSF protein kinase 2,SRPK2,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Mitogen-activated protein kinase 12,MAPK12,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Chaperone protein ClpB,clpB,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Type II secretion system protein E,epsE,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Sensor protein PhoQ,phoQ,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,DNA topoisomerase 4 subunit B,parE,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Galactokinase,GALK1,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Protein RecA,recA,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,DNA repair protein RAD51 homolog 1,RAD51,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Potassium-transporting ATPase B chain,kdpB,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Glycogen synthase kinase-3 beta,GSK3B,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Thymidylate kinase,DTYMK,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Chemotaxis protein CheA,cheA,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Insulin-like growth factor 1 receptor,IGF1R,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Serine/threonine-protein kinase pim-1,PIM1,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Dihydroxyacetone kinase,dhaK,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Pantothenate kinase,coaA,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Hexokinase-1,HK1,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Phosphoribosylglycinamide formyltransferase 2,purT,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Tyrosine-protein kinase Lck,LCK,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Casein kinase II subunit alpha,CSNK2A1,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Ephrin type-A receptor 2,EPHA2,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Argininosuccinate synthase,argG,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Mitogen-activated protein kinase 10,MAPK10,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,S-adenosylmethionine synthase,metK,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,UDP-N-acetylmuramate--L-alanine ligase,murC,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Osmolarity sensor protein EnvZ,envZ,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,DNA gyrase subunit B,gyrB,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,DNA mismatch repair protein MutL,mutL,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Kinesin-like protein KIF2C,KIF2C,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Inositol-trisphosphate 3-kinase A,ITPKA,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,DNA topoisomerase 2-beta,TOP2B,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Glutathione synthetase,GSS,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,4-diphosphocytidyl-2-C-methyl-D-erythritol kinase,ispE,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,"6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4",PFKFB4,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Aminoglycoside 3'-phosphotransferase,aphA,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Death-associated protein kinase 1,DAPK1,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Arsenical pump-driving ATPase,arsA,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,"Actin, alpha skeletal muscle",ACTA1,,unknown
Phosphoaminophosphonic Acid-Adenylate Ester,,Acetylglutamate kinase,argB,,unknown
Thiodigalactoside,,Heat-labile enterotoxin B chain,eltB,,unknown
Thiodigalactoside,,Lactose permease,lacY,,unknown
Thiodigalactoside,,Neurocan core protein,NCAN,,unknown
Thiodigalactoside,,Galectin-1,LGALS1,,unknown
Alpha-D-Glucose-1-Phosphate-6-Vanadate,,Phosphoglucomutase-1,PGM1,,unknown
Lactic Acid,,Bifunctional protein PutA,putA,,unknown
Lactic Acid,,NimA-related protein,,,unknown
"L-erythro-7,8-dihydrobiopterin",,Tyrosine 3-monooxygenase,TH,,unknown
"L-erythro-7,8-dihydrobiopterin",,Pterin-4-alpha-carbinolamine dehydratase,PCBD1,,unknown
"L-erythro-7,8-dihydrobiopterin",,Phenylalanine-4-hydroxylase,PAH,,unknown
"L-erythro-7,8-dihydrobiopterin",,Pteridine reductase 1,PTR1,,unknown
"L-erythro-7,8-dihydrobiopterin",,"Nitric oxide synthase, inducible",NOS2,,unknown
"L-erythro-7,8-dihydrobiopterin",,Dihydroneopterin aldolase,folB,,unknown
"[Formylmethyl]Trimethyl-Ammonium, N,N,N-Trimethylammonium Acetaldehyde",,Gamma-aminobutyraldehyde dehydrogenase,prr,,unknown
Allosamizoline,,Chitinase B,chiB,,unknown
Allosamizoline,,Chitinase A,chiA,,unknown
Allosamizoline,,Chitotriosidase-1,CHIT1,,unknown
"2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4'-Ethoxy-1,1'-Biphenyl-4-Yl)-4-Oxobutanoic Acid",,Macrophage metalloelastase,MMP12,,unknown
4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol,,Cyclin-dependent kinase 2,CDK2,,unknown
Ncs-Chromophore,,Neocarzinostatin,ncsA,,unknown
Naphthalene Trisulfonate,,Fibroblast growth factor 1,FGF1,,unknown
3-Phenylpropylamine,,Trypsin-2,PRSS2,,unknown
3-Phenylpropylamine,,Trypsin-1,PRSS1,,unknown
Alpha-N-Dichloroacetyl-P-Aminophenylserinol,,Chloramphenicol 3-O phosphotransferase,,,unknown
Heptamolybdate,,Sensor histidine kinase CitA,citA,,unknown
"R-2-{[4'-Methoxy-(1,1'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid",,Stromelysin-1,MMP3,,unknown
P-Nitrophenol,,Sulfotransferase 1A1,SULT1A1,,unknown
P-Nitrophenol,,Alpha-amylase 2B,AMY2B,,unknown
Adenylosuccinic Acid,,Adenylosuccinate synthetase isozyme 1,ADSSL1,,unknown
D-norleucine,,Parathyroid hormone,PTH,,unknown
D-norleucine,,Hepatocyte nuclear factor 1-alpha,HNF1A,,unknown
D-norleucine,,Phenylalanine-4-hydroxylase,PAH,,unknown
2-Amino-4-Mercapto-Butyric Acid,,5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase,metE,,unknown
2-Amino-4-Mercapto-Butyric Acid,,5-methyltetrahydrofolate S-homocysteine methyltransferase,,,unknown
2-Amino-4-Mercapto-Butyric Acid,,S-ribosylhomocysteine lyase,luxS,,unknown
RPR128515,,Trypsin-1,PRSS1,,unknown
"7,8-Dihydroneopterin",,Dihydroneopterin aldolase,folB,,unknown
Alpha-Methyl-N-Acetyl-D-Glucosamine,,Mannose-binding protein C,MBL2,,unknown
3-[[N-[4-Methyl-Piperazinyl]Carbonyl]-Phenylalaninyl-Amino]-5-Phenyl-Pentane-1-Sulfonic Acid Benzyloxy-Amide,,Cruzipain,,,unknown
4'-Hydroxyflavanone,,Sex hormone-binding globulin,SHBG,,unknown
3-(4-Phenylamino-Phenylamino)-2-(1h-Tetrazol-5-Yl)-Acrylonitrile,,Beta-lactamase TEM,bla,,unknown
3-(4-Phenylamino-Phenylamino)-2-(1h-Tetrazol-5-Yl)-Acrylonitrile,,Beta-lactamase TEM,bla,,unknown
ZK-805623,,Trypsin-1,PRSS1,,unknown
"N''-{3-[(3s,8ar)-1,4-Dioxooctahydropyrrolo[1,2-a]Pyrazin-3-Yl]Propyl}Guanidine",,Chitinase B,chiB,,unknown
Naphthyridine Inhibitor,,TGF-beta receptor type-1,TGFBR1,,unknown
3-Fluorotyrosine,,"Superoxide dismutase [Mn], mitochondrial",SOD2,,unknown
BVDU-MP,,Thymidine kinase,,,unknown
Modified Acarbose Pentasaccharide,,4-alpha-glucanotransferase,mgtA,,unknown
Nebularine,,Adenosine deaminase,ADA,,unknown
2-Fluoroadenosine,,Purine nucleoside phosphorylase DeoD-type,deoD,,unknown
"2-(2-Oxo-1,2-Dihydro-Pyridin-3-Yl)-1h-Benzoimidazole-5-Carboxamidine",,Trypsin-1,PRSS1,,unknown
Tetrafluoroaluminate Ion,,Acetylglutamate kinase,argB,,unknown
Tetrafluoroaluminate Ion,,Guanine nucleotide-binding protein G(i) subunit alpha-1,GNAI1,,unknown
Tetrafluoroaluminate Ion,,Sarcoplasmic/endoplasmic reticulum calcium ATPase 1,ATP2A1,,unknown
Tetrafluoroaluminate Ion,,Guanine nucleotide-binding protein G(t) subunit alpha-1,GNAT1,,unknown
Tetrafluoroaluminate Ion,,UMP-CMP kinase,CMPK1,,unknown
Tetrafluoroaluminate Ion,,Myosin-11,MYH11,,unknown
Tetrafluoroaluminate Ion,,Myosin-14,MYH14,,unknown
Tetrafluoroaluminate Ion,,Protein RecA,recA,,unknown
Tetrafluoroaluminate Ion,,Ribokinase,rbsK,,unknown
Mercuric iodide,,Bile salt sulfotransferase,SULT2A1,,unknown
Benzo[B]Thiophene-2-Carboxamidine,,Trypsin-1,PRSS1,,unknown
"1,4-Dithiothreitol",,Protease synthase and sporulation negative regulatory protein PAI 1,paiA,,unknown
"1,4-Dithiothreitol",,Holo-[acyl-carrier-protein] synthase,acpS,,unknown
"1,4-Dithiothreitol",,Histidinol dehydrogenase,hisD,,unknown
"1,4-Dithiothreitol",,Shikimate dehydrogenase,aroE,,unknown
"1,4-Dithiothreitol",,Galectin-1,LGALS1,,unknown
"1,4-Dithiothreitol",,Calcium/calmodulin-dependent protein kinase type II subunit alpha,CAMK2A,,unknown
"1,4-Dithiothreitol",,50S ribosomal protein L27,rpmA,,unknown
"1,4-Dithiothreitol",,Retinal dehydrogenase 1,ALDH1A1,,unknown
"1,4-Dithiothreitol",,Organic hydroperoxide resistance protein,ohr,,unknown
"1,4-Dithiothreitol",,"3-carboxy-cis,cis-muconate cycloisomerase",pcaB,,unknown
"1,4-Dithiothreitol",,Transient receptor potential cation channel subfamily M member 7,TRPM7,,unknown
"1,4-Dithiothreitol",,Unsaturated glucuronyl hydrolase,ugl,,unknown
"1,4-Dithiothreitol",,Cyclic pyranopterin monophosphate synthase,moaA,,unknown
"1,4-Dithiothreitol",,C protein alpha-antigen,bca,,unknown
"1,4-Dithiothreitol",,Mitochondrial peptide methionine sulfoxide reductase,MSRA,,unknown
"1,4-Dithiothreitol",,Chaperone protein TorD,torD,,unknown
"1,4-Dithiothreitol",,Axin-1,AXIN1,,unknown
"1,4-Dithiothreitol",,Peptidyl-prolyl cis-trans isomerase B,PPIB,,unknown
"1,4-Dithiothreitol",,Amylosucrase,ams,,unknown
"1,4-Dithiothreitol",,Thymidylate synthase,thyA,,unknown
"1,4-Dithiothreitol",,Triosephosphate isomerase,TPI1,,unknown
"1,4-Dithiothreitol",,Maleylacetoacetate isomerase,GSTZ1,,unknown
"1,4-Dithiothreitol",,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,,unknown
"1,4-Dithiothreitol",,Listeriolysin regulatory protein,prfA,,unknown
"2,4-Difluorobenzyl Alcohol 2,4-Difluoro-1-(Hydroxymethyl)Benzene",,Alcohol dehydrogenase 1C,ADH1C,,unknown
Heptyl 1-Thiohexopyranoside,,Rhodopsin,RHO,,unknown
Heptyl 1-Thiohexopyranoside,,NADPH:ferredoxin reductase,fpr,,unknown
Heptyl 1-Thiohexopyranoside,,Acyl carrier protein,acpP,,unknown
Heptyl 1-Thiohexopyranoside,,Biotin biosynthesis cytochrome P450,bioI,,unknown
4-Methylpiperazin-1-Yl Carbonyl Group,,Candidapepsin-2,SAP2,,unknown
4-Methylpiperazin-1-Yl Carbonyl Group,,Cathepsin L2,CTSV,,unknown
Aminoquinuride,,Lethal factor,lef,,unknown
"4-O-(4,6-Dideoxy-4-{[4-[(4-O-Hexopyranosylhexopyranosyl)Oxy]-5,6-Dihydroxy-3-(Hydroxymethyl)Cyclohex-2-En-1-Yl]Amino}Hexopyranosyl)Hexopyranose",,Pancreatic alpha-amylase,AMY2A,,unknown
Alpha-Aminobutyric Acid,,Pro-epidermal growth factor,EGF,,unknown
Alpha-Aminobutyric Acid,,Lantibiotic mersacidin,mrsA,,unknown
Alpha-Aminobutyric Acid,,"Glycine amidinotransferase, mitochondrial",GATM,,unknown
Alpha-Aminobutyric Acid,,Gag-Pol polyprotein,gag-pol,,unknown
"N,N,N-trimethylglycinium",,Glycine betaine-binding periplasmic protein,proX,,unknown
"N,N,N-trimethylglycinium",,Circadian clock protein KaiB,kaiB,,unknown
Arsenous acid,,Arsenical pump-driving ATPase,arsA,,unknown
Arsenous acid,,Arsenate reductase,arsC,,unknown
2'-Deoxyguanosine-5'-Monophosphate,,Deoxynucleotide monophosphate kinase,1,,unknown
2'-Deoxyguanosine-5'-Monophosphate,,Thymidylate synthase,thyA,,unknown
"3,4-Dichloroisocoumarin",,Complement factor D,CFD,,unknown
(C8-S)-Hydantocidin 5'-Phosphate,,Adenylosuccinate synthetase,purA,,unknown
Coproporphyrinogen III,,Uroporphyrinogen decarboxylase,UROD,,unknown
Tetrabromo-2-Benzotriazole,,Casein kinase II subunit alpha,CSNK2A1,,unknown
"3-(4-Amino-1-Tert-Butyl-1h-Pyrazolo[3,4-D]Pyrimidin-3-Yl)Phenol",,Carbonyl reductase [NADPH] 1,CBR1,,unknown
N-Formylmethionine,,Glutamate--cysteine ligase,gshA,,unknown
N-Formylmethionine,,Ribonuclease pancreatic,RNASE1,,unknown
N-Formylmethionine,,"Putative ATP-dependent Clp protease proteolytic subunit, mitochondrial",CLPP,,unknown
N-Formylmethionine,,Geranylgeranyl transferase type-2 subunit alpha,RABGGTA,,unknown
N-Formylmethionine,,Geranylgeranyl transferase type-2 subunit beta,RABGGTB,,unknown
N-Formylmethionine,,Photosynthetic reaction center cytochrome c subunit,pufC,,unknown
N-Formylmethionine,,Reaction center protein H chain,puhA,,unknown
N-Formylmethionine,,Reaction center protein L chain,pufL,,unknown
N-Formylmethionine,,Reaction center protein M chain,pufM,,unknown
N-Formylmethionine,,Light-harvesting protein B-800/820 alpha chain,,,unknown
N-Formylmethionine,,Light-harvesting protein B-800/820 beta chain,,,unknown
N-Formylmethionine,,Light-harvesting protein B-800/850 alpha chain,,,unknown
N-Formylmethionine,,Light-harvesting protein B-800/850 beta chain,,,unknown
N-Formylmethionine,,Antithrombin-III,SERPINC1,,unknown
N-Formylmethionine,,Beta-2-microglobulin,B2M,,unknown
N-Formylmethionine,,NADH-ubiquinone oxidoreductase chain 1,MT-ND1,,unknown
N-Formylmethionine,,"HLA class I histocompatibility antigen, B-27 alpha chain",HLA-B,,unknown
N-Formylmethionine,,Respiratory nitrate reductase 1 alpha chain,narG,,unknown
N-Formylmethionine,,Respiratory nitrate reductase 1 beta chain,narH,,unknown
N-Formylmethionine,,Respiratory nitrate reductase 1 gamma chain,narI,,unknown
N-Formylmethionine,,Protein S100-G,S100G,,unknown
N-Formylmethionine,,Rubredoxin,rub,,unknown
N-Formylmethionine,,"Cytochrome c oxidase subunit 4 isoform 1, mitochondrial",COX4I1,,unknown
N-Formylmethionine,,Cytochrome c oxidase subunit 1,MT-CO1,,unknown
N-Formylmethionine,,Cytochrome c oxidase subunit 2,MT-CO2,,unknown
N-Formylmethionine,,Cytochrome c oxidase subunit 3,MT-CO3,,unknown
N-Formylmethionine,,"Cytochrome c oxidase subunit 5A, mitochondrial",COX5A,,unknown
N-Formylmethionine,,"Cytochrome c oxidase subunit 5B, mitochondrial",COX5B,,unknown
N-Formylmethionine,,Cytochrome c oxidase subunit 6C,COX6C,,unknown
N-Formylmethionine,,"Cytochrome c oxidase subunit 7B, mitochondrial",COX7B,,unknown
N-Formylmethionine,,"Cytochrome c oxidase subunit 7C, mitochondrial",COX7C,,unknown
N-Formylmethionine,,"Cytochrome c oxidase subunit 8A, mitochondrial",COX8A,,unknown
N-Formylmethionine,,"Cytochrome c oxidase subunit 6A2, mitochondrial",COX6A2,,unknown
N-Formylmethionine,,Cytochrome c oxidase subunit 6B1,COX6B1,,unknown
N-Formylmethionine,,"Cytochrome c oxidase subunit 7A1, mitochondrial",COX7A1,,unknown
N-Formylmethionine,,Methionyl-tRNA formyltransferase,fmt,,unknown
N-Formylmethionine,,Streptavidin,,,unknown
N-Formylmethionine,,Protein S100-B,S100B,,unknown
N-Formylmethionine,,Delta-hemolysin,hld,,unknown
N-Formylmethionine,,Polyubiquitin-C,UBC,,unknown
N-Formylmethionine,,AtpH,atpH,,unknown
N-Formylmethionine,,Probable L-ascorbate-6-phosphate lactonase UlaG,ulaG,,unknown
N-Formylmethionine,,Immunoglobulin G-binding protein G,spg,,unknown
Lactose,,Glycosyltransferase 6 domain-containing protein 1,GLT6D1,,unknown
Lactose,,Glycolipid transfer protein,GLTP,,unknown
Lactose,,Enterotoxin type B,entB,,unknown
Lactose,,Sialidase,nedA,,unknown
Lactose,,Hydrolase,,,unknown
Lactose,,"Endo-1,4-beta-xylanase A",xlnA,,unknown
Lactose,,Beta-galactosidase,lacZ,,unknown
Lactose,,Tetanus toxin,tetX,,unknown
Lactose,,Galectin-3,LGALS3,,unknown
SR12813,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
N-(5'-phosphopyridoxyl)-L-alanine,,L-cysteine/cystine lyase C-DES,c-des,,unknown
N-(5'-phosphopyridoxyl)-L-alanine,,Alanine racemase,alr,,unknown
N-(5'-phosphopyridoxyl)-L-alanine,,Aspartate aminotransferase,aspC,,unknown
Afimoxifene,,Estrogen receptor beta,ESR2,,unknown
Afimoxifene,,Estrogen-related receptor gamma,ESRRG,,unknown
Afimoxifene,,Estrogen receptor alpha,ESR1,,unknown
Afimoxifene,,Trefoil factor 1,TFF1,,unknown
Afimoxifene,,Steroid hormone receptor ERR1,ESRRA,inhibitor,unknown
Afimoxifene,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Afimoxifene,,Sex hormone-binding globulin,SHBG,,unknown
"1-(4-Methoxyphenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester",,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,,unknown
CRA_10656,,Trypsin-1,PRSS1,,unknown
"2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol",,Estrogen receptor alpha,ESR1,,unknown
(R)-1-Para-Nitro-Phenyl-2-Azido-Ethanol,,Halohydrin dehalogenase,hheC,,unknown
(R)-1-Para-Nitro-Phenyl-2-Azido-Ethanol,,Galectin-9,LGALS9,,unknown
Alpha-L-Fucose,,Genome polyprotein,,,unknown
Alpha-L-Fucose,,Envelope glycoprotein gp160,env,,unknown
Alpha-L-Fucose,,Ig gamma-1 chain C region,IGHG1,,unknown
Alpha-L-Fucose,,Genome polyprotein,,,unknown
1-Anilino-8-Naphthalene Sulfonate,,UDP-N-acetylglucosamine 1-carboxyvinyltransferase,murA,,unknown
1-Anilino-8-Naphthalene Sulfonate,,Protein S100-A7,S100A7,,unknown
"Trencam-3,2-Hopo",,Neutrophil gelatinase-associated lipocalin,LCN2,,unknown
"N-1,2,3,4-Tetrahydronaphth-1-Yl-2'-[3,5-Dimethoxybenzamido]-2'-Deoxy-Adenosine",,"Glyceraldehyde-3-phosphate dehydrogenase, testis-specific",GAPDHS,,unknown
"Cp-166572, 2-Hydroxymethyl-4-(4-N,N-Dimethylaminosulfonyl-1-Piperazino)-Pyrimidine",,Sorbitol dehydrogenase,SORD,,unknown
"3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole",,TGF-beta receptor type-1,TGFBR1,,unknown
Meso-Erythritol,,5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase,metE,,unknown
Cmp-2-Keto-3-Deoxy-Octulosonic Acid,,3-deoxy-manno-octulosonate cytidylyltransferase,kdsB,,unknown
Cmp-2-Keto-3-Deoxy-Octulosonic Acid,,3-deoxy-manno-octulosonate cytidylyltransferase,kpsU,,unknown
2-deoxy-2-fluoro-β-D-mannose,,"Mannan endo-1,4-beta-mannosidase",manA,,unknown
Deoxythymidine,,Thymidine kinase,TK,,unknown
Deoxythymidine,,"Thymidine kinase 2, mitochondrial",TK2,,unknown
Deoxythymidine,,Glucose-1-phosphate thymidylyltransferase,rmlA,,unknown
Deoxythymidine,,Nucleoside-specific channel-forming protein tsx,tsx,,unknown
Deoxythymidine,,Thymidylate kinase,tmk,,unknown
Deoxythymidine,,Thymidine kinase,TK,,unknown
Deoxythymidine,,Uridine phosphorylase,udp,,unknown
N-Methylleucine,,C-X-C motif chemokine 10,CXCL10,,unknown
"(6r,7r)-3-[(Acetyloxy)Methyl]-7-{[(6s)-6-(Glycylamino)-7-Oxido-7-Oxoheptanoyl]Amino}-8-Oxo-5-Thia-1-Azabicyclo[4.2.0]Octane-2-Carboxylate",,D-alanyl-D-alanine carboxypeptidase,,,unknown
Guanidinoethylmercaptosuccinic acid,,Carboxypeptidase D,CPD,,unknown
3-(Mercaptomethylene)Pyridine,,Gag-Pol polyprotein,gag-pol,,unknown
Diisopropylphosphono Group,,Complement factor B,CFB,,unknown
Diisopropylphosphono Group,,Esterase EstB,estB,,unknown
Diisopropylphosphono Group,,Dipeptidyl peptidase 4,DPP4,,unknown
Diisopropylphosphono Group,,Subtilisin BPN',apr,,unknown
2-(acetylamino)-2-deoxy-4-O-sulfo-alpha-D-galactopyranose,,Chondroitinase-B,cslB,,unknown
Fructose-6-Phosphate,,"Fructose-1,6-bisphosphatase 1",FBP1,,unknown
Fructose-6-Phosphate,,"6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1",PFKFB1,,unknown
Fructose-6-Phosphate,,6-phosphofructokinase,pfkA,,unknown
Fructose-6-Phosphate,,"6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4",PFKFB4,,unknown
Fructose-6-Phosphate,,Glucose-6-phosphate isomerase,GPI,,unknown
Dihydroxy(oxo)molybdenum(6+),,Sensor histidine kinase CitA,citA,,unknown
RU81843,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
4-Phospho-D-Erythronohydroxamic Acid,,Ribose-5-phosphate isomerase B,rpiB,,unknown
Aspartate Semialdehyde,,Aspartate-semialdehyde dehydrogenase,asd,,unknown
R-Styrene Oxide,,Halohydrin dehalogenase,hheC,,unknown
Camphane,,Camphor 5-monooxygenase,camC,,unknown
WRR-204,,Cruzipain,,,unknown
Sp-722,,Thymidylate synthase,thyA,,unknown
"8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"Methyl(6s)-1-Thio-L-Manno-Hexodialdo-6,2-Pyranoside",,Hemagglutinin-neuraminidase,HN,,unknown
N-Methylnaloxonium,,Liver carboxylesterase 1,CES1,,unknown
3-phospho-D-glyceric acid,,Phosphoglycerate kinase 1,PGK1,,unknown
3-phospho-D-glyceric acid,,Bifunctional PGK/TIM,pgk/tpi,,unknown
3-phospho-D-glyceric acid,,Triosephosphate isomerase,TPI,,unknown
3-phospho-D-glyceric acid,,"2,3-bisphosphoglycerate-independent phosphoglycerate mutase",gpmI,,unknown
3-phospho-D-glyceric acid,,Phosphoglycerate mutase 2,PGAM2,,unknown
3-phospho-D-glyceric acid,,Triosephosphate isomerase,TPI1,,unknown
N-Succinyl Methionine,,N-acylamino acid racemase,Aaar,,unknown
2-Isobutyl-3-Methoxypyrazine,,Epididymal-specific lipocalin-9,LCN9,,unknown
N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide,,Calmodulin,CALM1,,unknown
N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide,,"Troponin C, slow skeletal and cardiac muscles",TNNC1,,unknown
N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide,,"Troponin I, cardiac muscle",TNNI3,,unknown
Phosphoric Acid-2'-[2'-Deoxy-Uridine]Ester-5'-Guanosine Ester,,Ribonuclease pancreatic,RNASE1,,unknown
6-deoxy-2-O-methyl-alpha-L-galactopyranose,,Chondroitinase-B,cslB,,unknown
2-Deoxy-Glucitol-6-Phosphate,,Inositol-3-phosphate synthase 1,ISYNA1,,unknown
Dipyrromethane Cofactor,,Porphobilinogen deaminase,hemC,,unknown
"3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol",,Cyclin-dependent kinase 2,CDK2,,unknown
Caprylic acid,,3-oxoacyl-[acyl-carrier-protein] synthase 1,fabB,,unknown
Caprylic acid,,Acyl-CoA thioesterase I,tesA,,unknown
Caprylic acid,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
"(3s,8ar)-3-(4-Hydroxybenzyl)Hexahydropyrrolo[1,2-a]Pyrazine-1,4-Dione",,Chitinase B,chiB,,unknown
"(3s,8ar)-3-(4-Hydroxybenzyl)Hexahydropyrrolo[1,2-a]Pyrazine-1,4-Dione",,Chitinase,chiB,,unknown
GSHNA,,Glutathione S-transferase A3,GSTA3,,unknown
Dexfosfoserine,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
Dexfosfoserine,,Anti-sigma F factor antagonist,spoIIAA,,unknown
Dexfosfoserine,,Fimbrial protein,pilE1,,unknown
Dexfosfoserine,,Alkaline phosphatase,phoA,,unknown
Dexfosfoserine,,Serpin B3,SERPINB3,,unknown
Dexfosfoserine,,"Endo-1,4-beta-xylanase Y",xynY,,unknown
Dexfosfoserine,,Rhodopsin,RHO,,unknown
Dexfosfoserine,,Serine/threonine-protein kinase TAO2,TAOK2,,unknown
Dexfosfoserine,,Potassium voltage-gated channel subfamily C member 4,KCNC4,,unknown
Dexfosfoserine,,Lithostathine-1-alpha,REG1A,,unknown
Dexfosfoserine,,Mothers against decapentaplegic homolog 2,SMAD2,,unknown
Dexfosfoserine,,Glutaminase 1,glsA1,,unknown
Dexfosfoserine,,Siroheme synthase,cysG,,unknown
Dexfosfoserine,,Phosphocarrier protein HPr,ptsH,,unknown
Dexfosfoserine,,Cystic fibrosis transmembrane conductance regulator,CFTR,,unknown
Dexfosfoserine,,3-phosphoinositide-dependent protein kinase 1,PDPK1,,unknown
Dexfosfoserine,,Serine/threonine-protein kinase pim-1,PIM1,,unknown
Dexfosfoserine,,Protein kinase C theta type,PRKCQ,,unknown
Dexfosfoserine,,"Glycogen phosphorylase, liver form",PYGL,,unknown
Dexfosfoserine,,Phosphomannomutase/phosphoglucomutase,algC,,unknown
Dexfosfoserine,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
Tert-Butyl(1s)-1-Cyclohexyl-2-Oxoethylcarbamate,,Cathepsin K,CTSK,,unknown
Malonyl-CoA,,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,,unknown
2-(Carboxymethoxy)-5-[(2s)-2-({(2s)-2-[(3-Carboxypropanoyl)Amino] -3-Phenylpropanoyl}Amino)-3-Oxo-3-(Pentylamino)Propyl]Benzoic Acid,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
L-Glycero-D-Manno-Heptopyranose,,Ferrichrome-iron receptor,fhuA,,unknown
Beta-Hydroxyasparagine,,Mannan-binding lectin serine protease 2,MASP2,,unknown
"2,4-Dinitrophenol",,Pentaerythritol tetranitrate reductase,onr,,unknown
Desvancosaminyl Vancomycin,,Glycosyltransferase GtfD,gtfD,,unknown
Desvancosaminyl Vancomycin,,Glycosyltransferase GtfA,gtfA,,unknown
"S,S-(2-Hydroxyethyl)Thiocysteine",,Serpin B5,SERPINB5,,unknown
"S,S-(2-Hydroxyethyl)Thiocysteine",,"dTDP-4-dehydrorhamnose 3,5-epimerase",rmlC,,unknown
"S,S-(2-Hydroxyethyl)Thiocysteine",,"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B",PDE1B,,unknown
"S,S-(2-Hydroxyethyl)Thiocysteine",,Sorting nexin-3,SNX3,,unknown
"S,S-(2-Hydroxyethyl)Thiocysteine",,Transcription antiterminator LicT,licT,,unknown
"S,S-(2-Hydroxyethyl)Thiocysteine",,Cytohesin-2,CYTH2,,unknown
"S,S-(2-Hydroxyethyl)Thiocysteine",,Thymidylate synthase,thyA,,unknown
"S,S-(2-Hydroxyethyl)Thiocysteine",,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,,unknown
"S,S-(2-Hydroxyethyl)Thiocysteine",,Thymidylate synthase,TYMS,,unknown
"S,S-(2-Hydroxyethyl)Thiocysteine",,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
"S,S-(2-Hydroxyethyl)Thiocysteine",,Serine/threonine-protein kinase pim-1,PIM1,,unknown
"S,S-(2-Hydroxyethyl)Thiocysteine",,Arginase-1,ARG1,,unknown
"S,S-(2-Hydroxyethyl)Thiocysteine",,Beta-galactosidase,lacZ,,unknown
"S,S-(2-Hydroxyethyl)Thiocysteine",,Isocitrate dehydrogenase [NADP],icd,,unknown
"S,S-(2-Hydroxyethyl)Thiocysteine",,Maltose-binding periplasmic protein,malE,,unknown
"S,S-(2-Hydroxyethyl)Thiocysteine",,Delta-aminolevulinic acid dehydratase,hemB,,unknown
Benzylcysteine,,Methylated-DNA--protein-cysteine methyltransferase,MGMT,,unknown
Indole,,Lysozyme,E,,unknown
Indole,,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
2-Amino-P-Cresol,,Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,cobT,,unknown
5-Nitroindazole,,"Nitric oxide synthase, inducible",NOS2,,unknown
5-Nitroindazole,,"Nitric oxide synthase, endothelial",NOS3,,unknown
L-Tryptophanamide,,Tryptophan--tRNA ligase,trpS,,unknown
L-Tryptophanamide,,"Tryptophan--tRNA ligase, cytoplasmic",WARS,,unknown
threo-3-methyl-L-aspartic acid,,3-methylaspartate ammonia-lyase,,,unknown
Glyphosate,,3-phosphoshikimate 1-carboxyvinyltransferase,aroA,inhibitor,unknown
Glyphosate,,3-phosphoshikimate 1-carboxyvinyltransferase,aroA,,unknown
Glyphosate,,Cytochrome P450 19A1,CYP19A1,,unknown
Cholesterol,,Nuclear receptor ROR-alpha,RORA,,unknown
Cholesterol,,Nuclear receptor subfamily 1 group I member 3,NR1I3,,unknown
Cholesterol,,Vitamin D3 receptor,VDR,,unknown
Cholesterol,,C-type lectin domain family 4 member E,CLEC4E,ligand,unknown
"(8ar)-Hexahydropyrrolo[1,2-a]Pyrazine-1,4-Dione",,Chitinase B,chiB,,unknown
3'-Azido-3'-Deoxythymidine-5'-Diphosphate,,Nucleoside diphosphate kinase A,NME1,,unknown
"2,6-Diamino-8-(1h-Imidazol-2-Ylsulfanylmethyl)-3h-Quinazoline-4-One",,Queuine tRNA-ribosyltransferase,tgt,,unknown
1-Deoxy-1-Acetylamino-Beta-D-Gluco-2-Heptulopyranosonamide,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
Afegostat,,Beta-glucosidase A,bglA,,unknown
Afegostat,,"Possible cellulase CelA1 (Endoglucanase) (Endo-1,4-beta-glucanase) (FI-cmcase) (Carboxymethyl cellulase)",celA1,,unknown
Afegostat,,Endoglucanase 5A,cel5A,,unknown
3-Deaza-Adenosine,,IAG-nucleoside hydrolase,,,unknown
Inhibitor Bea409,,Gag-Pol polyprotein,gag-pol,,unknown
4-Deoxy-D-Glucuronic Acid,,Hyaluronate lyase,hylB,,unknown
4-Deoxy-D-Glucuronic Acid,,Alginate lyase,aly,,unknown
4-Deoxy-D-Glucuronic Acid,,Hyaluronate lyase,,,unknown
4-Deoxy-D-Glucuronic Acid,,Chondroitinase-B,cslB,,unknown
"4-(Aminosulfonyl)-N-[(2,3,4-Trifluorophenyl)Methyl]-Benzamide",,Carbonic anhydrase 2,CA2,,unknown
"beta-D-fructofuranose 1,6-bisphosphate",,Glycerol kinase,glpK,,unknown
"beta-D-fructofuranose 1,6-bisphosphate",,Pyruvate kinase PKLR,PKLR,,unknown
Niflumic Acid,2.5 hours,Phospholipase A2,PLA2G1B,inhibitor,yes
Niflumic Acid,2.5 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Niflumic Acid,2.5 hours,Chloride channel protein ClC-Ka,CLCNKA,inducer,unknown
Niflumic Acid,2.5 hours,Prostaglandin G/H synthase 1,PTGS1,,unknown
Niflumic Acid,2.5 hours,Cytosolic phospholipase A2,PLA2G4A,,unknown
Niflumic Acid,2.5 hours,UDP-glucuronosyltransferase 1-9,UGT1A9,,unknown
2-Oxobutanoic Acid,,Methylmalonyl-CoA carboxyltransferase 5S subunit,,,unknown
2-Oxobutanoic Acid,,1-aminocyclopropane-1-carboxylate deaminase,acdS,,unknown
8-Bromoadenosine-5'-Diphosphate,,S-adenosylmethionine synthase,metK,,unknown
Cytidine-5'-Diphosphate,,"2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase",ispF,,unknown
Cytidine-5'-Diphosphate,,N-acylneuraminate cytidylyltransferase,neuA,,unknown
Cytidine-5'-Diphosphate,,Cytidylate kinase,cmk,,unknown
Cytidine-5'-Diphosphate,,CDP-paratose 2-epimerase,rfbE,,unknown
Cytidine-5'-Diphosphate,,"2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase",ispF,,unknown
Cytidine-5'-Diphosphate,,3-deoxy-manno-octulosonate cytidylyltransferase,kpsU,,unknown
3-[(1s)-1-(Dimethylamino)Ethyl]Phenol,,Acetylcholinesterase,ACHE,,unknown
Arachidonic Acid,,14 kDa fatty acid-binding protein,,,unknown
Arachidonic Acid,,Prostaglandin G/H synthase 1,PTGS1,,unknown
Arachidonic Acid,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Arachidonic Acid,,Bile acid receptor,NR1H4,ligand,unknown
Arachidonic Acid,,Retinoic acid receptor RXR-alpha,RXRA,,unknown
N-(Chlorophenyl)-N'-Hydroxyguanidine,,"Nitric oxide synthase, endothelial",NOS3,,unknown
"4,7-Dioxosebacic Acid",,Delta-aminolevulinic acid dehydratase,hemB,,unknown
"4,7-Dioxosebacic Acid",,Delta-aminolevulinic acid dehydratase,ALAD,,unknown
"4,7-Dioxosebacic Acid",,Delta-aminolevulinic acid dehydratase,hemB,,unknown
"4-Acetamido-2,4-Didexoy-D-Glycero-Beta-D-Galacto-Octopyranosylphosphonic Acid",,Sialidase,nanH,,unknown
Tricarballylic Acid,,"Aconitate hydratase, mitochondrial",ACO2,,unknown
CRA_9678,,Trypsin-1,PRSS1,,unknown
Gluconolactone,,Lactase-phlorizin hydrolase,LCT,,unknown
4-(Acetylamino)-3-[(Hydroxyacetyl)Amino]Benzoic Acid,,Neuraminidase,NA,,unknown
Inosinic Acid,,Inosine-5'-monophosphate dehydrogenase,guaB,,unknown
Inosinic Acid,,Adenylosuccinate synthetase isozyme 1,ADSSL1,,unknown
Inosinic Acid,,Hypoxanthine phosphoribosyltransferase,hpt,,unknown
Inosinic Acid,,Adenylosuccinate synthetase,purA,,unknown
Inosinic Acid,,Hypoxanthine-guanine phosphoribosyltransferase,HGPRTase,,unknown
Inosinic Acid,,"Glycogen phosphorylase, muscle form",PYGM,,unknown
Inosinic Acid,,Adenylosuccinate synthetase,purA,,unknown
Inosinic Acid,,Inosine-5'-monophosphate dehydrogenase 2,IMPDH2,,unknown
5-Aminoimidazole Ribonucleoside,,Putative sugar kinase,,,unknown
Formic Acid Benzyl Ester,,Thermolysin,nprS,,unknown
Latamoxef,1.6 hours,Penicillin-binding protein 3,pbpC,inhibitor,yes
Latamoxef,1.6 hours,Penicillin-binding protein 1A,mrcA,inhibitor,unknown
Latamoxef,1.6 hours,Penicillin-binding protein 1B,mrcB,inhibitor,unknown
Latamoxef,1.6 hours,D-alanyl-D-alanine carboxypeptidase DacB,dacB,inhibitor,unknown
Trioxsalen,,DNA,,cross-linking/alkylation,yes
Thiotepa,1.5 to 4.1 hours,DNA,,cross-linking/alkylation,yes
Estriol,,Estrogen receptor alpha,ESR1,agonist,yes
Estriol,,Estrogen receptor beta,ESR2,agonist,unknown
Estriol,,Sex hormone-binding globulin,SHBG,,unknown
Estrone sulfate,,Estrogen receptor alpha,ESR1,agonist,yes
Estrone sulfate,,Estrogen receptor beta,ESR2,agonist,unknown
Quinestrol,,Estrogen receptor alpha,ESR1,agonistmodulator,yes
Fleroxacin,,DNA topoisomerase 2-alpha,TOP2A,inhibitor,yes
Fleroxacin,,DNA gyrase subunit A,gyrA,inhibitor,yes
Fleroxacin,,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
1-(1-phenylcyclopentyl)methylamine,,Dipeptidyl peptidase 4,DPP4,,unknown
"(S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide",,Dipeptidyl peptidase 4,DPP4,,unknown
"N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-",,Cathepsin B,CTSB,,unknown
1-Methyl-2-quinolone,,Putative uncharacterized protein,,,unknown
1-benzylimidazole,,Glutaminyl-peptide cyclotransferase,QPCT,,unknown
"5-Carbamoyl-1,1':4',1''-terphenyl-3-carboxylic acid",,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
DEHYDRO-2(S)-AMINO-6-BORONOHEXANOIC ACID,,Arginase-1,ARG1,,unknown
2-bromophenol,,Thymidylate synthase,thyA,,unknown
"N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
(2R)-({4-[AMINO(IMINO)METHYL]PHENYL}AMINO){5-ETHOXY-2-FLUORO-3-[(3R)-TETRAHYDROFURAN-3-YLOXY]PHENYL}ACETICACID,,Coagulation factor VII,F7,,unknown
"N-{2,2-DIFLUORO-2-[(2R)-PIPERIDIN-2-YL]ETHYL}-2-[2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL][1,3]OXAZOLO[4,5-C]PYRIDIN-4-AMINE",,Prothrombin,F2,,unknown
3-Bromo-3-buten-1-ol,,Methane monooxygenase component A alpha chain,mmoX,,unknown
3-({1-[3-CARBAMIMIDOYL-1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-PROPYLCARBAMOYL]-2-METHYL-BUTYLSULFAMOYL}-METHYL)-BENZOIC ACID,,Coagulation factor VII,F7,,unknown
3-hydroxyglutaric acid,,"Hydroxymethylglutaryl-CoA lyase, mitochondrial",HMGCL,,unknown
"4-O-{4,6-O-[(1S)-1-Carboxyethylidene]-β-D-mannopyranosyl}-D-glucopyranuronic acid",,Xanthan lyase,xly,,unknown
"[4,6-O-(1-CARBOXYETHYLIDENE)-BETA-D-MANNOSE]",,Xanthan lyase,xly,,unknown
2-AMINO-4-CHLORO-3-HYDROXYBENZOIC ACID,,"3-hydroxyanthranilate 3,4-dioxygenase",nbaC,,unknown
Aniracetam,1-2.5 hours,5-hydroxytryptamine receptor 2A,HTR2A,,unknown
Aniracetam,1-2.5 hours,D(2) dopamine receptor,DRD2,,unknown
Aniracetam,1-2.5 hours,Glutamate receptor 2,GRIA2,,unknown
Aniracetam,1-2.5 hours,Glutamate receptor 3,GRIA3,,unknown
"4-[(3-BROMO-4-O-SULFAMOYLBENZYL)(4-CYANOPHENYL)AMINO]-4H-[1,2,4]-TRIAZOLE",,Carbonic anhydrase 2,CA2,,unknown
"4-[(4-O-SULFAMOYLBENZYL)(4-CYANOPHENYL)AMINO]-4H-[1,2,4]-TRIAZOLE",,Carbonic anhydrase 2,CA2,,unknown
PUROMYCIN AMINONUCLEOSIDE-5'-MONOPHOSPHATE,,60S ribosomal protein L37,RPL37,,unknown
5-iodotubercidin,,Casein kinase I isoform gamma-2,CSNK1G2,,unknown
5-iodotubercidin,,Serine/threonine-protein kinase haspin,GSG2,,unknown
5-iodotubercidin,,Mitogen-activated protein kinase 3,MAPK3,,unknown
5-Aminoisoquinoline,,Putative uncharacterized protein,,,unknown
2-[2-ETHANESULFONYLAMINO-3-(5-PROPOXY-1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIMIDOYL-BENZYLAMIDE),,Coagulation factor VII,F7,,unknown
"PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE",,Cyclin-dependent kinase 2,CDK2,,unknown
"9-HYDROXY-4-PHENYL-6H-PYRROLO[3,4-C]CARBAZOLE-1,3-DIONE",,Wee1-like protein kinase,WEE1,,unknown
INHIBITOR Q8467 OF DUPONT MERCK,,Gag-Pol polyprotein,gag-pol,,unknown
"7,8-dihydro-6-hydroxymethyl-7-methyl-7-[2-phenylethyl]-pterin",,2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase,folK,,unknown
"N-METHYLALANYL-3-METHYLVALYL-4-PHENOXY-N-(1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)PROLINAMIDE",,E3 ubiquitin-protein ligase XIAP,XIAP,,unknown
(R)-tacrine(10)-hupyridone,,Acetylcholinesterase,ACHE,,unknown
(S)-tacrine(10)-hupyridone,,Acetylcholinesterase,ACHE,,unknown
TACRINE(8)-4-AMINOQUINOLINE,,Acetylcholinesterase,ACHE,,unknown
"(9S)-9-[(8-AMMONIOOCTYL)AMINO]-1,2,3,4,9,10-HEXAHYDROACRIDINIUM",,Acetylcholinesterase,ACHE,,unknown
"4,6-DIDEOXY-4-{[4-[(4-O-HEXOPYRANOSYLHEXOPYRANOSYL)OXY]-5,6-DIHYDROXY-3-(HYDROXYMETHYL)CYCLOHEX-2-EN-1-YL]AMINO}HEXOPYRANOSYL-(1->4)HEXOPYRANOSYL-(1->4)HEXOPYRANOSE",,Pancreatic alpha-amylase,AMY2A,,unknown
ACETOPHENONE,,R-specific alcohol dehydrogenase,radh,,unknown
Cycloleucine,,"Glutamate receptor ionotropic, NMDA 1",GRIN1,,unknown
N-ACETYLHISTAMINE,,Glutaminyl-peptide cyclotransferase,QPCT,,unknown
"2-ETHOXYETHYL (2S,3S)-4-((S)-2-BENZYL-3-OXO-4-((3AR,8R,8AS)-2-OXO-3,3A,8,8A-TETRAHYDRO-2H-INDENO[1,2-D]OXAZOL-8-YL)-2,3-DIHYDRO-1H-PYRROL-2-YL)-3-HYDROXY-1-PHENYLBUTAN-2-YLCARBAMATE",,Pol protein,pol,,unknown
DERIVATIVE OF AKLANONIC ACID METHYL ESTER (AAME),,Aklanonic acid methyl ester cyclase,acma,,unknown
Apramycin,,16S rRNA,,,unknown
Cyclouridine,,Uridine phosphorylase,udp,,unknown
Allosamidin,,Chitinase B,chiB,,unknown
Allosamidin,,Chitinase A,chiA,,unknown
Aplyronine A,,"Actin, alpha skeletal muscle",ACTA1,,unknown
Aldosterone,,Mineralocorticoid receptor,NR3C2,,unknown
Aldosterone,,Glucocorticoid receptor,NR3C1,,unknown
Atpenin A5,,Succinate dehydrogenase flavoprotein subunit,sdhA,,unknown
Atpenin A5,,Succinate dehydrogenase iron-sulfur subunit,sdhB,,unknown
Atpenin A5,,Succinate dehydrogenase cytochrome b556 subunit,sdhC,,unknown
Atpenin A5,,Succinate dehydrogenase hydrophobic membrane anchor subunit,sdhD,,unknown
4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE,,Mitogen-activated protein kinase 14,MAPK14,,unknown
"N-ethyl-N-[3-(propylamino)propyl]propane-1,3-diamine",,Diamine acetyltransferase 1,SAT1,,unknown
N-BENZYLOXYCARBONYL-L-SERINE-BETALACTONE,,Genome polyprotein,,,unknown
N-BENZYLOXYCARBONYL-L-SERINE-BETALACTONE,,Genome polyprotein,,,unknown
N-BENZYLOXYCARBONYL-L-SERINE-BETALACTONE,,Genome polyprotein,,,unknown
Glutamine t-butyl ester,,Glutaminyl-peptide cyclotransferase,QPCT,,unknown
6-Bromo-1-hexanol,,Methane monooxygenase component A alpha chain,mmoX,,unknown
"2,5-DI-(TERT-BUTYL)-1,4,BENZOHYDROQUINONE",,Sarcoplasmic/endoplasmic reticulum calcium ATPase 1,ATP2A1,,unknown
Biphenylalanine,,Envelope glycoprotein gp160,env,,unknown
Biphenylalanine,,Ig gamma-1 chain C region,IGHG1,,unknown
"Naphthalene-2,6-disulfonic acid",,L-lactate dehydrogenase,,,unknown
"Naphthalene-2,6-disulfonic acid",,Bacterioferritin comigratory protein,,,unknown
"3,7-DIHYDROXYNAPHTHALENE-2-CARBOXYLIC ACID",,L-lactate dehydrogenase,,,unknown
"7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
"4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
"4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
"5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
Dibromothymoquinone,,Cytochrome b6,petB,,unknown
Dibromothymoquinone,,Cytochrome b6-f complex iron-sulfur subunit,petC,,unknown
Dibromothymoquinone,,Cytochrome b6-f complex subunit 4,petD,,unknown
Dibromothymoquinone,,Apocytochrome f,petA,,unknown
Dibromothymoquinone,,Cytochrome b6-f complex subunit 5,petG,,unknown
Dibromothymoquinone,,Cytochrome b6-f complex subunit 6,petL,,unknown
Dibromothymoquinone,,Cytochrome b6-f complex subunit 7,petM,,unknown
Dibromothymoquinone,,Cytochrome b6-f complex subunit 8,petN,,unknown
BOC-GAMMA-D-GLU-L-LYS(CBZ)-D-BOROALA,,D-alanyl-D-alanine carboxypeptidase DacA,dacA,,unknown
BOC-GAMMA-D-GLU-L-LYS(CBZ)-D-BOROALA,,D-alanyl-D-alanine carboxypeptidase DacA,dacA,,unknown
S-propylamine-L-cysteine,,Arginase-1,ARG1,,unknown
TETRAHEDRAL INTERMEDIATE OF BLASTICIDIN S,,Blasticidin-S deaminase,bsd,,unknown
"5-[(3AS,4R,6AR)-2-OXOHEXAHYDRO-1H-THIENO[3,4-D]IMIDAZOL-4-YL]PENTANOIC ACID",,Streptavidin,,,unknown
BIOTINOL-5-AMP,,Bifunctional protein BirA,birA,,unknown
Corticosterone,,Mineralocorticoid receptor,NR3C2,,unknown
Corticosterone,,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
Corticosterone,,Nuclear receptor coactivator 1,NCOA1,,unknown
CBZ-LEU-LEU-TYR-CH2F,,Calpain-1 catalytic subunit,CAPN1,,unknown
4-PIPERIDIN-4-YLBUTANAL,,Trypsin-1,PRSS1,,unknown
4-PIPERIDIN-4-YLBUTANAL,,Tryptase beta-2,TPSB2,,unknown
Metoprine,,Histamine N-methyltransferase,HNMT,,unknown
"1,3,4-TRIHYDROXY-5-(3-PHENOXYPROPYL)-CYCLOHEXANE-1-CARBOXYLIC A CID",,3-dehydroquinate dehydratase,aroQ,,unknown
Carboxin,,"Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial",SDHA,,unknown
"(1S,2R,3S,4R,5S)-8-AZABICYCLO[3.2.1]OCTANE-1,2,3,4-TETROL",,Beta-glucosidase A,bglA,,unknown
"(1S,2S,3R,4S,5S)-2,3,4-TRIHYDROXY-5-(HYDROXYMETHYL)CYCLOHEXYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE",,Lactase-phlorizin hydrolase,LCT,,unknown
Choline alfoscerate,,Ganglioside GM2 activator,GM2A,,unknown
Cis-tetracosenoyl sulfatide,,Antigen-presenting glycoprotein CD1d,CD1D,,unknown
OLOMOUCINE II,,Cyclin-dependent kinase 2,CDK2,,unknown
Cyclohexyl-pentyl-maltoside,,Cytochrome P450 2B6,CYP2B6,,unknown
Coumarin,,Cytochrome P450 2A6,CYP2A6,,unknown
TRIAZOLOPYRIMIDINE,,Cyclin-dependent kinase 2,CDK2,,unknown
L-CYSTEIN-S-1-(IMINOMETHYL)-L-ORNITHINE,,Arginine deiminase,arcA,,unknown
"cyclic 3',5'-thymidine monophosphate",,"5'(3')-deoxyribonucleotidase, mitochondrial",NT5M,,unknown
4-[(5-CHLOROINDOL-2-YL)SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL)PYRIMIDIN-2-YL]CARBONYL]PIPERAZINE,,Coagulation factor X,F10,,unknown
"2-HYDROXY-3,5-DIIODOBENZOIC ACID",,Endothelin-1 receptor,EDNRA,,unknown
"2-HYDROXY-3,5-DIIODOBENZOIC ACID",,Aldo-keto reductase family 1 member C1,AKR1C1,,unknown
Dansyllysine,,Ig alpha-2 chain C region,IGHA2,,unknown
N-METHYL-N-[(1R)-1-METHYL-2-PHENYLETHYL]PROP-2-EN-1-AMINE,,Amine oxidase [flavin-containing] B,MAOB,,unknown
H TYPE II TRISACCHARIDE,,Histo-blood group ABO system transferase,ABO,,unknown
H TYPE I TRISACCHARIDE,,Histo-blood group ABO system transferase,ABO,,unknown
GALACTOSE GREASE,,Histo-blood group ABO system transferase,ABO,,unknown
BETA-METHYLLACTOSIDE,,Histo-blood group ABO system transferase,ABO,,unknown
Octylphenoxy polyethoxyethanol,,"Troponin C, skeletal muscle",TNNC2,,unknown
"(2R)-3-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-2-[(9E)-HEXADEC-9-ENOYLOXY]PROPYL (9E)-OCTADEC-9-ENOATE",,Steroidogenic factor 1,NR5A1,,unknown
"1-{(2S,5S)-4-FLUORO-5-[(TRITYLOXY)METHYL]TETRAHYDROFURAN-2-YL}PYRIMIDINE-2,4(1H,3H)-DIONE",,"Deoxyuridine 5'-triphosphate nucleotidohydrolase, putative",,,unknown
"1-{(2S,5S)-4-FLUORO-5-[(TRITYLOXY)METHYL]TETRAHYDROFURAN-2-YL}PYRIMIDINE-2,4(1H,3H)-DIONE",,"Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial",DUT,,unknown
DIMETHYL THIOPHOSPHATE,,Phosphotriesterase,opdA,,unknown
Methylecgonine,,Ig gamma-2 chain C region,IGHG2,,unknown
Methylecgonine,,Ig kappa chain C region,IGKC,,unknown
2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Camptothecin,,DNA topoisomerase 1,TOP1,,unknown
"(13S)-13-METHYLDODECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE-3,17(2H,4H)-DIONE",,Steroid Delta-isomerase,ksi,,unknown
FARNESYL THIOPYROPHOSPHATE,,"Ditrans,polycis-undecaprenyl-diphosphate synthase ((2E,6E)-farnesyl-diphosphate specific)",ispU,,unknown
FARNESYL THIOPYROPHOSPHATE,,Geranylgeranyl pyrophosphate synthase,GGPS1,,unknown
FARNESYL THIOPYROPHOSPHATE,,Mevalonate kinase,MVK,,unknown
FARNESYL THIOPYROPHOSPHATE,,Dehydrosqualene synthase,crtM,,unknown
"4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN",,Thymidylate synthase,thyA,,unknown
TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE,,Prothrombin,F2,,unknown
"N-(1,4-DIHYDRO-5H-TETRAZOL-5-YLIDENE)-9-OXO-9H-XANTHENE-2-SULFONAMIDE",,3-dehydroquinate dehydratase,aroQ,,unknown
gamma-butyrolactone,,O-GlcNAcase NagJ,nagJ,,unknown
GLUTATHIONE SULFINATE,,Glutathione S-transferase kappa 1,GSTK1,,unknown
S-METHYL-GLUTATHIONE,,Glutathione S-transferase Mu 2,GSTM2,,unknown
"S-[(2E)-3,7-DIMETHYLOCTA-2,6-DIENYL] TRIHYDROGENTHIODIPHOSPHATE",,Prenyltransferase,,,unknown
HESPERIDIN,,Aurora kinase B,AURKB,,unknown
Hydroxyfasudil,,Rho-associated protein kinase 1,ROCK1,inhibitor,unknown
Hydroxyfasudil,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
Hydroxyfasudil,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
"(3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE",,Androgen receptor,AR,,unknown
4-Iodo-D-phenylalanine,,Aminopeptidase S,,,unknown
ISOPENTENYL PYROPHOSPHATE,,"Ditrans,polycis-undecaprenyl-diphosphate synthase ((2E,6E)-farnesyl-diphosphate specific)",ispU,,unknown
ISOPENTENYL PYROPHOSPHATE,,Farnesyl pyrophosphate synthase,FDPS,,unknown
ISOPENTENYL PYROPHOSPHATE,,Geranylgeranyl pyrophosphate synthase,GGPS1,,unknown
ISOPENTENYL PYROPHOSPHATE,,"2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase",ispF,,unknown
ISOPENTENYL PYROPHOSPHATE,,Decaprenyl diphosphate synthase,uppS,,unknown
ISOPENTENYL PYROPHOSPHATE,,4-hydroxy-3-methylbut-2-enyl diphosphate reductase,ispH,,unknown
IMIDAZOPYRIDAZIN 1,,Serine/threonine-protein kinase pim-1,PIM1,,unknown
"2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE",,Tyrosine-protein kinase JAK2,JAK2,,unknown
"2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE",,Death-associated protein kinase 3,DAPK3,,unknown
"2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE",,Tyrosine-protein kinase JAK1,JAK1,,unknown
"2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE",,Tyrosine-protein kinase JAK3,JAK3,,unknown
"2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE",,Non-receptor tyrosine-protein kinase TYK2,TYK2,,unknown
"DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE",,Casein kinase II subunit alpha,CSNK2A1,,unknown
"S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE",,Casein kinase II subunit alpha,CSNK2A1,,unknown
"N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE",,Casein kinase II subunit alpha,CSNK2A1,,unknown
"2-(3-CHLORO-6-{[2,2-DIFLUORO-2-(1-OXIDOPYRIDIN-2-YL)ETHYL]AMINO}-1-OXIDOPYRIDIN-2-YL)-N-[1-(3-CHLOROPHENYL)ETHYL]ACETAMIDE",,Prothrombin,F2,,unknown
2-(3-GUANIDINOPHENYL)-3-MERCAPTOPROPANOIC ACID,,Carboxypeptidase B,CPB1,,unknown
"(S)-2-((S)-3-ISOBUTYL-2,5-DIOXO-4-QUINOLIN-3-YLMETHYL-[1,4]DIAZEPAN-1YL)-N-METHYL-3-NAPHTALEN-2-YL-PROPIONAMIDE",,Integrin alpha-L,ITGAL,,unknown
Licofelone,,Group IIE secretory phospholipase A2,PLA2G2E,,unknown
Licofelone,,Prostaglandin G/H synthase 2,PTGS2,,unknown
Licofelone,,Arachidonate 5-lipoxygenase,ALOX5,,unknown
"N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FURO[2,3-D]PYRIMIDIN-5-YL}PHENYL)-N'-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]UREA",,Vascular endothelial growth factor receptor 2,KDR,,unknown
GENTAMICIN C1A,,30S ribosomal protein S12,rpsL,adduct,yes
GENTAMICIN C1A,,16S rRNA,,adduct,yes
1-ACETYL-2-LYSO-SN-GLYCERO-3-PHOSPHOETHANOLAMINE,,Lantibiotic cinnamycin,cinA,,unknown
N-(4-MORPHOLINE)CARBONYL-B-(1-NAPHTHYL)-L-ALANINE-L-LEUCINE BORONIC ACID,,Proteasome subunit alpha,prcA,,unknown
N-(4-MORPHOLINE)CARBONYL-B-(1-NAPHTHYL)-L-ALANINE-L-LEUCINE BORONIC ACID,,Proteasome subunit beta,prcB,,unknown
"1,6-DI-O-PHOSPHONO-D-MANNITOL",,Fructose-bisphosphate aldolase A,ALDOA,,unknown
Citraconic acid,,Fumarate reductase flavoprotein subunit,fccA,,unknown
MONOGALACTOSYL-DIACYLGLYCEROL,,Photosystem Q(B) protein 1,psbA1,,unknown
"2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE(BETA1-4)-2-ACETAMIDO-1,6-ANHYDRO-3-O-[(R)-1-CARBOXYETHYL]-2-DEOXY-BETA-D-GLUCOPYRANOSE-L-ALANYL-GAMMA-D-GLUTAMYL-MESO-DIAMINOPIMELYL-D-ALANINE",,Peptidoglycan recognition protein 3,PGLYRP3,,unknown
Motuporin,,Serine/threonine-protein phosphatase PP1-gamma catalytic subunit,PPP1CC,,unknown
4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
MOXALACTAM (HYDROLYZED),,Metallo-beta-lactamase L1,,,unknown
Myxothiazol,,"Cytochrome b-c1 complex subunit 1, mitochondrial",UQCRC1,,unknown
"(2R)-2-{(1R)-2-oxo-1-[(2-thienylacetyl)amino]ethyl}-5,6-dihydro-2h-1,3-thiazine-4-carboxylic acid",,D-alanyl-D-alanine carboxypeptidase,dac,,unknown
Nimesulide,1.8–4.7 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Nimesulide,1.8–4.7 hours,Group IIE secretory phospholipase A2,PLA2G2E,,unknown
Nimesulide,1.8–4.7 hours,Lactotransferrin,LTF,,unknown
2-OXOQUINOLINE,,"2-oxo-1,2-dihydroquinoline 8-monooxygenase, oxygenase component",oxoO,,unknown
"(10E,12Z)-octadeca-10,12-dienoic acid",,Putative aminooxidase,,,unknown
11-TRANS-13-TRANS-15-CIS-OCTADECATRIENOIC ACID,,Putative aminooxidase,,,unknown
2-(3-OXO-PROPYLSULFANYLCARBONYL)-ETHANETHIOLATE,,Beta-lactamase IMP-1,,,unknown
Purvalanol A,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
Purvalanol A,,Casein kinase I isoform gamma-3,CSNK1G3,,unknown
Purvalanol A,,Ribosomal protein S6 kinase alpha-1,RPS6KA1,,unknown
Phosphatidyl ethanol,,Steroidogenic factor 1,NR5A1,,unknown
"9-DEAZAINOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE",,Purine nucleoside phosphorylase,PNP,,unknown
"GUANOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE",,Purine nucleoside phosphorylase,PNP,,unknown
"GUANOSINE-2',3'-O-METHYLIDENEPHOSPHONATE",,Purine nucleoside phosphorylase,PNP,,unknown
2-[2-ETHANESULFONYLAMINO-3-(1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIM IDOYL-BENZYLAMIDE),,Coagulation factor VII,F7,,unknown
"PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-(3-METHYL-BENZYLAMIDE)",,Collagenase 3,MMP13,,unknown
"PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-(4-FLUORO-3-METHYL-BENZYLAMIDE)",,Collagenase 3,MMP13,,unknown
"PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-[(PYRIDIN-3-YLMETHYL)-AMIDE]",,Collagenase 3,MMP13,,unknown
N-PYRIDOXYL-D-GLUTAMIC ACID-5'-MONOPHOSPHATE,,Aspartate aminotransferase,aspC,,unknown
"1-N-(4-SULFAMOYLPHENYL-ETHYL)-2,4,6-TRIMETHYLPYRIDINIUM",,Carbonic anhydrase 2,CA2,,unknown
[4-(3-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-(5-PHENETHYL- PYRIDIN-3-YL)-METHANONE,,Tryptase beta-2,TPSB2,,unknown
N-PYRIDOXYL-2-METHYL-L-GLUTAMIC ACID-5'-MONOPHOSPHATE,,Aspartate aminotransferase,aspC,,unknown
N-[1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-3-METHYLSULFANYL-PROPYL]-3-HYDROXY-2-PROPOXYAMINO-BUTYRAMID,,Coagulation factor VII,F7,,unknown
Pyrithiamine Pyrophosphate,,Thiamin pyrophosphokinase 1,TPK1,,unknown
"5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE",,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,,unknown
"O6-(R)-ROSCOVITINE, R-2-(6-BENZYLOXY-9-ISOPROPYL-9H-PURIN-2-YLAMINO)-BUTAN-1-OL",,Pyridoxal kinase,PDXK,,unknown
1-GUANIDINO-4-(N-NITRO-BENZOYLAMINO-L-LEUCYL-L-PROLYLAMINO)BUTANE,,Prothrombin,F2,,unknown
1-GUANIDINO-4-(N-PHENYLMETHANESULFONYL-L-LEUCYL-L-PROLYLAMINO)BUTANE,,Prothrombin,F2,,unknown
METHYL (3R)-3-{[(3R)-3-{[(3R)-3-HYDROXYBUTANOYL]OXY}BUTANOYL]OXY}BUTANOATE,,"Polyhydroxybutyrate depolymerase, putative",,,unknown
Reidispongiolide A,,"Actin, alpha skeletal muscle",ACTA1,,unknown
Reidispongiolide C,,"Actin, alpha skeletal muscle",ACTA1,,unknown
(2R)-2-({6-[benzyl(methyl)amino]-9-isopropyl-9H-purin-2-yl}amino)butan-1-ol,,Pyridoxal kinase,PDXK,,unknown
(R)-4-Nitrostyrene oxide,,Halohydrin dehalogenase,hheC,,unknown
ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE,,Lactase-phlorizin hydrolase,LCT,,unknown
5-hydroxyvaleric acid,,Delta-aminolevulinic acid dehydratase,ALAD,,unknown
(S)-4-Nitrostyrene oxide,,"2,3-dichloro-1-propanol dehalogenase",dehB,,unknown
Sphinxolide B,,"Actin, alpha skeletal muscle",ACTA1,,unknown
(R)-1-phenylethanol,,R-specific alcohol dehydrogenase,radh,,unknown
Suramin,Approximately 36 to 60 days,P2Y purinoceptor 2,P2RY2,antagonist,yes
Suramin,Approximately 36 to 60 days,"NAD-dependent protein deacylase sirtuin-5, mitochondrial",SIRT5,inhibitor,yes
Suramin,Approximately 36 to 60 days,Follicle-stimulating hormone receptor,FSHR,antagonist,yes
Suramin,Approximately 36 to 60 days,Ryanodine receptor 1,RYR1,agonist,unknown
Suramin,Approximately 36 to 60 days,Prothrombin,F2,inhibitor,unknown
Suramin,Approximately 36 to 60 days,"Phospholipase A2, membrane associated",PLA2G2A,inhibitor,unknown
Suramin,Approximately 36 to 60 days,Complement control protein C3,,,unknown
Tanaproget,,Progesterone receptor,PGR,agonist,yes
Tagetitoxin,,DNA-directed RNA polymerase subunit beta,rpoB,,unknown
Tagetitoxin,,DNA-directed RNA polymerase subunit beta',rpoC,,unknown
5-methyltetrahydrofolic acid,,"Aminomethyltransferase, mitochondrial",AMT,,unknown
"2,5-bis-o-{3-[amino(imino)methyl]phenyl}-1,4:3,6-dianhydro-d-glucitol",,Trypsin-1,PRSS1,,unknown
"2-O-(4'-AMIDINOPHENYL)-5-O-(3''-AMIDINOPHENYL)-1,4:3,6-DIANHYDRO-D-SORBITOL",,Trypsin-1,PRSS1,,unknown
"2,5-O,O-BIS-{4',4''-AMIDINOPHENYL}-1,4:3,6-DIANHYDRO-D-SORBITOL",,Trypsin-1,PRSS1,,unknown
"1,4:3,6-Dianhydro-2-O-(3-carbamimidoylphenyl)-5-O-(4-carbamimidoylphenyl)-D-glucitol",,Trypsin-1,PRSS1,,unknown
Bifonazole,1-2 hours,Lanosterol 14-alpha demethylase,ERG11,inhibitor,yes
Bifonazole,1-2 hours,Cytochrome P450 2B6,CYP2B6,,unknown
Thenoyltrifluoroacetone,,Liver carboxylesterase 1,CES1,,unknown
Thenoyltrifluoroacetone,,"Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial",SDHA,,unknown
Inecalcitol,,Vitamin D3 receptor,VDR,,unknown
Triazolopyridine,,Mitogen-activated protein kinase 14,MAPK14,,unknown
THIO-ATPA,,Glutamate receptor 2,GRIA2,,unknown
"5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole",,"Cytochrome c1, heme protein, mitochondrial",CYC1,,unknown
"5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole",,Cytochrome b,MT-CYB,,unknown
"5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole",,"Cytochrome b-c1 complex subunit 1, mitochondrial",UQCRC1,,unknown
"5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole",,"Cytochrome b-c1 complex subunit 2, mitochondrial",UQCRC2,,unknown
"5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole",,"Cytochrome b-c1 complex subunit 6, mitochondrial",UQCRH,,unknown
"5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole",,Cytochrome b-c1 complex subunit 8,UQCRQ,,unknown
"5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole",,"Cytochrome b-c1 complex subunit Rieske, mitochondrial",UQCRFS1,,unknown
"5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole",,Cytochrome b-c1 complex subunit 10,UQCR11,,unknown
"5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole",,Cytochrome b-c1 complex subunit 7,UQCRB,,unknown
"5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole",,Cytochrome b-c1 complex subunit 9,UQCR10,,unknown
1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
(11E)-OCTADEC-11-ENOIC ACID,,Peroxisome proliferator-activated receptor delta,PPARD,,unknown
Verdoheme,,Heme oxygenase 1,HMOX1,,unknown
Virginiamycin S1,,60S ribosomal protein L37,RPL37,,unknown
4-NITROPHENYL-(6-S-ALPHA-D-XYLOPYRANOSYL)-BETA-D-GLUCOPYRANOSIDE,,Alpha-xylosidase,yicI,,unknown
SALOPHEN-10-PROPIONATE IRON CHELATE,,Heme oxygenase,hmuO,,unknown
Salophen-10-carboxylate iron chelate,,Heme oxygenase,hmuO,,unknown
Salophen iron chelate,,Heme oxygenase,hmuO,,unknown
Metamizole,,Prostaglandin G/H synthase 1,PTGS1,,unknown
Nialamide,,Amine oxidase [flavin-containing] B,MAOB,,unknown
Nialamide,,Amine oxidase [flavin-containing] A,MAOA,,unknown
Nialamide,,Catechol O-methyltransferase,COMT,,unknown
Nomifensine,,Sodium-dependent noradrenaline transporter,SLC6A2,,unknown
Nomifensine,,Sodium-dependent dopamine transporter,SLC6A3,,unknown
Nomifensine,,Amine oxidase [flavin-containing] B,MAOB,,unknown
Nomifensine,,Amine oxidase [flavin-containing] A,MAOA,,unknown
Nomifensine,,Myeloperoxidase,MPO,,unknown
Nomifensine,,Sodium-dependent serotonin transporter,SLC6A4,,unknown
Nomifensine,,Synaptic vesicular amine transporter,SLC18A2,,unknown
Phenolphthalein,,UDP-glucuronosyltransferase 1-9,UGT1A9,,unknown
Phenolphthalein,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Phenolphthalein,,Nuclear receptor subfamily 1 group I member 3,NR1I3,,unknown
Phenolphthalein,,Estrogen receptor alpha,ESR1,agonist,unknown
Phenolphthalein,,Sex hormone-binding globulin,SHBG,,unknown
Prenylamine,,Calmodulin,CALM1,,unknown
Prenylamine,,"Myosin light chain kinase 2, skeletal/cardiac muscle",MYLK2,,unknown
Zomepirac,,Prostaglandin D2 receptor 2,PTGDR2,,unknown
Lysergic Acid Diethylamide,3 hours,5-hydroxytryptamine receptor 1A,HTR1A,,unknown
Lysergic Acid Diethylamide,3 hours,5-hydroxytryptamine receptor 2B,HTR2B,agonist,unknown
Lysergic Acid Diethylamide,3 hours,5-hydroxytryptamine receptor 6,HTR6,,unknown
Zimelidine,8.4 +/- 2.0 hours for the parent compound and 19.4 +/- 3.6 hours for norzimelidine.,Sodium-dependent serotonin transporter,SLC6A4,,unknown
Zimelidine,8.4 +/- 2.0 hours for the parent compound and 19.4 +/- 3.6 hours for norzimelidine.,Amine oxidase [flavin-containing] B,MAOB,inhibitor,unknown
Zimelidine,8.4 +/- 2.0 hours for the parent compound and 19.4 +/- 3.6 hours for norzimelidine.,Amine oxidase [flavin-containing] A,MAOA,inhibitor,unknown
Maraviroc,14-18 hours,C-C chemokine receptor type 5,CCR5,antagonist,yes
Amineptine,48 minutes for the parent drug and 2.5 hours for the metabolites.,Sodium-dependent noradrenaline transporter,SLC6A2,,unknown
Amineptine,48 minutes for the parent drug and 2.5 hours for the metabolites.,Sodium-dependent serotonin transporter,SLC6A4,,unknown
Clofedanol,,Histamine H1 receptor,HRH1,antagonist,yes
Cyclandelate,,Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,inhibitor,unknown
Cyclandelate,,Liver carboxylesterase 1,CES1,,unknown
Cyproterone acetate,"Elimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively.",Androgen receptor,AR,antagonist,yes
Cyproterone acetate,"Elimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively.",Prostate-specific antigen,KLK3,,unknown
Debrisoquin,,Sodium-dependent noradrenaline transporter,SLC6A2,inducer,yes
Flunarizine,18 days,Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,inhibitor,yes
Flunarizine,18 days,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,inhibitor,yes
Flunarizine,18 days,Voltage-dependent T-type calcium channel subunit alpha-1I,CACNA1I,inhibitor,yes
Flunarizine,18 days,Histamine H1 receptor,HRH1,antagonist,unknown
Flunarizine,18 days,Calmodulin,CALM1,,unknown
Fluspirilene,,D(2) dopamine receptor,DRD2,antagonist,yes
Fluspirilene,,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,unknown
Fluspirilene,,Voltage-dependent calcium channel gamma-1 subunit,CACNG1,inhibitor,unknown
Mepenzolate,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Mepenzolate,,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Tetrabenazine,"α-HTBZ = 7 hours; 
β-HTBZ = 5 hours;
9-desmethyl-β-DHTBZ = 12 hours.",Synaptic vesicular amine transporter,SLC18A2,inhibitor,yes
Tetrabenazine,"α-HTBZ = 7 hours; 
β-HTBZ = 5 hours;
9-desmethyl-β-DHTBZ = 12 hours.",D(2) dopamine receptor,DRD2,inhibitor,unknown
Ixabepilone,52 hours,Tubulin beta-3 chain,TUBB3,inhibitor,yes
Celiprolol,5 hours,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Celiprolol,5 hours,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Roxadustat,,Egl nine homolog 1,EGLN1,,unknown
Roxadustat,,Egl nine homolog 2,EGLN2,,unknown
Roxadustat,,Egl nine homolog 3,EGLN3,,unknown
Cediranib,12 to 35 hours,Vascular endothelial growth factor receptor 2,KDR,,unknown
Posizolid,,23S rRNA,,antagonistblocker,yes
Posizolid,,Amine oxidase [flavin-containing] A,MAOA,,unknown
Biricodar dicitrate,,ATP-binding cassette sub-family B member 5,ABCB5,,unknown
Biricodar dicitrate,,Multidrug resistance-associated protein 1,ABCC1,,unknown
Biricodar dicitrate,,ATP-binding cassette sub-family G member 2,ABCG2,,unknown
Implitapide,,Microsomal triglyceride transfer protein large subunit,MTTP,,unknown
Binodenoson,10 &plusmn; 4 minutes,Adenosine receptor A2a,ADORA2A,,unknown
Febuxostat,~5-8 hours.,Xanthine dehydrogenase/oxidase,XDH,inhibitor,yes
Dronedarone,Elimination half-life: 13-19 hours,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Dronedarone,Elimination half-life: 13-19 hours,Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Dronedarone,Elimination half-life: 13-19 hours,Alpha-1D adrenergic receptor,ADRA1D,,unknown
Dronedarone,Elimination half-life: 13-19 hours,Alpha-2A adrenergic receptor,ADRA2A,,unknown
Dronedarone,Elimination half-life: 13-19 hours,Alpha-2B adrenergic receptor,ADRA2B,,unknown
Dronedarone,Elimination half-life: 13-19 hours,Alpha-2C adrenergic receptor,ADRA2C,,unknown
Dronedarone,Elimination half-life: 13-19 hours,Beta-1 adrenergic receptor,ADRB1,,unknown
Dronedarone,Elimination half-life: 13-19 hours,Potassium voltage-gated channel subfamily H member 2,KCNH2,,unknown
Dronedarone,Elimination half-life: 13-19 hours,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,,unknown
Dronedarone,Elimination half-life: 13-19 hours,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,,unknown
Dronedarone,Elimination half-life: 13-19 hours,Voltage-dependent L-type calcium channel subunit alpha-1F,CACNA1F,,unknown
Dronedarone,Elimination half-life: 13-19 hours,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,,unknown
Dronedarone,Elimination half-life: 13-19 hours,Voltage-dependent L-type calcium channel subunit beta-1,CACNB1,,unknown
Dronedarone,Elimination half-life: 13-19 hours,Voltage-dependent L-type calcium channel subunit beta-2,CACNB2,,unknown
Dronedarone,Elimination half-life: 13-19 hours,Voltage-dependent L-type calcium channel subunit beta-3,CACNB3,,unknown
Dronedarone,Elimination half-life: 13-19 hours,Voltage-dependent L-type calcium channel subunit beta-4,CACNB4,,unknown
Dronedarone,Elimination half-life: 13-19 hours,Sodium channel protein type 1 subunit alpha,SCN1A,inhibitor,unknown
Dronedarone,Elimination half-life: 13-19 hours,Potassium channel subfamily K member 2,KCNK2,inhibitor,unknown
Dexloxiglumide,,Cholecystokinin receptor type A,CCKAR,,unknown
Brasofensine,"Plasma terminal elimination half-lives were ~2 hr in rats, ~4 hr in monkeys, but ~24 hr in humans.",D(2) dopamine receptor,DRD2,,unknown
Tirapazamine,,DNA,,,unknown
Zanapezil,,Acetylcholinesterase,ACHE,,unknown
Isatoribine,,Toll-like receptor 7,TLR7,,unknown
Nebivolol,10 hours,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Nebivolol,10 hours,Beta-2 adrenergic receptor,ADRB2,antagonist,unknown
Merimepodib,,Inosine-5'-monophosphate dehydrogenase,guaB,,unknown
Lefradafiban,,Integrin alpha-IIb,ITGA2B,,unknown
Lefradafiban,,Integrin beta-3,ITGB3,,unknown
Huperzine A,,Acetylcholinesterase,ACHE,,unknown
Huperzine A,,Acetylcholinesterase,ACHE,,unknown
Omacetaxine mepesuccinate,Homoharringtonine has a half life of about 6 hours after subcutaneous administration.,50S ribosomal protein L2,rpl2,antagonist,yes
Omacetaxine mepesuccinate,Homoharringtonine has a half life of about 6 hours after subcutaneous administration.,60S ribosomal protein L3,RPL3,antagonist,yes
Halofuginone,23.8 to 72.1 hours,Collagen alpha-1(I) chain,COL1A1,,unknown
Halofuginone,23.8 to 72.1 hours,72 kDa type IV collagenase,MMP2,,unknown
Lintitript,,Cholecystokinin receptor type A,CCKAR,,unknown
Nilotinib,15 hours,Tyrosine-protein kinase ABL1,ABL1,inhibitor,yes
Nilotinib,15 hours,Mast/stem cell growth factor receptor Kit,KIT,antagonist,unknown
Olcegepant,,Calcitonin gene-related peptide 1,CALCA,,unknown
Olcegepant,,Calcitonin gene-related peptide type 1 receptor,CALCRL,,unknown
Lorcaserin,The plasma half life is approximately 11 hours.,5-hydroxytryptamine receptor 2C,HTR2C,,unknown
Osanetant,,Neuromedin-K receptor,TACR3,,unknown
Piboserod,,5-hydroxytryptamine receptor 4,HTR4,,unknown
Picoplatin,,DNA,,,unknown
Pralnacasan,,Caspase-1,CASP1,,unknown
Vildagliptin,The elimination half-life is approximately 90 minutes.,Dipeptidyl peptidase 4,DPP4,inhibitor,yes
Voacamine,,Multidrug resistance protein 1,ABCB1,,unknown
Voglibose,,"Maltase-glucoamylase, intestinal",MGAM,inhibitor,yes
Vatalanib,Approximately 6 hours.,Vascular endothelial growth factor receptor 1,FLT1,,unknown
Vatalanib,Approximately 6 hours.,Vascular endothelial growth factor receptor 2,KDR,,unknown
Vatalanib,Approximately 6 hours.,Vascular endothelial growth factor receptor 3,FLT4,,unknown
Enoximone,4-10 hours,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,inhibitor,yes
Elacridar,,Multidrug resistance protein 1,ABCB1,,unknown
Edotecarin,20 to 25 hours,DNA topoisomerase 1,TOP1,,unknown
Darusentan,,Endothelin-1 receptor,EDNRA,,unknown
Dapoxetine,Initial half-life of 1-2 hours.,5-hydroxytryptamine receptor 1A,HTR1A,,unknown
Dapoxetine,Initial half-life of 1-2 hours.,5-hydroxytryptamine receptor 1B,HTR1B,,unknown
Dapoxetine,Initial half-life of 1-2 hours.,5-hydroxytryptamine receptor 2C,HTR2C,,unknown
Cilansetron,The elimination half-life after 4- and 8-mg oral doses administered 3 times daily for 6 days was reported to be 1.6 to 1.9 hours.,5-hydroxytryptamine receptor 3A,HTR3A,,unknown
Calanolide A,20 hours for 800mg,Gag-Pol polyprotein,gag-pol,,unknown
Brecanavir,,Human immunodeficiency virus type 1 protease,pol,,unknown
Bifeprunox,,D(2) dopamine receptor,DRD2,,unknown
Bifeprunox,,5-hydroxytryptamine receptor 1A,HTR1A,,unknown
Bicifadine,,Sodium-dependent noradrenaline transporter,SLC6A2,,unknown
Bicifadine,,Sodium-dependent serotonin transporter,SLC6A4,,unknown
Bicifadine,,D(2) dopamine receptor,DRD2,,unknown
Bepotastine,Elimination half life = 2.5 hours,Histamine H1 receptor,HRH1,antagonist,yes
Becocalcidiol,,Mediator of RNA polymerase II transcription subunit 1,MED1,,unknown
Becocalcidiol,,Vitamin D3 receptor,VDR,,unknown
Phenserine,8 to 10 hours,Acetylcholinesterase,ACHE,,unknown
Phenserine,8 to 10 hours,Cholinesterase,BCHE,inhibitor,unknown
Phenserine,8 to 10 hours,Amyloid beta A4 protein,APP,,unknown
AZD3409,15–20 hours for the thiol-ester intermediate and 15–30 hours for the active thiol-acid metabolite.,Protein farnesyltransferase subunit beta,FNTB,,unknown
AZD3409,15–20 hours for the thiol-ester intermediate and 15–30 hours for the active thiol-acid metabolite.,Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha,FNTA,,unknown
Vapreotide,30 minutes,Somatostatin receptor type 2,SSTR2,inducer,yes
Vapreotide,30 minutes,Somatostatin receptor type 5,SSTR5,agonist,yes
Vapreotide,30 minutes,Substance-P receptor,TACR1,antagonist,unknown
Pegaptanib,"In humans, after a 3 mg monocular dose (10 times the recommended dose), the average (&#177; standard deviation) apparent plasma half-life of pegaptanib is 10 (&#177; 4) days.",Neuropilin-1,NRP1,,unknown
Milnacipran,"The terminal elimination half-life, when given to healthy subjects is 6-8 hours. When given to severe renal impairment patients is 7 - 10 hours. The active enantiomer, d-milnacipran, has a longer elimination half-life (8-10 hours) than the l-enantiomer (4-6 hours).",Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Milnacipran,"The terminal elimination half-life, when given to healthy subjects is 6-8 hours. When given to severe renal impairment patients is 7 - 10 hours. The active enantiomer, d-milnacipran, has a longer elimination half-life (8-10 hours) than the l-enantiomer (4-6 hours).",Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Milnacipran,"The terminal elimination half-life, when given to healthy subjects is 6-8 hours. When given to severe renal impairment patients is 7 - 10 hours. The active enantiomer, d-milnacipran, has a longer elimination half-life (8-10 hours) than the l-enantiomer (4-6 hours).",NMDA receptor,GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B,inhibitor,unknown
Ximelagatran,3-5 hours,Prothrombin,F2,inhibitor,yes
Nesiritide,Approximately 18 minutes,Atrial natriuretic peptide receptor 1,NPR1,binder,unknown
Nesiritide,Approximately 18 minutes,Atrial natriuretic peptide receptor 2,NPR2,,unknown
Nesiritide,Approximately 18 minutes,Atrial natriuretic peptide receptor 3,NPR3,,unknown
Galiximab,13 to 24 days,T-lymphocyte activation antigen CD80,CD80,,unknown
Pagoclone,,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,,unknown
Pagoclone,,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,,unknown
Tesmilifene,,Multidrug resistance protein 1,ABCB1,inducer,yes
Tesmilifene,,Histamine H1 receptor,HRH1,antagonist,unknown
Flibanserin,≈11 hours,5-hydroxytryptamine receptor 1A,HTR1A,agonist,yes
Flibanserin,≈11 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Flibanserin,≈11 hours,D(4) dopamine receptor,DRD4,antagonist,yes
Oxibendazole,,Tubulin beta-4B chain,TUBB4B,,unknown
Stannsoporfin,3.8 hours following i.v. administration of 1 mumole per kg body weight,Heme oxygenase 1,HMOX1,,unknown
Stannsoporfin,3.8 hours following i.v. administration of 1 mumole per kg body weight,Heme oxygenase 2,HMOX2,,unknown
Idronoxil,,Ecto-NOX disulfide-thiol exchanger 2,ENOX2,,unknown
Renzapride,,5-hydroxytryptamine receptor 3A,HTR3A,,unknown
Renzapride,,5-hydroxytryptamine receptor 4,HTR4,,unknown
Ceftobiprole,,MecA,mecA,,unknown
Ceftobiprole,,Penicillin-binding protein 2x,pbpX,,unknown
Ceftobiprole,,Peptidoglycan synthase FtsI,ftsI,,unknown
Alfimeprase,,Fibrinogen alpha chain,FGA,,unknown
Alfimeprase,,Fibrinogen beta chain,FGB,,unknown
Clevidipine,1 minute,Voltage-dependent L-type calcium channel subunit alpha-1F,CACNA1F,,unknown
Clevidipine,1 minute,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,,unknown
Clevidipine,1 minute,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,,unknown
Clevidipine,1 minute,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,,unknown
Itopride,,D(2) dopamine receptor,DRD2,,unknown
Itopride,,Muscarinic acetylcholine receptor M3,CHRM3,,unknown
Desmoteplase,,Plasminogen,PLG,,unknown
Neramexane,,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,,unknown
NM100060,,Squalene monooxygenase,SQLE,,unknown
DG031,,Arachidonate 5-lipoxygenase-activating protein,ALOX5AP,,unknown
Permethrin,,Sodium channel protein type 1 subunit alpha,SCN1A,inhibitor,yes
Permethrin,,Estrogen receptor alpha,ESR1,,unknown
Permethrin,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Afamelanotide,The plasma half-lives following SC dosing (0.08 to 0.21 mg/kg) ranged from 0.07 to 0.79 h for the absorption phase and from 0.8 to 1.7 h for the beta-phase.,Melanocyte-stimulating hormone receptor,MC1R,,unknown
Defibrotide,t1/2-alpha = minutes (10-20 minutes in rat); t1/2-beta = a few hours,Adenosine receptor A1,ADORA1,,unknown
Defibrotide,t1/2-alpha = minutes (10-20 minutes in rat); t1/2-beta = a few hours,Adenosine receptor A2a,ADORA2A,,unknown
Defibrotide,t1/2-alpha = minutes (10-20 minutes in rat); t1/2-beta = a few hours,Adenosine receptor A2b,ADORA2B,,unknown
Eritoran,50.4 to 62.7 hours,Toll-like receptor 4,TLR4,,unknown
Rifalazil,,DNA-directed RNA polymerase subunit beta,rpoB,,unknown
Ospemifene,Terminal half-life = 26 hours .,Estrogen receptor alpha,ESR1,antagonistagonist,yes
Crofelemer,"Since crofelemer is not significantly absorbed, the half life was not determined.",Cystic fibrosis transmembrane conductance regulator,CFTR,antagonist,yes
Crofelemer,"Since crofelemer is not significantly absorbed, the half life was not determined.",Anoctamin-1,ANO1,antagonist,yes
Tamibarotene,,Retinoic acid receptor alpha,RARA,agonist,yes
Tamibarotene,,Retinoic acid receptor beta,RARB,agonist,yes
Iloperidone,"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.",5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Iloperidone,"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.",D(2) dopamine receptor,DRD2,antagonist,yes
Iloperidone,"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.",D(1A) dopamine receptor,DRD1,antagonist,unknown
Iloperidone,"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.",D(3) dopamine receptor,DRD3,antagonist,unknown
Iloperidone,"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.",D(4) dopamine receptor,DRD4,antagonist,unknown
Iloperidone,"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.",5-hydroxytryptamine receptor 1A,HTR1A,antagonist,unknown
Iloperidone,"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.",5-hydroxytryptamine receptor 6,HTR6,antagonist,unknown
Iloperidone,"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.",5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Iloperidone,"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.",Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Iloperidone,"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.",Histamine H1 receptor,HRH1,antagonist,unknown
Iloperidone,"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.",Alpha-2C adrenergic receptor,ADRA2C,antagonist,unknown
Altropane,,Sodium-dependent dopamine transporter,SLC6A3,,unknown
Lofexidine,11 hours,Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Ranpirnase,,DNA,,,unknown
Pirfenidone,2-2.5 hours,Furin,FURIN,,unknown
Ezogabine,Terminal half-life = 7.5 hours,Potassium voltage-gated channel subfamily KQT member 2,KCNQ2,,unknown
Ezogabine,Terminal half-life = 7.5 hours,Potassium voltage-gated channel subfamily KQT member 3,KCNQ3,,unknown
Ezogabine,Terminal half-life = 7.5 hours,Potassium voltage-gated channel subfamily KQT member 4,KCNQ4,,unknown
Ezogabine,Terminal half-life = 7.5 hours,Potassium voltage-gated channel subfamily KQT member 5,KCNQ5,,unknown
Tecadenoson,,Adenosine receptor A1,ADORA1,,unknown
Afelimomab,44.7 hours,Tumor necrosis factor,TNF,,unknown
Azimilide,,Potassium voltage-gated channel subfamily E member 1,KCNE1,,unknown
Azimilide,,Potassium voltage-gated channel subfamily KQT member 1,KCNQ1,,unknown
Azimilide,,Potassium voltage-gated channel subfamily H member 2,KCNH2,,unknown
Epratuzumab,,B-cell receptor CD22,CD22,,unknown
HspE7,,"Keratin, type II cytoskeletal 7",KRT7,,unknown
HspE7,,E3 ubiquitin-protein ligase UBR4,UBR4,,unknown
Tipifarnib,,Protein farnesyltransferase subunit beta,FNTB,,unknown
Troxacitabine,,DNA,,,unknown
Oregovomab,,Mucin-16,MUC16,,unknown
Lucanthone,,DNA topoisomerase 2-alpha,TOP2A,inhibitor,yes
Lucanthone,,DNA-(apurinic or apyrimidinic site) lyase,APEX1,inhibitor,yes
Lucanthone,,DNA,,intercalation,yes
Lucanthone,,DNA topoisomerase 1,TOP1,inhibitor,yes
Lesopitron,1.1 to 5.6 hours,5-hydroxytryptamine receptor 1A,HTR1A,,unknown
Reglixane,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Reglixane,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Canfosfamide,18 min,Glutathione S-transferase P,GSTP1,,unknown
LErafAON,"In monkeys, the terminal plasma half-life of 30.36 +/- 23.87 hours was observed at an i.v. dose of 6.25 mg/kg.",RAF proto-oncogene serine/threonine-protein kinase,RAF1,,unknown
AP1903,,Serine/threonine-protein kinase mTOR,MTOR,,unknown
Banoxantrone,0.64 to 0.83 hours,DNA topoisomerase 2-alpha,TOP2A,,unknown
SP1049C,,DNA topoisomerase 2-alpha,TOP2A,,unknown
Talampanel,3-6 hours,Glutamate receptor 1,GRIA1,,unknown
Talampanel,3-6 hours,Glutamate receptor 2,GRIA2,,unknown
Talampanel,3-6 hours,Glutamate receptor 3,GRIA3,,unknown
Talampanel,3-6 hours,Glutamate receptor 4,GRIA4,,unknown
Denufosol,,P2Y purinoceptor 2,P2RY2,,unknown
Tigapotide,0.35 hours to 1.45 hours,40S ribosomal protein SA,RPSA,,unknown
IGN311,,Epidermal growth factor receptor,EGFR,,unknown
IGN311,,Receptor tyrosine-protein kinase erbB-2,ERBB2,,unknown
XL784,Approximately 8 hours,Disintegrin and metalloproteinase domain-containing protein 10,ADAM10,,unknown
AP5346,,DNA,,,unknown
Satraplatin,,DNA,,,unknown
ATL1102,,Integrin alpha-4,ITGA4,,unknown
AGRO100,,NF-kappa-B essential modulator,IKBKG,,unknown
PSN9301,,Dipeptidyl peptidase 4,DPP4,,unknown
Imexon,,Ribonucleoside-diphosphate reductase subunit M2,RRM2,,unknown
Imexon,,Ribonucleoside-diphosphate reductase large subunit,RRM1,,unknown
AC162352,,Neuropeptide Y receptor type 2,NPY2R,,unknown
AC162352,,Neuropeptide Y receptor type 1,NPY1R,,unknown
AC162352,,Neuropeptide Y receptor type 5,NPY5R,,unknown
AC162352,,Neuropeptide Y receptor type 4,NPY4R,,unknown
CCX282,,C-C chemokine receptor type 9,CCR9,,unknown
Apadenoson,,Adenosine receptor A2a,ADORA2A,,unknown
SGS-742,4 hours,Gamma-aminobutyric acid type B receptor subunit 1,GABBR1,,unknown
SGS-742,4 hours,Gamma-aminobutyric acid type B receptor subunit 2,GABBR2,,unknown
XEN2174,,Sodium-dependent noradrenaline transporter,SLC6A2,,unknown
Ingenol Mebutate,There is no half-life quantity since ingenol mebutate is a topical treatment.,Protein kinase C delta type,PRKCD,ligand,unknown
Ingenol Mebutate,There is no half-life quantity since ingenol mebutate is a topical treatment.,Protein kinase C alpha type,PRKCA,ligand,unknown
XL999,,Fibroblast growth factor receptor 3,FGFR3,,unknown
XL999,,Fibroblast growth factor receptor 1,FGFR1,,unknown
XL999,,Vascular endothelial growth factor receptor 2,KDR,,unknown
XL999,,Receptor-type tyrosine-protein kinase FLT3,FLT3,,unknown
XL999,,Platelet-derived growth factor receptor beta,PDGFRB,,unknown
XL999,,RET proto-oncogene,RET,,unknown
Belinostat,Displays a three-compartment pharmacokinetic property with elimination half life of 1.1 hours,Histone deacetylase,HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9,inhibitor,yes
YSIL6,,Tumor necrosis factor,TNF,,unknown
YSIL6,,Interleukin-6,IL6,,unknown
Migalastat,,Alpha-galactosidase A,GLA,,unknown
ANA380,,DNA polymerase,,,unknown
Amonafide,,DNA topoisomerase 2-alpha,TOP2A,,unknown
Amonafide,,DNA topoisomerase 2-beta,TOP2B,,unknown
ATL1101,,Insulin-like growth factor 1 receptor,IGF1R,,unknown
CTA018,,"1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial",CYP24A1,,unknown
CTA018,,Vitamin D3 receptor,VDR,,unknown
Arimoclomol,,Superoxide dismutase [Cu-Zn],SOD1,,unknown
REV131,Approximately 8 hours,Histamine H4 receptor,HRH4,,unknown
INCB7839,,Disintegrin and metalloproteinase domain-containing protein 9,ADAM9,,unknown
Ularitide,,Atrial natriuretic peptide receptor 1,NPR1,,unknown
Eprotirome,,Thyroid hormone receptor alpha,THRA,,unknown
Eprotirome,,Thyroid hormone receptor beta,THRB,,unknown
Grn163l,,Telomerase-binding protein EST1A,SMG6,,unknown
Grn163l,,N-terminal kinase-like protein,SCYL1,,unknown
Grn163l,,Prostaglandin E synthase 3,PTGES3,,unknown
Grn163l,,Telomerase reverse transcriptase,TERT,,unknown
AT7519,,Cyclin-dependent kinase 1,CDK1,,unknown
AT7519,,Cyclin-dependent kinase 2,CDK2,,unknown
Anatibant,,B2 bradykinin receptor,BDKRB2,antagonist,unknown
Indacaterol,"Indacaterol serum concentrations declined in a multi-phasic manner with an average terminal half-life ranging from 45.5 to 126 hours. The effective half-life, calculated from the accumulation of indacaterol after repeated dosing with once daily doses between 75 mcg and 600 mcg ranged from 40 to 56 hours which is consistent with the observed time-to-steady state of approximately 12-15 days.",Beta-2 adrenergic receptor,ADRB2,agonist,yes
RP101,,Uridine phosphorylase 1,UPP1,,unknown
RP101,,Uridine phosphorylase 2,UPP2,,unknown
SGS518,,5-hydroxytryptamine receptor 6,HTR6,,unknown
PSN357,,"Glycogen phosphorylase, liver form",PYGL,,unknown
Obinepitide,,Neuropeptide Y receptor type 4,NPY4R,,unknown
Obinepitide,,Neuropeptide Y receptor type 2,NPY2R,,unknown
V1003,,Kappa-type opioid receptor,OPRK1,,unknown
V1003,,Mu-type opioid receptor,OPRM1,,unknown
CX717,,Glutamate receptor 4,GRIA4,,unknown
CX717,,Brain-derived neurotrophic factor,BDNF,,unknown
CX717,,Glutamate receptor 1,GRIA1,,unknown
CX717,,Glutamate receptor 2,GRIA2,,unknown
CX717,,Glutamate receptor 3,GRIA3,,unknown
DDP733,,5-hydroxytryptamine receptor 3A,HTR3A,,unknown
ADL5859,,Delta-type opioid receptor,OPRD1,,unknown
MF101,,Estrogen receptor beta,ESR2,,unknown
MB-07803,,"Fructose-1,6-bisphosphatase 1",FBP1,,unknown
R1626,,RNA-dependent RNA-polymerase,NS5b,,unknown
INCB13739,,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
ATG003,,Neuronal acetylcholine receptor subunit alpha-10,CHRNA10,,unknown
ATG003,,Neuronal acetylcholine receptor subunit alpha-9,CHRNA9,,unknown
ADX10059,,Metabotropic glutamate receptor 5,GRM5,,unknown
AV608,,Substance-P receptor,TACR1,,unknown
SRT501,,NAD-dependent protein deacetylase sirtuin-1,SIRT1,,unknown
TG-100801,,Vascular endothelial growth factor receptor 1,FLT1,,unknown
TG-100801,,Vascular endothelial growth factor receptor 2,KDR,,unknown
TG-100801,,Vascular endothelial growth factor receptor 3,FLT4,,unknown
TG-100801,,Tyrosine-protein kinase CSK,CSK,,unknown
SLV319,,Cannabinoid receptor 1,CNR1,,unknown
AER001,,Interleukin-4 receptor subunit alpha,IL4R,,unknown
AER001,,Interleukin-13 receptor subunit alpha-2,IL13RA2,,unknown
HY10275,,Histamine H1 receptor,HRH1,,unknown
HY10275,,5-hydroxytryptamine receptor 2A,HTR2A,,unknown
OBE101,,Histamine H1 receptor,HRH1,,unknown
OBE101,,Histamine H3 receptor,HRH3,,unknown
Abaloparatide,The mean (SD) half-life if 1.7 (0.7) hrs.,Parathyroid hormone/parathyroid hormone-related peptide receptor,PTH1R,ligand,yes
TM30339,,Neuropeptide Y receptor type 4,NPY4R,,unknown
Ganaxolone,1.3-1.9 hours,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,,unknown
Ganaxolone,1.3-1.9 hours,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,,unknown
Ganaxolone,1.3-1.9 hours,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,,unknown
Ganaxolone,1.3-1.9 hours,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,,unknown
Ganaxolone,1.3-1.9 hours,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,,unknown
Ganaxolone,1.3-1.9 hours,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,,unknown
Tiomolibdate ion,,Amyloid beta A4 protein,APP,,unknown
M0002,,Vasopressin V2 receptor,AVPR2,,unknown
CDP323,,Integrin alpha-4,ITGA4,,unknown
Cimicoxib,,Prostaglandin G/H synthase 2,PTGS2,,unknown
LY2140023,,Metabotropic glutamate receptor 2,GRM2,,unknown
LY2140023,,Metabotropic glutamate receptor 3,GRM3,,unknown
Labetuzumab,,Carcinoembryonic antigen,,,unknown
Leptin,24.9+/-4.4 min,Leptin receptor,LEPR,,unknown
Ancrod,3 to 5 hours,Fibrinogen alpha chain,FGA,,unknown
Matuzumab,196 hours,Epidermal growth factor receptor,EGFR,,unknown
Rupintrivir,,Genome polyprotein,,,unknown
Asimadoline,,Kappa-type opioid receptor,OPRK1,,unknown
Pleconaril,,Polyprotein,,,unknown
16-Bromoepiandrosterone,,Glucose-6-phosphate 1-dehydrogenase,G6PD,,unknown
Trabectedin,33-50 hours,DNA,,binder,yes
VIR201,,Interferon gamma,IFNG,,unknown
Fontolizumab,,Interferon gamma,IFNG,,unknown
NN344,,Insulin receptor,INSR,,unknown
Thymectacin,,Thymidylate synthase,TYMS,,unknown
Rilapladib,,Platelet-activating factor acetylhydrolase,PLA2G7,,unknown
AT1391,,Insulin receptor,INSR,,unknown
1D09C3,,HLA-DR,,,yes
R1295,,Integrin alpha-4,ITGA4,,unknown
R1295,,Integrin beta-4,ITGB4,,unknown
R1295,,Integrin beta-7,ITGB7,,unknown
SC12267,,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
ANA971,,Toll-like receptor 7,TLR7,,unknown
Elsamitrucin,36–60 h,DNA,,,unknown
Elsamitrucin,36–60 h,DNA topoisomerase 1,TOP1,,unknown
Elsamitrucin,36–60 h,DNA topoisomerase 2-alpha,TOP2A,,unknown
INCB3284,,C-C chemokine receptor type 2,CCR2,,unknown
TTP889,20 hours,Coagulation factor IX,F9,,unknown
VP025,,Interleukin-1 beta,IL1B,,unknown
Tanespimycin,,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
Tanespimycin,,Heat shock protein HSP 90-beta,HSP90AB1,,unknown
Lobeline,,Neuronal acetylcholine receptor subunit alpha-9,CHRNA9,,unknown
Lobeline,,Neuronal acetylcholine receptor subunit alpha-10,CHRNA10,,unknown
Lobeline,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,,unknown
CR002,,Platelet-derived growth factor D,PDGFD,,unknown
LY2181308,,Baculoviral IAP repeat-containing protein 5,BIRC5,,unknown
ND7001,,"Phosphodiesterase 2A, cGMP-stimulated",PDE2A,,unknown
ND7001,,"cGMP-dependent 3',5'-cyclic phosphodiesterase",PDE2A,,unknown
XL820,,Vascular endothelial growth factor receptor 2,KDR,,unknown
XL820,,Mast/stem cell growth factor receptor Kit,KIT,,unknown
XL820,,Platelet-derived growth factor receptor alpha,PDGFRA,,unknown
XL820,,Platelet-derived growth factor receptor beta,PDGFRB,,unknown
CYT997,,Tubulin alpha-1A chain,TUBA1A,,unknown
CYT997,,Tubulin alpha-1B chain,TUBA1B,,unknown
CYT997,,Tubulin alpha-1C chain,TUBA1C,,unknown
CYT997,,Tubulin alpha-4A chain,TUBA4A,,unknown
CYT997,,Tubulin alpha-3C/D chain,TUBA3C,,unknown
CYT997,,Tubulin alpha-3E chain,TUBA3E,,unknown
CYT997,,Putative tubulin-like protein alpha-4B,TUBA4B,,unknown
CYT997,,Tubulin beta-1 chain,TUBB1,,unknown
CYT997,,Tubulin beta-2A chain,TUBB2A,,unknown
CYT997,,Tubulin beta-2B chain,TUBB2B,,unknown
CYT997,,Tubulin beta-4B chain,TUBB4B,,unknown
CYT997,,Tubulin beta-3 chain,TUBB3,,unknown
CYT997,,Tubulin beta-4A chain,TUBB4A,,unknown
CYT997,,Tubulin beta chain,TUBB,,unknown
CYT997,,Tubulin beta-6 chain,TUBB6,,unknown
XL844,,Serine/threonine-protein kinase Chk2,CHEK2,,unknown
XL844,,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
CAD106,,Amyloid beta A4 protein,APP,,unknown
NGX267,,Muscarinic acetylcholine receptor M1,CHRM1,,unknown
CR665,,Kappa-type opioid receptor,OPRK1,,unknown
KC706,,Mitogen-activated protein kinase 14,MAPK14,,unknown
KC706,,Mitogen-activated protein kinase 11,MAPK11,,unknown
KC706,,Mitogen-activated protein kinase 12,MAPK12,,unknown
KC706,,Mitogen-activated protein kinase 13,MAPK13,,unknown
CCX915,,C-C chemokine receptor type 2,CCR2,,unknown
Elafin,,Neutrophil elastase,ELANE,,unknown
Elafin,,Myeloblastin,PRTN3,,unknown
CMLVAX100,,BCR/ABL p210 fusion protein,BCR/ABL fusion,,unknown
LY2275796,,Eukaryotic translation initiation factor 4E,EIF4E,,unknown
APD668,,Glucose-dependent insulinotropic receptor,GPR119,,unknown
Vintafolide,,Folate receptor beta,FOLR2,,unknown
Vintafolide,,Folate receptor gamma,FOLR3,,unknown
Vintafolide,,Folate receptor alpha,FOLR1,,unknown
AT9283,,Aurora kinase A,AURKA,,unknown
AT9283,,Aurora kinase B,AURKB,,unknown
E-2012,,Gamma-secretase subunit APH-1A,APH1A,,unknown
E-2012,,Gamma-secretase subunit PEN-2,PSENEN,,unknown
DG051,,Leukotriene A-4 hydrolase,LTA4H,,unknown
MLN0415,,Inhibitor of nuclear factor kappa-B kinase subunit beta,IKBKB,,unknown
XL228,,Insulin-like growth factor 1 receptor,IGF1R,,unknown
XL228,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
XL228,,Tyrosine-protein kinase ABL1,ABL1,,unknown
XL228,,Abelson tyrosine-protein kinase 2,ABL2,,unknown
Elafibranor,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Elafibranor,,Peroxisome proliferator-activated receptor delta,PPARD,,unknown
Elafibranor,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
KD3010,,Peroxisome proliferator-activated receptor delta,PPARD,,unknown
XL281,,Serine/threonine-protein kinase B-raf,BRAF,,unknown
XL281,,RAF proto-oncogene serine/threonine-protein kinase,RAF1,,unknown
Atl146e,,Adenosine receptor A2a,ADORA2A,,unknown
MB07811,,Thyroid hormone receptor beta,THRB,,unknown
KB002,,Granulocyte-macrophage colony-stimulating factor receptor subunit alpha,CSF2RA,,unknown
KB002,,Granulocyte-macrophage colony-stimulating factor,CSF2,,unknown
KB002,,GM-CSF receptor alpha subunit,CSF2RA,,unknown
CYC116,,Aurora kinase A,AURKA,,unknown
CYC116,,Vascular endothelial growth factor receptor 2,KDR,,unknown
LX1031,,Tryptophan 5-hydroxylase 1,TPH1,,unknown
AT2220,,Lysosomal alpha-glucosidase,GAA,,unknown
V24343,,Cannabinoid receptor 1,CNR1,,unknown
Egaptivon pegol,,von Willebrand factor,VWF,,unknown
Egaptivon pegol,,Platelet glycoprotein Ib alpha chain,GP1BA,,unknown
SPP1148,,Angiotensin-converting enzyme 2,ACE2,,unknown
SPP1148,,Renin,REN,,unknown
XL418,,Tyrosine-protein kinase BTK,BTK,,unknown
CX157,,Amine oxidase [flavin-containing] A,MAOA,,unknown
SD118,,Tumor necrosis factor,TNF,,unknown
SD118,,Interleukin-1 receptor type 1,IL1R1,,unknown
SYM001,,Rhesus blood group D antigen,RHD,,unknown
SF1126,,Phosphatidylinositol 3-kinase regulatory subunit alpha,PIK3R1,,unknown
SF1126,,Phosphatidylinositol 3-kinase regulatory subunit beta,PIK3R2,,unknown
SF1126,,Phosphatidylinositol 3-kinase regulatory subunit gamma,PIK3R3,,unknown
SF1126,,DNA-dependent protein kinase catalytic subunit,PRKDC,,unknown
SF1126,,Serine/threonine-protein kinase mTOR,MTOR,,unknown
HE3286,,Nuclear factor NF-kappa-B p105 subunit,NFKB1,,unknown
HE3286,,Nuclear factor NF-kappa-B p100 subunit,NFKB2,,unknown
KD7040,,"Nitric oxide synthase, inducible",NOS2,,unknown
GMX1777,,Nicotinamide phosphoribosyltransferase,NAMPT,,unknown
PN0621,,Tumor necrosis factor,TNF,,unknown
Crisaborole,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,inhibitor,unknown
Crisaborole,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,inhibitor,unknown
Crisaborole,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4C",PDE4C,inhibitor,unknown
Crisaborole,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,inhibitor,unknown
Alisertib,,Aurora kinase A,AURKA,,unknown
KB001,,PcrV,pcrV,,unknown
Pracinostat,,Histone deacetylase 1,HDAC1,,unknown
Pracinostat,,Histone deacetylase 2,HDAC2,,unknown
Pracinostat,,Histone deacetylase 3,HDAC3,,unknown
Pracinostat,,Histone deacetylase 6,HDAC6,,unknown
REP8839,,Methionine--tRNA ligase,metG,,unknown
AM103,,Arachidonate 5-lipoxygenase-activating protein,ALOX5AP,,unknown
BTA9881,,Fusion glycoprotein F0,F,,unknown
APD791,,5-hydroxytryptamine receptor 2A,HTR2A,,unknown
RDEA806,,Gag-Pol polyprotein,gag-pol,,unknown
Beraprost,35–40 minutes,Prostacyclin receptor,PTGIR,,unknown
Tetrodotoxin,,Sodium channel protein type 1 subunit alpha,SCN1A,,unknown
Tetrodotoxin,,Sodium channel protein type 2 subunit alpha,SCN2A,,unknown
Tetrodotoxin,,Sodium channel protein type 3 subunit alpha,SCN3A,,unknown
Tetrodotoxin,,Sodium channel protein type 8 subunit alpha,SCN8A,,unknown
AP1081,,Estrogen receptor alpha,ESR1,,unknown
LGD2941,,Androgen receptor,AR,,unknown
NRP409,,Ketimine reductase mu-crystallin,CRYM,,unknown
NRP409,,Thyroid hormone receptor alpha,THRA,,unknown
Cobimetinib,Average half life was 44 hours.,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,inhibitor,yes
XL765,,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",PIK3CA,,unknown
XL765,,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,,unknown
XL765,,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",PIK3CD,,unknown
XL765,,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",PIK3CB,,unknown
XL765,,Serine/threonine-protein kinase mTOR,MTOR,,unknown
XL019,,Tyrosine-protein kinase JAK2,JAK2,,unknown
Silver sulfadiazine,,DNA,,binder,yes
Methsuximide,1.4-2.6 hours for mesuximide and 28-38 hours for the active metabolite.,Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,inhibitor,yes
FavId,,Granulocyte colony-stimulating factor receptor,CSF3R,,unknown
Fenoxaprop-ethyl,,"Nitric oxide synthase, inducible",NOS2,,unknown
Proellex,,Progesterone receptor,PGR,,unknown
Fibrinolysin,Almost completely inactivated after 24 hours.,Plasminogen activator inhibitor 1,SERPINE1,,unknown
Fibrinolysin,Almost completely inactivated after 24 hours.,Urokinase-type plasminogen activator,PLAU,,unknown
Ronacaleret,,Extracellular calcium-sensing receptor,CASR,,unknown
Ronacaleret,,Probable G-protein coupled receptor 110,ADGRF1,,unknown
Natural alpha interferon,,Interferon alpha/beta receptor 1,IFNAR1,,unknown
Glatiramer Acetate,,"HLA class II histocompatibility antigen, DRB1-1 beta chain",HLA-DRB1,binder,unknown
Gallium nitrate,"Alpha: 1 hour. Beta: 24 hours, but lengthens to 72 to 115 hours with prolonged intravenous infusion.",Ribonucleoside-diphosphate reductase subunit M2,RRM2,inhibitor,yes
Gallium nitrate,"Alpha: 1 hour. Beta: 24 hours, but lengthens to 72 to 115 hours with prolonged intravenous infusion.","V-type proton ATPase subunit B, brain isoform",ATP6V1B2,inhibitor,yes
Gallium nitrate,"Alpha: 1 hour. Beta: 24 hours, but lengthens to 72 to 115 hours with prolonged intravenous infusion.",Osteocalcin,BGLAP,antagonist,yes
Gallium nitrate,"Alpha: 1 hour. Beta: 24 hours, but lengthens to 72 to 115 hours with prolonged intravenous infusion.",Hydroxylapatite,,modulator,yes
Gallium nitrate,"Alpha: 1 hour. Beta: 24 hours, but lengthens to 72 to 115 hours with prolonged intravenous infusion.",Protein-tyrosine-phosphatase,PPI,inhibitor,unknown
Gallium nitrate,"Alpha: 1 hour. Beta: 24 hours, but lengthens to 72 to 115 hours with prolonged intravenous infusion.",Interleukin-1 beta,IL1B,antagonist,yes
Oxypurinol,23.3 +/- 6.0 hours,Xanthine dehydrogenase/oxidase,XDH,,unknown
NPI 32101,,Cytokine receptor common subunit beta,CSF2RB,,unknown
Ecabet,,NADPH oxidase organizer 1,NOXO1,antagonist,yes
Ecabet,,Urease subunit alpha,ureC,inhibitor,yes
Ibudilast,19 hours,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,inhibitor,yes
Ibudilast,19 hours,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,inhibitor,yes
Ibudilast,19 hours,"cAMP-specific 3',5'-cyclic phosphodiesterase 4C",PDE4C,inhibitor,yes
Ibudilast,19 hours,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,inhibitor,unknown
Ibudilast,19 hours,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,inhibitor,unknown
iCo-007,,RAF proto-oncogene serine/threonine-protein kinase,RAF1,,unknown
Rotigotine,"After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.",D(3) dopamine receptor,DRD3,agonist,yes
Rotigotine,"After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.",D(4) dopamine receptor,DRD4,agonist,yes
Rotigotine,"After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.",D(2) dopamine receptor,DRD2,agonist,yes
Rotigotine,"After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.",D(1B) dopamine receptor,DRD5,agonist,unknown
Rotigotine,"After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.",D(1A) dopamine receptor,DRD1,agonist,unknown
Rotigotine,"After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.",5-hydroxytryptamine receptor 1A,HTR1A,agonist,unknown
Rotigotine,"After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.",Alpha-2B adrenergic receptor,ADRA2B,antagonist,unknown
Hepatitis B Immune Globulin,,HBsAg,S gene,,unknown
S-8184,,Tubulin alpha-4A chain,TUBA4A,,unknown
S-8184,,Apoptosis regulator Bcl-2,BCL2,,unknown
MCC,,"Apoptosis-inducing factor 1, mitochondrial",AIFM1,,unknown
CA4P,,Tubulin beta chain,TUBB,,unknown
Tarenflurbil,,NF-kappa-B essential modulator,IKBKG,,unknown
SPP 301,,Endothelin-1 receptor,EDNRA,,unknown
Vandetanib,Median half life of 19 days.,Vascular endothelial growth factor A,VEGFA,inhibitor,unknown
Vandetanib,Median half life of 19 days.,Epidermal growth factor receptor,EGFR,inhibitor,unknown
Vandetanib,Median half life of 19 days.,Protein-tyrosine kinase 6,PTK6,inhibitor,unknown
Vandetanib,Median half life of 19 days.,Angiopoietin-1 receptor,TEK,inhibitor,unknown
Vandetanib,Median half life of 19 days.,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,,unknown
Eldecalcitol,,Vitamin D3 receptor,VDR,,unknown
Paclitaxel docosahexaenoic acid,,Apoptosis regulator Bcl-2,BCL2,,unknown
Tetomilast,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,,unknown
keyhole limpet hemocyanin,,Interleukin-2,IL2,,unknown
LAX-101,,Phospholipase D1,PLD1,,unknown
LAX-101,,Caspase-1,CASP1,,unknown
OMS-103HP,,Tumor necrosis factor,TNF,,unknown
OMS-103HP,,Interleukin-1 receptor type 1,IL1R1,,unknown
WX-G250,,Carbonic anhydrase 9,CA9,,unknown
WX-G250,,Interleukin-2,IL2,,unknown
Cintredekin Besudotox,,Interleukin-13,IL13,,unknown
CHF-1512,,Aromatic-L-amino-acid decarboxylase,DDC,,unknown
ANX-510,,Thymidylate synthase,TYMS,,unknown
TP-508,,Fibroblast growth factor 4,FGF4,,unknown
Ecallantide,"Following subcutaneous administration of 30 mg ecallantide, the mean elimination half-life was 2.0 ± 0.5 hours [FDA Label].",Plasma kallikrein,KLKB1,inhibitor,yes
Pimavanserin,,5-hydroxytryptamine receptor 2A,HTR2A,inverse agonist,yes
Pimavanserin,,D(2) dopamine receptor,DRD2,,unknown
TAK-475,,Squalene synthase,FDFT1,,unknown
TAK-475,,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,,unknown
oportuzumab monatox,,Epithelial cell adhesion molecule,EPCAM,,unknown
PEG-uricase,,Uric acid degradation bifunctional protein,uao,,unknown
Ranirestat,,Aldose reductase,AKR1B1,,unknown
VGV-1,,Gag-Pol polyprotein,gag-pol,,unknown
Romiplostim,"Immune thrombocytopenia patients, subQ = 3.5 days (median) (range 1-34 days)",Thrombopoietin receptor,MPL,agonist,yes
SOT-107,,Glioma pathogenesis-related protein 1,GLIPR1,,unknown
MN-305,,5-hydroxytryptamine receptor 1A,HTR1A,,unknown
C1-INH,,Plasma protease C1 inhibitor,SERPING1,,unknown
Arundic acid,,Protein S100-B,S100B,,unknown
SO-101,,Histamine H1 receptor,HRH1,,unknown
Dexlansoprazole,Dexlansoprazole is eliminated with a half-life of approximately one to two hours in healthy subjects and in patients with symptomatic GERD.,Potassium-transporting ATPase alpha chain 1,ATP4A,inhibitor,yes
Dexlansoprazole,Dexlansoprazole is eliminated with a half-life of approximately one to two hours in healthy subjects and in patients with symptomatic GERD.,Potassium-transporting ATPase subunit beta,ATP4B,inhibitor,yes
SR-123781A,,Antithrombin-III,SERPINC1,,unknown
SR-123781A,,Proteinase-activated receptor 1,F2R,,unknown
SSR-126517E,,Coagulation factor X,F10,,unknown
ROX-888,,C-C motif chemokine 3,CCL3,,unknown
Actelion-1,,Endothelin-1 receptor,EDNRA,,unknown
HZT-501,,Histamine H2 receptor,HRH2,,unknown
CP-945598,,Cannabinoid receptor 1,CNR1,,unknown
Rindopepimut,,Epidermal growth factor receptor,EGFR,,unknown
Histamine,,Histamine H1 receptor,HRH1,agonist,yes
Histamine,,Histamine H2 receptor,HRH2,agonist,yes
Histamine,,Histamine H3 receptor,HRH3,agonist,yes
Histamine,,Histamine H4 receptor,HRH4,agonist,unknown
Histamine,,Synaptic vesicular amine transporter,SLC18A2,,unknown
Iodine,,NADH-ubiquinone oxidoreductase chain 5,MT-ND5,,unknown
Pimagedine,,"Nitric oxide synthase, inducible",NOS2,inhibitor,unknown
Pimagedine,,Aldose reductase,AKR1B1,,unknown
Pimagedine,,Metalloproteinase inhibitor 3,TIMP3,,unknown
recombinant human GM-CSF,,Granulocyte-macrophage colony-stimulating factor receptor subunit alpha,CSF2RA,,unknown
recombinant human GM-CSF,,GM-CSF receptor alpha subunit,CSF2RA,,unknown
AE-941,,72 kDa type IV collagenase,MMP2,,unknown
AE-941,,Matrix metalloproteinase-9,MMP9,,unknown
AE-941,,Macrophage metalloelastase,MMP12,,unknown
WF10,,Macrophage erythroblast attacher,MAEA,,unknown
WF10,,Scavenger receptor cysteine-rich type 1 protein M130,CD163,,unknown
INS 316,,P2Y purinoceptor 2,P2RY2,,unknown
liposomal prostaglandin E1,,Platelet glycoprotein Ib alpha chain,GP1BA,,unknown
Amibegron,,Beta-3 adrenergic receptor,ADRB3,,unknown
C31G,,Gag-Pol polyprotein,gag-pol,,unknown
C31G,,CD9 antigen,CD9,,unknown
Succinobucol,,Vascular cell adhesion protein 1,VCAM1,,unknown
CEP-1347,,Mitogen-activated protein kinase 12,MAPK12,,unknown
AZD 3355,,Cellular tumor antigen p53,TP53,,unknown
TBC-3711,,Endothelin-1,EDN1,,unknown
Emricasan,,Caspase-1,CASP1,,unknown
Emricasan,,Caspase-3,CASP3,,unknown
Emricasan,,Caspase-7,CASP7,,unknown
Talmapimod,,Mitogen-activated protein kinase 14,MAPK14,,unknown
Talmapimod,,Tumor necrosis factor,TNF,,unknown
Talmapimod,,Interleukin-1 beta,IL1B,,unknown
Talmapimod,,Cytochrome c oxidase subunit 2,MT-CO2,,unknown
Tifuvirtide,,Plasma serine protease inhibitor,SERPINA5,,unknown
Pipendoxifene,,"Integrase, catalytic core",,,unknown
OSI-461,,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,,unknown
GW-501516,,Peroxisome proliferator-activated receptor delta,PPARD,agonist,unknown
GW-501516,,Peroxisome proliferator-activated receptor alpha,PPARA,agonist,unknown
GW 468816,,Glycine receptor subunit alpha-1,GLRA1,,unknown
GW 597599,,Substance-P receptor,TACR1,,unknown
ADX-10061,,Neuron-specific vesicular protein calcyon,CALY,,unknown
gallium maltolate,,Ribonucleoside-diphosphate reductase large subunit,RRM1,,unknown
CP-122721,,Substance-P receptor,TACR1,,unknown
OPC-14523,,Sodium-dependent serotonin transporter,SLC6A4,,unknown
ORG-34517,,Glucocorticoid receptor,NR3C1,,unknown
Canertinib,,Epidermal growth factor receptor,EGFR,,unknown
motexafin gadolinium,,"Thioredoxin reductase 1, cytoplasmic",TXNRD1,,unknown
motexafin gadolinium,,"Thioredoxin reductase 2, mitochondrial",TXNRD2,,unknown
motexafin gadolinium,,Ribonucleoside-diphosphate reductase subunit M2,RRM2,,unknown
CAT-213,,Eotaxin,CCL11,,unknown
MLN-977,,Arachidonate 5-lipoxygenase,ALOX5,,unknown
DAS-431 IV,,Neuron-specific vesicular protein calcyon,CALY,,unknown
ABT-510,,Fibroblast growth factor 2,FGF2,,unknown
ABT-510,,Hepatocyte growth factor,HGF,,unknown
ABT-510,,Vascular endothelial growth factor A,VEGFA,,unknown
ABT-510,,Interleukin-8,CXCL8,,unknown
Etiprednol dicloacetate,,Interleukin-1 beta,IL1B,,unknown
ADL 10-0101,,Kappa-type opioid receptor,OPRK1,,unknown
LJP 1082,,Beta-2-glycoprotein 1,APOH,,unknown
AVI-4557,,Hepatocyte nuclear factor 4-alpha,HNF4A,,unknown
PX-12,,"Thioredoxin reductase 1, cytoplasmic",TXNRD1,,unknown
FM-VP4,,Multidrug resistance protein 1,ABCB1,,unknown
P54,,Nuclear factor NF-kappa-B p100 subunit,NFKB2,,unknown
P54,,Nuclear factor NF-kappa-B p105 subunit,NFKB1,,unknown
PH-284,,Vasopressin V1a receptor,AVPR1A,,unknown
PH-284,,Vasopressin V1b receptor,AVPR1B,,unknown
SR 121463,,Vasopressin V1b receptor,AVPR1B,,unknown
OSI-7904L,,Thymidylate synthase,TYMS,,unknown
Pozanicline,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,,unknown
Pozanicline,,Neuronal acetylcholine receptor subunit beta-2,CHRNB2,,unknown
Briakinumab,,Interleukin-12 subunit beta,IL12B,,unknown
Briakinumab,,Interleukin-23 subunit alpha,IL23A,,unknown
Ezatiostat,,Glutathione S-transferase P,GSTP1,,unknown
OPC-28326,,5-hydroxytryptamine receptor 2B,HTR2B,,unknown
OPC-28326,,Alpha-2C adrenergic receptor,ADRA2C,,unknown
OPC-28326,,Alpha-2B adrenergic receptor,ADRA2B,,unknown
ISS-1018,,Toll-like receptor 9,TLR9,,unknown
NOX-700,,Nuclear factor NF-kappa-B p100 subunit,NFKB2,,unknown
NOX-700,,Nuclear factor NF-kappa-B p105 subunit,NFKB1,,unknown
Tandutinib,,Receptor-type tyrosine-protein kinase FLT3,FLT3,,unknown
Tandutinib,,Platelet-derived growth factor D,PDGFD,,unknown
R673,,Substance-P receptor,TACR1,,unknown
R667,,Retinoic acid receptor gamma,RARG,,unknown
R411,,Integrin alpha-4,ITGA4,,unknown
R450,,Alpha-1A adrenergic receptor,ADRA1A,,unknown
R450,,Alpha-1B adrenergic receptor,ADRA1B,,unknown
R450,,Alpha-1D adrenergic receptor,ADRA1D,,unknown
VX-702,,Mitogen-activated protein kinase 14,MAPK14,,unknown
VX-702,,Tumor necrosis factor,TNF,,unknown
VX-702,,Interleukin-1 beta,IL1B,,unknown
VX-702,,Interleukin-6,IL6,,unknown
SGN-30,,Nuclear factor NF-kappa-B p105 subunit,NFKB1,,unknown
SGN-30,,Nuclear factor NF-kappa-B p100 subunit,NFKB2,,unknown
omega interferon,,Interferon alpha/beta receptor 1,IFNAR1,,unknown
omega interferon,,Interferon alpha/beta receptor 2,IFNAR2,,unknown
Golotimod,,Toll-like receptor 2,TLR2,,unknown
Golotimod,,Toll-like receptor 4,TLR4,,unknown
Golotimod,,Toll-like receptor 7,TLR7,,unknown
Golotimod,,Toll-like receptor 9,TLR9,,unknown
WX-UK1,,Urokinase plasminogen activator surface receptor,PLAUR,,unknown
Pradefovir Mesylate,,Cytochrome P450 3A4,CYP3A4,,unknown
CZEN 002,,Melanocyte-stimulating hormone receptor,MC1R,,unknown
Recombinant alpha 1-antitrypsin,,Alpha-1-antitrypsin,SERPINA1,,unknown
7-ethyl-10-hydroxycamptothecin,,DNA topoisomerase 1,TOP1,,unknown
PCL-016,,E3 ubiquitin-protein ligase UBR4,UBR4,,unknown
PCL-016,,Zinc finger Y-chromosomal protein,ZFY,,unknown
MDX-018,,Interleukin-8,CXCL8,,unknown
Custirsen,,Estrogen receptor alpha,ESR1,,unknown
Custirsen,,Nuclear factor NF-kappa-B p100 subunit,NFKB2,,unknown
Custirsen,,Nuclear factor NF-kappa-B p105 subunit,NFKB1,,unknown
Technetium Tc-99m ciprofloxacin,,DNA gyrase subunit B,gyrB,,unknown
Technetium Tc-99m ciprofloxacin,,DNA topoisomerase 2-beta,TOP2B,,unknown
ACA 125,,Tyrosine-protein kinase transforming protein Abl,ABL,,unknown
T131,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Epicept NP-1,,Mu-type opioid receptor,OPRM1,,unknown
Epicept NP-1,,5-hydroxytryptamine receptor 2A,HTR2A,,unknown
Epicept NP-1,,5-hydroxytryptamine receptor 2B,HTR2B,,unknown
Epicept NP-1,,5-hydroxytryptamine receptor 2C,HTR2C,,unknown
Epicept NP-1,,Alpha-1A adrenergic receptor,ADRA1A,,unknown
Epicept NP-1,,Alpha-1B adrenergic receptor,ADRA1B,,unknown
Epicept NP-1,,Alpha-1D adrenergic receptor,ADRA1D,,unknown
Epicept NP-1,,Alpha-2A adrenergic receptor,ADRA2A,,unknown
Epicept NP-1,,Alpha-2B adrenergic receptor,ADRA2B,,unknown
Epicept NP-1,,Alpha-2C adrenergic receptor,ADRA2C,,unknown
Epicept NP-1,,Histamine H1 receptor,HRH1,,unknown
Epicept NP-1,,Nociceptin receptor,OPRL1,,unknown
Elacytarabine,,Deoxycytidine kinase,DCK,,unknown
PG-530742,,Matrix metalloproteinase-9,MMP9,,unknown
AMD-070,,C-X-C chemokine receptor type 4,CXCR4,,unknown
AMD-070,,C-C chemokine receptor type 5,CCR5,,unknown
NM-702,,Thromboxane-A synthase,TBXAS1,,unknown
ISIS 113715,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
VX-765,,Caspase-1,CASP1,,unknown
VX-765,,Interleukin-1 beta,IL1B,,unknown
LI-301,,Mu-type opioid receptor,OPRM1,,unknown
LI-301,,5-hydroxytryptamine receptor 1A,HTR1A,,unknown
Huperzine-A,,Acetylcholinesterase,ACHE,,unknown
Piclidenoson,,Adenosine receptor A3,ADORA3,,unknown
Atiprimod,,Interleukin-6,IL6,,unknown
Atiprimod,,Tumor necrosis factor,TNF,,unknown
Cobiprostone,,Chloride channel protein 2,CLCN2,,unknown
Managlinat dialanetil,,"Fructose-1,6-bisphosphatase 1",FBP1,,unknown
Telaprevir,Telaprevir has a half-life of elimination of 4.0-4.7 hours after a single dose and an effective half life of 9-11 hours at steady state [FDA Label].,NS3/4A protein,NS3/4A,inhibitor,yes
Telaprevir,Telaprevir has a half-life of elimination of 4.0-4.7 hours after a single dose and an effective half life of 9-11 hours at steady state [FDA Label].,Solute carrier organic anion transporter family member 1B1,SLCO1B1,inhibitor,unknown
Telaprevir,Telaprevir has a half-life of elimination of 4.0-4.7 hours after a single dose and an effective half life of 9-11 hours at steady state [FDA Label].,Solute carrier organic anion transporter family member 2B1,SLCO2B1,inhibitor,unknown
Pelitinib,,Epidermal growth factor receptor,EGFR,,unknown
Mipomersen,Mipomersem has a very long half life of 1-2 months.,mRNA of ApoB-100,,binder,yes
CPG 10101,,Toll-like receptor 9,TLR9,,unknown
BMS-488043,,Free fatty acid receptor 4,FFAR4,,unknown
QR-333,,Aldose reductase,AKR1B1,,unknown
Alanosine,,Adenylosuccinate synthetase isozyme 2,ADSS,,unknown
Alanosine,,Adenylosuccinate synthetase isozyme 1,ADSSL1,,unknown
Alanosine,,Aspartate carbamoyltransferase catalytic chain,pyrB,,unknown
Brivaracetam,7-8h [A19180].,Synaptic vesicle glycoprotein 2A,SV2A,unknown,yes
Brivaracetam,7-8h [A19180].,Sodium channel protein,SCN1ASCN10ASCN11ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCN1BSCN2BSCN3BSCN4B,inhibitor,yes
Naronapride,,5-hydroxytryptamine receptor 4,HTR4,agonist,unknown
Regrelor,,P2Y purinoceptor 12,P2RY12,antagonist,unknown
Ramucirumab,15 days,Vascular endothelial growth factor receptor 2,KDR,antagonist,yes
Farletuzumab,,Folate receptor alpha,FOLR1,antibody,yes
Sodium stibogluconate,,DNA topoisomerase 1,TOP1,inhibitor,yes
DDP-225,,5-hydroxytryptamine receptor 3A,HTR3A,,unknown
DDP-225,,Sodium-dependent noradrenaline transporter,SLC6A2,,unknown
KP-1461,,Gag-Pol polyprotein,gag-pol,,unknown
faropenem medoxomil,,Penicillin-binding protein 1A,ponA,,unknown
faropenem medoxomil,,Penicillin-binding protein 2B,penA,,unknown
faropenem medoxomil,,Peptidoglycan synthase FtsI,ftsI,,unknown
NP-50301,,Estrogen receptor alpha,ESR1,,unknown
Levoketoconazole,,"Cytochrome P450 11B1, mitochondrial",CYP11B1,,unknown
Levoketoconazole,,Lanosterol 14-alpha demethylase,CYP51A1,,unknown
Palifosfamide,,DNA (cytosine-5)-methyltransferase 1,DNMT1,,unknown
EP-2104R,,Fibrinogen alpha chain,FGA,,unknown
Apremilast,6-9 hours.,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,antagonist,yes
Apremilast,6-9 hours.,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,antagonist,yes
Apremilast,6-9 hours.,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,antagonist,yes
Apremilast,6-9 hours.,Tumor necrosis factor,TNF,,unknown
Apremilast,6-9 hours.,Interleukin-2,IL2,,unknown
Apremilast,6-9 hours.,Interferon gamma,IFNG,,unknown
Apremilast,6-9 hours.,"Nitric oxide synthase, endothelial",NOS3,,unknown
Ustekinumab,Mean half-life: 14.9–45.6 days following IV and sub-Q administration in patients with psoriasis.,Interleukin-12 subunit beta,IL12B,antibody,yes
Ustekinumab,Mean half-life: 14.9–45.6 days following IV and sub-Q administration in patients with psoriasis.,Interleukin-23,IL12BIL23A,,yes
FX06,,Cadherin-5,CDH5,,unknown
BL-1020,,D(2) dopamine receptor,DRD2,,unknown
BL-1020,,5-hydroxytryptamine receptor 2A,HTR2A,,unknown
CRx-119,,Sodium-dependent serotonin transporter,SLC6A4,,unknown
CRx-119,,Sodium-dependent noradrenaline transporter,SLC6A2,,unknown
NPS-2143,,Extracellular calcium-sensing receptor,CASR,,unknown
13-deoxydoxorubicin,,DNA topoisomerase 2-alpha,TOP2A,,unknown
13-deoxydoxorubicin,,DNA,,,unknown
GTS-21,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,,unknown
AZD-9684,,Carboxypeptidase B2,CPB2,,unknown
LY-517717,,Coagulation factor X,F10,,unknown
Flovagatran,,Prothrombin,F2,,unknown
MIV-701,,Cathepsin K,CTSK,,unknown
Varespladib methyl,,"Phospholipase A2, membrane associated",PLA2G2A,,unknown
Varespladib methyl,,Group 10 secretory phospholipase A2,PLA2G10,,unknown
CYT006-AngQb,4 months,Type-1 angiotensin II receptor,AGTR1,,unknown
CYT006-AngQb,4 months,Type-2 angiotensin II receptor,AGTR2,,unknown
RPI-78M,,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,,unknown
RPI-78M,,Neuronal acetylcholine receptor subunit beta-2,CHRNB2,,unknown
RPI-78M,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,,unknown
RPI-78M,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,,unknown
RPI-78M,,Neuronal acetylcholine receptor subunit alpha-10,CHRNA10,,unknown
RPI-78M,,Neuronal acetylcholine receptor subunit alpha-9,CHRNA9,,unknown
CRx-139,,Tumor necrosis factor,TNF,,unknown
CRx-139,,Interleukin-6,IL6,,unknown
CRx-139,,C-reactive protein,CRP,,unknown
CRx-139,,Interleukin-10,IL10,,unknown
MPI-674,,Cytochrome P450 19A1,CYP19A1,,unknown
AVE-1625,,Cannabinoid receptor 1,CNR1,,unknown
ALKS 27,,Muscarinic acetylcholine receptor M1,CHRM1,,unknown
ALKS 27,,Muscarinic acetylcholine receptor M2,CHRM2,,unknown
ALKS 27,,Muscarinic acetylcholine receptor M3,CHRM3,,unknown
ALKS 27,,Muscarinic acetylcholine receptor M4,CHRM4,,unknown
ALKS 27,,Muscarinic acetylcholine receptor M5,CHRM5,,unknown
CYT007-TNFQb,,Tumor necrosis factor,TNF,,unknown
ACP-104,,Muscarinic acetylcholine receptor M1,CHRM1,,unknown
ACP-104,,D(2) dopamine receptor,DRD2,,unknown
ACP-104,,D(3) dopamine receptor,DRD3,,unknown
Andrographolide,,Tumor necrosis factor,TNF,,unknown
Andrographolide,,Interleukin-1 beta,IL1B,,unknown
Andrographolide,,Interleukin-6,IL6,,unknown
Andrographolide,,Nuclear factor NF-kappa-B p100 subunit,NFKB2,,unknown
Andrographolide,,Nuclear factor NF-kappa-B p105 subunit,NFKB1,,unknown
LLL-3348,,Interleukin-10,IL10,,unknown
Trastuzumab emtansine,Trastuzumab emtansine has a long half life of about 4 days.,Receptor tyrosine-protein kinase erbB-2,ERBB2,antibody,yes
Thrombomodulin Alfa,"2–3 days after sc injection; 
19.82 +/- 2.10 hours after IV injection",Prothrombin,F2,inhibitor,yes
Thrombomodulin Alfa,"2–3 days after sc injection; 
19.82 +/- 2.10 hours after IV injection",Coagulation factor V,F5,,unknown
LGD-1550,,Retinoic acid receptor alpha,RARA,,unknown
LGD-1550,,Retinoic acid receptor beta,RARB,,unknown
LGD-1550,,Retinoic acid receptor gamma,RARG,,unknown
LGD-1550,,Transcription factor AP-1,JUN,,unknown
Irofulven,,Far upstream element-binding protein 1,FUBP1,,unknown
LM-609,,Integrin beta-3,ITGB3,,unknown
SR 140333,,Substance-P receptor,TACR1,,unknown
Arylacenamide,,"HCG20471, isoform CRA_c",SIGMAR1,,unknown
PRO-542,,Free fatty acid receptor 4,FFAR4,,unknown
Daglutril,,Neprilysin,MME,,unknown
TNX-901,,High affinity immunoglobulin epsilon receptor subunit alpha,FCER1A,,unknown
GEM-231,,cAMP-dependent protein kinase type II-alpha regulatory subunit,PRKAR2A,,unknown
GEM-231,,cAMP-dependent protein kinase type I-alpha regulatory subunit,PRKAR1A,,unknown
GTI 2040,,Ribonucleoside-diphosphate reductase subunit M2,RRM2,,unknown
Cositecan,,DNA topoisomerase 1,TOP1,,unknown
Abiraterone,Terminal elimination half-life = 5-14 hours,"Steroid 17-alpha-hydroxylase/17,20 lyase",CYP17A1,inhibitor,yes
GPI-1485,,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,,unknown
CNS-5161,,"Glutamate receptor ionotropic, NMDA 1",GRIN1,,unknown
Parathyroid hormone,The mean half-life is approximately 1.5 hours.,Parathyroid hormone/parathyroid hormone-related peptide receptor,PTH1R,activator,unknown
Parathyroid hormone,The mean half-life is approximately 1.5 hours.,Parathyroid hormone 2 receptor,PTH2R,activator,yes
ING-1,,Epithelial cell adhesion molecule,EPCAM,,unknown
OPC-51803,,Vasopressin V2 receptor,AVPR2,,unknown
Mito-4509,,Amyloid beta A4 protein,APP,,unknown
humanized SMART Anti-IL-12 Antibody,,Interleukin-12 subunit beta,IL12B,,unknown
NCX 950,,Beta-2 adrenergic receptor,ADRB2,,unknown
CLX-0921,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Rivanicline,,Neuronal acetylcholine receptor subunit beta-2,CHRNB2,,unknown
Rivanicline,,Interleukin-8,CXCL8,antagonist,unknown
PPI-2458,,Methionine aminopeptidase 2,METAP2,,unknown
99mTc-14 F7 Mab,,"Lactosylceramide alpha-2,3-sialyltransferase",ST3GAL5,,unknown
Ciluprevir,,Genome polyprotein,,,unknown
Ethyl pyruvate,,Tumor necrosis factor,TNF,,unknown
Ethyl pyruvate,,High mobility group protein B1,HMGB1,,unknown
UC-781,,Gag-Pol polyprotein,gag-pol,,unknown
PDE4,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,,unknown
AME-527,,Tumor necrosis factor,TNF,,unknown
CHF 4227,,Estrogen receptor alpha,ESR1,,unknown
CHF 4227,,Estrogen receptor beta,ESR2,,unknown
ABX-PTH,,Parathyroid hormone,PTH,,unknown
Seletracetam,Approximately 8 hours in healthy young male subjects.,Synaptic vesicle glycoprotein 2A,SV2A,modulator,yes
Seletracetam,Approximately 8 hours in healthy young male subjects.,Voltage-dependent N-type calcium channel subunit alpha-1B,CACNA1B,blocker,yes
Seletracetam,Approximately 8 hours in healthy young male subjects.,Glycine receptor (alpha-1/beta),GLRA1GLRB,binding,unknown
MEM 1414,,CAMP phosphodiesterase,PDE4,,unknown
Inotuzumab ozogamicin,The elimination half life at the end of Cycle 4 of administration is approximately 12.3 days in a 2-compartment model [L938].,B-cell receptor CD22,CD22,antibody,yes
VEGF-AS,,Vascular endothelial growth factor A,VEGFA,,unknown
RI 624,,Beta-nerve growth factor,NGF,,unknown
HGS-TR2J,,Tumor necrosis factor receptor superfamily member 10B,TNFRSF10B,,unknown
rhIGFBP-3,,Insulin-like growth factor 1 receptor,IGF1R,,unknown
TD-2749,,5-hydroxytryptamine receptor 4,HTR4,,unknown
OSI-930,,Mast/stem cell growth factor receptor Kit,KIT,,unknown
OSI-930,,Vascular endothelial growth factor receptor 1,FLT1,,unknown
MYO-029,,Growth/differentiation factor 8,MSTN,,unknown
CT-011,,Programmed cell death protein 1,PDCD1,,unknown
RTA 744,,DNA topoisomerase 2-alpha,TOP2A,,unknown
SB-559448,,Thrombopoietin receptor,MPL,,unknown
Pegdinetanib,,Vascular endothelial growth factor receptor 2,KDR,,unknown
Denibulin,,Vascular endothelial growth factor A,VEGFA,,unknown
Denibulin,,Vascular endothelial growth factor receptor 1,FLT1,,unknown
Denibulin,,Vascular endothelial growth factor receptor 3,FLT4,,unknown
CVT-6883,,Adenosine receptor A2b,ADORA2B,,unknown
Edonerpic,,Amyloid beta A4 protein,APP,,unknown
MK-0354,,G-protein coupled estrogen receptor 1,GPER1,,unknown
Resatorvid,,Cytokine receptor common subunit beta,CSF2RB,,unknown
Resatorvid,,Cytokine receptor common subunit gamma,IL2RG,,unknown
Varlitinib,,Receptor tyrosine-protein kinase erbB-2,ERBB2,,unknown
Varlitinib,,Epidermal growth factor receptor,EGFR,,unknown
MDX-1303,,Anthrax toxin receptor 2,ANTXR2,,unknown
MDX-1303,,Anthrax toxin receptor 1,ANTXR1,,unknown
Contulakin-G,,Voltage-dependent N-type calcium channel subunit alpha-1B,CACNA1B,,unknown
EVT-101,,Retinoic acid receptor RXR-alpha,RXRA,,unknown
EVT-101,,"Glutamate receptor ionotropic, NMDA 2B",GRIN2B,,unknown
ENMD-1198,,Tumor necrosis factor receptor superfamily member 11A,TNFRSF11A,,unknown
ENMD-1198,,Hypoxia-inducible factor 1-alpha,HIF1A,,unknown
ENMD-1198,,Signal transducer and activator of transcription 3,STAT3,,unknown
PPL-100,,Plasma protease C1 inhibitor,SERPING1,,unknown
PPL-100,,Plasma serine protease inhibitor,SERPINA5,,unknown
PPL-100,,Alpha-1-antitrypsin,SERPINA1,,unknown
TAS-108,,Estrogen receptor alpha,ESR1,,unknown
TAS-108,,Estrogen receptor beta,ESR2,,unknown
ANZ-100,,KiSS-1 receptor,KISS1R,,unknown
PR-104,,Tumor necrosis factor,TNF,,unknown
SNS-032,,Cyclin-dependent kinase 7,CDK7,,unknown
SNS-032,,Vascular endothelial growth factor A,VEGFA,,unknown
Archexin,,RAC-alpha serine/threonine-protein kinase,AKT1,,unknown
Bardoxolone methyl,,NF-kappa-B inhibitor alpha,NFKBIA,,unknown
RAF-265,,Vascular endothelial growth factor receptor 2,KDR,,unknown
RAF-265,,Serine/threonine-protein kinase B-raf,BRAF,,unknown
Obeticholic acid,Steady state half life: ~4 days,Bile acid receptor,NR1H4,agonist,yes
Plinabulin,,Tumor necrosis factor,TNF,,unknown
PRX-07034,,5-hydroxytryptamine receptor 6,HTR6,,unknown
Glembatumumab vedotin,,Transmembrane glycoprotein NMB,GPNMB,binder,unknown
Aldoxorubicin,,DNA topoisomerase 2-alpha,TOP2A,inhibitor,yes
Eteplirsen,"Mean half-life (dose of 30 mg/kg) = 3.3 hours, and mean half-life (dose of 50 mg/kg) = 3.2 hours (3)",DMD-001 gene (exon 51 target site),,binding,yes
Cariprazine,~1 week for the combined drug.,D(3) dopamine receptor,DRD3,agonistpartial agonist,yes
Cariprazine,~1 week for the combined drug.,D(2) dopamine receptor,DRD2,agonistpartial agonist,yes
Cariprazine,~1 week for the combined drug.,5-hydroxytryptamine receptor 1A,HTR1A,agonistpartial agonist,yes
Cariprazine,~1 week for the combined drug.,5-hydroxytryptamine receptor 2B,HTR2B,antagonist,yes
Cariprazine,~1 week for the combined drug.,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Cariprazine,~1 week for the combined drug.,Histamine H1 receptor,HRH1,antagonist,yes
AV-412,,Epidermal growth factor receptor,EGFR,,unknown
AV-412,,Receptor tyrosine-protein kinase erbB-2,ERBB2,,unknown
PA-1050040,,Gag polyprotein,gag,,unknown
Filanesib,,Kinesin-like protein KIF11,KIF11,,unknown
ZEN-012,,Tubulin beta chain,TUBB,,unknown
ZEN-012,,Tubulin beta-1 chain,TUBB1,,unknown
ZEN-012,,Tubulin beta-3 chain,TUBB3,,unknown
ZEN-012,,Tubulin beta-4A chain,TUBB4A,,unknown
ZEN-012,,DNA topoisomerase 2-alpha,TOP2A,,unknown
ZEN-012,,DNA topoisomerase 2-beta,TOP2B,,unknown
Olaratumab,Estimated value of 11 days,Platelet-derived growth factor receptor alpha,PDGFRA,antagonist,yes
XTL-6865,,Genome polyprotein,,,unknown
AZD-8330,,Mitogen-activated protein kinase kinase kinase 1,MAP3K1,,unknown
KAI-1455,,Protein kinase C epsilon type,PRKCE,,unknown
XMT-1001,,DNA topoisomerase 1,TOP1,,unknown
SNX-5422,,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
SNX-5422,,Heat shock protein HSP 90-beta,HSP90AB1,,unknown
CTS-21166,,Beta-secretase 1,BACE1,inhibitor,yes
Linsitinib,,Insulin-like growth factor 1 receptor,IGF1R,,unknown
Lumateperone,,5-hydroxytryptamine receptor 2A,HTR2A,,unknown
Lumateperone,,D(2) dopamine receptor,DRD2,,unknown
ABT-869,,Receptor-type tyrosine-protein kinase FLT3,FLT3,,unknown
ABT-869,,Vascular endothelial growth factor receptor 1,FLT1,,unknown
ABT-869,,Vascular endothelial growth factor receptor 2,KDR,,unknown
ABT-869,,Vascular endothelial growth factor receptor 3,FLT4,,unknown
ABT-869,,Mast/stem cell growth factor receptor Kit,KIT,,unknown
ABT-869,,Macrophage colony-stimulating factor 1 receptor,CSF1R,,unknown
Caplacizumab,,von Willebrand factor,VWF,,unknown
PX-478,,Hypoxia-inducible factor 1-alpha,HIF1A,,unknown
Tapinarof,,Interleukin-12 subunit beta,IL12B,,unknown
Tapinarof,,Interleukin-2,IL2,,unknown
Tapinarof,,Interleukin-6,IL6,,unknown
Tapinarof,,Interleukin-8,CXCL8,,unknown
ICA-105665,,Potassium voltage-gated channel subfamily KQT member 1,KCNQ1,,unknown
ICA-105665,,Potassium voltage-gated channel subfamily KQT member 3,KCNQ3,,unknown
ICA-105665,,Potassium voltage-gated channel subfamily KQT member 4,KCNQ4,,unknown
ICA-105665,,Potassium voltage-gated channel subfamily KQT member 5,KCNQ5,,unknown
ICA-105665,,Potassium voltage-gated channel subfamily KQT member 2,KCNQ2,,unknown
Bradanicline,,Alpha-7 nicotinic cholinergic receptor subunit,CHRNA7,,unknown
Apatorsen,,Heat shock protein beta-1,HSPB1,,unknown
NXN-188,,"Nitric oxide synthase, brain",NOS1,,unknown
NXN-188,,5-hydroxytryptamine receptor 1B,HTR1B,,unknown
NXN-188,,5-hydroxytryptamine receptor 1D,HTR1D,,unknown
GSK-923295,,Centromere-associated protein E,CENPE,,unknown
PRLX 93936,,Voltage-dependent anion-selective channel protein 2,VDAC2,,unknown
PRLX 93936,,Voltage-dependent anion-selective channel protein 3,VDAC3,,unknown
IMC-1C11,,Vascular endothelial growth factor receptor 1,FLT1,,unknown
IMC-1C11,,Vascular endothelial growth factor receptor 2,KDR,,unknown
IMC-1C11,,Vascular endothelial growth factor receptor 3,FLT4,,unknown
VX-148,,Inosine-5'-monophosphate dehydrogenase 1,IMPDH1,,unknown
VX-148,,Inosine-5'-monophosphate dehydrogenase 2,IMPDH2,,unknown
Eldelumab,,C-X-C motif chemokine 10,CXCL10,,unknown
L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal,,Calpain-3,CAPN3,,unknown
KRP-104,,Dipeptidyl peptidase 4,DPP4,,unknown
SNS-314,,Aurora kinase A,AURKA,,unknown
SNS-314,,Aurora kinase C,AURKC,,unknown
KX-01,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
IRL-1620,,Endothelin B receptor,EDNRB,,unknown
SUVN-502,,5-hydroxytryptamine receptor 6,HTR6,,unknown
Sertindole,3 days,D(2) dopamine receptor,DRD2,antagonist,yes
Sertindole,3 days,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Sertindole,3 days,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,yes
Sertindole,3 days,5-hydroxytryptamine receptor 6,HTR6,antagonist,yes
Sertindole,3 days,Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,unknown
Sertindole,3 days,Alpha-1A adrenergic receptor,ADRA1A,,unknown
Sertindole,3 days,Alpha-1B adrenergic receptor,ADRA1B,,unknown
Sertindole,3 days,Alpha-1D adrenergic receptor,ADRA1D,,unknown
Spiramycin,"Intravenous:
Young persons (18 to 32 years of age): Approximately 4.5 to 6.2 hours.
Elderly persons (73 to 85 years of age): Approximately 9.8 to 13.5 hours. 

Oral: 5.5-8 hours, Rectal in children: 8 hours",50S ribosomal protein L3,rplC,antagonistinhibitor,yes
Sulfathiazole,,Dihydropteroate synthetase,,inhibitor,yes
Mianserin,10-17 hours,Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Mianserin,10-17 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,unknown
Mianserin,10-17 hours,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Mianserin,10-17 hours,Histamine H1 receptor,HRH1,antagonist,unknown
Mianserin,10-17 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,unknown
Mianserin,10-17 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,unknown
Mianserin,10-17 hours,Histamine H4 receptor,HRH4,binder,unknown
Mianserin,10-17 hours,5-hydroxytryptamine receptor 1A,HTR1A,blocker,unknown
Mianserin,10-17 hours,Alpha-2C adrenergic receptor,ADRA2C,antagonist,unknown
Mianserin,10-17 hours,5-hydroxytryptamine receptor 2B,HTR2B,binder,unknown
Mianserin,10-17 hours,5-hydroxytryptamine receptor 1F,HTR1F,binder,unknown
Mianserin,10-17 hours,Alpha-2B adrenergic receptor,ADRA2B,antagonist,unknown
Mianserin,10-17 hours,D(3) dopamine receptor,DRD3,binder,unknown
Mianserin,10-17 hours,Kappa-type opioid receptor,OPRK1,agonist,unknown
Mianserin,10-17 hours,Sodium-dependent dopamine transporter,SLC6A3,binder,unknown
Mianserin,10-17 hours,5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Mianserin,10-17 hours,D(2) dopamine receptor,DRD2,antagonist,unknown
Mianserin,10-17 hours,5-hydroxytryptamine receptor 6,HTR6,binder,unknown
Mianserin,10-17 hours,Alpha-1 adrenergic receptors,ADRA1AADRA1BADRA1D,antagonist,unknown
Mianserin,10-17 hours,D(1) dopamine receptor,DRD1DRD5,binder,unknown
Teicoplanin,70-100 hours,D-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan,,inhibitor,yes
Acetylcysteine,"5.6 hours (adults), 11 hours (neonates)",Glutathione synthetase,GSS,stimulator,yes
Acetylcysteine,"5.6 hours (adults), 11 hours (neonates)",Cystine/glutamate transporter,SLC7A11,activator,yes
Acetylcysteine,"5.6 hours (adults), 11 hours (neonates)",NAPQI (N-acetyl-p-benzoquinone imine),,reducer,unknown
Acetylcysteine,"5.6 hours (adults), 11 hours (neonates)",Aminoacylase-1,ACY1,ligand,unknown
Acetylcysteine,"5.6 hours (adults), 11 hours (neonates)",Inhibitor of nuclear factor kappa-B kinase subunit beta,IKBKB,inhibitor,unknown
Acetylcysteine,"5.6 hours (adults), 11 hours (neonates)",Inhibitor of nuclear factor kappa-B kinase subunit alpha,CHUK,inhibitor,unknown
Acetylcysteine,"5.6 hours (adults), 11 hours (neonates)","Glutamate receptor ionotropic, NMDA 2B",GRIN2B,activator,unknown
Acetylcysteine,"5.6 hours (adults), 11 hours (neonates)","Glutamate receptor ionotropic, NMDA 1",GRIN1,activator,unknown
Acetylcysteine,"5.6 hours (adults), 11 hours (neonates)","Glutamate receptor ionotropic, NMDA 2A",GRIN2A,activator,unknown
Acetylcysteine,"5.6 hours (adults), 11 hours (neonates)","Glutamate receptor ionotropic, NMDA 2D",GRIN2D,activator,unknown
Acetylcysteine,"5.6 hours (adults), 11 hours (neonates)","Glutamate receptor ionotropic, NMDA 3A",GRIN3A,activator,unknown
Rimonabant,6 to 9 days with normal BMI and 16 days if BMI is greater than 30,Cannabinoid receptor 1,CNR1,antagonist,yes
Rimonabant,6 to 9 days with normal BMI and 16 days if BMI is greater than 30,G-protein coupled receptor 55,GPR55,,unknown
Tesofensine,,Sodium-dependent serotonin transporter,SLC6A4,,unknown
Tesofensine,,Sodium-dependent noradrenaline transporter,SLC6A2,,unknown
Tesofensine,,Sodium-dependent dopamine transporter,SLC6A3,,unknown
Istaroxime,,Sarcoplasmic/endoplasmic reticulum calcium ATPase 2,ATP2A2,,unknown
Istaroxime,,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,,unknown
Rubitecan,,DNA topoisomerase 1,TOP1,,unknown
Lumiliximab,,Low affinity immunoglobulin epsilon Fc receptor,FCER2,,unknown
Canakinumab,26 days,Interleukin-1 beta,IL1B,binder,yes
Noscapine,,Sigma non-opioid intracellular receptor 1,SIGMAR1,,unknown
Romidepsin,Approximately 3 hours,Histone deacetylase 1,HDAC1,antagonistinhibitor,yes
Romidepsin,Approximately 3 hours,Histone deacetylase 2,HDAC2,antagonistinhibitor,yes
Romidepsin,Approximately 3 hours,Histone deacetylase 4,HDAC4,inhibitor,no
Romidepsin,Approximately 3 hours,Histone deacetylase 6,HDAC6,inhibitor,no
Romidepsin,Approximately 3 hours,Multidrug resistance-associated protein 1,ABCC1,,unknown
Forodesine,,Purine nucleoside phosphorylase,PNP,,unknown
Ipilimumab,Terminal Elimination Half-life: 14.7 -15.4 days,Cytotoxic T-lymphocyte protein 4,CTLA4,,yes
Solabegron,,Beta-3 adrenergic receptor,ADRB3,agonist,unknown
Zosuquidar,,Multidrug resistance protein 1,ABCB1,,unknown
Elocalcitol,,Vitamin D3 receptor,VDR,,unknown
Seliciclib,,Cyclin-dependent kinase 1,CDK1,,unknown
Seliciclib,,Cyclin-dependent kinase 2,CDK2,,unknown
Seliciclib,,Mitogen-activated protein kinase 3,MAPK3,,unknown
Seliciclib,,Mitogen-activated protein kinase 1,MAPK1,,unknown
Seliciclib,,Cyclin-dependent kinase 7,CDK7,,unknown
Seliciclib,,Cyclin-dependent kinase 9,CDK9,,unknown
Seliciclib,,Casein kinase I isoform epsilon,CSNK1E,,unknown
Icatibant,"After subcutaneous administration, mean elimination half-life was 1.4 ± 0.4 hours.",B2 bradykinin receptor,BDKRB2,antagonist,yes
Icatibant,"After subcutaneous administration, mean elimination half-life was 1.4 ± 0.4 hours.",Aminopeptidase N,ANPEP,inhibitor,unknown
Atrasentan,,Endothelin-1 receptor,EDNRA,,unknown
Rufinamide,"Elimination half-life, healthy subjects and patients with epilepsy = 6-10 hours.",Metabotropic glutamate receptor 5,GRM5,inhibitor,unknown
Rufinamide,"Elimination half-life, healthy subjects and patients with epilepsy = 6-10 hours.",Sodium channel protein type 9 subunit alpha,SCN9A,modulator,unknown
Lasofoxifene,Elimination half-life is approximately 6 days [A19178].,Estrogen receptor alpha,ESR1,antagonistagonistnegative modulator,yes
Lasofoxifene,Elimination half-life is approximately 6 days [A19178].,Estrogen receptor beta,ESR2,agonist,yes
Lasofoxifene,Elimination half-life is approximately 6 days [A19178].,Cannabinoid receptor 2,CNR2,inverse agonist,unknown
Alogliptin,Terminal half-life = 21 hours,Dipeptidyl peptidase 4,DPP4,inhibitor,yes
Tapentadol,"Elimination half-life, IV: 4 hours.",Mu-type opioid receptor,OPRM1,agonist,yes
Tapentadol,"Elimination half-life, IV: 4 hours.",Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Tapentadol,"Elimination half-life, IV: 4 hours.",Kappa-type opioid receptor,OPRK1,,unknown
Tapentadol,"Elimination half-life, IV: 4 hours.",Delta-type opioid receptor,OPRD1,,unknown
Tapentadol,"Elimination half-life, IV: 4 hours.",5-hydroxytryptamine receptor 3A,HTR3A,,unknown
Tapentadol,"Elimination half-life, IV: 4 hours.",Sodium-dependent serotonin transporter,SLC6A4,inhibitor,unknown
Hyaluronidase (Human Recombinant),,Hyaluronan,,,yes
Hyaluronidase (Human Recombinant),,Transforming growth factor beta-1,TGFB1,inhibitor,unknown
Silodosin,"Silodosin = 13.3 ± 8.07 hours;
KMD-3213G = 24 hours;",Alpha-1A adrenergic receptor,ADRA1A,antagonist,yes
Silodosin,"Silodosin = 13.3 ± 8.07 hours;
KMD-3213G = 24 hours;",Alpha-1B adrenergic receptor,ADRA1B,antagonist,unknown
Silodosin,"Silodosin = 13.3 ± 8.07 hours;
KMD-3213G = 24 hours;",Alpha-1D adrenergic receptor,ADRA1D,antagonist,unknown
Prasugrel,The active metabolite has an elimination half-life of about 7.4 hours (range 2-15 hours).,P2Y purinoceptor 12,P2RY12,antagonist,yes
Eltrombopag,"About 21-32 hours in healthy patients.
About 26-35 hours in patients with idiopathic thrombocytopenic purpura.",Thrombopoietin receptor,MPL,agonist,unknown
Doripenem,"1 hour, in healthy non-elderly adults.",Penicillin-binding protein 1A,mrcA,antagonistinhibitor,yes
Doripenem,"1 hour, in healthy non-elderly adults.",Penicillin-binding protein 1B,mrcB,antagonistinhibitor,yes
Doripenem,"1 hour, in healthy non-elderly adults.",Penicillin-binding protein 2,mrdA,antagonistinhibitor,yes
Doripenem,"1 hour, in healthy non-elderly adults.",Penicillin-binding protein 3,pbpB,antagonistinhibitor,yes
Doripenem,"1 hour, in healthy non-elderly adults.",Penicillin-binding protein 4,pbp4,antagonistinhibitor,yes
Tolvaptan,"Terminal half life, oral dose = 12 hours.",Vasopressin V2 receptor,AVPR2,antagonist,yes
Tolvaptan,"Terminal half life, oral dose = 12 hours.",Vasopressin V1a receptor,AVPR1A,antagonist,no
Regadenoson,"Initial phase: 2-4 minutes;
Intermediate phase: 30 minutes (this phase coincides with a loss of the pharmacodynamic effect); 
Terminal phase: 2 hours",Adenosine receptor A2a,ADORA2A,agonist,yes
Asenapine,24 hours (range of 13.4 - 39.2 hours),D(2) dopamine receptor,DRD2,antagonist,yes
Asenapine,24 hours (range of 13.4 - 39.2 hours),5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Asenapine,24 hours (range of 13.4 - 39.2 hours),5-hydroxytryptamine receptor 1A,HTR1A,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),5-hydroxytryptamine receptor 1B,HTR1B,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),5-hydroxytryptamine receptor 2B,HTR2B,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),5-hydroxytryptamine receptor 2C,HTR2C,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),5-hydroxytryptamine receptor 5A,HTR5A,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),5-hydroxytryptamine receptor 6,HTR6,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),Alpha-2B adrenergic receptor,ADRA2B,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),Alpha-2C adrenergic receptor,ADRA2C,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),D(1A) dopamine receptor,DRD1,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),D(3) dopamine receptor,DRD3,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),D(4) dopamine receptor,DRD4,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),Histamine H1 receptor,HRH1,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),Histamine H2 receptor,HRH2,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),Beta-1 adrenergic receptor,ADRB1,antagonist,unknown
Asenapine,24 hours (range of 13.4 - 39.2 hours),Beta-2 adrenergic receptor,ADRB2,antagonist,unknown
Vernakalant,Elimination half life in CYP2D6 extensive metabolizers is 3 hours and 5.5 hours in poor metabolizers.,Sodium channel protein type 5 subunit alpha,SCN5A,blocker,yes
Vernakalant,Elimination half life in CYP2D6 extensive metabolizers is 3 hours and 5.5 hours in poor metabolizers.,Potassium voltage-gated channel subfamily A member 5,KCNA5,blocker,yes
Vernakalant,Elimination half life in CYP2D6 extensive metabolizers is 3 hours and 5.5 hours in poor metabolizers.,Potassium voltage-gated channel subfamily D member 3,KCND3,blocker,yes
Vernakalant,Elimination half life in CYP2D6 extensive metabolizers is 3 hours and 5.5 hours in poor metabolizers.,Potassium voltage-gated channel subfamily H member 2,KCNH2,blocker,unknown
Lacosamide,13 Hours,Sodium channel protein type 9 subunit alpha,SCN9A,,unknown
Lacosamide,13 Hours,Sodium channel protein type 3 subunit alpha,SCN3A,,unknown
Lacosamide,13 Hours,Sodium channel protein type 10 subunit alpha,SCN10A,,unknown
Rivaroxaban,The terminal half life is 5-9 hours in adults and 11-13 hours in the elderly.,Coagulation factor X,F10,antagonist,yes
Ocaperidone,,D(2) dopamine receptor,DRD2,,unknown
Ocaperidone,,Histamine H1 receptor,HRH1,,unknown
Ocaperidone,,Alpha-1A adrenergic receptor,ADRA1A,,unknown
Ocaperidone,,Alpha-1B adrenergic receptor,ADRA1B,,unknown
Ocaperidone,,Alpha-2A adrenergic receptor,ADRA2A,,unknown
Ocaperidone,,Alpha-1D adrenergic receptor,ADRA1D,,unknown
Ocaperidone,,Alpha-2B adrenergic receptor,ADRA2B,,unknown
Ocaperidone,,Alpha-2C adrenergic receptor,ADRA2C,,unknown
Ocaperidone,,5-hydroxytryptamine receptor 2A,HTR2A,,unknown
Ocaperidone,,5-hydroxytryptamine receptor 2B,HTR2B,,unknown
Ocaperidone,,5-hydroxytryptamine receptor 2C,HTR2C,,unknown
Nalmefene,"The terminal half-life is approximately 12.5 hours following oral administration [L1024]. After intravenous administration of 1 mg in adult males, the terminal half life was 10.8 ± 5.2 hours [FDA Label].",Mu-type opioid receptor,OPRM1,antagonist,yes
Nalmefene,"The terminal half-life is approximately 12.5 hours following oral administration [L1024]. After intravenous administration of 1 mg in adult males, the terminal half life was 10.8 ± 5.2 hours [FDA Label].",Kappa-type opioid receptor,OPRK1,partial agonist,yes
Nalmefene,"The terminal half-life is approximately 12.5 hours following oral administration [L1024]. After intravenous administration of 1 mg in adult males, the terminal half life was 10.8 ± 5.2 hours [FDA Label].",Delta-type opioid receptor,OPRD1,antagonist,yes
Caldaret,,Sodium/calcium exchanger 1,SLC8A1,,unknown
Ridaforolimus,,Serine/threonine-protein kinase mTOR,MTOR,,unknown
Maribavir,,Serine/threonine protein kinase UL97,UL97,,unknown
Maribavir,,Serine/threonine protein kinase UL97,UL97,,unknown
Avanafil,Mean elimination half-life = 5.36 - 10.66 hours,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,inhibitor,yes
Tariquidar,,Multidrug resistance protein 1,ABCB1,,unknown
Clenoliximab,,T-cell surface glycoprotein CD4,CD4,,unknown
Eflornithine,8 hours,Ornithine decarboxylase,ODC1,antagonistblocker,yes
Lanoteplase,,Urokinase plasminogen activator surface receptor,PLAUR,,unknown
Lanoteplase,,Fibrinogen alpha chain,FGA,,unknown
Lanoteplase,,Kallikrein-1,KLK1,,unknown
Lanoteplase,,Laminin subunit alpha-5,LAMA5,,unknown
Lanoteplase,,Coagulation factor X,F10,,unknown
Lanoteplase,,Fibronectin,FN1,,unknown
Lanoteplase,,Plasminogen activator inhibitor 2,SERPINB2,,unknown
Lanoteplase,,Tetranectin,CLEC3B,,unknown
Lanoteplase,,"Keratin, type II cytoskeletal 8",KRT8,,unknown
Lanoteplase,,Annexin A2,ANXA2,,unknown
Lanoteplase,,Laminin subunit beta-1,LAMB1,,unknown
Lanoteplase,,Laminin subunit gamma-1,LAMC1,,unknown
Lanoteplase,,Laminin subunit alpha-1,LAMA1,,unknown
Lanoteplase,,Calreticulin,CALR,,unknown
Lanoteplase,,Calnexin,CANX,,unknown
Lanoteplase,,Prolow-density lipoprotein receptor-related protein 1,LRP1,,unknown
Lanoteplase,,Laminin subunit alpha-3,LAMA3,,unknown
Exisulind,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,,unknown
Exisulind,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4C",PDE4C,,unknown
Exisulind,,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,,unknown
Exisulind,,"cGMP-dependent 3',5'-cyclic phosphodiesterase",PDE2A,,unknown
Exisulind,,Glutathione S-transferase P,GSTP1,inhibitor,unknown
Exisulind,,Aldose reductase,AKR1B1,inhibitor,unknown
Exisulind,,Aldo-keto reductase family 1 member B10,AKR1B10,inhibitor,unknown
CX516,,Glutamate receptor 1,GRIA1,,unknown
Amelubant,,Leukotriene B4 receptor 2,LTB4R2,,unknown
Amelubant,,Leukotriene B4 receptor 1,LTB4R,,unknown
Arzoxifene,,Estrogen receptor alpha,ESR1,,unknown
Arzoxifene,,Estrogen receptor beta,ESR2,,unknown
Bimoclomol,,Heat shock factor protein 1,HSF1,,unknown
Droxidopa,2-3 hours.,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Droxidopa,2-3 hours.,Alpha-1B adrenergic receptor,ADRA1B,agonist,yes
Droxidopa,2-3 hours.,Alpha-1D adrenergic receptor,ADRA1D,agonist,yes
Droxidopa,2-3 hours.,Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Droxidopa,2-3 hours.,Alpha-2B adrenergic receptor,ADRA2B,agonist,yes
Droxidopa,2-3 hours.,Alpha-2C adrenergic receptor,ADRA2C,agonist,yes
Droxidopa,2-3 hours.,Beta-1 adrenergic receptor,ADRB1,agonist,yes
Droxidopa,2-3 hours.,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Droxidopa,2-3 hours.,Beta-3 adrenergic receptor,ADRB3,agonist,yes
Droxidopa,2-3 hours.,Phenylalanine-4-hydroxylase,PAH,inhibitor,no
Amrubicin,"20-30 h [A32143]

In a study of dogs, Amrubicin plasma concentrations followed a biphasic pattern with peak concentrations observed immediately after dosing followed by α and β half-lives (t1/2) ± SD of 0.06 ± 0.01 and 2.0 ± 0.3 hours, respectively [L1710].",DNA topoisomerase 2-alpha,TOP2A,,unknown
Amrubicin,"20-30 h [A32143]

In a study of dogs, Amrubicin plasma concentrations followed a biphasic pattern with peak concentrations observed immediately after dosing followed by α and β half-lives (t1/2) ± SD of 0.06 ± 0.01 and 2.0 ± 0.3 hours, respectively [L1710].",DNA,,,unknown
Lonidamine,,Cystic fibrosis transmembrane conductance regulator,CFTR,,unknown
Lonidamine,,Hexokinase-1,HK1,,unknown
Udenafil,,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,inhibitor,yes
Sitaxentan,10 hours,Endothelin-1 receptor,EDNRA,antagonist,yes
Sitaxentan,10 hours,Endothelin B receptor,EDNRB,antagonist,unknown
Sulodexide,"The elimination half-life was 11.7 +/- 2.0 h after intravenous administration, 18.7 +/- 4.1 h after 50 mg per os, and 25.8 +/- 1.9 h after 100 mg per os.",Heparin cofactor 2,SERPIND1,agonist,yes
Sulodexide,"The elimination half-life was 11.7 +/- 2.0 h after intravenous administration, 18.7 +/- 4.1 h after 50 mg per os, and 25.8 +/- 1.9 h after 100 mg per os.",Antithrombin-III,SERPINC1,potentiator,yes
Tocilizumab,The half-life of tocilizumab is concentration-dependent. The concentration-dependent apparent half-life is up to 11 days for 4 mg/kg and up to 13 days for 8 mg/kg every 4 weeks in patients with RA at steady-state. The half-life in children with PJIA is up to 16 days. The half-life in pediatric patients with SJIA is up to 23 days.,Interleukin-6 receptor subunit alpha,IL6R,antibody,yes
Alvimopan,10 to 17 hours (gut metabolite: 10 to 18 hours),Mu-type opioid receptor,OPRM1,antagonist,yes
Alvimopan,10 to 17 hours (gut metabolite: 10 to 18 hours),Kappa-type opioid receptor,OPRK1,antagonist,unknown
Alvimopan,10 to 17 hours (gut metabolite: 10 to 18 hours),Delta-type opioid receptor,OPRD1,antagonist,unknown
Torcetrapib,,Cholesteryl ester transfer protein,CETP,antagonist,yes
Levocetirizine,8-9 hours.,Histamine H1 receptor,HRH1,antagonistinhibitor,yes
Teriparatide,,Parathyroid hormone/parathyroid hormone-related peptide receptor,PTH1R,binder,unknown
Temsirolimus,"Temsirolimus exhibits a bi-exponential decline in whole blood concentrations and the mean half-lives of temsirolimus and sirolimus were 17.3 hr and 54.6 hr, respectively.",Serine/threonine-protein kinase mTOR,MTOR,inhibitor,yes
Amisulpride,Approximately 12 hours,D(2) dopamine receptor,DRD2,antagonist,yes
Amisulpride,Approximately 12 hours,D(3) dopamine receptor,DRD3,antagonist,unknown
Amisulpride,Approximately 12 hours,5-hydroxytryptamine receptor 7,HTR7,antagonist,yes
Amisulpride,Approximately 12 hours,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,unknown
Simeprevir,The elimination half-life of simeprevir following 200mg dose administration is about 41 hours in HCV-positive patients and 10 to 13 hours in individuals without HCV infection.,NS3 protease,,inhibitor,yes
Dapagliflozin,13.8 hours with the consumption of a 50 mg dose.,Sodium/glucose cotransporter 2,SLC5A2,antagonist,yes
Apoptone,,Apoptosis regulator Bcl-2,BCL2,,unknown
Darapladib,,Cytosolic phospholipase A2,PLA2G4A,,unknown
Elotuzumab,,SLAM family member 7,SLAMF7,modulator,yes
Pegpleranib,,Platelet-derived growth factor subunit B,PDGFB,,unknown
Methoxyamine,,DNA,,,unknown
4-O-Demethylpenclomedine,,DNA,,,unknown
Trodusquemine,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
Trodusquemine,,Sodium-dependent dopamine transporter,SLC6A3,,unknown
Trodusquemine,,Sodium-dependent noradrenaline transporter,SLC6A2,,unknown
Saxagliptin,"Saxagliptin = 2.5 hours;
5-hydroxy saxagliptin = 3.1 hours;",Dipeptidyl peptidase 4,DPP4,inhibitor,yes
Coltuximab ravtansine,,B-lymphocyte antigen CD19,CD19,,unknown
Fiboflapon,,Arachidonate 5-lipoxygenase-activating protein,ALOX5AP,,unknown
Tezampanel,,"Glutamate receptor ionotropic, kainate 1",GRIK1,,unknown
Tezampanel,,Gamma-aminobutyric acid type B receptor subunit 1,GABBR1,,unknown
Iclaprim,,Dihydrofolate reductase,DHFR,,unknown
Lucatumumab,,Tumor necrosis factor receptor superfamily member 5,CD40,,unknown
Becatecarin,,DNA topoisomerase 2-alpha,TOP2A,,unknown
Becatecarin,,DNA topoisomerase 2-beta,TOP2B,,unknown
Pertuzumab,18 days,Receptor tyrosine-protein kinase erbB-2,ERBB2,antibody,yes
Relacatib,,Cathepsin K,CTSK,,unknown
Siplizumab,,T-cell surface antigen CD2,CD2,,unknown
Rilonacept,8.6 days,Interleukin-1 beta,IL1B,binder,unknown
Rilonacept,8.6 days,Interleukin-1 alpha,IL1A,binder,unknown
Rilonacept,8.6 days,Interleukin-1 receptor antagonist protein,IL1RN,binder,unknown
CHGN111,,Dual specificity protein kinase CLK1,CLK1,,unknown
Xaliproden,,5-hydroxytryptamine receptor 1A,HTR1A,,unknown
Bazedoxifene,~30 hours.,Estrogen receptor alpha,ESR1,antagonistagonist,yes
Bazedoxifene,~30 hours.,Estrogen receptor beta,ESR2,,unknown
Ambrisentan,Ambrisentan has a terminal half-life of 15 hours. It is thought that steady state is achieved after around 4 days of repeat-dosing.,Endothelin-1 receptor,EDNRA,antagonist,yes
Ambrisentan,Ambrisentan has a terminal half-life of 15 hours. It is thought that steady state is achieved after around 4 days of repeat-dosing.,Endothelin B receptor,EDNRB,antagonist,no
Human C1-esterase inhibitor,56 hours (range 11 to 108 hours) for a single dose and 62 hours (range 16 to 152 hours) for the double dose. Subcutaneous administration produces a half life of 199.6 hours [A19661].,Complement C1r subcomponent,C1R,inhibitor,yes
Human C1-esterase inhibitor,56 hours (range 11 to 108 hours) for a single dose and 62 hours (range 16 to 152 hours) for the double dose. Subcutaneous administration produces a half life of 199.6 hours [A19661].,Complement C1s subcomponent,C1S,inhibitor,yes
Human C1-esterase inhibitor,56 hours (range 11 to 108 hours) for a single dose and 62 hours (range 16 to 152 hours) for the double dose. Subcutaneous administration produces a half life of 199.6 hours [A19661].,Plasma kallikrein,KLKB1,inhibitor,yes
Human C1-esterase inhibitor,56 hours (range 11 to 108 hours) for a single dose and 62 hours (range 16 to 152 hours) for the double dose. Subcutaneous administration produces a half life of 199.6 hours [A19661].,Coagulation factor XII,F12,inhibitor,yes
Human C1-esterase inhibitor,56 hours (range 11 to 108 hours) for a single dose and 62 hours (range 16 to 152 hours) for the double dose. Subcutaneous administration produces a half life of 199.6 hours [A19661].,Prothrombin,F2,inhibitor,unknown
Human C1-esterase inhibitor,56 hours (range 11 to 108 hours) for a single dose and 62 hours (range 16 to 152 hours) for the double dose. Subcutaneous administration produces a half life of 199.6 hours [A19661].,Coagulation factor XI,F11,inhibitor,yes
Human C1-esterase inhibitor,56 hours (range 11 to 108 hours) for a single dose and 62 hours (range 16 to 152 hours) for the double dose. Subcutaneous administration produces a half life of 199.6 hours [A19661].,Tissue-type plasminogen activator,PLAT,inhibitor,yes
Idraparinux,,Coagulation factor X,F10,,unknown
Taribavirin,,RNA-directed RNA polymerase catalytic subunit,PB1,,unknown
Taribavirin,,Cytosolic purine 5'-nucleotidase,NT5C2,,unknown
Taribavirin,,Inosine-5'-monophosphate dehydrogenase 1,IMPDH1,,unknown
Taribavirin,,DNA,,,unknown
Taribavirin,,RNA-directed RNA polymerase L,L,,unknown
Taribavirin,,Ectonucleotide pyrophosphatase/phosphodiesterase family member 1,ENPP1,,unknown
Doxercalciferol,32 to 37 hours.,Vitamin D3 receptor,VDR,suppressor,unknown
Oxymetholone,,Androgen receptor,AR,agonistactivator,yes
Oxymetholone,,Natriuretic peptides B,NPPB,,unknown
Armodafinil,Terminal half-life is approximately 15 hours.,Sodium-dependent dopamine transporter,SLC6A3,antagonistinhibitor,yes
Etravirine,Half life of 9.05-41 hours.,Gag-Pol polyprotein,gag-pol,,unknown
Etravirine,Half life of 9.05-41 hours.,Gag-Pol polyprotein,gag-pol,,unknown
Cethromycin,,23S rRNA,,,unknown
Annamycin,,DNA topoisomerase 2-alpha,TOP2A,,unknown
Annamycin,,DNA,,,unknown
Declopramide,,DNA,,,unknown
Declopramide,,DNA topoisomerase 2-alpha,TOP2A,,unknown
Declopramide,,DNA topoisomerase 2-beta,TOP2B,,unknown
Ticalopride,,5-hydroxytryptamine receptor 4,HTR4,,unknown
Ticalopride,,5-hydroxytryptamine receptor 3A,HTR3A,,unknown
Talnetant,,Neuromedin-K receptor,TACR3,,unknown
Tezacitabine,,Ribonucleoside-diphosphate reductase large subunit,RRM1,,unknown
Semaxanib,,Vascular endothelial growth factor receptor 2,KDR,,unknown
Tyloxapol,,Lipoprotein lipase,LPL,inhibitor,yes
Cangrelor,The average elimination half-life of cangrelor is about 3-6 minutes.,P2Y purinoceptor 12,P2RY12,inhibitor,yes
Avasimibe,,Liver carboxylesterase 1,CES1,,unknown
Dexanabinol,,Tumor necrosis factor,TNF,,unknown
Dotarizine,,5-hydroxytryptamine receptor 2A,HTR2A,,unknown
Dotarizine,,5-hydroxytryptamine receptor 1A,HTR1A,,unknown
Dotarizine,,Voltage-dependent P/Q-type calcium channel subunit alpha-1A,CACNA1A,,unknown
Dotarizine,,5-hydroxytryptamine receptor 2C,HTR2C,,unknown
Lonafarnib,,Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha,FNTA,,unknown
Lonafarnib,,Insulin-like growth factor-binding protein 3,IGFBP3,,unknown
Aprinocarsen,,Protein kinase C alpha type,PRKCA,,unknown
Sarizotan,,5-hydroxytryptamine receptor 1A,HTR1A,,unknown
Sarizotan,,D(2) dopamine receptor,DRD2,partial agonist,unknown
Sarizotan,,D(3) dopamine receptor,DRD3,ligand,unknown
Tecastemizole,,Potassium voltage-gated channel subfamily H member 2,KCNH2,,unknown
Enrasentan,,Endothelin-1 receptor,EDNRA,,unknown
Enrasentan,,Endothelin B receptor,EDNRB,,unknown
Cariporide,,Sodium/hydrogen exchanger 1,SLC9A1,,unknown
Lestaurtinib,,Receptor-type tyrosine-protein kinase FLT3,FLT3,,unknown
clomethiazole,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,,unknown
Naxifylline,,Adenosine receptor A1,ADORA1,antagonist,unknown
Fradafiban,,Integrin alpha-IIb,ITGA2B,,unknown
Fradafiban,,Integrin beta-3,ITGB3,,unknown
Ruplizumab,,CD40 ligand,CD40LG,,unknown
Sumanirole,,D(2) dopamine receptor,DRD2,,unknown
Sumanirole,,D(3) dopamine receptor,DRD3,,unknown
Sumanirole,,D(4) dopamine receptor,DRD4,,unknown
Propentofylline,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,,unknown
Prucalopride,Terminal half-life is 24–30 hours.,5-hydroxytryptamine receptor 4,HTR4,agonist,yes
Manitimus,,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
Enzastaurin,,Protein kinase C beta type,PRKCB,,unknown
Enzastaurin,,Aurora kinase B,AURKB,,unknown
Enzastaurin,,Aurora kinase A,AURKA,,unknown
Enzastaurin,,Cyclin-dependent kinase 15,CDK15,,unknown
Enzastaurin,,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
Enzastaurin,,Serine/threonine-protein kinase Chk2,CHEK2,,unknown
Enzastaurin,,RAC-alpha serine/threonine-protein kinase,AKT1,,unknown
Enzastaurin,,Phosphatidylinositol 3-kinase regulatory subunit alpha,PIK3R1,,unknown
Mirococept,,Complement C3,C3,,unknown
Sufugolix,,Gonadotropin-releasing hormone receptor,GNRHR,,unknown
Onercept,,Tumor necrosis factor,TNF,,unknown
Repinotan,,5-hydroxytryptamine receptor 1A,HTR1A,,unknown
Muraglitazar,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Muraglitazar,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Deramciclane,,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,unknown
Deramciclane,,5-hydroxytryptamine receptor 2C,HTR2C,inverse agonist,unknown
Resiniferatoxin,,Transient receptor potential cation channel subfamily V member 1,TRPV1,,unknown
Ertiprotafib,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
Ertiprotafib,,Inhibitor of nuclear factor kappa-B kinase subunit beta,IKBKB,,unknown
Ertiprotafib,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Ertiprotafib,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Ganstigmine,,Acetylcholinesterase,ACHE,,unknown
Resiquimod,,Toll-like receptor 7,TLR7,,unknown
Resiquimod,,Toll-like receptor 8,TLR8,,unknown
Ragaglitazar,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Ragaglitazar,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Thrombopoietin,,Thrombopoietin receptor,MPL,,unknown
Tesaglitazar,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Tesaglitazar,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Robalzotan,,5-hydroxytryptamine receptor 1A,HTR1A,,unknown
Astaxanthin,,NF-kappa-B inhibitor alpha,NFKBIA,,unknown
Minodronic acid,,Farnesyl pyrophosphate synthase,FDPS,inhibitor,yes
Minodronic acid,,Geranylgeranyl pyrophosphate synthase,GGPS1,inhibitor,yes
Labradimil,,B2 bradykinin receptor,BDKRB2,,unknown
Bivatuzumab,,CD44 antigen,CD44,,unknown
Tezosentan,"A pronounced and rapid disposition phase (half-life 6 min), accounting for the major part of the elimination, was followed by a slower phase (half-life 3 h), probably caused by distribution from tissues.",Endothelin-1 receptor,EDNRA,,unknown
Tezosentan,"A pronounced and rapid disposition phase (half-life 6 min), accounting for the major part of the elimination, was followed by a slower phase (half-life 3 h), probably caused by distribution from tissues.",Endothelin B receptor,EDNRB,,unknown
Pascolizumab,,Interleukin-4,IL4,,unknown
Adipiplon,,GABA-A receptor (benzodiazepine site),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRG1GABRG2GABRG3,partial agonist,yes
Bevirimat,56.3 to 69.5 hours,Gag-Pol polyprotein,gag-pol,,unknown
Cetilistat,,Pancreatic triacylglycerol lipase,PNLIP,,unknown
Mitemcinal,,Motilin receptor,MLNR,,unknown
Pazopanib,35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.,Vascular endothelial growth factor receptor 1,FLT1,inhibitor,yes
Pazopanib,35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.,Vascular endothelial growth factor receptor 2,KDR,inhibitor,yes
Pazopanib,35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.,Vascular endothelial growth factor receptor 3,FLT4,,yes
Pazopanib,35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.,Platelet-derived growth factor receptor alpha,PDGFRA,inhibitor,yes
Pazopanib,35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.,Platelet-derived growth factor receptor beta,PDGFRB,inhibitor,yes
Pazopanib,35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.,Mast/stem cell growth factor receptor Kit,KIT,inhibitor,yes
Pazopanib,35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.,Fibroblast growth factor receptor 3,FGFR3,inhibitor,unknown
Pazopanib,35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.,Tyrosine-protein kinase ITK/TSK,ITK,inhibitor,unknown
Pazopanib,35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.,Fibroblast growth factor 1,FGF1,inhibitor,unknown
Pazopanib,35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.,SH2B adapter protein 3,SH2B3,inhibitor,unknown
Agomelatine,<2 hours,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,yes
Agomelatine,<2 hours,Melatonin receptor type 1A,MTNR1A,agonist,yes
Agomelatine,<2 hours,Melatonin receptor type 1B,MTNR1B,agonist,yes
Midostaurin,"Elimination half life is approximately 21 hrs for midostaurin, 32 hrs for CGP62221 and 482 hrs  for CGP52421.",Protein kinase C alpha type,PRKCA,antagonistinhibitor,yes
Midostaurin,"Elimination half life is approximately 21 hrs for midostaurin, 32 hrs for CGP62221 and 482 hrs  for CGP52421.",Vascular endothelial growth factor receptor 2,KDR,antagonistinhibitor,yes
Midostaurin,"Elimination half life is approximately 21 hrs for midostaurin, 32 hrs for CGP62221 and 482 hrs  for CGP52421.",Mast/stem cell growth factor receptor Kit,KIT,antagonistinhibitor,unknown
Midostaurin,"Elimination half life is approximately 21 hrs for midostaurin, 32 hrs for CGP62221 and 482 hrs  for CGP52421.",Platelet-derived growth factor receptor alpha,PDGFRA,antagonistinhibitor,yes
Midostaurin,"Elimination half life is approximately 21 hrs for midostaurin, 32 hrs for CGP62221 and 482 hrs  for CGP52421.",Platelet-derived growth factor receptor beta,PDGFRB,antagonistinhibitor,yes
Midostaurin,"Elimination half life is approximately 21 hrs for midostaurin, 32 hrs for CGP62221 and 482 hrs  for CGP52421.",Receptor-type tyrosine-protein kinase FLT3,FLT3,antagonistinhibitor,yes
Lexatumumab,,Tumor necrosis factor receptor superfamily member 10B,TNFRSF10B,,unknown
Reslizumab,The half-life is approximately 24 days [FDA Label].,Interleukin-5,IL5,antagonist,yes
Panobinostat,30 hours,Histone deacetylase,HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9,inhibitor,yes
Apixaban,"If administered orally, the half life is 12 hours (due to prolonged absorption). If administerd by I.V., the half-life is about 5 hours.",Coagulation factor X,F10,inhibitor,yes
Catumaxomab,Catumaxomab has an apparent half life of elimination of 2.5 days [FDA Label].,Epithelial cell adhesion molecule,EPCAM,ligand,no
Catumaxomab,Catumaxomab has an apparent half life of elimination of 2.5 days [FDA Label].,Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,agonist,yes
Catumaxomab,Catumaxomab has an apparent half life of elimination of 2.5 days [FDA Label].,Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,agonist,yes
Catumaxomab,Catumaxomab has an apparent half life of elimination of 2.5 days [FDA Label].,Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,agonist,yes
Catumaxomab,Catumaxomab has an apparent half life of elimination of 2.5 days [FDA Label].,T-cell surface glycoprotein CD3 epsilon chain,CD3E,agonist,yes
Catumaxomab,Catumaxomab has an apparent half life of elimination of 2.5 days [FDA Label].,High affinity immunoglobulin gamma Fc receptor I,FCGR1A,agonist,yes
Mepolizumab,The mean terminal half-life (t1/2) ranged from 16 to 22 days.,Interleukin-5,IL5,antagonist,yes
Peramivir,,Neuraminidase,NA,,unknown
Peramivir,,Neuraminidase,NA,,unknown
Peramivir,,Neuraminidase,NA,,unknown
Bosutinib,"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours",Breakpoint cluster region protein,BCR,inhibitor,yes
Bosutinib,"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours",Tyrosine-protein kinase ABL1,ABL1,inhibitor,yes
Bosutinib,"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours",Tyrosine-protein kinase Lyn,LYN,,unknown
Bosutinib,"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours",Tyrosine-protein kinase HCK,HCK,inhibitor,unknown
Bosutinib,"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours",Proto-oncogene tyrosine-protein kinase Src,SRC,inhibitor,unknown
Bosutinib,"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours",Cyclin-dependent kinase 2,CDK2,inhibitor,unknown
Bosutinib,"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours",Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,inhibitor,unknown
Bosutinib,"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours",Dual specificity mitogen-activated protein kinase kinase 2,MAP2K2,inhibitor,unknown
Bosutinib,"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours",Mitogen-activated protein kinase kinase kinase 2,MAP3K2,inhibitor,unknown
Bosutinib,"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours",Calcium/calmodulin-dependent protein kinase type II subunit gamma,CAMK2G,inhibitor,unknown
Flupirtine,"6.5 hrs (average), 11.2-16.8 hrs (average 14 hrs) (elderly), 8.7-10.9 hrs (average 9.8 hrs) (in those with moderate-level renal impairment).",Alpha-2A adrenergic receptor,ADRA2A,,unknown
Axitinib,Axitinib has a half life of 2.5 to 6.1 hours.,Vascular endothelial growth factor receptor 1,FLT1,inhibitor,yes
Axitinib,Axitinib has a half life of 2.5 to 6.1 hours.,Vascular endothelial growth factor receptor 2,KDR,inhibitor,yes
Axitinib,Axitinib has a half life of 2.5 to 6.1 hours.,Vascular endothelial growth factor receptor 3,FLT4,inhibitor,yes
Casopitant,,Cytochrome P450 3A4,CYP3A4,,unknown
Casopitant,,Substance-P receptor,TACR1,,unknown
Otamixaban,,Coagulation factor X,F10,,unknown
Dalfampridine,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;",Potassium voltage-gated channel subfamily A member 1,KCNA1,antagonist,yes
Dalfampridine,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;",Potassium voltage-gated channel subfamily A member 2,KCNA2,antagonist,yes
Dalfampridine,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;",Potassium voltage-gated channel subfamily A member 3,KCNA3,antagonist,yes
Dalfampridine,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;",Potassium voltage-gated channel subfamily A member 4,KCNA4,antagonist,yes
Dalfampridine,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;",Potassium voltage-gated channel subfamily A member 5,KCNA5,antagonist,yes
Dalfampridine,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;",Potassium voltage-gated channel subfamily A member 6,KCNA6,antagonist,yes
Dalfampridine,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;",Potassium voltage-gated channel subfamily A member 7,KCNA7,antagonist,yes
Dalfampridine,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;",Potassium voltage-gated channel subfamily A member 10,KCNA10,antagonist,yes
Dalfampridine,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;",Potassium voltage-gated channel subfamily B member 1,KCNB1,antagonist,yes
Dalfampridine,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;",Potassium voltage-gated channel subfamily B member 2,KCNB2,antagonist,yes
Dalfampridine,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;",Potassium voltage-gated channel subfamily C member 1,KCNC1,antagonist,yes
Dalfampridine,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;",Potassium voltage-gated channel subfamily C member 2,KCNC2,antagonist,yes
Dalfampridine,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;",Potassium voltage-gated channel subfamily C member 3,KCNC3,antagonist,yes
Dalfampridine,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;",Potassium voltage-gated channel subfamily D member 1,KCND1,antagonist,yes
Dalfampridine,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;",Potassium voltage-gated channel subfamily D member 2,KCND2,antagonist,yes
Dalfampridine,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;",Potassium voltage-gated channel subfamily D member 3,KCND3,antagonist,yes
Perifosine,,RAC-alpha serine/threonine-protein kinase,AKT1,,unknown
Perifosine,,Mitogen-activated protein kinase 1,MAPK1,,unknown
Perifosine,,Protein kinase C alpha type,PRKCA,,unknown
Bevasiranib,,Vascular endothelial growth factor A,VEGFA,,unknown
Denosumab,25.4 days,Tumor necrosis factor ligand superfamily member 11,TNFSF11,antibody,yes
Ofatumumab,"Approximately 14 days.
Range: 2.3 to 61.5 days",B-lymphocyte antigen CD20,MS4A1,inhibitor,yes
Vicriviroc,,C-C chemokine receptor type 5,CCR5,,unknown
Safinamide,22 h,Amine oxidase [flavin-containing] B,MAOB,antagonist,yes
Liraglutide,approximately 13 hours.,Glucagon-like peptide 1 receptor,GLP1R,agonist,yes
Saredutant,,Substance-K receptor,TACR2,,unknown
Pasireotide,The half-life is 12 hours.,Somatostatin receptor type 1,SSTR1,,unknown
Pasireotide,The half-life is 12 hours.,Somatostatin receptor type 2,SSTR2,,unknown
Pasireotide,The half-life is 12 hours.,Somatostatin receptor type 3,SSTR3,,unknown
Pasireotide,The half-life is 12 hours.,Somatostatin receptor type 5,SSTR5,,unknown
Odanacatib,Apparent half life observed to be 87.3-94.7h [A19389].,Cathepsin K,CTSK,inhibitor,unknown
Golimumab,Golimumab has a long half-life of about 2 weeks.,Tumor necrosis factor,TNF,antibody,yes
Clazosentan,,Endothelin-1 receptor,EDNRA,,unknown
Esmirtazapine,10 hours,Histamine H1 receptor,HRH1,inverse agonist,unknown
Esmirtazapine,10 hours,5-hydroxytryptamine receptor 2,HTR2AHTR2BHTR2C,inverse agonist,unknown
Esmirtazapine,10 hours,Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,antagonist,unknown
Asoprisnil,,Progesterone receptor,PGR,,unknown
Belatacept,"Mean terminal elimination half-life:
10 mg/kg, kidney transplant recipients= 9.8 days; 
5 mg/kg, kidney transplant recipient = 8.2 days",T-lymphocyte activation antigen CD86,CD86,,unknown
Belatacept,"Mean terminal elimination half-life:
10 mg/kg, kidney transplant recipients= 9.8 days; 
5 mg/kg, kidney transplant recipient = 8.2 days",T-lymphocyte activation antigen CD80,CD80,,unknown
Vilazodone,25.4h,5-hydroxytryptamine receptor 1A,HTR1A,agonist,unknown
Sipuleucel-T,,Prostatic acid phosphatase,ACPP,antagonistinhibitory immune response,unknown
Ethanolamine Oleate,,Calcium ions,,chelator,unknown
Ethanolamine Oleate,,Coagulation factor XII,F12,activator,unknown
Mepyramine,,Histamine H1 receptor,HRH1,antagonist,yes
Aprotinin,"Following this distribution phase, a plasma half-life of about 150 minutes is observed.  At later time points, (i.e., beyond 5 hours after dosing) there is a terminal elimination phase with a half-life of about 10 hours.",Trypsin-1,PRSS1,,unknown
Aprotinin,"Following this distribution phase, a plasma half-life of about 150 minutes is observed.  At later time points, (i.e., beyond 5 hours after dosing) there is a terminal elimination phase with a half-life of about 10 hours.",Chymotrypsinogen B,CTRB1,,unknown
Aprotinin,"Following this distribution phase, a plasma half-life of about 150 minutes is observed.  At later time points, (i.e., beyond 5 hours after dosing) there is a terminal elimination phase with a half-life of about 10 hours.",Plasminogen,PLG,,unknown
Aprotinin,"Following this distribution phase, a plasma half-life of about 150 minutes is observed.  At later time points, (i.e., beyond 5 hours after dosing) there is a terminal elimination phase with a half-life of about 10 hours.",Kallikrein-1,KLK1,,unknown
Mevastatin,,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,inhibitor,yes
Xylometazoline,,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Xylometazoline,,Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Xylometazoline,,Alpha-2B adrenergic receptor,ADRA2B,agonist,yes
Xylometazoline,,Alpha-1B adrenergic receptor,ADRA1B,agonist,unknown
Xylometazoline,,Alpha-1D adrenergic receptor,ADRA1D,agonist,unknown
Xylometazoline,,Alpha-2C adrenergic receptor,ADRA2C,agonist,unknown
Dabigatran etexilate,12-14 hours in healthy volunteers. 14-17 hours in patients treated for prevention of venous thromboembolism following hip- or knee-replacement surgery.,Prothrombin,F2,inhibitor,yes
Arbekacin,3 hours,30S ribosomal protein S12,rpsL,inhibitor,yes
Betahistine,3-4 hours,Histamine H1 receptor,HRH1,agonist,yes
Betahistine,3-4 hours,Histamine H3 receptor,HRH3,antagonist,yes
Degarelix,"Terminal half-life: 41.5 - 70.2 days; 
Absorption half-life: 32.9 hours; 
Half-life from injection site: 1.17 days.",Gonadotropin-releasing hormone receptor,GNRHR,antagonist,yes
Desvenlafaxine,The mean terminal half life is 11.1 hours and may be prolonged in patients with renal and/or moderate to severe hepatic impairment.,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Desvenlafaxine,The mean terminal half life is 11.1 hours and may be prolonged in patients with renal and/or moderate to severe hepatic impairment.,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Dexmethylphenidate,2-4 hours,Sodium-dependent dopamine transporter,SLC6A3,inhibitor,yes
Dexmethylphenidate,2-4 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Dexmethylphenidate,2-4 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,unknown
Fesoterodine,7-8 hours for the active metabolite 5-hydroxymethyl tolterodine,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Fesoterodine,7-8 hours for the active metabolite 5-hydroxymethyl tolterodine,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,unknown
Fesoterodine,7-8 hours for the active metabolite 5-hydroxymethyl tolterodine,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Fesoterodine,7-8 hours for the active metabolite 5-hydroxymethyl tolterodine,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Fesoterodine,7-8 hours for the active metabolite 5-hydroxymethyl tolterodine,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,unknown
Isometheptene,,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Isometheptene,,Synaptic vesicular amine transporter,SLC18A2,inhibitor,yes
Levonordefrin,,Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,agonist,yes
Methacholine,,Muscarinic acetylcholine receptor M3,CHRM3,agonist,yes
Methyltestosterone,6-8 hours,Androgen receptor,AR,agonist,yes
Methyltestosterone,6-8 hours,Estrogen receptor alpha,ESR1,,unknown
Naphazoline,,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Naphazoline,,Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Nilvadipine,,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,inhibitor,yes
Nilvadipine,,Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,inhibitor,yes
Nilvadipine,,Voltage-dependent L-type calcium channel subunit beta-2,CACNB2,inhibitor,yes
Nilvadipine,,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,inhibitor,unknown
Nilvadipine,,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,inhibitor,unknown
Nilvadipine,,Voltage-dependent calcium channel subunit alpha-2/delta-3,CACNA2D3,inhibitor,unknown
Norelgestromin,,Progesterone receptor,PGR,agonist,yes
Norelgestromin,,Serum albumin,ALB,,unknown
Norelgestromin,,Androgen receptor,AR,partial agonist,unknown
Propylhexedrine,,Synaptic vesicular amine transporter,SLC18A2,,yes
Propylhexedrine,,Trace amine-associated receptor 1,TAAR1,agonist,unknown
Potassium Iodide,,Tyrosine,,binder,unknown
Fospropofol,"When given to a patient, the half-lives are as follows: 
Fospropofol = 0.81 hours; 
Propofol metabolite = 1.13 hours",Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,potentiator,yes
Fospropofol,"When given to a patient, the half-lives are as follows: 
Fospropofol = 0.81 hours; 
Propofol metabolite = 1.13 hours",Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,potentiator,yes
Stanozolol,24 hours,Stanozolol Binding Protein (STBP),,other,unknown
Stanozolol,24 hours,Low-affinity glucocorticoid-binding protein (LAGS),,negative modulator,unknown
Buserelin,"The elimination half-life is approximately 50 to 80 minutes following intravenous administration, 80 minutes after subcutaneous administration and approximately 1 to 2 hours after intranasal administration.",Lutropin-choriogonadotropic hormone receptor,LHCGR,,yes
Buserelin,"The elimination half-life is approximately 50 to 80 minutes following intravenous administration, 80 minutes after subcutaneous administration and approximately 1 to 2 hours after intranasal administration.",Gonadotropin-releasing hormone receptor,GNRHR,,yes
Velaglucerase alfa,11-12 minutes.,Glucosylceramidase,GBA,,unknown
Lornoxicam,3-5 hours,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Lornoxicam,3-5 hours,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Bufuralol,,Beta adrenergic receptor,ADRB1ADRB2ADRB3,antagonist,unknown
Aniline,,Kallikrein-1,KLK1,,unknown
Aniline,,Serum albumin,ALB,,unknown
Sulfaphenazole,,Dihydropteroate synthase,folP,inhibitor,yes
Gestodene,16 to 18 hrs.,Probable G-protein coupled receptor 133,ADGRD1,,unknown
beta-Naphthoflavone,,Estrogen receptor alpha,ESR1,,unknown
beta-Naphthoflavone,,Steroid hormone receptor ERR1,ESRRA,,unknown
beta-Naphthoflavone,,COUP transcription factor 1,NR2F1,,unknown
beta-Naphthoflavone,,Aryl hydrocarbon receptor,AHR,,unknown
beta-Naphthoflavone,,Cytochrome P450 1B1,CYP1B1,,unknown
Bafilomycin A1,,V-type proton ATPase catalytic subunit A,ATP6V1A,inhibitor,yes
Bafilomycin B1,,V-type proton ATPase catalytic subunit A,ATP6V1A,inhibitor,yes
Aceclofenac,The mean plasma elimination half-life is approximately 4 hours [L868].,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Aceclofenac,The mean plasma elimination half-life is approximately 4 hours [L868].,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Ketobemidone,"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h",Mu-type opioid receptor,OPRM1,agonist,yes
Ketobemidone,"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h",Kappa-type opioid receptor,OPRK1,agonist,yes
Ketobemidone,"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h",Delta-type opioid receptor,OPRD1,agonist,yes
Ketobemidone,"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h",NMDA receptor,GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B,antagonist,unknown
Seratrodast,,Thromboxane A2 receptor,TBXA2R,antagonist,unknown
Gavestinel,,Glutamate (NMDA) receptor,GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B,antagonist,unknown
ginsenoside Rb1,,Solute carrier organic anion transporter family member 1B3,SLCO1B3,inhibitor,unknown
Ginsenoside Rg1,,Solute carrier organic anion transporter family member 1B3,SLCO1B3,,unknown
Drotaverine,7 to 12 hours,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,inhibitor,yes
Drotaverine,7 to 12 hours,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,inhibitor,unknown
Glycine betaine,14 hours,Apoptosis regulator Bcl-2,BCL2,,unknown
Manganese,,"Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial",IDH3A,,unknown
Manganese,,"Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial",IDH3G,,unknown
Manganese,,TGF-beta-activated kinase 1 and MAP3K7-binding protein 1,TAB1,,unknown
Manganese,,Arginase-1,ARG1,,unknown
Manganese,,Serotransferrin,TF,,unknown
Fomivirsen,"Intravitreal drug clearance studies have revealed first-order kinetics [A31989]. Following intravitreal administration, fomivirsen is slowly cleared from vitreous with a half-life of approximately 55 hours in humans [A31988]. The half life from retina in monkeys following administration of 115 mcg fomivirsen is estimated to be 78 hours [A31988].",30 kDa immediate-early protein 2,UL122,antisense oligonucleotide,yes
Fomivirsen,"Intravitreal drug clearance studies have revealed first-order kinetics [A31989]. Following intravitreal administration, fomivirsen is slowly cleared from vitreous with a half-life of approximately 55 hours in humans [A31988]. The half life from retina in monkeys following administration of 115 mcg fomivirsen is estimated to be 78 hours [A31988].",45 kDa immediate-early protein 2,UL122,antisense oligonucleotide,yes
Tetryzoline,,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Alcaftadine,The elimination half-life of the carboxylic acid metabolite is approximately 2 hours following topical ocular administration.,Histamine H1 receptor,HRH1,antagonist,unknown
Besifloxacin,The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.,DNA topoisomerase 4 subunit A,parC,antagonist,yes
Besifloxacin,The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.,DNA topoisomerase 4 subunit A,parC,antagonist,yes
Besifloxacin,The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.,DNA gyrase subunit A,gyrA,antagonist,yes
Besifloxacin,The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.,DNA gyrase subunit A,gyrA,antagonist,yes
Cabazitaxel,"Following a one-hour intravenous infusion, plasma concentrations of cabazitaxel can be described by a three-compartment pharmacokinetic model with α-, β-, and γ- half-lives of 4 minutes, 2 hours, and 95 hours, respectively.",Tubulin alpha-4A chain,TUBA4A,binder,yes
Cabazitaxel,"Following a one-hour intravenous infusion, plasma concentrations of cabazitaxel can be described by a three-compartment pharmacokinetic model with α-, β-, and γ- half-lives of 4 minutes, 2 hours, and 95 hours, respectively.",Tubulin beta-1 chain,TUBB1,binder,yes
Human calcitonin,Intravenous administration of human calcitonin presents a half-life in the range of 10.2-37.8 min.[A32110],Alpha-actinin-1,ACTN1,incorporation into and destabilization,yes
Capsaicin,"Following oral ingestion of equipotent dose of 26.6 mg of pure capsaicin, the half life was approximately 24.9 ± 5.0 min [A32319]. Following topical application of 3% solution of capsaicin, the half-life of capsaicin was approximately 24 h [A32319]. The mean population elimination half-life was 1.64 h following application of a topical patch containing 179 mg of capsaicin [A32319].",Transient receptor potential cation channel subfamily V member 1,TRPV1,agonist,yes
Capsaicin,"Following oral ingestion of equipotent dose of 26.6 mg of pure capsaicin, the half life was approximately 24.9 ± 5.0 min [A32319]. Following topical application of 3% solution of capsaicin, the half-life of capsaicin was approximately 24 h [A32319]. The mean population elimination half-life was 1.64 h following application of a topical patch containing 179 mg of capsaicin [A32319].",Prohibitin-2,PHB2,,unknown
Carglumic Acid,Median values for the terminal half-life was 5.6 hours (range 4.3-9.5).,"Carbamoyl-phosphate synthase [ammonia], mitochondrial",CPS1,allosteric modulator,yes
Sodium cellulose phosphate,,Calcium ions,,binder,yes
Chenodeoxycholic acid,,Bile acid receptor,NR1H4,other,unknown
Chenodeoxycholic acid,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Chenodeoxycholic acid,,G-protein coupled bile acid receptor 1,GPBAR1,,unknown
Chenodeoxycholic acid,,Aldo-keto reductase family 1 member C2,AKR1C2,substrate,unknown
Dalteparin,"Terminal Half life:
Intravenous - 2 hours. Subcutaneous - 3-5hours",Antithrombin-III,SERPINC1,potentiator,yes
Dalteparin,"Terminal Half life:
Intravenous - 2 hours. Subcutaneous - 3-5hours",Vascular endothelial growth factor A,VEGFA,inhibitor,yes
Dalteparin,"Terminal Half life:
Intravenous - 2 hours. Subcutaneous - 3-5hours",Tissue factor pathway inhibitor,TFPI,inhibitor,yes
Dalteparin,"Terminal Half life:
Intravenous - 2 hours. Subcutaneous - 3-5hours",P-selectin,SELP,inhibitor,unknown
Desoxycorticosterone acetate,,Mineralocorticoid receptor,NR3C2,agonist,unknown
Difluprednate,,Glucocorticoid receptor,NR3C1,agonist,yes
Dimercaprol,The drug has a short half life.,Arsenic,,chelator,yes
Dimercaprol,The drug has a short half life.,Cadmium,,chelator,yes
Dimercaprol,The drug has a short half life.,Mercury,,chelator,yes
Dimercaprol,The drug has a short half life.,Amyloid beta A4 protein,APP,,unknown
Ganirelix,16.2 hours.,Gonadotropin-releasing hormone receptor,GNRHR,antagonist,yes
Halcinonide,,Smoothened homolog,SMO,agonistactivator,unknown
Hexocyclium,,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,unknown
Hexocyclium,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Hexocyclium,,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Hexocyclium,,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,unknown
Histrelin,,Gonadotropin-releasing hormone receptor,GNRHR,agonist,yes
Hydroxyprogesterone caproate,Half-life = 16 days (±6 days). (3),Progesterone receptor,PGR,agonist,unknown
Lanreotide,Half-life is approximately 22 days (5),Somatostatin receptor type 2,SSTR2,agonist,unknown
Lanreotide,Half-life is approximately 22 days (5),Somatostatin receptor type 5,SSTR5,agonist,unknown
Lanthanum carbonate,Elimination half-life of 53 hours.,Phosphate,,binder,yes
Mafenide,,Carbonic anhydrase 6,CA6,antagonist,unknown
Methylnaltrexone,"terminal: 8.89 ± 2.59 h (intravenous) 
terminal: 6.14- 8.83 h (subcutaneous)",Mu-type opioid receptor,OPRM1,antagonist,yes
Methylnaltrexone,"terminal: 8.89 ± 2.59 h (intravenous) 
terminal: 6.14- 8.83 h (subcutaneous)",Kappa-type opioid receptor,OPRK1,antagonist,no
Nepafenac,,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Nepafenac,,Prostaglandin G/H synthase 2,PTGS2,inhibitor,unknown
Niclosamide,,DNA,,antagonist,unknown
Plerixafor,"Terminal elimination half-life, NHL patients: 4.4 hours;
Terminal elimination half-life, MM patients: 5.6 hours;
Terminal elimination half-life, Hodgkin's lymphoma patients: 3.5 hours; 
Distribution half-life: 0.3 hours",C-X-C chemokine receptor type 4,CXCR4,antagonist,yes
Plicamycin,,DNA,,antagonist,yes
Pralatrexate,12-18 hours,Dihydrofolate reductase,DHFR,inhibitor,yes
Pralatrexate,12-18 hours,Thymidylate synthase,TYMS,inhibitor,yes
Protokylol,,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Raltegravir,9 hours,Integrase,pol,inhibitor,yes
Phenylbutyric acid,For sodium phenylbutyrate the half life  is 0.77 hours. For phenylacetate the half life is 1.15 hours.,Aromatic-amino-acid aminotransferase,tyrB,,unknown
Phenylbutyric acid,For sodium phenylbutyrate the half life  is 0.77 hours. For phenylacetate the half life is 1.15 hours.,Thermolysin,npr,,unknown
Sulfameter,,Dihydropteroate synthase,folP,inhibitor,yes
Tinzaparin,Anti-Xa activity is 82 minutes. Anti-IIa activity is 71 minutes.,Antithrombin-III,SERPINC1,potentiator,yes
Tinzaparin,Anti-Xa activity is 82 minutes. Anti-IIa activity is 71 minutes.,Integrin alpha-4,ITGA4,inhibitor,unknown
Tinzaparin,Anti-Xa activity is 82 minutes. Anti-IIa activity is 71 minutes.,Stromal cell-derived factor 1,CXCL12,binder,unknown
Triptorelin,"The pharmacokinetics of triptorelin follows a 3 compartment model.  The half lives are estimated to be 6 minutes, 45 minutes, and 3 hours respectively.",Gonadotropin-releasing hormone receptor,GNRHR,agonist,yes
Viomycin,,70S ribosome,,,yes
5-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indole,,Leukotriene A-4 hydrolase,LTA4H,,unknown
4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
"(1-HYDROXYHEPTANE-1,1-DIYL)BIS(PHOSPHONIC ACID)",,Geranylgeranyl pyrophosphate synthase,GGPS1,,unknown
2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE,,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,,unknown
2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE,,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",PIK3CD,,unknown
"2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL",,Estrogen receptor beta,ESR2,,unknown
"2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL",,Nuclear receptor coactivator 1,NCOA1,,unknown
1-CYCLOHEXYL-N-{[1-(4-METHYLPHENYL)-1H-INDOL-3-YL]METHYL}METHANAMINE,,Steroid hormone receptor ERR1,ESRRA,,unknown
"N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide",,Tyrosine-protein kinase SYK,SYK,,unknown
(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-{(S)-HYDROXY[(1R)-2-METHYL-1-{[(2-PHENYLETHYL)SULFONYL]AMINO}PROPYL]PHOSPHORYL}PROPANOIC ACID,,Carboxypeptidase B,CPB1,,unknown
"N-(5-{4-Chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl}-4-methyl-1,3-thiazol-2-yl)acetamide",,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,,unknown
"N-(5-{4-Chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl}-4-methyl-1,3-thiazol-2-yl)acetamide",,Phosphatidylinositol 3-kinase catalytic subunit type 3,PIK3C3,,unknown
"(2R)-N~4~-hydroxy-2-(3-hydroxybenzyl)-N~1~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide",,A disintegrin and metalloproteinase with thrombospondin motifs 5,ADAMTS5,,unknown
methyl L-phenylalaninate,,Fimbrial protein,pilE1,,unknown
methyl L-phenylalaninate,,Prothrombin,F2,,unknown
"diethyl [(1R)-1,5-diaminopentyl]boronate",,Trypsin-1,PRSS1,,unknown
D-phenylalanyl-N-[(1S)-4-{[amino(iminio)methyl]amino}-1-(chloroacetyl)butyl]-L-prolinamide,,Prothrombin,F2,,unknown
(4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,,unknown
(4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,,unknown
"2',5'-DIDEOXY-ADENOSINE 3'-MONOPHOSPHATE",,Guanine nucleotide-binding protein G(s) subunit alpha isoforms short,GNAS,,unknown
"2',5'-DIDEOXY-ADENOSINE 3'-MONOPHOSPHATE",,Adenylate cyclase type 2,ADCY2,,unknown
"2',5'-DIDEOXY-ADENOSINE 3'-MONOPHOSPHATE",,Adenylate cyclase type 5,ADCY5,,unknown
"4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE",,Cyclin-A2,CCNA2,,unknown
"4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide,,Trypsin-1,PRSS1,,unknown
(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide,,Prothrombin,F2,,unknown
"5-[(3S)-3-(2-methoxybiphenyl-4-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine",,Dihydrofolate reductase (dfrB),dfrB,,unknown
"1-(1'-{[3-(methylsulfanyl)-2-benzothiophen-1-yl]carbonyl}spiro[1-benzofuran-3,4'-piperidin]-5-yl)methanamine",,Tryptase alpha/beta-1,TPSAB1,,unknown
"1-[1'-(3-phenylacryloyl)spiro[1-benzofuran-3,4'-piperidin]-5-yl]methanamine",,Tryptase alpha/beta-1,TPSAB1,,unknown
(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide,,Trypsin-1,PRSS1,,unknown
(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide,,Prothrombin,F2,,unknown
N-(pyridin-3-ylmethyl)aniline,,Inorganic pyrophosphatase,ppa,,unknown
N-(pyridin-3-ylmethyl)aniline,,Leukotriene A-4 hydrolase,LTA4H,,unknown
4-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLAMINO]-3-(1H-BENZIMIDAZOL-2-YL)-6-CHLOROQUINOLIN-2(1H)-ONE,,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide,,Trypsin-1,PRSS1,,unknown
N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide,,Prothrombin,F2,,unknown
6-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1H-benzoimidazole-5-carboxamidine,,Urokinase-type plasminogen activator,PLAU,,unknown
6-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1H-benzoimidazole-5-carboxamidine,,Trypsin-1,PRSS1,,unknown
6-FLUORO-2-[2-HYDROXY-3-(2-METHYL-CYCLOHEXYLOXY)-PHENYL]-1H-INDOLE-5-CARBOXAMIDINE,,Urokinase-type plasminogen activator,PLAU,,unknown
N-(4-CARBAMIMIDOYL-3-CHORO-PHENYL)-2-HYDROXY-3-IODO-5-METHYL-BENZAMIDE,,Urokinase-type plasminogen activator,PLAU,,unknown
N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide,,Prothrombin,F2,,unknown
N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide,,Trypsin-1,PRSS1,,unknown
N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE,,Prothrombin,F2,,unknown
"2-(2-chloropyridin-4-yl)-4-methyl-1H-isoindole-1,3(2H)-dione",,Thymidylate synthase,thyA,,unknown
6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE,,Prothrombin,F2,,unknown
2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID,,Caspase-3,CASP3,,unknown
"2-(3-CARBOXYPROPIONYL)-6-HYDROXY-CYCLOHEXA-2,4-DIENE CARBOXYLIC ACID",,o-succinylbenzoate synthase,menC,,unknown
6-CARBAMIMIDOYL-2-[2-HYDROXY-6-(4-HYDROXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID,,Prothrombin,F2,,unknown
6-CARBAMIMIDOYL-2-[2-HYDROXY-5-(3-METHOXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID,,Prothrombin,F2,,unknown
"3,6,9,12,15,18-HEXAOXAICOSANE",,Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1,PIN1,,unknown
N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide,,Prothrombin,F2,,unknown
1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE,,Prothrombin,F2,,unknown
"17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE",,Androgen receptor,AR,,unknown
17-METHYL-17-ALPHA-DIHYDROEQUILENIN,,Estrogen receptor alpha,ESR1,,unknown
17-METHYL-17-ALPHA-DIHYDROEQUILENIN,,Nuclear receptor coactivator 2,NCOA2,,unknown
"1-((2-HYDROXYETHOXY)METHYL)-5-(PHENYLTHIO)PYRIMIDINE-2,4(1H,3H)-DIONE",,Uridine phosphorylase,udp,,unknown
"1-((2-HYDROXYETHOXY)METHYL)-5-(3-(BENZYLOXY)BENZYL)PYRIMIDINE-2,4(1H,3H)-DIONE",,Uridine phosphorylase,udp,,unknown
"(6-[4-(AMINOMETHYL)-2,6-DIMETHYLPHENOXY]-2-{[4-(AMINOMETHYL)PHENYL]AMINO}-5-BROMOPYRIMIDIN-4-YL)METHANOL",,Gag-Pol polyprotein,gag-pol,,unknown
3-(3-FLUORO-4-HYDROXYPHENYL)-7-HYDROXY-1-NAPHTHONITRILE,,Estrogen receptor beta,ESR2,,unknown
3-(3-FLUORO-4-HYDROXYPHENYL)-7-HYDROXY-1-NAPHTHONITRILE,,Nuclear receptor coactivator 1,NCOA1,,unknown
"N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE",,Mitogen-activated protein kinase 1,MAPK1,,unknown
1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide,,Prothrombin,F2,,unknown
"5-(4'-AMINO-1'-ETHYL-5',8'-DIFLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLINE]-1-YLCARBONYL)PICOLINONITRILE",,"Nitric oxide synthase, inducible",NOS2,,unknown
"(1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-PROP-1-YN-1-YLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE",,Dipeptidyl peptidase 4,DPP4,,unknown
(1Z)-2-HYDROXY-3-OXOHEX-1-EN-1-YL DIHYDROGEN PHOSPHATE,,"2,3-diketo-5-methylthiopentyl-1-phosphate enolase",mtnW,,unknown
1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea,,Mitogen-activated protein kinase 14,MAPK14,,unknown
1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
4-HYDROXY-N'-(4-ISOPROPYLBENZYL)BENZOHYDRAZIDE,,Estrogen-related receptor gamma,ESRRG,,unknown
4-HYDROXY-N'-(4-ISOPROPYLBENZYL)BENZOHYDRAZIDE,,Nuclear receptor-interacting protein 1,NRIP1,,unknown
N-BENZYLOXYCARBONYL-ALA-PRO-3-AMINO-4-PHENYL-BUTAN-2-OL,,Subtilisin DY,apr,,unknown
"[(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
"(13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE",,Cyclin-dependent kinase 2,CDK2,,unknown
"3-(1H-tetrazol-5-ylmethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one",,Beta-lactamase,blaCTX-M-9a,,unknown
(2R)-2-PHENYL-N-PYRIDIN-4-YLBUTANAMIDE,,Lanosterol 14-alpha demethylase,ERG11,,unknown
"5-{[(4-AMINO-3-CHLORO-5-FLUOROPHENYL)SULFONYL]AMINO}-1,3,4-THIADIAZOLE-2-SULFONAMIDE",,Carbonic anhydrase 2,CA2,,unknown
"(5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide",,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,,unknown
1-DECANE-SULFONIC-ACID,,SDS hydrolase SdsA1,sdsA1,,unknown
1-DODECANOL,,SDS hydrolase SdsA1,sdsA1,,unknown
1-DODECANOL,,Fatty-acid amide hydrolase 1,FAAH,,unknown
"1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide",,Hepatocyte growth factor receptor,MET,,unknown
"3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol",,Serine/threonine-protein kinase PLK1,PLK1,,unknown
"4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol",,Estrogen receptor alpha,ESR1,,unknown
"4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol",,Nuclear receptor coactivator 2,NCOA2,,unknown
"N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOTHIAZIN-4-YL]ETHYL}ACETAMIDE",,Renin,REN,,unknown
1-[4-(hydroxymethyl)phenyl]guanidine,,Prostasin,PRSS8,,unknown
2-(2-HYDROXY-CYCLOPENTYL)-PENT-4-ENAL,,Chymotrypsin-like elastase family member 2A,CELA2A,,unknown
4-(1-methyl-1-phenylethyl)phenol,,Estrogen-related receptor gamma,ESRRG,,unknown
"(1S,3aS,5aR,8aS)-1,7,7-trimethyl-1,2,3,3a,5a,6,7,8-octahydrocyclopenta[c]pentalene-4-carboxylic acid",,1-deoxypentalenic acid 11-beta-hydroxylase,ptlH,,unknown
"(5S,6S)-6-[(R)ACETOXYETH-2-YL]-PENEM-3-CARBOXYLATEPROPANE",,Signal peptidase I,lepB,,unknown
"(2S,3S,4E,6E,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid",,Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform,PPP2R5C,,unknown
"(2S,3S,4E,6E,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid",,Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform,PPP2CA,,unknown
"(2S,3S,4E,6E,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid",,Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform,PPP2R1A,,unknown
2-AMINO-4-HYDROXYPYRIMIDINE-5-CARBOXYLIC ACID ETHYL ESTER,,Dihydroneopterin aldolase,folB,,unknown
"(2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID",,Nuclear receptor coactivator 1,NCOA1,,unknown
"(2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID",,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
"1-ethyl-N-(phenylmethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide",,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,,unknown
"[4-R-(4-ALPHA,6-BETA,7-BETA]-HEXAHYDRO-5,6-DI(HYDROXY)-1,3-DI(ALLYL)-4,7-BISPHENYLMETHYL)-2H-1,3-DIAZEPINONE",,Gag-Pol polyprotein,gag-pol,,unknown
D-leucyl-N-(3-chlorobenzyl)-L-prolinamide,,Prothrombin,F2,,unknown
"UNDECA-3,7-DIENE-1,3,7,11-TETRACARBALDEHYDE",,Lysozyme C,LYZ,,unknown
"(2R,3R)-3-{[3,5-BIS(TRIFLUOROMETHYL)PHENYL]AMINO}-2-CYANO-3-THIOXOPROPANAMIDE",,Genome polyprotein,,,unknown
"1-({2-[2-(4-CHLOROPHENYL)ETHYL]-1,3-DIOXOLAN-2-YL}METHYL)-1H-IMIDAZOLE",,Heme oxygenase 1,HMOX1,,unknown
"N-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-1-[2-(1H-IMIDAZOL-1-YL)-6-METHYLPYRIMIDIN-4-YL]-D-PROLINAMIDE",,"Nitric oxide synthase, inducible",NOS2,,unknown
(4-fluorophenyl)(pyridin-4-yl)methanone,,Leukotriene A-4 hydrolase,LTA4H,,unknown
2-(2-METHYLPHENYL)-1H-INDOLE-6-CARBOXIMIDAMIDE,,Trypsin-1,PRSS1,,unknown
D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide,,Prothrombin,F2,,unknown
Eribaxaban,,Coagulation factor X,F10,,unknown
(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(R)-HYDROXY{(1R)-2-METHYL-1-[(PHENYLSULFONYL)AMINO]PROPYL}PHOSPHORYL]PROPANOIC ACID,,Carboxypeptidase B,CPB1,,unknown
"2-[(1R)-1-carboxy-2-naphthalen-1-ylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylic acid",,Beta-lactamase,ampC,,unknown
2-(3-METHYLPHENYL)-1H-INDOLE-5-CARBOXIMIDAMIDE,,Trypsin-1,PRSS1,,unknown
(2R)-2-benzyl-3-nitropropanoic acid,,Carboxypeptidase A1,CPA1,,unknown
3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE,,Tyrosine-protein kinase Lck,LCK,,unknown
"(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid",,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
[5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE,,Estrogen receptor beta,ESR2,,unknown
[5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE,,Nuclear receptor coactivator 1,NCOA1,,unknown
[5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE,,Estrogen receptor alpha,ESR1,,unknown
(2S)-2-{[HYDROXY(4-IODOBENZYL)PHOSPHORYL]METHYL}PENTANEDIOIC ACID,,Glutamate carboxypeptidase 2,FOLH1,,unknown
1-butanoyl-N-(4-carbamimidoylbenzyl)-L-prolinamide,,Prothrombin,F2,,unknown
"N-[amino(imino)methyl]-2-(2,5-diphenyl-1H-pyrrol-1-yl)acetamide",,Beta-secretase 1,BACE1,,unknown
"(1-HYDROXYNONANE-1,1-DIYL)BIS(PHOSPHONIC ACID)",,Geranylgeranyl pyrophosphate synthase,GGPS1,,unknown
"10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine",,3-phosphoinositide-dependent protein kinase 1,PDPK1,,unknown
N-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamide,,Mitogen-activated protein kinase 10,MAPK10,,unknown
(1R)-3-chloro-1-phenylpropan-1-ol,,Lysozyme,E,,unknown
N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide,,Prothrombin,F2,,unknown
"4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL",,Estrogen receptor beta,ESR2,,unknown
4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide,,Vascular endothelial growth factor receptor 2,KDR,,unknown
"N-(TRANS-4-{(1S,2S)-2-AMINO-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-1-METHYL-3-OXOPROPYL}CYCLOHEXYL)-N-METHYLACETAMIDE",,Dipeptidyl peptidase 4,DPP4,,unknown
"N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide",,Mitogen-activated protein kinase 14,MAPK14,,unknown
(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide,,Protein S100-B,S100B,,unknown
N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide,,Prothrombin,F2,,unknown
(3S)-1-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}pyrrolidine-3-thiol,,Disintegrin and metalloproteinase domain-containing protein 17,ADAM17,,unknown
N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide,,Cyclin-A2,CCNA2,,unknown
N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide,,Cyclin-dependent kinase 2,CDK2,,unknown
N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide,,A disintegrin and metalloproteinase with thrombospondin motifs 5,ADAMTS5,,unknown
"(2S,3S)-3-(4-fluorophenyl)-2,3-dihydroxypropanoic acid",,"MIO-dependent tyrosine 2,3-aminomutase",,,unknown
1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide,,Prothrombin,F2,,unknown
2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE,,Cyclin-A2,CCNA2,,unknown
2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE,,Cyclin-dependent kinase 2,CDK2,,unknown
"N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]naphthalene-2-carbohydrazide",,3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ,fabZ,,unknown
"4-chloro-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide",,3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ,fabZ,,unknown
(3R)-3-ethyl-N-[(4-methylphenyl)sulfonyl]-L-aspartic acid,,Chymotrypsin-like elastase family member 1,CELA1,,unknown
(2S)-2-HYDROXY-2H-CHROMENE-2-CARBOXYLIC ACID,,2-hydroxychromene-2-carboxylate isomerase,nahD,,unknown
2-CHLORO-5-(3-CHLORO-PHENYL)-6-[(4-CYANO-PHENYL)-(3-METHYL-3H-IMIDAZOL-4-YL)- METHOXYMETHYL]-NICOTINONITRILE,,Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha,FNTA,,unknown
2-CHLORO-5-(3-CHLORO-PHENYL)-6-[(4-CYANO-PHENYL)-(3-METHYL-3H-IMIDAZOL-4-YL)- METHOXYMETHYL]-NICOTINONITRILE,,Protein farnesyltransferase subunit beta,FNTB,,unknown
"2-(cycloheptylmethyl)-1,1-dioxido-1-benzothiophen-6-yl sulfamate",,Carbonic anhydrase 2,CA2,,unknown
"3,4-bis(7-chloro-1H-indol-3-yl)-1H-pyrrole-2,5-dicarboxylic acid",,Cytochrome P450,staP,,unknown
"N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
(2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
(2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
"N-[(1R,2R,3E)-2-hydroxy-1-(hydroxymethyl)heptadec-3-en-1-yl]acetamide",,Neutral ceramidase,,,unknown
"5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"(5-(aminomethyl)-2H-spiro[benzofuran-3,4'-piperidine]-1'-yl)(5-(phenylethynyl)furan-2-yl)methanone",,Tryptase beta-2,TPSB2,,unknown
"3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide",,Serine/threonine-protein kinase PLK1,PLK1,,unknown
"5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
Hexylphosphonic acid (R)-2-methyl-3-phenylpropyl ester,,Lipase,lipA,,unknown
Hexylphosphonic acid (S)-2-methyl-3-phenylpropyl ester,,Lipase,lipA,,unknown
"6-ETHYL-5-[9-(3-METHOXYPROPYL)-9H-CARBAZOL-2-YL]PYRIMIDINE-2,4-DIAMINE",,Renin,REN,,unknown
"1,1'-HEXANE-1,6-DIYLBIS(1H-IMIDAZOLE)",,Azurin,azu,,unknown
"2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"2-CHLORO-N-(3-CYANO-5,6-DIHYDRO-4H-CYCLOPENTA[B]THIOPHEN-2-YL)-5-DIETHYLSULFAMOYL-BENZAMIDE",,UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase,murF,,unknown
"N-{2-[(4'-CYANO-1,1'-BIPHENYL-4-YL)OXY]ETHYL}-N'-HYDROXY-N-METHYLUREA",,Neutrophil collagenase,MMP8,,unknown
"7A-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7A-tetrahydro-1H-pyrrolo[1,2-A]pyrrole-7-carbonitrile",,Integrin alpha-L,ITGAL,,unknown
"4,4'-PROPANE-2,2-DIYLDIPHENOL",,Estrogen-related receptor gamma,ESRRG,,unknown
"5-hydroxy-4-(7-methoxy-1,1-dioxido-2H-1,2,4-benzothiadiazin-3-yl)-2-(3-methylbutyl)-6-phenylpyridazin-3(2H)-one",,Genome polyprotein,,,unknown
"1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA",,Cyclin-dependent kinase 2,CDK2,,unknown
(2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
"N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]-4-methoxybenzohydrazide",,3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ,fabZ,,unknown
"5-(dodecylthio)-1H-1,2,3-triazole-4-carboxylic acid",,Hydroxyacid oxidase 1,HAO1,,unknown
(2S)-2-(1H-indol-3-yl)hexanoic acid,,S-phase kinase-associated protein 1,SKP1,,unknown
(2S)-2-(1H-indol-3-yl)pentanoic acid,,S-phase kinase-associated protein 1,SKP1,,unknown
(2S)-8-[(tert-butoxycarbonyl)amino]-2-(1H-indol-3-yl)octanoic acid,,S-phase kinase-associated protein 1,SKP1,,unknown
"(5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol",,Cyclin-dependent kinase 2,CDK2,,unknown
"(1R,2R,3R,4S,5R)-4-(BENZYLAMINO)-5-(METHYLTHIO)CYCLOPENTANE-1,2,3-TRIOL",,Alpha-mannosidase 2,MAN2A1,,unknown
"2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
2-(4-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)PHENYL)ETHANAMIDE,,Lactotransferrin,LTF,,unknown
2-(4-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)PHENYL)ETHANAMIDE,,Group IIE secretory phospholipase A2,PLA2G2E,,unknown
2-HYDROXY-5-{[(1E)-2-PHENYLETHYLIDENE]AMINO}-L-TYROSINE,,Phenylethylamine oxidase,,,unknown
{4-[2-BENZYL-3-METHOXY-2-(METHOXYCARBONYL)-3-OXOPROPYL]PHENYL}SULFAMIC ACID,,Receptor-type tyrosine-protein phosphatase beta,PTPRB,,unknown
"4-[(1E,7E)-8-(2,6-DIOXO-1,2,3,6-TETRAHYDROPYRIMIDIN-4-YL)-3,6-DIOXA-2,7-DIAZAOCTA-1,7-DIEN-1-YL]BENZOIC ACID",,Uracil-DNA glycosylase,UNG,,unknown
"N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide",,Mitogen-activated protein kinase 14,MAPK14,,unknown
"(3,3-dimethylpiperidin-1-yl)(6-(3-fluoro-4-methylphenyl)pyridin-2-yl)methanone",,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
"(2S,3S)-4-cyclopropyl-3-{(3R,5R)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-yl}-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine",,Dipeptidyl peptidase 4,DPP4,,unknown
"(2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine",,Dipeptidyl peptidase 4,DPP4,,unknown
N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide,,Hepatocyte growth factor receptor,MET,,unknown
D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide,,Prothrombin,F2,,unknown
"2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide",,Hepatocyte growth factor receptor,MET,,unknown
"[(5R)-5-(2,3-dibromo-5-ethoxy-4-hydroxybenzyl)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid",,DNA polymerase III subunit beta,dnaN,,unknown
"N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide",,Serine/threonine-protein kinase B-raf,BRAF,,unknown
"N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide",,Serine/threonine-protein kinase B-raf,BRAF,,unknown
"(3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine",,"Nitric oxide synthase, endothelial",NOS3,,unknown
4-({4-[(4-methoxypyridin-2-yl)amino]piperidin-1-yl}carbonyl)benzonitrile,,"Nitric oxide synthase, inducible",NOS2,,unknown
"(2S)-2-methyl-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine",,"Nitric oxide synthase, inducible",NOS2,,unknown
2-[(5-hex-1-yn-1-ylfuran-2-yl)carbonyl]-N-methylhydrazinecarbothioamide,,Protein S100-B,S100B,,unknown
D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide,,Prothrombin,F2,,unknown
"9-HYDROXY-6-(3-HYDROXYPROPYL)-4-(2-METHOXYPHENYL)PYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE",,Wee1-like protein kinase,WEE1,,unknown
"(3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine",,"Nitric oxide synthase, inducible",NOS2,,unknown
"4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PYRIMIDINE",,"Nitric oxide synthase, inducible",NOS2,,unknown
"2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL",,Nuclear receptor coactivator 1,NCOA1,,unknown
"2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL",,Estrogen receptor beta,ESR2,,unknown
N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE,,Mitogen-activated protein kinase 1,MAPK1,,unknown
N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE,,Mitogen-activated protein kinase 10,MAPK10,,unknown
"(3S)-1-(1,3-BENZODIOXOL-5-YLMETHYL)-3-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PIPERIDINE",,"Nitric oxide synthase, inducible",NOS2,,unknown
"6-AMINO-3,7-DIHYDRO-IMIDAZO[4,5-G]QUINAZOLIN-8-ONE",,Queuine tRNA-ribosyltransferase,tgt,,unknown
TERT-BUTYL 4-({[4-(BUT-2-YN-1-YLAMINO)PHENYL]SULFONYL}METHYL)-4-[(HYDROXYAMINO)CARBONYL]PIPERIDINE-1-CARBOXYLATE,,Collagenase 3,MMP13,,unknown
"2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole",,Glycogen synthase kinase-3 beta,GSK3B,,unknown
"(3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinoxalin-2-ylcarbonyl)pyrrolidin-3-amine",,Dipeptidyl peptidase 4,DPP4,,unknown
"(3R)-8-(dioxidosulfanyl)-3-methyl-1,2,3,4-tetrahydroquinoline",,Prothrombin,F2,,unknown
"(5S)-2-{[(1S)-1-(4-fluorophenyl)ethyl]amino}-5-(1-hydroxy-1-methylethyl)-5-methyl-1,3-thiazol-4(5H)-one",,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
5-ETHYL-3-[(2-METHOXYETHYL)METHYLAMINO]-6-METHYL-4-(3-METHYLBENZYL)PYRIDIN-2(1H)-ONE,,Gag-Pol polyprotein,gag-pol,,unknown
"N-[(5R,14R)-5-AMINO-5,14-DIMETHYL-4-OXO-3-OXA-18-AZATRICYCLO[15.3.1.1~7,11~]DOCOSA-1(21),7(22),8,10,17,19-HEXAEN-19-YL]-N-METHYLMETHANESULFONAMIDE",,Beta-secretase 1,BACE1,,unknown
"N-{3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl}furan-2-carboxamide",,Mitogen-activated protein kinase 9,MAPK9,,unknown
"(7R,8R)-8-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydroimidazo[1,2-a:4,5-c']dipyridin-7-amine",,Dipeptidyl peptidase 4,DPP4,,unknown
3-Hydroxypropyl 3-[(7-carbamimidoyl-1-naphthyl)carbamoyl]benzenesulfonate,,Coagulation factor XI,F11,,unknown
"(1R)-2-{[AMINO(IMINO)METHYL]AMINO}-1-{4-[(4R)-4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL]PHENYL}ETHYL NICOTINATE",,Coagulation factor XI,F11,,unknown
"2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE",,Cyclin-dependent kinase 2,CDK2,,unknown
3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE,,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"(1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE",,Macrophage metalloelastase,MMP12,,unknown
D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide,,Prothrombin,F2,,unknown
(2-{[(4-BROMO-2-FLUOROBENZYL)AMINO]CARBONYL}-5-CHLOROPHENOXY)ACETIC ACID,,Aldose reductase,AKR1B1,,unknown
"4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]-6-METHYLPYRIMIDINE",,"Nitric oxide synthase, inducible",NOS2,,unknown
(5-CHLORO-2-{[(3-NITROBENZYL)AMINO]CARBONYL}PHENOXY)ACETIC ACID,,Aldose reductase,AKR1B1,,unknown
"3-Fluoro-4-{[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino}benzoic acid",,Retinoic acid receptor gamma,RARG,,unknown
2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL,,Estrogen receptor beta,ESR2,,unknown
5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE,,3-phosphoinositide-dependent protein kinase 1,PDPK1,,unknown
"2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"(2E)-3-{3-[(5-ETHYL-3-IODO-6-METHYL-2-OXO-1,2-DIHYDROPYRIDIN-4-YL)OXY]PHENYL}ACRYLONITRILE",,Gag-Pol polyprotein,gag-pol,,unknown
"(3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol",,Estrogen receptor beta,ESR2,,unknown
(2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL,,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
2-(cyclohexylamino)benzoic acid,,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
(2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide,,Androgen receptor,AR,,unknown
"2-amino-7-fluoro-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxamide",,DNA ligase,ligA,,unknown
"N-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-7-yl)-2-methylpropyl]-4-phenoxybenzamide",,DNA ligase,ligA,,unknown
"N-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-7-yl)-2-methylpropyl]-4-phenoxybenzamide",,DNA ligase,ligA,,unknown
"7-amino-2-tert-butyl-4-{[2-(1H-imidazol-4-yl)ethyl]amino}pyrido[2,3-d]pyrimidine-6-carboxamide",,DNA ligase,ligA,,unknown
"7-amino-2-tert-butyl-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrido[2,3-d]pyrimidine-6-carboxamide",,DNA ligase,ligA,,unknown
"3-bromo-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide",,3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ,fabZ,,unknown
"(2R,3R,4S,5R)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol",,BAG family molecular chaperone regulator 1,BAG1,,unknown
"(2R,3R,4S,5R)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol",,Heat shock cognate 71 kDa protein,HSPA8,,unknown
"2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide",,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,,unknown
"N-[(2R)-5-(aminosulfonyl)-2,3-dihydro-1H-inden-2-yl]-2-propylpentanamide",,Carbonic anhydrase 2,CA2,,unknown
(2R)-1-[(4-tert-butylphenyl)sulfonyl]-2-methyl-4-(4-nitrophenyl)piperazine,,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
"5-[(phenylsulfonyl)amino]-1,3,4-thiadiazole-2-sulfonamide",,Carbonic anhydrase 2,CA2,,unknown
"3,5-DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER",,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,,unknown
5'-S-ethyl-5'-thioadenosine,,Adenosylhomocysteinase,ahcY,,unknown
2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
(2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL,,Cyclin-dependent kinase 2,CDK2,,unknown
"2-[2-(1H-tetrazol-5-yl)ethyl]-1H-isoindole-1,3(2H)-dione",,Beta-lactamase,blaCTX-M-9a,,unknown
"2-(6-{[(3-chloro-2-methylphenyl)sulfonyl]amino}pyridin-2-yl)-N,N-diethylacetamide",,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
(3S)-1-(2-hydroxyphenyl)-5-oxopyrrolidine-3-carboxylic acid,,Beta-lactamase,ampC,,unknown
"5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione",,Glycogen synthase kinase-3 beta,GSK3B,,unknown
"N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOXAZIN-4-YL]ETHYL}ACETAMIDE",,Renin,REN,,unknown
3-(INDOL-3-YL) LACTATE,,Hydroxyacid oxidase 1,HAO1,,unknown
3-(INDOL-3-YL) LACTATE,,(S)-mandelate dehydrogenase,mdlB,,unknown
"1-(CYCLOHEXYLAMINO)-3-(6-METHYL-3,4-DIHYDRO-1H-CARBAZOL-9(2H)-YL)PROPAN-2-OL",,Glycylpeptide N-tetradecanoyltransferase 2,NMT2,,unknown
"N-{3-[4-hydroxy-1-(3-methylbutyl)-2-oxo-1,2-dihydropyrrolo[1,2-b]pyridazin-3-yl]-1,1-dioxido-2H-1,2,4-benzothiadiazin-7-yl}methanesulfonamide",,Genome polyprotein,,,unknown
"{3-[(4,5,7-TRIFLUORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-1H-INDOL-1-YL}ACETIC ACID",,Aldose reductase,AKR1B1,,unknown
"(4R)-4-(3-HYDROXYPHENYL)-N,N,7,8-TETRAMETHYL-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE",,Kinesin-like protein KIF11,KIF11,,unknown
"5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine",,Cyclin-dependent kinase 2,CDK2,,unknown
"2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
"(2S,3S)-3-{3-[4-(METHYLSULFONYL)PHENYL]-1,2,4-OXADIAZOL-5-YL}-1-OXO-1-PYRROLIDIN-1-YLBUTAN-2-AMINE",,Dipeptidyl peptidase 4,DPP4,,unknown
"(4-{4-[(TERT-BUTOXYCARBONYL)AMINO]-2,2-BIS(ETHOXYCARBONYL)BUTYL}PHENYL)SULFAMIC ACID",,Receptor-type tyrosine-protein phosphatase beta,PTPRB,,unknown
3-Hydroxyhippuric acid,,Kynureninase,KYNU,,unknown
(2S)-2-{3-[({[2-fluoro-4-(trifluoromethyl)phenyl]carbonyl}amino)methyl]-4-methoxybenzyl}butanoic acid,,Peroxisome proliferator-activated receptor delta,PPARD,,unknown
"(R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)GUANIDINE",,Coagulation factor XI,F11,,unknown
"(1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE",,Dipeptidyl peptidase 4,DPP4,,unknown
"5,5-dimethyl-2-morpholin-4-yl-5,6-dihydro-1,3-benzothiazol-7(4H)-one",,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,,unknown
6-CARBAMIMIDOYL-4-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-NAPHTHALENE-2-CARBOXYLIC ACID METHYL ESTER,,Coagulation factor XI,F11,,unknown
3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE,,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
6-[(Z)-AMINO(IMINO)METHYL]-N-[3-(CYCLOPENTYLOXY)PHENYL]-2-NAPHTHAMIDE,,Urokinase-type plasminogen activator,PLAU,,unknown
"(R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENYL)GUANIDINE",,Coagulation factor XI,F11,,unknown
"(3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
3-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}propane-1-thiol,,Disintegrin and metalloproteinase domain-containing protein 17,ADAM17,,unknown
"N-(2,2,2-TRIFLUOROETHYL)-N-{4-[2,2,2-TRIFLUORO-1-HYDROXY-1-(TRIFLUOROMETHYL)ETHYL]PHENYL}BENZENESULFONAMIDE",,Oxysterols receptor LXR-beta,NR1H2,,unknown
"N-(2,2,2-TRIFLUOROETHYL)-N-{4-[2,2,2-TRIFLUORO-1-HYDROXY-1-(TRIFLUOROMETHYL)ETHYL]PHENYL}BENZENESULFONAMIDE",,Nuclear receptor coactivator 2,NCOA2,,unknown
"N-(2,2,2-TRIFLUOROETHYL)-N-{4-[2,2,2-TRIFLUORO-1-HYDROXY-1-(TRIFLUOROMETHYL)ETHYL]PHENYL}BENZENESULFONAMIDE",,Retinoic acid receptor RXR-beta,RXRB,,unknown
"N-(2,2,2-TRIFLUOROETHYL)-N-{4-[2,2,2-TRIFLUORO-1-HYDROXY-1-(TRIFLUOROMETHYL)ETHYL]PHENYL}BENZENESULFONAMIDE",,Oxysterols receptor LXR-alpha,NR1H3,,unknown
"N-(2,2,2-TRIFLUOROETHYL)-N-{4-[2,2,2-TRIFLUORO-1-HYDROXY-1-(TRIFLUOROMETHYL)ETHYL]PHENYL}BENZENESULFONAMIDE",,Nuclear receptor coactivator 1,NCOA1,,unknown
"N-(2,2,2-TRIFLUOROETHYL)-N-{4-[2,2,2-TRIFLUORO-1-HYDROXY-1-(TRIFLUOROMETHYL)ETHYL]PHENYL}BENZENESULFONAMIDE",,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
"(2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE",,Dipeptidyl peptidase 4,DPP4,,unknown
"1,1,1,3,3,3-HEXAFLUORO-2-{4-[(2,2,2-TRIFLUOROETHYL)AMINO]PHENYL}PROPAN-2-OL",,Oxysterols receptor LXR-beta,NR1H2,,unknown
beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide,,Prothrombin,F2,,unknown
"N-(6,7,9,10,17,18,20,21-octahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecin-2-yl)acetamide",,Outer membrane protein F,ompF,,unknown
2-{[N-(2-ACETYL-5-CHLORO-4-FLUOROPHENYL)GLYCYL]AMINO}BENZOIC ACID,,Genome polyprotein,,,unknown
"4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL",,Nuclear receptor coactivator 2,NCOA2,,unknown
"4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL",,Estrogen receptor alpha,ESR1,,unknown
"4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL",,Estrogen receptor alpha,ESR1,,unknown
"4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL",,Nuclear receptor coactivator 2,NCOA2,,unknown
(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide,,Trypsin-1,PRSS1,,unknown
(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide,,Prothrombin,F2,,unknown
N-[amino(imino)methyl]-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)-3-thienyl]acetamide,,Beta-secretase 1,BACE1,,unknown
(3S)-N-(3-CHLORO-2-METHYLPHENYL)-1-CYCLOHEXYL-5-OXOPYRROLIDINE-3-CARBOXAMIDE,,Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,,unknown
(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide,,Trypsin-1,PRSS1,,unknown
(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide,,Prothrombin,F2,,unknown
"(2S,3S)-3-AMINO-4-(3,3-DIFLUOROPYRROLIDIN-1-YL)-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YLCYCLOHEXYL)BUTANAMIDE",,Dipeptidyl peptidase 4,DPP4,,unknown
"{3-[(5-CHLORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL}ACETIC ACID",,Aldose reductase,AKR1B1,,unknown
"1-(2,2'-bithiophen-5-yl)methanamine",,Leukotriene A-4 hydrolase,LTA4H,,unknown
(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide,,Trypsin-1,PRSS1,,unknown
(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide,,Prothrombin,F2,,unknown
"6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE",,Poly [ADP-ribose] polymerase 1,PARP1,,unknown
"4-tert-butyl-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide",,3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ,fabZ,,unknown
"4-bromo-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide",,3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ,fabZ,,unknown
N-[4-(benzyloxy)phenyl]glycinamide,,Leukotriene A-4 hydrolase,LTA4H,,unknown
"4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
PD-0325901,,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,,unknown
(2S)-2-amino-5-oxo-5-[(4-phenylmethoxyphenyl)amino]pentanoic acid,,Leukotriene A-4 hydrolase,LTA4H,,unknown
2-(4-METHYLPHENOXY)ETHYLPHOSPHINATE,,Thermolysin,npr,,unknown
4-amino-N-[4-(benzyloxy)phenyl]butanamide,,Leukotriene A-4 hydrolase,LTA4H,,unknown
2-[2-(4-CHLORO-PHENYLSULFANYL)-ACETYLAMINO]-3-(4-GUANIDINO-PHENYL)-PROPIONAMIDE,,Prothrombin,F2,,unknown
4-(DIMETHYLAMINO)BUTYL IMIDOTHIOCARBAMATE,,Histamine N-methyltransferase,HNMT,,unknown
(1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
(1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
"4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID",,Bcl-2-like protein 1,BCL2L1,,unknown
(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid,,O-methyltransferase,,,unknown
4-(4-FLUOROBENZYL)PIPERIDINE,,Beta-secretase 1,BACE1,,unknown
"(4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid",,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
N-[(4-HYDROXY-8-IODOISOQUINOLIN-3-YL)CARBONYL]GLYCINE,,Egl nine homolog 1,EGLN1,,unknown
"(2S)-6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2-(3,5-DIFLUOROPHENYL)-4-(3-METHOXYPROPYL)-2H-1,4-BENZOXAZIN-3(4H)-ONE",,Renin,REN,,unknown
4-[(METHYLSULFONYL)AMINO]BENZOIC ACID,,Beta-lactamase,ampC,,unknown
"N-(4-chlorobenzyl)-N-methylbenzene-1,4-disulfonamide",,Carbonic anhydrase 13,CA13,,unknown
1-(2-DEOXY-5-O-PHOSPHONO-BETA-D-ERYTHRO-PENTOFURANOSYL)-4-METHYL-1H-INDOLE,,Uracil-DNA glycosylase,UNG,,unknown
"5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE",,Matrix metalloproteinase-9,MMP9,,unknown
Hymecromone,,Arylsulfate sulfotransferase,assT,,unknown
1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL,,Nuclear receptor coactivator 1,NCOA1,,unknown
1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL,,Estrogen receptor beta,ESR2,,unknown
"N4-(N,N-DIPHENYLCARBAMOYL)-AMINOGUANIDINE",,Prothrombin,F2,,unknown
"4-({4-[(4-AMINOBUT-2-YNYL)OXY]PHENYL}SULFONYL)-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDE",,Disintegrin and metalloproteinase domain-containing protein 17,ADAM17,,unknown
1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine,,Urokinase-type plasminogen activator,PLAU,,unknown
N-(4-METHYLBENZOYL)-4-BENZYLPIPERIDINE,,Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,,unknown
"(2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE",,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
"4-(6-{[(1R)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid",,Death-associated protein kinase 3,DAPK3,,unknown
O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE,,Cyclin-A2,CCNA2,,unknown
O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE,,Cyclin-dependent kinase 2,CDK2,,unknown
"{4-[2,2-BIS(5-METHYL-1,2,4-OXADIAZOL-3-YL)-3-PHENYLPROPYL]PHENYL}SULFAMIC ACID",,Receptor-type tyrosine-protein phosphatase beta,PTPRB,,unknown
"N7-BUTYL-N2-(5-CHLORO-2-METHYLPHENYL)-5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-2,7-DIAMINE",,Prothrombin,F2,,unknown
"(2R)-1-(2,6-dimethylphenoxy)propan-2-amine",,Urokinase-type plasminogen activator,PLAU,,unknown
4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide,,Trypsin-1,PRSS1,,unknown
(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide,,Prothrombin,F2,,unknown
1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA,,3-phosphoinositide-dependent protein kinase 1,PDPK1,,unknown
D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide,,Prothrombin,F2,,unknown
"5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
"(2S,3S)-3-AMINO-4-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-5-YLCYCLOHEXYL)BUTANAMIDE",,Dipeptidyl peptidase 4,DPP4,,unknown
(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-{(R)-HYDROXY[(1R)-2-METHYL-1-{[(3-PHENYLPROPYL)SULFONYL]AMINO}PROPYL]PHOSPHORYL}PROPANOIC ACID,,Carboxypeptidase B,CPB1,,unknown
(2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE,,Cyclin-A2,CCNA2,,unknown
(2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE,,Cyclin-dependent kinase 2,CDK2,,unknown
Neflamapimod,,Mitogen-activated protein kinase 14,MAPK14,,unknown
3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid,,Aldose reductase,AKR1B1,,unknown
"5-[(3R)-3-(5-methoxybiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine",,Dihydrofolate reductase,DHFR,,unknown
"5-[(3R)-3-(5-methoxybiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine",,Dihydrofolate reductase (dfrB),dfrB,,unknown
"5-[(3R)-3-(5-methoxy-4'-methylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine",,Dihydrofolate reductase,DHFR,,unknown
"5-[(3R)-3-(5-methoxy-3',5'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine",,Dihydrofolate reductase,DHFR,,unknown
"5-[(3R)-3-(5-methoxy-3',5'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine",,Dihydrofolate reductase (dfrB),dfrB,,unknown
D-phenylalanyl-N-benzyl-L-prolinamide,,Prothrombin,F2,,unknown
"5-[(3R)-3-(5-methoxy-2',6'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine",,Dihydrofolate reductase,DHFR,,unknown
(2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE,,Disintegrin and metalloproteinase domain-containing protein 17,ADAM17,,unknown
"2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE",,Tyrosine-protein kinase Lck,LCK,,unknown
"methyl (1R,2S)-2-(hydroxycarbamoyl)-1-{4-[(2-methylquinolin-4-yl)methoxy]benzyl}cyclopropanecarboxylate",,Disintegrin and metalloproteinase domain-containing protein 17,ADAM17,,unknown
"(6S)-1-chloro-3-[(4-fluorobenzyl)oxy]-6-(pyrrolidin-1-ylcarbonyl)pyrrolo[1,2-a]pyrazin-4(6H)-one",,Prolyl endopeptidase,PREP,,unknown
"(7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one",,Glycogen synthase kinase-3 beta,GSK3B,,unknown
4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME,,Nuclear receptor coactivator 1,NCOA1,,unknown
4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME,,Estrogen receptor beta,ESR2,,unknown
4-(4-hydroxy-3-methylphenyl)-6-phenylpyrimidin-2(5H)-one,,Serine/threonine-protein kinase pim-1,PIM1,,unknown
N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide,,TGF-beta receptor type-1,TGFBR1,,unknown
"6-methyl-5-[3-methyl-3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine",,Dihydrofolate reductase (dfrB),dfrB,,unknown
"(3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-METHYL-1,4-DIAZEPAN-2-ONE",,Dipeptidyl peptidase 4,DPP4,,unknown
(3S)-1-CYCLOHEXYL-5-OXO-N-PHENYLPYRROLIDINE-3-CARBOXAMIDE,,Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,,unknown
"(4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione",,Insulin-like growth factor 1 receptor,IGF1R,,unknown
"(5R,6S,8S)-8-[3-(AMINOMETHYL)PHENYL]-6-HYDROXY-5-ISOPROPYL-3-OXO-1-PHENYL-2,7-DIOXA-4-AZA-6-PHOSPHANONAN-9-OIC ACID 6-OXIDE",,Carboxypeptidase B,CPB1,,unknown
"5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",,Tyrosine-protein kinase SYK,SYK,,unknown
"N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCINE",,Cathepsin B,CTSB,,unknown
5-phenyl-1H-indazol-3-amine,,Tyrosine-protein kinase JAK2,JAK2,,unknown
4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide,,Tyrosine-protein kinase JAK2,JAK2,,unknown
5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE,,Cyclin-dependent kinase 2,CDK2,,unknown
"N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine",,Cyclin-A2,CCNA2,,unknown
"N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine",,Cyclin-dependent kinase 2,CDK2,,unknown
N-(5-CHLORO-BENZO[B]THIOPHEN-3-YLMETHYL)-2-[6-CHLORO-OXO-3-(2-PYRIDIN-2-YL-ETHYLAMINO)-2H-PYRAZIN-1-YL]-ACETAMIDE,,Prothrombin,F2,,unknown
5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE,,Macrophage colony-stimulating factor 1 receptor,CSF1R,,unknown
[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile,,Calcium/calmodulin-dependent protein kinase type II subunit beta,CAMK2B,,unknown
"5R-(3,4-DICHLOROPHENYLMETHYL)-3-(2-THIOPHENESULFONYLAMINO)-4-OXO-2-THIONOTHIAZOLIDINE",,Genome polyprotein,,,unknown
"5'-FLUORO-2',5'-DIDEOXYADENOSINE",,5'-fluoro-5'-deoxy-adenosine synthase,flA,,unknown
"5-(2-hydroxyethyl)nonane-1,9-diol",,Endothelin-converting enzyme 1,ECE1,,unknown
"(5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid",,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
"7-(5-DEOXY-BETA-D-RIBOFURANOSYL)-5-IODO-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE",,Adenosine kinase,ADK,,unknown
"6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-4-(3-METHOXYPROPYL)-2,2-DIMETHYL-2H-1,4-BENZOXAZIN-3(4H)-ONE",,Renin,REN,,unknown
N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide,,Beta-secretase 1,BACE1,,unknown
"(5E,13E)-11-HYDROXY-9,15-DIOXOPROSTA-5,13-DIEN-1-OIC ACID",,Prostaglandin reductase 1,PTGR1,,unknown
"(5E,13E)-11-HYDROXY-9,15-DIOXOPROSTA-5,13-DIEN-1-OIC ACID",,Prostaglandin reductase 2,PTGR2,,unknown
5-PENTYL-2-PHENOXYPHENOL,,Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,,unknown
"3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide",,Cyclin-dependent kinase 2,CDK2,,unknown
"5-[(Z)-(5-Chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N,2,4-trimethyl-1H-pyrrole-3-carboxamide",,Serine/threonine-protein kinase Nek2,NEK2,,unknown
"4'-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamide",,Dipeptidyl peptidase 4,DPP4,,unknown
(2S)-2-(3-{[AMINO(IMINO)METHYL]AMINO}PHENYL)-3-[(S)-HYDROXY(3-PHENYLPROPYL)PHOSPHORYL]PROPANOIC ACID,,Carboxypeptidase B,CPB1,,unknown
N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide,,Vascular endothelial growth factor receptor 2,KDR,,unknown
"6-(cyclohexylsulfanyl)-1-(ethoxymethyl)-5-(1-methylethyl)pyrimidine-2,4(1H,3H)-dione",,Gag-Pol polyprotein,gag-pol,,unknown
2-{[(4-CHLOROPHENOXY)ACETYL]AMINO}BENZOIC ACID,,Genome polyprotein,,,unknown
"4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE",,Aurora kinase A,AURKA,,unknown
"4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE",,Serine/threonine-protein kinase PLK1,PLK1,,unknown
6-[(5-CHLORO-3-METHYL-1-BENZOFURAN-2-YL)SULFONYL]PYRIDAZIN-3(2H)-ONE,,Aldose reductase,AKR1B1,,unknown
"(3S)-1-CYCLOHEXYL-N-(3,5-DICHLOROPHENYL)-5-OXOPYRROLIDINE-3-CARBOXAMIDE",,Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,,unknown
"(1S,3R,6S)-4-oxo-6-{4-[(2-phenylquinolin-4-yl)methoxy]phenyl}-5-azaspiro[2.4]heptane-1-carboxylic acid",,Disintegrin and metalloproteinase domain-containing protein 17,ADAM17,,unknown
3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide,,Prothrombin,F2,,unknown
(3S)-N-(3-BROMOPHENYL)-1-CYCLOHEXYL-5-OXOPYRROLIDINE-3-CARBOXAMIDE,,Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,,unknown
"(2R,3R)-7-(methylsulfonyl)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amine",,Dipeptidyl peptidase 4,DPP4,,unknown
"2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide",,Tyrosine-protein kinase SYK,SYK,,unknown
"4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL",,Estrogen receptor alpha,ESR1,,unknown
"4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL",,Nuclear receptor coactivator 2,NCOA2,,unknown
N-methyl-1-(2-thiophen-2-ylphenyl)methanamine,,Leukotriene A-4 hydrolase,LTA4H,,unknown
4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE,,Estrogen receptor beta,ESR2,,unknown
5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE,,Nuclear receptor coactivator 1,NCOA1,,unknown
"(2S,4S,5R)-1-(4-TERT-BUTYLBENZOYL)-2-ISOBUTYL-5-(1,3-THIAZOL-2-YL)PYRROLIDINE-2,4-DICARBOXYLIC ACID",,Genome polyprotein,,,unknown
"(2S,4S,5R)-1-(4-TERT-BUTYLBENZOYL)-2-ISOBUTYL-5-(1,3-THIAZOL-2-YL)PYRROLIDINE-2,4-DICARBOXYLIC ACID",,RNA-dependent RNA-polymerase,NS5b,,unknown
"(2S,4S,5R)-2-ISOBUTYL-5-(2-THIENYL)-1-[4-(TRIFLUOROMETHYL)BENZOYL]PYRROLIDINE-2,4-DICARBOXYLIC ACID",,Genome polyprotein,,,unknown
"(2S,4S,5R)-2-ISOBUTYL-5-(2-THIENYL)-1-[4-(TRIFLUOROMETHYL)BENZOYL]PYRROLIDINE-2,4-DICARBOXYLIC ACID",,RNA-dependent RNA-polymerase,NS5b,,unknown
6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE,,Macrophage colony-stimulating factor 1 receptor,CSF1R,,unknown
6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE,,Cyclin-A2,CCNA2,,unknown
6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE,,Cyclin-dependent kinase 2,CDK2,,unknown
"(1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE",,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
"(1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE",,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,"Tyrosine--tRNA ligase, cytoplasmic",YARS,,unknown
6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE,,Beta-secretase 1,BACE1,,unknown
2-(4-HYDROXY-5-PHENYL-1H-PYRAZOL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE,,Coagulation factor VII,F7,,unknown
2-(4-HYDROXY-5-PHENYL-1H-PYRAZOL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE,,Tissue factor,F3,,unknown
"(8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid",,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
"(8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid",,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
"3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",,Cyclin-dependent kinase 2,CDK2,,unknown
(2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE,,Prothrombin,F2,,unknown
(2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE,,Coagulation factor X,F10,,unknown
N-(7-CARBAMIMIDOYL-NAPHTHALEN-1-YL)-3-HYDROXY-2-METHYL-BENZAMIDE,,Coagulation factor XI,F11,,unknown
"(5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"2-METHYL-2-(4-{[({4-METHYL-2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL}CARBONYL)AMINO]METHYL}PHENOXY)PROPANOIC ACID",,Nuclear receptor coactivator 1,NCOA1,,unknown
"2-METHYL-2-(4-{[({4-METHYL-2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL}CARBONYL)AMINO]METHYL}PHENOXY)PROPANOIC ACID",,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
"(11S)-8-CHLORO-11-[1-(METHYLSULFONYL)PIPERIDIN-4-YL]-6-PIPERAZIN-1-YL-11H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDINE",,Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha,FNTA,,unknown
"(11S)-8-CHLORO-11-[1-(METHYLSULFONYL)PIPERIDIN-4-YL]-6-PIPERAZIN-1-YL-11H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDINE",,Protein farnesyltransferase subunit beta,FNTB,,unknown
"N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide",,Mitogen-activated protein kinase 10,MAPK10,,unknown
"6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE",,C-Jun-amino-terminal kinase-interacting protein 1,MAPK8IP1,,unknown
"6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE",,Mitogen-activated protein kinase 8,MAPK8,,unknown
"BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE",,Cathepsin B,CTSB,,unknown
"N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
"(2,2-DIPHOSPHONOETHYL)(DODECYL)DIMETHYLPHOSPHONIUM",,Geranylgeranyl pyrophosphate synthase,GGPS1,,unknown
(3S)-N-(5-CHLORO-2-METHYLPHENYL)-1-CYCLOHEXYL-5-OXOPYRROLIDINE-3-CARBOXAMIDE,,Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,,unknown
"METHYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE",,Cathepsin B,CTSB,,unknown
"N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ALANINE",,Cathepsin B,CTSB,,unknown
"N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ISOLEUCINE",,Cathepsin B,CTSB,,unknown
"N-[4-(2-CHLOROPHENYL)-1,3-DIOXO-1,2,3,6-TETRAHYDROPYRROLO[3,4-C]CARBAZOL-9-YL]FORMAMIDE",,Wee1-like protein kinase,WEE1,,unknown
4-[(5-{[4-(3-CHLOROPHENYL)-3-OXOPIPERAZIN-1-YL]METHYL}-1H-IMIDAZOL-1-YL)METHYL]BENZONITRILE,,Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha,FNTA,,unknown
4-[(5-{[4-(3-CHLOROPHENYL)-3-OXOPIPERAZIN-1-YL]METHYL}-1H-IMIDAZOL-1-YL)METHYL]BENZONITRILE,,Protein farnesyltransferase subunit beta,FNTB,,unknown
4-[(5-{[4-(3-CHLOROPHENYL)-3-OXOPIPERAZIN-1-YL]METHYL}-1H-IMIDAZOL-1-YL)METHYL]BENZONITRILE,,Geranylgeranyl transferase type-1 subunit beta,PGGT1B,,unknown
1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA,,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"3-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-5-METHOXY-1,1'-BIPHENYL-2-OLATE",,Trypsin-1,PRSS1,,unknown
3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE,,Estrogen receptor beta,ESR2,,unknown
3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE,,Nuclear receptor coactivator 1,NCOA1,,unknown
"N-({(2S,3S)-3-[(BENZYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINE",,Cathepsin B,CTSB,,unknown
Veliparib,,Poly [ADP-ribose] polymerase 1,PARP1,,unknown
Veliparib,,Poly [ADP-ribose] polymerase 2,PARP2,,unknown
N-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}-5-methyl-D-tryptophan,,Disintegrin and metalloproteinase domain-containing protein 17,ADAM17,,unknown
"3-{[(1R)-1-phenylethyl]amino}-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione",,MAP kinase-activated protein kinase 2,MAPKAPK2,,unknown
"N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE",,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL,,Estrogen receptor beta,ESR2,,unknown
3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL,,Nuclear receptor coactivator 1,NCOA1,,unknown
{4-[(2R)-pyrrolidin-2-ylmethoxy]phenyl}(4-thiophen-3-ylphenyl)methanone,,Leukotriene A-4 hydrolase,LTA4H,,unknown
Nesbuvir,,Genome polyprotein,,,unknown
Nesbuvir,,Genome polyprotein,,,unknown
7-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1H-benzimidazole-5-carbonitrile,,Dipeptidyl peptidase 4,DPP4,,unknown
"7-carboxy-5-hydroxy-12,13-dihydro-6H-indolo[2,3-a]pyrrolo[3,4-c]carbazole",,Putative FAD-monooxygenase,rbmD,,unknown
"(4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile",,Death-associated protein kinase 3,DAPK3,,unknown
"(4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile",,Serine/threonine-protein kinase pim-1,PIM1,,unknown
"(3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE",,"Nitric oxide synthase, endothelial",NOS3,,unknown
"5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE",,Renin,REN,,unknown
6-[2-(3'-METHOXYBIPHENYL-3-YL)ETHYL]PYRIDIN-2-AMINE,,Beta-secretase 1,BACE1,,unknown
"(2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE",,Matrix metalloproteinase-9,MMP9,,unknown
"[2'-HYDROXY-3'-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-BIPHENYL-3-YLMETHYL]-UREA",,Coagulation factor VII,F7,,unknown
"[2'-HYDROXY-3'-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-BIPHENYL-3-YLMETHYL]-UREA",,Tissue factor,F3,,unknown
"7-PYRIDIN-2-YL-N-(3,4,5-TRIMETHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE",,Focal adhesion kinase 1,PTK2,,unknown
"N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine",,Ephrin type-B receptor 4,EPHB4,,unknown
"N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3,4,5- TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINE",,Ephrin type-B receptor 4,EPHB4,,unknown
"N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE",,Ephrin type-B receptor 4,EPHB4,,unknown
"3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide",,Ephrin type-B receptor 4,EPHB4,,unknown
"N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine",,Ephrin type-B receptor 4,EPHB4,,unknown
"N-[3-[[4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL]AMINO]PHENYL]METHANESULFONAMIDE",,Ephrin type-B receptor 4,EPHB4,,unknown
"N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-MORPHOLIN-4-YLPHENYL)PYRIMIDINE-2,4-DIAMINE",,Ephrin type-B receptor 4,EPHB4,,unknown
"3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE",,Ephrin type-B receptor 4,EPHB4,,unknown
"4-(2-chlorophenyl)-8-(2-hydroxyethyl)-6-methylpyrrolo[3,4-e]indole-1,3(2H,6H)-dione",,Wee1-like protein kinase,WEE1,,unknown
(R)-pyridin-4-yl[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanol,,Leukotriene A-4 hydrolase,LTA4H,,unknown
1-(4-thiophen-2-ylphenyl)methanamine,,Leukotriene A-4 hydrolase,LTA4H,,unknown
N-benzyl-4-[(2R)-pyrrolidin-2-ylmethoxy]aniline,,Leukotriene A-4 hydrolase,LTA4H,,unknown
"THIENO[3,2-B]PYRIDINE-2-SULFONIC ACID [1-(1-AMINO-ISOQUINOLIN-7-YLMETHYL)-2-OXO-PYRROLDIN-3-YL]-AMIDE",,Coagulation factor X,F10,,unknown
1-{[N-(1-IMINO-GUANIDINO-METHYL)]SULFANYLMETHYL}-3-TRIFLUOROMETHYL-BENZENE,,Dihydrofolate reductase,folA,,unknown
"[{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE,,Mitogen-activated protein kinase 1,MAPK1,,unknown
"3-(9-HYDROXY-1,3-DIOXO-4-PHENYL-2,3-DIHYDROPYRROLO[3,4-C]CARBAZOL-6(1H)-YL)PROPANOIC ACID",,Wee1-like protein kinase,WEE1,,unknown
"8-ethyl-3,10,10-trimethyl-4,5,6,8,10,12-hexahydropyrazolo[4',3':6,7]cyclohepta[1,2-b]pyrrolo[2,3-f]indol-9(1H)-one",,Aurora kinase A,AURKA,,unknown
2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine,,TGF-beta receptor type-1,TGFBR1,,unknown
2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE,,Mitogen-activated protein kinase 8,MAPK8,,unknown
(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(R)-[(1R)-1-{[(BENZYLOXY)CARBONYL]AMINO}-2-METHYLPROPYL](HYDROXY)PHOSPHORYL]PROPANOIC ACID,,Carboxypeptidase B,CPB1,,unknown
"N-[7-(3-AMINOPHENYL)-5-METHOXY-1,3-BENZOXAZOL-2-YL]-2,5-DICHLOROBENZENESULFONAMIDE",,"Fructose-1,6-bisphosphatase 1",FBP1,,unknown
"4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one",,Dipeptidyl peptidase 4,DPP4,,unknown
"N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE",,C-Jun-amino-terminal kinase-interacting protein 1,MAPK8IP1,,unknown
"N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE",,Mitogen-activated protein kinase 8,MAPK8,,unknown
1-[(2-AMINO-4-CHLORO-5-METHYLPHENYL)SULFONYL]-L-PROLINE,,Genome polyprotein,,,unknown
"N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide",,Vascular endothelial growth factor receptor 2,KDR,,unknown
"3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1-(3-methylbutyl)quinolin-2(1H)-one",,Genome polyprotein,,,unknown
"5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE",,C-Jun-amino-terminal kinase-interacting protein 1,MAPK8IP1,,unknown
"5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE",,Mitogen-activated protein kinase 8,MAPK8,,unknown
2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE,,Prothrombin,F2,,unknown
2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE,,Coagulation factor X,F10,,unknown
2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHENESULFONAMIDE,,Prothrombin,F2,,unknown
2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHENESULFONAMIDE,,Coagulation factor X,F10,,unknown
N-ETHYL-N-ISOPROPYL-3-METHYL-5-{[(2S)-2-(PYRIDIN-4-YLAMINO)PROPYL]OXY}BENZAMIDE,,Prothrombin,F2,,unknown
5-[4-(DIMETHYLAMINO)PHENYL]-6-[(6-MORPHOLIN-4-YLPYRIDIN-3-YL)ETHYNYL]PYRIMIDIN-4-AMINE,,Adenosine kinase,ADK,,unknown
"N~3~-BENZYLPYRIDINE-2,3-DIAMINE",,Beta-secretase 1,BACE1,,unknown
"N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE",,Beta-secretase 1,BACE1,,unknown
"(3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID",,Matrix metalloproteinase-9,MMP9,,unknown
BMS-564929,,Androgen receptor,AR,,unknown
"2-(2,4-DICHLOROPHENOXY)-5-(PYRIDIN-2-YLMETHYL)PHENOL",,Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,,unknown
N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide,,Vascular endothelial growth factor receptor 1,FLT1,,unknown
5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
(2R)-2-{[(4-FLUORO-3-METHYLPHENYL)SULFONYL]AMINO}-N-HYDROXY-2-TETRAHYDRO-2H-PYRAN-4-YLACETAMIDE,,Lethal factor,lef,,unknown
5-amino-1-(4-chlorophenyl)-1H-pyrazole-4-carbonitrile,,Inorganic pyrophosphatase,ppa,,unknown
"4-(2-amino-1,3-thiazol-4-yl)phenol",,Leukotriene A-4 hydrolase,LTA4H,,unknown
benzyl (2-oxopropyl)carbamate,,Replicase polyprotein 1ab,rep,,unknown
"3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acid",,Retinoic acid receptor gamma,RARG,,unknown
2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
(5Z)-3-(4-CHLOROPHENYL)-4-HYDROXY-5-(1-NAPHTHYLMETHYLENE)FURAN-2(5H)-ONE,,UDP-N-acetylenolpyruvoylglucosamine reductase,murB,,unknown
"5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE",,Tyrosine-protein kinase Lck,LCK,,unknown
"3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
4-METHYL-PENTANOIC ACID {1-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL-PROPYL}-AMIDE,,Coagulation factor XI,F11,,unknown
"2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine",,3-phosphoinositide-dependent protein kinase 1,PDPK1,,unknown
9H-CARBAZOLE,,Ferredoxin CarAc,carAc,,unknown
9H-CARBAZOLE,,Terminal oxygenase component of carbazole,carAa,,unknown
"(9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid",,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
"N~3~-[3-(5-METHOXYPYRIDIN-3-YL)BENZYL]PYRIDINE-2,3-DIAMINE",,Beta-secretase 1,BACE1,,unknown
5-[2-(TRIFLUOROMETHOXY)PHENYL]-2-FUROIC ACID,,Methionine aminopeptidase,map,,unknown
5-(2-CHLORO-4-NITROPHENYL)-2-FUROIC ACID,,Methionine aminopeptidase,map,,unknown
ETHYL 4-[(4-CHLOROPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE,,"Nitric oxide synthase, inducible",NOS2,,unknown
N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide,,Mitogen-activated protein kinase 14,MAPK14,,unknown
5-(2-CHLOROBENZYL)-2-FUROIC ACID,,Methionine aminopeptidase,map,,unknown
5-BROMO-2-{[(4-CHLOROPHENYL)SULFONYL]AMINO}BENZOIC ACID,,Methionine aminopeptidase 2,METAP2,,unknown
"(5S)-2-{[(1S)-1-(2-fluorophenyl)ethyl]amino}-5-methyl-5-(trifluoromethyl)-1,3-thiazol-4(5H)-one",,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
"18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"2,5-DICHLORO-N-(5-CHLORO-1,3-BENZOXAZOL-2-YL)BENZENESULFONAMIDE",,"Fructose-1,6-bisphosphatase 1",FBP1,,unknown
5-METHYL-2-[(PHENYLSULFONYL)AMINO]BENZOIC ACID,,Methionine aminopeptidase 2,METAP2,,unknown
"1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"5-chloro-N-{4-[(1R)-1,2-dihydroxyethyl]phenyl}-1H-indole-2-carboxamide",,"Glycogen phosphorylase, liver form",PYGL,,unknown
"N-{1-[(1-carbamoylcyclopropyl)methyl]piperidin-4-yl}-N-cyclopropyl-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide",,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
(3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one,,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"N-[2-(4-AMINO-5,8-DIFLUORO-1,2-DIHYDROQUINAZOLIN-2-YL)ETHYL]-3-FURAMIDE",,"Nitric oxide synthase, inducible",NOS2,,unknown
"6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"2,5-DICHLORO-N-[5-METHOXY-7-(6-METHOXYPYRIDIN-3-YL)-1,3-BENZOXAZOL-2-YL]BENZENESULFONAMIDE",,"Fructose-1,6-bisphosphatase 1",FBP1,,unknown
"2-[(PHENYLSULFONYL)AMINO]-5,6,7,8-TETRAHYDRONAPHTHALENE-1-CARBOXYLIC ACID",,Methionine aminopeptidase 2,METAP2,,unknown
"2-[({2-[(1Z)-3-(DIMETHYLAMINO)PROP-1-ENYL]-4-FLUOROPHENYL}SULFONYL)AMINO]-5,6,7,8-TETRAHYDRONAPHTHALENE-1-CARBOXYLIC ACID",,Methionine aminopeptidase 2,METAP2,,unknown
"3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE,,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide",,Vascular endothelial growth factor receptor 2,KDR,,unknown
"(2-ACETYL-5-METHYLANILINO)(2,6-DIBROMOPHENYL)ACETAMIDE",,Gag-Pol polyprotein,gag-pol,,unknown
"(2-ACETYL-5-METHYLANILINO)(2,6-DIBROMOPHENYL)ACETAMIDE",,Gag-Pol polyprotein,gag-pol,,unknown
"METHYL 4-{[({[(2R,5S)-5-{[(2S)-2-(AMINOMETHYL)PYRROLIDIN-1-YL]CARBONYL}PYRROLIDIN-2-YL]METHYL}AMINO)CARBONYL]AMINO}BENZOATE",,Dipeptidyl peptidase 4,DPP4,,unknown
1-[N-4'-NITROBENZYL-N-4'-CARBOXYBUTYLAMINO]METHYLPHOSPHONIC ACID,,Ig gamma-2 chain C region,IGHG2,,unknown
trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium,,Poly [ADP-ribose] polymerase 1,PARP1,,unknown
2-(4-NITROPHENYL)ACETIC ACID,,Penicillin G acylase,pac,,unknown
"ALPHA-(2,6-DICHLOROPHENYL)-ALPHA-(2-ACETYL-5-METHYLANILINO)ACETAMIDE",,Gag-Pol polyprotein,gag-pol,,unknown
"ALPHA-(2,6-DICHLOROPHENYL)-ALPHA-(2-ACETYL-5-METHYLANILINO)ACETAMIDE",,Gag-Pol polyprotein,gag-pol,,unknown
"N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE",,Vascular endothelial growth factor receptor 2,KDR,,unknown
"N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE",,Vascular endothelial growth factor receptor 2,KDR,,unknown
"3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL",,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,,unknown
"3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL",,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL,,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"4-[4-AMINO-6-(5-CHLORO-1H-INDOL-4-YLMETHYL)-[1,3,5]TRIAZIN-2-YLAMINO]-BENZONITRILE",,Gag-Pol polyprotein,gag-pol,,unknown
5-[2-CHLORO-4-(TRIFLUOROMETHYL)PHENOXY]-2-NITROBENZOIC ACID,,Protoporphyrinogen oxidase,hemY,,unknown
5-[2-CHLORO-4-(TRIFLUOROMETHYL)PHENOXY]-2-NITROBENZOIC ACID,,Protoporphyrinogen oxidase,hemY,,unknown
"(3S)-3-hydroxy-1-methyl-2,3-dihydro-1H-indole-5,6-dione",,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,,unknown
"N~6~-cyclohexyl-N~2~-(4-morpholin-4-ylphenyl)-9H-purine-2,6-diamine",,Aurora kinase B,AURKB,,unknown
"N~6~-cyclohexyl-N~2~-(4-morpholin-4-ylphenyl)-9H-purine-2,6-diamine",,Inner centromere protein,INCENP,,unknown
"octyl 3-amino-3-deoxy-2-O-(2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)-beta-D-galactopyranoside",,Histo-blood group ABO system transferase,ABO,,unknown
1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone,,Heme oxygenase 1,HMOX1,,unknown
"4-[4-AMINO-6-(2,6-DICHLORO-PHENOXY)-[1,3,5]TRIAZIN-2-YLAMINO]-BENZONITRILE",,Gag-Pol polyprotein,gag-pol,,unknown
"3,6,9,12,15-PENTAOXAHEPTADECAN-1-OL",,"Malonyl-CoA-acyl carrier protein transacylase, mitochondrial",MCAT,,unknown
4-(2-aminoethyl)-2-cyclohexylphenol,,Beta-secretase 1,BACE1,,unknown
4-(2-aminoethyl)-2-ethylphenol,,Beta-secretase 1,BACE1,,unknown
4-(2-Aminoethyl)Benzenesulfonyl Fluoride,,Glyceraldehyde-3-phosphate dehydrogenase,GAPDH,,unknown
4-(2-Aminoethyl)Benzenesulfonyl Fluoride,,"V-type proton ATPase subunit B, brain isoform",ATP6V1B2,,unknown
Brefeldin A,,Cytohesin-2,CYTH2,,unknown
Brefeldin A,,ADP-ribosylation factor 1,ARF1,,unknown
"(1S)-2-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-1-[(PENTANOYLOXY)METHYL]ETHYL OCTANOATE",,Respiratory nitrate reductase 1 alpha chain,narG,,unknown
"(1S)-2-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-1-[(PENTANOYLOXY)METHYL]ETHYL OCTANOATE",,Respiratory nitrate reductase 1 beta chain,narH,,unknown
"(1S)-2-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-1-[(PENTANOYLOXY)METHYL]ETHYL OCTANOATE",,Respiratory nitrate reductase 1 gamma chain,narI,,unknown
"(1S)-2-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-1-[(PENTANOYLOXY)METHYL]ETHYL OCTANOATE",,Aquaporin Z,aqpZ,,unknown
(2E)-N-hydroxy-3-[1-methyl-4-(phenylacetyl)-1H-pyrrol-2-yl]prop-2-enamide,,Histone deacetylase 8,HDAC8,,unknown
O-(((1R)-((N-(PHENYL-METHOXY-CARBONYL)-ALANYL)-AMINO)METHYL)HYDROXYPHOSPHINYL)3-L-PHENYLLACTATE,,Carboxypeptidase A1,CPA1,,unknown
Apigenin,,3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ,fabZ,,unknown
"4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL",,Prothrombin,F2,,unknown
"2,3-DIMETHOXY-12H-[1,3]DIOXOLO[5,6]INDENO[1,2-C]ISOQUINOLIN-6-IUM",,DNA topoisomerase 1,TOP1,,unknown
3-(heptyloxy)benzoic acid,,UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase,lpxC,,unknown
"(1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-ETHYNYLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE",,Dipeptidyl peptidase 4,DPP4,,unknown
"4-AMINO-2-HEXYLOXY-6-HYDROXYMETHYL-TETRAHYDRO-PYRAN-3,5-DIOL",,Histo-blood group ABO system transferase,ABO,,unknown
"2-amino-N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]benzamide",,Glucokinase,GCK,,unknown
"3-[(4-fluorophenyl)sulfanyl]-N-(4-methyl-1,3-thiazol-2-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxamide",,Glucokinase,GCK,,unknown
"1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea",,Aurora kinase A,AURKA,,unknown
"1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea",,Aurora kinase A,AURKA,,unknown
"THIOPHENE-2,5-DISULFONIC ACID 2-AMIDE-5-(4-METHYL-BENZYLAMIDE)",,Carbonic anhydrase 2,CA2,,unknown
"6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE",,Cyclin-dependent kinase 5,CDK5,,unknown
"6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE",,Cyclin-dependent kinase 5 activator 1,CDK5R1,,unknown
NAPHTHALEN-2-YL-3-ALANINE,,Periplasmic oligopeptide-binding protein,oppA,,unknown
NAPHTHALEN-2-YL-3-ALANINE,,Pol polyprotein,pol,,unknown
2-[N'-(4-AMINO-BUTYL)-HYDRAZINOCARBONYL]-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER,,Prothrombin,F2,,unknown
"(3Z,5S,6R,7S,8S,8aR)-3-(octylimino)hexahydro[1,3]oxazolo[3,4-a]pyridine-5,6,7,8-tetrol",,Beta-glucosidase A,bglA,,unknown
4-(METHYLSULFONYL)BENZENECARBOXIMIDAMIDE,,Trypsin-1,PRSS1,,unknown
"N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide",,Hepatocyte growth factor receptor,MET,,unknown
"(3Z,5S,6R,7S,8R,8aS)-3-(octylimino)hexahydro[1,3]thiazolo[3,4-a]pyridine-5,6,7,8-tetrol",,Beta-glucosidase A,bglA,,unknown
3-(10-methyl-9-anthryl)propanoic acid,,Ig gamma-1 chain C region,IGHG1,,unknown
"ANDROSTA-1,4-DIENE-3,17-DIONE",,Pentaerythritol tetranitrate reductase,onr,,unknown
Anisomycin,,60S ribosomal protein L10-like,RPL10L,,unknown
Anisomycin,,60S ribosomal protein L13a,RPL13A,,unknown
Anisomycin,,60S ribosomal protein L23,RPL23,,unknown
Anisomycin,,60S ribosomal protein L15,RPL15,,unknown
Anisomycin,,60S ribosomal protein L19,RPL19,,unknown
Anisomycin,,60S ribosomal protein L23a,RPL23A,,unknown
Anisomycin,,Probable ribosome biogenesis protein RLP24,RSL24D1,,unknown
Anisomycin,,60S ribosomal protein L26-like 1,RPL26L1,,unknown
Anisomycin,,60S ribosomal protein L8,RPL8,,unknown
Anisomycin,,60S ribosomal protein L37,RPL37,,unknown
Anisomycin,,60S ribosomal protein L3,RPL3,,unknown
Anisomycin,,60S ribosomal protein L11,RPL11,,unknown
Anisomycin,,NHP2-like protein 1,SNU13,,unknown
"5-BETA-ANDROSTANE-3,17-DIONE",,Ig gamma-2 chain C region,IGHG2,,unknown
"5-BETA-ANDROSTANE-3,17-DIONE",,Ig gamma-1 chain C region,IGHG1,,unknown
"5-BETA-ANDROSTANE-3,17-DIONE",,Ig kappa chain C region,IGKC,,unknown
"5-BETA-ANDROSTANE-3,17-DIONE",,Ig kappa chain V-II region RPMI 6410,,,unknown
5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONIC ACID(DANSYL ACID),,Prothrombin,F2,,unknown
5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONIC ACID(DANSYL ACID),,Coagulation factor VII,F7,,unknown
"N'-((2S,3R)-3-AMINO-2-HYDROXY-5-(ISOPROPYLSULFANYL)PENTANOYL)-N-3-CHLOROBENZOYL HYDRAZIDE",,Methionine aminopeptidase 2,METAP2,,unknown
"4-AMINO-2-OCTYLOXY-6-HYDROXYMETHYL-TETRAHYDRO-PYRAN-3,5-DIOL",,Histo-blood group ABO system transferase,ABO,,unknown
(2S)-2-({6-[(3-amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methylbutan-1-ol,,Cyclin-dependent kinase 6,CDK6,,unknown
(2S)-2-({6-[(3-amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methylbutan-1-ol,,Cyclin homolog,72,,unknown
"1,1,1-TRIFLUORO-3-ACETAMIDO-4-PHENYL BUTAN-2-ONE(N-ACETYL-L-PHENYLALANYL TRIFLUOROMETHYL KETONE)",,Chymotrypsinogen B,CTRB1,,unknown
S-Atrolactic Acid,,Mandelate racemase,mdlA,,unknown
"N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine",,Serine/threonine-protein kinase/endoribonuclease IRE1,ERN1,,unknown
"N-(1-BENZYL-3,3,3-TRIFLUORO-2,2-DIHYDROXY-PROPYL)-ACETAMIDE",,Chymotrypsinogen B,CTRB1,,unknown
1-ACETYL-2-CARBOXYPIPERIDINE,,"ATP synthase subunit alpha, mitochondrial",ATP5A1,,unknown
1-ACETYL-2-CARBOXYPIPERIDINE,,"ATP synthase subunit beta, mitochondrial",ATP5B,,unknown
1-ACETYL-2-CARBOXYPIPERIDINE,,"ATP synthase subunit gamma, mitochondrial",ATP5C1,,unknown
"3-(HYDROXYMETHYL)-1-METHYL-5-(2-METHYLAZIRIDIN-1-YL)-2-PHENYL-1H-INDOLE-4,7-DIONE",,NAD(P)H dehydrogenase [quinone] 1,NQO1,,unknown
3-(BUTYLSULPHONYL)-PROPANOIC ACID,,Triosephosphate isomerase,TPI1,,unknown
ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE,,"Nitric oxide synthase, inducible",NOS2,,unknown
ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE,,"Nitric oxide synthase, endothelial",NOS3,,unknown
N-[2-(6-AMINO-4-METHYLPYRIDIN-2-YL)ETHYL]-4-CYANOBENZAMIDE,,"Nitric oxide synthase, inducible",NOS2,,unknown
"2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE",,Stromelysin-1,MMP3,,unknown
"(2S)-2-AMINO-1-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)PROPAN-1-ONE",,Proline iminopeptidase,pip,,unknown
"2-CHLORO-4-ISOPROPYLAMINO-6-ETHYLAMINO -1,3,5-TRIAZINE",,Photosynthetic reaction center cytochrome c subunit,pufC,,unknown
"2-CHLORO-4-ISOPROPYLAMINO-6-ETHYLAMINO -1,3,5-TRIAZINE",,Reaction center protein H chain,puhA,,unknown
"2-CHLORO-4-ISOPROPYLAMINO-6-ETHYLAMINO -1,3,5-TRIAZINE",,Reaction center protein L chain,pufL,,unknown
"2-CHLORO-4-ISOPROPYLAMINO-6-ETHYLAMINO -1,3,5-TRIAZINE",,Reaction center protein M chain,pufM,,unknown
"2-(2-PHENYL-3-PYRIDIN-2-YL-4,5,6,7-TETRAHYDRO-2H-ISOPHOSPHINDOL-1-YL)PYRIDINE",,"Glutathione reductase, mitochondrial",GSR,,unknown
AUROVERTIN B,,"ATP synthase subunit alpha, mitochondrial",ATP5A1,,unknown
AUROVERTIN B,,"ATP synthase subunit beta, mitochondrial",ATP5B,,unknown
AUROVERTIN B,,"ATP synthase subunit gamma, mitochondrial",ATP5C1,,unknown
"4-[3-(2-Chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid",,"Glycogen phosphorylase, liver form",PYGL,,unknown
"1-{2-[3-(2-Chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid",,"Glycogen phosphorylase, liver form",PYGL,,unknown
"(5S)-5-(2-amino-2-oxoethyl)-4-oxo-N-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methyl]-3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidine-2-carboxamide",,Neutrophil collagenase,MMP8,,unknown
"2-[(CYCLOPROPYLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE",,Serine/threonine-protein kinase PknG,pknG,,unknown
1-ETHOXYCARBONYL-D-PHE-PRO-2(4-AMINOBUTYL)HYDRAZINE,,Prothrombin,F2,,unknown
METHYL (2Z)-2-(2-{[6-(2-CYANOPHENOXY)PYRIMIDIN-4-YL]OXY}PHENYL)-3-METHOXYACRYLATE,,"Cytochrome c1, heme protein, mitochondrial",CYC1,,unknown
METHYL (2Z)-2-(2-{[6-(2-CYANOPHENOXY)PYRIMIDIN-4-YL]OXY}PHENYL)-3-METHOXYACRYLATE,,Cytochrome b,MT-CYB,,unknown
METHYL (2Z)-2-(2-{[6-(2-CYANOPHENOXY)PYRIMIDIN-4-YL]OXY}PHENYL)-3-METHOXYACRYLATE,,"Cytochrome b-c1 complex subunit 1, mitochondrial",UQCRC1,,unknown
METHYL (2Z)-2-(2-{[6-(2-CYANOPHENOXY)PYRIMIDIN-4-YL]OXY}PHENYL)-3-METHOXYACRYLATE,,"Cytochrome b-c1 complex subunit 2, mitochondrial",UQCRC2,,unknown
METHYL (2Z)-2-(2-{[6-(2-CYANOPHENOXY)PYRIMIDIN-4-YL]OXY}PHENYL)-3-METHOXYACRYLATE,,"Cytochrome b-c1 complex subunit 6, mitochondrial",UQCRH,,unknown
METHYL (2Z)-2-(2-{[6-(2-CYANOPHENOXY)PYRIMIDIN-4-YL]OXY}PHENYL)-3-METHOXYACRYLATE,,Cytochrome b-c1 complex subunit 8,UQCRQ,,unknown
METHYL (2Z)-2-(2-{[6-(2-CYANOPHENOXY)PYRIMIDIN-4-YL]OXY}PHENYL)-3-METHOXYACRYLATE,,"Cytochrome b-c1 complex subunit Rieske, mitochondrial",UQCRFS1,,unknown
METHYL (2Z)-2-(2-{[6-(2-CYANOPHENOXY)PYRIMIDIN-4-YL]OXY}PHENYL)-3-METHOXYACRYLATE,,Cytochrome b-c1 complex subunit 10,UQCR11,,unknown
METHYL (2Z)-2-(2-{[6-(2-CYANOPHENOXY)PYRIMIDIN-4-YL]OXY}PHENYL)-3-METHOXYACRYLATE,,Cytochrome b-c1 complex subunit 7,UQCRB,,unknown
METHYL (2Z)-2-(2-{[6-(2-CYANOPHENOXY)PYRIMIDIN-4-YL]OXY}PHENYL)-3-METHOXYACRYLATE,,Cytochrome b-c1 complex subunit 9,UQCR10,,unknown
"4-[(3-CHLORO-4-{[(2R)-3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPANOYL]AMINO}PHENYL)SULFONYL]-N,N-DIMETHYLBENZAMIDE",,"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial",PDK1,,unknown
"(1-HYDROXY-1-PHOSPHONO-2-[1,1';3',1'']TERPHENYL-3-YL-ETHYL)-PHOSPHONIC ACID",,"Ditrans,polycis-undecaprenyl-diphosphate synthase ((2E,6E)-farnesyl-diphosphate specific)",ispU,,unknown
"1-(6-CYANO-3-PYRIDYLCARBONYL)-5',8'-DIFLUOROSPIRO[PIPERIDINE-4,2'(1'H)-QUINAZOLINE]-4'-AMINE",,"Nitric oxide synthase, inducible",NOS2,,unknown
"(4R)-N-[4-({[2-(DIMETHYLAMINO)ETHYL]AMINO}CARBONYL)-1,3-THIAZOL-2-YL]-4-METHYL-1-OXO-2,3,4,9-TETRAHYDRO-1H-BETA-CARBOLINE-6-CARBOXAMIDE",,MAP kinase-activated protein kinase 2,MAPKAPK2,,unknown
5-(2-METHOXYPHENYL)-2-FUROIC ACID,,Methionine aminopeptidase,map,,unknown
5-(2-NITROPHENYL)-2-FUROIC ACID,,Methionine aminopeptidase,map,,unknown
"(1-HYDROXY-1-PHOSPHONO-2-[1,1';4',1'']TERPHENYL-3-YL-ETHYL)-PHOSPHONIC ACID",,"Ditrans,polycis-undecaprenyl-diphosphate synthase ((2E,6E)-farnesyl-diphosphate specific)",ispU,,unknown
[2-(3-DIBENZOFURAN-4-YL-PHENYL)-1-HYDROXY-1-PHOSPHONO-ETHYL]-PHOSPHONIC ACID,,Geranylgeranyl pyrophosphate synthase,GGPS1,,unknown
[2-(3-DIBENZOFURAN-4-YL-PHENYL)-1-HYDROXY-1-PHOSPHONO-ETHYL]-PHOSPHONIC ACID,,"Ditrans,polycis-undecaprenyl-diphosphate synthase ((2E,6E)-farnesyl-diphosphate specific)",ispU,,unknown
PHENYLALANINE BORONIC ACID,,Alpha-lytic protease,alpha-LP,,unknown
1-biphenyl-2-ylmethanamine,,Dipeptidyl peptidase 4,DPP4,,unknown
5'-S-[2-(decylamino)ethyl]-5'-thioadenosine,,Hydroxymycolate synthase MmaA4,mmaA4,,unknown
"(5S)-1-benzyl-3-(1,1-dioxido-1,2-benzisothiazol-3-yl)-4-hydroxy-5-(1-methylethyl)-1,5-dihydro-2H-pyrrol-2-one",,Genome polyprotein,,,unknown
4-[(1S)-1-(3-fluoro-4-methoxyphenyl)-2-(2-methoxy-5-nitrophenyl)ethyl]-1H-imidazol-2-amine,,Beta-secretase 1,BACE1,,unknown
(2S)-2-(BUTYRYLOXY)-3-HYDROXYPROPYL NONANOATE,,pH-gated potassium channel KcsA,kcsA,,unknown
(2S)-2-(BUTYRYLOXY)-3-HYDROXYPROPYL NONANOATE,,Ig kappa chain C region,IGKC,,unknown
(2S)-2-(BUTYRYLOXY)-3-HYDROXYPROPYL NONANOATE,,pH-gated potassium channel KcsA,kcsA,,unknown
bis(4-nitrophenyl) hydrogen phosphate,,Uncharacterized protein PA1000,,,unknown
S-23,,Androgen receptor,AR,,unknown
(1R)-4-(3-phenoxyphenyl)-1-phosphonobutane-1-sulfonic acid,,Dehydrosqualene synthase,crtM,,unknown
"4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile",,Androgen receptor,AR,,unknown
(2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide,,Androgen receptor,AR,,unknown
(2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide,,Androgen receptor,AR,,unknown
tripotassium (1R)-4-biphenyl-4-yl-1-phosphonatobutane-1-sulfonate,,Dehydrosqualene synthase,crtM,,unknown
Sobetirome,,"Thyroid hormone receptor, alpha isoform 1 variant",,,unknown
Sobetirome,,Thyroid hormone receptor beta,THRB,,unknown
"[1-HYDROXY-2-(1,1':3',1''-TERPHENYL-3-YLOXY)ETHANE-1,1-DIYL]BIS(PHOSPHONIC ACID)",,"Ditrans,polycis-undecaprenyl-diphosphate synthase ((2E,6E)-farnesyl-diphosphate specific)",ispU,,unknown
2-[(2-methoxy-5-methylphenoxy)methyl]pyridine,,Hemoglobin subunit alpha,HBA1,,unknown
2-[(2-methoxy-5-methylphenoxy)methyl]pyridine,,Hemoglobin subunit beta,HBB,,unknown
4-[(5-methoxy-2-methylphenoxy)methyl]pyridine,,Hemoglobin subunit alpha,HBA1,,unknown
4-[(5-methoxy-2-methylphenoxy)methyl]pyridine,,Hemoglobin subunit beta,HBB,,unknown
2-({[4-bromo-3-(diethylsulfamoyl)phenyl]carbonyl}amino)benzoic acid,,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,,unknown
"(10R)-10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one",,MAP kinase-activated protein kinase 2,MAPKAPK2,,unknown
"(3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one",,MAP kinase-activated protein kinase 2,MAPKAPK2,,unknown
"(3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one",,Cyclin-dependent kinase 2,CDK2,,unknown
"[[(3R,4R,5S,6R)-3-(butanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-ylidene]amino] N-phenylcarbamate",,Beta-hexosaminidase,nagZ,,unknown
"[[(3R,4R,5S,6R)-3-(butanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-ylidene]amino] N-phenylcarbamate",,O-GlcNAcase BT_4395,,,unknown
(TERT-BUTYLOXYCARBONYL)-ALANYL-AMINO ETHYL-FORMAMIDE,,Chymotrypsin-like elastase family member 1,CELA1,,unknown
HONH-BENZYLMALONYL-L-ALANYLGLYCINE-P-NITROANILIDE,,Thermolysin,npr,,unknown
"1,2,3-TRIHYDROXY-1,2,3,4-TETRAHYDROBENZO[A]PYRENE",,DNA polymerase kappa,POLK,,unknown
"1,2,3-TRIHYDROXY-1,2,3,4-TETRAHYDROBENZO[A]PYRENE",,DNA polymerase I,polA,,unknown
N-(1-PHENYL-PROPYL)-FORMAMIDE,,Capsid scaffolding protein,UL80,,unknown
"1-((2-HYDROXYETHOXY)METHYL)-5-BENZYLPYRIMIDINE-2,4(1H,3H)-DIONE",,Uridine phosphorylase,udp,,unknown
"1-((2-HYDROXYETHOXY)METHYL)-5-BENZYLPYRIMIDINE-2,4(1H,3H)-DIONE",,Uridine phosphorylase 1,UPP1,,unknown
"1-((2-HYDROXYETHOXY)METHYL)-5-(3-(BENZYLOXY)BENZYL)-6-HYDROXYPYRIMIDINE-2,4(1H,3H)-DIONE",,Uridine phosphorylase,udp,,unknown
4-TERT-BUTYLBENZENESULFONIC ACID,,Prothrombin,F2,,unknown
"3-{[(9-CYANO-9,10-DIHYDRO-10-METHYLACRIDIN-9-YL)CARBONYL]AMINO}PROPANOIC ACID",,Ig gamma-1 chain C region,IGHG1,,unknown
"3-{[(9-CYANO-9,10-DIHYDRO-10-METHYLACRIDIN-9-YL)CARBONYL]AMINO}PROPANOIC ACID",,Ig kappa chain C region,IGKC,,unknown
(2Z)-N-biphenyl-4-yl-2-cyano-3-hydroxybut-2-enamide,,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
"6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE",,Death-associated protein kinase 1,DAPK1,,unknown
"N'-[(1E)-(3,5-DIBROMO-2,4-DIHYDROXYPHENYL)METHYLENE]NICOTINOHYDRAZIDE",,3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ,fabZ,,unknown
N-(biphenyl-4-ylsulfonyl)-D-leucine,,Macrophage metalloelastase,MMP12,,unknown
5beta-dihydrotestosterone,,3-oxo-5-beta-steroid 4-dehydrogenase,AKR1D1,,unknown
(2S)-3-[(R)-[(1S)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid,,Cytosol aminopeptidase,LAP3,,unknown
N-[(1S)-1-(AMINOCARBONYL)-4-(ETHANIMIDOYLAMINO)BUTYL]BENZAMIDE,,Protein-arginine deiminase type-4,PADI4,,unknown
(R)-minalrestat,,Aldose reductase,AKR1B1,,unknown
1-(5-BROMO-PYRIDIN-2-YL)-3-[2-(6-FLUORO-2-HYDROXY-3-PROPIONYL-PHENYL)-CYCLOPROPYL]-UREA,,Gag-Pol polyprotein,gag-pol,,unknown
"2,6-diamino-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,Queuine tRNA-ribosyltransferase,tgt,,unknown
2-PHENYL-4H-BENZO[H]CHROMEN-4-ONE,,Cytochrome P450 1A2,CYP1A2,,unknown
(R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE,,Androgen receptor,AR,,unknown
"N,N'-[biphenyl-4,4'-diyldi(2R)propane-2,1-diyl]dimethanesulfonamide",,Glutamate receptor 2,GRIA2,,unknown
"3-(1H-indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidinyl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione",,3-phosphoinositide-dependent protein kinase 1,PDPK1,,unknown
"3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE",,3-phosphoinositide-dependent protein kinase 1,PDPK1,,unknown
"3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione",,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE,,Mitogen-activated protein kinase 14,MAPK14,,unknown
2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE,,Focal adhesion kinase 1,PTK2,,unknown
"3-AMINO-3-BENZYL-9-CARBOXAMIDE[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE",,Prothrombin,F2,,unknown
"(3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE",,Catechol O-methyltransferase,COMT,,unknown
"(3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(butylsulfanyl)methyl]pyrrolidin-3-ol",,5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase,mtnN,,unknown
1(R)-1-ACETAMIDO-2-(3-CARBOXY-2-HYDROXYPHENYL)ETHYL BORONIC ACID,,Beta-lactamase TEM,bla,,unknown
"(1S,3S,5S)-2-{(2S)-2-amino-2-[(1R,3S,5R,7S)-3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl]acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile",,Dipeptidyl peptidase 4,DPP4,,unknown
(1R)-2-PHENYLACETAMIDO-2-(3-CARBOXYPHENYL)ETHYL BORONIC ACID,,Beta-lactamase TEM,bla,,unknown
"4-chloro-N-[(2S)-2-methyl-2,3-dihydro-1H-indol-1-yl]-3-sulfamoylbenzamide",,Carbonic anhydrase 2,CA2,,unknown
"(3aS)-3a-hydroxy-5-methyl-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one",,Myosin-14,MYH14,,unknown
"(3aS)-3a-hydroxy-7-methyl-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one",,Myosin-14,MYH14,,unknown
"(3aS)-3a-hydroxy-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one",,Myosin-14,MYH14,,unknown
"5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE",,Cyclin-A2,CCNA2,,unknown
"5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
"(R)-(+)9B-(3-METHYL)PHENYL-2,3-DIHYDROTHIAZOLO[2,3-A]ISOINDOL-5(9BH)-ONE",,Gag-Pol polyprotein,gag-pol,,unknown
"(R)-(+) 5(9BH)-OXO-9B-PHENYL-2,3-DIHYDROTHIAZOLO[2,3-A]ISOINDOL-3-CARBOXYLIC ACID METHYL ESTER",,Gag-Pol polyprotein,gag-pol,,unknown
3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE,,Insulin-like growth factor 1 receptor,IGF1R,,unknown
N-[4-(AMINOSULFONYL)PHENYL]-2-MERCAPTOBENZAMIDE,,Carbonic anhydrase 2,CA2,,unknown
Felbinac,,Cathepsin L1,CTSL,,unknown
"1,1'-BIPHENYL-3,4-DIOL",,"1,2-dihydroxynaphthalene dioxygenase",doxG,,unknown
"(1S)-1,2,3,4-TETRAHYDRO-BENZO[C]PHENANTHRENE-2,3,4-TRIOL",,DNA polymerase beta,POLB,,unknown
4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
"tert-butyl [(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl]carbamate",,Queuine tRNA-ribosyltransferase,tgt,,unknown
(2R)-N-[(2R)-2-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-N-[(5R)-5-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-L-PROLINAMIDE,,Dipeptidyl peptidase 4,DPP4,,unknown
"1,1'-BIPHENYL-2-SULFINIC ACID",,2'-hydroxybiphenyl-2-sulfinate desulfinase,soxB,,unknown
"(2R)-4,4-dihydroxy-5-nitro-2-(phenylmethyl)pentanoic acid",,Carboxypeptidase A1,CPA1,,unknown
"4,4'-cyclohexane-1,1-diyldiphenol",,Estrogen-related receptor gamma,ESRRG,,unknown
"3-({4-[(1E)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)aniline",,Integrin alpha-L,ITGAL,,unknown
"(6-METHYL-3,4-DIHYDRO-2H-CHROMEN-2-YL)METHYLPHOSPHINATE",,Thermolysin,npr,,unknown
"{(2Z)-4-AMINO-2-[(4-METHOXYPHENYL)IMINO]-2,3-DIHYDRO-1,3-THIAZOL-5-YL}(4-METHOXYPHENYL)METHANONE",,Casein kinase I isoform gamma-3,CSNK1G3,,unknown
"4-Amino-2-[(3-chlorophenyl)amino]-5-(4-fluorobenzoyl)-1,3-thiazol-3-ium",,Casein kinase I isoform gamma-3,CSNK1G3,,unknown
"2-[1-(4-CHLORO-PHENYL)-ETHYL]-4,6-DINITRO-PHENOL",,Fumarate reductase flavoprotein subunit,frdA,,unknown
"2-[1-(4-CHLORO-PHENYL)-ETHYL]-4,6-DINITRO-PHENOL",,Fumarate reductase iron-sulfur subunit,frdB,,unknown
"2-[1-(4-CHLORO-PHENYL)-ETHYL]-4,6-DINITRO-PHENOL",,Fumarate reductase subunit C,frdC,,unknown
"2-[1-(4-CHLORO-PHENYL)-ETHYL]-4,6-DINITRO-PHENOL",,Fumarate reductase subunit D,frdD,,unknown
"5-amino-2,4,6-tribromobenzene-1,3-dicarboxylic acid",,Trypsin-1,PRSS1,,unknown
BROMAMPHENICOL,,Dr hemagglutinin structural subunit,draA,,unknown
"(2Z)-5'-BROMO-2,3'-BIINDOLE-2',3(1H,1'H)-DIONE AMMONIATE",,Cyclin-dependent kinase 2,CDK2,,unknown
"(3-EXO)-3-(10,11-DIHYDRO-5H-DIBENZO[A,D][7]ANNULEN-5-YLOXY)-8,8-DIMETHYL-8-AZONIABICYCLO[3.2.1]OCTANE",,CHRNA7-FAM7A fusion protein,CHRFAM7A,,unknown
"5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"1,3-DIPHENYLUREA",,Epoxide hydrolase,,,unknown
"5-(HEXAHYDRO-2-OXO-1H-THIENO[3,4-D]IMIDAZOL-6-YL)PENTANAL",,Biotin/lipoyl attachment protein,yngHB,,unknown
"5-(HEXAHYDRO-2-OXO-1H-THIENO[3,4-D]IMIDAZOL-6-YL)PENTANAL",,"Pyruvate carboxylase, mitochondrial",PC,,unknown
"5-(HEXAHYDRO-2-OXO-1H-THIENO[3,4-D]IMIDAZOL-6-YL)PENTANAL",,Pyruvate carboxylase,pycA,,unknown
"4-[3-(3-NITROPHENYL)-1,2,4-OXADIAZOL-5-YL]BUTANOIC ACID",,Aldose reductase,AKR1B1,,unknown
"N-(4-{[amino(imino)methyl]amino}butyl)-2,4'-bi-1,3-thiazole-4-carboxamide",,Gag-Pol polyprotein,gag-pol,,unknown
(2E)-1-[2-hydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one,,Group IIE secretory phospholipase A2,PLA2G2E,,unknown
(2S)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol,,Cyclin-dependent kinase 2,CDK2,,unknown
"4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"(5E)-5-[(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)METHYLENE]-1,3-THIAZOLIDINE-2,4-DIONE",,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,,unknown
(2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol,,Cyclin-dependent kinase 2,CDK2,,unknown
"N-({(3R,4R)-4-[(benzyloxy)methyl]pyrrolidin-3-yl}methyl)-N-(2-methylpropyl)benzenesulfonamide",,Gag-Pol polyprotein,gag-pol,,unknown
L-BENZYLSUCCINIC ACID,,Carboxypeptidase A1,CPA1,,unknown
L-BENZYLSUCCINIC ACID,,Thermolysin,npr,,unknown
L-BENZYLSUCCINIC ACID,,Retinoid-inducible serine carboxypeptidase,SCPEP1,,unknown
"2-(4-hydroxybiphenyl-3-yl)-4-methyl-1H-isoindole-1,3(2H)-dione",,Thymidylate synthase,thyA,,unknown
4-(5-BENZENESULFONYLAMINO-1-METHYL-1H-BENZOIMIDAZOL-2-YLMETHYL)-BENZAMIDINE,,Prothrombin,F2,,unknown
difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
"3-fluoro-6-(4-fluorophenyl)-2-hydroxy-6-oxohexa-2,4-dienoic acid",,"2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate hydrolase",bphD,,unknown
"4-(4-methyl-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)benzonitrile",,Thymidylate synthase,thyA,,unknown
7-[(3-CHLOROBENZYL)OXY]-2-OXO-2H-CHROMENE-4-CARBALDEHYDE,,Amine oxidase [flavin-containing] B,MAOB,,unknown
7-[(3-CHLOROBENZYL)OXY]-4-[(METHYLAMINO)METHYL]-2H-CHROMEN-2-ONE,,Amine oxidase [flavin-containing] B,MAOB,,unknown
"3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one",,Vascular endothelial growth factor receptor 2,KDR,,unknown
"1-(2-{[(6-AMINO-2-METHYLPYRIDIN-3-YL)METHYL]AMINO}ETHYL)-6-CHLORO-3-[(2,2-DIFLUORO-2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL",,Prothrombin,F2,,unknown
"(2Z,4E)-3-chloro-2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid",,"2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate hydrolase",bphD,,unknown
(2R)-2-ETHYL-1-HEXANESULFONIC ACID,,Putative alkylsulfatase,atsK,,unknown
"(6R)-2-amino-6-[2-(3'-methoxybiphenyl-3-yl)ethyl]-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one",,Beta-secretase 1,BACE1,,unknown
"N-[1-(AMINOMETHYL)CYCLOPROPYL]-3-(MORPHOLIN-4-YLSULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)ETHYL]-L-ALANINAMIDE",,Cathepsin S,CTSS,,unknown
"6-CHLORO-1-(2-{[(5-CHLORO-1-BENZOTHIEN-3-YL)METHYL]AMINO}ETHYL)-3-[(2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL",,Prothrombin,F2,,unknown
"N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]NAPHTHALENE-2-SULFONAMIDE",,Prothrombin,F2,,unknown
"N-phenyl-1H-pyrrolo[2,3-b]pyridin-3-amine",,Serine/threonine-protein kinase pim-1,PIM1,,unknown
"3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine",,Fibroblast growth factor receptor 1,FGFR1,,unknown
N-[4-({[5-(DIMETHYLAMINO)-1-NAPHTHYL]SULFONYL}AMINO)BUTYL]-3-SULFANYLPROPANAMIDE,,Beta-lactamase IMP-1,,,unknown
"N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]-4-METHOXY-2,3,6-TRIMETHYLBENZENESULFONAMIDE",,Prothrombin,F2,,unknown
3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one,,Vascular endothelial growth factor receptor 2,KDR,,unknown
"2-IMINO-5-(1-PYRIDIN-2-YL-METH-(E)-YLIDENE)-1,3-THIAZOLIDIN-4-ONE",,Cyclin-dependent kinase 2,CDK2,,unknown
"(1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol",,Nuclear receptor coactivator 1,NCOA1,,unknown
"(1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol",,Vitamin D3 receptor,VDR,,unknown
"4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE",,Cyclin-A2,CCNA2,,unknown
"4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE",,Cyclin-A2,CCNA2,,unknown
"4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
2-amino-6-[2-(1H-indol-6-yl)ethyl]pyrimidin-4(3H)-one,,Beta-secretase 1,BACE1,,unknown
"N-{(1S,2R)-2-hydroxy-1-[(hydroxyamino)carbonyl]propyl}-4-{[4-(morpholin-4-ylmethyl)phenyl]ethynyl}benzamide",,UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase,lpxC,,unknown
"N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide",,Vascular endothelial growth factor receptor 2,KDR,,unknown
"4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE",,Cyclin-A2,CCNA2,,unknown
"4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID",,Cyclin-A2,CCNA2,,unknown
"4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
4-(dihydroxyboranyl)-2-({[4-(phenylsulfonyl)thiophen-2-yl]sulfonyl}amino)benzoic acid,,Beta-lactamase,ampC,,unknown
5-AMINO-6-CYCLOHEXYL-4-HYDROXY-2-ISOBUTYL-HEXANOIC ACID,,Cathepsin D,CTSD,,unknown
(2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol,,Lysozyme,E,,unknown
(2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol,,Beta-2 adrenergic receptor,ADRB2,,unknown
N'-(5-CHLOROBENZOFURAN-2-CARBONYL)-2-(TRIFLUOROMETHYL)BENZENESULFONOHYDRAZIDE,,"Branched-chain-amino-acid aminotransferase, cytosolic",BCAT1,,unknown
N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE,,Aurora kinase A,AURKA,,unknown
[1-(6-{6-[(1-methylethyl)amino]-1H-indazol-1-yl}pyrazin-2-yl)-1H-pyrrol-3-yl]acetic acid,,Casein kinase II subunit alpha',CSNK2A2,,unknown
5-(4-CYANOPHENYL)-3-{[(2-METHYLPHENYL)SULFONYL]AMINO}THIOPHENE-2-CARBOXYLIC ACID,,Genome polyprotein,,,unknown
"2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-6-PYRIDINYL)METHYL]ACETAMIDE",,Prothrombin,F2,,unknown
"2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-3-METHYL-6-PYRIDINYL)METHYL]ACETAMIDE",,Prothrombin,F2,,unknown
"2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(1-OXIDO-2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUOROPHENYL)METHYL]ACETAMIDE",,Prothrombin,F2,,unknown
"(2S)-2-{[4-chloro-6-(ethylamino)-1,3,5-triazin-2-yl]amino}-2-methylbutanenitrile",,Photosynthetic reaction center cytochrome c subunit,pufC,,unknown
"(2S)-2-{[4-chloro-6-(ethylamino)-1,3,5-triazin-2-yl]amino}-2-methylbutanenitrile",,Reaction center protein H chain,puhA,,unknown
"(2S)-2-{[4-chloro-6-(ethylamino)-1,3,5-triazin-2-yl]amino}-2-methylbutanenitrile",,Reaction center protein L chain,pufL,,unknown
"(2S)-2-{[4-chloro-6-(ethylamino)-1,3,5-triazin-2-yl]amino}-2-methylbutanenitrile",,Reaction center protein M chain,pufM,,unknown
"(2R)-2-{[4-chloro-6-(ethylamino)-1,3,5-triazin-2-yl]amino}-2-methylbutanenitrile",,Photosynthetic reaction center cytochrome c subunit,pufC,,unknown
"(2R)-2-{[4-chloro-6-(ethylamino)-1,3,5-triazin-2-yl]amino}-2-methylbutanenitrile",,Reaction center protein H chain,puhA,,unknown
"(2R)-2-{[4-chloro-6-(ethylamino)-1,3,5-triazin-2-yl]amino}-2-methylbutanenitrile",,Reaction center protein L chain,pufL,,unknown
"(2R)-2-{[4-chloro-6-(ethylamino)-1,3,5-triazin-2-yl]amino}-2-methylbutanenitrile",,Reaction center protein M chain,pufM,,unknown
"9,9,9-TRIFLUORO-8-OXO-N-PHENYLNONANAMIDE",,Histone deacetylase-like amidohydrolase,hdaH,,unknown
"Hydroxy(oxo)(2-{(1S)-2,2,2-trifluoro-1-[2-(trimethylarsonio)ethoxy]ethyl}phenyl)ammonium",,Acetylcholinesterase,ACHE,,unknown
N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE,,Macrophage metalloelastase,MMP12,,unknown
N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE,,Interstitial collagenase,MMP1,,unknown
"(5BETA)-PREGNANE-3,20-DIONE",,Nuclear receptor coactivator 1,NCOA1,,unknown
"(5BETA)-PREGNANE-3,20-DIONE",,Retinoic acid receptor RXR-alpha,RXRA,,unknown
"(5BETA)-PREGNANE-3,20-DIONE",,Nuclear receptor subfamily 1 group I member 3,NR1I3,,unknown
"(5BETA)-PREGNANE-3,20-DIONE",,3-oxo-5-beta-steroid 4-dehydrogenase,AKR1D1,,unknown
2-ACETYLAMINO-4-METHYL-PENTANOIC ACID [1-(1-FORMYL-PENTYLCARBAMOYL)-3-METHYL-BUTYL]-AMIDE,,Proteasome subunit alpha type-7,PSMA7,,unknown
"(2Z)-2-cyano-N-(2,2'-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide",,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide,,Lanosterol 14-alpha demethylase,ERG11,,unknown
(2Z)-2-cyano-N-(3'-ethoxybiphenyl-4-yl)-3-hydroxybut-2-enamide,,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
"N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE",,Cyclin-dependent kinase 2,CDK2,,unknown
"N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE",,Cyclin-A2,CCNA2,,unknown
"1-{7-cyclohexyl-6-[4-(4-methylpiperazin-1-yl)benzyl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl}methanamine",,Cathepsin K,CTSK,,unknown
"6-amino-2-[(2-morpholin-4-ylethyl)amino]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,Queuine tRNA-ribosyltransferase,tgt,,unknown
Chloramphenicol succinate,,Dr hemagglutinin structural subunit,draA,,unknown
"(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL",,Estrogen receptor alpha,ESR1,,unknown
"(2S)-2-[(2,1,3-BENZOTHIADIAZOL-4-YLSULFONYL)AMINO]-2-PHENYL-N-PYRIDIN-4-YLACETAMIDE",,Lanosterol 14-alpha demethylase,ERG11,,unknown
CIS-4-METHYL-N-[(1S)-3-(METHYLSULFANYL)-1-(PYRIDIN-4-YLCARBAMOYL)PROPYL]CYCLOHEXANECARBOXAMIDE,,Lanosterol 14-alpha demethylase,ERG11,,unknown
3-CYCLOHEXYL-1-(2-MORPHOLIN-4-YL-2-OXOETHYL)-2-PHENYL-1H-INDOLE-6-CARBOXYLIC ACID,,Genome polyprotein,,,unknown
"N~2~-[(BENZYLOXY)CARBONYL]-N-[(1S,2S)-2-HYDROXY-1-(4-HYDROXYBENZYL)PROPYL]-L-LEUCINAMIDE",,ATP-dependent Clp protease proteolytic subunit,clpP,,unknown
3-{[(4-methylphenyl)sulfonyl]amino}propyl pyridin-4-ylcarbamate,,Lanosterol 14-alpha demethylase,ERG11,,unknown
"(2S)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol",,Beta-secretase 1,BACE1,,unknown
"2-MERCAPTO-N-[1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDRO-BENZO[A]HEPTALEN-7-YL]ACETAMIDE",,Stathmin-4,STMN4,,unknown
"2-MERCAPTO-N-[1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDRO-BENZO[A]HEPTALEN-7-YL]ACETAMIDE",,Tubulin beta-2B chain,TUBB2B,,unknown
"2-MERCAPTO-N-[1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDRO-BENZO[A]HEPTALEN-7-YL]ACETAMIDE",,Tubulin alpha-1A chain,TUBA1A,,unknown
"2-MERCAPTO-N-[1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDRO-BENZO[A]HEPTALEN-7-YL]ACETAMIDE",,Tubulin alpha-1C chain,TUBA1C,,unknown
"2-MERCAPTO-N-[1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDRO-BENZO[A]HEPTALEN-7-YL]ACETAMIDE",,Tubulin alpha-1B chain,TUBA1B,,unknown
"2,4-DIAMINO-1,5-DIPHENYL-3-HYDROXYPENTANE",,Gag-Pol polyprotein,gag-pol,,unknown
"6-ETHYL-5-PHENYLPYRIMIDINE-2,4-DIAMINE",,Thymidylate synthase,TYMS,,unknown
"3-[4-(2-METHYL-IMIDAZO[4,5-C]PYRIDIN-1-YL)BENZYL]-3H-BENZOTHIAZOL-2-ONE",,Gag-Pol polyprotein,gag-pol,,unknown
"BIS-1,2-{[(Z)-2-CARBOXY-2-METHYL-1,3-DIOXANE]-5-YLOXYCARBAMOYL}-ETHANE",,Serum amyloid P-component,APCS,,unknown
"BIS-1,2-{[(Z)-2CARBOXY-2-METHYL-1,3-DIOXANE]-5-YLOXYCARBONYL}-PIPERAZINE",,Serum amyloid P-component,APCS,,unknown
5-AMINO-6-CYCLOHEXYL-4-HYDROXY-2-ISOPROPYL-HEXANOIC ACID,,Gag-Pol polyprotein,gag-pol,,unknown
"N-[(2R,3S)-1-((2S)-2-{[(CYCLOPENTYLAMINO)CARBONYL]AMINO}-3-METHYLBUTANOYL)-2-(1-FORMYL-1-CYCLOBUTYL)PYRROLIDINYL]CYCLOPROPANECARBOXAMIDE",,Genome polyprotein,,,unknown
"N-[(2R,3S)-1-((2S)-2-{[(CYCLOPENTYLAMINO)CARBONYL]AMINO}-3-METHYLBUTANOYL)-2-(1-FORMYL-1-CYCLOBUTYL)PYRROLIDINYL]CYCLOPROPANECARBOXAMIDE",,NS3 protease,,,unknown
"(4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE",,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
"(4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE",,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
"N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine",,RAC-alpha serine/threonine-protein kinase,AKT1,,unknown
"N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine",,Glycogen synthase kinase-3 beta,GSK3B,,unknown
"5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine",,RAC-alpha serine/threonine-protein kinase,AKT1,,unknown
"5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine",,Glycogen synthase kinase-3 beta,GSK3B,,unknown
"5-(4-METHYL-BENZOYLAMINO)-BIPHENYL-3,4'-DICARBOXYLIC ACID 3-DIMETHYLAMIDE-4'-HYDROXYAMIDE",,Histone deacetylase 8,HDAC8,,unknown
"N-(1-CYANOCYCLOPROPYL)-3-({[(2S)-5-OXOPYRROLIDIN-2-YL]METHYL}SULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)ETHYL]-L-ALANINAMIDE",,Cathepsin S,CTSS,,unknown
"3,4-DI-1H-INDOL-3-YL-1H-PYRROLE-2,5-DICARBOXYLIC ACID",,Cytochrome P450,staP,,unknown
"N-[1-(AMINOMETHYL)CYCLOPROPYL]-3-(BENZYLSULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-HYDROXYPHENYL)ETHYL]-L-ALANINAMIDE",,Cathepsin S,CTSS,,unknown
"S-[3-(3,4-DICHLOROPHENYL)-3-OXOPROPYL]-L-CYSTEINE",,Sortase B,srtB,,unknown
N1-CYCLOPENTYL-N2-(THIAZOL-2-YL)OXALAMIDE,,Methionine aminopeptidase,map,,unknown
(1R)-2-METHYL-1-(PHENYLMETHYL)PROPYL[(1S)-1-FORMYLPENTYL]CARBAMATE,,Cathepsin K,CTSK,,unknown
1-(PHENYLMETHYL)CYCLOPENTYL[(1S)-1-FORMYLPENTYL]CARBAMATE,,Cathepsin K,CTSK,,unknown
"4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL",,Heat shock protein HSP 90-beta,HSP90AB1,,unknown
"4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"(5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE",,Cyclin-dependent kinase 2,CDK2,,unknown
"(17beta)-17-(cyanomethyl)-2-methoxyestra-1(10),2,4-trien-3-yl sulfamate",,Carbonic anhydrase 2,CA2,,unknown
"CIS-(1R,2S)-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-OL",,Phenylethanolamine N-methyltransferase,PNMT,,unknown
"2,3,6A,7,8,9-HEXAHYDRO-11H-[1,4]DIOXINO[2,3-G]PYRROLO[2,1-B][1,3]BENZOXAZIN-11-ONE",,Glutamate receptor 2,GRIA2,,unknown
[(2-AMINO-ALPHA-METHOXYIMINO-4-THIAZOLYLACETYL)AMINO]METHYLBORONIC ACID,,Beta-lactamase TEM,bla,,unknown
"4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE,,Epidermal growth factor receptor,EGFR,,unknown
"(6AR,11AS,11BR)-10-ACETYL-9-HYDROXY-7,7-DIMETHYL-2,6,6A,7,11A,11B-HEXAHYDRO-11H-PYRROLO[1',2':2,3]ISOINDOLO[4,5,6-CD]INDOL-11-ONE",,Sarcoplasmic/endoplasmic reticulum calcium ATPase 1,ATP2A1,,unknown
"2-({4-[(5-CHLORO-1H-INDOL-2-YL)SULFONYL]PIPERAZIN-1-YL}CARBONYL)THIENO[3,2-B]PYRIDINE 4-OXIDE",,Coagulation factor X,F10,,unknown
"6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE",,Cyclin-dependent kinase 2,CDK2,,unknown
4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE,,Mitogen-activated protein kinase 14,MAPK14,,unknown
N-(5-{[(2S)-4-amino-2-(3-chlorophenyl)butanoyl]amino}-1H-indazol-3-yl)benzamide,,Dual specificity tyrosine-phosphorylation-regulated kinase 1A,DYRK1A,,unknown
"N,N-DIMETHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE",,Cytochrome P450 2A6,CYP2A6,,unknown
"NAPHTHALENE-1,2-DIOL",,"1,2-dihydroxynaphthalene dioxygenase",doxG,,unknown
DECANE-1-THIOL,,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,,unknown
6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE,,Cyclin-dependent kinase 2,CDK2,,unknown
3-phenyl-5-(1H-pyrazol-3-yl)isoxazole,,Hematopoietic prostaglandin D synthase,HPGDS,,unknown
"PHENYL-5-(1H-PYRAZOL-3-YL)-1,3-THIAZOLE",,Hematopoietic prostaglandin D synthase,HPGDS,,unknown
Tranilast,,Hematopoietic prostaglandin D synthase,HPGDS,,unknown
"4-{[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino}-2-hydroxybenzoic acid",,Hematopoietic prostaglandin D synthase,HPGDS,,unknown
N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE,,Cytochrome P450 2A6,CYP2A6,,unknown
"2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
"N-cyclopropyl-N-(trans-4-pyridin-3-ylcyclohexyl)-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide",,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
"2-[(2,4-DICHLORO-5-METHYLPHENYL)SULFONYL]-1,3-DINITRO-5-(TRIFLUOROMETHYL)BENZENE",,Replicase polyprotein 1ab,rep,,unknown
"2-[(2,4-DICHLORO-5-METHYLPHENYL)SULFONYL]-1,3-DINITRO-5-(TRIFLUOROMETHYL)BENZENE",,Replicase polyprotein 1a,,,unknown
(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE,,Cytochrome P450 2A6,CYP2A6,,unknown
"1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA",,Cyclin-dependent kinase 2,CDK2,,unknown
"4,4'-DIPYRIDYL DISULFIDE",,Cytochrome P450 2A6,CYP2A6,,unknown
"1-{[(3R)-3-methyl-4-({4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]phenyl}sulfonyl)piperazin-1-yl]methyl}cyclopropanecarboxamide",,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
"4-(2-aminoethoxy)-N-(2,5-diethoxyphenyl)-3,5-dimethylbenzamide",,Urokinase-type plasminogen activator,PLAU,,unknown
"4-(2-aminoethoxy)-N-(3-chloro-2-ethoxy-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide",,Urokinase-type plasminogen activator,PLAU,,unknown
(2S)-4-METHYL-2-(3-PHENYLTHIOUREIDO)-N-((3S)-TETRAHYDRO-2-HYDROXY-3-FURANYL)PENTANAMIDE,,Calpain-1 catalytic subunit,CAPN1,,unknown
"6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one",,Pyruvate kinase PKM,PKM,,unknown
"N-((1R,2S)-2-(5-CHLORO-1H-INDOLE-2-CARBOXAMIDO)CYCLOHEXYL)-5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXAMIDE",,Coagulation factor X,F10,,unknown
"N-((1R,2R)-2-(5-CHLORO-1H-INDOLE-2-CARBOXAMIDO)CYCLOHEXYL)-5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXAMIDE",,Coagulation factor X,F10,,unknown
"N-DODECYL-N,N-DIMETHYLGLYCINATE",,AppA protein,appA,,unknown
"5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide",,Carbonic anhydrase 2,CA2,,unknown
octyl 3-deoxy-2-O-(6-deoxy-alpha-L-galactopyranosyl)-beta-D-xylo-hexopyranoside,,Histo-blood group ABO system transferase,ABO,,unknown
"(2,6-DIMETHYL-PHENOXY)-ACETIC ACID",,Gag-Pol polyprotein,gag-pol,,unknown
bis(4-hydroxyphenyl)methanone,,Lanosterol 14-alpha demethylase,ERG11,,unknown
"5-HEPTYL-6-HYDROXY-1,3-BENZOTHIAZOLE-4,7-DIONE",,Cytochrome b,MT-CYB,,unknown
"5-HEPTYL-6-HYDROXY-1,3-BENZOTHIAZOLE-4,7-DIONE",,"Cytochrome b-c1 complex subunit Rieske, mitochondrial",UQCRFS1,,unknown
"5-HEPTYL-6-HYDROXY-1,3-BENZOTHIAZOLE-4,7-DIONE",,"Cytochrome c1, heme protein, mitochondrial",CYC1,,unknown
"5-HEPTYL-6-HYDROXY-1,3-BENZOTHIAZOLE-4,7-DIONE",,Cytochrome b-c1 complex subunit 7,UQCRB,,unknown
"5-HEPTYL-6-HYDROXY-1,3-BENZOTHIAZOLE-4,7-DIONE",,Cytochrome b-c1 complex subunit 9,UQCR10,,unknown
Dibromotyrosine,,Erythropoietin receptor,EPOR,,unknown
"(3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL",,Estrogen receptor alpha,ESR1,,unknown
"(3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL",,Estrogen receptor beta,ESR2,,unknown
3-(7-DIAMINOMETHYL-NAPHTHALEN-2-YL)-PROPIONIC ACID ETHYL ESTER,,Prothrombin,F2,,unknown
"2-decyl-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione",,Sulfide-quinone reductase,sqr,,unknown
"2-decyl-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione",,"Sulfide-quinone reductase, putative",,,unknown
DECYL(DIMETHYL)PHOSPHINE OXIDE,,Amine oxidase [flavin-containing] A,MAOA,,unknown
"5-{[1-(2-fluorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine",,m7GpppX diphosphatase,DCPS,,unknown
"5-{[1-(2,3-dichlorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine",,m7GpppX diphosphatase,DCPS,,unknown
"5-[(1S)-1-(3-chlorophenyl)ethoxy]quinazoline-2,4-diamine",,m7GpppX diphosphatase,DCPS,,unknown
SEBACIC ACID,,Hemoglobin subunit alpha,HBA1,,unknown
SEBACIC ACID,,Hemoglobin subunit beta,HBB,,unknown
"UNDECYLAMINE-N,N-DIMETHYL-N-OXIDE",,Light-harvesting protein B-800/850 beta 1 chain,B1,,unknown
"UNDECYLAMINE-N,N-DIMETHYL-N-OXIDE",,Light-harvesting protein B-800/850 alpha chain,A1,,unknown
"UNDECYLAMINE-N,N-DIMETHYL-N-OXIDE",,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
"(2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"(2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"(3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(benzylsulfanyl)methyl]pyrrolidin-3-ol",,5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase,mtnN,,unknown
DECYL FORMATE,,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,,unknown
N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
"1-[2-DEOXYRIBOFURANOSYL]-2,4-DIFLUORO-5-METHYL-BENZENE-5'MONOPHOSPHATE",,DNA polymerase kappa,POLK,,unknown
"1-[2-DEOXYRIBOFURANOSYL]-2,4-DIFLUORO-5-METHYL-BENZENE-5'MONOPHOSPHATE",,Ribonuclease H,rnhA,,unknown
"N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"(5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
PHOSPHONIC ACID 2-DODECANOYLAMINO-HEXYL ESTER PROPYL ESTER,,Phospholipase A2,PLA2G1B,,unknown
AC-(D)PHE-PRO-BOROLYS-OH,,Prothrombin,F2,,unknown
AC-(D)PHE-PRO-BOROHOMOLYS-OH,,Prothrombin,F2,,unknown
AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH,,Prothrombin,F2,,unknown
"1,6-DIHYDROXY NAPHTHALENE",,Prenyltransferase,,,unknown
N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE,,Epidermal growth factor receptor,EGFR,,unknown
"2-[(1R)-1-CARBOXY-2-(4-HYDROXYPHENYL)ETHYL]-1,3-DIOXOISOINDOLINE-5-CARBOXYLIC ACID",,Beta-lactamase,ampC,,unknown
"5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE",,Casein kinase I isoform gamma-3,CSNK1G3,,unknown
"5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE",,STE20-like serine/threonine-protein kinase,SLK,,unknown
"5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE",,Calcium/calmodulin-dependent protein kinase type IV,CAMK4,,unknown
"5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE",,Dual specificity protein kinase CLK3,CLK3,,unknown
"5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE",,Abelson tyrosine-protein kinase 2,ABL2,,unknown
"N-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-fluorophenyl}acetamide",,Prothrombin,F2,,unknown
"(3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE",,Dipeptidyl peptidase 4,DPP4,,unknown
"2-((3',5'-DIMETHYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID",,Streptavidin,,,unknown
3-(4-DIETHYLAMINO-2-HYDROXY-PHENYL)-2-METHYL-PROPIONIC ACID,,Chymotrypsinogen B,CTRB1,,unknown
"2,3-DIMETHYL-1,4-NAPHTHOQUINONE",,Fumarate reductase flavoprotein subunit,frdA,,unknown
"2,3-DIMETHYL-1,4-NAPHTHOQUINONE",,Fumarate reductase iron-sulfur subunit,frdB,,unknown
"2,3-DIMETHYL-1,4-NAPHTHOQUINONE",,Fumarate reductase cytochrome b subunit,frdC,,unknown
4-METHYL-N-METHYL-N-(2-PHENYL-2H-PYRAZOL-3-YL)BENZENESULFONAMIDE,,Cytochrome P450 2C18,CYP2C18,,unknown
"2-[1-METHYLHEXYL]-4,6-DINITROPHENOL",,Succinate dehydrogenase flavoprotein subunit,sdhA,,unknown
"2-[1-METHYLHEXYL]-4,6-DINITROPHENOL",,Succinate dehydrogenase iron-sulfur subunit,sdhB,,unknown
"2-[1-METHYLHEXYL]-4,6-DINITROPHENOL",,Succinate dehydrogenase cytochrome b556 subunit,sdhC,,unknown
"2-[1-METHYLHEXYL]-4,6-DINITROPHENOL",,Succinate dehydrogenase hydrophobic membrane anchor subunit,sdhD,,unknown
TRANS-2-(DIMETHYLPHENYLSILYL)-PIPERIDINE-N-OXIDE,,Ig gamma-1 chain C region,IGHG1,,unknown
DEAMINO-METHYL-PHENYLALANINE,,Thermolysin,npr,,unknown
"O,O-DIETHYL HYDROGEN THIOPHOSPHATE",,Phosphotriesterase,opdA,,unknown
(2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
"3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one",,Glycogen synthase kinase-3 beta,GSK3B,,unknown
"3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one",,Calcium/calmodulin-dependent protein kinase type IV,CAMK4,,unknown
"2-methyl-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one",,Poly [ADP-ribose] polymerase 3,PARP3,,unknown
"(9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL",,Estrogen receptor alpha,ESR1,,unknown
"(9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL",,Nuclear receptor coactivator 2,NCOA2,,unknown
"(9S,12S)-9-(1-methylethyl)-7,10-dioxo-2-oxa-8,11-diazabicyclo[12.2.2]octadeca-1(16),14,17-triene-12-carboxylic acid",,Gag-Pol polyprotein,gag-pol,,unknown
[(1S)-1-(5-CHLORO-1-BENZOTHIEN-3-YL)-2-(2-NAPHTHYLAMINO)-2-OXOETHYL]PHOSPHONIC ACID,,Chymase,CMA1,,unknown
DODECANESULFONATE ION,,Cholinesterase,BCHE,,unknown
"N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine",,Macrophage metalloelastase,MMP12,,unknown
5-(DIMETHYLAMINO)-2-NAPHTHALENESULFONIC ACID,,Tissue-type plasminogen activator,PLAT,,unknown
"4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE",,Cyclin-A2,CCNA2,,unknown
"METHYL 1-(4-{[(2,4-DIAMINOPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)PIPERIDINE-4-CARBOXYLATE",,Putative dehydrogenase/reductase SDR family member 4-like 2,DHRS4L1,,unknown
"2-({[3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]carbonyl}amino)benzoic acid",,Peroxisome proliferator-activated receptor delta,PPARD,,unknown
"1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine",,Pyruvate kinase PKM,PKM,,unknown
methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate,,Caspase-3,CASP3,,unknown
"1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine",,Pyruvate kinase PKM,PKM,,unknown
"3-(3-aminophenyl)-N-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-amine",,Serine/threonine-protein kinase haspin,GSG2,,unknown
"3-CARBOXAMIDO-1,3,5(10)-ESTRATRIEN-17(R)-SPIRO-2'(5',5'-DIMETHYL-6'OXO)TETRAHYDROPYRAN",,Aldo-keto reductase family 1 member C3,AKR1C3,,unknown
"1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON-2-YL)METHYL]PIPERIDINE",,Acetylcholinesterase,ACHE,,unknown
"(16ALPHA,17ALPHA)-ESTRA-1,3,5(10)-TRIENE-3,16,17-TRIOL",,Nuclear receptor coactivator 5,NCOA5,,unknown
"(16ALPHA,17ALPHA)-ESTRA-1,3,5(10)-TRIENE-3,16,17-TRIOL",,Estrogen receptor beta,ESR2,,unknown
"(3R,4S,5S,7R,9E,11R,12R)-12-ETHYL-4-HYDROXY-3,5,7,11-TETRAMETHYLOXACYCLODODEC-9-ENE-2,8-DIONE",,Type I polyketide synthase PikAIV,pikAIV,,unknown
"6-AMINO-4-[2-(4-METHOXYPHENYL)ETHYL]-1,7-DIHYDRO-8H-IMIDAZO[4,5-G]QUINAZOLIN-8-ONE",,Queuine tRNA-ribosyltransferase,tgt,,unknown
"1-[(2S)-2-[(4-CHLOROBENZYL)OXY]-2-(2,4-DICHLOROPHENYL)ETHYL]-1H-IMIDAZOLE",,Cytochrome P450 130,cyp130,,unknown
"1-[(2S)-2-[(4-CHLOROBENZYL)OXY]-2-(2,4-DICHLOROPHENYL)ETHYL]-1H-IMIDAZOLE",,Lanosterol 14-alpha demethylase,CYP51A1,,unknown
2-Hydroxyestradiol,,Adenylate cyclase,cyaC,,unknown
"(9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL",,Estrogen receptor alpha,ESR1,,unknown
"(9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL",,Nuclear receptor coactivator 2,NCOA2,,unknown
3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,,Estrogen receptor alpha,ESR1,,unknown
3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,,Nuclear receptor coactivator 2,NCOA2,,unknown
PHENYLALANYLAMINODI(ETHYLOXY)ETHYL BENZENESULFONAMIDEAMINOCARBONYLBENZENESULFONAMIDE,,Carbonic anhydrase 2,CA2,,unknown
"(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol",,Adenosine deaminase,ADA,,unknown
3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,,Estrogen receptor alpha,ESR1,,unknown
3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,,Nuclear receptor coactivator 2,NCOA2,,unknown
"(1S)-1-{[(4'-methoxy-1,1'-biphenyl-4-yl)sulfonyl]amino}-2-methylpropylphosphonic acid",,Neutrophil collagenase,MMP8,,unknown
"6-(3-METHYL-1,4-DIOXO-1,4-DIHYDRONAPHTHALEN-2-YL)HEXANOIC ACID",,"Glutathione reductase, mitochondrial",GSR,,unknown
Emodin,,Casein kinase II subunit alpha,CSNK2A1,,unknown
Emodin,,Putative ketoacyl reductase,actIII,,unknown
Emodin,,3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ,fabZ,,unknown
Emodin,,Aryl hydrocarbon receptor,AHR,agonist,unknown
"(4Z)-2,8:7,12:11,15:14,18:17,22-PENTAANHYDRO-4,5,6,9,10,13,19,20,21-NONADEOXY-D-ARABINO-D-ALLO-D-ALLO-DOCOSA-4,9,20-TRIENITOL",,Ig kappa chain C region,IGKC,,unknown
"(5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE",,Androgen receptor,AR,,unknown
3-(4-HYDROXY-PHENYL)PYRUVIC ACID,,Prothrombin,F2,,unknown
3-(4-HYDROXY-PHENYL)PYRUVIC ACID,,Macrophage migration inhibitory factor,MIF,,unknown
3-(4-HYDROXY-PHENYL)PYRUVIC ACID,,Prephenate dehydrogenase,tyrA,,unknown
"[(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
Epibatidine,,CHRNA7-FAM7A fusion protein,CHRFAM7A,,unknown
Epibatidine,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,,unknown
Epibatidine,,Neuronal acetylcholine receptor subunit beta-2,CHRNB2,,unknown
Epibatidine,,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,agonist,unknown
Epibatidine,,Neuronal acetylcholine receptor subunit alpha-3,CHRNA3,agonist,unknown
Epibatidine,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,agonist,unknown
Epibatidine,,Neuronal acetylcholine receptor subunit beta-4,CHRNB4,agonist,unknown
DIETHYL 4-METHOXYPHENYL PHOSPHATE,,Phosphotriesterase,opdA,,unknown
3-(4-NITRO-PHENOXY)-PROPAN-1-OL,,Pol polyprotein,pol,,unknown
3-(5-methoxy-1H-indol-3-yl)propanoic acid,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Indeglitazar,,Nuclear receptor coactivator 1,NCOA1,,unknown
Indeglitazar,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Indeglitazar,,Peroxisome proliferator-activated receptor delta,PPARD,,unknown
Indeglitazar,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
"2-tert-butylbenzene-1,4-diol",,Hemagglutinin,HA,,unknown
"2-tert-butylbenzene-1,4-diol",,Hemagglutinin,HA,,unknown
"2-[2-(2-FLUOROPHENYL)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE",,MAP kinase-activated protein kinase 2,MAPKAPK2,,unknown
"2-[2-(2-FLUOROPHENYL)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE",,MAP kinase-activated protein kinase 3,MAPKAPK3,,unknown
3-fluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzamide,,Beta-lactamase,blaCTX-M-9a,,unknown
"5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
"4-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOL",,Cyclin-dependent kinase 2,CDK2,,unknown
2-[(2-NAPHTHYLSULFONYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE,,Tryptophan synthase alpha chain,trpA,,unknown
2-[(2-NAPHTHYLSULFONYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE,,Tryptophan synthase beta chain,trpB,,unknown
"1-METHYL-3-TRIFLUOROMETHYL-1H-THIENO[2,3-C]PYRAZOLE-5-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)-AMIDE",,Caspase-1,CASP1,,unknown
N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide,,Beta-secretase 1,BACE1,,unknown
"N-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide",,Beta-secretase 1,BACE1,,unknown
(2S)-4-(4-fluorobenzyl)-N-(2-sulfanylethyl)piperazine-2-carboxamide,,Beta-secretase 1,BACE1,,unknown
(2S)-4-(4-fluorobenzyl)-N-(3-sulfanylpropyl)piperazine-2-carboxamide,,Beta-secretase 1,BACE1,,unknown
"N-[1-(5-bromo-2,3-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide",,Beta-secretase 1,BACE1,,unknown
"(3R)-3-(FLUOROMETHYL)-7-(THIOMORPHOLIN-4-YLSULFONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE",,Phenylethanolamine N-methyltransferase,PNMT,,unknown
"(7R,12R,13R)-13-formyl-12,14-dihydroxy-3,5,7-trimethyltetradeca-2,4-dienoic acid",,"Hydroxymethylglutaryl-CoA synthase, cytoplasmic",HMGCS1,,unknown
"4-(1R,3AS,4R,8AS,8BR)-[1-DIFLUOROMETHYL-2-(4-FLUOROBENZYL)-3-OXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZAMIDINE",,Prothrombin,F2,,unknown
"N-(2,3-DIFLUORO-BENZYL)-4-SULFAMOYL-BENZAMIDE",,Carbonic anhydrase 2,CA2,,unknown
"S-[5-(TRIFLUOROMETHYL)-4H-1,2,4-TRIAZOL-3-YL] 5-(PHENYLETHYNYL)FURAN-2-CARBOTHIOATE",,Replicase polyprotein 1ab,rep,,unknown
"S-[5-(TRIFLUOROMETHYL)-4H-1,2,4-TRIAZOL-3-YL] 5-(PHENYLETHYNYL)FURAN-2-CARBOTHIOATE",,Replicase polyprotein 1a,,,unknown
Z-Val-Ala-Asp fluoromethyl ketone,,Caspase-1,CASP1,,unknown
2-{[4-(TRIFLUOROMETHOXY)BENZOYL]AMINO}ETHYL DIHYDROGEN PHOSPHATE,,Tryptophan synthase alpha chain,trpA,,unknown
2-{[4-(TRIFLUOROMETHOXY)BENZOYL]AMINO}ETHYL DIHYDROGEN PHOSPHATE,,Tryptophan synthase beta chain,trpB,,unknown
3-ETHYL-6-{[(4-FLUOROPHENYL)SULFONYL]AMINO}-2-METHYLBENZOIC ACID,,Methionine aminopeptidase 2,METAP2,,unknown
"(3R)-N-(4-CHLOROPHENYL)-3-(HYDROXYMETHYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE",,Phenylethanolamine N-methyltransferase,PNMT,,unknown
2-({[4-(TRIFLUOROMETHOXY)PHENYL]SULFONYL}AMINO)ETHYL DIHYDROGEN PHOSPHATE,,Tryptophan synthase alpha chain,trpA,,unknown
2-({[4-(TRIFLUOROMETHOXY)PHENYL]SULFONYL}AMINO)ETHYL DIHYDROGEN PHOSPHATE,,Tryptophan synthase beta chain,trpB,,unknown
2-ACETYLAMINO-4-METHYL-PENTANOIC ACID (1-FORMYL-2-PHENYL-ETHYL)-AMIDE,,Chymotrypsinogen B,CTRB1,,unknown
"(2R)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol",,Cyclin-dependent kinase 2,CDK2,,unknown
"(2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol",,Cyclin-dependent kinase 2,CDK2,,unknown
N-({(1R)-1-carboxy-2-[(4-fluorobenzyl)sulfanyl]ethyl}carbamoyl)-L-glutamic acid,,Glutamate carboxypeptidase 2,FOLH1,,unknown
"(2S)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol",,Cyclin-dependent kinase 2,CDK2,,unknown
"1-[3-({[(4-AMINO-5-FLUORO-2-METHYLQUINOLIN-3-YL)METHYL]THIO}METHYL)PHENYL]-2,2,2-TRIFLUOROETHANE-1,1-DIOL",,Acetylcholinesterase,ACHE,,unknown
"(9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one",,Estrogen receptor beta,ESR2,,unknown
"5-(2,5-DICHLOROPHENYL)-2-FUROIC ACID",,Methionine aminopeptidase,map,,unknown
5-[2-(TRIFLUOROMETHYL)PHENYL]-2-FUROIC ACID,,Methionine aminopeptidase,map,,unknown
"3-[(1E,7E)-8-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-3,6-dioxa-2,7-diazaocta-1,7-dien-1-yl]benzoic acid",,Uracil-DNA glycosylase,UNG,,unknown
"(2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol",,Cyclin-dependent kinase 2,CDK2,,unknown
4-(N-ACETYLAMINO)-3-[N-(2-ETHYLBUTANOYLAMINO)]BENZOIC ACID,,Neuraminidase,NA,,unknown
"(5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE",,"Cytochrome c1, heme protein, mitochondrial",CYC1,,unknown
"(5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE",,Cytochrome b,MT-CYB,,unknown
"(5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE",,"Cytochrome b-c1 complex subunit 1, mitochondrial",UQCRC1,,unknown
"(5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE",,"Cytochrome b-c1 complex subunit 2, mitochondrial",UQCRC2,,unknown
"(5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE",,"Cytochrome b-c1 complex subunit 6, mitochondrial",UQCRH,,unknown
"(5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE",,Cytochrome b-c1 complex subunit 8,UQCRQ,,unknown
"(5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE",,"Cytochrome b-c1 complex subunit Rieske, mitochondrial",UQCRFS1,,unknown
"(5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE",,Cytochrome b-c1 complex subunit 10,UQCR11,,unknown
"(5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE",,Cytochrome b-c1 complex subunit 7,UQCRB,,unknown
"(5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE",,Cytochrome b-c1 complex subunit 9,UQCR10,,unknown
FLUORESCIN,,Ig gamma-1 chain C region,IGHG1,,unknown
"METHYL 1-(4-{[(2,4-DIAMINOPTERIDIN-6-YL)METHYL](METHYL)AMINO}BENZOYL)PIPERIDINE-4-CARBOXYLATE",,Putative dehydrogenase/reductase SDR family member 4-like 2,DHRS4L1,,unknown
"(2Z,3E)-2,3'-BIINDOLE-2',3(1H,1'H)-DIONE 3-{O-[(3R)-3,4-DIHYDROXYBUTYL]OXIME}",,Calcium/calmodulin-dependent protein kinase type II subunit alpha,CAMK2A,,unknown
"(2Z,3E)-2,3'-BIINDOLE-2',3(1H,1'H)-DIONE 3-{O-[(3R)-3,4-DIHYDROXYBUTYL]OXIME}",,Cyclin-dependent kinase 16,CDK16,,unknown
Ferulic acid,,"Endo-1,4-beta-xylanase Y",xynY,,unknown
Ferulic acid,,"Endo-1,4-beta-xylanase Z",xynZ,,unknown
Ferulic acid,,Est1e,,,unknown
Ferulic acid,,O-methyltransferase,,,unknown
"(10ALPHA,13ALPHA,14BETA,17ALPHA)-17-HYDROXYANDROST-4-EN-3-ONE",,Aldo-keto reductase family 1 member C1,AKR1C1,,unknown
"(10ALPHA,13ALPHA,14BETA,17ALPHA)-17-HYDROXYANDROST-4-EN-3-ONE",,Aldo-keto reductase family 1 member C2,AKR1C2,,unknown
S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE,,Androgen receptor,AR,,unknown
5-(4-FLUOROPHENYL)-3-{[(4-METHYLPHENYL)SULFONYL]AMINO}THIOPHENE-2-CARBOXYLIC ACID,,Genome polyprotein,,,unknown
"[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID",,GTPase KRas,KRAS,,unknown
"[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID",,Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha,FNTA,,unknown
"[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID",,Protein farnesyltransferase subunit beta,FNTB,,unknown
"(1R)-1-{[(4'-methoxy-1,1'-biphenyl-4-yl)sulfonyl]amino}-2-methylpropylphosphonic acid",,Neutrophil collagenase,MMP8,,unknown
5-FLUOROINDOLE PROPANOL PHOSPHATE,,Tryptophan synthase alpha chain,trpA,,unknown
5-FLUOROINDOLE PROPANOL PHOSPHATE,,Tryptophan synthase beta chain,trpB,,unknown
Flavone,,Neocarzinostatin,ncsA,,unknown
Flavone,,Steroid hormone receptor ERR1,ESRRA,agonist,unknown
Flavone,,Steroid hormone receptor ERR2,ESRRB,agonist,unknown
Flavone,,Cytochrome P450 1B1,CYP1B1,,unknown
FAMOXADONE,,"Cytochrome c1, heme protein, mitochondrial",CYC1,,unknown
FAMOXADONE,,Cytochrome b,MT-CYB,,unknown
FAMOXADONE,,"Cytochrome b-c1 complex subunit 1, mitochondrial",UQCRC1,,unknown
FAMOXADONE,,"Cytochrome b-c1 complex subunit 2, mitochondrial",UQCRC2,,unknown
FAMOXADONE,,"Cytochrome b-c1 complex subunit 6, mitochondrial",UQCRH,,unknown
FAMOXADONE,,Cytochrome b-c1 complex subunit 8,UQCRQ,,unknown
FAMOXADONE,,"Cytochrome b-c1 complex subunit Rieske, mitochondrial",UQCRFS1,,unknown
FAMOXADONE,,Cytochrome b-c1 complex subunit 10,UQCR11,,unknown
FAMOXADONE,,Cytochrome b-c1 complex subunit 7,UQCRB,,unknown
FAMOXADONE,,Cytochrome b-c1 complex subunit 9,UQCR10,,unknown
N-({(2S)-1-[(3R)-3-AMINO-4-(2-FLUOROPHENYL)BUTANOYL]PYRROLIDIN-2-YL}METHYL)BENZAMIDE,,Dipeptidyl peptidase 4,DPP4,,unknown
FARNESYL DIPHOSPHATE,,Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha,FNTA,,unknown
FARNESYL DIPHOSPHATE,,Protein farnesyltransferase subunit beta,FNTB,,unknown
FARNESYL DIPHOSPHATE,,GTPase KRas,KRAS,,unknown
FARNESYL DIPHOSPHATE,,"2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase",ispF,,unknown
FARNESYL DIPHOSPHATE,,Farnesyl pyrophosphate synthase,FDPS,,unknown
FARNESYL DIPHOSPHATE,,"Ditrans,polycis-undecaprenyl-diphosphate synthase ((2E,6E)-farnesyl-diphosphate specific)",ispU,,unknown
FARNESYL DIPHOSPHATE,,Lantibiotic nisin-Z,nisZ,,unknown
FARNESYL DIPHOSPHATE,,Geranylgeranyl pyrophosphate synthase,GGPS1,,unknown
FARNESYL DIPHOSPHATE,,"(2Z,6E)-farnesyl diphosphate synthase",,,unknown
FARNESYL DIPHOSPHATE,,Geranylgeranyl transferase type-2 subunit alpha,RABGGTA,,unknown
FARNESYL DIPHOSPHATE,,Geranylgeranyl transferase type-2 subunit beta,RABGGTB,,unknown
N-[[3-FLUORO-4-ETHOXY-PYRID-2-YL]ETHYL]-N'-[5-NITRILOMETHYL-PYRIDYL]-THIOUREA,,Gag-Pol polyprotein,gag-pol,,unknown
4-AMINO-2-TRIFLUOROMETHYL-5-HYDROXYMETHYLPYRIMIDINE PYROPHOSPHATE,,Thiamine-phosphate synthase,thiE,,unknown
1-((1R)-1-(HYDROXYMETHYL)-3-{6-[(3-PHENYLPROPANOYL)AMINO]-1H-INDOL-1-YL}PROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE,,Adenosine deaminase,ADA,,unknown
"[4-(4-ACETYLAMINO-PHENYL)-3,5-DIOXO-4-AZA-TRICYCLO[5.2.2.0 2,6]UNDEC-1-YLCARBAMOYLOXY]-ACETIC ACID",,Ig kappa chain C region,IGKC,,unknown
"1-{(1R,2S)-2-HYDROXY-1-[2-(2-NAPHTHYLOXY)ETHYL]PROPYL}-1H-IMIDAZONE-4-CARBOXAMIDE",,Adenosine deaminase,ADA,,unknown
"1-((1R,2S)-1-{2-[2-(4-CHLOROPHENYL)-1,3-BENZOXAZOL-7-YL]ETHYL}-2-HYDROXYPROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE",,Adenosine deaminase,ADA,,unknown
"5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE",,Poly [ADP-ribose] polymerase 1,PARP1,,unknown
"(3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE",,Mitogen-activated protein kinase 1,MAPK1,,unknown
"1-[5-methyl-2-(trifluoromethyl)furan-3-yl]-3-[(2Z)-5-(2-{[6-(1H-1,2,4-triazol-3-ylamino)pyrimidin-4-yl]amino}ethyl)-1,3-thiazol-2(3H)-ylidene]urea",,Serine/threonine-protein kinase PLK1,PLK1,,unknown
N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE,,Cyclin-dependent kinase 2,CDK2,,unknown
4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE,,Cyclin-dependent kinase 2,CDK2,,unknown
"(S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
"(2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
"5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE",,Mitogen-activated protein kinase 1,MAPK1,,unknown
"3,7,3',4'-TETRAHYDROXYFLAVONE",,Cyclin homolog,72,,unknown
"3,7,3',4'-TETRAHYDROXYFLAVONE",,Cyclin-dependent kinase 6,CDK6,,unknown
"(3ASR,4RS,8ASR,8BRS)-4-(2-(4-FLUOROBENZYL)-1,3-DIOXODEACAHYDROPYRROLO[3,4-A] PYRROLIZIN-4-YL)BENZAMIDINE",,Prothrombin,F2,,unknown
N-[[3-FLUORO-4-ETHOXY-PYRID-2-YL]ETHYL]-N'-[5-CHLORO-PYRIDYL]-THIOUREA,,Gag-Pol polyprotein,gag-pol,,unknown
"(3R)-3-(FLUOROMETHYL)-N-(3,3,3-TRIFLUOROPROPYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE",,Phenylethanolamine N-methyltransferase,PNMT,,unknown
N-(2-(((5-CHLORO-2-PYRIDINYL)AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE,,Coagulation factor X,F10,,unknown
N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide,,Aurora kinase A,AURKA,,unknown
"3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE",,Casein kinase II subunit alpha,CSNK2A1,,unknown
2-phenyl-1H-imidazole-4-carboxylic acid,,Beta-lactamase,ampC,,unknown
"5-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1H-1,2,4-TRIAZOLE-3-SULFONAMIDE",,Coagulation factor X,F10,,unknown
"3-CHLORO-2,2-DIMETHYL-N-[4-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE",,D-alanine--D-alanine ligase,ddl,,unknown
"(2R,4S)-2-[(R)-BENZYLCARBAMOYL-PHENYLACETYL-METHYL]-5,5-DIMETHYL-THIAZOLIDINE-4-CARBOXYLIC ACID",,Gag-Pol polyprotein,gag-pol,,unknown
"(3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
"(1S,2R)-2-[(2,5-difluorophenyl)carbamoyl]cyclopropanecarboxylic acid",,Beta-lactamase,blaCTX-M-9a,,unknown
4-({[4-(3-METHYLBENZOYL)PYRIDIN-2-YL]AMINO}METHYL)BENZENECARBOXIMIDAMIDE,,Prothrombin,F2,,unknown
"3-(4-HYDROXYPHENYL)-1-(2,4,6-TRIHYDROXYPHENYL)PROPAN-1-ONE",,HTH-type transcriptional regulator TtgR,ttgR,,unknown
"N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide",,Mitogen-activated protein kinase 14,MAPK14,,unknown
"N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide",,RAC-beta serine/threonine-protein kinase,AKT2,,unknown
"N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide",,Glycogen synthase kinase-3 beta,GSK3B,,unknown
GLYCYLALANYL-N-2-NAPHTHYL-L-PROLINEAMIDE,,Prolyl tripeptidyl peptidase,ptpA,,unknown
GIBBERELLIN A3,,Arylacetamide deacetylase-like 2,AADACL2,,unknown
GIBBERELLIN A4,,Arylacetamide deacetylase-like 2,AADACL2,,unknown
N-(P-CYANOPHENYL)-N'-DIPHENYLMETHYL-GUANIDINE-ACETIC ACID,,Ig gamma-1 chain C region,IGHG1,,unknown
"1-{3-[(4-pyridin-2-ylpiperazin-1-yl)sulfonyl]phenyl}-3-(1,3-thiazol-2-yl)urea",,Phenylalanine--tRNA ligase alpha subunit,pheS,,unknown
"1-{3-[(4-pyridin-2-ylpiperazin-1-yl)sulfonyl]phenyl}-3-(1,3-thiazol-2-yl)urea",,Phenylalanine--tRNA ligase beta subunit,pheT,,unknown
"(2E)-3-(2,4-DICHLOROPHENYL)-N-HYDROXYACRYLAMIDE",,Botulinum neurotoxin type A,botA,,unknown
"(2E)-3-(2,4-DICHLOROPHENYL)-N-HYDROXYACRYLAMIDE",,BoNT/A,bont/a,,unknown
(2E)-3-(4-CHLOROPHENYL)-N-HYDROXYACRYLAMIDE,,Botulinum neurotoxin type A,botA,,unknown
(2E)-3-(4-CHLOROPHENYL)-N-HYDROXYACRYLAMIDE,,BoNT/A,bont/a,,unknown
"6-(3',5'-DIMETHYLBENZYL)-1-ETHOXYMETHYL-5-ISOPROPYLURACIL",,Gag-Pol polyprotein,gag-pol,,unknown
"(1R)-1,2,2-trimethylpropyl (R)-methylphosphinate",,Liver carboxylesterase 1,CES1,,unknown
"(1R)-1,2,2-trimethylpropyl (R)-methylphosphinate",,Platelet-activating factor acetylhydrolase IB subunit gamma,PAFAH1B3,,unknown
"(1R)-1,2,2-trimethylpropyl (R)-methylphosphinate",,Platelet-activating factor acetylhydrolase,PLA2G7,,unknown
"(2S)-2-[(3aR,4R,7S,7aS)-1,3-dioxooctahydro-2H-4,7-methanoisoindol-2-yl]propanoic acid",,Beta-lactamase,blaCTX-M-9a,,unknown
"(2S)-2-[(3aR,4R,7S,7aS)-1,3-dioxooctahydro-2H-4,7-methanoisoindol-2-yl]propanoic acid",,Beta-lactamase,ampC,,unknown
"4-ethyl-5-methyl-2-(1H-tetrazol-5-yl)-1,2-dihydro-3H-pyrazol-3-one",,Beta-lactamase,blaCTX-M-9a,,unknown
"4-ethyl-5-methyl-2-(1H-tetrazol-5-yl)-1,2-dihydro-3H-pyrazol-3-one",,Beta-lactamase,ampC,,unknown
(3S)-1-(4-acetylphenyl)-5-oxopyrrolidine-3-carboxylic acid,,Beta-lactamase,ampC,,unknown
2-[4-chloro-2-(phenylcarbonyl)phenoxy]-N-phenylacetamide,,Gag-Pol polyprotein,gag-pol,,unknown
"4-{[1-METHYL-2,4-DIOXO-6-(3-PHENYLPROP-1-YN-1-YL)-1,4-DIHYDROQUINAZOLIN-3(2H)-YL]METHYL}BENZOIC ACID",,Collagenase 3,MMP13,,unknown
4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE,,Mitogen-activated protein kinase 14,MAPK14,,unknown
"(4R,5R)-5-AMINO-1-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-2-ONE",,Dipeptidyl peptidase 4,DPP4,,unknown
"2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE",,Tyrosine-protein kinase ABL1,ABL1,,unknown
"4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde",,Mitogen-activated protein kinase 14,MAPK14,,unknown
"N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide",,Mitogen-activated protein kinase 14,MAPK14,,unknown
"N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide",,Mitogen-activated protein kinase 14,MAPK14,,unknown
"N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide",,Mitogen-activated protein kinase 14,MAPK14,,unknown
1-DECYL-3-TRIFLUORO ETHYL-SN-GLYCERO-2-PHOSPHOMETHANOL,,Phospholipase A2,PLA2G1B,,unknown
"[4-(5-naphthalen-2-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl]acetic acid",,Serine/threonine-protein kinase Sgk1,SGK1,,unknown
(Z)-3-BENZYL-5-(2-HYDROXY-3-NITROBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE,,Glycylpeptide N-tetradecanoyltransferase 2,NMT2,,unknown
"N~2~-1,3-BENZOXAZOL-2-YL-3-CYCLOHEXYL-N-{2-[(4-METHOXYPHENYL)AMINO]ETHYL}-L-ALANINAMIDE",,Cathepsin S,CTSS,,unknown
"(E)-[4-(3,5-difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol",,Fibroblast growth factor receptor 1,FGFR1,,unknown
Geranylgeranyl diphosphate,,Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha,FNTA,,unknown
Geranylgeranyl diphosphate,,Geranylgeranyl transferase type-1 subunit beta,PGGT1B,,unknown
Geranylgeranyl diphosphate,,Protein farnesyltransferase subunit beta,FNTB,,unknown
Geranylgeranyl diphosphate,,Geranylgeranyl pyrophosphate synthase,GGPS1,,unknown
Geranylgeranyl diphosphate,,Farnesyl pyrophosphate synthase,FDPS,,unknown
Geranylgeranyl diphosphate,,Geranylgeranyl transferase type-2 subunit alpha,RABGGTA,,unknown
Geranylgeranyl diphosphate,,Geranylgeranyl transferase type-2 subunit beta,RABGGTB,,unknown
(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
5-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1-BENZOTHIOPHENE-2-SULFONAMIDE,,Coagulation factor X,F10,,unknown
6-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1-BENZOTHIOPHENE-2-SULFONAMIDE,,Coagulation factor X,F10,,unknown
"2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide",,Mitogen-activated protein kinase 8,MAPK8,,unknown
"1S,3AS,8AS-TRIMETHYL-1-OXIDO-1,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL 2-ETHYLPHENYLCARBAMATE",,Acetylcholinesterase,ACHE,,unknown
6-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-(4-MORPHOLINYL)-2-OXO ETHYL]-2-OXO-3-PYRROLIDINYL}-2-NAPHTHALENESULFONAMIDE,,Coagulation factor X,F10,,unknown
5-Chloro-N-{(3S)-1-[(2S)-1-(4-morpholinyl)-1-oxo-2-propanyl]-2-oxo-3-pyrrolidinyl}-1H-indole-2-sulfonamide,,Coagulation factor X,F10,,unknown
S-NONYL-CYSTEINE,,Glutathione S-transferase P,GSTP1,,unknown
"(1R,2S)-2-(5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)cyclohexanecarboxylic acid",,Beta-lactamase,ampC,,unknown
"(3R,4S)-1-(3,4-DIMETHOXYPHENYL)-3-(3-METHYLPHENYL)PIPERIDIN-4-AMINE",,Dipeptidyl peptidase 4,DPP4,,unknown
"1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID",,Cyclin-A2,CCNA2,,unknown
"1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID",,Cyclin-dependent kinase 2,CDK2,,unknown
"[4-({4-[(5-CYCLOPROPYL-1H-PYRAZOL-3-YL)AMINO]QUINAZOLIN-2-YL}IMINO)CYCLOHEXA-2,5-DIEN-1-YL]ACETONITRILE",,STE20-like serine/threonine-protein kinase,SLK,,unknown
"[4-({4-[(5-CYCLOPROPYL-1H-PYRAZOL-3-YL)AMINO]QUINAZOLIN-2-YL}IMINO)CYCLOHEXA-2,5-DIEN-1-YL]ACETONITRILE",,Calcium/calmodulin-dependent protein kinase type II subunit delta,CAMK2D,,unknown
"[4-({4-[(5-CYCLOPROPYL-1H-PYRAZOL-3-YL)AMINO]QUINAZOLIN-2-YL}IMINO)CYCLOHEXA-2,5-DIEN-1-YL]ACETONITRILE",,Serine/threonine-protein kinase MST4,STK26,,unknown
N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
(S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
(S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
(2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
(2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
(2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
(2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE,,RAC-beta serine/threonine-protein kinase,AKT2,,unknown
4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE,,Glycogen synthase kinase-3 beta,GSK3B,,unknown
(2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
(2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
(2R)-N-hydroxy-3-naphthalen-2-yl-2-[(naphthalen-2-ylsulfonyl)amino]propanamide,,UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase,lpxC,,unknown
"7-(1-ETHYL-PROPYL)-7H-PYRROLO-[3,2-F]QUINAZOLINE-1,3-DIAMINE",,"Dihydrofolate reductase, mitochondrial",DHFRL1,,unknown
2-chloro-5-nitro-N-phenylbenzamide,,Nuclear receptor coactivator 2,NCOA2,,unknown
2-chloro-5-nitro-N-phenylbenzamide,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
2-chloro-5-nitro-N-phenylbenzamide,,Retinoic acid receptor RXR-alpha,RXRA,,unknown
4-[(CYCLOPROPYLETHYNYL)OXY]-6-FLUORO-3-ISOPROPYLQUINOLIN-2(1H)-ONE,,Gag-Pol polyprotein,gag-pol,,unknown
3-(1H-tetrazol-5-ylamino)cyclohex-2-en-1-one,,Beta-lactamase,blaCTX-M-9a,,unknown
"(5S)-2-(cyclooctylamino)-5-methyl-5-propyl-1,3-thiazol-4(5H)-one",,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
6-CHLORO-4-(CYCLOHEXYLOXY)-3-PROPYLQUINOLIN-2(1H)-ONE,,Gag-Pol polyprotein,gag-pol,,unknown
6-CHLORO-4-(CYCLOHEXYLSULFANYL)-3-PROPYLQUINOLIN-2(1H)-ONE,,Gag-Pol polyprotein,gag-pol,,unknown
6-CHLORO-4-(CYCLOHEXYLSULFINYL)-3-PROPYLQUINOLIN-2(1H)-ONE,,Gag-Pol polyprotein,gag-pol,,unknown
(2S)-2-(4-{[3-CHLORO-5-(TRIFLUOROMETHYL)PYRIDIN-2-YL]OXY}PHENOXY)PROPANOIC ACID,,Acetyl-CoA carboxylase 2,ACACB,,unknown
6-CHLORO-4-(CYCLOHEXYLOXY)-3-ISOPROPYLQUINOLIN-2(1H)-ONE,,Gag-Pol polyprotein,gag-pol,,unknown
5-chloro-N-[(3R)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)pyrrolidin-3-yl]thiophene-2-carboxamide,,Coagulation factor X,F10,,unknown
"(1-HYDROXYDODECANE-1,1-DIYL)BIS(PHOSPHONIC ACID)",,Geranylgeranyl pyrophosphate synthase,GGPS1,,unknown
"(6S)-2-amino-6-(3'-methoxybiphenyl-3-yl)-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one",,Beta-secretase 1,BACE1,,unknown
"5-Chloro-thiophene-2-carboxylic acid ((3S,4S)-1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-4-hydroxy-pyrrolidin-3-yl)-amide",,Coagulation factor X,F10,,unknown
(S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
(S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
(S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE,,Rho-associated protein kinase 1,ROCK1,,unknown
"8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE",,Heat shock protein HSP 90-beta,HSP90AB1,,unknown
"8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"N-[(1S)-1-{1-[(1R,3E)-1-ACETYLPENT-3-EN-1-YL]-1H-1,2,3-TRIAZOL-4-YL}-1,2-DIMETHYLPROPYL]BENZAMIDE",,Cathepsin S,CTSS,,unknown
"N-hydroxy-5-[(3-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)carbonyl]thiophene-2-carboxamide",,Histone deacetylase 4,HDAC4,,unknown
2-((4'-HYDROXYPHENYL)-AZO)BENZOIC ACID,,Streptavidin,,,unknown
N-{[2-({[1-(4-CARBOXYBUTANOYL)AMINO]-2-PHENYLETHYL}-HYDROXYPHOSPHINYL)OXY]ACETYL}-2-PHENYLETHYLAMINE,,Ig gamma-1 chain C region,IGHG1,,unknown
"4-{4-[2-(1A,7A-DIMETHYL-4-OXY-OCTAHYDRO-1-OXA-4-AZA-CYCLOPROPA[A]NAPHTHALEN-4-YL) -ACETYLAMINO]-PHENYLCARBAMOYL}-BUTYRIC ACID",,Ig kappa chain C region,IGKC,,unknown
(2-AMINO-3-PHENYL-BICYCLO[2.2.1]HEPT-2-YL)-PHENYL-METHANONE,,Ig gamma-1 chain C region,IGHG1,,unknown
"ISOPROPYL (2S)-2-ETHYL-7-FLUORO-3-OXO-3,4-DIHYDROQUINOXALINE-1(2H)-CARBOXYLATE",,Gag-Pol polyprotein,gag-pol,,unknown
Talviraline,,Gag-Pol polyprotein,gag-pol,,unknown
"(R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)BENZYL)GUANIDINE",,Coagulation factor XI,F11,,unknown
"3-(4-HYDROXYPHENYL)-4,5-DIHYDRO-5-ISOXAZOLE-ACETIC ACID METHYL ESTER",,Macrophage migration inhibitory factor,MIF,,unknown
"(2S)-1-(Dimethylamino)-3-(4-{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}phenoxy)-2-propanol",,Cyclin-dependent kinase 2,CDK2,,unknown
4-(2-HYDROXYPHENYLTHIO)-1-BUTENYLPHOSPHONIC ACID,,Tryptophan synthase alpha chain,trpA,,unknown
4-(2-HYDROXYPHENYLTHIO)-1-BUTENYLPHOSPHONIC ACID,,Tryptophan synthase beta chain,trpB,,unknown
1-(2-HYDROXYETHYLOXYMETHYL)-6-PHENYL THIOTHYMINE,,Gag-Pol polyprotein,gag-pol,,unknown
PHENYL[1-(N-SUCCINYLAMINO)PENTYL]PHOSPHONATE,,Ig kappa chain C region,IGKC,,unknown
4-(2-HYDROXY-4-FLUOROPHENYLTHIO)-BUTYLPHOSPHONIC ACID,,Tryptophan synthase alpha chain,trpA,,unknown
4-(2-HYDROXY-4-FLUOROPHENYLTHIO)-BUTYLPHOSPHONIC ACID,,Tryptophan synthase beta chain,trpB,,unknown
ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID,,Protein farnesyltransferase subunit beta,FNTB,,unknown
ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID,,Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha,FNTA,,unknown
(2S)-hydroxy(4-hydroxyphenyl)ethanoic acid,,4-hydroxymandelate synthase,,,unknown
1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE,,Prothrombin,F2,,unknown
2-(BUTYRYLOXY)-1-{[(TETRAHYDROXYPHOSPHORANYL)OXY]METHYL}ETHYL BUTYRATE,,Phospholipase D,,,unknown
(2S) N-acetyl-L-alanyl-αL-phenylalanyl-chloroethylketone,,Chymotrypsinogen B,CTRB1,,unknown
3-FORMYL-2-HYDROXY-5-METHYL-HEXANOIC ACID HYDROXYAMIDE,,Neutrophil collagenase,MMP8,,unknown
5-CHLORO-6-METHYL-N-(2-PHENYLETHYL)-2-PYRIDIN-2-YLPYRIMIDIN-4-AMINE,,Methionine aminopeptidase 1,METAP1,,unknown
"TERT-BUTYL {2-[(1,3-THIAZOL-2-YLAMINO)CARBONYL]PYRIDIN-3-YL}CARBAMATE",,Methionine aminopeptidase 1,METAP1,,unknown
"3-[(2,2-DIMETHYLPROPANOYL)AMINO]-N-1,3-THIAZOL-2-YLPYRIDINE-2-CARBOXAMIDE",,Methionine aminopeptidase 1,METAP1,,unknown
"(1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione",,Mitogen-activated protein kinase 1,MAPK1,,unknown
"[(3R)-7-NITRO-1,2,3,4-TETRAHYDROISOQUINOLIN-3-YL]METHANOL",,Phenylethanolamine N-methyltransferase,PNMT,,unknown
(2S)-2-HYDROXYOCTANOIC ACID,,Hydroxyacid oxidase 1,HAO1,,unknown
(2S)-2-HYDROXYOCTANOIC ACID,,(S)-mandelate dehydrogenase,mdlB,,unknown
7-HYDROXY-4-METHYL-3-(2-HYDROXY-ETHYL)COUMARIN,,Profilin-1,PFN1,,unknown
"(1S,2S,5S)2-(4-GLUTARIDYLBENZYL)-5-PHENYL-1-CYCLOHEXANOL",,Uncharacterized protein,,,unknown
"(1S,2S,5S)2-(4-GLUTARIDYLBENZYL)-5-PHENYL-1-CYCLOHEXANOL",,Ig gamma-1 chain C region,IGHG1,,unknown
"(1S,2S,5S)2-(4-GLUTARIDYLBENZYL)-5-PHENYL-1-CYCLOHEXANOL",,Ig kappa chain C region,IGKC,,unknown
"(2S)-2-amino-3-phenylpropane-1,1-diol",,Gag-Pol polyprotein,gag-pol,,unknown
"(2S)-2-amino-3-phenylpropane-1,1-diol",,Gag-Pol polyprotein,gag-pol,,unknown
"(2S)-2-amino-3-phenylpropane-1,1-diol",,Gag-Pol polyprotein,gag-pol,,unknown
"(3E)-2,6-DIOXO-6-PHENYLHEX-3-ENOATE",,"2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate hydrolase",bphD,,unknown
"(3E)-2,6-DIOXO-6-PHENYLHEX-3-ENOATE",,"4,5:9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oate hydrolase",hsaD,,unknown
2-OXOHEPTYLPHOSPHONIC ACID,,Enolase-phosphatase E1,ENOPH1,,unknown
HOMOPHENYLALANINYLMETHANE,,Cathepsin F,CTSF,,unknown
"2-hydroxy-6-oxo-6-phenyl-2,4-hexadienoic acid",,Glutathione S-transferase,bphK,,unknown
"2-hydroxy-6-oxo-6-phenyl-2,4-hexadienoic acid",,"Catechol 2,3-dioxygenase",,,unknown
"(2E,4E)-2-Hydroxy-6-oxo-6-phenyl-2,4-hexadienoic acid",,"2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate hydrolase",bphD,,unknown
3-{6-[(8-HYDROXY-QUINOLINE-2-CARBONYL)-AMINO]-2-THIOPHEN-2-YL-HEXANOYLAMINO}-4-OXO-BUTYRI ACID,,Caspase-1,CASP1,,unknown
4-(BENZHYDRYLOXY)-1-[3-(1H-TETRAAZOL-5-YL)PROPYL]PIPERIDINE,,Hematopoietic prostaglandin D synthase,HPGDS,,unknown
2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE,,Fumarate reductase flavoprotein subunit,frdA,,unknown
2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE,,Fumarate reductase iron-sulfur subunit,frdB,,unknown
2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE,,Fumarate reductase subunit C,frdC,,unknown
2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE,,Fumarate reductase subunit D,frdD,,unknown
2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE,,"Formate dehydrogenase, nitrate-inducible, major subunit",fdnG,,unknown
2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE,,"Formate dehydrogenase, nitrate-inducible, iron-sulfur subunit",fdnH,,unknown
2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE,,"Formate dehydrogenase, nitrate-inducible, cytochrome b556(fdn) subunit",fdnI,,unknown
2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE,,NapC/NirT cytochrome c family protein,,,unknown
2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE,,"Cytochrome c nitrite reductase, catalytic subunit NfrA, putative",,,unknown
7-METHOXY-1-METHYL-9H-BETA-CARBOLINE,,Amine oxidase [flavin-containing] A,MAOA,,unknown
N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide,,Macrophage metalloelastase,MMP12,,unknown
2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide,,Macrophage metalloelastase,MMP12,,unknown
N-oxo-2-(phenylsulfonylamino)ethanamide,,Macrophage metalloelastase,MMP12,,unknown
octyl alpha-L-altropyranoside,,Aquaporin Z,aqpZ,,unknown
octyl beta-D-galactopyranoside,,Aquaporin Z,aqpZ,,unknown
4-(2-HYDROXYPHENYLSULFINYL)-BUTYLPHOSPHONIC ACID,,Tryptophan synthase alpha chain,trpA,,unknown
4-(2-HYDROXYPHENYLSULFINYL)-BUTYLPHOSPHONIC ACID,,Tryptophan synthase beta chain,trpB,,unknown
N-[3-(N'-HYDROXYCARBOXAMIDO)-2-(2-METHYLPROPYL)-PROPANOYL]-O-TYROSINE-N-METHYLAMIDE,,Interstitial collagenase,MMP1,,unknown
3-[(4-Carboxy-2-hydroxyphenyl)sulfamoyl]-2-thiophenecarboxylic acid,,Beta-lactamase,ampC,,unknown
N-(2-OXOTETRAHYDROFURAN-3-YL)OCTANAMIDE,,Regulatory protein SdiA,sdiA,,unknown
"N-(TERT-BUTYL)-3,5-DIMETHYL-N'-[(5-METHYL-2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)CARBONYL]BENZOHYDRAZIDE",,Oxysterols receptor LXR-alpha,NR1H3,,unknown
"N-(TERT-BUTYL)-3,5-DIMETHYL-N'-[(5-METHYL-2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)CARBONYL]BENZOHYDRAZIDE",,Retinoic acid receptor RXR-beta,RXRB,,unknown
(3R)-3-HYDROXYDODECANOIC ACID,,Peroxisomal acyl-coenzyme A oxidase 1,ACOX1,,unknown
Hexestrol,,Aldo-keto reductase family 1 member C1,AKR1C1,,unknown
Hexestrol,,Estrogen receptor alpha,ESR1,,unknown
Hexestrol,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Hexestrol,,Nuclear receptor subfamily 1 group I member 3,NR1I3,,unknown
"dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate",,Estrogen receptor alpha,ESR1,,unknown
"dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate",,Nuclear receptor coactivator 2,NCOA2,,unknown
Erteberel,,Estrogen receptor beta,ESR2,,unknown
Erteberel,,Estrogen receptor alpha,ESR1,,unknown
[[CYCLOHEXANESULFONYL-GLYCYL]-3[PYRIDIN-4-YL-AMINOMETHYL]ALANYL]PIPERIDINE,,Prothrombin,F2,,unknown
"5-[(5-fluoro-3-methyl-1H-indazol-4-yl)oxy]benzene-1,3-dicarbonitrile",,Reverse transcriptase/RNaseH,pol,,unknown
N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine,,Cyclin-dependent kinase 2,CDK2,,unknown
"2-butoxy-9-(2,6-difluorobenzyl)-N-(2-morpholin-4-ylethyl)-9H-purin-6-amine",,Glutamate racemase,murI,,unknown
"5-[[(2R)-2-cyclopropyl-7,8-dimethoxy-chroman-5-yl]methyl]pyrimidine-2,4-diamine",,Dihydrofolate reductase,folA,,unknown
N-(3-MERCAPTOPROPANOYL)-D-ALANINE,,Metallo-beta-lactamase L1,,,unknown
"9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE",,Cholinesterase,BCHE,,unknown
PH-797804,,Mitogen-activated protein kinase 14,MAPK14,,unknown
2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine,,Mitogen-activated protein kinase 14,MAPK14,,unknown
2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxoethanol,,Mitogen-activated protein kinase 14,MAPK14,,unknown
N-{3-METHYL-5-[2-(PYRIDIN-4-YLAMINO)-ETHOXY]-PHENYL}-BENZENESULFONAMIDE,,Prothrombin,F2,,unknown
"N-[2-({[amino(imino)methyl]amino}oxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide",,Prothrombin,F2,,unknown
ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE,,RAC-beta serine/threonine-protein kinase,AKT2,,unknown
ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE,,Glycogen synthase kinase-3 beta,GSK3B,,unknown
"({[(3E)-2'-OXO-2',7'-DIHYDRO-2,3'-BIINDOL-3(7H)-YLIDENE]AMINO}OXY)ACETIC ACID",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
1H-INDOL-3-YLACETIC ACID,,Group IIE secretory phospholipase A2,PLA2G2E,,unknown
1H-INDOL-3-YLACETIC ACID,,S-phase kinase-associated protein 1,SKP1,,unknown
1H-INDOL-3-YLACETIC ACID,,Kynurenine--oxoglutarate transaminase 1,CCBL1,,unknown
N-[1H-INDOL-3-YL-ACETYL]ASPARTIC ACID,,Tryptophan synthase alpha chain,trpA,,unknown
N-[1H-INDOL-3-YL-ACETYL]ASPARTIC ACID,,Tryptophan synthase beta chain,trpB,,unknown
N-[1H-INDOL-3-YL-ACETYL]GLYCINE ACID,,Tryptophan synthase alpha chain,trpA,,unknown
N-[1H-INDOL-3-YL-ACETYL]GLYCINE ACID,,Tryptophan synthase beta chain,trpB,,unknown
N-[1H-INDOL-3-YL-ACETYL]VALINE ACID,,Tryptophan synthase alpha chain,trpA,,unknown
N-[1H-INDOL-3-YL-ACETYL]VALINE ACID,,Tryptophan synthase beta chain,trpB,,unknown
3-isobutyl-1-methyl-7H-xanthine,,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,,unknown
3-isobutyl-1-methyl-7H-xanthine,,"cGMP-inhibited 3',5'-cyclic phosphodiesterase B",PDE3B,,unknown
3-isobutyl-1-methyl-7H-xanthine,,"High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A",PDE7A,,unknown
3-isobutyl-1-methyl-7H-xanthine,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,,unknown
3-isobutyl-1-methyl-7H-xanthine,,"High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A",PDE9A,,unknown
3-isobutyl-1-methyl-7H-xanthine,,"High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A",PDE8A,,unknown
3-isobutyl-1-methyl-7H-xanthine,,"cGMP-dependent 3',5'-cyclic phosphodiesterase",PDE2A,,unknown
3-isobutyl-1-methyl-7H-xanthine,,"Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma",PDE6G,,unknown
(2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE,,Chymotrypsin-like elastase family member 1,CELA1,,unknown
[1-(3-CHLORO-2-FORMYL-PHENYLCARBAMOYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER,,Chymotrypsin-like elastase family member 1,CELA1,,unknown
METHYL(2-ACETOXY-2-(2-CARBOXY-4-AMINO-PHENYL))ACETATE,,Chymotrypsin-like elastase family member 1,CELA1,,unknown
(2-CARBAMOYLMETHYL-5-PROPYL-OCTAHYDRO-INDOL-7-YL)ACETIC ACID,,Group IIE secretory phospholipase A2,PLA2G2E,,unknown
3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE,,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"5-ACETAMIDO-5,6-DIHYDRO-4-HYDROXY-6-ISOBUTOXY-4H-PYRAN-2-CARBOXYLIC ACID",,Sialidase-2,NEU2,,unknown
"1-(4-CYANO-PHENYL)-3-[2-(2,6-DICHLORO-PHENYL)-1-IMINO-ETHYL]-THIOUREA",,Gag-Pol polyprotein,gag-pol,,unknown
"(3S)-4-{[4-(BUT-2-YNYLOXY)PHENYL]SULFONYL}-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDE",,Disintegrin and metalloproteinase domain-containing protein 17,ADAM17,,unknown
6-(cyclohexylamino)-9-[2-(4-methylpiperazin-1-yl)-ethyl]-9H-purine-2-carbonitrile,,Cathepsin K,CTSK,,unknown
[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
9-CYCLOPENTYL-6-[2-(3-IMIDAZOL-1-YL-PROPOXY)-PHENYLAMINO]-9H-PURINE-2-CARBONITRILE,,Cathepsin K,CTSK,,unknown
N-(2-CHLORO-4-FLUOROBENZOYL)-N'-(5-HYDROXY-2-METHOXYPHENYL)UREA,,"Glycogen phosphorylase, liver form",PYGL,,unknown
3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol,,Hepatocyte growth factor receptor,MET,,unknown
5-[(2-methyl-5-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)amino]pyridine-3-carboxamide,,Ephrin type-A receptor 7,EPHA7,,unknown
"5-AMINO-2-{4-[(4-AMINOPHENYL)SULFANYL]PHENYL}-1H-ISOINDOLE-1,3(2H)-DIONE",,Cytochrome P450 130,cyp130,,unknown
1-(3-METHYLPHENYL)-1H-BENZIMIDAZOL-5-AMINE,,Cytochrome P450 130,cyp130,,unknown
N-(1-ISOPROPYLPIPERIDIN-4-YL)-1-(3-METHOXYBENZYL)-1H-INDOLE-2-CARBOXAMIDE,,Coagulation factor X,F10,,unknown
1-{2-[(4-CHLOROPHENYL)AMINO]-2-OXOETHYL}-N-(1-ISOPROPYLPIPERIDIN-4-YL)-1H-INDOLE-2-CARBOXAMIDE,,Coagulation factor X,F10,,unknown
"2-({[3,5-DIFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID",,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
3-{[(3-FLUORO-3'-METHOXYBIPHENYL-4-YL)AMINO]CARBONYL}THIOPHENE-2-CARBOXYLIC ACID,,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
"3-({[3,5-DIFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)THIOPHENE-2-CARBOXYLIC ACID",,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
"2-({[2,3,5,6-TETRAFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)CYCLOPENTA-1,3-DIENE-1-CARBOXYLIC ACID",,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
"(2E)-3-(3,4-DIHYDROXYPHENYL)-2-IMINOPROPANOIC ACID",,D-amino-acid oxidase,DAO,,unknown
2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-n-[(1R)-1-(hydroxymethyl)propyl]acetamide,,Prostaglandin G/H synthase 1,PTGS1,,unknown
2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol,,Cyclin-dependent kinase 2,CDK2,,unknown
1-(4-IODOBENZOYL)-5-METHOXY-2-METHYL INDOLE-3-ACETIC ACID,,Prostaglandin G/H synthase 1,PTGS1,,unknown
2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-n-[(1S)-1-(hydroxymethyl)propyl]acetamide,,Prostaglandin G/H synthase 1,PTGS1,,unknown
+/-METHYL 4-(AMINOIMINOMETHYL)-BETA-[3- INH (AMINOIMINO)PHENYL]BENZENE PENTANOATE,,Trypsin-1,PRSS1,,unknown
[4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID,,Stromelysin-1,MMP3,,unknown
"[2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER",,Stromelysin-1,MMP3,,unknown
"2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE",,Stromelysin-1,MMP3,,unknown
2-(ACETYL-HYDROXY-AMINO)-4-METHYL-PENTANOIC ACID METHYL ESTER,,Thermolysin,npr,,unknown
"(RP,SP)-O-(2R)-(1-PHENOXYBUT-2-YL)-METHYLPHOSPHONIC ACID CHLORIDE",,Lipase,lipA,,unknown
N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE,,Estrogen receptor alpha,ESR1,,unknown
"N~3~-[3-(1H-INDOL-6-YL)BENZYL]PYRIDINE-2,3-DIAMINE",,Beta-secretase 1,BACE1,,unknown
"N~3~-[5-(1H-INDOL-6-YL)-2-(PYRIDIN-2-YLMETHOXY)BENZYL]PYRIDINE-2,3-DIAMINE",,Beta-secretase 1,BACE1,,unknown
N-[2-(4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
N-[2-(4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
N-[2-(4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE,,Serine/threonine-protein kinase haspin,GSG2,,unknown
5-(2-methylpiperazine-1-sulfonyl)isoquinoline,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
5-(2-methylpiperazine-1-sulfonyl)isoquinoline,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
"{4-[(CARBOXYMETHOXY)CARBONYL]-3,3-DIOXIDO-1-OXONAPHTHO[1,2-D]ISOTHIAZOL-2(1H)-YL}ACETIC ACID",,Aldose reductase,AKR1B1,,unknown
"2-(CARBOXYMETHYL)-1-OXO-1,2-DIHYDRONAPHTHO[1,2-D]ISOTHIAZOLE-4-CARBOXYLIC ACID 3,3-DIOXIDE",,Aldose reductase,AKR1B1,,unknown
5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
ISOTHIAZOLIDINONE ANALOG,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
"(2S)-2-{[3-(3-aminophenyl)imidazo[1,2-b]pyridazin-6-yl]amino}-3-methylbutan-1-ol",,Serine/threonine-protein kinase haspin,GSG2,,unknown
4-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamide,,Mitogen-activated protein kinase 10,MAPK10,,unknown
"N-anthracen-2-yl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
(2R)-3-{[(BENZYLAMINO)CARBONYL]AMINO}-2-HYDROXYPROPANOIC ACID,,Chymotrypsin-like elastase family member 1,CELA1,,unknown
"5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine",,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
"5-[(E)-(5-CHLORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]-N-[2-(DIETHYLAMINO)ETHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE",,Calcium/calmodulin-dependent protein kinase type 1G,CAMK1G,,unknown
"(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime",,Mitogen-activated protein kinase 10,MAPK10,,unknown
"(3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oxime",,Mitogen-activated protein kinase 10,MAPK10,,unknown
(METHYLPYRIDAZINE PIPERIDINE ETHYLOXYPHENYL)ETHYLACETATE,,Genome polyprotein,,,unknown
(METHYLPYRIDAZINE PIPERIDINE ETHYLOXYPHENYL)ETHYLACETATE,,Genome polyprotein,,,unknown
(METHYLPYRIDAZINE PIPERIDINE PROPYLOXYPHENYL)ETHYLACETATE,,Genome polyprotein,,,unknown
(METHYLPYRIDAZINE PIPERIDINE PROPYLOXYPHENYL)ETHYLACETATE,,Genome polyprotein,,,unknown
(METHYLPYRIDAZINE PIPERIDINE BUTYLOXYPHENYL)ETHYLACETATE,,Genome polyprotein,,,unknown
(METHYLPYRIDAZINE PIPERIDINE BUTYLOXYPHENYL)ETHYLACETATE,,Genome polyprotein,,,unknown
"(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oxime",,Mitogen-activated protein kinase 10,MAPK10,,unknown
"4-(6-CHLORO-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL) BUTYL PHOSPHATE",,"6,7-dimethyl-8-ribityllumazine synthase",ribH,,unknown
3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE,,Genome polyprotein,,,unknown
3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE,,Genome polyprotein,,,unknown
"N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE",,"Nitric oxide synthase, brain",NOS1,,unknown
"N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE",,"Nitric oxide synthase, endothelial",NOS3,,unknown
"N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine",,"Nitric oxide synthase, brain",NOS1,,unknown
"N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine",,"Nitric oxide synthase, endothelial",NOS3,,unknown
"(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL",,Estrogen receptor beta,ESR2,,unknown
"(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL",,Estrogen receptor alpha,ESR1,,unknown
5-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide,,Mitogen-activated protein kinase 10,MAPK10,,unknown
"(2S)-1,3-benzothiazol-2-yl{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}ethanenitrile",,Serine/threonine-protein kinase pim-1,PIM1,,unknown
"N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine",,Mitogen-activated protein kinase 10,MAPK10,,unknown
1-[2-(S)-AMINO-3-BIPHENYL-4-YL-PROPIONYL]-PYRROLIDINE-2-(S)-CARBONITRILE,,Dipeptidyl peptidase 4,DPP4,,unknown
"N-{2'-[(4-FLUOROPHENYL)AMINO]-4,4'-BIPYRIDIN-2-YL}-4-METHOXYCYCLOHEXANECARBOXAMIDE",,Mitogen-activated protein kinase 10,MAPK10,,unknown
"2-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-N-methylacetamide",,Mitogen-activated protein kinase 10,MAPK10,,unknown
1-(3-chloro-4-methylphenyl)-3-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)thio]ethyl}urea,,Gag-Pol polyprotein,gag-pol,,unknown
"BUT-3-ENYL-[5-(4-CHLORO-PHENYL)-3,6-DIHYDRO-[1,3,4]THIADIAZIN-2-YLIDENE]-AMINE",,Neutrophil collagenase,MMP8,,unknown
N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide,,Stromelysin-1,MMP3,,unknown
3-[(4'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide,,Stromelysin-1,MMP3,,unknown
"N-[(13-CYCLOHEXYL-6,7-DIHYDROINDOLO[1,2-D][1,4]BENZOXAZEPIN-10-YL)CARBONYL]-2-METHYL-L-ALANINE",,Genome polyprotein,,,unknown
"N,N-DIETHYL-2-[(2-THIENYLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE",,Kinesin-like protein KIF11,KIF11,,unknown
"(5R)-N,N-DIETHYL-5-METHYL-2-[(THIOPHEN-2-YLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE",,Kinesin-like protein KIF11,KIF11,,unknown
"(E)-3,4-DIHYDROXY-N'-[(2-METHOXYNAPHTHALEN-1-YL)METHYLENE]BENZOHYDRAZIDE",,Gag-Pol polyprotein,gag-pol,,unknown
"1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE",,Androgen receptor,AR,,unknown
"6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one",,Putative FAD-monooxygenase,rbmD,,unknown
"(2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide",,Kinesin-like protein KIF11,KIF11,,unknown
"L-alanyl-N-[(1S,2R)-1-benzyl-2-hydroxypropyl]-L-alaninamide",,Kallikrein-7,KLK7,,unknown
"(3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE",,Calmodulin,CALM1,,unknown
"(3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE",,Calcium/calmodulin-dependent protein kinase type II subunit delta,CAMK2D,,unknown
N-[(2R)-2-benzyl-4-(hydroxyamino)-4-oxobutanoyl]-L-alanine,,Leukotriene A-4 hydrolase,LTA4H,,unknown
3-BENZYLOXYCARBONYLAMINO-2-HYDROXY-4-PHENYL-BUTYRIC ACID,,Gag-Pol polyprotein,gag-pol,,unknown
"N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine",,Vascular endothelial growth factor receptor 2,KDR,,unknown
1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA,,Tyrosine-protein kinase ABL1,ABL1,,unknown
"(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE",,Dipeptidyl peptidase 4,DPP4,,unknown
"4-{4-[4-(3-AMINOPROPOXY)PHENYL]-1H-PYRAZOL-5-YL}-6-CHLOROBENZENE-1,3-DIOL",,Heat shock protein HSP 90-beta,HSP90AB1,,unknown
2-chloro-5-[(1S)-1-hydroxy-3-oxo-2H-isoindol-1-yl]benzenesulfonamide,,Carbonic anhydrase 2,CA2,,unknown
"4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol",,Estrogen receptor alpha,ESR1,,unknown
"4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol",,Nuclear receptor coactivator 2,NCOA2,,unknown
"4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL",,Estrogen receptor alpha,ESR1,,unknown
"4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL",,Nuclear receptor coactivator 2,NCOA2,,unknown
"7,8-dihydroxy-4-phenyl-2H-chromen-2-one",,Catechol O-methyltransferase,COMT,,unknown
5-phenyl-2-keto-valeric acid,,Indole-3-pyruvate decarboxylase,ipdC,,unknown
"(2R)-4-(2-BENZOYL-1,2-DIAZEPAN-1-YL)-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE",,Dipeptidyl peptidase 4,DPP4,,unknown
"1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
"1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
"1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
"N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine",,Tyrosine-protein kinase Lck,LCK,,unknown
"N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine",,Tyrosine-protein kinase Lck,LCK,,unknown
"N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine",,Tyrosine-protein kinase Lck,LCK,,unknown
"4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one",,Poly [ADP-ribose] polymerase 3,PARP3,,unknown
"(1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE",,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,,unknown
"(1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE",,Serine/threonine-protein kinase PLK1,PLK1,,unknown
"(1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE",,Phosphatidylinositol 3-kinase regulatory subunit alpha,PIK3R1,,unknown
"(1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE",,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",PIK3CA,,unknown
4-(2-AMINOPHENYL)-4-OXOBUTANOIC ACID,,Serine--pyruvate aminotransferase,AGXT,,unknown
4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE,,Prothrombin,F2,,unknown
"3-(4-CHLOROPHENYL)-5-(METHYLTHIO)-4H-1,2,4-TRIAZOLE",,Prothrombin,F2,,unknown
"1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE",,Retinoic acid receptor RXR-alpha,RXRA,,unknown
"1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE",,Oxysterols receptor LXR-alpha,NR1H3,,unknown
N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA,,Mitogen-activated protein kinase 14,MAPK14,,unknown
2-(1H-pyrazol-3-yl)-1H-benzimidazole,,Aurora kinase A,AURKA,,unknown
N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE,,Aurora kinase A,AURKA,,unknown
N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE,,Cyclin-dependent kinase 2,CDK2,,unknown
4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM,,Tyrosine-protein kinase JAK2,JAK2,,unknown
N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-,,Mitogen-activated protein kinase 14,MAPK14,,unknown
"4-AMINO-5-(2-METHYLPHENYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOLE-3-THIONE",,Metallo-beta-lactamase L1,,,unknown
2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
"(2S)-1-methyl-2-[(2S,4R)-2-methyl-4-phenylpentyl]piperidine",,Probable L-lysine-epsilon aminotransferase,lat,,unknown
"4-(2-AMINOETHOXY)-3,5-DICHLORO-N-[3-(1-METHYLETHOXY)PHENYL]BENZAMIDE",,Urokinase-type plasminogen activator,PLAU,,unknown
(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE,,RAC-beta serine/threonine-protein kinase,AKT2,,unknown
(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE,,Glycogen synthase kinase-3 beta,GSK3B,,unknown
(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
3-(3-methylbut-2-en-1-yl)-3H-purin-6-amine,,Biotin carboxylase,accC,,unknown
"4-(2-amino-1,3-thiazol-4-yl)pyrimidin-2-amine",,Biotin carboxylase,accC,,unknown
"4-[1-(2,6-dichlorobenzyl)-2-methyl-1H-imidazol-4-yl]pyrimidin-2-amine",,Biotin carboxylase,accC,,unknown
"2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID",,Hemoglobin subunit alpha,HBA1,,unknown
"2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID",,Hemoglobin subunit beta,HBB,,unknown
{4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy}acetic acid,,Peroxisome proliferator-activated receptor delta,PPARD,,unknown
AMG-208,,Met proto-oncogene variant,,,unknown
LATRUNCULIN B,,"Actin, alpha skeletal muscle",ACTA1,,unknown
LATRUNCULIN B,,MKL/myocardin-like protein 1,MKL1,,unknown
LATRUNCULIN B,,Protein spire homolog 2,SPIRE2,,unknown
3-OXO-OCTANOIC ACID (2-OXO-TETRAHYDRO-FURAN-3-YL)-AMIDE,,Transcriptional activator protein TraR,traR,,unknown
3-OXO-OCTANOIC ACID (2-OXO-TETRAHYDRO-FURAN-3-YL)-AMIDE,,Probable transcriptional activator protein TraR,traR,,unknown
3-OXO-OCTANOIC ACID (2-OXO-TETRAHYDRO-FURAN-3-YL)-AMIDE,,Probable transcriptional repressor TraM,traM,,unknown
N-(2-AMINOETHYL)-P-CHLOROBENZAMIDE,,Amine oxidase [flavin-containing] B,MAOB,,unknown
"2-(1,3-thiazol-4-yl)-1H-benzimidazole-5-sulfonamide",,Carbonic anhydrase 2,CA2,,unknown
IDD594,,Aldose reductase,AKR1B1,,unknown
1-(4-HEXYLPHENYL)PROP-2-EN-1-ONE,,Thyroid hormone receptor beta,THRB,,unknown
N-[12-(1H-imidazol-1-yl)dodecanoyl]-L-leucine,,Bifunctional P-450/NADPH-P450 reductase,cyp102A1,,unknown
"4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE",,Androgen receptor,AR,,unknown
"2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile",,Androgen receptor,AR,,unknown
LGD-2226,,Androgen receptor,AR,,unknown
"(3Z,5S,6R,7S,8R,8aR)-3-(octylimino)hexahydro[1,3]oxazolo[3,4-a]pyridine-5,6,7,8-tetrol",,Beta-glucosidase A,bglA,,unknown
3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE,,Mitogen-activated protein kinase 14,MAPK14,,unknown
3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide,,Mitogen-activated protein kinase 14,MAPK14,,unknown
3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE,,Mitogen-activated protein kinase 14,MAPK14,,unknown
"(4-AMINO-2-{[1-(METHYLSULFONYL)PIPERIDIN-4-YL]AMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONE",,Cyclin-dependent kinase 2,CDK2,,unknown
"3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA",,Mitogen-activated protein kinase 14,MAPK14,,unknown
"8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM",,Mitogen-activated protein kinase 14,MAPK14,,unknown
"2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE",,Mitogen-activated protein kinase 14,MAPK14,,unknown
"{[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-yl]thio}acetic acid",,Aldose reductase,AKR1B1,,unknown
"6-ethyl-5-[(2S)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine",,Renin,REN,,unknown
N-[(6-butoxynaphthalen-2-yl)sulfonyl]-L-glutamic acid,,UDP-N-acetylmuramoylalanine--D-glutamate ligase,murD,,unknown
N-[(6-butoxynaphthalen-2-yl)sulfonyl]-D-glutamic acid,,UDP-N-acetylmuramoylalanine--D-glutamate ligase,murD,,unknown
N-{[6-(PENTYLOXY)NAPHTHALEN-2-YL]SULFONYL}-D-GLUTAMIC ACID,,UDP-N-acetylmuramoylalanine--D-glutamate ligase,murD,,unknown
N-({6-[(4-CYANOBENZYL)OXY]NAPHTHALEN-2-YL}SULFONYL)-D-GLUTAMIC ACID,,UDP-N-acetylmuramoylalanine--D-glutamate ligase,murD,,unknown
"(1S,4R,7AR)-4-BUTOXY-1-[(1R)-1-FORMYLPROPYL]-2,4,5,6,7,7A-HEXAHYDRO-1H-ISOINDOLE-3-CARBOXYLIC ACID",,Beta-lactamase,ampC,,unknown
"(1R,4S,7AS)-1-(1-FORMYLPROP-1-EN-1-YL)-4-METHOXY-2,4,5,6,7,7A-HEXAHYDRO-1H-ISOINDOLE-3-CARBOXYLIC ACID",,Beta-lactamase,ampC,,unknown
"4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]phenol",,Met proto-oncogene variant,,,unknown
N-({6-[(4-CYANO-2-FLUOROBENZYL)OXY]NAPHTHALEN-2-YL}SULFONYL)-D-GLUTAMIC ACID,,UDP-N-acetylmuramoylalanine--D-glutamate ligase,murD,,unknown
3-pyridin-4-yl-1H-indazole,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
3-pyridin-4-yl-1H-indazole,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
"5-benzyl-1,3-thiazol-2-amine",,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
"5-benzyl-1,3-thiazol-2-amine",,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
2-aminoethyl naphthalen-1-ylacetate,,Gag-Pol polyprotein,gag-pol,,unknown
"(3R)-4-{[(3,4-dihydroxyphenyl)acetyl]oxy}-N-(2-formylindolizin-3-yl)-3-sulfino-D-valine",,Beta-lactamase SHV-1,bla,,unknown
"2-(methylamino)-N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]benzamide",,Glucokinase,GCK,,unknown
"1,1,1-TRIFLUORO-3-((N-ACETYL)-L-LEUCYLAMIDO)-4-PHENYL-BUTAN-2-ONE(N-ACETYL-L-LEUCYL-L-PHENYLALANYL TRIFLUOROMETHYL KETONE)",,Chymotrypsinogen B,CTRB1,,unknown
"6,8-DIMERCAPTO-OCTANOIC ACID AMIDE",,Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex,,,unknown
(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
"N-METHYL-4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
"N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
"3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
"3-{[4-([AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE",,Cyclin-dependent kinase 2,CDK2,,unknown
"(1S,4R,9S)-5-(trifluoromethyl)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-9-amine",,Phenylethanolamine N-methyltransferase,PNMT,,unknown
(1R)-2-amino-1-[3-(trifluoromethyl)phenyl]ethanol,,Phenylethanolamine N-methyltransferase,PNMT,,unknown
"N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine",,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,,unknown
"2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-3-METHYL-BUTYRIC ACID",,Thymidylate synthase,thyA,,unknown
5-hydroxynaphthalene-1-sulfonamide,,Cyclin-dependent kinase 2,CDK2,,unknown
N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide,,Cyclin-dependent kinase 2,CDK2,,unknown
4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide,,Cyclin-dependent kinase 2,CDK2,,unknown
N-phenyl-1H-pyrazole-3-carboxamide,,Cyclin-dependent kinase 2,CDK2,,unknown
4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide,,Cyclin-dependent kinase 2,CDK2,,unknown
(4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide,,Cyclin-dependent kinase 2,CDK2,,unknown
"{[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide",,Cyclin-dependent kinase 2,CDK2,,unknown
"5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile",,Cyclin-dependent kinase 2,CDK2,,unknown
"5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide",,Cyclin-dependent kinase 2,CDK2,,unknown
"5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID ((3S,4S)-4-FLUORO- 1-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYLCARBAMOYL]-METHYL}-PYRROLIDIN-3-YL)-AMIDE",,Coagulation factor X,F10,,unknown
"6-(2,6-dibromophenyl)pyrido[2,3-d]pyrimidine-2,7-diamine",,Biotin carboxylase,accC,,unknown
"6-(2,6-DIMETHOXYPHENYL)PYRIDO[2,3-D]PYRIMIDINE-2,7-DIAMINE",,Biotin carboxylase,accC,,unknown
"7-(2,5-dihydropyrrol-1-yl)-6-phenyl-pyrido[6,5-d]pyrimidin-2-amine",,Biotin carboxylase,accC,,unknown
"4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
"1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine",,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
"1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine",,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
"1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine",,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
"1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine",,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
"4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium",,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
"4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium",,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
"(5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
{(2S)-1-[N-(tert-butoxycarbonyl)glycyl]pyrrolidin-2-yl}methyl (3-chlorophenyl)acetate,,Prothrombin,F2,,unknown
"(5E)-14-CHLORO-15,17-DIHYDROXY-4,7,8,9,10,11-HEXAHYDRO-2-BENZOXACYCLOPENTADECINE-1,12(3H,13H)-DIONE",,Heat shock protein HSP 90-beta,HSP90AB1,,unknown
3-chloro-5-[2-chloro-5-(1H-indazol-3-ylmethoxy)phenoxy]benzonitrile,,Gag-Pol polyprotein,gag-pol,,unknown
N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE,,Carbonic anhydrase 1,CA1,,unknown
N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE,,Carbonic anhydrase 2,CA2,,unknown
3-[4-(AMINOSULFONYL)PHENYL]PROPANOIC ACID,,Carbonic anhydrase 1,CA1,,unknown
3-[4-(AMINOSULFONYL)PHENYL]PROPANOIC ACID,,Carbonic anhydrase 2,CA2,,unknown
ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE,,Carbonic anhydrase 1,CA1,,unknown
ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE,,Carbonic anhydrase 2,CA2,,unknown
"2,4-DINITROPHENYL 2-DEOXY-2-FLUORO-BETA-D-MANNOPYRANOSIDE",,Beta-mannosidase,,,unknown
"4-(5,11-DIOXO-5H-INDENO[1,2-C]ISOQUINOLIN-6(11H)-YL)BUTANOATE",,DNA topoisomerase 1,TOP1,,unknown
"(2S)-2-AMINO-4-(METHYLSULFANYL)-1-(1,3-THIAZOL-2-YL)BUTANE-1,1-DIOL",,Methionine aminopeptidase,map,,unknown
(S)-2-(MERCAPTOMETHYL)-5-PHENYLPENTANOIC ACID,,Class B carbapenemase VIM-2,VIM-2,,unknown
Fasudil,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
Fasudil,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
Fasudil,,Rho-associated protein kinase 1,ROCK1,,unknown
Fasudil,,Rho-associated protein kinase 2,ROCK2,,unknown
5'-{[4-(aminooxy)butyl](methyl)amino}-5'-deoxy-8-ethenyladenosine,,S-adenosylmethionine decarboxylase proenzyme,AMD1,,unknown
"(3R,4R)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-3-AMINE",,Dipeptidyl peptidase 4,DPP4,,unknown
indane-5-sulfonamide,,Carbonic anhydrase 2,CA2,,unknown
"(4R)-7-chloro-9-methyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile",,Serine/threonine-protein kinase pim-1,PIM1,,unknown
Methylthioninium,,Acetylcholinesterase,ACHE,,unknown
Methylthioninium,,"Bacterial regulatory protein, TetR family",,,unknown
7-AMINO-4-METHYL-CHROMEN-2-ONE,,Peptidyl-prolyl cis-trans isomerase A,ppiA,,unknown
7-AMINO-4-METHYL-CHROMEN-2-ONE,,"Peptidyl-prolyl cis-trans isomerase F, mitochondrial",PPIF,,unknown
7-AMINO-4-METHYL-CHROMEN-2-ONE,,Histone deacetylase 8,HDAC8,,unknown
(2Z)-N-biphenyl-4-yl-2-cyano-3-cyclopropyl-3-hydroxyprop-2-enamide,,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
"(1R)-N,6-DIHYDROXY-7-METHOXY-2-[(4-METHOXYPHENYL)SULFONYL]-1,2,3,4-TETRAHYDROISOQUINOLINE-1-CARBOXAMIDE",,Matrilysin,MMP7,,unknown
11-MERCAPTOUNDECANOIC ACID,,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,,unknown
(2Z)-N-(3-chloro-2'-methoxybiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide,,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
5-CHLORO-N-(2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)ETHYL)THIOPHENE-2-CARBOXAMIDE,,Coagulation factor X,F10,,unknown
"5-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO) CYCLOPENTYL)THIOPHENE-2-CARBOXAMIDE",,Coagulation factor X,F10,,unknown
"(2E,4E)-11-METHOXY-3,7,11-TRIMETHYLDODECA-2,4-DIENOIC ACID",,Nuclear receptor coactivator 2,NCOA2,,unknown
"(2E,4E)-11-METHOXY-3,7,11-TRIMETHYLDODECA-2,4-DIENOIC ACID",,Retinoic acid receptor RXR-beta,RXRB,,unknown
"(2E,4E)-11-METHOXY-3,7,11-TRIMETHYLDODECA-2,4-DIENOIC ACID",,Oxysterols receptor LXR-alpha,NR1H3,,unknown
(1Z)-4-(4-FLUOROPHENYL)-2-METHYLIDENEBUTAN-1-IMINE,,Amine oxidase [flavin-containing] B,MAOB,,unknown
(E)-3-(5((5-(4-CHLOROPHENYL)FURAN-2-YL)METHYLENE)-4-OXO-2-THIOXOTHIAZOLIDIN-3-YL)PROPANOIC ACID,,Lethal factor,lef,,unknown
"4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine",,Cyclin-A2,CCNA2,,unknown
"methyl 4-(2,3-dihydroxy-5-methylphenoxy)-2-hydroxy-6-methylbenzoate",,Lactoylglutathione lyase,GLO1,,unknown
2-[METHYL-(5-GERANYL-4-METHYL-PENT-3-ENYL)-AMINO]-ETHYL-DIPHOSPHATE,,Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha,FNTA,,unknown
2-[METHYL-(5-GERANYL-4-METHYL-PENT-3-ENYL)-AMINO]-ETHYL-DIPHOSPHATE,,Geranylgeranyl transferase type-1 subunit beta,PGGT1B,,unknown
2-((3'-METHYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID,,Streptavidin,,,unknown
"4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine",,Cyclin-A2,CCNA2,,unknown
2-(2-METHYLPHENYL)-1H-INDOLE-5-CARBOXIMIDAMIDE,,Trypsin-1,PRSS1,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,Elongation factor Tu,tuf,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S12,rpsL,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S10,rpsJ,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S11,rpsK,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S13,rpsM,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S14 type Z,rpsZ,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S15,rpsO,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S16,rpsP,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S17,rpsQ,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S18,rpsR,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S19,rpsS,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S20,rpsT,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S4,rpsD,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S5,rpsE,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S6,rpsF,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S7,rpsG,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S8,rpsH,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S9,rpsI,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein Thx,rpsU,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S17,rpsQ,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S20,rpsT,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S2,rpsB,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S3,rpsC,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S9,rpsI,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S19,rpsS,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S2,rpsB,,unknown
2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,30S ribosomal protein S3,rpsC,,unknown
(3E)-4-(1-METHYL-1H-INDOL-3-YL)BUT-3-EN-2-ONE,,Histone acetyltransferase KAT2B,KAT2B,,unknown
METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE,,Prothrombin,F2,,unknown
Emivirine,,Gag-Pol polyprotein,gag-pol,,unknown
N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide,,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,,unknown
"4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid",,Serine/threonine-protein kinase Sgk1,SGK1,,unknown
2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
2-(3-NITROPHENYL)ACETIC ACID,,Penicillin G acylase,pac,,unknown
"4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
(1R)-2-[(CYANOMETHYL)AMINO]-1-({[2-(DIFLUOROMETHOXY)BENZYL]SULFONYL}METHYL)-2-OXOETHYL MORPHOLINE-4-CARBOXYLATE,,Cathepsin S,CTSS,,unknown
"2-((3',5'-DIMETHOXY-4'-HYDROXYPHENYL)AZO)BENZOIC ACID",,Streptavidin,,,unknown
"(5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"[(4R)-4-(3-HYDROXYPHENYL)-1,6-DIMETHYL-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL](PHENYL)METHANONE",,Kinesin-like protein KIF11,KIF11,,unknown
N-[(BENZYLOXY)CARBONYL]-L-CYSTEINYLGLYCINE,,Metallo-beta-lactamase L1,,,unknown
(1R)-menthyl hexyl phosphonate group,,Cholinesterase,BCHE,,unknown
(1S)-menthyl hexyl phosphonate group,,Cholinesterase,BCHE,,unknown
4-({[(4-METHYLPIPERAZIN-1-YL)AMINO]CARBONOTHIOYL}AMINO)BENZENESULFONAMIDE,,Carbonic anhydrase 2,CA2,,unknown
"7-[2-METHOXY-1-(METHOXYMETHYL)ETHYL]-7H-PYRROLO[3,2-F] QUINAZOLINE-1,3-DIAMINE",,"Dihydrofolate reductase, mitochondrial",DHFRL1,,unknown
3-DIPHENOL-6-NITRO-3H-BENZO[DE]ISOCHROMEN-1-ONE,,Thymidylate synthase,thyA,,unknown
"2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE",,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,,unknown
2-(4-DIMETHYLAMINOPHENYL)DIAZENYLBENZOIC ACID,,FMN-dependent NADH-azoreductase 1,azoR1,,unknown
"2-AMINO-4-FLUORO-5-[(1-METHYL-1H-IMIDAZOL-2-YL)SULFANYL]-N-(1,3-THIAZOL-2-YL)BENZAMIDE",,Glucokinase,GCK,,unknown
5-bromo-3-(pyrrolidin-1-ylsulfonyl)-1H-indole-2-carboxamide,,Gag-Pol polyprotein,gag-pol,,unknown
1-[2-(3-ACETYL-2-HYDROXY-6-METHOXY-PHENYL)-CYCLOPROPYL]-3-(5-CYANO-PYRIDIN-2-YL)-THIOUREA,,Gag-Pol polyprotein,gag-pol,,unknown
"1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE",,Caspase-3,CASP3,,unknown
4-(1H-IMIDAZOL-1-YL)PHENOL,,"Nitric oxide synthase, inducible",NOS2,,unknown
2-T-BUTYLAMINO-4-ETHYLAMINO-6-METHYLTHIO-S-TRIAZINE,,Photosynthetic reaction center cytochrome c subunit,pufC,,unknown
2-T-BUTYLAMINO-4-ETHYLAMINO-6-METHYLTHIO-S-TRIAZINE,,Reaction center protein H chain,puhA,,unknown
2-T-BUTYLAMINO-4-ETHYLAMINO-6-METHYLTHIO-S-TRIAZINE,,Reaction center protein L chain,pufL,,unknown
2-T-BUTYLAMINO-4-ETHYLAMINO-6-METHYLTHIO-S-TRIAZINE,,Reaction center protein M chain,pufM,,unknown
2-T-BUTYLAMINO-4-ETHYLAMINO-6-METHYLTHIO-S-TRIAZINE,,Reaction center protein L chain,pufL,,unknown
2-T-BUTYLAMINO-4-ETHYLAMINO-6-METHYLTHIO-S-TRIAZINE,,Reaction center protein M chain,pufM,,unknown
2-T-BUTYLAMINO-4-ETHYLAMINO-6-METHYLTHIO-S-TRIAZINE,,Reaction center protein H chain,puhA,,unknown
2-((3'-TERTBUTYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID,,Streptavidin,,,unknown
"S-[(1-Hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl] methanesulfonothioate",,Eukaryotic translation initiation factor 4E,EIF4E,,unknown
"S-[(1-Hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl] methanesulfonothioate",,Uncharacterized protein,,,unknown
"S-[(1-Hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl] methanesulfonothioate",,Carcinoembryonic antigen-related cell adhesion molecule 5,CEACAM5,,unknown
"S-[(1-Hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl] methanesulfonothioate",,Afimbrial adhesin AFA-III,afaE3,,unknown
"HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM",,Cyclin-A2,CCNA2,,unknown
"HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE",,Cyclin-A2,CCNA2,,unknown
"4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE",,Cyclin-dependent kinase 2,CDK2,,unknown
"(8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid",,Nuclear receptor coactivator 1,NCOA1,,unknown
"(8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid",,Bile acid receptor,NR1H4,,unknown
N-{4-METHYL-3-[(3-PYRIMIDIN-4-YLPYRIDIN-2-YL)AMINO]PHENYL}-3-(TRIFLUOROMETHYL)BENZAMIDE,,Angiopoietin-1 receptor,TEK,,unknown
METHOXYUNDECYLPHOSPHINIC ACID,,Colipase,CLPS,,unknown
METHOXYUNDECYLPHOSPHINIC ACID,,Pancreatic triacylglycerol lipase,PNLIP,,unknown
"(1S,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-7-METHYL-8-[2-[(2R,4R)-TETRAHYDRO-4-HY DROXY-6-OXO-2H-PYRAN-2-YL]ETHYL]-1-NAPHTHALENOL",,Liver carboxylesterase 1,CES1,,unknown
Myxopyronin B,,DNA-directed RNA polymerase subunit alpha,rpoA,,unknown
Myxopyronin B,,DNA-directed RNA polymerase subunit beta,rpoB,,unknown
Myxopyronin B,,DNA-directed RNA polymerase subunit beta',rpoC,,unknown
Myxopyronin B,,DNA-directed RNA polymerase subunit omega,rpoZ,,unknown
Myxopyronin B,,RNA polymerase sigma factor,sigA,,unknown
"1-(1-HYDROXY-2,2,6,6-TETRAMETHYLPIPERIDIN-4-YL)PYRROLIDINE-2,5-DIONE",,Maltose-binding periplasmic protein,malE,,unknown
"5,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one",,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,,unknown
[N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID,,Caspase-3,CASP3,,unknown
"5,7-DIHYDROXY-2-(3,4,5-TRIHYDROXYPHENYL)-4H-CHROMEN-4-ONE",,Serine/threonine-protein kinase pim-1,PIM1,,unknown
Myristic acid,,Genome polyprotein,,,unknown
Myristic acid,,Genome polyprotein,,,unknown
Myristic acid,,Genome polyprotein,,,unknown
Myristic acid,,Genome polyprotein,,,unknown
Myristic acid,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
Myristic acid,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
Myristic acid,,Genome polyprotein,,,unknown
Myristic acid,,Genome polyprotein,,,unknown
Myristic acid,,Genome polyprotein,,,unknown
Myristic acid,,Genome polyprotein,,,unknown
Myristic acid,,Genome polyprotein,,,unknown
Myristic acid,,Fatty acid metabolism regulator protein,fadR,,unknown
Myristic acid,,"Enoyl-CoA delta isomerase 2, mitochondrial",ECI2,,unknown
Myristic acid,,Recoverin,RCVRN,,unknown
Myristic acid,,Calmodulin,CALM1,,unknown
Myristic acid,,Non-fluorescent flavoprotein,luxF,,unknown
Myristic acid,,Genome polyprotein,,,unknown
Myristic acid,,Tyrosine-protein kinase ABL1,ABL1,,unknown
Myristic acid,,UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase,lpxC,,unknown
Myristic acid,,Genome polyprotein,,,unknown
Myristic acid,,Hepatocyte nuclear factor 4-alpha,HNF4A,,unknown
Myristic acid,,Nuclear receptor coactivator 1,NCOA1,,unknown
Myristic acid,,Protein Nef,nef,,unknown
Myristic acid,,Ferrichrome-iron receptor,fhuA,,unknown
Myristic acid,,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,,unknown
Myristic acid,,Calcineurin subunit B type 1,PPP3R1,,unknown
Myristic acid,,Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform,PPP3CA,,unknown
Myristic acid,,Alpha-pyrone synthesis polyketide synthase-like Pks18,pks18,,unknown
Myristic acid,,Gag-Pol polyprotein,gag-pol,,unknown
Myristic acid,,Trafficking protein particle complex subunit 3,TRAPPC3,,unknown
Myristic acid,,Insulin,INS,,unknown
Myristic acid,,Genome polyprotein,,,unknown
Myristic acid,,Polyprotein,,,unknown
Myristic acid,,Ganglioside GM2 activator,GM2A,,unknown
Myristic acid,,ADP-ribosylation factor 6,ARF6,,unknown
Myristic acid,,Lymphocyte antigen 96,LY96,,unknown
Myristic acid,,Protein TonB,tonB,,unknown
Myristic acid,,Gag polyprotein,gag,,unknown
Myristic acid,,Gag-Pol polyprotein,gag-pol,,unknown
Myristic acid,,ADP-ribosylation factor 1,ARF1,,unknown
Myristic acid,,Guanylyl cyclase-activating protein 1,GUCA1A,,unknown
Myristic acid,,R2-like ligand binding oxidase,nrdB,,unknown
Myristic acid,,Poliovirus receptor,PVR,,unknown
Myristic acid,,Toll-like receptor 4,TLR4,,unknown
Myristic acid,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
"[5-(5-Amino-1H-pyrrolo[3,2-b]pyridin-2-yl)-6-hydroxy-3'-nitro-3-biphenylyl]acetic acid",,Coagulation factor VII,F7,,unknown
"[5-(5-Amino-1H-pyrrolo[3,2-b]pyridin-2-yl)-6-hydroxy-3'-nitro-3-biphenylyl]acetic acid",,Tissue factor,F3,,unknown
6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE,,Cyclin-A2,CCNA2,,unknown
6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE,,Cyclin-dependent kinase 2,CDK2,,unknown
"5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine",,Dihydrofolate reductase,dfrA,,unknown
"5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine",,Dihydrofolate reductase,DHFR,,unknown
"5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine",,Dihydrofolate reductase (dfrB),dfrB,,unknown
"5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine",,Dihydrofolate reductase,folA,,unknown
N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide,,Actin-related protein 2/3 complex subunit 1B,ARPC1B,,unknown
N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide,,Actin-related protein 2,ACTR2,,unknown
N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide,,Actin-related protein 3,ACTR3,,unknown
N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide,,Actin-related protein 2/3 complex subunit 2,ARPC2,,unknown
N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide,,Actin-related protein 2/3 complex subunit 3,ARPC3,,unknown
N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide,,Actin-related protein 2/3 complex subunit 4,ARPC4,,unknown
N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide,,Actin-related protein 2/3 complex subunit 5,ARPC5,,unknown
"(2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one",,Actin-related protein 2/3 complex subunit 1B,ARPC1B,,unknown
"(2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one",,Actin-related protein 2,ACTR2,,unknown
"(2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one",,Actin-related protein 3,ACTR3,,unknown
"(2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one",,Actin-related protein 2/3 complex subunit 2,ARPC2,,unknown
"(2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one",,Actin-related protein 2/3 complex subunit 3,ARPC3,,unknown
"(2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one",,Actin-related protein 2/3 complex subunit 4,ARPC4,,unknown
"(2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one",,Actin-related protein 2/3 complex subunit 5,ARPC5,,unknown
2'-deoxy-N-(naphthalen-1-ylmethyl)guanosine 5'-(dihydrogen phosphate),,DNA polymerase kappa,POLK,,unknown
5-AMINO-NAPHTALENE-2-MONOSULFONATE,,Fibroblast growth factor 1,FGF1,,unknown
"(2S)-4-(2,5-DIFLUOROPHENYL)-N-METHYL-2-PHENYL-N-PIPERIDIN-4-YL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE",,Kinesin-like protein KIF11,KIF11,,unknown
N-(4-CHLOROPHENYL)-3-(PHOSPHONOOXY)NAPHTHALENE-2-CARBOXAMIDE,,Fructose-bisphosphate aldolase A,ALDOA,,unknown
4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE,,Cyclin-A2,CCNA2,,unknown
4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE,,Cyclin-dependent kinase 2,CDK2,,unknown
"N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide",,Mitogen-activated protein kinase 14,MAPK14,,unknown
"(1S)-1-CYCLOPROPYL-2-[(2S)-4-(2,5-DIFLUOROPHENYL)-2-PHENYL-2,5-DIHYDRO-1H-PYRROL-1-YL]-2-OXOETHANAMINE",,Kinesin-like protein KIF11,KIF11,,unknown
1-(2-DEOXY-5-O-PHOSPHONO-BETA-D-ERYTHRO-PENTOFURANOSYL)-5-NITRO-1H-INDOLE,,DNA polymerase,43,,unknown
"(2S)-4-(2,5-DIFLUOROPHENYL)-N,N-DIMETHYL-2-PHENYL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE",,Kinesin-like protein KIF11,KIF11,,unknown
6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE,,Cyclin-dependent kinase 2,CDK2,,unknown
3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE,,Cyclin-A2,CCNA2,,unknown
3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE,,Cyclin-dependent kinase 2,CDK2,,unknown
"3,6,9,12,15-PENTAOXATRICOSAN-1-OL",,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,,unknown
"3,6,9,12,15-PENTAOXATRICOSAN-1-OL",,Fatty acid oxidation complex subunit alpha,fadB,,unknown
"3,6,9,12,15-PENTAOXATRICOSAN-1-OL",,3-ketoacyl-CoA thiolase,fadA,,unknown
"3,6,9,12,15-PENTAOXATRICOSAN-1-OL",,Ferripyoverdine receptor,fpvA,,unknown
"(5S)-5-(3-AMINOPROPYL)-3-(2,5-DIFLUOROPHENYL)-N-ETHYL-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE",,Kinesin-like protein KIF11,KIF11,,unknown
4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID,,Caspase-3,CASP3,,unknown
2-((4'-HYDROXYNAPHTHYL)-AZO)BENZOIC ACID,,Streptavidin,,,unknown
NAM NAPTHYLAMINOALANINE,,Pol polyprotein,pol,,unknown
2-NAPHTHALENESULFONIC ACID,,Prothrombin,F2,,unknown
2-NAPHTHALENESULFONIC ACID,,Trypsin-1,PRSS1,,unknown
"(3AR,5R,6S,7R,7AR)-5-(HYDROXYMETHYL)-2-PROPYL-5,6,7,7A-TETRAHYDRO-3AH-PYRANO[3,2-D][1,3]THIAZOLE-6,7-DIOL",,O-GlcNAcase BT_4395,,,unknown
N-[(CYCLOHEXYLAMINO)CARBONYL]GLYCINE,,Bifunctional epoxide hydrolase 2,EPHX2,,unknown
4-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}BUTANOIC ACID,,Bifunctional epoxide hydrolase 2,EPHX2,,unknown
6-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEXANOIC ACID,,Bifunctional epoxide hydrolase 2,EPHX2,,unknown
7-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEPTANOIC ACID,,Bifunctional epoxide hydrolase 2,EPHX2,,unknown
"(1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide",,Beta-glucosidase A,bglA,,unknown
"2-hydroxy-7-methoxy-5-methyl-naphthalene-1-carboxylic acid meso-2,5-dihydroxy-cyclopent-3-enyl ester",,Neocarzinostatin,ncsA,,unknown
"2,6-dicarboxynaphthalene",,Hemoglobin subunit alpha,HBA1,,unknown
"2,6-dicarboxynaphthalene",,Hemoglobin subunit beta,HBB,,unknown
N-(carboxycarbonyl)-D-phenylalanine,,Hypoxia-inducible factor 1-alpha inhibitor,HIF1AN,,unknown
"(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene",,"Naphthalene 1,2-dioxygenase subunit alpha",ndoB,,unknown
"(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene",,"Naphthalene 1,2-dioxygenase subunit beta",ndoC,,unknown
"2-(TOLUENE-4-SULFONYL)-2H-BENZO[D][1,2,3]DIAZABORININ-1-OL",,Enoyl-[acyl-carrier-protein] reductase [NADH] FabI,fabI,,unknown
"Methyl [(1E,5R)-5-{3-[(2E,4E)-2,5-dimethyl-2,4-octadienoyl]-2,4-dioxo-3,4-dihydro-2H-pyran-6-yl}hexylidene]carbamate",,DNA-directed RNA polymerase subunit alpha,rpoA,,unknown
"Methyl [(1E,5R)-5-{3-[(2E,4E)-2,5-dimethyl-2,4-octadienoyl]-2,4-dioxo-3,4-dihydro-2H-pyran-6-yl}hexylidene]carbamate",,DNA-directed RNA polymerase subunit beta,rpoB,,unknown
"Methyl [(1E,5R)-5-{3-[(2E,4E)-2,5-dimethyl-2,4-octadienoyl]-2,4-dioxo-3,4-dihydro-2H-pyran-6-yl}hexylidene]carbamate",,DNA-directed RNA polymerase subunit beta',rpoC,,unknown
"Methyl [(1E,5R)-5-{3-[(2E,4E)-2,5-dimethyl-2,4-octadienoyl]-2,4-dioxo-3,4-dihydro-2H-pyran-6-yl}hexylidene]carbamate",,DNA-directed RNA polymerase subunit omega,rpoZ,,unknown
"Methyl [(1E,5R)-5-{3-[(2E,4E)-2,5-dimethyl-2,4-octadienoyl]-2,4-dioxo-3,4-dihydro-2H-pyran-6-yl}hexylidene]carbamate",,RNA polymerase sigma factor,sigA,,unknown
"6-amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,Queuine tRNA-ribosyltransferase,tgt,,unknown
"6-AMINO-4-[2-(4-METHYLPHENYL)ETHYL]-1,7-DIHYDRO-8H-IMIDAZO[4,5-G]QUINAZOLIN-8-ONE",,Queuine tRNA-ribosyltransferase,tgt,,unknown
"N-(2-AMINOETHYL)-N~2~-{(1S)-1-[4'-(AMINOSULFONYL)BIPHENYL-4-YL]-2,2,2-TRIFLUOROETHYL}-L-LEUCINAMIDE",,Cathepsin K,CTSK,,unknown
N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID,,Stromelysin-2,MMP10,,unknown
N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID,,Macrophage metalloelastase,MMP12,,unknown
N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID,,Stromelysin-1,MMP3,,unknown
N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID,,Matrix metalloproteinase-20,MMP20,,unknown
(4S)-4-(2-NAPHTHYLMETHYL)-D-GLUTAMIC ACID,,Glutamate racemase,murI,,unknown
4-HYDROXY-5-IODO-3-NITROPHENYLACETYL-EPSILON-AMINOCAPROIC ACID ANION,,Ig heavy chain V-I region ND,IGHV1-2,,unknown
4-HYDROXY-5-IODO-3-NITROPHENYLACETYL-EPSILON-AMINOCAPROIC ACID ANION,,Ig lambda chain V region 4A,,,unknown
"6,7,8,9-TETRAHYDRO-4-HYDROXY-3-(1-PHENYLPROPYL)CYCLOHEPTA[B]PYRAN-2-ONE",,Gag-Pol polyprotein,gag-pol,,unknown
N-DODECANOYL-L-TYROSINE,,Long-chain N-acyl amino acid synthase,,,unknown
trifluoro-[hydroxy-[hydroxy-[2-(N-methyl-2-nitro-anilino)ethoxy]phosphoryl]oxy-phosphoryl]oxy-beryllium(1-),,Myosin-14,MYH14,,unknown
"2-(2-CHLORO-4-FLUOROPHENOXY)-2-METHYL-N-[(1R,2S,3S,5S,7S)-5-(METHYLSULFONYL)-2-ADAMANTYL]PROPANAMIDE",,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
"1-(2-CYCLOPROPYLETHYL)-3-(1,1-DIOXIDO-2H-1,2,4-BENZOTHIADIAZIN-3-YL)-6-FLUORO-4-HYDROXYQUINOLIN-2(1H)-ONE",,Genome polyprotein,,,unknown
3-{ISOPROPYL[(TRANS-4-METHYLCYCLOHEXYL)CARBONYL]AMINO}-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID,,Genome polyprotein,,,unknown
"(1S,3R,4S,5S,7S)-4-{[2-(4-METHOXYPHENOXY)-2-METHYLPROPANOYL]AMINO}ADAMANTANE-1-CARBOXAMIDE",,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
"O-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl] (4-bromophenyl)thiocarbamate",,Gag-Pol polyprotein,gag-pol,,unknown
"O-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl] (4-chlorophenyl)thiocarbamate",,Gag-Pol polyprotein,gag-pol,,unknown
"(2R,3R,4R,5S)-2-(HYDROXYMETHYL)-1-NONYLPIPERIDINE-3,4,5-TRIOL",,Glucosylceramidase,GBA,,unknown
"O-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl] (4-iodophenyl)thiocarbamate",,Gag-Pol polyprotein,gag-pol,,unknown
"(2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol",,Cyclin-dependent kinase 2,CDK2,,unknown
"(2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol",,Cyclin-A2,CCNA2,,unknown
NAPHTHYLOXYACETIC ACID,,Gag-Pol polyprotein,gag-pol,,unknown
NAPHTHYLOXYACETIC ACID,,Gag-Pol polyprotein,gag-pol,,unknown
"(1R,2R)-N-(2-AMINOETHYL)-2-{[(4-METHOXYPHENYL)SULFONYL]METHYL}CYCLOHEXANECARBOXAMIDE",,Cathepsin K,CTSK,,unknown
N-(PARA-GLUTARAMIDOPHENYL-ETHYL)-PIPERIDINIUM-N-OXIDE,,Ig kappa chain C region,IGKC,,unknown
N-(3-AMINOPROPYL)-2-NITROBENZENAMINE,,Histone acetyltransferase KAT2B,KAT2B,,unknown
"(5Z)-12-CHLORO-13,15-DIHYDROXY-4,7,8,9-TETRAHYDRO-2-BENZOXACYCLOTRIDECINE-1,10(3H,11H)-DIONE",,Heat shock protein HSP 90-beta,HSP90AB1,,unknown
"(5E)-12-CHLORO-13,15-DIHYDROXY-4,7,8,9-TETRAHYDRO-2-BENZOXACYCLOTRIDECINE-1,10(3H,11H)-DIONE",,Heat shock protein HSP 90-beta,HSP90AB1,,unknown
2-(4-HYDROXY-3-NITROPHENYL)ACETIC ACID,,Ig heavy chain V-I region ND,IGHV1-2,,unknown
2-(4-HYDROXY-3-NITROPHENYL)ACETIC ACID,,Ig gamma-1 chain C region,IGHG1,,unknown
4-HYDROXY-3-NITROPHENYLACETYL-EPSILON-AMINOCAPROIC ACID ANION,,Ig heavy chain V-I region ND,IGHV1-2,,unknown
4-HYDROXY-3-NITROPHENYLACETYL-EPSILON-AMINOCAPROIC ACID ANION,,Ig lambda chain V region 4A,,,unknown
5-(PARA-NITROPHENYL PHOSPHONATE)-PENTANOIC ACID,,Ig gamma-1 chain C region,IGHG1,,unknown
ORTHONITROPHENYL-BETA-D-FUCOPYRANOSIDE,,Lactose operon repressor,lacI,,unknown
"4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid",,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,,unknown
"4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid",,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,,unknown
"4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid",,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,,unknown
"1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,,unknown
N-({[4-(AMINOSULFONYL)PHENYL]AMINO}CARBONYL)-4-METHYLBENZENESULFONAMIDE,,Carbonic anhydrase 2,CA2,,unknown
3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
"(3S)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide",,Glutamate receptor 2,GRIA2,,unknown
"(3R)-3-cyclopentyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxide",,Glutamate receptor 2,GRIA2,,unknown
"(3R)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxide",,Glutamate receptor 2,GRIA2,,unknown
3-[(3-Nitrophenyl)sulfamoyl]-2-thiophenecarboxylic acid,,Beta-lactamase,ampC,,unknown
"2-{HYDROXY[2-NITRO-4-(TRIFLUOROMETHYL)PHENYL]METHYLENE}CYCLOHEXANE-1,3-DIONE",,4-hydroxyphenylpyruvate dioxygenase,hpd,,unknown
"SUCCINIC ACID MONO-(13-METHYL-3-OXO-2,3,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL) ESTER",,Steroid Delta-isomerase,ksi,,unknown
3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL,,Cyclin-dependent kinase 2,CDK2,,unknown
3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL,,Cyclin-A2,CCNA2,,unknown
"N-[(2R)-2-{[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl}hexyl]-N-hydroxyformamide",,Peptide deformylase,def,,unknown
"6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE",,Cyclin-dependent kinase 2,CDK2,,unknown
nocodazole,,Hematopoietic prostaglandin D synthase,HPGDS,,unknown
"(2-AMINO-1,3-OXAZOL-5-YL)-(3-BROMOPHENYL)METHANONE",,Biotin carboxylase,accC,,unknown
"2-AMINO-N,N-BIS(PHENYLMETHYL)-1,3-OXAZOLE-5-CARBOXAMIDE",,Biotin carboxylase,accC,,unknown
"4-amino-7,7-dimethyl-7,8-dihydroquinazolin-5(6H)-one",,Biotin carboxylase,accC,,unknown
"5-methyl-6-phenylquinazoline-2,4-diamine",,Biotin carboxylase,accC,,unknown
"6-(2-phenoxyethoxy)-1,3,5-triazine-2,4-diamine",,Biotin carboxylase,accC,,unknown
"2'-HYDROXY-1,1'-BIPHENYL-2-SULFINIC ACID",,2'-hydroxybiphenyl-2-sulfinate desulfinase,soxB,,unknown
"DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE",,Estrogen receptor alpha,ESR1,,unknown
"DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE",,Nuclear receptor coactivator 2,NCOA2,,unknown
"(1S,2S,3R,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol",,Alpha-mannosidase 2,MAN2A1,,unknown
"2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
3-OXO-N-[(3S)-2-OXOPYRROLIDIN-3-YL]DODECANAMIDE,,Ig gamma-2 chain C region,IGHG2,,unknown
N-3-OXO-DODECANOYL-L-HOMOSERINE LACTONE,,Transcriptional activator protein LasR,lasR,,unknown
2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9-ISOPROPYLPURINE,,Casein kinase I isoform gamma-1,CSNK1G1,,unknown
2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9-ISOPROPYLPURINE,,Tyrosine-protein kinase Mer,MERTK,,unknown
"2-(6-HYDROXY-1,3-BENZOTHIAZOL-2-YL)-1,3-THIAZOL-4(5H)-ONE",,Long-chain-fatty-acid--CoA ligase ACSBG1,ACSBG1,,unknown
"2-(3,6-DIHYDROXYPHENYL)ACETIC ACID",,Penicillin G acylase,pac,,unknown
PANTOTHENYL-AMINOETHANOL-11-PIVALIC ACID,,Acetyl-CoA acetyltransferase,phbA,,unknown
Sulthiame,,Carbonic anhydrase 2,CA2,,unknown
METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE,,"Cytochrome c1, heme protein, mitochondrial",CYC1,,unknown
METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE,,Cytochrome b,MT-CYB,,unknown
METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE,,"Cytochrome b-c1 complex subunit 1, mitochondrial",UQCRC1,,unknown
METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE,,"Cytochrome b-c1 complex subunit 2, mitochondrial",UQCRC2,,unknown
METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE,,"Cytochrome b-c1 complex subunit 6, mitochondrial",UQCRH,,unknown
METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE,,Cytochrome b-c1 complex subunit 8,UQCRQ,,unknown
METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE,,"Cytochrome b-c1 complex subunit Rieske, mitochondrial",UQCRFS1,,unknown
METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE,,Cytochrome b-c1 complex subunit 10,UQCR11,,unknown
METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE,,Cytochrome b-c1 complex subunit 7,UQCRB,,unknown
METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE,,Cytochrome b-c1 complex subunit 9,UQCR10,,unknown
"N-1H-imidazol-2-yl-N'-[4-(1H-imidazol-2-ylamino)phenyl]benzene-1,4-diamine",,Gag-Pol polyprotein,gag-pol,,unknown
9-(2-carboxyethyl)-10-methylanthracene endoperoxide,,Ig gamma-1 chain C region,IGHG1,,unknown
4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME,,Macrophage migration inhibitory factor,MIF,,unknown
3-FLUORO-4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME,,Macrophage migration inhibitory factor,MIF,,unknown
"4-HYDROXYBENZALDEHYDE O-(3,3-DIMETHYLBUTANOYL)OXIME",,Macrophage migration inhibitory factor,MIF,,unknown
"2-Methyl-2-propanyl [(1R)-2-methyl-1-(1,3,4-oxadiazol-2-yl)propyl]carbamate",,Beta-lactamase,ampC,,unknown
"2-Methyl-2-propanyl [(1S)-2-methyl-1-(1,3,4-oxadiazol-2-yl)propyl]carbamate",,Beta-lactamase,ampC,,unknown
"19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one",,Casein kinase II subunit alpha,CSNK2A1,,unknown
"6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}-8-METHYLPYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE",,Tyrosine-protein kinase ABL1,ABL1,,unknown
"N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE",,Casein kinase II subunit alpha,CSNK2A1,,unknown
"4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide",,Protein-tyrosine kinase 2-beta,PTK2B,,unknown
S-PALMITOYL-L-CYSTEINE,,Trafficking protein particle complex subunit 6A,TRAPPC6A,,unknown
S-PALMITOYL-L-CYSTEINE,,Trafficking protein particle complex subunit 3,TRAPPC3,,unknown
S-PALMITOYL-L-CYSTEINE,,Trafficking protein particle complex subunit 6B,TRAPPC6B,,unknown
S-PALMITOYL-L-CYSTEINE,,Trafficking protein particle complex subunit 5,TRAPPC5,,unknown
S-PALMITOYL-L-CYSTEINE,,Trafficking protein particle complex subunit 4,TRAPPC4,,unknown
S-PALMITOYL-L-CYSTEINE,,Trafficking protein particle complex subunit 1,TRAPPC1,,unknown
4-chloro-N-(3-methoxypropyl)-N-[(3S)-1-(2-phenylethyl)piperidin-3-yl]benzamide,,Bifunctional protein GlmU,glmU,,unknown
"4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE",,Casein kinase II subunit alpha,CSNK2A1,,unknown
"(5Z)-13-CHLORO-14,16-DIHYDROXY-3,4,7,8,9,10-HEXAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,11(12H)-DIONE",,Heat shock protein HSP 90-beta,HSP90AB1,,unknown
4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile,,Beta-1 adrenergic receptor,ADRB1,,unknown
"N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE",,Exotoxin A,eta,,unknown
"N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE",,Elongation factor 2,EEF2,,unknown
"N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE",,Cholix toxin,chxA,,unknown
"N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE",,Poly [ADP-ribose] polymerase 3,PARP3,,unknown
"N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE",,Poly [ADP-ribose] polymerase 15,PARP15,,unknown
"N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide",,Mitogen-activated protein kinase 14,MAPK14,,unknown
"5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE",,Tyrosine-protein kinase ABL1,ABL1,,unknown
N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide,,Mitogen-activated protein kinase 14,MAPK14,,unknown
"6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine",,Mitogen-activated protein kinase 14,MAPK14,,unknown
"2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE",,Casein kinase II subunit alpha,CSNK2A1,,unknown
"2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE",,Casein kinase II subunit alpha,CSNK2A1,,unknown
"1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid",,Cyclin-A2,CCNA2,,unknown
"1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-[4-(4-methoxyphenyl)-5-methyl-1H-pyrazol-3-yl]benzene-1,3-diol",,"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial",PDK4,,unknown
1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE,,Acetylcholinesterase,ACHE,,unknown
1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE,,Uncharacterized lipoprotein YbbD,nagZ,,unknown
1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE,,Phosphoenolpyruvate-protein phosphotransferase,ptsP,,unknown
"2-(2-QUINOLIN-3-YLPYRIDIN-4-YL)-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE",,MAP kinase-activated protein kinase 2,MAPKAPK2,,unknown
"2-(2-QUINOLIN-3-YLPYRIDIN-4-YL)-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE",,MAP kinase-activated protein kinase 3,MAPKAPK3,,unknown
2-PHENYLAMINO-4-METHYL-5-ACETYL THIAZOLE,,3-oxoacyl-[acyl-carrier-protein] synthase 1,fabB,,unknown
"2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE",,Casein kinase II subunit alpha,CSNK2A1,,unknown
"2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide",,Tyrosine-protein kinase SYK,SYK,,unknown
"N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE",,Casein kinase II subunit alpha,CSNK2A1,,unknown
1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine,,Cellular tumor antigen p53,TP53,,unknown
1-{[(1E)-(3-HYDROXY-2-METHYL-5-{[(TRIHYDROXY-LAMBDA^5^-PHOSPHANYL)OXY]METHYL}PYRIDIN-4-YL)METHYLIDENE]AMINO}UNDECAN-2-ONE,,CAI-1 autoinducer synthase,cqsA,,unknown
"8-bromo-4-(2-chlorophenyl)-N-(2-hydroxyethyl)-6-methyl-1,3-dioxo-1,2,3,6-tetrahydropyrrolo[3,4-e]indole-7-carboxamide",,Wee1-like protein kinase,WEE1,,unknown
"3-({3-[(1S,4aS,6S,7S,9S,9aR)-1,6-dimethyl-2-oxodecahydro-6,9-epoxy-4a,7-methanobenzo[7]annulen-1-yl]propanoyl}amino)-2,4-dihydroxybenzoic acid",,3-oxoacyl-[acyl-carrier-protein] synthase 2,fabF,,unknown
(R)-2-(FORMYLOXY)-3-(PHOSPHONOOXY)PROPYL PENTANOATE,,Rhomboid protease GlpG,glpG,,unknown
"OCTANE-1,3,5,7-TETRACARBOXYLIC ACID",,Carboxypeptidase A1,CPA1,,unknown
1-(biphenyl-4-ylmethyl)-1H-imidazole,,Cytochrome P450 2B6,CYP2B6,,unknown
S-(4-BROMOBENZYL)CYSTEINE,,Glutathione S-transferase P,GSTP1,,unknown
PARA-(BENZOYL)-PHENYLALANINE,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
PARA-(BENZOYL)-PHENYLALANINE,,"Tyrosine--tRNA ligase, cytoplasmic",YARS,,unknown
1-[2-(4-ETHOXY-3-FLUOROPYRIDIN-2-YL)ETHYL]-3-(5-METHYLPYRIDIN-2-YL)THIOUREA,,Gag-Pol polyprotein,gag-pol,,unknown
1-[2-(4-ETHOXY-3-FLUOROPYRIDIN-2-YL)ETHYL]-3-(5-METHYLPYRIDIN-2-YL)THIOUREA,,Gag-Pol polyprotein,gag-pol,,unknown
"4,4'-BIS([H]METHYLSULFONYL)-2,2',5,5'-TETRACHLOROBIPHENYL",,Uteroglobin,SCGB1A1,,unknown
(3S)-3-Amino-1-chloro-4-phenyl-2-butanone,,Chymotrypsinogen B,CTRB1,,unknown
PCNOTAXIME Group,,Penicillin-binding protein 1A,pbpA,,unknown
PCNOTAXIME Group,,Beta-lactamase Toho-1,bla,,unknown
PCNOTAXIME Group,,Beta-lactamase,ampC,,unknown
"(2R)-3-(phosphonooxy)propane-1,2-diyl diheptanoate",,Phospholipase D,,,unknown
N-[4-(4-nitrophenylphospho)butanoyl]-D-alanine,,Ig gamma-1 chain C region,IGHG1,,unknown
"4-[4-(2,5-DIOXO-PYRROLIDIN-1-YL)-PHENYLAMINO]-4-HYDROXY-BUTYRIC ACID",,Myosin light chain 6B,MYL6B,,unknown
"4-[4-(2,5-DIOXO-PYRROLIDIN-1-YL)-PHENYLAMINO]-4-HYDROXY-BUTYRIC ACID",,Myosin regulatory light chain 12A,MYL12A,,unknown
"4-[4-(2,5-DIOXO-PYRROLIDIN-1-YL)-PHENYLAMINO]-4-HYDROXY-BUTYRIC ACID",,Myosin-7,MYH7,,unknown
6-(4-chloro-2-fluoro-3-phenoxybenzyl)pyridazin-3(2H)-one,,Gag-Pol polyprotein,gag-pol,,unknown
Gosogliptin,,Dipeptidyl peptidase 4,DPP4,,yes
"4,5-bis(4-methoxyphenyl)-2-thiophen-2-yl-1H-imidazole",,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",PDE10A,,unknown
2-({4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline,,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",PDE10A,,unknown
4-(quinolin-3-ylmethyl)piperidine-1-carboxylic acid,,Fatty-acid amide hydrolase 1,FAAH,,unknown
2-{[4-(4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline,,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",PDE10A,,unknown
2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline,,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",PDE10A,,unknown
"5-(2-ETHOXYETHYL)-5-[4-(4-FLUOROPHENOXY)PHENOXY]PYRIMIDINE-2,4,6(1H,3H,5H)-TRIONE",,Collagenase 3,MMP13,,unknown
"6,7-DIMETHOXY-4-[(3R)-3-(2-NAPHTHYLOXY)PYRROLIDIN-1-YL]QUINAZOLINE",,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",PDE10A,,unknown
"(6S)-6-CYCLOPENTYL-6-[2-(3-FLUORO-4-ISOPROPOXYPHENYL)ETHYL]-4-HYDROXY-5,6-DIHYDRO-2H-PYRAN-2-ONE",,Genome polyprotein,,,unknown
"6,7-DIMETHOXY-4-[(3R)-3-(QUINOXALIN-2-YLOXY)PYRROLIDIN-1-YL]QUINAZOLINE",,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",PDE10A,,unknown
"2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
PARA-NITROPHENYLPHOSPHONOBUTANOYL-GLYCINE,,Ig gamma-1 chain C region,IGHG1,,unknown
2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE,,Mitogen-activated protein kinase 14,MAPK14,,unknown
"4-{[(Z)-(5-OXO-2-PHENYL-1,3-OXAZOL-4(5H)-YLIDENE)METHYL]AMINO}BUTANOIC ACID",,Ig heavy chain V-III region CAM,IGHV3-30,,unknown
6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
"2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine",,Estrogen receptor alpha,ESR1,,unknown
"2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine",,Nuclear receptor coactivator 2,NCOA2,,unknown
PICEATANNOL,,"ATP synthase subunit alpha, mitochondrial",ATP5A1,,unknown
PICEATANNOL,,"ATP synthase subunit beta, mitochondrial",ATP5B,,unknown
PICEATANNOL,,"ATP synthase subunit gamma, mitochondrial",ATP5C1,,unknown
4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzyl)piperidine-1-carboxylic acid,,Fatty-acid amide hydrolase 1,FAAH,,unknown
(2E)-2-({(2S)-2-CARBOXY-2-[(PHENOXYACETYL)AMINO]ETHOXY}IMINO)PENTANEDIOIC ACID,,Penicillin-binding protein 1B,pbp1b,,unknown
"2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID",,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
"2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID",,Nuclear receptor coactivator 2,NCOA2,,unknown
"2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID",,Retinoic acid receptor RXR-alpha,RXRA,,unknown
METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID,,Interstitial collagenase,MMP1,,unknown
METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID,,Neutrophil collagenase,MMP8,,unknown
"S-(2-{[N-(2-HYDROXY-4-{[HYDROXY(OXIDO)PHOSPHINO]OXY}-3,3-DIMETHYLBUTANOYL)-BETA-ALANYL]AMINO}ETHYL) HEXANETHIOATE",,Acyl carrier protein,acpP,,unknown
"S-(2-{[N-(2-HYDROXY-4-{[HYDROXY(OXIDO)PHOSPHINO]OXY}-3,3-DIMETHYLBUTANOYL)-BETA-ALANYL]AMINO}ETHYL) HEPTANETHIOATE",,Acyl carrier protein,acpP,,unknown
"[N-(2,4-DIAMINOPTERIDIN-6-YL)-METHYL]-DIBENZ[B,F]AZEPINE",,Dihydrofolate reductase,DHFR,,unknown
PLATENSIMYCIN,,3-oxoacyl-[acyl-carrier-protein] synthase 2,fabF,,unknown
"(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-({3-oxo-3-[(2-sulfanylethyl)amino]propyl}amino)butyl 2,2-dimethylpropanoate",,Acetyl-CoA acetyltransferase,phbA,,unknown
4-NITRO-BENZYLPHOSPHONOBUTANOYL-GLYCINE,,Ig gamma-1 chain C region,IGHG1,,unknown
4-NITRO-BENZYLPHOSPHONOBUTANOYL-GLYCINE,,Ig gamma-2 chain C region,IGHG2,,unknown
PARA-NITROBENZYL GLUTARYL GLYCINIC ACID,,Ig gamma-1 chain C region,IGHG1,,unknown
N-[4-(4-nitrophenylphospho)butanoyl]-L-alanine,,Ig gamma-1 chain C region,IGHG1,,unknown
6-{4-[HYDROXY-(4-NITRO-PHENOXY)-PHOSPHORYL]-BUTYRYLAMINO}-HEXANOIC ACID,,Ig gamma-1 chain C region,IGHG1,,unknown
METHYL-PHOSPHONIC ACID MONO-(4-NITRO-PHENYL) ESTER,,Ig kappa chain C region,IGKC,,unknown
METHYL-PHOSPHONIC ACID MONO-(4-NITRO-PHENYL) ESTER,,"Alkaline phosphatase, placental type",ALPP,,unknown
"6-CHLORO-2-(1-FURO[2,3-C]PYRIDIN-5-YL-ETHYLSULFANYL)-PYRIMIDIN-4-YLAMINE",,Gag-Pol polyprotein,gag-pol,,unknown
"(9BETA,13ALPHA,14BETA,17ALPHA)-2-METHOXYESTRA-1,3,5(10)-TRIENE-3,17-DIYL DISULFAMATE",,Carbonic anhydrase 2,CA2,,unknown
"(4aS,4bR,10bS,12aS)-12a-methyl-1,3-dioxo-2-(pyridin-3-ylmethyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-dodecahydronaphtho[2,1-f]isoquinolin-8-yl sulfamate",,Carbonic anhydrase 2,CA2,,unknown
(1S)-1-(PHENOXYMETHYL)PROPYL METHYLPHOSPHONOCHLORIDOATE,,Lipase,lipA,,unknown
1-{[1-(2-AMINO-3-PHENYL-PROPIONYL)-PYRROLIDINE-2-CARBONYL]-AMINO}-2-(3-CYANO-PHENYL)-ETHANEBORONIC ACID,,Trypsin-1,PRSS1,,unknown
PIPERIDINE-2-CARBOXYLIC ACID TERT-BUTYLAMIDE,,Gag-Pol polyprotein,gag-pol,,unknown
[PHENYLALANINYL-PROLINYL]-[2-(PYRIDIN-4-YLAMINO)-ETHYL]-AMINE,,Prothrombin,F2,,unknown
[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE,,Mitogen-activated protein kinase 14,MAPK14,,unknown
"[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE",,Mitogen-activated protein kinase 14,MAPK14,,unknown
"THIENO[3,2-B]PYRIDINE-2-SULFONIC ACID [2-OXO-1-(1H-PYRROLO[2,3-C]PYRIDIN-2-YLMETHYL)-PYRROLIDIN-3-YL]-AMIDE",,Coagulation factor X,F10,,unknown
PREPHENIC ACID,,Chorismate mutase AroH,aroH,,unknown
3(S)-AMINO-4-PHENYL-BUTAN-2(S)-OL,,Gag-Pol polyprotein,gag-pol,,unknown
3(S)-AMINO-4-PHENYL-BUTAN-2(S)-OL,,Gag-Pol polyprotein,gag-pol,,unknown
N-({(2S)-1-[(3R)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamide,,Dipeptidyl peptidase 4,DPP4,,unknown
PARA-NITROPHENYL 1-THIO-BETA-D-GLUCOPYRANOSIDE,,Lactase-like protein,LCTL,,unknown
"[(3R,4S)-4-HYDROXY-3-METHYL-2-OXOHEXYL]PHOSPHONIC ACID",,Type I polyketide synthase PikAIV,pikAIV,,unknown
THYMIDINE-5'-THIOPHOSPHATE,,DNA polymerase I,polA,,unknown
phenyl ethenesulfonate,,Tyrosine-protein phosphatase YopH,yopH,,unknown
2-METHYLCARBAMOYL-3-(4-PHOSPHONOOXY-PHENYL)-CYCLOPROPANECARBOXYLIC ACID,,Tyrosine-protein kinase transforming protein Src,V-SRC,,unknown
"(5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid",,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
"8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
Puromycin,,60S ribosomal protein L10-like,RPL10L,,unknown
Puromycin,,60S ribosomal protein L13a,RPL13A,,unknown
Puromycin,,60S ribosomal protein L23,RPL23,,unknown
Puromycin,,60S ribosomal protein L15,RPL15,,unknown
Puromycin,,60S ribosomal protein L19,RPL19,,unknown
Puromycin,,60S ribosomal protein L23a,RPL23A,,unknown
Puromycin,,Probable ribosome biogenesis protein RLP24,RSL24D1,,unknown
Puromycin,,60S ribosomal protein L26-like 1,RPL26L1,,unknown
Puromycin,,60S ribosomal protein L8,RPL8,,unknown
Puromycin,,60S ribosomal protein L37,RPL37,,unknown
Puromycin,,60S ribosomal protein L3,RPL3,,unknown
Puromycin,,60S ribosomal protein L11,RPL11,,unknown
Puromycin,,Leucyl/phenylalanyl-tRNA--protein transferase,aat,,unknown
"(2E,4R,5S)-2,3,4,5-TETRAHYDROXY-6-(PALMITOYLOXY)HEX-2-ENOIC ACID",,Hyaluronate lyase,,,unknown
Parecoxib,22 minutes (parecoxib); 8 hours (valdecoxib),Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Parecoxib,22 minutes (parecoxib); 8 hours (valdecoxib),Lactotransferrin,LTF,,unknown
"N-1,10-phenanthrolin-5-ylacetamide",,Soluble cytochrome b562,cybC,,unknown
"6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
"4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"3-[2-bromo-4-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-methylbenzonitrile",,Gag-Pol polyprotein,gag-pol,,unknown
"(3R,4S)-1-[6-(6-METHOXYPYRIDIN-3-YL)PYRIMIDIN-4-YL]-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE",,Dipeptidyl peptidase 4,DPP4,,unknown
"3-[6-bromo-2-fluoro-3-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-chlorobenzonitrile",,Gag-Pol polyprotein,gag-pol,,unknown
3-{3-[(DIMETHYLAMINO)METHYL]-1H-INDOL-7-YL}PROPAN-1-OL,,Group IIE secretory phospholipase A2,PLA2G2E,,unknown
"(4aS)-5-[(2,4-diaminopteridin-6-yl)methyl]-4a,5-dihydro-2H-dibenzo[b,f]azepin-8-ol",,Dihydrofolate reductase,DHFR,,unknown
"2-(3-((4,5,7-trifluorobenzo[d]thiazol-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)acetic acid",,Aldose reductase,AKR1B1,,unknown
N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine,,TGF-beta receptor type-1,TGFBR1,,unknown
N-(QUINOLIN-8-YL)METHANESULFONAMIDE,,Methionine aminopeptidase,map,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,"Cytochrome c1, heme protein, mitochondrial",CYC1,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,Cytochrome b,MT-CYB,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,"Cytochrome b-c1 complex subunit 1, mitochondrial",UQCRC1,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,"Cytochrome b-c1 complex subunit 2, mitochondrial",UQCRC2,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,"Cytochrome b-c1 complex subunit 6, mitochondrial",UQCRH,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,Cytochrome b-c1 complex subunit 8,UQCRQ,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,"Cytochrome b-c1 complex subunit Rieske, mitochondrial",UQCRFS1,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,Cytochrome b-c1 complex subunit 10,UQCR11,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,Cytochrome b-c1 complex subunit 7,UQCRB,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,Cytochrome b-c1 complex subunit 9,UQCR10,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,Cytochrome b6,petB,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,Apocytochrome f,petA,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,Cytochrome b6-f complex iron-sulfur subunit,petC,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,Cytochrome b6-f complex subunit 4,petD,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,Cytochrome b6-f complex subunit 5,petG,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,Cytochrome b6-f complex subunit 6,petL,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,Cytochrome b6-f complex subunit 7,petM,,unknown
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,Cytochrome b6-f complex subunit 8,petN,,unknown
N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE,,Calcium/calmodulin-dependent protein kinase type 1D,CAMK1D,,unknown
"S-[(1-Hydroxy-2,2,5,5-tetramethyl-4-phenyl-2,5-dihydro-1H-pyrrol-3-yl)methyl] methanesulfonothioate",,Lysozyme,E,,unknown
"4-(3,5-DIMETHYLPHENOXY)-5-(FURAN-2-YLMETHYLSULFANYLMETHYL)-3-IODO-6-METHYLPYRIDIN-2(1H)-ONE",,Gag-Pol polyprotein,gag-pol,,unknown
(4-BROMOPHENYL)[4-({(2E)-4-[CYCLOPROPYL(METHYL)AMINO]BUT-2-ENYL}OXY)PHENYL]METHANONE,,Squalene--hopene cyclase,shc,,unknown
"3-chloro-5-[2-chloro-5-(1H-pyrazolo[3,4-b]pyridin-3-ylmethoxy)phenoxy]benzonitrile",,Gag-Pol polyprotein,gag-pol,,unknown
"3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridin-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile",,Gag-Pol polyprotein,gag-pol,,unknown
"3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL",,Androgen receptor,AR,,unknown
N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
(2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol,,Cyclin-dependent kinase 2,CDK2,,unknown
(2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol,,Cyclin-A2,CCNA2,,unknown
"METHYL 3-CHLORO-2-{3-[(2,5-DIHYDROXY-4-METHOXYPHENYL)AMINO]-3-OXOPROPYL}-4,6-DIHYDROXYBENZOATE",,Heat shock protein HSP 90-beta,HSP90AB1,,unknown
"METHYL 3-CHLORO-2-{3-[(2,5-DIHYDROXY-4-METHOXYPHENYL)AMINO]-3-OXOPROPYL}-4,6-DIHYDROXYBENZOATE",,Endoplasmin,HSP90B1,,unknown
"2-(3-AMINO-2,5,6-TRIMETHOXYPHENYL)ETHYL 5-CHLORO-2,4-DIHYDROXYBENZOATE",,Heat shock protein HSP 90-beta,HSP90AB1,,unknown
"2-(3-AMINO-2,5,6-TRIMETHOXYPHENYL)ETHYL 5-CHLORO-2,4-DIHYDROXYBENZOATE",,Endoplasmin,HSP90B1,,unknown
"5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol",,Leukotriene A-4 hydrolase,LTA4H,,unknown
"tert-butyl 4-(3-thiophen-2-yl-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate",,HTH-type transcriptional regulator EthR,ethR,,unknown
"3-(4-fluorophenyl)-5-phenyl-4H-1,2,4-triazole",,HTH-type transcriptional regulator EthR,ethR,,unknown
"1-(thiophen-2-ylacetyl)-4-(3-thiophen-2-yl-1,2,4-oxadiazol-5-yl)piperidine",,HTH-type transcriptional regulator EthR,ethR,,unknown
(R)-Fluoxetine,,Transporter,snf,,unknown
"5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole",,Casein kinase II subunit alpha,CSNK2A1,,unknown
3-(CARBOXYAMIDE(2-CARBOXYAMIDE-2-TERTBUTYLETHYL))PENTAN,,Gag-Pol polyprotein,gag-pol,,unknown
"[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl hydrogen hex-5-enylphosphonate",,Lipase EstA,estA,,unknown
3-AMINO-AZACYCLOTRIDECAN-2-ONE,,Neutrophil collagenase,MMP8,,unknown
N-[2-chloro-5-(trifluoromethyl)phenyl]imidodicarbonimidic diamide,,Thymidylate synthase,TYMS,,unknown
"N-(3,5-dimethoxyphenyl)imidodicarbonimidic diamide",,Thymidylate synthase,TYMS,,unknown
4-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN,,Amine oxidase [flavin-containing] B,MAOB,,unknown
"4-METHYL-N-{(5E)-5-[(5-METHYL-2-FURYL)METHYLENE]-4-OXO-4,5-DIHYDRO-1,3-THIAZOL-2-YL}BENZENESULFONAMIDE",,Genome polyprotein,,,unknown
[[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER,,Interstitial collagenase,MMP1,,unknown
4-AMINO-N-[(2-SULFANYLETHYL)CARBAMOYL]BENZENESULFONAMIDE,,"Fructose-1,6-bisphosphatase 1",FBP1,,unknown
"(1S,4S,5S)-1,4,5-TRIHYDROXY-3-[3-(PHENYLTHIO)PHENYL]CYCLOHEX-2-ENE-1-CARBOXYLIC ACID",,3-dehydroquinate dehydratase,aroQ,,unknown
Efaproxiral,,Hemoglobin subunit alpha,HBA1,,unknown
Efaproxiral,,Hemoglobin subunit beta,HBB,,unknown
3-({4-[(6-CHLORO-1-BENZOTHIEN-2-YL)SULFONYL]-2-OXOPIPERAZIN-1-YL}METHYL)BENZENECARBOXIMIDAMIDE,,Coagulation factor X,F10,,unknown
"4-{[(E)-2-(5-CHLOROTHIEN-2-YL)VINYL]SULFONYL}-1-(1H-PYRROLO[3,2-C]PYRIDIN-2-YLMETHYL)PIPERAZIN-2-ONE",,Coagulation factor X,F10,,unknown
"N4-HYDROXY-2-ISOBUTYL-N1-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YL)-SUCCINAMIDE",,Matrilysin,MMP7,,unknown
CTS-1027,,Collagenase 3,MMP13,,unknown
N-HYDROXY-2-[4-(4-PHENOXY-BENZENESULFONYL)-TETRAHYDRO-PYRAN-4-YL]-ACETAMIDE,,Interstitial collagenase,MMP1,,unknown
(2E)-3-(2-OCT-1-YN-1-YLPHENYL)ACRYLIC ACID,,Arachidonate 15-lipoxygenase,ALOX15,,unknown
"5-METHYL-3-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YLCARBAMOYL)-HEXANOIC ACID",,Matrilysin,MMP7,,unknown
"S-{2-[(2-chloro-4-sulfamoylphenyl)amino]-2-oxoethyl} 6-methyl-3,4-dihydroquinoline-1(2H)-carbothioate",,Gag-Pol polyprotein,gag-pol,,unknown
4-({4-[(6-CHLORO-1-BENZOTHIEN-2-YL)SULFONYL]-2-OXOPIPERAZIN-1-YL}METHYL)BENZENECARBOXIMIDAMIDE,,Coagulation factor X,F10,,unknown
"(1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate",,Caspase-3,CASP3,,unknown
"(1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate",,Caspase-3,CASP3,,unknown
"N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide",,Caspase-3,CASP3,,unknown
"(3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
"DIETHYL PROPANE-1,3-DIYLBISCARBAMATE",,Shiga-like toxin 1 subunit B,stxB,,unknown
Capravirine,,Gag-Pol polyprotein,gag-pol,,unknown
"(3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol",,"Glycogen phosphorylase, muscle form",PYGM,,unknown
"6-(4-{(1S,2S)-2-AMINO-1-[(DIMETHYLAMINO)CARBONYL]-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-3-OXOPROPYL}PHENYL)-1H-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-4-IUM",,Dipeptidyl peptidase 4,DPP4,,unknown
methyl 4-bromo-N-[8-(hydroxyamino)-8-oxooctanoyl]-L-phenylalaninate,,Histone deacetylase-like amidohydrolase,hdaH,,unknown
N-{(2S)-3-[(1R)-1-aminoethyl](hydroxy)phosphoryl-2-benzylpropanoyl}-L-phenylalanine,,Aminopeptidase N,pepN,,unknown
N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID,,Stromelysin-1,MMP3,,unknown
N-BENZOYL-D-ALANINE,,Penicillin-binding protein 1b,pbp1b,,unknown
1-[6-(2-CHLORO-4-METHYXYPHENOXY)-HEXYL]-IMIDAZOLE,,Genome polyprotein,,,unknown
5-ALPHA-PREGNANE-3-BETA-OL-HEMISUCCINATE,,Ig gamma-2 chain C region,IGHG2,,unknown
"6-amino-2-methyl-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,Queuine tRNA-ribosyltransferase,tgt,,unknown
"6-amino-2-[(1-naphthylmethyl)amino]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,Queuine tRNA-ribosyltransferase,tgt,,unknown
[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID,,Mitogen-activated protein kinase 1,MAPK1,,unknown
[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID,,Insulin receptor,INSR,,unknown
[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID,,Insulin receptor substrate 1,IRS1,,unknown
"6-amino-2-[(thiophen-2-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,Queuine tRNA-ribosyltransferase,tgt,,unknown
"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,Proteasome subunit alpha type-1,PSMA1,,unknown
"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,Proteasome subunit alpha type-2,PSMA2,,unknown
"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,Proteasome subunit alpha type-3,PSMA3,,unknown
"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,Proteasome subunit alpha type-4,PSMA4,,unknown
"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,Proteasome subunit alpha type-5,PSMA5,,unknown
"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,Proteasome subunit alpha type-6,PSMA6,,unknown
"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,Proteasome subunit alpha type-7,PSMA7,,unknown
"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,Proteasome subunit beta type-1,PSMB1,,unknown
"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,Proteasome subunit beta type-2,PSMB2,,unknown
"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,Proteasome subunit beta type-3,PSMB3,,unknown
"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,Proteasome subunit beta type-4,PSMB4,,unknown
"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,Proteasome subunit beta type-5,PSMB5,,unknown
"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,Proteasome subunit beta type-6,PSMB6,,unknown
"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,Proteasome subunit beta type-7,PSMB7,,unknown
(S)-(+)-2-[4-(FLUOROBENZYLOXY-BENZYLAMINO)PROPIONAMIDE],,Amine oxidase [flavin-containing] B,MAOB,,unknown
"(2S)-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-2,3-dihydro-4H-chromen-4-one",,3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ,fabZ,,unknown
"N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine",,Vascular endothelial growth factor receptor 2,KDR,,unknown
"(21S)-1AZA-4,4-DIMETHYL-6,19-DIOXA-2,3,7,20-TETRAOXOBICYCLO[19.4.0] PENTACOSANE",,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,,unknown
4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE,,Mitogen-activated protein kinase 14,MAPK14,,unknown
4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE,,Mitogen-activated protein kinase 1,MAPK1,,unknown
4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE,,Mitogen-activated protein kinase 14,MAPK14,,unknown
[HYDROXY(3-PHENYLPROPYL)AMINO]METHANOL,,Peptide deformylase,def,,unknown
[HYDROXY(3-PHENYLPROPYL)AMINO]METHANOL,,Peptide deformylase,def,,unknown
2-(3-BENZOYLPHENOXY)ETHYL(HYDROXY)FORMAMIDE,,Peptide deformylase,def,,unknown
HYDROXY[3-(6-METHYLPYRIDIN-2-YL)PROPYL]FORMAMIDE,,Peptide deformylase,def,,unknown
CARBOBENZYLOXY-(L)-LEUCINYL-(L)LEUCINYL METHOXYMETHYLKETONE,,Pro-cathepsin H,CTSH,,unknown
"1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE",,Cyclin-A2,CCNA2,,unknown
"1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
"2-AMINO-6-(3,5-DIMETHYLPHENYL)SULFONYLBENZONITRILE",,Gag-Pol polyprotein,gag-pol,,unknown
"(6E,11E)-HEPTADECA-6,11-DIENE-9,9-DIYLBIS(PHOSPHONIC ACID)",,Geranylgeranyl pyrophosphate synthase,GGPS1,,unknown
"7-BENZYL-1,3-DIMETHYL-8-PIPERAZIN-1-YL-3,7-DIHYDRO-PURINE-2,6-DIONE",,Dipeptidyl peptidase 4,DPP4,,unknown
"5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",,Cyclin-dependent kinase 2,CDK2,,unknown
"6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine",,Cyclin-dependent kinase 2,CDK2,,unknown
"3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine",,Cyclin-dependent kinase 2,CDK2,,unknown
"5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",,Cyclin-dependent kinase 2,CDK2,,unknown
"3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",,Cyclin-dependent kinase 2,CDK2,,unknown
"3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine",,Cyclin-dependent kinase 2,CDK2,,unknown
"3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine",,Cyclin-dependent kinase 2,CDK2,,unknown
"N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine",,Cyclin-dependent kinase 2,CDK2,,unknown
"3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",,Cyclin-dependent kinase 2,CDK2,,unknown
"2-[4-(2H-1,4-BENZOTHIAZINE-3-YL)-PIPERAZINE-1-LY]-1,3-THIAZOLE-4-CARBOXYLIC ACID ETHYLESTER",,Genome polyprotein,,,unknown
"[(3S)-9-hydroxy-1-methyl-10-oxo-4,10-dihydro-3H-benzo[g]isochromen-3-yl]acetic acid",,ActII protein,actII,,unknown
"3,4-dihydroxy-9,10-secoandrosta-1(10),2,4-triene-9,17-dione",,Iron-dependent extradiol dioxygenase,hsaC,,unknown
1-[2-HYDROXY-3-(4-CYCLOHEXYL-PHENOXY)-PROPYL]-4-(2-PYRIDYL)-PIPERAZINE,,Genome polyprotein,,,unknown
(S)-Fluoxetine,,Transporter,snf,,unknown
(1R)-1-PHENYLETHYL 4-(ACETYLAMINO)BENZYLPHOSPHONATE,,Hepatitis B virus receptor binding protein,,,unknown
"4-[(3AS,4R,7R,8AS,8BR)-2-(1,3-BENZODIOXOL-5-YLMETHYL)-7-HYDROXY-1,3-DIOXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE",,Prothrombin,F2,,unknown
PROGESTERONE-11-ALPHA-OL-HEMISUCCINATE,,Ig gamma-2 chain C region,IGHG2,,unknown
"[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl hydrogen hex-5-enylphosphonate",,Lipase EstA,estA,,unknown
"(3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
"7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline",,Phenylethanolamine N-methyltransferase,PNMT,,unknown
(1R)-1-(2-THIENYLACETYLAMINO)-1-(3-CARBOXYPHENYL)METHYLBORONIC ACID,,Beta-lactamase,ampC,,unknown
(1R)-1-(2-THIENYLACETYLAMINO)-1-(3-CARBOXYPHENYL)METHYLBORONIC ACID,,Beta-lactamase TEM,bla,,unknown
(1R)-1-(2-THIENYLACETYLAMINO)-1-(3-CARBOXYPHENYL)METHYLBORONIC ACID,,Beta-lactamase,blaCTX-M-9a,,unknown
(1R)-1-(2-thienylacetylamino)-1-phenylmethylboronic acid,,Beta-lactamase,ampC,,unknown
"(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime",,Serine/threonine-protein kinase B-raf,BRAF,,unknown
N-(3-carboxypropanoyl)-L-norvaline,,Putative ornithine carbamoyltransferase,,,unknown
N-(3-carboxypropanoyl)-L-norvaline,,N-acetylornithine carbamoyltransferase,argF',,unknown
"1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline",,Mitogen-activated protein kinase 10,MAPK10,,unknown
"5'-ACETYL-4-{[(2,4-DIMETHYLPHENYL)SULFONYL]AMINO}-2,2'-BITHIOPHENE-5-CARBOXYLIC ACID",,Genome polyprotein,,,unknown
"2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL",,Acyl-[acyl-carrier-protein]--UDP-N-acetylglucosamine O-acyltransferase,lpxA,,unknown
"2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL",,Diacylglycerol acyltransferase/mycolyltransferase Ag85C,fbpC,,unknown
"2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL",,Beta-1 adrenergic receptor,ADRB1,,unknown
"2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL",,Lactase-phlorizin hydrolase,LCT,,unknown
"N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide",,Penicillin G acylase,pac,,unknown
3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
"BENZYL 6-BENZYL-5,7-DIOXO-6,7-DIHYDRO-5H-[1,3]THIAZOLO[3,2-C]PYRIMIDINE-2-CARBOXYLATE",,Collagenase 3,MMP13,,unknown
4-(4-STYRYL-PHENYLCARBAMOYL)-BUTYRIC ACID,,Ig kappa chain C region,IGKC,,unknown
4-(4-STYRYL-PHENYLCARBAMOYL)-BUTYRIC ACID,,Ig gamma-1 chain C region,IGHG1,,unknown
4-(4-STYRYL-PHENYLCARBAMOYL)-BUTYRIC ACID,,Ig kappa chain V-II region TEW,IGKV2D-28,,unknown
(2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide,,Proto-oncogene tyrosine-protein kinase Src,SRC,,unknown
L-1-naphthyl-2-acetamido-ethane boronic acid,,Chymotrypsinogen B,CTRB1,,unknown
D-1-naphthyl-2-acetamido-ethane boronic acid,,Chymotrypsinogen B,CTRB1,,unknown
(2S)-1-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}-3-PHENYLPROPAN-2-AMINE,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
(2S)-1-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}-3-PHENYLPROPAN-2-AMINE,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
"3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE",,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
"3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE",,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
4-(ACETYLAMINO)-3-HYDROXY-5-NITROBENZOIC ACID,,Neuraminidase,NA,,unknown
4-(ACETYLAMINO)-3-HYDROXY-5-NITROBENZOIC ACID,,Neuraminidase,NA,,unknown
4-(ACETYLAMINO)-5-AMINO-3-HYDROXYBENZOIC ACID,,Neuraminidase,NA,,unknown
4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE,,Cyclin-A2,CCNA2,,unknown
4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE,,Cyclin-dependent kinase 2,CDK2,,unknown
3-[(4-CHLOROANILINO)SULFONYL]THIOPHENE-2-CARBOXYLIC ACID,,Beta-lactamase,ampC,,unknown
"(5R)-2-SULFANYL-5-[4-(TRIFLUOROMETHYL)BENZYL]-1,3-THIAZOL-4-ONE",,Afadin,MLLT4,,unknown
"2-[(1S)-1-BENZYL-2-SULFANYLETHYL]-1H-IMIDAZO[4,5-C]PYRIDIN-5-IUM",,Neprilysin,MME,,unknown
"1-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)-2-(METHYLAMINO)ETHANONE",,Proline iminopeptidase,pip,,unknown
3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE,,Fibroblast growth factor receptor 1,FGFR1,,unknown
4-[(5-bromopyridin-2-yl)amino]-4-oxobutanoic acid,,Genome polyprotein,,,unknown
"4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}aniline",,Genome polyprotein,,,unknown
4-bromo-2-{[(2R)-2-(2-chlorobenzyl)pyrrolidin-1-yl]carbonyl}aniline,,Genome polyprotein,,,unknown
"4-[(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)amino]-4-oxobutanoic acid",,Genome polyprotein,,,unknown
"N-(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)-4-morpholin-4-yl-4-oxobutanamide",,Genome polyprotein,,,unknown
"2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide",,Tyrosine-protein kinase ABL1,ABL1,,unknown
"6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline",,Hepatocyte growth factor receptor,MET,,unknown
"S-[2-({N-[(2S)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alanyl}amino)ethyl] hexanethioate",,Actinorhodin polyketide synthase acyl carrier protein,,,unknown
"S-[2-({N-[(2S)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alanyl}amino)ethyl] octanethioate",,Actinorhodin polyketide synthase acyl carrier protein,,,unknown
SINAPINATE,,"Endo-1,4-beta-xylanase Y",xynY,,unknown
2-({2-[(3R)-3-AMINOPIPERIDIN-1-YL]-4-OXOQUINAZOLIN-3(4H)-YL}METHYL)BENZONITRILE,,Dipeptidyl peptidase 4,DPP4,,unknown
SYRINGATE,,"Endo-1,4-beta-xylanase Y",xynY,,unknown
1-(3-HYDROXYPROPYL)-2-[(3-NITROBENZOYL)AMINO]-1H-BENZIMIDAZOL-5-YL PIVALATE,,Interleukin-1 receptor-associated kinase 4,IRAK4,,unknown
"5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
"1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE",,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
TERT-BUTYL 2-CYANO-2-METHYLHYDRAZINECARBOXYLATE,,Cathepsin K,CTSK,,unknown
"4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL",,Estrogen receptor alpha,ESR1,,unknown
"4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL",,Nuclear receptor coactivator 2,NCOA2,,unknown
5'-deoxy-5'-piperidin-1-ylthymidine,,Ribonuclease pancreatic,RNASE1,,unknown
"6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine",,Activin receptor type-1,ACVR1,,unknown
"6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine",,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,,unknown
"4-CHLORO-8-METHYL-7-(3-METHYL-BUT-2-ENYL)-6,7,8,9-TETRAHYDRO-2H-2,7,9A-TRIAZA-BENZO[CD]AZULENE-1-THIONE",,Gag-Pol polyprotein,gag-pol,,unknown
"4-CHLORO-8-METHYL-7-(3-METHYL-BUT-2-ENYL)-6,7,8,9-TETRAHYDRO-2H-2,7,9A-TRIAZA-BENZO[CD]AZULENE-1-THIONE",,Gag-Pol polyprotein,gag-pol,,unknown
N-[(4-methoxyphenyl)sulfonyl]-D-alanine,,Macrophage metalloelastase,MMP12,,unknown
"5-CHLORO-8-METHYL-7-(3-METHYL-BUT-2-ENYL)-6,7,8,9-TETRAHYDRO-2H-2,7,9A-TRIAZA-BENZO[CD]AZULENE-1-THIONE",,Gag-Pol polyprotein,gag-pol,,unknown
tributylstannanyl,,Nuclear receptor coactivator 2,NCOA2,,unknown
tributylstannanyl,,Retinoic acid receptor RXR-alpha,RXRA,,unknown
"3-(2,6-difluorophenyl)-2-(methylthio)quinazolin-4(3H)-one",,"High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A",PDE7A,,unknown
N-[(1S)-5-amino-1-(chloroacetyl)pentyl]-4-methylbenzenesulfonamide,,Protease 1,,,unknown
Triclosan,"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).",Enoyl-[acyl-carrier-protein] reductase [NADH] FabI,fabI,,unknown
Triclosan,"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).",Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,,unknown
Triclosan,"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).",Enoyl-[acyl-carrier-protein] reductase [NADH] FabI,fabI,,unknown
Triclosan,"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).",Enoyl-[acyl-carrier-protein] reductase [NADH],fabI,,unknown
Triclosan,"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).",Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI,fabI,,unknown
Triclosan,"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).",Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Triclosan,"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).",Androgen receptor,AR,,unknown
Triclosan,"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).",Nuclear receptor subfamily 1 group I member 3,NR1I3,inverse agonist,unknown
Triclosan,"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).",Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Triclosan,"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).",Thyroid peroxidase,TPO,weak inhibitor,unknown
"6-METHYL-2(PROPANE-1-SULFONYL)-2H-THIENO[3,2-D][1,2,3]DIAZABORININ-1-OL",,"2,4-dienoyl-CoA reductase, mitochondrial",DECR1,,unknown
"6-METHYL-2(PROPANE-1-SULFONYL)-2H-THIENO[3,2-D][1,2,3]DIAZABORININ-1-OL",,Enoyl-[acyl-carrier-protein] reductase [NADH] FabI,fabI,,unknown
"(3R,4S)-1-[(4-AMINO-5H-PYRROLO[3,2-D]PYRIMIDIN-7-YL)METHYL]-4-[(METHYLSULFANYL)METHYL]PYRROLIDIN-3-OL",,5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase,mtnN,,unknown
"(5R)-5-(4-{[(2R)-6-HYDROXY-2,5,7,8-TETRAMETHYL-3,4-DIHYDRO-2H-CHROMEN-2-YL]METHOXY}BENZYL)-1,3-THIAZOLIDINE-2,4-DIONE",,Cytochrome P450 2C8,CYP2C8,,unknown
"4-({(2R,5S)-2,5-DIMETHYL-4-[(2R)-3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPANOYL]PIPERAZIN-1-YL}CARBONYL)BENZONITRILE",,"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 2, mitochondrial",PDK2,,unknown
"(2R)-N-{4-[Ethyl(phenyl)sulfamoyl]-2-methylphenyl}-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide",,"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 2, mitochondrial",PDK2,,unknown
N-(2-AMINOETHYL)-2-{3-CHLORO-4-[(4-ISOPROPYLBENZYL)OXY]PHENYL} ACETAMIDE,,"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 2, mitochondrial",PDK2,,unknown
"2-[(2',3',4'-TRIFLUOROBIPHENYL-2-YL)OXY]ETHANOL",,Cathepsin S,CTSS,,unknown
"1,1,1-TRIFLUORO-3-(OCTYLTHIO)ACETONE",,Putative inactive carboxylesterase 4,CES1P1,,unknown
"2,2,2-TRIFLUORO-1-{5-[(3-PHENYL-5,6-DIHYDROIMIDAZO[1,2-A]PYRAZIN-7(8H)-YL)CARBONYL]THIOPHEN-2-YL}ETHANE-1,1-DIOL",,Histone deacetylase 4,HDAC4,,unknown
"3-[[(METHYLAMINO)SULFONYL]AMINO]-2-OXO-6-PHENYL-N-[3,3,3-TRIFLUORO-1-(1-METHYLETHYL)-2-OXOPHENYL]-1(2H)-PYRIDINE ACETAMIDE",,Chymotrypsin-like elastase family member 1,CELA1,,unknown
"2-[4-(DIMETHYLAMINO)PHENYL]-6-HYDROXY-3-METHYL-1,3-BENZOTHIAZOL-3-IUM",,Acetylcholinesterase,ACHE,,unknown
"4-(2,2,2-TRIFLUOROETHYL)-L-PHENYLALANINE",,"Tyrosine--tRNA ligase, cytoplasmic",YARS,,unknown
3-(HYDROXY-PHENYL-PHOSPHINOYLOXY)-8-METHYL-8-AZA-BICYCLO[3.2.1]OCTANE-2-CARBOXYLIC ACID METHYL ESTER,,Ig gamma-2 chain C region,IGHG2,,unknown
Testosterone succinate,,Neocarzinostatin,ncsA,,unknown
"{(2Z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide",,CHRNA7-FAM7A fusion protein,CHRFAM7A,,unknown
Thiamphenicol,,Dr hemagglutinin structural subunit,draA,,unknown
"4-(4-CHLORO-PHENYL)-1-{3-[2-(4-FLUORO-PHENYL)-[1,3]DITHIOLAN-2-YL]-PROPYL}-PIPERIDIN-4-OL",,Gag-Pol polyprotein,gag-pol,,unknown
"2-[CARBOXY-(2-THIOPHEN-2-YL-ACETYLAMINO)-METHYL]-5-METHYLENE-5,6-DIHYDRO-2H-[1,3]THIAZINE-4-CARBOXYLIC ACID",,Beta-lactamase,ampC,,unknown
BENZOTHIAZOLE,,Prothrombin,F2,,unknown
BENZOTHIAZOLE,,Aryl hydrocarbon receptor,AHR,,unknown
Thiorphan,,Neprilysin,MME,inhibitor,unknown
"(5R)-4-HYDROXY-3,5-DIMETHYL-5-[(1E,3E)-2-METHYLPENTA-1,3-DIENYL]THIOPHEN-2(5H)-ONE",,3-oxoacyl-[acyl-carrier-protein] synthase 1,fabB,,unknown
"(5R)-5-[(1E)-BUTA-1,3-DIENYL]-4-HYDROXY-3,5-DIMETHYLTHIOPHEN-2(5H)-ONE",,3-oxoacyl-[acyl-carrier-protein] synthase 1,fabB,,unknown
"N1-(2-AMINO-4-METHYLPENTYL)OCTAHYDRO-PYRROLO[1,2-A] PYRIMIDINE",,"ATP synthase subunit alpha, mitochondrial",ATP5A1,,unknown
"N1-(2-AMINO-4-METHYLPENTYL)OCTAHYDRO-PYRROLO[1,2-A] PYRIMIDINE",,"ATP synthase subunit beta, mitochondrial",ATP5B,,unknown
"N1-(2-AMINO-4-METHYLPENTYL)OCTAHYDRO-PYRROLO[1,2-A] PYRIMIDINE",,"ATP synthase subunit gamma, mitochondrial",ATP5C1,,unknown
"N-(4-CHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE",,Phenylethanolamine N-methyltransferase,PNMT,,unknown
"1,3,5-BENZENETRICARBOXYLIC ACID",,Hemoglobin subunit alpha,HBA1,,unknown
"1,3,5-BENZENETRICARBOXYLIC ACID",,Hemoglobin subunit beta,HBB,,unknown
TNP-470,,Methionine aminopeptidase 2,METAP2,,unknown
6-BENZYL-1-BENZYLOXYMETHYL-5-ISOPROPYL URACIL,,Gag-Pol polyprotein,gag-pol,,unknown
N-(TRANS-4'-NITRO-4-STILBENYL)-N-METHYL-5-AMINO-PENTANOIC ACID,,Ig heavy chain V-III region CAM,IGHV3-30,,unknown
2-Hydroxybenzalpyruvate,,2-hydroxychromene-2-carboxylate isomerase,nahD,,unknown
4-(2-METHOXYPHENYL)-2-OXOBUT-3-ENOIC ACID,,2-hydroxychromene-2-carboxylate isomerase,nahD,,unknown
2-AMINO-3-(1-HYDROPEROXY-1H-INDOL-3-YL)PROPAN-1-OL,,Catalase-peroxidase,katG,,unknown
Dapivirine,,Gag-Pol polyprotein,gag-pol,,unknown
"(2S,3S)-3-FORMYL-2-({[(4-METHYLPHENYL)SULFONYL]AMINO}METHYL)PENTANOIC ACID",,Chymotrypsin-like elastase family member 1,CELA1,,unknown
"(2S,3S)-3-FORMYL-2-({[(4-NITROPHENYL)SULFONYL]AMINO}METHYL)PENTANOIC ACID",,Chymotrypsin-like elastase family member 1,CELA1,,unknown
"(2R,6S)-6-{[methyl(3,4,5-trimethoxyphenyl)amino]methyl}-1,2,5,6,7,8-hexahydroquinazoline-2,4-diamine",,Dihydrofolate reductase,DHFR,,unknown
2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER,,Stromelysin-1,MMP3,,unknown
{1-[2-(1-FORMYL-PROPYL)-3-METHANESULFONYLAMINO-PYRROLIDINE-1-CARBONYL]-2-METHYL-PROPYL}-CARBAMIC ACID TERT-BUTYL ESTER,,Genome polyprotein,,,unknown
"6-CHLORO-3-(DICHLOROMETHYL)-3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE 1,1-DIOXIDE",,Carbonic anhydrase 2,CA2,,unknown
TRW3-(2-AMINO-3-HYDROXY-PROPYL)-6-(N'-CYCLOHEXYL-HYDRAZINO)OCTAHYDRO-INDOL-7-OL,,Amicyanin,mauC,,unknown
TRW3-(2-AMINO-3-HYDROXY-PROPYL)-6-(N'-CYCLOHEXYL-HYDRAZINO)OCTAHYDRO-INDOL-7-OL,,Methylamine dehydrogenase heavy chain,mauB,,unknown
TRW3-(2-AMINO-3-HYDROXY-PROPYL)-6-(N'-CYCLOHEXYL-HYDRAZINO)OCTAHYDRO-INDOL-7-OL,,Methylamine dehydrogenase light chain,mauA,,unknown
TRW3-(2-AMINO-3-HYDROXY-PROPYL)-6-(N'-CYCLOHEXYL-HYDRAZINO)OCTAHYDRO-INDOL-7-OL,,Cytochrome c-L,moxG,,unknown
TRW3-(2-AMINO-3-HYDROXY-PROPYL)-6-(N'-CYCLOHEXYL-HYDRAZINO)OCTAHYDRO-INDOL-7-OL,,Quinohemoprotein amine dehydrogenase subunit gamma,qhnDH,,unknown
TRW3-(2-AMINO-3-HYDROXY-PROPYL)-6-(N'-CYCLOHEXYL-HYDRAZINO)OCTAHYDRO-INDOL-7-OL,,Quinohemoprotein amine dehydrogenase 60 kDa subunit,,,unknown
TRW3-(2-AMINO-3-HYDROXY-PROPYL)-6-(N'-CYCLOHEXYL-HYDRAZINO)OCTAHYDRO-INDOL-7-OL,,Quinohemoprotein amine dehydrogenase 40 kDa subunit,,,unknown
TRAZEOLIDE,,Ig kappa chain C region,IGKC,,unknown
"(1R,3S,5S,8R)-8-Hydroxy-2-oxabicyclo[3.3.1]non-6-ene-3,5-dicarboxylic acid",,P-protein,pheA,,unknown
"(1R,3S,5S,8R)-8-Hydroxy-2-oxabicyclo[3.3.1]non-6-ene-3,5-dicarboxylic acid",,Chorismate mutase AroH,aroH,,unknown
"(1R,3S,5S,8R)-8-Hydroxy-2-oxabicyclo[3.3.1]non-6-ene-3,5-dicarboxylic acid",,Secreted chorismate mutase,,,unknown
(1S)-1-AMINO-2-(1H-INDOL-3-YL)ETHANOL,,Aralkylamine dehydrogenase light chain,aauA,,unknown
(1S)-1-AMINO-2-(1H-INDOL-3-YL)ETHANOL,,Aralkylamine dehydrogenase heavy chain,aauB,,unknown
3'-THIO-THYMIDINE-5'-PHOSPHATE,,Type-2 restriction enzyme EcoRV,ecoRVR,,unknown
3'-THIO-THYMIDINE-5'-PHOSPHATE,,DNA topoisomerase 2-beta,TOP2B,,unknown
2-(1H-INDOL-3-YL)ACETAMIDE,,Aralkylamine dehydrogenase light chain,aauA,,unknown
2-(1H-INDOL-3-YL)ACETAMIDE,,Aralkylamine dehydrogenase heavy chain,aauB,,unknown
2-(1H-INDOL-3-YL)ETHANAMINE,,Aralkylamine dehydrogenase light chain,aauA,,unknown
2-(1H-INDOL-3-YL)ETHANAMINE,,Aralkylamine dehydrogenase heavy chain,aauB,,unknown
"TRANS-(1S,2S)-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-OL",,Phenylethanolamine N-methyltransferase,PNMT,,unknown
"9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE",,CREB-binding protein,CREBBP,,unknown
5-amino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide,,Replicase polyprotein 1ab,rep,,unknown
2-(4-(2-((3-(5-(PYRIDIN-2-YLTHIO)THIAZOL-2-YL)UREIDO)METHYL)-1H-IMIDAZOL-4-YL)PHENOXY)ACETIC ACID,,Trans-2-enoyl-ACP reductase II,fabK,,unknown
ETHYL HYDROGEN DIETHYLAMIDOPHOSPHATE,,Cholinesterase,BCHE,,unknown
2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide,,Carbonic anhydrase 2,CA2,,unknown
"1,2,5,8-tetrahydroxyanthracene-9,10-dione",,Casein kinase II subunit alpha,CSNK2A1,,unknown
"1-(2,5-dideoxy-5-pyrrolidin-1-yl-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione",,Ribonuclease pancreatic,RNASE1,,unknown
3-[1-(4-BROMO-PHENYL)-2-METHYL-PROPYL]-4-HYDROXY-CHROMEN-2-ONE,,Gag-Pol polyprotein,gag-pol,,unknown
4-HYDROXY-7-METHOXY-3-(1-PHENYL-PROPYL)-CHROMEN-2-ONE,,Gag-Pol polyprotein,gag-pol,,unknown
({3-[1-(4-HYDROXY-2-OXO-2H-CHROMEN-3-YL)-PROPYL]-PHENYLCARBAMOYL}-METHYL)-CARBAMIC ACID TERT-BUTYL ESTER,,Gag-Pol polyprotein,gag-pol,,unknown
"6,11-DIHYDRO-11-ETHYL-6-METHYL-9-NITRO-5H-PYRIDO[2,3-B][1,5]BENZODIAZEPIN-5-ONE",,Gag-Pol polyprotein,gag-pol,,unknown
5-imino-4-(3-trifluoromethyl-phenylazo)-5H-pyrazol-3-ylamine,,Methionine aminopeptidase,map,,unknown
4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine,,Methionine aminopeptidase,map,,unknown
3-(5-amino-3-imino-3H-pyrazol-4-ylazo)-benzoic acid,,Methionine aminopeptidase,map,,unknown
"METHYL N-[(2S,3R)-3-AMINO-2-HYDROXY-3-(4-METHYLPHENYL)PROPANOYL]-D-ALANYL-D-LEUCINATE",,Methionine aminopeptidase,map,,unknown
"METHYL N-[(2S,3R)-3-AMINO-2-HYDROXY-3-(4-ISOPROPYLPHENYL)PROPANOYL]-D-ALANYL-D-LEUCINATE",,Methionine aminopeptidase,map,,unknown
5-IMINO-4-(2-TRIFLUOROMETHYL-PHENYLAZO)-5H-PYRAZOL-3-YLAMINE,,Methionine aminopeptidase,map,,unknown
4-[(3R)-3-{[2-(4-FLUOROPHENYL)-2-OXOETHYL]AMINO}BUTYL]BENZAMIDE,,Dipeptidyl peptidase 4,DPP4,,unknown
"4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE",,Cyclin-dependent kinase 2,CDK2,,unknown
"(20S)-19,20,21,22-TETRAHYDRO-19-OXO-5H-18,20-ETHANO-12,14-ETHENO-6,10-METHENO-18H-BENZ[D]IMIDAZO[4,3-K][1,6,9,12]OXATRIAZA-CYCLOOCTADECOSINE-9-CARBONITRILE",,Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha,FNTA,,unknown
"(20S)-19,20,21,22-TETRAHYDRO-19-OXO-5H-18,20-ETHANO-12,14-ETHENO-6,10-METHENO-18H-BENZ[D]IMIDAZO[4,3-K][1,6,9,12]OXATRIAZA-CYCLOOCTADECOSINE-9-CARBONITRILE",,Protein farnesyltransferase subunit beta,FNTB,,unknown
"(5Z)-7-{(1R,4S,5R,6R)-6-[(1E)-1-Octen-1-yl]-2,3-diazabicyclo[2.2.1]hept-2-en-5-yl}-5-heptenoic acid",,Prostacyclin synthase,PTGIS,,unknown
"(20S)-19,20,22,23-TETRAHYDRO-19-OXO-5H,21H-18,20-ETHANO-12,14-ETHENO-6,10-METHENOBENZ[D]IMIDAZO[4,3-L][1,6,9,13]OXATRIAZACYCLONOADECOSINE-9-CARBONITRILE",,Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha,FNTA,,unknown
"(20S)-19,20,22,23-TETRAHYDRO-19-OXO-5H,21H-18,20-ETHANO-12,14-ETHENO-6,10-METHENOBENZ[D]IMIDAZO[4,3-L][1,6,9,13]OXATRIAZACYCLONOADECOSINE-9-CARBONITRILE",,Protein farnesyltransferase subunit beta,FNTB,,unknown
N-(5-ISOPROPYL-THIAZOL-2-YL)-2-PYRIDIN-3-YL-ACETAMIDE,,Cyclin-dependent kinase 2,CDK2,,unknown
(4-ETHYLPHENYL)SULFAMIC ACID,,Receptor-type tyrosine-protein phosphatase beta,PTPRB,,unknown
N-{3-[(E)-(tert-butoxyimino)methyl]-4-chlorophenyl}-2-methylfuran-3-carbimidothioic acid,,Gag-Pol polyprotein,gag-pol,,unknown
1-METHYL ETHYL 2-CHLORO-5-[[[(1-METHYLETHOXY)THIOOXO]METHYL]AMINO]-BENZOATE,,Gag-Pol polyprotein,gag-pol,,unknown
"1-METHYL ETHYL 1-CHLORO-5-[[(5,6DIHYDRO-2-METHYL-1,4-OXATHIIN-3-YL)CARBONYL]AMINO]BENZOATE",,Gag-Pol polyprotein,gag-pol,,unknown
"REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
O-DECYL HYDROGEN THIOCARBONATE,,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,,unknown
"1-(1,4-dimethyl-1,2,3,4-tetrahydroquinoxalin-6-yl)methanamine",,Glutaryl-CoA dehydrogenase,,,unknown
"5,6,7,8,9,10-HEXAHYDRO-4-HYDROXY-3-(1-PHENYLPROPYL)CYCLOOCTA[B]PYRAN-2-ONE",,Gag-Pol polyprotein,gag-pol,,unknown
FG-2216,,Egl nine homolog 1,EGLN1,,unknown
FG-2216,,Hypoxia-inducible factor 1-alpha,HIF1A,,unknown
undecan-2-one,,Acyl-coenzyme A thioesterase 13,ACOT13,,unknown
UBIQUINONE-1,,Photosynthetic reaction center cytochrome c subunit,pufC,,unknown
UBIQUINONE-1,,Reaction center protein H chain,puhA,,unknown
UBIQUINONE-1,,Reaction center protein L chain,pufL,,unknown
UBIQUINONE-1,,Reaction center protein M chain,pufM,,unknown
UBIQUINONE-1,,"Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial",SDHA,,unknown
UBIQUINONE-1,,"Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial",SDHB,,unknown
UBIQUINONE-1,,"Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial",SDHD,,unknown
UBIQUINONE-1,,"Succinate dehydrogenase cytochrome b560 subunit, mitochondrial",SDHC,,unknown
UBIQUINONE-1,,Thiol:disulfide interchange protein DsbA,dsbA,,unknown
UBIQUINONE-1,,Disulfide bond formation protein B,dsbB,,unknown
UBIQUINONE-1,,NrfC protein,nrfC,,unknown
UBIQUINONE-1,,Thiosulfate reductase,,,unknown
UBIQUINONE-1,,Hypothetical membrane spanning protein,,,unknown
UBIQUINONE-2,,Succinate dehydrogenase flavoprotein subunit,sdhA,,unknown
UBIQUINONE-2,,Succinate dehydrogenase iron-sulfur subunit,sdhB,,unknown
UBIQUINONE-2,,Succinate dehydrogenase cytochrome b556 subunit,sdhC,,unknown
UBIQUINONE-2,,Succinate dehydrogenase hydrophobic membrane anchor subunit,sdhD,,unknown
UBIQUINONE-2,,"Cytochrome c1, heme protein, mitochondrial",CYC1,,unknown
UBIQUINONE-2,,Cytochrome b,MT-CYB,,unknown
UBIQUINONE-2,,"Cytochrome b-c1 complex subunit 1, mitochondrial",UQCRC1,,unknown
UBIQUINONE-2,,"Cytochrome b-c1 complex subunit 2, mitochondrial",UQCRC2,,unknown
UBIQUINONE-2,,"Cytochrome b-c1 complex subunit 6, mitochondrial",UQCRH,,unknown
UBIQUINONE-2,,Cytochrome b-c1 complex subunit 8,UQCRQ,,unknown
UBIQUINONE-2,,"Cytochrome b-c1 complex subunit Rieske, mitochondrial",UQCRFS1,,unknown
UBIQUINONE-2,,Cytochrome b-c1 complex subunit 10,UQCR11,,unknown
UBIQUINONE-2,,Cytochrome b-c1 complex subunit 7,UQCRB,,unknown
UBIQUINONE-2,,Cytochrome b-c1 complex subunit 9,UQCR10,,unknown
UBIQUINONE-2,,Photosynthetic reaction center cytochrome c subunit,pufC,,unknown
UBIQUINONE-2,,Reaction center protein H chain,puhA,,unknown
UBIQUINONE-2,,Reaction center protein L chain,pufL,,unknown
UBIQUINONE-2,,Reaction center protein M chain,pufM,,unknown
UBIQUINONE-2,,Disulfide bond formation protein B,dsbB,,unknown
UBIQUINONE-2,,Cytochrome b,petB,,unknown
UBIQUINONE-2,,Ubiquinol-cytochrome c reductase iron-sulfur subunit,petA,,unknown
UBIQUINONE-2,,Cytochrome c1,petC,,unknown
UBIQUINONE-2,,Reaction center protein L chain,pufL,,unknown
UBIQUINONE-2,,Reaction center protein M chain,pufM,,unknown
UBIQUINONE-2,,Reaction center protein H chain,puhA,,unknown
"ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate",,Dual specificity protein kinase CLK1,CLK1,,unknown
"ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate",,Dual specificity protein kinase CLK3,CLK3,,unknown
D-1-(4-chlorophenyl)-2-(acetamido)ethane boronic acid,,Chymotrypsinogen B,CTRB1,,unknown
L-1-(4-chlorophenyl)-2-(acetamido)ethane boronic acid,,Chymotrypsinogen B,CTRB1,,unknown
"9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidin-4-ol",,Cyclin-dependent kinase 2,CDK2,,unknown
"9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidin-4-ol",,Cyclin-A2,CCNA2,,unknown
3-(4-nitrophenyl)-1H-pyrazole,,Hematopoietic prostaglandin D synthase,HPGDS,,unknown
"4-(2-aminoethoxy)-N-(3-chloro-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide",,Urokinase-type plasminogen activator,PLAU,,unknown
"1-[(3S)-5-PHENYL-3-THIOPHEN-2-YL-3H-1,4-BENZODIAZEPIN-2-YL]AZETIDIN-3-OL",,Glutamate racemase,murI,,unknown
"1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",,Calcium/calmodulin-dependent protein kinase type II subunit gamma,CAMK2G,,unknown
"2-(3-BROMOPHENYL)-6-[(2-HYDROXYETHYL)AMINO]-1H-BENZO[DE]ISOQUINOLINE-1,3(2H)-DIONE",,Genome polyprotein,,,unknown
"2-(3-BROMOPHENYL)-6-[(2-HYDROXYETHYL)AMINO]-1H-BENZO[DE]ISOQUINOLINE-1,3(2H)-DIONE",,Genome polyprotein,,,unknown
"2,5-DIPHENYLFURAN-3,4-DICARBOXYLIC ACID",,Metallo-beta-lactamase L1,,,unknown
"12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one",,Mitogen-activated protein kinase kinase kinase 9,MAP3K9,,unknown
"[[(3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(pentanoylamino)oxan-2-ylidene]amino] N-phenylcarbamate",,Beta-hexosaminidase,nagZ,,unknown
"6-(5-BROMO-2-HYDROXYPHENYL)-2-OXO-4-PHENYL-1,2-DIHYDROPYRIDINE-3-CARBONITRILE",,Serine/threonine-protein kinase pim-1,PIM1,,unknown
"(2S)-({(5Z)-5-[(5-ETHYL-2-FURYL)METHYLENE]-4-OXO-4,5-DIHYDRO-1,3-THIAZOL-2-YL}AMINO)(4-FLUOROPHENYL)ACETIC ACID",,Genome polyprotein,,,unknown
"4-[3-(4-chlorophenyl)-2,1-benzisoxazol-5-yl]pyrimidin-2-amine",,Serine/threonine-protein kinase pim-1,PIM1,,unknown
"N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine",,Serine/threonine-protein kinase pim-1,PIM1,,unknown
"2,3-diphenyl-1H-indole-7-carboxylic acid",,Serine/threonine-protein kinase pim-1,PIM1,,unknown
"(5Z)-5-[(5-ETHYL-2-FURYL)METHYLENE]-2-{[(S)-(4-FLUOROPHENYL)(1H-TETRAZOL-5-YL)METHYL]AMINO}-1,3-THIAZOL-4(5H)-ONE",,Genome polyprotein,,,unknown
Methyl vanillate,,"Endo-1,4-beta-xylanase Y",xynY,,unknown
11-[(MERCAPTOCARBONYL)OXY]UNDECANOIC ACID,,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,,unknown
"2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2N-METHYL-2H-TETRAZOL-5-YL]-PHENOL",,Genome polyprotein,,,unknown
"2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[4-METHYL-2H-TETRAZOL-2-YL]-PHENOL",,Genome polyprotein,,,unknown
"2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2-METHYL-4-ISOXAZOLYL]-PHENOL",,Genome polyprotein,,,unknown
"[(2S)-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-2-yl]acetic acid",,Carboxylesterase,,,unknown
"4-(3-ethylthiophen-2-yl)benzene-1,2-diol",,Methionine aminopeptidase,map,,unknown
"5-(5-(6-CHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE",,Genome polyprotein,,,unknown
"5-(5-(4-(4,5-dihydro-2-oxazoly)phenoxy)pentyl)-3-methyl osoxazole",,Genome polyprotein,,,unknown
"5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole",,Genome polyprotein,,,unknown
5-(7-(6-chloro-4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole,,Genome polyprotein,,,unknown
"5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE",,Genome polyprotein,,,unknown
"5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE",,Genome polyprotein,,,unknown
5-(5-(4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole,,Genome polyprotein,,,unknown
"(S)-5-(7-(4-(4-Ethyl-4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methylisoxazole",,Genome polyprotein,,,unknown
"5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole",,Genome polyprotein,,,unknown
"5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole",,Genome polyprotein,,,unknown
"5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole",,Genome polyprotein,,,unknown
"3-Methyl-5-(7-{4-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]phenoxy}heptyl)-1,2-oxazole",,Genome polyprotein,,,unknown
"5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole",,Genome polyprotein,,,unknown
"5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole",,Genome polyprotein,,,unknown
"5-ethoxy-4-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)thiophene-2-sulfonamide",,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,,unknown
3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE,,Mitogen-activated protein kinase 14,MAPK14,,unknown
"2-[(1R)-2-carboxy-1-(naphthalen-1-ylmethyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylic acid",,Beta-lactamase,ampC,,unknown
NALPHA-[(BENZYLOXY)CARBONYL]-N-[(1R)-4-HYDROXY-1-METHYL-2-OXOBUTYL]-L-PHENYLALANINAMIDE,,Replicase polyprotein 1ab,rep,,unknown
NALPHA-[(BENZYLOXY)CARBONYL]-N-[(1R)-4-HYDROXY-1-METHYL-2-OXOBUTYL]-L-PHENYLALANINAMIDE,,Replicase polyprotein 1a,,,unknown
"(2R,3R)-N^1^-[(1S)-2,2-DIMETHYL-1-(METHYLCARBAMOYL)PROPYL]-N^4^-HYDROXY-2-(2-METHYLPROPYL)-3-{[(1,3-THIAZOL-2-YLCARBONYL)AMINO]METHYL}BUTANEDIAMIDE",,Disintegrin and metalloproteinase domain-containing protein 28,ADAM28,,unknown
"6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE",,Thymidylate synthase,TYMS,,unknown
"(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL",,Estrogen receptor alpha,ESR1,,unknown
1-{3-oxo-3-[(2S)-2-(pyrrolidin-1-ylcarbonyl)pyrrolidin-1-yl]propyl}-3-phenylquinoxalin-2(1H)-one,,Prolyl endopeptidase,PREP,,unknown
"2-{3-[(2S)-4,4-difluoro-2-(pyrrolidin-1-ylcarbonyl)pyrrolidin-1-yl]-3-oxopropyl}-isoindole-1,3(2H)-dione",,Prolyl endopeptidase,PREP,,unknown
"CYCLOHEXYLMETHYL-2,3-DIHYDROXY-5-METHYL-HEXYLAMIDE",,Cathepsin D,CTSD,,unknown
"5-[[(2R)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl]methyl]pyrimidine-2,4-diamine",,Dihydrofolate reductase,folA,,unknown
"1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z)",,Nuclear receptor coactivator 1,NCOA1,,unknown
"1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z)",,Vitamin D3 receptor,VDR,,unknown
"2-({8-[(3R)-3-AMINOPIPERIDIN-1-YL]-1,3-DIMETHYL-2,6-DIOXO-1,2,3,6-TETRAHYDRO-7H-PURIN-7-YL}METHYL)BENZONITRILE",,Dipeptidyl peptidase 4,DPP4,,unknown
"6-methoxy-9-methyl[1,3]dioxolo[4,5-h]quinolin-8(9H)-one",,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,,unknown
4-[[(1E)-2-(4-CHLOROPHENYL)ETHENYL]SULFONYL]-1-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINONE,,Coagulation factor X,F10,,unknown
1-[[(1E)-2-(4-CHLOROPHENYL)ETHENYL]SULFONYL]-4-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINE,,Coagulation factor X,F10,,unknown
"(11R)-10-acetyl-11-(2,4-dichlorophenyl)-6-hydroxy-3,3-dimethyl-2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]diazepin-1-one",,Genome polyprotein,,,unknown
4-(DIMETHYLAMINO)BENZOIC ACID,,Replicase polyprotein 1ab,rep,,unknown
4-(DIMETHYLAMINO)BENZOIC ACID,,Orf1a polyprotein,orf1ab,,unknown
3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE,,Beta-secretase 1,BACE1,,unknown
"1-[4-(AMINOMETHYL)BENZOYL]-5'-FLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLIN]-4'-AMINE",,"Nitric oxide synthase, inducible",NOS2,,unknown
"N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE",,GTPase HRas,HRAS,,unknown
N-[(1S)-2-[(4-cyano-1-methylpiperidin-4-yl)amino]-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide,,Cathepsin S,CTSS,,unknown
"4-{(1E)-3-OXO-3-[(2-PHENYLETHYL)AMINO]PROP-1-EN-1-YL}-1,2-PHENYLENE DIACETATE",,Peptide deformylase,def,,unknown
"(2E)-3-(3,4-DIHYDROXYPHENYL)-N-[2-(4-HYDROXYPHENYL)ETHYL]ACRYLAMIDE",,Peptide deformylase,def,,unknown
N-[(1S)-2-{[(1R)-2-(benzyloxy)-1-cyano-1-methylethyl]amino}-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide,,Cathepsin S,CTSS,,unknown
(R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
(R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE,,cAMP-dependent protein kinase inhibitor alpha,PKIA,,unknown
(R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE,,Rho-associated protein kinase 1,ROCK1,,unknown
(R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE,,Rho-associated protein kinase 2,ROCK2,,unknown
5-(2-chlorophenyl)furan-2-carbohydrazide,,Methionine aminopeptidase,map,,unknown
"IMIDAZO[2,1-A]ISOQUINOLINE-2-CARBOHYDRAZIDE",,Methionine aminopeptidase,map,,unknown
"[(3R,4S,5S,7R)-4,8-DIHYDROXY-3,5,7-TRIMETHYL-2-OXOOCTYL]PHOSPHONIC ACID",,Type I polyketide synthase PikAIV,pikAIV,,unknown
(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
"(3S,6S)-3,6-bis(4-hydroxybenzyl)piperazine-2,5-dione",,Mycocyclosin synthase,cyp121,,unknown
O-(((1R)-((N-PHENYLMETHOXYCARBONYL-L-ALANYL)AMINO)ETHYL)HYDROXYPHOSPHONO)-L-BENZYLACETIC ACID,,Carboxypeptidase A1,CPA1,,unknown
[N-(BENZYLOXYCARBONYL)AMINO](4-AMIDINOPHENYL)METHANE-PHOSPHONATE,,Trypsin-1,PRSS1,,unknown
"6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE",,Carbonic anhydrase 2,CA2,,unknown
"6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE",,Macrophage migration inhibitory factor,MIF,,unknown
"L-PROLINE, 1-[(2S)-3-MERCAPTO-2-METHYL-1-OXOPROPYL]-4-(PHENYLTHIO)-, 4S",,Cytosol aminopeptidase,LAP3,,unknown
2-(4-METHOXYPHENYL)ACETAMIDE,,Aralkylamine dehydrogenase light chain,aauA,,unknown
2-(4-METHOXYPHENYL)ACETAMIDE,,Aralkylamine dehydrogenase heavy chain,aauB,,unknown
N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE,,Cyclin-dependent kinase 2,CDK2,,unknown
"4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol",,Adenosine receptor A2a,ADORA2A,,unknown
"(5R)-2-[(2-fluorophenyl)amino]-5-(1-methylethyl)-1,3-thiazol-4(5H)-one",,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,,unknown
"3,4-DIHYDRO-4-OXO-3-((5-TRIFLUOROMETHYL-2-BENZOTHIAZOLYL)METHYL)-1-PHTHALAZINE ACETIC ACID",,Aldo-keto reductase family 1 member B10,AKR1B10,,unknown
"3,4-DIHYDRO-4-OXO-3-((5-TRIFLUOROMETHYL-2-BENZOTHIAZOLYL)METHYL)-1-PHTHALAZINE ACETIC ACID",,Aldose reductase,AKR1B1,,unknown
RALOXIFENE CORE,,Estrogen receptor alpha,ESR1,,unknown
RALOXIFENE CORE,,Nuclear receptor coactivator 2,NCOA2,,unknown
"1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
Nα-[(Benzyloxy)carbonyl]-N-[(2S)-4-fluoro-3-oxo-2-butanyl]-L-tyrosinamide,,Cathepsin F,CTSF,,unknown
"N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"[4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol,,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
6-MORPHOLIN-4-YL-9H-PURINE,,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
"1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE",,Serine/threonine-protein kinase Chk1,CHEK1,,unknown
4-(2-AMINOETHYL)BENZENESULFONAMIDE,,Carbonic anhydrase 2,CA2,,unknown
(4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid,,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,unknown
2-(4-CHLORO-PHENYLAMINO)-NICOTINIC ACID,,NmrA-like family domain-containing protein 1,NMRAL1,,unknown
4-METHYL-2H-CHROMEN-2-ONE,,Endoglucanase H,celH,,unknown
4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine,,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
"2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE",,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID,,Hematopoietic prostaglandin D synthase,HPGDS,,unknown
"1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE",,Hepatocyte growth factor receptor,MET,,unknown
Azidocillin,,Penicillin-binding protein 2a,pbp2a,inhibitor,yes
Azidocillin,,Penicillin-binding protein 1b,pbp1b,inhibitor,yes
Azidocillin,,Penicillin-binding protein 3,pbp3,inhibitor,yes
Azidocillin,,Penicillin-binding protein 1A,pbpA,inhibitor,yes
Azidocillin,,Penicillin-binding protein 2B,penA,inhibitor,yes
Sulfamoxole,,Dihydropteroate synthetase,,inhibitor,yes
Antazoline,,Histamine H1 receptor,HRH1,antagonist,yes
Chloropyramine,,Histamine H1 receptor,HRH1,antagonist,yes
Dimetindene,,Histamine H1 receptor,HRH1,antagonist,yes
Dimetindene,,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Isothipendyl,,Histamine H1 receptor,HRH1,antagonist,yes
Nandrolone decanoate,,Androgen receptor,AR,agonist,yes
Metiamide,,Histamine H2 receptor,HRH2,antagonist,yes
Roxatidine acetate,5-6 hours,Histamine H2 receptor,HRH2,antagonist,yes
Bopindolol,,Beta-1 adrenergic receptor,ADRB1,partial agonist,yes
Bopindolol,,Beta-2 adrenergic receptor,ADRB2,partial agonist,unknown
Bopindolol,,5-hydroxytryptamine receptor 1A,HTR1A,,unknown
Bopindolol,,5-hydroxytryptamine receptor 1B,HTR1B,,unknown
Bopindolol,,Beta-3 adrenergic receptor,ADRB3,,unknown
Bupranolol,2-4 hours,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Bupranolol,2-4 hours,Beta-2 adrenergic receptor,ADRB2,antagonist,unknown
Bupranolol,2-4 hours,Beta-3 adrenergic receptor,ADRB3,antagonist,unknown
Dichloroacetic Acid,,"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial",PDK1,inhibitor,yes
Dichloroacetic Acid,,Maleylacetoacetate isomerase,GSTZ1,,unknown
Cinitapride,3-5 h during the first 8 h and a residual half-life greater than 15 h thereafter.,5-hydroxytryptamine receptor 1A,HTR1A,agonist,yes
Cinitapride,3-5 h during the first 8 h and a residual half-life greater than 15 h thereafter.,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Cinitapride,3-5 h during the first 8 h and a residual half-life greater than 15 h thereafter.,5-hydroxytryptamine receptor 4,HTR4,agonist,unknown
Tofisopam,6-8 hours,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,inhibitor,unknown
Tofisopam,6-8 hours,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",PDE10A,inhibitor,unknown
Tofisopam,6-8 hours,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,inhibitor,unknown
Tofisopam,6-8 hours,"cGMP-dependent 3',5'-cyclic phosphodiesterase",PDE2A,inhibitor,unknown
Nadroparin,"In healthy patients, the half life is between 3.5hrs to 11.2hrs following subcutaneous administration.",Antithrombin-III,SERPINC1,potentiator,yes
Nadroparin,"In healthy patients, the half life is between 3.5hrs to 11.2hrs following subcutaneous administration.",P-selectin,SELP,inhibitor,unknown
Nadroparin,"In healthy patients, the half life is between 3.5hrs to 11.2hrs following subcutaneous administration.",Proto-oncogene c-Fos,FOS,inhibitor,unknown
Nadroparin,"In healthy patients, the half life is between 3.5hrs to 11.2hrs following subcutaneous administration.",Myc proto-oncogene protein,MYC,inhibitor,unknown
Triflusal,"In the healthy human, the half-life is 0.5 +/- 0.1h, while that of HTB is 34.3 +/- 5.3h.[L1186]",Prostaglandin G/H synthase 1,PTGS1,antagonist,yes
Triflusal,"In the healthy human, the half-life is 0.5 +/- 0.1h, while that of HTB is 34.3 +/- 5.3h.[L1186]",Nuclear factor NF-kappa-B p105 subunit,NFKB1,antagonist,yes
Triflusal,"In the healthy human, the half-life is 0.5 +/- 0.1h, while that of HTB is 34.3 +/- 5.3h.[L1186]","Nitric oxide synthase, inducible",NOS2,agonist,yes
Triflusal,"In the healthy human, the half-life is 0.5 +/- 0.1h, while that of HTB is 34.3 +/- 5.3h.[L1186]","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",PDE10A,antagonist,yes
Lurasidone,"40 mg dose= 18 hours 
120 mg - 160 mg dose = 29-37 hours",D(2) dopamine receptor,DRD2,antagonist,yes
Lurasidone,"40 mg dose= 18 hours 
120 mg - 160 mg dose = 29-37 hours",5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Lurasidone,"40 mg dose= 18 hours 
120 mg - 160 mg dose = 29-37 hours",5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Lurasidone,"40 mg dose= 18 hours 
120 mg - 160 mg dose = 29-37 hours",5-hydroxytryptamine receptor 1A,HTR1A,antagonist,unknown
Lurasidone,"40 mg dose= 18 hours 
120 mg - 160 mg dose = 29-37 hours",Alpha-2C adrenergic receptor,ADRA2C,antagonist,unknown
Lurasidone,"40 mg dose= 18 hours 
120 mg - 160 mg dose = 29-37 hours",Alpha-2A adrenergic receptor,ADRA2A,,unknown
Ticagrelor,"Ticagrelor has a half life of 7 hours, while its active metabolite has a half life of 9 hours.",P2Y purinoceptor 12,P2RY12,inhibitor,yes
Hyaluronic acid,,CD44 antigen,CD44,,yes
Hyaluronic acid,,Intercellular adhesion molecule 1,ICAM1,,yes
Hyaluronic acid,,Hyaluronan mediated motility receptor,HMMR,,yes
Hyaluronic acid,,Neurocan core protein,NCAN,binder,unknown
Hyaluronic acid,,Versican core protein,VCAN,binder,unknown
Hyaluronic acid,,"Complement component 1 Q subcomponent-binding protein, mitochondrial",C1QBP,binder,unknown
Hyaluronic acid,,Hyaluronan and proteoglycan link protein 1,HAPLN1,binder,unknown
Hyaluronic acid,,Hyaluronan and proteoglycan link protein 3,HAPLN3,binder,unknown
Hyaluronic acid,,Hyaluronan and proteoglycan link protein 4,HAPLN4,binder,unknown
Hyaluronic acid,,Hyaluronan-binding protein 2,HABP2,binder,unknown
Hyaluronic acid,,Layilin,LAYN,binder,unknown
Hyaluronic acid,,Stabilin-2,STAB2,binder,unknown
Hyaluronic acid,,Tumor necrosis factor-inducible gene 6 protein,TNFAIP6,binder,unknown
Hyaluronic acid,,Interphotoreceptor matrix proteoglycan 2,IMPG2,binder,unknown
Hyaluronic acid,,Intracellular hyaluronan-binding protein 4,HABP4,binder,unknown
Tafluprost,,Prostaglandin F2-alpha receptor,PTGFR,agonist,yes
Ivacaftor,The apparent terminal half-life was approximately 12 hours following a single dose [FDA Label].,Cystic fibrosis transmembrane conductance regulator,CFTR,potentiator,yes
Azilsartan medoxomil,"The half-life is 11 hours, and it takes about 5 days to reach steady state concentrations.",Type-1 angiotensin II receptor,AGTR1,antagonist,yes
Lomitapide,Lomitapide half-life is about 39.7 hours.,Microsomal triglyceride transfer protein large subunit,MTTP,antagonist,yes
Vismodegib,"The half-life after a single dose is 12 days, and after continuous daily dosing is 4 days.",Smoothened homolog,SMO,antagonist,yes
Spaglumic Acid,,Glutamate carboxypeptidase 2,FOLH1,ligand,unknown
Temocapril,13.1 hours in patients with normal liver function.,Angiotensin-converting enzyme,ACE,inhibitor,unknown
Tetraethylammonium,,pH-gated potassium channel KcsA,kcsA,inhibitor,unknown
Tetraethylammonium,,Neuronal acetylcholine receptor subunit alpha-9,CHRNA9,agonistinhibitor,unknown
Tetraethylammonium,,Calcium-activated potassium channel subunit alpha-1,Kcnma1,inhibitor,unknown
Tetraethylammonium,,Potassium voltage-gated channel subfamily A member 1,KCNA1,blocker,unknown
Agmatine,,Alpha-2C adrenergic receptor,ADRA2C,agonist,yes
Agmatine,,Nischarin,NISCH,agonist,yes
Agmatine,,Acetylcholine receptor subunit alpha,CHRNA1,antagonist,yes
Agmatine,,"Glutamate receptor ionotropic, NMDA 1",GRIN1,antagonist,yes
Agmatine,,ATP-sensitive inward rectifier potassium channel 1,KCNJ1,antagonist,yes
Agmatine,,Voltage-dependent N-type calcium channel subunit alpha-1B,CACNA1B,antagonist,yes
Agmatine,,Acid-sensing ion channel 3,ASIC3,agonist,yes
Serotonin,,Sodium-dependent serotonin transporter,SLC6A4,,unknown
Serotonin,,5-hydroxytryptamine receptor 2A,HTR2A,,unknown
Serotonin,,5-hydroxytryptamine receptor 3A,HTR3A,,unknown
Serotonin,,5-hydroxytryptamine receptor 3B,HTR3B,,unknown
Serotonin,,Synaptic vesicular amine transporter,SLC18A2,,unknown
Uric Acid,,"Glycogen phosphorylase, liver form",PYGL,,unknown
Oxogluric acid,,Aspartate aminotransferase,aspC,,unknown
Ellagic Acid,,Carbonic anhydrase 1,CA1,inhibitor,unknown
Ellagic Acid,,Carbonic anhydrase 2,CA2,inhibitor,unknown
Ellagic Acid,,Carbonic anhydrase 3,CA3,inhibitor,unknown
Ellagic Acid,,Carbonic anhydrase 4,CA4,inhibitor,unknown
Ellagic Acid,,"Carbonic anhydrase 5A, mitochondrial",CA5A,inhibitor,unknown
Ellagic Acid,,"Carbonic anhydrase 5B, mitochondrial",CA5B,inhibitor,unknown
Ellagic Acid,,Carbonic anhydrase 6,CA6,inhibitor,unknown
Ellagic Acid,,Carbonic anhydrase 7,CA7,inhibitor,unknown
Ellagic Acid,,Carbonic anhydrase 9,CA9,inhibitor,unknown
Ellagic Acid,,Carbonic anhydrase 12,CA12,inhibitor,unknown
Ellagic Acid,,Carbonic anhydrase 14,CA14,inhibitor,unknown
Ellagic Acid,,Casein kinase II subunit alpha,CSNK2A1,inhibitor,unknown
Ellagic Acid,,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,,unknown
Ellagic Acid,,Protein kinase C alpha type,PRKCA,,unknown
Ellagic Acid,,Protein kinase C beta type,PRKCB,,unknown
Ellagic Acid,,Tyrosine-protein kinase SYK,SYK,inhibitor,unknown
Ellagic Acid,,Squalene monooxygenase,SQLE,inhibitor,unknown
Guvacine,,Sodium- and chloride-dependent GABA transporter 2,SLC6A13,inhibitor,unknown
Guvacine,,Sodium- and chloride-dependent GABA transporter 1,SLC6A1,inhibitor,unknown
Guvacine,,Sodium- and chloride-dependent GABA transporter 3,SLC6A11,inhibitor,unknown
Guvacine,,Sodium- and chloride-dependent betaine transporter,SLC6A12,inhibitor,unknown
Leukotriene C4,,Cysteinyl leukotriene receptor 1,CYSLTR1,,unknown
Leukotriene C4,,Cysteinyl leukotriene receptor 2,CYSLTR2,,unknown
Leukotriene C4,,Multidrug resistance-associated protein 1,ABCC1,,unknown
Pitavastatin,Plasma elimination half-lfie = 12 hours,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,inhibitor,yes
Cholecystokinin,2.5 min [L1642],Cholecystokinin receptor type A,CCKAR,agonist,unknown
Cholecystokinin,2.5 min [L1642],RAF proto-oncogene serine/threonine-protein kinase,RAF1,agonist,unknown
Cholecystokinin,2.5 min [L1642],Mitogen-activated protein kinase 3,MAPK3,,unknown
Cholecystokinin,2.5 min [L1642],Pro-epidermal growth factor,EGF,,unknown
Cholecystokinin,2.5 min [L1642],Protein kinase C beta type,PRKCB,agonist,unknown
Cholecystokinin,2.5 min [L1642],Gastrin/cholecystokinin type B receptor,CCKBR,agonist,unknown
Rilpivirine,"Plasma drug elimination is really slow, giving rilpivirine a half-life of 34-55 hours after oral administration.[A31331]",Reverse transcriptase/RNaseH,pol,inhibitor,yes
Rilpivirine,"Plasma drug elimination is really slow, giving rilpivirine a half-life of 34-55 hours after oral administration.[A31331]",Nuclear receptor subfamily 1 group I member 2,NR1I2,agonist,unknown
Crizotinib,"Plasma terminal half-life, patients = 42 hours",ALK tyrosine kinase receptor,ALK,inhibitor,yes
Crizotinib,"Plasma terminal half-life, patients = 42 hours",Hepatocyte growth factor receptor,MET,inhibitor,yes
Ulipristal,"Mean elimination half-life, single oral dose, healthy subject = 32.4 ± 6.3 hours",Progesterone receptor,PGR,modulator,yes
Ulipristal,"Mean elimination half-life, single oral dose, healthy subject = 32.4 ± 6.3 hours",Glucocorticoid receptor,NR3C1,antagonist,yes
Ulipristal,"Mean elimination half-life, single oral dose, healthy subject = 32.4 ± 6.3 hours",Androgen receptor,AR,,unknown
Fingolimod,6-9 days,Sphingosine 1-phosphate receptor 5,S1PR5,modulator,yes
Fingolimod,6-9 days,Histone deacetylase 1,HDAC1,inhibitor,unknown
Tesamorelin,"26 and 38 minutes in healthy subjects and HIV-infected patients, respectively.",Growth hormone-releasing hormone receptor,GHRHR,binder,yes
Brentuximab vedotin,The terminal half-life is approximately 4-6 days [FDA label].,Tumor necrosis factor receptor superfamily member 8,TNFRSF8,binder,yes
Eribulin,about 40 hours,Apoptosis regulator Bcl-2,BCL2,,unknown
Eribulin,about 40 hours,Tubulin beta-1 chain,TUBB1,,unknown
Gabapentin Enacarbil,The elimination half-life of gabapentin is 5.1 to 6.0 hours.,Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,,unknown
Gabapentin Enacarbil,The elimination half-life of gabapentin is 5.1 to 6.0 hours.,Voltage-dependent calcium channel subunit alpha-2/delta-2,CACNA2D2,,unknown
Boceprevir,Boceprevir has a mean half-life of elimination of 3.4 hours [FDA Label].,NS3/4A protein,NS3/4A,inhibitor,yes
Fidaxomicin,"200 mg, healthy subjects = 11.7 hours",RNA polymerase sigma factor,sigA1,inhibitor,yes
Cabozantinib,Cabozantinib has a long half-life of 55 hours.,Hepatocyte growth factor receptor,MET,antagonist,yes
Cabozantinib,Cabozantinib has a long half-life of 55 hours.,Vascular endothelial growth factor receptor 2,KDR,antagonist,yes
Cabozantinib,Cabozantinib has a long half-life of 55 hours.,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,antagonist,yes
Taliglucerase Alfa,The half life is between 18.9 to 28.7 min.,Glucocerebroside,,,unknown
Ruxolitinib,"Mean elimination half-life, 15 mg, healthy subject = 2.8 hours.",Tyrosine-protein kinase JAK1,JAK1,inhibitor,yes
Ruxolitinib,"Mean elimination half-life, 15 mg, healthy subject = 2.8 hours.",Tyrosine-protein kinase JAK2,JAK2,inhibitor,yes
Belimumab,"Terminal elimination half-life, 10 mg/kg, SLE patients= 19.4 days; Distribution half-life, 10 mg/kg, SLE patients = 1.75 days.",Tumor necrosis factor ligand superfamily member 13B,TNFSF13B,neutralizer,yes
Teriflunomide,The median half-life is 18 to 19 days.,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,inhibitor,unknown
Vemurafenib,The elimination half-life of Vemurafenib is estimated to be 57 hours (range of 30-120 hours).[A31274],Serine/threonine-protein kinase B-raf,BRAF,inhibitor,yes
Linagliptin,"Terminal half life = 131 hours. Because of this long half-life, inhibition of DPP-4 activity is sustained which indicates that once-daily dosing is appropriate. Effective half-life for accumulation of drug is 12 hours when multiple oral doses of 5 mg are given.",Dipeptidyl peptidase 4,DPP4,inhibitor,yes
Perampanel,Perampanel has a long elmination half-life of about 105 hours.,Glutamate receptor 1,GRIA1,antagonist,yes
Aflibercept,"Intravitreal half-life= 7.13 days in humans; 
Terminal elimination half-life of free aflibercept in plasma was 5 to 6 days after IV injection of 2 - 4 mg/kg dose.",Vascular endothelial growth factor A,VEGFA,binder,yes
Aflibercept,"Intravitreal half-life= 7.13 days in humans; 
Terminal elimination half-life of free aflibercept in plasma was 5 to 6 days after IV injection of 2 - 4 mg/kg dose.",Placenta growth factor,PGF,binder,yes
Aflibercept,"Intravitreal half-life= 7.13 days in humans; 
Terminal elimination half-life of free aflibercept in plasma was 5 to 6 days after IV injection of 2 - 4 mg/kg dose.",Vascular endothelial growth factor B,VEGFB,binder,yes
Ocriplasmin,,Fibronectin,FN1,cleavage,yes
Ocriplasmin,,Alpha-2-macroglobulin,A2M,ligand,no
Ocriplasmin,,Alpha-2-antiplasmin,SERPINF2,ligand,no
Carfilzomib,"Following intravenous administration of doses ≥ 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of ≤ 1 hour on Day 1 of Cycle 1.",Proteasome subunit beta type-5,PSMB5,inhibitor,yes
Carfilzomib,"Following intravenous administration of doses ≥ 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of ≤ 1 hour on Day 1 of Cycle 1.",Proteasome subunit beta type-8,PSMB8,inhibitor,yes
Carfilzomib,"Following intravenous administration of doses ≥ 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of ≤ 1 hour on Day 1 of Cycle 1.",Proteasome subunit beta type-1,PSMB1,inhibitor,yes
Carfilzomib,"Following intravenous administration of doses ≥ 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of ≤ 1 hour on Day 1 of Cycle 1.",Proteasome subunit beta type-9,PSMB9,inhibitor,yes
Carfilzomib,"Following intravenous administration of doses ≥ 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of ≤ 1 hour on Day 1 of Cycle 1.",Proteasome subunit beta type-2,PSMB2,inhibitor,yes
Carfilzomib,"Following intravenous administration of doses ≥ 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of ≤ 1 hour on Day 1 of Cycle 1.",Proteasome subunit beta type-10,PSMB10,inhibitor,yes
Linaclotide,"Because linaclotide is not systemically absorbed, half life cannot be calculated.",Heat-stable enterotoxin receptor,GUCY2C,agonist,yes
Arbaclofen,,Gamma-aminobutyric acid type B receptor subunit 1,GABBR1,agonist,yes
Arbaclofen,,Gamma-aminobutyric acid type B receptor subunit 2,GABBR2,agonist,yes
Arbaclofen Placarbil,IV bolus administration of AP to rats showed that AP was converted to R-baclofen with a half life of 6 minutes.,Gamma-aminobutyric acid type B receptor subunit 1,GABBR1,agonist,yes
Arbaclofen Placarbil,IV bolus administration of AP to rats showed that AP was converted to R-baclofen with a half life of 6 minutes.,Gamma-aminobutyric acid type B receptor subunit 2,GABBR2,agonist,yes
Mirabegron,Terminal elimination half-life = 50 hours,Beta-3 adrenergic receptor,ADRB3,agonist,yes
Peginesatide,"IV dose, healthy subjects = 25.0 ± 7.6 hours;
SubQ, healthy subjects = 53.0 ± 17.7 hours;
IV dose, dialysis patients = 47.9 ± 16.5 hours;",Erythropoietin receptor,EPOR,stimulator,yes
Tofacitinib,~3 hours,Tyrosine-protein kinase JAK1,JAK1,inhibitor,yes
Tofacitinib,~3 hours,Tyrosine-protein kinase JAK2,JAK2,antagonistinhibitor,yes
Tofacitinib,~3 hours,Tyrosine-protein kinase JAK3,JAK3,inhibitor,yes
Tofacitinib,~3 hours,Non-receptor tyrosine-protein kinase TYK2,TYK2,,unknown
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",Vascular endothelial growth factor receptor 1,FLT1,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",Vascular endothelial growth factor receptor 2,KDR,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",Vascular endothelial growth factor receptor 3,FLT4,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",Mast/stem cell growth factor receptor Kit,KIT,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",Platelet-derived growth factor receptor alpha,PDGFRA,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",Platelet-derived growth factor receptor beta,PDGFRB,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",Fibroblast growth factor receptor 1,FGFR1,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",Fibroblast growth factor receptor 2,FGFR2,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",Angiopoietin-1 receptor,TEK,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",Discoidin domain-containing receptor 2,DDR2,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",High affinity nerve growth factor receptor,NTRK1,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",Ephrin type-A receptor 2,EPHA2,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",RAF proto-oncogene serine/threonine-protein kinase,RAF1,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",Serine/threonine-protein kinase B-raf,BRAF,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",Mitogen-activated protein kinase 11,MAPK11,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",Tyrosine-protein kinase FRK,FRK,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",Tyrosine-protein kinase ABL1,ABL1,inhibitor,yes
Regorafenib,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);",Proto-oncogene tyrosine-protein kinase receptor Ret,RET,inhibitor,yes
Aclidinium,"Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). 
Effective half-life = 5-8 hours.",Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Aclidinium,"Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). 
Effective half-life = 5-8 hours.",Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Aclidinium,"Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). 
Effective half-life = 5-8 hours.",Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Aclidinium,"Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). 
Effective half-life = 5-8 hours.",Muscarinic acetylcholine receptor M4,CHRM4,antagonist,yes
Aclidinium,"Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). 
Effective half-life = 5-8 hours.",Muscarinic acetylcholine receptor M5,CHRM5,antagonist,yes
Glucarpidase,"In healthy patients not taking methotrexate, glucarpidase has an elimination half-life of 5.6 hours. In patients with severe renal impairment (creatinine clearance <30 mL/min), glucarpidase has an longer elimination half-life at 8.2 hours.",Methotrexate,,metabolizer,yes
Enzalutamide,"The mean terminal half-life (t1/2) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days). Following a single 160 mg oral dose of enzalutamide in healthy volunteers, the mean terminal t1/2 for N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.",Androgen receptor,AR,inhibitor,yes
Teduglutide,"Terminal half-life, healthy subjects = 2 hours;
Terminal half-life, SBS patients = 1.3 hours",Glucagon-like peptide 2 receptor,GLP2R,agonist,yes
Ponatinib,"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).",Tyrosine-protein kinase ABL1,ABL1,inhibitor,yes
Ponatinib,"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).",Breakpoint cluster region protein,BCR,inhibitor,yes
Ponatinib,"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).",Mast/stem cell growth factor receptor Kit,KIT,inhibitor,unknown
Ponatinib,"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).",Proto-oncogene tyrosine-protein kinase receptor Ret,RET,inhibitor,unknown
Ponatinib,"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).",Angiopoietin-1 receptor,TEK,inhibitor,unknown
Ponatinib,"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).",Receptor-type tyrosine-protein kinase FLT3,FLT3,inhibitor,unknown
Ponatinib,"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).",Fibroblast growth factor receptor 1,FGFR1,inhibitor,unknown
Ponatinib,"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).",Fibroblast growth factor receptor 2,FGFR2,inhibitor,unknown
Ponatinib,"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).",Fibroblast growth factor receptor 3,FGFR3,inhibitor,unknown
Ponatinib,"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).",Fibroblast growth factor receptor 4,FGFR4,inhibitor,unknown
Ponatinib,"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).",Tyrosine-protein kinase Lck,LCK,inhibitor,unknown
Ponatinib,"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).",Proto-oncogene tyrosine-protein kinase Src,SRC,inhibitor,unknown
Ponatinib,"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).",Tyrosine-protein kinase Lyn,LYN,inhibitor,unknown
Ponatinib,"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).",Vascular endothelial growth factor receptor 2,KDR,inhibitor,unknown
Ponatinib,"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).",Platelet-derived growth factor receptor alpha,PDGFRA,inhibitor,unknown
Raxibacumab,"Mean terminal elimination half-lives of raxibacumab are as follows:
IM dose = 15-19 days;
IV dose = 16-19 days",Protective antigen,pagA,antibody,yes
Bedaquiline,"Terminal elimination half-life, bedaquiline and M2 = 5.5 months. This long half-life suggests slow release of bedaquiline and M2 from peripheral tissues.",ATP synthase subunit c,atpE,inhibitor,yes
Certolizumab pegol,Terminal plasma elimation half-life = 14 days (for all doses);,Tumor necrosis factor,TNF,neutralizer,yes
Fluticasone furoate,"Elimination phase half-life, IV dose = 15.1 hours;
Elimination phase half-life, inhaled = 17 - 24 hours;",Glucocorticoid receptor,NR3C1,agonist,yes
Canagliflozin,"The apparent terminal half-life (t1/2) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively.",Sodium/glucose cotransporter 2,SLC5A2,inhibitor,yes
Canagliflozin,"The apparent terminal half-life (t1/2) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively.",Sodium/glucose cotransporter 1,SLC5A1,inhibitor,unknown
Dimethyl fumarate,"MMF has a short half life of about 1 hour, and MMF does not accumulate after repeated doses of dimethyl fumarate.",Kelch-like ECH-associated protein 1,KEAP1,binder,yes
Dimethyl fumarate,"MMF has a short half life of about 1 hour, and MMF does not accumulate after repeated doses of dimethyl fumarate.",Transcription factor p65,RELA,,unknown
Pomalidomide,"Healthy subjects = 9.4 hours;
Multiple myeloma patients = 7.5 hours.",Protein cereblon,CRBN,inhibitor,yes
Pomalidomide,"Healthy subjects = 9.4 hours;
Multiple myeloma patients = 7.5 hours.",Tumor necrosis factor,TNF,inhibitor,yes
Pomalidomide,"Healthy subjects = 9.4 hours;
Multiple myeloma patients = 7.5 hours.",Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Trametinib,Elimination half-life = 3.9-4.8 days.,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,inhibitor,yes
Trametinib,Elimination half-life = 3.9-4.8 days.,Dual specificity mitogen-activated protein kinase kinase 2,MAP2K2,inhibitor,yes
Dabrafenib,"Dabrafenib = 8 hours; 
Hydroxy-dabrafenib = 10 hours;
Carboxy-dabrafenib = 21-22 hours;
Desmethyl-dabrafenib = 21- 22 hours.",Serine/threonine-protein kinase B-raf,BRAF,inhibitor,yes
Dabrafenib,"Dabrafenib = 8 hours; 
Hydroxy-dabrafenib = 10 hours;
Carboxy-dabrafenib = 21-22 hours;
Desmethyl-dabrafenib = 21- 22 hours.",RAF proto-oncogene serine/threonine-protein kinase,RAF1,inhibitor,yes
Dabrafenib,"Dabrafenib = 8 hours; 
Hydroxy-dabrafenib = 10 hours;
Carboxy-dabrafenib = 21-22 hours;
Desmethyl-dabrafenib = 21- 22 hours.",Serine/threonine-protein kinase SIK1,SIK1,inhibitor,unknown
Dabrafenib,"Dabrafenib = 8 hours; 
Hydroxy-dabrafenib = 10 hours;
Carboxy-dabrafenib = 21-22 hours;
Desmethyl-dabrafenib = 21- 22 hours.",Serine/threonine-protein kinase Nek11,NEK11,inhibitor,unknown
Dabrafenib,"Dabrafenib = 8 hours; 
Hydroxy-dabrafenib = 10 hours;
Carboxy-dabrafenib = 21-22 hours;
Desmethyl-dabrafenib = 21- 22 hours.",LIM domain kinase 1,LIMK1,inhibitor,unknown
Aleglitazar,,Peroxisome proliferator-activated receptor alpha,PPARA,agonist,yes
Aleglitazar,,Peroxisome proliferator-activated receptor gamma,PPARG,agonist,yes
Aleglitazar,,Nuclear receptor coactivator 1,NCOA1,,unknown
Afatinib,"Cancer patients, repeat dosing = 37 hours",Epidermal growth factor receptor,EGFR,inhibitor,yes
Afatinib,"Cancer patients, repeat dosing = 37 hours",Receptor tyrosine-protein kinase erbB-2,ERBB2,inhibitor,yes
Afatinib,"Cancer patients, repeat dosing = 37 hours",Receptor tyrosine-protein kinase erbB-4,ERBB4,inhibitor,yes
Levomilnacipran,12 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Levomilnacipran,12 hours,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Perospirone,The elimination half life is approximately 1.9 hours following oral ingestion of 8mg perospirone [A19677].,5-hydroxytryptamine receptor 2A,HTR2A,inverse agonist,yes
Perospirone,The elimination half life is approximately 1.9 hours following oral ingestion of 8mg perospirone [A19677].,D(2) dopamine receptor,DRD2,antagonist,yes
Perospirone,The elimination half life is approximately 1.9 hours following oral ingestion of 8mg perospirone [A19677].,5-hydroxytryptamine receptor 1A,HTR1A,partial agonist,yes
Perospirone,The elimination half life is approximately 1.9 hours following oral ingestion of 8mg perospirone [A19677].,Histamine H1 receptor,HRH1,inverse agonist,unknown
Perospirone,The elimination half life is approximately 1.9 hours following oral ingestion of 8mg perospirone [A19677].,D(4) dopamine receptor,DRD4,antagonist,unknown
Perospirone,The elimination half life is approximately 1.9 hours following oral ingestion of 8mg perospirone [A19677].,Alpha-1 adrenergic receptors,ADRA1AADRA1BADRA1D,antagonist,unknown
Amperozide,,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,unknown
Dolutegravir,The half-life of dolutegravir is 14 hours.[A7514],Integrase,pol,inhibitor,yes
Riociguat,About 12 hours in patients and 7 hours in healthy subjects.,Guanylate cyclase soluble subunit alpha-2,GUCY1A2,agoniststimulator,yes
Macitentan,"The half life of macitentan is 16 hours, and the half life of it's active metabolite is 48 hours.",Endothelin-1 receptor,EDNRA,antagonist,yes
Macitentan,"The half life of macitentan is 16 hours, and the half life of it's active metabolite is 48 hours.",Endothelin B receptor,EDNRB,antagonist,yes
Luliconazole,The half life of luliconazole has yet to be determined.,Lanosterol 14-alpha demethylase,ERG11,inhibitor,yes
Sofosbuvir,Sofosbuvir has a terminal half life of 0.4 hours [FDA Label].,RNA-dependent RNA-polymerase,NS5b,inhibitor,yes
Obinutuzumab,The half life of obinutuzumab is 28.4 days.,B-lymphocyte antigen CD20,MS4A1,antibody,yes
Chlorcyclizine,about 12 h.,Histamine H1 receptor,HRH1,antagonist,yes
Inositol nicotinate,Mean elimination half life in healthy human adults is approximately one hour [A19550].,Hydroxycarboxylic acid receptor 3,HCAR3,agonist,yes
Inositol nicotinate,Mean elimination half life in healthy human adults is approximately one hour [A19550].,Hydroxycarboxylic acid receptor 2,HCAR2,agonist,yes
Indoramin,,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Ifenprodil,,"Glutamate receptor ionotropic, NMDA 1",GRIN1,antagonist,yes
Ifenprodil,,"Glutamate receptor ionotropic, NMDA 2B",GRIN2B,antagonist,yes
Gemeprost,,Prostaglandin E2 receptor EP2 subtype,PTGER2,agonist,unknown
Gemeprost,,Prostaglandin E2 receptor EP3 subtype,PTGER3,agonist,yes
Diosmin,,Aryl hydrocarbon receptor,AHR,agonist,unknown
Dimetacrine,Approximately 10 hours. (PMID 5312397),Acetylcholinesterase,ACHE,antagonist,yes
Clinofibrate,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Clinofibrate,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Clinofibrate,,Peroxisome proliferator-activated receptor delta,PPARD,,unknown
Befunolol,,Beta-1 adrenergic receptor,ADRB1,,unknown
Befunolol,,Beta-2 adrenergic receptor,ADRB2,,unknown
Captodiame,,5-hydroxytryptamine receptor 2C,HTR2C,antagonist,yes
Captodiame,,Sigma non-opioid intracellular receptor 1,SIGMAR1,agonist,yes
Captodiame,,D(3) dopamine receptor,DRD3,agonist,yes
Butriptyline,,Sodium-dependent serotonin transporter,SLC6A4,antagonistinhibitor,yes
Butriptyline,,Histamine H1 receptor,HRH1,antagonist,yes
Butriptyline,,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Bromopride,,D(2) dopamine receptor,DRD2,antagonist,yes
Aliskiren,Approximate accumulation half‐life of 24 hours.,Renin,REN,inhibitor,yes
Ledipasvir,The median terminal half-life of ledipasvir is 47 hours [FDA Label].,Nonstructural protein 5A,NS5A,inhibitor,yes
Cytisine,4.8 hours.,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,agonist,unknown
Cytisine,4.8 hours.,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,agonist,unknown
Cytisine,4.8 hours.,Neuronal acetylcholine receptor subunit alpha-3,CHRNA3,agonist,unknown
Cytisine,4.8 hours.,Neuronal acetylcholine receptor subunit alpha-6,CHRNA6,agonist,unknown
Cytisine,4.8 hours.,Neuronal acetylcholine receptor subunit beta-2,CHRNB2,partial agonist,unknown
Secukinumab,22-31 days,Interleukin-17A,IL17A,antagonist,yes
Vorapaxar,Vorapaxar has an effective half life of 3-4 days and an apparent terminal half life of 8 days.,Proteinase-activated receptor 1,F2R,antagonist,yes
Miltefosine,The primary elimination half life is 7.05 days (range: 5.45-9.10 days) and the terminal half-life is 30.9 days (range: 30.8-31.2 days).,Multidrug resistance protein 1,ABCB1,,unknown
Vedolizumab,Vedolizumab has a long terminal elimination half life of 336 to 362 hr.,Integrin alpha-4,ITGA4,antibody,yes
Vedolizumab,Vedolizumab has a long terminal elimination half life of 336 to 362 hr.,Integrin beta-7,ITGB7,antibody,yes
Suvorexant,Mean half life is approximately 12 hours.,Orexin receptor type 1,HCRTR1,antagonist,yes
Suvorexant,Mean half life is approximately 12 hours.,Orexin receptor type 2,HCRTR2,antagonist,yes
Nivolumab,26.7 days,Programmed cell death protein 1,PDCD1,antibody,yes
Siltuximab,The mean terminal half life after the first intravenous infusion of 11 mg/kg is 20.6 days.,Interleukin-6,IL6,antagonistantibody,yes
Pembrolizumab,23 days,Programmed cell death protein 1,PDCD1,antagonistantibody,yes
Empagliflozin,Terminal elimination half life was found to be 12.4 h based on population pharmacokinetic analysis.,Sodium/glucose cotransporter 2,SLC5A2,antagonistinhibitor,unknown
Eliglustat,6.5 hours in EM (extensive metabolizers) and 8.9 hours in PM (poor metabolizers).,Ceramide glucosyltransferase,UGCG,antagonist,yes
Efinaconazole,29.9 hours in healthy patients.,Lanosterol 14-alpha demethylase,ERG11,inhibitor,yes
Tavaborole,28.5 hr,Cytosolic leucyl-tRNA synthetase,CDC60,inhibitor,yes
Albiglutide,4-7 days.,Glucagon-like peptide 1 receptor,GLP1R,agonist,yes
Dulaglutide,Approximately 5 days.,Glucagon-like peptide 1 receptor,GLP1R,agonist,yes
Metreleptin,3.8 to 4.7 hours,Leptin receptor,LEPR,agonist,yes
Finafloxacin,,DNA gyrase subunit A,gyrA,inhibitor,yes
Finafloxacin,,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Finafloxacin,,DNA topoisomerase 2-alpha,TOP2A,inhibitor,yes
Netupitant,96 hours with CV% of 61.,Substance-P receptor,TACR1,antagonist,yes
Naloxegol,6-11 hours.,Mu-type opioid receptor,OPRM1,antagonist,yes
Ceftolozane,"2.77 hours on day 1 of treatment.
3.12 hours on day 10 of treatment.",Penicillin-binding protein 1B,ponB,inhibitor,yes
Ceftolozane,"2.77 hours on day 1 of treatment.
3.12 hours on day 10 of treatment.",Penicillin-binding protein 3,pbpB,inhibitor,yes
Blinatumomab,"2.11 hours, standard deviation 1.42.",B-lymphocyte antigen CD19,CD19,activator,yes
Blinatumomab,"2.11 hours, standard deviation 1.42.",T-cell surface glycoprotein CD3 delta chain,CD3D,activator,yes
Ibrutinib,The elimination half-life of ibrutinib is of approximately 4-6 hours.[T148],Tyrosine-protein kinase BTK,BTK,inhibitor,yes
Idelalisib,The terminal elimination half-life is 8.2 hours.,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (P110δ)",,inhibitor,yes
Anthrax immune globulin human,24.3 days,Protective antigen,pagA,antibody,yes
Avibactam,Ceftazidime-avibactam has a half life of ~2.7-3.0 hours.,Beta-lactamase TEM,bla,inhibitor,yes
Avibactam,Ceftazidime-avibactam has a half life of ~2.7-3.0 hours.,Beta-lactamase CTX-M,blaCTX-M-14,inhibitor,yes
Avibactam,Ceftazidime-avibactam has a half life of ~2.7-3.0 hours.,Beta-lactamase AmpC,ampC,inhibitor,yes
Avibactam,Ceftazidime-avibactam has a half life of ~2.7-3.0 hours.,Beta-lactamase SHV-1,bla,inhibitor,yes
Avibactam,Ceftazidime-avibactam has a half life of ~2.7-3.0 hours.,Beta-lactamase SHV-2,bla,inhibitor,yes
Avibactam,Ceftazidime-avibactam has a half life of ~2.7-3.0 hours.,Beta-lactamase SHV-1,bla,inhibitor,yes
Avibactam,Ceftazidime-avibactam has a half life of ~2.7-3.0 hours.,Class D OXA-48 carbapenemase,OXA-48,inhibitor,yes
Avibactam,Ceftazidime-avibactam has a half life of ~2.7-3.0 hours.,Carbapenem-hydrolyzing beta-lactamase KPC,bla,inhibitor,yes
Avibactam,Ceftazidime-avibactam has a half life of ~2.7-3.0 hours.,Beta-lactamase CTX-M-15,blaUOE-1,inhibitor,yes
Avibactam,Ceftazidime-avibactam has a half life of ~2.7-3.0 hours.,Extended-spectrum beta-lactamase PER-1,per1,inhibitor,yes
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Cannabinoid receptor 1,CNR1,antagonist,yes
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Cannabinoid receptor 2,CNR2,antagonist,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",G-protein coupled receptor 12,GPR12,inverse agonist,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Glycine receptor subunit alpha-1,GLRA1,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Glycine receptor (alpha-1/beta),GLRA1GLRB,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Glycine receptor subunit alpha-3,GLRA3,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",N-arachidonyl glycine receptor,GPR18,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",G-protein coupled receptor 55,GPR55,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",5-hydroxytryptamine receptor 1A,HTR1A,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",5-hydroxytryptamine receptor 2A,HTR2A,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Delta-type opioid receptor,OPRD1,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Mu-type opioid receptor,OPRM1,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Transient receptor potential cation channel subfamily V member 1,TRPV1,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Voltage-dependent T-type calcium channel subunit alpha-1I,CACNA1I,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Transient receptor potential cation channel subfamily A member 1,TRPA1,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Transient receptor potential cation channel subfamily M member 8,TRPM8,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Transient receptor potential cation channel subfamily V member 2,TRPV2,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Transient receptor potential cation channel subfamily V member 3,TRPV3,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Transient receptor potential cation channel subfamily V member 4,TRPV4,,unknown
Cannabidiol,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.",Voltage-dependent anion-selective channel protein 1,VDAC1,,unknown
Ceritinib,The terminal half life is 41 hours.,ALK tyrosine kinase receptor,ALK,antagonist,yes
Ciprofibrate,,Peroxisome proliferator-activated receptor alpha,PPARA,,unknown
Corticorelin ovine triflutate,Plasma half-lives for IR-corticorelin are 11.6 ± 1.5 minutes (mean ± SE) for the fast component and 73 ± 8 minutes for the slow component.,Corticotropin-releasing factor receptor 1,CRHR1,ligand,yes
Vortioxetine,Mean terminal half­life is approximately 66 hours,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Vortioxetine,Mean terminal half­life is approximately 66 hours,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,yes
Vortioxetine,Mean terminal half­life is approximately 66 hours,5-hydroxytryptamine receptor 7,HTR7,antagonist,yes
Vortioxetine,Mean terminal half­life is approximately 66 hours,5-hydroxytryptamine receptor 1B,HTR1B,partial agonist,yes
Vortioxetine,Mean terminal half­life is approximately 66 hours,5-hydroxytryptamine receptor 1A,HTR1A,agonist,yes
Vortioxetine,Mean terminal half­life is approximately 66 hours,Beta-1 adrenergic receptor,ADRB1,ligand,unknown
Vortioxetine,Mean terminal half­life is approximately 66 hours,solute carrier family 6 member 2,,blocker,unknown
Trimetazidine,Half life of the modified release (MR) formulation was reported to be ∼8 h in young volunteers (25 ± 8) and ∼12 h in elderly (72 ± 4) (Barré et al. 2003).,"3-ketoacyl-CoA thiolase, peroxisomal",ACAA1,inhibitor,yes
Tibolone,The elimination half-life is approximately 45 h [L1720].,Estrogen receptor alpha,ESR1,antagonistagonist,yes
Tasimelteon,The observed mean elimination half-life for tasimelteon is 1.3 ± 0.4 hours.,Melatonin receptor type 1A,MTNR1A,agonist,yes
Tasimelteon,The observed mean elimination half-life for tasimelteon is 1.3 ± 0.4 hours.,Melatonin receptor type 1B,MTNR1B,agonist,yes
Palbociclib,The mean plasma elimination half-life is 29 hours.,Cyclin-dependent kinase 4,CDK4,inhibitor,yes
Palbociclib,The mean plasma elimination half-life is 29 hours.,Cyclin-dependent kinase 6,CDK6,inhibitor,yes
Olaparib,"11.9 hours, standard deviation 4.8 hours.",Poly [ADP-ribose] polymerase 1,PARP1,inhibitor,yes
Olaparib,"11.9 hours, standard deviation 4.8 hours.",Poly [ADP-ribose] polymerase 2,PARP2,inhibitor,yes
Olaparib,"11.9 hours, standard deviation 4.8 hours.",Poly [ADP-ribose] polymerase 3,PARP3,inhibitor,yes
Edoxaban,The terminal elimination half-life of edoxaban following oral administration is 10 to 14 hours.,Coagulation factor X,F10,inhibitor,yes
Umeclidinium,The effective half-life after once daily dosing is 11 hours.,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,no
Umeclidinium,The effective half-life after once daily dosing is 11 hours.,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Umeclidinium,The effective half-life after once daily dosing is 11 hours.,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Umeclidinium,The effective half-life after once daily dosing is 11 hours.,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,no
Umeclidinium,The effective half-life after once daily dosing is 11 hours.,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,no
Dinutuximab,The terminal half-life is 10 days,Ganglioside GD2,,inhibitor,yes
Lenvatinib,The terminal elimination half­life of lenvatinib is approximately 28 hours.,Vascular endothelial growth factor receptor 1,FLT1,inhibitor,yes
Lenvatinib,The terminal elimination half­life of lenvatinib is approximately 28 hours.,Vascular endothelial growth factor receptor 2,KDR,inhibitor,yes
Lenvatinib,The terminal elimination half­life of lenvatinib is approximately 28 hours.,Vascular endothelial growth factor receptor 3,FLT4,inhibitor,yes
Lenvatinib,The terminal elimination half­life of lenvatinib is approximately 28 hours.,Fibroblast growth factor receptor 1,FGFR1,inhibitor,yes
Lenvatinib,The terminal elimination half­life of lenvatinib is approximately 28 hours.,Fibroblast growth factor receptor 2,FGFR2,inhibitor,yes
Lenvatinib,The terminal elimination half­life of lenvatinib is approximately 28 hours.,Fibroblast growth factor receptor 3,FGFR3,inhibitor,yes
Lenvatinib,The terminal elimination half­life of lenvatinib is approximately 28 hours.,Fibroblast growth factor receptor 4,FGFR4,inhibitor,yes
Lenvatinib,The terminal elimination half­life of lenvatinib is approximately 28 hours.,Platelet derived growth factor receptor alpha,,inhibitor,yes
Lenvatinib,The terminal elimination half­life of lenvatinib is approximately 28 hours.,RET,,inhibitor,yes
Lenvatinib,The terminal elimination half­life of lenvatinib is approximately 28 hours.,Mast/stem cell growth factor receptor Kit,KIT,inhibitor,yes
Nintedanib,9.5 hours,Vascular endothelial growth factor receptor 1,FLT1,inhibitor,yes
Nintedanib,9.5 hours,Vascular endothelial growth factor receptor 2,KDR,inhibitor,yes
Nintedanib,9.5 hours,Vascular endothelial growth factor receptor 3,FLT4,inhibitor,yes
Nintedanib,9.5 hours,Platelet derived growth factor receptor alpha,,inhibitor,yes
Nintedanib,9.5 hours,Platelet derived growth factor receptor beta,,inhibitor,yes
Nintedanib,9.5 hours,Fibroblast growth factor receptor 1,FGFR1,inhibitor,yes
Nintedanib,9.5 hours,Fibroblast growth factor receptor 2,FGFR2,inhibitor,yes
Nintedanib,9.5 hours,Fibroblast growth factor receptor 3,FGFR3,inhibitor,yes
Nintedanib,9.5 hours,Receptor-type tyrosine-protein kinase FLT3,FLT3,inhibitor,unknown
Nintedanib,9.5 hours,Tyrosine-protein kinase Lck,LCK,inhibitor,unknown
Nintedanib,9.5 hours,Tyrosine-protein kinase Lyn,LYN,inhibitor,unknown
Nintedanib,9.5 hours,Proto-oncogene tyrosine-protein kinase Src,SRC,inhibitor,unknown
Olodaterol,"The terminal half-life following intravenous administration is 22 hours. The terminal half-life following inhalation in contrast is about 45 hours, indicating that the latter is determined by absorption rather than by elimination processes.",Beta-2 adrenergic receptor,ADRB2,agonist,yes
Vilanterol,21.3 hr,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Tetracaine,"Tetracaine is hydrolyzed rapidly in the plasma; therefore, half-life has not been determined.",Ryanodine receptor 1,RYR1,modulator,yes
Tetracaine,"Tetracaine is hydrolyzed rapidly in the plasma; therefore, half-life has not been determined.",Ryanodine receptor 2,RYR2,modulator,yes
Tetracaine,"Tetracaine is hydrolyzed rapidly in the plasma; therefore, half-life has not been determined.",Voltage gated sodium channel,,antagonist,yes
Eugenol,,Estrogen receptor alpha,ESR1,,unknown
Eugenol,,Estrogen receptor beta,ESR2,,unknown
Eugenol,,Androgen receptor,AR,antagonist,unknown
Eugenol,,Transient receptor potential cation channel subfamily V member 3,TRPV3,,unknown
Amylocaine,A lack of detailed information regarding the specificities of amylocaine relate to a lack of information on its pharmacokinetics at the time of its primary use in the early 1900s [T146].,Voltage gated sodium channel,,antagonist,yes
Trimebutine,"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].",Mu-type opioid receptor,OPRM1,agonist,yes
Trimebutine,"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].",Voltage dependent L type calcium channel,CACNA1CCACNA1DCACNA1FCACNA1SCACNB1CACNB2CACNB3CACNB4,inhibitor,yes
Trimebutine,"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].",Calcium-activated potassium channel,KCNMA1KCNMB1KCNMB2KCNMB3KCNMB4KCNN4KCNN1KCNN2KCNN3,inhibitor,yes
Trimebutine,"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].",Voltage-dependent T-type calcium channel,CACNA1GCACNA1HCACNA1I,activator,unknown
Pinaverium,The mean elimination half life is approximately 1.5 hours [L873].,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,antagonistinhibitor,yes
Tixocortol,Tixocortol presents a shorter half-life than cortisol.[A31447],Glucocorticoid receptor,NR3C1,binder,yes
Tixocortol,Tixocortol presents a shorter half-life than cortisol.[A31447],Histone deacetylase 2,HDAC2,stimulator,yes
Xanthinol,The reported elimination half-life of xanthinol is 1.67h.,60S ribosomal protein L3,RPL3,binder,no
Xanthinol,The reported elimination half-life of xanthinol is 1.67h.,"NAD(P) transhydrogenase, mitochondrial",NNT,cofactor,yes
Xanthinol,The reported elimination half-life of xanthinol is 1.67h.,Glyceraldehyde-3-phosphate dehydrogenase,GAPDH,cofactor,yes
Xanthinol,The reported elimination half-life of xanthinol is 1.67h.,"Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial",IDH3A,cofactor,yes
Xanthinol,The reported elimination half-life of xanthinol is 1.67h.,"2-oxoglutarate dehydrogenase, mitochondrial",OGDH,cofactor,yes
Xanthinol,The reported elimination half-life of xanthinol is 1.67h.,"Malate dehydrogenase, mitochondrial",MDH2,cofactor,yes
Chlortetracycline,The half-life of Chlortetracycline is 5.6 hours [A1424].,16S rRNA,,inhibitor,yes
Chlortetracycline,The half-life of Chlortetracycline is 5.6 hours [A1424].,30S ribosomal protein S3,rpsC,inhibitor,yes
Chlortetracycline,The half-life of Chlortetracycline is 5.6 hours [A1424].,30S ribosomal protein S8,rpsH,inhibitor,yes
Chlortetracycline,The half-life of Chlortetracycline is 5.6 hours [A1424].,30S ribosomal protein S19,rpsS,inhibitor,yes
Chlortetracycline,The half-life of Chlortetracycline is 5.6 hours [A1424].,30S ribosomal protein S14,rpsN,inhibitor,yes
Chlortetracycline,The half-life of Chlortetracycline is 5.6 hours [A1424].,30S ribosomal protein S7,rpsG,inhibitor,yes
Difluocortolone,The half-life of diflucortolone is approximately in the range of 4 to 5 h while the half-life of 3H-diflucortolone valerate is approximately 9 h.[A31459],Annexin A3,ANXA3,inducer,yes
Difluocortolone,The half-life of diflucortolone is approximately in the range of 4 to 5 h while the half-life of 3H-diflucortolone valerate is approximately 9 h.[A31459],Glucocorticoid receptor,NR3C1,binder,yes
Quinagolide,The terminal half-life for parent drug is 11.5 hours following single dose and 17 hours at steady state.,D(2) dopamine receptor,DRD2,agonist,unknown
Quinagolide,The terminal half-life for parent drug is 11.5 hours following single dose and 17 hours at steady state.,D(1) dopamine receptor,DRD1DRD5,agonist,unknown
Somatrem,"The mean terminal half-life after subcutaneous administration is 2.1 +/- 0.43 hours while the mean terminal half-life after intravenous administration is determined to be 19.5 +/- 3.1 minutes [L1896, FDA Label].",Growth hormone receptor,GHR,agonist,yes
Somatrem,"The mean terminal half-life after subcutaneous administration is 2.1 +/- 0.43 hours while the mean terminal half-life after intravenous administration is determined to be 19.5 +/- 3.1 minutes [L1896, FDA Label].",Insulin-like growth factor 1 receptor,IGF1R,,yes
Elvitegravir,The median terminal plasma half-life following administration of elvitegravir and ritonavir was approximately 8.7 hours.,Integrase,pol,inhibitor,yes
Daclatasvir,"Following multiple dose administration of daclatasvir in HCV-infected subjects, with doses ranging from 1 mg to 100 mg once daily, the terminal elimination half-life of daclatasvir ranged from approximately 12 to 15 hours.",Nonstructural Protein 5A (NS5A),,inhibitor,unknown
Ancestim,"In clinical trials, the reported half life for ancestim was between 2-5 hours.[L1089]",Mast/stem cell growth factor receptor Kit,KIT,agonist,yes
Asfotase Alfa,Approximately 5 days.,Sphingosine 1-phosphate receptor 1,S1PR1,agonist,yes
Asfotase Alfa,Approximately 5 days.,Pyrophosphate,,ligand,yes
Methoxy polyethylene glycol-epoetin beta,"In CKD patients on peritoneal dialysis with IV administration: 134 ± 65 hours
In CKD patients on peritoneal dialysis with SC administration: 139 ± 67 hours",Erythropoietin receptor,EPOR,stimulator,yes
Simoctocog Alfa,"At initial assessment following administration of 50 IU/kg simoctocog alfa in adolescent or adult patients with severe haemophilia A, the mean terminal half-life (T1/2) was 17.05 ± 11.23 h [L1115]. The mean T1/2 in pediatric patients was 12.50 ± 4.17 h [L1115]. 

At 6-month assessment in adolescent or adult patients with the same dose, the value was 14.05 ± 4.70 h [L1115].",von Willebrand factor,VWF,binding,yes
Turoctocog alfa,"In pre-clinical studies, turoctocog half-life was reported to be 16 hours.[A31506] In knockout mice there are reports of half-life of 7-8 hours.[L1108]",Coagulation factor IX,F9,activator,yes
Turoctocog alfa,"In pre-clinical studies, turoctocog half-life was reported to be 16 hours.[A31506] In knockout mice there are reports of half-life of 7-8 hours.[L1108]",Coagulation factor X,F10,activator,yes
Turoctocog alfa,"In pre-clinical studies, turoctocog half-life was reported to be 16 hours.[A31506] In knockout mice there are reports of half-life of 7-8 hours.[L1108]",Prothrombin,F2,binder,yes
Nitrous acid,Half life of 0.4-0.78h [A19444].,Hemoglobin subunit alpha,HBA1,oxidizer,yes
Nitrous acid,Half life of 0.4-0.78h [A19444].,Hemoglobin subunit beta,HBB,oxidizer,yes
Nitrous acid,Half life of 0.4-0.78h [A19444].,Myoglobin,MB,oxidizer,unknown
Calcium carbimide,Calcium carbimide is metabolized and eliminated very rapidly so the apparent half-life is of 92.4 minutes.[L1114],Aldehyde dehydrogenase family 3 member B2,ALDH3B2,antagonistinhibitor,yes
Stiripentol,"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].",GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,agonistpositive allosteric modulator,yes
Stiripentol,"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].",L-lactate dehydrogenase A chain,LDHA,inhibitor,yes
Stiripentol,"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].",L-lactate dehydrogenase B chain,LDHB,inhibitor,yes
Eslicarbazepine acetate,The apparent plasma half-life of eslicarbazepine is 10-20 hours in healthy subjects and 13-20 hours in epilepsy patients. Steady-state plasma concentrations are attained after 4 to 5 days of once daily dosing.,P2X purinoceptor 4,P2RX4,antagonist,yes
Zucapsaicin,"In rats, the elimination half life of zucapsaicin and its metabolites is approximately 7 to 11 hours [L877].",Transient receptor potential cation channel subfamily V member 1,TRPV1,agonistactivator,yes
Aurothioglucose,"The biological half-life of gold salts (like aurothioglucose) following a single 50 mg dose demonstrates a biological half-life of about 3-27 days, where the half-life seemingly increases with increased number of doses [T147]. Following successive weekly doses, the half-life increases and may become 14-40 days after the third dose and up to 168 days after the eleventh weekly dose [L1925].",Adenylate cyclase type 1,ADCY1,,unknown
Aurothioglucose,"The biological half-life of gold salts (like aurothioglucose) following a single 50 mg dose demonstrates a biological half-life of about 3-27 days, where the half-life seemingly increases with increased number of doses [T147]. Following successive weekly doses, the half-life increases and may become 14-40 days after the third dose and up to 168 days after the eleventh weekly dose [L1925].",Adenylate cyclase type 2,ADCY2,,unknown
Aurothioglucose,"The biological half-life of gold salts (like aurothioglucose) following a single 50 mg dose demonstrates a biological half-life of about 3-27 days, where the half-life seemingly increases with increased number of doses [T147]. Following successive weekly doses, the half-life increases and may become 14-40 days after the third dose and up to 168 days after the eleventh weekly dose [L1925].",Adenylate cyclase type 5,ADCY5,,unknown
Dienogest,Elimination half-life of dienogest is around 9-10 hours. The half-life of urinary metabolites excretion is 14 hours [L931].,Progesterone receptor,PGR,agonist,yes
Dienogest,Elimination half-life of dienogest is around 9-10 hours. The half-life of urinary metabolites excretion is 14 hours [L931].,Androgen receptor,AR,antagonist,yes
Medrogestone,The half-life of medrogestone is reported to be of 4 hours.[T79],Progesterone receptor,PGR,ligand,yes
Chorionic Gonadotropin (Human),,Lutropin-choriogonadotropic hormone receptor,LHCGR,ligand,yes
Brexpiprazole,"Brexpiprazole and its major metabolite, DM-3411 have half lives of 91 and 96 hours respectively.",5-hydroxytryptamine receptor 1A,HTR1A,agonistpartial agonist,yes
Brexpiprazole,"Brexpiprazole and its major metabolite, DM-3411 have half lives of 91 and 96 hours respectively.",D(2) dopamine receptor,DRD2,agonistpartial agonist,yes
Brexpiprazole,"Brexpiprazole and its major metabolite, DM-3411 have half lives of 91 and 96 hours respectively.",5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Brexpiprazole,"Brexpiprazole and its major metabolite, DM-3411 have half lives of 91 and 96 hours respectively.",Alpha-2C adrenergic receptor,ADRA2C,antagonist,yes
Brexpiprazole,"Brexpiprazole and its major metabolite, DM-3411 have half lives of 91 and 96 hours respectively.",Alpha-1B adrenergic receptor,ADRA1B,antagonist,yes
Chromic chloride,31- 41 hours,Insulin receptor,INSR,activator,yes
Copper,,Amyloid beta A4 protein,APP,aggregation inhibitor,unknown
Copper,,Adenosylhomocysteinase,AHCY,allosteric modulator,unknown
Copper,,Histone H2B type 1-C/E/F/G/I,HIST1H2BC,,unknown
Copper,,Glyceraldehyde-3-phosphate dehydrogenase,GAPDH,,unknown
Copper,,Nucleoside diphosphate kinase A,NME1,,unknown
Copper,,Histone H1.4,HIST1H1E,,unknown
Copper,,Peroxiredoxin-1,PRDX1,,unknown
Copper,,Protein S100-A8,S100A8,,unknown
Copper,,40S ribosomal protein SA,RPSA,,unknown
Copper,,"Actin, cytoplasmic 2",ACTG1,,unknown
Copper,,Alpha-enolase,ENO1,,unknown
Copper,,Elongation factor 1-alpha 1,EEF1A1,,unknown
Copper,,"Keratin, type II cytoskeletal 8",KRT8,,unknown
Copper,,Protein disulfide-isomerase,P4HB,,unknown
Copper,,Protein disulfide-isomerase A3,PDIA3,,unknown
Copper,,"60 kDa heat shock protein, mitochondrial",HSPD1,,unknown
Copper,,Heat shock 70 kDa protein 13,HSPA13,,unknown
Copper,,78 kDa glucose-regulated protein,HSPA5,,unknown
Copper,,Endoplasmin,HSP90B1,,unknown
Copper,,Serotransferrin,TF,,unknown
Copper,,Cell growth-regulating nucleolar protein,Lyar,,unknown
Copper,,40S ribosomal protein S2,RPS2,,unknown
Copper,,Serine/arginine-rich splicing factor 1,SRSF1,,unknown
Copper,,Heterogeneous nuclear ribonucleoproteins A2/B1,HNRNPA2B1,,unknown
Copper,,Heterogeneous nuclear ribonucleoprotein H,HNRNPH1,,unknown
Copper,,Heterogeneous nuclear ribonucleoprotein H3,HNRNPH3,,unknown
Copper,,Cobalt-precorrin-5B C(1)-methyltransferase,cbiD,,unknown
Copper,,Heterogeneous nuclear ribonucleoprotein L,HNRNPL,,unknown
Copper,,"Splicing factor, proline- and glutamine-rich",SFPQ,,unknown
Copper,,Splicing factor 3A subunit 2,SF3A2,,unknown
Copper,,Receptor of activated protein C kinase 1,RACK1,,unknown
Copper,,Alpha-actinin-1,ACTN1,,unknown
Copper,,Aminoacylase-1,ACY1,,unknown
Copper,,Annexin A4,ANXA4,,unknown
Copper,,Annexin A5,ANXA5,,unknown
Copper,,Calreticulin,CALR,,unknown
Copper,,Pyruvate kinase PKM,PKM,,unknown
Copper,,Alcohol dehydrogenase [NADP(+)],AKR1A1,,unknown
Copper,,NADH-cytochrome b5 reductase 3,CYB5R3,,unknown
Copper,,"Glutathione reductase, mitochondrial",GSR,,unknown
Copper,,Transketolase,TKT,,unknown
Copper,,Peroxiredoxin-2,PRDX2,,unknown
Copper,,Peroxiredoxin-6,PRDX6,,unknown
Copper,,Peptidyl-prolyl cis-trans isomerase A,PPIA,,unknown
Copper,,Heat shock cognate 71 kDa protein,HSPA8,,unknown
Copper,,Heat shock protein HSP 90-alpha,HSP90AA1,,unknown
Copper,,Prostaglandin E synthase 3,PTGES3,,unknown
Copper,,Stress-induced-phosphoprotein 1,STIP1,,unknown
Copper,,Translation elongation factor 1 alpha 1-like 14,EEF1A1L14,,unknown
Copper,,Eukaryotic translation initiation factor 6,EIF6,,unknown
Copper,,Eukaryotic initiation factor 4A-I,EIF4A1,,unknown
Copper,,Glucose-6-phosphate isomerase,GPI,,unknown
Copper,,L-lactate dehydrogenase A chain,LDHA,,unknown
Copper,,Phosphoglycerate kinase 1,PGK1,,unknown
Copper,,Tubulin alpha-3C/D chain,TUBA3C,,unknown
Copper,,Tubulin beta chain,TUBB,,unknown
Copper,,Cofilin-1,CFL1,,unknown
Copper,,14-3-3 protein beta/alpha,YWHAB,,unknown
Copper,,"Aspartate aminotransferase, cytoplasmic",GOT1,,unknown
Copper,,Glutathione synthetase,GSS,,unknown
Copper,,Hepatoma-derived growth factor,HDGF,,unknown
Copper,,"Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial",IDH3A,,unknown
Copper,,Chloride intracellular channel protein 1,CLIC1,,unknown
Copper,,Proteasome activator complex subunit 1,PSME1,,unknown
Copper,,Phosphatidylethanolamine-binding protein 1,PEBP1,,unknown
Copper,,Phosphoglycerate mutase 1,PGAM1,,unknown
Copper,,Ran-specific GTPase-activating protein,RANBP1,,unknown
Copper,,UDP-glucose 6-dehydrogenase,UGDH,,unknown
Copper,,Beta-2-microglobulin,B2M,,unknown
Copper,,"Protein SCO1 homolog, mitochondrial",SCO1,,unknown
Copper,,Alternative prion protein,PRNP,,unknown
Copper,,Glycine receptor subunit alpha-1,GLRA1,,unknown
Copper,,Huntingtin,HTT,,unknown
Copper,,Endonuclease 8-like 1,NEIL1,,unknown
Copper,,Endonuclease 8-like 2,NEIL2,,unknown
Copper,,Hephaestin-like protein 1,HEPHL1,cofactor,unknown
Copper,,Plasminogen activator inhibitor 1,SERPINE1,,unknown
Copper,,Protein S100-A2,S100A2,,unknown
Copper,,Protein S100-A4,S100A4,,unknown
Copper,,Alpha-synuclein,SNCA,,unknown
Copper,,Brain-derived neurotrophic factor,BDNF,cofactor,unknown
Copper,,Protein DJ-1,PARK7,,unknown
Copper,,Islet amyloid polypeptide,IAPP,,unknown
Copper,,Tachykinin-3,TAC3,,unknown
Copper,,Alpha-1B-glycoprotein,A1BG,,unknown
Copper,,Afamin,AFM,,unknown
Copper,,Angiotensinogen,AGT,,unknown
Copper,,Alpha-2-HS-glycoprotein,AHSG,,unknown
Copper,,Serum amyloid P-component,APCS,,unknown
Copper,,Apolipoprotein A-I,APOA1,,unknown
Copper,,Apolipoprotein A-II,APOA2,,unknown
Copper,,Apolipoprotein A-IV,APOA4,,unknown
Copper,,Apolipoprotein B receptor,APOBR,,unknown
Copper,,Apolipoprotein C-II,APOC2,,unknown
Copper,,Apolipoprotein C-III,APOC3,,unknown
Copper,,Apolipoprotein D,APOD,,unknown
Copper,,Apolipoprotein E,APOE,,unknown
Copper,,Beta-2-glycoprotein 1,APOH,,unknown
Copper,,Zinc-alpha-2-glycoprotein,AZGP1,,unknown
Copper,,Complement C1q subcomponent subunit C,C1QC,,unknown
Copper,,Complement C1s subcomponent,C1S,,unknown
Copper,,Complement C3,C3,,unknown
Copper,,Complement C4-B,C4B,,unknown
Copper,,C4b-binding protein alpha chain,C4BPA,,unknown
Copper,,Complement C5,C5,,unknown
Copper,,Complement component C8 beta chain,C8B,,unknown
Copper,,Complement component C9,C9,,unknown
Copper,,Complement factor H,CFH,,unknown
Copper,,Complement factor I,CFI,,unknown
Copper,,Tetranectin,CLEC3B,,unknown
Copper,,Clusterin,CLU,,unknown
Copper,,Prothrombin,F2,,unknown
Copper,,"Complement component 1 Q subcomponent-binding protein, mitochondrial",C1QBP,,unknown
Copper,,Gelsolin,GSN,,unknown
Copper,,Hemoglobin subunit alpha,HBA1,,unknown
Copper,,Hemoglobin subunit beta,HBB,,unknown
Copper,,Chromobox protein homolog 5,CBX5,,unknown
Copper,,Haptoglobin-related protein,HPR,,unknown
Copper,,Insulin-like growth factor-binding protein complex acid labile subunit,IGFALS,,unknown
Copper,,Ig gamma-1 chain C region,IGHG1,,unknown
Copper,,Ig gamma-4 chain C region,IGHG4,,unknown
Copper,,Ig kappa chain V-III region GOL,,,unknown
Copper,,Immunoglobulin lambda-like polypeptide 1,IGLL1,,unknown
Copper,,Inter-alpha-trypsin inhibitor heavy chain H2,ITIH2,,unknown
Copper,,Kininogen-1,KNG1,,unknown
Copper,,"Keratin, type II cytoskeletal 1",KRT1,,unknown
Copper,,"Keratin, type I cytoskeletal 10",KRT10,,unknown
Copper,,"Keratin, type II cytoskeletal 2 epidermal",KRT2,,unknown
Copper,,"Keratin, type I cytoskeletal 9",KRT9,,unknown
Copper,,Leucine-rich alpha-2-glycoprotein,LRG1,,unknown
Copper,,Lumican,LUM,,unknown
Copper,,N-acetylmuramoyl-L-alanine amidase,PGLYRP2,,unknown
Copper,,Plasminogen,PLG,,unknown
Copper,,Serum paraoxonase/arylesterase 1,PON1,,unknown
Copper,,Platelet basic protein,PPBP,,unknown
Copper,,Alpha-1-antitrypsin,SERPINA1,,unknown
Copper,,Kallistatin,SERPINA4,,unknown
Copper,,Corticosteroid-binding globulin,SERPINA6,,unknown
Copper,,Thyroxine-binding globulin,SERPINA7,,unknown
Copper,,Antithrombin-III,SERPINC1,,unknown
Copper,,Heparin cofactor 2,SERPIND1,,unknown
Copper,,Pigment epithelium-derived factor,SERPINF1,,unknown
Copper,,Alpha-2-antiplasmin,SERPINF2,,unknown
Copper,,Plasma protease C1 inhibitor,SERPING1,,unknown
Copper,,Transthyretin,TTR,,unknown
Copper,,Vitronectin,VTN,,unknown
Copper,,Amyloid-like protein 1,APLP1,cofactor,unknown
Cupric Chloride,,Vitamin K-dependent protein C,PROC,,unknown
Cupric Chloride,,Cystatin-B,CSTB,,unknown
Oxygen,Approximately 122.24 seconds,Cytochrome c oxidase subunit 1,MT-CO1,agonistactivator,unknown
Oxygen,Approximately 122.24 seconds,NADPH oxidase 1,NOX1,agonistactivator,unknown
Oxygen,Approximately 122.24 seconds,Hemoglobin subunit alpha,HBA1,,unknown
Oxygen,Approximately 122.24 seconds,Hemoglobin subunit beta,HBB,,unknown
Sonidegib,Half-life ~ 28 days (2),Smoothened homolog,SMO,antagonist,unknown
Iron saccharate,6 hours.,Hemoglobin subunit alpha,HBA1,component of,yes
Ferric pyrophosphate,,Ferritin light chain,FTL,binder,yes
Ferric pyrophosphate,,Hemoglobin subunit alpha,HBA1,binder,yes
Ferric pyrophosphate,,Hemoglobin subunit beta,HBB,binder,yes
Florbetaben (18F),1 hr,Amyloid beta A4 protein,APP,binder,yes
Florbetapir (18F),,Amyloid beta A4 protein,APP,binder,yes
Flutemetamol (18F),,Amyloid beta A4 protein,APP,binder,yes
Technetium Tc-99m pyrophosphate,,Hydroxyapatite,,ligand,no
Technetium Tc-99m pyrophosphate,,Amorphous calcium phosphate,,ligand,no
Etizolam,The average elimination half life of etizolam following a single oral dose of 0.5mg is 3.4 hours but may be increased up to 17 hours depending on the rate of metabolism [L884]. The main metabolite α-hydroxyetizolam displays a longer elimination half life of 8.2 hours [A19776].,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,agonist,yes
Etizolam,The average elimination half life of etizolam following a single oral dose of 0.5mg is 3.4 hours but may be increased up to 17 hours depending on the rate of metabolism [L884]. The main metabolite α-hydroxyetizolam displays a longer elimination half life of 8.2 hours [A19776].,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,agonist,yes
Etizolam,The average elimination half life of etizolam following a single oral dose of 0.5mg is 3.4 hours but may be increased up to 17 hours depending on the rate of metabolism [L884]. The main metabolite α-hydroxyetizolam displays a longer elimination half life of 8.2 hours [A19776].,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,agonist,yes
Etizolam,The average elimination half life of etizolam following a single oral dose of 0.5mg is 3.4 hours but may be increased up to 17 hours depending on the rate of metabolism [L884]. The main metabolite α-hydroxyetizolam displays a longer elimination half life of 8.2 hours [A19776].,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,agonist,yes
Etizolam,The average elimination half life of etizolam following a single oral dose of 0.5mg is 3.4 hours but may be increased up to 17 hours depending on the rate of metabolism [L884]. The main metabolite α-hydroxyetizolam displays a longer elimination half life of 8.2 hours [A19776].,Platelet-activating factor receptor,PTAFR,antagonist,unknown
Dosulepin,The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].,5-hydroxytryptamine receptor 1A,HTR1A,antagonist,yes
Dosulepin,The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Dosulepin,The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].,Histamine H1 receptor,HRH1,antagonist,yes
Dosulepin,The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Dosulepin,The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Dosulepin,The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Dosulepin,The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].,Muscarinic acetylcholine receptor M4,CHRM4,antagonist,yes
Dosulepin,The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].,Muscarinic acetylcholine receptor M5,CHRM5,antagonist,yes
Dosulepin,The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].,Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,antagonist,yes
Dosulepin,The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].,Alpha-1 adrenergic receptors,ADRA1AADRA1BADRA1D,antagonist,yes
Dosulepin,The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Dosulepin,The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].,Sodium-dependent serotonin transporter,SLC6A4,inhibitor,yes
Dasabuvir,The half-life of elimination of dasabuvir is 5.5 to 6 hours [FDA Label].,Nonstructural protein 5B (NS5B),NS5b,inhibitor,yes
Viloxazine,Elimination half life is approximately 3-4 hours [A19786].,Sodium-dependent noradrenaline transporter,SLC6A2,inhibitor,yes
Nisoxetine,,Sodium-dependent serotonin transporter,SLC6A4,,unknown
Etoperidone,After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350],Alpha-1 adrenergic receptors,ADRA1AADRA1BADRA1D,antagonist,unknown
Etoperidone,After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350],Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,antagonist,unknown
Etoperidone,After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350],D(2) dopamine receptor,DRD2,antagonist,unknown
Etoperidone,After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350],Histamine H1 receptor,HRH1,antagonist,unknown
Etoperidone,After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350],Muscarinic acetylcholine receptor,CHRM1CHRM2CHRM3CHRM4CHRM5,antagonist,unknown
Etoperidone,After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350],5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Etoperidone,After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350],5-hydroxytryptamine receptor 2C,HTR2C,agonist,yes
Lorpiprazole,"The estimated half-life for drugs like lorpiprazole, a serotonin antagonist and reuptake inhibitor, is in the range of 11-23 hours.[T86]",5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Lorpiprazole,"The estimated half-life for drugs like lorpiprazole, a serotonin antagonist and reuptake inhibitor, is in the range of 11-23 hours.[T86]",5-hydroxytryptamine receptor 2C,HTR2C,antagonist,yes
Lorpiprazole,"The estimated half-life for drugs like lorpiprazole, a serotonin antagonist and reuptake inhibitor, is in the range of 11-23 hours.[T86]",Alpha-1 adrenergic receptors,ADRA1AADRA1BADRA1D,antagonist,yes
Lorpiprazole,"The estimated half-life for drugs like lorpiprazole, a serotonin antagonist and reuptake inhibitor, is in the range of 11-23 hours.[T86]",Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,antagonist,yes
Lorpiprazole,"The estimated half-life for drugs like lorpiprazole, a serotonin antagonist and reuptake inhibitor, is in the range of 11-23 hours.[T86]",Histamine H1 receptor,HRH1,antagonist,yes
Lorpiprazole,"The estimated half-life for drugs like lorpiprazole, a serotonin antagonist and reuptake inhibitor, is in the range of 11-23 hours.[T86]",Sodium-dependent serotonin transporter,SLC6A4,antagonist,yes
Lobeglitazone,"Following an intravenous dosage of 1 mg/kg, the half life was found to be 110 min [A19749].",Peroxisome proliferator-activated receptor gamma,PPARG,activator,yes
Ciglitazone,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Cirazoline,,Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Cirazoline,,Alpha-1B adrenergic receptor,ADRA1B,partial agonist,yes
Cirazoline,,Alpha-1D adrenergic receptor,ADRA1D,partial agonist,yes
Cirazoline,,Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,antagonist,yes
Synephrine,,Alpha-1 adrenergic receptors,ADRA1AADRA1BADRA1D,,unknown
Arotinolol,The reported half-life of arotinolol is 7.2 hours.[T87],Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Arotinolol,The reported half-life of arotinolol is 7.2 hours.[T87],Beta-2 adrenergic receptor,ADRB2,antagonist,yes
Arotinolol,The reported half-life of arotinolol is 7.2 hours.[T87],Alpha-1 adrenergic receptors,ADRA1AADRA1BADRA1D,antagonist,yes
Moxisylyte,The half-life of moxisylyte was of 1-2 hours.[L1174],Alpha adrenergic receptor,ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C,antagonist,yes
AS-8112,,D(2) dopamine receptor,DRD2,antagonist,unknown
AS-8112,,D(3) dopamine receptor,DRD3,antagonist,unknown
AS-8112,,5HT3 serotonin receptor,,antagonist,unknown
Pegloticase,,Uric acid,,metabolizer,yes
Pholcodine,"After oral administration of 60 mg of pholcodine, the half-life in plasma, saliva and urine are 45, 55 and 45 hours respectively.[A31738]",Mu-type opioid receptor,OPRM1,antagonist,yes
Pholcodine,"After oral administration of 60 mg of pholcodine, the half-life in plasma, saliva and urine are 45, 55 and 45 hours respectively.[A31738]",Kappa-type opioid receptor,OPRK1,antagonist,yes
Pholcodine,"After oral administration of 60 mg of pholcodine, the half-life in plasma, saliva and urine are 45, 55 and 45 hours respectively.[A31738]",Delta-type opioid receptor,OPRD1,antagonist,unknown
Limaprost,The mean half life of elimination is 1.64 hours [A19715].,Prostaglandin E2 receptor EP1 subtype,PTGER1,agonist,unknown
Limaprost,The mean half life of elimination is 1.64 hours [A19715].,Prostaglandin E2 receptor EP2 subtype,PTGER2,agonist,yes
Limaprost,The mean half life of elimination is 1.64 hours [A19715].,Prostaglandin E2 receptor EP3 subtype,PTGER3,agonist,unknown
Limaprost,The mean half life of elimination is 1.64 hours [A19715].,Prostaglandin E2 receptor EP4 subtype,PTGER4,,unknown
Loxoprofen,The elimination half-life of Loxoprofen is approximately 15 hours [L1268].Steady concentration is achieved after 2-3 doses [L1268].,Prostaglandin G/H synthase 2,PTGS2,antagonist,yes
Loxoprofen,The elimination half-life of Loxoprofen is approximately 15 hours [L1268].Steady concentration is achieved after 2-3 doses [L1268].,Prostaglandin G/H synthase 1,PTGS1,antagonist,yes
Dexibuprofen,Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254].,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Dexibuprofen,Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254].,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Dexibuprofen,Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254].,Apoptosis regulator Bcl-2,BCL2,negative modulator,unknown
Dexibuprofen,Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254].,Thrombomodulin,THBD,modulator,unknown
Dexibuprofen,Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254].,Tissue-type plasminogen activator,PLAT,modulator,unknown
Dexibuprofen,Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254].,"Fatty acid-binding protein, intestinal",FABP2,binder,unknown
Dexibuprofen,Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254].,Peroxisome proliferator-activated receptor gamma,PPARG,activator,unknown
Dexibuprofen,Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254].,Cystic fibrosis transmembrane conductance regulator,CFTR,inhibitor,unknown
Dexketoprofen,1.65 h [L1299],Prostaglandin G/H synthase 1,PTGS1,antagonist,unknown
Dexketoprofen,1.65 h [L1299],Prostaglandin G/H synthase 2,PTGS2,antagonist,unknown
Droxicam,Data not available for prodrug. See [DB00554] for information on the active compound.,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Droxicam,Data not available for prodrug. See [DB00554] for information on the active compound.,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Tolfenamic Acid,"The estimated half-life of tolfenamic acid is 8.01-13.50 hours.[A31842] When tested intravenously, the reported half-life was 6.1h.[A31849]",Prostaglandin G/H synthase 1,PTGS1,antagonist,yes
Tolfenamic Acid,"The estimated half-life of tolfenamic acid is 8.01-13.50 hours.[A31842] When tested intravenously, the reported half-life was 6.1h.[A31849]",Prostaglandin G/H synthase 2,PTGS2,antagonist,yes
Firocoxib,,Prostaglandin G/H synthase 2,PTGS2,,unknown
Nicorandil,The elimination half life is approximately 1 hour [A20328].,ATP-binding cassette sub-family C member 9,ABCC9,activator,yes
Polaprezinc,The half-life of polaprezinc has been studied in rats and found to be approximately 2 hours [L1311].,Tumor necrosis factor,TNF,inhibitor,unknown
Polaprezinc,The half-life of polaprezinc has been studied in rats and found to be approximately 2 hours [L1311].,Interleukin-6,IL6,inhibitor,unknown
Polaprezinc,The half-life of polaprezinc has been studied in rats and found to be approximately 2 hours [L1311].,Interleukin-3,IL3,inhibitor,unknown
Polaprezinc,The half-life of polaprezinc has been studied in rats and found to be approximately 2 hours [L1311].,Vascular endothelial growth factor receptor 1,FLT1,agonist,unknown
Polaprezinc,The half-life of polaprezinc has been studied in rats and found to be approximately 2 hours [L1311].,Beta-nerve growth factor,NGF,agonist,unknown
Polaprezinc,The half-life of polaprezinc has been studied in rats and found to be approximately 2 hours [L1311].,Platelet-derived growth factor receptor beta,PDGFRB,agonist,unknown
Polaprezinc,The half-life of polaprezinc has been studied in rats and found to be approximately 2 hours [L1311].,Heat shock protein HSP 90-alpha,HSP90AA1,agonist,unknown
Polaprezinc,The half-life of polaprezinc has been studied in rats and found to be approximately 2 hours [L1311].,Heat shock protein HSP 90-beta,HSP90AB1,agonist,unknown
Blonanserin,Blonanserin has a half life of elimination of 10.7-16.2 h [A31487].,D(2) dopamine receptor,DRD2,antagonist,yes
Blonanserin,Blonanserin has a half life of elimination of 10.7-16.2 h [A31487].,D(3) dopamine receptor,DRD3,antagonist,yes
Blonanserin,Blonanserin has a half life of elimination of 10.7-16.2 h [A31487].,5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Melperone,"Approximately 3-4 hours after oral administration [A31862]. After intramuscular injection, the half-life has been found to be approximately 6 hours [A31862].",D(2) dopamine receptor,DRD2,antagonist,yes
Zotepine,The half-life of zotepine is reported to be of 21 hours.[A31893],D(1) dopamine receptor,DRD1DRD5,antagonist,yes
Zotepine,The half-life of zotepine is reported to be of 21 hours.[A31893],D(2) dopamine receptor,DRD2,antagonist,yes
Zotepine,The half-life of zotepine is reported to be of 21 hours.[A31893],5-hydroxytryptamine receptor 2A,HTR2A,antagonist,yes
Zotepine,The half-life of zotepine is reported to be of 21 hours.[A31893],5-hydroxytryptamine receptor 6,HTR6,antagonist,unknown
Zotepine,The half-life of zotepine is reported to be of 21 hours.[A31893],5-hydroxytryptamine receptor 7,HTR7,antagonist,yes
Zotepine,The half-life of zotepine is reported to be of 21 hours.[A31893],Sodium-dependent noradrenaline transporter,SLC6A2,antagonist,yes
Zotepine,The half-life of zotepine is reported to be of 21 hours.[A31893],Sodium-dependent serotonin transporter,SLC6A4,antagonist,yes
Barnidipine,"In a two-compartment analytical model, the median terminal elimination half life of barnidipine was 20 hours after repeated administration [L1131].",Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,antagonist,yes
Conestat alfa,,Complement C1r subcomponent,C1R,inhibitor,yes
Conestat alfa,,Complement C1s subcomponent,C1S,inhibitor,yes
Conestat alfa,,Plasma kallikrein,KLKB1,inhibitor,yes
Conestat alfa,,Coagulation factor XII,F12,inhibitor,yes
Conestat alfa,,Prothrombin,F2,inhibitor,yes
Conestat alfa,,Coagulation factor XI,F11,inhibitor,yes
Conestat alfa,,Tissue-type plasminogen activator,PLAT,inhibitor,yes
Aranidipine,The elimination half-life of aranidipine and the M-1 metabolite are 1.1-1.2 hour and 2.7-3.5 hour respectively.[L1343],Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,antagonist,yes
Aranidipine,The elimination half-life of aranidipine and the M-1 metabolite are 1.1-1.2 hour and 2.7-3.5 hour respectively.[L1343],Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,antagonist,yes
Aranidipine,The elimination half-life of aranidipine and the M-1 metabolite are 1.1-1.2 hour and 2.7-3.5 hour respectively.[L1343],Voltage-dependent L-type calcium channel subunit alpha-1F,CACNA1F,antagonist,yes
Aranidipine,The elimination half-life of aranidipine and the M-1 metabolite are 1.1-1.2 hour and 2.7-3.5 hour respectively.[L1343],Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,antagonist,yes
Aranidipine,The elimination half-life of aranidipine and the M-1 metabolite are 1.1-1.2 hour and 2.7-3.5 hour respectively.[L1343],Alpha adrenergic receptor,ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C,agonist,unknown
Azelnidipine,16 –28 hours [L1383].,Voltage-dependent L-type calcium channel subunit beta-1,CACNB1,agonist,unknown
Benidipine,The elimination half-life of benidipine is registered to be of approximate 1 hour.[A31950],Voltage dependent L type calcium channel,CACNA1CCACNA1DCACNA1FCACNA1SCACNB1CACNB2CACNB3CACNB4,antagonist,yes
Benidipine,The elimination half-life of benidipine is registered to be of approximate 1 hour.[A31950],Voltage-dependent N-type calcium channel subunit alpha-1B,CACNA1B,antagonist,yes
Benidipine,The elimination half-life of benidipine is registered to be of approximate 1 hour.[A31950],Voltage-dependent T-type calcium channel,CACNA1GCACNA1HCACNA1I,antagonist,yes
Cilnidipine,The half-life of the hypotensive effect for cilnidipine is of about 20.4 min.[A32004],Voltage-dependent N-type calcium channel subunit alpha-1B,CACNA1B,antagonist,yes
Cilnidipine,The half-life of the hypotensive effect for cilnidipine is of about 20.4 min.[A32004],Voltage dependent L type calcium channel,CACNA1CCACNA1DCACNA1FCACNA1SCACNB1CACNB2CACNB3CACNB4,antagonist,yes
Efonidipine,Peak plasma concentration is achieved at about 1.5 to 3.67 hours after ingestion. Half-life is approximately 4 hours [L1450].,Voltage-dependent T-type calcium channel subunit alpha-1I,CACNA1I,antagonist,unknown
Efonidipine,Peak plasma concentration is achieved at about 1.5 to 3.67 hours after ingestion. Half-life is approximately 4 hours [L1450].,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,,unknown
Lacidipine,The average terminal half-life of lacidipine ranges from between 13 and 19 hours at steady state [L1126].,Voltage dependent L type calcium channel,CACNA1CCACNA1DCACNA1FCACNA1SCACNB1CACNB2CACNB3CACNB4,antagonist,yes
Levamlodipine,The plasma elimination half-life of Levamlodipine has been found to be 31 ± 13 hrs [L1484].,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,antagonist,unknown
Levamlodipine,The plasma elimination half-life of Levamlodipine has been found to be 31 ± 13 hrs [L1484].,"Nitric oxide synthase, endothelial",NOS3,agonist,unknown
Levamlodipine,The plasma elimination half-life of Levamlodipine has been found to be 31 ± 13 hrs [L1484].,"Nitric oxide synthase, inducible",NOS2,agonist,unknown
Manidipine,"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.",Voltage dependent L type calcium channel,CACNA1CCACNA1DCACNA1FCACNA1SCACNB1CACNB2CACNB3CACNB4,blocker,yes
Manidipine,"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.",Voltage-dependent T-type calcium channel,CACNA1GCACNA1HCACNA1I,blocker,yes
Niguldipine,,Alpha-1A adrenergic receptor,ADRA1A,antagonist,unknown
Methylene blue,5–6.5 hours (after IV dose).,Guanylate cyclase soluble subunit alpha-2,GUCY1A2,antagonist,yes
Methylene blue,5–6.5 hours (after IV dose).,"Nitric oxide synthase, brain",NOS1,antagonist,yes
Moxonidine,Plasma elimination half life is 2.2 - 2.3 hours while renal elimination half life is 2.6-2.8 hours. [FDA label],Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Moxonidine,Plasma elimination half life is 2.2 - 2.3 hours while renal elimination half life is 2.6-2.8 hours. [FDA label],Nischarin,NISCH,agonist,yes
Pirlindole,0.7±0.3 in one study of healthy volunteers [L1390],Amine oxidase [flavin-containing] A,MAOA,antagonist,unknown
Pirlindole,0.7±0.3 in one study of healthy volunteers [L1390],5-hydroxytryptamine receptor 1A,HTR1A,antagonist,unknown
Pirlindole,0.7±0.3 in one study of healthy volunteers [L1390],Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Toloxatone,1-3 h [A31957],Amine oxidase [flavin-containing] A,MAOA,antagonist,unknown
Gimeracil,"Following a single dose of Teysuno, T1/2 values ranged from 6.7 to 11.3 hours for tegafur, from 3.1 to 4.1 hours for gimeracil, and from 1.8 to 9.5 hours for oteracil [L933].",Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,inhibitor,no
Bemiparin,"Bemiparin, when administered in the dose range of 2,500 IU to 12,500 (therapeutic dosing), it has an approximate half-life of 5-6 hours [L1462].",Coagulation factor X,F10,antagonist,yes
Bemiparin,"Bemiparin, when administered in the dose range of 2,500 IU to 12,500 (therapeutic dosing), it has an approximate half-life of 5-6 hours [L1462].",Antithrombin-III,SERPINC1,antagonist,unknown
Bemiparin,"Bemiparin, when administered in the dose range of 2,500 IU to 12,500 (therapeutic dosing), it has an approximate half-life of 5-6 hours [L1462].",Heparin cofactor 2,SERPIND1,antagonist,unknown
Imidafenacin,The half life of elimination is 3 h [A19796].,Muscarinic acetylcholine receptor M1,CHRM1,antagonist,yes
Imidafenacin,The half life of elimination is 3 h [A19796].,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,yes
Imidafenacin,The half life of elimination is 3 h [A19796].,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Patiromer,,Potassium,,binder,yes
Idarucizumab,"initial half-life: 47 minutes 
terminal half-life: 10.3 h",Dabigatran etexilate,,antibody,yes
Lixisenatide,3h [FDA Label],Glucagon-like peptide 1 receptor,GLP1R,agonist,yes
Technetium Tc-99m tilmanocept,Technetium Tc99m tilmanocept decays by isomeric transition with a physical half-life of approximately 6 hours. The half-life at the injection site of 1.8 to 3.1 hours [FDA Label].,Macrophage mannose receptor 1,MRC1,ligand,yes
Ubidecarenone,The pharmacokinetic properties may vary between different brands but studies have reported a half-life of ubidecarenone of 21.7 h.[A31414],"NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial",NDUFV3,cofactor,yes
Ubidecarenone,The pharmacokinetic properties may vary between different brands but studies have reported a half-life of ubidecarenone of 21.7 h.[A31414],"Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial",SDHA,cofactor,yes
Eluxadoline,The mean plasma elimination half-life ranged from 3.7 hours to 6 hours.,Mu-type opioid receptor,OPRM1,agonist,yes
Eluxadoline,The mean plasma elimination half-life ranged from 3.7 hours to 6 hours.,Delta-type opioid receptor,OPRD1,antagonist,yes
Eluxadoline,The mean plasma elimination half-life ranged from 3.7 hours to 6 hours.,Kappa-type opioid receptor,OPRK1,agonist,yes
Doxofylline,"Following administration of a single intravenous dose of 100 mg over 10 minutes in adults with chronic bronchitis, the elimination half life of doxofylline was 1.83 ± 0.37 hours. Following oral administration of 400 mg twice daily for 5 days in adults with chronic bronchitis, the mean elimination half life was 7.01 ± 0.80 hours [L1169].","Phosphodiesterase 2A, cGMP-stimulated",PDE2A,inhibitor,yes
Doxofylline,"Following administration of a single intravenous dose of 100 mg over 10 minutes in adults with chronic bronchitis, the elimination half life of doxofylline was 1.83 ± 0.37 hours. Following oral administration of 400 mg twice daily for 5 days in adults with chronic bronchitis, the mean elimination half life was 7.01 ± 0.80 hours [L1169].",Adenosine receptor A2a,ADORA2A,antagonist,unknown
Doxofylline,"Following administration of a single intravenous dose of 100 mg over 10 minutes in adults with chronic bronchitis, the elimination half life of doxofylline was 1.83 ± 0.37 hours. Following oral administration of 400 mg twice daily for 5 days in adults with chronic bronchitis, the mean elimination half life was 7.01 ± 0.80 hours [L1169].",Beta-2 adrenergic receptor,ADRB2,agonist,yes
Artesunate,Half life of elimination after intravenous bolus was observed to be less than 5 min for artesunate and 21-64 min for DHA [L891]. Half life after intramuscular administration is 48 min in children and 41 min in adults.,Malaria protein EXP-1,EXP-1,inhibitor,yes
Bismuth Subcitrate,The elimination half-life of bismuth is approximately 5 days,ATP-dependent Clp protease ATP-binding subunit ClpX,clpX,antagonist,unknown
Fimasartan,The half life of elimination is 7-10 h [A20319].,Type-1 angiotensin II receptor,AGTR1,antagonist,yes
Lumacaftor,The half-life of lumacaftor is approximately 26 hours [FDA Label].,Cystic fibrosis transmembrane conductance regulator,CFTR,modulator,yes
Molsidomine,,Guanylate cyclase soluble subunit alpha-2,GUCY1A2,agonist,unknown
Trapidil,The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].,Platelet derived growth factor receptor beta,,antagonist,unknown
Trapidil,The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].,Cyclic nucleotide phosphodiesterase,PDE1APDE1BPDE1CPDE10APDE4APDE4BPDE4CPDE4DPDE7BPDE2APDE3APDE3BPDE5APDE6CPDE11APDE7APDE8APDE8BPDE9APDE6APDE6B,inhibitor,yes
Morniflumate,2h [L1498],Arachidonate 5-lipoxygenase,ALOX5,antagonist,unknown
Morniflumate,2h [L1498],Prostaglandin G/H synthase 2,PTGS2,,unknown
Morniflumate,2h [L1498],Leukotriene B4 receptor 1,LTB4R,antagonist,unknown
Morniflumate,2h [L1498],Thromboxane A2 receptor,TBXA2R,,unknown
Pipamperone,17-26h [L1522],D(2) dopamine receptor,DRD2,antagonist,unknown
Pipamperone,17-26h [L1522],5-hydroxytryptamine receptor 2A,HTR2A,agonist,unknown
Pipamperone,17-26h [L1522],Alpha-1 adrenergic receptors,ADRA1AADRA1BADRA1D,antagonist,unknown
Pipamperone,17-26h [L1522],D(4) dopamine receptor,DRD4,antagonist,unknown
Pipamperone,17-26h [L1522],D(1A) dopamine receptor,DRD1,antagonist,unknown
Pipamperone,17-26h [L1522],D(3) dopamine receptor,DRD3,,unknown
Pipamperone,17-26h [L1522],5-hydroxytryptamine receptor 2B,HTR2B,,unknown
Pipamperone,17-26h [L1522],Alpha-2A adrenergic receptor,ADRA2A,antagonist,unknown
Propacetamol,The half-life of propacetamol is of 3.6 h.[L1509],Prostaglandin G/H synthase 1,PTGS1,antagonist,yes
Propacetamol,The half-life of propacetamol is of 3.6 h.[L1509],Prostaglandin G/H synthase 2,PTGS2,antagonist,yes
Propacetamol,The half-life of propacetamol is of 3.6 h.[L1509],Transient receptor potential cation channel subfamily V member 1,TRPV1,antagonist,yes
Propacetamol,The half-life of propacetamol is of 3.6 h.[L1509],Cannabinoid receptor 1,CNR1,antagonist,yes
Tianeptine,2.5h [L14529],Sodium-dependent serotonin transporter,SLC6A4,,unknown
Tianeptine,2.5h [L14529],5-hydroxytryptamine receptor 1A,HTR1A,antagonist,unknown
Tianeptine,2.5h [L14529],Glutamate receptor 1,GRIA1,,unknown
Ramosetron,,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,unknown
Rolapitant,Mean terminal half life ranged from 169 to 183 hours (~7 days).,Neurokinin-1 Receptor (NK1R),,antagonist,yes
Sacubitril,"The half life of sacubitril is 1.1 to 3.6 hours, and the half life of it's metabolite LBQ657 is 9.9 to 11.1 hours.",Neprilysin,MME,antagonistinhibitor,yes
Talniflumate,Approximately 2h in 12 subjects [A31964],Prostaglandin G/H synthase 1,PTGS1,antagonist,unknown
Talniflumate,Approximately 2h in 12 subjects [A31964],Prostaglandin G/H synthase 2,PTGS2,antagonist,unknown
Talniflumate,Approximately 2h in 12 subjects [A31964],Chloride channel protein ClC-Ka,CLCNKA,antagonist,unknown
Ombitasvir,Ombitasvir has a half life of elimination of 21-25 hours [FDA Label],Nonstructural protein 5A,NS5A,inhibitor,yes
Paritaprevir,5.5 hr [FDA Label],NS3/4A protein,NS3/4A,inhibitor,yes
Tenofovir alafenamide,0.51 h,Reverse transcriptase/RNaseH,pol,inhibitor,yes
Butylscopolamine,The half life of elimination is 1-5 hours [A7905].,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Butylscopolamine,The half life of elimination is 1-5 hours [A7905].,Muscarinic acetylcholine receptor M2,CHRM2,antagonist,unknown
Chondroitin sulfate,"The approximate half-life of chondroitin sulfate and its derivative metabolites is 15 hours.[A32066] After intramuscular administration of chondroitin sulfate in humans, the elimination half-life of the chondroitin sulfate was of 275 min. When administered orally, the elimination half-life was presented at 310 min.[A32068]",Brain-derived neurotrophic factor,BDNF,,unknown
Chondroitin sulfate,"The approximate half-life of chondroitin sulfate and its derivative metabolites is 15 hours.[A32066] After intramuscular administration of chondroitin sulfate in humans, the elimination half-life of the chondroitin sulfate was of 275 min. When administered orally, the elimination half-life was presented at 310 min.[A32068]",Glial cell line-derived neurotrophic factor,GDNF,,unknown
Chondroitin sulfate,"The approximate half-life of chondroitin sulfate and its derivative metabolites is 15 hours.[A32066] After intramuscular administration of chondroitin sulfate in humans, the elimination half-life of the chondroitin sulfate was of 275 min. When administered orally, the elimination half-life was presented at 310 min.[A32068]",Vascular endothelial growth factor A,VEGFA,,unknown
Chondroitin sulfate,"The approximate half-life of chondroitin sulfate and its derivative metabolites is 15 hours.[A32066] After intramuscular administration of chondroitin sulfate in humans, the elimination half-life of the chondroitin sulfate was of 275 min. When administered orally, the elimination half-life was presented at 310 min.[A32068]",C-C motif chemokine 2,CCL2,,unknown
Alirocumab,"In monotherapy, the median half-life of alirocumab at steady state was 17–20 days in patients receiving alirocumab at SC doses of 75 or 150 mg every 2 weeks. As statin therapy increases the production of PCSK9, statin co-administration is thought to shorten alirocumab half-life; therefore the median apparent half-life of alirocumab was reduced to 12 days at equivalent alirocumab doses. However, this difference is not considered clinically significant and does not change dosing recommendations.",Proprotein convertase subtilisin/kexin type 9,PCSK9,inhibitor,yes
Setiptiline,,Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,antagonist,unknown
Setiptiline,,Serotonin Receptors,HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR6HTR7,antagonist,unknown
"Synthetic Conjugated Estrogens, A","The half life of baseline-corrected estrone and equilin was found to be 10.6 hr and 9.7 hr, respectively.",Estrogen receptor alpha,ESR1,ligand,yes
"Synthetic Conjugated Estrogens, B","The half life of baseline-corrected estrone and equilin was found to be 23.46 hr and 15.09 hr, respectively.",Estrogen receptor alpha,ESR1,ligand,yes
Carbenicillin indanyl,,Penicillin-binding protein,,inhibitor,yes
Benzathine benzylpenicillin,In adults with normal renal function is reportedly 0.4–0.9 hours.,Penicillin-binding protein 2,penA,binding,unknown
Benzathine benzylpenicillin,In adults with normal renal function is reportedly 0.4–0.9 hours.,Beta-lactam-inducible penicillin-binding protein,pbp,binding,unknown
Sulbactam,~1 hr,Beta-lactamase,blaZ,inhibitor,yes
Tegafur-uracil,The presence of uracil generates an increase in the half-life of tegafur and it is registered to be of 11 hours.[A1821] The elimination half-life of uracil is of 20-40 minutes.[L934],Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,antagonist,yes
Tegafur-uracil,The presence of uracil generates an increase in the half-life of tegafur and it is registered to be of 11 hours.[A1821] The elimination half-life of uracil is of 20-40 minutes.[L934],Thymidylate synthase,TYMS,antagonist,yes
Tegafur-uracil,The presence of uracil generates an increase in the half-life of tegafur and it is registered to be of 11 hours.[A1821] The elimination half-life of uracil is of 20-40 minutes.[L934],RNA,,,yes
Tegafur-uracil,The presence of uracil generates an increase in the half-life of tegafur and it is registered to be of 11 hours.[A1821] The elimination half-life of uracil is of 20-40 minutes.[L934],DNA,,,yes
"Antihemophilic Factor (Recombinant), PEGylated","This drug exhibits an extended terminal half-life through pegylation of the parent molecule, which reduces binding to the physiological factor VIII clearance receptor (LRP1) [FDA label]. 

The clearance was 1.79 mL(-1)  h(-1)  kg(-1).  The mean terminal half-life of N8-GP was 19.0 h (range: 11.6-27.3 h), 1.6-fold longer than that of the patients' previous products.
CONCLUSIONS:

Children <6 years: 11.8 ± 2.43 hours; Children 6 to <12 years: 12.4 ± 1.67 hours; Children and Adolescents 12 to <18 years: 13.43 ± 4.05 hours; Adults ≥18 years: 14.69 ± 3.79 hours [L1539]

The average half-life (T1/2) of FVIII products is in the range of 10 to 14 hours.  This requires administration of Factor VIII every other day, or every 2 to 3 days when based on each patient’s individual pharmacokinetic (PK) profile [A32069].

 The pharmacokinetic studies of PEG-FVIII conducted in hemophilic mouse models demonstrated that the half-life of PEGylated factor is more than doubled (4.9 hours) when compared to non-PEGylated full-length recombinant FVIII (1.9 hours) [A32067].",von Willebrand factor,VWF,,unknown
"Antihemophilic Factor (Recombinant), PEGylated","This drug exhibits an extended terminal half-life through pegylation of the parent molecule, which reduces binding to the physiological factor VIII clearance receptor (LRP1) [FDA label]. 

The clearance was 1.79 mL(-1)  h(-1)  kg(-1).  The mean terminal half-life of N8-GP was 19.0 h (range: 11.6-27.3 h), 1.6-fold longer than that of the patients' previous products.
CONCLUSIONS:

Children <6 years: 11.8 ± 2.43 hours; Children 6 to <12 years: 12.4 ± 1.67 hours; Children and Adolescents 12 to <18 years: 13.43 ± 4.05 hours; Adults ≥18 years: 14.69 ± 3.79 hours [L1539]

The average half-life (T1/2) of FVIII products is in the range of 10 to 14 hours.  This requires administration of Factor VIII every other day, or every 2 to 3 days when based on each patient’s individual pharmacokinetic (PK) profile [A32069].

 The pharmacokinetic studies of PEG-FVIII conducted in hemophilic mouse models demonstrated that the half-life of PEGylated factor is more than doubled (4.9 hours) when compared to non-PEGylated full-length recombinant FVIII (1.9 hours) [A32067].",Coagulation factor IX,F9,,unknown
"Antihemophilic Factor (Recombinant), PEGylated","This drug exhibits an extended terminal half-life through pegylation of the parent molecule, which reduces binding to the physiological factor VIII clearance receptor (LRP1) [FDA label]. 

The clearance was 1.79 mL(-1)  h(-1)  kg(-1).  The mean terminal half-life of N8-GP was 19.0 h (range: 11.6-27.3 h), 1.6-fold longer than that of the patients' previous products.
CONCLUSIONS:

Children <6 years: 11.8 ± 2.43 hours; Children 6 to <12 years: 12.4 ± 1.67 hours; Children and Adolescents 12 to <18 years: 13.43 ± 4.05 hours; Adults ≥18 years: 14.69 ± 3.79 hours [L1539]

The average half-life (T1/2) of FVIII products is in the range of 10 to 14 hours.  This requires administration of Factor VIII every other day, or every 2 to 3 days when based on each patient’s individual pharmacokinetic (PK) profile [A32069].

 The pharmacokinetic studies of PEG-FVIII conducted in hemophilic mouse models demonstrated that the half-life of PEGylated factor is more than doubled (4.9 hours) when compared to non-PEGylated full-length recombinant FVIII (1.9 hours) [A32067].",Coagulation factor X,F10,,unknown
Osimertinib,The population estimated mean half-life is 48 hours.,Epidermal growth factor receptor,EGFR,inhibitor,yes
Daratumumab,Approximately 18 days.,ADP-ribosyl cyclase 1,CD38,antibody,unknown
Kappadione,"Mean elimination half-life of menadione was 27.17 min in the plasma of rabbits, in one study [L1574].",Prothrombin,F2,agonist,unknown
Kappadione,"Mean elimination half-life of menadione was 27.17 min in the plasma of rabbits, in one study [L1574].",Coagulation factor VII,F7,agonist,unknown
Kappadione,"Mean elimination half-life of menadione was 27.17 min in the plasma of rabbits, in one study [L1574].",Coagulation factor IX,F9,agonist,unknown
Kappadione,"Mean elimination half-life of menadione was 27.17 min in the plasma of rabbits, in one study [L1574].",Coagulation factor X,F10,agonist,unknown
Kappadione,"Mean elimination half-life of menadione was 27.17 min in the plasma of rabbits, in one study [L1574].",Vitamin K-dependent protein C,PROC,agonist,unknown
Kappadione,"Mean elimination half-life of menadione was 27.17 min in the plasma of rabbits, in one study [L1574].",Vitamin K-dependent gamma-carboxylase,GGCX,agonist,unknown
Kappadione,"Mean elimination half-life of menadione was 27.17 min in the plasma of rabbits, in one study [L1574].",Vitamin K-dependent protein S,PROS1,agonist,unknown
Iopodic acid,,Thyroxine 5-deiodinase,DIO3,antagonist,yes
Seractide acetate,,Adrenocorticotropic hormone receptor,MC2R,agonist,yes
Technetium Tc-99m nofetumomab merpentan,The radioactive half-life of the Tc-99m nm is of 6 hours. It is important to consider this short half-life as the use of this agent should be done within the active time.[L1652] Tc-99m nm presents a serum half-life of 1.5 hours and an elimination phase half-life of 10.5 hours.[L1668],Epithelial cell adhesion molecule,EPCAM,binder,yes
Technetium Tc-99m nofetumomab merpentan,The radioactive half-life of the Tc-99m nm is of 6 hours. It is important to consider this short half-life as the use of this agent should be done within the active time.[L1652] Tc-99m nm presents a serum half-life of 1.5 hours and an elimination phase half-life of 10.5 hours.[L1668],B-lymphocyte antigen CD20,MS4A1,binder,yes
Mersalyl,,"Alkaline phosphatase, tissue-nonspecific isozyme",ALPL,antagonist,unknown
Mersalyl,,Aquaporin-1,AQP1,,unknown
Mersalyl,,Monocarboxylate transporter 1,SLC16A1,antagonist,unknown
Propoxycaine,,Voltage gated sodium channel,,antagonist,unknown
Tipiracil,Tipiracil mean elmination half-life is 2.1 hours.[A31259],Thymidine phosphorylase,TYMP,inhibitor,yes
Pramocaine,,Voltage gated sodium channel,,antagonistinhibitor,yes
beta-Propiolactone,The half-life of β-propiolactone in water is of 225 minutes.[A32148],DNA,,adduct,yes
Levobetaxolol,The mean half life of levobetaxolol is 20 h [FDA Label].,Beta-1 adrenergic receptor,ADRB1,antagonist,yes
Dexpanthenol,Half life have not been reported,Muscarinic acetylcholine receptor M3,CHRM3,antagonist,yes
Rauwolfia serpentina root,"After oral ingestion, an initial half-life of approximately 5 hours is followed by a terminal half-life of approximately 200 hours [L1626].",Synaptic vesicular amine transporter,SLC18A2,inhibitor,yes
Polyestradiol phosphate,,Estrogen receptor alpha,ESR1,agonist,yes
Norethynodrel,,Estrogen receptor alpha,ESR1,,unknown
Norethynodrel,,Androgen receptor,AR,,unknown
Norethynodrel,,Sex hormone-binding globulin,SHBG,,unknown
Norgestrel,,Progesterone receptor,PGR,binder,yes
Norgestrel,,3-oxo-5-alpha-steroid 4-dehydrogenase 1,SRD5A1,inhibitor,yes
Norgestrel,,Androgen receptor,AR,agonist,unknown
Propoxyphene napsylate,6 to 12 hours,Mu-type opioid receptor,OPRM1,agonist,yes
Propoxyphene napsylate,6 to 12 hours,Kappa-type opioid receptor,OPRK1,agonist,yes
Propoxyphene napsylate,6 to 12 hours,Delta-type opioid receptor,OPRD1,agonist,yes
Isosorbide,,Apoptosis regulator Bcl-2,BCL2,,unknown
Isosorbide,,Bcl-2-like protein 1,BCL2L1,,unknown
Isosorbide,,Induced myeloid leukemia cell differentiation protein Mcl-1,MCL1,,unknown
Magnesium acetate tetrahydrate,Elimination half-life has been reported to be 27.7 hours following an overdose of 400mEq magnesium in an adult.,Glutamate (NMDA) receptor,GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B,ligand,unknown
Protirelin,,Thyrotropin Releasing Hormone Receptor,TRHR,ligand,yes
Soybean oil,,Peroxisome proliferator-activated receptor alpha,PPARA,activator,yes
Sodium carbonate,,Carbonic anhydrase 1,CA1,inhibitor,unknown
Sodium carbonate,,Carbonic anhydrase 2,CA2,inhibitor,unknown
Sodium carbonate,,Carbonic anhydrase 4,CA4,inhibitor,unknown
Sodium carbonate,,Carbonic anhydrase 9,CA9,inhibitor,unknown
Glycerin,30 - 45 minutes,Peroxisome proliferator-activated receptor delta,PPARD,agonist,yes
Glycerin,30 - 45 minutes,Hematopoietic prostaglandin D synthase,HPGDS,,unknown
Glycerin,30 - 45 minutes,Endoglucanase G,celCCG,,unknown
Glycerin,30 - 45 minutes,Glutathione S-transferase P,GSTP1,,unknown
Glycerin,30 - 45 minutes,Group IIE secretory phospholipase A2,PLA2G2E,,unknown
Glycerin,30 - 45 minutes,Inositol-3-phosphate synthase 1,ISYNA1,,unknown
Glycerin,30 - 45 minutes,C4-dicarboxylate transport transcriptional regulatory protein DctD,dctD,,unknown
Glycerin,30 - 45 minutes,Alcohol dehydrogenase 1B,ADH1B,,unknown
Glycerin,30 - 45 minutes,"Inositol 1,4,5-trisphosphate receptor type 1",ITPR1,,unknown
Glycerin,30 - 45 minutes,Glycodelin,PAEP,,unknown
Glycerin,30 - 45 minutes,Alpha-N-acetylgalactosaminidase,NAGA,,unknown
Glycerin,30 - 45 minutes,Cytochrome c4,cc4,,unknown
Glycerin,30 - 45 minutes,Bacterioferritin,bfr,,unknown
Glycerin,30 - 45 minutes,TGF-beta receptor type-2,TGFBR2,,unknown
Glycerin,30 - 45 minutes,Argininosuccinate synthase,argG,,unknown
Glycerin,30 - 45 minutes,Enolase,eno,,unknown
Glycerin,30 - 45 minutes,ADP-ribosylation factor 1,ARF1,,unknown
Glycerin,30 - 45 minutes,Multidrug resistance protein MexA,mexA,,unknown
Glycerin,30 - 45 minutes,Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1,PAPSS1,,unknown
Glycerin,30 - 45 minutes,Histidinol dehydrogenase,hisD,,unknown
Glycerin,30 - 45 minutes,DNA mismatch repair protein MutL,mutL,,unknown
Glycerin,30 - 45 minutes,Glycerol uptake facilitator protein,glpF,,unknown
Glycerin,30 - 45 minutes,Ribonucleoside-diphosphate reductase 1 subunit beta,nrdB,,unknown
Glycerin,30 - 45 minutes,A/G-specific adenine glycosylase,mutY,,unknown
Glycerin,30 - 45 minutes,tRNA (cytosine(38)-C(5))-methyltransferase,TRDMT1,,unknown
Sodium sulfate,Serum sulfate: 8.5 hours,Carbonic anhydrase 2,CA2,inhibitor,yes
Sodium sulfate,Serum sulfate: 8.5 hours,Carbonic anhydrase 1,CA1,inhibitor,yes
Enalaprilat,11 hr,Angiotensin-converting enzyme,ACE,inhibitor,yes
Enalaprilat,11 hr,B1 bradykinin receptor,BDKRB1,,unknown
Magnesium carbonate,Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].,Glutamate (NMDA) receptor,GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B,blocker,unknown
Acrivastine,The mean terminal half-life for acrivastine was 1.9 ± 0.3 hours following single oral doses and increased to 3.5 ± 1.9 hours at steady state. The terminal half-life for the propionic acid metabolite was 3.8 ± 1.4 hours.,Histamine H1 receptor,HRH1,antagonist,yes
Urea C-13,,Urease,ureB,substrate,yes
Urea C-14,14C-urea that is not hydrolyzed by H. pylori is excreted in the urine with a half-life of approximately 12 hours. About 10% of the 14C remains in the body at 72 hours and is gradually excreted with a biological half-life of 40 days.,Urease,ureB,substrate,yes
Sodium ferric gluconate complex,"The terminal elimination half-life for drug bound iron was approximately 1 hour, with the value varying by dose but not by rate of administration. In adults, the shortest terminal elimination half-life of 0.825h occurs with the 62.5 mg/4 min dosing regimen and the longest value of 1.45h is achieved with 125 mg/7 min regimen. In pediatric patients, the half-life was 2 hours following administration of 1.5 mg/kg dose and 2.5 hours following administration of 3.0mg/kg dose.",Ferritin light chain,FTL,binding,yes
Sodium ferric gluconate complex,"The terminal elimination half-life for drug bound iron was approximately 1 hour, with the value varying by dose but not by rate of administration. In adults, the shortest terminal elimination half-life of 0.825h occurs with the 62.5 mg/4 min dosing regimen and the longest value of 1.45h is achieved with 125 mg/7 min regimen. In pediatric patients, the half-life was 2 hours following administration of 1.5 mg/kg dose and 2.5 hours following administration of 3.0mg/kg dose.",Hemoglobin subunit alpha,HBA1,binding,unknown
Sodium ferric gluconate complex,"The terminal elimination half-life for drug bound iron was approximately 1 hour, with the value varying by dose but not by rate of administration. In adults, the shortest terminal elimination half-life of 0.825h occurs with the 62.5 mg/4 min dosing regimen and the longest value of 1.45h is achieved with 125 mg/7 min regimen. In pediatric patients, the half-life was 2 hours following administration of 1.5 mg/kg dose and 2.5 hours following administration of 3.0mg/kg dose.",Hemoglobin subunit beta,HBB,binding,yes
Hydroquinone,,Tyrosinase,TYR,inhibitor,yes
Human secretin,The elimination half life of synthetic human secretin is 45 minutes [FDA Label].,Secretin receptor,SCTR,ligand,yes
Octocrylene,"Ecamsule is only used topically, it does not have half life",Estrogen receptor alpha,ESR1,,unknown
Octocrylene,"Ecamsule is only used topically, it does not have half life",Estrogen receptor beta,ESR2,,unknown
Titanium dioxide,The kinetics of TiO2 elimination in the rat lung following its deposition after 7 hr exposure at 10 and 50 mg/cu m were determined for periods up to 140 days...The retention half-time was 14 days for the first clearance phase and 88 days thereafter.,Macrophage receptor MARCO,MARCO,,unknown
Thonzonium,,V-type proton ATPase subunit C 1,ATP6V1C1,inhibitor,yes
Dexchlorpheniramine maleate,20-30 h,Histamine H1 receptor,HRH1,antagonist,yes
Necitumumab,Elimination half life is approximately 14 days.,Epidermal growth factor receptor,EGFR,antagonist,yes
Insulin Degludec,"The half-life after subcutaneous administration is determined primarily by the rate of absorption from the subcutaneous tissue. On average, the half-life at steady state is approximately 25 hours independent of dose.",Insulin receptor,INSR,ligand,yes
Homosalate,"For local use only, no systemic absorption.",Progesterone receptor,PGR,antagonist,unknown
Homosalate,"For local use only, no systemic absorption.",Androgen receptor,AR,antagonist,unknown
Homosalate,"For local use only, no systemic absorption.",Estrogen receptor alpha,ESR1,,unknown
Phenyl salicylate,,Estrogen receptor alpha,ESR1,,unknown
Hypromellose,,Epithelial cell adhesion molecule,EPCAM,,unknown
Polyethylene glycol 400,Great than 24h [L1789].,Ectonucleotide pyrophosphatase/phosphodiesterase family member 1,ENPP1,other,unknown
Trolamine salicylate,,Prostaglandin G/H synthase 1,PTGS1,inhibitor,yes
Trolamine salicylate,,Prostaglandin G/H synthase 2,PTGS2,inhibitor,yes
Aluminum chloride,,"Glutamate dehydrogenase 1, mitochondrial",GLUD1,inactivator,unknown
Resorcinol,,Thyroid peroxidase,TPO,,unknown
Pyrethrum extract,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Potassium nitrate,,Potassium voltage-gated channel subfamily H member 2,KCNH2,agonist,unknown
Calcium Citrate,,Extracellular calcium-sensing receptor,CASR,agonist,yes
Calcium Citrate,,Calreticulin,CALR,ligand,no
Calcium Citrate,,Calcium and integrin-binding protein 1,CIB1,ligand,unknown
Calcium Citrate,,Programmed cell death protein 6,PDCD6,agonist,unknown
Calcium Citrate,,Sorcin,SRI,ligand,unknown
Calcium Citrate,,Calcineurin B homologous protein 1,CHP1,agonist,unknown
Calcium Citrate,,SPARC,SPARC,ligand,no
Calcium Citrate,,Calnexin,CANX,ligand,no
Calcium Citrate,,Fibrillin-2,FBN2,ligand,no
Calcium Citrate,,Protein S100-B,S100B,ligand,no
Calcium Citrate,,Calsequestrin-2,CASQ2,ligand,no
Calcium Citrate,,Regucalcin,RGN,ligand,no
Calcium Citrate,,Peflin,PEF1,ligand,no
Calcium Citrate,,Protein S100-A6,S100A6,ligand,unknown
Calcium Citrate,,Translationally-controlled tumor protein,TPT1,ligand,no
Calcium Citrate,,Calcium and integrin-binding family member 2,CIB2,ligand,unknown
Calcium Citrate,,Protein S100-A13,S100A13,ligand,no
Calcium Citrate,,Calsequestrin-1,CASQ1,ligand,no
Calcium Citrate,,Nucleobindin-1,NUCB1,ligand,unknown
Calcium Citrate,,Nucleobindin-2,NUCB2,ligand,unknown
Calcium Citrate,,Calmodulin,CALM1,agonist,unknown
Calcium Citrate,,Fibrillin-3,FBN3,ligand,unknown
Calcium Citrate,,Grancalcin,GCA,ligand,unknown
Calcium Citrate,,Calcium-dependent secretion activator 1,CADPS,agonist,unknown
Calcium Citrate,,Calmodulin-2,CALM2,agonist,unknown
Calcium Citrate,,Calmodulin-3,CALM3,agonist,unknown
Calcium Citrate,,Protein S100-A16,S100A16,ligand,unknown
Calcium Citrate,,Calretinin,CALB2,ligand,unknown
Calcium Citrate,,Calcyphosin,CAPS,ligand,unknown
Calcium Citrate,,Calcium-dependent secretion activator 2,CADPS2,agonist,unknown
Calcium Citrate,,Calreticulin-3,CALR3,ligand,unknown
Calcium Citrate,,Neurexin-1,NRXN1,agonist,unknown
Calcium Citrate,,Neuronal calcium sensor 1,NCS1,ligand,unknown
Vitamin D,"Although certain studies suggest the half-life of 1,25-hydroxyvitamin D3 may be approximately 15 hours, the half-life of 25-hydroxyvitamin D3 appears to have a half-life of about 15 days [L1782]. Intriguingly however, the half-lives of any particular administration of vitamin d can vary and in general the half-lives of vitamin D2 metabolites have been demonstrated to be shorter overall than vitamin D3 half-lives with this being affected by vitamin d binding protein concentrations and genotype in particular individuals [A32185].",Vitamin D3 receptor,VDR,,unknown
Vitamin D,"Although certain studies suggest the half-life of 1,25-hydroxyvitamin D3 may be approximately 15 hours, the half-life of 25-hydroxyvitamin D3 appears to have a half-life of about 15 days [L1782]. Intriguingly however, the half-lives of any particular administration of vitamin d can vary and in general the half-lives of vitamin D2 metabolites have been demonstrated to be shorter overall than vitamin D3 half-lives with this being affected by vitamin d binding protein concentrations and genotype in particular individuals [A32185].",Vitamin D-binding protein,GC,,unknown
Potassium bicarbonate,"Some reports have shown that after absorption, most body potassium exchanges rapidly with a half-life of less than 7 hours.[A32222]",Pepsin,,inhibitor,yes
Potassium bicarbonate,"Some reports have shown that after absorption, most body potassium exchanges rapidly with a half-life of less than 7 hours.[A32222]",Hydrogen ions,,neutralizer,yes
Turpentine,"Eight male volunteers were exposed to 450 mg/cu m turpentine by inhalation (2 hr, 50 W) in an exposure chamber. The mean half lives of the last phase of alpha-pinene, beta-pinene, and 3-carene (components of turpentine) averaged 32, 25, and 42 hours, respectively.",Mitogen-activated protein kinase 1,MAPK1,,unknown
Racepinephrine,"To refer to the pharmacokinetic data of L-epinephrine, refer to the drug entry for [DB00668].",Alpha-1A adrenergic receptor,ADRA1A,agonist,yes
Racepinephrine,"To refer to the pharmacokinetic data of L-epinephrine, refer to the drug entry for [DB00668].",Alpha-1B adrenergic receptor,ADRA1B,agonist,yes
Racepinephrine,"To refer to the pharmacokinetic data of L-epinephrine, refer to the drug entry for [DB00668].",Alpha-2A adrenergic receptor,ADRA2A,agonist,yes
Racepinephrine,"To refer to the pharmacokinetic data of L-epinephrine, refer to the drug entry for [DB00668].",Alpha-2B adrenergic receptor,ADRA2B,agonist,yes
Racepinephrine,"To refer to the pharmacokinetic data of L-epinephrine, refer to the drug entry for [DB00668].",Alpha-2C adrenergic receptor,ADRA2C,agonist,yes
Racepinephrine,"To refer to the pharmacokinetic data of L-epinephrine, refer to the drug entry for [DB00668].",Beta-1 adrenergic receptor,ADRB1,agonist,yes
Racepinephrine,"To refer to the pharmacokinetic data of L-epinephrine, refer to the drug entry for [DB00668].",Beta-2 adrenergic receptor,ADRB2,agonist,yes
Opium,The half-life of opium ranges between 3-10 hours.[T136],Delta-type opioid receptor,OPRD1,agonist,yes
Opium,The half-life of opium ranges between 3-10 hours.[T136],Kappa-type opioid receptor,OPRK1,agonist,yes
Opium,The half-life of opium ranges between 3-10 hours.[T136],Mu-type opioid receptor,OPRM1,agonist,yes
Capsicum oleoresin,"For pharmacokinetic properties of capsaicin, refer to the drug entry for [DB06774].",Transient receptor potential cation channel subfamily V member 1,TRPV1,agonistactivator,yes
Silicon dioxide,,Macrophage receptor MARCO,MARCO,,unknown
Omega-3 fatty acids,"Approximate half-life values in a compartmental study of ALA, EPA and DHA are 1h, 39-67h and 20h, respectively [A19369, A19370].",Peroxisome proliferator-activated receptor gamma,PPARG,ligand,yes
Omega-3 fatty acids,"Approximate half-life values in a compartmental study of ALA, EPA and DHA are 1h, 39-67h and 20h, respectively [A19369, A19370].",Peroxisome proliferator-activated receptor alpha,PPARA,activator,unknown
Omega-3 fatty acids,"Approximate half-life values in a compartmental study of ALA, EPA and DHA are 1h, 39-67h and 20h, respectively [A19369, A19370].",Sterol regulatory element-binding protein 1,SREBF1,inhibitor,unknown
Chromium,The elimination half-life of hexavalent chromium is 15 to 41 hours [L1982].,Cytochrome b5,CYB5A,substrate,unknown
Pyrantel,"In pigs, following intravenous administration, pyrantel exhibited a half-life of 1.75 +/- 0.19 h [A32291].",G-protein coupled receptor 35,GPR35,,unknown
Pyrantel,"In pigs, following intravenous administration, pyrantel exhibited a half-life of 1.75 +/- 0.19 h [A32291].",Muscarinic acetylcholine receptor M1,CHRM1,antagonistagonist,no
Anthralin,,"Keratin, type II cytoskeletal 2 epidermal",KRT2,antagonist,yes
Anthralin,,C-Jun-amino-terminal kinase-interacting protein 1,MAPK8IP1,agonist,unknown
Anthralin,,"Keratin, type I cytoskeletal 12",KRT12,antagonist,yes
Antithrombin Alfa,"Dose of:
50IU/kg: 11.6 h
100IU/kg: 17.7 h",Prothrombin,F2,inhibitor,yes
Antithrombin Alfa,"Dose of:
50IU/kg: 11.6 h
100IU/kg: 17.7 h",Coagulation factor X,F10,inhibitor,yes
Homatropine,,Liver carboxylesterase 1,CES1,,unknown
Enzacamene,,Progesterone receptor,PGR,antagonist,unknown
Enzacamene,,Androgen receptor,AR,antagonist,unknown
Enzacamene,,Estrogen receptor beta,ESR2,,unknown
Enzacamene,,Estrogen receptor alpha,ESR1,,unknown
Coccidioides immitis spherule,,"HLA class I histocompatibility antigen, A-2 alpha chain",HLA-A,binder,unknown
Coccidioides immitis spherule,,HLA-DR,,binder,unknown
Coccidioides immitis spherule,,"HLA class I histocompatibility antigen, A-3 alpha chain",HLA-A,,unknown
Coccidioides immitis spherule,,"HLA class I histocompatibility antigen, B-27 alpha chain",HLA-B,,unknown
Thrombin,,Proteinase-activated receptor 1,F2R,,unknown
Thrombin,,Proteinase-activated receptor 4,F2RL3,,unknown
Prothrombin,Approximately 60h [A19411].,Fibrinogen alpha chain,FGA,cleavage,yes
Prothrombin,Approximately 60h [A19411].,Fibrinogen beta chain,FGB,cleavage,yes
Prothrombin,Approximately 60h [A19411].,Coagulation factor XIII A chain,F13A1,agonist,yes
Prothrombin,Approximately 60h [A19411].,Carboxypeptidase B2,CPB2,agonist,yes
Calcium Phosphate,,Extracellular calcium-sensing receptor,CASR,agonist,yes
Calcium Phosphate,,Calreticulin,CALR,ligand,no
Calcium Phosphate,,Calcium and integrin-binding protein 1,CIB1,ligand,unknown
Calcium Phosphate,,Programmed cell death protein 6,PDCD6,agonist,unknown
Calcium Phosphate,,Sorcin,SRI,ligand,unknown
Calcium Phosphate,,Calcineurin B homologous protein 1,CHP1,agonist,unknown
Calcium Phosphate,,SPARC,SPARC,ligand,no
Calcium Phosphate,,Calnexin,CANX,ligand,no
Calcium Phosphate,,Fibrillin-2,FBN2,ligand,no
Calcium Phosphate,,Protein S100-B,S100B,ligand,no
Calcium Phosphate,,Calsequestrin-2,CASQ2,ligand,no
Calcium Phosphate,,Regucalcin,RGN,ligand,no
Calcium Phosphate,,Peflin,PEF1,ligand,no
Calcium Phosphate,,Protein S100-A6,S100A6,ligand,unknown
Calcium Phosphate,,Translationally-controlled tumor protein,TPT1,ligand,no
Calcium Phosphate,,Calcium and integrin-binding family member 2,CIB2,ligand,unknown
Calcium Phosphate,,Protein S100-A13,S100A13,ligand,no
Calcium Phosphate,,Calsequestrin-1,CASQ1,ligand,no
Calcium Phosphate,,Nucleobindin-1,NUCB1,ligand,unknown
Calcium Phosphate,,Nucleobindin-2,NUCB2,ligand,unknown
Calcium Phosphate,,Calmodulin,CALM1,agonist,unknown
Calcium Phosphate,,Fibrillin-3,FBN3,ligand,unknown
Calcium Phosphate,,Grancalcin,GCA,ligand,unknown
Calcium Phosphate,,Calcium-dependent secretion activator 1,CADPS,agonist,unknown
Calcium Phosphate,,Calmodulin-2,CALM2,agonist,unknown
Calcium Phosphate,,Calmodulin-3,CALM3,agonist,unknown
Calcium Phosphate,,Protein S100-A16,S100A16,ligand,unknown
Calcium Phosphate,,Calretinin,CALB2,ligand,unknown
Calcium Phosphate,,Calcyphosin,CAPS,ligand,unknown
Calcium Phosphate,,Calcium-dependent secretion activator 2,CADPS2,agonist,unknown
Calcium Phosphate,,Calreticulin-3,CALR3,ligand,unknown
Calcium Phosphate,,Neurexin-1,NRXN1,agonist,unknown
Calcium Phosphate,,Neuronal calcium sensor 1,NCS1,ligand,unknown
Guaiacol,,Serum albumin,ALB,,unknown
Selexipag,Selexipag's terminal half life is 0.8-2.5 hours. The active metabolite's terminal half life is 6.2-13.5 hours.,Prostacyclin receptor,PTGIR,agonist,yes
Alectinib,The mean elimination half life is 33 hr for alectinib and 31 hr for M4.,ALK tyrosine kinase receptor,ALK,inhibitor,yes
Sennosides,,Reverse transcriptase/RNaseH,pol,inhibitor,unknown
Cefroxadine,The serum half life is 0.9-1.1 h [A20320].,Penicillin-binding protein 1B,mrcB,inhibitor,yes
Chlorobutanol,,Potassium voltage-gated channel subfamily H member 2,KCNH2,,unknown
Imidacloprid,,CHRNA7-FAM7A fusion protein,CHRFAM7A,,unknown
Lesinurad,,Solute carrier family 22 member 12,SLC22A12,inhibitor,yes
Lesinurad,,Solute carrier family 22 member 11,SLC22A11,inhibitor,yes
Ixekizumab,13 days,Interleukin-17A,IL17A,antibody,yes
Elbasvir,The geometric mean apparent terminal half-life for Grazoprevir is 24 hours in HCV-infected subjects [FDA Label].,Nonstructural Protein 5A (NS5A),,inhibitor,yes
Grazoprevir,The geometric mean apparent terminal half-life for Grazoprevir is 31 hours in HCV-infected subjects [FDA Label].,NS3/4A protein,NS3/4A,antagonist,yes
Indigotindisulfonic Acid,,Aryl hydrocarbon receptor,AHR,,unknown
Venetoclax,26 hr,Apoptosis regulator Bcl-2,BCL2,inhibitor,yes
Thiocolchicoside,Approximately 7.7h [L1670].,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,antagonist,yes
Thiocolchicoside,Approximately 7.7h [L1670].,Glycine receptor subunit alpha-1,GLRA1,antagonist,unknown
Thiocolchicoside,Approximately 7.7h [L1670].,Tumor necrosis factor ligand superfamily member 11,TNFSF11,antagonist,unknown
Asunaprevir,,Hepatitis C virus NS3 protease/helicase,NS3,antagonist,yes
Thimerosal,"A study was done to study the pharmacokinetics of Thimerosal in mice. Estimated half-lives (in days) were 8.8 for blood, 10.7 for brain, 7.8 for heart, 7.7 for liver and 45.2 for kidney [L1685].

The the long half-life of ethylmercury (~50 days on average in humans) results in accumulation that may be harmful to the developing fetal brain, as it is more susceptible to organomercurial compounds than the adult brain [L1687].",Methionine synthase,MTR,antagonist,unknown
Thimerosal,"A study was done to study the pharmacokinetics of Thimerosal in mice. Estimated half-lives (in days) were 8.8 for blood, 10.7 for brain, 7.8 for heart, 7.7 for liver and 45.2 for kidney [L1685].

The the long half-life of ethylmercury (~50 days on average in humans) results in accumulation that may be harmful to the developing fetal brain, as it is more susceptible to organomercurial compounds than the adult brain [L1687].",Cystine/glutamate transporter,SLC7A11,antagonist,unknown
Thimerosal,"A study was done to study the pharmacokinetics of Thimerosal in mice. Estimated half-lives (in days) were 8.8 for blood, 10.7 for brain, 7.8 for heart, 7.7 for liver and 45.2 for kidney [L1685].

The the long half-life of ethylmercury (~50 days on average in humans) results in accumulation that may be harmful to the developing fetal brain, as it is more susceptible to organomercurial compounds than the adult brain [L1687].",Sodium/potassium-transporting ATPase subunit gamma,FXYD2,antagonist,unknown
Bilastine,The mean half life of elimination is 14.5h [FDA Label].,Histamine H1 receptor,HRH1,antagonist,yes
Atezolizumab,27 days,Programmed cell death 1 ligand 1,CD274,antibody,yes
Levoleucovorin,"The mean terminal half-life for total-THF and (6S)-5-methyl-5,6,7,8-tetrahydrofolate was 5.1 and 6.8 hours, respectively.",Serine hydroxymethyltransferase,glyA,,unknown
Levoleucovorin,"The mean terminal half-life for total-THF and (6S)-5-methyl-5,6,7,8-tetrahydrofolate was 5.1 and 6.8 hours, respectively.",Dihydrofolate reductase,folA,,unknown
Human Rho(D) immune globulin,The half life is 16 ± 4 days following IV administration and 18 ± 5 days following IM administration.,Rhesus blood group D antigen,RHD,antibody,yes
Antithrombin III human,2.5 - 3.8 hs,Antithrombin-III,SERPINC1,agonist,unknown
Tuberculin Purified Protein Derivative,,Toll-like receptor 2,TLR2,ligand,yes
Human rabies virus immune globulin,,Rabies lyssavirus,,antibody,yes
Tetanus Immune Globulin,Half life is about 23 days [FDA Label].,Tetanus toxin,tetX,antibody,yes
Myrrh,,Bile acid receptor,NR1H4,antagonist,unknown
Myrrh,,Nuclear receptor subfamily 1 group I member 2,NR1I2,partial agonist,unknown
Myrrh,,Peroxisome proliferator-activated receptor alpha,PPARA,agonist,unknown
Susoctocog alfa,"The terminal half-life ranges from 2-17 hours in a non-bleeding state. Following intravenous dose of 5000U to patients with acquired haemophilia in a non-bleeding state, the terminal half life was approximately 3.8 hours [L1130].",von Willebrand factor,VWF,binding,yes
Efmoroctocog alfa,"Following a single intravenous dose of 50 IU/kg in previously-treated adult patients with severe haemophilia A, mean half life (t1/2) ranged from 19 to 20.9 h. Mean t1/2 in adolescent patients 12 to 18 years of age ranged from 16 to 17.5 h. Mean t1/2 in pediatric patients < 12 years of age ranged from 12.3 to 15.9 h [FDA Label].",von Willebrand factor,VWF,binding,yes
Lifitegrast,"Not possible to calculate plasma elimination half-life based on plasma concentrations of lifitegrast, but reported to be relatively short in rat I.V. pharmacokinetics study [A19223].",Integrin alpha-L,ITGAL,antagonist,yes
Velpatasvir,15h [FDA Label].,Nonstructural Protein 5A (NS5A),,inhibitor,yes
Rupatadine,"The half life of elimination is 15.9 h in children 2-5 years old, 12.3 h in children 6-11 years old, 5.9 h in adults, and 8.7 h in geriatric patients [FDA Label].",Platelet-activating factor receptor,PTAFR,antagonist,yes
Rupatadine,"The half life of elimination is 15.9 h in children 2-5 years old, 12.3 h in children 6-11 years old, 5.9 h in adults, and 8.7 h in geriatric patients [FDA Label].",Histamine H1 receptor,HRH1,antagonist,yes
Gestrinone,Plasma half-life is 24 hr [L1695].,Sex hormone-binding globulin,SHBG,antagonist,unknown
Gestrinone,Plasma half-life is 24 hr [L1695].,Progesterone receptor,PGR,antagonistagonist,unknown
Gestrinone,Plasma half-life is 24 hr [L1695].,Glucocorticoid receptor,NR3C1,antagonist,unknown
Gestrinone,Plasma half-life is 24 hr [L1695].,Androgen receptor,AR,antagonist,unknown
Gestrinone,Plasma half-life is 24 hr [L1695].,Gonadotropin-releasing hormone receptor,GNRHR,antagonist,unknown
Gestrinone,Plasma half-life is 24 hr [L1695].,Estrogen receptor alpha,ESR1,antagonistagonist,unknown
Candoxatrilat,,Neprilysin,MME,inhibitor,yes
Tasonermin,Tasonermin has a terminal half life of 20-30 min at doses of 150 μg/m² [L1339]. This value increases as dosage increases.,Tumor necrosis factor receptor superfamily member 1A,TNFRSF1A,agonist,yes
Tasonermin,Tasonermin has a terminal half life of 20-30 min at doses of 150 μg/m² [L1339]. This value increases as dosage increases.,Tumor necrosis factor receptor superfamily member 1B,TNFRSF1B,agonist,unknown
Isavuconazole,"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].",Lanosterol 14-alpha demethylase,ERG11,inhibitor,yes
Isavuconazole,"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].",Potassium voltage-gated channel subfamily H member 2,KCNH2,inhibitor,no
Isavuconazole,"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].",Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,inhibitor,no
Isavuconazole,"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].",G protein-activated inward rectifier potassium channel 2,KCNJ6,inhibitor,no
Isavuconazole,"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].",G protein-activated inward rectifier potassium channel 3,KCNJ9,inhibitor,no
Isavuconazole,"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].",ATP-sensitive inward rectifier potassium channel 11,KCNJ11,inhibitor,no
Isavuconazole,"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].",Potassium voltage-gated channel subfamily A member 5,KCNA5,inhibitor,no
Isavuconazole,"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].",Potassium voltage-gated channel subfamily D member 3,KCND3,inhibitor,no
Isavuconazole,"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].",Potassium voltage-gated channel subfamily KQT member 1,KCNQ1,inhibitor,no
Isavuconazole,"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].",Sodium channel protein type 5 subunit alpha,SCN5A,inhibitor,no
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Actin, cytoplasmic 2",ACTG1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Alpha-aminoadipic semialdehyde dehydrogenase,ALDH7A1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Annexin A2,ANXA2,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"ATP synthase subunit alpha, mitochondrial",ATP5A1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"ATP synthase subunit g, mitochondrial",ATP5L,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"ATP synthase subunit O, mitochondrial",ATP5O,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Calpastatin,CAST,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,T-complex protein 1 subunit gamma,CCT3,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Cofilin-1,CFL1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Chloride intracellular channel protein 1,CLIC1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Cysteine and glycine-rich protein 1,CSRP1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Dihydropyrimidinase-related protein 2,DPYSL2,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Desmoplakin,DSP,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Elongation factor 1-alpha 1,EEF1A1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Alpha-enolase,ENO1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Filamin-A,FLNA,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Alpha-ketoglutarate-dependent dioxygenase FTO,FTO,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Glucose-6-phosphate 1-dehydrogenase,G6PD,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Glyceraldehyde-3-phosphate dehydrogenase, testis-specific",GAPDHS,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Glucose-6-phosphate isomerase,GPI,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Heterogeneous nuclear ribonucleoproteins A2/B1,HNRNPA2B1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Heterogeneous nuclear ribonucleoprotein D0,HNRNPD,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Heterogeneous nuclear ribonucleoprotein K,HNRNPK,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Heterochromatin protein 1-binding protein 3,HP1BP3,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Heat shock protein beta-1,HSPB1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Ras GTPase-activating-like protein IQGAP1,IQGAP1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Far upstream element-binding protein 2,KHSRP,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,L-lactate dehydrogenase A chain,LDHA,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,L-lactate dehydrogenase B chain,LDHB,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Galectin-1,LGALS1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Microtubule-associated protein 4,MAP4,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Malate dehydrogenase, cytoplasmic",MDH1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Puromycin-sensitive aminopeptidase,NPEPPS,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Profilin-1,PFN1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Phosphoglycerate kinase 1,PGK1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Pyruvate kinase PKM,PKM,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Peptidyl-prolyl cis-trans isomerase A,PPIA,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Peroxiredoxin-1,PRDX1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,60S ribosomal protein L10,RPL10,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,60S ribosomal protein L14,RPL14,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,60S ribosomal protein L18,RPL18,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,60S ribosomal protein L23a,RPL23A,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,60S ribosomal protein L35,RPL35,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,60S ribosomal protein L4,RPL4,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,40S ribosomal protein S13,RPS13,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,40S ribosomal protein S17,RPS17,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,40S ribosomal protein S18,RPS18,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,40S ribosomal protein S19,RPS19,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,40S ribosomal protein S28,RPS28,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,40S ribosomal protein S5,RPS5,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,40S ribosomal protein S6,RPS6,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,40S ribosomal protein S8,RPS8,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,40S ribosomal protein S9,RPS9,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Splicing factor 1,SF1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Splicing factor, proline- and glutamine-rich",SFPQ,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Small nuclear ribonucleoprotein Sm D2,SNRPD2,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Signal recognition particle 14 kDa protein,SRP14,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Serine/arginine-rich splicing factor 4,SRSF4,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Transgelin,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Transgelin-2,TAGLN2,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Triosephosphate isomerase,TPI1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Tropomyosin alpha-1 chain,TPM1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Tubulin alpha-1A chain,TUBA1A,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Vimentin,VIM,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Zyxin,ZYX,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Heat shock cognate 71 kDa protein,HSPA8,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Tubulin beta-6 chain,TUBB6,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Tubulin beta-4A chain,TUBB4A,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Tubulin beta chain,TUBB,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Fructose-bisphosphate aldolase A,ALDOA,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Glyceraldehyde-3-phosphate dehydrogenase,GAPDH,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Cytochrome c,CYCS,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Phosphoglycerate mutase 1,PGAM1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Myosin-9,MYH9,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Protein disulfide-isomerase,P4HB,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Probable ATP-dependent RNA helicase DDX5,DDX5,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Serine hydroxymethyltransferase, mitochondrial",SHMT2,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Spliceosome RNA helicase DDX39B,DDX39B,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Temporary name for P06748,NPM1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Translationally-controlled tumor protein homolog,TCTP,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,P-type Ca2+-transporting ATPase,serca,antagonist,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Ornithine aminotransferase,OAT,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Elongation factor 1-alpha,MEF-1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Multidrug resistance protein,MDR1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Elongation factor 2,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Actin-1,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Glyceraldehyde-3-phosphate dehydrogenase,GAPDH,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Fructose-bisphosphate aldolase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Cell division cycle protein 48 homologue,putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Heat shock protein 90,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Eukaryotic initiation factor 4A,H45,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Pyruvate kinase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,L-lactate dehydrogenase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Protein disulfide-isomerase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Thioredoxin-related protein, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Spermidine synthase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Probable ATP-dependent 6-phosphofructokinase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Glutamate dehydrogenase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Endoplasmin homolog, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Hypoxanthine-guanine-xanthine phosphoribosyltransferase,LACZ,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Enolase,ENO,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,40S ribosomal protein S3,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Non-SERCA-type Ca2+-transporting P-ATPase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Tubulin alpha chain,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Knob-associated histidine-rich protein,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,S-adenosylmethionine synthase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"V-type H(+)-translocating pyrophosphatase, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,60S ribosomal protein L4,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Phosphoethanolamine N-methyltransferase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,40S ribosomal protein S3a,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Conserved Plasmodium membrane protein,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,60S ribosomal protein L3,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,High molecular weight rhoptry protein 2,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Serine repeat antigen 5,SERA5,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,40S ribosomal protein S19,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Glycophorin-binding protein,GBP,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Calcium-transporting ATPase,ATP6,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,V-type proton ATPase catalytic subunit A,vapA,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,60S ribosomal protein L2,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Acyl-CoA synthetase,ACS3,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Plasmepsin IV,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Plasmepsin-1,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Chloroquine resistance transporter,CRT,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,14-3-3 protein,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Isoleucine--tRNA ligase, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Plasmodium exported protein,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Tubulin beta chain,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,60S ribosomal protein L27,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Sec62, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Autophagy-related protein 18, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Mature parasite-infected erythrocyte surface antigen,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Importin-7, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Karyopherin alpha,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Peptidyl-prolyl cis-trans isomerase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"DnaJ protein, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Merozoite surface protein 1,MSP-1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Glutamate--tRNA ligase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,T-complex protein 1 subunit eta,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Plasmepsin-2,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Chaperone, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Rhoptry neck protein 3,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"40S ribosomal protein S5, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Skeleton-binding protein 1,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Purine nucleotide phosphorylase, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Adenosylhomocysteinase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Adenosine deaminase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Methionine--tRNA ligase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Carbamoyl phosphate synthetase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Aspartate carbamoyltransferase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Signal recognition particle receptor, beta subunit",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Parasite-infected erythrocyte surface protein,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Coatomer alpha subunit, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Hexokinase,HK,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Proteasome subunit alpha type,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Haloacid dehalogenase-like hydrolase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Insulinase, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,40S ribosomal protein S21,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Ubiquitin-conjugating enzyme E2,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Eukaryotic translation initiation factor 3 subunit C,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"60S ribosomal protein L24, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,60S ribosomal protein L23,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"60S ribosomal protein L17, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,NADP-specific glutamate dehydrogenase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,HAP protein,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Heat shock protein 110, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"60S ribosomal protein L10, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Lysophospholipase, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Polyadenylate-binding protein,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Ubiquitin-60S ribosomal protein L40,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Phosphoribosylpyrophosphate synthetase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Thioredoxin peroxidase 1,TPx1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Protein transport protein SEC31,Sec31p,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Dipeptidyl aminopeptidase 1,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Ring-infected erythrocyte surface antigen,RESA,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,ATP-dependent RNA helicase UAP56,UAP56,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Calcium-dependent protein kinase 4,CPK4,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,GTP-binding nuclear protein Ran,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Nucleoside transporter 2,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Anamorsin homolog,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Glutamine synthetase, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"60S ribosomal protein L30e, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Casein kinase 2, alpha subunit",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Threonine--tRNA ligase,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,cAMP-dependent protein kinase regulatory subunit,PKAr,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"Elongation factor 1-gamma, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Thioredoxin-like protein,tlp1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,60S ribosomal protein L21,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"60S ribosomal protein L14, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Inner membrane complex sub-compartment protein 3,,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,"HSP40, subfamily A, putative",,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Pyridoxal 5'-phosphate synthase subunit Pdx1,pdx1,ligand,unknown
Artenimol,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,Serum albumin,ALB,ligand,unknown
Dibotermin alfa,"When injected intravenously, the terminal half-life of dibotermin alfa was 16 minutes in rats and 6.7 minutes in cynomolgus monkeys [L1391].",Bone morphogenetic protein receptor type-2,BMPR2,ligand,yes
Dibotermin alfa,"When injected intravenously, the terminal half-life of dibotermin alfa was 16 minutes in rats and 6.7 minutes in cynomolgus monkeys [L1391].",Bone morphogenetic protein receptor type-1A,BMPR1A,ligand,yes
Pitolisant,Pitolisant has a plasma half-life of 10-12 hours [L1471].,Histamine H3 receptor,HRH3,antagonistinverse agonist,yes
Pitolisant,Pitolisant has a plasma half-life of 10-12 hours [L1471].,Potassium voltage-gated channel subfamily H member 2,KCNH2,blocker,no
Tucatinib,,Receptor tyrosine-protein kinase erbB-2,ERBB2,,unknown
Latanoprostene Bunod,"The half-life after application of latanoprostene bunod in rabbits was 1.8 hours in cornea, 2.1 hours in aqueous humor, and 4.6 hours in the iris/ciliary body [A31285].",Prostaglandin F2-alpha receptor,PTGFR,agonist,yes
Curcumin,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Curcumin,,Vitamin D3 receptor,VDR,,unknown
Curcumin,,Multidrug resistance-associated protein 5,ABCC5,inhibitor,unknown
Curcumin,,Carbonyl reductase [NADPH] 1,CBR1,,unknown
Curcumin,,Glutathione S-transferase P,GSTP1,,unknown
Equol,,Estrogen receptor beta,ESR2,agonist,unknown
Equol,,Sex hormone-binding globulin,SHBG,,unknown
Naldemedine,The terminal elimination half life is 11 h [FDA Label].,Mu-type opioid receptor,OPRM1,antagonist,yes
Naldemedine,The terminal elimination half life is 11 h [FDA Label].,Delta-type opioid receptor,OPRD1,antagonist,yes
Naldemedine,The terminal elimination half life is 11 h [FDA Label].,Kappa-type opioid receptor,OPRK1,antagonist,yes
Voclosporin,,Calcineurin subunit B type 1,PPP3R1,,unknown
Voclosporin,,Calcineurin subunit B type 2,PPP3R2,,unknown
Tropisetron,5.7 h.,5-hydroxytryptamine receptor 3A,HTR3A,antagonist,yes
Acalabrutinib,"After administering a single oral dose of 100 mg acalabrutinib, the median terminal elimination half-life of the drug was found to be 0.9 (with a range of 0.6 to 2.8) hours [FDA Label].

The half-life of the active metabolite, ACP-5862, is about 6.9 hours [FDA Label].",Tyrosine-protein kinase BTK,BTK,inhibitor,yes
Tezacaftor,The apparent half-life of tezafacor is approximately 15 hours.[A32094],Cystic fibrosis transmembrane conductance regulator,CFTR,activator,yes
Durvalumab,Mean elimination half-life is approximately 12 days with 23.2% coefficient of variation.,Programmed cell death 1 ligand 1,CD274,binder,yes
Durvalumab,Mean elimination half-life is approximately 12 days with 23.2% coefficient of variation.,T-lymphocyte activation antigen CD80,CD80,binder,yes
Dutogliptin,10-13 hours,Dipeptidyl peptidase 4,DPP4,,unknown
Ribociclib,32.6 hours,Cyclin-dependent kinase 4,CDK4,antagonistinhibitor,yes
Ribociclib,32.6 hours,Cyclin-dependent kinase 6,CDK6,antagonistinhibitor,yes
Depatuxizumab mafodotin,,Epidermal growth factor receptor,EGFR,antibody,no
Depatuxizumab mafodotin,,Tubulin beta chain,TUBB,nucleotide exchange blocker,yes
Icotinib,5.5 hrs,Epidermal growth factor receptor,EGFR,antagonist,unknown
Rilmenidine,,Alpha-2A adrenergic receptor,ADRA2A,,unknown
MK-1775,,Wee1-like protein kinase,WEE1,inhibitor,yes
Sarilumab,"The half life will depend on the administered concentration. At 200 mg every 2 weeks, half-life is up to 10 days in patients with RA at steady state. At 150 mg every 2 weeks, half-life is up to 8 days in patients with RA at steady state. After the last steady state dose of 150 mg and 200 mg, the time to reach nondetectable concentration is 28 and 43 days, respectively [L1000].",Interleukin-6 receptor subunit alpha,IL6R,antagonistantibody,yes
Sarilumab,"The half life will depend on the administered concentration. At 200 mg every 2 weeks, half-life is up to 10 days in patients with RA at steady state. At 150 mg every 2 weeks, half-life is up to 8 days in patients with RA at steady state. After the last steady state dose of 150 mg and 200 mg, the time to reach nondetectable concentration is 28 and 43 days, respectively [L1000].",High affinity immunoglobulin gamma Fc receptor I,FCGR1A,unknown,unknown
Sarilumab,"The half life will depend on the administered concentration. At 200 mg every 2 weeks, half-life is up to 10 days in patients with RA at steady state. At 150 mg every 2 weeks, half-life is up to 8 days in patients with RA at steady state. After the last steady state dose of 150 mg and 200 mg, the time to reach nondetectable concentration is 28 and 43 days, respectively [L1000].",Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,unknown,unknown
Sarilumab,"The half life will depend on the administered concentration. At 200 mg every 2 weeks, half-life is up to 10 days in patients with RA at steady state. At 150 mg every 2 weeks, half-life is up to 8 days in patients with RA at steady state. After the last steady state dose of 150 mg and 200 mg, the time to reach nondetectable concentration is 28 and 43 days, respectively [L1000].",Low affinity immunoglobulin gamma Fc region receptor II-b,FCGR2B,unknown,unknown
Sarilumab,"The half life will depend on the administered concentration. At 200 mg every 2 weeks, half-life is up to 10 days in patients with RA at steady state. At 150 mg every 2 weeks, half-life is up to 8 days in patients with RA at steady state. After the last steady state dose of 150 mg and 200 mg, the time to reach nondetectable concentration is 28 and 43 days, respectively [L1000].",Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,unknown,unknown
Sarilumab,"The half life will depend on the administered concentration. At 200 mg every 2 weeks, half-life is up to 10 days in patients with RA at steady state. At 150 mg every 2 weeks, half-life is up to 8 days in patients with RA at steady state. After the last steady state dose of 150 mg and 200 mg, the time to reach nondetectable concentration is 28 and 43 days, respectively [L1000].",Low affinity immunoglobulin gamma Fc region receptor III-B,FCGR3B,unknown,unknown
Pilaralisib,,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",PIK3CA,,unknown
Danoprevir,,Genome polyprotein,,,unknown
Tosedostat,,Puromycin-sensitive aminopeptidase,NPEPPS,,unknown
Tosedostat,,Leukotriene A-4 hydrolase,LTA4H,,unknown
Niraparib,"Following multiple daily doses of 300 mg niraparib, the mean half-life (t1/2) is 36 hours.",Poly [ADP-ribose] polymerase 1,PARP1,antagonist,yes
Niraparib,"Following multiple daily doses of 300 mg niraparib, the mean half-life (t1/2) is 36 hours.",Poly [ADP-ribose] polymerase 2,PARP2,antagonist,yes
Bictegravir,"17. 3h [FDA LABEL, L1219]",Reverse transcriptase/RNaseH,pol,antagonist,yes
Bictegravir,"17. 3h [FDA LABEL, L1219]",Integrase,pol,antagonist,yes
Arhalofenate,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Baricitinib,Mean half-life in patients with rheumatoid arthritis is approximately 12.5 hrs (CV = 27.4 %) [FDA Label].,Tyrosine-protein kinase JAK1,JAK1,inhibitor,yes
Baricitinib,Mean half-life in patients with rheumatoid arthritis is approximately 12.5 hrs (CV = 27.4 %) [FDA Label].,Tyrosine-protein kinase JAK2,JAK2,inhibitor,yes
Baricitinib,Mean half-life in patients with rheumatoid arthritis is approximately 12.5 hrs (CV = 27.4 %) [FDA Label].,Protein-tyrosine kinase 2-beta,PTK2B,inhibitor,yes
Baricitinib,Mean half-life in patients with rheumatoid arthritis is approximately 12.5 hrs (CV = 27.4 %) [FDA Label].,Tyrosine-protein kinase JAK3,JAK3,inhibitor,yes
Ertugliflozin,The terminal elimination half-life of ertugliflozin is 11-17 hours.[A31583],Sodium/glucose cotransporter 2,SLC5A2,antagonist,yes
Neratinib,"The mean half life of elimination ranges from 7-17 h following a single dose [FDA Label]. The mean plasma half life during multiple doses is 14.6 h for neratinib, 21.6 h for M3, 13.8 h for M6, and 10.4 h for M7.",Epidermal growth factor receptor,EGFR,inhibitor,yes
Mocetinostat,,Histone deacetylase 1,HDAC1,,unknown
Mocetinostat,,Histone deacetylase 3,HDAC3,,unknown
Mocetinostat,,Histone deacetylase 2,HDAC2,,unknown
Dinitrochlorobenzene,,Methylated-DNA--protein-cysteine methyltransferase,MGMT,,unknown
Dinitrochlorobenzene,,Glutathione S-transferase P,GSTP1,,unknown
Guselkumab,Mean half-life of guselkumab is approximately 15 to 18 days in subjects with plaque psoriasis [FDA Label].,Interleukin-23 subunit alpha,IL23A,blocker,yes
Angiotensin II,The plasma half-life of intravenously administered angiotensin II is less than one minute [FDA Label].,Type-1 angiotensin II receptor,AGTR1,agonist,yes
Astodrimer,,Envelope glycoprotein gp160,env,,unknown
Leukotriene D4,,Cysteinyl leukotriene receptor 1,CYSLTR1,,unknown
Leukotriene D4,,Cysteinyl leukotriene receptor 2,CYSLTR2,,unknown
Apalutamide,The mean effective half-life for apalutamide in patients with NM-CRPC was approximately 3 days at steady-state [FDA Label].,Androgen receptor,AR,antagonist,yes
Apalutamide,The mean effective half-life for apalutamide in patients with NM-CRPC was approximately 3 days at steady-state [FDA Label].,GABA-A receptor (anion channel),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ,antagonist,unknown
Lebrikizumab,,Interleukin-13,IL13,,unknown
Lebrikizumab,,IL13 protein,IL13,,unknown
Valbenazine,Both valbenazine and its active metabolite [+]-α-HTBZ have a half life of 15-22 hours [FDA Label].,vesicular monoamine transporter 2 (VMAT2),VMAT2,antagonist,yes
Kynurenic Acid,,Aryl hydrocarbon receptor,AHR,,unknown
Kynurenic Acid,,G-protein coupled receptor 35,GPR35,,unknown
Delafloxacin,The mean half life of elimination of Delafloxacin is 3.7 hours after a single intravenous administration [FDA Label]. The mean half life of elimination for multple oral administrations is 4.2-8.5 hours.,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
Delafloxacin,The mean half life of elimination of Delafloxacin is 3.7 hours after a single intravenous administration [FDA Label]. The mean half life of elimination for multple oral administrations is 4.2-8.5 hours.,DNA gyrase subunit A,gyrA,inhibitor,yes
Avelumab,The terminal half-life is approximately 6.1 days in patients receiving 10 mg/kg.,Programmed cell death 1 ligand 1,CD274,antagonist,yes
Lapachone,,Retinol-binding protein 3,RBP3,,unknown
Vestipitant,,Substance-P receptor,TACR1,,unknown
Binimetinib,,Interleukin-6,IL6,,unknown
Binimetinib,,Tumor necrosis factor,TNF,,unknown
Binimetinib,,Interleukin-1 beta,IL1B,,unknown
Tesevatinib,50-70 hours,Pro-epidermal growth factor,EGF,,unknown
Tesevatinib,50-70 hours,Ephrin type-B receptor 4,EPHB4,,unknown
Tesevatinib,50-70 hours,Receptor tyrosine-protein kinase erbB-2,ERBB2,,unknown
Elagolix,,Gonadotropin-releasing hormone receptor,GNRHR,,unknown
Ocrelizumab,The terminal elimination half-life was 26 days [FDA Label].,B-lymphocyte antigen CD20,MS4A1,antagonistantibody,yes
Diacerein,4-10h [A19300].,Oxysterols receptor LXR-alpha,NR1H3,inhibitor,unknown
Diacerein,4-10h [A19300].,Oxysterols receptor LXR-beta,NR1H2,inhibitor,unknown
Diacerein,4-10h [A19300].,Arylamine N-acetyltransferase (Helicobacter pylori),,inhibitor,unknown
Diacerein,4-10h [A19300].,Arachidonate 5-lipoxygenase,ALOX5,inhibitor,unknown
Diacerein,4-10h [A19300].,Cytochrome P450 1A2,CYP1A2,inhibitor,unknown
Diacerein,4-10h [A19300].,CYP3A,CYP3A4CYP3A43CYP3A5CYP3A7,inhibitor,unknown
Diacerein,4-10h [A19300].,Cytochrome P450 2E1,CYP2E1,inhibitor,unknown
Diacerein,4-10h [A19300].,Cytochrome P450 2C9,CYP2C9,inhibitor,unknown
Diacerein,4-10h [A19300].,Cytochrome P450 2D6,CYP2D6,inhibitor,unknown
Abemaciclib,The mean plasma elimination half-life for abemaciclib in patients was 18.3 hours (72% CV) [FDA Label].,Cyclin-dependent kinase 4,CDK4,inhibitor,yes
Abemaciclib,The mean plasma elimination half-life for abemaciclib in patients was 18.3 hours (72% CV) [FDA Label].,Cyclin-dependent kinase 6,CDK6,inhibitor,yes
Benralizumab,The half-life of Benralizumab is estimated to be 15-18 days.[A31293],Interleukin-5 receptor subunit alpha,IL5RA,antibody,yes
Benralizumab,The half-life of Benralizumab is estimated to be 15-18 days.[A31293],Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,binding,yes
Voxilaprevir,33 hr [FDA Label],NS3/4A protein,NS3/4A,inhibitor,yes
Pardoprunox,,D(2) dopamine receptor,DRD2,,unknown
Pardoprunox,,D(3) dopamine receptor,DRD3,,unknown
Pardoprunox,,D(4) dopamine receptor,DRD4,,unknown
Pardoprunox,,5-hydroxytryptamine receptor 1A,HTR1A,,unknown
Letermovir,The mean terminal half-life was observed to be 12 hours following administration of Letemovir 480 mg IV once daily [FDA Label].,Tripartite terminase subunit 1,TRM1,inhibitor,yes
Letermovir,The mean terminal half-life was observed to be 12 hours following administration of Letemovir 480 mg IV once daily [FDA Label].,Tripartite terminase subunit 2,TRM2,inhibitor,yes
Letermovir,The mean terminal half-life was observed to be 12 hours following administration of Letemovir 480 mg IV once daily [FDA Label].,Tripartite terminase subunit 3,TRM3,inhibitor,yes
Tetrahydropalmatine,,D(1A) dopamine receptor,DRD1,antagonist,unknown
Tetrahydropalmatine,,D(2) dopamine receptor,DRD2,antagonist,unknown
Telotristat ethyl,4–12 h,Tryptophan 5-hydroxylase 2,TPH2,antagonist,yes
Telotristat ethyl,4–12 h,Tryptophan 5-hydroxylase 1,TPH1,antagonist,yes
m-Chlorophenylpiperazine,,5-hydroxytryptamine receptor 2C,HTR2C,agonist,unknown
Epigallocatechin Gallate,,Aryl hydrocarbon receptor,AHR,,unknown
Epigallocatechin Gallate,,DNA (cytosine-5)-methyltransferase 1,DNMT1,inhibitor,unknown
Epigallocatechin Gallate,,"Dihydrofolate reductase, mitochondrial",DHFRL1,,unknown
Sotatercept,,Activin receptor type-2A,ACVR2A,,unknown
Gevokizumab,,Interleukin-1 beta,IL1B,,unknown
Ulimorelin,,Growth hormone secretagogue receptor type 1,GHSR,,unknown
Tideglusib,,Glycogen synthase kinase-3 beta,GSK3B,antagonist,yes
Dilmapimod,,Tumor necrosis factor,TNF,,unknown
Dilmapimod,,Interleukin-1 beta,IL1B,,unknown
Dilmapimod,,Interleukin-6,IL6,,unknown
Dupilumab,,Interleukin-4 receptor subunit alpha,IL4R,antagonist,yes
Deutetrabenazine,The half-life of total (α+β)-HTBZ from deutetrabenazine is approximately 9 to 10 hours [FDA Label].,Synaptic vesicular amine transporter,SLC18A2,inhibitor,yes
Sarpogrelate,,5-hydroxytryptamine receptor 2C,HTR2C,,unknown
Sarpogrelate,,5-hydroxytryptamine receptor 2A,HTR2A,inverse agonist,unknown
Obatoclax,,Apoptosis regulator Bcl-2,BCL2,,unknown
Tivantinib,,Hepatocyte growth factor receptor,MET,,unknown
Zalutumumab,,Epidermal growth factor receptor,EGFR,antagonist,yes
Telcagepant,,Calcitonin gene-related peptide 1,CALCA,,unknown
Telcagepant,,Calcitonin gene-related peptide 2,CALCB,,unknown
Telcagepant,,Calcitonin gene-related peptide type 1 receptor,CALCRL,,unknown
Tulobuterol,,Beta-2 adrenergic receptor,ADRB2,,unknown
Cixutumumab,148 h (3 mg/kg dose level) 209 h (6mg/kg dose level),Insulin-like growth factor 1 receptor,IGF1R,,unknown
Brigatinib,The half-life of brigatinib at steady-state was 25 hours.[L1028],ALK tyrosine kinase receptor,ALK,inhibitor,yes
Brigatinib,The half-life of brigatinib at steady-state was 25 hours.[L1028],Epidermal growth factor receptor,EGFR,inhibitor,yes
Brigatinib,The half-life of brigatinib at steady-state was 25 hours.[L1028],Tyrosine-protein kinase ABL1,ABL1,inhibitor,unknown
Brigatinib,The half-life of brigatinib at steady-state was 25 hours.[L1028],Insulin-like growth factor 1 receptor,IGF1R,inhibitor,unknown
Brigatinib,The half-life of brigatinib at steady-state was 25 hours.[L1028],Receptor-type tyrosine-protein kinase FLT3,FLT3,inhibitor,unknown
Brigatinib,The half-life of brigatinib at steady-state was 25 hours.[L1028],Insulin receptor,INSR,binding,no
Brigatinib,The half-life of brigatinib at steady-state was 25 hours.[L1028],Hepatocyte growth factor receptor,MET,inhibitor,unknown
Brigatinib,The half-life of brigatinib at steady-state was 25 hours.[L1028],Receptor tyrosine-protein kinase erbB-4,ERBB4,inhibitor,unknown
Brigatinib,The half-life of brigatinib at steady-state was 25 hours.[L1028],Receptor tyrosine-protein kinase erbB-2,ERBB2,inhibitor,unknown
Verubecestat,,Beta-secretase 1,BACE1,inhibitor,yes
Dasotraline,,Sodium-dependent dopamine transporter,SLC6A3,,unknown
Dasotraline,,Sodium-dependent serotonin transporter,SLC6A4,,unknown
Dasotraline,,Sodium-dependent noradrenaline transporter,SLC6A2,,unknown
Foretinib,,Hepatocyte growth factor,HGF,,unknown
Foretinib,,Vascular endothelial growth factor receptor 2,KDR,,unknown
Benzbromarone,,Cytochrome P450 2C9,CYP2C9,inhibitor,unknown
Benzbromarone,,Cytochrome P450 2C19,CYP2C19,inhibitor,unknown
Radotinib,,Tyrosine-protein kinase ABL1,ABL1,antagonist,yes
Cantharidin,,Aryl hydrocarbon receptor,AHR,agonist,unknown
Rucaparib,"Following a single oral dose of 600mg rucaparib, the mean terminal half life (t1/2) was 17-19 hours [FDA Label].",Poly [ADP-ribose] polymerase 1,PARP1,antagonist,yes
Rucaparib,"Following a single oral dose of 600mg rucaparib, the mean terminal half life (t1/2) was 17-19 hours [FDA Label].",Poly [ADP-ribose] polymerase 2,PARP2,antagonist,yes
Rucaparib,"Following a single oral dose of 600mg rucaparib, the mean terminal half life (t1/2) was 17-19 hours [FDA Label].",Poly [ADP-ribose] polymerase 3,PARP3,antagonist,yes
Milataxel,,Tubulin beta-1 chain,TUBB1,,unknown
Milataxel,,Tubulin beta chain,TUBB,,unknown
Radezolid,,Ribosome-binding protein 1,RRBP1,,unknown
Radezolid,,60S ribosome subunit biogenesis protein NIP7 homolog,NIP7,,unknown
Navitoclax,,Apoptosis regulator Bcl-2,BCL2,,unknown
Navitoclax,,Bcl-2-like protein 2,BCL2L2,,unknown
Navitoclax,,Bcl2 antagonist of cell death,BAD,,unknown
Betrixaban,Betrixaban presents a long half-life of between 19-27 hours [A7708].,Coagulation factor X,F10,inhibitor,yes
Indirubin,,Cytochrome P450 1A1,CYP1A1,substrate,unknown
Indirubin,,Aryl hydrocarbon receptor,AHR,agonist,unknown
Saccharin,,Carbonic anhydrase 3,CA3,inhibitor,unknown
Vofopitant,,Substance-P receptor,TACR1,,unknown
Alvespimycin,"The half-life across all dose levels ranged from 9.9 to 54.1 h (median, 18.2 h) [A19251].",Heat shock protein HSP 90-alpha,HSP90AA1,inhibitor,yes
Nitroaspirin,,Prostaglandin G/H synthase 1,PTGS1,inhibitor,unknown
Propyl Gallate,,Estrogen receptor alpha,ESR1,,unknown
Muscimol,,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,,unknown
Muscimol,,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,,unknown
Muscimol,,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,,unknown
Ketanserin,,5-hydroxytryptamine receptor 2A,HTR2A,inverse agonist,unknown
Piribedil,,D(2) dopamine receptor,DRD2,,unknown
Piribedil,,D(3) dopamine receptor,DRD3,,unknown
Copanlisib,The geometric mean terminal elimination half-life of copanlisib is 39.1 (range: 14.6 to 82.4; SD: 15.0) hours [FDA Label].,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",PIK3CA,inhibitor,yes
Copanlisib,The geometric mean terminal elimination half-life of copanlisib is 39.1 (range: 14.6 to 82.4; SD: 15.0) hours [FDA Label].,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",PIK3CD,inhibitor,yes
Raclopride,,D(2) dopamine receptor,DRD2,antagonist,unknown
Plozalizumab,,C-C chemokine receptor type 2,CCR2,,unknown
Sparsentan,,Angiotensinogen,AGT,,unknown
Sparsentan,,Endothelin-1 receptor,EDNRA,,unknown
Nelotanserin,,5-hydroxytryptamine receptor 2A,HTR2A,,unknown
Abexinostat,,Histone deacetylase 1,HDAC1,,unknown
Tonapofylline,,Adenosine receptor A1,ADORA1,,unknown
Piperine,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Dacetuzumab,,Tumor necrosis factor receptor superfamily member 5,CD40,,unknown
Nafamostat,Approximately 8 minutes [A19227],Prothrombin,F2,inhibitor,yes
Nafamostat,Approximately 8 minutes [A19227],Coagulation factor X,F10,inhibitor,yes
Nafamostat,Approximately 8 minutes [A19227],Coagulation factor XII,F12,inhibitor,yes
Nafamostat,Approximately 8 minutes [A19227],Trypsin-1,PRSS1,inhibitor,yes
Nafamostat,Approximately 8 minutes [A19227],Kallikrein-1,KLK1,inhibitor,yes
Nafamostat,Approximately 8 minutes [A19227],Intercellular adhesion molecule 1,ICAM1,inhibitor,unknown
Ebselen,,Bifunctional epoxide hydrolase 2,EPHX2,inhibitor,unknown
Onapristone,,Glucocorticoid receptor,NR3C1,,unknown
Onapristone,,Probable G-protein coupled receptor 133,ADGRD1,,unknown
Bardoxolone,,Caspase-8,CASP8,,unknown
Naveglitazar,,Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Rolofylline,,Adenosine receptor A1,ADORA1,,unknown
Ritanserin,,5-hydroxytryptamine receptor 2A,HTR2A,inverse agonist,unknown
Phenethyl Isothiocyanate,,"Actin, aortic smooth muscle",ACTA2,,unknown
Phenethyl Isothiocyanate,,"Actin, cytoplasmic 1",ACTB,,unknown
Phenethyl Isothiocyanate,,"ATP synthase subunit beta, mitochondrial",ATP5B,,unknown
Phenethyl Isothiocyanate,,"ATP synthase subunit e, mitochondrial",ATP5I,,unknown
Phenethyl Isothiocyanate,,"ATP synthase subunit g, mitochondrial",ATP5L,,unknown
Phenethyl Isothiocyanate,,Cytochrome b5 type B,CYB5B,,unknown
Phenethyl Isothiocyanate,,"Diablo homolog, mitochondrial",DIABLO,,unknown
Phenethyl Isothiocyanate,,F-box only protein 41,FBXO41,,unknown
Phenethyl Isothiocyanate,,Heterogeneous nuclear ribonucleoprotein F,HNRNPF,,unknown
Phenethyl Isothiocyanate,,Heterogeneous nuclear ribonucleoprotein K,HNRNPK,,unknown
Phenethyl Isothiocyanate,,Heat shock 70 kDa protein 4,HSPA4,,unknown
Phenethyl Isothiocyanate,,Heat shock protein beta-1,HSPB1,,unknown
Phenethyl Isothiocyanate,,"10 kDa heat shock protein, mitochondrial",HSPE1,,unknown
Phenethyl Isothiocyanate,,Heat shock protein 105 kDa,HSPH1,,unknown
Phenethyl Isothiocyanate,,NADH-ubiquinone oxidoreductase chain 1,MT-ND1,,unknown
Phenethyl Isothiocyanate,,Nuclear migration protein nudC,NUDC,,unknown
Phenethyl Isothiocyanate,,Pappalysin-1,PAPPA,,unknown
Phenethyl Isothiocyanate,,Proteasome subunit alpha type-3,PSMA3,,unknown
Phenethyl Isothiocyanate,,26S protease regulatory subunit 6A,PSMC3,,unknown
Phenethyl Isothiocyanate,,Ran-specific GTPase-activating protein,RANBP1,,unknown
Phenethyl Isothiocyanate,,Protein S100-A10,S100A10,,unknown
Phenethyl Isothiocyanate,,Splicing factor 3A subunit 3,SF3A3,,unknown
Phenethyl Isothiocyanate,,SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1,SMARCE1,,unknown
Phenethyl Isothiocyanate,,"Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial",SUCLG2,,unknown
Phenethyl Isothiocyanate,,Tumor protein D54,TPD52L2,,unknown
Phenethyl Isothiocyanate,,Tropomyosin alpha-1 chain,TPM1,,unknown
Phenethyl Isothiocyanate,,Tropomyosin alpha-3 chain,TPM3,,unknown
Phenethyl Isothiocyanate,,Tropomyosin alpha-4 chain,TPM4,,unknown
Phenethyl Isothiocyanate,,Tubulin alpha-1A chain,TUBA1A,,unknown
Phenethyl Isothiocyanate,,Tubulin alpha-3C/D chain,TUBA3C,,unknown
Phenethyl Isothiocyanate,,Tubulin alpha-4A chain,TUBA4A,,unknown
Phenethyl Isothiocyanate,,Tubulin beta-1 chain,TUBB1,,unknown
Phenethyl Isothiocyanate,,Tubulin beta-2A chain,TUBB2A,,unknown
Phenethyl Isothiocyanate,,Tubulin beta-3 chain,TUBB3,,unknown
Phenethyl Isothiocyanate,,Tubulin beta-4B chain,TUBB4B,,unknown
Phenethyl Isothiocyanate,,Thioredoxin,TXN,,unknown
Phenethyl Isothiocyanate,,Ubiquitin carboxyl-terminal hydrolase isozyme L1,UCHL1,,unknown
Phenethyl Isothiocyanate,,Ubiquitin carboxyl-terminal hydrolase 14,USP14,,unknown
Phenethyl Isothiocyanate,,Transitional endoplasmic reticulum ATPase,VCP,,unknown
Phenethyl Isothiocyanate,,Vimentin,VIM,,unknown
Phenethyl Isothiocyanate,,14-3-3 protein beta/alpha,YWHAB,,unknown
Phenethyl Isothiocyanate,,14-3-3 protein epsilon,YWHAE,,unknown
Phenethyl Isothiocyanate,,14-3-3 protein eta,YWHAH,,unknown
Phenethyl Isothiocyanate,,14-3-3 protein theta,YWHAQ,,unknown
Phenethyl Isothiocyanate,,14-3-3 protein zeta/delta,YWHAZ,,unknown
Ibalizumab,"The half-life of ibalizumab is 3 to 3.5 days on average. The half-life was estimated from a multiple-dose study evaluating weekly ibalizumab 10 mg/kg in 1 study arm and biweekly ibalizumab 25 mg/kg in another study arm, given via intravenous (IV) infusion in adults with HIV [L1555].  In one clinical trial, the elimination half-life increased from 2.7 to 64 hours as the dose increased from 0.3 to 25 mg/kg (0.01 to 0.9 times the approved recommended loading dose based on a 70 kg patient) [FDA label].",T-cell surface glycoprotein CD4,CD4,antagonist,unknown
Ibalizumab,"The half-life of ibalizumab is 3 to 3.5 days on average. The half-life was estimated from a multiple-dose study evaluating weekly ibalizumab 10 mg/kg in 1 study arm and biweekly ibalizumab 25 mg/kg in another study arm, given via intravenous (IV) infusion in adults with HIV [L1555].  In one clinical trial, the elimination half-life increased from 2.7 to 64 hours as the dose increased from 0.3 to 25 mg/kg (0.01 to 0.9 times the approved recommended loading dose based on a 70 kg patient) [FDA label].",C-C chemokine receptor type 5,CCR5,antagonist,unknown
Ibalizumab,"The half-life of ibalizumab is 3 to 3.5 days on average. The half-life was estimated from a multiple-dose study evaluating weekly ibalizumab 10 mg/kg in 1 study arm and biweekly ibalizumab 25 mg/kg in another study arm, given via intravenous (IV) infusion in adults with HIV [L1555].  In one clinical trial, the elimination half-life increased from 2.7 to 64 hours as the dose increased from 0.3 to 25 mg/kg (0.01 to 0.9 times the approved recommended loading dose based on a 70 kg patient) [FDA label].",C-X-C chemokine receptor type 4,CXCR4,antagonist,unknown
Velusetrag,,5-hydroxytryptamine receptor 4,HTR4,,unknown
Daporinad,,Nicotinamide phosphoribosyltransferase,NAMPT,,unknown
Dipraglurant,,Metabotropic glutamate receptor 5,GRM5,,unknown
Amuvatinib,,Mast/stem cell growth factor receptor Kit,KIT,,unknown
Amuvatinib,,Hepatocyte growth factor receptor,MET,,unknown
Amuvatinib,,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,,unknown
Amuvatinib,,Platelet-derived growth factor receptor alpha,PDGFRA,,unknown
Amuvatinib,,Receptor-type tyrosine-protein kinase FLT3,FLT3,,unknown
Amuvatinib,,DNA repair protein RAD51 homolog 1,RAD51,,unknown
Tertomotide,,Telomerase reverse transcriptase,TERT,,unknown
Lometrexol,,Dihydrofolate reductase,folA,,unknown
Sifalimumab,,Interferon alpha-2,IFNA2,,unknown
Dinoprost,,Prostaglandin D2 receptor 2,PTGDR2,agonist,unknown
Gabexate,,Plasma kallikrein,KLKB1,inhibitor,yes
Gabexate,,Prothrombin,F2,inhibitor,yes
Gabexate,,Plasminogen,PLG,inhibitor,yes
Amatuximab,,Mesothelin,MSLN,,unknown
Etelcalcetide,3 to 4 days,Extracellular calcium-sensing receptor,CASR,agonist,yes
Vonicog Alfa,Clinical trials have shown a terminal half-life of 21.9 hours for vonicog alfa which can be modified by the coadministration of the factor VIII.[A32262],Coagulation factor VIII,F8,stabilization,yes
Vonicog Alfa,Clinical trials have shown a terminal half-life of 21.9 hours for vonicog alfa which can be modified by the coadministration of the factor VIII.[A32262],Collagen alpha-1(I) chain,COL1A1,binder,yes
Quizartinib,,Receptor-type tyrosine-protein kinase FLT3,FLT3,,unknown
Dihydrexidine,,D(1A) dopamine receptor,DRD1,,unknown
Ozenoxacin,,DNA gyrase subunit A,gyrA,inhibitor,yes
Ozenoxacin,,DNA topoisomerase 4 subunit A,parC,inhibitor,yes
INCB-9471,,C-C chemokine receptor type 5,CCR5,,unknown
Leukotriene B4,,Leukotriene B4 receptor 1,LTB4R,,unknown
Leukotriene B4,,Leukotriene B4 receptor 2,LTB4R2,,unknown
Leukotriene B4,,Peroxisome proliferator-activated receptor alpha,PPARA,activator,unknown
Cortivazol,,Glucocorticoid receptor,NR3C1,,unknown
Hypericin,,Glutathione S-transferase A1,GSTA1,,unknown
Hypericin,,Glutathione S-transferase P,GSTP1,,unknown
Tiapride,2.9–3.6 hours,D(2) dopamine receptor,DRD2,blocker,yes
Tiapride,2.9–3.6 hours,D(3) dopamine receptor,DRD3,blocker,yes
Tiapride,2.9–3.6 hours,Serotonin Receptors,HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR6HTR7,antagonist,yes
Tiapride,2.9–3.6 hours,Alpha-1 adrenergic receptors,ADRA1AADRA1BADRA1D,antagonist,yes
Tiapride,2.9–3.6 hours,Alpha-2 adrenergic receptors,ADRA2AADRA2BADRA2C,antagonist,yes
Tiapride,2.9–3.6 hours,Histamine H1 receptor,HRH1,antagonist,yes
Ramatroban,,Prostaglandin D2 receptor 2,PTGDR2,,unknown
Gossypol,,Bcl-2-like protein 1,BCL2L1,,unknown
MLN8054,,Aurora kinase A,AURKA,,unknown
Macimorelin,The mean terminal half-life (T1/2) is 4.1 hours following administration of a single oral dose of 0.5 mg macimorelin/kg body weight in healthy subjects [FDA Label].,Growth hormone secretagogue receptor type 1,GHSR,agonist,unknown
Talarozole,,Cytochrome P450 26A1,CYP26A1,,unknown
Meclocycline,Half life estimated to be ~5.6h based on that of chlortetracycline due to structural similarity [A1424].,30S ribosomal protein S7,rpsG,antagonist,yes
GSK-364735,,Gag-Pol polyprotein,gag-pol,,unknown
Von Willebrand Factor Human,The reported terminal half-life of the concentrate of vWF and factor VIII is of 15.8 hours.[A32279],Coagulation factor VIII,F8,stabilization,yes
Von Willebrand Factor Human,The reported terminal half-life of the concentrate of vWF and factor VIII is of 15.8 hours.[A32279],Collagen alpha-1(I) chain,COL1A1,binder,yes
Levosalbutamol,3.3 - 4 hours,Beta-2 adrenergic receptor,ADRB2,agonist,yes
Bezlotoxumab,19 Days,Clostridium difficile Toxin B,toxB,antibody,yes
Lenograstim,"The pharmacokinetic profile of lenograstim  is similar in healthy volunteers and cancer patients with elimination half-life (t½β) values of 2.3 - 3.3 hrs (volunteers); 2.8-7.5 hrs (cancer patients) following sc administration, and 0.8 - 2.1 hrs (volunteers); 1.1 - 4.0 hrs (cancer patients) following iv administration.",Granulocyte colony-stimulating factor receptor,CSF3R,agonist,yes
Nedaplatin,,Glutathione,,ligand,unknown
Nedaplatin,,DNA,,ligand,yes
Fluciclovine (18F),"Fluciclovine is a cyclotron produced radionuclide that decays by positron emission (ß+ decay, 96.7%) and orbital electron capture (3.3%) to stable oxygen 18 with a physical half-life of 109.7 minutes.[A31383]",Neutral amino acid transporter B(0),SLC1A5,binder,yes
Fluciclovine (18F),"Fluciclovine is a cyclotron produced radionuclide that decays by positron emission (ß+ decay, 96.7%) and orbital electron capture (3.3%) to stable oxygen 18 with a physical half-life of 109.7 minutes.[A31383]",Y+L amino acid transporter 1,SLC7A7,binder,yes
Fluciclovine (18F),"Fluciclovine is a cyclotron produced radionuclide that decays by positron emission (ß+ decay, 96.7%) and orbital electron capture (3.3%) to stable oxygen 18 with a physical half-life of 109.7 minutes.[A31383]",Cationic amino acid transporter 3,SLC7A3,binder,yes
Fluciclovine (18F),"Fluciclovine is a cyclotron produced radionuclide that decays by positron emission (ß+ decay, 96.7%) and orbital electron capture (3.3%) to stable oxygen 18 with a physical half-life of 109.7 minutes.[A31383]",Glutamate (NMDA) receptor,GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B,inhibitor,no
Fluciclovine (18F),"Fluciclovine is a cyclotron produced radionuclide that decays by positron emission (ß+ decay, 96.7%) and orbital electron capture (3.3%) to stable oxygen 18 with a physical half-life of 109.7 minutes.[A31383]",Glutamate receptor 1,GRIA1,inhibitor,no
Fluciclovine (18F),"Fluciclovine is a cyclotron produced radionuclide that decays by positron emission (ß+ decay, 96.7%) and orbital electron capture (3.3%) to stable oxygen 18 with a physical half-life of 109.7 minutes.[A31383]",Glutamate receptor 2,GRIA2,inhibitor,no
Fluciclovine (18F),"Fluciclovine is a cyclotron produced radionuclide that decays by positron emission (ß+ decay, 96.7%) and orbital electron capture (3.3%) to stable oxygen 18 with a physical half-life of 109.7 minutes.[A31383]",Glutamate receptor 3,GRIA3,inhibitor,no
Fluciclovine (18F),"Fluciclovine is a cyclotron produced radionuclide that decays by positron emission (ß+ decay, 96.7%) and orbital electron capture (3.3%) to stable oxygen 18 with a physical half-life of 109.7 minutes.[A31383]",Glutamate receptor 4,GRIA4,inhibitor,no
Protein S human,,Coagulation factor V,F5,antagonist,yes
Protein S human,,Coagulation factor X,F10,antagonist,yes
Protein S human,,Vitamin K-dependent protein C,PROC,cofactor,yes
Coagulation factor VII human,5 h,Tissue factor,F3,activator,yes
Coagulation factor VII human,5 h,Coagulation factor X,F10,activator,yes
Coagulation factor VII human,5 h,Coagulation factor IX,F9,activator,yes
Anti-inhibitor coagulant complex,"Plasma half lives of included clotting factors are as follows [A19411]:
Prothrombin - 65h
Factor VII - 5h
Factor IX - 25h
Factor X - 40h",Coagulation factor X,F10,agonist,yes
Anti-inhibitor coagulant complex,"Plasma half lives of included clotting factors are as follows [A19411]:
Prothrombin - 65h
Factor VII - 5h
Factor IX - 25h
Factor X - 40h",Prothrombin,F2,agonist,yes
Anti-inhibitor coagulant complex,"Plasma half lives of included clotting factors are as follows [A19411]:
Prothrombin - 65h
Factor VII - 5h
Factor IX - 25h
Factor X - 40h",Fibrinogen alpha chain,FGA,cleavage,yes
Anti-inhibitor coagulant complex,"Plasma half lives of included clotting factors are as follows [A19411]:
Prothrombin - 65h
Factor VII - 5h
Factor IX - 25h
Factor X - 40h",Fibrinogen beta chain,FGB,cleavage,yes
Anti-inhibitor coagulant complex,"Plasma half lives of included clotting factors are as follows [A19411]:
Prothrombin - 65h
Factor VII - 5h
Factor IX - 25h
Factor X - 40h",Coagulation factor XIII A chain,F13A1,agonist,yes
Anti-inhibitor coagulant complex,"Plasma half lives of included clotting factors are as follows [A19411]:
Prothrombin - 65h
Factor VII - 5h
Factor IX - 25h
Factor X - 40h",Coagulation factor V,F5,agonist,yes
Anti-inhibitor coagulant complex,"Plasma half lives of included clotting factors are as follows [A19411]:
Prothrombin - 65h
Factor VII - 5h
Factor IX - 25h
Factor X - 40h",Coagulation factor VIII,F8,agonist,yes
Anti-inhibitor coagulant complex,"Plasma half lives of included clotting factors are as follows [A19411]:
Prothrombin - 65h
Factor VII - 5h
Factor IX - 25h
Factor X - 40h",Coagulation factor VII,F7,agonist,yes
Coagulation Factor IX Human,18.8 ± 5.4 hours.,Coagulation factor X,F10,activator,yes
Coagulation Factor IX Human,18.8 ± 5.4 hours.,Coagulation factor XI,F11,ligand,yes
Coagulation Factor IX Human,18.8 ± 5.4 hours.,Coagulation factor VII,F7,ligand,yes
Coagulation Factor IX Human,18.8 ± 5.4 hours.,Coagulation factor VIII,F8,cofactor,yes
Coagulation Factor IX Human,18.8 ± 5.4 hours.,Prothrombin,F2,,unknown
Coagulation Factor IX Human,18.8 ± 5.4 hours.,Prolow-density lipoprotein receptor-related protein 1,LRP1,,unknown
Coagulation Factor IX Human,18.8 ± 5.4 hours.,Vitamin K-dependent gamma-carboxylase,GGCX,,unknown
Parachlorophenol,,Sodium channel protein type 4 subunit alpha,SCN4A,,unknown
Esculin,Absorption half life about 1 hour and elimination half life about 20 hours,Androgen receptor,AR,agonist,unknown
Clobetasone,N/A,Glucocorticoid receptor,NR3C1,agonist,yes
Nusinersen,"The mean terminal elimination half-life is estimated to be 135 to 177 days in CSF, and 63 to 87 days in plasma [FDA Label].",Survival motor neuron protein,SMN2,antisense oligonucleotide,yes
Olmutinib,8-11h [L766].,Epidermal growth factor receptor,EGFR,inhibitor,yes
Ripasudil,The half life of Ripasudil is 0.455 hrs.,Rho-associated protein kinase 1,ROCK1,inhibitor,unknown
Ripasudil,The half life of Ripasudil is 0.455 hrs.,Rho-associated protein kinase 2,ROCK2,inhibitor,unknown
Zofenopril,,Angiotensin-converting enzyme,ACE,inhibitor,yes
Alclofenac,The plasma half-life varies between 1.5 and 5.5 hours.,Prostaglandin G/H synthase 2,PTGS2,antagonist,yes
Plecanatide,half-life (t½) cannot be calculated due to negligible systemic absorbance,Guanylate cyclase soluble subunit alpha-2,GUCY1A2,agonist,yes
Cerliponase alfa,Refer to FDA Label,Cation-independent mannose-6-phosphate receptor,IGF2R,ligand,unknown
Rhein,4-10h [A19300].,Oxysterols receptor LXR-alpha,NR1H3,inhibitor,unknown
Rhein,4-10h [A19300].,Oxysterols receptor LXR-beta,NR1H2,inhibitor,unknown
Rhein,4-10h [A19300].,Arylamine N-acetyltransferase (Helicobacter pylori),,inhibitor,unknown
Rhein,4-10h [A19300].,Arachidonate 5-lipoxygenase,ALOX5,inhibitor,unknown
Troleandomycin,,50S ribosomal protein L32,rpmF,inhibitor,yes
Troleandomycin,,50S ribosomal protein L4,rplD,inhibitor,yes
Troleandomycin,,Nuclear receptor subfamily 1 group I member 2,NR1I2,activator,unknown
Phosphocreatine,,Guanidinoacetate N-methyltransferase,GAMT,product of,yes
Phosphocreatine,,Sodium- and chloride-dependent creatine transporter 1,SLC6A8,,yes
Phosphocreatine,,Creatine kinase M-type,CKM,ligand,yes
Phosphocreatine,,"Creatine kinase U-type, mitochondrial",CKMT1A,ligand,yes
Phosphocreatine,,"Creatine kinase S-type, mitochondrial",CKMT2,ligand,yes
Phosphocreatine,,Creatine kinase B-type,CKB,ligand,yes
Antihemophilic factor human,The mean half-life of human antihemophilic factor administered in hemophilic A patients is 14.8 hours.[L1056],Coagulation factor IX,F9,activator,yes
Antihemophilic factor human,The mean half-life of human antihemophilic factor administered in hemophilic A patients is 14.8 hours.[L1056],Coagulation factor X,F10,activator,yes
Metergoline,,Sodium channel protein type 2 subunit alpha,SCN2A,inhibitor,unknown
Mifamurtide,"Following intravenous administration of 4 mg mifamurtide in healthy adult subjects, the half life was 2.05 ± 0.40 hours. In pediatric and adult patients with psteosarcoma, the half life was 2.04 ± 0.456 hours after intravenous infusion of 2 mg/m^2 [L1203].",Toll-like receptor 4,TLR4,ligand,yes
Mifamurtide,"Following intravenous administration of 4 mg mifamurtide in healthy adult subjects, the half life was 2.05 ± 0.40 hours. In pediatric and adult patients with psteosarcoma, the half life was 2.04 ± 0.456 hours after intravenous infusion of 2 mg/m^2 [L1203].",Nucleotide-binding oligomerization domain-containing protein 2,NOD2,ligand,yes
Xamoterol,,Beta-1 adrenergic receptor,ADRB1,partial agonist,yes
Acemetacin,The elimination half-life of acemetacin after steady-state is 4.5 hours.[A31356],Prostaglandin G/H synthase 1,PTGS1,antagonist,yes
Acemetacin,The elimination half-life of acemetacin after steady-state is 4.5 hours.[A31356],Prostaglandin G/H synthase 2,PTGS2,antagonist,yes
Adefovir,,DNA polymerase/reverse transcriptase,P,inhibitor,yes
2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol,,Estrogen receptor beta,ESR2,,unknown
2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol,,Estrogen receptor alpha,ESR1,,unknown
Lormetazepam,The terminal phase half life is 11 h [L927].,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,positive allosteric modulator,yes
Lormetazepam,The terminal phase half life is 11 h [L927].,Gamma-aminobutyric acid receptor subunit gamma-2,GABRG2,positive allosteric modulator,yes
Lormetazepam,The terminal phase half life is 11 h [L927].,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,positive allosteric modulator,yes
Lormetazepam,The terminal phase half life is 11 h [L927].,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,positive allosteric modulator,yes
Lormetazepam,The terminal phase half life is 11 h [L927].,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,positive allosteric modulator,yes
Fenofibric acid,"Following once daily dosing, fenofibric acid demonstrates an elimination associated with a half-life of about 20 hours after absorption [FDA Label].",Peroxisome proliferator-activated receptor alpha,PPARA,agonist,yes
Fenofibric acid,"Following once daily dosing, fenofibric acid demonstrates an elimination associated with a half-life of about 20 hours after absorption [FDA Label].",Metalloproteinase,mmp20,unknown,unknown
Fenofibric acid,"Following once daily dosing, fenofibric acid demonstrates an elimination associated with a half-life of about 20 hours after absorption [FDA Label].",Peroxisome proliferator-activated receptor gamma,PPARG,,unknown
Fenofibric acid,"Following once daily dosing, fenofibric acid demonstrates an elimination associated with a half-life of about 20 hours after absorption [FDA Label].",Peroxisome proliferator-activated receptor delta,PPARD,unknown,unknown
Fenofibric acid,"Following once daily dosing, fenofibric acid demonstrates an elimination associated with a half-life of about 20 hours after absorption [FDA Label].",Nuclear receptor subfamily 1 group I member 2,NR1I2,partial agonist,unknown
Enasidenib,Enasidenib has a terminal half-life of 137 hours [FDA Label].,"Isocitrate dehydrogenase [NADP], mitochondrial",IDH2,inhibitor,yes
Harmaline,,Histamine N-methyltransferase,HNMT,inhibitor,unknown
Brofaromine,,Amine oxidase [flavin-containing] A,MAOA,inhibitor,unknown
Iniparib,,Poly [ADP-ribose] polymerase 1,PARP1,,unknown
Pibrentasvir,The elimination half life (t1/2) is approximately 13 hours [FDA Label].,Nonstructural Protein 5A (NS5A),,inhibitor,yes
Glecaprevir,The elimination half life (t1/2) is approximately 6 hours [FDA Label].,NS3 protease,,inhibitor,yes
Tisagenlecleucel,The mean half life was 16.8 days in pediatric and young adult relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) patients [FDA Label].,B-lymphocyte antigen CD19,CD19,antibody,yes
Volixibat,,Ileal sodium/bile acid cotransporter,SLC10A2,inhibitor,yes
Axicabtagene ciloleucel,,B-lymphocyte antigen CD19,CD19,antibody,yes
Candesartan,,Type-1 angiotensin II receptor,AGTR1,antagonist,yes
Emicizumab,"Emcicizumab presents a long half-life ranging from 27.8 to 34.4 days.[FDA label, A31279]",Coagulation factor IX,F9,cofactor,yes
Emicizumab,"Emcicizumab presents a long half-life ranging from 27.8 to 34.4 days.[FDA label, A31279]",Coagulation factor X,F10,activator,yes
Dotatate gallium Ga-68,The half-life of gallium 68 is estimated to be of 68 min.[A31362],Somatostatin receptor type 2,SSTR2,binder,yes
Semaglutide,One of the major properties of semaglutide is its long half-life of 168 h.[A31425],Glucagon-like peptide 1 receptor,GLP1R,agonist,yes
Relcovaptan,,Oxytocin receptor,OXTR,antagonist,unknown
Relcovaptan,,Vasopressin V1a receptor,AVPR1A,antagonist,unknown
Ulixertinib,,Mitogen-activated protein kinase 3,MAPK3,inhibitor,unknown
Ulixertinib,,Mitogen-activated protein kinase 1,MAPK1,inhibitor,unknown
Netarsudil,The half-life of netarsudil incubated *in vitro* with human corneal tissue is 175 minutes [A31475].,Rho-associated protein kinase 1,ROCK1,inhibitor,yes
Netarsudil,The half-life of netarsudil incubated *in vitro* with human corneal tissue is 175 minutes [A31475].,Rho-associated protein kinase 2,ROCK2,inhibitor,yes
Netarsudil,The half-life of netarsudil incubated *in vitro* with human corneal tissue is 175 minutes [A31475].,solute carrier family 6 member 2,,inhibitor,yes
Voretigene Neparvovec,"Based on the pharmacokinetic preclinical studies performed with VN-rzyl and previous studies with different AAVV, it is possible to determine that the half-life of VN-rzyl is approximately 1.7 hours.[A31485]",Retinoid isomerohydrolase,RPE65,gene replacement,yes
Nonacog beta pegol,The terminal half life of nonacog beta pegol is in the range of 96-110 hours which is 5 times longer than an unmodified coagulation factor IX.[A31500],Coagulation factor VII,F7,cofactor,yes
Nonacog beta pegol,The terminal half life of nonacog beta pegol is in the range of 96-110 hours which is 5 times longer than an unmodified coagulation factor IX.[A31500],Coagulation factor VIII,F8,cofactor,yes
Nonacog beta pegol,The terminal half life of nonacog beta pegol is in the range of 96-110 hours which is 5 times longer than an unmodified coagulation factor IX.[A31500],Coagulation factor X,F10,agonist,yes
Ligandrol,,Androgen receptor,AR,antagonistagonist,unknown
"2,5-Dimethoxy-4-ethylthioamphetamine",,5-hydroxytryptamine receptor 2A,HTR2A,agonist,unknown
"2,5-Dimethoxy-4-ethylthioamphetamine",,5-hydroxytryptamine receptor 2C,HTR2C,agonist,unknown
Testosterone cypionate,"The half-life of testosterone cypionate is one of the longest, being approximately of 8 days.[L1151]",Androgen receptor,AR,agonist,yes
Testosterone cypionate,"The half-life of testosterone cypionate is one of the longest, being approximately of 8 days.[L1151]",Estrogen receptor alpha,ESR1,,unknown
Testosterone cypionate,"The half-life of testosterone cypionate is one of the longest, being approximately of 8 days.[L1151]",Mineralocorticoid receptor,NR3C2,,unknown
Testosterone enanthate,Testosterone enanthate presents a long half-life in the range of 7-9 days.[A31616],Androgen receptor,AR,agonist,yes
Testosterone enanthate,Testosterone enanthate presents a long half-life in the range of 7-9 days.[A31616],Estrogen receptor alpha,ESR1,,unknown
Testosterone enanthate,Testosterone enanthate presents a long half-life in the range of 7-9 days.[A31616],Mineralocorticoid receptor,NR3C2,,unknown
Testosterone undecanoate,The reported elimination half-life of testosterone undecanoate is very long and it ranges between 18-24 days.[A31632],Androgen receptor,AR,agonist,yes
Testosterone undecanoate,The reported elimination half-life of testosterone undecanoate is very long and it ranges between 18-24 days.[A31632],Estrogen receptor alpha,ESR1,,unknown
Testosterone undecanoate,The reported elimination half-life of testosterone undecanoate is very long and it ranges between 18-24 days.[A31632],Mineralocorticoid receptor,NR3C2,,unknown
"N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine",,5-hydroxytryptamine receptor 2A,HTR2A,agonist,unknown
Stanolone acetate,,Androgen receptor,AR,,unknown
Stanolone acetate,,Estradiol 17-beta-dehydrogenase 1,HSD17B1,,unknown
Stanolone acetate,,Estrogen receptor alpha,ESR1,,unknown
Stanolone acetate,,Mineralocorticoid receptor,NR3C2,,unknown
Estradiol acetate,,Estrogen receptor alpha,ESR1,agonist,yes
Estradiol acetate,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Estradiol acetate,,Estrogen receptor beta,ESR2,agonist,yes
Estradiol acetate,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,,unknown
Estradiol acetate,,Nuclear receptor coactivator 2,NCOA2,,unknown
Estradiol acetate,,G-protein coupled estrogen receptor 1,GPER1,,unknown
Estradiol acetate,,ATP synthase subunit a,MT-ATP6,,unknown
Estradiol acetate,,Beclin-1,BECN1,,unknown
Estradiol acetate,,Estradiol 17-beta-dehydrogenase 2,HSD17B2,,unknown
Estradiol acetate,,Estrogen-related receptor gamma,ESRRG,ligand,unknown
Estradiol benzoate,,Estrogen receptor alpha,ESR1,agonist,yes
Estradiol benzoate,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Estradiol benzoate,,Estrogen receptor beta,ESR2,agonist,yes
Estradiol benzoate,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,,unknown
Estradiol benzoate,,Nuclear receptor coactivator 2,NCOA2,,unknown
Estradiol benzoate,,G-protein coupled estrogen receptor 1,GPER1,,unknown
Estradiol benzoate,,ATP synthase subunit a,MT-ATP6,,unknown
Estradiol benzoate,,Beclin-1,BECN1,,unknown
Estradiol benzoate,,Estradiol 17-beta-dehydrogenase 2,HSD17B2,,unknown
Estradiol benzoate,,Estrogen-related receptor gamma,ESRRG,ligand,unknown
Estradiol cypionate,,Estrogen receptor alpha,ESR1,agonist,yes
Estradiol cypionate,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Estradiol cypionate,,Estrogen receptor beta,ESR2,agonist,yes
Estradiol cypionate,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,,unknown
Estradiol cypionate,,Nuclear receptor coactivator 2,NCOA2,,unknown
Estradiol cypionate,,G-protein coupled estrogen receptor 1,GPER1,,unknown
Estradiol cypionate,,ATP synthase subunit a,MT-ATP6,,unknown
Estradiol cypionate,,Beclin-1,BECN1,,unknown
Estradiol cypionate,,Estradiol 17-beta-dehydrogenase 2,HSD17B2,,unknown
Estradiol cypionate,,Estrogen-related receptor gamma,ESRRG,ligand,unknown
Estradiol dienanthate,,Estrogen receptor alpha,ESR1,agonist,yes
Estradiol dienanthate,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Estradiol dienanthate,,Estrogen receptor beta,ESR2,agonist,yes
Estradiol dienanthate,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,,unknown
Estradiol dienanthate,,Nuclear receptor coactivator 2,NCOA2,,unknown
Estradiol dienanthate,,G-protein coupled estrogen receptor 1,GPER1,,unknown
Estradiol dienanthate,,ATP synthase subunit a,MT-ATP6,,unknown
Estradiol dienanthate,,Beclin-1,BECN1,,unknown
Estradiol dienanthate,,Estradiol 17-beta-dehydrogenase 2,HSD17B2,,unknown
Estradiol dienanthate,,Estrogen-related receptor gamma,ESRRG,ligand,unknown
Estradiol valerate,,Estrogen receptor alpha,ESR1,agonist,yes
Estradiol valerate,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
Estradiol valerate,,Estrogen receptor beta,ESR2,agonist,yes
Estradiol valerate,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,,unknown
Estradiol valerate,,Nuclear receptor coactivator 2,NCOA2,,unknown
Estradiol valerate,,G-protein coupled estrogen receptor 1,GPER1,,unknown
Estradiol valerate,,ATP synthase subunit a,MT-ATP6,,unknown
Estradiol valerate,,Beclin-1,BECN1,,unknown
Estradiol valerate,,Estradiol 17-beta-dehydrogenase 2,HSD17B2,,unknown
Estradiol valerate,,Estrogen-related receptor gamma,ESRRG,ligand,unknown
Selisistat,,NAD-dependent protein deacetylase sirtuin-1,SIRT1,inhibitor,unknown
Besilesomab,"Whole blood concentration-time radioactivity curves show a two-phase course, which can be subdivided into an early phase (0-2 h) and a late phase (5-24 h) [FDA Label]. After correcting for the decay of radionuclide, the calculated half-life of the early phase is approximately 0.5 h while the late phase demonstrates a calculated half-life of 16 h [FDA Label]. The terminal half-life in man is estimated to be approximately 23 h [L1623].",Carcinoembryonic antigen,,,no
"5,7,2′-trihydroxy-6,8-dimethoxyflavone",,GABA-A receptor (benzodiazepine site),GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRG1GABRG2GABRG3,ligand,unknown
Lutetium Lu 177 dotatate,The mean (± standard deviation) effective blood elimination half-life is 3.5 (±1.4) hours and the mean terminal blood half-life is 71 (± 28) hours [FDA Label].,Somatostatin receptor type 2,SSTR2,agonist,yes
Lutetium Lu 177 dotatate,The mean (± standard deviation) effective blood elimination half-life is 3.5 (±1.4) hours and the mean terminal blood half-life is 71 (± 28) hours [FDA Label].,Somatostatin receptor type 1,SSTR1,agonist,yes
Lutetium Lu 177 dotatate,The mean (± standard deviation) effective blood elimination half-life is 3.5 (±1.4) hours and the mean terminal blood half-life is 71 (± 28) hours [FDA Label].,Somatostatin receptor type 3,SSTR3,agonist,yes
Lutetium Lu 177 dotatate,The mean (± standard deviation) effective blood elimination half-life is 3.5 (±1.4) hours and the mean terminal blood half-life is 71 (± 28) hours [FDA Label].,Somatostatin receptor type 4,SSTR4,agonist,yes
Lutetium Lu 177 dotatate,The mean (± standard deviation) effective blood elimination half-life is 3.5 (±1.4) hours and the mean terminal blood half-life is 71 (± 28) hours [FDA Label].,Somatostatin receptor type 5,SSTR5,agonist,yes
SB-269970,,5-hydroxytryptamine receptor 7,HTR7,antagonist,unknown
Ferric pyrophosphate citrate,The half-life of ferric pyrophosphate is 1.48 hours.[A31994],Ferritin light chain,FTL,binder,yes
Ferric pyrophosphate citrate,The half-life of ferric pyrophosphate is 1.48 hours.[A31994],Ferritin heavy chain,FTH1,binder,yes
Ferric pyrophosphate citrate,The half-life of ferric pyrophosphate is 1.48 hours.[A31994],Hemoglobin subunit alpha,HBA1,binder,yes
Ferric pyrophosphate citrate,The half-life of ferric pyrophosphate is 1.48 hours.[A31994],Hemoglobin subunit beta,HBB,binder,yes
Magnesium acetate,,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,,unknown
Lonoctocog alfa,8.4-19.3 hrs,Coagulation factor X,F10,activator,yes
Lonoctocog alfa,8.4-19.3 hrs,"Phytanoyl-CoA dioxygenase, peroxisomal",PHYH,antagonist,unknown
Lonoctocog alfa,8.4-19.3 hrs,Coagulation factor IX,F9,cofactor,yes
Lonoctocog alfa,8.4-19.3 hrs,Asialoglycoprotein receptor 2,ASGR2,binder,unknown
Lonoctocog alfa,8.4-19.3 hrs,78 kDa glucose-regulated protein,HSPA5,chaperone,unknown
Lonoctocog alfa,8.4-19.3 hrs,Calreticulin,CALR,chaperone,unknown
Lonoctocog alfa,8.4-19.3 hrs,Calnexin,CANX,chaperone,unknown
Lonoctocog alfa,8.4-19.3 hrs,Protein ERGIC-53,LMAN1,chaperone,unknown
Lonoctocog alfa,8.4-19.3 hrs,Prolow-density lipoprotein receptor-related protein 1,LRP1,modulator,unknown
Lonoctocog alfa,8.4-19.3 hrs,Multiple coagulation factor deficiency protein 2,MCFD2,modulator,unknown
Lonoctocog alfa,8.4-19.3 hrs,von Willebrand factor,VWF,binder,yes
Moroctocog alfa,8.4-19.3 hrs,Coagulation factor X,F10,activator,yes
Moroctocog alfa,8.4-19.3 hrs,"Phytanoyl-CoA dioxygenase, peroxisomal",PHYH,antagonist,unknown
Moroctocog alfa,8.4-19.3 hrs,Coagulation factor IX,F9,cofactor,yes
Moroctocog alfa,8.4-19.3 hrs,Asialoglycoprotein receptor 2,ASGR2,binder,unknown
Moroctocog alfa,8.4-19.3 hrs,78 kDa glucose-regulated protein,HSPA5,chaperone,unknown
Moroctocog alfa,8.4-19.3 hrs,Calreticulin,CALR,chaperone,unknown
Moroctocog alfa,8.4-19.3 hrs,Calnexin,CANX,chaperone,unknown
Moroctocog alfa,8.4-19.3 hrs,Protein ERGIC-53,LMAN1,chaperone,unknown
Moroctocog alfa,8.4-19.3 hrs,Prolow-density lipoprotein receptor-related protein 1,LRP1,modulator,unknown
Moroctocog alfa,8.4-19.3 hrs,Multiple coagulation factor deficiency protein 2,MCFD2,modulator,unknown
Moroctocog alfa,8.4-19.3 hrs,von Willebrand factor,VWF,binder,yes
alpha-Tocopherol succinate,,SEC14-like protein 4,SEC14L4,,unknown
alpha-Tocopherol succinate,,SEC14-like protein 3,SEC14L3,,unknown
alpha-Tocopherol succinate,,SEC14-like protein 2,SEC14L2,,unknown
alpha-Tocopherol succinate,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
alpha-Tocopherol succinate,,Protein kinase C beta type,PRKCB,,unknown
alpha-Tocopherol succinate,,Arachidonate 5-lipoxygenase,ALOX5,,unknown
alpha-Tocopherol succinate,,Protein kinase C alpha type,PRKCA,,unknown
alpha-Tocopherol succinate,,Diacylglycerol kinase alpha,DGKA,,unknown
alpha-Tocopherol succinate,,Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform,PPP2CB,,unknown
alpha-Tocopherol succinate,,Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform,PPP2CA,,unknown
D-alpha-Tocopherol acetate,,SEC14-like protein 4,SEC14L4,,unknown
D-alpha-Tocopherol acetate,,SEC14-like protein 3,SEC14L3,,unknown
D-alpha-Tocopherol acetate,,SEC14-like protein 2,SEC14L2,,unknown
D-alpha-Tocopherol acetate,,Nuclear receptor subfamily 1 group I member 2,NR1I2,,unknown
D-alpha-Tocopherol acetate,,Protein kinase C beta type,PRKCB,,unknown
D-alpha-Tocopherol acetate,,Arachidonate 5-lipoxygenase,ALOX5,,unknown
D-alpha-Tocopherol acetate,,Protein kinase C alpha type,PRKCA,,unknown
D-alpha-Tocopherol acetate,,Diacylglycerol kinase alpha,DGKA,,unknown
D-alpha-Tocopherol acetate,,Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform,PPP2CB,,unknown
D-alpha-Tocopherol acetate,,Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform,PPP2CA,,unknown
Tildrakizumab,The half-life is approximately 23 days (23%) [L1858].,Interleukin-23,IL12BIL23A,antagonist,yes
